

APPENDICES FOR CHAPTERS 9 AND 10

TABLE OF CONTENTS

[Chapter 9 Appendices - AD Causes Queries](#)

[Appendix 9A-1 - AD Causes Query - Visual Inspection Approach](#)

[Appendix 9A-2 - Unambiguous MeSH Terms - Streamlined Approach](#)

[Chapter 10 Appendices - Bibliography References](#)

[Appendix 10C1-a. Example references for each existing AD treatment identified](#)

[Appendix 10C2-a. Additional AD treatment articles based on references in AD treatment review papers](#)

[Appendix 10C3-a. Additional AD treatment references based on linking terms in title](#)

Chapter 9 Appendices - AD Causes Queries

Appendix 9A-1 - AD Causes Query - Visual Inspection Approach

I. Core Literature Retrieval Thomson Medline (76,663 records retrieved - core only)

TOPIC

Alzheimer*

OR

MESH HEADING

Alzheimer Disease

NOT

TOPIC

(streptozotocin OR scopolamine OR colchicine OR LPS-induc* OR polymorphism* OR Abeta-induc* OR "beta-amyloid-induc*" OR "amyloid-beta-induc*" OR "beta-amyloid peptide-induc*" OR "Abeta25-35-induc*" OR "Abeta25-35 peptide-induc*" OR Abeta40-induc* OR nontoxic OR non-toxic)

AND

Remainder of Query Intersected with Core Literature

II. TEXT FIELD TERMS

IIA. NON-LIFESTYLE-SPECIFIC COMPONENT - TOPIC

("2,4,6- triiodobenzoic acid" OR "3-deazaneplanocin A" OR "5AZA" OR "5-aza-deoxycytidine" OR "5-fluorouracil" OR "9-alpha fluorocortisol" OR "9-alpha fluoroprednisolone" OR "9-hydroxy-2-methylellipticinium" OR "acarbose" OR "ACE inhibitor*" OR "acetaminophen" OR "acetazolamide" OR "acetylsalicylic acid" OR "acyclovir" OR "adalimumab" OR "adefovir" OR "adriamycin" OR "alclofenac" OR "aliskiren" OR "alizapride" OR "allopurinol" OR "all-trans-retinoic acid" OR "alpha-mercaptopropionylglycine" OR "amikacin" OR "Aminoglycoside*" OR "Amiodarone" OR "amitriptyline" OR "amlodipine" OR "amoxicillin" OR "amphetamine*" OR "amphotericin b" OR "ampicillin" OR "ampiroxicam" OR "anabolic steroid*" OR "Anaesthetic*" OR "Analgesic*" OR "anesthesia" OR "androgen deprivation therapy" OR "anesthetic*" OR "anthracycline" OR "antiadrenergic agent*" OR "anti-adrenergic agent*" OR "antiadrenergic drug*" OR "anti-adrenergic drug*" OR "antiallergic agent*" OR "Anti-Allergic agent*" OR "antiallergic drug*" OR "Anti-Allergic drug*" OR "antiandrogen* agent*" OR "anti-androgen* agent*" OR "antiandrogen* drug*" OR "anti-androgen* drug*" OR "antianginal

agent*" OR "anti-anginal agent*" OR "antianginal drug*" OR "anti-anginal drug*" OR "antiangiogenesis agent*" OR "anti-angiogenesis agent*" OR "antiangiogenesis drug*" OR "anti-angiogenesis drug*" OR "antiarrhythmic agent*" OR "antiarrhythmic drug*" OR "anti-arrythmic agent*" OR "anti-arrythmic drug*" OR "antiasthmatic agent*" OR "anti-asthmatic agent*" OR "antiasthmatic drug*" OR "anti-asthmatic drug*" OR "antibacterial agent*" OR "Anti-bacterial agent*" OR "antibacterial drug*" OR "Anti-bacterial drug*" OR "antibiotic*" OR "antibone-loss agent*" OR "Anti-Bone-Loss agent*" OR "antibone-loss drug*" OR "Anti-Bone-Loss drug*" OR "anticholinergic agent*" OR "anti-cholinergic agent*" OR "anti-cholinergic drug*" OR "anticholinergic* drug*" OR "anticoagulant*" OR "Anti-coagulant*" OR "anticonvulsant*" OR "anti-convulsant*" OR "antidepressant*" OR "anti-depressant*" OR "Antidiabetic agent*" OR "anti-diabetic agent*" OR "Antidiabetic drug*" OR "anti-diabetic drug*" OR "antidiarrheal agent*" OR "anti-diarrheal agent*" OR "antidiarrheal drug*" OR "anti-diarrheal drug*" OR "anti-emetic" OR "antiemetic*" OR "antifungal agent*" OR "anti-fungal agent*" OR "antifungal drug*" OR "anti-fungal drug*" OR "antigonadotropic agent*" OR "antigonadotropic agent*" OR "antigonadotropic drug*" OR "anti-gonadotropic drug*" OR "antigout agent*" OR "anti-gout agent*" OR "antigout drug*" OR "anti-gout drug*" OR "antihistamine agent*" OR "anti-histamine agent*" OR "antihistamine drug*" OR "anti-histamine drug*" OR "Antihypertensive agent*" OR "anti-hypertensive agent*" OR "Antihypertensive drug*" OR "anti-hypertensive drug*" OR "antiinfective agent*" OR "Anti-Infective agent*" OR "antiinfective drug*" OR "Anti-Infective drug*" OR "anti-infective*" OR "antiinflammatory agent*" OR "Anti-Inflammatory agent*" OR "antiinflammatory drug*" OR "Anti-Inflammatory drug*" OR "antimalarial agent*" OR "anti-malarial agent*" OR "antimalarial drug*" OR "anti-malarial drug*" OR "antimetabolite agent*" OR "anti-metabolite agent*" OR "antimetabolite drug*" OR "anti-metabolite drug*" OR "antimigraine agent*" OR "anti-migraine agent*" OR "antimigraine drug*" OR "anti-migraine drug*" OR "Antineoplastic Agent*" OR "anti-neoplastic agent*" OR "Antineoplastic drug*" OR "anti-neoplastic drug*" OR "antiparkinson agent*" OR "anti-parkinson agent*" OR "antiparkinson drug*" OR "anti-parkinson drug*" OR "antiplatelet agent*" OR "anti-platelet agent*" OR "antiplatelet drug*" OR "anti-platelet drug*" OR "antipseudomonal agent*" OR "anti-pseudomonal agent*" OR "antipseudomonal drug*" OR "anti-pseudomonal drug*" OR "antipsoriatic agent*" OR "anti-psoriatic agent*" OR "antipsoriatic drug*" OR "anti-psoriatic drug*" OR "Antipsychotic Agent*" OR "Anti-psychotic agent*" OR "Antipsychotic drug*" OR "Anti-psychotic drug*" OR "Antiretroviral Agent*" OR "Anti-retroviral Agent*" OR "Antiretroviral drug*" OR "Antiretroviral drug*" OR "antiretroviral therapy" OR "Antirheumatic Agent*" OR "anti-rheumatic agent*" OR "Antirheumatic drug*" OR "anti-rheumatic drug*" OR "antiseptic agent*" OR "anti-septic agent*" OR "antiseptic drug*" OR "anti-septic drug*" OR "antispasmodic agent*" OR "anti-spasmodic agent*" OR "antispasmodic drug*" OR "anti-spasmodic drug*" OR "anti-thymocyte serum" OR "Antithyroid Agent*" OR "Anti-thyroid Agent*" OR "Antithyroid drug*" OR "Anti-thyroid drug*" OR "antitoxin*" OR "anti-toxin*" OR "antituberculosis agent*" OR "anti-tuberculosis agent*" OR "antituberculosis drug*" OR "anti-tuberculosis drug*" OR "antitussive agent*" OR "anti-tussive

agent*" OR "antitussive drug*" OR "anti-tussive drug*" OR "antivenin*" OR "antivertigo agent*" OR "anti-vertigo agent*" OR "antivertigo drug*" OR "anti-vertigo drug*" OR "Antiviral agent*" OR "Anti-viral agent*" OR "Antiviral drug*" OR "Anti-viral drug*" OR "aprotinin" OR "aspirin" OR "AT1 receptor antagonists" OR "atazanavir" OR "atorvastatin" OR "axitinib" OR "azacitadine" OR "azathioprine" OR "azithromycin" OR "Azole*" OR "Barbiturate*" OR "bardoxolone methyl" OR "benfluorex" OR "benoxaprofen" OR "beta-lactam" OR "bevacizumab" OR "bezafibrate" OR "bisacodyl" OR "Bisphosphonate*" OR "Bleomycin" OR "bortezomib" OR "bucillamine" OR "bupivacaine" OR "buspirone" OR "caffeine" OR "calcineurin inhibitor*" OR "calcitriol" OR "Calcium Channel Blocker" OR "Calcium channel blocker*" OR "capecitabine" OR "captopril" OR "carbamazepine" OR "carbenoxolone" OR "carbimazole" OR "carboplatin" OR "Cardiovascular Agent*" OR "carmustine" OR "C-arylsuccinimides" OR "cediranib" OR "cefdinir" OR "cefoxitin" OR "ceftriaxone" OR "cefuroxime" OR "celecoxib" OR "Central Nervous System Agent*" OR "cephaloridine" OR "cephalosporins" OR "Cephems" OR "cetuximab" OR "chlorambucil" OR "Chloramphenicol" OR "chlormezanone" OR "chloroquine" OR "Chlorpromazine" OR "chlorprothixene" OR "chlorthalidone" OR "cidofovir" OR "cimetidine" OR "ciprofibrate" OR "ciprofloxacin" OR "cisplatin" OR "clarithromycin" OR "clometacin" OR "clomipramine" OR "clopentixol" OR "clopidogrel" OR "cloxacillin" OR "clozapine" OR "colchicine" OR "colistin" OR "contrast medium" OR "coronary artery bypass" OR "corosolic acid" OR "Corticosteroid*" OR "cyclophosphamide" OR "cycloserine" OR "cyclosporine" OR "cytarabine" OR "cytosine arabinoside" OR "dasatinib" OR "daunomycin" OR "daunorubicin" OR "decitabine" OR "deferasirox" OR "deferoxamine" OR "demeclocycline" OR "deoxycorticosterone acetate" OR "desipramine" OR "dexamethasone" OR "dexfenfluramine" OR "dexmethylphenidate" OR "dextran" OR "diaziquone" OR "diclofenac" OR "didecyldimethylammonium chloride" OR "diethyacylurea" OR "diflunisal" OR "Digitalis" OR "diltiazem" OR "diphenylhydantoin" OR "diphosphonates" OR "dipivalyl adrenaline hydrochloride" OR "dipyron" OR "disopyramide" OR "Diuretic*" OR "doxepin" OR "doxorubicin" OR "doxycycline" OR "d-penicillamine" OR "dRK6" OR "efavirenz" OR "enoxaparin" OR "epoetin" OR "erythromycin" OR "erythropoietin" OR "esomeprazole" OR "etanercept" OR "ethambutol" OR "ethosuximide" OR "famotidine" OR "fenbufen" OR "fenclofenac" OR "fenfluramine" OR "fenofibrate" OR "fenoldopam" OR "fenoprofen" OR "Fibrate therapy" OR "flubiprofen" OR "flucloxacillin" OR "fluindione" OR "Fluoroquinolones" OR "flupenthixol" OR "fluphenazine" OR "flurbiprofen" OR "flurithromycin" OR "fondaparinux sodium" OR "foscarnet" OR "furantoin" OR "furosemide" OR "fusidic acid" OR "FYX-051" OR "gabapentin" OR "gadodiamide" OR "Gadolinium" OR "gadopentetate dimeglumine" OR "Gastrointestinal Agent*" OR "gatifloxacin" OR "GBCA" OR "GCCA" OR "gefitinib" OR "gemcitabine" OR "gemfibrozil" OR "gentamicin" OR "germicide*" OR "Glucocorticoid*" OR "glycyrrhizinic acid" OR "Haloperidol" OR "Halothane" OR "Hematologic Agent*" OR "heparin" OR "hetastarch" OR "high insulin" OR "hydralazine" OR "hydrochlorothiazide" OR "hydroxychloroquine" OR "hydroxyethylstarch" OR "hydroxymethylglutaryl-CoA reductase inhibitor*" OR "hylan G-F 20" OR "Hypnotic

Agent*" OR "iatrogenic" OR "ibuprofen" OR "ifosfamide" OR "IGF-1" OR "iloprost" OR "imatinib" OR "imipramine" OR "imiquimod" OR "Immunosuppressive Agent*" OR "indinavir" OR "indomethacin" OR "infliximab" OR "Interferon*" OR "intravenous immunoglobulin*" OR "Iodine" OR "iodixanol" OR "iohexol" OR "ionizing radiation" OR "iopamidol" OR "ioxilan" OR "iron sucrose" OR "iron-induced" OR "iron-overload" OR "isocarboxazid" OR "isoniazid" OR "isoprenaline" OR "ketamine" OR "Ketoconazole" OR "ketoprofen" OR "ketorolac" OR "lansoprazole" OR "lapatinib" OR "leflunomide" OR "levetiracetam" OR "levofloxacin" OR "Lipid Regulating Agent*" OR "lithium" OR "lopinavir" OR "loratadine" OR "loxapine" OR "mannitol" OR "maprotiline" OR "mefanamic acid" OR "meropenem" OR "mesalamine" OR "mesalazine" OR "mesoridazine" OR "metamizole" OR "metformin" OR "methicillin" OR "methimazole" OR "methocarbamol" OR "methotrexate" OR "methotrimeprazine" OR "methoxyflurane" OR "methyldopa" OR "methylphenidate" OR "methysergide" OR "metolazone" OR "metoprolol" OR "Metronidazole" OR "midecamycin acetate" OR "Mineralcorticoid*" OR "minocycline" OR "mirtazapine" OR "mitomycin" OR "Mood Stabilizer*" OR "morphine" OR "Movement Stabilizer*" OR "moxifloxacin" OR "Muscle Relaxant*" OR "Mustard gas" OR "muzolimine" OR "nafcillin" OR "naphazoline hydrochloride" OR "naproxen" OR "N-arylsuccinimides" OR "Nasal decongestant*" OR "nelfinavir" OR "neomycin" OR "Niacin" OR "nifedipine" OR "niflumic acid" OR "nimesulide" OR "nitrendipine" OR "nitrofurantoin" OR "nitrogen mustard" OR "Nitroglycerin" OR "nitrosureas" OR "nomifensine" OR "Nonsteroidal anti-inflammatory drug*" OR "norepinephrine" OR "norfloxacin" OR "nortriptyline" OR "NSAID*" OR "NVP-BKM120" OR "ofloxacin" OR "olanzapine" OR "olmetin" OR "olsalazine" OR "omeprazole" OR "orlistat" OR "oxaliplatin" OR "oxymetazoline hydrochloride" OR "oxytetracycline" OR "ozurdex" OR "paliperidone" OR "pamidronate" OR "panitumumab" OR "pantoprazole" OR "papaverine" OR "paracetamol" OR "paroxetine" OR "pazopanib" OR "pefloxacin" OR "Penams" OR "penicillamine" OR "penicillin" OR "pentamidine" OR "pentazocine" OR "pericyazine" OR "perphenazine" OR "phenacetin" OR "phenindione" OR "phenobarbital" OR "phenylbutazone" OR "phenylephrine" OR "phenylpropanolamine" OR "phenytoin" OR "phosphatidylinositol-3-kinase inhibitor*" OR "physostigmine" OR "pimozide" OR "piperacillin" OR "piroxicam" OR "pirprofen" OR "platelet aggregation inhibitor*" OR "polymyxin B" OR "pranlukast" OR "prednisolone" OR "Primaquine" OR "probenecid" OR "procainamide" OR "prochlorperazine" OR "propoxyphene" OR "propylthiouracil" OR "protamine" OR "Proton pump inhibitor*" OR "prulifloxacin" OR "pseudoephedrine hydrochloride" OR "ptu-induced" OR "puromycin" OR "quetiapine" OR "quinacrine" OR "quinidine" OR "quinine" OR "quinolone" OR "rabeprazole" OR "radiofrequency-induced cosmetic volume reduction" OR "ranitidine" OR "rapamycin" OR "rhuepo-induced" OR "rifampicin" OR "rifampin" OR "risperidone" OR "Ritalin" OR "ritodrine hydrochloride" OR "ritonavir" OR "rofecoxib" OR "rosuvastatin" OR "scopolamine" OR "selegiline" OR "sibutramine" OR "simvastatin" OR "sodium barbital" OR "sodium valproate" OR "sorafenib" OR "spirapril" OR "spironolactone" OR "Statin*" OR "Steroid*" OR "Stimulant*" OR "streptomycin" OR "streptozocin" OR "streptozotocin" OR "Succinimide

derivative*" OR "sulfadiazine" OR "sulfamethoxazole" OR "sulfasalazine" OR "Sulfonamide*" OR "sulfonylureas" OR "sulfur mustard" OR "sulindac" OR "sulphinpyrazone" OR "sulpiride" OR "sunitinib" OR "superdrol" OR "tacrolimus" OR "Tamoxifen" OR "tazobactam" OR "telazol" OR "telithromycin" OR "tenofovir" OR "testosterone" OR "tetrabenazine" OR "Tetracycline*" OR "tetrahydrozoline hydrochloride" OR "tetrandrine" OR "thiazides" OR "thiopropazate" OR "thiopropazine" OR "Thioridazine" OR "thiothixene" OR "thrombolytic therapy" OR "ticlopidine" OR "tiletamine" OR "tiopronin" OR "tobramicin" OR "triamterene" OR "trichostatin A" OR "Tricyclics" OR "trimethadione" OR "trimethoprim" OR "trimipramine" OR "tripelennamine" OR "valdecocix" OR "Valproic Acid" OR "valpromide" OR "vancomycin" OR "venlafaxine" OR "verapamil" OR "verteporfin" OR "warfarin" OR "whole-body irradiation" OR "wortmannin" OR "yohimbine" OR "zoledronate" OR "zopiclone" OR "zotepine" OR "zuclopenthixol" OR "4-HNE" OR "7-Ketocholesterol" OR "aflatoxin" OR "Aipysurus laevis venom" OR "amorimia exotropa" OR "anti-mouse-GBM sera" OR "AOPP-modified rat serum albumin" OR "apoferritin" OR "bee sting*" OR "beta-conglycinin" OR "bovine serum albumin" OR "cantharidin" OR "ceramide" OR "citrinin" OR "concanavalin A" OR "connective tissue growth factor" OR "cow milk processing" OR "CTGF" OR "cylindrospermopsin" OR "deoxynivalenol" OR "D-fructofuranosyl" OR "Endotoxin*" OR "Exotoxin*" OR "fumonisins B1" OR "homopolysaccharide" OR "indican" OR "indoxyl sulfate" OR "levan" OR "lipopolysaccharide" OR "lipopolysaccharide-induced" OR "L-NAME" OR "L-NNA" OR "lps-induced" OR "monocrotaline" OR "monosodium urate crystal" OR "mycobacterial infection*" OR "Mycotoxin*" OR "nephritogenoside" OR "NG-nitro-L-arginine methyl ester" OR "Nitroarginine" OR "nivalenol" OR "Nω-nitro-L-arginine" OR "oak toxicosis" OR "ochratoxin A" OR "Ochratoxin*" OR "O-glycosylated IgA rheumatoid factor" OR "p-Cresyl sulfate" OR "PDGF-BB" OR "penicillic acid" OR "Platelet-derived growth factor-BB" OR "pufferfish tetrodotoxin" OR "quercus calliprinos" OR "scorpion sting*" OR "sea anemone Phyllodiscus semoni" OR "sea snake venom" OR "snake bite" OR "stinging insect venom" OR "tetrodotoxin" OR "Tityus serrulatus scorpion venom" OR "Tricothecene*" OR "U1-70-kDa small nuclear ribonucleoprotein/snRNP70" OR "viper snake venom" OR "vomitoxin" OR "wasp sting*" OR "yew" OR "*"Bacteri*" OR "*"Chia" OR "*"Ococcus" OR "*"Omonas" OR "adenine" OR "Aspergillus " OR "Bartonella henselae" OR "beta-hemolysin " OR "Brucella" OR "Burkholderia pseudomallei" OR "C. difficile toxin A" OR "C. difficile toxin B" OR "Campylobacter jejuni" OR "Campylobacter jejuni" OR "Candida albicans" OR "Candida tropicalis" OR "Candidemia" OR "Capillaria hepatica" OR "Chlamydia pneumoniae" OR "Chlamydia" OR "Chlamydophila" OR "Citrobacter rodentium" OR "Clostridium" OR "Corynebacterium diphtheriae" OR "diphtheria toxin" OR "Corynebacterium renale" OR "Dirofilaria immitis" OR "Echinococcus" OR "Ehrlichia canis" OR "Enterococcus faecalis" OR "Escherichia coli" OR "e. coli" OR "falciparum malaria" OR "malaria" OR "Fusarium graminearum" OR "Gemella haemolysans" OR "Haemophilus" OR "Helicobacter pylori" OR "Klebsiella pneumoniae" OR "leprosy" OR "Mycobacterium leprae" OR "Mycobacterium lepromatosis" OR "Leptospirosis" OR "leptospira" OR "marcescens" OR "Mycoplasma" OR

"Neisseria" OR "Nematode*" OR "Parasite*" OR "Penicillium aurantiogriseum" OR "Penicillium aurantiogriseum" OR "Plasmodium brasilianum" OR "Propionibacterium acnes" OR "Proteus mirabilis" OR "Pseudomonas aeruginosa" OR "Rickettsia" OR "Rochalimaea" OR "salmonella" OR "Schistosoma haematobium" OR "Schistosoma mansoni" OR "Serratia marcescens" OR "staphylococcal infection*" OR "Staphylococcus aureus" OR "Streptococcus agalactiae" OR "Streptococcus mutans" OR "Streptococcus pyogenes" OR "streptococcal pyrogenic exotoxin B" OR "Thy-1.1 monoclonal antibody" OR "Toxocara canis" OR "Treponema" OR "Trichinella spiralis" OR "Trypanosoma brucei" OR "Tyrophagus putrescentiae" OR "Vibrio" OR "Yersinia" OR "*OBACTER" OR "*nitrophenol*" OR "*benzene" OR "*ethane" OR "*phthalate" OR "*toluene" OR "1,1,1-trichloroethane" OR "12-O-tetradecanoylphorbol-13-acetate " OR "1-methyl-4-phenylpyridinium" OR "2,3,5-triiodobenzoic acid" OR "2,3,7,8-tetrachlorodibenzo-p-dioxin" OR "2-Amino-4-(ethylthio)butyric acid) " OR "acetaldehyde" OR "acrolein" OR "Air pollutant*" OR "air pollution" OR "aldrin" OR "alloxan" OR "alpha-Naphthylisothiocyanate" OR "aluminium" OR "aluminum" OR "ammonium perchlorate" OR "anti-trinitrophenol switch variant mAbs" OR "arsenic" OR "asbestos" OR "asphalt" OR "atrazine" OR "beryllium" OR "Bis(2-ethylhexyl) phthalate" OR "bismuth" OR "bitumen" OR "bromodichloromethane" OR "bromoform" OR "cadmium" OR "carbon tetrachloride" OR "cedar dust" OR "cerium oxide nanoparticles" OR "chloroform" OR "chlorpyrifos" OR "chromic acid " OR "chromium" OR "copper sulphate " OR "copper" OR "cotton pellets" OR "cyromazine" OR "decabrom*" OR "DEHP" OR "diazinon" OR "dibromochloromethane" OR "dichloro*" OR "diesel" OR "diethylene glycol" OR "dimethylnitrosamine " OR "dinitro*" OR "dinitrochlorobenzene" OR "dioxane" OR "dioxin " OR "domestic gas" OR "ethionine " OR "ethylene dibromide " OR "ethylene glycol" OR "fiberglass" OR "fibreglass" OR "fluoro-10-methyl-1-2-benzanthracene " OR "formaldehyde" OR "gasoline" OR "germanium" OR "glycerol" OR "grain dust" OR "halomethane* " OR "hcy-induced " OR "Heavy metal*" OR "Herbicide*" OR "hexabrom*" OR "hexachloro*" OR "hgcl2" OR "homocysteine" OR "house dust mite" OR "Hydrocarbons" OR "Insecticide*" OR "isopropyl alcohol" OR "jatropha curcas phorbol ester" OR "ketones" OR "malathion" OR "maleic vinyl ether anhydride " OR "Maneb" OR "melamine" OR "menadione sodium bisulfite" OR "mercuric chloride" OR "Mercury" OR "methyl tertiary-butyl ether " OR "methylene chloride" OR "methylglyoxal" OR "multiwalled carbon nanotube*" OR "N,N'-dimethyl-4,4'-bipyridinium dichloride" OR "N,N'-diacetylbenzidine " OR "N-3-5-dichlorophenyl-succinimide" OR "nanocopper" OR "n-methyl-n 1-nitro-n-nitroso guanidine " OR "nonylphenol" OR "octylphenol" OR "oxalates" OR "oxidant-induced" OR "p-Aminophenol" OR "parachloro*" OR "paraphenylenediamine" OR "paraquat " OR "Particulates" OR "pb" OR "pentachloro*" OR "pentachlorophenol" OR "perchloroethylene" OR "perfluor*" OR "perfluoroalkyl chemicals" OR "perfluorooctane sulfonate" OR "perfluorooctanoic acid" OR "Pesticide*" OR "Phenols" OR "phenylenediamine " OR "picric acid" OR "plant growth regulator* " OR "polybrom*" OR "polychlor*" OR "polychlorinated organic compound* " OR "polyfluor*" OR "polymethyl methacrylate " OR "potassium bichromate " OR "pristane" OR "p-xylene" OR "pyrinuron" OR

"pyruvaldehyde " OR "silane " OR "silica" OR "silicon dioxide" OR "single wall carbon nanotube*" OR "styrene" OR "tetrabrom*" OR "tetrachloro*" OR "tetrachloroethylene" OR "thioacetamide " OR "titanium dioxide nanoparticles" OR "toluene" OR "trichloro*" OR "trichloroethylene" OR "trimethylpentane" OR "trinitrobenzenesulfonic acid " OR "Trinitrophenol" OR "uranium" OR "uranyl nitrate" OR "vapor" OR "wood dust" OR "wood preservatives" OR "xylene" OR "zinc phosphide" OR "sediment-associated" OR "particle-associated" OR "traffic-related" OR "work-related" OR EMF) near/20 ("poison*" OR "ecotoxologic* effect*" OR "occupation*" OR pollut* OR "*virus*" OR environmental OR "induc*" OR "damage-caus*" OR "drug*-caus*" OR "infect*-caus*" OR "chemotherapy-caus*" OR "treat*-caus*" OR "anesthesia-caus*" OR "chemical*-caus*" OR "cytokine*-caus*" OR "surg*-caus*" OR "radiation-caus*" OR "steroid-caus*" OR "mechanically-caus*" OR "promot* progression" OR "caus* accumulation" OR "caus* * accumulation" OR "progression of" OR expos* OR contamina* OR chemicals OR abuse* OR induc* OR "long-term effect*" OR "inhibit* *protection" OR dysfunction* OR aggregation OR accumulation OR "disease link* to" OR "chemical initiator*" OR "stimulat* microglia" OR "activat* microglia" OR "increas* risk*" OR "increas* the risk*" OR "adverse event*" OR "adverse reaction*" OR "adverse * event*" OR "adverse * reaction" OR "adverse effect*" OR "adverse * effect*" OR hypersensitivity OR aggravat* OR exacerbat* OR detriment* OR "caus* *toxi*" OR "increas* *toxi*" OR "produc* *toxi*" OR "enhanc* *toxi*" OR "stimulat* *toxi*" OR "accelerat* *toxi*" OR "caus* degrad*" OR "increas* degrad*" OR "caus* damag*" OR "increas* damag*" OR "caus* * *toxi*" OR "increas* * *toxi*" OR "produc* * *toxi*" OR "enhanc* * *toxi*" OR "stimulat* * *toxi*" OR "accelerat* * *toxi*" OR "caus* * degrad*" OR "increas* * degrad*" OR "caus* * damag*" OR "increas* * damag*" OR "*toxi* caus* by" OR "*toxi* increas* by" OR "*toxi* produc* by" OR "*toxi* enhanc* by" OR "*toxi* stimulat* by" OR "*toxi* accelerat* by" OR "damag* caus* by" OR "*damag* increas* by" OR deleterious OR deteriorat* OR trigger* OR worsen* OR harm* OR hazard* OR "side-effect*" OR dangerous OR destructive OR injurious OR unsafe OR "increas* amyloid-beta" OR "increas* beta-amyloid" OR "increas* Abeta" OR "increas* senile plaque*" OR "increas* tau aggregat*" OR "increas* T-tau" OR "increas* P-tau" OR "increas*total tau" OR "increas* phospho-tau" OR "increas* tau protein*" OR "increas* hyperphosphorylated tau" OR "increas* neurofibrillary tangle*" OR "enhanc* amyloid-beta" OR "enhanc* beta-amyloid" OR "enhanc* Abeta" OR "enhanc* senile plaque*" OR "enhanc* tau aggregat*" OR "enhanc* T-tau" OR "enhanc* P-tau" OR "enhanc*total tau" OR "enhanc* phospho-tau" OR "enhanc* tau protein*" OR "enhanc* hyperphosphorylated tau" OR "enhanc* neurofibrillary tangle*" OR "stimulat* amyloid-beta" OR "stimulat* beta-amyloid" OR "stimulat* Abeta" OR "stimulat* senile plaque*" OR "stimulat* tau aggregat*" OR "stimulat* T-tau" OR "stimulat* P-tau" OR "stimulat*total tau" OR "stimulat* phospho-tau" OR "stimulat* tau protein*" OR "stimulat* hyperphosphorylated tau" OR "stimulat* neurofibrillary tangle*" OR "elevat* amyloid-beta" OR "elevat* beta-amyloid" OR "elevat* Abeta" OR "elevat* senile plaque*" OR "elevat* tau aggregat*" OR "elevat* T-tau" OR "elevat* P-tau" OR "elevat*total tau" OR "elevat* phospho-tau" OR "elevat* tau protein*" OR "elevat* hyperphosphorylated tau"

OR "elevat* neurofibrillary tangle*" OR "induc* amyloid-beta" OR "induc* beta-amyloid" OR "induc* Abeta" OR "induc* senile plaque*" OR "induc* tau aggregat*" OR "induc* T-tau" OR "induc* P-tau" OR "induc*total tau" OR "induc* phospho-tau" OR "induc* tau protein*" OR "induc* hyperphosphorylated tau" OR "induc* neurofibrillary tangle*" OR "produc* amyloid-beta" OR "produc* beta-amyloid" OR "produc* Abeta" OR "produc* senile plaque*" OR "produc* tau aggregat*" OR "produc* T-tau" OR "produc* P-tau" OR "produc*total tau" OR "produc* phospho-tau" OR "produc* tau protein*" OR "produc* hyperphosphorylated tau" OR "produc* neurofibrillary tangle*" OR "accelerat* amyloid-beta" OR "accelerat* beta-amyloid" OR "accelerat* Abeta" OR "accelerat* senile plaque*" OR "accelerat* tau aggregat*" OR "accelerat* T-tau" OR "accelerat* P-tau" OR "accelerat*total tau" OR "accelerat* phospho-tau" OR "accelerat* tau protein*" OR "accelerat* hyperphosphorylated tau" OR "accelerat* neurofibrillary tangle*" OR "amyloid-beta induc* by" OR "beta-amyloid induc* by" OR "Abeta induc* by" OR "senile plaque* induc* by" OR "tau aggregat* induc* by" OR "T-tau induc* by" OR "P-tau induc* by" OR "total tau induc* by" OR "phospho-tau induc* by" OR "tau protein* induc* by" OR "hyperphosphorylated tau induc* by" OR "neurofibrillary tangle* induc* by" OR "amyloid-beta produc* by" OR "beta-amyloid produc* by" OR "Abeta produc* by" OR "senile plaque* produc* by" OR "tau aggregat* produc* by" OR "T-tau produc* by" OR "P-tau produc* by" OR "total tau produc* by" OR "phospho-tau produc* by" OR "tau protein* produc* by" OR "hyperphosphorylated tau produc* by" OR "neurofibrillary tangle* produc* by" OR "caus* Alzheimer*" OR "caus* dementia" OR "caus* cognitive decline" OR "caus* brain* decline" OR "caus* functional decline" OR "caus* memory decline" OR "caus* cognitive deficit*" OR "caus* language deficit*" OR "caus* memory deficit*" OR "caus* plasticity deficit*" OR "caus* behavioral deficit*" OR "caus* saccade deficit*" OR "caus* learning deficit*" OR "caus* neuropsychological deficit*" OR "caus* cognitive impair*" OR "caus* vascular impair*" OR "caus* memory impair*" OR "caus* neurogenesis impair*" OR "caus* neuropsychological impair*" OR "caus* mind impair*" OR "caus* functional impair*" OR "caus* learning impair*" OR "caus* executive function impair*" OR "caus* cognitive loss*" OR "caus* neuronal loss*" OR "caus* synaptic loss*" OR "caus* memory loss*" OR "caus* loss of memory" OR "caus* hearing loss*" OR "caus* volume loss*" OR "caus* Impair* face recognition" OR "caus* Impair* reasoning" OR "caus* Impair* judgment" OR "caus* Impair* problem solving" OR "caus* inflamm*" OR "caus* oxidative stress" OR "caus* neuropathology" OR "caus* diabetes" OR "caus* hypertension" OR "caus* high cholesterol" OR "caus* hypercholesterolemia" OR "caus* obesity" OR "caus* metabolic syndrome" OR "induc* Alzheimer*" OR "induc* dementia" OR "induc* cognitive decline" OR "induc* brain* decline" OR "induc* functional decline" OR "induc* memory decline" OR "induc* cognitive deficit*" OR "induc* language deficit*" OR "induc* memory deficit*" OR "induc* plasticity deficit*" OR "induc* behavioral deficit*" OR "induc* saccade deficit*" OR "induc* learning deficit*" OR "induc* neuropsychological deficit*" OR "induc* cognitive impair*" OR "induc* vascular impair*" OR "induc* memory impair*" OR "induc* neurogenesis impair*" OR "induc* neuropsychological impair*" OR "induc* mind impair*" OR "induc* functional impair*" OR "induc* learning

impair*" OR "induc* executive function impair*" OR "induc* cognitive loss*" OR "induc* neuronal loss*" OR "induc* synaptic loss*" OR "induc* memory loss*" OR "induc* loss of memory" OR "induc* hearing loss*" OR "induc* volume loss*" OR "induc* Impair* face recognition" OR "induc* Impair* reasoning" OR "induc* Impair* judgment" OR "induc* Impair* problem solving" OR "induc* inflamm*" OR "induc* oxidative stress" OR "induc* neuropathology" OR "induc* diabetes" OR "induc* hypertension" OR "induc* high cholesterol" OR "induc* hypercholesterolemia" OR "induc* obesity" OR "induc* metabolic syndrome" OR "produc* Alzheimer*" OR "produc* dementia" OR "produc* cognitive decline" OR "produc* brain* decline" OR "produc* functional decline" OR "produc* memory decline" OR "produc* cognitive deficit*" OR "produc* language deficit*" OR "produc* memory deficit*" OR "produc* plasticity deficit*" OR "produc* behavioral deficit*" OR "produc* saccade deficit*" OR "produc* learning deficit*" OR "produc* neuropsychological deficit*" OR "produc* cognitive impair*" OR "produc* vascular impair*" OR "produc* memory impair*" OR "produc* neurogenesis impair*" OR "produc* neuropsychological impair*" OR "produc* mind impair*" OR "produc* functional impair*" OR "produc* learning impair*" OR "produc* executive function impair*" OR "produc* cognitive loss*" OR "produc* neuronal loss*" OR "produc* synaptic loss*" OR "produc* memory loss*" OR "produc* loss of memory" OR "produc* hearing loss*" OR "produc* volume loss*" OR "produc* Impair* face recognition" OR "produc* Impair* reasoning" OR "produc* Impair* judgment" OR "produc* Impair* problem solving" OR "produc* inflamm*" OR "produc* oxidative stress" OR "produc* neuropathology" OR "produc* diabetes" OR "produc* hypertension" OR "produc* high cholesterol" OR "produc* hypercholesterolemia" OR "produc* obesity" OR "produc* metabolic syndrome" OR "increas* Alzheimer*" OR "increas* dementia" OR "increas* cognitive decline" OR "increas* brain* decline" OR "increas* functional decline" OR "increas* memory decline" OR "increas* cognitive deficit*" OR "increas* language deficit*" OR "increas* memory deficit*" OR "increas* plasticity deficit*" OR "increas* behavioral deficit*" OR "increas* saccade deficit*" OR "increas* learning deficit*" OR "increas* neuropsychological deficit*" OR "increas* cognitive impair*" OR "increas* vascular impair*" OR "increas* memory impair*" OR "increas* neurogenesis impair*" OR "increas* neuropsychological impair*" OR "increas* mind impair*" OR "increas* functional impair*" OR "increas* learning impair*" OR "increas* executive function impair*" OR "increas* cognitive loss*" OR "increas* neuronal loss*" OR "increas* synaptic loss*" OR "increas* memory loss*" OR "increas* loss of memory" OR "increas* hearing loss*" OR "increas* volume loss*" OR "increas* Impair* face recognition" OR "increas* Impair* reasoning" OR "increas* Impair* judgment" OR "increas* Impair* problem solving" OR "increas* inflamm*" OR "increas* oxidative stress" OR "increas* neuropathology" OR "increas* diabetes" OR "increas* hypertension" OR "increas* high cholesterol" OR "increas* hypercholesterolemia" OR "increas* obesity" OR "increas* metabolic syndrome" OR "exacerbat* Alzheimer*" OR "exacerbat* dementia" OR "exacerbat* cognitive decline" OR "exacerbat* brain* decline" OR "exacerbat* functional decline" OR "exacerbat* memory decline" OR "exacerbat* cognitive deficit*" OR "exacerbat* language deficit*" OR

"exacerbat* memory deficit*" OR "exacerbat* plasticity deficit*" OR "exacerbat* behavioral deficit*" OR "exacerbat* saccade deficit*" OR "exacerbat* learning deficit*" OR "exacerbat* neuropsychological deficit*" OR "exacerbat* cognitive impair*" OR "exacerbat* vascular impair*" OR "exacerbat* memory impair*" OR "exacerbat* neurogenesis impair*" OR "exacerbat* neuropsychological impair*" OR "exacerbat* mind impair*" OR "exacerbat* functional impair*" OR "exacerbat* learning impair*" OR "exacerbat* executive function impair*" OR "exacerbat* cognitive loss*" OR "exacerbat* neuronal loss*" OR "exacerbat* synaptic loss*" OR "exacerbat* memory loss*" OR "exacerbat* loss of memory" OR "exacerbat* hearing loss*" OR "exacerbat* volume loss*" OR "exacerbat* Impair* face recognition" OR "exacerbat* Impair* reasoning" OR "exacerbat* Impair* judgment" OR "exacerbat* Impair* problem solving" OR "exacerbat* inflamm*" OR "exacerbat* oxidative stress" OR "exacerbat* neuropathology" OR "exacerbat* diabetes" OR "exacerbat* hypertension" OR "exacerbat* high cholesterol" OR "exacerbat* hypercholesterolemia" OR "exacerbat* obesity" OR "exacerbat* metabolic syndrome" OR "trigger* Alzheimer*" OR "trigger* dementia" OR "trigger* cognitive decline" OR "trigger* brain* decline" OR "trigger* functional decline" OR "trigger* memory decline" OR "trigger* cognitive deficit*" OR "trigger* language deficit*" OR "trigger* memory deficit*" OR "trigger* plasticity deficit*" OR "trigger* behavioral deficit*" OR "trigger* saccade deficit*" OR "trigger* learning deficit*" OR "trigger* neuropsychological deficit*" OR "trigger* cognitive impair*" OR "trigger* vascular impair*" OR "trigger* memory impair*" OR "trigger* neurogenesis impair*" OR "trigger* neuropsychological impair*" OR "trigger* mind impair*" OR "trigger* functional impair*" OR "trigger* learning impair*" OR "trigger* executive function impair*" OR "trigger* cognitive loss*" OR "trigger* neuronal loss*" OR "trigger* synaptic loss*" OR "trigger* memory loss*" OR "trigger* loss of memory" OR "trigger* hearing loss*" OR "trigger* volume loss*" OR "trigger* Impair* face recognition" OR "trigger* Impair* reasoning" OR "trigger* Impair* judgment" OR "trigger* Impair* problem solving" OR "trigger* inflamm*" OR "trigger* oxidative stress" OR "trigger* neuropathology" OR "trigger* diabetes" OR "trigger* hypertension" OR "trigger* high cholesterol" OR "trigger* hypercholesterolemia" OR "trigger* obesity" OR "trigger* metabolic syndrome" OR "accelerat* Alzheimer*" OR "accelerat* dementia" OR "accelerat* cognitive decline" OR "accelerat* brain* decline" OR "accelerat* functional decline" OR "accelerat* memory decline" OR "accelerat* cognitive deficit*" OR "accelerat* language deficit*" OR "accelerat* memory deficit*" OR "accelerat* plasticity deficit*" OR "accelerat* behavioral deficit*" OR "accelerat* saccade deficit*" OR "accelerat* learning deficit*" OR "accelerat* neuropsychological deficit*" OR "accelerat* cognitive impair*" OR "accelerat* vascular impair*" OR "accelerat* memory impair*" OR "accelerat* neurogenesis impair*" OR "accelerat* neuropsychological impair*" OR "accelerat* mind impair*" OR "accelerat* functional impair*" OR "accelerat* learning impair*" OR "accelerat* executive function impair*" OR "accelerat* cognitive loss*" OR "accelerat* neuronal loss*" OR "accelerat* synaptic loss*" OR "accelerat* memory loss*" OR "accelerat* loss of memory" OR "accelerat* hearing loss*" OR "accelerat* volume loss*" OR "accelerat* Impair* face

recognition" OR "accelerat* Impair* reasoning" OR "accelerat* Impair* judgment" OR "accelerat* Impair* problem solving" OR "accelerat* inflamm*" OR "accelerat* oxidative stress" OR "accelerat* neuropathology" OR "accelerat* diabetes" OR "accelerat* hypertension" OR "accelerat* high cholesterol" OR "accelerat* hypercholesterolemia" OR "accelerat* obesity" OR "accelerat* metabolic syndrome" OR "Alzheimer* * caused by" OR "dementia caused by" OR "cognitive decline caused by" OR "brain* decline caused by" OR "functional decline caused by" OR "memory decline caused by" OR "cognitive deficit* caused by" OR "language deficit* caused by" OR "memory deficit* caused by" OR "plasticity deficit* caused by" OR "behavioral deficit* caused by" OR "saccade deficit* caused by" OR "learning deficit* caused by" OR "neuropsychological deficit* caused by" OR "cognitive impair* caused by" OR "vascular impair* caused by" OR "memory impair* caused by" OR "neurogenesis impair* caused by" OR "neuropsychological impair* caused by" OR "mind impair* caused by" OR "functional impair* caused by" OR "learning impair* caused by" OR "executive function impair* caused by" OR "cognitive loss* caused by" OR "neuronal loss* caused by" OR "synaptic loss* caused by" OR "memory loss* caused by" OR "loss of memory caused by" OR "hearing loss* caused by" OR "volume loss* caused by" OR "Impair* face recognition caused by" OR "Impair* reasoning caused by" OR "Impair* judgment caused by" OR "Impair* problem solving caused by" OR "inflamm* caused by" OR "oxidative stress caused by" OR "neuropathology caused by" OR "diabetes caused by" OR "hypertension caused by" OR "high cholesterol caused by" OR "hypercholesterolemia caused by" OR "obesity caused by" OR "metabolic syndrome caused by" OR "Alzheimer* * induced by" OR "dementia induced by" OR "cognitive decline induced by" OR "brain* decline induced by" OR "functional decline induced by" OR "memory decline induced by" OR "cognitive deficit* induced by" OR "language deficit* induced by" OR "memory deficit* induced by" OR "plasticity deficit* induced by" OR "behavioral deficit* induced by" OR "saccade deficit* induced by" OR "learning deficit* induced by" OR "neuropsychological deficit* induced by" OR "cognitive impair* induced by" OR "vascular impair* induced by" OR "memory impair* induced by" OR "neurogenesis impair* induced by" OR "neuropsychological impair* induced by" OR "mind impair* induced by" OR "functional impair* induced by" OR "learning impair* induced by" OR "executive function impair* induced by" OR "cognitive loss* induced by" OR "neuronal loss* induced by" OR "synaptic loss* induced by" OR "memory loss* induced by" OR "loss of memory induced by" OR "hearing loss* induced by" OR "volume loss* induced by" OR "Impair* face recognition induced by" OR "Impair* reasoning induced by" OR "Impair* judgment induced by" OR "Impair* problem solving induced by" OR "inflamm* induced by" OR "oxidative stress induced by" OR "neuropathology induced by" OR "diabetes induced by" OR "hypertension induced by" OR "high cholesterol induced by" OR "hypercholesterolemia induced by" OR "obesity induced by" OR "metabolic syndrome induced by")

OR

IIB. LIFESTYLE-SPECIFIC COMPONENT

IIB1. LIFESTYLE-SPECIFIC COMPONENT - TOPIC

("2,3-Pentanedione" OR "acidogenic diet*" OR "acrylamide" OR "activity restriction" OR "acute stress" OR "additives" OR "advanced glycation end product*" OR "Advanced glycosylation end product*" OR "adverse food" OR "alcohol abuse*" OR "alcohol consum*" OR "alcohol intake" OR "alcoholic*" OR "alcohol-induc*" OR "alcoholism" OR "Amanita phalloides" OR "amphetamine*" OR "anabolic steroid*" OR "areca nut chewing" OR arnica OR "aspartame" OR "betel nut chewing" OR "binge eating" OR "biomass fuel for cooking" OR "bitter orange" OR "caffeine" OR "childhood adversity" OR "chinese herb*" OR "chlorogenic acid" OR "cholesterol-induced" OR "cigarette*" OR "cocaine" OR "cola" OR "competitive strength exercise training" OR cortinarius OR "dehydration" OR "depression-caus*" OR "depression-induc*" OR dextrose OR diet* near/1 effect* OR diet*-caus* OR diet*-induc* OR dietborne OR "djenkol beans" OR "early-life abuse" OR "eating fast" OR "effort-reward imbalance" OR "emotional abuse" OR ephedra OR "exercise-caus*" OR "folic acid-induc*" OR "food additive" OR "food poisoning" OR "free-fatty-acid-induced" OR "fructose" OR "germ-free" OR "glucose-induc*" OR "glucose-peaks-short-term" OR "gluten" OR glycerin OR guarana OR "heat stroke" OR "heroin" OR "high home temperature" OR "high insulin" OR "high meat" OR "high selenium diet" OR "high-fat-diet*" OR "high-glucose-induc*" OR "High-glycemic-load diet*" OR "high-phosphate" OR "high-phosphorous-diet*" OR "high-protein-diet*" OR "high-protein-induc*" OR "high-protein-intake*" OR "high-salt-diet*" OR "high-salt-intake*" OR "high-saturated-fat diet*" OR "high-sodium-diet*" OR "high-sodium-intake*" OR "high-soybean oil" OR "high-sucrose-diet*" OR "high-sugar-diet*" OR "high-tryptophan-diet*" OR "Highway proximity" OR hypothermia OR "hypoxia-induced" OR "insufficient sleep" OR "job strain" OR "laxative abuse" OR "low fiber diet*" OR "low fiber intake" OR "low legumes intake" OR "low manganese intake" OR "low melatonin" OR "low potassium intake" OR "low pulses intake" OR "low-Vitamin D intake" OR "meat" OR "milk processing" OR "morphine" OR mothball* OR "mushrooms" OR noise OR "overfeeding" OR palmitate OR "palmitic acid" OR "parental hypertension" OR "parental occupation*" OR "parental sucrose" OR "persistent organic pollutants" OR "phosphorus additive*" OR "physical inactivity" OR "prenatal hypoxia" OR "preserved food*" OR "preserved meat*" OR "prolonged sitting" OR "psychogenic polydipsia" OR "psychological trauma" OR "refined carbohydrate*" OR "refined cereal*" OR "refined grain*" OR "refined flour" OR "residential remoteness" OR "salt-induced" OR "saturated fat*" OR "sedentary" OR "short sleep duration" OR "sitting time" OR "sleep deprivation" OR "smoking" OR "social environment" OR "sodium additive*" OR "soft drink*" OR "soybean oil heated repeatedly" OR "soy-rich diet" OR "star fruit" OR "sucralose" OR "sunflower oil" OR "tobacco" OR "trans-fat*" OR "water-borne" OR "zinc-deficient diet" OR low near/2 sunlight OR waterborne)

OR

IIB2. LIFESTYLE-SPECIFIC COMPONENT - TITLE

(diet* near/1 effect* OR "adverse food" OR "additives" OR exercise-induc* OR diet*-induc* OR exercise-caus* OR diet*-caus* OR waterborne OR "water-borne" OR dietborne OR "acidogenic diet*" OR "activity restriction" OR "advanced glycation end product*" OR "Advanced glycosylation end product*" OR "alcohol abuse*" OR "alcohol consum*" OR "alcohol intake" OR "alcoholic*" OR "alcohol-induc*" OR "alcoholism" OR "amphetamine*" OR "anabolic steroid*" OR "areca nut chewing" OR "betel nut chewing" OR "binge eating" OR "caffeine" OR "childhood adversity" OR "chinese herb*" OR "cholesterol-induced" OR "cigarette*" OR "cocaine" OR "cola" OR "milk processing" OR "dehydration" OR "depression-induc*" OR "depression-caus*" OR "effort-reward imbalance" OR "emotional abuse" OR "Exercise-induced" OR "folic acid-induc*" OR "free-fatty-acid-induced" OR "fructose" OR "germ-free" OR "glucose-induc*" OR "glucose-peaks-short-term" OR "gluten" OR "heat stroke" OR "heroin" OR "high-fat-diet*" OR "high-glucose-induc*" OR "High-glycemic-load diet*" OR "high home temperature" OR "high insulin" OR "high meat" OR "high-phosphate" OR "high-phosphorous-diet*" OR "high-protein-diet*" OR "high-protein-intake*" OR "high-protein-induc*" OR "high-salt-diet*" OR "high-salt-intake*" OR "high-saturated-fat diet*" OR "high selenium diet" OR "high-sodium-intake*" OR "high-sodium-diet*" OR "high-soybean oil" OR "high-sucrose-diet*" OR "high-tryptophan-diet*" OR "job strain" OR "laxative abuse" OR "psychological trauma" OR "competitive strength exercise training" OR "low fiber diet*" OR "low fiber intake" OR "low legumes intake" OR "low manganese intake" OR "low melatonin" OR "low potassium intake" OR "low pulses intake" OR "low-Vitamin D intake" OR "meat" OR "morphine" OR "mothball abuse" OR "mushrooms" OR "parental sucrose" OR "phosphorus additive*" OR "physical inactivity" OR "refined cereal*" OR "residential remoteness" OR "salt-induced" OR "sedentary" OR "short sleep duration" OR "sitting time" OR "sleep deprivation" OR "smoking" OR "social environment" OR "sodium additive*" OR "soybean oil heated repeatedly" OR "soy-rich diet" OR "star fruit" OR "stress-induced" OR "sunflower oil" OR "tobacco" OR "overfeeding" OR "zinc-deficient diet" OR "TRANS-FAT*" OR "2,3-Pentanedione" OR "acute stress" OR "biomass fuel for cooking" OR "early-life abuse" OR "Highway proximity" OR "parental occupation*" OR "Sugar" OR "Refined Carbohydrate*" OR "Acrylamide" OR "Aspartame" OR "Sucralose" OR "Preserved Meat*" OR "Refined Flour" OR "Saturated Fat*" OR "Soft Drink*" OR "Preserved Food*" OR "Insufficient Sleep")

OR

III. MESH FIELD TERMS

RUN 3A1 AND 3B1 AS ONE QUERY

IIIA. MESH QUALIFIERS - MESH HEADING

IIIA1. NON-LIFESTYLE-SPECIFIC COMPONENT

(/"chemically induced" OR /toxicity OR /poisoning)

OR

IIIB. MESH GENERIC TERMS - MESH HEADING NO EXPLODE

IIIB1. NON-LIFESTYLE-SPECIFIC COMPONENT - MESH HEADING NO EXPLODE

Abnormalities, Drug-Induced OR Aids Related Opportunistic Infections OR Air Pollutants, Occupational OR Bacterial Infections OR Congenital Abnormalities OR Congenital Disorders Of Glycosylation OR Dermatitis, Occupational OR Drug Eruptions OR Drug Hypersensitivity OR Drug Toxicity OR Environmental Exposure OR Environmental Illness OR Environmental Monitoring OR Environmental Pollutants OR Fossil Fuels OR Hazardous Substances OR Herbicides OR Household Products OR HTLV I Infections OR Iatrogenic Disease OR Inhalation Exposure OR Insecticides OR Marine Toxins OR Maternal Exposure OR Mutagens OR Mycotoxins OR Neurotoxins OR Nonprescription Drugs OR Occupational Diseases OR Occupational Exposure OR Occupations OR Opportunistic Infections OR Organic Chemicals OR Paternal Exposure OR Pesticides OR Plant Poisoning OR Plants, Toxic OR Poisoning OR Poisons OR Prenatal Exposure Delayed Effects OR Simplexvirus OR Soil Pollutants OR Solvents OR Streptococcal Infections OR Vehicle Emissions OR Water Pollutants, Chemical OR Welding

OR

IIIB2. LIFESTYLE-SPECIFIC COMPONENT - MESH HEADING NO EXPLODE

Alcohol Drinking OR Alcoholic Intoxication OR Alcoholism OR Alcohol-Related Disorders OR Amphetamine-Related Disorders OR Amphetamines OR Appetite Depressants OR Carbonated Beverages OR Cocaine OR Cocaine-Related Disorders OR Cola OR Contraceptive Agents OR Contraceptives, Oral OR Cooking And Eating Utensils OR Cosmetics OR Diet, High-Fat OR Fast Foods OR Food Additives OR Food Contamination OR Food Habits OR Food Preservatives OR Fructose OR Glycemic Index OR Glycosylation End Products, Advanced/adverse effects OR Hair Dyes OR Hallucinogens OR Hazardous Substances OR Heat Stroke OR Heroin OR Heroin Dependence OR Laxatives OR Leisure Activities OR Marijuana Abuse OR Methadone OR Mushroom Poisoning OR Narcotics OR Nonprescription Drugs OR Plant Poisoning OR Plants, Toxic OR Prenatal Exposure Delayed Effects OR Smoking OR Sodium Chloride, Dietary OR Sodium, Dietary OR Street Drugs OR Substance-Related Disorders OR Sweetening Agents OR Tattooing OR Tobacco OR Tobacco Smoke Pollution OR Tobacco Use Disorder OR Substance Withdrawal Syndrome OR Obesity OR Meat OR Foodborne Diseases OR Food Handling OR Dietary Fats OR Dietary Carbohydrates OR Plants Genetically Modified OR Sucrose OR Behavior Addictive OR Meat Products OR Poverty OR Maternal Exposure OR Flavoring Agents OR Diet High Fat OR Coffee OR Dairy Products OR Nutrition Disorders OR Prenatal Care OR Child Abuse OR Television OR Hygiene OR Doping In Sports OR Maternal Behavior OR

Dietary Sucrose OR Thiamine Deficiency OR Folic Acid Deficiency OR Vitamin D Deficiency OR Cholesterol Dietary OR Lifestyle OR Sedentary Lifestyle OR Eating Disorders OR Sleep Disorders OR Paternal Exposure

OR

MESH TERMS DRUGS

IIIB3a. TITLE

("poison*" OR "ecotoxologic* effect*" OR "occupation*" OR pollut* OR "*virus*" OR environmental OR "induc*" OR "damage-caus*" OR "drug*-caus*" OR "infect*-caus*" OR "chemotherapy-caus*" OR "treat*-caus*" OR "anesthesia-caus*" OR "chemical*-caus*" OR "cytokine*-caus*" OR "surg*-caus*" OR "radiation-caus*" OR "steroid-caus*" OR "mechanically-caus*" OR "promot* progression" OR "caus* accumulation" OR "caus* * accumulation" OR "progression of" OR expos* OR contamina* OR abuse* OR induc* OR "long-term effect*" OR "inhibit* *protection" OR dysfunction* OR aggregation OR accumulation OR "disease link* to" OR "chemical initiator*" OR "stimulat* microglia" OR "activat* microglia" OR "increas* risk*" OR "increas* the risk*" OR "adverse event*" OR "adverse reaction*" OR "adverse * event*" OR "adverse * reaction" OR "adverse effect*" OR "adverse * effect*" OR hypersensitivity OR aggravat* OR exacerbat* OR detriment* OR "caus* *toxi*" OR "increas* *toxi" OR "produc* *toxi*" OR "enhanc* *toxi*" OR "stimulat* *toxi*" OR "accelerat* *toxi*" OR "caus* degrad*" OR "increas* degrad*" OR "caus* damag*" OR "increas* damag*" OR "caus* * *toxi*" OR "increas* * *toxi" OR "produc* * *toxi*" OR "enhanc* * *toxi*" OR "stimulat* * *toxi*" OR "accelerat* * *toxi*" OR "caus* * degrad*" OR "increas* * degrad*" OR "caus* * damag*" OR "increas* * damag*" OR "*toxi* caus* by" OR "*toxi* increas* by" OR "*toxi* produc* by" OR "*toxi* enhanc* by" OR "*toxi* stimulat* by" OR "*toxi* accelerat* by" OR "damag* caus* by" OR "*damag* increas* by" OR deleterious OR deteriorat* OR trigger* OR worsen* OR harm* OR hazard* OR "side-effect*" OR dangerous OR destructive OR injurious OR unsafe)

AND

MESH HEADING NO EXPLODE

Antineoplastic Agents OR Anticoagulants OR Antineoplastic Combined Chemotherapy Protocols OR Anti-Inflammatory Agents, Non-Steroidal OR Hypoglycemic Agents OR Anti-Bacterial Agents OR Antipsychotic Agents OR Immunosuppressive Agents OR Anticonvulsants OR Platelet Aggregation Inhibitors OR Glucocorticoids OR Analgesics, Opioid OR Drug-Related Side Effects and Adverse Reactions OR Warfarin OR Analgesics OR Doxorubicin OR Cisplatin OR Protein Kinase Inhibitors OR Fibrinolytic Agents OR Fluorouracil OR Antirheumatic Agents OR Antihypertensive Agents OR Pyridines OR Cyclophosphamide OR Bone Density Conservation Agents OR Antiviral Agents OR Bleomycin OR Antidepressive

Agents OR Serotonin Uptake Inhibitors OR Thiophenes OR Antibiotics, Antineoplastic OR Angiogenesis Inhibitors OR Drug Hypersensitivity OR Proton Pump Inhibitors OR Deoxycytidine OR Ticlopidine OR Organoplatinum Compounds OR Anti-Arrhythmia Agents OR Angiotensin-Converting Enzyme Inhibitors OR Anti-HIV Agents OR Paclitaxel OR Chemotherapy, Adjuvant OR Acetaminophen OR Quinazolines OR Taxoids OR Vasodilator Agents OR Pilocarpine OR Triazoles OR Benzodiazepines OR Anti-Infective Agents OR Estrogens OR Thiazolidinediones OR Antineoplastic Agents, Hormonal OR Antineoplastic Agents, Phytogenic OR Cyclooxygenase 2 Inhibitors OR Anti-Ulcer Agents OR Cyclosporine OR Vasoconstrictor Agents OR Anthracyclines OR Anticarcinogenic Agents OR Convulsants OR Calcium Channel Blockers OR Cardiotonic Agents OR Dermatologic Agents OR Isoproterenol OR Antifungal Agents OR Ribavirin OR Antiparkinson Agents OR Clozapine OR Carboplatin OR Tamoxifen OR Antiretroviral Therapy, Highly Active OR Vincristine OR Cholinesterase Inhibitors OR Antidepressive Agents, Second-Generation OR Antitubercular Agents OR Hypolipidemic Agents OR Antineoplastic Agents, Alkylating OR Gastrointestinal Agents OR Aromatase Inhibitors OR Antithyroid Agents OR Organophosphonates OR Cyclooxygenase Inhibitors OR Antidepressive Agents, Tricyclic OR Antimanic Agents OR Phosphodiesterase 5 Inhibitors OR Dipeptidyl-Peptidase IV Inhibitors OR Anti-Retroviral Agents OR Methyl Ethers OR Chelating Agents OR Anticholesteremic Agents OR Contraceptive Agents, Female OR Anti-Asthmatic Agents OR Dopamine Uptake Inhibitors OR HIV Protease Inhibitors OR N-Methyl-3,4-methylenedioxymphetamine OR Mycophenolic Acid OR Bronchodilator Agents OR Hydroxychloroquine OR Neurotransmitter Agents OR Anti-Obesity Agents OR Anabolic Agents OR Anesthetics OR Cardiovascular Agents OR Histone Deacetylase Inhibitors OR Alkylating Agents OR Chloroquine OR Antifibrinolytic Agents OR Benzoxazines OR Protease Inhibitors OR Fertility Agents, Female OR Dopamine Agents OR Anti-Infective Agents, Local OR Reverse Transcriptase Inhibitors OR Neuromuscular Agents OR Anti-Allergic Agents OR Monoamine Oxidase Inhibitors OR Neuromuscular Nondepolarizing Agents OR Nootropic Agents OR Photosensitizing Agents OR 5-alpha Reductase Inhibitors OR Sweetening Agents OR Sensory System Agents OR Adrenergic Agents OR Adrenergic Uptake Inhibitors OR Indicators and Reagents OR Antitussive Agents OR Surface-Active Agents OR Antimutagenic Agents

OR

IIIB3b. TOPIC

("increas* amyloid-beta" OR "increas* beta-amyloid" OR "increas* Abeta" OR "increas* senile plaque*" OR "increas* tau aggregat*" OR "increas* T-tau" OR "increas* P-tau" OR "increas*total tau" OR "increas* phospho-tau" OR "increas* tau protein*" OR "increas* hyperphosphorylated tau" OR "increas* neurofibrillary tangle*" OR "enhanc* amyloid-beta" OR "enhanc* beta-amyloid" OR "enhanc* Abeta" OR "enhanc* senile plaque*" OR "enhanc* tau aggregat*" OR "enhanc* T-tau" OR "enhanc* P-tau" OR "enhanc*total tau" OR "enhanc*

phospho-tau" OR "enhanc* tau protein*" OR "enhanc* hyperphosphorylated tau" OR "enhanc* neurofibrillary tangle*" OR "stimulat* amyloid-beta" OR "stimulat* beta-amyloid" OR "stimulat* Abeta" OR "stimulat* senile plaque*" OR "stimulat* tau aggregat*" OR "stimulat* T-tau" OR "stimulat* P-tau" OR "stimulat*total tau" OR "stimulat* phospho-tau" OR "stimulat* tau protein*" OR "stimulat* hyperphosphorylated tau" OR "stimulat* neurofibrillary tangle*" OR "elevat* amyloid-beta" OR "elevat* beta-amyloid" OR "elevat* Abeta" OR "elevat* senile plaque*" OR "elevat* tau aggregat*" OR "elevat* T-tau" OR "elevat* P-tau" OR "elevat*total tau" OR "elevat* phospho-tau" OR "elevat* tau protein*" OR "elevat* hyperphosphorylated tau" OR "elevat* neurofibrillary tangle*" OR "induc* amyloid-beta" OR "induc* beta-amyloid" OR "induc* Abeta" OR "induc* senile plaque*" OR "induc* tau aggregat*" OR "induc* T-tau" OR "induc* P-tau" OR "induc*total tau" OR "induc* phospho-tau" OR "induc* tau protein*" OR "induc* hyperphosphorylated tau" OR "induc* neurofibrillary tangle*" OR "produc* amyloid-beta" OR "produc* beta-amyloid" OR "produc* Abeta" OR "produc* senile plaque*" OR "produc* tau aggregat*" OR "produc* T-tau" OR "produc* P-tau" OR "produc*total tau" OR "produc* phospho-tau" OR "produc* tau protein*" OR "produc* hyperphosphorylated tau" OR "produc* neurofibrillary tangle*" OR "accelerat* amyloid-beta" OR "accelerat* beta-amyloid" OR "accelerat* Abeta" OR "accelerat* senile plaque*" OR "accelerat* tau aggregat*" OR "accelerat* T-tau" OR "accelerat* P-tau" OR "accelerat*total tau" OR "accelerat* phospho-tau" OR "accelerat* tau protein*" OR "accelerat* hyperphosphorylated tau" OR "accelerat* neurofibrillary tangle*" OR "amyloid-beta induc* by" OR "beta-amyloid induc* by" OR "Abeta induc* by" OR "senile plaque* induc* by" OR "tau aggregat* induc* by" OR "T-tau induc* by" OR "P-tau induc* by" OR "total tau induc* by" OR "phospho-tau induc* by" OR "tau protein* induc* by" OR "hyperphosphorylated tau induc* by" OR "neurofibrillary tangle* induc* by" OR "amyloid-beta produc* by" OR "beta-amyloid produc* by" OR "Abeta produc* by" OR "senile plaque* produc* by" OR "tau aggregat* produc* by" OR "T-tau produc* by" OR "P-tau produc* by" OR "total tau produc* by" OR "phospho-tau produc* by" OR "tau protein* produc* by" OR "hyperphosphorylated tau produc* by" OR "neurofibrillary tangle* produc* by" OR "caus* Alzheimer*" OR "caus* dementia" OR "caus* cognitive decline" OR "caus* brain* decline" OR "caus* functional decline" OR "caus* memory decline" OR "caus* cognitive deficit*" OR "caus* language deficit*" OR "caus* memory deficit*" OR "caus* plasticity deficit*" OR "caus* behavioral deficit*" OR "caus* saccade deficit*" OR "caus* learning deficit*" OR "caus* neuropsychological deficit*" OR "caus* cognitive impair*" OR "caus* vascular impair*" OR "caus* memory impair*" OR "caus* neurogenesis impair*" OR "caus* neuropsychological impair*" OR "caus* mind impair*" OR "caus* functional impair*" OR "caus* learning impair*" OR "caus* executive function impair*" OR "caus* cognitive loss*" OR "caus* neuronal loss*" OR "caus* synaptic loss*" OR "caus* memory loss*" OR "caus* loss of memory" OR "caus* hearing loss*" OR "caus* volume loss*" OR "caus* Impair* face recognition" OR "caus* Impair* reasoning" OR "caus* Impair* judgment" OR "caus* Impair* problem solving" OR "caus* inflamm*" OR "caus* oxidative stress" OR "caus* neuropathology" OR "caus* diabetes" OR "caus* hypertension" OR "caus* high cholesterol" OR "caus* hypercholesterolemia" OR

"caus* obesity" OR "caus* metabolic syndrome" OR "induc* Alzheimer*" OR "induc* dementia" OR "induc* cognitive decline" OR "induc* brain* decline" OR "induc* functional decline" OR "induc* memory decline" OR "induc* cognitive deficit*" OR "induc* language deficit*" OR "induc* memory deficit*" OR "induc* plasticity deficit*" OR "induc* behavioral deficit*" OR "induc* saccade deficit*" OR "induc* learning deficit*" OR "induc* neuropsychological deficit*" OR "induc* cognitive impair*" OR "induc* vascular impair*" OR "induc* memory impair*" OR "induc* neurogenesis impair*" OR "induc* neuropsychological impair*" OR "induc* mind impair*" OR "induc* functional impair*" OR "induc* learning impair*" OR "induc* executive function impair*" OR "induc* cognitive loss*" OR "induc* neuronal loss*" OR "induc* synaptic loss*" OR "induc* memory loss*" OR "induc* loss of memory" OR "induc* hearing loss*" OR "induc* volume loss*" OR "induc* Impair* face recognition" OR "induc* Impair* reasoning" OR "induc* Impair* judgment" OR "induc* Impair* problem solving" OR "induc* inflamm*" OR "induc* oxidative stress" OR "induc* neuropathology" OR "induc* diabetes" OR "induc* hypertension" OR "induc* high cholesterol" OR "induc* hypercholesterolemia" OR "induc* obesity" OR "induc* metabolic syndrome" OR "produc* Alzheimer*" OR "produc* dementia" OR "produc* cognitive decline" OR "produc* brain* decline" OR "produc* functional decline" OR "produc* memory decline" OR "produc* cognitive deficit*" OR "produc* language deficit*" OR "produc* memory deficit*" OR "produc* plasticity deficit*" OR "produc* behavioral deficit*" OR "produc* saccade deficit*" OR "produc* learning deficit*" OR "produc* neuropsychological deficit*" OR "produc* cognitive impair*" OR "produc* vascular impair*" OR "produc* memory impair*" OR "produc* neurogenesis impair*" OR "produc* neuropsychological impair*" OR "produc* mind impair*" OR "produc* functional impair*" OR "produc* learning impair*" OR "produc* executive function impair*" OR "produc* cognitive loss*" OR "produc* neuronal loss*" OR "produc* synaptic loss*" OR "produc* memory loss*" OR "produc* loss of memory" OR "produc* hearing loss*" OR "produc* volume loss*" OR "produc* Impair* face recognition" OR "produc* Impair* reasoning" OR "produc* Impair* judgment" OR "produc* Impair* problem solving" OR "produc* inflamm*" OR "produc* oxidative stress" OR "produc* neuropathology" OR "produc* diabetes" OR "produc* hypertension" OR "produc* high cholesterol" OR "produc* hypercholesterolemia" OR "produc* obesity" OR "produc* metabolic syndrome" OR "increas* Alzheimer*" OR "increas* dementia" OR "increas* cognitive decline" OR "increas* brain* decline" OR "increas* functional decline" OR "increas* memory decline" OR "increas* cognitive deficit*" OR "increas* language deficit*" OR "increas* memory deficit*" OR "increas* plasticity deficit*" OR "increas* behavioral deficit*" OR "increas* saccade deficit*" OR "increas* learning deficit*" OR "increas* neuropsychological deficit*" OR "increas* cognitive impair*" OR "increas* vascular impair*" OR "increas* memory impair*" OR "increas* neurogenesis impair*" OR "increas* neuropsychological impair*" OR "increas* mind impair*" OR "increas* functional impair*" OR "increas* learning impair*" OR "increas* executive function impair*" OR "increas* cognitive loss*" OR "increas* neuronal loss*" OR "increas* synaptic loss*" OR "increas* memory loss*" OR "increas* loss of memory" OR

"increas* hearing loss*" OR "increas* volume loss*" OR "increas* Impair* face recognition" OR "increas* Impair* reasoning" OR "increas* Impair* judgment" OR "increas* Impair* problem solving" OR "increas* inflamm*" OR "increas* oxidative stress" OR "increas* neuropathology" OR "increas* diabetes" OR "increas* hypertension" OR "increas* high cholesterol" OR "increas* hypercholesterolemia" OR "increas* obesity" OR "increas* metabolic syndrome" OR "exacerbat* Alzheimer*" OR "exacerbat* dementia" OR "exacerbat* cognitive decline" OR "exacerbat* brain* decline" OR "exacerbat* functional decline" OR "exacerbat* memory decline" OR "exacerbat* cognitive deficit*" OR "exacerbat* language deficit*" OR "exacerbat* memory deficit*" OR "exacerbat* plasticity deficit*" OR "exacerbat* behavioral deficit*" OR "exacerbat* saccade deficit*" OR "exacerbat* learning deficit*" OR "exacerbat* neuropsychological deficit*" OR "exacerbat* cognitive impair*" OR "exacerbat* vascular impair*" OR "exacerbat* memory impair*" OR "exacerbat* neurogenesis impair*" OR "exacerbat* neuropsychological impair*" OR "exacerbat* mind impair*" OR "exacerbat* functional impair*" OR "exacerbat* learning impair*" OR "exacerbat* executive function impair*" OR "exacerbat* cognitive loss*" OR "exacerbat* neuronal loss*" OR "exacerbat* synaptic loss*" OR "exacerbat* memory loss*" OR "exacerbat* loss of memory" OR "exacerbat* hearing loss*" OR "exacerbat* volume loss*" OR "exacerbat* Impair* face recognition" OR "exacerbat* Impair* reasoning" OR "exacerbat* Impair* judgment" OR "exacerbat* Impair* problem solving" OR "exacerbat* inflamm*" OR "exacerbat* oxidative stress" OR "exacerbat* neuropathology" OR "exacerbat* diabetes" OR "exacerbat* hypertension" OR "exacerbat* high cholesterol" OR "exacerbat* hypercholesterolemia" OR "exacerbat* obesity" OR "exacerbat* metabolic syndrome" OR "trigger* Alzheimer*" OR "trigger* dementia" OR "trigger* cognitive decline" OR "trigger* brain* decline" OR "trigger* functional decline" OR "trigger* memory decline" OR "trigger* cognitive deficit*" OR "trigger* language deficit*" OR "trigger* memory deficit*" OR "trigger* plasticity deficit*" OR "trigger* behavioral deficit*" OR "trigger* saccade deficit*" OR "trigger* learning deficit*" OR "trigger* neuropsychological deficit*" OR "trigger* cognitive impair*" OR "trigger* vascular impair*" OR "trigger* memory impair*" OR "trigger* neurogenesis impair*" OR "trigger* neuropsychological impair*" OR "trigger* mind impair*" OR "trigger* functional impair*" OR "trigger* learning impair*" OR "trigger* executive function impair*" OR "trigger* cognitive loss*" OR "trigger* neuronal loss*" OR "trigger* synaptic loss*" OR "trigger* memory loss*" OR "trigger* loss of memory" OR "trigger* hearing loss*" OR "trigger* volume loss*" OR "trigger* Impair* face recognition" OR "trigger* Impair* reasoning" OR "trigger* Impair* judgment" OR "trigger* Impair* problem solving" OR "trigger* inflamm*" OR "trigger* oxidative stress" OR "trigger* neuropathology" OR "trigger* diabetes" OR "trigger* hypertension" OR "trigger* high cholesterol" OR "trigger* hypercholesterolemia" OR "trigger* obesity" OR "trigger* metabolic syndrome" OR "accelerat* Alzheimer*" OR "accelerat* dementia" OR "accelerat* cognitive decline" OR "accelerat* brain* decline" OR "accelerat* functional decline" OR "accelerat* memory decline" OR "accelerat* cognitive deficit*" OR "accelerat* language deficit*" OR "accelerat* memory deficit*" OR "accelerat* plasticity

deficit*" OR "accelerat* behavioral deficit*" OR "accelerat* saccade deficit*" OR "accelerat* learning deficit*" OR "accelerat* neuropsychological deficit*" OR "accelerat* cognitive impair*" OR "accelerat* vascular impair*" OR "accelerat* memory impair*" OR "accelerat* neurogenesis impair*" OR "accelerat* neuropsychological impair*" OR "accelerat* mind impair*" OR "accelerat* functional impair*" OR "accelerat* learning impair*" OR "accelerat* executive function impair*" OR "accelerat* cognitive loss*" OR "accelerat* neuronal loss*" OR "accelerat* synaptic loss*" OR "accelerat* memory loss*" OR "accelerat* loss of memory" OR "accelerat* hearing loss*" OR "accelerat* volume loss*" OR "accelerat* Impair* face recognition" OR "accelerat* Impair* reasoning" OR "accelerat* Impair* judgment" OR "accelerat* Impair* problem solving" OR "accelerat* inflamm*" OR "accelerat* oxidative stress" OR "accelerat* neuropathology" OR "accelerat* diabetes" OR "accelerat* hypertension" OR "accelerat* high cholesterol" OR "accelerat* hypercholesterolemia" OR "accelerat* obesity" OR "accelerat* metabolic syndrome" OR "Alzheimer* * caused by" OR "dementia caused by" OR "cognitive decline caused by" OR "brain* decline caused by" OR "functional decline caused by" OR "memory decline caused by" OR "cognitive deficit* caused by" OR "language deficit* caused by" OR "memory deficit* caused by" OR "plasticity deficit* caused by" OR "behavioral deficit* caused by" OR "saccade deficit* caused by" OR "learning deficit* caused by" OR "neuropsychological deficit* caused by" OR "cognitive impair* caused by" OR "vascular impair* caused by" OR "memory impair* caused by" OR "neurogenesis impair* caused by" OR "neuropsychological impair* caused by" OR "mind impair* caused by" OR "functional impair* caused by" OR "learning impair* caused by" OR " executive function impair* caused by" OR "cognitive loss* caused by" OR "neuronal loss* caused by" OR "synaptic loss* caused by" OR "memory loss* caused by" OR "loss of memory caused by" OR "hearing loss* caused by" OR "volume loss* caused by" OR "Impair* face recognition caused by" OR "Impair* reasoning caused by" OR "Impair* judgment caused by" OR "Impair* problem solving caused by" OR "inflamm* caused by" OR "oxidative stress caused by" OR "neuropathology caused by" OR "diabetes caused by" OR "hypertension caused by" OR "high cholesterol caused by" OR "hypercholesterolemia caused by" OR "obesity caused by" OR "metabolic syndrome caused by" OR "Alzheimer* * induced by" OR "dementia induced by" OR "cognitive decline induced by" OR "brain* decline induced by" OR "functional decline induced by" OR "memory decline induced by" OR "cognitive deficit* induced by" OR "language deficit* induced by" OR "memory deficit* induced by" OR "plasticity deficit* induced by" OR "behavioral deficit* induced by" OR "saccade deficit* induced by" OR "learning deficit* induced by" OR "neuropsychological deficit* induced by" OR "cognitive impair* induced by" OR "vascular impair* induced by" OR "memory impair* induced by" OR "neurogenesis impair* induced by" OR "neuropsychological impair* induced by" OR "mind impair* induced by" OR "functional impair* induced by" OR "learning impair* induced by" OR " executive function impair* induced by" OR "cognitive loss* induced by" OR "neuronal loss* induced by" OR "synaptic loss* induced by" OR "memory loss* induced by" OR "loss of memory induced by" OR "hearing loss* induced by" OR "volume loss* induced by" OR "Impair* face recognition induced by" OR

"Impair* reasoning induced by" OR "Impair* judgment induced by" OR "Impair* problem solving induced by" OR "inflamm* induced by" OR "oxidative stress induced by" OR "neuropathology induced by" OR "diabetes induced by" OR "hypertension induced by" OR "high cholesterol induced by" OR "hypercholesterolemia induced by" OR "obesity induced by" OR "metabolic syndrome induced by")

AND

MESH HEADING NO EXPLODE

Antineoplastic Agents OR Anticoagulants OR Antineoplastic Combined Chemotherapy Protocols OR Anti-Inflammatory Agents, Non-Steroidal OR Hypoglycemic Agents OR Anti-Bacterial Agents OR Antipsychotic Agents OR Immunosuppressive Agents OR Anticonvulsants OR Platelet Aggregation Inhibitors OR Glucocorticoids OR Analgesics, Opioid OR Drug-Related Side Effects and Adverse Reactions OR Warfarin OR Analgesics OR Doxorubicin OR Cisplatin OR Protein Kinase Inhibitors OR Fibrinolytic Agents OR Fluorouracil OR Antirheumatic Agents OR Antihypertensive Agents OR Pyridines OR Cyclophosphamide OR Bone Density Conservation Agents OR Antiviral Agents OR Bleomycin OR Antidepressive Agents OR Serotonin Uptake Inhibitors OR Thiophenes OR Antibiotics, Antineoplastic OR Angiogenesis Inhibitors OR Drug Hypersensitivity OR Proton Pump Inhibitors OR Deoxycytidine OR Ticlopidine OR Organoplatinum Compounds OR Anti-Arrhythmia Agents OR Angiotensin-Converting Enzyme Inhibitors OR Anti-HIV Agents OR Paclitaxel OR Chemotherapy, Adjuvant OR Acetaminophen OR Quinazolines OR Taxoids OR Vasodilator Agents OR Pilocarpine OR Triazoles OR Benzodiazepines OR Anti-Infective Agents OR Estrogens OR Thiazolidinediones OR Antineoplastic Agents, Hormonal OR Antineoplastic Agents, Phytogenic OR Cyclooxygenase 2 Inhibitors OR Anti-Ulcer Agents OR Cyclosporine OR Vasoconstrictor Agents OR Anthracyclines OR Anticarcinogenic Agents OR Convulsants OR Calcium Channel Blockers OR Cardiotonic Agents OR Dermatologic Agents OR Isoproterenol OR Antifungal Agents OR Ribavirin OR Antiparkinson Agents OR Clozapine OR Carboplatin OR Tamoxifen OR Antiretroviral Therapy, Highly Active OR Vincristine OR Cholinesterase Inhibitors OR Antidepressive Agents, Second-Generation OR Antitubercular Agents OR Hypolipidemic Agents OR Antineoplastic Agents, Alkylating OR Gastrointestinal Agents OR Aromatase Inhibitors OR Antithyroid Agents OR Organophosphonates OR Cyclooxygenase Inhibitors OR Antidepressive Agents, Tricyclic OR Antimanic Agents OR Phosphodiesterase 5 Inhibitors OR Dipeptidyl-Peptidase IV Inhibitors OR Anti-Retroviral Agents OR Methyl Ethers OR Chelating Agents OR Anticholesteremic Agents OR Contraceptive Agents, Female OR Anti-Asthmatic Agents OR Dopamine Uptake Inhibitors OR HIV Protease Inhibitors OR N-Methyl-3,4-methylenedioxymphetamine OR Mycophenolic Acid OR Bronchodilator Agents OR Hydroxychloroquine OR Neurotransmitter Agents OR Anti-Obesity Agents OR Anabolic Agents OR Anesthetics OR Cardiovascular Agents OR Histone Deacetylase Inhibitors OR Alkylating Agents OR Chloroquine OR Antifibrinolytic Agents OR

Benzoxazines OR Protease Inhibitors OR Fertility Agents, Female OR Dopamine Agents OR Anti-Infective Agents, Local OR Reverse Transcriptase Inhibitors OR Neuromuscular Agents OR Anti-Allergic Agents OR Monoamine Oxidase Inhibitors OR Neuromuscular Nondepolarizing Agents OR Nootropic Agents OR Photosensitizing Agents OR 5-alpha Reductase Inhibitors OR Sweetening Agents OR Sensory System Agents OR Adrenergic Agents OR Adrenergic Uptake Inhibitors OR Indicators and Reagents OR Antitussive Agents OR Surface-Active Agents OR Antimutagenic Agents

OR

MESH TERMS CHEMICALS

IIIB4a - TITLE

("poison*" OR "ecotoxologic* effect*" OR "occupation*" OR pollut* OR "*virus*" OR environmental OR "induc*" OR "damage-caus*" OR "drug*-caus*" OR "infect*-caus*" OR "chemotherapy-caus*" OR "treat*-caus*" OR "anesthesia-caus*" OR "chemical*-caus*" OR "cytokine*-caus*" OR "surg*-caus*" OR "radiation-caus*" OR "steroid-caus*" OR "mechanically-caus*" OR "promot* progression" OR "caus* accumulation" OR "caus* * accumulation" OR "progression of" OR expos* OR contamina* OR chemicals OR abuse* OR induc* OR "long-term effect*" OR "inhibit* *protection" OR dysfunction* OR aggregation OR accumulation OR "disease link* to" OR "chemical initiator*" OR "stimulat* microglia" OR "activat* microglia" OR "increas* risk*" OR "increas* the risk*" OR "adverse event*" OR "adverse reaction*" OR "adverse * event*" OR "adverse * reaction" OR "adverse effect*" OR "adverse * effect*" OR hypersensitivity OR aggravat* OR exacerbat* OR detriment* OR *TOXI* OR "caus* * degrad*" OR "increas* * degrad*" OR "caus* * damag*" OR "increas* * damag*" OR "*toxi* caus* by" OR "*toxi* increas* by" OR "*toxi* produc* by" OR "*toxi* enhanc* by" OR "*toxi* stimulat* by" OR "*toxi* accelerat* by" OR "damag* caus* by" OR "*damag* increas* by" OR deleterious OR deteriorat* OR trigger* OR worsen* OR harm* OR hazard* OR "side-effect*" OR dangerous OR destructive OR injurious OR unsafe)

AND

MESH HEADING NO EXPLODE

Lipopolysaccharides OR Malondialdehyde OR Neurotoxicity Syndromes OR Carbon Tetrachloride OR Formaldehyde OR 9,10-Dimethyl-1,2-benzanthracene OR Trinitrobenzenesulfonic Acid OR Insecticides OR Endocrine Disruptors OR Diethylnitrosamine OR Hydrogen Peroxide OR Benzhydryl Compounds OR Chemical Warfare Agents OR Asbestos OR Herbicides OR Organometallic Compounds OR Scopolamine Hydrobromide OR Silicon Dioxide OR Polychlorinated Biphenyls OR 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine OR Benzo(a)pyrene OR Fluorocarbons OR Nitrogen Dioxide OR Polycyclic Hydrocarbons, Aromatic OR Tetrachlorodibenzodioxin OR Metals, Heavy OR Hydrocarbons, Chlorinated OR

Chemical Industry OR 1,2-Dimethylhydrazine OR Ethylene Glycol OR Nitrosamines OR Benzene OR Fluorides OR Agricultural Workers' Diseases OR Bromodeoxyuridine OR Chromium OR Organophosphorus Compounds OR Organic Chemicals OR Carbon Monoxide OR Benzalkonium Compounds OR Chlorpyrifos OR Organophosphates OR Organophosphate Poisoning OR Volatile Organic Compounds OR Diethylhexyl Phthalate OR Sulfur Dioxide OR Petroleum OR Methylmercury Compounds OR Chlorine OR Dichlorodiphenyl Dichloroethylene OR Hydrocarbons OR Trichloroethylene OR Carbon Tetrachloride Poisoning OR 3,4-Dihydroxyphenylacetic Acid OR Alkanesulfonic Acids OR Plasticizers OR Halogenated Diphenyl Ethers OR Benzene Derivatives OR Dinitrofluorobenzene OR Toluene 2,4-Diisocyanate OR Benzopyrenes OR Cyclohexenes OR Nitrobenzenes OR Plastics OR Trihalomethanes OR Hydrocarbons, Brominated

OR

IIIB4b. TOPIC

("increas* amyloid-beta" OR "increas* beta-amyloid" OR "increas* Abeta" OR "increas* senile plaque*" OR "increas* tau aggregat*" OR "increas* T-tau" OR "increas* P-tau" OR "increas*total tau" OR "increas* phospho-tau" OR "increas* tau protein*" OR "increas* hyperphosphorylated tau" OR "increas* neurofibrillary tangle*" OR "enhanc* amyloid-beta" OR "enhanc* beta-amyloid" OR "enhanc* Abeta" OR "enhanc* senile plaque*" OR "enhanc* tau aggregat*" OR "enhanc* T-tau" OR "enhanc* P-tau" OR "enhanc*total tau" OR "enhanc* phospho-tau" OR "enhanc* tau protein*" OR "enhanc* hyperphosphorylated tau" OR "enhanc* neurofibrillary tangle*" OR "stimulat* amyloid-beta" OR "stimulat* beta-amyloid" OR "stimulat* Abeta" OR "stimulat* senile plaque*" OR "stimulat* tau aggregat*" OR "stimulat* T-tau" OR "stimulat* P-tau" OR "stimulat*total tau" OR "stimulat* phospho-tau" OR "stimulat* tau protein*" OR "stimulat* hyperphosphorylated tau" OR "stimulat* neurofibrillary tangle*" OR "elevat* amyloid-beta" OR "elevat* beta-amyloid" OR "elevat* Abeta" OR "elevat* senile plaque*" OR "elevat* tau aggregat*" OR "elevat* T-tau" OR "elevat* P-tau" OR "elevat*total tau" OR "elevat* phospho-tau" OR "elevat* tau protein*" OR "elevat* hyperphosphorylated tau" OR "elevat* neurofibrillary tangle*" OR "induc* amyloid-beta" OR "induc* beta-amyloid" OR "induc* Abeta" OR "induc* senile plaque*" OR "induc* tau aggregat*" OR "induc* T-tau" OR "induc* P-tau" OR "induc*total tau" OR "induc* phospho-tau" OR "induc* tau protein*" OR "induc* hyperphosphorylated tau" OR "induc* neurofibrillary tangle*" OR "produc* amyloid-beta" OR "produc* beta-amyloid" OR "produc* Abeta" OR "produc* senile plaque*" OR "produc* tau aggregat*" OR "produc* T-tau" OR "produc* P-tau" OR "produc*total tau" OR "produc* phospho-tau" OR "produc* tau protein*" OR "produc* hyperphosphorylated tau" OR "produc* neurofibrillary tangle*" OR "accelerat* amyloid-beta" OR "accelerat* beta-amyloid" OR "accelerat* Abeta" OR "accelerat* senile plaque*" OR "accelerat* tau aggregat*" OR "accelerat* T-tau" OR "accelerat* P-tau" OR "accelerat*total tau" OR "accelerat* phospho-tau" OR "accelerat* tau protein*" OR "accelerat* hyperphosphorylated tau" OR "accelerat*

neurofibrillary tangle*" OR "amyloid-beta induc* by" OR "beta-amyloid induc* by" OR "Abeta induc* by" OR "senile plaque* induc* by" OR "tau aggregat* induc* by" OR "T-tau induc* by" OR "P-tau induc* by" OR "total tau induc* by" OR "phospho-tau induc* by" OR "tau protein* induc* by" OR "hyperphosphorylated tau induc* by" OR "neurofibrillary tangle* induc* by" OR "amyloid-beta produc* by" OR "beta-amyloid produc* by" OR "Abeta produc* by" OR "senile plaque* produc* by" OR "tau aggregat* produc* by" OR "T-tau produc* by" OR "P-tau produc* by" OR "total tau produc* by" OR "phospho-tau produc* by" OR "tau protein* produc* by" OR "hyperphosphorylated tau produc* by" OR "neurofibrillary tangle* produc* by" OR "caus* Alzheimer*" OR "caus* dementia" OR "caus* cognitive decline" OR "caus* brain* decline" OR "caus* functional decline" OR "caus* memory decline" OR "caus* cognitive deficit*" OR "caus* language deficit*" OR "caus* memory deficit*" OR "caus* plasticity deficit*" OR "caus* behavioral deficit*" OR "caus* saccade deficit*" OR "caus* learning deficit*" OR "caus* neuropsychological deficit*" OR "caus* cognitive impair*" OR "caus* vascular impair*" OR "caus* memory impair*" OR "caus* neurogenesis impair*" OR "caus* neuropsychological impair*" OR "caus* mind impair*" OR "caus* functional impair*" OR "caus* learning impair*" OR "caus* executive function impair*" OR "caus* cognitive loss*" OR "caus* neuronal loss*" OR "caus* synaptic loss*" OR "caus* memory loss*" OR "caus* loss of memory" OR "caus* hearing loss*" OR "caus* volume loss*" OR "caus* Impair* face recognition" OR "caus* Impair* reasoning" OR "caus* Impair* judgment" OR "caus* Impair* problem solving" OR "caus* inflamm*" OR "caus* oxidative stress" OR "caus* neuropathology" OR "caus* diabetes" OR "caus* hypertension" OR "caus* high cholesterol" OR "caus* hypercholesterolemia" OR "caus* obesity" OR "caus* metabolic syndrome" OR "induc* Alzheimer*" OR "induc* dementia" OR "induc* cognitive decline" OR "induc* brain* decline" OR "induc* functional decline" OR "induc* memory decline" OR "induc* cognitive deficit*" OR "induc* language deficit*" OR "induc* memory deficit*" OR "induc* plasticity deficit*" OR "induc* behavioral deficit*" OR "induc* saccade deficit*" OR "induc* learning deficit*" OR "induc* neuropsychological deficit*" OR "induc* cognitive impair*" OR "induc* vascular impair*" OR "induc* memory impair*" OR "induc* neurogenesis impair*" OR "induc* neuropsychological impair*" OR "induc* mind impair*" OR "induc* functional impair*" OR "induc* learning impair*" OR "induc* executive function impair*" OR "induc* cognitive loss*" OR "induc* neuronal loss*" OR "induc* synaptic loss*" OR "induc* memory loss*" OR "induc* loss of memory" OR "induc* hearing loss*" OR "induc* volume loss*" OR "induc* Impair* face recognition" OR "induc* Impair* reasoning" OR "induc* Impair* judgment" OR "induc* Impair* problem solving" OR "induc* inflamm*" OR "induc* oxidative stress" OR "induc* neuropathology" OR "induc* diabetes" OR "induc* hypertension" OR "induc* high cholesterol" OR "induc* hypercholesterolemia" OR "induc* obesity" OR "induc* metabolic syndrome" OR "produc* Alzheimer*" OR "produc* dementia" OR "produc* cognitive decline" OR "produc* brain* decline" OR "produc* functional decline" OR "produc* memory decline" OR "produc* cognitive deficit*" OR "produc* language deficit*" OR "produc* memory deficit*" OR "produc* plasticity deficit*" OR "produc* behavioral deficit*" OR "produc* saccade deficit*"

OR "produc* learning deficit*" OR "produc* neuropsychological deficit*" OR "produc* cognitive impair*" OR "produc* vascular impair*" OR "produc* memory impair*" OR "produc* neurogenesis impair*" OR "produc* neuropsychological impair*" OR "produc* mind impair*" OR "produc* functional impair*" OR "produc* learning impair*" OR "produc* executive function impair*" OR "produc* cognitive loss*" OR "produc* neuronal loss*" OR "produc* synaptic loss*" OR "produc* memory loss*" OR "produc* loss of memory" OR "produc* hearing loss*" OR "produc* volume loss*" OR "produc* Impair* face recognition" OR "produc* Impair* reasoning" OR "produc* Impair* judgment" OR "produc* Impair* problem solving" OR "produc* inflamm*" OR "produc* oxidative stress" OR "produc* neuropathology" OR "produc* diabetes" OR "produc* hypertension" OR "produc* high cholesterol" OR "produc* hypercholesterolemia" OR "produc* obesity" OR "produc* metabolic syndrome" OR "increas* Alzheimer*" OR "increas* dementia" OR "increas* cognitive decline" OR "increas* brain* decline" OR "increas* functional decline" OR "increas* memory decline" OR "increas* cognitive deficit*" OR "increas* language deficit*" OR "increas* memory deficit*" OR "increas* plasticity deficit*" OR "increas* behavioral deficit*" OR "increas* saccade deficit*" OR "increas* learning deficit*" OR "increas* neuropsychological deficit*" OR "increas* cognitive impair*" OR "increas* vascular impair*" OR "increas* memory impair*" OR "increas* neurogenesis impair*" OR "increas* neuropsychological impair*" OR "increas* mind impair*" OR "increas* functional impair*" OR "increas* learning impair*" OR "increas* executive function impair*" OR "increas* cognitive loss*" OR "increas* neuronal loss*" OR "increas* synaptic loss*" OR "increas* memory loss*" OR "increas* loss of memory" OR "increas* hearing loss*" OR "increas* volume loss*" OR "increas* Impair* face recognition" OR "increas* Impair* reasoning" OR "increas* Impair* judgment" OR "increas* Impair* problem solving" OR "increas* inflamm*" OR "increas* oxidative stress" OR "increas* neuropathology" OR "increas* diabetes" OR "increas* hypertension" OR "increas* high cholesterol" OR "increas* hypercholesterolemia" OR "increas* obesity" OR "increas* metabolic syndrome" OR "exacerbat* Alzheimer*" OR "exacerbat* dementia" OR "exacerbat* cognitive decline" OR "exacerbat* brain* decline" OR "exacerbat* functional decline" OR "exacerbat* memory decline" OR "exacerbat* cognitive deficit*" OR "exacerbat* language deficit*" OR "exacerbat* memory deficit*" OR "exacerbat* plasticity deficit*" OR "exacerbat* behavioral deficit*" OR "exacerbat* saccade deficit*" OR "exacerbat* learning deficit*" OR "exacerbat* neuropsychological deficit*" OR "exacerbat* cognitive impair*" OR "exacerbat* vascular impair*" OR "exacerbat* memory impair*" OR "exacerbat* neurogenesis impair*" OR "exacerbat* neuropsychological impair*" OR "exacerbat* mind impair*" OR "exacerbat* functional impair*" OR "exacerbat* learning impair*" OR "exacerbat* executive function impair*" OR "exacerbat* cognitive loss*" OR "exacerbat* neuronal loss*" OR "exacerbat* synaptic loss*" OR "exacerbat* memory loss*" OR "exacerbat* loss of memory" OR "exacerbat* hearing loss*" OR "exacerbat* volume loss*" OR "exacerbat* Impair* face recognition" OR "exacerbat* Impair* reasoning" OR "exacerbat* Impair* judgment" OR "exacerbat* Impair* problem solving" OR "exacerbat* inflamm*" OR "exacerbat* oxidative

stress" OR "exacerbat* neuropathology" OR "exacerbat* diabetes" OR "exacerbat* hypertension" OR "exacerbat* high cholesterol" OR "exacerbat* hypercholesterolemia" OR "exacerbat* obesity" OR "exacerbat* metabolic syndrome" OR "trigger* Alzheimer*" OR "trigger* dementia" OR "trigger* cognitive decline" OR "trigger* brain* decline" OR "trigger* functional decline" OR "trigger* memory decline" OR "trigger* cognitive deficit*" OR "trigger* language deficit*" OR "trigger* memory deficit*" OR "trigger* plasticity deficit*" OR "trigger* behavioral deficit*" OR "trigger* saccade deficit*" OR "trigger* learning deficit*" OR "trigger* neuropsychological deficit*" OR "trigger* cognitive impair*" OR "trigger* vascular impair*" OR "trigger* memory impair*" OR "trigger* neurogenesis impair*" OR "trigger* neuropsychological impair*" OR "trigger* mind impair*" OR "trigger* functional impair*" OR "trigger* learning impair*" OR "trigger* executive function impair*" OR "trigger* cognitive loss*" OR "trigger* neuronal loss*" OR "trigger* synaptic loss*" OR "trigger* memory loss*" OR "trigger* loss of memory" OR "trigger* hearing loss*" OR "trigger* volume loss*" OR "trigger* Impair* face recognition" OR "trigger* Impair* reasoning" OR "trigger* Impair* judgment" OR "trigger* Impair* problem solving" OR "trigger* inflamm*" OR "trigger* oxidative stress" OR "trigger* neuropathology" OR "trigger* diabetes" OR "trigger* hypertension" OR "trigger* high cholesterol" OR "trigger* hypercholesterolemia" OR "trigger* obesity" OR "trigger* metabolic syndrome" OR "accelerat* Alzheimer*" OR "accelerat* dementia" OR "accelerat* cognitive decline" OR "accelerat* brain* decline" OR "accelerat* functional decline" OR "accelerat* memory decline" OR "accelerat* cognitive deficit*" OR "accelerat* language deficit*" OR "accelerat* memory deficit*" OR "accelerat* plasticity deficit*" OR "accelerat* behavioral deficit*" OR "accelerat* saccade deficit*" OR "accelerat* learning deficit*" OR "accelerat* neuropsychological deficit*" OR "accelerat* cognitive impair*" OR "accelerat* vascular impair*" OR "accelerat* memory impair*" OR "accelerat* neurogenesis impair*" OR "accelerat* neuropsychological impair*" OR "accelerat* mind impair*" OR "accelerat* functional impair*" OR "accelerat* learning impair*" OR "accelerat* executive function impair*" OR "accelerat* cognitive loss*" OR "accelerat* neuronal loss*" OR "accelerat* synaptic loss*" OR "accelerat* memory loss*" OR "accelerat* loss of memory" OR "accelerat* hearing loss*" OR "accelerat* volume loss*" OR "accelerat* Impair* face recognition" OR "accelerat* Impair* reasoning" OR "accelerat* Impair* judgment" OR "accelerat* Impair* problem solving" OR "accelerat* inflamm*" OR "accelerat* oxidative stress" OR "accelerat* neuropathology" OR "accelerat* diabetes" OR "accelerat* hypertension" OR "accelerat* high cholesterol" OR "accelerat* hypercholesterolemia" OR "accelerat* obesity" OR "accelerat* metabolic syndrome" OR "Alzheimer* * caused by" OR "dementia caused by" OR "cognitive decline caused by" OR "brain* decline caused by" OR "functional decline caused by" OR "memory decline caused by" OR "cognitive deficit* caused by" OR "language deficit* caused by" OR "memory deficit* caused by" OR "plasticity deficit* caused by" OR "behavioral deficit* caused by" OR "saccade deficit* caused by" OR "learning deficit* caused by" OR "neuropsychological deficit* caused by" OR "cognitive impair* caused by" OR "vascular impair* caused by" OR "memory impair* caused by" OR "neurogenesis impair* caused by" OR

"neuropsychological impair* caused by" OR "mind impair* caused by" OR "functional impair* caused by" OR "learning impair* caused by" OR "executive function impair* caused by" OR "cognitive loss* caused by" OR "neuronal loss* caused by" OR "synaptic loss* caused by" OR "memory loss* caused by" OR "loss of memory caused by" OR "hearing loss* caused by" OR "volume loss* caused by" OR "Impair* face recognition caused by" OR "Impair* reasoning caused by" OR "Impair* judgment caused by" OR "Impair* problem solving caused by" OR "inflamm* caused by" OR "oxidative stress caused by" OR "neuropathology caused by" OR "diabetes caused by" OR "hypertension caused by" OR "high cholesterol caused by" OR "hypercholesterolemia caused by" OR "obesity caused by" OR "metabolic syndrome caused by" OR "Alzheimer* * induced by" OR "dementia induced by" OR "cognitive decline induced by" OR "brain* decline induced by" OR "functional decline induced by" OR "memory decline induced by" OR "cognitive deficit* induced by" OR "language deficit* induced by" OR "memory deficit* induced by" OR "plasticity deficit* induced by" OR "behavioral deficit* induced by" OR "saccade deficit* induced by" OR "learning deficit* induced by" OR "neuropsychological deficit* induced by" OR "cognitive impair* induced by" OR "vascular impair* induced by" OR "memory impair* induced by" OR "neurogenesis impair* induced by" OR "neuropsychological impair* induced by" OR "mind impair* induced by" OR "functional impair* induced by" OR "learning impair* induced by" OR "executive function impair* induced by" OR "cognitive loss* induced by" OR "neuronal loss* induced by" OR "synaptic loss* induced by" OR "memory loss* induced by" OR "loss of memory induced by" OR "hearing loss* induced by" OR "volume loss* induced by" OR "Impair* face recognition induced by" OR "Impair* reasoning induced by" OR "Impair* judgment induced by" OR "Impair* problem solving induced by" OR "inflamm* induced by" OR "oxidative stress induced by" OR "neuropathology induced by" OR "diabetes induced by" OR "hypertension induced by" OR "high cholesterol induced by" OR "hypercholesterolemia induced by" OR "obesity induced by" OR "metabolic syndrome induced by")

AND

MESH HEADING NO EXPLODE

Lipopolysaccharides OR Malondialdehyde OR Neurotoxicity Syndromes OR Carbon Tetrachloride OR Formaldehyde OR 9,10-Dimethyl-1,2-benzanthracene OR Trinitrobenzenesulfonic Acid OR Insecticides OR Endocrine Disruptors OR Diethylnitrosamine OR Hydrogen Peroxide OR Benzhydryl Compounds OR Chemical Warfare Agents OR Asbestos OR Herbicides OR Organometallic Compounds OR Scopolamine Hydrobromide OR Silicon Dioxide OR Polychlorinated Biphenyls OR 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine OR Benzo(a)pyrene OR Fluorocarbons OR Nitrogen Dioxide OR Polycyclic Hydrocarbons, Aromatic OR Tetrachlorodibenzodioxin OR Metals, Heavy OR Hydrocarbons, Chlorinated OR Chemical Industry OR 1,2-Dimethylhydrazine OR Ethylene Glycol OR Nitrosamines OR Benzene OR Fluorides OR Agricultural Workers' Diseases OR Bromodeoxyuridine OR

Chromium OR Organophosphorus Compounds OR Organic Chemicals OR Carbon Monoxide OR Benzalkonium Compounds OR Chlorpyrifos OR Organophosphates OR Organophosphate Poisoning OR Volatile Organic Compounds OR Diethylhexyl Phthalate OR Sulfur Dioxide OR Petroleum OR Methylmercury Compounds OR Chlorine OR Dichlorodiphenyl Dichloroethylene OR Hydrocarbons OR Trichloroethylene OR Carbon Tetrachloride Poisoning OR 3,4-Dihydroxyphenylacetic Acid OR Alkanesulfonic Acids OR Plasticizers OR Halogenated Diphenyl Ethers OR Benzene Derivatives OR Dinitrofluorobenzene OR Toluene 2,4-Diisocyanate OR Benzopyrenes OR Cyclohexenes OR Nitrobenzenes OR Plastics OR Trihalomethanes OR Hydrocarbons, Brominated

Appendix 9A-2 - Unambiguous MeSH Terms - Streamlined Approach

("Drug-Related Side Effects AND Adverse Reactions" OR Abnormalities, Drug Induced OR Abnormalities, Radiation-Induced OR Agricultural Workers Diseases OR Aids Related Opportunistic Infections OR Air Pollutants OR Air Pollutants, Occupational OR Air Pollutants, Radioactive OR Air Pollution OR Air Pollution, Indoor OR Air Pollution, Radioactive OR Alcohol Drinking OR Alcohol Related Disorders OR Alcoholic Beverages OR Alcoholic Intoxication OR Alcoholism OR Amphetamine Related Disorders OR Amphetamines OR Arsenic Poisoning OR Asthma, Aspirin-Induced OR Asthma, Exercise-Induced OR Asthma, Occupational OR Behavior, Addictive OR Bullying OR Cadmium Poisoning OR Carbon Monoxide Poisoning OR Carbon Tetrachloride Poisoning OR Carcinogenicity Tests OR Carcinogens OR Carcinogens, Environmental OR Causality OR Cardiomegaly, Exercise-Induced OR Chemical Warfare Agents OR Chemically-Induced Disorders OR Child Abuse OR Child Abuse, Sexual OR Cholesterol, Dietary OR Ciguatera Poisoning OR Cocaine Related Disorders OR Cytomegalovirus Infections OR Dermatitis, Occupational OR Diet, Atherogenic OR Diet, High Fat OR Dietary Carbohydrates OR Dietary Fats OR Dietary Fats, Unsaturated OR Dietary Fiber OR Dietary Sucrose OR Domestic Violence OR Drug Contamination OR Drug Eruptions OR Drug Hypersensitivity OR Drug Overdose OR Drug-Induced Liver Injury OR Dyskinesia, Drug Induced OR Eating Disorders OR Environmental Exposure OR Environmental Illness OR Environmental Pollutants OR Environmental Pollution OR Environmental Pollution OR Escherichia Coli Infections OR Fast Foods OR Fluoride Poisoning OR Food Additives OR Food Contamination OR Food Hypersensitivity OR Foodborne Diseases OR Gas Poisoning OR Hazardous Substances OR Hazardous Waste OR Hearing Loss, Noise Induced OR Heavy Metal Poisoning, Nervous System OR Hepatitis A, Chronic OR Hepatitis B, Chronic OR Hepatitis C, Chronic OR Heroin Dependence OR Herpesviridae Infections OR Htlv I Infections OR Hypersensitivity OR Hypersensitivity, Delayed OR Hypersensitivity, Immediate OR Iatrogenic Disease OR Inhalation Exposure OR Iron Overload OR Lead Poisoning OR Lead Poisoning, Nervous System OR Lead Poisoning, Nervous System, Adult OR Lead Poisoning, Nervous System, Childhood OR Leukemia, Radiation Induced OR Manganese Poisoning OR Marijuana Abuse OR Maternal Exposure OR Mercury Poisoning OR Mercury Poisoning, Nervous System OR Morphine Dependence OR Mptp Poisoning OR Mushroom Poisoning OR Mutagenicity Tests OR Mutagens OR Neoplasms, Radiation Induced OR Neurotoxicity Syndromes OR Occupational Diseases OR Occupational Exposure OR Opioid Related Disorders OR Opportunistic Infections OR Organophosphate Poisoning OR Paternal Exposure OR Plant Poisoning OR Pneumonia, Ventilator-Associated OR Poisoning OR Poisons OR Prenatal Exposure Delayed Effects OR Psychoses, Substance Induced OR Radiation Effects OR Radiation Injuries OR Radioactive Hazard Release OR Radioactive Pollutants OR Respiratory Hypersensitivity OR Salmonella Food Poisoning OR Sedentary Lifestyle OR Shellfish Poisoning OR Sleep Deprivation OR Sleep Disorders OR Sodium Chloride, Dietary OR Sodium, Dietary OR Soil Pollutants OR Soil Pollutants, Radioactive OR Spouse Abuse OR Staphylococcal Food Poisoning OR Staphylococcal Infections OR Streptococcal Infections OR Substance Abuse,

Intravenous OR Substance Withdrawal Syndrome OR Substance-Related Disorders OR Teratogens OR Tobacco Smoke Pollution OR Tobacco Use Disorder OR Toxicity Tests, Chronic OR Virus Diseases OR Vitamin D Deficiency OR Water Pollutants OR Water Pollutants, Chemical OR Water Pollutants, Radioactive OR Water Pollution OR Water Pollution, Chemical)

Chapter 10 Appendices - Bibliography References

Appendix 10C1-a. Example references for each existing AD treatment identified

Ahmed ME, Khan MM, Javed H, Vaibhav K, Khan A, Tabassum R, et al. Amelioration of cognitive impairment and neurodegeneration by catechin hydrate in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. *Neurochemistry International*. 2013;62(4):492-501.

Ahmed T, Gilani A-H. Therapeutic potential of turmeric in Alzheimer's disease: curcumin or curcuminoids? *Phytotherapy research : PTR*. 2014;28(4):517-25.

Ali MRA-A, Abo-Youssef AMH, Messiha BAS, Khattab MM. Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotrophic factor, neuroinflammation and oxido-nitrosative stress. *Naunyn-Schmiedeberg's archives of pharmacology*. 2016;389(6):637-56.

Alonso E, Fuwa H, Vale C, Suga Y, Goto T, Konno Y, et al. Design and synthesis of skeletal analogues of gambierol: attenuation of amyloid-beta and tau pathology with voltage-gated potassium channel and N-methyl-D-aspartate receptor implications. *Journal of the American Chemical Society*. 2012;134(17):7467-79.

Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. *European journal of neurology*. 2011;18(1):59-68.

Amtul Z, Westaway D, Cechetto DF, Rozmahel RF. Oleic acid ameliorates amyloidosis in cellular and mouse models of Alzheimer's disease. *Brain pathology (Zurich, Switzerland)*. 2011;21(3):321-9.

Anderson JJ, Holtz G, Baskin PP, Turner M, Rowe B, Wang B, et al. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. *Biochemical pharmacology*. 2005;69(4):689-98.

Anekonda TS, Quinn JF. Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine. *Biochimica et biophysica acta*. 2011;1812(12):1584-90.

Annweiler C, Rolland Y, Schott AM, Blain H, Vellas B, Herrmann FR, et al. Higher vitamin D dietary intake is associated with lower risk of Alzheimer's disease: a 7-year follow-up. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2012;67(11):1205-11.

Ano Y, Dohata A, Taniguchi Y, Hoshi A, Uchida K, Takashima A, et al. Iso-alpha-acids, Bitter Components of Beer, Prevent Inflammation and Cognitive Decline Induced in a Mouse Model of Alzheimer's Disease. *The Journal of biological chemistry*. 2017;292(9):3720-8.

Arbel-Ornath M, Becker M, Rabinovich-Toidman P, Gartner M, Solomon B. Immunomodulation of AbetaPP processing alleviates amyloid-beta-related pathology in Alzheimer's disease transgenic mice. *Journal of Alzheimer's disease : JAD*. 2010;22(2):469-82.

Arunsundar M, Shanmugarajan TS, Ravichandran V. 3,4-dihydroxyphenylethanol attenuates spatio-cognitive deficits in an Alzheimer's disease mouse model: modulation of the molecular signals in neuronal survival-apoptotic programs. *Neurotoxicity research*. 2015;27(2):143-55.

Asadbegi M, Yaghmaei P, Salehi I, Ebrahim-Habibi A, Komaki A. Neuroprotective effects of metformin against Abeta-mediated inhibition of long-term potentiation in rats fed a high-fat diet. *Brain research bulletin*. 2016;121:178-85.

Asberom T, Zhao Z, Bara TA, Clader JW, Greenlee WJ, Hyde LA, et al. Discovery of gamma-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2007;17(2):511-6.

Aso E, Juves S, Maldonado R, Ferrer I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP/PS1 mice. *Journal of Alzheimer's disease : JAD*. 2013;35(4):847-58.

Aso E, Sanchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I. Cannabis-based medicine reduces multiple pathological processes in AbetaPP/PS1 mice. *Journal of Alzheimer's disease : JAD*. 2015;43(3):977-91.

Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. *The Journal of biological chemistry*. 2013;288(2):1295-306.

Azad N, Rasoolijazi H, Joghataie MT, Soleimani S. Neuroprotective effects of carnosic Acid in an experimental model of Alzheimer's disease in rats. *Cell journal*. 2011;13(1):39-44.

Bachstetter AD, Norris CM, Sompol P, Wilcock DM, Goulding D, Neltner JH, et al. Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2012;32(30):10201-10.

Baek I-S, Kim T-K, Seo J-S, Lee K-W, Lee YA, Cho J, et al. AAD-2004 Attenuates Progressive Neuronal Loss in the Brain of Tg-betaCTF99/B6 Mouse Model of Alzheimer Disease. *Experimental neurobiology*. 2013;22(1):31-7.

Baek S-H, Park SJ, In Jeong J, Hyun Kim S, Han J, Won Kyung J, et al. Inhibition of Drp1 Ameliorates Synaptic Depression, Abeta Deposition and Cognitive Impairment in Alzheimer's Disease Model. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017.

Baglietto-Vargas D, Medeiros R, Martinez-Coria H, LaFerla FM, Green KN. Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. *Biological psychiatry*. 2013;74(5):357-66.

Bajda M, Jonczyk J, Malawska B, Czarnecka K, Girek M, Olszewska P, et al. Synthesis, biological evaluation and molecular modeling of new tetrahydroacridine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease. *Bioorganic & medicinal chemistry*. 2015;23(17):5610-8.

Bao X-Q, Li N, Wang T, Kong X-C, Tai W-J, Sun H, et al. FLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylation. *PloS one*. 2013;8(11):e78033.

Bardgett ME, Davis NN, Schultheis PJ, Griffith MS. Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease. *Neurobiology of learning and memory*. 2011;95(1):64-72.

Bastianetto S, Ramassamy C, Poirier J, Quirion R. Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. *Brain research Molecular brain research*. 1999;66(1-2):35-41.

Bautmans I, Demarteau J, Cruts B, Lemper J-C, Mets T. Dysphagia in elderly nursing home residents with severe cognitive impairment can be attenuated by cervical spine mobilization. *Journal of rehabilitation medicine*. 2008;40(9):755-60.

Beach TG, Walker DG, Potter PE, Sue LI, Fisher A. Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. *Brain research*. 2001;905(1-2):220-3.

Beauquis J, Pavia P, Pomilio C, Vinuesa A, Podlutska N, Galvan V, et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease. *Experimental neurology*. 2013;239:28-37.

Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, et al. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid

accumulation in a mouse model of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2004;24(17):4181-6.

Bernardi A, Frozza RL, Meneghetti A, Hoppe JB, Battastini AMO, Pohlmann AR, et al. Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Abeta1-42 in Alzheimer's disease models. *International journal of nanomedicine*. 2012;7:4927-42.

Bhardwaj M, Deshmukh R, Kaundal M, Krishna Reddy BV. Pharmacological induction of hemeoxygenase-1 activity attenuates intracerebroventricular streptozotocin induced neurocognitive deficit and oxidative stress in rats. *European journal of pharmacology*. 2016;772:43-50.

Bhattacharya S, Maelicke A, Montag D. Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice. *Journal of Alzheimer's disease : JAD*. 2015;46(1):123-36.

Biasibetti R, Tramontina AC, Costa AP, Dutra MF, Quincozes-Santos A, Nardin P, et al. Green tea (-)epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia. *Behavioural brain research*. 2013;236(1):186-93.

Biradar SM, Joshi H, Chheda TK. Biochanin-A ameliorates behavioural and neurochemical derangements in cognitive-deficit mice for the betterment of Alzheimer's disease. *Human & experimental toxicology*. 2014;33(4):369-82.

Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. *The Cochrane database of systematic reviews*. 2015(4):CD001191.

Biscaro B, Lindvall O, Tesco G, Ekdahl CT, Nitsch RM. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease. *Neuro-degenerative diseases*. 2012;9(4):187-98.

Boast C, Bartolomeo AC, Morris H, Moyer JA. 5HT antagonists attenuate MK801-impaired radial arm maze performance in rats. *Neurobiology of learning and memory*. 1999;71(3):259-71.

Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. *Archives of neurology*. 1997;54(4):465-73.

Bolea-Alamanac BM, Davies SJC, Christmas DM, Baxter H, Cullum S, Nutt DJ. Cyproterone to treat aggressivity in dementia: a clinical case and systematic review. *Journal of psychopharmacology (Oxford, England)*. 2011;25(1):141-5.

Bolognesi ML, Cavalli A, Melchiorre C. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*. 2009;6(1):152-62.

Braden BA, Gaspar PM. Implementation of a baby doll therapy protocol for people with dementia: Innovative practice. *Dementia (London, England)*. 2015;14(5):696-706.

Braidy N, Behzad S, Habtemariam S, Ahmed T, Daglia M, Nabavi SM, et al. Neuroprotective Effects of Citrus Fruit-Derived Flavonoids, Nobiletin and Tangeretin in Alzheimer's and Parkinson`s disease. *CNS & neurological disorders drug targets*. 2017.

Broersen LM, Kuipers AAM, Balvers M, van Wijk N, Savelkoul PJM, de Wilde MC, et al. A specific multi-nutrient diet reduces Alzheimer-like pathology in young adult AbetaPPswe/PS1dE9 mice. *Journal of Alzheimer's disease : JAD*. 2013;33(1):177-90.

Brueggen K, Kasper E, Ochmann S, Pfaff H, Webel S, Schneider W, et al. Cognitive Rehabilitation in Alzheimer's Disease: A Controlled Intervention Trial. *Journal of Alzheimers Disease*. 2017;57(4):1315-24.

Bryleva EY, Rogers MA, Chang CCY, Buen F, Harris BT, Rousselet E, et al. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(7):3081-6.

Bungart BL, Dong L, Sobek D, Sun GY, Yao G, Lee JCM. Nanoparticle-emitted light attenuates amyloid-beta-induced superoxide and inflammation in astrocytes. *Nanomedicine : nanotechnology, biology, and medicine*. 2014;10(1):15-7.

Burgess A, Dubey S, Yeung S, Hough O, Eterman N, Aubert I, et al. Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behavior. *Radiology*. 2014;273(3):736-45.

Burov IV, Robakidze TN, Kadyshcheva LV, Voronin AE, Shaposhnikova GI. Study of anti-amnesic activity of amiridin in a model of amnesic syndrome. *Biulleten' eksperimental'noi biologii i meditsiny*. 1991;111(6):614-7.

Buxbaum JD, Cullen EI, Friedhoff LT. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. *Frontiers in bioscience : a journal and virtual library*. 2002;7:a50-9.

Caccamo A, De Pinto V, Messina A, Branca C, Oddo S. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by

restoring hippocampal gene expression signature. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(23):7988-98.

Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(52):22687-92.

Cai C, Dai X, Zhu Y, Lian M, Xiao F, Dong F, et al. A specific RAGE-binding peptide biopanning from phage display random peptide library that ameliorates symptoms in amyloid beta peptide-mediated neuronal disorder. *Applied microbiology and biotechnology*. 2016;100(2):825-35.

Cakala M, Malik AR, Strosznajder JB. Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice. *Pharmacological reports : PR*. 2007;59(2):164-72.

Cakir S, Kulaksizoglu IB. The efficacy of mirtazapine in agitated patients with Alzheimer's disease: A 12-week open-label pilot study. *Neuropsychiatric disease and treatment*. 2008;4(5):963-6.

Calkin PA, Kunik ME, Orengo CA, Molinari V, Workman R. Tolerability of clonazepam in demented and non-demented geropsychiatric patients. *International journal of geriatric psychiatry*. 1997;12(7):745-9.

Camargos EF, Louzada LL, Quintas JL, Naves JOS, Louzada FM, Nobrega OT. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2014;22(12):1565-74.

Cantarella G, Di Benedetto G, Puzzo D, Privitera L, Loreto C, Saccone S, et al. Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease. *Brain : a journal of neurology*. 2015;138(Pt 1):203-16.

Cao CH, Wang L, Lin XY, Mamcarz M, Zhang C, Bai G, et al. Caffeine Synergizes with Another Coffee Component to Increase Plasma GCSF: Linkage to Cognitive Benefits in Alzheimer's Mice. *Journal of Alzheimers Disease*. 2011;25(2):323-35.

Cao C, Li Y, Liu H, Bai G, Mayl J, Lin X, et al. The potential therapeutic effects of THC on Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;42(3):973-84.

Cao Y, Jia X, Wei Y, Liu M, Liu J, Li H. Traditional Chinese Medicine Huannao Yicong Decoction Extract Decreases Tau Hyperphosphorylation in the Brain of Alzheimer's Disease

Model Rats Induced by Abeta1-42. Evidence-based complementary and alternative medicine : eCAM. 2016;2016:6840432.

Capsoni S, Giannotta S, Stebel M, Garcia AA, De Rosa R, Villetti G, et al. Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice. American journal of Alzheimer's disease and other dementias. 2004;19(3):153-60.

Castello NA, Nguyen MH, Tran JD, Cheng D, Green KN, LaFerla FM. 7,8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal loss. PloS one. 2014;9(3):e91453.

Cattepoel S, Hanenberg M, Kulic L, Nitsch RM. Chronic intranasal treatment with an anti-Abeta(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PloS one. 2011;6(4):e18296.

Cha M-Y, Kwon Y-W, Ahn H-S, Jeong H, Lee YY, Moon M, et al. Protein-Induced Pluripotent Stem Cells Ameliorate Cognitive Dysfunction and Reduce Aβ Deposition in a Mouse Model of Alzheimer's Disease. Stem cells translational medicine. 2017;6(1):293-305.

Chai G-S, Duan D-X, Ma R-H, Shen J-Y, Li H-L, Ma Z-W, et al. Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid beta-peptide in rats. Neuroscience bulletin. 2014;30(6):923-35.

Chai G-S, Jiang X, Ni Z-F, Ma Z-W, Xie A-J, Cheng X-S, et al. Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. Journal of neurochemistry. 2013;124(3):388-96.

Chai J-X, Li H-H, Wang Y-Y, Chai Q, He W-X, Zhou Y-M, et al. Effect of diallyl disulfide on learning and memory abilities and hippocampal synapses in mouse models of Alzheimer's disease. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2016;36(10):1417-22.

Chan A, Shea TB. Supplementation with apple juice attenuates presenilin-1 overexpression during dietary and genetically-induced oxidative stress. Journal of Alzheimer's disease : JAD. 2006;10(4):353-8.

Chang C-Y, Chen S-M, Lu H-E, Lai S-M, Lai P-S, Shen P-W, et al. N-butyridenephthalide attenuates Alzheimer's disease-like cytopathy in Down syndrome induced pluripotent stem cell-derived neurons. Scientific reports. 2015;5:8744.

Charlesworth G, Sadek S, Schepers A, Spector A. Cognitive Behavior Therapy for Anxiety in People With Dementia: A Clinician Guideline for a Person-Centered Approach. Behavior Modification. 2015;39(3):390-412.

Chauhan NB. Effect of aged garlic extract on APP processing and tau phosphorylation in Alzheimer's transgenic model Tg2576. *Journal of ethnopharmacology*. 2006;108(3):385-94.

Chauhan NB, Siegel GJ, Feinstein DL. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576. *Neuropharmacology*. 2005;48(1):93-104.

Chavant F, Deguil J, Pain S, Ingrand I, Milin S, Fauconneau B, et al. Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease. *The Journal of pharmacology and experimental therapeutics*. 2010;332(2):505-14.

Chen C-Y, Jang J-H, Park MH, Hwang SJ, Surh Y-J, Park OJ. Attenuation of Abeta-induced apoptosis of plant extract (Saengshik) mediated by the inhibition of mitochondrial dysfunction and antioxidative effect. *Annals of the New York Academy of Sciences*. 2007;1095:399-411.

Chen J-L, Zhang D-L, Sun Y, Zhao Y-X, Zhao K-X, Pu D, et al. Angiotensin-(1-7) administration attenuates Alzheimer's disease-like neuropathology in rats with streptozotocin-induced diabetes via Mas receptor activation. *Neuroscience*. 2017;346:267-77.

Chen L-M, Xiong Y-S, Kong F-L, Qu M, Wang Q, Chen X-Q, et al. Neuroglobin attenuates Alzheimer-like tau hyperphosphorylation by activating Akt signaling. *Journal of neurochemistry*. 2012;120(1):157-64.

Chen P, Yan Q, Wang S, Wang C, Zhao P. Transfer of three transcription factors via a lentiviral vector ameliorates spatial learning and memory impairment in a mouse model of Alzheimer's disease. *Gene*. 2016;587(1):59-63.

Chen Y, Wang B, Liu D, Li JJ, Xue Y, Sakata K, et al. Hsp90 chaperone inhibitor 17-AAG attenuates Abeta-induced synaptic toxicity and memory impairment. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(7):2464-70.

Chen Y-J, Zheng H-Y, Huang X-X, Han S-X, Zhang D-S, Ni J-Z, et al. Neuroprotective Effects of Icaritin on Brain Metabolism, Mitochondrial Functions, and Cognition in Triple-Transgenic Alzheimer's Disease Mice. *CNS neuroscience & therapeutics*. 2016;22(1):63-73.

Cheng D, Spiro AS, Jenner AM, Garner B, Karl T. Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. *Journal of Alzheimer's disease : JAD*. 2014;42(4):1383-96.

Cheng JS, Dubal DB, Kim DH, Legleiter J, Cheng IH, Yu G-Q, et al. Collagen VI protects neurons against Abeta toxicity. *Nature neuroscience*. 2009;12(2):119-21.

Cheng L, Zhang J, Li X-Y, Yuan L, Pan Y-F, Chen X-R, et al. A novel antibody targeting sequence 31-35 in amyloid beta protein attenuates Alzheimer's disease-related neuronal damage. *Hippocampus*. 2017;27(2):122-33.

Cheng Y-S, Chen Z-T, Liao T-Y, Lin C, Shen HCH, Wang Y-H, et al. An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. *EMBO molecular medicine*. 2017;9(5):703-15.

Cheng Y, Dong Z, Liu S. beta-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARgamma pathway. *Pharmacology*. 2014;94(1-2):1-12.

Chiapinotto Spiazzi C, Bucco Soares M, Pinto Izaguirry A, Musacchio Vargas L, Zanchi MM, Frasson Pavin N, et al. Selenofuranoside Ameliorates Memory Loss in Alzheimer-Like Sporadic Dementia: AChE Activity, Oxidative Stress, and Inflammation Involvement. *Oxidative medicine and cellular longevity*. 2015;2015:976908.

Choi JG, Moon M, Kim HG, Mook-Jung I, Chung SY, Kang TH, et al. Gami-Chunghyuldan ameliorates memory impairment and neurodegeneration induced by intrahippocampal Abeta 1-42 oligomer injection. *Neurobiology of learning and memory*. 2011;96(2):306-14.

Choi SJ, Oh SS, Kim CR, Kwon YK, Suh SH, Kim JK, et al. Perilla frutescens Extract Ameliorates Acetylcholinesterase and Trimethyltin Chloride-Induced Neurotoxicity. *Journal of medicinal food*. 2016;19(3):281-9.

Choi YY, Maeda T, Fujii H, Yokozawa T, Kim HY, Cho EJ, et al. Oligonol improves memory and cognition under an amyloid beta(25-35)-induced Alzheimer's mouse model. *Nutrition research (New York, NY)*. 2014;34(7):595-603.

Choi Y, Lee K, Ryu J, Kim HG, Jeong AY, Woo R-S, et al. Neuritin attenuates cognitive function impairments in tg2576 mouse model of Alzheimer's disease. *PloS one*. 2014;9(8):e104121.

Choi Y, Jeong HJ, Liu QF, Oh ST, Koo B-S, Kim Y, et al. Clozapine Improves Memory Impairment and Reduces Abeta Level in the Tg-APPswe/PS1dE9 Mouse Model of Alzheimer's Disease. *Molecular neurobiology*. 2017;54(1):450-60.

Chou P-S, Ho B-L, Yang Y-H. Effects of pioglitazone on the incidence of dementia in patients with diabetes. *Journal of diabetes and its complications*. 2017;31(6):1053-7.

Chu C, Zhang X, Ma W, Li L, Wang W, Shang L, et al. Induction of autophagy by a novel small molecule improves abeta pathology and ameliorates cognitive deficits. *PloS one*. 2013;8(6):e65367.

Chu J, Li JG, Giannopoulos PF, Blass BE, Childers W, Abou-Gharbia M, et al. Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Abeta and tau neuropathology in the triple-transgenic mice. *Molecular psychiatry*. 2015;20(11):1329-38.

Chuang Y-F, Breitner JCS, Chiu Y-L, Khachaturian A, Hayden K, Corcoran C, et al. Use of diuretics is associated with reduced risk of Alzheimer's disease: the Cache County Study. *Neurobiology of aging*. 2014;35(11):2429-35.

Cifelli JL, Chung TS, Liu H, Prangko P, Mayer M, Yang J. Benzothiazole Amphiphiles Ameliorate Amyloid beta-Related Cell Toxicity and Oxidative Stress. *ACS chemical neuroscience*. 2016;7(6):682-8.

Cirillo C, Capoccia E, Iuvone T, Cuomo R, Sarnelli G, Steardo L, et al. S100B Inhibitor Pentamidine Attenuates Reactive Gliosis and Reduces Neuronal Loss in a Mouse Model of Alzheimer's Disease. *BioMed research international*. 2015;2015:508342.

Cisternas P, Lindsay CB, Salazar P, Silva-Alvarez C, Retamales RM, Serrano FG, et al. The increased potassium intake improves cognitive performance and attenuates histopathological markers in a model of Alzheimer's disease. *Biochimica et biophysica acta*. 2015;1852(12):2630-44.

Collier L, McPherson K, Ellis-Hill C, Staal J, Bucks R. Multisensory stimulation to improve functional performance in moderate to severe dementia--interim results. *American journal of Alzheimer's disease and other dementias*. 2010;25(8):698-703.

Cooney C, Murphy S, Tessema H, Freyne A. Use of low-dose gabapentin for aggressive behavior in vascular and Mixed Vascular/Alzheimer Dementia. *The Journal of neuropsychiatry and clinical neurosciences*. 2013;25(2):120-5.

Costa M, Bernardi J, Fiuza T, Costa L, Brandao R, Pereira ME. N-acetylcysteine protects memory decline induced by streptozotocin in mice. *Chemico-biological interactions*. 2016;253:10-7.

Cotroneo A, Gareri P, Nicoletti N, Lacava R, Grassone D, Maina E, et al. Effectiveness and safety of hypnotic drugs in the treatment of insomnia in over 70-year old people. *Archives of gerontology and geriatrics*. 2007;44 Suppl 1:121-4.

Craft JM, Van Eldik LJ, Zasadzki M, Hu W, Watterson DM. Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation. *Journal of molecular neuroscience : MN*. 2004;24(1):115-22.

Cramer PE, Cirrito JR, Wesson DW, Lee CYD, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. *Science (New York, NY)*. 2012;335(6075):1503-6.

Crump CJ, Castro SV, Wang F, Pozdnyakov N, Ballard TE, Sisodia SS, et al. BMS-708,163 targets presenilin and lacks notch-sparing activity. *Biochemistry*. 2012;51(37):7209-11.

Crupi R, Marino A, Cuzzocrea S. n-3 fatty acids: role in neurogenesis and neuroplasticity. *Current medicinal chemistry*. 2013;20(24):2953-63.

Cuadrado-Tejedor M, Ricobaraza AL, Torrijo R, Franco R, Garcia-Osta A. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimers disease-like phenotype of a commonly used mouse model. *Current pharmaceutical design*. 2013;19(28):5076-84.

Cui J, Wang Y, Dong Q, Wu S, Xiao X, Hu J, et al. Morphine protects against intracellular amyloid toxicity by inducing estradiol release and upregulation of Hsp70. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2011;31(45):16227-40.

Cui J, Wang X, Li X, Wang X, Zhang C, Li W, et al. Targeting the gamma-/beta-secretase interaction reduces beta-amyloid generation and ameliorates Alzheimer's disease-related pathogenesis. *Cell discovery*. 2015;1:15021.

Cui Y-Q, Wang Q, Zhang D-M, Wang J-Y, Xiao B, Zheng Y, et al. Triptolide Rescues Spatial Memory Deficits and Amyloid-beta Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice. *Current Alzheimer research*. 2016;13(3):288-96.

Cummings JL, Nadel A, Masterman D, Cyrus PA. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease. *Journal of geriatric psychiatry and neurology*. 2001;14(2):101-8.

D'Agostino G, Russo R, Avagliano C, Cristiano C, Meli R, Calignano A. Palmitoylethanolamide protects against the amyloid-beta₂₅₋₃₅-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2012;37(7):1784-92.

Daiello LA, Gongvatana A, Dunsiger S, Cohen RA, Ott BR, Alzheimer's Disease Neuroimaging I. Association of fish oil supplement use with preservation of brain volume and cognitive function. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2015;11(2):226-35.

Dalla Y, Singh N, Jaggi AS, Singh D. Memory restorative role of statins in experimental dementia: an evidence of their cholesterol dependent and independent actions. *Pharmacological reports : PR*. 2010;62(5):784-96.

Davenport CM, Sevastou IG, Hooper C, Pocock JM. Inhibiting p53 pathways in microglia attenuates microglial-evoked neurotoxicity following exposure to Alzheimer peptides. *Journal of neurochemistry*. 2010;112(2):552-63.

Deshmukh R, Kaundal M, Bansal V, Samardeep. Caffeic acid attenuates oxidative stress, learning and memory deficit in intra-cerebroventricular streptozotocin induced experimental dementia in rats. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2016;81:56-62.

Dhanasekaran M, Holcomb LA, Hitt AR, Tharakan B, Porter JW, Young KA, et al. Centella asiatica extract selectively decreases amyloid beta levels in hippocampus of Alzheimer's disease animal model. *Phytotherapy research : PTR*. 2009;23(1):14-9.

Dhawan G, Combs CK. Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease. *Journal of neuroinflammation*. 2012;9:117.

Dhurandhar EJ, Allison DB, van Groen T, Kadish I. Hunger in the absence of caloric restriction improves cognition and attenuates Alzheimer's disease pathology in a mouse model. *PloS one*. 2013;8(4):e60437.

Di Meco A, Joshi YB, Lauretti E, Pratico D. Maternal dexamethasone exposure ameliorates cognition and tau pathology in the offspring of triple transgenic AD mice. *Molecular psychiatry*. 2016;21(3):403-10.

Dinamarca MC, Cerpa W, Garrido J, Hancke JL, Inestrosa NC. Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. *Molecular psychiatry*. 2006;11(11):1032-48.

Ding Y, Qiao A, Fan G-H. Indirubin-3'-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer's disease. *Neurobiology of disease*. 2010;39(2):156-68.

Dinkins MB, Enasko J, Hernandez C, Wang GH, Kong J, Helwa I, et al. Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse. *Journal of Neuroscience*. 2016;36(33):8653-67.

Do Carmo S, Hanzel CE, Jacobs ML, Machnes Z, Iulita MF, Yang J, et al. Rescue of Early bace-1 and Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves Cognition in an Alzheimer's Model. *Scientific reports*. 2016;6:34051.

Dobarro M, Gerenu G, Ramirez MJ. Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice. *The international journal of neuropsychopharmacology*. 2013;16(10):2245-57.

Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, Ikeyama M, et al. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease. *The American journal of pathology*. 2009;175(5):2121-32.

Dong Y, Wang Y, Liu Y, Yang N, Zuo P. Phytoestrogen alpha-zearalanol ameliorates memory impairment and neuronal DNA oxidation in ovariectomized mice. *Clinics (Sao Paulo, Brazil)*. 2013;68(9):1255-62.

Dorostkar MM, Burgold S, Filser S, Barghorn S, Schmidt B, Anumala UR, et al. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model. *Brain : a journal of neurology*. 2014;137(Pt 12):3319-26.

Dourado MCN, Laks J. Psychological Interventions for Neuropsychiatric Disturbances in Mild and Moderate Alzheimer's Disease: Current Evidences and Future Directions. *Current Alzheimer research*. 2016;13(10):1100-11.

Drouet B, Pincon-Raymond M, Chambaz J, Pillot T. Laminin 1 attenuates beta-amyloid peptide Abeta(1-40) neurotoxicity of cultured fetal rat cortical neurons. *Journal of neurochemistry*. 1999;73(2):742-9.

Du J, Liang Y, Xu F, Sun B, Wang Z. Trehalose rescues Alzheimer's disease phenotypes in APP/PS1 transgenic mice. *The Journal of pharmacy and pharmacology*. 2013;65(12):1753-6.

Du L-L, Chai D-M, Zhao L-N, Li X-H, Zhang F-C, Zhang H-B, et al. AMPK activation ameliorates Alzheimer's disease-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer's disease model in rats. *Journal of Alzheimer's disease : JAD*. 2015;43(3):775-84.

Du Y, Bales KR, Dodel RC, Liu X, Glinn MA, Horn JW, et al. Alpha2-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. *Journal of neurochemistry*. 1998;70(3):1182-8.

Duan S, Guan X, Lin R, Liu X, Yan Y, Lin R, et al. Silibinin inhibits acetylcholinesterase activity and amyloid beta peptide aggregation: a dual-target drug for the treatment of Alzheimer's disease. *Neurobiology of aging*. 2015;36(5):1792-807.

Dubois B, Chupin M, Hampel H, Lista S, Cavedo E, Croisile B, et al. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2015;11(9):1041-9.

Dumont M, Kipiani K, Yu FM, Wille E, Katz M, Calingasan NY, et al. Coenzyme Q10 Decreases Amyloid Pathology and Improves Behavior in a Transgenic Mouse Model of Alzheimer's Disease. *Journal of Alzheimers Disease*. 2011;27(1):211-23.

Durairajan SSK, Liu L-F, Lu J-H, Chen L-L, Yuan Q, Chung SK, et al. Berberine ameliorates beta-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model. *Neurobiology of aging*. 2012;33(12):2903-19.

Duru Asiret G, Kapucu S. The Effect of Reminiscence Therapy on Cognition, Depression, and Activities of Daily Living for Patients With Alzheimer Disease. *Journal of geriatric psychiatry and neurology*. 2016;29(1):31-7.

Echeverria V, Zeitlin R, Burgess S, Patel S, Barman A, Thakur G, et al. Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice. *Journal of Alzheimer's disease : JAD*. 2011;24(4):817-35.

El Dayem SMA, Ahmed HH, Metwally F, Foda FMA, Shalby AB, Zaazaa AMA. Alpha-chymotrypsin ameliorates neuroinflammation and apoptosis characterizing Alzheimer's disease-induced in ovariectomized rats. *Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie*. 2013;65(5):477-83.

El-Khadragy MF, Al-Olayan EM, Abdel Moneim AE. Neuroprotective effects of Citrus reticulata in scopolamine-induced dementia oxidative stress in rats. *CNS & neurological disorders drug targets*. 2014;13(4):684-90.

ElAli A, Bordeleau M, Theriault P, Filali M, Lampron A, Rivest S. Tissue-Plasminogen Activator Attenuates Alzheimer's Disease-Related Pathology Development in APPswe/PS1 Mice. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2016;41(5):1297-307.

Elcioglu H, Kabasakal L, Alan S, Salva E, Tufan F, Karan M. Thalidomide attenuates learning and memory deficits induced by intracerebroventricular administration of streptozotocin in rats. *Biotechnic & histochemistry : official publication of the Biological Stain Commission*. 2013;88(3-4):145-52.

Erdmann A, Schnepf W. Conditions, components and outcomes of Integrative Validation Therapy in a long-term care facility for people with dementia. A qualitative evaluation study. *Dementia (London, England)*. 2016;15(5):1184-204.

Escribano L, Simon A-M, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garcia-Osta A, et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2010;35(7):1593-604.

Esmaeili Tazangi P, Moosavi SMS, Shabani M, Haghani M. Erythropoietin improves synaptic plasticity and memory deficits by decrease of the neurotransmitter release probability in the rat model of Alzheimer's disease. *Pharmacology, biochemistry, and behavior*. 2015;130:15-21.

Espinosa J, Rocha A, Nunes F, Costa MS, Schein V, Kazlauckas V, et al. Caffeine consumption prevents memory impairment, neuronal damage, and adenosine A2A receptors upregulation in the hippocampus of a rat model of sporadic dementia. *Journal of Alzheimer's disease : JAD*. 2013;34(2):509-18.

Esteves IM, Lopes-Aguiar C, Rossignoli MT, Ruggiero RN, Broggin ACS, Bueno-Junior LS, et al. Chronic nicotine attenuates behavioral and synaptic plasticity impairments in a streptozotocin model of Alzheimer's disease. *Neuroscience*. 2017;353:87-97.

Fakhfour G, Ahmadiani A, Rahimian R, Grolla AA, Moradi F, Haeri A. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-gamma pathway. *Neuropharmacology*. 2012;63(4):653-66.

Fan J-T, Chen K-M. Using silver yoga exercises to promote physical and mental health of elders with dementia in long-term care facilities. *International psychogeriatrics*. 2011;23(8):1222-30.

Farfara D, Tuby H, Trudler D, Doron-Mandel E, Maltz L, Vassar RJ, et al. Low-level laser therapy ameliorates disease progression in a mouse model of Alzheimer's disease. *Journal of molecular neuroscience : MN*. 2015;55(2):430-6.

Farias GG, Godoy JA, Vazquez MC, Adani R, Meshulam H, Avila J, et al. The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. *Neurobiology of disease*. 2005;18(1):176-83.

Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, et al. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. *Journal of Alzheimer's disease : JAD*. 2010;20(2):509-16.

Fava A, Pirritano D, Plastino M, Cristiano D, Puccio G, Colica C, et al. The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer's Disease. *Journal of neurodegenerative diseases*. 2013;2013:454253.

Figueiro M, Ilha J, Linck VM, Herrmann AP, Nardin P, Menezes CB, et al. The Amazonian herbal Marapuama attenuates cognitive impairment and neuroglial degeneration in a mouse Alzheimer model. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2011;18(4):327-33.

Fine JM, Renner DB, Forsberg AC, Cameron RA, Galick BT, Le C, et al. Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation. *Neuroscience letters*. 2015;584:362-7.

Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. The Cochrane database of systematic reviews. 2005(2):CD000269.

Fischhof PK, Saletu B, Ruther E, Litschauer G, Moslinger-Gehmayr R, Herrmann WM. Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID). Neuropsychobiology. 1992;26(1-2):65-70.

Fisher A. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. Japanese journal of pharmacology. 2000;84(2):101-12.

Frenkel D, Maron R, Burt DS, Weiner HL. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. The Journal of clinical investigation. 2005;115(9):2423-33.

Frost JL, Liu B, Rahfeld J-U, Kleinschmidt M, O'Nuallain B, Le KX, et al. An anti-pyroglutamate-3 Abeta vaccine reduces plaques and improves cognition in APPswe/PS1DeltaE9 mice. Neurobiology of aging. 2015;36(12):3187-99.

Fu AKY, Hung K-W, Huang H, Gu S, Shen Y, Cheng EYL, et al. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(27):9959-64.

Fu AKY, Hung K-W, Yuen MYF, Zhou X, Mak DSY, Chan ICW, et al. IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(19):E2705-13.

Fu L, Li Y, Hu Y, Zheng Y, Yu B, Zhang H, et al. Norovirus P particle-based active Abeta immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer's disease. Scientific reports. 2017;7:41041.

Fu X, Wang Q, Wang Z, Kuang H, Jiang P. Danggui-Shaoyao-San: New Hope for Alzheimer's Disease. Aging and disease. 2016;7(4):502-13.

Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, et al. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2010;30(33):11157-66.

Fukumoto K, Mizoguchi H, Takeuchi H, Horiuchi H, Kawanokuchi J, Jin S, et al. Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid beta-induced memory impairment. Behavioural brain research. 2014;268:88-93.

Fukushima T, Nakamura A, Iwakami N, Nakada Y, Hattori H, Hoki S, et al. T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice. *Biochemical and biophysical research communications*. 2011;407(4):730-4.

Furlan JC, Henri-Bhargava A, Freedman M. Clomipramine in the treatment of compulsive behavior in frontotemporal dementia: a case series. *Alzheimer disease and associated disorders*. 2014;28(1):95-8.

Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD, et al. Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2012;32(46):16129-40.

Gangwar AK, Rawat A, Tiwari S, Tiwari SC, Narayan J, Tiwari S. Role of Vitamin-D in the prevention and treatment of Alzheimer's disease. *Indian journal of physiology and pharmacology*. 2015;59(1):94-9.

Gao A-S, Du H, Gao Q, Wang Y-J, Wang X-Y, Liu J-W, et al. Tong Luo Jiu Nao, a Chinese Medicine Formula, Reduces Inflammatory Stress in a Mouse Model of Alzheimer's Disease. *American journal of Alzheimer's disease and other dementias*. 2016;31(5):413-21.

Gao C, Liu Y, Jiang Y, Ding J, Li L. Geniposide ameliorates learning memory deficits, reduces tau phosphorylation and decreases apoptosis via GSK3beta pathway in streptozotocin-induced alzheimer rat model. *Brain pathology (Zurich, Switzerland)*. 2014;24(3):261-9.

Gao J, He H, Jiang W, Chang X, Zhu L, Luo F, et al. Salidroside ameliorates cognitive impairment in a d-galactose-induced rat model of Alzheimer's disease. *Behavioural brain research*. 2015;293:27-33.

Gao N, Sun H, Dong K, Ren J, Qu X. Gold-nanoparticle-based multifunctional amyloid-beta inhibitor against Alzheimer's disease. *Chemistry (Weinheim an der Bergstrasse, Germany)*. 2015;21(2):829-35.

Garay RP, Citrome L, Grossberg GT, Cavero I, Llorca P-M. Investigational drugs for treating agitation in persons with dementia. *Expert opinion on investigational drugs*. 2016;25(8):973-83.

Garay RP, Grossberg GT. AVP-786 for the treatment of agitation in dementia of the Alzheimer's type. *Expert opinion on investigational drugs*. 2017;26(1):121-32.

Gareri P, Castagna A, Cotroneo AM, Putignano D, Conforti R, Santamaria F, et al. The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study. *Journal of Alzheimer's disease : JAD*. 2017;56(2):557-65.

Ge Y-S, Teng W-Y, Zhang C-D. Protective effect of cyclophilin A against Alzheimer's amyloid beta-peptide (25-35)-induced oxidative stress in PC12 cells. Chinese medical journal. 2009;122(6):716-24.

Ghofrani S, Joghataei M-T, Mohseni S, Baluchnejadmojarad T, Bagheri M, Khamse S, et al. Naringenin improves learning and memory in an Alzheimer's disease rat model: Insights into the underlying mechanisms. European journal of pharmacology. 2015;764:195-201.

Giannopoulos PF, Chu J, Joshi YB, Sperow M, Li J-G, Kirby LG, et al. 5-lipoxygenase activating protein reduction ameliorates cognitive deficit, synaptic dysfunction, and neuropathology in a mouse model of Alzheimer's disease. Biological psychiatry. 2013;74(5):348-56.

Gimenez-Llort L, Rivera-Hernandez G, Marin-Argany M, Sanchez-Quesada JL, Villegas S. Early intervention in the 3xTg-AD mice with an amyloid beta-antibody fragment ameliorates first hallmarks of Alzheimer disease. mAbs. 2013;5(5):665-77.

Glass OM, Forester BP, Hermida AP. Electroconvulsive therapy (ECT) for treating agitation in dementia (major neurocognitive disorder) - a promising option. International psychogeriatrics. 2017;29(5):717-26.

Goldsmith HS. A new approach to the treatment of Alzheimer's disease: the need for a controlled study. Journal of Alzheimer's disease : JAD. 2011;25(2):209-12.

Gomez-Isla T, Blesa R, Boada M, Clarimon J, Del Ser T, Domenech G, et al. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer disease and associated disorders. 2008;22(1):21-9.

Gong B, Chen F, Pan Y, Arrieta-Cruz I, Yoshida Y, Haroutunian V, et al. SCFFbx2-E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function. Aging cell. 2010;9(6):1018-31.

Gong EJ, Park HR, Kim ME, Piao S, Lee E, Jo D-G, et al. Morin attenuates tau hyperphosphorylation by inhibiting GSK3beta. Neurobiology of disease. 2011;44(2):223-30.

Goni F, Herline K, Peyser D, Wong K, Ji Y, Sun Y, et al. Immunomodulation targeting of both Abeta and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models. Journal of neuroinflammation. 2013;10:150.

Gontier G, George C, Chaker Z, Holzenberger M, Aid S. Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-beta Clearance. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2015;35(33):11500-13.

Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. *Journal of Alzheimer's disease : JAD*. 2011;26(1):187-97.

Graff MJL, Vernooij-Dassen MJM, Thijssen M, Dekker J, Hoefnagels WHL, Rikkert MGMO. Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial. *BMJ (Clinical research ed)*. 2006;333(7580):1196.

Grossi C, Francese S, Casini A, Rosi MC, Luccarini I, Fiorentini A, et al. Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2009;17(2):423-40.

Grundman M. Vitamin E and Alzheimer disease: the basis for additional clinical trials. *The American journal of clinical nutrition*. 2000;71(2):630S-6S.

Grundman M, Capparelli E, Kim HT, Morris JC, Farlow M, Rubin EH, et al. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. *Life sciences*. 2003;73(5):539-53.

Gu X, Cai Z, Cai M, Liu K, Liu D, Zhang Q, et al. Protective effect of paeoniflorin on inflammation and apoptosis in the cerebral cortex of a transgenic mouse model of Alzheimer's disease. *Molecular medicine reports*. 2016;13(3):2247-52.

Gu X-H, Xu L-J, Liu Z-Q, Wei B, Yang Y-J, Xu G-G, et al. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease. *Behavioural brain research*. 2016;311:309-21.

Guo H, Cao M, Zou S, Ye B, Dong Y. Cranberry Extract Standardized for Proanthocyanidins Alleviates beta-Amyloid Peptide Toxicity by Improving Proteostasis Through HSF-1 in *Caenorhabditis elegans* Model of Alzheimer's Disease. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2016;71(12):1564-73.

Guo W, Sha S, Xing X, Jiang T, Cao Y. Reduction of cerebral Abeta burden and improvement in cognitive function in Tg-APPswe/PSEN1dE9 mice following vaccination with a multivalent Abeta3-10 DNA vaccine. *Neuroscience letters*. 2013;549:109-15.

Guo X-D, Sun G-L, Zhou T-T, Xu X, Zhu Z-Y, Rukachaisirikul V, et al. Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid beta production and clearance. *Acta pharmacologica Sinica*. 2016;37(10):1281-97.

Guo Z, Chen Y, Mao Y-F, Zheng T, Jiang Y, Yan Y, et al. Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer's rat model. *Scientific reports*. 2017;7:45971.

Guzman A, Robinson L, Rochester L, James IA, Hughes JC. A process evaluation of a Psychomotor Dance Therapy Intervention (DANCIN) for behavior change in dementia: attitudes and beliefs of participating residents and staff. *International psychogeriatrics*. 2017;29(2):313-22.

Halagappa VKM, Guo Z, Pearson M, Matsuoka Y, Cutler RG, Laferla FM, et al. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. *Neurobiology of disease*. 2007;26(1):212-20.

Han JW, Lee H, Hong JW, Kim K, Kim T, Byun HJ, et al. Multimodal Cognitive Enhancement Therapy for Patients with Mild Cognitive Impairment and Mild Dementia: A Multi-Center, Randomized, Controlled, Double-Blind, Crossover Trial. *Journal of Alzheimer's disease : JAD*. 2017;55(2):787-96.

Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2005;25(26):6213-20.

Hasegawa H, Liu L, Tooyama I, Murayama S, Nishimura M. The FAM3 superfamily member ILEI ameliorates Alzheimer's disease-like pathology by destabilizing the penultimate amyloid-beta precursor. *Nature communications*. 2014;5:3917.

Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. *JAMA psychiatry*. 2014;71(4):397-403.

Hawkes CA, Deng L-H, Shaw JE, Nitz M, McLaurin J. Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease. *The European journal of neuroscience*. 2010;31(2):203-13.

Hayama T, Murakami K, Watanabe T, Maeda R, Kamata M, Kondo S. Single administration of a novel gamma-secretase modulator ameliorates cognitive dysfunction in aged C57BL/6J mice. *Brain research*. 2016;1633:52-61.

He F-Q, Qiu B-Y, Zhang X-H, Li T-K, Xie Q, Cui D-J, et al. Tetrandrine attenuates spatial memory impairment and hippocampal neuroinflammation via inhibiting NF-kappaB activation in a rat model of Alzheimer's disease induced by amyloid-beta(1-42). *Brain research*. 2011;1384:89-96.

Hipkiss AR. Could carnosine or related structures suppress Alzheimer's disease? *Journal of Alzheimer's disease : JAD*. 2007;11(2):229-40.

Hiramatsu M, Takiguchi O, Nishiyama A, Mori H. Cilostazol prevents amyloid beta peptide(25-35)-induced memory impairment and oxidative stress in mice. *British journal of pharmacology*. 2010;161(8):1899-912.

Hock C, Maddalena A, Raschig A, Muller-Spahn F, Eschweiler G, Hager K, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. *Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis*. 2003;10(1):1-6.

Hoffmann T, Meyer A, Heiser U, Kurat S, Bohme L, Kleinschmidt M, et al. Glutaminy Cyclase Inhibitor PQ912 improves cognition in mouse models of Alzheimer's disease - studies on relation to effective target occupancy. *The Journal of pharmacology and experimental therapeutics*. 2017.

Hosono T, Nishitsuji K, Nakamura T, Jung C-G, Kontani M, Tokuda H, et al. Arachidonic acid diet attenuates brain Abeta deposition in Tg2576 mice. *Brain research*. 2015;1613:92-9.

Hou D-r, Xue L, Tang J-c, Zhou J, Sun J-j. Butylphthalide improves learning and memory abilities of rats with Alzheimer's disease possibly by enhancing protein disulfide isomerase and inhibiting P53 expressions. *Nan fang yi ke da xue xue bao = Journal of Southern Medical University*. 2010;30(9):2104-7.

Hou Y, Wang Y, Zhao J, Li X, Cui J, Ding J, et al. Smart Soup, a traditional Chinese medicine formula, ameliorates amyloid pathology and related cognitive deficits. *PloS one*. 2014;9(11):e111215.

Howland RH. Buspirone: Back to the Future. *Journal of psychosocial nursing and mental health services*. 2015;53(11):21-4.

Hsu T-J, Tsai H-T, Hwang A-C, Chen L-Y, Chen L-K. Predictors of non-pharmacological intervention effect on cognitive function and behavioral and psychological symptoms of older people with dementia. *Geriatrics & gerontology international*. 2017;17 Suppl 1:28-35.

Hsu W-Y, Ku Y, Zanto TP, Gazzaley A. Effects of noninvasive brain stimulation on cognitive function in healthy aging and Alzheimer's disease: a systematic review and meta-analysis. *Neurobiology of aging*. 2015;36(8):2348-59.

Hu D, Li C, Han N, Miao L, Wang D, Liu Z, et al. Deoxyschizandrin isolated from the fruits of *Schisandra chinensis* ameliorates Aβ₁₋₄₂-induced memory impairment in mice. *Planta medica*. 2012;78(12):1332-6.

Hu H-y, Chen Z-y, Xu D-m, Zhang Y-h, Wang Y-r, Wang W-h, et al. Study on the Mechanism of Three Kinds Extracts of Qingxin Kaiqiao Recipe in Improving Learning and Memory

Capabilities of AD Rats. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine*. 2015;35(5):595-602.

Hu H-Y, Cui Z-H, Li H-Q, Wang Y-R, Chen X, Li J-H, et al. Fumanjian, a Classic Chinese Herbal Formula, Can Ameliorate the Impairment of Spatial Learning and Memory through Apoptotic Signaling Pathway in the Hippocampus of Rats with Abeta 1-40 -Induced Alzheimer's Disease. *Evidence-based complementary and alternative medicine : eCAM*. 2014;2014:942917.

Hu Y, Li C, Shen W. Gastrodin alleviates memory deficits and reduces neuropathology in a mouse model of Alzheimer's disease. *Neuropathology : official journal of the Japanese Society of Neuropathology*. 2014;34(4):370-7.

Hua H, Munter L, Harmeier A, Georgiev O, Multhaup G, Schaffner W. Toxicity of Alzheimer's disease-associated Abeta peptide is ameliorated in a *Drosophila* model by tight control of zinc and copper availability. *Biological chemistry*. 2011;392(10):919-26.

Huang J-Z, Wu J, Xiang S, Sheng S, Jiang Y, Yang Z, et al. Catalpol preserves neural function and attenuates the pathology of Alzheimer's disease in mice. *Molecular medicine reports*. 2016;13(1):491-6.

Huang S, Mao J, Ding K, Zhou Y, Zeng X, Yang W, et al. Polysaccharides from *Ganoderma lucidum* Promote Cognitive Function and Neural Progenitor Proliferation in Mouse Model of Alzheimer's Disease. *Stem cell reports*. 2017;8(1):84-94.

Huang W, Li Z, Zhao L, Zhao W. Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2017;92:46-57.

Huang X, Chen Y, Zhang H, Ma Q, Zhang Y-w, Xu H. Salubrinal attenuates beta-amyloid-induced neuronal death and microglial activation by inhibition of the NF-kappaB pathway. *Neurobiology of aging*. 2012;33(5):1007.e9-17.

Huo D-S, Sun J-F, Zhang B, Yan X-S, Wang H, Jia J-X, et al. Protective effects of testosterone on cognitive dysfunction in Alzheimer's disease model rats induced by oligomeric beta amyloid peptide 1-42. *Journal of toxicology and environmental health Part A*. 2016;79(19):856-63.

Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. *Nature*. 2016;540(7632):230-5.

Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, et al. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. *British journal of pharmacology*. 2009;156(6):982-93.

Imbimbo BP, Troetel WM, Martelli P, Lucchelli F. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease. *Dementia and geriatric cognitive disorders*. 2000;11(1):17-24.

Imbimbo BP, Peretto I. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease. *Current opinion in investigational drugs* (London, England : 2000). 2009;10(7):721-30.

Inestrosa NC, Tapia-Rojas C, Griffith TN, Carvajal FJ, Benito MJ, Rivera-Dictter A, et al. Tetrahydrohyperfornin prevents cognitive deficit, Abeta deposition, tau phosphorylation and synaptotoxicity in the APP^{swe}/PSEN1^{DeltaE9} model of Alzheimer's disease: a possible effect on APP processing. *Translational psychiatry*. 2011;1:e20.

Irwin RW, Brinton RD. Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise. *Progress in neurobiology*. 2014;113:40-55.

Iwasaki K, Satoh-Nakagawa T, Maruyama M, Monma Y, Nemoto M, Tomita N, et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. *The Journal of clinical psychiatry*. 2005;66(2):248-52.

Iwasaki Y, Negishi T, Inoue M, Tashiro T, Tabira T, Kimura N. Sendai virus vector-mediated brain-derived neurotrophic factor expression ameliorates memory deficits and synaptic degeneration in a transgenic mouse model of Alzheimer's disease. *Journal of neuroscience research*. 2012;90(5):981-9.

Javed H, Khan MM, Khan A, Vaibhav K, Ahmad A, Khuwaja G, et al. S-allyl cysteine attenuates oxidative stress associated cognitive impairment and neurodegeneration in mouse model of streptozotocin-induced experimental dementia of Alzheimer's type. *Brain research*. 2011;1389:133-42.

Jeon S, Bose S, Hur J, Jun K, Kim Y-K, Cho KS, et al. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Abeta level in the Tg-APP^{swe}/PS1^{dE9} mouse model of Alzheimer's disease. *Journal of ethnopharmacology*. 2011;137(1):783-9.

Jeon S, Park J-E, Lee J, Liu QF, Jeong HJ, Pak SC, et al. Illite improves memory impairment and reduces Abeta level in the Tg-APP^{swe}/PS1^{dE9} mouse model of Alzheimer's disease through Akt/CREB and GSK-3 β phosphorylation in the brain. *Journal of ethnopharmacology*. 2015;160:69-77.

Jeong JJ, Woo JY, Kim KA, Han MJ, Kim DH. Lactobacillus pentosus var. plantarum C29 ameliorates age-dependent memory impairment in Fischer 344 rats. *Letters in applied microbiology*. 2015;60(4):307-14.

Jeong JH, Jeong HR, Jo YN, Kim HJ, Shin JH, Heo HJ. Ameliorating effects of aged garlic extracts against A β -induced neurotoxicity and cognitive impairment. *BMC complementary and alternative medicine*. 2013;13:268.

Jhamandas JH, Wie MB, Harris K, MacTavish D, Kar S. Fucoidan inhibits cellular and neurotoxic effects of beta-amyloid (A β) in rat cholinergic basal forebrain neurons. *The European journal of neuroscience*. 2005;21(10):2649-59.

Ji C, Song C, Aisa HA, Yang N, Liu Y-Y, Li Q, et al. Gossypium herbaceum L. extracts ameliorate disequilibrium of IL-1RA/IL-1 β ratio to attenuate inflammatory process induced by amyloid β in rats. *Current Alzheimer research*. 2012;9(8):953-61.

Ji L, Zhao X, Hua Z. Potential therapeutic implications of gelsolin in Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2015;44(1):13-25.

Ji Z-H, Xu Z-Q, Zhao H, Yu X-Y. Neuroprotective effect and mechanism of daucosterol palmitate in ameliorating learning and memory impairment in a rat model of Alzheimer's disease. *Steroids*. 2017;119:31-5.

Jia S, Lu Z, Gao Z, An J, Wu X, Li X, et al. Chitosan oligosaccharides alleviate cognitive deficits in an amyloid- β 1-42-induced rat model of Alzheimer's disease. *International journal of biological macromolecules*. 2016;83:416-25.

Jiang J, Wang Z-H, Qu M, Gao D, Liu X-P, Zhu L-Q, et al. Stimulation of EphB2 attenuates tau phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3 β . *Scientific reports*. 2015;5:11765.

Jiang X, Huang J, Song D, Deng R, Wei J, Zhang Z. Increased Consumption of Fruit and Vegetables Is Related to a Reduced Risk of Cognitive Impairment and Dementia: Meta-Analysis. *Frontiers in aging neuroscience*. 2017;9:18.

Jiang X, Chai G-S, Wang Z-H, Hu Y, Li X-G, Ma Z-W, et al. Spatial training preserves associative memory capacity with augmentation of dendrite ramification and spine generation in Tg2576 mice. *Scientific reports*. 2015;5:9488.

Jiao SS, Shen LL, Zhu C, Bu XL, Liu YH, Liu CH, et al. Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease. *Translational Psychiatry*. 2016;6.

Jimbo D, Kimura Y, Taniguchi M, Inoue M, Urakami K. Effect of aromatherapy on patients with Alzheimer's disease. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2009;9(4):173-9.

Jin H, Wang W, Zhao S, Yang W, Qian Y, Jia N, et al. Abeta-HBc virus-like particles immunization without additional adjuvant ameliorates the learning and memory and reduces Abeta deposit in PDAPP mice. *Vaccine*. 2014;32(35):4450-6.

Johnson ML, Parikh N, Kunik ME, Schulz PE, Patel JG, Chen H, et al. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2012;8(5):437-44.

Jones RS, Minogue AM, Fitzpatrick O, Lynch MA. Inhibition of JAK2 attenuates the increase in inflammatory markers in microglia from APP/PS1 mice. *Neurobiology of aging*. 2015;36(10):2716-24.

Justin Thenmozhi A, Dhivyabharathi M, William Raja TR, Manivasagam T, Essa MM. Tannoid principles of *Emblica officinalis* renovate cognitive deficits and attenuate amyloid pathologies against aluminum chloride induced rat model of Alzheimer's disease. *Nutritional neuroscience*. 2016;19(6):269-78.

Justin Thenmozhi A, William Raja TR, Manivasagam T, Janakiraman U, Essa MM. Hesperidin ameliorates cognitive dysfunction, oxidative stress and apoptosis against aluminium chloride induced rat model of Alzheimer's disease. *Nutritional neuroscience*. 2016:1-9.

Kamalinia G, Khodagholi F, Shaerzadeh F, Tavssolian F, Chaharband F, Atyabi F, et al. Cationic albumin-conjugated chelating agent as a novel brain drug delivery system in neurodegeneration. *Chemical biology & drug design*. 2015;86(5):1203-14.

Kamat PK, Kyles P, Kalani A, Tyagi N. Hydrogen Sulfide Ameliorates Homocysteine-Induced Alzheimer's Disease-Like Pathology, Blood-Brain Barrier Disruption, and Synaptic Disorder. *Molecular neurobiology*. 2016;53(4):2451-67.

Kang L, Li S, Xing Z, Li J, Su Y, Fan P, et al. Dihydrotestosterone treatment delays the conversion from mild cognitive impairment to Alzheimer's disease in SAMP8 mice. *Hormones and behavior*. 2014;65(5):505-15.

Kang S, Kim C-H, Jung H, Kim E, Song H-T, Lee JE. Agmatine ameliorates type 2 diabetes induced-Alzheimer's disease-like alterations in high-fat diet-fed mice via reactivation of blunted insulin signalling. *Neuropharmacology*. 2017;113(Pt A):467-79.

Kang S, Moon NR, Kim DS, Kim SH, Park S. Central acylated ghrelin improves memory function and hippocampal AMPK activation and partly reverses the impairment of energy and glucose metabolism in rats infused with beta-amyloid. *Peptides*. 2015;71:84-93.

Kao C-C, Lin L-C, Wu S-C, Lin K-N, Liu C-K. Effectiveness of different memory training programs on improving hyperphagic behaviors of residents with dementia: a longitudinal single-blind study. *Clinical interventions in aging*. 2016;11:707-20.

Kasper S, Schubert H. Ginkgo biloba extract EGb 761 in the treatment of dementia: evidence of efficacy and tolerability. *Fortschritte der Neurologie-Psychiatrie*. 2009;77(9):494-506.

Kasturirangan S, Boddapati S, Sierks MR. Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity. *Biochemistry*. 2010;49(21):4501-8.

Kato A, Fukunari A, Sakai Y, Nakajima T. Prevention of amyloid-like deposition by a selective prolyl endopeptidase inhibitor, Y-29794, in senescence-accelerated mouse. *The Journal of pharmacology and experimental therapeutics*. 1997;283(1):328-35.

Kawahara K, Suenobu M, Ohtsuka H, Kuniyasu A, Sugimoto Y, Nakagomi M, et al. Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;42(2):587-605.

Kent K, Charlton K, Roodenrys S, Batterham M, Potter J, Traynor V, et al. Consumption of anthocyanin-rich cherry juice for 12 weeks improves memory and cognition in older adults with mild-to-moderate dementia. *European Journal of Nutrition*. 2017;56(1):333-41.

Khan A, Vaibhav K, Javed H, Khan MM, Tabassum R, Ahmed ME, et al. Attenuation of Abeta-induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress. *Molecular and cellular biochemistry*. 2012;369(1-2):55-65.

Khodagholi F, Ashabi G. Dietary supplementation with *Salvia sahendica* attenuates memory deficits, modulates CREB and its down-stream molecules and decreases apoptosis in amyloid beta-injected rats. *Behavioural brain research*. 2013;241:62-9.

Kiasalari Z, Heydarifard R, Khalili M, Afshin-Majd S, Baluchnejadmojarad T, Zahedi E, et al. Ellagic acid ameliorates learning and memory deficits in a rat model of Alzheimer's disease: an exploration of underlying mechanisms. *Psychopharmacology*. 2017.

Kim C, Nam DW, Park SY, Song H, Hong HS, Boo JH, et al. O-linked beta-N-acetylglucosaminidase inhibitor attenuates beta-amyloid plaque and rescues memory impairment. *Neurobiology of aging*. 2013;34(1):275-85.

Kim DSHL, Kim J-Y, Han YS. Alzheimer's disease drug discovery from herbs: neuroprotectivity from beta-amyloid (1-42) insult. *Journal of alternative and complementary medicine (New York, NY)*. 2007;13(3):333-40.

Kim H-H. Effects of experience-based group therapy on cognitive and physical functions and psychological symptoms of elderly people with mild dementia. *Journal of physical therapy science*. 2015;27(7):2069-71.

Kim HY, Kim HV, Yoon JH, Kang BR, Cho SM, Lee S, et al. Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease. *Scientific reports*. 2014;4:7467.

Kim H-J, Shin E-J, Lee B-H, Choi S-H, Jung S-W, Cho I-H, et al. Oral Administration of Gintonin Attenuates Cholinergic Impairments by Scopolamine, Amyloid-beta Protein, and Mouse Model of Alzheimer's Disease. *Molecules and cells*. 2015;38(9):796-805.

Kim H, Kim G, Jang W, Kim SY, Chang N. Association between intake of B vitamins and cognitive function in elderly Koreans with cognitive impairment. *Nutrition journal*. 2014;13(1):118.

Kim H, Kim G, Jang W, Kim SY, Chang N. Association between intake of B vitamins and cognitive function in elderly Koreans with cognitive impairment. *Nutrition journal*. 2014;13(1):118.

Kim TI, Lee YK, Park SG, Choi IS, Ban JO, Park HK, et al. l-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways. *Free radical biology & medicine*. 2009;47(11):1601-10.

Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, et al. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. *Journal of immunology (Baltimore, Md : 1950)*. 2011;187(12):6539-49.

Klein C, Mathis C, Leva G, Patte-Mensah C, Cassel J-C, Maitre M, et al. gamma-Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer's disease. *Neurobiology of aging*. 2015;36(2):832-44.

Klein J. Phenserine. *Expert opinion on investigational drugs*. 2007;16(7):1087-97.

Klein PJ. Tai Chi Chuan in the management of Parkinson's disease and Alzheimer's disease. *Medicine and sport science*. 2008;52:173-81.

Knight A, Bryan J, Murphy K. Is the Mediterranean diet a feasible approach to preserving cognitive function and reducing risk of dementia for older adults in Western countries? New insights and future directions. *Ageing research reviews*. 2016;25:85-101.

Konrath EL, Passos CdS, Klein LC, Jr., Henriques AT. Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer's disease. *The Journal of pharmacy and pharmacology*. 2013;65(12):1701-25.

Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. *Alzheimer's research & therapy*. 2014;6(4):44.

Koo B-S, Kim Y-K, Park K-S, Chung K-H, Kim C-H. Attenuating effect of a traditional korean formulation, Paeng-Jo-Yeon-Nyeon-Baek-Ja-In-Hwan (PJBH), on hydrogen peroxide-induced injury in PC12 cells. *Phytotherapy research : PTR*. 2004;18(6):488-93.

Koo J-H, Kang E-B, Oh Y-S, Yang D-S, Cho J-Y. Treadmill exercise decreases amyloid-beta burden possibly via activation of SIRT-1 signaling in a mouse model of Alzheimer's disease. *Experimental neurology*. 2017;288:142-52.

Koronyo-Hamaoui M, Ko MK, Koronyo Y, Azoulay D, Seksenyan A, Kunis G, et al. Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. *Journal of neurochemistry*. 2009;111(6):1409-24.

Kosaraju J, Gali CC, Khatwal RB, Dubala A, Chinni S, Holsinger RMD, et al. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. *Neuropharmacology*. 2013;72:291-300.

Kosaraju J, Holsinger RMD, Guo L, Tam KY. Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease. *Molecular neurobiology*. 2016.

Kosaraju J, Madhunapantula SV, Chinni S, Khatwal RB, Dubala A, Muthureddy Nataraj SK, et al. Dipeptidyl peptidase-4 inhibition by *Pterocarpus marsupium* and *Eugenia jambolana* ameliorates streptozotocin induced Alzheimer's disease. *Behavioural brain research*. 2014;267:55-65.

Kosaraju J, Murthy V, Khatwal RB, Dubala A, Chinni S, Muthureddy Nataraj SK, et al. Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. *The Journal of pharmacy and pharmacology*. 2013;65(12):1773-84.

Kudoh C, Arita R, Honda M, Kishi T, Komatsu Y, Asou H, et al. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2016;16(2):85-92.

Kuiper JS, Zuidersma M, Oude Voshaar RC, Zuidema SU, van den Heuvel ER, Stolk RP, et al. Social relationships and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies. *Ageing research reviews*. 2015;22:39-57.

Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. *BMC neuroscience*. 2007;8:54.

Kupersmidt L, Amit T, Bar-Am O, Weinreb O, Youdim MBH. Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice. *Molecular neurobiology*. 2012;46(1):217-20.

Kurata T, Miyazaki K, Kozuki M, Panin V-L, Morimoto N, Ohta Y, et al. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. *Brain research*. 2011;1371:161-70.

Kurita M, Sato T, Nishino S, Ohtomo K, Shirakawa H, Mashiko H, et al. Effects of fluvoxamine on behavioral and psychological symptoms of dementia in Alzheimer's disease: a report of three cases. *Fukushima journal of medical science*. 2006;52(2):143-8.

Kurz A. The therapeutic potential of tacrine. *Journal of neural transmission Supplementum*. 1998;54:295-9.

La Porte SL, Bollini SS, Lanz TA, Abdiche YN, Rusnak AS, Ho W-H, et al. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. *Journal of molecular biology*. 2012;421(4-5):525-36.

Lang M, Wang L, Fan Q, Xiao G, Wang X, Zhong Y, et al. Genetic inhibition of solute-linked carrier 39 family transporter 1 ameliorates abeta pathology in a Drosophila model of Alzheimer's disease. *PLoS genetics*. 2012;8(4):e1002683.

Lavretsky H, Siddarth P, Irwin MR. Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2010;18(2):154-62.

Lee ATC, Richards M, Chan WC, Chiu HFK, Lee RSY, Lam LCW. Lower risk of incident dementia among Chinese older adults having three servings of vegetables and two servings of fruits a day. *Age and ageing*. 2017:1-6.

Lee B, Shim I, Lee H, Hahm D-H. *Rehmannia glutinosa* ameliorates scopolamine-induced learning and memory impairment in rats. *Journal of microbiology and biotechnology*. 2011;21(8):874-83.

Lee C-L, Kuo T-F, Wang J-J, Pan T-M. Red mold rice ameliorates impairment of memory and learning ability in intracerebroventricular amyloid beta-infused rat by repressing amyloid beta accumulation. *Journal of neuroscience research*. 2007;85(14):3171-82.

Lee YK, Choi IS, Ban JO, Lee HJ, Lee US, Han SB, et al. 4-O-methylhonokiol attenuated beta-amyloid-induced memory impairment through reduction of oxidative damages via inactivation of p38 MAP kinase. *The Journal of nutritional biochemistry*. 2011;22(5):476-86.

Lee YW, Kim DH, Jeon SJ, Park SJ, Kim JM, Jung JM, et al. Neuroprotective effects of salvianolic acid B on an Abeta25-35 peptide-induced mouse model of Alzheimer's disease. *European journal of pharmacology*. 2013;704(1-3):70-7.

Leinenga G, Gotz J. Scanning ultrasound removes amyloid-beta and restores memory in an Alzheimer's disease mouse model. *Science translational medicine*. 2015;7(278):278ra33.

Leiros M, Alonso E, Rateb ME, Ebel R, Jaspars M, Alfonso A, et al. The Streptomyces metabolite anhydroexfoliamycin ameliorates hallmarks of Alzheimer's disease in vitro and in vivo. *Neuroscience*. 2015;305:26-35.

Lemke MR. Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. *The Journal of clinical psychiatry*. 1995;56(8):354-7.

Levy A, Brandeis R, Treves TA, Meshulam Y, Mawassi F, Feiler D, et al. Transdermal physostigmine in the treatment of Alzheimer's disease. *Alzheimer disease and associated disorders*. 1994;8(1):15-21.

Li B, Yu D, Xu Z. Activated protein C inhibits amyloid beta production via promoting expression of ADAM-10. *Brain research*. 2014;1545:35-44.

Li F-J, Shen L, Ji H-F. Dietary intakes of vitamin E, vitamin C, and beta-carotene and risk of Alzheimer's disease: a meta-analysis. *Journal of Alzheimer's disease : JAD*. 2012;31(2):253-8.

Li G, Zhang X, Cheng H, Shang X, Xie H, Zhang X, et al. Acupuncture improves cognitive deficits and increases neuron density of the hippocampus in middle-aged SAMP8 mice. *Acupuncture in medicine : journal of the British Medical Acupuncture Society*. 2012;30(4):339-45.

Li H, Wu X, Wu Q, Gong D, Shi M, Guan L, et al. Green tea polyphenols protect against okadaic acid-induced acute learning and memory impairments in rats. *Nutrition (Burbank, Los Angeles County, Calif)*. 2014;30(3):337-42.

Li J, Ding X, Zhang R, Jiang W, Sun X, Xia Z, et al. Harpagoside ameliorates the amyloid-beta-induced cognitive impairment in rats via up-regulating BDNF expression and MAPK/PI3K pathways. *Neuroscience*. 2015;303:103-14.

Li L, Yu L, Kong Q. Exogenous galanin attenuates spatial memory impairment and decreases hippocampal beta-amyloid levels in rat model of Alzheimer's disease. *The International journal of neuroscience*. 2013;123(11):759-65.

Li L, Xu S, Liu L, Feng R, Gong Y, Zhao X, et al. Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-alpha and IL-1beta in an Abeta25-35-induced Rat Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;56(4):1403-17.

Li S, Yan Y, Jiao Y, Gao Z, Xia Y, Kong L, et al. Neuroprotective Effect of Osthole on Neuron Synapses in an Alzheimer's Disease Cell Model via Upregulation of MicroRNA-9. *Journal of molecular neuroscience : MN*. 2016;60(1):71-81.

Li W, Jiang M, Xiao Y, Zhang X, Cui S, Huang G. Folic acid inhibits tau phosphorylation through regulation of PP2A methylation in SH-SY5Y cells. *The journal of nutrition, health & aging*. 2015;19(2):123-9.

Li X-H, Li C-Y, Xiang Z-G, Zhong F, Chen Z-Y, Lu J-M. Allicin can reduce neuronal death and ameliorate the spatial memory impairment in Alzheimer's disease models. *Neurosciences (Riyadh, Saudi Arabia)*. 2010;15(4):237-43.

Li X, Zhu H, Sun X, Zuo F, Lei J, Wang Z, et al. Human Neural Stem Cell Transplantation Rescues Cognitive Defects in APP/PS1 Model of Alzheimer's Disease by Enhancing Neuronal Connectivity and Metabolic Activity. *Frontiers in aging neuroscience*. 2016;8:282.

Liang J, Lopez-Valdes HE, Martinez-Coria H, Lindemeyer AK, Shen Y, Shao XM, et al. Dihydromyricetin ameliorates behavioral deficits and reverses neuropathology of transgenic mouse models of Alzheimer's disease. *Neurochemical research*. 2014;39(6):1171-81.

Light SA, Holroyd S. The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia. *Journal of psychiatry & neuroscience : JPN*. 2006;31(2):132-4.

Lin J, Huang L, Yu J, Xiang S, Wang J, Zhang J, et al. Fucoxanthin, a Marine Carotenoid, Reverses Scopolamine-Induced Cognitive Impairments in Mice and Inhibits Acetylcholinesterase in Vitro. *Marine drugs*. 2016;14(4).

Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, et al. MER5101, a novel Abeta1-15:DT conjugate vaccine, generates a robust anti-Abeta antibody response and attenuates Abeta pathology and cognitive deficits in APPswe/PS1DeltaE9 transgenic mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(16):7027-37.

Liu D, Pitta M, Jiang H, Lee J-H, Zhang G, Chen X, et al. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. *Neurobiology of aging*. 2013;34(6):1564-80.

Liu D, Pitta M, Lee J-H, Ray B, Lahiri DK, Furukawa K, et al. The KATP channel activator diazoxide ameliorates amyloid-beta and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2010;22(2):443-57.

Liu G-P, Wei W, Zhou X, Shi H-R, Liu X-H, Chai G-S, et al. Silencing PP2A inhibitor by lenti-shRNA interference ameliorates neuropathologies and memory deficits in tg2576 mice. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2013;21(12):2247-57.

Liu J, Li C, Xing G, Zhou L, Dong M, Geng Y, et al. Beta-asarone attenuates neuronal apoptosis induced by Beta amyloid in rat hippocampus. *Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan*. 2010;130(5):737-46.

Liu M, Guo H, Li C, Wang D, Wu J, Wang C, et al. Cognitive improvement of compound danshen in an Abeta25-35 peptide-induced rat model of Alzheimer's disease. *BMC complementary and alternative medicine*. 2015;15:382.

Liu P, Zou L, Jiao Q, Chi T, Ji X, Qi Y, et al. Xanthoceraside attenuates learning and memory deficits via improving insulin signaling in STZ-induced AD rats. *Neuroscience letters*. 2013;543:115-20.

Liu P, Zhao L, Zhang S-L, Xiang J-Z. Modified Wendan Decoction can Attenuate Neurotoxic Action Associated with Alzheimer's Disease. *Evidence-based complementary and alternative medicine : eCAM*. 2009;6(3):325-30.

Liu RT, Tang JT, Zou LB, Fu JY, Lu QJ. Liquiritigenin attenuates the learning and memory deficits in an amyloid protein precursor transgenic mouse model and the underlying mechanisms. *European journal of pharmacology*. 2011;669(1-3):76-83.

Liu S, Tang S-Q, Cui H-J, Yin S, Yin M, Zhao H, et al. Dipotassium N-stearoyltyrosinate ameliorated pathological injuries intriple-transgenic mouse model of Alzheimer's disease. *Journal of pharmacological sciences*. 2016;132(1):92-9.

Liu S, Wu H, Xue G, Ma X, Wu J, Qin Y, et al. Metabolic alteration of neuroactive steroids and protective effect of progesterone in Alzheimer's disease-like rats. *Neural regeneration research*. 2013;8(30):2800-10.

Liu T, Xia Z, Zhang W-W, Xu J-r, Ge X-X, Li J, et al. Bis(9)-(-)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice. *Pharmacology, biochemistry, and behavior*. 2013;104:138-43.

Liu Y-m, Li Z-y, Hu H, Xu S-p, Chang Q, Liao Y-h, et al. Tenuifolin, a secondary saponin from hydrolysates of polygalasaponins, counteracts the neurotoxicity induced by Abeta25-35 peptides in vitro and in vivo. *Pharmacology, biochemistry, and behavior*. 2015;128:14-22.

Liu Y, Jiang L, Li X. kappa-‘carrageenan’-derived pentasaccharide attenuates Abeta25-35-induced apoptosis in SH-‘SY5Y cells via suppression of the JNK signaling pathway. *Molecular medicine reports*. 2017;15(1):285-90.

Liu Y, Liu X, Hao W, Decker Y, Schomburg R, Fulop L, et al. IKKbeta deficiency in myeloid cells ameliorates Alzheimer's disease-related symptoms and pathology. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(39):12982-99.

Liu Y-L, Chen W-T, Lin Y-Y, Lu P-H, Hsieh S-L, Cheng IH-J. Amelioration of amyloid-beta-induced deficits by DcR3 in an Alzheimer's disease model. *Molecular neurodegeneration*. 2017;12(1):30.

Liu Y, Xu L-P, Dai W, Dong H, Wen Y, Zhang X. Graphene quantum dots for the inhibition of beta amyloid aggregation. *Nanoscale*. 2015;7(45):19060-5.

Liu Z-b, Niu W-m, Yang X-h, Niu X-m, Wang Y. Effect of "Xiusanzhen" on learning-memory ability and hippocampal ChAT and AChE activity in Alzheimer disease rats. *Zhen ci yan jiu = Acupuncture research*. 2009;34(1):48-51.

Liu Z, Zhao X, Liu B, Liu A-j, Li H, Mao X, et al. Jujuboside A, a neuroprotective agent from semen Ziziphi Spinosae ameliorates behavioral disorders of the dementia mouse model induced by Abeta 1-42. *European journal of pharmacology*. 2014;738:206-13.

Lo AC, Callaerts-Vegh Z, Nunes AF, Rodrigues CMP, D'Hooge R. Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice. *Neurobiology of disease*. 2013;50:21-9.

Lou G, Zhang Q, Xiao F, Xiang Q, Su Z, Huang Y. Intranasal TAT-haFGF Improves Cognition and Amyloid-beta Pathology in an AbetaPP/PS1 Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;51(4):985-90.

Lu D, Song H, Hao Z, Wu T, McCleery J. Naftidrofuryl for dementia. *The Cochrane database of systematic reviews*. 2011(12):CD002955.

Lu Y-Q, Luo Y, He Z-F, Chen J, Yan B-L, Wang Y, et al. Hydroxysafflor yellow A ameliorates homocysteine-induced Alzheimer-like pathologic dysfunction and memory/synaptic disorder. *Rejuvenation research*. 2013;16(6):446-52.

Lull ME, Levesque S, Surace MJ, Block ML. Chronic apocynin treatment attenuates beta amyloid plaque size and microglial number in hAPP(751)(SL) mice. *PloS one*. 2011;6(5):e20153.

Luo G, Liu M, He J, Guo H, Xue M, Wang X, et al. Quetiapine attenuates recognition memory impairment and hippocampal oxidative stress in a transgenic mouse model of Alzheimer's disease. *Neuroreport*. 2014;25(9):647-50.

Ma B, Meng X, Wang J, Sun J, Ren X, Qin M, et al. Notoginsenoside R1 attenuates amyloid-beta-induced damage in neurons by inhibiting reactive oxygen species and modulating MAPK activation. *International immunopharmacology*. 2014;22(1):151-9.

Ma J, Gao Y, Jiang L, Chao F-L, Huang W, Zhou C-N, et al. Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APP^{swe}/PSEN1^{dE9} double transgenic Alzheimer's disease mice. *Oncotarget*. 2017;8(17):27676-92.

Ma Q, Ruan Y-y, Xu H, Shi X-m, Wang Z-x, Hu Y-l. Safflower yellow reduces lipid peroxidation, neuropathology, tau phosphorylation and ameliorates amyloid beta-induced impairment of learning and memory in rats. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2015;76:153-64.

Ma T, Trinh MA, Wexler AJ, Bourbon C, Gatti E, Pierre P, et al. Suppression of eIF2 α kinases alleviates Alzheimer's disease-related plasticity and memory deficits. *Nature neuroscience*. 2013;16(9):1299-305.

Ma Y, Tian S, Sun L, Yao S, Liang Z, Li S, et al. The effect of acori graminei rhizoma and extract fractions on spatial memory and hippocampal neurogenesis in amyloid beta 1-42 injected mice. *CNS & neurological disorders drug targets*. 2015;14(3):411-20.

Majlessi N, Choopani S, Kamalinejad M, Azizi Z. Amelioration of amyloid beta-induced cognitive deficits by Zataria multiflora Boiss. essential oil in a rat model of Alzheimer's disease. *CNS neuroscience & therapeutics*. 2012;18(4):295-301.

Makarova EG, Gordon RY, Podolski IY. Fullerene C60 prevents neurotoxicity induced by intrahippocampal microinjection of amyloid-beta peptide. *Journal of nanoscience and nanotechnology*. 2012;12(1):119-26.

Marco-Contelles J, Unzeta M, Bolea I, Esteban G, Ramsay RR, Romero A, et al. ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy. *Frontiers in neuroscience*. 2016;10:294.

Marioni RE, Proust-Lima C, Amieva H, Brayne C, Matthews FE, Dartigues J-F, et al. Social activity, cognitive decline and dementia risk: a 20-year prospective cohort study. *BMC public health*. 2015;15:1089.

Martinez-Coria H, Yeung ST, Ager RR, Rodriguez-Ortiz CJ, Baglietto-Vargas D, LaFerla FM. Repeated cognitive stimulation alleviates memory impairments in an Alzheimer's disease mouse model. *Brain research bulletin*. 2015;117:10-5.

Martorell M, Forman K, Castro N, Capo X, Tejada S, Sureda A. Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease. *Current pharmaceutical biotechnology*. 2016;17(11):994-1001.

Marwarha G, Dasari B, Prasanthi JRP, Schommer J, Ghribi O. Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. *Journal of Alzheimer's disease : JAD*. 2010;19(3):1007-19.

Masliah E, Xie F, Dayan S, Rockenstein E, Mante M, Adame A, et al. Genetic deletion of Nogo/Rtn4 ameliorates behavioral and neuropathological outcomes in amyloid precursor protein transgenic mice. *Neuroscience*. 2010;169(1):488-94.

Matsuda Y, Kishi T, Shibayama H, Iwata N. Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. *Human psychopharmacology*. 2013;28(1):80-6.

McClure R, Ong H, Janve V, Barton S, Zhu M, Li B, et al. Aerosol Delivery of Curcumin Reduced Amyloid-beta Deposition and Improved Cognitive Performance in a Transgenic Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;55(2):797-811.

McDonald CL, Hennessy E, Rubio-Araiz A, Keogh B, McCormack W, McGuirk P, et al. Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer's disease. *Brain, behavior, and immunity*. 2016;58:191-200.

McIntire LBJ, Berman DE, Myaeng J, Staniszewski A, Arancio O, Di Paolo G, et al. Reduction of Synaptotagmin 1 Ameliorates Synaptic and Behavioral Impairments in a Mouse Model of Alzheimer's Disease. *Journal of Neuroscience*. 2012;32(44):15271-6.

McIntire LBJ, Berman DE, Myaeng J, Staniszewski A, Arancio O, Di Paolo G, et al. Reduction of synaptotagmin 1 ameliorates synaptic and behavioral impairments in a mouse model of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2012;32(44):15271-6.

McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, et al. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. *Brain research*. 2008;1207:225-36.

McNeal KM, Meyer RP, Lukacs K, Senseney A, Mintzer J. Using risperidone for Alzheimer's dementia-associated psychosis. *Expert opinion on pharmacotherapy*. 2008;9(14):2537-43.

Mei Z, Zhang F, Tao L, Zheng W, Cao Y, Wang Z, et al. Cryptotanshinone, a compound from *Salvia miltiorrhiza* modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro. *Neuroscience letters*. 2009;452(2):90-5.

Meinhold JM, Blake LM, Mini LJ, Welge JA, Schwiers M, Hughes A. Effect of divalproex sodium on behavioural and cognitive problems in elderly dementia. *Drugs & aging*. 2005;22(7):615-26.

Menna LF, Santaniello A, Gerardi F, Di Maggio A, Milan G. Evaluation of the efficacy of animal-assisted therapy based on the reality orientation therapy protocol in Alzheimer's disease patients: a pilot study. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2016;16(4):240-6.

Meunier J, Villard V, Givalois L, Maurice T. The gamma-secretase inhibitor 2- (1R)-1- (4-chlorophenyl)sulfonyl (2,5-difluorophenyl) amino ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Abeta1-42 seeding and short-term memory deficits in the Abeta25-35 mouse model of Alzheimer's disease. *European journal of pharmacology*. 2013;698(1-3):193-9.

Midorikawa T, Komatsu T, Mitani T, Togo F. Effects of bright light exposure on the behavioral and psychological symptoms of dementia and the burden on caregivers in institutionalized elderly with cognitive decline. *Nihon Ronen Igakkai zasshi Japanese journal of geriatrics*. 2014;51(2):184-90.

Mitani Y, Yarimizu J, Akashiba H, Shitaka Y, Ni K, Matsuoka N. Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Abeta42 without affecting other Abeta pools. *Journal of neurochemistry*. 2013;125(3):465-72.

Mizuno T, Doi Y, Mizoguchi H, Jin S, Noda M, Sonobe Y, et al. Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-beta neurotoxicity. *The American journal of pathology*. 2011;179(4):2016-27.

Modi KK, Jana A, Ghosh S, Watson R, Pahan K. A physically-modified saline suppresses neuronal apoptosis, attenuates tau phosphorylation and protects memory in an animal model of Alzheimer's disease. *PloS one*. 2014;9(8):e103606.

Modi KK, Roy A, Brahmachari S, Rangasamy SB, Pahan K. Cinnamon and Its Metabolite Sodium Benzoate Attenuate the Activation of p21^{rac} and Protect Memory and Learning in an Animal Model of Alzheimer's Disease. *PloS one*. 2015;10(6):e0130398.

Mohammad Abdul H, Butterfield DA. Protection against amyloid beta-peptide (1-42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer's disease. *Biochimica et biophysica acta*. 2005;1741(1-2):140-8.

Mokhber N, Abdollahian E, Soltanifar A, Samadi R, Saghebi A, Haghighi MB, et al. Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. *Pharmacopsychiatry*. 2014;47(4-5):131-40.

Mokhtari Z, Baluchnejadmojarad T, Nikbakht F, Mansouri M, Roghani M. Riluzole ameliorates learning and memory deficits in Abeta25-35-induced rat model of Alzheimer's disease and is independent of cholinceptor activation. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2017;87:135-44.

Moore E, Mander A, Ames D, Carne R, Sanders K, Watters D. Cognitive impairment and vitamin B12: a review. *International psychogeriatrics*. 2012;24(4):541-56.

Moreno LCGEI, Puerta E, Suarez-Santiago JE, Santos-Magalhaes NS, Ramirez MJ, Irache JM. Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer's disease. *International journal of pharmaceutics*. 2017;517(1-2):50-7.

Morey LC, Ban TA, Cassano G, Santini V, Placidi GF, Modafferi A, et al. Glycosaminoglycan polysulfate in old-age dementias: a factor-analytic study of change in psychopathologic symptoms. *Neuropsychobiology*. 1988;19(3):135-8.

Mori T, Koyama N, Guillot-Sestier M-V, Tan J, Town T. Ferulic acid is a nutraceutical beta-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. *PloS one*. 2013;8(2):e55774.

Mori T, Rezai-Zadeh K, Koyama N, Arendash GW, Yamaguchi H, Kakuda N, et al. Tannic acid is a natural beta-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. *The Journal of biological chemistry*. 2012;287(9):6912-27.

Mori T, Town T, Tan J, Yada N, Horikoshi Y, Yamamoto J, et al. Arundic Acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. *The Journal of pharmacology and experimental therapeutics*. 2006;318(2):571-8.

Morris MC, Evans DA, Bienias JL, Scherr PA, Tangney CC, Hebert LE, et al. Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. *Journal of neurology, neurosurgery, and psychiatry*. 2004;75(8):1093-9.

Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, et al. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. *Journal of neuroinflammation*. 2017;14(1):1.

Mowla A, Pani A. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. *Journal of clinical psychopharmacology*. 2010;30(1):40-3.

Moyle W, Murfield JE, O'Dwyer S, Van Wyk S. The effect of massage on agitated behaviours in older people with dementia: a literature review. *Journal of clinical nursing*. 2013;22(5-6):601-10.

Munoz L, Ralay Ranaivo H, Roy SM, Hu W, Craft JM, McNamara LK, et al. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. *Journal of neuroinflammation*. 2007;4:21.

Muradashvili N, Tyagi R, Metreveli N, Tyagi SC, Lominadze D. Ablation of MMP9 gene ameliorates paracellular permeability and fibrinogen-amyloid beta complex formation during hyperhomocysteinemia. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2014;34(9):1472-82.

Na J-Y, Song K, Lee J-W, Kim S, Kwon J. 6-Shogaol has anti-amyloidogenic activity and ameliorates Alzheimer's disease via CysLT1R-mediated inhibition of cathepsin B. *Biochemical and biophysical research communications*. 2016;477(1):96-102.

Naaldijk Y, Jager C, Fabian C, Leovsky C, Bluher A, Rudolph L, et al. Effect of systemic transplantation of bone marrow-derived mesenchymal stem cells on neuropathology markers in APP/PS1 Alzheimer mice. *Neuropathology and applied neurobiology*. 2017;43(4):299-314.

Nakajima A, Aoyama Y, Shin E-J, Nam Y, Kim H-C, Nagai T, et al. Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble Abeta levels in a triple transgenic mouse model of Alzheimer's disease (3XTg-AD). *Behavioural brain research*. 2015;289:69-77.

Nehlig A. The neuroprotective effects of cocoa flavanol and its influence on cognitive performance. *British journal of clinical pharmacology*. 2013;75(3):716-27.

Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. *Experimental neurology*. 2007;205(1):166-76.

Newberg AB, Serruya M, Wintering N, Moss AS, Reibel D, Monti DA. Meditation and neurodegenerative diseases. *Annals of the New York Academy of Sciences*. 2014;1307:112-23.

Newton W, McManus A. Consumption of fish and Alzheimer's disease. *The journal of nutrition, health & aging*. 2011;15(7):551-4552.

Niikura T, Sidahmed E, Hirata-Fukae C, Aisen PS, Matsuoka Y. A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. *PloS one*. 2011;6(1):e16259.

Nikolic WV, Hou H, Town T, Zhu Y, Giunta B, Sanberg CD, et al. Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice. *Stem cells and development*. 2008;17(3):423-39.

Nilsson K, Warkentin S, Hultberg B, Faldt R, Gustafson L. Treatment of cobalamin deficiency in dementia, evaluated clinically and with cerebral blood flow measurements. *Aging (Milan, Italy)*. 2000;12(3):199-207.

Nishizaki T, Nomura T, Matuoka T, Kondoh T, Enikolopov G, Enikolopo G, et al. The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors. *Brain research Molecular brain research*. 2000;80(1):53-62.

Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. *Annals of neurology*. 2000;48(6):913-8.

Niu YX, Tan JP, Guan JQ, Zhang ZQ, Wang LN. Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer's disease: a randomized controlled trial. *Clinical Rehabilitation*. 2010;24(12):1102-11.

O'Neal-Moffitt G, Delic V, Bradshaw PC, Olcese J. Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AbetaPP(swe)/PS1 mice. *Molecular neurodegeneration*. 2015;10:27.

Oddo S, Caccamo A, Cheng D, LaFerla FM. Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. *Brain pathology (Zurich, Switzerland)*. 2009;19(3):421-30.

Ogino R, Murayama N, Noshita T, Takemoto N, Toba T, Oka T, et al. SUN11602 has basic fibroblast growth factor-like activity and attenuates neuronal damage and cognitive deficits in a rat model of Alzheimer's disease induced by amyloid beta and excitatory amino acids. *Brain research*. 2014;1585:159-66.

Ohba T, Yoshino Y, Ishisaka M, Abe N, Tsuruma K, Shimazawa M, et al. Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice. *Bioscience, biotechnology, and biochemistry*. 2015;79(11):1838-44.

Ohyagi Y. A drug targeting intracellular amyloid-beta and oxidative stress: apomorphine. *Rinsho shinkeigaku = Clinical neurology*. 2011;51(11):884-7.

Olajide OJ, Yawson EO, Gbadamosi IT, Arogundade TT, Lambe E, Obasi K, et al. Ascorbic acid ameliorates behavioural deficits and neuropathological alterations in rat model of Alzheimer's disease. *Environmental toxicology and pharmacology*. 2017;50:200-11.

Oliveira TG, Chan RB, Tian H, Laredo M, Shui G, Staniszewski A, et al. Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2010;30(49):16419-28.

Ongali B, Nicolakakis N, Tong X-K, Aboukassim T, Papadopoulos P, Rosa-Neto P, et al. Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model. *Neurobiology of disease*. 2014;68:126-36.

Onishi T, Iwashita H, Uno Y, Kunitomo J, Saitoh M, Kimura E, et al. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4- (S)-methylsulfinyl phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease. *Journal of neurochemistry*. 2011;119(6):1330-40.

Orgeta V, Qazi A, Spector A, Orrell M. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis. *The British journal of psychiatry : the journal of mental science*. 2015;207(4):293-8.

Ostrovskaya RU, Vakhitova YV, Kuzmina US, Salimgareeva MK, Zainullina LF, Gudasheva TA, et al. Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. *Journal of biomedical science*. 2014;21:74.

Ozarowski M, Mikolajczak PL, Bogacz A, Gryszczynska A, Kujawska M, Jodynis-Liebert J, et al. *Rosmarinus officinalis* L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain. *Fitoterapia*. 2013;91:261-71.

Ozbeyli D, Sari G, Ozkan N, Karademir B, Yuksel M, Cilingir Kaya OT, et al. Protective effects of different exercise modalities in an Alzheimer's disease-like model. *Behavioural brain research*. 2017;328:159-77.

Palacios HH, Yendluri BB, Parvathaneni K, Shadlinski VB, Obrenovich ME, Leszek J, et al. Mitochondrion-specific antioxidants as drug treatments for Alzheimer disease. *CNS & neurological disorders drug targets*. 2011;10(2):149-62.

Pan X, Chen Z, Fei G, Pan S, Bao W, Ren S, et al. Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease. *Neuroscience bulletin*. 2016;32(6):591-6.

Pan Y, Chen Y, Yu X, Wang J, Zhang L, He Y, et al. The synthesis of a novel chalcone and evaluation for anti-free radical activity and antagonizing the learning impairments in Alzheimer's model. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2012;29(5-6):949-58.

Panza F, Frisardi V, Imbimbo BP, D'Onofrio G, Pietrarossa G, Seripa D, et al. Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. *Immunotherapy*. 2010;2(6):767-82.

Panza F, Solfrizzi V, Imbimbo BP, Giannini M, Santamato A, Seripa D, et al. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. *Expert review of neurotherapeutics*. 2014;14(9):973-86.

Park J-C, Ma J, Jeon WK, Han J-S. Fructus mume extracts alleviate cognitive impairments in 5XFAD transgenic mice. *BMC complementary and alternative medicine*. 2016;16:54.

Park S-Y, Kim M-J, Kim YJ, Lee Y-H, Bae D, Kim S, et al. Selective PCAF inhibitor ameliorates cognitive and behavioral deficits by suppressing NF-kappaB-mediated neuroinflammation induced by Abeta in a model of Alzheimer's disease. *International journal of molecular medicine*. 2015;35(4):1109-18.

Park S, Kang S, Kim DS, Moon BR. *Agrimonia pilosa* Ledeb., *Cinnamomum cassia* Blume, and *Lonicera japonica* Thunb. protect against cognitive dysfunction and energy and glucose dysregulation by reducing neuroinflammation and hippocampal insulin resistance in beta-amyloid-infused rats. *Nutritional neuroscience*. 2017;20(2):77-88.

Park Y-J, Ko JW, Jeon S, Kwon YH. Protective Effect of Genistein against Neuronal Degeneration in ApoE^{-/-} Mice Fed a High-Fat Diet. *Nutrients*. 2016;8(11).

Parnetti L, Mecocci P, Petrini A, Longo A, Buccolieri A, Senin U. Neuropsychological results of long-term therapy with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia in comparison with a control group. *Neuropsychobiology*. 1989;22(2):97-100.

Pasinetti GM. Novel role of red wine-derived polyphenols in the prevention of Alzheimer's disease dementia and brain pathology: experimental approaches and clinical implications. *Planta medica*. 2012;78(15):1614-9.

Passeri M, Cucinotta D. Ateroid in the clinical treatment of multi-infarct dementia. *Modern problems of pharmacopsychiatry*. 1989;23:85-94.

Pate KM, Rogers M, Reed JW, van der Munnik N, Vance SZ, Moss MA. Anthoxanthin Polyphenols Attenuate Abeta Oligomer-induced Neuronal Responses Associated with Alzheimer's Disease. *CNS neuroscience & therapeutics*. 2017;23(2):135-44.

Patel NV, Gordon MN, Connor KE, Good RA, Engelman RW, Mason J, et al. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. *Neurobiology of aging*. 2005;26(7):995-1000.

Pazini AM, Gomes GM, Villarinho JG, da Cunha C, Pinheiro F, Ferreira APO, et al. Selegiline reverses abeta β , γ , δ , ϵ , ζ , η , θ , ι , κ , λ , μ , ν , ξ , \omicron , π , ρ , σ , τ , υ , ϕ , χ , ψ , ω -induced cognitive deficit in male mice. *Neurochemical research*. 2013;38(11):2287-94.

Peng Y, Hu Y, Xu S, Rong X, Li J, Li P, et al. Potassium 2-(1-hydroxypentyl)-benzoate improves memory deficits and attenuates amyloid and tau pathologies in a mouse model of Alzheimer's disease. *The Journal of pharmacology and experimental therapeutics*. 2014;350(2):361-74.

Peng Y, Sun J, Hon S, Nylander AN, Xia W, Feng Y, et al. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2010;30(24):8180-9.

Plosker GL. Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease. *Drugs*. 2015;75(8):887-97.

Polydoro M, de Calignon A, Suarez-Calvet M, Sanchez L, Kay KR, Nicholls SB, et al. Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(33):13300-11.

Portugal EMM, Vasconcelos PGT, Souza R, Lattari E, Monteiro-Junior RS, Machado S, et al. Aging process, cognitive decline and Alzheimer's disease: can strength training modulate these responses? *CNS & neurological disorders drug targets*. 2015;14(9):1209-13.

Prakash A, Medhi B, Chopra K. Granulocyte colony stimulating factor (GCSF) improves memory and neurobehavior in an amyloid-beta induced experimental model of Alzheimer's disease. *Pharmacology, biochemistry, and behavior*. 2013;110:46-57.

Prakash A, Kumar A. Implicating the role of lycopene in restoration of mitochondrial enzymes and BDNF levels in beta-amyloid induced Alzheimer's disease. *European journal of pharmacology*. 2014;741:104-11.

Prema A, Justin Thenmozhi A, Manivasagam T, Mohamed Essa M, Guillemin GJ. Fenugreek Seed Powder Attenuated Aluminum Chloride-Induced Tau Pathology, Oxidative Stress, and

Inflammation in a Rat Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017.

Puri V, Wang X, Vardigan JD, Kuduk SD, Uslander JM. The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model. *Behavioural brain research*. 2015;287:96-9.

Qi L, Chen Z, Wang Y, Liu X, Liu X, Ke L, et al. Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3 β . *American journal of translational research*. 2017;9(2):247-60.

Qosa H, Batarseh YS, Mohyeldin MM, El Sayed KA, Keller JN, Kaddoumi A. Oleocanthal enhances amyloid-beta clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model. *ACS chemical neuroscience*. 2015;6(11):1849-59.

Qosa H, Mohamed LA, Batarseh YS, Alqahtani S, Ibrahim B, LeVine H, 3rd, et al. Extra-virgin olive oil attenuates amyloid-beta and tau pathologies in the brains of TgSwDI mice. *The Journal of nutritional biochemistry*. 2015;26(12):1479-90.

Qu M-H, Yang X, Wang Y, Tang Q, Han H, Wang J, et al. Docosahexaenoic Acid-Phosphatidylcholine Improves Cognitive Deficits in an A β 23-35-Induced Alzheimer's Disease Rat Model. *Current topics in medicinal chemistry*. 2016;16(5):558-64.

Quinn JF, Harris CJ, Cobb KE, Domes C, Ralle M, Brewer G, et al. A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2010;21(3):903-14.

Rankin ED, Layne RD. The use of olanzapine in the treatment of negative symptoms in Alzheimer's disease. *The Journal of neuropsychiatry and clinical neurosciences*. 2005;17(3):423-4.

Ribeiro CA, Oliveira SM, Guido LF, Magalhaes A, Valencia G, Arsequell G, et al. Transthyretin stabilization by iododiflunisal promotes amyloid-beta peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model. *Journal of Alzheimer's disease : JAD*. 2014;39(2):357-70.

Richardson A, Galvan V, Lin A-L, Oddo S. How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story. *Experimental gerontology*. 2015;68:51-8.

Riekkinen P, Jr., Riekkinen M. THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 1999;20(4):357-64.

Rocha FL, Hara C, Ramos MG, Kascher GG, Santos MA, de Oliveira Lanca G, et al. An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia. *Dementia and geriatric cognitive disorders*. 2006;22(5-6):445-8.

Rodrigues L, Biasibetti R, Swarowsky A, Leite MC, Quincozes-Santos A, Quilfeldt JA, et al. Hippocampal alterations in rats submitted to streptozotocin-induced dementia model are prevented by aminoguanidine. *Journal of Alzheimer's disease : JAD*. 2009;17(1):193-202.

Rojanathammanee L, Floden AM, Manocha GD, Combs CK. Attenuation of microglial activation in a mouse model of Alzheimer's disease via NFAT inhibition. *Journal of neuroinflammation*. 2015;12:42.

Rosenberg PB, Lanctot KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. *The Journal of clinical psychiatry*. 2013;74(8):810-6.

Rozkalne A, Hyman BT, Spires-Jones TL. Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice. *Neurobiology of disease*. 2011;41(3):650-4.

Ryu JK, Cho T, Wang YT, McLarnon JG. Neural progenitor cells attenuate inflammatory reactivity and neuronal loss in an animal model of inflamed AD brain. *Journal of neuroinflammation*. 2009;6:39.

Sachdeva AK, Kuhad A, Chopra K. Naringin ameliorates memory deficits in experimental paradigm of Alzheimer's disease by attenuating mitochondrial dysfunction. *Pharmacology, biochemistry, and behavior*. 2014;127:101-10.

Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, et al. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. *The American journal of pathology*. 2004;165(3):937-48.

Sain M, Kovacic V, Radic J, Ljutic D, Jelcic I. Potential beneficial effects of low molecular weight heparin on cognitive impairment in elderly patients on haemodialysis. *Drugs & aging*. 2012;29(1):1-7.

Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. *Proceedings of the National Academy of Sciences of the United States of America*. 2012;109(42):E2895-903.

Sanchez-Mejia RO, Newman JW, Toh S, Yu G-Q, Zhou Y, Halabisky B, et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. *Nature neuroscience*. 2008;11(11):1311-8.

Sander R. Acupressure reduces agitated behaviour in people with dementia. *Nursing older people*. 2007;19(3):39.

Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G, et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. *PloS one*. 2015;10(5):e0125614.

Sanz JM, Chiozzi P, Colaianna M, Zotti M, Ferrari D, Trabace L, et al. Nimodipine inhibits IL-1beta release stimulated by amyloid beta from microglia. *British journal of pharmacology*. 2012;167(8):1702-11.

Saumier D, Duong A, Haine D, Garceau D, Sampalis J. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study. *The journal of nutrition, health & aging*. 2009;13(9):808-12.

Scharre DW, Davis RA, Warner JL, Chang S-I, Beversdorf DQ. A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer disease. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2003;11(6):687-91.

Schellenberg R, Todorova A, Wedekind W, Schober F, Dimpfel W. Pathophysiology and psychopharmacology of dementia--a new study design. 2. Cyclandelate treatment--a placebo-controlled double-blind clinical trial. *Neuropsychobiology*. 1997;35(3):132-42.

Schmitt B, Bernhardt T, Moeller H-J, Heuser I, Frolich L. Combination therapy in Alzheimer's disease: a review of current evidence. *CNS drugs*. 2004;18(13):827-44.

Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC, et al. Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2009;29(6):1846-54.

Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, et al. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. *Proceedings of the National Academy of Sciences of the United States of America*. 2012;109(9):3510-5.

Sell GL, Schaffer TB, Margolis SS. Reducing expression of synapse-restricting protein Ephexin5 ameliorates Alzheimer's-like impairment in mice. *The Journal of clinical investigation*. 2017;127(5):1646-50.

Senin U, Abate G, Fieschi C, Gori G, Guala A, Marini G, et al. Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology*. 1991;1(4):511-7.

Sereno L, Coma M, Rodriguez M, Sanchez-Ferrer P, Sanchez MB, Gich I, et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. *Neurobiology of disease*. 2009;35(3):359-67.

Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. *Nature*. 2016;537(7618):50-6.

Shao B-Y, Xia Z, Xie Q, Ge X-X, Zhang W-W, Sun J, et al. Meserine, a novel carbamate AChE inhibitor, ameliorates scopolamine-induced dementia and alleviates amyloidogenesis of APP/PS1 transgenic mice. *CNS neuroscience & therapeutics*. 2014;20(2):165-71.

Shao H, Zhang Y, Dong Y, Yu B, Xia W, Xie Z. Chronic treatment with anesthetic propofol improves cognitive function and attenuates caspase activation in both aged and Alzheimer's disease transgenic mice. *Journal of Alzheimer's disease : JAD*. 2014;41(2):499-513.

Shaykhalishahi H, Taghizadeh M, Yazdanparast R, Chang Y-T. Anti-amyloidogenic effect of AA3E2 attenuates beta-amyloid induced toxicity in SK-N-MC cells. *Chemico-biological interactions*. 2010;186(1):16-23.

Shi L, Zhang Z, Li L, Holscher C. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. *Behavioural brain research*. 2017;327:65-74.

Shi T-Y, Zhao D-Q, Wang H-B, Feng S, Liu S-B, Xing J-H, et al. A new chiral pyrrolyl alpha-nitronyl nitroxide radical attenuates beta-amyloid deposition and rescues memory deficits in a mouse model of Alzheimer disease. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*. 2013;10(2):340-53.

Shih P-H, Wu C-H, Yeh C-T, Yen G-C. Protective effects of anthocyanins against amyloid beta-peptide-induced damage in neuro-2A cells. *Journal of agricultural and food chemistry*. 2011;59(5):1683-9.

Shin KY, Lee GH, Park CH, Kim HJ, Park S-H, Kim S, et al. A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models. *Journal of neuroscience research*. 2007;85(11):2500-11.

Shin M-K, Kim H-G, Baek S-H, Jung W-R, Park D-I, Park J-S, et al. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived

neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques. *Neurobiology of aging*. 2014;35(5):990-1001.

Shindo T, Takasaki K, Uchida K, Onimura R, Kubota K, Uchida N, et al. Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer's disease incorporating additional cerebrovascular disease factors. *Biological & pharmaceutical bulletin*. 2012;35(12):2141-7.

Shropshire TD, Reifert J, Rajagopalan S, Baker D, Feinstein SC, Daugherty PS. Amyloid beta peptide cleavage by kallikrein 7 attenuates fibril growth and rescues neurons from Abeta-mediated toxicity in vitro. *Biological chemistry*. 2014;395(1):109-18.

Siahmard Z, Alaei H, Reisi P, Pilehvarian AA. The effect of red grape juice on Alzheimer's disease in rats. *Advanced biomedical research*. 2012;1:63.

Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016;12(2):110-20.

Sigurdsson EM, Knudsen E, Asuni A, Fitzner-Attas C, Sage D, Quartermain D, et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2004;24(28):6277-82.

Sil S, Ghosh T, Gupta P, Ghosh R, Kabir SN, Roy A. Dual Role of Vitamin C on the Neuroinflammation Mediated Neurodegeneration and Memory Impairments in Colchicine Induced Rat Model of Alzheimer Disease. *Journal of molecular neuroscience : MN*. 2016;60(4):421-35.

Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. *Nature neuroscience*. 2005;8(10):1343-9.

Sodhi RK, Singh N. Liver X receptor agonist T0901317 reduces neuropathological changes and improves memory in mouse models of experimental dementia. *European journal of pharmacology*. 2014;732:50-9.

Soheili M, Tavirani MR, Salami M. *Lavandula angustifolia* extract improves deteriorated synaptic plasticity in an animal model of Alzheimer's disease. *Iranian journal of basic medical sciences*. 2015;18(11):1147-52.

Soncrant TT, Raffaele KC, Asthana S, Berardi A, Morris PP, Haxby JV. Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease. *Psychopharmacology*. 1993;112(4):421-7.

Song G, Zhang Z, Wen L, Chen C, Shi Q, Zhang Y, et al. Selenomethionine ameliorates cognitive decline, reduces tau hyperphosphorylation, and reverses synaptic deficit in the triple transgenic mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;41(1):85-99.

Song JM, DiBattista AM, Sung YM, Ahn JM, Turner RS, Yang J, et al. A tetra(ethylene glycol) derivative of benzothiazole aniline ameliorates dendritic spine density and cognitive function in a mouse model of Alzheimer's disease. *Experimental neurology*. 2014;252:105-13.

Song Y, Kim H-D, Lee M-K, Hong I-H, Won C-K, Bai H-W, et al. Maysin and Its Flavonoid Derivative from Centipede Grass Attenuates Amyloid Plaques by Inducing Humoral Immune Response with Th2 Skewed Cytokine Response in the Tg (APP^{swe}, PS1^{dE9}) Alzheimer's Mouse Model. *PloS one*. 2017;12(1):e0169509.

Song Y, Cui T, Xie N, Zhang X, Qian Z, Liu J. Protocatechuic acid improves cognitive deficits and attenuates amyloid deposits, inflammatory response in aged AbetaPP/PS1 double transgenic mice. *International immunopharmacology*. 2014;20(1):276-81.

Soodi M, Saeidnia S, Sharifzadeh M, Hajimehdipour H, Dashti A, Sepand MR, et al. *Satureja bachtiarica* ameliorate beta-amyloid induced memory impairment, oxidative stress and cholinergic deficit in animal model of Alzheimer's disease. *Metabolic brain disease*. 2016;31(2):395-404.

Souza ACG, Sari MHM, Pinton S, Luchese C, Neto JSS, Nogueira CW. 2-Phenylethynyl-butyltellurium attenuates amyloid-beta peptide(25-35)-induced learning and memory impairments in mice. *Journal of neuroscience research*. 2013;91(6):848-53.

Spencer B, Verma I, Desplats P, Morvinski D, Rockenstein E, Adame A, et al. A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis. *The Journal of biological chemistry*. 2014;289(25):17917-31.

Spilman P, Descamps O, Gorostiza O, Peters-Libeu C, Poksay KS, Matalis A, et al. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model. *Brain research*. 2014;1551:25-44.

St-Amour I, Pare I, Tremblay C, Coulombe K, Bazin R, Calon F. IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Abeta pathology. *Journal of neuroinflammation*. 2014;11:54.

Stacpoole M, Hockley J, Thompsell A, Simard J, Volicer L. The Namaste Care programme can reduce behavioural symptoms in care home residents with advanced dementia. *International journal of geriatric psychiatry*. 2015;30(7):702-9.

Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. *Molecular psychiatry*. 2013;18(8):889-97.

Subaiea GM, Adwan LI, Ahmed AH, Stevens KE, Zawia NH. Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice. *Neurobiology of aging*. 2013;34(10):2421-30.

Subash S, Braidy N, Essa MM, Zayana A-B, Ragini V, Al-Adawi S, et al. Long-term (15 mo) dietary supplementation with pomegranates from Oman attenuates cognitive and behavioral deficits in a transgenic mice model of Alzheimer's disease. *Nutrition (Burbank, Los Angeles County, Calif)*. 2015;31(1):223-9.

Subash S, Essa MM, Braidy N, Al-Jabri A, Vaishnav R, Al-Adawi S, et al. Consumption of fig fruits grown in Oman can improve memory, anxiety, and learning skills in a transgenic mice model of Alzheimer's disease. *Nutritional neuroscience*. 2016;19(10):475-83.

Suganthi N, Malar DS, Devi KP. *Rhizophora mucronata* attenuates beta-amyloid induced cognitive dysfunction, oxidative stress and cholinergic deficit in Alzheimer's disease animal model. *Metabolic brain disease*. 2016;31(4):937-49.

Sutalangka C, Wattanathorn J. Neuroprotective and cognitive-enhancing effects of the combined extract of *Cyperus rotundus* and *Zingiber officinale*. *BMC complementary and alternative medicine*. 2017;17(1):135.

Szaniszlo P, German P, Hajas G, Saenz DN, Kruzel M, Boldogh I. New insights into clinical trial for Colostrinin in Alzheimer's disease. *The journal of nutrition, health & aging*. 2009;13(3):235-41.

Takamura R, Watamura N, Nikkuni M, Ohshima T. All-trans retinoic acid improved impaired proliferation of neural stem cells and suppressed microglial activation in the hippocampus in an Alzheimer's mouse model. *Journal of neuroscience research*. 2017;95(3):897-906.

Tam SW, Zaczek R. Linopirdine. A depolarization-activated releaser of transmitters for treatment of dementia. *Advances in experimental medicine and biology*. 1995;363:47-56.

Tan L, Yang HP, Pang W, Li HQ, Liu W, Sun SD, et al. Investigation on the Role of BDNF in the Benefits of Blueberry Extracts for the Improvement of Learning and Memory in Alzheimer's Disease Mouse Model. *Journal of Alzheimers Disease*. 2017;56(2):629-40.

Tan L, Tan L, Wang H-F, Wang J, Tan C-C, Tan M-S, et al. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis. *Alzheimer's research & therapy*. 2015;7(1):20.

Tan M-S, Yu J-T, Jiang T, Zhu X-C, Guan H-S, Tan L. IL12/23 p40 inhibition ameliorates Alzheimer's disease-associated neuropathology and spatial memory in SAMP8 mice. *Journal of Alzheimer's disease : JAD*. 2014;38(3):633-46.

Tariska P, Paksy A. Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia. *Orvosi hetilap*. 2000;141(22):1189-93.

Teng E, Taylor K, Bilousova T, Weiland D, Pham T, Zuo X, et al. Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Abeta pathology and modulates Abeta oligomerization. *Neurobiology of disease*. 2015;82:552-60.

Thienhaus OJ, Wheeler BG, Simon S, Zemlan FP, Hartford JT. A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia. *Journal of the American Geriatrics Society*. 1987;35(3):219-23.

Thomas KS, Baier R, Kosar C, Ogarek J, Trepman A, Mor V. Individualized Music Program is Associated with Improved Outcomes for U.S. Nursing Home Residents with Dementia. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2017.

Tian Y, Zhang X, Li Y, Shoup TM, Teng X, Elmaleh DR, et al. Crown ethers attenuate aggregation of amyloid beta of Alzheimer's disease. *Chemical communications (Cambridge, England)*. 2014;50(99):15792-5.

Tiribuzi R, Crispoltoni L, Chiurchio V, Casella A, Montecchiani C, Del Pino AM, et al. Trans-crocetin improves amyloid-beta degradation in monocytes from Alzheimer's Disease patients. *Journal of the neurological sciences*. 2017;372:408-12.

Tobinick E. Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. *Medscape journal of medicine*. 2008;10(6):135.

Tohda C, Nakada R, Urano T, Okonogi A, Kuboyama T. Kamikihi-to (KKT) rescues axonal and synaptic degeneration associated with memory impairment in a mouse model of Alzheimer's disease, 5XFAD. *The International journal of neuroscience*. 2011;121(12):641-8.

Tohda C, Tamura T, Komatsu K. Repair of amyloid beta(25-35)-induced memory impairment and synaptic loss by a Kampo formula, Zokumei-to. *Brain research*. 2003;990(1-2):141-7.

Toide K, Shinoda M, Fujiwara T, Iwamoto Y. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. *Pharmacology, biochemistry, and behavior*. 1997;56(3):427-34.

Tomata Y, Zhang S, Sugiyama K, Kaiho Y, Sugawara Y, Tsuji I. Changes in time spent walking and the risk of incident dementia in older Japanese people: the Ohsaki Cohort 2006 Study. *Age and ageing*. 2017;1-4.

Torika N, Asraf K, Roasso E, Danon A, Fleisher-Berkovich S. Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease. *Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology*. 2016;11(4):774-85.

Tramontina AC, Wartchow KM, Rodrigues L, Biasibetti R, Quincozes-Santos A, Bobermin L, et al. The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer's disease in rats. *Journal of neural transmission (Vienna, Austria : 1996)*. 2011;118(11):1641-9.

Tsai GE, Falk WE, Gunther J, Coyle JT. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. *The American journal of psychiatry*. 1999;156(3):467-9.

Tsai S-J, Chiu CP, Yang H-T, Yin M-C. s-Allyl cysteine, s-ethyl cysteine, and s-propyl cysteine alleviate beta-amyloid, glycation, and oxidative injury in brain of mice treated by D-galactose. *Journal of agricultural and food chemistry*. 2011;59(11):6319-26.

Tsai-Teng T, Chin-Chu C, Li-Ya L, Wan-Ping C, Chung-Kuang L, Chien-Chang S, et al. Erinacine A-enriched *Hericium erinaceus* mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice. *Journal of biomedical science*. 2016;23(1):49.

Tuszynski MH, Yang JH, Barba D, U H-S, Bakay RAE, Pay MM, et al. Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease. *JAMA neurology*. 2015;72(10):1139-47.

Tweedie D, Ferguson RA, Fishman K, Frankola KA, Van Praag H, Holloway HW, et al. Tumor necrosis factor- α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. *Journal of neuroinflammation*. 2012;9:106.

Tzanoulinou S, Brandi R, Arisi I, D'Onofrio M, Urfer SM, Sandi C, et al. Pathogen-free husbandry conditions alleviate behavioral deficits and neurodegeneration in AD10 anti-NGF mice. *Journal of Alzheimer's disease : JAD*. 2014;38(4):951-64.

Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of *Bacopa monnieri* in Alzheimer's disease model. *Journal of ethnopharmacology*. 2010;127(1):26-31.

Ueda K, Yagami T, Kageyama H, Kawasaki K. Protein kinase inhibitor attenuates apoptotic cell death induced by amyloid beta protein in culture of the rat cerebral cortex. *Neuroscience letters*. 1996;203(3):175-8.

Ukai M, Kobayashi T, Kameyama T. Dynorphin A-(1-13) attenuates basal forebrain-lesion-induced amnesia in rats. *Brain research*. 1993;625(2):355-6.

Umeda T, Ono K, Sakai A, Yamashita M, Mizuguchi M, Klein WL, et al. Rifampicin is a candidate preventive medicine against amyloid-beta and tau oligomers. *Brain : a journal of neurology*. 2016;139(Pt 5):1568-86.

Valikovics A, Csanyi A, Nemeth L. Study of the effects of vinpocetin on cognitive functions. *Ideggyogyaszati szemle*. 2012;65(3-4):115-20.

Van der Auwera I, Wera S, Van Leuven F, Henderson ST. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. *Nutrition & metabolism*. 2005;2:28.

van der Ven AT, Pape JC, Hermann D, Schloesser R, Genius J, Fischer N, et al. Methylene Blue (Tetramethylthionine Chloride) Influences the Mobility of Adult Neural Stem Cells: A Potentially Novel Therapeutic Mechanism of a Therapeutic Approach in the Treatment of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;57(2):531-40.

van Dijk KRA, Scherder EJA, Scheltens P, Sergeant JA. Effects of transcutaneous electrical nerve stimulation (TENS) on non-pain related cognitive and behavioural functioning. *Reviews in the neurosciences*. 2002;13(3):257-70.

van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Gotz J, et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(31):13888-93.

van Gijssel-Bonnello M, Baranger K, Benech P, Rivera S, Khrestchatisky M, de Reggi M, et al. Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer's disease: Alleviation by pantethine. *PloS one*. 2017;12(4):e0175369.

Vepsalainen S, Koivisto H, Pekkarinen E, Makinen P, Dobson G, McDougall GJ, et al. Anthocyanin-enriched bilberry and blackcurrant extracts modulate amyloid precursor protein processing and alleviate behavioral abnormalities in the APP/PS1 mouse model of Alzheimer's disease. *The Journal of nutritional biochemistry*. 2013;24(1):360-70.

Verhey FRJ, Verkaaik M, Lousberg R, Olanzapine-Haloperidol in Dementia Study g. Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. *Dementia and geriatric cognitive disorders*. 2006;21(1):1-8.

Verma M, Beaulieu-Abdelahad D, Ait-Ghezala G, Li R, Crawford F, Mullan M, et al. Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD. *PLoS one*. 2015;10(5):e0128224.

Viayna E, Gomez T, Galdeano C, Ramirez L, Ratia M, Badia A, et al. Novel huprine derivatives with inhibitory activity toward beta-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates. *ChemMedChem*. 2010;5(11):1855-70.

Vonck K, Raedt R, Naulaerts J, De Vogelaere F, Thiery E, Van Roost D, et al. Vagus nerve stimulation 25 years later! What do we know about the effects on cognition? *Neuroscience and biobehavioral reviews*. 2014;45:63-71.

Voronkova KV, Meleshkov MN. Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia. *Neuroscience and behavioral physiology*. 2009;39(5):501-6.

Wang C-J, Chen C-C, Tsay H-J, Chiang F-Y, Wu M-F, Shiao Y-J. *Cudrania cochinchinensis* attenuates amyloid beta protein-mediated microglial activation and promotes glia-related clearance of amyloid beta protein. *Journal of biomedical science*. 2013;20:55.

Wang D, Li X, Gao K, Lu D, Zhang X, Ma C, et al. Cardiotrophin-1 (CTF1) ameliorates glucose-uptake defects and improves memory and learning deficits in a transgenic mouse model of Alzheimer's disease. *Pharmacology, biochemistry, and behavior*. 2013;107:48-57.

Wang D, Yang L, Su J, Niu Y, Lei X, Xiong J, et al. Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline. *Biochemical and biophysical research communications*. 2011;410(2):229-34.

Wang EM, Zhu HH, Wang XF, Gower AC, Wallack M, Blusztajn JK, et al. Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer's Disease Mouse Model. *Journal of Alzheimers Disease*. 2017;56(1):47-61.

Wang HH, Chou CJ, Liao JF, Chen CF. Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. *European journal of pharmacology*. 2001;413(2-3):221-5.

Wang H, Wang H, Cheng H, Che Z. Ameliorating effect of luteolin on memory impairment in an Alzheimer's disease model. *Molecular medicine reports*. 2016;13(5):4215-20.

Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. *The Journal of clinical investigation*. 2007;117(11):3393-402.

Wang J, Ono K, Dickstein DL, Arrieta-Cruz I, Zhao W, Qian X, et al. Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. *Neurobiology of aging*. 2011;32(12):2321.e1-12.

Wang K, Fernandez-Escobar A, Han S, Zhu P, Wang J-H, Sun Y. Lamotrigine Reduces Inflammatory Response and Ameliorates Executive Function Deterioration in an Alzheimer's-Like Mouse Model. *BioMed research international*. 2016;2016:7810196.

Wang Q-H, Wang Y-R, Zhang T, Jiao S-S, Liu Y-H, Zeng F, et al. Intramuscular delivery of p75NTR ectodomain by an AAV vector attenuates cognitive deficits and Alzheimer's disease-like pathologies in APP/PS1 transgenic mice. *Journal of neurochemistry*. 2016;138(1):163-73.

Wang S-W, Yang S-G, Liu W, Zhang Y-X, Xu P-X, Wang T, et al. Alpha-tocopherol quinine ameliorates spatial memory deficits by reducing beta-amyloid oligomers, neuroinflammation and oxidative stress in transgenic mice with Alzheimer's disease. *Behavioural brain research*. 2016;296:109-17.

Wang S-Y, Liu J-P, Ji W-W, Chen W-J, Fu Q, Feng L, et al. Qifu-Yin attenuates AGEs-induced Alzheimer-like pathophysiological changes through the RAGE/NF-kappaB pathway. *Chinese journal of natural medicines*. 2014;12(12):920-8.

Wang S, Yu L, Yang H, Li C, Hui Z, Xu Y, et al. Oridonin Attenuates Synaptic Loss and Cognitive Deficits in an Abeta1-42-Induced Mouse Model of Alzheimer's Disease. *PloS one*. 2016;11(3):e0151397.

Wang X, Wu J, Yu C, Tang Y, Liu J, Chen H, et al. Lychee Seed Saponins Improve Cognitive Function and Prevent Neuronal Injury via Inhibiting Neuronal Apoptosis in a Rat Model of Alzheimer's Disease. *Nutrients*. 2017;9(2).

Wang Y-J, Thomas P, Zhong J-H, Bi F-F, Kosaraju S, Pollard A, et al. Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. *Neurotoxicity research*. 2009;15(1):3-14.

Wang ZG, Xiong L, Wan WB, Duan LJ, Bai XJ, Zu HB. Intranasal BMP9 Ameliorates Alzheimer Disease-Like Pathology and Cognitive Deficits in APP/PS1 Transgenic Mice. *Frontiers in Molecular Neuroscience*. 2017;10.

Wang Z, Xiong L, Wan W, Duan L, Bai X, Zu H. Intranasal BMP9 Ameliorates Alzheimer Disease-Like Pathology and Cognitive Deficits in APP/PS1 Transgenic Mice. *Frontiers in molecular neuroscience*. 2017;10:32.

Wei C, Zhang W, Zhou Q, Zhao C, Du Y, Yan Q, et al. Mithramycin A Alleviates Cognitive Deficits and Reduces Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. *Neurochemical research*. 2016;41(8):1924-38.

Wei L, Yang H, Xie Z, Yang S, Yang H, Zhao C, et al. A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-beta deposition in an AbetaPP/PS1 transgenic mouse model. *Journal of Alzheimer's disease : JAD*. 2012;30(3):531-43.

Wei L, Lv S, Huang Q, Wei J, Zhang S, Huang R, et al. Pratensein attenuates Abeta-induced cognitive deficits in rats: enhancement of synaptic plasticity and cholinergic function. *Fitoterapia*. 2015;101:208-17.

Weinreb O, Amit T, Bar-Am O, Youdim MBH. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. *Current drug targets*. 2012;13(4):483-94.

Wettstein A, Hanhart U. Milieu therapy for patients with dementia. Appropriate, regular stimulation by pleasant experiences. *Praxis*. 2000;89(7):281-6.

Weyerer S, Schaufele M, Wiese B, Maier W, Tebarth F, van den Bussche H, et al. Current alcohol consumption and its relationship to incident dementia: results from a 3-year follow-up study among primary care attenders aged 75 years and older. *Age and ageing*. 2011;40(4):456-63.

Whear R, Coon JT, Bethel A, Abbott R, Stein K, Garside R. What is the impact of using outdoor spaces such as gardens on the physical and mental well-being of those with dementia? A systematic review of quantitative and qualitative evidence. *Journal of the American Medical Directors Association*. 2014;15(10):697-705.

Wiesmann M, Jansen D, Zerbi V, Broersen LM, Garthe A, Kiliaan AJ. Improved spatial learning strategy and memory in aged Alzheimer AbetaPPswe/PS1dE9 mice on a multi-nutrient diet. *Journal of Alzheimer's disease : JAD*. 2013;37(1):233-45.

Winblad B, Fioravanti M, Dolezal T, Logina I, Milanov IG, Popescu DC, et al. Therapeutic use of nicergoline. *Clinical drug investigation*. 2008;28(9):533-52.

Wu G, Li L, Li HM, Zeng Y, Wu WC. Electroacupuncture ameliorates spatial learning and memory impairment via attenuating NOX2-related oxidative stress in a rat model of Alzheimer's disease induced by Abeta1-42. *Cellular and molecular biology (Noisy-le-Grand, France)*. 2017;63(4):38-45.

Wu G-M, Hou X-Y. Oligomerized Abeta25-35 induces increased tyrosine phosphorylation of NMDA receptor subunit 2A in rat hippocampal CA1 subfield. *Brain research*. 2010;1343:186-93.

Wu J, Wang Y, Wang Z. The effectiveness of massage and touch on behavioural and psychological symptoms of dementia: A quantitative systematic review and meta-analysis. *Journal of advanced nursing*. 2017.

Wu W-h, Liu Q, Sun X, Yu J-s, Zhao D-s, Yu Y-p, et al. Fibrillar seeds alleviate amyloid-beta cytotoxicity by omitting formation of higher-molecular-weight oligomers. *Biochemical and biophysical research communications*. 2013;439(3):321-6.

Wu Y, Luo X, Liu X, Liu D, Wang X, Guo Z, et al. Intraperitoneal Administration of a Novel TAT-BDNF Peptide Ameliorates Cognitive Impairments via Modulating Multiple Pathways in Two Alzheimer's Rodent Models. *Scientific reports*. 2015;5:15032.

Wu Z, Zhao L, Chen X, Cheng X, Zhang Y. Galantamine attenuates amyloid-beta deposition and astrocyte activation in APP/PS1 transgenic mice. *Experimental gerontology*. 2015;72:244-50.

Wu Z, Yang B, Liu C, Liang G, Liu W, Pickup S, et al. Long-term dantrolene treatment reduced intraneuronal amyloid in aged Alzheimer triple transgenic mice. *Alzheimer disease and associated disorders*. 2015;29(3):184-91.

Xia Z, Peng W, Cheng S, Zhong B, Sheng C, Zhang C, et al. Naoling decoction restores cognitive function by inhibiting the neuroinflammatory network in a rat model of Alzheimer's disease. *Oncotarget*. 2017.

Xian Y-F, Lin Z-X, Zhao M, Mao Q-Q, Ip S-P, Che C-T. *Uncaria rhynchophylla* ameliorates cognitive deficits induced by D-galactose in mice. *Planta medica*. 2011;77(18):1977-83.

Xie K, Liu Y, Hao W, Walter S, Penke B, Hartmann T, et al. Tenascin-C deficiency ameliorates Alzheimer's disease-related pathology in mice. *Neurobiology of aging*. 2013;34(10):2389-98.

Xie Y, Tan Y, Zheng Y, Du X, Liu Q. Ebselen ameliorates beta-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice. *Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry*. 2017.

Xu J, Barger SW, Drew PD. The PPAR-gamma Agonist 15-Deoxy-Delta-Prostaglandin J(2) Attenuates Microglial Production of IL-12 Family Cytokines: Potential Relevance to Alzheimer's Disease. *PPAR research*. 2008;2008:349185.

Xu J, de Winter F, Farrokhi C, Rockenstein E, Mante M, Adame A, et al. Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model. *Scientific reports*. 2016;6:31692.

Xu M, Dong Y, Wan S, Yan T, Cao J, Wu L, et al. Schisantherin B ameliorates Abeta1-42-induced cognitive decline via restoration of GLT-1 in a mouse model of Alzheimer's disease. *Physiology & behavior*. 2016;167:265-73.

Xu M-f, Xiong Y-y, Liu J-k, Qian J-j, Zhu L, Gao J. Asiatic acid, a pentacyclic triterpene in *Centella asiatica*, attenuates glutamate-induced cognitive deficits in mice and apoptosis in SH-SY5Y cells. *Acta pharmacologica Sinica*. 2012;33(5):578-87.

Xu W, Liu J, Ma D, Yuan G, Lu Y, Yang Y. Capsaicin reduces Alzheimer-associated tau changes in the hippocampus of type 2 diabetes rats. *PloS one*. 2017;12(2):e0172477.

Xu W, Yang Y, Yuan G, Zhu W, Ma D, Hu S. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes. *Journal of investigative medicine : the official publication of the American Federation for Clinical Research*. 2015;63(2):267-72.

Xu Z-P, Li L, Bao J, Wang Z-H, Zeng J, Liu E-J, et al. Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model. *PloS one*. 2014;9(9):e108645.

Xue S, Chen C, Dong W, Hui G, Liu T, Guo L. Therapeutic effects of human amniotic epithelial cell transplantation on double-transgenic mice co-expressing APP^{swe} and PS1^{DeltaE9}-deleted genes. *Science China Life sciences*. 2012;55(2):132-40.

Xue X, Wang L-R, Sato Y, Jiang Y, Berg M, Yang D-S, et al. Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer's disease. *Nano letters*. 2014;14(9):5110-7.

Yadav R, Murthy RV, Kikkeri R. Sialic Acid Hydroxamate: A Potential Antioxidant and Inhibitor of Metal-Induced beta-Amyloid Aggregates. *Chembiochem : a European journal of chemical biology*. 2015;16(10):1448-53.

Yaffe K, Krueger K, Cummings SR, Blackwell T, Henderson VW, Sarkar S, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. *The American journal of psychiatry*. 2005;162(4):683-90.

Yamada M, Chiba T, Sasabe J, Terashita K, Aiso S, Matsuoka M. Nasal colivelin treatment ameliorates memory impairment related to Alzheimer's disease. *Neuropsychopharmacology*. 2008;33(8):2020-32.

Yamagami S, Mui K, Hirayama E, Furutsuka D, Soma T, Soejima S, et al. The clinical effect of bifemelane hydrochloride on dementia in aged patients. *Drugs under experimental and clinical research*. 1991;17(4):217-23.

Yamazaki H, Jin Y, Tsuchiya A, Kanno T, Nishizaki T. Adipose-derived stem cell-conditioned medium ameliorates antidepressant-related behaviors in the mouse model of Alzheimer's disease. *Neuroscience letters*. 2015;609:53-7.

Yamazaki M, Okabe M, Yamamoto N, Yarimizu J, Harada K. Novel 5-HT_{5A} receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats. *Journal of pharmacological sciences*. 2015;127(3):362-9.

Yang D-S, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. *Brain : a journal of neurology*. 2011;134(Pt 1):258-77.

Yang E-J, Ahn S, Ryu J, Choi M-S, Choi S, Chong YH, et al. Phloroglucinol Attenuates the Cognitive Deficits of the 5XFAD Mouse Model of Alzheimer's Disease. *PloS one*. 2015;10(8):e0135686.

Yang H, Zhuo J-M, Chu J, Chinnici C, Pratico D. Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase. *Biological psychiatry*. 2010;68(10):922-9.

Yang IH, Orti JED, Sabater PS, Castillo SS, Rochina MJ, Ramon NM, et al. COCONUT OIL: NON-ALTERNATIVE DRUG TREATMENT AGAINST ALZHEIMER'S DISEASE. *Nutricion Hospitalaria*. 2015;32(6):2822-7.

Yang N-C, Lin H-C, Wu J-H, Ou H-C, Chai Y-C, Tseng C-Y, et al. Ergothioneine protects against neuronal injury induced by beta-amyloid in mice. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*. 2012;50(11):3902-11.

Yang S-g, Wang S-w, Zhao M, Zhang R, Zhou W-w, Li Y-n, et al. A peptide binding to the beta-site of APP improves spatial memory and attenuates Abeta burden in Alzheimer's disease transgenic mice. *PloS one*. 2012;7(11):e48540.

Yang S, Gong Q, Wu Q, Li F, Lu Y, Shi J. Alkaloids enriched extract from *Dendrobium nobile* Lindl. attenuates tau protein hyperphosphorylation and apoptosis induced by lipopolysaccharide in rat brain. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2014;21(5):712-6.

Yang Z-Y, Kuboyama T, Kazuma K, Konno K, Tohda C. Active Constituents from *Drynaria fortunei* Rhizomes on the Attenuation of Abeta(25-35)-Induced Axonal Atrophy. *Journal of natural products*. 2015;78(9):2297-300.

Yao L, Gu X, Song Q, Wang X, Huang M, Hu M, et al. Nanoformulated alpha-mangostin ameliorates Alzheimer's disease neuropathology by elevating LDLR expression and accelerating amyloid-beta clearance. *Journal of controlled release : official journal of the Controlled Release Society*. 2016;226:1-14.

Yao Z, Yang W, Gao Z, Jia P. Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. *Neuroscience letters*. 2017;647:133-40.

Yasar S, Xia J, Yao W, Furberg CD, Xue Q-L, Mercado CI, et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. *Neurology*. 2013;81(10):896-903.

Yates LA, Ziser S, Spector A, Orrell M. Cognitive leisure activities and future risk of cognitive impairment and dementia: systematic review and meta-analysis. *International psychogeriatrics*. 2016;28(11):1791-806.

Ye M, Chung H-S, Lee C, Yoon MS, Yu AR, Kim JS, et al. Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer's disease. *Journal of neuroinflammation*. 2016;13:10.

Yi JH, Park HJ, Lee S, Jung JW, Kim BC, Lee YC, et al. Cassia obtusifolia seed ameliorates amyloid beta-induced synaptic dysfunction through anti-inflammatory and Akt/GSK-3 β pathways. *Journal of ethnopharmacology*. 2016;178:50-7.

Yin J, Zhao F, Chojnacki JE, Fulp J, Klein WL, Zhang S, et al. NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer's Disease. *Molecular neurobiology*. 2017.

Yu D, Tao B-B, Yang Y-Y, Du L-S, Yang S-S, He X-J, et al. The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2015;43(1):291-302.

Yu J, Chu J-M, Gao L-A, Zhang Y-S, Bao Y-H. Effects of grain-sized moxibustion on learning and memory ability and amyloid deposition of transgenic Alzheimer's disease mice. *Zhen ci yan jiu = Acupuncture research*. 2014;39(1):58-62, 82.

Yu L, Wang S, Chen X, Yang H, Li X, Xu Y, et al. Orientin alleviates cognitive deficits and oxidative stress in Abeta1-42-induced mouse model of Alzheimer's disease. *Life sciences*. 2015;121:104-9.

Yu N-N, Wang X-X, Yu J-T, Wang N-D, Lu R-C, Miao D, et al. Blocking beta2-adrenergic receptor attenuates acute stress-induced amyloid beta peptides production. *Brain research*. 2010;1317:305-10.

Yu X-L, Li Y-N, Zhang H, Su Y-J, Zhou W-W, Zhang Z-P, et al. Rutin inhibits amylin-induced neurocytotoxicity and oxidative stress. *Food & function*. 2015;6(10):3296-306.

Yuan P, Grutzendler J. Attenuation of beta-Amyloid Deposition and Neurotoxicity by Chemogenetic Modulation of Neural Activity. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2016;36(2):632-41.

Yuan Y, Li LH, Huang YJ, Lei LF. Tiapride is more effective and causes fewer adverse effects than risperidone in the treatment of senile dementia. *European review for medical and pharmacological sciences*. 2016;20(14):3119-22.

Yue W, Li Y, Zhang T, Jiang M, Qian Y, Zhang M, et al. ESC-Derived Basal Forebrain Cholinergic Neurons Ameliorate the Cognitive Symptoms Associated with Alzheimer's Disease in Mouse Models. *Stem cell reports*. 2015;5(5):776-90.

Zemlan FP. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group. *Journal of neural transmission (Vienna, Austria : 1996)*. 1996;103(8-9):1105-16.

Zhang C, Hu W-H, Wu D-L, Zhang K, Zhang J-G. Behavioral effects of deep brain stimulation of the anterior nucleus of thalamus, entorhinal cortex and fornix in a rat model of Alzheimer's disease. *Chinese medical journal*. 2015;128(9):1190-5.

Zhang C, Kuo C-C, Moghadam SH, Monte L, Campbell SN, Rice KC, et al. Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016;12(5):527-37.

Zhang F-F, Li J. Inhibitory effect of chloroquine derivatives on presenilin 1 and ubiquilin 1 expression in Alzheimer's disease. *International journal of clinical and experimental pathology*. 2015;8(6):7640-3.

Zhang H, Sun R, Liu X-Y, Shi X-M, Wang W-F, Yu L-G, et al. A tetramethylpyrazine piperazine derivate CXC137 prevents cell injury in SH-SY5Y cells and improves memory dysfunction of rats with vascular Dementia. *Neurochemical research*. 2014;39(2):276-86.

Zhang J, Zhang R, Zhan Z, Li X, Zhou F, Xing A, et al. Beneficial Effects of Sulforaphane Treatment in Alzheimer's Disease May Be Mediated through Reduced HDAC1/3 and Increased P75NTR Expression. *Frontiers in aging neuroscience*. 2017;9:121.

Zhang L-N, Sun Y-J, Pan S, Li J-X, Qu Y-E, Li Y, et al. Na⁺-K⁺-ATPase, a potent neuroprotective modulator against Alzheimer disease. *Fundamental & clinical pharmacology*. 2013;27(1):96-103.

Zhang M, Wang Y, Qian F, Li P, Xu X. Hypericin inhibits oligomeric amyloid beta42-induced inflammation response in microglia and ameliorates cognitive deficits in an amyloid beta injection mouse model of Alzheimer's disease by suppressing MKL1. *Biochemical and biophysical research communications*. 2016;481(1-2):71-6.

Zhang Q, Li J, Liu C, Song C, Li P, Yin F, et al. Protective effects of low molecular weight chondroitin sulfate on amyloid beta (A β)-induced damage in vitro and in vivo. *Neuroscience*. 2015;305:169-82.

Zhang S-L, Yang X-J, Liu T-F. Effect and mechanism of jiannao yizhi decoction on learning and memory in rats with similar Alzheimer's disease. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi* = Chinese journal of integrated traditional and Western medicine. 2008;28(6):529-31.

Zhang S-F, Dong Y-C, Zhang X-F, Wu X-G, Cheng J-J, Guan L-H, et al. Flavonoids from *Scutellaria* attenuate okadaic acid-induced neuronal damage in rats. *Brain injury*. 2015;29(11):1376-82.

Zhang W, Zhi D, Ren H, Wang D, Wang X, Zhang Z, et al. Shengmai Formula Ameliorates Pathological Characteristics in AD *C.elegans*. *Cellular and molecular neurobiology*. 2016;36(8):1291-302.

Zhang X, Heng X, Li T, Li L, Yang D, Zhang X, et al. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer's disease transgenic mouse model. *Journal of Alzheimer's disease : JAD*. 2011;24(4):739-49.

Zhang YY, Yang LQ, Guo LM. Effect of phosphatidylserine on memory in patients and rats with Alzheimer's disease. *Genetics and molecular research : GMR*. 2015;14(3):9325-33.

Zhang Y, Pi Z, Song F, Liu Z. Ginsenosides attenuate d-galactose- and AlCl₃-induced spatial memory impairment by restoring the dysfunction of the neurotransmitter systems in the rat model of Alzheimer's disease. *Journal of ethnopharmacology*. 2016;194:188-95.

Zhang Y, Yang X, Jin G, Yang X, Zhang Y. Polysaccharides from *Pleurotus ostreatus* alleviate cognitive impairment in a rat model of Alzheimer's disease. *International journal of biological macromolecules*. 2016;92:935-41.

Zhang Y, Li Q, Liu C, Gao S, Ping H, Wang J, et al. MiR-214-3p attenuates cognition defects via the inhibition of autophagy in SAMP8 mouse model of sporadic Alzheimer's disease. *Neurotoxicology*. 2016;56:139-49.

Zhang Y, Zou J, Yang J, Yao Z. 4A β 1-15-Derived Monoclonal Antibody Reduces More A β Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice. *Current Alzheimer research*. 2015;12(4):384-97.

Zhang Z-X, Zhao R-P, Wang D-S, Li Y-B. Fuzhisan Ameliorates the Memory Deficits in Aged SAMP8 Mice via Decreasing A β Production and Tau Hyperphosphorylation of the Hippocampus. *Neurochemical research*. 2016;41(11):3074-82.

Zhang Z-Y, Schluesener HJ. Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. *Journal of neuropathology and experimental neurology*. 2013;72(3):178-85.

Zhao B, Pan Y, Wang Z, Xu H, Song X. Hyperbaric Oxygen Pretreatment Improves Cognition and Reduces Hippocampal Damage Via p38 Mitogen-Activated Protein Kinase in a Rat Model. *Yonsei medical journal*. 2017;58(1):131-8.

Zhao B-Q, Guo Y-R, Li X-L, Zang T, Qu H-Y, Zhou J-P, et al. Amelioration of dementia induced by Abeta 22-35 through rectal delivery of undecapeptide-hEGF to mouse brain. *International journal of pharmaceutics*. 2011;405(1-2):1-8.

Zhao J, Li Z, Cong Y, Zhang J, Tan M, Zhang H, et al. Repetitive transcranial magnetic stimulation improves cognitive function of Alzheimer's disease patients. *Oncotarget*. 2017;8(20):33864-71.

Zhao L, Gong N, Liu M, Pan X, Sang S, Sun X, et al. Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model. *Neurobiology of aging*. 2014;35(12):2736-45.

Zhao L, Wang J-L, Liu R, Li X-X, Li J-F, Zhang L. Neuroprotective, anti-amyloidogenic and neurotrophic effects of apigenin in an Alzheimer's disease mouse model. *Molecules (Basel, Switzerland)*. 2013;18(8):9949-65.

Zhao S-s, Yang W-n, Jin H, Ma K-g, Feng G-f. Puerarin attenuates learning and memory impairments and inhibits oxidative stress in STZ-induced SAD mice. *Neurotoxicology*. 2015;51:166-71.

Zheng GH, Xia R, Zhou WJ, Tao J, Chen LD. Aerobic exercise ameliorates cognitive function in older adults with mild cognitive impairment: a systematic review and meta-analysis of randomised controlled trials. *British Journal of Sports Medicine*. 2016;50(23):1443-+.

Zheng J-Y, Liang K-S, Wang X-J, Zhou X-Y, Sun J, Zhou S-N. Chronic Estradiol Administration During the Early Stage of Alzheimer's Disease Pathology Rescues Adult Hippocampal Neurogenesis and Ameliorates Cognitive Deficits in Abeta1-42 Mice. *Molecular neurobiology*. 2016.

Zhou NN, Zhu R, Zhao XM, Liang P. Effect and mechanism of traditional Chinese herbs against Abeta expression in brain tissues of mice with Alzheimer's disease. *Zhonghua bing li xue za zhi = Chinese journal of pathology*. 2016;45(11):780-5.

Zhou S, Yu G, Chi L, Zhu J, Zhang W, Zhang Y, et al. Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats. *Neurotoxicology*. 2013;38:136-45.

Zhou W, Fukumoto S, Yokogoshi H. Components of lemon essential oil attenuate dementia induced by scopolamine. *Nutritional neuroscience*. 2009;12(2):57-64.

Zhu CQ, Cao XD. Regulatory effect of tiaoxin recipe drug serum on animal's Alzheimer disease related tau protein phosphorylation. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi* = Chinese journal of integrated traditional and Western medicine. 2001;21(11):834-6.

Zhu L, Yang J-y, Xue X, Dong Y-x, Liu Y, Miao F-r, et al. A novel phosphodiesterase-5 Inhibitor: Yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP/PS1 transgenic mice model. *Mechanisms of ageing and development*. 2015;150:34-45.

Zhu X, Chen C, Ye D, Guan D, Ye L, Jin J, et al. Diammonium glycyrrhizinate upregulates PGC-1alpha and protects against Abeta1-42-induced neurotoxicity. *PloS one*. 2012;7(4):e35823.

Zhu X, Wang S, Yu L, Yang H, Tan R, Yin K, et al. TL-2 attenuates beta-amyloid induced neuronal apoptosis through the AKT/GSK-3beta/beta-catenin pathway. *The international journal of neuropsychopharmacology*. 2014;17(9):1511-9.

Zhu Z, Yan J, Jiang W, Yao X-g, Chen J, Chen L, et al. Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both beta-amyloid production and clearance. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(32):13138-49.

Zuo Y-m, Zhang Z-l, Wang Q-h, Xie N, Kuang H-x. Effects of Valeriana amurensis on the expressions of beta-APP, Abeta(1-40) and caspase-3 in Alzheimer's disease model rat's brain. *Zhong yao cai* = Zhongyaocai = Journal of Chinese medicinal materials. 2010;33(2):233-6.

Zwilling D, Huang S-Y, Sathyaikumar KV, Notarangelo FM, Guidetti P, Wu H-Q, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. *Cell*. 2011;145(6):863-74.

Appendix 10C2-a. Additional AD treatment articles based on references in AD treatment review papers

Abraham I, El Sayed K, Chen Z-S, Guo H. Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance. *Marine Drugs*. 2012;10(10):2312-21.

Abrahamson EE, Ikonomic MD, Ciallella JR, Hope CE, Paljug WR, Isanski BA, et al. Caspase inhibition therapy abolishes brain trauma-induced increases in A beta peptide: Implications for clinical outcome. *Experimental Neurology*. 2006;197(2):437-50.

Abuznait AH, Cain C, Ingram D, Burk D, Kaddoumi A. Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease. *Journal of Pharmacy and Pharmacology*. 2011;63(8):1111-8.

Adam F, Bordenave L, Sessler DI, Chauvin M. Effects of a single 1200-mg preoperative dose of gabapentin on anxiety and memory. *Annales francaises d'anesthesie et de reanimation*. 2012;31(10):e223-7.

Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial A beta. *Neuron*. 2008;59(1):43-55.

Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antonietto K, et al. An Effector-Reduced Anti-beta-Amyloid (A beta) Antibody with Unique A beta Binding Properties Promotes Neuroprotection and Glial Engulfment of A beta. *Journal of Neuroscience*. 2012;32(28):9677-89.

Aguglia E, Onor ML, Saina M, Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. *Current Medical Research and Opinion*. 2004;20(11):1747-52.

Ahmed HH. Modulatory effects of vitamin E, acetyl-L-carnitine and alpha-lipoic acid on new potential biomarkers for Alzheimer's disease in rat model. *Experimental and Toxicologic Pathology*. 2012;64(6):549-56.

Ahmed MA, Darwish ES, Khedr EM, El Serogy YM, Ali AM. Effects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer's dementia. *Journal of Neurology*. 2012;259(1):83-92.

Aisen PS. The development of anti-amyloid therapy for Alzheimer's disease - From secretase modulators to polymerisation inhibitors. *Cns Drugs*. 2005;19(12):989-96.

Aisen PS, Davis KL. INFLAMMATORY MECHANISMS IN ALZHEIMERS-DISEASE - IMPLICATIONS FOR THERAPY. *American Journal of Psychiatry*. 1994;151(8):1105-13.

Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer's disease. *Neurology*. 2000;54(3):588-93.

Aisen PS, Marin DB, Brickman AM, Santoro J, Fusco M. Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease. *Alzheimer Disease & Associated Disorders*. 2001;15(2):96-101.

Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. *Neurology*. 2006;67(10):1757-63.

Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial. *Jama-Journal of the American Medical Association*. 2003;289(21):2819-26.

Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. *Neurology*. 2002;58(7):1050-4.

Aisen PS. Clinical trial methodologies for disease-modifying therapeutic approaches. *Neurobiology of Aging*. 2011;32:S64-S6.

Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, et al. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). *Archives of Medical Science*. 2011;7(1):102-11.

Aisen PS, Gauthier S, Vellas B, Briand R, Saurnier D, Laurin J, et al. Alzhemed: A potential treatment for Alzheimer's disease. *Current Alzheimer Research*. 2007;4(4):473-8.

Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease - A randomized controlled trial. *Jama-Journal of the American Medical Association*. 2008;300(15):1774-83.

Akintade L, Zaiac M, Ieni JR, McRae T. AD2000: design and conclusions. *Lancet*. 2004;364(9441):1214-.

Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. *Neurobiology of Aging*. 2000;21(3):383-421.

Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? *British Journal of Clinical Pharmacology*. 2011;71(3):365-76.

Albert ML, Reches A, Silverberg R. ASSOCIATIVE VISUAL AGNOSIA WITHOUT ALEXIA. *Neurology*. 1975;25(4):322-6.

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers & Dementia*. 2011;7(3):270-9.

Albuquerque EX, Santos MD, Alkondon M, Pereira EFR, Maelicke A. Modulation of nicotinic receptor activity in the central nervous system: A novel approach to the treatment of Alzheimer disease. *Alzheimer Disease & Associated Disorders*. 2001;15:S19-S25.

Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. CORNELL SCALE FOR DEPRESSION IN DEMENTIA. *Biological Psychiatry*. 1988;23(3):271-84.

Alkadhi KA, Alzoubi KH, Srivareerat M, Tran TT. Elevation of BACE in an A beta rat model of Alzheimer's disease: exacerbation by chronic stress and prevention by nicotine. *International Journal of Neuropsychopharmacology*. 2012;15(2):223-33.

Alkam T, Nitta A, Mizoguchi H, Saito K, Seshima M, Itoh A, et al. Restraining tumor necrosis factor-alpha by thalidomide prevents the Amyloid beta-induced impairment of recognition memory in mice. *Behavioural Brain Research*. 2008;189(1):100-6.

Allegri RF, Guekht A. CEREBROLYSIN IMPROVES SYMPTOMS AND DELAYS PROGRESSION IN PATIENTS WITH ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA. *Drugs of Today*. 2012;48:25-41.

Alonso D, Dorronsoro I, Rubio L, Munoz P, Garcia-Palomero E, Del Monte M, et al. Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. *Bioorganic & Medicinal Chemistry*. 2005;13(24):6588-97.

Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. *European Journal of Neurology*. 2006;13(1):43-54.

Alvarez XA, Cacabelos R, Sampedro C, Couceiro V, Aleixandre M, Vargas M, et al. Combination Treatment in Alzheimer's Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil. *Current Alzheimer Research*. 2011;8(5):583-91.

Alvarez XA, Lombardi VRM, Fernandez-Novoa L, Garcia M, Sampedro C, Cagiao A, et al. Cerebrolysin (R) reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. *Journal of Neural Transmission-Supplement*. 2000(59):281-92.

Alvarez XA, Fuentes P. CEREBROLYSIN IN ALZHEIMER'S DISEASE. *Drugs of Today*. 2011;47(7):487-513.

Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, "Über eine eigenartige Erkrankung der Hirnrinde". *Clinical anatomy* (New York, NY). 1995;8(6):429-31.

Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103(8):2892-7.

Amijee H, Scopes DIC. The Quest for Small Molecules as Amyloid Inhibiting Therapies for Alzheimer's Disease. *Journal of Alzheimers Disease*. 2009;17(1):33-47.

Amit T, Avramovich-Tirosh Y, Youdim MBH, Mandel S. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. *Faseb Journal*. 2008;22(5):1296-305.

Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, et al. Selective cognitive dysfunction in acetylcholine M-1 muscarinic receptor mutant mice. *Nature Neuroscience*. 2003;6(1):51-8.

Anand P, Singh B. Synthesis and evaluation of novel 4- (3H,3aH,6aH)-3-phenyl)-4,6-dioxo-2-phenyldihydro-2H-pyrrolo 3,4-d isoxazol-5(3H,6H,6aH)-yl benzoic acid derivatives as potent acetylcholinesterase inhibitors and anti-amnestic agents. *Bioorganic & Medicinal Chemistry*. 2012;20(1):521-30.

Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer's disease. *Archives of Pharmacal Research*. 2013;36(4):375-99.

Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer's disease: Past, present and future. *Neuropharmacology*. 2014;76:27-50.

Anand R, Messina J, Hartman R. Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. *International Journal of Geriatric Psychopharmacology*. 2000;2(2):68-72.

Andersson C, Blennow K, Johansson S-E, Almkvist O, Engfeldt P, Lindau M, et al. Differential CSF biomarker levels in APOE-epsilon 4-positive and -negative patients with memory impairment. *Dementia and Geriatric Cognitive Disorders*. 2007;23(2):87-95.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-A beta 42 as diagnostic markers for Alzheimer disease in clinical practice. *Archives of Neurology*. 2001;58(3):373-9.

Andrieu S, Gillette S, Amouyal K, Nourhashemi F, Reynish E, Ousset PJ, et al. Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a

population of women aged 75 years and older from the EPIDOS study. *Journals of Gerontology Series a-Biological Sciences and Medical Sciences*. 2003;58(4):372-7.

Andrieux A, Salin P, Schweitzer A, Begou M, Pachoud B, Brun P, et al. Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. *Biological Psychiatry*. 2006;60(11):1224-30.

Anekonda TS, Quinn JF, Harris C, Frahler K, Wadsworth TL, Woltjer RL. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. *Neurobiology of Disease*. 2011;41(1):62-70.

Anisuzzaman ASM, Uwada J, Masuoka T, Yoshiki H, Nishio M, Ikegaya Y, et al. Novel contribution of cell surface and intracellular M1-muscarinic acetylcholine receptors to synaptic plasticity in hippocampus. *Journal of Neurochemistry*. 2013;126(3):360-71.

Annweiler C, Allali G, Allain P, Bridenbaugh S, Schott AM, Kressig RW, et al. Vitamin D and cognitive performance in adults: a systematic review. *European Journal of Neurology*. 2009;16(10):1083-9.

Annweiler C, Fantino B, Parot-Schinkel E, Thiery S, Gautier J, Beauchet O. Alzheimer's disease - input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. *Trials*. 2011;12.

Annweiler C, Herrmann FR, Fantino B, Brugg B, Beauchet O. Effectiveness of the Combination of Memantine Plus Vitamin D on Cognition in Patients With Alzheimer Disease: A Pre-Post Pilot Study. *Cognitive and Behavioral Neurology*. 2012;25(3):121-7.

Ansari MA, Abdul HM, Joshi G, Opii WO, Butterfield DA. Protective effect of quercetin in primary neurons against A beta(1-42): relevance to Alzheimer's disease. *Journal of Nutritional Biochemistry*. 2009;20(4):269-75.

Antanitus DS. A theory of cortical neuron-astrocyte interaction. *Neuroscientist*. 1998;4(3):154-9.

Apfel SC. Is the therapeutic application of neurotrophic factors dead? *Annals of Neurology*. 2002;51(1):8-11.

Apostolova LG, Dutton RA, Dinov ID, Hayashi KM, Toga AW, Cummings JL, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. *Archives of Neurology*. 2006;63(5):693-9.

Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchian S, Morra JH, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. *Neurobiology of Aging*. 2010;31(8):1284-303.

Appleby BS, Roy P, Valenti A, Lee HB. Diagnosis and treatment of depression in Alzheimer's disease: impact on mood and cognition. *Panminerva Medica*. 2007;49(3):139-49.

Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A Review: Treatment of Alzheimer's Disease Discovered in Repurposed Agents. *Dementia and Geriatric Cognitive Disorders*. 2013;35(1-2):1-22.

Aracava Y, Pereira EFR, Maelicke A, Albuquerque EX. Memantine blocks alpha 7*nicotinic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons. *Journal of Pharmacology and Experimental Therapeutics*. 2005;312(3):1195-205.

Arai H. A Combination Therapy of Donepezil and Cilostazol for Patients With Moderate Alzheimer Disease: Pilot Follow-Up Study. *American Journal of Geriatric Psychiatry*. 2009;17(4):353-4.

Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, et al. RAGE potentiates A beta-induced perturbation of neuronal function in transgenic mice. *Embo Journal*. 2004;23(20):4096-105.

Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, et al. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. *Neuroscience*. 2006;142(4):941-52.

Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, et al. Caffeine Reverses Cognitive Impairment and Decreases Brain Amyloid-beta Levels in Aged Alzheimer's Disease Mice. *Journal of Alzheimers Disease*. 2009;17(3):661-80.

Arendt T, Holzer M, Fruth R, Bruckner MK, Gartner U. PAIRED HELICAL FILAMENT-LIKE PHOSPHORYLATION OF TAU, DEPOSITION OF BETA/A4-AMYLOID AND MEMORY IMPAIRMENT IN RAT INDUCED BY CHRONIC INHIBITION OF PHOSPHATASE-1 AND PHOSPHATASE-2A. *Neuroscience*. 1995;69(3):691-8.

Armato U, Chakravarthy B, Pacchiana R, Whitfield JF. Alzheimer's disease: An update of the roles of receptors, astrocytes and primary cilia (Review). *International Journal of Molecular Medicine*. 2013;31(1):3-10.

Americ SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW, Briggs CA, et al. POTENTIAL TREATMENT OF ALZHEIMER-DISEASE USING CHOLINERGIC CHANNEL ACTIVATORS (CHCAS) WITH COGNITIVE ENHANCEMENT, ANXIOLYTIC-LIKE, AND CYTOPROTECTIVE PROPERTIES. *Alzheimer Disease & Associated Disorders*. 1995;9:50-61.

Arriagada PV, Growdon JH, Hedleywhyte ET, Hyman BT. NEUROFIBRILLARY TANGLES BUT NOT SENILE PLAQUES PARALLEL DURATION AND SEVERITY OF ALZHEIMERS-DISEASE. *Neurology*. 1992;42(3):631-9.

Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. *Neurology*. 2008;70(19):1795-802.

Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. *Archives of Neurology*. 2004;61(5):661-6.

Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabo B, et al. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. *Journal of Neurochemistry*. 2006;96(2):533-40.

Asano T, Mori T, Shimoda T, Shinagawa R, Satoh S, Yada N, et al. Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. *Current Drug Targets - CNS and Neurological Disorders*. 2005;4(2):127-42.

Ashani Y, Peggins JO, Doctor BP. MECHANISM OF INHIBITION OF CHOLINESTERASES BY HUPERZINE-A. *Biochemical and Biophysical Research Communications*. 1992;184(2):719-26.

Ashburn TT, Thor KB. Drug repositioning: Identifying and developing new uses for existing drugs. *Nature Reviews Drug Discovery*. 2004;3(8):673-83.

Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, et al. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. *Neurology*. 2004;63(5):828-31.

Atack JR. Preclinical and clinical pharmacology of the GABA(A) receptor alpha 5 subtype-selective inverse agonist alpha 5IA. *Pharmacology & Therapeutics*. 2010;125(1):11-26.

Atamna H, Kumar R. Protective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c Oxidase. *Journal of Alzheimers Disease*. 2010;20:S439-S52.

Atamna H, Nguyen A, Schultz C, Boyle K, Newberry J, Kato H, et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. *Faseb Journal*. 2008;22(3):703-12.

Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. *Alzheimers Research & Therapy*. 2013;5(1).

Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. *Alzheimer Disease & Associated Disorders*. 2008;22(3):209-21.

Atwood CS, Huang XD, Khatri A, Scarpa RC, Kim YS, Moir RD, et al. Copper catalyzed oxidation of alzheimer A beta. *Cellular and Molecular Biology*. 2000;46(4):777-83.

Atwood CS, Moir RD, Huang XD, Scarpa RC, Bacarra NME, Romano DM, et al. Dramatic aggregation of Alzheimer A beta by Cu(II) is induced by conditions representing physiological acidosis. *Journal of Biological Chemistry*. 1998;273(21):12817-26.

Atwood CS, Obrenovich ME, Liu TB, Chan H, Perry G, Smith MA, et al. Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. *Brain Research Reviews*. 2003;43(1):1-16.

Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. *Progress in Neurobiology*. 2002;68(3):209-45.

Autio H, Matlik K, Rantamaki T, Lindemann L, Hoener MC, Chao M, et al. Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus. *Neuropharmacology*. 2011;61(8):1291-6.

Azizi G, Navabi SS, Al-Shukaili A, Seyedzadeh MH, Yazdani R, Mirshafiey A. The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's Disease. *Sultan Qaboos University medical journal*. 2015;15(3):e305-16.

Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Selective dihydropyridine compounds facilitate the clearance of beta-amyloid across the blood-brain barrier. *European Journal of Pharmacology*. 2011;659(2-3):124-9.

Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. In: Slikker W, Andrews RJ, Trembly B, editors. *Neuroprotective Agents*. Annals of the New York Academy of Sciences. 9932003. p. 334-44.

Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, et al. Antihistamine agent dimebon as a novel neuroprotector and a cognition enhancer. In: Slikker W, Trembly B, editors. *Neuroprotective Agents*. Annals of the New York Academy of Sciences. 9392001. p. 425-35.

Bacskaï BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. *Journal of Neuroscience*. 2002;22(18):7873-8.

Badiola N, Alcalde V, Pujol A, Muentert L-M, Multhaup G, Lleo A, et al. The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production. *Plos One*. 2013;8(3).

Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine Lowers A beta and Increases sAPP alpha Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons. *Plos One*. 2011;6(7).

Bajda M, Guzior N, Ignasik M, Malawska B. Multi-Target-Directed Ligands in Alzheimer's Disease Treatment. *Current Medicinal Chemistry*. 2011;18(32):4949-75.

Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: Results of a randomised, double-blind, placebo-controlled 6-month study. *Journal of Alzheimers Disease*. 2008;13(1):97-107.

Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, et al. Effects of Aerobic Exercise on Mild Cognitive Impairment A Controlled Trial. *Archives of Neurology*. 2010;67(1):71-9.

Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, et al. Reduction of Hippocampal Hyperactivity Improves Cognition in Amnesic Mild Cognitive Impairment. *Neuron*. 2012;74(3):467-74.

Bales KR, Verina T, Dodel RC, Du YS, Altstiel L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. *Nature Genetics*. 1997;17(3):263-4.

Ballard CG, Chalmers KA, Todd C, McKeith IG, O'Brien JT, Wilcock G, et al. Cholinesterase inhibitors reduce cortical A beta in dementia with Lewy bodies. *Neurology*. 2007;68(20):1726-9.

Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. *Cochrane Database of Systematic Reviews*. 2006(1).

Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S. Cholinesterases: Roles in the brain during health and disease. *Current Alzheimer Research*. 2005;2(3):307-18.

Ballard C, Brown R, Fossey J, Douglas S, Bradley P, Hancock J, et al. Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial). *American Journal of Geriatric Psychiatry*. 2009;17(9):726-33.

Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. *Lancet Neurology*. 2009;8(2):151-7.

Ballard C, Sorensen S, Sharp S. Pharmacological therapy for people with Alzheimer's disease: The balance of clinical effectiveness, ethical issues and social and Healthcare costs. *Journal of Alzheimers Disease*. 2007;12(1):53-9.

Ballatore C, Lee VMY, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. *Nature Reviews Neuroscience*. 2007;8(9):663-72.

Baloyannis SJ. Dendritic pathology in Alzheimer's disease. *Journal of the Neurological Sciences*. 2009;283(1-2):153-7.

Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial - a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. *Health Technology Assessment*. 2013;17(7):1-+.

Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. *Lancet*. 2011;378(9789):403-11.

Bannerman DM, Deacon RMJ, Brady S, Sprengel R, Seeburg PH, Rawlins JNP. A comparison of GluR-A-Deficient and wild-type mice on a test battery assessing sensorimotor, affective, and cognitive behaviors. *Behavioral Neuroscience*. 2004;118(3):643-7.

Bar-Am O, Amit T, Weinreb O, Youdim MBH, Mandel S. Propargylamine Containing Compounds as Modulators of Proteolytic Cleavage of Amyloid-beta Protein Precursor: Involvement of MAPK and PKC Activation. *Journal of Alzheimers Disease*. 2010;21(2):361-71.

Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S. Fish, meat, and risk of dementia: cohort study. *British Medical Journal*. 2002;325(7370):932-+.

Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, et al. Dietary patterns and risk of dementia - The three-city cohort study. *Neurology*. 2007;69(20):1921-30.

Barco A, Pittenger C, Kandel ER. CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. *Expert Opinion on Therapeutic Targets*. 2003;7(1):101-14.

Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. *Nature Medicine*. 2000;6(8):916-9.

Barone E, Di Domenico F, Butterfield DA. Statins more than cholesterol lowering agents in Alzheimer disease: Their pleiotropic functions as potential therapeutic targets. *Biochemical Pharmacology*. 2014;88(4):605-16.

Baronio D, Gonchoroski T, Castro K, Zanatta G, Gottfried C, Riesgo R. Histaminergic system in brain disorders: lessons from the translational approach and future perspectives. *Annals of General Psychiatry*. 2014;13.

Barron AM, Fuller SJ, Verdile G, Martins RN. Reproductive hormones modulate oxidative stress in Alzheimer's disease. *Antioxidants & Redox Signaling*. 2006;8(11-12):2047-59.

Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, et al. Dynamics of beta-amyloid reductions in brain, cerebrospinal fluid, and plasma of beta-amyloid precursor protein transgenic mice treated with a gamma-secretase inhibitor. *Journal of Pharmacology and Experimental Therapeutics*. 2005;312(2):635-43.

Barten DM, Meredith JE, Jr., Zaczek R, Houston JG, Albright CF. Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. *Drugs in R&D*. 2006;7(2):87-97.

Bartus RT, Dean RL, Beer B, Lippa AS. THE CHOLINERGIC HYPOTHESIS OF GERIATRIC MEMORY DYSFUNCTION. *Science*. 1982;217(4558):408-17.

Basi GS, Hemphill S, Brigham EF, Liao A, Aubele DL, Baker J, et al. Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease. *Alzheimers Research & Therapy*. 2010;2(6).

Bassil N, Grossberg GT. Novel Regimens and Delivery Systems in the Pharmacological Treatment of Alzheimer's Disease. *Cns Drugs*. 2009;23(4):293-307.

Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. *Expert Opinion on Pharmacotherapy*. 2010;11(10):1765-71.

Bastianetto S, Yao ZX, Papadopoulos V, Quirion R. Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. *European Journal of Neuroscience*. 2006;23(1):55-64.

Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. *Alzheimers Research & Therapy*. 2011;3(1).

Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. *Nature medicine*. 2006;12(7):856-61.

Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, et al. A gamma-Secretase Inhibitor Decreases Amyloid-beta Production in the Central Nervous System. *Annals of Neurology*. 2009;66(1):48-54.

Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. *New England Journal of Medicine*. 2012;367(9):795-804.

Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. *Molecular Psychiatry*. 2009;14(5):469-86.

Baum L, Lam CWK, Cheung SK-K, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. *Journal of Clinical Psychopharmacology*. 2008;28(1):110-3.

Bay E. APHASIA AND NON-VERBAL DISORDERS OF LANGUAGE. *Brain*. 1962;85(3):411-&.

Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, et al. Evaluation of the safety and immunogenicity of synthetic A beta 42 (AN1792) in patients with AD. *Neurology*. 2005;64(1):94-101.

Beal MF. MECHANISMS OF EXCITOTOXICITY IN NEUROLOGIC DISEASES. *Faseb Journal*. 1992;6(15):3338-44.

Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q(10) as a potential treatment. *Journal of Bioenergetics and Biomembranes*. 2004;36(4):381-6.

Beal MF. Mitochondria take center stage in aging and neurodegeneration. *Annals of Neurology*. 2005;58(4):495-505.

Becker RE. Lessons from Darwin: 21(st) century designs for clinical trials. *Current Alzheimer Research*. 2007;4(4):458-67.

Becker RE, Greig NH. Alzheimer's disease drug development in 2008 and beyond: Problems and opportunities. *Current Alzheimer Research*. 2008;5(4):346-57.

Becker RE, Greig NH, Giacobini E. Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices? *Journal of Alzheimers Disease*. 2008;15(2):303-25.

Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, et al. The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. *Alzheimers & Dementia*. 2010;6(3):257-64.

Beal AJ, Sanders CR. Substrate specificity of gamma-secretase and other intramembrane proteases. *Cellular and Molecular Life Sciences*. 2008;65(9):1311-34.

Behr D, Clarke EE, Wrigley JDJ, Martin ACL, Nadin A, Churcher I, et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site - Evidence for an allosteric mechanism. *Journal of Biological Chemistry*. 2004;279(42):43419-26.

Behr D, Graham SL. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. *Expert Opinion on Investigational Drugs*. 2005;14(11):1385-409.

Bell KFS, de Kort GJL, Steggerda S, Shigemoto R, Ribeiro-da-Silva A, Cuellar AC. Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology. *Neuroscience Letters*. 2003;353(2):143-7.

Bell KFS, Zheng L, Fahrenholz F, Cuellar AC. ADAM-10 over-expression increases cortical synaptogenesis. *Neurobiology of Aging*. 2008;29(4):554-65.

Belluti F, Rampa A, Piazzini L, Bisi A, Gobbi S, Bartolini M, et al. Cholinesterase inhibitors: Xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. *Journal of Medicinal Chemistry*. 2005;48(13):4444-56.

Bencherif M, Bane AJ, Miller CH, Dull GM, Gatto GJ. TC-2559: A novel orally active ligand selective at neuronal acetylcholine receptors. *European Journal of Pharmacology*. 2000;409(1):45-55.

Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F. Statins and Cognitive Functioning in the Elderly: A Population-Based Study. *Journal of Alzheimers Disease*. 2010;21(1):95-102.

Benowitz NL, Kuyt F, Jacob P, Jones RT, Osman AL. COTININE DISPOSITION AND EFFECTS. *Clinical Pharmacology & Therapeutics*. 1983;34(5):604-11.

Bentham P, Gray R, Raftery J, Hills R, Sellwood E, Courtney C, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. *Lancet*. 2004;363(9427):2105-15.

Bentley P, Driver J, Dolan RJ. Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory. *Brain*. 2009;132:2356-71.

Bentwich J, Dobronevsky E, Aichenbaum S, Shorer R, Peretz R, Khaigrekht M, et al. Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study. *Journal of Neural Transmission*. 2011;118(3):463-71.

Berg L, McKeel DW, Miller JP, Storandt M, Rubin EH, Morris JC, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease - Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. *Archives of Neurology*. 1998;55(3):326-35.

Berger-Sweeney J. The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers. *Neuroscience and Biobehavioral Reviews*. 2003;27(4):401-11.

Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. *Immunology Letters*. 2008;117(2):198-202.

Bernardi A, Frozza RL, Meneghetti A, Hoppe JB, Battastini AMO, Pohlmann AR, et al. Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by A beta 1-42 in Alzheimer's disease models. *International Journal of Nanomedicine*. 2012;7:4927-42.

Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. *Nature Reviews Neuroscience*. 2008;9(10):768-78.

Beydoun MA, Beason-Held LL, Kitner-Triolo MH, Beydoun HA, Ferrucci L, Resnick SM, et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. *Journal of Epidemiology and Community Health*. 2011;65(11):949-57.

Bezprozvanny I. THE RISE AND FALL OF DIMEBON. *Drug News & Perspectives*. 2010;23(8):518-23.

Bi M, Ittner A, Ke YD, Goetz J, Ittner LM. Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice. *Plos One*. 2011;6(12).

Bilikiewicz A, Gaus W. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. *Journal of Alzheimers Disease*. 2004;6(1):17-26.

Birks J. Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database of Systematic Reviews*. 2006(1).

Birks J. The evidence for the efficacy of cholinesterase inhibitors in the treatment of Alzheimer's disease is convincing. *International Psychogeriatrics*. 2008;20(2):279-86.

Birks J, Evans JG, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer's disease. *Cochrane Database of Systematic Reviews*. 2009(2).

Biscaro B, Lindvall O, Hock C, Ekdahl CT, Nitsch RM. A beta Immunotherapy Protects Morphology and Survival of Adult-Born Neurons in Doubly Transgenic APP/PS1 Mice. *Journal of Neuroscience*. 2009;29(45):14108-19.

Biscaro B, Lindvall O, Tesco G, Ekdahl CT, Nitsch RM. Inhibition of Microglial Activation Protects Hippocampal Neurogenesis and Improves Cognitive Deficits in a Transgenic Mouse Model for Alzheimer's Disease. *Neurodegenerative Diseases*. 2012;9(4):187-98.

Bischoff F, Berthelot D, De Cleyn M, Macdonald G, Minne G, Oehlrich D, et al. Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent gamma-Secretase Modulators. *Journal of Medicinal Chemistry*. 2012;55(21):9089-106.

Bishop KM, Hofer EK, Mehta A, Ramirez A, Sun L, Tuszynski M, et al. Therapeutic potential of CERE-110 (AAV2-NGF): Targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. *Experimental Neurology*. 2008;211(2):574-84.

Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention - Systematic review and meta-analysis. *Jama-Journal of the American Medical Association*. 2007;297(8):842-57.

Black RS, Sperling RA, Safrstein B, Motter RN, Pallay A, Nichols A, et al. A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease. *Alzheimer Disease & Associated Disorders*. 2010;24(2):198-203.

Black R, Greenberg B, Ryan JM, Posner H, Seeburger J, Amatniek J, et al. Scales as outcome measures for Alzheimer's disease. *Alzheimers & Dementia*. 2009;5(4):324-39.

Black SA, Espino DV, Mahurin R, Lichtenstein MJ, Hazuda HP, Fabrizio D, et al. The influence of noncognitive factors on the mini-mental state examination in older Mexican-Americans: Findings from the Hispanic EPESE. *Journal of Clinical Epidemiology*. 1999;52(11):1095-102.

Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. Efficacy and tolerability of donepezil in vascular dementia - Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. *Stroke*. 2003;34(10):2323-30.

Black SE, Szalai JP. Are there long-term benefits of donepezil in Alzheimer's disease? *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2004;171(10):1174-5.

Blackard WG, Sood GK, Crowe DR, Fallon MB. Tacrine - A cause of fatal hepatotoxicity? *Journal of Clinical Gastroenterology*. 1998;26(1):57-9.

Blalock EM, Phelps JT, Pancani T, Searcy JL, Anderson KL, Gant JC, et al. Effects of Long-Term Pioglitazone Treatment on Peripheral and Central Markers of Aging. *Plos One*. 2010;5(4).

Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease? *Molecular and Chemical Neuropathology*. 1995;26(3):231-45.

Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. *NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics*. 2004;1(2):213-25.

Blennow K. Biomarkers in Alzheimer's disease drug development. *Nature Medicine*. 2010;16(11):1218-22.

Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. *Lancet*. 2006;368(9533):387-403.

Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, et al. Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease. *Archives of Neurology*. 2012;69(8):1002-10.

Blesch A. Neurotrophic factors in neurodegeneration. *Brain Pathology*. 2006;16(4):295-303.

Blessed G, Tomlinso.Be, Roth M. ASSOCIATION BETWEEN QUANTITATIVE MEASURES OF DEMENTIA AND OF SENILE CHANGE IN CEREBRAL GREY MATTER OF ELDERLY SUBJECTS. *British Journal of Psychiatry*. 1968;114(512):797-+.

Bleumink GS, Feenstra J, Sturkenboom M, Stricker BHC. Nonsteroidal anti-inflammatory drugs and heart failure. *Drugs*. 2003;63(6):525-34.

Blom MAA, van Twillert MGH, de Vries SC, Engels F, Finch CE, Veerhuis R, et al. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes: the involvement of prostaglandin E-2. *Brain Research*. 1997;777(1-2):210-8.

Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Mueller F-J, Loring JF, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(32):13594-9.

Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after A beta 42 immunisation in Alzheimer's disease. *Acta Neuropathologica*. 2010;120(1):13-20.

Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. *Archives of Neurology*. 1997;54(4):465-73.

Boguski MS, Mandl KD, Sukhatme VP. Repurposing with a Difference. *Science*. 2009;324(5933):1394-5.

Bohning DE, Shastri A, Wassermann EM, Ziemann U, Lorberbaum JP, Nahas Z, et al. BOLD-fMRI response to single-pulse transcranial magnetic stimulation (TMS). *Journal of Magnetic Resonance Imaging*. 2000;11(6):569-74.

Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: A Novel Human Anti-A beta Antibody Demonstrates Sustained Cerebral Amyloid-beta Binding and Elicits Cell-Mediated Removal of Human Amyloid-beta. *Journal of Alzheimers Disease*. 2012;28(1):49-69.

Boimel M, Grigoriadis N, Loubopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. *Experimental Neurology*. 2010;224(2):472-85.

Boimel M, Grigoriadis N, Loubopoulos A, Touloumi O, Rosenmann D, Abramsky O, et al. Statins Reduce the Neurofibrillary Tangle Burden in a Mouse Model of Tauopathy. *Journal of Neuropathology and Experimental Neurology*. 2009;68(3):314-25.

Bokde ALW, Karmann M, Teipel SJ, Born C, Lieb M, Reiser ME, et al. Decreased Activation Along the Dorsal Visual Pathway After a 3-Month Treatment With Galantamine in Mild Alzheimer Disease A Functional Magnetic Resonance Imaging Study. *Journal of Clinical Psychopharmacology*. 2009;29(2):147-56.

Boller F, Verny M, Hugonot-Diener L, Saxton J. Clinical features and assessment of severe dementia. A review. *European Journal of Neurology*. 2002;9(2):125-36.

Bolognesi ML, Bartolini M, Cavalli A, Andrisano V, Rosini M, Minarini A, et al. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. *Journal of Medicinal Chemistry*. 2004;47(24):5945-52.

Bolognesi ML, Matera R, Minarini A, Rosini M, Melchiorre C. Alzheimer's disease: new approaches to drug discovery. *Current Opinion in Chemical Biology*. 2009;13(3):303-8.

Bolognesi ML, Cavalli A, Melchiorre C. Memoquin: A Multi-Target-Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease. *Neurotherapeutics*. 2009;6(1):152-62.

Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel J-C, Decker H, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated A beta oligomers. *Journal of Clinical Investigation*. 2012;122(4):1339-53.

Bondy SC, Guo-Ross SX, Truong AT. Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. *Brain Research*. 1998;799(1):91-6.

Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, Baloyannis S. Systemic immune aberrations in Alzheimer's disease patients. *Journal of Neuroimmunology*. 2008;193(1-2):183-7.

Boothby LA, Doering PL. Vitamin C and vitamin E for Alzheimer's disease. *Annals of Pharmacotherapy*. 2005;39(12):2073-80.

Bordji K, Becerril-Ortega J, Buisson A. Synapses, NMDA receptor activity and neuronal A beta production in Alzheimer's disease. *Reviews in the Neurosciences*. 2011;22(3):285-94.

Bosel J, Gandor F, Harms C, Synowitz M, Harms U, Djoufack PC, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. *Journal of Neurochemistry*. 2005;92(6):1386-98.

Boutajangout A, Sigurdsson EM, Krishnamurthy PK. Tau as a Therapeutic Target for Alzheimer's Disease. *Current Alzheimer Research*. 2011;8(6):666-77.

Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. *Journal of Neurochemistry*. 2011;118(4):658-67.

Bowen DM, Smith CB, White P, Davison AN. NEUROTRANSMITTER-RELATED ENZYMES AND INDEXES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES. *Brain*. 1976;99(SEP):459-96.

Bowen RL, Smith MA, Harris PLR, Kubat Z, Martins RN, Castellani RJ, et al. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. *Journal of Neuroscience Research*. 2002;70(3):514-8.

Bowman ER, McKennis H. STUDIES ON METABOLISM OF (-) COTININE IN HUMAN. *Journal of Pharmacology and Experimental Therapeutics*. 1962;135(3):306-&.

Braak H, Del Tredici K. Alzheimer's pathogenesis: is there neuron-to-neuron propagation? *Acta Neuropathologica*. 2011;121(5):589-95.

Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. *Acta Neuropathologica*. 2011;121(2):171-81.

Braak H, Del Tredici K. Where, when, and in what form does sporadic Alzheimer's disease begin? *Current Opinion in Neurology*. 2012;25(6):708-14.

Bradke F, Dotti CG. Establishment of neuronal polarity: lessons from cultured hippocampal neurons. *Current Opinion in Neurobiology*. 2000;10(5):574-81.

Breitner JCS, Haneuse SJPA, Walker R, Dublin S, Crane PK, Gray SL, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. *Neurology*. 2009;72(22):1899-905.

Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. *Alzheimers & Dementia*. 2011;7(4):402-11.

Brendza RP, Bacsikai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, et al. Anti-A beta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. *Journal of Clinical Investigation*. 2005;115(2):428-33.

Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, et al. SURVEY OF THE DISTRIBUTION OF A NEWLY CHARACTERIZED RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS IN TISSUES. *American Journal of Pathology*. 1993;143(6):1699-712.

Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD. Discovery of Histamine H-3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer's Disease. *Journal of Pharmacology and Experimental Therapeutics*. 2011;336(1):38-46.

Brode S, Cooke A. Immune-potentiating effects chemotherapeutic drug of the cyclophosphamide. *Critical Reviews in Immunology*. 2008;28(2):109-26.

Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. *American Journal of Public Health*. 1998;88(9):1337-42.

Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. *Alzheimers & Dementia*. 2007;3(3):186-91.

Bruel-Jungerman E, Lucassen PJ, Francis F. Cholinergic influences on cortical development and adult neurogenesis. *Behavioural Brain Research*. 2011;221(2):379-88.

Brunden KR, Yao Y, Potuzak JS, Ferrer NI, Ballatore C, James MJ, et al. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. *Pharmacological Research*. 2011;63(4):341-51.

Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan A-ML, et al. Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy. *Journal of Neuroscience*. 2010;30(41):13861-6.

Buccafusco JJ, Weiser T, Winter K, Klinder K, Terry AV. The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys. *Neuropharmacology*. 2004;46(1):10-22.

Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. *Brain Research Reviews*. 2000;33(1):95-130.

Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. *Brain*. 2006;129:3035-41.

Buisson B, Bertrand D. Open-channel blockers at the human alpha 4 beta 2 neuronal nicotinic acetylcholine receptor. *Molecular Pharmacology*. 1998;53(3):555-63.

Bulic B, Pickhardt M, Schmidt B, Mandelkow E-M, Waldmann H, Mandelkow E. Development of Tau Aggregation Inhibitors for Alzheimer's Disease. *Angewandte Chemie-International Edition*. 2009;48(10):1741-52.

Bullock R, Touchon J, Bergman H, Gambina G, He YS, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. *Current Medical Research and Opinion*. 2005;21(8):1317-27.

Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, et al. ASSEMBLY AND AGGREGATION PROPERTIES OF SYNTHETIC ALZHEIMERS A4/BETA AMYLOID PEPTIDE ANALOGS. *Journal of Biological Chemistry*. 1992;267(1):546-54.

Burkhardt MS, Foster JK, Laws SM, Baker LD, Craft S, Gandy SE, et al. Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon 4. *Journal of Alzheimers Disease*. 2004;6(3):221-8.

Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, et al. The effects of donepezil in Alzheimer's disease - Results from a multinational trial. *Dementia and Geriatric Cognitive Disorders*. 1999;10(3):237-44.

Burstein AH, Zhao Q, Ross J, Styren S, Landen JW, Ma WW, et al. Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease. *Clinical Neuropharmacology*. 2013;36(1):8-13.

Bush AI. The metallobiology of Alzheimer's disease. *Trends in Neurosciences*. 2003;26(4):207-14.

Bush AI, Multhaup G, Moir RD, Williamson TG, Small DH, Rumble B, et al. A NOVEL ZINC(II) BINDING-SITE MODULATES THE FUNCTION OF THE BETA-A4 AMYLOID PROTEIN-PRECURSOR OF ALZHEIMERS-DISEASE. *Journal of Biological Chemistry*. 1993;268(22):16109-12.

Bush AI, Pettingell WH, Multhaup G, Paradis MD, Vonsattel JP, Gusella JF, et al. RAPID INDUCTION OF ALZHEIMER A-BETA AMYLOID FORMATION BY ZINC. *Science*. 1994;265(5177):1464-7.

Bush AI, Pettingell WH, Paradis MD, Tanzi RE. MODULATION OF A-BETA ADHESIVENESS AND SECRETASE SITE CLEAVAGE BY ZINC. *Journal of Biological Chemistry*. 1994;269(16):12152-8.

Bush AI, Tanzi RE. Therapeutics for Alzheimer's disease based on the Metal Hypothesis. *Neurotherapeutics*. 2008;5(3):421-32.

Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer's disease - Therapeutic implications. *Cns Drugs*. 2003;17(9):641-52.

Butterfield DA, Poon HF. The senescence-accelerated prone mouse (SAMP8): A model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. *Experimental Gerontology*. 2005;40(10):774-83.

Butterfield DA, Barone E, Di Domenico F, Cenini G, Sultana R, Murphy MP, et al. Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. *International Journal of Neuropsychopharmacology*. 2012;15(7):981-7.

Butterfield DA, Barone E, Mancuso C. Cholesterol-independent neuroprotective and neurotoxic activities of statins: Perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. *Pharmacological Research*. 2011;64(3):180-6.

Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, et al. beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. *Journal of Neuroscience*. 2005;25(40):9096-101.

Buxbaum JD, Cullen EI, Friedhoff LT. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. *Frontiers in Bioscience*. 2002;7:A50-A9.

Cabrol C, Huzarska MA, Dinolfo C, Rodriguez MC, Reinstatler L, Ni J, et al. Small-Molecule Activators of Insulin-Degrading Enzyme Discovered through High-Throughput Compound Screening. *Plos One*. 2009;4(4).

Cacabelos R. Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. *Neuropsychiatric disease and treatment*. 2007;3(3):303-33.

Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. *Neuron*. 2006;49(5):671-82.

Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. *American Journal of Pathology*. 2007;170(5):1669-75.

Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. *Lancet*. 2001;358(9280):461-7.

Cahoon L. The curious case of clioquinol. *Nature Medicine*. 2009;15(4):356-9.

Cai HB, Wang YS, McCarthy D, Wen HJ, Borchelt DR, Price DL, et al. BACE1 is the major beta-secretase for generation of A beta peptides by neurons. *Nature Neuroscience*. 2001;4(3):233-4.

Cai XD, Golde TE, Younkin SG. RELEASE OF EXCESS AMYLOID BETA-PROTEIN FROM A MUTANT AMYLOID BETA-PROTEIN PRECURSOR. *Science*. 1993;259(5094):514-6.

Cai Z, Ratka A. Opioid System and Alzheimer's Disease. *Neuromolecular Medicine*. 2012;14(2):91-111.

Cai Z, Zhao Y, Yao S, Zhao B. Increases in beta-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-kappa B pathway activation. *Pharmacological Reports*. 2011;63(2):381-91.

Calabrese P, Essner U, Foerstl H. Memantine (Ebixa (R)) in clinical practice - Results of an observational study. *Dementia and Geriatric Cognitive Disorders*. 2007;24(2):111-7.

Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. *Human Molecular Genetics*. 2011;20(23):4515-29.

Calkins MJ, Reddy PH. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. *Biochimica Et Biophysica Acta-Molecular Basis of Disease*. 2011;1812(4):507-13.

Callaway E. Alzheimer's drugs take a new tack. *Nature*. 2012;489(7414):13-4.

Callaway NL, Riha PD, Bruchey AK, Munshi Z, Gonzalez-Lima F. Methylene blue improves brain oxidative metabolism and memory retention in rats. *Pharmacology Biochemistry and Behavior*. 2004;77(1):175-81.

Cameron AR, Wallace K, Logie L, Prescott AR, Unterman TG, Harthill J, et al. The anti-neurodegenerative agent clioquinol regulates the transcription factor FOXO1a. *Biochemical Journal*. 2012;443:57-64.

Camins A, Verdaguer E, Junyent F, Yeste-Velasco M, Pelegri C, Vilaplana J, et al. Potential Mechanisms Involved in the Prevention of Neurodegenerative Diseases by Lithium. *Cns Neuroscience & Therapeutics*. 2009;15(4):333-44.

Campbell N, Ayub A, Boustani MA, Fox C, Farlow M, Maidment I, et al. Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: A meta-analysis. *Clinical Interventions in Aging*. 2008;3(4):719-28.

Canas PM, Porciuncula LO, Cunha GMA, Silva CG, Machado NJ, Oliveira JMA, et al. Adenosine A(2A) Receptor Blockade Prevents Synaptotoxicity and Memory Dysfunction Caused by beta-Amyloid Peptides via p38 Mitogen-Activated Protein Kinase Pathway. *Journal of Neuroscience*. 2009;29(47):14741-51.

Cancino GI, Toledo EM, Leal NR, Hernandez DE, Yevenes LF, Inestrosa NC, et al. STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits. *Brain*. 2008;131:2425-42.

Canevari L, Clark JB. Alzheimer's disease and cholesterol: The fat connection. *Neurochemical Research*. 2007;32(4-5):739-50.

Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T, et al. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts. *Journal of Neurology Neurosurgery and Psychiatry*. 2010;81(12):1363-8.

Cano-Cuenca N, Solis-Garcia del Pozoc JE, Jordan J. Evidence for the Efficacy of Latrepirdine (Dimebon) Treatment for Improvement of Cognitive Function: A Meta-Analysis. *Journal of Alzheimers Disease*. 2014;38(1):155-64.

Canobbio I, Catricala S, Balduini C, Torti M. Calmodulin regulates the non-amyloidogenic metabolism of amyloid precursor protein in platelets. *Biochimica Et Biophysica Acta-Molecular Cell Research*. 2011;1813(3):500-6.

Canter PH, Ernst E. Ginkgo biloba is not a smart drug: an updated systematic review of randomised clinical trials testing the nootropic effects of G-biloba extracts in healthy people. *Human Psychopharmacology-Clinical and Experimental*. 2007;22(5):265-78.

Canu N, Dus L, Barbato C, Ciotti MT, Brancolini C, Rinaldi AW, et al. Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis. *Journal of Neuroscience*. 1998;18(18):7061-74.

Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, et al. Caffeine Suppresses Amyloid-beta Levels in Plasma and Brain of Alzheimer's Disease Transgenic Mice. *Journal of Alzheimers Disease*. 2009;17(3):681-97.

Cappai R, Barnham KJ. Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. *Neurochemical Research*. 2008;33(3):526-32.

Cappell J, Herrmann N, Cornish S, Lancot KL. The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimer's Disease. *Cns Drugs*. 2010;24(11):909-27.

Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2002;99(19):12432-7.

Capsoni S, Marinelli S, Ceci M, Vignone D, Amato G, Malerba F, et al. Intranasal "painless" Human Nerve Growth Factors Slows Amyloid Neurodegeneration and Prevents Memory Deficits in App X PS1 Mice. *Plos One*. 2012;7(5).

Cardinali DP, Furio AM, Brusco LI. Clinical Aspects of Melatonin Intervention in Alzheimer's Disease Progression. *Current Neuropharmacology*. 2010;8(3):218-27.

Carli M, Balducci C, Samanin R. Stimulation of 5-HT_{1A} receptors in the dorsal raphe ameliorates the impairment of spatial learning caused by intrahippocampal 7-chloro-kynurenic acid in naive and pretrained rats. *Psychopharmacology*. 2001;158(1):39-47.

Carlson MC, Helms MJ, Steffens DC, Burke JR, Potter GG, Plassman BL. Midlife activity predicts risk of dementia in older male twin pairs. *Alzheimers & Dementia*. 2008;4(5):324-31.

Carlsson CM. Type 2 Diabetes Mellitus, Dyslipidemia, and Alzheimer's Disease. *Journal of Alzheimers Disease*. 2010;20(3):711-22.

Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Kosciuk RL, et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. *Journal of Alzheimers Disease*. 2008;13(2):187-97.

Carroll JC, Rosario ER. The Potential Use of Hormone-Based Therapeutics for the Treatment of Alzheimer's Disease. *Current Alzheimer Research*. 2012;9(1):18-34.

Casadesus G, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, et al. Luteinizing hormone modulates cognition and amyloid-deposition in Alzheimer APP transgenic mice. *Biochimica Et Biophysica Acta-Molecular Basis of Disease*. 2006;1762(4):447-52.

Casadesus G, Garrett MR, Webber KM, Hartzler AW, Atwood CS, Perry G, et al. The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease. *Drugs in R&D*. 2006;7(3):187-93.

Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, et al. Mitochondrial A beta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. *Faseb Journal*. 2005;19(12):2040-+.

Castellani RJ, Lee HG, Zhu XW, Nunomura A, Perry G, Smith MA. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. *Acta Neuropathologica*. 2006;111(6):503-9.

Castellani RJ, Lee H-g, Zhu X, Perry G, Smith MA. Alzheimer disease pathology as a host response. *Journal of Neuropathology and Experimental Neurology*. 2008;67(6):523-31.

Castellani RJ, Perry G. Pathogenesis and Disease-modifying Therapy in Alzheimer's Disease: The Flat Line of Progress. *Archives of Medical Research*. 2012;43(8):694-8.

Castellani RJ, Perry G. The complexities of the pathology-pathogenesis relationship in Alzheimer disease. *Biochemical Pharmacology*. 2014;88(4):671-6.

Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE Isoforms Differentially Regulate Brain Amyloid-beta Peptide Clearance. *Science Translational Medicine*. 2011;3(89).

Castello MA, Soriano S. Rational heterodoxy: Cholesterol reformation of the amyloid doctrine. *Ageing Research Reviews*. 2013;12(1):282-8.

Cattaneo A, Capsoni S, Paoletti F. Towards Non Invasive Nerve Growth Factor Therapies for Alzheimer's Disease. *Journal of Alzheimers Disease*. 2008;15(2):255-83.

Cavas M, Navarro JF. Effects of selective neuronal nitric oxide synthase inhibition on sleep and wakefulness in the rat. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 2006;30(1):56-67.

Cechetto DF, Hachinski V, Whitehead SN. Vascular risk factors and Alzheimer's disease. *Expert review of neurotherapeutics*. 2008;8(5):743-50.

Chadwick W, Mitchell N, Carroll J, Zhou Y, Park S-S, Wang L, et al. Amitriptyline-Mediated Cognitive Enhancement in Aged 3xTg Alzheimer's Disease Mice Is Associated with Neurogenesis and Neurotrophic Activity. *Plos One*. 2011;6(6).

Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, et al. Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models REDUCTION OF TAU PATHOLOGY AND DELAY OF DISEASE PROGRESSION. *Journal of Biological Chemistry*. 2011;286(39):34457-67.

Chakroborty S, Briggs C, Miller MB, Goussakov I, Schneider C, Kim J, et al. Stabilizing ER Ca²⁺ Channel Function as an Early Preventative Strategy for Alzheimer's Disease. *Plos One*. 2012;7(12).

Chalmers DT, Watson SJ. COMPARATIVE ANATOMICAL DISTRIBUTION OF 5-HT_{1A} RECEPTOR MESSENGER-RNA AND 5-HT_{1A} BINDING IN RAT-BRAIN - A COMBINED INSITU HYBRIDIZATION INVITRO RECEPTOR AUTORADIOGRAPHIC STUDY. *Brain Research*. 1991;561(1):51-60.

Chalmers K, Wilcock GK, Love S. APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. *Neuropathology and Applied Neurobiology*. 2003;29(3):231-8.

Chalmers KA, Wilcock GK, Vinters HV, Perry EK, Perry R, Ballard CG, et al. Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. *Journal of Neurology*. 2009;256(5):717-20.

Chan A, Paskavitz J, Remington R, Rasmussen S, Shea TB. Efficacy of a Vitamin/Nutriceutical Formulation for Early-stage Alzheimer's Disease: A 1-year, Open-label Pilot Study With a 16-Month Caregiver Extension. *American Journal of Alzheimers Disease and Other Dementias*. 2008;23(6):571-85.

Chan A, Shea TB. Folate deprivation increases presenilin expression, gamma-secretase activity, and Abeta levels in murine brain: potentiation by ApoE deficiency and alleviation by dietary S-adenosyl methionine. *Journal of Neurochemistry*. 2007;102(3):753-60.

Chan SL, Mayne M, Holden CP, Geiger JD, Mattson MP. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. *Journal of Biological Chemistry*. 2000;275(24):18195-200.

Chandra V, Ganguli M, Pandav R, Johnston J, Belle S, DeKosky ST. Prevalence of Alzheimer's disease and other dementias in rural India - The Indo-US study. *Neurology*. 1998;51(4):1000-8.

Chandra V, Pandav R, Dodge HH, Johnston JM, Belle SH, DeKosky ST, et al. Incidence of Alzheimer's disease in a rural community in India - The Indo-US Study. *Neurology*. 2001;57(6):985-9.

Chang W-P, Downs D, Huang X-P, Da H, Fung K-M, Tang J. Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization. *Faseb Journal*. 2007;21(12):3184-96.

Chang W-P, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, et al. beta-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. *Faseb Journal*. 2011;25(2):775-84.

Chao MV, Rajagopal R, Lee FS. Neurotrophin signalling in health and disease. *Clinical Science*. 2006;110(2):167-73.

Chappell AS, Gonzales C, Williams J, Witte MM, Mohs RC, Sperling R. AMPA potentiator treatment of cognitive deficits in Alzheimer disease. *Neurology*. 2007;68(13):1008-12.

Chatellier G, Lacomblez L. TACRINE (TETRAHYDROAMINOACRIDINE - THA) AND LECITHIN IN SENILE DEMENTIA OF THE ALZHEIMER TYPE - A MULTICENTER TRIAL. *British Medical Journal*. 1990;300(6723):495-9.

Chauhan V, Ji L, Chauhan A. Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease. *Biogerontology*. 2008;9(6):381-9.

Chazot PL. THERAPEUTIC POTENTIAL OF HISTAMINE H-3 RECEPTOR ANTAGONISTS IN DEMENTIAS. *Drug News & Perspectives*. 2010;23(2):99-103.

Check E. Nerve inflammation halts trial for Alzheimer's drug. *Nature*. 2002;415(6871):462-.

Chen C, Eastwood SL, Hope T, McDonald B, Francis PT, Esiri MM. Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. *Neuropathology and Applied Neurobiology*. 2000;26(4):347-55.

Chen H-K, Ji Z-S, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, et al. Apolipoprotein E4 Domain Interaction Mediates Detrimental Effects on Mitochondria and Is a Potential Therapeutic Target for Alzheimer Disease. *Journal of Biological Chemistry*. 2011;286(7):5215-21.

Chen KS, Gage FH. SOMATIC GENE-TRANSFER OF NGF TO THE AGED BRAIN - BEHAVIORAL AND MORPHOLOGICAL AMELIORATION. *Journal of Neuroscience*. 1995;15(4):2819-25.

Chen KS, Nishimura MC, Armanini MP, Crowley C, Spencer SD, Phillips HS. Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. *Journal of Neuroscience*. 1997;17(19):7288-96.

Chen X, Walker DG, Schmidt AM, Arancio O, Lue L-F, Du Yan S. RAGE: A potential target for a mediated cellular perturbation in Alzheimer's disease. *Current Molecular Medicine*. 2007;7(8):735-42.

Chen YH, Zhang YH, Zhang HJ, Liu DZ, Gu M, Li JY, et al. Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. *Journal of Medicinal Chemistry*. 2006;49(5):1613-23.

Chen Y, Zhou K, Wang R, Liu Y, Kwak Y-D, Ma T, et al. Antidiabetic drug metformin (Glucophage(R)) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(10):3907-12.

Cheng IH, Searce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. *Journal of Biological Chemistry*. 2007;282(33):23818-28.

Cheng Y-F, Wang C, Lin H-B, Li Y-F, Huang Y, Xu J-P, et al. Inhibition of phosphodiesterase-4 reverses memory deficits produced by A beta 25-35 or A beta 1-40 peptide in rats. *Psychopharmacology*. 2010;212(2):181-91.

Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. *Neuron*. 2001;30(3):665-76.

Chernyak BV, Antonenko YN, Domnina LV, Ivanova OY, Lyamzaev KG, Pustovidko AV, et al. Novel Penetrating Cations for Targeting Mitochondria. *Current Pharmaceutical Design*. 2013;19(15):2795-806.

Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. *Neurology*. 2001;57(1):80-8.

Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER, et al. The role of aromatization in testosterone supplementation - Effects on cognition in older men. *Neurology*. 2005;64(2):290-6.

Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. *Neurology*. 2005;64(12):2063-8.

Cheung K-H, Shineman D, Mueller M, Cardenas C, Mei L, Yang J, et al. Mechanism of Ca²⁺ disruption in Alzheimer's disease by presenilin regulation of InsP(3) receptor channel gating. *Neuron*. 2008;58(6):871-83.

Chien WL, Liang KC, Teng CM, Kuo SC, Lee FY, Fu WM. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole. *Molecular Pharmacology*. 2003;63(6):1322-8.

Chien WL, Liang KC, Teng CM, Kuo SC, Lee FY, Fu WM. Enhancement of learning behaviour by a potent nitric oxide-guanylate cyclase activator YC-1. *European Journal of Neuroscience*. 2005;21(6):1679-88.

Childers WE, Abou-Gharbia MA, Kelly MG, Andree TH, Harrison BL, Ho DM, et al. Synthesis and biological evaluation of benzodioxanypiperazine derivatives as potent serotonin 5-HT_{1A} antagonists: The discovery of lecozotan. *Journal of Medicinal Chemistry*. 2005;48(10):3467-70.

Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B. Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. *Frontiers in Cellular Neuroscience*. 2015;9.

Chiu C-C, Su K-P, Cheng T-C, Liu H-C, Chang C-J, Dewey ME, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 2008;32(6):1538-44.

Chiu HFK, Lam LCW. Relevance of outcome measures in different cultural groups - does one size fit all? *International Psychogeriatrics*. 2007;19(3):457-66.

Chohan MO, Iqbal K. From tau to toxicity: Emerging roles of NMDA receptor in Alzheimer's disease. *Journal of Alzheimers Disease*. 2006;10(1):81-7.

Choi S-H, Aid S, Caracciolo L, Minami SS, Niikura T, Matsuoka Y, et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. *Journal of Neurochemistry*. 2013;124(1):59-68.

Choi SH, Kim SY, Na HR, Kim B-K, Yang DW, Kwon JC, et al. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*. 2008;25(5):445-50.

Choi YT, Jung CH, Lee SR, Bae JH, Baek WK, Suh MH, et al. The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. *Life Sciences*. 2001;70(5):603-14.

Choi Y, Kim H-S, Shin KY, Kim E-M, Kim M, Kim H-S, et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's Disease models. *Neuropsychopharmacology*. 2007;32(11):2393-404.

Christen WG, Gaziano JM, Hennekens CH, Steering Comm Physicians Hlth S. Design of physicians' health study II - A randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. *Annals of Epidemiology*. 2000;10(2):125-34.

Chu DCM, Penney JB, Young AB. CORTICAL GABA-B AND GABA-A RECEPTORS IN ALZHEIMERS-DISEASE - A QUANTITATIVE AUTORADIOGRAPHIC STUDY. *Neurology*. 1987;37(9):1454-9.

Chu J, Pratico D. Pharmacologic Blockade of 5-Lipoxygenase Improves the Amyloidotic Phenotype of an Alzheimer's Disease Transgenic Mouse Model Involvement of gamma-Secretase. *American Journal of Pathology*. 2011;178(4):1762-9.

Chui DH, Tabira T, Izumi S, Koya G, Ogata J. DECREASED BETA-AMYLOID AND INCREASED ABNORMAL TAU-DEPOSITION IN THE BRAIN OF AGED PATIENTS WITH LEPROSY. *American Journal of Pathology*. 1994;145(4):771-5.

Chui HC, Zheng L, Reed BR, Vinters HV, Mack WJ. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. *Alzheimers Research & Therapy*. 2012;4(1).

Churcher I. Tau therapeutic strategies for the treatment of Alzheimer's disease. *Current Topics in Medicinal Chemistry*. 2006;6(6):579-95.

Cibickova L, Palicka V, Cibicek N, Cermakova E, Micuda S, Bartosova L, et al. Differential effects of statins and alendronate on cholinesterases in serum and brain of rats. *Physiological Research*. 2007;56(6):765-70.

Cifariello A, Pompili A, Gasbarri A. 5-HT₇ receptors in the modulation of cognitive processes. *Behavioural Brain Research*. 2008;195(1):171-9.

Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, et al. Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. *Proceedings of the National Academy of Sciences of the United States of America*. 2011;108(36):14968-73.

Citron M. Strategies for disease modification in Alzheimer's disease. *Nature Reviews Neuroscience*. 2004;5(9):677-85.

Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, et al. MUTATION OF THE BETA-AMYLOID PRECURSOR PROTEIN IN FAMILIAL ALZHEIMERS-DISEASE INCREASES BETA-PROTEIN PRODUCTION. *Nature*. 1992;360(6405):672-4.

Citron M. Alzheimer's disease: strategies for disease modification. *Nature Reviews Drug Discovery*. 2010;9(5):387-98.

Clare L, Linden DEJ, Woods RT, Whitaker R, Evans SJ, Parkinson CH, et al. Goal-Oriented Cognitive Rehabilitation for People With Early-Stage Alzheimer Disease: A Single-Blind Randomized Controlled Trial of Clinical Efficacy. *American Journal of Geriatric Psychiatry*. 2010;18(10):928-39.

Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and beta-amyloid - How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? *Archives of Neurology*. 2003;60(12):1696-702.

Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of Florbetapir-PET for Imaging beta-Amyloid Pathology. *Jama-Journal of the American Medical Association*. 2011;305(3):275-83.

Clarke EE, Churcher I, Ellis S, Wrigley JDJ, Lewis HD, Harrison T, et al. Intra- or intercomplex binding to the gamma-secretase enzyme. *Journal of Biological Chemistry*. 2006;281(42):31279-89.

Clarke N. AD2000: design and conclusions. *Lancet*. 2004;364(9441):1215-6.

Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. HYPERHOMOCYSTEINEMIA - AN INDEPENDENT RISK FACTOR FOR VASCULAR-DISEASE. *New England Journal of Medicine*. 1991;324(17):1149-55.

Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B-12, and serum total homocysteine levels in confirmed Alzheimer disease. *Archives of Neurology*. 1998;55(11):1449-55.

Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, et al. Sex and ApoE Genotype Differences in Treatment Response to Two Doses of Intranasal Insulin in Adults with Mild Cognitive Impairment or Alzheimer's Disease. *Journal of Alzheimers Disease*. 2013;35(4):789-97.

Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-protein specifically disrupt cognitive function. *Nature Neuroscience*. 2005;8(1):79-84.

Clerici F, Vanacore N, Elia A, Spila-Alegiani S, Pomati S, Da Cas R, et al. Memantine in Moderately-Severe-to-Severe Alzheimer's Disease A Postmarketing Surveillance Study. *Drugs & Aging*. 2009;26(4):321-32.

Clerici F, Vanacore N, Elia A, Spila-Alegiani S, Pomati S, Da Cas R, et al. Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study. *Neurological Sciences*. 2012;33(1):23-31.

Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ. Molecular and cellular mechanisms of DNA vaccines. *Human Vaccines*. 2008;4(6):453-7.

Cochet M, Donneger R, Cassier E, Gaven F, Lichtenthaler SF, Marin P, et al. 5-HT₄ Receptors Constitutively Promote the Non-Amyloidogenic Pathway of APP Cleavage and Interact with ADAM10. *Acs Chemical Neuroscience*. 2013;4(1):130-40.

Codony X, Miguel Vela J, Javier Ramirez M. 5-HT₆ receptor and cognition. *Current Opinion in Pharmacology*. 2011;11(1):94-100.

Cohen KB, Hunter L. Getting started in text mining. *Plos Computational Biology*. 2008;4(1).

Cohen-Mansfield J, Libin A. Assessment of agitation in elderly patients with dementia: correlations between informant rating and direct observation. *International Journal of Geriatric Psychiatry*. 2004;19(9):881-91.

Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, Cattabeni F, et al. alpha-secretase ADAM10 as well as alpha APPs is reduced in platelets and CSF of Alzheimer disease patients. *Molecular Medicine*. 2002;8(2):67-74.

Cole GM, Morihara T, Lim GP, Yang FS, Begum A, Frautschy SA. NSAID and antioxidant prevention of Alzheimer's disease lessons from in vitro and animal models. In: Lahiri DK, editor. *Protective Strategies for Neurodegenerative Diseases*. Annals of the New York Academy of Sciences. 10352004. p. 68-84.

Cole GM, Yang F, Lim GP, Cummings JL, Masterman DL, Frautschy SA. A rationale for curcuminoids for the prevention or treatment of Alzheimer's disease. *Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents*. 2003;3(1):15-25.

Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, et al. Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. *Neurobiology of aging*. 2005;26 Suppl 1:133-6.

Cole JT, McMullen DC, Kean WS, Yarnell AM, Lucky JJ, Selak MA, et al. Manipulating thyroid status alters endoplasmic reticulum calcium homeostasis in rat cerebellum. *Indian Journal of Experimental Biology*. 2012;50(1):7-18.

Collina S, Gaggeri R, Marra A, Bassi A, Negrinotti S, Negri F, et al. Sigma receptor modulators: a patent review. *Expert Opinion on Therapeutic Patents*. 2013;23(5):597-613.

Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. *Lancet Neurology*. 2009;8(4):334-44.

Collins FS. Reengineering Translational Science: The Time Is Right. *Science Translational Medicine*. 2011;3(90).

Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study C. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360(9326):23-33.

Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study C. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360(9326):7-22.

Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. *Current Neuropharmacology*. 2013;11(3):315-35.

Colton CA, Chernyshev ON, Gilbert DL, Vitek MP. Microglial contribution to oxidative stress in Alzheimer's disease. In: Chiueh CC, editor. *Reactive Oxygen Species: from Radiation to Molecular Biology: a Festschrift in Honor of Daniel L Gilbert*. Annals of the New York Academy of Sciences. 8992000. p. 292-307.

Colton CA, Vitek MP, Wink DA, Xu Q, Cantillana V, Previti ML, et al. NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103(34):12867-72.

Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong XH, et al. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. *Journal of Neuroscience*. 2005;25(39):8898-902.

Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. *Autophagy*. 2012;8(4):609-22.

Connelly PJ, Prentice NP, Cousland G, Bonham J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. *International Journal of Geriatric Psychiatry*. 2008;23(2):155-60.

Conner JM, Darracq MA, Roberts J, Tuszynski MH. Nontropic actions of neurotrophins: Subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. *Proceedings of the National Academy of Sciences of the United States of America*. 2001;98(4):1941-6.

Connor DJ, Sabbagh MN. Administration and Scoring Variance on the ADAS-Cog. *Journal of Alzheimers Disease*. 2008;15(3):461-4.

Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. *Journal of Clinical Psychiatry*. 2007;68(4):613-8.

Cooney C, Murphy S, Tessema H, Freyne A. Use of Low-Dose Gabapentin for Aggressive Behavior in Vascular and Mixed Vascular/Alzheimer Dementia. *Journal of Neuropsychiatry and Clinical Neurosciences*. 2013;25(2):120-5.

Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, et al. Drug repositioning for Alzheimer's disease. *Nature Reviews Drug Discovery*. 2012;11(11):833-46.

Corbyn Z. New set of Alzheimer's trials focus on prevention. *Lancet*. 2013;381(9867):614-5.

Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. GENE DOSE OF APOLIPOPROTEIN-E TYPE-4 ALLELE AND THE RISK OF ALZHEIMERS-DISEASE IN LATE-ONSET FAMILIES. *Science*. 1993;261(5123):921-3.

Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. *Journal of Biological Chemistry*. 2005;280(40):34202-9.

Cordle A, Landreth G. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. *Journal of Neuroscience*. 2005;25(2):299-307.

Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer's disease (Review). *Molecular Membrane Biology*. 2006;23(1):111-22.

Coria F, Rubio I, Bayon C. ALZHEIMERS-DISEASE, BETA-AMYLOIDOSIS, AND AGING. *Reviews in the Neurosciences*. 1994;5(4):275-92.

Cornelius C, Fastbom J, Winblad B, Viitanen M. Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. *Neuroepidemiology*. 2004;23(3):135-43.

Corrada MM, Kawas CH, Hallfrisch J, Muller D, Brookmeyer R. Reduced risk of Alzheimer's disease with high folate intake: the Baltimore Longitudinal Study of Aging. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2005;1(1):11-8.

Costa R, Speretta E, Crowther DC, Cardoso I. Testing the Therapeutic Potential of Doxycycline in a *Drosophila melanogaster* Model of Alzheimer Disease. *Journal of Biological Chemistry*. 2011;286(48):41647-55.

Costa RO, Ferreiro E, Oliveira CR, Pereira CMF. Inhibition of mitochondrial cytochrome c oxidase potentiates A beta-induced ER stress and cell death in cortical neurons. *Molecular and Cellular Neuroscience*. 2013;52:1-8.

Costa VDS, Duchatelle P, Boulouard M, Dauphin F. Selective 5-HT₆ Receptor Blockade Improves Spatial Recognition Memory and Reverses Age-Related Deficits in Spatial Recognition Memory in the Mouse. *Neuropsychopharmacology*. 2009;34(2):488-500.

Costantini LC, Barr LJ, Vogel JL, Henderson ST. Hypometabolism as a therapeutic target in Alzheimer's disease. *Bmc Neuroscience*. 2008;9.

Cotelli M, Manenti R, Cappa SF, Zanetti O, Miniussi C. Transcranial magnetic stimulation improves naming in Alzheimer disease patients at different stages of cognitive decline. *European Journal of Neurology*. 2008;15(12):1286-92.

Cotelli M, Calabria M, Manenti R, Rosini S, Zanetti O, Cappa SF, et al. Improved language performance in Alzheimer disease following brain stimulation. *Journal of Neurology Neurosurgery and Psychiatry*. 2011;82(7):794-7.

Cotelli M, Manenti R, Cappa SF, Geroldi C, Zanetti O, Rossini PM, et al. Effect of transcranial magnetic stimulation on action naming in patients with Alzheimer disease. *Archives of Neurology*. 2006;63(11):1602-4.

Cottrell DA, Borthwick GM, Johnson MA, Ince PG, Turnbull DM. The role of cytochrome c oxidase deficient hippocampal neurones in Alzheimer's disease. *Neuropathology and Applied Neurobiology*. 2002;28(5):390-6.

Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. *Lancet (London, England)*. 2004;363(9427):2105-15.

Cowley TR, O'Sullivan J, Blau C, Deighan BF, Jones R, Kerskens C, et al. Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP. *Neurobiology of Aging*. 2012;33(1):162-75.

Coyle JT, Price DL, DeLong MR. ALZHEIMERS-DISEASE - A DISORDER OF CORTICAL CHOLINERGIC INNERVATION. *Science*. 1983;219(4589):1184-90.

Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease. *Biological Psychiatry*. 2001;49(3):289-99.

Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD, et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. *Archives of General Psychiatry*. 1999;56(12):1135-40.

Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. *Neurobiology of aging*. 2005;26 Suppl 1:65-9.

Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. *Alzheimer Disease & Associated Disorders*. 2006;20(4):298-301.

Craft S. Insulin resistance and Alzheimer's disease pathogenesis: Potential mechanisms and implications for treatment. *Current Alzheimer Research*. 2007;4(2):147-52.

Craft S. The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia Two Roads Converged. *Archives of Neurology*. 2009;66(3):300-5.

Craft S. The Role of Insulin Dysregulation in Aging and Alzheimer's Disease. In: Craft S, Christen Y, editors. Diabetes, Insulin and Alzheimer's Disease. Research and Perspectives in Alzheimers Disease 2010. p. 109-27.

Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnesic Mild Cognitive Impairment A Pilot Clinical Trial. Archives of Neurology. 2012;69(1):29-38.

Craig MC, Maki PM, Murphy DGM. The women's health initiative memory study: findings and implications for treatment. Lancet Neurology. 2005;4(3):190-4.

Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71(5):344-50.

Cramer PE, Cirrito JR, Wesson DW, Lee CYD, Karlo JC, Zinn AE, et al. ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models. Science. 2012;335(6075):1503-6.

Crawford JG. Alzheimer's disease risk factors as related to cerebral blood flow: additional evidence. Medical Hypotheses. 1998;50(1):25-36.

Crespi GAN, Ascher DB, Parker MW, Miles LA. Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-beta. Acta Crystallographica Section F-Structural Biology and Crystallization Communications. 2014;70:374-7.

Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon S. Age-Associated Memory Impairment: Proposed Diagnostic Criteria and Measures of Clinical Change - Report of a National Institute of Mental Health Work Group. Developmental Neuropsychology. 1986;2(4):261-76.

Crowe A, Huang W, Ballatore C, Johnson RL, Hogan A-ML, Huang R, et al. Identification of Amino-thienopyridazine Inhibitors of Tau Assembly by Quantitative High-Throughput Screening. Biochemistry. 2009;48(32):7732-45.

Csuk R, Barthel A, Raschke C, Kluge R, Stroehl D, Trieschmann L, et al. Synthesis of Monomeric and Dimeric Acridine Compounds as Potential Therapeutics in Alzheimer and Prion Diseases. Archiv Der Pharmazie. 2009;342(12):699-709.

Cuadrado-Tejedor M, Hervias I, Ricobaraza A, Puerta E, Perez-Roldan JM, Garcia-Barroso C, et al. Sildenafil restores cognitive function without affecting beta-amyloid burden in a mouse model of Alzheimer's disease. British Journal of Pharmacology. 2011;164(8):2029-41.

Cuajungco MP, Frederickson CJ, Bush AI. Amyloid-beta metal interaction and metal chelation. *Alzheimer's Disease: Cellular and Molecular Aspects of Amyloid*. 2005;38:235-54.

Cuajungco MP, Lees GJ. Zinc metabolism in the brain: Relevance to human neurodegenerative disorders. *Neurobiology of Disease*. 1997;4(3-4):137-69.

Cuello AC, Ferretti MT, Leon WC, Iulita MF, Melis T, Ducatzenzeiler A, et al. Early-Stage Inflammation and Experimental Therapy in Transgenic Models of the Alzheimer-Like Amyloid Pathology. *Neurodegenerative Diseases*. 2010;7(1-3):96-8.

Cummings JL. Use of cholinesterase inhibitors in clinical practice - Evidence-based recommendations. *American Journal of Geriatric Psychiatry*. 2003;11(2):131-45.

Cummings JL. Drug therapy - Alzheimer's disease. *New England Journal of Medicine*. 2004;351(1):56-67.

Cummings JL, Mega M, Gray K, Rosenbergthompson S, Carusi DA, Gornbein J. THE NEUROPSYCHIATRIC INVENTORY - COMPREHENSIVE ASSESSMENT OF PSYCHOPATHOLOGY IN DEMENTIA. *Neurology*. 1994;44(12):2308-14.

Cummings JL. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2006;2(4):263-71.

Cummings JL. Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies. *Reviews in neurological diseases*. 2007;4(2):57-62.

Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT. Rivastigmine Transdermal Patch Skin Tolerability Results of a 1-Year Clinical Trial in Patients with Mild-to-Moderate Alzheimer's Disease. *Clinical Drug Investigation*. 2010;30(1):41-9.

Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, et al. Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm(2)) in Alzheimer's Disease. *Dementia and Geriatric Cognitive Disorders*. 2012;33(5):341-53.

Cummings J, Gould H, Zhong K. Advances in designs for Alzheimer's disease clinical trials. *American journal of neurodegenerative disease*. 2012;1(3):205-16.

Cupino TL, Zabel MK. Alzheimer's Silent Partner: Cerebral Amyloid Angiopathy. *Translational Stroke Research*. 2014;5(3):330-7.

Cupp MJ. Herbal remedies: Adverse effects and drug interactions. *American Family Physician*. 1999;59(5):1239-44.

Daccache A, Lion C, Sibille N, Gerard M, Slomianny C, Lippens G, et al. Oleuropein and derivatives from olives as Tau aggregation inhibitors. *Neurochemistry International*. 2011;58(6):700-7.

Daffner KR. Promoting Successful Cognitive Aging: A Comprehensive Review. *Journal of Alzheimers Disease*. 2010;19(4):1101-22.

Dai H, Kaneko K, Kato H, Fujii S, Jing Y, Xu A, et al. Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors. *Neuroscience Research*. 2007;57(2):306-13.

Dall'Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. *Experimental Neurology*. 2007;203(1):241-5.

Daneschvar HL, Aronson MD, Smetana GW. Do statins prevent Alzheimer's disease? A narrative review. *European Journal of Internal Medicine*. 2015;26(9):666-9.

Danscher G, Jensen KB, Frederickson CJ, Kemp K, Andreasen A, Juhl S, et al. Increased amount of zinc in the hippocampus and amygdala of Alzheimer's diseased brains: A proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. *Journal of Neuroscience Methods*. 1997;76(1):53-9.

Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. *International Journal of Clinical Practice*. 2006;60(1):110-8.

Danysz W, Parsons CG. Alzheimer's disease, beta-amyloid, glutamate, NMDA receptors and memantine - searching for the connections. *British Journal of Pharmacology*. 2012;167(2):324-52.

Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-beta immunization effectively reduces amyloid deposition in FcR gamma(-/-) knock-out mice. *Journal of Neuroscience*. 2003;23(24):8532-8.

David R, Mulin E, Mallea P, Robert PH. Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders. *Pharmaceuticals (Basel, Switzerland)*. 2010;3(8):2387-97.

Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias. *Journal of Alzheimers Disease*. 2011;26(4):699-708.

Davies P, Maloney AJF. SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMERS-DISEASE. *Lancet*. 1976;2(8000):1403-.

Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES, Jr., Cox NJ, et al. National Institutes of Health State-of-the-Science Conference Statement: Preventing Alzheimer Disease and Cognitive Decline. *Annals of Internal Medicine*. 2010;153(3):176-U72.

Davis AA, Fritz JJ, Wess J, Lah JJ, Levey AI. Deletion of M-1 Muscarinic Acetylcholine Receptors Increases Amyloid Pathology In Vitro and In Vivo. *Journal of Neuroscience*. 2010;30(12):4190-6.

Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF TACRINE FOR ALZHEIMERS-DISEASE. *New England Journal of Medicine*. 1992;327(18):1253-9.

Davtyan H, Ghochikyan A, Petrushina I, Hovakimyan A, Davtyan A, Poghosyan A, et al. Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial. *Journal of Neuroscience*. 2013;33(11):4923-34.

De Felice FG, Vieira MNN, Bomfim TR, Decker H, Velasco PT, Lambert MP, et al. Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of A beta oligomers. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(6):1971-6.

de Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M, Borm G, et al. No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial. *Plos One*. 2008;3(1).

de Jong D, Kremer BPH, Olde Rikkert MGM, Verbeek MM. Current state and future directions of neurochemical biomarkers for Alzheimer's disease. *Clinical Chemistry and Laboratory Medicine*. 2007;45(11):1421-34.

de Jonghe JFM, Wetzels RB, Mulders A, Zuidema SU, Koopmans RTCM. Validity of the Severe Impairment Battery Short Version. *Journal of Neurology Neurosurgery and Psychiatry*. 2009;80(9):954-9.

de la Monte SM, Jhaveri A, Maron BA, Wands JR. Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery. *Journal of Neuropathology and Experimental Neurology*. 2007;66(4):272-83.

de Medeiros K, Robert P, Gauthier S, Stella F, Politis A, Leoutsakos J, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised

assessment of neuropsychiatric symptoms in dementia. *International Psychogeriatrics*. 2010;22(6):984-94.

De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. *Nature*. 1999;398(6727):518-22.

Deane R, Wu ZH, Sagare A, Davis J, Yan SD, Hamm K, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of A beta isoforms. *Neuron*. 2004;43(3):333-44.

Deane R, Wu ZH, Zlokovic BV. RAGE (Yin) versus LRP (Yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. *Stroke*. 2004;35(11):2628-31.

Deane R, Yan SD, Subramanyam RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. *Nature Medicine*. 2003;9(7):907-13.

Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. *Journal of Clinical Investigation*. 2012;122(4):1377-92.

DeBattista C, Belanoff J. C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease. *Current Alzheimer Research*. 2005;2(2):125-9.

DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. *Archives of Neurology*. 2007;64(1):108-15.

Dedeoglu A, Cormier K, Payton S, Tseitlin KA, Kremesky JN, Lai L, et al. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. *Experimental Gerontology*. 2004;39(11-12):1641-9.

Deftereos SN, Andronis C, Friedla EJ, Persidis A, Persidis A. Drug repurposing and adverse event prediction using high-throughput literature analysis. *Wiley Interdisciplinary Reviews-Systems Biology and Medicine*. 2011;3(3):323-34.

Deiana S, Harrington CR, Wischik CM, Riedel G. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. *Psychopharmacology*. 2009;202(1-3):53-65.

Dejong R, Osterlund OW, Roy GW. MEASUREMENT OF QUALITY-OF-LIFE CHANGES IN PATIENTS WITH ALZHEIMERS-DISEASE. *Clinical Therapeutics*. 1989;11(4):545-54.

DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al. Ginkgo biloba for Prevention of Dementia A Randomized Controlled Trial. *Jama-Journal of the American Medical Association*. 2008;300(19):2253-62.

del Ser T, Steinwachs KC, Gertz HJ, Andres MV, Gomez-Carrillo B, Medina M, et al. Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study. *Journal of Alzheimers Disease*. 2013;33(1):205-15.

Delrieu J, Ousset PJ, Vellas B. Gantenerumab for the treatment of Alzheimer's disease. *Expert Opinion on Biological Therapy*. 2012;12(8):1077-86.

DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2001;98(15):8850-5.

DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. *Science*. 2002;295(5563):2264-7.

Deng J, Shen C, Wang Y-J, Zhang M, Li J, Xu Z-Q, et al. Nicotine exacerbates tau phosphorylation and cognitive impairment induced by amyloid-beta 25-35 in rats. *European Journal of Pharmacology*. 2010;637(1-3):83-8.

Denner LA, Rodriguez-Rivera J, Haidacher SJ, Jahrling JB, Carmical JR, Hernandez CM, et al. Cognitive Enhancement with Rosiglitazone Links the Hippocampal PPAR gamma and ERK MAPK Signaling Pathways. *Journal of Neuroscience*. 2012;32(47):16725-+.

Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J. A Role for Synaptic Zinc in Activity-Dependent A beta Oligomer Formation and Accumulation at Excitatory Synapses. *Journal of Neuroscience*. 2009;29(13):4004-15.

Devanand DP, Jacobs DM, Tang MX, DelCastilloCastaneda C, Sano M, Marder K, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. *Archives of General Psychiatry*. 1997;54(3):257-63.

Devi L, Ohno M. Effects of levetiracetam, an antiepileptic drug, on memory impairments associated With aging and Alzheimer's disease in mice. *Neurobiology of Learning and Memory*. 2013;102:7-11.

Devore EE, Grodstein F, van Rooij FJA, Hofman A, Stampfer MJ, Witteman JCM, et al. Dietary Antioxidants and Long-term Risk of Dementia. *Archives of Neurology*. 2010;67(7):819-25.

Dhikav V, Anand KS. Glucocorticoids may initiate Alzheimer's disease: A Potential therapeutic role for mifepristone (RU-486). *Medical Hypotheses*. 2007;68(5):1088-92.

Dhull DK, Jindal A, Dhull RK, Aggarwal S, Bhateja D, Padi SSV. Neuroprotective Effect of Cyclooxygenase Inhibitors in ICV-STZ Induced Sporadic Alzheimer's Disease in Rats. *Journal of Molecular Neuroscience*. 2012;46(1):223-35.

Di Stefano A, Iannitelli A, Laserra S, Sozio P. Drug delivery strategies for Alzheimer's disease treatment. *Expert Opinion on Drug Delivery*. 2011;8(5):581-603.

Dickerson BC, Stoub TR, Shah RC, Sperling RA, Killiany RJ, Albert MS, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. *Neurology*. 2011;76(16):1395-402.

Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *Journal of Clinical Investigation*. 2007;117(3):648-58.

Dicou E, Rangon CM, Guimiot F, Spedding M, Gressens P. Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain. *Brain Research*. 2003;970(1-2):221-5.

Dinamarca MC, Rios JA, Inestrosa NC. Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer's disease. *Frontiers in Physiology*. 2012;3.

Diomedede L, Cassata G, Fiordaliso F, Salio M, Ami D, Natalello A, et al. Tetracycline and its analogues protect *Caenorhabditis elegans* from beta amyloid-induced toxicity by targeting oligomers. *Neurobiology of Disease*. 2010;40(2):424-31.

Divinski I, Mittelman L, Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. *Journal of Biological Chemistry*. 2004;279(27):28531-8.

Dobarro M, Orejana L, Aguirre N, Javier Ramirez M. Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model. *Neuropharmacology*. 2013;64:137-44.

Dobarro M, Orejana L, Aguirre N, Ramirez MJ. Propranolol reduces cognitive deficits, amyloid beta levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration. *International Journal of Neuropsychopharmacology*. 2013;16(6):1351-60.

Dobson CM. Protein folding and misfolding. *Nature*. 2003;426(6968):884-90.

Dockens R, Wang J-S, Castaneda L, Sverdllov O, Huang S-P, Slemmon R, et al. A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and

Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects. *Clinical Pharmacokinetics*. 2012;51(10):681-93.

Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain A beta burden in Alzheimer's disease model. *Nature Neuroscience*. 2002;5(5):452-7.

Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. *Journal of Neurology Neurosurgery and Psychiatry*. 2004;75(10):1472-4.

Dodel R, Hampel H, Depboylu C, Lin SZ, Gao F, Shock S, et al. Human antibodies against amyloid beta peptide: A potential treatment for Alzheimer's disease. *Annals of Neurology*. 2002;52(2):253-6.

Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, et al. Intravenous Immunoglobulins as a Treatment for Alzheimer's Disease Rationale and Current Evidence. *Drugs*. 2010;70(5):513-28.

Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Foerster S, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. *Lancet Neurology*. 2013;12(3):233-43.

Dodge HH, Zitzelberger T, Oken BS, Howieson D, Kaye J. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. *Neurology*. 2008;70(19):1809-17.

Domercq M, Matute C. Neuroprotection by tetracyclines. *Trends in Pharmacological Sciences*. 2004;25(12):609-12.

Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. *Journal of Biological Chemistry*. 2005;280(35):30797-806.

Dominguez E, Chin T-Y, Chen C-P, Wu T-Y. Management of moderate to severe Alzheimer's disease: Focus on memantine. *Taiwanese Journal of Obstetrics & Gynecology*. 2011;50(4):415-23.

Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, et al. Donepezil treatment of patients with MCI A 48-week randomized, placebo-controlled trial. *Neurology*. 2009;72(18):1555-61.

Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD, Donepezil Study G. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. *Archives of Neurology*. 2001;58(3):427-33.

Doody RS. We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development. *Alzheimers & Dementia*. 2008;4(1):S21-S5.

Doody RS. DIMEBON AS A POTENTIAL THERAPY FOR ALZHEIMER'S DISEASE. *Cns Spectrums*. 2009;14(8):14-6.

Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. *Lancet*. 2008;372(9634):207-15.

Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease. *New England Journal of Medicine*. 2013;369(4):341-50.

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease. *New England Journal of Medicine*. 2014;370(4):311-21.

Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Meta-analysis of six-month memantine trials in Alzheimer's disease. *Alzheimers & Dementia*. 2007;3(1):7-17.

Doraiswamy PM, Krishen A, Stallone F, Martin WL, Potts NL, Metz A, et al. COGNITIVE PERFORMANCE ON THE ALZHEIMERS-DISEASE ASSESSMENT SCALE - EFFECT OF EDUCATION. *Neurology*. 1995;45(11):1980-4.

Douillet P, Orgogozo JM. What we have learned from the xaliproden Sanofi-aventis trials. *Journal of Nutrition Health & Aging*. 2009;13(4):365-6.

Dovey HF, John V, Anderson JP, Chen LZ, Andrieu PD, Fang LY, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. *Journal of Neurochemistry*. 2001;76(1):173-81.

Drachman DA, Leavitt J. HUMAN MEMORY AND CHOLINERGIC SYSTEM - RELATIONSHIP TO AGING. *Archives of Neurology*. 1974;30(2):113-21.

Drever BD, Riedel G, Platt B. The cholinergic system and hippocampal plasticity. *Behavioural Brain Research*. 2011;221(2):505-14.

Drewes G. MARKing tau for tangles and toxicity. *Trends in Biochemical Sciences*. 2004;29(10):548-55.

Driscoll M, Gerstbrein B. Dying for a cause: Invertebrate genetics takes on human neurodegeneration. *Nature Reviews Genetics*. 2003;4(3):181-94.

Drott J, Desire L, Drouin D, Pando M, Haun F. Etazolate improves performance in a foraging and homing task in aged rats. *European Journal of Pharmacology*. 2010;634(1-3):95-100.

Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. *Nature Medicine*. 1996;2(5):561-6.

Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. *Neurology*. 2001;57(5):801-5.

Duan W, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B, et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. *Neurobiology of Disease*. 2008;30(3):312-22.

Duara R, Loewenstein DA, Potter E, Appel J, Greig MT, Urs R, et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. *Neurology*. 2008;71(24):1986-92.

Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. *The Lancet Neurology*. 2010;9(11):1118-27.

Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. *Lancet Neurology*. 2010;9(11):1118-27.

Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurology*. 2007;6(8):734-46.

Dufouil C, Richard F, Fievet N, Dartigues JF, Ritchie K, Tzourio C, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia - The Three-City Study. *Neurology*. 2005;64(9):1531-8.

Dufouil C, Alperovitch A. Epidemiology of Alzheimer's disease. *La Revue du praticien*. 2005;55(17):1869-78.

Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova N, et al. Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. *Human Molecular Genetics*. 2012;21(23):5091-105.

Dumont M, Wille E, Calingasan NY, Tampellini D, Williams C, Gouras GK, et al. Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. *Journal of Neurochemistry*. 2009;109(2):502-12.

Dunbar GC, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M, Wamsley J. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). *Journal of Psychopharmacology*. 2007;21(2):171-8.

Dunbar GC, Kuchibhatla R. Cognitive enhancement in man with ispronicline, a nicotinic partial agonist. *Journal of Molecular Neuroscience*. 2006;30(1-2):169-71.

Duong FHT, Warter JM, Poindron P, Passilly P. Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons. *British Journal of Pharmacology*. 1999;128(7):1385-92.

Duong TH, Nikolaeva M, Acton PJ. C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease. *Brain Research*. 1997;749(1):152-6.

Durga J, van Boxtel MPJ, Schouten EG, Kok FJ, Jolles J, Katan MB, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. *Lancet*. 2007;369(9557):208-16.

Dysken MW, Guarino PD, Vertrees JE, Asthana S, Sano M, Llorente M, et al. Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data. *Alzheimers & Dementia*. 2014;10(1):36-44.

Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, et al. Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease The TEAM-AD VA Cooperative Randomized Trial. *Jama-Journal of the American Medical Association*. 2014;311(1):33-44.

Eagger SA, Levy R, Sahakian BJ. TACRINE IN ALZHEIMERS-DISEASE. *Lancet*. 1991;337(8748):989-92.

Echavarri C, Burgmans S, Cristina Caballero M, Garcia-Bragado F, Verhey FRJ, Uylings HBM. Co-occurrence of Different Pathologies in Dementia: Implications for Dementia Diagnosis. *Journal of Alzheimers Disease*. 2012;30(4):909-17.

Echeverria V, Zeitlin R. Cotinine: A Potential New Therapeutic Agent against Alzheimer's disease. *Cns Neuroscience & Therapeutics*. 2012;18(7):517-23.

Echeverria V, Zeitlin R, Burgess S, Patel S, Barman A, Thakur G, et al. Cotinine Reduces Amyloid-beta Aggregation and Improves Memory in Alzheimer's Disease Mice. *Journal of Alzheimers Disease*. 2011;24(4):817-35.

Eckert GP, Renner K, Eckert SH, Eckmann J, Hagl S, Abdel-Kader RM, et al. Mitochondrial Dysfunction-A Pharmacological Target in Alzheimer's Disease. *Molecular Neurobiology*. 2012;46(1):136-50.

Eckman CB, Eckman EA. An update on the amyloid hypothesis. *Neurologic Clinics*. 2007;25(3):669-+.

Eckman EA, Eckman CB. A beta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. *Biochemical Society Transactions*. 2005;33:1101-5.

Eckman EA, Reed DK, Eckman CB. Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. *Journal of Biological Chemistry*. 2001;276(27):24540-8.

Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, et al. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. *Journal of Biological Chemistry*. 2006;281(41):30471-8.

Eder J, Hommel U, Cumin F, Martoglio B, Gerhartz B. Aspartic proteases in drug discovery. *Current Pharmaceutical Design*. 2007;13(3):271-85.

Egan M, Yaari R, Liu L, Ryan M, Peng Y, Lines C, et al. Pilot Randomized Controlled Study of a Histamine Receptor Inverse Agonist in the Symptomatic Treatment of AD. *Current Alzheimer Research*. 2012;9(4):481-90.

Egefjord L, Gejl M, Moller A, Braendgaard H, Gottrup H, Antropova O, et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease - protocol for a controlled, randomized double-blinded trial. *Danish Medical Journal*. 2012;59(10).

Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. *Journal of Cell Biology*. 2003;160(1):113-23.

Ehret MJ, Chamberlin KW. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials? *Clinical Therapeutics*. 2015;37(8):1604-16.

Eisele YS, Obermueller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, et al. Peripherally Applied A beta-Containing Inoculates Induce Cerebral beta-Amyloidosis. *Science*. 2010;330(6006):980-2.

Ekdahl CT, Kokaia Z, Lindvall O. BRAIN INFLAMMATION AND ADULT NEUROGENESIS: THE DUAL ROLE OF MICROGLIA. *Neuroscience*. 2009;158(3):1021-9.

El Mouedden M, Vandermeeren M, Meert T, Mercken M. Reduction of A beta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: A novel non-transgenic model for A beta production inhibitors. *Current Pharmaceutical Design*. 2006;12(6):671-6.

Elcioglu HK, Kabasakal L, Alan S, Salva E, Tufan F, Karan MA. Thalidomide attenuates learning and memory deficits induced by intracerebroventricular administration of streptozotocin in rats. *Biotechnic & Histochemistry*. 2013;88(3-4):145-52.

Elder GA, De Gasperi R, Sosa MAG. Research update: Neurogenesis in adult brain and neuropsychiatric disorders. *Mount Sinai Journal of Medicine*. 2006;73(7):931-40.

Elliott MSJ, Ballard CG, Kalaria RN, Perry R, Hortobagyi T, Francis PT. Increased binding to 5-HT_{1A} and 5-HT_{2A} receptors is associated with large vessel infarction and relative preservation of cognition. *Brain*. 2009;132:1858-65.

Ellison DW, Beal MF, Mazurek MF, Bird ED, Martin JB. A POSTMORTEM STUDY OF AMINO-ACID NEUROTRANSMITTERS IN ALZHEIMERS-DISEASE. *Annals of Neurology*. 1986;20(5):616-21.

Emerich DF, Winn SR, Harper J, Hammang JP, Baetge EE, Kordower JH. IMPLANTS OF POLYMER-ENCAPSULATED HUMAN NGF-SECRETING CELLS IN THE NONHUMAN PRIMATE - RESCUE AND SPROUTING OF DEGENERATING CHOLINERGIC BASAL FOREBRAIN NEURONS. *Journal of Comparative Neurology*. 1994;349(1):148-64.

Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. *New England Journal of Medicine*. 2004;351(24):2509-18.

Emre M, Bernabei R, Blesa R, Bullock R, Cunha L, Daniels H, et al. Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease. *Cns Neuroscience & Therapeutics*. 2010;16(4):246-53.

Endo T, Tominaga T, Olson L. Cortical Changes Following Spinal Cord Injury with Emphasis on the Nogo Signaling System. *Neuroscientist*. 2009;15(3):291-9.

Endoh M, Kunishita T, Tabira T. No effect of anti-leprosy drugs in the prevention of Alzheimer's disease and beta-amyloid neurotoxicity. *Journal of the Neurological Sciences*. 1999;165(1):28-30.

Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F. Chronic lithium administration to FTDP-17 tau and GSK-3 beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. *Journal of Neurochemistry*. 2006;99(6):1445-55.

Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Holman A, Witteman JCM, et al. Dietary intake of antioxidants and risk of Alzheimer disease. *Jama-Journal of the American Medical Association*. 2002;287(24):3223-9.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. *Brain*. 2006;129:2856-66.

Englund H, Sehlin D, Johansson A-S, Nilsson LNG, Gellerfors P, Paulie S, et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. *Journal of Neurochemistry*. 2007;103(1):334-45.

Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, et al. Exercise training increases size of hippocampus and improves memory. *Proceedings of the National Academy of Sciences of the United States of America*. 2011;108(7):3017-22.

Erickson MA, Banks WA. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. *Journal of Cerebral Blood Flow and Metabolism*. 2013;33(10):1500-13.

Eriksdotter-Jonhagen M, Linderöth B, Lind G, Aladellie L, Almkvist O, Andreasen N, et al. Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer's Disease. *Dementia and Geriatric Cognitive Disorders*. 2012;33(1):18-28.

Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower A beta 42 in vivo. *Journal of Clinical Investigation*. 2003;112(3):440-9.

Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. *Lancet*. 2002;359(9314):1283-90.

Ernst RL, Hay JW. THE US ECONOMIC AND SOCIAL COSTS OF ALZHEIMERS-DISEASE REVISITED. *American Journal of Public Health*. 1994;84(8):1261-4.

Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD. The histamine H(3) receptor: an attractive target for the treatment of cognitive disorders. *British Journal of Pharmacology*. 2008;154(6):1166-81.

Escribano L, Simon A-M, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garcia-Osta A, et al. Rosiglitazone Rescues Memory Impairment in Alzheimer's Transgenic Mice: Mechanisms Involving a Reduced Amyloid and Tau Pathology. *Neuropsychopharmacology*. 2010;35(7):1593-604.

Escribano L, Simon A-M, Perez-Mediavilla A, Salazaf-Colocho P, Del Rio J, Frechilla D. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. *Biochemical and Biophysical Research Communications*. 2009;379(2):406-10.

Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife Coffee and Tea Drinking and the Risk of Late-Life Dementia: A Population-Based CAIDE Study. *Journal of Alzheimers Disease*. 2009;16(1):85-91.

Espinoza R. Limitations of MMSE when screening for dementia. *Geriatrics*. 2001;56(9):14-.

Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der Auwera I, Wera S, et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2004;101(30):11141-6.

Evatt ML. Vitamin D and Risk of Cognitive Decline in Elderly Persons. *Archives of Neurology*. 2010;67(12):1513-5.

Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. *Embo Molecular Medicine*. 2009;1(8-9):371-80.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. *Archives of Neurology*. 2007;64(3):343-9.

Fagan R, Swindells M, Overington J, Weir M. Nicastrin, a presenilin-interacting protein, contains an aminopeptidase/transferrin receptor superfamily domain. *Trends in Biochemical Sciences*. 2001;26(4):213-4.

Fan J, Donkin J, Wellington C. Greasing the wheels of A beta clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E. *Biofactors*. 2009;35(3):239-48.

Farlow MR. NMDA receptor antagonists - A new therapeutic approach for Alzheimer's disease. *Geriatrics*. 2004;59(6):22-7.

Farlow MR, Small GW, Quarg P, Krause A. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: Results of a meta-analysis. *Dementia and Geriatric Cognitive Disorders*. 2005;20(2-3):192-7.

Farlow M, Anand R, Messina J, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. *European Neurology*. 2000;44(4):236-41.

Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolanuren J. A CONTROLLED TRIAL OF TACRINE IN ALZHEIMERS-DISEASE. *Jama-Journal of the American Medical Association*. 1992;268(18):2523-9.

Farlow MR, Brosch JR. Immunotherapy for Alzheimer's Disease. *Neurologic Clinics*. 2013;31(3):869-+.

Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer's disease. *Drug Safety*. 2008;31(7):577-85.

Farlow MR, Miller ML, Pejovic V. Treatment options in Alzheimer's disease: Maximizing benefit, managing expectations. *Dementia and Geriatric Cognitive Disorders*. 2008;25(5):408-22.

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. Effectiveness and Tolerability of High-Dose (23 mg/d) Versus Standard-Dose (10 mg/d) Donepezil in Moderate to Severe Alzheimer's Disease: A 24-Week, Randomized, Double-Blind Study. *Clinical Therapeutics*. 2010;32(7):1234-51.

Farlow M, Amold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of Solanezumab in patients with Alzheimer's disease. *Alzheimers & Dementia*. 2012;8(4):261-71.

Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. *Bmc Neurology*. 2011;11.

Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100(7):4162-7.

Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides A beta 42 and A beta 40 in vitro and in vivo. *Proceedings of the National Academy of Sciences of the United States of America*. 2001;98(10):5856-61.

Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, et al. PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. *Journal of Alzheimers Disease*. 2010;20(2):509-16.

Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease LEADe. *Neurology*. 2010;74(12):956-64.

Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. *Lancet Neurology*. 2007;6(6):501-12.

Ferreira A, Bigio EH. Calpain-Mediated Tau Cleavage: A Mechanism Leading to Neurodegeneration Shared by Multiple Tauopathies. *Molecular Medicine*. 2011;17(7-8):676-85.

Ferrer I, Rovira MB, Guerra MLS, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. *Brain Pathology*. 2004;14(1):11-20.

Ferretti MT, Allard S, Partridge V, Ducatenzeiler A, Cuello AC. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. *Journal of Neuroinflammation*. 2012;9.

Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. *Lancet*. 2005;366(9503):2112-7.

Ferrington L, Miners JS, Palmer LE, Bond SM, Povey JE, Kelly PAT, et al. Angiotensin II-inhibiting drugs have no effect on intraneuronal A beta or oligomeric A beta levels in a triple transgenic mouse model of Alzheimer's disease. *American Journal of Translational Research*. 2011;3(2):197-208.

Ferrington L, Palmer LE, Love S, Horsburgh KJ, Kelly PAT, Kehoe PG. Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse. *American Journal of Translational Research*. 2012;4(2):151-64.

Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, et al. ADCS prevention instrument project: Overview and initial results. *Alzheimer Disease & Associated Disorders*. 2006;20(4):S109-S23.

Festuccia WT, Oztezcan S, Laplante M, Berthiaume M, Michel C, Dohgu S, et al. Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. *Endocrinology*. 2008;149(5):2121-30.

Fillenbaum GG, Kuchibhatla MN, Hanlon JT, Artz MB, Pieper CF, Schmader KE, et al. Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E. *Annals of Pharmacotherapy*. 2005;39(12):2009-14.

Fillit H, Hess G, Hill J, Bonnet P, Toso C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. *Neurology*. 2009;73(3):180-5.

Finefrock AE, Bush AI, Doraiswamy PM. Current status of metals as therapeutic targets in Alzheimer's disease. *Journal of the American Geriatrics Society*. 2003;51(8):1143-8.

First MB. Paradigm Shifts and the Development of the Diagnostic and Statistical Manual of Mental Disorders: Past Experiences and Future Aspirations. *Canadian Journal of Psychiatry- Revue Canadienne De Psychiatrie*. 2010;55(11):692-700.

Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai L-H. Recovery of learning and memory is associated with chromatin remodelling. *Nature*. 2007;447(7141):178-U2.

Fisher A, Brandeis R, Bar-Ner RHN, Kliger-Spatz M, Natan N, Sonogo H, et al. AF150(S) and AF267B - M1 muscarinic agonists as innovative therapies for Alzheimer's disease. *Journal of Molecular Neuroscience*. 2002;19(1-2):145-53.

Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, et al. M-1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease - Implications in future therapy. *Journal of Molecular Neuroscience*. 2003;20(3):349-56.

Fisher A. Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. *Neurotherapeutics*. 2008;5(3):433-42.

Fisher A. M1 muscarinic Agonists target major hallmarks of Alzheimer's disease the pivotal role of brain M1 receptors. *Neurodegenerative Diseases*. 2008;5(3-4):237-40.

Fisher A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. *Journal of Neurochemistry*. 2012;120:22-33.

Fitz NF, Cronican AA, Lefterov I, Koldamova R. Comment on "ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models". *Science*. 2013;340(6135).

Fjord-Larsen L, Kusk P, Emerich DF, Thanos C, Torp M, Bintz B, et al. Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer. *Gene Therapy*. 2012;19(10):1010-7.

Fleck D, Garratt AN, Haass C, Willem M. BACE1 Dependent Neuregulin Processing: Review. *Current Alzheimer Research*. 2012;9(2):178-83.

Fleischman DA, Wilson RS, Gabrieli JDE, Schneider JA, Bienias JL, Bennett DA. Implicit memory and Alzheimer's disease neuropathology. *Brain*. 2005;128:2006-15.

Fleisher AS, Truran D, Mai JT, Langbaum JBS, Aisen PS, Cummings JL, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. *Neurology*. 2011;77(13):1263-71.

Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild

Cognitive Impairment or Dementia Due to Alzheimer Disease. *Archives of Neurology*. 2011;68(11):1404-11.

Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. *Archives of Neurology*. 2008;65(8):1031-8.

Floyd RA. Neuroinflammatory processes are important in neurodegenerative diseases: An hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. *Free Radical Biology and Medicine*. 1999;26(9-10):1346-55.

Foley AG, Murphy KJ, Hirst WD, Gallagher HC, Hagan JJ, Upton N, et al. The 5-HT₆ receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. *Neuropsychopharmacology*. 2004;29(1):93-100.

Folstein MF, Folstein SE, McHugh PR. MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN. *Journal of Psychiatric Research*. 1975;12(3):189-98.

Fonseca ACRG, Resende R, Oliveira CR, Pereira CMF. Cholesterol and statins in Alzheimer's disease: Current controversies. *Experimental Neurology*. 2010;223(2):282-93.

Fontana DJ, Daniels SE, Wong EHF, Clark RD, Eglen RM. The effects of novel, selective 5-hydroxytryptamine (5-HT)₄ receptor ligands in rat spatial navigation. *Neuropharmacology*. 1997;36(4-5):689-96.

Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment. *Archives of Internal Medicine*. 2002;162(18):2046-52.

Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. *Lancet*. 1998;352(9137):1347-51.

Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnesic mild cognitive impairment: randomised controlled trial. *British Journal of Psychiatry*. 2011;198(5):351-6.

Forlenza OV, Torres CA, Talib LL, de Paula VJ, Joaquim HPG, Diniz BS, et al. Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. *Journal of Psychiatric Research*. 2011;45(2):220-4.

Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. *Febs Letters*. 2001;487(3):404-7.

Forloni G, Salmona M, Marcon G, Tagliavini F. Tetracyclines and Prion Infectivity. *Infectious Disorders - Drug Targets*. 2009;9(1):23-30.

Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PIB Retention in Alzheimer's Disease is an Early Event with Complex Relationship with CSF Biomarkers and Functional Parameters. *Current Alzheimer Research*. 2010;7(1):56-66.

Forti P, Pisacane N, Rietti E, Lucicesare A, Olivelli V, Mariani E, et al. Metabolic Syndrome and Risk of Dementia in Older Adults. *Journal of the American Geriatrics Society*. 2010;58(3):487-92.

Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. *Nature Clinical Practice Neurology*. 2009;5(3):140-52.

Fournier J, Steinberg R, Gauthier T, Keane PE, Guzzi U, Coude FX, et al. PROTECTIVE EFFECTS OF SR-57746A IN CENTRAL AND PERIPHERAL MODELS OF NEURODEGENERATIVE DISORDERS IN RODENTS AND PRIMATES. *Neuroscience*. 1993;55(3):629-41.

Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of A beta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. *Neurology*. 2005;64(9):1563-72.

Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease - Power calculations and estimates of sample size to detect treatment effects. *Archives of Neurology*. 2000;57(3):339-44.

Fraering PC, Ye WJ, LaVoie MJ, Ostaszewski BL, Selkoe DJ, Wolfe MS. gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. *Journal of Biological Chemistry*. 2005;280(51):41987-96.

Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? *Trends in Pharmacological Sciences*. 2005;26(2):104-11.

Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. *Journal of Neurology Neurosurgery and Psychiatry*. 1999;66(2):137-47.

Frank B, Gupta S. A review of antioxidants and Alzheimer's disease. *Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists*. 2005;17(4):269-86.

Frankiewicz T, Parsons CG. Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg²⁺ in hippocampal slices. *Neuropharmacology*. 1999;38(9):1253-9.

Freeman GB, Lin JC, Pons J, Raha NM. 39-Week Toxicity and Toxicokinetic Study of Ponezumab (PF-04360365) in Cynomolgus Monkeys with 12-Week Recovery Period. *Journal of Alzheimers Disease*. 2012;28(3):531-41.

Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma A beta levels do not reflect brain A beta levels. *Journal of Neuropathology and Experimental Neurology*. 2007;66(4):264-71.

Freitas C, Mondragon-Llorca H, Pascual-Leone A. Noninvasive brain stimulation in Alzheimer's disease: Systematic review and perspectives for the future. *Experimental Gerontology*. 2011;46(8):611-27.

Frenkel D, Solomon B, Benhar I. Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody. *Journal of Neuroimmunology*. 2000;106(1-2):23-31.

Freund-Levi Y, Basun H, Cederholm T, Faxen-Irving G, Garlind A, Grut M, et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. *International Journal of Geriatric Psychiatry*. 2008;23(2):161-9.

Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, et al. omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study - A randomized double-blind trial. *Archives of Neurology*. 2006;63(10):1402-+.

Freund-Levi Y, Hjorth E, Lindberg C, Cederholm T, Faxen-Irving G, Vedin I, et al. Effects of Omega-3 Fatty Acids on Inflammatory Markers in Cerebrospinal Fluid and Plasma in Alzheimer's Disease: The OmegAD Study. *Dementia and Geriatric Cognitive Disorders*. 2009;27(5):481-90.

Friedhoff LT, Cullen EI, Geoghagen NSM, Buxbaum JD. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. *International Journal of Neuropsychopharmacology*. 2001;4(2):127-30.

Frisoni GB, Fox NC, Jack CR, Jr., Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. *Nature Reviews Neurology*. 2010;6(2):67-77.

Froelich L, Ashwood T, Nilsson J, Eckerwall G, Sirocco I. Effects of AZD3480 on Cognition in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase IIb Dose-Finding Study. *Journal of Alzheimers Disease*. 2011;24(2):363-74.

Froestl W, Gallagher M, Jenkins H, Madrid A, Melcher T, Teichman S, et al. SGS742: the first GABA(B) receptor antagonist in clinical trials. *Biochemical Pharmacology*. 2004;68(8):1479-87.

Froestl W, Muhs A, Pfeifer A. Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. *Journal of Alzheimers Disease*. 2013;33(3):547-658.

Fu AL, Zhou CY, Chen X. Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer's disease. *Neuropharmacology*. 2010;58(4-5):722-9.

Fu HJ, Liu B, Frost JL, Lemere CA. Amyloid-beta Immunotherapy for Alzheimer's Disease. *Cns & Neurological Disorders-Drug Targets*. 2010;9(2):197-206.

Fu Q, Hue J, Li S. Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition. *Journal of Neuroscience*. 2007;27(15):4154-64.

Fuentes P, Catalan J. A Clinical Perspective: Anti Tau's Treatment in Alzheimer's Disease. *Current Alzheimer Research*. 2011;8(6):686-8.

Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. *Archives of Neurology*. 2002;59(9):1381-9.

Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, et al. A Noncompetitive BACE1 Inhibitor TAK-070 Ameliorates A beta Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease. *Journal of Neuroscience*. 2010;30(33):11157-66.

Fumagalli F, Racagni G, Riva MA. The expanding role of BDNF: a therapeutic target for Alzheimer's disease? *Pharmacogenomics Journal*. 2006;6(1):8-15.

Fumagalli F, Molteni R, Calabrese F, Maj PF, Racagni G, Riva MA. Neurotrophic Factors in Neurodegenerative Disorders Potential for Therapy. *Cns Drugs*. 2008;22(12):1005-19.

Furukawa K, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM, et al. Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. *Journal of Neurochemistry*. 1996;67(5):1882-96.

Fuschillo C, Ascoli E, Franzese G, Campana F, Cello C, Galdi M, et al. Alzheimer's disease and acetylcholinesterase inhibitor agents: A two-year longitudinal study. *Archives of Gerontology and Geriatrics*. 2004:187-94.

Gabbita SP, Srivastava MK, Eslami P, Johnson MF, Kobritz NK, Tweedie D, et al. Early intervention with a small molecule inhibitor for tumor necrosis factor-alpha prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. *Journal of Neuroinflammation*. 2012;9.

Gahete MD, Rubio A, Duran-Prado M, Avila J, Luque RM, Castano JP. Expression of Somatostatin, Cortistatin, and Their Receptors, as well as Dopamine Receptors, but not of

Neprilysin, are Reduced in the Temporal Lobe of Alzheimer's Disease Patients. *Journal of Alzheimers Disease*. 2010;20(2):465-75.

Gahr M, Nowak DA, Connemann BJ, Schoenfeldt-Lecuona C. Cerebral amyloid angiopathy-A disease with implications for neurology and psychiatry. *Brain Research*. 2013;1519:19-30.

Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. *Alzheimer Disease & Associated Disorders*. 1997;11:S33-S9.

Galasko D, Schmitt F, Thomas R, Jin S, Bennett D, Ferris S, et al. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. *Journal of the International Neuropsychological Society*. 2005;11(4):446-53.

Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, et al. Safety, tolerability, pharmacokinetics, and A beta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. *Alzheimer Disease & Associated Disorders*. 2007;21(4):292-9.

Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, et al. Antioxidants for Alzheimer Disease A Randomized Clinical Trial With Cerebrospinal Fluid Biomarker Measures. *Archives of Neurology*. 2012;69(7):836-41.

Galbussera A, Tremolizzo L, Isella V, Gelosa G, Vezzo R, Vigore L, et al. Lack of evidence for *Borrelia burgdorferi* seropositivity in Alzheimer disease. *Alzheimer Disease & Associated Disorders*. 2008;22(3):308-.

Galimberti D, Ghezzi L, Scarpini E. Immunotherapy against amyloid pathology in Alzheimer's disease. *Journal of the Neurological Sciences*. 2013;333(1-2):50-4.

Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, et al. Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100(17):10032-7.

Gan L. Therapeutic potential of sirtuin-activating compounds in Alzheimer's disease. *Drug News & Perspectives*. 2007;20(4):233-9.

Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. *Journal of Clinical Investigation*. 2005;115(5):1121-9.

Gandy S, Martins RN, Buxbaum J. Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease. *Alzheimer Disease & Associated Disorders*. 2003;17(4):259-66.

Gao X, Zheng CY, Yang L, Tang XC, Zhang HY. Huperzine A protects isolated rat brain mitochondria against beta-amyloid peptide. *Free Radical Biology and Medicine*. 2009;46(11):1454-62.

Garber K. Genentech's Alzheimer's antibody trial to study disease prevention. *Nature Biotechnology*. 2012;30(8):731-2.

Garcia ML, Cleveland DV. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. *Current Opinion in Cell Biology*. 2001;13(1):41-8.

Garcia-Osta A, Cuadrado-Tejedor M, Garcia-Barroso C, Oyarzabal J, Franco R. Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease. *Acs Chemical Neuroscience*. 2012;3(11):832-44.

Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W. Astrocytes are important mediators of A beta-induced neurotoxicity and tau phosphorylation in primary culture. *Cell Death & Disease*. 2011;2.

Garwood CJ, Cooper JD, Hanger DP, Noble W. Anti-inflammatory impact of minocycline in a mouse model of tauopathy. *Frontiers in psychiatry*. 2010;1:136-.

Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. *Journal of Neuroscience*. 2001;21(8):2561-70.

Gastard MC, Troncoso JC, Koliatsos VE. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. *Annals of Neurology*. 2003;54(3):393-8.

Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, et al. TC-1734: An orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. *Cns Drug Reviews*. 2004;10(2):147-66.

Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, et al. Effect of tramiprosate in patients with mild-to-moderate alzheimer's disease: Exploratory analyses of the MRI sub-group of the alphase study. *Journal of Nutrition Health & Aging*. 2009;13(6):550-7.

Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. *International Psychogeriatrics*. 2002;14(4):389-404.

Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. *International Journal of Geriatric Psychiatry*. 2008;23(5):537-45.

Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. *International Journal of Geriatric Psychiatry*. 2005;20(5):459-64.

Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, et al. Management of behavioral problems in Alzheimer's disease. *International Psychogeriatrics*. 2010;22(3):346-72.

Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. *Alzheimers & Dementia*. 2013;9(3):326-31.

Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, et al. Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. *Alzheimers & Dementia*. 2013;9(5):602-8.

Geerts H. Drug evaluation: (R)-flurbiprofen - an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. *Idrugs*. 2007;10(2):121-33.

Gelber RP, Petrovitch H, Masaki KH, Ross GW, White LR. Coffee Intake in Midlife and Risk of Dementia and its Neuropathologic Correlates. *Journal of Alzheimers Disease*. 2011;23(4):607-15.

Geldenhuys WJ, Van der Schyf CJ. Serotonin 5-HT₆ receptor antagonists for the treatment of Alzheimer's disease. *Current Topics in Medicinal Chemistry*. 2008;8(12):1035-48.

Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, et al. Realistic expectations for treatment success in Alzheimer's disease. *Journal of Nutrition Health & Aging*. 2006;10(5):417-29.

Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. *Journal of the American Geriatrics Society*. 2003;51(7):937-44.

Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients With Alzheimer Disease. *Archives of Neurology*. 2011;68(1):45-50.

Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia. *American Journal of Occupational Therapy*. 1999;53(5):471-81.

Geng S, Gao Y-d, Yang J, Zou J-j, Guo W. Potential role of store-operated Ca²⁺ entry in Th-2 response induced by histamine in human monocyte-derived dendritic cells. *International Immunopharmacology*. 2012;12(2):358-67.

Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102(7):2273-6.

Gerlai R. Gene-targeting studies of mammalian behavior: Is it the mutation or the background genotype? *Trends in Neurosciences*. 1996;19(5):177-81.

Gervais F, Chalifour R, Garceau D, Kong XQ, Laurin J, McLaughlin R, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. *Amyloid-Journal of Protein Folding Disorders*. 2001;8:28-35.

Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al. Targeting soluble A beta peptide with Tramiprosate for the treatment of brain amyloidosis. *Neurobiology of Aging*. 2007;28(4):537-47.

Geula C, Wu CK, Saroff D, Lorenzo A, Yuan ML, Yankner BA. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. *Nature Medicine*. 1998;4(7):827-31.

Ghiso J, Frangione B. Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia. *Journal of Alzheimer's Disease*. 2001;3(1):65-73.

Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, Cribbs DH, et al. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-A beta antibody response with Alum to Quil A adjuvant switch. *Vaccine*. 2006;24(13):2275-82.

Ghosh AK, Brindisi M, Tang J. Developing ss-secretase inhibitors for treatment of Alzheimer's disease. *Journal of Neurochemistry*. 2012;120:71-83.

Ghosh AK, Gemma S, Tang J. beta-secretase as a therapeutic target for Alzheimer's disease. *Neurotherapeutics*. 2008;5(3):399-408.

Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni SS, Xu X, Chang W, et al. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. *Journal of Medicinal Chemistry*. 2007;50(10):2399-407.

Ghosh SS, Swerdlow RH, Miller SW, Sheeman B, Parker D, Davis RE. Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. In: Blass JP, McDowell FH, editors. *Oxidative/Energy Metabolism in Neurodegenerative Disorders*. Annals of the New York Academy of Sciences. 893/1999. p. 176-91.

Ghribi O, Golovko MY, Larsen B, Schrag M, Murphy EJ. Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. *Journal of Neurochemistry*. 2006;99(2):438-49.

Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. In: Growdon JH, Wurtman RJ, Corkin S, Nitsch RM, editors. *Molecular Basis of Dementia*. Annals of the New York Academy of Sciences. 9202000. p. 321-7.

Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand S-LT, et al. Syncope and Its Consequences in Patients With Dementia Receiving Cholinesterase Inhibitors A Population-Based Cohort Study. *Archives of Internal Medicine*. 2009;169(9):867-73.

Gilling KE, Jatzke C, Hechenberger M, Parsons CG. Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors. *Neuropharmacology*. 2009;56(5):866-75.

Gillman KW, Starrett JE, Jr., Parker MF, Xie K, Bronson JJ, Marcin LR, et al. Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable gamma-Secretase Inhibitor. *Acs Medicinal Chemistry Letters*. 2010;1(3):120-4.

Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of A beta immunization (AN1792) in patients with AD in an interrupted trial. *Neurology*. 2005;64(9):1553-62.

Giommarelli C, Zuco V, Favini E, Pisano C, Dal Piaz F, De Tommasi N, et al. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. *Cellular and Molecular Life Sciences*. 2010;67(6):995-1004.

Giulian D, Haverkamp LJ, Yu JH, Karshin M, Tom D, Li J, et al. The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer's disease. *Journal of Biological Chemistry*. 1998;273(45):29719-26.

Glabe CG. Structural Classification of Toxic Amyloid Oligomers. *Journal of Biological Chemistry*. 2008;283(44):29639-43.

Gladkevich A, Bosker F, Korf J, Yenkovyan K, Vahradyan H, Aghajyanov M. Proline-rich polypeptides in Alzheimer's disease and neurodegenerative disorders - Therapeutic potential or a mirage? *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 2007;31(7):1347-55.

Glass DJ, Hall N. A brief history of the hypothesis. *Cell*. 2008;134(3):378-81.

Glenner GG, Wong CW. ALZHEIMERS-DISEASE - INITIAL REPORT OF THE PURIFICATION AND CHARACTERIZATION OF A NOVEL CEREBROVASCULAR

AMYLOID PROTEIN. Biochemical and Biophysical Research Communications. 1984;120(3):885-90.

Glennier GG, Wong CW. ALZHEIMERS-DISEASE AND DOWNS-SYNDROME - SHARING OF A UNIQUE CEREBROVASCULAR AMYLOID FIBRIL PROTEIN. Biochemical and Biophysical Research Communications. 1984;122(3):1131-5.

Goedert M, Klug A, Crowther RA. Tau protein, the paired helical filament and Alzheimer's disease. Journal of Alzheimers Disease. 2006;9:195-207.

Goedert M, Klug A, Crowther RA. Tau protein, the paired helical filament and Alzheimer's disease. Alzheimer's Disease: a Century of Scientific and Clinical Research. 2006:195-207.

Goekoop R, Scheltens P, Barkhof F, Rombouts S. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation - a pharmacological fMRI study. Brain. 2006;129:141-57.

Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, et al. Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study. Dementia and Geriatric Cognitive Disorders. 2010;30(2):131-46.

Golde TE. Disease modifying therapy for AD? Journal of Neurochemistry. 2006;99(3):689-707.

Golde TE, Kukar TL. Avoiding Unintended Toxicity. Science. 2009;324(5927):603-4.

Golde TE, Lamb BT, Galasko D. Right sizing funding for Alzheimer's disease. Alzheimers Research & Therapy. 2011;3(3).

Golde TE, Petrucelli L, Lewis J. Targeting A beta and tau in Alzheimer's disease, an early interim report. Experimental Neurology. 2010;223(2):252-66.

Golde TE, Schneider LS, Koo EH. Anti-A beta Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift. Neuron. 2011;69(2):203-13.

Gomez-Ramos A, Dominguez J, Zafra D, Corominola H, Gomis R, Guinovart JJ, et al. Inhibition of GSK3 dependent tau phosphorylation by metals. Current Alzheimer Research. 2006;3(2):123-7.

Gong B, Vitolo OV, Trinchese F, Liu SM, Shelanski M, Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. Journal of Clinical Investigation. 2004;114(11):1624-34.

Gong CX, Liu F, Grundke-Iqbal I, Iqbal K. Post-translational modifications of tau protein in Alzheimer's disease. Journal of Neural Transmission. 2005;112(6):813-38.

Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundkeiqbal I, Iqbal K. PHOSPHATASE-ACTIVITY TOWARD ABNORMALLY PHOSPHORYLATED-TAU - DECREASE IN ALZHEIMER-DISEASE BRAIN. *Journal of Neurochemistry*. 1995;65(2):732-8.

Gong YS, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100(18):10417-22.

Goni F, Sigurdsson EM. New directions towards safer and effective vaccines for Alzheimer's disease. *Current Opinion in Molecular Therapeutics*. 2005;7(1):17-23.

Gonzalez-Martinez A, Rosado B, Pesini P, Suarez M-L, Santamarina G, Garcia-Belenguer S, et al. Plasma beta-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease. *Experimental Gerontology*. 2011;46(7):590-6.

Goodman Y, Steiner MR, Steiner SM, Mattson MP. NORDIHYDROGUAIARETIC ACID PROTECTS HIPPOCAMPAL-NEURONS AGAINST AMYLOID BETA-PEPTIDE TOXICITY, AND ATTENUATES FREE-RADICAL AND CALCIUM ACCUMULATION. *Brain Research*. 1994;654(1):171-6.

Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, Iadecola C, et al. Vascular Contributions to Cognitive Impairment and Dementia A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2011;42(9):2672-713.

Goto M, Kimura T, Hagio S, Ueda K, Kitajima SI, Tokunaga H, et al. NEUROPATHOLOGICAL ANALYSIS OF DEMENTIA IN A JAPANESE LEPROSARIUM. *Dementia*. 1995;6(3):157-61.

Gozes I, Divinski I. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. *Journal of Alzheimers Disease*. 2004;6(6):S37-S41.

Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE. Activity-dependent neurotrophic factor: Intranasal administration of femtomolar-acting peptides improve performance in a water maze. *Journal of Pharmacology and Experimental Therapeutics*. 2000;293(3):1091-8.

Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, et al. NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). *Cns Drug Reviews*. 2005;11(4):353-68.

Gozes I. NAP (Davunetide) Provides Functional and Structural Neuroprotection. *Current Pharmaceutical Design*. 2011;17(10):1040-4.

Gozes I, Divinski I, Piltzer I. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). *Bmc Neuroscience*. 2008;9.

Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: The heart and estrogen/progestin replacement study. *American Journal of Medicine*. 2002;113(7):543-8.

Graham DP, Cully JA, Snow AL, Massman P, Doody R. The Alzheimer's disease assessment scale - Cognitive subscale - Normative data for older adult controls. *Alzheimer Disease & Associated Disorders*. 2004;18(4):236-40.

Graves AB, Vanduijn CM, Chandra V, Fratiglioni L, Heyman A, Jorm AF, et al. OCCUPATIONAL EXPOSURES TO SOLVENTS AND LEAD AS RISK-FACTORS FOR ALZHEIMERS-DISEASE - A COLLABORATIVE REANALYSIS OF CASE-CONTROL STUDIES. *International Journal of Epidemiology*. 1991;20:S58-S61.

Gravius A, Laszy J, Pietraszek M, Saghy K, Nagel J, Chambon C, et al. Effects of 5-HT₆ antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity. *Behavioural Pharmacology*. 2011;22(2):122-35.

Green DR, Reed JC. Mitochondria and apoptosis. *Science*. 1998;281(5381):1309-12.

Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. *Journal of Neuroscience*. 2006;26(35):9047-56.

Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. *Journal of Neuroscience*. 2007;27(16):4385-95.

Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, et al. Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a Mechanism Involving Sirtuin Inhibition and Selective Reduction of Thr231-Phosphotau. *Journal of Neuroscience*. 2008;28(45):11500-10.

Green RC, Schneider LS, Hendrix S, Zavitz K, Swabb E. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18 month multicenter phase 3 trial Late breaking news. *European Journal of Neurology*. 2008;15:412-.

Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease A Randomized Controlled Trial. *Jama-Journal of the American Medical Association*. 2009;302(23):2557-64.

Greenamyre JT, Young AB. EXCITATORY AMINO-ACIDS AND ALZHEIMERS-DISEASE. *Neurobiology of Aging*. 1989;10(5):593-602.

Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 angstrom resolution. *Febs Letters*. 1999;463(3):321-6.

Greer MM. Inflammation and the pathophysiology of Alzheimer's disease. *Dialogues in clinical neuroscience*. 2000;2(3):233-9.

Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI. *Proceedings of the National Academy of Sciences of the United States of America*. 2004;101(13):4637-42.

Greig NH, Sambamurti K, Yu Q-s, Brossi A, Bruinsma GB, Lahiri DK. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. *Current Alzheimer Research*. 2005;2(3):281-90.

Griffiths HH, Morten IJ, Hooper NM. Emerging and potential therapies for Alzheimer's disease. *Expert Opinion on Therapeutic Targets*. 2008;12(6):693-704.

Grigor'ev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. *Bulletin of Experimental Biology and Medicine*. 2003;136(5):474-7.

Grossi C, Francese S, Casini A, Rosi MC, Luccarini I, Fiorentini A, et al. Clioquinol Decreases Amyloid-beta Burden and Reduces Working Memory Impairment in a Transgenic Mouse Model of Alzheimer's Disease. *Journal of Alzheimers Disease*. 2009;17(2):423-40.

Grote HE, Bull ND, Howard ML, van Dellen A, Blakemore C, Bartlett PF, et al. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. *European Journal of Neuroscience*. 2005;22(8):2081-8.

Grundman M, Capparelli E, Kim HT, Morris JC, Farlow M, Rubin EH, et al. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin (TM)) in mild Alzheimer's disease patients. *Life Sciences*. 2003;73(5):539-53.

Grundman M, DiBernardo A, Raghavan N, Krams M, Yuen E. 2012: A WATERSHED YEAR FOR ALZHEIMER'S DISEASE RESEARCH. *Journal of Nutrition Health & Aging*. 2013;17(1):51-3.

Gu J, Sigurdsson EM. Immunotherapy for Tauopathies. *Journal of Molecular Neuroscience*. 2011;45(3):690-5.

Guan J-S, Haggarty SJ, Giacometti E, Dannenberg J-H, Joseph N, Gao J, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. *Nature*. 2009;459(7243):55-U8.

Guentert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL, et al. Plasma Gelsolin is Decreased and Correlates with Rate of Decline in Alzheimer's Disease. *Journal of Alzheimers Disease*. 2010;21(2):585-96.

Gunasingh MJ, Philip JE, Ashok BS, Kirubakaran R, Jebaraj WCE, Davis GDJ, et al. Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogenic amine catabolism. *Life Sciences*. 2008;83(3-4):96-102.

Guo JT, Yu J, Grass D, de Beer FC, Kindy MS. Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. *Journal of Neuroscience*. 2002;22(14):5900-9.

Guo J-P, Yu S, McGeer PL. Simple In Vitro Assays to Identify Amyloid-beta Aggregation Blockers for Alzheimer's Disease Therapy. *Journal of Alzheimers Disease*. 2010;19(4):1359-70.

Gupta A, Pansari K. Inflammation and Alzheimer's disease. *International Journal of Clinical Practice*. 2003;57(1):36-9.

Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. *Neuropharmacology*. 2011;60(6):910-20.

Gura T. Hope in Alzheimer's fight emerges from unexpected places. *Nature Medicine*. 2008;14(9):894-.

Guse B, Falkai P, Wobrock T. Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: a systematic review. *Journal of Neural Transmission*. 2010;117(1):105-22.

Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. *Journal of Neural Transmission-Supplement*. 1998(54):301-10.

Guzior N, Wieckowska A, Panek D, Malawska B. Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer's Disease. *Current Medicinal Chemistry*. 2015;22(3):373-404.

Ha GT, Wong RK, Zhang Y. Huperzine A as Potential Treatment of Alzheimer's Disease: An Assessment on Chemistry, Pharmacology, and Clinical Studies. *Chemistry & Biodiversity*. 2011;8(7):1189-204.

Haag MDM, Hofman A, Koudstaal PJ, Stricker BHC, Breteler MMB. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. *Journal of Neurology Neurosurgery and Psychiatry*. 2009;80(1):13-7.

Haan MN, Wallace R. Can dementia be prevented? Brain aging in a population-based context. *Annual Review of Public Health*. 2004;25:1-24.

Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nature Reviews Molecular Cell Biology*. 2007;8(2):101-12.

Hager K, Kenklies M, McAfoose J, Engel J, Muench G. alpha-Lipoic acid as a new treatment option for Alzheimer's disease - a 48 months follow-up analysis. *Journal of Neural Transmission-Supplement*. 2007(72):189-93.

Haik S, Brandel JP, Salomon D, Sazdovitch V, Delasnerie-Laupretre N, Laplanche JL, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. *Neurology*. 2004;63(12):2413-5.

Hajjar I, Brown L, Mack WJ, Chui H. Impact of Angiotensin Receptor Blockers on Alzheimer Disease Neuropathology in a Large Brain Autopsy Series. *Archives of Neurology*. 2012;69(12):1632-8.

Hamano T, Yen S-H, Gendron T, Ko L-w, Kuriyama M. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. *Neurobiology of Aging*. 2012;33(10):2306-20.

Hamon M, Doucet E, Lefevre K, Miquel MC, Lanfumey L, Insausti R, et al. Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT₆ receptors. *Neuropsychopharmacology*. 1999;21(2):S68-S76.

Hampel H, Buerger K, Teipel SJ, Bokde ALW, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. *Alzheimers & Dementia*. 2008;4(1):38-48.

Hampel H, Ewers M, Buerger K, Annas P, Moertberg A, Bogstedt A, et al. Lithium Trial in Alzheimer's Disease: A Randomized, Single-Blind, Placebo-Controlled, Multicenter 10-Week Study. *Journal of Clinical Psychiatry*. 2009;70(6):922-31.

Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. *Nature Reviews Drug Discovery*. 2010;9(7):560-74.

Hampel H, Lista S, Khachaturian ZS. Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot. *Alzheimers & Dementia*. 2012;8(4):312-36.

Hampson RE, Rogers G, Lynch G, Deadwyler SA. Facilitative effects of the ampakine CX516 on short-term memory in rats: Enhancement of delayed-nonmatch-to-sample performance. *Journal of Neuroscience*. 1998;18(7):2740-7.

Hansen RA, Gartlehner G, Lohr KN, Kaufer DI. Functional outcomes of drug treatment in Alzheimer's disease - A systematic review and meta-analysis. *Drugs & Aging*. 2007;24(2):155-67.

Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. *Clinical Interventions in Aging*. 2008;3(2):211-25.

Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, et al. Evaluation of plasma A beta(40) and A beta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. *Neurobiology of Aging*. 2010;31(3):357-67.

Hanyu H, Hirao K, Shimizu S, Sato T, Kiuchi A, Iwamoto T. Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. *International Journal of Geriatric Psychiatry*. 2007;22(12):1264-6.

Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. *Journal of the American Geriatrics Society*. 2009;57(1):177-9.

Hanyu H, Sato T, Sakurai H, Iwamoto T. THE ROLE OF TUMOR NECROSIS FACTOR-ALPHA IN COGNITIVE IMPROVEMENT AFTER PEROXISOME PROLIFERATOR-ACTIVATOR RECEPTOR GAMMA AGONIST PIOGLITAZONE TREATMENT IN ALZHEIMER'S DISEASE. *Journal of the American Geriatrics Society*. 2010;58(5):1000-1.

Harder JA, Maclean CJ, Alder JT, Francis PT, Ridley RM. The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. *Psychopharmacology*. 1996;127(3):245-54.

Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. *Nature Reviews Neuroscience*. 2010;11(10):682-96.

Hardy JA, Higgins GA. ALZHEIMERS-DISEASE - THE AMYLOID CASCADE HYPOTHESIS. *Science*. 1992;256(5054):184-5.

Hardy J, Allsop D. AMYLOID DEPOSITION AS THE CENTRAL EVENT IN THE ETIOLOGY OF ALZHEIMERS-DISEASE. *Trends in Pharmacological Sciences*. 1991;12(10):383-8.

Hardy J, Selkoe DJ. Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science*. 2002;297(5580):353-6.

Hardy J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? *Current Alzheimer Research*. 2006;3(1):71-3.

Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. *Journal of Neurochemistry*. 2009;110(4):1129-34.

Harikumar KB, Aggarwal BB. Resveratrol - A multitargeted agent for age-associated chronic diseases. *Cell Cycle*. 2008;7(8):1020-35.

Harkany T, Abraham I, Timmerman W, Laskay G, Toth B, Sasvari M, et al. beta-Amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. *European Journal of Neuroscience*. 2000;12(8):2735-45.

Harmeier A, Wozny C, Rost BR, Munter L-M, Hua H, Georgiev O, et al. Role of Amyloid-beta Glycine 33 in Oligomerization, Toxicity, and Neuronal Plasticity. *Journal of Neuroscience*. 2009;29(23):7582-90.

Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, et al. Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimer's Disease: Two Phase 3 Studies. *Current Alzheimer Research*. 2011;8(5):592-606.

Harris ME, Hensley K, Butterfield DA, Leedle RA, Carney JM. DIRECT EVIDENCE OF OXIDATIVE INJURY PRODUCED BY THE ALZHEIMERS BETA-AMYLOID PEPTIDE (1-40) IN CULTURED HIPPOCAMPAL-NEURONS. *Experimental Neurology*. 1995;131(2):193-202.

Harrison J, Psychol C, Minassian SL, Jenkins L, Black RS, Koller M, et al. A neuropsychological test battery for use in Alzheimer disease clinical trials. *Archives of Neurology*. 2007;64(9):1323-9.

Harrison SM, Harper AJ, Hawkins J, Duddy G, Grau E, Pugh PL, et al. BACE1 (beta-secretase) transgenic neurochemical deficits and knockout mice: identification of and behavioral changes. *Molecular and Cellular Neuroscience*. 2003;24(3):646-55.

Harry RDJ, Zakzanis KK. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. *Human Psychopharmacology-Clinical and Experimental*. 2005;20(3):183-7.

Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. *Journal of Neuroscience*. 2005;25(26):6213-20.

Hartmann D, Tournoy J, Saftig P, Annaert W, De Strooper B. Implication of APP secretases in notch signaling. *Journal of Molecular Neuroscience*. 2001;17(2):171-81.

Hartmann S, Mobius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. *International Clinical Psychopharmacology*. 2003;18(2):81-5.

Hartsel SC, Weiland TR. Amphotericin B binds to amyloid fibrils and delays their formation: A therapeutic mechanism? *Biochemistry*. 2003;42(20):6228-33.

Hashimoto K. Can Minocycline Prevent the Onset of Alzheimer's Disease? *Annals of Neurology*. 2011;69(4):739-.

Hashimoto M, Bogdanovic N, Volkmann I, Aoki M, Winblad B, Tjernberg LO. Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of A beta 42 and Alzheimer's disease neuropathology. *Acta Neuropathologica*. 2010;119(5):543-54.

Hashimoto Y, Kaneko Y, Tsukamoto E, Frankowski H, Kouyama K, Kita Y, et al. Molecular characterization of neurohybrid cell death induced by Alzheimer's amyloid-beta peptides via p75NTR/PLAIDD. *Journal of Neurochemistry*. 2004;90(3):549-58.

Hashioka S, Klegeris A, McGeer PL. Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. *Neuropharmacology*. 2012;63(4):685-91.

Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Paulson OB, et al. Reduced 5-HT_{2A} receptor binding in patients with mild cognitive impairment. *Neurobiology of Aging*. 2008;29(12):1830-8.

Hatcher H, Planalp R, Cho J, Tortia FM, Torti SV. Curcumin: From ancient medicine to current clinical trials. *Cellular and Molecular Life Sciences*. 2008;65(11):1631-52.

Hauptmann S, Scherping I, Droese S, Brandt U, Schulz KL, Jendrach M, et al. Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. *Neurobiology of Aging*. 2009;30(10):1574-86.

Hayashi T, Shishido N, Nakayama K, Nunomura A, Smith MA, Perry G, et al. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. *Free Radical Biology and Medicine*. 2007;43(11):1552-9.

Haydar SN, Ghiron C, Bettinetti L, Bothmann H, Comery TA, Dunlop J, et al. SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist. *Bioorganic & Medicinal Chemistry*. 2009;17(14):5247-58.

Hayden KM, Zandi PP, Khachaturian AS, Szekely CA, Fotuhi M, Norton MC, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache county study. *Neurology*. 2007;69(3):275-82.

He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. *Nature*. 2010;467(7311):95-U129.

He P, Ouyang X, Zhou S, Yin W, Tang C, Laudon M, et al. A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease. *Hormones and Behavior*. 2013;64(1):1-7.

He P, Cheng X, Staufenbiel M, Li R, Shen Y. Long-Term Treatment of Thalidomide Ameliorates Amyloid-Like Pathology through Inhibition of beta-Secretase in a Mouse Model of Alzheimer's Disease. *Plos One*. 2013;8(2).

Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, et al. A two-year study with fibrillar beta-amyloid (A beta) immunization in aged canines: Effects on cognitive function and brain A beta. *Journal of Neuroscience*. 2008;28(14):3555-66.

Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population - Prevalence estimates using the 2000 census. *Archives of Neurology*. 2003;60(8):1119-22.

Hedlund PB, Sutcliffe JG. Functional, molecular and pharmacological advances in 5-HT7 receptor research. *Trends in Pharmacological Sciences*. 2004;25(9):481-6.

Hegde ML, Anitha S, Latha KS, Mustak MS, Stein R, Ravid R, et al. First evidence for helical transitions in supercoiled DNA by amyloid beta peptide (1-42) and aluminum - A new insight in understanding Alzheimer's disease. *Journal of Molecular Neuroscience*. 2004;22(1-2):19-31.

Hegde ML, Bharathi P, Suram A, Venugopal C, Jagannathan R, Poddar P, et al. Challenges Associated with Metal Chelation Therapy in Alzheimer's Disease. *Journal of Alzheimers Disease*. 2009;17(3):457-68.

Heinrich JN, Butera JA, Carrick T, Kramer A, Kowal D, Lock T, et al. Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M(1)-preferring receptor agonists. *European Journal of Pharmacology*. 2009;605(1-3):53-6.

Hellstrom-Lindahl E, Court J, Keverne J, Svedberg M, Lee M, Marutle A, et al. Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. *European Journal of Neuroscience*. 2004;19(10):2703-10.

Hellstrom-Lindahl E, Moore H, Nordberg Y. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. *Journal of Neurochemistry*. 2000;74(2):777-84.

Hellweg R, Ziegenhorn A, Heuser I, Deuschle M. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. *Pharmacopsychiatry*. 2008;41(2):66-71.

Hellweg R, Wirth Y, Janetzky W, Hartmann S. Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD. *International Journal of Geriatric Psychiatry*. 2012;27(6):651-6.

Hemming ML, Selkoe DJ, Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. *Neurobiology of Disease*. 2007;26(1):273-81.

Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. *Nutrition & Metabolism*. 2009;6.

Henderson VW. Estrogen-containing hormone therapy and Alzheimer's disease risk: Understanding discrepant inferences from observational and experimental research. *Neuroscience*. 2006;138(3):1031-9.

Hendrix SB, Wilcock GK. What we have learned from the myriad trials. *Journal of Nutrition Health & Aging*. 2009;13(4):362-4.

Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, et al. Acute treatment with the PPAR gamma agonist pioglitazone and ibuprofen reduces glial inflammation and A beta 1-42 levels in APPV717I transgenic mice. *Brain*. 2005;128:1442-53.

Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. *Expert Opinion on Pharmacotherapy*. 2009;10(10):1657-64.

Henriksen K, Christiansen C, Karsdal MA. Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioning. *Drug Discovery Today*. 2011;16(21-22):967-75.

Hermann D, Mezler M, Mueller MK, Wicke K, Gross G, Draguhn A, et al. Synthetic A beta oligomers (A beta(1-42) globulomer) modulate presynaptic calcium currents: Prevention of A beta-induced synaptic deficits by calcium channel blockers. *European Journal of Pharmacology*. 2013;702(1-3):44-55.

Hernandez CM, Dineley KT. α 7 Nicotinic Acetylcholine Receptors in Alzheimer's Disease: Neuroprotective, Neurotrophic or Both? *Current Drug Targets*. 2012;13(5):613-22.

Herrmann N. Trials and tribulations of evidence-based medicine: The case of Alzheimer disease therapeutics. *Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie*. 2007;52(10):617-9.

Herrmann N, Lanctot KL, Rothenburg LS, Eryavec G. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*. 2007;23(2):116-9.

Herrmann N, Lanctot KL, Sambrook R, Lesnikova N, Hebert R, McCracken P, et al. The contribution of neuropsychiatric symptoms to the cost of dementia care. *International Journal of Geriatric Psychiatry*. 2006;21(10):972-6.

Herrmann N, Li A, Lanctot K. Memantine in dementia: a review of the current evidence. *Expert Opinion on Pharmacotherapy*. 2011;12(5):787-800.

Hibberd C, Yau JLW, Seckl JR. Glucocorticoids and the ageing hippocampus. *Journal of Anatomy*. 2000;197:553-62.

Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. *Journal of Neuroscience*. 2008;28(33):8354-60.

Hicks DA, Nalivaeva NN, Turner AJ. Lipid rafts and Alzheimer's disease: protein-lipid interactions and perturbation of signaling. *Frontiers in Physiology*. 2012;3.

Hiller KO, Asmus KD. TL2+ AND AG2+ METAL-ION-INDUCED OXIDATION OF METHIONINE IN AQUEOUS-SOLUTION - A PULSE-RADIOLYSIS STUDY. *International Journal of Radiation Biology*. 1981;40(6):597-604.

Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, et al. Apomorphine Treatment in Alzheimer Mice Promoting Amyloid-beta Degradation. *Annals of Neurology*. 2011;69(2):248-56.

Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. *British Medical Journal*. 2010;340.

Hiramatsu M, Takiguchi O, Nishiyama A, Mori H. Cilostazol prevents amyloid beta peptide(25-35)-induced memory impairment and oxidative stress in mice. *British Journal of Pharmacology*. 2010;161(8):1899-912.

Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, et al. SB-399885 is a potent, selective 5-HT₆ receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. *European Journal of Pharmacology*. 2006;553(1-3):109-19.

Ho L, Chen LH, Wang J, Zhao W, Talcott ST, Ono K, et al. Heterogeneity in Red Wine Polyphenolic Contents Differentially Influences Alzheimer's Disease-type Neuropathology and Cognitive Deterioration. *Journal of Alzheimers Disease*. 2009;16(1):59-72.

Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. *Nature Medicine*. 2002;8(11):1270-5.

Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. *Neuron*. 2003;38(4):547-54.

Hock C, Maddalena A, Raschig A, Muller-Spahn F, Eschweiler G, Hager K, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta(42) in patients with Alzheimer's disease. *Amyloid-Journal of Protein Folding Disorders*. 2003;10(1):1-6.

Hock C, Nitsch RM. Clinical Observations with AN-1792 Using TAPIR Analyses. *Neurodegenerative Diseases*. 2005;2(5):273-6.

Hogan DB, Goldlist B, Naglie G, Patterson C. Comparison studies of cholinesterase inhibitors for Alzheimer's disease. *Lancet Neurology*. 2004;3(10):622-6.

Hogan DB, Patterson C. Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias - Review and comparison of the cholinesterase inhibitors. *Canadian Journal of Neurological Sciences*. 2002;29(4):306-14.

Hogan DB, Bailey P, Carswell A, Clarke B, Cohen C, Forbes D, et al. Management of mild to moderate Alzheimer's disease and dementia. *Alzheimers & Dementia*. 2007;3(4):355-84.

Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: A meta-analysis. *Neuroscience*. 2000;101(3):485-512.

Hoglund K, Thelen KM, Syversen S, Sjogren M, von Bergmann K, Wallin A, et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*. 2005;19(5-6):256-65.

Hoglund K, Blennow K. Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels - Implications for Alzheimer's disease. *Cns Drugs*. 2007;21(6):449-62.

Holland D, McEvoy LK, Desikan RS, Dale AM, Alzheimer's Dis N. Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials. *Plos One*. 2012;7(10).

Holmes C, Burns A, Passmore P, Forsyth D, Wilkinson D. AD2000: design and conclusions. *Lancet*. 2004;364(9441):1213-4.

Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. *Neurology*. 2004;63(2):214-9.

Holmes C. Intravenous immunoglobulin for Alzheimer's disease. *Lancet Neurology*. 2013;12(3):218-9.

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of A beta(42) immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. *Lancet*. 2008;372(9634):216-23.

Holmes C, Cotterell D. Role of Infection in the Pathogenesis of Alzheimer's Disease Implications for Treatment. *Cns Drugs*. 2009;23(12):993-1002.

Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. *Pharmacology & Therapeutics*. 2007;113(1):154-64.

Holsinger RMD, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. *Annals of Neurology*. 2002;51(6):783-6.

Hong M, Chen DCR, Klein PS, Lee VMY. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. *Journal of Biological Chemistry*. 1997;272(40):25326-32.

Hongpaisan J, Sun M-K, Alkon DL. PKC epsilon Activation Prevents Synaptic Loss, A beta Elevation, and Cognitive Deficits in Alzheimer's Disease Transgenic Mice. *Journal of Neuroscience*. 2011;31(2):630-43.

Hoogendam JM, Ramakers GMJ, Di Lazzaro V. Physiology of repetitive transcranial magnetic stimulation of the human brain. *Brain Stimulation*. 2010;3(2):95-118.

Hoozemans JJM, Veerhuis R, Janssen I, Rozemuller AJM, Eikelenboom P. Interleukin-1 beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. *Experimental Gerontology*. 2001;36(3):559-70.

Hoozemans JJM, Veerhuis R, Janssen I, van Elk EJ, Rozemuller AJM, Eikelenboom P. The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E-2 secretion by cultured human adult microglia: Implications for Alzheimer's disease. *Brain Research*. 2002;951(2):218-26.

Hoozemans JJM, Veerhuis R, Rozemuller JM, Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. *International Journal of Developmental Neuroscience*. 2006;24(2-3):157-65.

Hopkins AL. Network pharmacology: the next paradigm in drug discovery. *Nature Chemical Biology*. 2008;4(11):682-90.

Hopkins CR. ACS Chemical Neuroscience Molecule Spotlight on ELND006: Another gamma-Secretase Inhibitor Fails in the Clinic. *Acs Chemical Neuroscience*. 2011;2(6):279-80.

Hopkins TJ, Rupprecht LE, Hayes MR, Blendy JA, Schmidt HD. Galantamine, an Acetylcholinesterase Inhibitor and Positive Allosteric Modulator of Nicotinic Acetylcholine Receptors, Attenuates Nicotine Taking and Seeking in Rats. *Neuropsychopharmacology*. 2012;37(10):2310-21.

Horsdal HT, Olesen AV, Gasse C, Sorensen HT, Green RC, Johnsen SP. Use of Statins and Risk of Hospitalization With Dementia A Danish Population-based Case-control Study. *Alzheimer Disease & Associated Disorders*. 2009;23(1):18-22.

Howard RJ, Juszcak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al. Donepezil for the treatment of agitation in Alzheimer's disease. *New England Journal of Medicine*. 2007;357(14):1382-92.

Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. *New England Journal of Medicine*. 2012;366(10):893-903.

Howe I. AD2000: design and conclusions. *Lancet*. 2004;364(9441):1214-5.

Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice. *Science*. 1996;274(5284):99-102.

Hu J-P, Xie J-W, Wang C-Y, Wang T, Wang X, Wang S-L, et al. Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways. *Brain Research Bulletin*. 2011;85(3-4):194-200.

Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, et al. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. *Neurobiology of Disease*. 2009;33(2):193-206.

Hu X, He W, Diaconu C, Tang X, Kidd GJ, Macklin WB, et al. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. *Faseb Journal*. 2008;22(8):2970-80.

Huang EJ, Reichardt LF. Neurotrophins: Roles in neuronal development and function. *Annual Review of Neuroscience*. 2001;24:677-736.

Huang H-J, Chen Y-H, Liang K-C, Jheng Y-S, Jhao J-J, Su M-T, et al. Exendin-4 Protected against Cognitive Dysfunction in Hyperglycemic Mice Receiving an Intrahippocampal Lipopolysaccharide Injection. *Plos One*. 2012;7(7).

Huang H-C, Klein PS. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease. *Current Drug Targets*. 2006;7(11):1389-97.

Huang L, Su T, Shan W, Luo Z, Sun Y, He F, et al. Inhibition of cholinesterase activity and amyloid aggregation by berberine-phenyl-benzoheterocyclic and tacrine-phenyl-benzoheterocyclic hybrids. *Bioorganic & Medicinal Chemistry*. 2012;20(9):3038-48.

Huang XD, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. *Biochemistry*. 1999;38(24):7609-16.

Huang XD, Atwood CS, Moir RD, Hartshorn MA, Vonsattel JP, Tanzi RE, et al. Zinc-induced Alzheimer's A beta 1-40 aggregation is mediated by conformational factors. *Journal of Biological Chemistry*. 1997;272(42):26464-70.

Huang XD, Cuajungco MP, Atwood CS, Moir RD, Tanzi RE, Bush AI. Alzheimer's disease, beta-amyloid protein and zinc. *Journal of Nutrition*. 2000;130(5):1488S-92S.

Huang YD. Apolipoprotein E and Alzheimer disease. *Neurology*. 2006;66:S79-S85.

Hughes A, Musher J, Thomas SK, Beusterien KM, Strunk B, Arcona S. Gastrointestinal adverse events in a general population sample of nursing home residents taking cholinesterase inhibitors. *The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists*. 2004;19(8):713-20.

Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman RJ, et al. ACTIVATION OF PROTEIN-KINASE-C INHIBITS CELLULAR PRODUCTION OF THE AMYLOID BETA-PROTEIN. *Journal of Biological Chemistry*. 1993;268(31):22959-62.

Hung CH-L, Ho Y-S, Chang RC-C. Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease. *Ageing Research Reviews*. 2010;9(4):447-56.

Hunter K, Hoelscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. *Bmc Neuroscience*. 2012;13.

Hussain I, Powell D, Howlett DR, Tew DG, Week TD, Chapman C, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. *Molecular and Cellular Neuroscience*. 1999;14(6):419-27.

Hussain I, Fabregue J, Anderes L, Ousson S, Borlat F, Eligert V, et al. The Role of gamma-Secretase Activating Protein (GSAP) and Imatinib in the Regulation of gamma-Secretase Activity and Amyloid-beta Generation. *Journal of Biological Chemistry*. 2013;288(4):2521-31.

Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. *Journal of Neurochemistry*. 2007;100(3):802-9.

Hyman BT. Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease. *Archives of Neurology*. 2011;68(8):1062-4.

Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. *Neurochemistry International*. 2004;45(5):583-95.

Iadecola C. Cerebrovascular effects of amyloid-beta peptides: Mechanisms and implications for Alzheimer's dementia. *Cellular and Molecular Neurobiology*. 2003;23(4-5):681-9.

Ibach B, Haen E, Marienhagen J, Hajak G. Clioquinol treatment in familial early onset of Alzheimer's disease. *Pharmacopsychiatry*. 2005;38(4):178-.

Ikonomovic MD, Wecker L, Abrahamson EE, Wu J, Counts SE, Ginsberg SD, et al. Cortical alpha 7 Nicotinic Acetylcholine Receptor and beta-Amyloid Levels in Early Alzheimer Disease. *Archives of Neurology*. 2009;66(5):646-51.

Illenberger S, Zheng-Fischhofer QY, Preuss U, Stamer K, Baumann K, Trinczek B, et al. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: Implications for Alzheimer's disease. *Molecular Biology of the Cell*. 1998;9(6):1495-512.

Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, et al. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. *British Journal of Pharmacology*. 2009;156(6):982-93.

Imbimbo BP, Martelli P, Troetel WM, Lucchelli F, Lucca U, Thal LJ, et al. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. *Neurology*. 1999;52(4):700-8.

Imbimbo BP, Troetel WM, Martelli P, Lucchelli F, Eptastigmine Study G. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*. 2000;11(1):17-24.

Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. *Current Topics in Medicinal Chemistry*. 2008;8(1):54-61.

Imbimbo BP. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. *Expert Opinion on Investigational Drugs*. 2009;18(8):1147-68.

Imbimbo BP. Why Did Tarenflurbil Fail in Alzheimer's Disease? *Journal of Alzheimers Disease*. 2009;17(4):757-60.

Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, Logroscino G, et al. Therapeutic intervention for Alzheimer's disease with gamma gamma-secretase inhibitors: still a viable option? *Expert Opinion on Investigational Drugs*. 2011;20(3):325-41.

Imbimbo BP, Peretto I. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease. *Current Opinion in Investigational Drugs*. 2009;10(7):721-30.

Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? *Frontiers in Aging Neuroscience*. 2010;2.

in 't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. *New England Journal of Medicine*. 2001;345(21):1515-21.

Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, et al. Early A beta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. *Neurology*. 2004;62(6):925-31.

Innocent N, Cousins SL, Stephenson FA. NMDA receptor/amyloid precursor protein interactions: A comparison between wild-type and amyloid precursor protein mutations associated with familial Alzheimer's disease. *Neuroscience Letters*. 2012;515(2):131-6.

Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(33):14621-6.

Iqbal K, Alonso AD, El-Akkad E, Gong CX, Haque N, Khatoon S, et al. Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. *Journal of Molecular Neuroscience*. 2002;19(1-2):95-9.

Iqbal K, Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. *Journal of Cellular and Molecular Medicine*. 2008;12(1):38-55.

Iqbal K, Grundke-Iqbal I. Pharmacological approaches of neurofibrillary degeneration. *Current Alzheimer Research*. 2005;2(3):335-41.

Iqbal K, Grundke-Iqbal I. Discoveries of Tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: A personal historical perspective. *Journal of Alzheimers Disease*. 2006;9:219-42.

Irwin JA, Wong HE, Kwon I. Different Fates of Alzheimer's Disease Amyloid-beta Fibrils Remodeled by Biocompatible Small Molecules. *Biomacromolecules*. 2013;14(1):264-74.

Ittner LM, Goetz J. Amyloid-beta and tau - a toxic pas de deux in Alzheimer's disease. *Nature Reviews Neuroscience*. 2011;12(2):67-72.

Iuvone T, De Filippis D, Esposito G, D'Amico A, Izzo AA. The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-beta peptide-induced neurotoxicity. *Journal of Pharmacology and Experimental Therapeutics*. 2006;317(3):1143-9.

Ivachtchenko AV, Ivanenkov YA, Tkachenko SE. 5-hydroxytryptamine subtype 6 receptor modulators: a patent survey. *Expert Opinion on Therapeutic Patents*. 2010;20(9):1171-96.

Iwata N, Higuchi M, Saido TC. Metabolism of amyloid-beta peptide and Alzheimer's disease. *Pharmacology & Therapeutics*. 2005;108(2):129-48.

Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. *Journal of Neuroscience*. 2004;24(4):991-8.

Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major A beta(1-42)-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. *Nature Medicine*. 2000;6(2):143-50.

Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. VISUALIZATION OF A-BETA-42(43) AND A-BETA-40 IN SENILE PLAQUES WITH END-SPECIFIC A-BETA MONOCLONALS - EVIDENCE THAT AN INITIALLY DEPOSITED SPECIES IS A-BETA-42(43). *Neuron*. 1994;13(1):45-53.

Jack CR, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. *Neurology*. 2000;55(4):484-9.

Jack CR, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. *Neurology*. 2003;60(2):253-60.

Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurology*. 2013;12(2):207-16.

Jack CR, Jr., Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. *Brain*. 2009;132:1355-65.

Jack CR, Jr., Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. *Neurobiology of Aging*. 2008;29(9):1285-95.

Jacobsen JS, Comery TA, Martone RL, Elokda H, Crandall DL, Oganessian A, et al. Enhanced clearance of A beta in brain by sustaining the plasmin proteolysis cascade. *Proceedings of the National Academy of Sciences of the United States of America*. 2008;105(25):8754-9.

Jacobsen JS, Reinhart P, Pangalos MN. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. *NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics*. 2005;2(4):612-26.

Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. *Nature Cell Biology*. 2001;3(2):193-7.

Jan A, Adolfsson O, Allaman I, Buccarello A-L, Magistretti PJ, Pfeifer A, et al. A beta 42 Neurotoxicity Is Mediated by Ongoing Nucleated Polymerization Process Rather than by Discrete A beta 42 Species. *Journal of Biological Chemistry*. 2011;286(10):8585-96.

Jang S-W, Liu X, Chan C-B, Weinshenker D, Hall RA, Xiao G, et al. Amitriptyline is a TrkA and TrkB Receptor Agonist that Promotes TrkA/TrkB Heterodimerization and Has Potent Neurotrophic Activity. *Chemistry & Biology*. 2009;16(6):644-56.

Jansen KLR, Faull RLM, Dragunow M, Synek BL. ALZHEIMERS-DISEASE - CHANGES IN HIPPOCAMPAL N-METHYL-D-ASPARTATE, QUISQUALATE, NEUROTENSIN, ADENOSINE, BENZODIAZEPINE, SEROTONIN AND OPIOID RECEPTORS - AN AUTORADIOGRAPHIC STUDY. *Neuroscience*. 1990;39(3):613-27.

Janssen IM, Sturtz S, Skipka G, Zentner A, Velasco Garrido M, Busse R. Ginkgo biloba in Alzheimer's disease: a systematic review. *Wiener medizinische Wochenschrift (1946)*. 2010;160(21-22):539-46.

Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. *Journal of Neuroscience*. 2002;22(6):2246-54.

Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. *Nature*. 2000;408(6815):979-82.

Janusz M, Zablocka A. Colostral Proline-Rich Polypeptides - Immunoregulatory Properties and Prospects of Therapeutic Use in Alzheimer's Disease. *Current Alzheimer Research*. 2010;7(4):323-33.

Janusz M, Woszczyna M, Lisowski M, Kubis A, Macala J, Gotszalk T, et al. Ovine colostrum nanopепptide affects amyloid beta aggregation. *Febs Letters*. 2009;583(1):190-6.

Javed H, Khan MM, Ahmad A, Vaibhav K, Ahmad ME, Khan A, et al. RUTIN PREVENTS COGNITIVE IMPAIRMENTS BY AMELIORATING OXIDATIVE STRESS AND NEUROINFLAMMATION IN RAT MODEL OF SPORADIC DEMENTIA OF ALZHEIMER TYPE. *Neuroscience*. 2012;210:340-52.

Javier Ramirez M. 5-HT₆ receptors and Alzheimer's disease. *Alzheimers Research & Therapy*. 2013;5(2).

Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. *Journal of Neurology Neurosurgery and Psychiatry*. 2006;77(4):429-38.

Jenagaratnam L, McShane R. Clioquinol for the treatment of Alzheimer's disease. *Cochrane Database of Systematic Reviews*. 2006(1).

Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. *Neurology*. 2004;63(7):S13-S22.

Jeppsson F, Eketjall S, Janson J, Karlstrom S, Gustavsson S, Olsson L-L, et al. Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease. *Journal of Biological Chemistry*. 2012;287(49):41245-57.

Jessen F, Traeber F, Freymann K, Maier W, Schild HH, Block W. Treatment monitoring and response prediction with proton MR spectroscopy in AD. *Neurology*. 2006;67(3):528-30.

Jia J-y, Zhao Q-h, Liu Y, Gui Y-z, Liu G-y, Zhu D-y, et al. Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease. *Acta Pharmacologica Sinica*. 2013;34(7):976-82.

Jia Q, Deng Y, Qing H. Potential Therapeutic Strategies for Alzheimer's Disease Targeting or Beyond. beta-Amyloid: Insights from Clinical Trials. *Biomed Research International*. 2014.

Jiang L-h, Zhang Y-n, Wu X-w, Song F-f, Guo D-y. Effect of insulin on the cognizing function and expression of hippocampal A beta(1-40) of rat with Alzheimer disease. *Chinese Medical Journal*. 2008;121(9):827-31.

Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-gamma (PPAR gamma) in Alzheimer's disease. *Cns Drugs*. 2008;22(1):1-14.

Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoE promotes the proteolytic degradation of A beta. *Neuron*. 2008;58(5):681-93.

Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. *Archives of Neurology*. 2006;63(5):674-81.

Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. *Lancet*. 2000;356(9242):1627-31.

Jinwal UK, Miyata Y, Koren J, III, Jones JR, Trotter JH, Chang L, et al. Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability. *Journal of Neuroscience*. 2009;29(39):12079-88.

Joffres C, Graham J, Rockwood K. Qualitative analysis of the Clinician Interview-Based Impression of Change (Plus): Methodological issues and implications for clinical research. *International Psychogeriatrics*. 2000;12(3):403-13.

John V, Beck JP, Bienkowski MJ, Sinha S, Heinrikson RL. Human beta-secretase (BACE) and BACE inhibitors. *Journal of Medicinal Chemistry*. 2003;46(22):4625-30.

Jones DP. Extracellular redox state: Refining the definition of oxidative stress in aging. *Rejuvenation Research*. 2006;9(2):169-81.

Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. *International Journal of Geriatric Psychiatry*. 2010;25(6):547-53.

Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. *International Journal of Geriatric Psychiatry*. 2004;19(1):58-67.

Jones RW. Dimebon disappointment. *Alzheimers Research & Therapy*. 2010;2(5).

Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, et al. The atorvastatin/donepezil in Alzheimer's disease study (LEADe): Design and baseline characteristics. *Alzheimers & Dementia*. 2008;4(2):145-53.

Jonhagen ME. Nerve growth factor treatment in dementia. *Alzheimer Disease & Associated Disorders*. 2000;14:S31-S8.

Jonhagen ME, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*. 1998;9(5):246-57.

Joseph JA, Denisova NA, Arendash G, Gordon M, Diamond D, Shukitt-Hale B, et al. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. *Nutritional Neuroscience*. 2003;6(3):153-62.

Jost BC, Grossberg GT. THE NATURAL-HISTORY OF ALZHEIMERS-DISEASE - A BRAIN BANK STUDY. *Journal of the American Geriatrics Society*. 1995;43(11):1248-55.

Julio Rodriguez J, Noristani HN, Verkhatsky A. The serotonergic system in ageing and Alzheimer's disease. *Progress in Neurobiology*. 2012;99(1):15-41.

Justin Thenmozhi A, William Raja TR, Manivasagam T, Janakiraman U, Essa MM. Hesperidin ameliorates cognitive dysfunction, oxidative stress and apoptosis against aluminium chloride induced rat model of Alzheimer's disease. *Nutritional neuroscience*. 2017;20(6):360-8.

Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A. PET imaging of cortical C-11-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. *Psychopharmacology*. 2006;188(4):509-20.

Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. *Annals of Neurology*. 2008;63(5):621-31.

Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. *British Medical Journal*. 2005;331(7512):321-3.

Kaether C, Haass C, Steiner H. Assembly, trafficking and function of gamma-secretase. *Neurodegenerative Diseases*. 2006;3(4-5):275-83.

Kakuda N, Akazawa K, Hatsuta H, Murayama S, Ihara Y, Japanese Alzheimer's Dis N. Suspected limited efficacy of gamma-secretase modulators. *Neurobiology of Aging*. 2013;34(4):1101-4.

Kakuda N, Shoji M, Arai H, Furukawa K, Ikeuchi T, Akazawa K, et al. Altered γ -secretase activity in mild cognitive impairment and Alzheimer's disease. *Embo Molecular Medicine*. 2012;4(4):344-52.

Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. *Lancet Neurology*. 2008;7(9):812-26.

Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. *American Journal of Psychiatry*. 2007;164(10):1568-76.

Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio R, et al. Trends in Antipsychotic Use in Dementia 1999-2007. *Archives of General Psychiatry*. 2011;68(2):190-7.

Kalmijn S, Launer LJ, Ott A, Witteman JCM, Hofman A, Breteler MMB. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. *Annals of Neurology*. 1997;42(5):776-82.

Kalmijn S, van Boxtel MPJ, Ocke M, Verschuren WMM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. *Neurology*. 2004;62(2):275-80.

Kamal MA, Al-Jafari AA, Yu QS, Greig NH. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. *Biochimica Et Biophysica Acta-General Subjects*. 2006;1760(2):200-6.

Kamal MA, Klein P, Yu Q-s, Tweedie D, Li Y, Holloway HW, et al. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. *Journal of Alzheimers Disease*. 2006;10(1):43-51.

Kamath AF, Chauhan AK, Kisucka J, Dole VS, Loscalzo J, Handy DE, et al. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. *Blood*. 2006;107(2):591-3.

Kambe T, Yamaguchi-Iwai Y, Sasaki R, Nagao M. Overview of mammalian zinc transporters. *Cellular and Molecular Life Sciences*. 2004;61(1):49-68.

Kang HJ, Yoon WJ, Moon GJ, Kim DY, Sohn S, Kwon HJ, et al. Caspase-3-mediated cleavage of PHF-1 tau during apoptosis irrespective of excitotoxicity and oxidative stress: an implication to Alzheimer's disease. *Neurobiology of Disease*. 2005;18(3):450-8.

Kanninen K, Malm TM, Jyrkkanen H-K, Goldsteins G, Keksa-Goldsteine V, Tanila H, et al. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. *Molecular and Cellular Neuroscience*. 2008;39(3):302-13.

Kanowski S, Hoerr R. Ginkgo biloba extract EGb 761(R) in dementia: Intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. *Pharmacopsychiatry*. 2003;36(6):297-303.

Kapay NA, Isaev NK, Stelmashook EV, Popova OV, Zorov DB, Skrebitsky VG, et al. In vivo injected mitochondria-targeted plastoquinone antioxidant SkQR1 prevents beta-amyloid-induced decay of long-term potentiation in rat hippocampal slices. *Biochemistry-Moscow*. 2011;76(12):1367-70.

Karanth S, Lyson K, McCann SM. ROLE OF NITRIC-OXIDE IN INTERLEUKIN-2-INDUCED CORTICOTROPIN-RELEASING FACTOR RELEASE FROM INCUBATED HYPOTHALAMI. *Proceedings of the National Academy of Sciences of the United States of America*. 1993;90(8):3383-7.

Karapetyan YE, Sferrazza GF, Zhou M, Ottenberg G, Spicer T, Chase P, et al. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(17):7044-9.

Karczewska-Kupczewska M, Lelental N, Adamska A, Nikolajuk A, Kowalska I, Gorska M, et al. The influence of insulin infusion on the metabolism of amyloid beta peptides in plasma. *Alzheimers & Dementia*. 2013;9(4):400-5.

Karlen A, Karlsson TE, Mattsson A, Lundstromer K, Codeluppi S, Pham TM, et al. Nogo receptor 1 regulates formation of lasting memories. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(48):20476-81.

Karran E, Hardy J. Antiamyloid Therapy for Alzheimer's Disease - Are We on the Right Road? *New England Journal of Medicine*. 2014;370(4):377-8.

Karuppagounder SS, Pinto JT, Xu H, Chen H-L, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. *Neurochemistry International*. 2009;54(2):111-8.

Kato H, Kurosaki R, Oki C, Araki T. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. *Brain Research*. 2004;1030(1):66-73.

Kauwe JSK, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, et al. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. *Neurogenetics*. 2009;10(1):13-7.

Kavirajan H. Memantine: a comprehensive review of safety and efficacy. *Expert Opinion on Drug Safety*. 2009;8(1):89-109.

Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. *Lancet Neurology*. 2007;6(9):782-92.

Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? *Lancet Neurology*. 2007;6(4):373-8.

Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. *Neurology*. 2005;64(7):1152-6.

Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M. Autoantibodies against beta-Amyloid Are Common in Alzheimer's Disease and Help Control Plaque Burden. *Annals of Neurology*. 2009;65(1):24-31.

Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical Antioxidants as Novel Neuroprotective Agents. *Molecules*. 2010;15(11):7792-814.

Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells - Antioxidant and antiapoptotic properties. *Journal of Biological Chemistry*. 2001;276(7):4588-96.

Kem WR. The brain alpha 7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). *Behavioural Brain Research*. 2000;113(1-2):169-81.

Kenche VB, Barnham KJ. Alzheimer's disease & metals: therapeutic opportunities. *British Journal of Pharmacology*. 2011;163(2):211-9.

Kendall I, Slotten HA, Codony X, Burgueno J, Pauwels PJ, Vela JM, et al. E-6801, a 5-HT₆ receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. *Psychopharmacology*. 2011;213(2-3):413-30.

Kennedy BP, Ziegler MG, Alford M, Hansen LA, Thal LJ, Masliah E. Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease. *Journal of Neural Transmission*. 2003;110(7):789-801.

Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, et al. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. *International Journal of Geriatric Psychiatry*. 2005;20(11):1020-7.

Kennelly SP, Abdullah L, Paris D, Parish J, Mathura V, Mullan M, et al. Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study. *International Journal of Geriatric Psychiatry*. 2011;26(10):1038-45.

Keowkase R, Aboukhatwa M, Luo Y. Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in *Caenorhabditis elegans*. *Neuropharmacology*. 2010;59(4-5):358-65.

Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, et al. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103(3):702-7.

Kerchner GA, Boxer AL. Bapineuzumab. *Expert Opinion on Biological Therapy*. 2010;10(7):1121-30.

Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, et al. Antihypertensive medication use and incident Alzheimer disease - The Cache County Study. *Archives of Neurology*. 2006;63(5):686-92.

Khalili M, Hamzeh F. Effects of active constituents of *Crocus sativus* L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats. *Iranian Biomedical Journal*. 2010;14(1/2):59-65.

Kharmate G, Liu Z, Patterson E, Khan MM. Histamine affects STAT6 phosphorylation via its effects on IL-4 secretion: Role of H1 receptors in the regulation of IL-4 production. *International Immunopharmacology*. 2007;7(3):277-86.

Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(50):21830-5.

Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, et al. alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block a beta-amyloid-induced neurotoxicity. *Journal of Biological Chemistry*. 2001;276(17):13541-6.

Kim D-H, Huh J-W, Jang M, Suh J-H, Kim T-W, Park J-S, et al. Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures. *Neurobiology of Disease*. 2012;46(1):52-8.

Kim H, Han SH, Quan HY, Jung YJ, An J, Kang P, et al. BRYOSTATIN-1 PROMOTES LONG-TERM POTENTIATION VIA ACTIVATION OF PKC alpha AND PKC epsilon IN THE HIPPOCAMPUS. *Neuroscience*. 2012;226:348-55.

Kim TI, Lee YK, Park SG, Choi IS, Ban JO, Park HK, et al. l-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways. *Free radical biology & medicine*. 2009;47(11):1601-10.

Kimura M, Akasofu S, Ogura H, Sawada K. Protective effect of donepezil against A beta(1-40) neurotoxicity in rat septal neurons. *Brain Research*. 2005;1047(1):72-84.

Kimura T, Goto M. EXISTENCE OF SENILE PLAQUES IN THE BRAINS OF ELDERLY LEPROSY PATIENTS. *Lancet*. 1993;342(8883):1364-.

King MV, Marsden CA, Fone KCF. A role for the 5-HT(1A), 5-HT(4) and 5-HT(6) receptors in learning and memory. *Trends in Pharmacological Sciences*. 2008;29(9):482-92.

King ME, Kan H-M, Baas PW, Erisir A, Glabe CG, Bloom GS. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. *Journal of Cell Biology*. 2006;175(4):541-6.

Kins S, Cramer A, Evans DRH, Hemmings BA, Nitsch RM, Gotz J. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. *Journal of Biological Chemistry*. 2001;276(41):38193-200.

Kircher TTJ, Erb M, Grodd W, Leube DT. Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease - Preliminary findings from a pharmaco-fMRI study. *American Journal of Geriatric Psychiatry*. 2005;13(11):1006-13.

Kittner B, Rossner M, Rother M. Clinical trials in dementia with propentofylline. In: de la Torre JC, Hachinski V, editors. *Cerebrovascular Pathology in Alzheimer's Disease*. Annals of the New York Academy of Sciences. 826:1997. p. 307-16.

Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. *British Medical Journal*. 2001;322(7300):1447-51.

Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. *Lancet Neurology*. 2006;5(9):735-41.

Klein J. Phenserine. *Expert Opinion on Investigational Drugs*. 2007;16(7):1087-97.

Klugman A, Naughton DP, Isaac M, Shah I, Petroczi A, Tabet N. Antioxidant Enzymatic Activities in Alzheimer's Disease: The Relationship to Acetylcholinesterase Inhibitors. *Journal of Alzheimers Disease*. 2012;30(3):467-74.

Klunk WE, Engler H, Nordberg A, Wang YM, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Annals of Neurology*. 2004;55(3):306-19.

Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, et al. A 30-WEEK RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE TACRINE IN PATIENTS WITH ALZHEIMERS-DISEASE. *Jama-Journal of the American Medical Association*. 1994;271(13):985-91.

Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. *Journal of Neuropathology and Experimental Neurology*. 2003;62(11):1087-95.

Knopman DS. "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease. *Alzheimers & Dementia*. 2007;3(1):21-2.

Knopman DS. Mild cognitive impairment and on to dementia Down the slippery slope but faster. *Neurology*. 2010;74(12):942-4.

Knutson MD, Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. *Nutrition Reviews*. 2008;66(10):591-6.

Kodamo M, Fujioko T, Duman RS. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. *Biological Psychiatry*. 2004;56(8):570-80.

Koehler CA, da Silva WC, Benetti F, Bonini JS. Histaminergic Mechanisms for Modulation of Memory Systems. *Neural Plasticity*. 2011.

Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, et al. Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-A beta Antibody Administration in PDAPP Mice. *Journal of Neuroscience*. 2008;28(52):14156-64.

Koistinaho M, Kettunen MI, Goldsteins G, Keinanen R, Salminen A, Ort M, et al. beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: Role of inflammation. *Proceedings of the National Academy of Sciences of the United States of America*. 2002;99(3):1610-5.

Komater VA, Buckley MJ, Browman KE, Pan JB, Hancock AA, Decker MW, et al. Effects of histamine H-3 receptor antagonists in two models of spatial learning. *Behavioural Brain Research*. 2005;159(2):295-300.

Kong M, Ba M. Protective effects of diazoxide against A beta(25-35)-induced PC12 cell apoptosis due to prevention of endoplasmic reticulum stress. *Neuroreport*. 2012;23(8):493-7.

Korth C, May BCH, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2001;98(17):9836-41.

Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta 42(43). *Neurology*. 1997;48(3):741-5.

Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. *European Journal of Pharmacology*. 2000;389(2-3):173-9.

Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. *Neuroscience Research*. 2006;56(2):159-64.

Kou J, Song M, Pattanayak A, Lim J-E, Yang J, Cao D, et al. Combined treatment of A beta immunization with statin in a mouse model of Alzheimer's disease. *Journal of Neuroimmunology*. 2012;244(1-2):70-83.

Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, et al. Modulation of gamma-Secretase Reduces beta-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease. *Neuron*. 2010;67(5):769-80.

Kozauer N, Katz R. Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease. *New England Journal of Medicine*. 2013;368(13):1169-71.

Kozikowski AP, Chen Y, Subhasish T, Lewin NE, Blumberg PM, Zhong Z, et al. Searching for Disease Modifiers-PKC Activation and HDAC Inhibition-A Dual Drug Approach to Alzheimer's Disease that Decreases A beta Production while Blocking Oxidative Stress. *Chemmedchem*. 2009;4(7):1095-105.

Kretner B, Fukumori A, Gutsmedl A, Page RM, Luebbbers T, Galley G, et al. Attenuated A beta(42) Responses to Low Potency gamma-Secretase Modulators Can Be Overcome for Many Pathogenic Presenilin Mutants by Second-generation Compounds. *Journal of Biological Chemistry*. 2011;286(17):15240-51.

Krishnan KRR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. *American Journal of Psychiatry*. 2003;160(11):2003-11.

Kruman, II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. *Journal of Neuroscience*. 2002;22(5):1752-62.

Krysicio RJ, Abner EL, Schmitt FA, Goodman PJ, Mendiondo M, Caban-Holt A, et al. A RANDOMIZED CONTROLLED ALZHEIMER'S DISEASE PREVENTION TRIAL'S EVOLUTION INTO AN EXPOSURE TRIAL: THE PREADVISE TRIAL. *Journal of Nutrition Health & Aging*. 2013;17(1):72-5.

Krysicio RJ, Mendiondo MS, Schmitt FA, Markesbery WR. Designing a large prevention trial: statistical issues. *Statistics in Medicine*. 2004;23(2):285-96.

Kubo T, Yamaguchi A, Iwata N, Yamashita T. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. *Therapeutics and clinical risk management*. 2008;4(3):605-15.

Kuhn P-H, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. *Embo Journal*. 2010;29(17):3020-32.

Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, et al. Substrate-targeting gamma-secretase modulators. *Nature*. 2008;453(7197):925-U62.

Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. *Bmc Neuroscience*. 2007;8.

Kumar A, Dogra S. Neuropathology and therapeutic management of Alzheimer's disease - an update. *Drugs of the Future*. 2008;33(5):433-46.

Kumar A, Prakash A, Pahwa D, Mishra J. Montelukast potentiates the protective effect of rofecoxib against kainic acid-induced cognitive dysfunction in rats. *Pharmacology Biochemistry and Behavior*. 2012;103(1):43-52.

Kumar V, Kinsella LJ. Healthy Brain Aging: Effect of Head Injury, Alcohol and Environmental Toxins. *Clinics in Geriatric Medicine*. 2010;26(1):29-+.

Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens KI, Corsmit E, et al. Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased A beta 42 and decreased A beta 40. *Human Mutation*. 2006;27(7):686-95.

Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. *Geriatrics & Gerontology International*. 2012;12(2):207-14.

Kupersmidt L, Amit T, Bar-Am O, Youdim MBH, Weinreb O. The Novel Multi-Target Iron Chelating-Radical Scavenging Compound M30 Possesses Beneficial Effects on Major Hallmarks of Alzheimer's Disease. *Antioxidants & Redox Signaling*. 2012;17(6):860-77.

Kurakhmaeva KB, Djindjikhshvili IA, Petrov VE, Balabanyan VU, Voronina TA, Trofimov SS, et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. *Journal of Drug Targeting*. 2009;17(8):564-74.

Kurata T, Kawai H, Miyazaki K, Kozuki M, Morimoto N, Ohta Y, et al. Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain. *Journal of the Neurological Sciences*. 2012;322(1-2):59-63.

Kurata T, Miyazaki K, Kozuki M, Morimoto N, Ohta Y, Ikeda Y, et al. Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease. *Neurological Research*. 2012;34(6):601-10.

Kurata T, Miyazaki K, Morimoto N, Kawai H, Ohta Y, Ikeda Y, et al. Atorvastatin and pitavastatin reduce oxidative stress and improve IR/LDL-R signals in Alzheimer's disease. *Neurological Research*. 2013;35(2):193-205.

Kurz A, Van Baelen B. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: A review based on meta-analyses by the Cochrane Collaboration. *Dementia and Geriatric Cognitive Disorders*. 2004;18(2):217-26.

Kurz A, Pernecky R. Novel insights for the treatment of Alzheimer's disease. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 2011;35(2):373-9.

Kwiatkowski DJ, Mehl R, Yin HL. GENOMIC ORGANIZATION AND BIOSYNTHESIS OF SECRETED AND CYTOPLASMIC FORMS OF GELSOLIN. *Journal of Cell Biology*. 1988;106(2):375-84.

La Porte SL, Bollini SS, Lanz TA, Abdiche YN, Rusnak AS, Ho W-H, et al. Structural Basis of C-terminal beta-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease. *Journal of Molecular Biology*. 2012;421(4-5):525-36.

Laakso MP, Soininen H, Partanen K, Lehtovirta M, Hallikainen M, Hanninen T, et al. MRI of the hippocampus in Alzheimer's disease: Sensitivity, specificity, and analysis of the incorrectly classified subjects. *Neurobiology of Aging*. 1998;19(1):23-31.

Labie C, Lafon C, Marmouget C, Saubusse P, Fournier J, Keane PE, et al. Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex. *British Journal of Pharmacology*. 1999;127(1):139-44.

Lacerda ACR, Marubayashi U, Coimbra CC. Nitric oxide pathway is an important modulator of heat loss in rats during exercise. *Brain Research Bulletin*. 2005;67(1-2):110-6.

LaDu MJ, Reardon C, Van Eldik L, Fagan AM, Bu GJ, Holtzman D, et al. Lipoproteins in the central nervous system. In: Kalaria RN, Ince P, editors. *Vascular Factors in Alzheimer's Disease*. Annals of the New York Academy of Sciences. 9032000. p. 167-75.

LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. *Nature Reviews Neuroscience*. 2007;8(7):499-509.

Lagostena L, Rosato-Siri M, D'Onofrio M, Brandi R, Arisi I, Capsoni S, et al. In the Adult Hippocampus, Chronic Nerve Growth Factor Deprivation Shifts GABAergic Signaling from the Hyperpolarizing to the Depolarizing Direction. *Journal of Neuroscience*. 2010;30(3):885-93.

Lahiri DK, Chen D, Maloney B, Holloway HW, Yu Q-s, Utsuki T, et al. The experimental Alzheimer's disease drug posiphen (+)-phenserine lowers amyloid-beta peptide levels in cell culture and mice. *Journal of Pharmacology and Experimental Therapeutics*. 2007;320(1):386-96.

Lahiri DK, Maloney B, Basha MR, Ge YW, Zawia NH. How and when environmental agents and dietary factors affect the course of Alzheimer's disease: The "LEARn" model (Latent Early-

Life Associated Regulation) may explain the triggering of AD. *Current Alzheimer Research*. 2007;4(2):219-28.

Lahiri DK, Zawia NH, Greig NH, Sambamurti K, Maloney B. Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model. *Biogerontology*. 2008;9(6):375-9.

Lahmy V, Meunier J, Malmstroem S, Naert G, Givalois L, Kim SH, et al. Blockade of Tau Hyperphosphorylation and A beta(1-42) Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and sigma(1) Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer's Disease. *Neuropsychopharmacology*. 2013;38(9):1706-23.

Lai EC. Notch signaling: control of cell communication and cell fate. *Development*. 2004;131(5):965-73.

Lai MK, Tsang SW, Alder JT, Keene J, Hope T, Esiri MM, et al. Loss of serotonin 5-HT_{2A} receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. *Psychopharmacology*. 2005;179(3):673-7.

Lambert J-C, Amouyel P. Genetics of Alzheimer's disease: new evidences for an old hypothesis? *Current Opinion in Genetics & Development*. 2011;21(3):295-301.

Lambracht-Washington D, Rosenberg RN. Active DNA A beta 42 vaccination as immunotherapy for alzheimer disease. *Translational Neuroscience*. 2012;3(4):307-13.

Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. *Proceedings of the National Academy of Sciences of the United States of America*. 1999;96(7):3922-7.

Lancot KL, Herrmann N, Yau KK, Khan LR, Liu BA, Loulou MM, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. *Canadian Medical Association Journal*. 2003;169(6):557-64.

Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB, Jr., et al. Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study. *Clinical Neuropharmacology*. 2013;36(1):14-23.

Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, et al. Response to Comments on "ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models". *Science*. 2013;340(6135).

Landreth G, Jiang Q, Mandrekar S, Heneka M. PPAR gamma agonists as therapeutics for the treatment of Alzheimer's disease. *Neurotherapeutics*. 2008;5(3):481-9.

Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. *International Journal of Neuropsychopharmacology*. 2006;9(1):101-24.

Langbaum JBS, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Neuroimage*. 2009;45(4):1107-16.

Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. *Pharmacology & Therapeutics*. 2008;117(2):232-43.

Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting A beta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. *Lancet Neurology*. 2008;7(9):779-86.

Lansbury PT. Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. *Nature Medicine*. 2004;10(7):S51-S7.

Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, et al. The gamma-secretase inhibitor N- N-(3,5-difluorophenacetyl)-L-alanyl -S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. *Journal of Pharmacology and Experimental Therapeutics*. 2003;305(3):864-71.

LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, et al. The Amino Terminus of Tau Inhibits Kinesin-Dependent Axonal Transport: Implications for Filament Toxicity. *Journal of Neuroscience Research*. 2009;87(2):440-51.

Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kaye R. Tau Oligomers as Potential Targets for Immunotherapy for Alzheimer's Disease and Tauopathies. *Current Alzheimer Research*. 2011;8(6):659-65.

Lashuel HA, Hartley DM, Balakhaneh D, Aggarwal A, Teichberg S, Callaway DJE. New class of inhibitors of amyloid-beta fibril formation - Implications for the mechanism of pathogenesis in Alzheimer's disease. *Journal of Biological Chemistry*. 2002;277(45):42881-90.

Lathia JD, Mattson MP, Cheng A. Notch: from neural development to neurological disorders. *Journal of Neurochemistry*. 2008;107(6):1471-81.

Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. *Neurobiology of Aging*. 2000;21(1):49-55.

Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. *Nature*. 2009;457(7233):1128-U84.

Laurin D, Masaki KH, Foley DJ, White LR, Launer LJ. Midlife dietary intake of antioxidants and risk of late-life incident dementia - The Honolulu-Asia Aging Study. *American Journal of Epidemiology*. 2004;159(10):959-67.

Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease - A randomized trial. *Jama-Journal of the American Medical Association*. 2008;300(9):1027-37.

Lauterbach EC, Mendez MF. Psychopharmacological Neuroprotection in Neurodegenerative Diseases, Part III: Criteria-Based Assessment: A Report of the ANPA Committee on Research. *Journal of Neuropsychiatry and Clinical Neurosciences*. 2011;23(3):242-60.

Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF. Psychopharmacological Neuroprotection in Neurodegenerative Disease: Assessing the Preclinical Data. *Journal of Neuropsychiatry and Clinical Neurosciences*. 2010;22(1):8-18.

Lavie V, Becker M, Cohen-Kupiec R, Yacoby I, Koppel R, Wedenig M, et al. EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. *Journal of Molecular Neuroscience*. 2004;24(1):105-13.

Lawlor BA, Davis KL. DOES MODULATION OF GLUTAMATERGIC FUNCTION REPRESENT A VIABLE THERAPEUTIC STRATEGY IN ALZHEIMERS-DISEASE. *Biological Psychiatry*. 1992;31(4):337-50.

Le Bars PL, Kieser M, Itil K. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 (R) in dementia. *Dementia and Geriatric Cognitive Disorders*. 2000;11(4):230-7.

Le Corre S, Klafki HW, Plesnila N, Hubinger G, Obermeier A, Sahagun H, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103(25):9673-8.

LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. *Jama-Journal of the American Medical Association*. 1997;278(16):1327-32.

Leber P. Slowing the progression of Alzheimer disease: Methodologic issues. *Alzheimer Disease & Associated Disorders*. 1997;11:S10-S20.

Leber P. Not in our methods, but in our ignorance. *Archives of General Psychiatry*. 2002;59(3):279-80.

Leber P, Post SG, Green RC, Whitehouse PJ, Rabins PV, Liebler ET, et al. Slowing the progression of Alzheimer disease: Ethical issues - General discussion. *Alzheimer Disease & Associated Disorders*. 1997;11:S37-S9.

LeBlanc A. Estrogen and Alzheimer's disease. *Current opinion in investigational drugs* (London, England : 2000). 2002;3(5):768-73.

Lee CYD, Landreth GE. The role of microglia in amyloid clearance from the AD brain. *Journal of Neural Transmission*. 2010;117(8):949-60.

Lee DH, Folsom AR, Harnack L, Halliwell B, Jacobs DR. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? *American Journal of Clinical Nutrition*. 2004;80(5):1194-200.

Lee D, Long SA, Adams JL, Chan G, Vaidya KS, Francis TA, et al. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. *Journal of Biological Chemistry*. 2000;275(21):16007-14.

Lee HG, Casadesus G, Zhu XW, Takeda A, Perry G, Smith MA. Challenging the amyloid cascade hypothesis - Senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. In: DeGrey ADN, editor. *Strategies for Engineered Negligible Senescence: Why Genuine Control of Aging May Be Foreseeable*. Annals of the New York Academy of Sciences. 10192004. p. 1-4.

Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2002;99(11):7705-10.

Lee JY, Friedman JE, Angel I, Kozak A, Koh JY. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. *Neurobiology of Aging*. 2004;25(10):1315-21.

Lee JW, Lee YK, Ban JO, Ha TY, Yun YP, Han SB, et al. Green Tea (-)-Epigallocatechin-3-Gallate Inhibits beta-Amyloid-Induced Cognitive Dysfunction through Modification of Secretase Activity via Inhibition of ERK and NF-kappa B Pathways in Mice. *Journal of Nutrition*. 2009;139(10):1987-93.

Lee J, Boo JH, Ryu H. The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start? *Advanced Drug Delivery Reviews*. 2009;61(14):1316-23.

Lee RH-C, Tseng T-Y, Wu CY-C, Chen P-Y, Chen M-F, Kuo J-S, et al. Memantine Inhibits alpha 3 beta 2-nAChRs-Mediated Nitroergic Neurogenic Vasodilation in Porcine Basilar Arteries. *Plos One*. 2012;7(7).

Lee SJ, Drabik K, Van Wagoner NJ, Lee S, Choi C, Dong Y, et al. ICAM-1-induced expression of proinflammatory cytokines in astrocytes: Involvement of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways. *Journal of Immunology*. 2000;165(8):4658-66.

Lee VMY. DISRUPTION OF THE CYTOSKELETON IN ALZHEIMERS-DISEASE. *Current Opinion in Neurobiology*. 1995;5(5):663-8.

Lee VMY, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. *Annual Review of Neuroscience*. 2001;24:1121-59.

Lee VM, Trojanowski JQ. The disordered neuronal cytoskeleton in Alzheimer's disease. *Current opinion in neurobiology*. 1992;2(5):653-6.

Lee VMY, Trojanowski JQ. Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. *Journal of Alzheimers Disease*. 2006;9:257-62.

Lee VMY, Trojanowski JQ. Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. *Alzheimer's Disease: a Century of Scientific and Clinical Research*. 2006:257-62.

Lefevre G, Sedek G, Jhee SS, Leibowitz MT, Huang HL, Enz A, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. *Clinical Pharmacology & Therapeutics*. 2008;83(1):106-14.

Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. *Nature Medicine*. 2012;18(2):291-5.

Leissring MA, Farris W, Chang AY, Walsh DM, Wu XN, Sun XY, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. *Neuron*. 2003;40(6):1087-93.

Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, et al. Magnetic resonance imaging of the neuroprotective effect of Xaliproden in rats. *Investigative Radiology*. 2002;37(6):321-7.

Lemere CA. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. In: Verhaagen J, Hol EM, Huitenga I, Wijnholds J, Bergen AB, Boer GJ, et al., editors.

Neurotherapy: Progress in Restorative Neuroscience and Neurology. Progress in Brain Research. 1752009. p. 83-93.

Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nature Reviews Neurology. 2010;6(2):108-19.

Lenzen SC, Lanni C, Govoni S, Lucchelli A, Schettini G, Racchi M. Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chemico-Biological Interactions. 2007;165(2):138-45.

Leoutsakos J-MS, Muthen BO, Breitner JCS, Lyketsos CG, Team AR. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. International Journal of Geriatric Psychiatry. 2012;27(4):364-74.

Lerch JP, Pruessner J, Zijdenbos AP, Collins DL, Teipel SJ, Hampel H, et al. Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiology of Aging. 2008;29(1):23-30.

Lermontova NN, Redkozubov AE, Shevtsova EF, Serkova TP, Kireeva EG, Bachurin SO. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca²⁺ channels. Bulletin of Experimental Biology and Medicine. 2001;132(5):1079-83.

Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3 beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathology and Applied Neurobiology. 2007;33(1):43-55.

Leroy K, Ando K, Heraud C, Yilmaz Z, Authalet M, Boeynaems J-M, et al. Lithium Treatment Arrests the Development of Neurofibrillary Tangles in Mutant Tau Transgenic Mice with Advanced Neurofibrillary Pathology. Journal of Alzheimers Disease. 2010;19(2):705-19.

Lesne S, Koh MT, Kotilinek L, Kaye R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440(7082):352-7.

Leszek J, Inglot AD, Janusz M, Byczkiewicz F, Kiejna A, Georgiades J, et al. Colostrinin proline-rich polypeptide complex from ovine colostrum--a long-term study of its efficacy in Alzheimer's disease. Medical science monitor : international medical journal of experimental and clinical research. 2002;8(10):PI93-6.

Leuchtenberger S, Behr D, Weggen S. Selective modulation of A beta 42 production in Alzheimer's disease: Non-steroidal anti-inflammatory drugs and beyond. Current Pharmaceutical Design. 2006;12(33):4337-55.

Leurs R, Bakker RA, Timmerman H, de Esch IJP. The histamine H-3 receptor: From gene cloning to H-3 receptor drugs. *Nature Reviews Drug Discovery*. 2005;4(2):107-U18.

Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. IDENTIFICATION AND LOCALIZATION OF MUSCARINIC ACETYLCHOLINE-RECEPTOR PROTEINS IN BRAIN WITH SUBTYPE-SPECIFIC ANTIBODIES. *Journal of Neuroscience*. 1991;11(10):3218-26.

Levin ED. Nicotinic receptor subtypes and cognitive function. *Journal of Neurobiology*. 2002;53(4):633-40.

Levites Y, Amit T, Mandel S, Youdim MBH. Neuroprotection and neurorescue against A beta toxicity and PKC-dependent release of non-amyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. *Faseb Journal*. 2003;17(3):952-+.

Lewis HD, Revuelta BIP, Nadin A, Neduvellil JG, Harrison T, Pollack SJ, et al. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between notch S3 and beta-APP cleavages. *Biochemistry*. 2003;42(24):7580-6.

Lewis JM. VITAMIN-A AND ALZHEIMERS-DISEASE. *Neuroepidemiology*. 1992;11(3):163-8.

Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. *Science*. 2001;293(5534):1487-91.

Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H, et al. Increase of BDNF Serum Concentration in Lithium Treated Patients with Early Alzheimer's Disease. *Journal of Alzheimers Disease*. 2009;16(3):649-56.

Leyva MJ, DeGiacomo F, Kaltenbach LS, Holcomb J, Zhang N, Gafni J, et al. Identification and Evaluation of Small Molecule Pan-Caspase Inhibitors in Huntington's Disease Models. *Chemistry & Biology*. 2010;17(11):1189-200.

Li C, Carlier PR, Ren H, Kan KKW, Hui K, Wang H, et al. Alkylene tether-length dependent gamma-aminobutyric acid type A receptor competitive antagonism by tacrine dimers. *Neuropharmacology*. 2007;52(2):436-43.

Li GB, Faibushevich A, Turunen BJ, Yoon SO, Georg G, Michaelis ML, et al. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. *Journal of Neurochemistry*. 2003;84(2):347-62.

Li G, Higdon R, Kukull WA, Peskind E, Moore KV, Tsuang D, et al. Statin therapy and risk of dementia in the elderly - A community-based prospective cohort study. *Neurology*. 2004;63(9):1624-8.

Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. *Neurology*. 2007;69(9):878-85.

Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, et al. Age-Varying Association Between Statin Use and Incident Alzheimer's Disease. *Journal of the American Geriatrics Society*. 2010;58(7):1311-7.

Li J, Deng J, Sheng W, Zuo Z. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. *Pharmacology Biochemistry and Behavior*. 2012;101(4):564-74.

Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. *FEBS letters*. 2004;566(1-3):261-9.

Li L, Cao D, Kim H, Lester R, Fukuchi K-i. Simvastatin enhances learning and memory independent of amyloid load in mice. *Annals of Neurology*. 2006;60(6):729-39.

Li L, Zhang S, Zhang X, Li T, Tang Y, Liu H, et al. Autophagy Enhancer Carbamazepine Alleviates Memory Deficits and Cerebral Amyloid-beta Pathology in a Mouse Model of Alzheimer's Disease. *Current Alzheimer Research*. 2013;10(4):433-41.

Li N-C, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. *British Medical Journal*. 2010;340.

Li Q, Zhao HF, Zhang ZF, Liu ZG, Pei XR, Wang JB, et al. LONG-TERM GREEN TEA CATECHIN ADMINISTRATION PREVENTS SPATIAL LEARNING AND MEMORY IMPAIRMENT IN SENESCENCE-ACCELERATED MOUSE PRONE-8 MICE BY DECREASING A beta(1-42) OLIGOMERS AND UPREGULATING SYNAPTIC PLASTICITY-RELATED PROTEINS IN THE HIPPOCAMPUS. *Neuroscience*. 2009;163(3):741-9.

Li R, Lindholm K, Yang LB, Yue X, Citron M, Yao RQ, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. *Proceedings of the National Academy of Sciences of the United States of America*. 2004;101(10):3632-7.

Li Y, Chigurupati S, Holloway HW, Mughal M, Tweedie D, Bruestle DA, et al. Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis. *Plos One*. 2012;7(2).

Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, et al. GLP-1 Receptor Stimulation Reduces Amyloid-beta Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease. *Journal of Alzheimers Disease*. 2010;19(4):1205-19.

Lian QY, Ladner CJ, Magnuson D, Lee JM. Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex. *Experimental Neurology*. 2001;167(1):158-65.

Lichtenstein MP, Carriba P, Antonia Baltrons M, Wojciak-Stothard B, Peterson JR, Garcia A, et al. Secretase-Independent and RhoGTPase/PAK/ERK-Dependent Regulation of Cytoskeleton Dynamics in Astrocytes by NSAIDs and Derivatives. *Journal of Alzheimers Disease*. 2010;22(4):1135-55.

Lichtenthaler SF, Haass C. Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. *Journal of Clinical Investigation*. 2004;113(10):1384-7.

Lim GP, Calon F, Morihara T, Yang FS, Teter B, Ubeda O, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. *Journal of Neuroscience*. 2005;25(12):3032-40.

Lim GP, Chu T, Yang FS, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. *Journal of Neuroscience*. 2001;21(21):8370-7.

Limon A, Reyes-Ruiz JM, Miledi R. GABAergic drugs and Alzheimer's disease. *Future Medicinal Chemistry*. 2011;3(2):149-53.

Lin NH, Gunn DE, Ryther KB, Garvey DS, DonnellyRoberts DL, Decker MW, et al. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine (ABT-089): An orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. *Journal of Medicinal Chemistry*. 1997;40(3):385-90.

Lin T-W, Kuo Y-M. Exercise benefits brain function: the monoamine connection. *Brain sciences*. 2013;3(1):39-53.

Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, et al. Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. *American Journal of Epidemiology*. 2002;156(5):445-53.

Lippiello PM, Bencherif M, Gray JA, Peters S, Grigoryan G, Hodges H, et al. RJR-2403: A nicotinic agonist with CNS selectivity .2. In vivo characterization. *Journal of Pharmacology and Experimental Therapeutics*. 1996;279(3):1422-9.

Lippiello P, Letchworth SR, Gatto GJ, Traina VM, Bencherif M. Ispronicline - A novel alpha 4 beta 2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. *Journal of Molecular Neuroscience*. 2006;30(1-2):19-20.

Lipton SA, Chen HSV. Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. *Cell Death and Differentiation*. 2004;11(1):18-20.

Lipton SA. Pathologically-activated therapeutics for neuroprotection: Mechanism of NMDA receptor block by memantine and S-nitrosylation. *Current Drug Targets*. 2007;8(5):621-32.

Little JT, Walsh S, Aisen PS. An update on huperzine A as a treatment for Alzheimer's disease. *Expert Opinion on Investigational Drugs*. 2008;17(2):209-15.

Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, et al. MER5101, a Novel A beta 1-15:DT Conjugate Vaccine, Generates a Robust Anti-A beta Antibody Response and Attenuates A beta Pathology and Cognitive Deficits in APPswe/PS1 Delta E9 Transgenic Mice. *Journal of Neuroscience*. 2013;33(16):7027-37.

Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nature Reviews Neurology*. 2013;9(2):106-18.

Liu D, Xu Y, Feng Y, Liu H, Shen X, Chen K, et al. Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of beta-amyloid peptide. *Biochemistry*. 2006;45(36):10963-72.

Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2004;101(29):10804-9.

Liu G, Garrett MR, Men P, Zhu XW, Perry G, Smith MA. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. *Biochimica Et Biophysica Acta-Molecular Basis of Disease*. 2005;1741(3):246-52.

Liu G, Men P, Harris PLR, Rolston RK, Perry G, Smith MA. Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. *Neuroscience Letters*. 2006;406(3):189-93.

Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Trans-Synaptic Spread of Tau Pathology In Vivo. *Plos One*. 2012;7(2).

Liu YY, Sparatore A, Del Soldato P, Bian JS. H₂S RELEASING ASPIRIN PROTECTS AMYLOID BETA INDUCED CELL TOXICITY IN BV-2 MICROGLIAL CELLS. *Neuroscience*. 2011;193:80-8.

Livingston G, Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. *International Journal of Geriatric Psychiatry*. 2004;19(10):919-25.

Livingston G, Katona C, Roch B, Guillaume C, Rive B. A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care - the LASER-AD study. *Current Medical Research and Opinion*. 2004;20(7):1007-16.

Lleo A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, et al. Nonsteroidal anti-inflammatory drugs lower A beta(42) and change presenilin 1 conformation. *Nature Medicine*. 2004;10(10):1065-6.

Llewellyn DJ, Lang IA, Langa KM, Muniz-Terrera G, Phillips CL, Cherubini A, et al. Vitamin D and Risk of Cognitive Decline in Elderly Persons. *Archives of Internal Medicine*. 2010;170(13):1135-41.

Lloret A, Badia M-C, Mora NJ, Pallardo FV, Alonso M-D, Vina J. Vitamin E Paradox in Alzheimer's Disease: It Does Not Prevent Loss of Cognition and May Even Be Detrimental. *Journal of Alzheimers Disease*. 2009;17(1):143-9.

Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (A beta) peptide-related cerebral amyloidosis. *Brain*. 2007;130:2607-15.

Lockhart IA, Mitchell SA, Kelly S. Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer's Disease: Systematic Review of the 'Real-World' Evidence. *Dementia and Geriatric Cognitive Disorders*. 2009;28(5):389-403.

Lodge JK. Vitamin E bioavailability in humans. *Journal of Plant Physiology*. 2005;162(7):790-6.

Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. *Journal of the American Geriatrics Society*. 2004;52(3):381-7.

Loeffler DA. Intravenous immunoglobulin and Alzheimer's disease: what now? *Journal of Neuroinflammation*. 2013;10.

Logothetis NK. The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. *Philosophical Transactions of the Royal Society of London Series B-Biological Sciences*. 2002;357(1424):1003-37.

Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. *Journal of Neuroscience*. 2003;23(34):10879-83.

Long DD, Armstrong SR, Beattie DT, Choi S-K, Fatheree PR, Gendron RAL, et al. Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT₄ receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation. *Bioorganic & Medicinal Chemistry Letters*. 2012;22(19):6048-52.

Long Z, Zheng M, Zhao L, Xie P, Song C, Chu Y, et al. Valproic Acid Attenuates Neuronal Loss in the Brain of APP/PS1 Double Transgenic Alzheimer's Disease Mice Model. *Current Alzheimer Research*. 2013;10(3):261-9.

Long-Smith CM, Manning S, McClean PL, Coakley MF, O'Halloran DJ, Holscher C, et al. The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-beta Plaque and Glial Pathology in a Mouse Model of Alzheimer's Disease. *Neuromolecular Medicine*. 2013;15(1):102-14.

Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JMO, et al. Effects of long-term supplementation on and cancer vitamin E cardiovascular events - A randomized controlled trial. *Jama-Journal of the American Medical Association*. 2005;293(11):1338-47.

Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. *Journal of Neurology Neurosurgery and Psychiatry*. 2009;80(6):600-7.

Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, Dekosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. *Journal of Neurology Neurosurgery and Psychiatry*. 2002;72(3):310-4.

Lopez-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, et al. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. *Dementia and Geriatric Cognitive Disorders*. 2005;19(4):189-95.

Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, Soderberg L, et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. *Neurobiology of Disease*. 2009;36(3):425-34.

Lorke DE, Lu G, Cho E, Yew DT. Serotonin 5-HT_{2A} and 5-HT₆ receptors in the prefrontal cortex of Alzheimer and normal aging patients. *Bmc Neuroscience*. 2006;7.

Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. *Nature Reviews Neuroscience*. 2006;7(2):93-102.

Lovell MA, Geiger H, Van Zant GE, Lynn BC, Markesbery WR. Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain. *Neurobiology of Aging*. 2006;27(7):909-17.

Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. *Journal of the Neurological Sciences*. 1998;158(1):47-52.

Lovell MA, Xie C, Xiong S, Markesbery WR. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. *Journal of Alzheimer's disease : JAD*. 2003;5(3):229-39.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. *Health Technology Assessment*. 2006;10(1):III-+.

Lovenberg TW, Roland BL, Wilson SJ, Jiang XX, Pyati J, Huvar A, et al. Cloning and functional expression of the human histamine H-3 receptor. *Molecular Pharmacology*. 1999;55(6):1101-7.

Lovestone S, Davis DR, Webster MT, Kaech S, Brion JP, Matus A, et al. Lithium reduces tau phosphorylation: Effects in living cells and in neurons at therapeutic concentrations. *Biological Psychiatry*. 1999;45(8):995-1003.

Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, et al. ALZHEIMER'S DISEASE-LIKE PHOSPHORYLATION OF THE MICROTUBULE-ASSOCIATED PROTEIN TAU BY GLYCOGEN SYNTHASE KINASE-3 IN TRANSFECTED MAMMALIAN CELLS. *Current Biology*. 1994;4(12):1077-86.

Lovestone S, Francis P, Kloszewska I, Mecocci P, Simmons A, Soininen H, et al. AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease. In: Lovestone S, editor. *Biomarkers in Brain Disease*. Annals of the New York Academy of Sciences. 11802009. p. 36-46.

Lowe SL, Francis PT, Procter AW, Palmer AM, Davison AN, Bowen DM. GAMMA-AMINOBUTYRIC ACID CONCENTRATION IN BRAIN-TISSUE AT 2 STAGES OF ALZHEIMERS-DISEASE. *Brain*. 1988;111:785-99.

Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. *Cochrane Database of Systematic Reviews*. 2006(1).

Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. *Archives of Neurology*. 2006;63(2):177-85.

Lu P, Mamiya T, Lu LL, Mouri A, Zou LB, Nagai T, et al. Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. *British Journal of Pharmacology*. 2009;157(7):1270-7.

Lu PH, Lee GJ, Raven EP, Tingus K, Khoo T, Thompson PM, et al. Age-related slowing in cognitive processing speed is associated with myelin integrity in a very healthy elderly sample. *Journal of Clinical and Experimental Neuropsychology*. 2011;33(10):1059-68.

Luchetti S, Huitinga I, Swaab DF. NEUROSTEROID AND GABA-A RECEPTOR ALTERATIONS IN ALZHEIMER'S DISEASE, PARKINSON'S DISEASE AND MULTIPLE SCLEROSIS. *Neuroscience*. 2011;191:6-21.

Luchsinger JA, Tang MX, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. *Archives of Neurology*. 2003;60(2):203-8.

Luchsinger JA, Tang MX, Siddiqui M, Shea S, Mayeux R. Alcohol intake and risk of dementia. *Journal of the American Geriatrics Society*. 2004;52(4):540-6.

Luckmann R. Review: Cholinesterase inhibitors may be effective in Alzheimer's disease. *Evidence-based medicine*. 2006;11(1):23-.

Lue LF, Walker DG. Modeling Alzheimer's disease immune therapy mechanisms: Interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide. *Journal of Neuroscience Research*. 2002;70(4):599-610.

Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: Identification of a cellular activation mechanism. *Experimental Neurology*. 2001;171(1):29-45.

Luedtke RR, Perez E, Yang S-H, Liu R, Vangveravong S, Tu Z, et al. Neuroprotective effects of high affinity sigma 1 receptor selective compounds. *Brain Research*. 2012;1441:17-26.

Luisa Sosa-Ortiz A, Acosta-Castillo I, Prince MJ. Epidemiology of Dementias and Alzheimer's Disease. *Archives of Medical Research*. 2012;43(8):600-8.

Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S, Morales-Garcia JA, Martinez A, Santos A, et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: Potential therapeutic role in brain disorders. *Journal of Neuroscience*. 2007;27(21):5766-76.

Lundkvist J, Naslund J. gamma-Secretase: a complex target for Alzheimer's disease. *Current Opinion in Pharmacology*. 2007;7(1):112-8.

Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(22):9511-6.

Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. *Nature Neuroscience*. 2001;4(3):231-2.

Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. *Proceedings of the National Academy of Sciences of the United States of America*. 2002;99(19):12197-202.

Luo Y, Vali S, Sun S, Chen X, Liang X, Drozhzhina T, et al. A beta 42-Binding Peptoids as Amyloid Aggregation Inhibitors and Detection Ligands. *Acs Chemical Neuroscience*. 2013;4(6):952-62.

Lupp A, Appenroth D, Fang L, Decker M, Lehmann J, Fleck C. Tacrine-NO donor and tacrine-ferulic acid hybrid molecules as new anti-Alzheimer agents: hepatotoxicity and influence on the cytochrome P450 system in comparison to tacrine. *Arzneimittel-Forschung-Drug Research*. 2010;60(5):229-37.

Lyketsos CG, Grp AR. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. *Neurology*. 2007;68(21):1800-8.

Lyketsos CG, Sheppard JME, Steele CD, Kopunek S, Steinberg M, Baker AS, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the depression in Alzheimer's disease study. *American Journal of Psychiatry*. 2000;157(10):1686-9.

Ma Q-L, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, et al. beta-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin. *Journal of Neuroscience*. 2009;29(28):9078-89.

Ma Q-L, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, et al. Curcumin Suppresses Soluble Tau Dimers and Corrects Molecular Chaperone, Synaptic, and Behavioral Deficits in Aged Human Tau Transgenic Mice. *Journal of Biological Chemistry*. 2013;288(6):4056-65.

Maccacchini ML, Chang MY, Pan C, John V, Zetterberg H, Greig NH. Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: target engagement, tolerability and pharmacokinetics in humans. *Journal of Neurology Neurosurgery and Psychiatry*. 2012;83(9):894-902.

Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and tolerability study of lithium in Alzheimer's disease. *International Journal of Geriatric Psychiatry*. 2008;23(7):704-11.

MacMillan KS, Naidoo J, Liang J, Melito L, Williams NS, Morlock L, et al. Development of Proneurogenic, Neuroprotective Small Molecules. *Journal of the American Chemical Society*. 2011;133(5):1428-37.

Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, et al. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. *Advanced Drug Delivery Reviews*. 2008;60(13-14):1463-70.

Maczurek A, Shanmugam K, Muench G. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease. In: Schleicher E, Somoza V, Shieberle P, editors. *Maillard Reaction: Recent Advances in Food and Biomedical Sciences*. Annals of the New York Academy of Sciences. 11262008. p. 147-51.

Madine J, Wang X, Brown DR, Middleton DA. Evaluation of beta-Alanine- and GABA-Substituted Peptides as Inhibitors of Disease-Linked Protein Aggregation. *Chembiochem*. 2009;10(12):1982-7.

Madjid N, Tottie EE, Luttgen M, Meister B, Sandin J, Kuzmin A, et al. 5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: Interactions with cholinergic and glutamatergic mechanisms. *Journal of Pharmacology and Experimental Therapeutics*. 2006;316(2):581-91.

Maelicke A, Hoeffle-Maas A, Ludwig J, Maus A, Samochocki M, Jordis U, et al. Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy. *Journal of Molecular Neuroscience*. 2010;40(1-2):135-7.

Maeshiba Y, Kiyota Y, Yamashita KJ, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. *Arzneimittel-Forschung/Drug Research*. 1997;47(1):29-35.

Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al. Human intravenous immunoglobulin provides protection against A beta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. *Journal of Neuroinflammation*. 2010;7.

Magnoni S, Brody DL. New Perspectives on Amyloid-beta Dynamics After Acute Brain Injury Moving Between Experimental Approaches and Studies in the Human Brain. *Archives of Neurology*. 2010;67(9):1068-73.

Maher-Edwards G, Zvartau-Hind M, Hunter AJ, Gold M, Hopton G, Jacobs G, et al. Double-Blind, Controlled Phase II Study of a 5-HT₆ Receptor Antagonist, SB-742457, in Alzheimer's Disease. *Current Alzheimer Research*. 2010;7(5):374-85.

Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. *International Journal of Geriatric Psychiatry*. 2011;26(5):536-44.

Maia L, de Mendonca A. Does caffeine intake protect from Alzheimer's disease? *European Journal of Neurology*. 2002;9(4):377-82.

Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: A systematic meta-analysis. *Annals of Pharmacotherapy*. 2008;42(1):32-8.

Maier JKK, Lahoua Z, Gendron NH, Fetni R, Johnston A, Davoodi J, et al. The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. *Journal of Neuroscience*. 2002;22(6):2035-43.

Maier M, Seabrook TJ, Lazo ND, Jiang LY, Das P, Janus C, et al. Short amyloid-beta(A beta) immunogens reduce cerebral A beta load and learning deficits in an Alzheimer's disease mouse model in the absence of an A beta-specific cellular immune response. *Journal of Neuroscience*. 2006;26(18):4717-28.

Maki P, Hogervorst E. HRT and cognitive decline. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2003;17(1):105-22.

Makrides V, Shen TE, Bhatia R, Smith BL, Thimm J, Lal R, et al. Microtubule-dependent oligomerization of tau - Implications for physiological tau function and tauopathies. *Journal of Biological Chemistry*. 2003;278(35):33298-304.

Malouf R, Evans JG. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. *Cochrane Database of Systematic Reviews*. 2008(4).

Mancuso C, Santangelo R, Calabrese V. THE HEME OXYGENASE/BILIVERDIN REDUCTASE SYSTEM: A POTENTIAL DRUG TARGET IN ALZHEIMER'S DISEASE. *Journal of Biological Regulators and Homeostatic Agents*. 2013;27(2):75-87.

Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, et al. Mitochondria-Targeted Antioxidants Protect Against Amyloid-beta Toxicity in Alzheimer's Disease Neurons. *Journal of Alzheimers Disease*. 2010;20:S609-S31.

Mandel RJ. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. *Current Opinion in Molecular Therapeutics*. 2010;12(2):240-7.

Mandel SA, Amit T, Kalfon L, Reznichenko L, Weinreb O, Youdim MBH. Cell Signaling Pathways and Iron Chelation in the Neurorestorative Activity of Green Tea Polyphenols: Special

Reference to Epigallocatechin Gallate (EGCG). *Journal of Alzheimers Disease*. 2008;15(2):211-22.

Mandel S, Amit T, Bar-Am O, Youdim MBH. Iron dysregulation in Alzheimer's disease: Multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. *Progress in Neurobiology*. 2007;82(6):348-60.

Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-gamma-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease. *Journal of Neuroscience*. 2012;32(30):10117-28.

Mandrekar-Colucci S, Landreth GE. Nuclear receptors as therapeutic targets for Alzheimer's disease. *Expert Opinion on Therapeutic Targets*. 2011;15(9):1085-97.

Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. *Lancet Neurology*. 2010;9(7):702-16.

Mani RB. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. *Statistics in Medicine*. 2004;23(2):305-14.

Mannick JB, Schonhoff C, Papeta N, Ghafourifar P, Szibor M, Fang KZ, et al. S-nitrosylation of mitochondrial caspases. *Journal of Cell Biology*. 2001;154(6):1111-6.

Manning CA, Stone WS, Korol DL, Gold PE. Glucose enhancement of 24-h memory retrieval in healthy elderly humans. *Behavioural Brain Research*. 1998;93(1-2):71-6.

Manuel Dominguez J, Fuertes A, Orozco L, del Monte-Millan M, Delgado E, Medina M. Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3 beta by Tideglusib. *Journal of Biological Chemistry*. 2012;287(2):893-904.

Marazziti D, Baroni S, Pirone A, Giannaccini G, Betti L, Schmid L, et al. Distribution of Serotonin Receptor of Type 6 (5-HT6) in Human Brain Post-mortem. A Pharmacology, Autoradiography and Immunohistochemistry Study. *Neurochemical Research*. 2012;37(5):920-7.

Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. *Journal of Neurochemistry*. 2008;106(1):392-404.

Marco-Contelles J, Leon R, de los Rios C, Guglietta A, Terencio J, Lopez MG, et al. Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease. *Journal of Medicinal Chemistry*. 2006;49(26):7607-10.

Maria Garcia-Martinez E, Sanz-Blasco S, Karachitos A, Bandez MJ, Fernandez-Gomez FJ, Perez-Alvarez S, et al. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. *Biochemical Pharmacology*. 2010;79(2):239-50.

Marighetto A, Valerio S, Desmedt A, Philippin JN, Trocme-Thibierge C, Morain P. Comparative effects of the alpha 7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. *Psychopharmacology*. 2008;197(3):499-508.

Mark RJ, Ashford JW, Goodman Y, Mattson MP. ANTICONVULSANTS ATTENUATE AMYLOID BETA-PEPTIDE NEUROTOXICITY, CA²⁺ DEREGLATION, AND CYTOSKELETAL PATHOLOGY. *Neurobiology of Aging*. 1995;16(2):187-98.

Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. *Brain Pathology*. 1999;9(1):133-46.

Marlatt MW, Potter MC, Bayer TA, van Praag H, Lucassen PJ. Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer's disease. *Current topics in behavioral neurosciences*. 2013;15:313-40.

Marques AR, Straus SE, Fahle G, Weir S, Csako G, Fischer SH. Lack of association between HSV-1 DNA in the brain, Alzheimer's disease and apolipoprotein E4. *Journal of Neurovirology*. 2001;7(1):82-3.

Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. *Journal of Neuroscience*. 2003;23(6):1992-6.

Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, et al. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. *Journal of Neurochemistry*. 1997;69(5):1995-2004.

Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JCS, Craft S, et al. Cognitive function over time in the Alzheimer's disease anti-inflammatory prevention trial (ADAPT) - Results of a randomized, controlled trial of naproxen and celecoxib. *Archives of Neurology*. 2008;65(7):896-905.

Martin HL, Mounsey RB, Mustafa S, Sathe K, Teismann P. Pharmacological manipulation of peroxisome proliferator-activated receptor gamma (PPAR gamma) reveals a role for anti-oxidant protection in a model of Parkinson's disease. *Experimental Neurology*. 2012;235(2):528-38.

Martina M, Comas T, Mealing GAR. Selective pharmacological modulation of pyramidal neurons and interneurons in the CA1 region of the rat hippocampus. *Frontiers in Pharmacology*. 2013;4.

Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. *Medicinal Research Reviews*. 2002;22(4):373-84.

Martinez A, Perez DI. GSK-3 Inhibitors: A Ray of Hope for the Treatment of Alzheimer's Disease? *Journal of Alzheimers Disease*. 2008;15(2):181-91.

Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, et al. Memantine Improves Cognition and Reduces Alzheimer's-Like Neuropathology in Transgenic Mice. *American Journal of Pathology*. 2010;176(2):870-80.

Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, et al. Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein gamma-Secretase for the Treatment of Alzheimer's Disease. *Journal of Pharmacology and Experimental Therapeutics*. 2009;331(2):598-608.

Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. *Neurology*. 2000;54(6):1265-72.

Maskell PD, Speder P, Newberry NR, Bermudez I. Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. *British Journal of Pharmacology*. 2003;140(7):1313-9.

Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. A beta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. *Neurology*. 2005;64(1):129-31.

Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. *Journal of Clinical Investigation*. 2010;120(5):1774-85.

Massoud F, Desmarais JE, Gauthier S. Switching cholinesterase inhibitors in older adults with dementia. *International Psychogeriatrics*. 2011;23(3):372-8.

Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, Iwatsubo T, et al. Small molecule inhibitors of alpha-synuclein filament assembly. *Biochemistry*. 2006;45(19):6085-94.

Matsuoka Y, Saito M, LaFrancois J, Gaynor K, Olm V, Wang LL, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. *Journal of Neuroscience*. 2003;23(1):29-33.

Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. *Journal of Molecular Neuroscience*. 2007;31(2):165-70.

Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li H-F, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. *Journal of Pharmacology and Experimental Therapeutics*. 2008;325(1):146-53.

Mattila J, Soininen H, Koikkalainen J, Rueckert D, Wolz R, Waldemar G, et al. Optimizing the Diagnosis of Early Alzheimer's Disease in Mild Cognitive Impairment Subjects. *Journal of Alzheimers Disease*. 2012;32(4):969-79.

Matveychuk D, Nunes E, Ullah N, Velazquez-Martinez CA, MacKenzie EM, Baker GB. Comparison of phenelzine and geometric isomers of its active metabolite, beta-phenylethylidenhydrazine, on rat brain levels of amino acids, biogenic amine neurotransmitters and methylamine. *Journal of Neural Transmission*. 2013;120(6):987-96.

Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. *Journal of managed care pharmacy : JMCP*. 2005;11(3):231-51.

Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased Clearance of CNS beta-Amyloid in Alzheimer's Disease. *Science*. 2010;330(6012):1774-.

Maxwell CJ, Hicks MS, Hogan DB, Basran J, Ebly EM. Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. *Dementia and Geriatric Cognitive Disorders*. 2005;20(1):45-51.

May PC, Yang ZX, Li WY, Hyslop PA, Siemers E, Boggs LN. Multi-compartmental pharmacodynamic assessment of the functional gamma-secretase inhibitor LY450139 in PDAPP transgenic mice and non-transgenic mice. *Neurobiology of Aging*. 2004;25:S65-S.

May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, et al. Robust Central Reduction of Amyloid-beta in Humans with an Orally Available, Non-Peptidic beta-Secretase Inhibitor. *Journal of Neuroscience*. 2011;31(46):16507-16.

Mayer SC, Kreft AF, Harrison B, Abou-Gharbia M, Antane M, Aschmies S, et al. Discovery of Begacestat, a Notch-1-Sparing gamma-Secretase Inhibitor for the Treatment of Alzheimer's Disease. *Journal of Medicinal Chemistry*. 2008;51(23):7348-51.

Mayeux R. Epidemiology of neurodegeneration. *Annual Review of Neuroscience*. 2003;26:81-104.

Mayeux R, Sano M. Drug therapy - Treatment of Alzheimer's disease. *New England Journal of Medicine*. 1999;341(22):1670-9.

Mazurov A, Hauser T, Miller CH. Selective alpha 7 nicotinic acetylcholine receptor ligands. *Current Medicinal Chemistry*. 2006;13(13):1567-84.

Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. *European Journal of Neurology*. 2006;13(9):981-5.

McArthur RA, Gray J, Schreiber R. Cognitive effects of muscarinic M-1 functional agonists in non-human primates and clinical trials. *Current Opinion in Investigational Drugs*. 2010;11(7):740-60.

McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. *International Journal of Geriatric Psychiatry*. 1998;13(4):235-9.

McCarney R, Fisher P, Iliffe S, van Haselen R, Griffin M, van der Meulen J, et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. *International Journal of Geriatric Psychiatry*. 2008;23(12):1222-30.

McClellan PL, Gault VA, Harriott P, Hoelscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. *European Journal of Pharmacology*. 2010;630(1-3):158-62.

McClellan PL, Parthasarathy V, Faivre E, Hoelscher C. The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease. *Journal of Neuroscience*. 2011;31(17):6587-94.

McDowell I, Hill G, Lindsay J, Helliwell B, Costa L, Beattie L, et al. THE CANADIAN STUDY OF HEALTH AND AGING - RISK-FACTORS FOR ALZHEIMERS-DISEASE IN CANADA. *Neurology*. 1994;44(11):2073-80.

McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? *Current Opinion in Immunology*. 2009;21(4):418-24.

McGeer PL, Harada N, Kimura H, McGeer EG, Schulzer M. PREVALENCE OF DEMENTIA AMONGST ELDERLY JAPANESE WITH LEPROSY - APPARENT EFFECT OF CHRONIC DRUG-THERAPY. *Dementia*. 1992;3(3):146-9.

McGeer PL, McGeer E, Rogers J, Sibley J. ANTIINFLAMMATORY DRUGS AND ALZHEIMER-DISEASE. *Lancet*. 1990;335(8696):1037-.

McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. *Neurology*. 1996;47(2):425-32.

McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. *Neurobiology of Aging*. 2007;28(5):639-47.

McGleenon BM, Dynan KB, Passmore AP. Acetylcholinesterase inhibitors in Alzheimer's disease. *British Journal of Clinical Pharmacology*. 1999;48(4):471-80.

McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. *Cochrane Database of Systematic Reviews*. 2009(2).

McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. *Cochrane Database of Systematic Reviews*. 2010(8).

McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Cochrane review on 'Statins for the treatment of dementia'. *International Journal of Geriatric Psychiatry*. 2013;28(2):119-26.

McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. *Lancet*. 2000;356(9247):2031-6.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. CLINICAL-DIAGNOSIS OF ALZHEIMERS-DISEASE - REPORT OF THE NINCDS-ADRDA WORK GROUP UNDER THE AUSPICES OF DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES TASK-FORCE ON ALZHEIMERS-DISEASE. *Neurology*. 1984;34(7):939-44.

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers & Dementia*. 2011;7(3):263-9.

McKoy AF, Chen J, Schupbach T, Hecht MH. A Novel Inhibitor of Amyloid beta (A beta) Peptide Aggregation FROM HIGH THROUGHPUT SCREENING TO EFFICACY IN AN

ANIMAL MODEL OF ALZHEIMER DISEASE. *Journal of Biological Chemistry*. 2012;287(46):38992-9000.

McLaurin J, Franklin T, Chakrabartty A, Fraser PE. Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. *Journal of Molecular Biology*. 1998;278(1):183-94.

McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit A beta-induced toxicity. *Journal of Biological Chemistry*. 2000;275(24):18495-502.

McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MHL, Phinney AL, et al. Cyclohexanhexol inhibitors of A beta aggregation prevent and reverse Alzheimer phenotype in a mouse model. *Nature Medicine*. 2006;12(7):801-8.

McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of A beta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Annals of Neurology*. 1999;46(6):860-6.

McManus MJ, Murphy MP, Franklin JL. The Mitochondria-Targeted Antioxidant MitoQ Prevents Loss of Spatial Memory Retention and Early Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. *Journal of Neuroscience*. 2011;31(44):15703-15.

McShane R, Sastre AA, Minakaran N. Memantine for dementia. *Cochrane Database of Systematic Reviews*. 2006(2).

Mecocci P, Bladstroem A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. *International Journal of Geriatric Psychiatry*. 2009;24(5):532-8.

Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. *Biochimica Et Biophysica Acta-Molecular Basis of Disease*. 2012;1822(5):631-8.

Medeiros R, Kitazawa M, Caccamo A, Baglietto-Vargas D, Estrada-Hernandez T, Cribbs DH, et al. Loss of Muscarinic M-1 Receptor Exacerbates Alzheimer's Disease-Like Pathology and Cognitive Decline. *American Journal of Pathology*. 2011;179(2):980-91.

Medhurst AD, Roberts JC, Lee J, Chen CPLH, Brown SH, Roman S, et al. Characterization of histamine H-3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice. *British Journal of Pharmacology*. 2009;157(1):130-8.

Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, et al. GSK189254, a novel H-3 receptor antagonist that binds to histamine H-3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. *Journal of Pharmacology and Experimental Therapeutics*. 2007;321(3):1032-45.

Medina DX, Caccamo A, Oddo S. Methylene Blue Reduces A beta Levels and Rescues Early Cognitive Deficit by Increasing Proteasome Activity. *Brain Pathology*. 2011;21(2):140-9.

Meethal SV, Smith MA, Bowen RL, Atwood CS. The gonadotropin connection in Alzheimer's disease. *Endocrine*. 2005;26(3):317-25.

Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, et al. Metabolic patterns associated with the clinical response to galantamine therapy - A fludeoxyglucose F 18 positron emission tomographic study. *Archives of Neurology*. 2005;62(5):721-8.

Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Searce-Levie K, et al. Neprilysin Overexpression Inhibits Plaque Formation But Fails to Reduce Pathogenic A beta Oligomers and Associated Cognitive Deficits in Human Amyloid Precursor Protein Transgenic Mice. *Journal of Neuroscience*. 2009;29(7):1977-86.

Meinert CL, Breitner JCS. Chronic disease long-term drug prevention trials: Lessons from the Alzheimer's disease anti-inflammatory prevention trial (ADAPT). *Alzheimers & Dementia*. 2008;4(1):S7-S14.

Meinert CL, McCaffrey LD, Breitner JCS, Grp AR. Alzheimer's Disease Anti-Inflammatory Prevention Trial: Design, methods, and baseline results. *Alzheimers & Dementia*. 2009;5(2):93-104.

Melani A, Pantoni L, Bordoni F, Gianfriddo M, Bianchi L, Vannucchi MG, et al. The selective A(2A) receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. *Brain Research*. 2003;959(2):243-50.

Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a Serotonin(2A) Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis. *Neuropsychopharmacology*. 2010;35(4):881-92.

Mendes CT, Mury FB, Moreira EdS, Alberto FL, Forlenza OV, Dias-Neto E, et al. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. *European Archives of Psychiatry and Clinical Neuroscience*. 2009;259(1):16-22.

Mendez MF. Frontotemporal Dementia: Therapeutic Interventions. In: Giannakopoulos P, Hof PR, editors. *Dementia in Clinical Practice*. Frontiers of Neurology and Neuroscience. 242009. p. 168-78.

Meraz-Rios MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernandez J, Campos-Pena V. Inflammatory process in Alzheimer's Disease. *Frontiers in integrative neuroscience*. 2013;7:59-.

Merla R, Ye Y, Lin Y, Manickavasagam S, Huang M-H, Perez-Polo RJ, et al. The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. *American Journal of Physiology-Heart and Circulatory Physiology*. 2007;293(3):H1918-H28.

Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. *Endocrine*. 2003;22(1):41-8.

Messer WS. The utility of muscarinic agonists in the treatment of Alzheimer's disease. *Journal of Molecular Neuroscience*. 2002;19(1-2):187-93.

Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, et al. Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnesic mice. *Proceedings of the National Academy of Sciences of the United States of America*. 1998;95(21):12683-8.

Mi K, Johnson GVW. The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. *Current Alzheimer Research*. 2006;3(5):449-63.

Micchelli CA, Esler WP, Kimberly WT, Jack C, Berezovska O, Kornilova A, et al. gamma-Secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in *Drosophila*. *FASEB Journal*. 2003;17(1):79-81.

Michaelis ML, Ranciat N, Chen Y, Bechtel M, Ragan R, Hepperle M, et al. Protection against beta-amyloid toxicity in primary neurons by paclitaxel (Taxol). *Journal of Neurochemistry*. 1998;70(4):1623-7.

Miguel Rubio-Perez J, Maria Morillas-Ruiz J. A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines. *Scientific World Journal*. 2012.

Miguel-Hidalgo JJ, Paul IA, Wanzo V, Banerjee PK. Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid beta(1-40). *European Journal of Pharmacology*. 2012;692(1-3):38-45.

Mikulca JA, Nguyen V, Gajdosik DA, Teklu SG, Giunta EA, Lessa EA, et al. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. *Journal of Clinical Pharmacy and Therapeutics*. 2014;39(1):25-37.

Miller BW, Willett KC, Desilets AR. Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease. *Annals of Pharmacotherapy*. 2011;45(11):1416-24.

Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. *Annals of Internal Medicine*. 2005;142(1):37-46.

Miller G. Stopping Alzheimer's Before It Starts. *Science*. 2012;337(6096):790-2.

Miller LG, Thompson ML, Byrnes JJ, Greenblatt DJ, Shemer A. KINETICS, BRAIN UPTAKE AND RECEPTOR-BINDING OF TANDOSPIRONE AND ITS METABOLITE 1-(2-PYRIMIDINYL)-PIPERAZINE. *Journal of Clinical Psychopharmacology*. 1992;12(5):341-5.

Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. *Journal of Structural Biology*. 2006;155(1):30-7.

Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, et al. Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. *Revue Neurologique*. 2013;169(10):737-43.

Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, et al. Multifunctional Tacrine Derivatives in Alzheimer's Disease. *Current Topics in Medicinal Chemistry*. 2013;13(15):1771-86.

Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. THE CONSORTIUM TO ESTABLISH A REGISTRY FOR ALZHEIMERS-DISEASE (CERAD) .2. STANDARDIZATION OF THE NEUROPATHOLOGIC ASSESSMENT OF ALZHEIMERS-DISEASE. *Neurology*. 1991;41(4):479-86.

Mizuguchi H, Ono S, Hattori M, Fukui H. Inverse Agonistic Activity of Antihistamines and Suppression of Histamine H-1 Receptor Gene Expression. *Journal of Pharmacological Sciences*. 2012;118(1):117-21.

Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. *European Journal of Neurology*. 2010;17(3):405-12.

Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AMA. N-acetylaspartate in the CNS: From neurodiagnostics to neurobiology. *Progress in Neurobiology*. 2007;81(2):89-131.

Moher D. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (vol 8, pg 336, 2010). *International Journal of Surgery*. 2010;8(8):658-.

Mohs RC. The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials. *Genes Brain and Behavior*. 2005;4(3):129-33.

Mohs RC, Cohen L. ALZHEIMERS-DISEASE ASSESSMENT SCALE (ADAS). Psychopharmacology Bulletin. 1988;24(4):627-8.

Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57(3):481-8.

Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's disease assessment scale that broaden its scope. Alzheimer Disease & Associated Disorders. 1997;11:S13-S21.

Molloy DW, Standish TI, Zhou Q, Guyatt G, Grp DS. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial. International Journal of Geriatric Psychiatry. 2013;28(5):463-70.

Monsonogo A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. Journal of Clinical Investigation. 2003;112(3):415-22.

Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, et al. Increased CSF F-2-isoprostane concentration in probable AD. Neurology. 1999;52(3):562-5.

Morales R, Green KM, Soto C. Cross Currents in Protein Misfolding Disorders: Interactions and Therapy. Cns & Neurological Disorders-Drug Targets. 2009;8(5):363-71.

Moreira PI, Santos MS, Moreno A, Oliveira C. Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Bioscience Reports. 2001;21(6):789-800.

Moreira PI, Harris PLR, Zhu X, Santos MS, Oliveira CR, Smith MA, et al. Lipoic acid and n-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. Journal of Alzheimers Disease. 2007;12(2):195-206.

Moreth J, Mavoungou C, Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immunity & Ageing. 2013;10.

Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408(6815):982-5.

Morgan D. Mechanisms of A beta Plaque Clearance following Passive A beta Immunization. Neurodegenerative Diseases. 2005;2(5):261-6.

Mori E, Hashimoto M, Krishnan KR, Doraiswamy PM. What constitutes clinical evidence for neuroprotection in Alzheimer disease - Support for the cholinesterase inhibitors? *Alzheimer Disease & Associated Disorders*. 2006;20(2):S19-S26.

Morihara T, Chu T, Ubeda O, Beech W, Cole GM. Selective inhibition of A beta 42 production by NSAID R-enantiomers. *Journal of Neurochemistry*. 2002;83(4):1009-12.

Morinaga A, Ono K, Ikeda T, Ikeda Y, Shima K, Noguchi-Shinohara M, et al. A Comparison of the Diagnostic Sensitivity of MRI, CBF-SPECT, FDG-PET and Cerebrospinal Fluid Biomarkers for Detecting Alzheimer's Disease in a Memory Clinic. *Dementia and Geriatric Cognitive Disorders*. 2010;30(4):285-92.

Morris JC. THE CLINICAL DEMENTIA RATING (CDR) - CURRENT VERSION AND SCORING RULES. *Neurology*. 1993;43(11):2412-4.

Morris JC. Early-stage and preclinical Alzheimer disease. *Alzheimer Disease & Associated Disorders*. 2005;19(3):163-5.

Morris JC, Aisen PS, Bateman RJ, Benzinger TLS, Cairns NJ, Fagan AM, et al. Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network. *Clinical Investigation*. 2012;2(10):975-84.

Morris JC, McKeel DW, Storandt M, Rubin EH, Price JL, Grant EA, et al. VERY MILD ALZHEIMERS-DISEASE - INFORMANT-BASED CLINICAL, PSYCHOMETRIC, AND PATHOLOGICAL DISTINCTION FROM NORMAL AGING. *Neurology*. 1991;41(4):469-78.

Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease. *Archives of Neurology*. 2009;66(12):1469-75.

Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. *Archives of Neurology*. 2003;60(7):940-6.

Morris MS. Homocysteine and Alzheimer's disease. *Lancet Neurology*. 2003;2(7):425-8.

Morris MC, Evans DA, Schneider JA, Tangney CC, Bienias JL, Aggarwal NT. Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease. *Journal of Alzheimers Disease*. 2006;9(4):435-43.

Morse LJ, Payton SM, Cuny GD, Rogers JT. FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. *Journal of Molecular Neuroscience*. 2004;24(1):129-36.

Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease - FDG-PET studies in MCI and AD. *European Journal of Nuclear Medicine and Molecular Imaging*. 2005;32(4):486-510.

Moss DE, Berlanga P, Hagan MM, Sandoval H, Ishida C. Methanesulfonyl fluoride (MSF): A double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type. *Alzheimer Disease & Associated Disorders*. 1999;13(1):20-5.

Moss DE, Fariello RG, Sahlmann J, Sumaya I, Pericle F, Braglia E. A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease. *British Journal of Clinical Pharmacology*. 2013;75(5):1231-9.

Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, et al. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: A "real world" study. *Archives of Gerontology and Geriatrics*. 2004:297-307.

Motawaj M, Burban A, Davenas E, Arrang JM. Activation of Brain Histaminergic Neurotransmission: A Mechanism for Cognitive Effects of Memantine in Alzheimer's Disease. *Journal of Pharmacology and Experimental Therapeutics*. 2011;336(2):479-87.

Motawaj M, Burban A, Davenas E, Gbahou F, Faucard R, Morisset S, et al. The Histaminergic System: a Target for Innovative Treatments of Cognitive Deficits. *Therapie*. 2010;65(5):415-22.

Motawaj M, Peoc'h K, Callebert J, Arrang J-M. CSF Levels of the Histamine Metabolite tele-Methylhistamine are only Slightly Decreased in Alzheimer's Disease. *Journal of Alzheimers Disease*. 2010;22(3):861-71.

Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. *Alzheimers Research & Therapy*. 2013;5(5).

Mountjoy CQ, Rossor MN, Iversen LL, Roth M. CORRELATION OF CORTICAL CHOLINERGIC AND GABA DEFICITS WITH QUANTITATIVE NEUROPATHOLOGICAL FINDINGS IN SENILE DEMENTIA. *Brain*. 1984;107(JUN):507-18.

Mousavi M, Hellstrom-Lindahl E. Nicotinic receptor agonists and antagonists increase sAPP alpha secretion and decrease A beta levels in vitro. *Neurochemistry International*. 2009;54(3-4):237-44.

Mozayan M, Lee TJF. Statins prevent cholinesterase inhibitor blockade of sympathetic alpha 7-nAChR-mediated currents in rat superior cervical ganglion neurons. *American Journal of Physiology-Heart and Circulatory Physiology*. 2007;293(3):H1737-H44.

Muayqil T, Camicioli R. Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias. *Dementia and geriatric cognitive disorders extra*. 2012;2(1):546-72.

Mudher A, Lovestone S. Alzheimer's disease - do tauists and baptists finally shake hands? *Trends in Neurosciences*. 2002;25(1):22-6.

Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, et al. GSK-3 beta inhibition reverses axonal transport defects and behavioural phenotypes in *Drosophila*. *Molecular Psychiatry*. 2004;9(5):522-30.

Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens V, Meerschman C, et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(23):9810-5.

Mukhejee P, Faber AC, Shelton LM, Baek RC, Chiles TC, Seyfried TN. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a. *Journal of Lipid Research*. 2008;49(5):929-38.

Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, et al. A PATHOGENIC MUTATION FOR PROBABLE ALZHEIMERS-DISEASE IN THE APP GENE AT THE N-TERMINUS OF BETA-AMYLOID. *Nature Genetics*. 1992;1(5):345-7.

Mullard A. Protein-protein interaction inhibitors get into the groove. *Nature reviews Drug discovery*. 2012;11(3):173-5.

Muller AP, Ferreira GK, Pires AJ, de Bem Silveira G, de Souza DL, Brandolfi JdA, et al. Gold nanoparticles prevent cognitive deficits, oxidative stress and inflammation in a rat model of sporadic dementia of Alzheimer's type. *Materials science & engineering C, Materials for biological applications*. 2017;77:476-83.

Mulnard RI, Cotman CW, Kawas C, van Dyck CH, Sano H, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease - A randomized controlled trial. *Jama-Journal of the American Medical Association*. 2000;283(8):1007-15.

Multhaup G, Mechler H, Masters CL. CHARACTERIZATION OF THE HIGH-AFFINITY HEPARIN-BINDING SITE OF THE ALZHEIMERS-DISEASE BETA-A4 AMYLOID PRECURSOR PROTEIN (APP) AND ITS ENHANCEMENT BY ZINC(II). *Journal of Molecular Recognition*. 1995;8(4):247-57.

Mungas D. IN-OFFICE MENTAL STATUS TESTING - A PRACTICAL GUIDE. *Geriatrics*. 1991;46(7):54-&.

Munoz L, Ranaivo HR, Roy SM, Hu W, Craft JM, McNamara LK, et al. Novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. *Journal of Neuroinflammation*. 2007;4.

Muresanu DF, Rainer M, Moessler H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin (R). *Journal of Neural Transmission-Supplement*. 2002(62):277-85.

Murphy MF, Hardiman ST, Nash RJ, Huff FJ, Demkovich JJ, Dobson C, et al. EVALUATION OF HP-029 (VELNACRINE MALEATE) IN ALZHEIMERS-DISEASE. *Annals of the New York Academy of Sciences*. 1991;640:253-62.

Murphy MP, Smith RAJ. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. *Annual Review of Pharmacology and Toxicology*. Annual Review of Pharmacology and Toxicology. 472007. p. 629-56.

Musiek ES, Holtzman DM. Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. *Current Opinion in Neurology*. 2012;25(6):715-20.

Naddafi F, Mirshafiey A. The Neglected Role of Histamine in Alzheimer's Disease. *American Journal of Alzheimers Disease and Other Dementias*. 2013;28(4):327-36.

Naddafi F, Reza Haidari M, Azizi G, Sedaghat R, Mirshafiey A. Novel therapeutic approach by nicotine in experimental model of multiple sclerosis. *Innovations in clinical neuroscience*. 2013;10(4):20-5.

Nagabukuro H, Hashimoto T, Iwata M, Doi T. Effects of TAK-802, a novel acetylcholinesterase inhibitor, and tamsulosin, an alpha(1)-adrenoceptor antagonist, and their synergistic effects on the urodynamic characteristics in a guinea-pig model of functional bladder outlet obstruction. *Bju International*. 2005;95(7):1071-6.

Nagahara AH, Bernot T, Moseanko R, Brignolo L, Blesch A, Conner JM, et al. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. *Experimental Neurology*. 2009;215(1):153-9.

Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. *Nature Medicine*. 2009;15(3):331-7.

Nagy CF, Kumar D, Perdomo CA, Wason S, Cullen EI, Pratt RD. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes

and safety following single and multiple oral doses. *British Journal of Clinical Pharmacology*. 2004;58:25-33.

Nakaya K, Nakagawasai O, Arai Y, Onogi H, Sato A, Nijima F, et al. Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: Involvement of dopamine D-2 and 5-HT_{2A} receptors. *Behavioural Brain Research*. 2011;218(1):165-73.

Naldi M, Fiori J, Pistolozzi M, Drake AF, Bertucci C, Wu R, et al. Amyloid beta-Peptide 25-35 Self-Assembly and Its Inhibition: A Model Undecapeptide System to Gain Atomistic and Secondary Structure Details of the Alzheimer's Disease Process and Treatment. *Acs Chemical Neuroscience*. 2012;3(11):952-62.

Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? *Journal of Neurochemistry*. 2012;120:167-85.

Nalivaeva NN, Belyaev ND, Lewis DI, Pickles AR, Makova NZ, Bagrova DI, et al. Effect of Sodium Valproate Administration on Brain Neprilysin Expression and Memory in Rats. *Journal of Molecular Neuroscience*. 2012;46(3):569-77.

Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. *Current Alzheimer Research*. 2008;5(2):212-24.

Namba Y, Kawatsu K, Izumi S, Ueki A, Ikeda K. NEUROFIBRILLARY TANGLES AND SENILE PLAQUES IN BRAIN OF ELDERLY LEPROSY PATIENTS. *Lancet*. 1992;340(8825):978-.

Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. *Jama-Journal of the American Medical Association*. 2000;283(12):1571-7.

Nathan PJ, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, et al. The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H-3 Receptor Antagonist in Patients with Mild to Moderate Alzheimer's Disease: A Preliminary Investigation. *Current Alzheimer Research*. 2013;10(3):240-51.

Necula M, Breydo L, Milton S, Kaye R, van der Veer WE, Tone P, et al. Methylene blue inhibits amyloid A beta oligomerization by promoting fibrillization. *Biochemistry*. 2007;46(30):8850-60.

Necula M, Kaye R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. *Journal of Biological Chemistry*. 2007;282(14):10311-24.

Nelson C, Wengreen HJ, Munger RG, Corcoran CD, Cache Cty I. DIETARY FOLATE, VITAMIN B-12, VITAMIN B-6 AND INCIDENT ALZHEIMER'S DISEASE: THE CACHE COUNTY MEMORY, HEALTH, AND AGING STUDY. *Journal of Nutrition Health & Aging*. 2009;13(10):899-905.

Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. *Journal of Neuropathology and Experimental Neurology*. 2012;71(5):362-81.

Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. *Experimental Neurology*. 2007;205(1):166-76.

Nenov MN, Laezza F, Haidacher SJ, Zhao Y, Sadygov RG, Starkey JM, et al. Cognitive Enhancing Treatment with a PPAR gamma Agonist Normalizes Dentate Granule Cell Presynaptic Function in Tg2576 APP Mice. *Journal of Neuroscience*. 2014;34(3):1028-36.

Netzer WJ, Dou F, Cai DM, Veach D, Jean S, Li YM, et al. Gleevec inhibits beta-amyloid production but not Notch cleavage. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100(21):12444-9.

Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, et al. Nicotine treatment of mild cognitive impairment A 6-month double-blind pilot clinical trial. *Neurology*. 2012;78(2):91-101.

Ng T-P, Chiam P-C, Lee T, Chua H-C, Lim L, Kua E-H. Curry consumption and cognitive function in the elderly. *American Journal of Epidemiology*. 2006;164(9):898-906.

Ni R, Marutle A, Nordberg A. Modulation of alpha 7 Nicotinic Acetylcholine Receptor and Fibrillar Amyloid-beta Interactions in Alzheimer's Disease Brain. *Journal of Alzheimers Disease*. 2013;33(3):841-51.

Ni Y, Zhao X, Bao G, Zou L, Teng L, Wang Z, et al. Activation of beta(2)-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. *Nature Medicine*. 2006;12(12):1390-6.

Nicolakakis N, Aboukassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. *Journal of Neuroscience*. 2008;28(37):9287-96.

Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. *Nature Medicine*. 2003;9(4):448-52.

Nikolaev A, McLaughlin T, O'Leary DDM, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. *Nature*. 2009;457(7232):981-U1.

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *New England Journal of Medicine*. 2007;356(24):2457-71.

Nitsch RM, Deng MH, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total A beta in cerebrospinal fluid of patients with Alzheimer's disease. *Annals of Neurology*. 2000;48(6):913-8.

Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. RELEASE OF ALZHEIMER AMYLOID PRECURSOR DERIVATIVES STIMULATED BY ACTIVATION OF MUSCARINIC ACETYLCHOLINE-RECEPTORS. *Science*. 1992;258(5080):304-7.

Niva C, Parkinson J, Olsson F, van Schaick E, Lundkvist J, Visser SAG. Has inhibition of A beta production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of gamma-secretase inhibitor data. *European Journal of Clinical Pharmacology*. 2013;69(6):1247-60.

Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102(19):6990-5.

Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. *FASEB Journal*. 2009;23(3):739-50.

Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. *Alzheimer Disease & Associated Disorders*. 2006;20(2):S12-S8.

Nordberg A, Winblad B. REDUCED NUMBER OF H-3 NICOTINE AND H-3 ACETYLCHOLINE BINDING-SITES IN THE FRONTAL-CORTEX OF ALZHEIMER BRAINS. *Neuroscience Letters*. 1986;72(1):115-9.

Nordberg A. Amyloid Imaging in Early Detection of Alzheimer's Disease. *Neurodegenerative Diseases*. 2010;7(1-3):136-8.

Norton MC, Smith KR, Ostbye T, Tschanz JT, Corcoran C, Schwartz S, et al. Greater Risk of Dementia When Spouse Has Dementia? The Cache County Study. *Journal of the American Geriatrics Society*. 2010;58(5):895-900.

Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi C, et al. Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. *Drug Design Development and Therapy*. 2013;7:1359-64.

Novelli A, Reilly JA, Lysko PG, Henneberry RC. GLUTAMATE BECOMES NEUROTOXIC VIA THE N-METHYL-D-ASPARTATE RECEPTOR WHEN INTRACELLULAR ENERGY-LEVELS ARE REDUCED. *Brain Research*. 1988;451(1-2):205-12.

Nunes MA, Viel TA, Buck HS. Microdose Lithium Treatment Stabilized Cognitive Impairment in Patients with Alzheimer's Disease. *Current Alzheimer Research*. 2013;10(1):104-7.

Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. *British Journal of Psychiatry*. 2007;190:359-60.

Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*. 2001;60(8):759-67.

Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*. 2006;65(7):631-41.

O'Brien RJ, Wong PC. Amyloid Precursor Protein Processing and Alzheimer's Disease. In: Hyman SE, Jessell TM, Shatz CJ, Stevens CF, Zoghbi HY, editors. *Annual Review of Neuroscience*, Vol 34. *Annual Review of Neuroscience*. 342011. p. 185-204.

O'Donnell BF, Drachman DA, Barnes HJ, Peterson KE, Swearer JM, Lew RA. Incontinence and troublesome behaviors predict institutionalization in dementia. *Journal of geriatric psychiatry and neurology*. 1992;5(1):45-52.

O'Leary JC, III, Li Q, Marinec P, Blair LJ, Congdon EE, Johnson AG, et al. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. *Molecular Neurodegeneration*. 2010;5.

Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. A beta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. *Neuron*. 2004;43(3):321-32.

Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM. Reduction of soluble A beta and Tau, but not soluble A beta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. *Journal of Biological Chemistry*. 2006;281(51):39413-23.

Oehlrich D, Berthelot DJC, Gijsen HJM. gamma-Secretase Modulators as Potential Disease Modifying Anti-Alzheimer's Drugs. *Journal of Medicinal Chemistry*. 2011;54(3):669-98.

Ofengeim D, Shi P, Miao B, Fan J, Xia X, Fan Y, et al. Identification of Small Molecule Inhibitors of Neurite Loss Induced by A beta peptide using High Content Screening. *Journal of Biological Chemistry*. 2012;287(12):8714-23.

Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. *Neuron*. 2004;41(1):27-33.

Okamura N, Funaki Y, Tashiro M, Kato M, Ishikawa Y, Maruyama M, et al. In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease. *British Journal of Clinical Pharmacology*. 2008;65(4):472-9.

Okamura N, Yanai K. Florbetapir (F-18), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease. *Idrugs*. 2010;13(12):890-9.

Okun I, Tkachenko SE, Khvat A, Mitkin O, Kazey V, Ivachtchenko AV. From Anti-allergic to Anti-Alzheimer's: Molecular Pharmacology of Dimebon (TM). *Current Alzheimer Research*. 2010;7(2):97-112.

Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. *Journal of Pineal Research*. 2009;47(1):82-96.

Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease - Rationale and background. *American Journal of Geriatric Psychiatry*. 2002;10(2):129-41.

Olin JT, Schneider LS, Doody RS, Clark CM, Ferris SH, Morris JC, et al. Clinical evaluation of global change in Alzheimer's disease: Identifying consensus. *Journal of Geriatric Psychiatry and Neurology*. 1996;9(4):176-80.

Oliveira AA, Jr., Hodges HM. Alzheimer's disease and neural transplantation as prospective cell therapy. *Current Alzheimer Research*. 2005;2(1):79-95.

Oliveira TG, Chan RB, Tian H, Laredo M, Shui G, Staniszewski A, et al. Phospholipase D2 Ablation Ameliorates Alzheimer's Disease-Linked Synaptic Dysfunction and Cognitive Deficits. *Journal of Neuroscience*. 2010;30(49):16419-28.

Olson L, Nordberg A, Vonholst H, Backman L, Ebendal T, Alafuzoff I, et al. NERVE GROWTH-FACTOR AFFECTS C-11 NICOTINE BINDING, BLOOD-FLOW, EEG, AND VERBAL EPISODIC MEMORY IN AN ALZHEIMER PATIENT. *Journal of Neural Transmission-Parkinsons Disease and Dementia Section*. 1992;4(1):79-95.

Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid((1-42)), total tau, and phosphorylated tau (Thr(181)) in cerebrospinal fluid by the xMAP technology. *Clinical Chemistry*. 2005;51(2):336-45.

Ono K, Hasegawa K, Naiki H, Yamada M. Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro. *Biochimica Et Biophysica Acta-Molecular Basis of Disease*. 2004;1690(3):193-202.

Ono K, Hirohata M, Yamada M. alpha-Lipoic acid exhibits anti-amyloidogenicity for beta-amyloid fibrils in vitro. *Biochemical and Biophysical Research Communications*. 2006;341(4):1046-52.

Ono K, Condron MM, Ho L, Wang J, Zhao W, Pasinetti GM, et al. Effects of Grape Seed-derived Polyphenols on Amyloid beta-Protein Self-assembly and Cytotoxicity. *Journal of Biological Chemistry*. 2008;283(47):32176-87.

Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimer's disease: an update. *Clinical Interventions in Aging*. 2007;2(1):17-32.

Onyango IG, Tuttle JB, Bennett JP. Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE). *Molecular and Cellular Neuroscience*. 2005;29(2):333-43.

Opii W, Joshi G, Head E, Milgram NW, Muggenburg BA, Kleine JB, et al. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: Relevance to Alzheimer's disease. *Neurobiology of Aging*. 2008;29(1):51-70.

Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, et al. Drug Repurposing from an Academic Perspective. *Drug discovery today Therapeutic strategies*. 2011;8(3-4):61-9.

Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, et al. Wine consumption and dementia in the elderly: A prospective community study in the Bordeaux area. *Revue Neurologique*. 1997;153(3):185-92.

Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after A beta 42 immunization. *Neurology*. 2003;61(1):46-54.

Orr SK, Bazinet RP. The emerging role of docosahexaenoic acid in neuroinflammation. *Current Opinion in Investigational Drugs*. 2008;9(7):735-43.

Orsucci D, Mancuso M, Ienco EC, Simoncini C, Siciliano G, Bonuccelli U. Vascular Factors and Mitochondrial Dysfunction: a Central Role in the Pathogenesis of Alzheimer's Disease. *Current Neurovascular Research*. 2013;10(1):76-80.

Ory MG, Hoffman RR, Yee JL, Tennstedt S, Schulz R. Prevalence and impact of caregiving: A detailed comparison between dementia and nondementia caregivers. *Gerontologist*. 1999;39(2):177-85.

Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab. *Archives of Neurology*. 2012;69(2):198-207.

Othman AA, Haig G, Florian H, Locke C, Zhang J, Dutta S. Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers. *British Journal of Clinical Pharmacology*. 2013;75(5):1299-311.

Ott A, Breteler MMB, van Harskamp F, Stijnen T, Hofman A. Incidence and risk of dementia - The Rotterdam Study. *American Journal of Epidemiology*. 1998;147(6):574-80.

Ott BR, Owens NJ. Complementary and alternative medicines for Alzheimer's disease. *Journal of Geriatric Psychiatry and Neurology*. 1998;11(4):163-73.

Oules B, Del Prete D, Greco B, Zhang X, Lauritzen I, Sevalle J, et al. Ryanodine Receptor Blockade Reduces Amyloid-beta Load and Memory Impairments in Tg2576 Mouse Model of Alzheimer Disease. *Journal of Neuroscience*. 2012;32(34):11820-34.

Owen AM, Hampshire A, Grahn JA, Stenton R, Dajani S, Burns AS, et al. Putting brain training to the test. *Nature*. 2010;465(7299):775-U6.

Oz M, Lorke DE, Petroianu GA. Methylene blue and Alzheimer's disease. *Biochemical Pharmacology*. 2009;78(8):927-32.

Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. The Effect of HMG-CoA Reductase Inhibitors on Cognition in Patients With Alzheimer's Dementia: A Prospective Withdrawal and Rechallenge Pilot Study. *American Journal of Geriatric Pharmacotherapy*. 2012;10(5):296-302.

Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, et al. Methylphenidate for Apathy and Functional Status in Dementia of the Alzheimer Type. *American Journal of Geriatric Psychiatry*. 2010;18(4):371-4.

Page RM, Baumann K, Tomioka M, Perez-Revuelta BI, Fukumori A, Jacobsen H, et al. Generation of A beta(38) and A beta(42) is independently and differentially affected by familial

Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. *Journal of Biological Chemistry*. 2008;283(2):677-83.

Pakrasi S, Mukaetova-Ladinska EB, McKeith IG, O'Brien JT. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle. *International Journal of Geriatric Psychiatry*. 2003;18(10):879-86.

Pakrasi S, O'Brien JT. Emission tomography in dementia. *Nuclear Medicine Communications*. 2005;26(3):189-96.

Pallebage-Gamarallage M, Lam V, Takechi R, Galloway S, Clark K, Mamo J. Restoration of dietary-fat induced blood-brain barrier dysfunction by anti-inflammatory lipid-modulating agents. *Lipids in Health and Disease*. 2012;11.

Pang YP, Kozikowski AP. PREDICTION OF THE BINDING-SITE OF 1-BENZYL-4- (5,6-DIMETHOXY-1-INDANON-2-YL)METHYL PIPERIDINE IN ACETYLCHOLINESTERASE BY DOCKING STUDIES WITH THE SYSDOC PROGRAM. *Journal of Computer-Aided Molecular Design*. 1994;8(6):683-93.

Panisset M, Gauthier S, Moessler H, Windisch M, The Cerebrolysin Study G. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. *Journal of Neural Transmission*. 2002;109(7-8):1089-104.

Panisset M, Roudier M, Saxton J, Boller F. A NEUROPSYCHOLOGICAL TEST BATTERY FOR THE ASSESSMENT OF SEVERELY DEMENTED PATIENTS - VALIDATION-STUDY. *Presse Medicale*. 1992;21(27):1271-4.

Panza F, Frisardi V, Imbimbo BP, D'Onofrio G, Pietrarossa G, Seripa D, et al. Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. *Immunotherapy*. 2010;2(6):767-82.

Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A. Monoclonal antibodies against beta-amyloid (A beta) for the treatment of Alzheimer's disease: the A beta target at a crossroads. *Expert Opinion on Biological Therapy*. 2011;11(6):679-86.

Panza F, Logroscino G, Imbimbo BP, Solfrizzi V. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? *Current Opinion in Psychiatry*. 2014;27(2):128-37.

Papadopoulos P, Rosa-Neto P, Rochford J, Hamel E. Pioglitazone Improves Reversal Learning and Exerts Mixed Cerebrovascular Effects in a Mouse Model of Alzheimer's Disease with Combined Amyloid-beta and Cerebrovascular Pathology. *Plos One*. 2013;8(7).

Parachikova A, Green KN, Hendrix C, LaFerla FM. Formulation of a Medical Food Cocktail for Alzheimer's Disease: Beneficial Effects on Cognition and Neuropathology in a Mouse Model of the Disease. *Plos One*. 2010;5(11).

Parachikova A, Vasilevko V, Cribbs DH, LaFerla FM, Green KN. Reductions in Amyloid-beta-Derived Neuroinflammation, with Minocycline, Restore Cognition but do not Significantly Affect Tau Hyperphosphorylation. *Journal of Alzheimers Disease*. 2010;21(2):527-42.

Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, et al. Nilvadipine antagonizes both A beta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. *Brain Research*. 2004;999(1):53-61.

Paris D, Bachmeier C, Patel N, Quadros A, Volmar C-H, Laporte V, et al. Selective Antihypertensive Dihydropyridines Lower A beta Accumulation by Targeting both the Production and the Clearance of A beta across the Blood-Brain Barrier. *Molecular Medicine*. 2011;17(3-4):149-62.

Park JH, Gimbel DA, GrandPre T, Lee JK, Kim JE, Li WW, et al. Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. *Journal of Neuroscience*. 2006;26(5):1386-95.

Park JH, Strittmatter SM. Nogo receptor interacts with brain APP and A beta to reduce pathologic changes in Alzheimer's transgenic mice. *Current Alzheimer Research*. 2007;4(5):568-70.

Park JH, Widi GA, Gimbel DA, Harel NY, Lee DHS, Strittmatter SM. Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice. *Journal of Neuroscience*. 2006;26(51):13279-86.

Park SM, Ki SH, Han NR, Cho IJ, Ku SK, Kim SC, et al. Tacrine, an Oral Acetylcholinesterase Inhibitor, Induced Hepatic Oxidative Damage, Which Was Blocked by Liquiritigenin through GSK3-beta Inhibition. *Biological & Pharmaceutical Bulletin*. 2015;38(2):184-92.

Park SH, Kim JH, Bae SS, Hong KW, Lee D-S, Leem JY, et al. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation. *Biochemical and Biophysical Research Communications*. 2011;408(4):602-8.

Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study. *Plos Medicine*. 2009;6(9).

Parker WD, Parks J, Filley CM, Kleinschmidt-Demasters BK. ELECTRON-TRANSPORT CHAIN DEFECTS IN ALZHEIMERS-DISEASE BRAIN. *Neurology*. 1994;44(6):1090-6.

Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, et al. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(26):11062-7.

Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, et al. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. *Neurological Sciences*. 2002;23:S95-S6.

Parri RH, Dineley TK. Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences. *Current Alzheimer research*. 2010;7(1):27-39.

Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. *Neuropharmacology*. 1999;38(6):735-67.

Parsons CG, Stoeffer A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. *Neuropharmacology*. 2007;53(6):699-723.

Parthasarathy V, Hoelscher C. Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model. *Plos One*. 2013;8(3).

Parthasarathy V, Hoelscher C. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. *European Journal of Pharmacology*. 2013;700(1-3):42-50.

Passani MB, Blandina P. Cognitive implications for H-3 and 5-HT3 receptor modulation of cortical cholinergic function: A parallel story. *Methods and Findings in Experimental and Clinical Pharmacology*. 1998;20(8):725-33.

Patat A, Parks V, Raje S, Plotka A, Chassard D, Le Coz F. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. *British Journal of Clinical Pharmacology*. 2009;67(3):299-308.

Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nature Reviews Drug Discovery*. 2010;9(3):203-14.

Paulson JB, Ramsden M, Forster C, Sherman MA, McGowan E, Ashe KH. Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. *American Journal of Pathology*. 2008;173(3):762-72.

Payao SLM, Smith MD, Bertolucci PHF. Differential chromosome sensitivity to 5-azacytidine in Alzheimer's disease. *Gerontology*. 1998;44(5):267-71.

Payton S, Cahill CM, Randall JD, Gullans SR, Rogers JT. Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region - The action of paroxetine and dimercaptopropanol. *Journal of Molecular Neuroscience*. 2003;20(3):267-75.

Pedersen WA, Flynn ER. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. *Neurobiology of Disease*. 2004;17(3):500-6.

Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. *Experimental Neurology*. 2006;199(2):265-73.

Pei J-J, Sjoegren M, Winblad B. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets. *Current Opinion in Psychiatry*. 2008;21(6):555-61.

Peng J, Liang G, Inan S, Wu Z, Joseph DJ, Meng Q, et al. Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. *Neuroscience Letters*. 2012;516(2):274-9.

Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. *Experimental Neurology*. 2008;210(1):154-63.

Peng Y, Lee DYW, Jiang L, Ma Z, Schachter SC, Lemere CA. Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695. *Neuroscience*. 2007;150(2):386-95.

Perry EK, Perry RH, Blessed G, Tomlinson BE. NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA. *Lancet*. 1977;1(8004):189-.

Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. CORRELATION OF CHOLINERGIC ABNORMALITIES WITH SENILE PLAQUES AND MENTAL TEST-SCORES IN SENILE DEMENTIA. *British Medical Journal*. 1978;2(6150):1457-9.

Perry G, Taddeo MA, Petersen RB, Castellani RJ, Harris PLR, Siedlak SL, et al. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. *Biometals*. 2003;16(1):77-81.

Perry T, Lahiri DK, Sambamurti K, Chen DM, Mattson MP, Egan JM, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (A beta) levels and protects hippocampal

neurons from death induced by A beta and iron. *Journal of Neuroscience Research*. 2003;72(5):603-12.

Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. *American Journal of Geriatric Psychiatry*. 2006;14(8):704-15.

Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. *Lancet Neurology*. 2008;7(8):683-9.

Petersen CAH, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I, et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. *Proceedings of the National Academy of Sciences of the United States of America*. 2008;105(35):13145-50.

Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. *Archives of Neurology*. 2001;58(12):1985-92.

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment - Clinical characterization and outcome. *Archives of Neurology*. 1999;56(3):303-8.

Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. *New England Journal of Medicine*. 2005;352(23):2379-88.

Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, et al. Mannan-Abeta(28) conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. *Journal of Neuroinflammation*. 2008;5.

Pfaffendorf M, Bruning TA, Batink HD, vanZwieten PA. The interaction between methylene blue and the cholinergic system. *British Journal of Pharmacology*. 1997;122(1):95-8.

Phan HTT, Hata T, Morita M, Yoda T, Hamada T, Vestergaard MdC, et al. The effect of oxysterols on the interaction of Alzheimer's amyloid beta with model membranes. *Biochimica Et Biophysica Acta-Biomembranes*. 2013;1828(11):2487-95.

Phiel CJ, Wilson CA, Lee VMY, Klein PS. GSK-3 alpha regulates production of Alzheimer's disease amyloid-beta peptides. *Nature*. 2003;423(6938):435-9.

Philippu A, Prast H. Importance of histamine in modulatory processes, locomotion and memory. *Behavioural Brain Research*. 2001;124(2):151-9.

Pierrot N, Tyteca D, D'Auria L, Dewachter I, Gailly P, Hendrickx A, et al. Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. *Embo Molecular Medicine*. 2013;5(4):608-25.

Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB. Functional network disruption in the degenerative dementias. *Lancet Neurology*. 2011;10(9):829-43.

Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. NEURODEGENERATION INDUCED BY BETA-AMYLOID PEPTIDES INVITRO - THE ROLE OF PEPTIDE ASSEMBLY STATE. *Journal of Neuroscience*. 1993;13(4):1676-87.

Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. INVITRO AGING OF BETA-AMYLOID PROTEIN CAUSES PEPTIDE AGGREGATION AND NEUROTOXICITY. *Brain Research*. 1991;563(1-2):311-4.

Pike CJ, Walencewiczwasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. STRUCTURE-ACTIVITY ANALYSES OF BETA-AMYLOID PEPTIDES - CONTRIBUTIONS OF THE BETA-25-35 REGION TO AGGREGATION AND NEUROTOXICITY. *Journal of Neurochemistry*. 1995;64(1):253-65.

Pilotto A, Franceschi M, D'Onofrio G, Bizzarro A, Mangialasche F, Cascavilla L, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. *Neurology*. 2009;73(10):761-7.

Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. *International Journal of Biochemistry & Cell Biology*. 2009;41(6):1261-8.

Pinero DJ, Hu J, Connor JR. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. *Cellular and Molecular Biology*. 2000;46(4):761-76.

Pinto T, Lanctot KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. *Ageing Research Reviews*. 2011;10(4):404-12.

Pippi M, Mecocci P, Saxton J, Bartorelli L, Pettenati C, Bonaiuto S, et al. Neuropsychological assessment of the severely impaired elderly patient: Validation of the Italian short version of the Severe Impairment Battery (SIB). *Aging-Clinical and Experimental Research*. 1999;11(4):221-6.

Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperli T, et al. Effects of insulin therapy on cognitive impairment in patients with Alzheimer disease and Diabetes Mellitus type-2. *Journal of the Neurological Sciences*. 2010;288(1-2):112-6.

Plattner F, Angelo M, Giese KP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. *Journal of Biological Chemistry*. 2006;281(35):25457-65.

Plosker GL, Gauthier S. Cerebrolysin A Review of its Use in Dementia. *Drugs & Aging*. 2009;26(11):893-915.

Pocernich CB, Lange MLB, Sultana R, Butterfield DA. Nutritional Approaches to Modulate Oxidative Stress in Alzheimer's Disease. *Current Alzheimer Research*. 2011;8(5):452-69.

Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, et al. AGGREGATION OF SECRETED AMYLOID BETA-PROTEIN INTO SODIUM DODECYL SULFATE-STABLE OLIGOMERS IN CELL-CULTURE. *Journal of Biological Chemistry*. 1995;270(16):9564-70.

Pogacic V, Herrling P. List of drugs in development for neurodegenerative diseases. *Neurodegenerative Diseases*. 2007;4(6):443-86.

Pohanka M. Alpha7 Nicotinic Acetylcholine Receptor Is a Target in Pharmacology and Toxicology. *International Journal of Molecular Sciences*. 2012;13(2):2219-38.

Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. *Proceedings of the National Academy of Sciences of the United States of America*. 1995;92(26):12260-4.

Poirier R, Wolfer DP, Welzl H, Tracy J, Galsworthy MJ, Nitsch RM, et al. Neuronal neprilysin overexpression is associated with attenuation of A beta-related spatial memory deficit. *Neurobiology of Disease*. 2006;24(3):475-83.

Polinsky RJ. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. *Clinical Therapeutics*. 1998;20(4):634-47.

Polizzi S, Pira E, Ferrara M, Bugiani M, Papaleo A, Albera R, et al. Neurotoxic effects of aluminium among foundry workers and Alzheimer's disease. *Neurotoxicology*. 2002;23(6):761-74.

Pollack SJ, Lewis H. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. *Current opinion in investigational drugs (London, England : 2000)*. 2005;6(1):35-47.

Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. *American Journal of Psychiatry*. 2002;159(3):460-5.

Pomara N, Doraiswamy PM, Tun H, Ferris S. Mifepristone (RU 486) for Alzheimer's disease. *Neurology*. 2002;58(9):1436-7.

Popovic M, Caballero-Bleda M, Popovic N, Bokonjic D, Dobric S. Neuroprotective effect of chronic verapamil treatment on cognitive and noncognitive deficits in an experimental Alzheimer's disease in rats. *International Journal of Neuroscience*. 1997;92(1-2):79-93.

Porrino LJ, Daunais JB, Rogers GA, Hampson RE, Deadwyler SA. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. *Plos Biology*. 2005;3(9):1639-52.

Porsteinsson AP, Tariot PN, Erb R, Gaile S. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. *American Journal of Geriatric Psychiatry*. 1997;5(4):344-51.

Porsteinsson AP, Tariot PN, Jakimovich LJ, Kowalski N, Holt C, Erb R, et al. Valproate therapy for agitation in dementia - Open-label extension of a double-blind trial. *American Journal of Geriatric Psychiatry*. 2003;11(4):434-40.

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Memantine MEMMDSG. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial. *Current Alzheimer Research*. 2008;5(1):83-9.

Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. *Journal of Clinical Investigation*. 2004;113(10):1456-64.

Postina R. Activation of α -secretase cleavage. *Journal of Neurochemistry*. 2012;120:46-54.

Poteet E, Winters A, Yan L-J, Shufelt K, Green KN, Simpkins JW, et al. Neuroprotective Actions of Methylene Blue and Its Derivatives. *Plos One*. 2012;7(10).

Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. *Psychopharmacology*. 1999;142(4):334-42.

Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer's disease. *Neurochemical Research*. 1998;23(1):81-8.

Prasanthi JRP, Dasari B, Marwarha G, Larson T, Chen X, Geiger JD, et al. Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. *Free Radical Biology and Medicine*. 2010;49(7):1212-20.

Pratico D, Clark CM, Lee VMY, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8,12-iso-iPF(2 α)-VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. *Annals of Neurology*. 2000;48(5):809-12.

Pratico D, Uryu K, Leight S, Trojanowski JQ, Lee VMY. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. *Journal of Neuroscience*. 2001;21(12):4183-7.

Pratico D, Uryu K, Sung S, Tang S, Trojanowski JQ, Lee VMY. Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. *Faseb Journal*. 2002;16(7):1138-+.

Price AR, Xu G, Sieminski ZB, Smithson LA, Borchelt DR, Golde TE, et al. Comment on "ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models". *Science*. 2013;340(6135).

Price DL, Bonhaus DW, McFarland K. Pimavanserin, a 5-HT_{2A} receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. *Behavioural Pharmacology*. 2012;23(4):426-33.

Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. *Annals of Neurology*. 1999;45(3):358-68.

Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, et al. EVP-6124, a novel and selective alpha 7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha 7 nicotinic acetylcholine receptors. *Neuropharmacology*. 2012;62(2):1099-110.

Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS. Progress in the active immunotherapeutic approach to Alzheimer's disease: Clinical investigations into AN1792-Associated meningoencephalitis. *Neurodegenerative Diseases*. 2008;5(3-4):194-6.

Proffen LA, Porsteinsson AP, Faraone SV. Meta-Analysis of Alzheimer's Disease Risk with Obesity, Diabetes, and Related Disorders. *Biological Psychiatry*. 2010;67(6):505-12.

Prokselj T, Jerin A, Kogoj A. Memantine may affect pseudobulbar affect in patients with Alzheimer's disease. *Acta Neuropsychiatrica*. 2013;25(6):361-6.

Prusiner SB. A Unifying Role for Prions in Neurodegenerative Diseases. *Science*. 2012;336(6088):1511-3.

Puzzo D, Staniszewski A, Shi X, Privitera L, Leznik E, Liu S, et al. Phosphodiesterase 5 Inhibition Improves Synaptic Function, Memory, and Amyloid-beta Load in an Alzheimer's Disease Mouse Model. *Journal of Neuroscience*. 2009;29(25):8075-86.

Qin W, Haroutunian V, Katsel P, Cardozo CP, Ho L, Buxbaum JD, et al. PGC-1 alpha Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia. *Archives of Neurology*. 2009;66(3):352-61.

Qing H, He G, Ly PTT, Fox CJ, Staufenbiel M, Cai F, et al. Valproic acid inhibits A beta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. *Journal of Experimental Medicine*. 2008;205(12):2781-9.

Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang JM, Podlisny MB, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. *Journal of Biological Chemistry*. 1998;273(49):32730-8.

Qosa H, Abuznait AH, Hill RA, Kaddoumi A. Enhanced Brain Amyloid-beta Clearance by Rifampicin and Caffeine as a Possible Protective Mechanism Against Alzheimer's Disease. *Journal of Alzheimers Disease*. 2012;31(1):151-65.

Qu BX, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN. A beta(42) gene vaccination reduces brain amyloid plaque burden in transgenic mice. *Journal of the Neurological Sciences*. 2006;244(1-2):151-8.

Qu BX, Rosenberg RN, Li LP, Boyer PJ, Johnston SA. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. *Archives of Neurology*. 2004;61(12):1859-64.

Querfurth HW, LaFerla FM. MECHANISMS OF DISEASE Alzheimer's Disease. *New England Journal of Medicine*. 2010;362(4):329-44.

Quinn J, Kulhanek D, Nowlin J, Jones R, Pratico D, Rokach J, et al. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: Implications for clinical trials. *Brain Research*. 2005;1037(1-2):209-13.

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease A Randomized Trial. *Jama-Journal of the American Medical Association*. 2010;304(17):1903-11.

Quirk JC, Nisenbaum ES. LY404187: A novel positive allosteric modulator of AMPA receptors. *Cns Drug Reviews*. 2002;8(3):255-82.

Raber J, Huang YD, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. *Neurobiology of Aging*. 2004;25(5):641-50.

Rabinovich-Nikitin I, Rakover IS, Becker M, Solomon B. Beneficial Effect of Antibodies against beta- Secretase Cleavage Site of App on Alzheimer's-Like Pathology in Triple-Transgenic Mice. *Plos One*. 2012;7(10).

Racchi M, Mazzucchelli M, Porrello E, Lanni C, Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. *Pharmacological Research*. 2004;50(4):441-51.

Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. *Journal of Neuroscience*. 2005;25(3):629-36.

Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. *Neurology*. 2011;76(16):1389-94.

Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. *Annals of Internal Medicine*. 2008;148(5):379-W85.

Raje S, Patat AA, Parks V, Schechter L, Plotka A, Paul J, et al. A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease. *Clinical Pharmacology & Therapeutics*. 2008;83(1):86-96.

Rajendran L, Schneider A, Schlechtingen G, Weidlich S, Ries J, Braxmeier T, et al. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. *Science*. 2008;320(5875):520-3.

Rakover I, Arbel M, Solomon B. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain A beta levels. *Neurodegenerative Diseases*. 2007;4(5):392-402.

Ramassamy C, Longpre F, Christen Y. Ginkgo biloba extract (EGb 761) in Alzheimer's disease: Is there any evidence? *Current Alzheimer Research*. 2007;4(3):253-62.

Rametti A, Esclaire F, Yardin C, Cogne N, Terro F. Lithium down-regulates tau in cultured cortical neurons: A possible mechanism of neuroprotection. *Neuroscience Letters*. 2008;434(1):93-8.

Ramirez MJ, Lai MKP, Tordera RM, Francis PT. Serotonergic Therapies for Cognitive Symptoms in Alzheimer's Disease: Rationale and Current Status. *Drugs*. 2014;74(7):729-36.

Ramirez-Bermudez J. Alzheimer's Disease: Critical Notes on the History of a Medical Concept. *Archives of Medical Research*. 2012;43(8):595-9.

Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: An update. *Current Neuropharmacology*. 2008;6(1):55-78.

Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes

antagonise 5-HT₃ receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. *Neuroscience Letters*. 2001;306(1-2):81-4.

Rammes G, Hasenjaeger A, Sroka-Saidi K, Deussing JM, Parsons CG. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. *Neuropharmacology*. 2011;60(6):982-90.

Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, et al. Expression of Nrf2 in neurodegenerative diseases. *Journal of Neuropathology and Experimental Neurology*. 2007;66(1):75-85.

Rao SD, Banack SA, Cox PA, Weiss JH. BMAA selectively injures motor neurons via AMPA/kainate receptor activation. *Experimental Neurology*. 2006;201(1):244-52.

Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. *Proceedings of the National Academy of Sciences of the United States of America*. 2002;99(9):6364-9.

Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomised trials. *Plos Medicine*. 2007;4(11):1818-28.

Raskind MA, Peskind ER, Wessel T, Yuan W, Galantamine USASG. Galantamine in AD - A 6-month randomized, placebo-controlled trial with a 6-month extension. *Neurology*. 2000;54(12):2261-8.

Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al. Neuroprotective agents for clinical trials in Parkinson's disease - A systematic assessment. *Neurology*. 2003;60(8):1234-40.

Razavi SF, Khoobi M, Nadri H, Sakhteman A, Moradi A, Emami S, et al. Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors. *European Journal of Medicinal Chemistry*. 2013;64:252-9.

Razay G, Wilcock GK. Galantamine in Alzheimer's disease. *Expert review of neurotherapeutics*. 2008;8(1):9-17.

Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, et al. Statin use and the risk of incident dementia - The cardiovascular health study. *Archives of Neurology*. 2005;62(7):1047-51.

Reddy AS, Izmitli A, de Pablo JJ. Effect of trehalose on amyloid beta (29-40)-membrane interaction. *Journal of Chemical Physics*. 2009;131(8).

Reddy PH, Reddy TP. Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases. *Current Alzheimer Research*. 2011;8(4):393-409.

Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. *Trends in Molecular Medicine*. 2008;14(2):45-53.

Rees TM, Brimijoin S. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. *Drugs of Today*. 2003;39(1):75-83.

Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. *Neurobiology of Disease*. 2001;8(5):890-9.

Refolo LM, Sambamurti K, Efthimiopoulos S, Pappolla MA, Robakis NK. EVIDENCE THAT SECRETASE CLEAVAGE OF CELL-SURFACE ALZHEIMER AMYLOID PRECURSOR OCCURS AFTER NORMAL ENDOCYTIC INTERNALIZATION. *Journal of Neuroscience Research*. 1995;40(5):694-706.

Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. *Neurobiology of Aging*. 2004;25(3):311-4.

Reger MA, Watson GS, Frey WH, Baker LD, Cholerton B, Keeling ML, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. *Neurobiology of Aging*. 2006;27(3):451-8.

Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. *Neurology*. 2008;70(6):440-8.

Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. *Journal of Alzheimers Disease*. 2008;13(3):323-31.

Reid PR, Bridges TM, Sheffler DJ, Cho HP, Lewis LM, Days E, et al. Discovery and optimization of a novel, selective and brain penetrant M-1 positive allosteric modulator (PAM): The development of ML169, an MLPCN probe. *Bioorganic & Medicinal Chemistry Letters*. 2011;21(9):2697-701.

Reiman EM, Caselli RJ, Yun LS, Chen KW, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. *New England Journal of Medicine*. 1996;334(12):752-8.

Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(16):6820-5.

Reiman EM, Langbaum JBS, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, et al. Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments. *Journal of Alzheimers Disease*. 2011;26:321-9.

Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib - No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. *Neurology*. 2004;62(1):66-71.

Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. BEHAVIORAL SYMPTOMS IN ALZHEIMERS-DISEASE - PHENOMENOLOGY AND TREATMENT. *Journal of Clinical Psychiatry*. 1987;48:9-15.

Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. *Archives of Neurology*. 2006;63(1):49-54.

Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. *New England Journal of Medicine*. 2003;348(14):1333-41.

Reisberg B, Ferris SH, Deleon MJ, Crook T. THE GLOBAL DETERIORATION SCALE FOR ASSESSMENT OF PRIMARY DEGENERATIVE DEMENTIA. *American Journal of Psychiatry*. 1982;139(9):1136-9.

Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. *Nature Reviews Neurology*. 2011;7(3):137-52.

Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. *Neurobiology of Aging*. 2009;30(11):1728-36.

Relman AS. TACRINE AS A TREATMENT FOR ALZHEIMERS DEMENTIA. *New England Journal of Medicine*. 1991;324(5):349-.

Remington R, Chan A, Paskavitz J, Shea TB. Efficacy of a Vitamin/Nutriceutical Formulation for Moderate-stage to Later-stage Alzheimer's disease: A Placebo-controlled Pilot Study. *American Journal of Alzheimers Disease and Other Dementias*. 2009;24(1):27-33.

Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, et al. Cognition, Reserve, and Amyloid Deposition in Normal Aging. *Annals of Neurology*. 2010;67(3):353-64.

Revett TJ, Baker GB, Jhamandas J, Kar S. Glutamate system, amyloid beta peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. *Journal of Psychiatry & Neuroscience*. 2013;38(1):6-23.

Reynolds GP, Mason SL, Meldrum A, Dekecz S, Parnes H, Eglen RM, et al. 5-HYDROXYTRYPTAMINE (5-HT)_{2A} RECEPTORS IN POST-MORTEM HUMAN BRAIN-TISSUE - DISTRIBUTION, PHARMACOLOGY AND EFFECTS OF NEURODEGENERATIVE DISEASES. *British Journal of Pharmacology*. 1995;114(5):993-8.

Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, et al. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. *Brain Research*. 2008;1214:177-87.

Reznichenko L, Amit T, Zheng H, Avramovich-Tirosh Y, Youdim MBH, Weinreb O, et al. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. *Journal of Neurochemistry*. 2006;97(2):527-36.

Ribizzi G, Fiordoro S, Barocci S, Ferrari E, Megna M. Cytokine polymorphisms and Alzheimer disease: possible associations. *Neurological Sciences*. 2010;31(3):321-5.

Ricciarelli R, Canepa E, Marengo B, Marinari UM, Poli G, Pronzato MA, et al. Cholesterol and Alzheimer's disease: A still poorly understood correlation. *Iubmb Life*. 2012;64(12):931-5.

Riccio A, Alvania RS, Lonze BE, Ramanan N, Kim T, Huang YF, et al. A nitric oxide signaling pathway controls CREB-mediated gene expression in neurons. *Molecular Cell*. 2006;21(2):283-94.

Richardson C, Gard PR, Klugman A, Isaac M, Tabet N. Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors. *International Journal of Geriatric Psychiatry*. 2013;28(12):1312-7.

Ridha BH, Anderson VM, Barnes J, Boyes RG, Price SL, Rossor MN, et al. Volumetric MRI and cognitive measures in Alzheimer disease - Comparison of markers of progression. *Journal of Neurology*. 2008;255(4):567-74.

Riepe MW, Adler G, Ibach B, Weinkauff B, Tracik F, Gunay I. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine. *Dementia and Geriatric Cognitive Disorders*. 2007;23(5):301-6.

Riha PD, Rojas JC, Gonzalez-Lima F. Beneficial network effects of methylene blue in an amnesic model. *Neuroimage*. 2011;54(4):2623-34.

Ring RH, Lyons JM. Failure to detect Chlamydia pneumoniae in the late-onset Alzheimer's brain. *Journal of Clinical Microbiology*. 2000;38(7):2591-4.

Ringman JM. What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: A review. *Journal of Geriatric Psychiatry and Neurology*. 2005;18(4):228-33.

Ringman JM, Coppola G. New genes and new insights from old genes: update on Alzheimer disease. *Continuum (Minneapolis, Minn)*. 2013;19(2 Dementia):358-71.

Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. Potential role of the curry spice curcumin in Alzheimer's disease. *Current Alzheimer Research*. 2005;2(2):131-6.

Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. *Alzheimers Research & Therapy*. 2012;4(5).

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. C-11-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. *Lancet Neurology*. 2010;9(4):363-72.

Risner ME, Saunders AM, Altman JFB, Ormandy GC, Craft S, Foley IM, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. *Pharmacogenomics Journal*. 2006;6(4):246-54.

Rissman RA, De Blas AL, Armstrong DM. GABA(A) receptors in aging and Alzheimer's disease. *Journal of Neurochemistry*. 2007;103(4):1285-92.

Ritchie CW, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the efficacy and safety of Donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. *American Journal of Geriatric Psychiatry*. 2004;12(4):358-69.

Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A beta amyloid deposition and toxicity in Alzheimer disease - A pilot phase 2 clinical trial. *Archives of Neurology*. 2003;60(12):1685-91.

Rivera-Oliver M, Diaz-Rios M. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: A review. *Life Sciences*. 2014;101(1-2):1-9.

Rizzo S, Bartolini M, Ceccarini L, Piazzzi L, Gobbi S, Cavalli A, et al. Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238. *Bioorganic & Medicinal Chemistry*. 2010;18(5):1749-60.

Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. *Human Molecular Genetics*. 2001;10(12):1317-24.

Roberson ED, Scarce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science*. 2007;316(5825):750-4.

Robert R, Wark KL. Engineered antibody approaches for Alzheimer's disease immunotherapy. *Archives of Biochemistry and Biophysics*. 2012;526(2):132-8.

Robert SJ, Zugaza JL, Fischmeister R, Gardier AM, Lezoualc'h F. The human serotonin 5-HT₄ receptor regulates secretion of non-amyloidogenic precursor protein. *Journal of Biological Chemistry*. 2001;276(48):44881-8.

Robinson DM, Plosker GL. Galantamine extended release in Alzheimer's disease - Profile report. *Drugs & Aging*. 2006;23(10):839-42.

Robinson RAS, Joshi G, Huang Q, Sultana R, Baker AS, Cai J, et al. Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid beta-peptide deposition: Insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease. *Proteomics*. 2011;11(21):4243-56.

Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E. The neuroprotective effects of Cerebrolysin (TM) in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. *Journal of Neural Transmission*. 2003;110(11):1313-27.

Rockenstein E, Mallory M, Mante M, Alford M, Windisch M, Moessler H, et al. Effects of Cerebrolysin (TM) on amyloid-beta deposition in a transgenic model of Alzheimer's disease. *Journal of Neural Transmission-Supplement*. 2002(62):327-36.

Rockenstein E, Mante M, Adame A, Crews L, Moessler H, Masliah E. Effects of Cerebrolysin (TM) on neurogenesis in an APP transgenic model of Alzheimer's disease. *Acta Neuropathologica*. 2007;113(3):265-75.

Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3 beta signaling pathway in a transgenic

model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. *Journal of Neuroscience*. 2007;27(8):1981-91.

Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, et al. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a Transgenic model of Alzheimer's disease. *Journal of Neuroscience Research*. 2006;83(7):1252-61.

Rockwood K, Fay S, Song XW, MacKnight C, Gorman M, Investigators V. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. *Canadian Medical Association Journal*. 2006;174(8):1099-105.

Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. *Archives of Neurology*. 2002;59(2):223-7.

Rockwood K, Fay S, Gorman M, Carver D, Graham JE. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. *Bmc Neurology*. 2007;7.

Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. *International Psychogeriatrics*. 2009;21(5):813-24.

Rodrigues Simoes MC, Dias Viegas FP, Moreira MS, Silva MdF, Riquiel MM, da Rosa PM, et al. Donepezil: An Important Prototype to the Design of New Drug Candidates for Alzheimer's Disease. *Mini-Reviews in Medicinal Chemistry*. 2014;14(1):2-19.

Rodriguez-Rivera J, Denner L, Dineley KT. Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. *Behavioural Brain Research*. 2011;216(1):255-61.

Rogaeva E, Kawarai T, St George-Hyslop P. Genetic complexity of Alzheimer's disease: Successes and challenges. *Journal of Alzheimers Disease*. 2006;9:381-7.

Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimer's disease. *Current Drug Targets*. 2004;5(6):535-51.

Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. CLINICAL-TRIAL OF INDOMETHACIN IN ALZHEIMERS-DISEASE. *Neurology*. 1993;43(8):1609-11.

Rogers SL, Doody RS, Mohs RC, Friedhoff LT, Donepezil Study G. Donepezil improves cognition and global function in Alzheimer disease - A 15-week, double-blind, placebo-controlled study. *Archives of Internal Medicine*. 1998;158(9):1021-31.

Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. *European Neuropsychopharmacology*. 2000;10(3):195-203.

Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J, et al. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. *Biochemistry*. 2002;41(37):11080-90.

Roher AE, Cribbs DH, Kim RC, Maarouf CL, Whiteside CM, Kokjohn TA, et al. Bapineuzumab Alters A beta Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy. *Plos One*. 2013;8(3).

Rohn TT, Head E, Nesse WH, Cotman CW, Cribbs DH. Activation of caspase-8 in the Alzheimer's disease brain. *Neurobiology of Disease*. 2001;8(6):1006-16.

Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective Interaction of Lansoprazole and Astemizole with Tau Polymers: Potential New Clinical Use in Diagnosis of Alzheimer's Disease. *Journal of Alzheimers Disease*. 2010;19(2):573-89.

Romero A, Cacabelos R, Oset-Gasque MJ, Samadi A, Marco-Contelles J. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. *Bioorganic & Medicinal Chemistry Letters*. 2013;23(7):1916-22.

Ronnemaa E, Zethelius B, Sundelof J, Sundstrom J, Degerman-Gunnarsson M, Berne C, et al. Impaired insulin secretion increases the risk of Alzheimer disease. *Neurology*. 2008;71(14):1065-71.

Rosen WG, Mohs RC, Davis KL. A NEW RATING-SCALE FOR ALZHEIMERS-DISEASE. *American Journal of Psychiatry*. 1984;141(11):1356-64.

Rosenberg H, Allard D. Women and statin use: A women's health advocacy perspective. *Scandinavian Cardiovascular Journal*. 2008;42(4):268-73.

Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, et al. Sertraline for the Treatment of Depression in Alzheimer Disease. *American Journal of Geriatric Psychiatry*. 2010;18(2):136-45.

Rosenberg RN. Explaining the cause of the amyloid burden in Alzheimer disease. *Archives of Neurology*. 2002;59(9):1367-8.

Rosenberg RN. Metal chelation therapy for Alzheimer disease. *Archives of Neurology*. 2003;60(12):1678-9.

Rosenberg RN. Translational research on the way to effective therapy for Alzheimer disease. *Archives of General Psychiatry*. 2005;62(11):1186-92.

Rosenmann H. Immunotherapy for Targeting Tau Pathology in Alzheimer's Disease and Tauopathies. *Current Alzheimer Research*. 2013;10(3):217-28.

Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. *Archives of Neurology*. 2006;63(10):1459-67.

Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. *British Medical Journal*. 1999;318(7184):633-8.

Ross J, Brough D, Gibson RM, Loddick SA, Rothwell NJ. A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat. *Neuropharmacology*. 2007;53(5):638-42.

Rossor MN, Garrett NJ, Johnson AL, Mountjoy CQ, Roth M, Iversen LL. A POSTMORTEM STUDY OF THE CHOLINERGIC AND GABA SYSTEMS IN SENILE DEMENTIA. *Brain*. 1982;105(JUN):313-30.

Roth AD, Ramirez G, Alarcon R, von Bernhardi R. Oligodendrocytes damage in Alzheimer's disease: Beta amyloid toxicity and inflammation. *Biological Research*. 2005;38(4):381-7.

Rothwell PM. Treating Individuals 1 - External validity of randomised controlled trials: "To whom do the results of this trial apply?". *Lancet*. 2005;365(9453):82-93.

Rountree SD, Atri A, Lopez OL, Doody RS. Effectiveness of antimentia drugs in delaying Alzheimer's disease progression. *Alzheimers & Dementia*. 2013;9(3):338-45.

Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. *Alzheimers Research & Therapy*. 2009;1(2).

Rovio S, Kareholt I, Helkala EL, Viitanen M, Winblad B, Tuomilehto J, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. *Lancet Neurology*. 2005;4(11):705-11.

Rueter LE, Anderson DJ, Briggs CA, Donnelly-Roberts DL, Gintant GA, Gopalakrishnan M, et al. ABT-089: Pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. *Cns Drug Reviews*. 2004;10(2):167-82.

Ruether E, Husmann R, Kinzler E, Diabl E, Klingler D, Spatt J, et al. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. *International Clinical Psychopharmacology*. 2001;16(5):253-63.

Rusanen M, Kivipelto M, Quesenberry CP, Jr., Zhou J, Whitmer RA. Heavy Smoking in Midlife and Long-term Risk of Alzheimer Disease and Vascular Dementia. *Archives of Internal Medicine*. 2011;171(4):333-9.

Russ TC, Batty GD, Hearnshaw GF, Fenton C, Starr JM. Geographical variation in dementia: systematic review with meta-analysis. *International Journal of Epidemiology*. 2012;41(4):1012-32.

Russo I, Caracciolo L, Tweedie D, Choi S-H, Greig NH, Barlati S, et al. 3,6 '-Dithiothalidomide, a new TNF-alpha synthesis inhibitor, attenuates the effect of A beta(1-42) intracerebroventricular injection on hippocampal neurogenesis and memory deficit. *Journal of Neurochemistry*. 2012;122(6):1181-92.

Ryan JM, Grundman M. Anti-Amyloid-beta Immunotherapy in Alzheimer's Disease: ACC-001 Clinical Trials Are Ongoing. *Journal of Alzheimers Disease*. 2009;17(2):243-.

Ryu JK, Franciosi S, Sattayaprasert P, Kim SU, McLarnon JG. Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. *Glia*. 2004;48(1):85-90.

Ryu JK, McLarnon JG. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. *Neurobiology of Disease*. 2008;29(2):254-66.

Rzhetsky A, Seringhaus M, Gerstein MB. Getting Started in Text Mining: Part Two. *Plos Computational Biology*. 2009;5(7).

Sabayan B, Foroughinia F, Mowla A, Borhani-Haghighi A. Role of insulin metabolism disturbances in the development of Alzheimer disease: Mini review. *American Journal of Alzheimers Disease and Other Dementias*. 2008;23(2):192-9.

Sabbagh JJ, Kinney JW, Cummings JL. Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. *Neurobiology of Aging*. 2013;34(1):169-83.

Sabbagh MN. Drug Development for Alzheimer's Disease: Where Are We Now and Where Are We Headed? *American Journal of Geriatric Pharmacotherapy*. 2009;7(3):167-85.

Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease. *Alzheimer Disease & Associated Disorders*. 2011;25(3):206-12.

Sabbagh MN, Farlow MR, Relkin N, Beach TG. Do cholinergic therapies have disease-modifying effects in Alzheimer's disease? *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2006;2(2):118-25.

Sabbagh MN, Shah F, Reid RT, Sue L, Connor DJ, Peterson LKN, et al. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. *Archives of Neurology*. 2006;63(12):1771-6.

Sabbagh MN, Walker DG, Reid RT, Stadnick T, Anand K, Lue L-F. Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind). *Neuroscience Letters*. 2008;448(2):217-20.

Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, et al. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103(49):18787-92.

Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. *Nature Medicine*. 2007;13(9):1029-31.

Saharia K, Arya U, Kumar R, Sahu R, Das CK, Gupta K, et al. Reserpine modulates neurotransmitter release to extend lifespan and alleviate age-dependent A beta proteotoxicity in *Caenorhabditis elegans*. *Experimental Gerontology*. 2012;47(2):188-97.

Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang SM, et al. Somatostatin regulates brain amyloid beta peptide A beta(42) through modulation of proteolytic degradation. *Nature Medicine*. 2005;11(4):434-9.

Sakai K, Yamada M. Abeta immunotherapy for Alzheimer's disease. *Brain and nerve = Shinkei kenkyu no shinpo*. 2013;65(4):461-8.

Sakurai H, Hanyu H, Sato T, Kume K, Hirao K, Kanetaka H, et al. Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study. *Geriatrics & Gerontology International*. 2013;13(1):90-7.

Sala SG, Munoz U, Bartolome F, Bermejo F, Martin-Requero A. HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G(1)/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. *Journal of Pharmacology and Experimental Therapeutics*. 2008;324(1):352-9.

Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment - A randomized placebo-controlled trial. *Neurology*. 2004;63(4):651-7.

Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. *Neurology*. 2009;73(24):2061-70.

Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. *Neurology*. 2011;77(13):1253-62.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. *New England Journal of Medicine*. 2014;370(4):322-33.

Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. *British Journal of Clinical Pharmacology*. 2012;73(4):504-17.

Samadi H, Sultzer D. Solanezumab for Alzheimer's disease. *Expert Opinion on Biological Therapy*. 2011;11(6):787-98.

Sampson E, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. *Cochrane Database of Systematic Reviews*. 2008(1).

Samson K. NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues. *Annals of neurology*. 2010;68(4):A9-A12.

Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. *Proceedings of the National Academy of Sciences of the United States of America*. 2012;109(42):E2895-E903.

Sanchez-Mejia RO, Newman JW, Toh S, Yu G-Q, Zhou Y, Halabisky B, et al. Phospholipase A(2) reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. *Nature Neuroscience*. 2008;11(11):1311-8.

Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. *Neurology*. 2011;77(6):556-63.

Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. *New England Journal of Medicine*. 1997;336(17):1216-22.

Santa-Maria I, Hernandez F, Del Rio J, Moreno FJ, Avila J. Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. *Molecular Neurodegeneration*. 2007;2.

SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. *Science*. 2005;309(5733):476-81.

Santos DB, Peres KC, Ribeiro RP, Colle D, dos Santos AA, Moreira ELG, et al. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid beta peptide in mice. *Experimental Neurology*. 2012;233(2):767-75.

Sanz-Blasco S, Valero RA, Rodriguez-Crespo I, Villalobos C, Nunez L. Mitochondrial Ca²⁺ Overload Underlies A beta Oligomers Neurotoxicity Providing an Unexpected Mechanism of Neuroprotection by NSAIDs. *Plos One*. 2008;3(7).

Sarasa M, Pesini P. Natural Non-Transgenic Animal Models for Research in Alzheimer's Disease. *Current Alzheimer Research*. 2009;6(2):171-8.

Sarazin M, de Souza LC, Lehericy S, Dubois B. Clinical and Research Diagnostic Criteria for Alzheimer's Disease. *Neuroimaging Clinics of North America*. 2012;22(1):23-+.

Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. *Brain Research*. 2001;888(2):256-62.

Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPAR gamma. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103(2):443-8.

Sato N, Shinohara M, Rakugi H, Morishita R. Dual Effects of Statins on A beta Metabolism: Upregulation of the Degradation of APP-CTF and A beta Clearance. *Neurodegenerative Diseases*. 2012;10(1-4):305-8.

Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. *Neurobiology of Aging*. 2011;32(9):1626-33.

Satoh H, Takeuchi K. Management of NSAID/Aspirin-Induced Small Intestinal Damage by GI-Sparing NSAIDs, Anti-Ulcer Drugs and Food Constituents. *Current Medicinal Chemistry*. 2012;19(1):82-9.

Saumier D, Duong A, Haine D, Garceau D, Sampalis J. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase study. *Journal of Nutrition Health & Aging*. 2009;13(9):808-12.

Saura J, Luque JM, Cesura AM, Daprada M, Chanpalay V, Huber G, et al. INCREASED MONOAMINE-OXIDASE-B ACTIVITY IN PLAQUE-ASSOCIATED ASTROCYTES OF ALZHEIMER BRAINS REVEALED BY QUANTITATIVE ENZYME AUTORADIOGRAPHY. *Neuroscience*. 1994;62(1):15-30.

Saver JL, Kalafut M. Combination therapies and the theoretical limits of evidence-based medicine. *Neuroepidemiology*. 2001;20(2):57-64.

Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, et al. Age, Neuropathology, and Dementia. *New England Journal of Medicine*. 2009;360(22):2302-9.

Sawasdee P, Sabphon C, Sitthiwongwanit D, Kokpol U. Anticholinesterase Activity of 7-Methoxyflavones Isolated from *Kaempferia parviflora*. *Phytotherapy Research*. 2009;23(12):1792-4.

Saxena A, Qian NF, Kovach IM, Kozikowski AP, Pang YP, Vellom DC, et al. IDENTIFICATION OF AMINO-ACID-RESIDUES INVOLVED IN THE BINDING OF HUPERZINE-A TO CHOLINESTERASES. *Protein Science*. 1994;3(10):1770-8.

Saxton J, Kastango KB, Hugonot-Diener L, Boller F, Verny M, Sarles CE, et al. Development of a short form of the severe impairment battery. *American Journal of Geriatric Psychiatry*. 2005;13(11):999-1005.

Sayas CL, Moreno-Flores MT, Avila J, Wandosell F. The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation. *Journal of Biological Chemistry*. 1999;274(52):37046-52.

Scarpini E, Bruno G, Zappala G, Adami M, Richarz U, Gaudig M, et al. Cessation versus Continuation of Galantamine Treatment after 12 Months of Therapy in Patients with Alzheimer's Disease: A Randomized, Double Blind, Placebo Controlled Withdrawal Trial. *Journal of Alzheimers Disease*. 2011;26(2):211-20.

Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease - The Framingham heart study. *Archives of Neurology*. 2006;63(11):1545-50.

Schaeffer EL, De-Paula VJ, da Silva ER, Novaes BdA, Skaf HD, Forlenza OV, et al. Inhibition of phospholipase A(2) in rat brain decreases the levels of total Tau protein. *Journal of Neural Transmission*. 2011;118(9):1273-9.

Schaeffer EL, Forlenza OV, Gattaz WF. Phospholipase A(2) activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. *Psychopharmacology*. 2009;202(1-3):37-51.

Schaffer BAJ, Bertram L, Miller BL, Mullin K, Weintraub S, Johnson N, et al. Association of GSK3B with Alzheimer disease and frontotemporal dementia. *Archives of Neurology*. 2008;65(10):1368-74.

Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac misoprostol in Alzheimer's disease. *Neurology*. 1999;53(1):197-201.

Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, et al. Lecozotan (SRA-333): A selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. *Journal of Pharmacology and Experimental Therapeutics*. 2005;314(3):1274-89.

Scheltens P, Kamphuis PJGH, Verhey FRJ, Rikker MGM, Wurtman RJ, Wilkinson D, et al. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. *Alzheimers & Dementia*. 2010;6(1):1-10.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. *Nature*. 1999;400(6740):173-7.

Schenk D, Basi GS, Pangalos MN. Treatment Strategies Targeting Amyloid beta-Protein. *Cold Spring Harbor Perspectives in Medicine*. 2012;2(9).

Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nature Medicine*. 1996;2(8):864-70.

Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. *Journal of Neural Transmission*. 2006;113(11):1625-44.

Schlieb ML, Gitlin JD. Copper homeostasis in the CNS - A novel link between the NMDA receptor and copper homeostasis in the hippocampus. *Molecular Neurobiology*. 2006;33(2):81-90.

Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. INCREASED AMYLOID BETA-PEPTIDE DEPOSITION IN CEREBRAL-CORTEX AS A CONSEQUENCE OF APOLIPOPROTEIN-E GENOTYPE IN LATE-ONSET ALZHEIMER-DISEASE. *Proceedings of the National Academy of Sciences of the United States of America*. 1993;90(20):9649-53.

Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. *Current Opinion in Investigational Drugs*. 2009;10(7):672-80.

Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, et al. The severe impairment battery: Concurrent validity and the assessment of longitudinal change in Alzheimer's disease. *Alzheimer Disease & Associated Disorders*. 1997;11:S51-S6.

Schmitt FA, Wichems CH. A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Primary care companion to the *Journal of clinical psychiatry*. 2006;8(3):158-9.

Schmitt U, Hiemke C, Fahrenholz F, Schroeder A. Over-expression of two different forms of the alpha-secretase ADAM10 affects learning and memory in mice. *Behavioural Brain Research*. 2006;175(2):278-84.

Schneeberger A, Mandler M, Otava O, Zauner W, Mattner F, Schmidt W. DEVELOPMENT OF AFFITOPE VACCINES FOR ALZHEIMER'S DISEASE (AD) - FROM CONCEPT TO CLINICAL TESTING. *Journal of Nutrition Health & Aging*. 2009;13(3):264-7.

Schneeberger A, Mandler M, Mattner F, Schmidt W. AFFITOME (R) technology in neurodegenerative diseases The doubling advantage. *Human Vaccines*. 2010;6(11):948-52.

Schneider A, Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. *Neurotherapeutics*. 2008;5(3):443-57.

Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The Neuropathology of Probable Alzheimer Disease and Mild Cognitive Impairment. *Annals of Neurology*. 2009;66(2):200-8.

Schneider LS. AD2000: donepezil in Alzheimer's disease. *Lancet*. 2004;363(9427):2100-1.

Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia - Meta-analysis of randomized placebo-controlled trials. *Jama-Journal of the American Medical Association*. 2005;294(15):1934-43.

Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. *American Journal of Geriatric Psychiatry*. 2006;14(3):191-210.

Schneider LS, Olin JT. OVERVIEW OF CLINICAL-TRIALS OF HYDERGINE IN DEMENTIA. *Archives of Neurology*. 1994;51(8):787-98.

Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's Disease cooperative study - Clinical global impression of change. *Alzheimer Disease & Associated Disorders*. 1997;11:S22-S32.

Schneider LS, Qizilbash N. Delay in nursing home placement with donepezil. *Journal of the American Geriatrics Society*. 2004;52(6):1024-6.

Schneider LS. Open-label extension studies and misinformation. *Archives of Neurology*. 2006;63(7):1036-.

Schneider LS. Ginkgo biloba Extract and Preventing Alzheimer Disease. *Jama-Journal of the American Medical Association*. 2008;300(19):2306-8.

Schneider LS. Prevention therapeutics of dementia. *Alzheimers & Dementia*. 2008;4(1):S122-S30.

Schneider LS. Pharmacological Treatment of Alzheimer's Disease. In: Hampel H, Carrillo MC, editors. *Alzheimer's Disease - Modernizing Concept, Biological Diagnosis and Therapy*. *Advances in Biological Psychiatry*. 282012. p. 122-67.

Schneider LS, Dagerman KS, Higgins JPT, McShane R. Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease. *Archives of Neurology*. 2011;68(8):991-8.

Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. *Current Alzheimer Research*. 2005;2(5):541-51.

Schneider LS, Insel PS, Weiner MW, Alzheimers Dis N. Treatment With Cholinesterase Inhibitors and Memantine of Patients in the Alzheimer's Disease Neuroimaging Initiative. *Archives of Neurology*. 2011;68(1):58-66.

Schneider LS, Lahiri DK. The Perils of Alzheimer's Drug Development. *Current Alzheimer Research*. 2009;6(1):77-8.

Schneider LS, Sano M. Current Alzheimer's disease clinical trials: Methods and placebo outcomes. *Alzheimers & Dementia*. 2009;5(5):388-97.

Schneider LS. "Meta-analysis of six-month memantine trials in Alzheimer's disease." Wuthering forest plots: Distinguishing the forest from the plots. *Alzheimers & Dementia*. 2007;3(1):18-20.

Schneider P, Tanrikulu Y, Schneider G. Self-Organizing Maps in Drug Discovery: Compound Library Design, Scaffold-Hopping, Repurposing. *Current Medicinal Chemistry*. 2009;16(3):258-66.

Schor NF. What the Halted Phase III gamma-Secretase Inhibitor Trial May (or May Not) Be Telling Us. *Annals of Neurology*. 2011;69(2):237-9.

Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC. Measuring atrophy in Alzheimer disease - A serial MRI study over 6 and 12 months. *Neurology*. 2005;65(1):119-24.

Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. *Journal of Neuroscience*. 2008;28(27):6787-93.

Schultheiss D, Muller SV, Nager W, Stief CG, Schlote N, Jonas U, et al. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. *World Journal of Urology*. 2001;19(1):46-50.

Scott LE, Telpoukhovskaia M, Rodriguez-Rodriguez C, Merkel M, Bowen ML, Page BDG, et al. N-Aryl-substituted 3-(beta-D-glucopyranosyloxy)-2-methyl-4(1H)-pyridinones as agents for Alzheimer's therapy. *Chemical Science*. 2011;2(4):642-8.

Seabrook TJ, Jiang LY, Maier M, Lemere CA. Minocycline affects microglia activation, A beta deposition, and behavior in APP-tg mice. *Glia*. 2006;53(7):776-82.

Searcy JL, Phelps JT, Pancani T, Kadish I, Popovic J, Anderson KL, et al. Long-Term Pioglitazone Treatment Improves Learning and Attenuates Pathological Markers in a Mouse Model of Alzheimer's Disease. *Journal of Alzheimers Disease*. 2012;30(4):943-61.

Sekiyama K, Fujita M, Sekigawa A, Takamatsu Y, Waragai M, Takenouchi T, et al. Ibuprofen ameliorates protein aggregation and astrocytic gliosis, but not cognitive dysfunction, in a transgenic mouse expressing dementia with Lewy bodies-linked P123H beta-synuclein. *Neuroscience Letters*. 2012;515(1):97-101.

Selenica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, et al. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. *British Journal of Pharmacology*. 2007;152(6):959-79.

Selkoe DJ. THE MOLECULAR PATHOLOGY OF ALZHEIMERS-DISEASE. *Neuron*. 1991;6(4):487-98.

Selkoe DJ. Amyloid beta-protein and the genetics of Alzheimer's disease. *Journal of Biological Chemistry*. 1996;271(31):18295-8.

Selkoe DJ. Presenilins, beta-amyloid precursor protein and the molecular basis of Alzheimer's disease. *Clinical Neuroscience Research*. 2001;1(1-2):91-103.

Selkoe DJ. Alzheimer disease: Mechanistic understanding predicts novel therapies. *Annals of Internal Medicine*. 2004;140(8):627-38.

Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. *Annual Review of Genomics and Human Genetics*. 2002;3:67-99.

Selkoe DJ, Schenk D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. *Annual Review of Pharmacology and Toxicology*. 2003;43:545-84.

Seltzer B. Donepezil: an update. *Expert Opinion on Pharmacotherapy*. 2007;8(7):1011-23.

Seltzer B. Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. *Clinical Interventions in Aging*. 2010;5:1-6.

Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. *Neuroscience Letters*. 2000;278(3):169-72.

Sereno L, Coma M, Rodriguez M, Sanchez-Ferrer P, Sanchez MB, Gich I, et al. A novel GSK-3 beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. *Neurobiology of Disease*. 2009;35(3):359-67.

Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological Alterations in Alzheimer Disease. *Cold Spring Harbor Perspectives in Medicine*. 2011;1(1).

Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *New England Journal of Medicine*. 2002;346(7):476-83.

Seshadri S. Elevated plasma homocysteine levels: Risk factor or risk marker for the development of dementia and Alzheimer's disease? *Journal of Alzheimers Disease*. 2006;9(4):393-8.

Seubert P, Barbour R, Khan K, Motter R, Tang P, Kholodenko D, et al. Antibody capture of soluble A beta does not reduce cortical A beta amyloidosis in the PDAPP mouse. *Neurodegenerative Diseases*. 2008;5(2):65-71.

Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML, et al. Growth hormone secretagogue MK-677 No clinical effect on AD progression in a randomized trial. *Neurology*. 2008;71(21):1702-8.

Sevigny JJ, Peng Y, Liu L, Lines CR. Item Analysis of ADAS-Cog: Effect of Baseline Cognitive Impairment in a Clinical AD Trial. *American Journal of Alzheimers Disease and Other Dementias*. 2010;25(2):119-24.

Shah RS, Lee H-G, Zhu X, Perry G, Smith MA, Castellani RJ. Current approaches in the treatment of Alzheimer's disease. *Biomedicine & Pharmacotherapy*. 2008;62(4):199-207.

Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nature Medicine*. 2008;14(8):837-42.

Shanks M, Kivipelto M, Bullock R, Lane R. Cholinesterase inhibition: is there evidence for disease-modifying effects? *Current Medical Research and Opinion*. 2009;25(10):2439-46.

Shaw KTY, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, et al. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. *Proceedings of the National Academy of Sciences of the United States of America*. 2001;98(13):7605-10.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease Neuroimaging Initiative Subjects. *Annals of Neurology*. 2009;65(4):403-13.

Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T. Effect of Intranasal Insulin on Cognitive Function: A Systematic Review. *Journal of Clinical Endocrinology & Metabolism*. 2012;97(2):366-76.

Shemesh OA, Spira ME. Rescue of neurons from undergoing hallmark tau-induced Alzheimer's disease cell pathologies by the antimitotic drug paclitaxel. *Neurobiology of Disease*. 2011;43(1):163-75.

Shen F, Smith JAM, Chang R, Bourdet DL, Tsuruda PR, Obedencio GP, et al. 5-HT₄ receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment. *Neuropharmacology*. 2011;61(1-2):69-79.

Shen J, Kelleher RJ, III. The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(2):403-9.

Shen Y, Zhang J, Sheng R, Dong X, He Q, Yang B, et al. Synthesis and biological evaluation of novel flavonoid derivatives as dual binding acetylcholinesterase inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*. 2009;24(2):372-80.

Shen Y, Yang L, Li R. What does complement do in Alzheimer's disease? Old molecules with new insights. *Translational neurodegeneration*. 2013;2(1):21-.

Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol Level and Statin Use in Alzheimer Disease I. Review of Epidemiological and Preclinical Studies. *Archives of Neurology*. 2011;68(10):1239-44.

Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol Level and Statin Use in Alzheimer Disease II. Review of Human Trials and Recommendations. *Archives of Neurology*. 2011;68(11):1385-92.

Shepherd J, Blauw GJ, Murphy MB, Bollen E, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*. 2002;360(9346):1623-30.

Shi C, Wu F, Xu J. H₂O₂ and PAF mediate A beta 1-42-induced Ca²⁺ dyshomeostasis that is blocked by EGb761. *Neurochemistry International*. 2010;56(8):893-905.

Shi J-Q, Shen W, Chen J, Wang B-R, Zhong L-L, Zhu Y-W, et al. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. *Brain Research*. 2011;1368:239-47.

Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer's amyloid-beta(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. *Journal of Clinical Investigation*. 2000;106(12):1489-99.

Shimohama S, Sasaki Y, Fujimoto S, Kamiya S, Taniguchi T, Takenawa T, et al. Phospholipase C isozymes in the human brain and their changes in Alzheimer's disease. *Neuroscience*. 1998;82(4):999-1007.

Shimohama S. Nicotinic Receptor-Mediated Neuroprotection in Neurodegenerative Disease Models. *Biological & Pharmaceutical Bulletin*. 2009;32(3):332-6.

Shindo T, Takasaki K, Uchida K, Onimura R, Kubota K, Uchida N, et al. Ameliorative Effects of Telmisartan on the Inflammatory Response and Impaired Spatial Memory in a Rat Model of Alzheimer's Disease Incorporating Additional Cerebrovascular Disease Factors. *Biological & Pharmaceutical Bulletin*. 2012;35(12):2141-7.

Shinohara M, Sato N, Shimamura M, Kurinami H, Hamasaki T, Chatterjee A, et al. Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. *Frontiers in Aging Neuroscience*. 2014;6.

Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, et al. A Randomized Placebo-Controlled Pilot Trial of Omega-3 Fatty Acids and Alpha Lipoic Acid in Alzheimer's Disease. *Journal of Alzheimers Disease*. 2014;38(1):111-20.

Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. *Neurobiology of Disease*. 2009;34(2):381-8.

Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. *American Journal of Geriatric Psychiatry*. 2002;10(1):24-35.

Short RA, Bowen RL, O'Brien PC, Graff-Radford NR. Elevated gonadotropin levels in patients with Alzheimer disease. *Mayo Clinic Proceedings*. 2001;76(9):906-9.

Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal

women - The Women's Health Initiative Memory Study: A randomized controlled trial. *Jama-Journal of the American Medical Association*. 2003;289(20):2651-62.

Siedlak SL, Casadesus G, Webber KM, Pappolla MA, Atwood CS, Smith MA, et al. Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. *Free Radical Research*. 2009;43(2):156-64.

Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. *Neurology*. 2006;66(4):602-4.

Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. *Clinical Neuropharmacology*. 2005;28(3):126-32.

Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. *Clinical Neuropharmacology*. 2007;30(6):317-25.

Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, et al. Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid beta After a Single Administration of an Amyloid beta Monoclonal Antibody in Subjects With Alzheimer Disease. *Clinical Neuropharmacology*. 2010;33(2):67-73.

Siemers ER, Paul SM. Commentary on "A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium". *Alzheimers & Dementia*. 2008;4(3):171-3.

Sigurdsson EM. Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies. *Journal of Alzheimers Disease*. 2008;15(2):157-68.

Silverman DHS, Geist CL, Kenna HA, Williams K, Wroolie T, Powers B, et al. Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. *Psychoneuroendocrinology*. 2011;36(4):502-13.

Silvestrelli G, Lanari A, Parnetti L, Tomassoni D, Amenta F. Treatment of Alzheimer's disease: From pharmacology to a better understanding of disease pathophysiology. *Mechanisms of Ageing and Development*. 2006;127(2):148-57.

Silvestri L, Camaschella C. A potential pathogenetic role of iron in Alzheimer's disease. *Journal of Cellular and Molecular Medicine*. 2008;12(5A):1548-50.

Simons M, Keller P, Dichgans J, Schulz JB. Cholesterol and Alzheimer's disease - Is there a link? *Neurology*. 2001;57(6):1089-93.

Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. *Annals of Neurology*. 2002;52(3):346-50.

Sims NR, Bowen DM, Allen SJ, Smith CCT, Neary D, Thomas DJ, et al. PRE-SYNAPTIC CHOLINERGIC DYSFUNCTION IN PATIENTS WITH DEMENTIA. *Journal of Neurochemistry*. 1983;40(2):503-9.

Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. *Nature*. 1999;402(6761):537-40.

Sirk D, Zhu Z, Wadia JS, Shulyakova N, Phan N, Fong J, et al. Chronic exposure to sub-lethal beta-amyloid (A beta) inhibits the import of nuclear-encoded proteins to mitochondria in differentiated PC12 cells*. *Journal of Neurochemistry*. 2007;103(5):1989-2003.

Sitzer DI, Twamley EW, Jeste DV. Cognitive training in Alzheimer's disease: a meta-analysis of the literature. *Acta Psychiatrica Scandinavica*. 2006;114(2):75-90.

Skoldunger A, Johnell K, Winblad B, Wimo A. Mortality and Treatment Costs have a Great Impact on the Cost-Effectiveness of Disease Modifying Treatment in Alzheimer's Disease - A Simulation Study. *Current Alzheimer Research*. 2013;10(2):207-16.

Skov V, Glintborg D, Knudsen S, Tan Q, Jensen T, Kruse TA, et al. Pioglitazone Enhances Mitochondrial Biogenesis and Ribosomal Protein Biosynthesis in Skeletal Muscle in Polycystic Ovary Syndrome. *Plos One*. 2008;3(6).

Slotkin TA, Seidler FJ, Crain BJ, Bell JM, Bissette G, Nemeroff CB. REGULATORY CHANGES IN PRESYNAPTIC CHOLINERGIC FUNCTION ASSESSED IN RAPID AUTOPSY MATERIAL FROM PATIENTS WITH ALZHEIMER-DISEASE - IMPLICATIONS FOR ETIOLOGY AND THERAPY. *Proceedings of the National Academy of Sciences of the United States of America*. 1990;87(7):2452-5.

Small DH, Nurcombe V, Reed G, Clarris H, Moir R, Beyreuther K, et al. A HEPARIN-BINDING DOMAIN IN THE AMYLOID PROTEIN-PRECURSOR OF ALZHEIMERS-DISEASE IS INVOLVED IN THE REGULATION OF NEURITE OUTGROWTH. *Journal of Neuroscience*. 1994;14(4):2117-27.

Small DH, Gasperini R, Vincent AJ, Hung AC, Foa L. The Role of A beta-Induced Calcium Dysregulation in the Pathogenesis of Alzheimer's Disease. *Journal of Alzheimers Disease*. 2009;16(2):225-33.

Small GW, Bookheimer SY, Thompson PM, Cole GM, Huang SC, Kepe V, et al. Current and future uses of neuroimaging for cognitively impaired patients. *Lancet Neurology*. 2008;7(2):161-72.

Small G, Bullock R. Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease. *Alzheimers & Dementia*. 2011;7(2):177-84.

Small SA, Duff K. Linking A beta and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis. *Neuron*. 2008;60(4):534-42.

Smart TG, Hosie AM, Miller PS. Zn(2+) ions: Modulators of excitatory and inhibitory synaptic activity. *Neuroscientist*. 2004;10(5):432-42.

Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. *British Journal of Clinical Pharmacology*. 2009;67(1):99-109.

Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial. *Plos One*. 2010;5(9).

Smith AM, Gibbons HM, Dragunow M. VALPROIC ACID ENHANCES MICROGLIAL PHAGOCYTOSIS OF AMYLOID-beta(1-42). *Neuroscience*. 2010;169(1):505-15.

Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. *International Journal of Pharmaceutics*. 2010;389(1-2):207-12.

Smith DE, Roberts J, Gage FH, Tuszynski MH. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. *Proceedings of the National Academy of Sciences of the United States of America*. 1999;96(19):10893-8.

Smith NW, Annunziata O, Dzyuba SV. Amphotericin B interactions with soluble oligomers of amyloid A beta 1-42 peptide. *Bioorganic & Medicinal Chemistry*. 2009;17(6):2366-70.

Snitz BE, O'Meara ES, Carlson MC, Arnold AM, Ives DG, Rapp SR, et al. Ginkgo biloba for Preventing Cognitive Decline in Older Adults A Randomized Trial. *Jama-Journal of the American Medical Association*. 2009;302(24):2663-70.

Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, et al. A Double-Blind, Placebo-Controlled Study to Assess the Mitochondria-Targeted Antioxidant MitoQ as a Disease-Modifying Therapy in Parkinson's Disease. *Movement Disorders*. 2010;25(11):1670-4.

Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease - The nun study. *Jama-Journal of the American Medical Association*. 1997;277(10):813-7.

Soderberg M, Edlund C, Kristensson K, Dallner G. FATTY-ACID COMPOSITION OF BRAIN PHOSPHOLIPIDS IN AGING AND IN ALZHEIMERS-DISEASE. *Lipids*. 1991;26(6):421-5.

Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. *Annual Review of Neuroscience*. 2001;24:1217-81.

Soininen H, West C, Robbins J, Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*. 2007;23(1):8-21.

Sole-Padulles C, Bartres-Faz D, Junque C, Clemente IC, Molinuevo JL, Bargallo N, et al. Repetitive transcranial magnetic stimulation effects on brain function and cognition among elders with memory dysfunction. A randomized sham-controlled study. *Cerebral Cortex*. 2006;16(10):1487-93.

Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, et al. Advances in the prevention of Alzheimer's disease and dementia. *Journal of Internal Medicine*. 2014;275(3):229-50.

Solomon A, Kivipelto M. Cholesterol-modifying strategies for Alzheimer's disease. *Expert Review of Neurotherapeutics*. 2009;9(5):695-709.

Solomon B. Immunological approach for the treatment of Alzheimer's disease. *Journal of Molecular Neuroscience*. 2003;20(3):283-6.

Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R. Ginkgo for memory enhancement - A randomized controlled trial. *Jama-Journal of the American Medical Association*. 2002;288(7):835-40.

Sona A, Zhang P, Ames D, Bush AI, Lautenschlager NT, Martins RN, et al. Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. *International Psychogeriatrics*. 2012;24(2):197-204.

Sontag E, Hladik C, Montgomery L, Luangpirom A, Mudrak I, Ogris E, et al. Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. *Journal of Neuropathology and Experimental Neurology*. 2004;63(10):1080-91.

Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, Speciale S, et al. Altered expression levels of the protein phosphatase 2A AB alpha C enzyme are associated with Alzheimer disease pathology. *Journal of Neuropathology and Experimental Neurology*. 2004;63(4):287-301.

Sparks DL, Connor DJ, Browne PJ, Lopez JE, Sabbagh MN. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. *The journal of nutrition, health & aging*. 2002;6(5):324-31.

Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's disease cholesterol-lowering treatment (ADCLT) trial. *Acta Neurologica Scandinavica*. 2006;114:3-7.

Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease - Preliminary results. *Archives of Neurology*. 2005;62(5):753-7.

Sparks DL, Scheff SW, Hunsaker JC, Liu HC, Landers T, Gross DR. INDUCTION OF ALZHEIMER-LIKE BETA-AMYLOID IMMUNOREACTIVITY IN THE BRAINS OF RABBITS WITH DIETARY-CHOLESTEROL. *Experimental Neurology*. 1994;126(1):88-94.

Sparks DL, Kryscio RJ, Connor DJ, Sabbagh MN, Sparks LM, Lin Y, et al. Cholesterol and Cognitive Performance in Normal Controls and the Influence of Elective Statin Use after Conversion to Mild Cognitive Impairment: Results in a Clinical Trial Cohort. *Neurodegenerative Diseases*. 2010;7(1-3):183-6.

Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. *Current Alzheimer Research*. 2008;5(4):416-21.

Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M, et al. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia - Randomised controlled trial. *British Journal of Psychiatry*. 2003;183:248-54.

Spencer JPE. Food for thought: the role of dietary flavonoids in enhancing human memory, learning and neuro-cognitive performance. *Proceedings of the Nutrition Society*. 2008;67(2):238-52.

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers & Dementia*. 2011;7(3):280-92.

Sperling RA, Jack CR, Jr., Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. *Alzheimers & Dementia*. 2011;7(4):367-85.

Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 Study: Stopping AD Before Symptoms Begin? *Science Translational Medicine*. 2014;6(228).

Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. *Lancet Neurology*. 2012;11(3):241-9.

Spierings D, McStay G, Saleh M, Bender C, Chipuk J, Maurer U, et al. Connected to death: The (unexpurgated) mitochondrial pathway of apoptosis. *Science*. 2005;310(5745):66-7.

Srinivasan V, Pandi-Perumal SR, Maestroni GJM, Esquifino AI, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerative diseases. *Neurotoxicity Research*. 2005;7(4):293-318.

Srivareerat M, Tran TT, Salim S, Aleisa AM, Alkadhi KA. Chronic nicotine restores normal A beta levels and prevents short-term memory and E-LTP impairment in A beta rat model of Alzheimer's disease. *Neurobiology of Aging*. 2011;32(5):834-44.

St George-Hyslop PH, Morris JC. Will anti-amyloid therapies work for Alzheimer's disease? *Lancet*. 2008;372(9634):180-2.

Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. *Experimental Neurology*. 2003;184(1):510-20.

Standridge JB. Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer's disease. *Evidence-based mental health*. 2004;7(4):112-.

Steele JW, Gandy S. Latrepirdine (Dimebon (R)), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. *Autophagy*. 2013;9(4):617-8.

Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, et al. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. *Journal of the Neurological Sciences*. 2006;251(1-2):124-8.

Stefanova E, Wall A, Almkvist O, Nilsson A, Forsberg A, Langstrom B, et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. *Journal of Neural Transmission*. 2006;113(2):205-18.

Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. *Molecular Biology of the Cell*. 2007;18(12):5060-8.

Sternfeld F, Carling RW, Jelley RA, Ladduwahetty T, Merchant KJ, Moore KW, et al. Selective, orally active gamma-aminobutyric acid(A) alpha 5 receptor inverse agonists as cognition enhancers. *Journal of Medicinal Chemistry*. 2004;47(9):2176-9.

Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. *Neurology*. 1997;48(3):626-32.

Stoltenberg M, Bruhn M, Sondergaard C, Doering P, West MJ, Larsen A, et al. Immersion autometallographic tracing of zinc ions in Alzheimer beta-amyloid plaques. *Histochemistry and Cell Biology*. 2005;123(6):605-11.

Stone JG, Casadesus G, Gustaw-Rothenberg K, Siedlak SL, Wang X, Zhu X, et al. Frontiers in Alzheimer's disease therapeutics. *Therapeutic advances in chronic disease*. 2011;2(1):9-23.

Storozhevsky TP, Senilova YE, Brustovetsky T, Pinelis VG, Brustovetsky N. Neuroprotective Effect of KB-R7943 Against Glutamate Excitotoxicity is Related to Mild Mitochondrial Depolarization. *Neurochemical Research*. 2010;35(2):323-35.

Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. *Lancet*. 1999;353(9147):118-9.

Strong MJ, Yang W, Strong WL, Leystra-Lantz C, Jaffe H, Pant HC. Tau protein hyperphosphorylation in sporadic ALS with cognitive impairment. *Neurology*. 2006;66(11):1770-1.

Strozyk D, Blennow K, White LR, Launer LJ. CSF A beta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. *Neurology*. 2003;60(4):652-6.

Sturchbary G, Munch G. Alzheimer's associated inflammation, potential drug targets and future therapies. *Journal of Neural Transmission*. 2005;112(3):429-53.

Subasinghe S, Unabia S, Barrow CJ, Mok SS, Aguilar MI, Small DH. Cholesterol is necessary both for the toxic effect of A beta peptides on vascular smooth muscle cells and for A beta binding to vascular smooth muscle cell membranes. *Journal of Neurochemistry*. 2003;84(3):471-9.

Sugaya K, Alvarez A, Marutle A, Kwak YD, Choumkin E. Stem cell strategies for Alzheimer's disease therapy. *Panminerva Medica*. 2006;48(2):87-96.

Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF ACETYLCHOLINESTERASE INHIBITORS - 1-BENZYL-4-(5,6-DIMETHOXY-1-OXOINDAN-2-YL)METHYL PIPERIDINE HYDROCHLORIDE AND RELATED-COMPOUNDS. *Journal of Medicinal Chemistry*. 1995;38(24):4821-9.

Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. *Brain Research*. 2000;852(2):274-8.

Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin(1A) partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study. *Schizophrenia Research*. 2007;95(1-3):158-68.

Sun M-K, Alkon DL. Protein kinase C isozymes: Memory therapeutic potential. *Current Drug Targets - CNS and Neurological Disorders*. 2005;4(5):541-52.

Sun M, Zhou T, Zhou L, Chen Q, Yu Y, Yang H, et al. Formononetin Protects Neurons Against Hypoxia-Induced Cytotoxicity Through Upregulation of ADAM10 and sA beta PP alpha. *Journal of Alzheimers Disease*. 2012;28(4):795-808.

Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased beta-amyloid(1-42) and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. *Jama-Journal of the American Medical Association*. 2003;289(16):2094-103.

Sung S, Yao YM, Uryu K, Yang HX, Lee VMY, Trojanowski JQ, et al. Early Vitamin E supplementation in young but not aged mice reduces A beta levels and amyloid deposition in a transgenic model of Alzheimer's disease. *Faseb Journal*. 2003;17(15):323-+.

Sung S, Yao Y, Uryu K, Yang H, Lee VMY, Trojanowski JQ, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. *FASEB Journal*. 2004;18(2):323-5.

Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hilbush BS. Peripheral Reduction of beta-Amyloid Is Sufficient To Reduce Brain beta-Amyloid: Implications for Alzheimer's Disease. *Journal of Neuroscience Research*. 2011;89(6):808-14.

Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Eckman C, et al. AN INCREASED PERCENTAGE OF LONG AMYLOID-BETA PROTEIN SECRETED BY FAMILIAL AMYLOID-BETA PROTEIN-PRECURSOR (BETA-APP(717)) MUTANTS. *Science*. 1994;264(5163):1336-40.

Swanoski MT. Homotaurine: A failed drug for Alzheimer's disease and now a nutraceutical for memory protection. *American Journal of Health-System Pharmacy*. 2009;66(21):1950-3.

Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A Meta-Analysis of Cytokines in Alzheimer's Disease. *Biological Psychiatry*. 2010;68(10):930-41.

Swerdlow RH. Alzheimer's Disease Pathologic Cascades: Who Comes First, What Drives What. *Neurotoxicity Research*. 2012;22(3):182-94.

Swerdlow RH, Burns JM, Khan SM. The Alzheimer's Disease Mitochondrial Cascade Hypothesis. *Journal of Alzheimers Disease*. 2010;20:S265-S79.

Szekely CA, Breitner JCS, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, et al. NSAID use and dementia risk in the cardiovascular health study - Role of APOE and NSAID type. *Neurology*. 2008;70(1):17-24.

Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JCS, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. *Neuroepidemiology*. 2004;23(4):159-69.

Szekely CA, Zandi PP. Non-Steroidal Anti-Inflammatory Drugs and Alzheimer's Disease: The Epidemiological Evidence. *Cns & Neurological Disorders-Drug Targets*. 2010;9(2):132-9.

Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. *Journal of Pharmacology and Experimental Therapeutics*. 2003;306(2):772-7.

Takahashi H, Fukumoto H, Maeda R, Terauchi J, Kato K, Miyamoto M. Ameliorative effects of a non-competitive BACE1 inhibitor TAK-070 on A beta peptide levels and impaired learning behavior in aged rats. *Brain Research*. 2010;1361:146-56.

Takasugi N, Sasaki T, Ebinuma I, Osawa S, Isshiki H, Takeo K, et al. FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-beta Production in Neurons. *Plos One*. 2013;8(5).

Takata K, Hirata-Fukae C, Becker AG, Chishiro S, Gray AJ, Nishitomi K, et al. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. *European Journal of Neuroscience*. 2007;26(9):2458-68.

Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. *International Journal of Geriatric Psychiatry*. 2006;21(1):17-28.

Takeda S, Sato N, Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. *Frontiers in Aging Neuroscience*. 2014;6.

Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, et al. Angiotensin Receptor Blocker Prevented beta-Amyloid-Induced Cognitive Impairment Associated With Recovery of Neurovascular Coupling. *Hypertension*. 2009;54(6):1345-U125.

Tam JHK, Pasternak SH. Amyloid and Alzheimer's Disease: Inside and Out. *Canadian Journal of Neurological Sciences*. 2012;39(3):286-98.

Tamaki C, Ohtsuki S, Terasaki T. Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1-40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. *Molecular Pharmacology*. 2007;72(4):850-5.

Tanaka T, Zhong J, Iqbal K, Trenkner E, Grundke-Iqbal I. The regulation of phosphorylation of tau in SY5Y neuroblastoma cells: the role of protein phosphatases. *Febs Letters*. 1998;426(2):248-54.

Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. *Journal of Biological Chemistry*. 2005;280(9):7614-23.

Tanimukai H, Grundke-Iqbal I, Iqbal K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. *American Journal of Pathology*. 2005;166(6):1761-71.

Tanimukai H, Kudo T, Tanaka T, Grundke-Iqbal I, Iqbal K, Takeda M. Novel therapeutic strategies for neurodegenerative disease. *Psychogeriatrics*. 2009;9(2):103-9.

Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. *Cell*. 2005;120(4):545-55.

Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's A beta peptide: The many roads to perdition. *Neuron*. 2004;43(5):605-8.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. *Journal of the American Geriatrics Society*. 2001;49(12):1590-9.

Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. *American Journal of Psychiatry*. 1998;155(1):54-61.

Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil - A randomized controlled trial. *Jama-Journal of the American Medical Association*. 2004;291(3):317-24.

Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation - A randomized, controlled trial. *American Journal of Geriatric Psychiatry*. 2005;13(11):942-9.

Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. *Neurology*. 2000;54(12):2269-76.

Tariot PN, Aisen PS. Can Lithium or Valproate Untie Tangles in Alzheimer's Disease? *Journal of Clinical Psychiatry*. 2009;70(6):919-21.

Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, et al. Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease. *Archives of General Psychiatry*. 2011;68(8):853-61.

Tauskela JS. Drug evaluation: MitoQ - a mitochondria-targeted antioxidant. *Idrugs*. 2007;10(6):399-412.

Tayeb HO, Murray ED, Price BH, Tarazi FI. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? *Expert Opinion on Biological Therapy*. 2013;13(7):1075-84.

Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors. *Pharmacology & Therapeutics*. 2012;134(1):8-25.

Teng L, Zhao J, Wang F, Ma L, Pei G. A GPCR/secretase complex regulates beta- and gamma-secretase specificity for A beta production and contributes to AD pathogenesis. *Cell Research*. 2010;20(2):138-53.

Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Treatment of agitation in AD - A randomized, placebo-controlled clinical trial. *Neurology*. 2000;55(9):1271-8.

Terry RD. The pathogenesis of Alzheimer disease: An alternative to the amyloid hypothesis. *Journal of Neuropathology and Experimental Neurology*. 1996;55(10):1023-5.

Terry RD, Masliah E, Salmon DP, Butters N, Deteresa R, Hill R, et al. PHYSICAL BASIS OF COGNITIVE ALTERATIONS IN ALZHEIMERS-DISEASE - SYNAPSE LOSS IS THE MAJOR CORRELATE OF COGNITIVE IMPAIRMENT. *Annals of Neurology*. 1991;30(4):572-80.

Terry RD, Weiss M, Gonatas NK. ULTRASTRUCTURAL STUDIES IN ALZHEIMERS PRESENILE DEMENTIA. *American Journal of Pathology*. 1964;44(2):269-&.

Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, et al. Comment on "ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models". *Science*. 2013;340(6135).

Thal DR, Holzer M, Rub U, Waldmann G, Gunzel S, Zedlick D, et al. Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. *Experimental Neurology*. 2000;163(1):98-110.

Thal DR, Griffin WST, Braak H. Parenchymal and vascular A beta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. *Journal of Cellular and Molecular Medicine*. 2008;12(5B):1848-62.

Thal LJ, Calvani M, Amato A, Carta A, Acetyl LCSG. A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. *Neurology*. 2000;55(6):805-10.

Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. *Neurology*. 1996;47(3):705-11.

Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. *Neurology*. 1999;52(6):1146-52.

Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. *Neuropsychopharmacology*. 2005;30(6):1204-15.

Thal LJ, Forrest M, Loft H, Mengel H, Lu25-109 Study G. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. *Neurology*. 2000;54(2):421-6.

Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. *Neurology*. 2003;61(11):1498-502.

Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. *Neurology*. 1996;47(6):1389-95.

Thathiah A, De Strooper B. The role of G protein-coupled receptors in the pathology of Alzheimer's disease. *Nature Reviews Neuroscience*. 2011;12(2):73-87.

Thathiah A, Horre K, Snellinx A, Vandewyer E, Huang Y, Ciesielska M, et al. beta-arrestin 2 regulates A beta generation and gamma-secretase activity in Alzheimer's disease. *Nature Medicine*. 2013;19(1):43-9.

Thathiah A, Spittaels K, Hoffmann M, Staes M, Cohen A, Horre K, et al. The Orphan G Protein-Coupled Receptor 3 Modulates Amyloid-Beta Peptide Generation in Neurons. *Science*. 2009;323(5916):946-51.

Thatte U. Phenserine Axonyx. *Current opinion in investigational drugs* (London, England : 2000). 2005;6(7):729-39.

Thinakaran G, Koo EH. Amyloid Precursor Protein Trafficking, Processing, and Function. *Journal of Biological Chemistry*. 2008;283(44):29615-9.

Thompson S, Lanctot KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. *Expert opinion on drug safety*. 2004;3(5):425-40.

Thomsen T, Zendeh B, Fischer JP, Kewitz H. INVITRO EFFECTS OF VARIOUS CHOLINESTERASE-INHIBITORS ON ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE OF HEALTHY-VOLUNTEERS. *Biochemical Pharmacology*. 1991;41(1):139-41.

Thomson AM, Rogers JT, Leedman PJ. Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation. *International Journal of Biochemistry & Cell Biology*. 1999;31(10):1139-52.

Threlfell S, Cragg SJ, Kallo I, Turi GF, Coen CW, Greenfield SA. Histamine h3 receptors inhibit serotonin release in substantia nigra pars reticulata. *Journal of Neuroscience*. 2004;24(40):8704-10.

Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. *Journal of Neuroinflammation*. 2008;5.

Toda N, Tago K, Marumoto S, Takami K, Ori M, Yamada N, et al. Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. *Bioorganic & Medicinal Chemistry*. 2003;11(9):1935-55.

Tokita K, Inoue T, Yamazaki S, Wang F, Yamaji T, Matsuoka N, et al. FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. *European Journal of Pharmacology*. 2005;527(1-3):111-20.

Tokuda T, Tamaoka A, Matsuno S, Sakurai S, Shimada H, Morita H, et al. Plasma levels of amyloid beta proteins did not differ between subjects taking statins and those not taking statins. *Annals of Neurology*. 2001;49(4):546-7.

Toledo EM, Inestrosa NC. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APP^{swe}/PSEN1 Delta E9 mouse model of Alzheimer's disease. *Molecular Psychiatry*. 2010;15(3):272-85.

Tombaugh TN, McIntyre NJ. THE MINI-MENTAL-STATE-EXAMINATION - A COMPREHENSIVE REVIEW. *Journal of the American Geriatrics Society*. 1992;40(9):922-35.

Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. *Expert Review of Neurotherapeutics*. 2009;9(5):661-79.

Tomiya T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, et al. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin - Its possible function as a hydroxyl radical scavenger. *Journal of Biological Chemistry*. 1996;271(12):6839-44.

Toney JH, Fasick JJ, Singh S, Beyrer C, Sullivan DJ, Jr. Purposeful Learning with Drug Repurposing. *Science*. 2009;325(5946):1339-40.

Tong G, Wang J-S, Sverdlow O, Huang S-P, Slemmon R, Croop R, et al. Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral gamma-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers. *Clinical Therapeutics*. 2012;34(3):654-67.

Tong X-K, Lecrux C, Hamel E. Age-Dependent Rescue by Simvastatin of Alzheimer's Disease Cerebrovascular and Memory Deficits. *Journal of Neuroscience*. 2012;32(14):4705-15.

Tong X-K, Nicolakakis N, Fernandes P, Ongali B, Brouillette J, Quirion R, et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. *Neurobiology of Disease*. 2009;35(3):406-14.

Townsend KP, Pratico D. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. *FASEB Journal*. 2005;19(12):1592-601.

Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. *Annals of Neurology*. 2006;60(6):668-76.

Toyohara J, Hashimoto K. alpha7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease. *The open medicinal chemistry journal*. 2010;4:37-56.

Trompet S, van Vliet P, de Craen AJM, Jolles J, Buckley BM, Murphy MB, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. *Journal of Neurology*. 2010;257(1):85-90.

Truchot L, Costes SN, Zimmer L, Laurent B, Le Bars D, Thomas-Anterion C, et al. Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. *Neurology*. 2007;69(10):1012-7.

Truelsen T, Thudium D, Gronbaek M. Amount and type of alcohol and risk of dementia - The Copenhagen City Heart Study. *Neurology*. 2002;59(9):1313-9.

Tsuji A, Saheki A, Tamai I, Terasaki T. TRANSPORT MECHANISM OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS AT THE BLOOD-

BRAIN-BARRIER. Journal of Pharmacology and Experimental Therapeutics. 1993;267(3):1085-90.

Tucker S, Ahl M, Cho H-H, Bandyopadhyay S, Cuny GD, Bush AI, et al. RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Current Alzheimer Research. 2006;3(3):221-7.

Tully T, Bourtchouladze R, Scott R, Tallman J. Targeting the CREB pathway for memory enhancers. Nature Reviews Drug Discovery. 2003;2(4):267-77.

Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. International Journal of Biochemistry & Cell Biology. 2005;37(2):289-305.

Turner AJ, Tanzawa K. Mammalian membrane metalloproteinases: NEP, ECE, KELL, and PEX. FASEB Journal. 1997;11(5):355-64.

Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Progress in Neurobiology. 2003;70(1):1-32.

Turon-Estrada A, Lopez-Pousa S, Gelada-Batlle E, Garre-Olmo J, Lozano-Gallego M, Hernandez-Ferrandiz M, et al. Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer's disease over a six-month period. Revista De Neurologia. 2003;36(5):421-4.

Tuszynski MH. Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurology. 2002;1(1):51-7.

Tuszynski MH, Roberts J, Senut MC, U HS, Gage FH. Gene therapy in the adult primate brain: Intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Therapy. 1996;3(4):305-14.

Tuszynski MH, Thal L, Pay M, Salmon DP, Sang UH, Bakay R, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nature Medicine. 2005;11(5):551-5.

Tweedie D, Ferguson RA, Fishman K, Frankola KA, Van Praag H, Holloway HW, et al. Tumor necrosis factor- α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. Journal of Neuroinflammation. 2012;9.

Tweedie D, Luo W, Short RG, Brossi A, Holloway HW, Li Y, et al. A cellular model of inflammation for identifying TNF- α synthesis inhibitors. Journal of Neuroscience Methods. 2009;183(2):182-7.

Tweedie D, Rachmany L, Rubovitch V, Lehrmann E, Zhang Y, Becker KG, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. *Experimental Neurology*. 2013;239:170-82.

Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, et al. A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying F-18 FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease. *Journal of Alzheimers Disease*. 2010;22(4):1241-56.

Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. *Archives of Internal Medicine*. 2003;163(9):1069-75.

Uberti D, Bianchi I, Olivari L, Ferrari-Toninelli G, PierLuigi C, Memo M. Pramipexole prevents neurotoxicity induced by oligomers of beta-amyloid. *European Journal of Pharmacology*. 2007;569(3):194-6.

Ubhi K, Rockenstein E, Doppler E, Mante M, Adame A, Patrick C, et al. Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. *Acta Neuropathologica*. 2009;117(6):699-712.

Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, et al. Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid beta Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease. *Clinical Neuropharmacology*. 2012;35(1):25-9.

Ulrich D. Amyloid-beta Impairs Synaptic Inhibition via GABA(A) Receptor Endocytosis. *Journal of Neuroscience*. 2015;35(24):9205-10.

Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT₆ receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. *Neurotherapeutics*. 2008;5(3):458-69.

van Bebber F, Paquet D, Hruscha A, Schmid B, Haass C. Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. *Neurobiology of Disease*. 2010;39(3):265-71.

van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. *Journal of Clinical Epidemiology*. 2003;56(4):367-76.

van Dongen M, van Rossum E, Kessels AGH, Sielhorst HJG, Knipschild PG. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial. *Journal of the American Geriatrics Society*. 2000;48(10):1183-94.

van Dyck CH, Tariot PN, Meyers B, Resnick EM, Memantine MEMMDSG. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. *Alzheimer Disease & Associated Disorders*. 2007;21(2):136-43.

Van Gool WA, Weinstein HC, Scheltens PK, Walstra GJM. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. *Lancet*. 2001;358(9280):455-60.

van Marum RJ. Current and future therapy in Alzheimer's disease. *Fundamental & Clinical Pharmacology*. 2008;22(3):265-74.

Vassar R. The beta-secretase, BACE - A prime drug target for Alzheimer's disease. *Journal of Molecular Neuroscience*. 2001;17(2):157-70.

Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *Science*. 1999;286(5440):735-41.

Vasto S, Candore G, Listi F, Balistreri CR, Colonna-Romano G, Malavolta M, et al. Inflammation, genes and zinc in Alzheimer's disease. *Brain Research Reviews*. 2008;58(1):96-105.

Vatassery GT, Smith WE, Quach HT, Lai JCK. IN-VITRO OXIDATION OF VITAMIN-E, VITAMIN-C, THIOLS AND CHOLESTEROL IN RAT-BRAIN MITOCHONDRIA INCUBATED WITH FREE-RADICALS. *Neurochemistry International*. 1995;26(5):527-35.

Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. *Stroke*. 1999;30(9):1969-73.

Ved HS, Koenig ML, Dave JR, Doctor BP. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. *Neuroreport*. 1997;8(4):963-8.

Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, et al. Comment on "ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models". *Science*. 2013;340(6135).

Veinbergs I, Mallory M, Sagara Y, Masliah E. Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice. *European Journal of Neuroscience*. 2000;12(12):4541-6.

Veinbergs I, Mante M, Mallory M, Masliah E. Neurotrophic effects of Cerebrolysin (R) in animal models of excitotoxicity. *Journal of Neural Transmission-Supplement*. 2000(59):273-80.

Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. *Journal of Neuroscience*. 2000;20(5):1657-65.

Velez-Pardo C, Ospina GG, del Rio MJ. A beta(25-35) peptide and iron promote apoptosis in lymphocytes by an oxidative stress mechanism: Involvement of H₂O₂, caspase-3, NF-kappa B, p53 and c-Jun. *Neurotoxicology*. 2002;23(3):351-65.

Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H, GuidAge Study G. The GuidAge study - Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 (R) for prevention of Alzheimer disease in patients over 70 with a memory complaint. *Neurology*. 2006;67(9):S6-S11.

Vellas B, Sol O, Snyder PJ, Ousset PJ, Haddad R, Maurin M, et al. EHT0202 in Alzheimer's Disease: A 3-Month, Randomized, Placebo-Controlled, Double-Blind Study. *Current Alzheimer Research*. 2011;8(2):203-12.

Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, et al. Prevention trials in Alzheimer's disease: An EU-US task force report. *Progress in Neurobiology*. 2011;95(4):594-600.

Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer's disease: a European task force consensus. *Lancet Neurology*. 2008;7(5):436-50.

Vellas B, Andrieu S, Sampaio C, Wilcock G, European Task Force G. Disease-modifying trials in Alzheimer's disease: a European task force consensus. *Lancet Neurology*. 2007;6(1):56-62.

Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, et al. Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders. *Current Alzheimer Research*. 2009;6(2):144-51.

Vellas B, Coley N, Ousset P-J, Berrut G, Dartigues J-F, Dubois B, et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. *Lancet Neurology*. 2012;11(10):851-9.

Verdurand M, Berod A, Le Bars D, Zimmer L. Effects of amyloid-beta peptides on the serotonergic 5-HT_{1A} receptors in the rat hippocampus. *Neurobiology of Aging*. 2011;32(1):103-14.

Verhoeff NPLG. Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease. *Expert review of neurotherapeutics*. 2005;5(2):277-84.

Vigen CLP, Mack WJ, Keefe RSE, Sano M, Sultzer DL, Stroup TS, et al. Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD. *American Journal of Psychiatry*. 2011;168(8):831-9.

VijayaPadma V, Ramyaa P, Pavithra D, Krishnasamy R. Protective effect of lutein against benzo(a) pyrene-induced oxidative stress in human erythrocytes. *Toxicology and Industrial Health*. 2014;30(3):284-93.

Vilaro MT, Cortes R, Mengod G. Serotonin 5-HT₄ receptors and their mRNAs in rat and guinea pig brain: Distribution and effects of neurotoxic lesions. *Journal of Comparative Neurology*. 2005;484(4):418-39.

Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. *Lancet Neurology*. 2013;12(4):357-67.

Vingtdeux V, Drees-Werringloer U, Zhao H, Davies P, Marambaud P. Therapeutic potential of resveratrol in Alzheimer's disease. *Bmc Neuroscience*. 2008;9.

Vingtdeux V, Marambaud P. Identification and biology of α -secretase. *Journal of Neurochemistry*. 2012;120:34-45.

Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. *Neurobiology of Aging*. 2009;30(9):1350-60.

Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone releasing hormone improves the cognition of healthy older adults. *Neurobiology of Aging*. 2006;27(2):318-23.

Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling. *Proceedings of the National Academy of Sciences of the United States of America*. 2002;99(20):13217-21.

Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VMY. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. *Experimental Neurology*. 2001;168(2):402-12.

Vozzo R, Wittert GA, Horowitz M, Morley JE, Chapman IM. Effect of nitric oxide synthase inhibitors on short-term appetite and food intake in humans. *American Journal of Physiology-Regulatory Integrative and Comparative Physiology*. 1999;276(6):R1562-R8.

Wadsworth TL, Bishop JA, Pappu AS, Woltjer RL, Quinn JF. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. *Journal of Alzheimers Disease*. 2008;14(2):225-34.

Wagner G, Icks A, Abholz H-H, Schroeder-Bernhardi D, Rathmann W, Kostev K. Antihypertensive treatment and risk of dementia: a retrospective database study. *International Journal of Clinical Pharmacology and Therapeutics*. 2012;50(3):195-201.

Wagner T, Valero-Cabre A, Pascual-Leone A. Noninvasive human rain stimulation. *Annual Review of Biomedical Engineering*. Annual Review of Biomedical Engineering. 92007. p. 527-65.

Wahlberg LU, Lind G, Almqvist PM, Kusk P, Tornoe J, Juliusson B, et al. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery Clinical article. *Journal of Neurosurgery*. 2012;117(2):340-7.

Wald DS, Kasturiratne A, Simmonds M. Effect of Folic Acid, with or without Other B Vitamins, on Cognitive Decline: Meta-Analysis of Randomized Trials. *American Journal of Medicine*. 2010;123(6):522-U9.

Walker LC, Ibegbu CC, Todd CW, Robinson HL, Jucker M, LeVine H, et al. Emerging prospects for the disease-modifying treatment of Alzheimer's disease. *Biochemical Pharmacology*. 2005;69(7):1001-8.

Wallace TL, Bertrand D. Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex. *Biochemical Pharmacology*. 2013;85(12):1713-20.

Walle T. Bioavailability of resveratrol. In: Vang O, Das DK, editors. *Resveratrol and Health*. Annals of the New York Academy of Sciences. 12152011. p. 9-15.

Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O, et al. Certain inhibitors of synthetic amyloid beta-peptide (A beta) fibrillogenesis block oligomerization of natural A beta and thereby rescue long-term potentiation. *Journal of Neuroscience*. 2005;25(10):2455-62.

Walsh DM, Selkoe DJ. A beta Oligomers - a decade of discovery. *Journal of Neurochemistry*. 2007;101(5):1172-84.

Walton HS, Dodd PR. Glutamate-glutamine cycling in Alzheimer's disease. *Neurochemistry International*. 2007;50(7-8):1052-66.

Wang B-s, Wang H, Wei Z-h, Song Y-y, Zhang L, Chen H-z. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. *Journal of Neural Transmission*. 2009;116(4):457-65.

Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang T-Y, et al. Site-specific UBITH (R) amyloid-beta vaccine for immunotherapy of Alzheimer's disease. *Vaccine*. 2007;25(16):3041-52.

Wang JZ, Wang ZF. Role of melatonin in Alzheimer-like neurodegeneration. *Acta Pharmacologica Sinica*. 2006;27(1):41-9.

Wang J-Z, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. *European Journal of Neuroscience*. 2007;25(1):59-68.

Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. *Journal of Clinical Investigation*. 2007;117(11):3393-402.

Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, et al. Grape-derived polyphenolics prevent A beta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. *Journal of Neuroscience*. 2008;28(25):6388-92.

Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein DL, et al. Moderate consumption of Cabernet Sauvignon attenuates A beta neuropathology in a mouse model of Alzheimer's disease. *Faseb Journal*. 2006;20(13):2313-20.

Wang P, Myers JG, Wu P, Cheewatrakoolpong B, Egan RW, Billah MM. Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. *Biochemical and Biophysical Research Communications*. 1997;234(2):320-4.

Wang QW, Rowan MJ, Anwyl R. beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. *Journal of Neuroscience*. 2004;24(27):6049-56.

Wang R, Tang XC. Neuroprotective effects of huperzine A - A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. *Neurosignals*. 2005;14(1-2):71-82.

Wang S, Zhu L, Shi H, Zheng H, Tian Q, Wang Q, et al. Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5. *Neurochemical Research*. 2007;32(8):1329-35.

Wang T, Wang C-Y, Shan Z-Y, Teng W-P, Wang Z-Y. Clioquinol Reduces Zinc Accumulation in Neuritic Plaques and Inhibits the Amyloidogenic Pathway in A beta PP/PS1 Transgenic Mouse Brain. *Journal of Alzheimers Disease*. 2012;29(3):549-59.

Wang X, Su B, Lee H-g, Li X, Perry G, Smith MA, et al. Impaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease. *Journal of Neuroscience*. 2009;29(28):9090-103.

Wang YE, Yue DX, Tang XC. ANTICHOLINESTERASE ACTIVITY OF HUPERZINE-A. *Acta Pharmacologica Sinica*. 1986;7(2):110-3.

Wang Y, Branicky R, Stepanyan Z, Carroll M, Guimond M-P, Hihi A, et al. The Anti-neurodegeneration Drug Clioquinol Inhibits the Aging-associated Protein CLK-1. *Journal of Biological Chemistry*. 2009;284(1):314-23.

Wang Y, Tang XC, Zhang HY. Huperzine A Alleviates Synaptic Deficits and Modulates Amyloidogenic and Nonamyloidogenic Pathways in APPswe/PS1dE9 Transgenic Mice. *Journal of Neuroscience Research*. 2012;90(2):508-17.

Wang Z, Yang D, Zhang X, Li T, Li J, Tang Y, et al. Hypoxia-Induced Down-Regulation of Neprilysin by Histone Modification in Mouse Primary Cortical and Hippocampal Neurons. *Plos One*. 2011;6(4).

Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. HEPATOTOXIC EFFECTS OF TACRINE ADMINISTRATION IN PATIENTS WITH ALZHEIMERS-DISEASE. *Jama- Journal of the American Medical Association*. 1994;271(13):992-8.

Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early Alzheimer disease and amnesic mild cognitive impairment during treatment with rosiglitazone - A preliminary study. *American Journal of Geriatric Psychiatry*. 2005;13(11):950-8.

Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease - Implications for treatment. *Cns Drugs*. 2003;17(1):27-45.

Webber KM, Casadesus G, Atwood CS, Bowen RL, Perry G, Smith MA. Gonadotropins: A cohesive gender-based etiology of Alzheimer disease. *Molecular and Cellular Endocrinology*. 2007;260:271-5.

Webster SJ, Mruthinti S, Hill WD, Buccafusco JJ, Terry AV, Jr. An Aqueous Orally Active Vaccine Targeted Against a RAGE/AB Complex as a Novel Therapeutic for Alzheimer's Disease. *Neuromolecular Medicine*. 2012;14(2):119-30.

Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic A beta 42 independently of cyclooxygenase activity. *Nature*. 2001;414(6860):212-6.

Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. A beta 42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. *Journal of Biological Chemistry*. 2003;278(33):30748-54.

Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. *Journal of Biological Chemistry*. 2003;278(34):31831-7.

Wei Q, Holzer M, Brueckner MK, Liu Y, Arendt T. Dephosphorylation of tau protein by calcineurin triturated into neural living cells. *Cellular and Molecular Neurobiology*. 2002;22(1):13-24.

Wei ZH, He QB, Wang H, Su BH, Chen HZ. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. *Journal of Neural Transmission*. 2007;114(5):629-34.

Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. *Nature Reviews Immunology*. 2006;6(5):404-16.

Weinreb O, Amit T, Bar-Am O, Youdim MBH. A NOVEL ANTI-ALZHEIMER'S DISEASE DRUG, LADOSTIGIL: NEUROPROTECTIVE, MULTIMODAL BRAIN-SELECTIVE MONOAMINE OXIDASE AND CHOLINESTERASE INHIBITOR. In: Youdim MBH, Riederer P, editors. *Monoamine Oxidases and Their Inhibitors. International Review of Neurobiology*. 1002011. p. 191-215.

Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T, et al. Multifunctional Neuroprotective Derivatives of Rasagiline as Anti-Alzheimer's Disease Drugs. *Neurotherapeutics*. 2009;6(1):163-74.

Weinstock M, Bejar C, Wang RH, Poltyrev T, Gross A, Finberg JPM, et al. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. *Journal of Neural Transmission Supplement*. 2000;60:157-69.

Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, et al. Sertraline for the Treatment of Depression in Alzheimer Disease: Week-24 Outcomes. *American Journal of Geriatric Psychiatry*. 2010;18(4):332-40.

Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. *Experimental Gerontology*. 2002;37(7):943-8.

Wen Y, Li W, Poteet EC, Xie L, Tan C, Yan L-J, et al. Alternative Mitochondrial Electron Transfer as a Novel Strategy for Neuroprotection. *Journal of Biological Chemistry*. 2011;286(18).

Wen Y, Planel E, Herman M, Figueroa HY, Wang L, Liu L, et al. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads

to differential effects on tau phosphorylation and amyloid precursor protein processing. *Journal of Neuroscience*. 2008;28(10):2624-32.

Wenk GL, Baker LM, Stoehr JD, Hauss-Wegrzyniak B, Danysz W. Neuroprotection by novel antagonists at the NMDA receptor channel and glycine(B) sites. *European Journal of Pharmacology*. 1998;347(2-3):183-7.

Wenk GL, Parsons CG, Danysz W. Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. *Behavioural Pharmacology*. 2006;17(5-6):411-24.

Weyer G, Erzigkeit H, Kanowski S, Ihl R, Hadler D. Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial. *International psychogeriatrics*. 1997;9(2):123-38.

Wharton W, Stein JH, Korcarz C, Sachs J, Olson SR, Zetterberg H, et al. The Effects of Ramipril in Individuals at Risk for Alzheimer's Disease: Results of a Pilot Clinical Trial. *Journal of Alzheimers Disease*. 2012;32(1):147-56.

Whelton A, Hamilton CW. NONSTEROIDAL ANTIINFLAMMATORY DRUGS - EFFECTS ON KIDNEY-FUNCTION. *Journal of Clinical Pharmacology*. 1991;31(7):588-98.

White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, et al. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. *Journal of Biological Chemistry*. 2006;281(26):17670-80.

Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. *International Journal of Geriatric Psychiatry*. 2004;19(7):624-33.

Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. ALZHEIMERS-DISEASE AND SENILE DEMENTIA - LOSS OF NEURONS IN THE BASAL FOREBRAIN. *Science*. 1982;215(4537):1237-9.

Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology*. 2005;64(2):277-81.

Widiapradja A, Vegh V, Lok KZ, Manzanero S, Thundiyil J, Gelderblom M, et al. Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways. *Journal of Neurochemistry*. 2012;122(2):321-32.

Wienrich M, Meier D, Ensinger HA, Gaida W, Raschig A, Walland A, et al. Pharmacodynamic profile of the M-1 agonist talsaclidine in animals and man. *Life Sciences*. 2001;68(22-23):2593-600.

Wiessner C, Wiederhold K-H, Tissot AC, Frey P, Danner S, Jacobson LH, et al. The Second-Generation Active A beta Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects. *Journal of Neuroscience*. 2011;31(25):9323-31.

Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, et al. Intracranially administered anti-A beta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. *Journal of Neuroscience*. 2003;23(9):3745-51.

Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates A beta plaque removal following intracranial anti-A beta antibody administration. *Neurobiology of Disease*. 2004;15(1):11-20.

Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. *Journal of Neuroscience*. 2004;24(27):6144-51.

Wilcock DM, Colton CA. Anti-Amyloid-beta Immunotherapy in Alzheimer's Disease: Relevance of Transgenic Mouse Studies to Clinical Trials. *Journal of Alzheimers Disease*. 2008;15(4):555-69.

Wilcock DM, Gharkholonarehe N, Van Nostrand WE, Davis J, Vitek MP, Colton CA. Amyloid Reduction by Amyloid-beta Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer's Disease. *Journal of Neuroscience*. 2009;29(25):7957-65.

Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against A beta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. *Journal of Neuroinflammation*. 2004;1.

Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. *Drugs & Aging*. 2003;20(10):777-89.

Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: A pooled analysis of 3 studies. *Journal of Clinical Psychiatry*. 2008;69(3):341-8.

Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. *Lancet Neurology*. 2008;7(6):483-93.

Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FCV, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. *International Journal of Clinical Practice*. 2002;56(6):441-6.

Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*. 2007;24(2):138-45.

Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, et al. Control of peripheral nerve myelination by the beta-secretase BACE1. *Science*. 2006;314(5799):664-6.

Williams LR, Varon S, Peterson GM, Wictorin K, Fischer W, Bjorklund A, et al. CONTINUOUS INFUSION OF NERVE GROWTH-FACTOR PREVENTS BASAL FOREBRAIN NEURONAL DEATH AFTER FIMBRIA FORNIX TRANSECTION. *Proceedings of the National Academy of Sciences of the United States of America*. 1986;83(23):9231-5.

Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, et al. The action to control cardiovascular risk in diabetes memory in diabetes study (ACCORD-MIND): Rationale, design, and methods. *American Journal of Cardiology*. 2007;99(12A):112I-22I.

Wimo A, Jonsson L, Bond J, Prince M, Winblad B, Alzheimer Dis I. The worldwide economic impact of dementia 2010. *Alzheimers & Dementia*. 2013;9(1):1-11.

Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: Estimates for 2009. *Alzheimers & Dementia*. 2010;6(2):98-103.

Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. *Neurology*. 2001;57(3):489-95.

Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. *Neurology*. 2008;70(22):2024-35.

Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, et al. A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. *Neurology*. 2007;69:S14-S22.

Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. *Lancet*. 2006;367(9516):1057-65.

Winblad B, Poritis N. Memantine in severe dementia: Results of the M-9-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). *International Journal of Geriatric Psychiatry*. 1999;14(2):135-46.

Winblad B. Donepezil in Severe Alzheimer's Disease. *American Journal of Alzheimers Disease and Other Dementias*. 2009;24(3):185-92.

Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active A beta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. *Lancet Neurology*. 2012;11(7):597-604.

Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. *International Journal of Geriatric Psychiatry*. 2007;22(5):456-67.

Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. *Dementia and Geriatric Cognitive Disorders*. 2007;24(1):20-7.

Wischik CM, Edwards PC, Lai RYK, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. *Proceedings of the National Academy of Sciences of the United States of America*. 1996;93(20):11213-8.

Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy. *Journal of Nutrition Health & Aging*. 2009;13(4):367-9.

Wisniewski T. Active immunotherapy for Alzheimer's disease. *Lancet Neurology*. 2012;11(7):571-2.

Wisniewski T, Konietzko U. Amyloid-beta immunisation for Alzheimer's disease. *Lancet Neurology*. 2008;7(9):805-11.

Witt A, Macdonald N, Kirkpatrick P. Memantine hydrochloride. *Nature Reviews Drug Discovery*. 2004;3(2):109-10.

Wolfe MS. Therapeutic strategies for Alzheimer's disease. *Nature Reviews Drug Discovery*. 2002;1(11):859-66.

Wolfe MS. Inhibition and modulation of gamma-secretase for Alzheimer's disease. *Neurotherapeutics*. 2008;5(3):391-8.

Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Archives of Neurology*. 2000;57(10):1439-43.

Wong BX, Hung YH, Bush AI, Duce JA. Metals and cholesterol: two sides of the same coin in Alzheimer's disease pathology. *Frontiers in Aging Neuroscience*. 2014;6.

Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. *Journal of Biological Chemistry*. 2004;279(13):12876-82.

Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJS, Trumbauer ME, et al. Presenilin 1 is required for Notch1 DII1 expression in the paraxial mesoderm. *Nature*. 1997;387(6630):288-92.

Woodhouse A, Dickson TC, Vickers JC. Vaccination strategies for Alzheimer's disease - A new hope? *Drugs & Aging*. 2007;24(2):107-19.

Wozniak MA, Frost AL, Preston CM, Itzhaki RF. Antivirals Reduce the Formation of Key Alzheimer's Disease Molecules in Cell Cultures Acutely Infected with Herpes Simplex Virus Type 1. *Plos One*. 2011;6(10).

Wozniak MA, Itzhaki RF. Antiviral agents in Alzheimer's disease: hope for the future? *Therapeutic advances in neurological disorders*. 2010;3(3):141-52.

Wozniak MA, Itzhaki RF. Intravenous immunoglobulin reduces beta amyloid and abnormal tau formation caused by herpes simplex virus type 1. *Journal of Neuroimmunology*. 2013;257(1-2):7-12.

Wright TM. Tramiprosate. *Drugs of Today*. 2006;42(5):291-8.

Wu H-M, Tzeng N-S, Qian L, Wei S-J, Hu X, Chen S-H, et al. Novel Neuroprotective Mechanisms of Memantine: Increase in Neurotrophic Factor Release from Astroglia and Anti-Inflammation by Preventing Microglial Activation. *Neuropsychopharmacology*. 2009;34(10):2344-57.

Wu J, Li Q, Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington's disease. *Molecular Neurodegeneration*. 2008;3.

Wuest DM, Lee KH. Amyloid-beta concentration and structure influences the transport and immunomodulatory effects of IVIG. *Journal of Neurochemistry*. 2014;130(1):136-44.

Xia M, Huang R, Guo V, Southall N, Cho M-H, Inglese J, et al. Identification of compounds that potentiate CREB signaling as possible enhancers of long-term memory. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(7):2412-7.

Xiang GQ, Tang SS, Jiang LY, Hong H, Li Q, Wang C, et al. PPAR γ agonist pioglitazone improves scopolamine-induced memory impairment in mice. *Journal of Pharmacy and Pharmacology*. 2012;64(4):589-96.

Xiao H, Su Y, Cao X, Sun S, Liang Z. A Meta-analysis of Mood Stabilizers for Alzheimer's Disease. *Journal of Huazhong University of Science and Technology-Medical Sciences*. 2010;30(5):652-8.

Xie L, Li W, Winters A, Yuan F, Jin K, Yang S. Methylene blue induces macroautophagy through 5' adenosine monophosphate-activated protein kinase pathway to protect neurons from serum deprivation. *Frontiers in Cellular Neuroscience*. 2013;7.

Xiong HG, Baskys A, Wojtowicz JM. Brain-derived peptides inhibit synaptic transmission via presynaptic GABA(B) receptors in CA1 area of rat hippocampal slices. *Brain Research*. 1996;737(1-2):188-94.

Xiong H, Wojtowicz JM, Baskys A. BRAIN-TISSUE HYDROLYSATE ACTS ON PRESYNAPTIC ADENOSINE RECEPTORS IN THE RAT HIPPOCAMPUS. *Canadian Journal of Physiology and Pharmacology*. 1995;73(8):1194-7.

Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. *Diabetologia*. 2009;52(6):1031-9.

Xu Y, Yan J, Zhou P, Li J, Gao H, Xia Y, et al. Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. *Progress in Neurobiology*. 2012;97(1):1-13.

Yaari R, Corey-Bloom J. Alzheimer's disease. *Seminars in Neurology*. 2007;27(1):32-41.

Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women - Effects on cognitive function and dementia. *Jama-Journal of the American Medical Association*. 1998;279(9):688-95.

Yaffe K. Antioxidants and prevention of cognitive decline does - Duration of use matter? *Archives of Internal Medicine*. 2007;167(20):2167-8.

Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. PPAR γ /RXR α -Induced and CD36-Mediated Microglial Amyloid-beta Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice. *Journal of Neuroscience*. 2012;32(48):17321-31.

Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, et al. Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice. *Journal of Neuroscience*. 2009;29(34):10706-14.

Yan RQ, Bienkowski MJ, Shuck ME, Miao HY, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. *Nature*. 1999;402(6761):533-7.

Yan SD, Chen X, Fu J, Chen M, Zhu HJ, Roher A, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. *Nature*. 1996;382(6593):685-91.

Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer's Disease: A Progression Factor for Amyloid-beta-Induced Cellular Perturbation? *Journal of Alzheimers Disease*. 2009;16(4):833-43.

Yang FS, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. *Journal of Biological Chemistry*. 2005;280(7):5892-901.

Yang LB, Lindholm K, Yan RQ, Citron M, Xia WM, Yang XL, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. *Nature Medicine*. 2003;9(1):3-4.

Yang Q, Bermingham NA, Finegold MJ, Zoghbi HY. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. *Science*. 2001;294(5549):2155-8.

Yang X, Yang Y, Li G, Wang J, Yang ES. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. *Journal of Molecular Neuroscience*. 2008;34(2):165-71.

Yang Y, Ma D, Wang Y, Jiang T, Hu S, Zhang M, et al. Intranasal Insulin Ameliorates Tau Hyperphosphorylation in a Rat Model of Type 2 Diabetes. *Journal of Alzheimers Disease*. 2013;33(2):329-38.

Yao YM, Clark CM, Trojanowski JQ, Lee VMY, Pratico D. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. *Annals of Neurology*. 2005;58(4):623-6.

Yao Y, Chinnici C, Tang H, Trojanowski JQ, Lee VMY, Pratico D. Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. *Journal of Neuroinflammation*. 2004;1.

Yasar S, Corrada M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. *Neurobiology of Aging*. 2005;26(2):157-63.

Yasojima K, McGeer EG, McGeer PL. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. *Brain Research*. 2001;919(1):115-21.

Yatin SM, Varadarajan S, Butterfield DA. Vitamin E prevents Alzheimer's amyloid beta-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. *Journal of Alzheimer's Disease*. 2000;2(2):123-31.

Yeh ETH. A new perspective on the biology of C-reactive protein. *Circulation Research*. 2005;97(7):609-11.

Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. *Therapeutic Advances in Neurological Disorders*. 2013;6(1):19-33.

Yin Q-Q, Pei J-J, Xu S, Luo D-Z, Dong S-Q, Sun M-H, et al. Pioglitazone Improves Cognitive Function via Increasing Insulin Sensitivity and Strengthening Antioxidant Defense System in Fructose-Drinking Insulin Resistance Rats. *Plos One*. 2013;8(3).

Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MBH. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. *Faseb Journal*. 2006;20(12):2177-+.

Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element "decoy" of nuclear factor-kB binding site as a novel molecular strategy. *Gene Therapy*. 2001;8(21):1635-42.

Yoshiyama Y, Lee VMY, Trojanowski JQ. Therapeutic strategies for tau mediated neurodegeneration. *Journal of Neurology Neurosurgery and Psychiatry*. 2013;84(7):784-95.

Youdim MBH, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, et al. Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition. *Journal of Neuroscience Research*. 2005;79(1-2):172-9.

Youdim MBH, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. *Trends in Pharmacological Sciences*. 2005;26(1):27-35.

Youdim MBH, Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 (N-propargyl-3R)aminoindan-5-YL)-ethyl methyl carbamate. *Cellular and Molecular Neurobiology*. 2001;21(6):555-73.

Youdim MBH. The path from anti Parkinson drug selegiline and rasagiline to multi-functional neuroprotective anti Alzheimer drugs ladostigil and M30. *Current Alzheimer Research*. 2006;3(5):541-50.

Young AJ, Johnson S, Steffens DC, Doraiswamy PM. Coenzyme Q10: A review of its promise as a neuroprotectant. *Cns Spectrums*. 2007;12(1):62-8.

Younkin SG. EVIDENCE THAT A-BETA-42 IS THE REAL CULPRIT IN ALZHEIMERS-DISEASE. *Annals of Neurology*. 1995;37(3):287-8.

Yu F, Rose KM, Burgener SC, Cunningham C, Buettner LL, Beattie E, et al. Cognitive Training for Early-Stage Alzheimer's Disease and Dementia. *Journal of Gerontological Nursing*. 2009;35(3):23-9.

Yu Q-s, Reale M, Kamal MA, Holloway HW, Luo W, Sambamurti K, et al. Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N-1-norPosiphen, (+)-N-8-norPosiphen and (+)-N-1, N-8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, alpha-Synuclein Synthesis, Interleukin-1 beta Release, and Cholinergic Action. *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry*. 2013;12(2):117-28.

Yu Y, Zhang L, Li X, Run X, Liang Z, Li Y, et al. Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation. *Plos One*. 2012;7(4).

Yuan X, Shan B, Ma Y, Tian J, Jiang K, Cao Q, et al. Multi-Center Study on Alzheimer's Disease Using FDG PET: Group and Individual Analyses. *Journal of Alzheimers Disease*. 2010;19(3):927-35.

Yue Y, Hu L, Tian Q-j, Jiang J-m, Dong Y-l, Jin Z-y, et al. Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes. *Acta Pharmacologica Sinica*. 2007;28(8):1129-35.

Yumoto S, Kakimi S, Ohsaki A, Ishikawa A. Demonstration of aluminum in amyloid fibers in the cores of senile plaques in the brains of patients with Alzheimer's disease. *Journal of Inorganic Biochemistry*. 2009;103(11):1579-84.

Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. *Alzheimers & Dementia*. 2010;6(6):456-64.

Zadori D, Veres G, Szalardy L, Klivenyi P, Toldi J, Vecsei L. Glutamatergic Dysfunctioning in Alzheimer's Disease and Related Therapeutic Targets. *Journal of Alzheimers Disease*. 2014;42:S177-S87.

Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, et al. Vascular alterations in PDAPP mice after anti-Abeta immunotherapy: Implications for amyloid-related imaging abnormalities. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013;9(5 Suppl):S105-15.

Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JCS, et al. Reduced incidence of AD with NSAID but not H-2 receptor antagonists - The Cache County Study. *Neurology*. 2002;59(6):880-6.

Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements - The Cache County Study. *Archives of Neurology*. 2004;61(1):82-8.

Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women - The Cache County Study. *Jama-Journal of the American Medical Association*. 2002;288(17):2123-9.

Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The cache county study. *Archives of General Psychiatry*. 2005;62(2):217-24.

Zeitlin R, Patel S, Burgess S, Arendash GW, Echeverria V. Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice. *Brain Research*. 2011;1417:127-36.

Zemer D, Livneh A, Langevitz P. REVERSAL OF THE NEPHROTIC SYNDROME BY COLCHICINE IN AMYLOIDOSIS OF FAMILIAL MEDITERRANEAN FEVER. *Annals of Internal Medicine*. 1992;116(5):426-.

Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. *Archives of Neurology*. 2008;65(8):1102-7.

Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102(1):227-31.

Zhang HY, Tang XC. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. *Trends in Pharmacological Sciences*. 2006;27(12):619-25.

Zhang HY, Yan H, Tang XC. Non-cholinergic effects of huperzine A: Beyond inhibition of acetylcholinesterase. *Cellular and Molecular Neurobiology*. 2008;28(2):173-83.

Zhang H, Wu L-M, Wu J. Cross-Talk between Apolipoprotein E and Cytokines. *Mediators of Inflammation*. 2011.

Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I. Role of Presenilins in Neuronal Calcium Homeostasis. *Journal of Neuroscience*. 2010;30(25):8566-80.

Zhang L-l, Sui H-j, Liang B, Wang H-m, Qu W-h, Yu S-x, et al. Atorvastatin prevents amyloid-beta peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway. *Acta Pharmacologica Sinica*. 2014;35(6):716-26.

Zhang S, Hedskog L, Petersen CAH, Winblad B, Ankarcrona M. Dimebon (Latrepirdine) Enhances Mitochondrial Function and Protects Neuronal Cells from Death. *Journal of Alzheimers Disease*. 2010;21(2):389-402.

Zhang Y-H, Raymick J, Sarkar S, Lahiri DK, Ray B, Holtzman D, et al. Efficacy and Toxicity of Clioquinol Treatment and A-beta(42) Inoculation in the APP/PS1 Mouse Model of Alzheimer's Disease. *Current Alzheimer Research*. 2013;10(5):494-506.

Zhang Y-W, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. *Molecular Brain*. 2011;4.

Zhang Y-W, Xu H. Alteration of beta-secretase traffic by the receptor tyrosine kinase signaling pathway - a new mechanism for regulating Alzheimer's beta-amyloid production. *Cell Research*. 2007;17(5):385-6.

Zhao BL, Li XJ, He RG, Cheng SJ, Xin WJ. SCAVENGING EFFECT OF EXTRACTS OF GREEN TEA AND NATURAL ANTIOXIDANTS ON ACTIVE OXYGEN RADICALS. *Cell Biophysics*. 1989;14(2):175-85.

Zhao H, Michaelis ML, Blagg BSJ. Hsp90 Modulation for the Treatment of Alzheimer's Disease. In: Michaelis EK, Michaelis ML, editors. *Current State of Alzheimer's Disease Research and Therapeutics*. *Advances in Pharmacology*. 642012. p. 1-25.

Zhao WQ, Feng C, Alkon DL. Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts. *Neurobiology of Disease*. 2003;14(3):458-69.

Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. *Neuroscience*. 2002;115(1):201-11.

Zhou J, Zhang S, Zhao X, Wei T. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-beta(1-42). *Journal of Pineal Research*. 2008;45(2):157-65.

Zhu S, He J, Zhang R, Kong L, Tempier A, Kong J, et al. Therapeutic Effects of Quetiapine on Memory Deficit and Brain beta-Amyloid Plaque Pathology in a Transgenic Mouse Model of Alzheimer's Disease. *Current Alzheimer Research*. 2013;10(3):270-8.

Zhu X, Lee H-g, Perry G, Smith MA. Alzheimer disease, the two-hit hypothesis: An update. *Biochimica Et Biophysica Acta-Molecular Basis of Disease*. 2007;1772(4):494-502.

Zlokovic BV. Clearing amyloid through the blood-brain barrier. *Journal of Neurochemistry*. 2004;89(4):807-11.

Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid beta-peptide from brain: transport or metabolism? *Nature Medicine*. 2000;6(7):718-.

Zoladz PR, Campbell AM, Park CR, Schaefer D, Danysz W, Diamond DM. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. *Pharmacology Biochemistry and Behavior*. 2006;85(2):298-306.

Zotova E, Nicoll JAR, Kalaria R, Holmes C, Boche D. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. *Alzheimers Research & Therapy*. 2010;2(1).

Zou L, Wang Z, Shen L, Bao GB, Wang T, Kang JH, et al. Receptor tyrosine kinases positively regulate BACE activity and Amyloid-beta production through enhancing BACE internalization. *Cell Research*. 2007;17(5):389-401.

Zou Z, Liu C, Che C, Huang H. Clinical Genetics of Alzheimer's Disease. *Biomed Research International*. 2014.

Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. *Nature Reviews Neurology*. 2009;5(6):311-22.

Appendix 10C3-a. Additional AD treatment references based on linking terms in title

A colourful approach to improving nutrition for people with dementia. Nursing standard (Royal College of Nursing (Great Britain) : 1987). 2015;30(2):8.

A heart condition may foreshadow dementia, even without a stroke. New studies show resolving heart problems now may preserve brain function later. Harvard women's health watch. 2013;20(12):3.

Aalbers T, Baars L, Rikkert MO. The Mediterranean diet as prevention strategy for dementia as a multicausal geriatric syndrome. The American journal of clinical nutrition. 2013;97(6):1411.

Aalinkeel R, Kutscher HL, Singh A, Cwiklinski K, Khechen N, Schwartz SA, et al. Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer's disease? Journal of drug targeting. 2017;1-12.

Aamodt WW, Terracina KA, Schillerstrom JE. Cognitive profiles of elder adult protective services clients living in squalor. Journal of elder abuse & neglect. 2015;27(1):65-73.

Aasmul I, Husebo BS, Flo E. Staff Distress Improves by Treating Pain in Nursing Home Patients With Dementia: Results From a Cluster-Randomized Controlled Trial. Journal of pain and symptom management. 2016;52(6):795-805.

Abada Y-SK, Nguyen HP, Ellenbroek B, Schreiber R. Reversal learning and associative memory impairments in a BACHD rat model for Huntington disease. PloS one. 2013;8(11):e71633.

Abarova S, Koynova R, Tancheva L, Tenchov B. A novel DSC approach for evaluating protectant drugs efficacy against dementia. Biochimica et biophysica acta. 2017;1863(11):2934-41.

Abbasi MA, Saeed A, Aziz Ur R, Mohmmmed Khan K, Ashraf M, Ejaz SA. Synthesis of brominated 2-phenitidine derivatives as valuable inhibitors of cholinesterases for the treatment of Alzheimer's disease. Iranian journal of pharmaceutical research : IJPR. 2014;13(1):87-94.

Abbate C, Caputo L, Damanti S, Zappa C, Nicolini P, Rossi PD, et al. Reversible Parkinson's Dementia Associated with Withdrawal of Androgen-Deprivation Therapy for Prostate Cancer. Journal of the American Geriatrics Society. 2016;64(10):e115-e7.

Abbondante S, Baglietto-Vargas D, Rodriguez-Ortiz CJ, Estrada-Hernandez T, Medeiros R, Laferla FM. Genetic ablation of tau mitigates cognitive impairment induced by type 1 diabetes. The American journal of pathology. 2014;184(3):819-26.

Abd El-Kader SM, Al-Jiffri OH. Aerobic exercise improves quality of life, psychological well-being and systemic inflammation in subjects with Alzheimer's disease. *African health sciences*. 2016;16(4):1045-55.

Abd Razik BM, Osman H, Basiri A, Salhin A, Kia Y, Ezzat MO, et al. Ionic liquid mediated synthesis and molecular docking study of novel aromatic embedded Schiff bases as potent cholinesterase inhibitors. *Bioorganic chemistry*. 2014;57:162-8.

AbdAlla S, El Hakim A, Abdelbaset A, Elfaramawy Y, Quitterer U. Inhibition of ACE Retards Tau Hyperphosphorylation and Signs of Neuronal Degeneration in Aged Rats Subjected to Chronic Mild Stress. *BioMed research international*. 2015;2015:917156.

AbdAlla S, Langer A, Fu X, Quitterer U. ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer's disease. *International journal of molecular sciences*. 2013;14(8):16917-42.

Abd-El-Fattah MA, Abdelakader NF, Zaki HF. Pyrrolidine dithiocarbamate protects against scopolamine-induced cognitive impairment in rats. *European journal of pharmacology*. 2014;723:330-8.

Abdel-Magid AF. beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease and Down's Syndrome. *ACS medicinal chemistry letters*. 2013;4(7):578-9.

Abdel-Magid AF. Inhibition of O-GlcNAcase (OGA): A Potential Therapeutic Target to Treat Alzheimer's Disease. *ACS medicinal chemistry letters*. 2014;5(12):1270-1.

Abdel-Zaher AO, Farghaly HSM, Farrag MMY, Abdel-Rahman MS, Abdel-Wahab BA. A potential mechanism for the ameliorative effect of thymoquinone on pentylene-tetrazole-induced kindling and cognitive impairments in mice. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2017;88:553-61.

Abdel-Zaher AO, Hamdy MM, Abdel-Rahman MS, Abd El-Hamid DH. Protective effect of citicoline against aluminum-induced cognitive impairments in rats. *Toxicology and industrial health*. 2017;33(4):308-17.

Abdenour B, Charles R. Innovative anthocyanins formulation protects neuronal-like cells against oxidative stress-induced damage: Pharmacotherapeutic application for Alzheimer's disease. *Free radical biology & medicine*. 2014;75 Suppl 1:S45.

Abdou HM, Yousef MI, El Mekrawy DA, Al-Shami AS. Prophylactic neuroprotective efficiency of co-administration of Ginkgo biloba and Trifolium pretense against sodium arsenite-induced neurotoxicity and dementia in different regions of brain and spinal cord of rats. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*. 2016;94:112-27.

Abdullah A, Hirayama A, Yatsushiro S, Matsumae M, Kuroda K. Cerebrospinal fluid image segmentation using spatial fuzzy clustering method with improved evolutionary Expectation Maximization. Conference proceedings : Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual Conference. 2013;2013:3359-62.

Abe K. 111th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: 10. Dementia prevention by best medical treatment. Nihon Naika Gakkai zasshi The Journal of the Japanese Society of Internal Medicine. 2014;103(9):2292-9.

Aboulafia-Brakha T, Suchecki D, Gouveia-Paulino F, Nitrini R, Ptak R. Cognitive-behavioural group therapy improves a psychophysiological marker of stress in caregivers of patients with Alzheimer's disease. Aging & mental health. 2014;18(6):801-8.

Abraham JN, Kedracki D, Prado E, Gourmel C, Maroni P, Nardin C. Effect of the Interaction of the amyloid beta (1-42) peptide with short single-stranded synthetic nucleotide sequences: morphological characterization of the inhibition of fibrils formation and fibrils disassembly. Biomacromolecules. 2014;15(9):3253-8.

Abstracts for the Second International Meeting of the Milan Center for Neuroscience (Neuromi): Prediction and Prevention of Dementia: New Hope (Milan, July 6-8, 2016). Journal of Alzheimer's disease : JAD. 2016;53 Suppl 1:S1-S74.

Abuznait AH, Qosa H, Busnena BA, El Sayed KA, Kaddoumi A. Olive-oil-derived oleocanthal enhances beta-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies. ACS chemical neuroscience. 2013;4(6):973-82.

Acerra N, Kad NM, Cheruvara H, Mason JM. Intracellular selection of peptide inhibitors that target disulphide-bridged Abeta42 oligomers. Protein science : a publication of the Protein Society. 2014;23(9):1262-74.

Acharyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, et al. Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Molecular neurodegeneration. 2016;11(1):74.

Achour M, Le Gras S, Keime C, Parmentier F, Lejeune F-X, Boutillier A-L, et al. Neuronal identity genes regulated by super-enhancers are preferentially down-regulated in the striatum of Huntington's disease mice. Human molecular genetics. 2015;24(12):3481-96.

Acquaah-Mensah GK, Taylor RC. Brain in situ hybridization maps as a source for reverse-engineering transcriptional regulatory networks: Alzheimer's disease insights. Gene. 2016;586(1):77-86.

Adak A, Das G, Barman S, Mohapatra S, Bhunia D, Jana B, et al. Biodegradable Neuro-Compatible Peptide Hydrogel Promotes Neurite Outgrowth, Shows Significant Neuroprotection, and Delivers Anti-Alzheimer Drug. *ACS applied materials & interfaces*. 2017;9(6):5067-76.

Adam S, Bonsang E, Grotz C, Perelman S. Occupational activity and cognitive reserve: implications in terms of prevention of cognitive aging and Alzheimer's disease. *Clinical interventions in aging*. 2013;8:377-90.

Adanyeguh IM, Rinaldi D, Henry P-G, Caillet S, Valabregue R, Durr A, et al. Triheptanoin improves brain energy metabolism in patients with Huntington disease. *Neurology*. 2015;84(5):490-5.

Addington J, Liu L, Perkins DO, Carrion RE, Keefe RSE, Woods SW. The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms. *Schizophrenia bulletin*. 2017;43(1):57-63.

Adegoke OO, Qiao F, Liu Y, Longley K, Feng S, Wang H. Overexpression of Ubiquilin-1 Alleviates Alzheimer's Disease-Caused Cognitive and Motor Deficits and Reduces Amyloid-beta Accumulation in Mice. *Journal of Alzheimer's disease : JAD*. 2017;59(2):575-90.

Adler BL, Yarchoan M, Hwang HM, Louneva N, Blair JA, Palm R, et al. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. *Neurobiology of aging*. 2014;35(4):793-801.

Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions. *International journal of clinical practice*. 2014;68(4):465-70.

Adwan L, Subaiea GM, Zawia NH. Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers. *Neuropharmacology*. 2014;79:596-602.

Aerts L, Heffernan M, Kochan NA, Crawford JD, Draper B, Trollor JN, et al. Effects of MCI subtype and reversion on progression to dementia in a community sample. *Neurology*. 2017;88(23):2225-32.

Agadjanyan MG, Petrovsky N, Ghochikyan A. A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2015;11(10):1246-59.

Agar M, Beattie E, Lockett T, Phillips J, Luscombe G, Goodall S, et al. Pragmatic cluster randomised controlled trial of facilitated family case conferencing compared with usual care for improving end of life care and outcomes in nursing home residents with advanced dementia and their families: the IDEAL study protocol. *BMC palliative care*. 2015;14:63.

Ager RR, Davis JL, Agazaryan A, Benavente F, Poon WW, LaFerla FM, et al. Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss. *Hippocampus*. 2015;25(7):813-26.

Agholme L, Nath S, Domert J, Marcusson J, Kagedal K, Hallbeck M. Proteasome inhibition induces stress kinase dependent transport deficits--implications for Alzheimer's disease. *Molecular and cellular neurosciences*. 2014;58:29-39.

Agostini S, Mancuso R, Baglio F, Clerici M. A protective role for herpes simplex virus type-1-specific humoral immunity in Alzheimer's Disease. *Expert review of anti-infective therapy*. 2017;15(2):89-91.

Aharony I, Ehrnhoefer DE, Shruster A, Qiu X, Franciosi S, Hayden MR, et al. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. *Human molecular genetics*. 2015;24(9):2604-14.

Ahmad W, Ebert PR. Metformin Attenuates Abeta Pathology Mediated Through Levamisole Sensitive Nicotinic Acetylcholine Receptors in a *C. elegans* Model of Alzheimer's Disease. *Molecular neurobiology*. 2017;54(7):5427-39.

Ahmed AS, Elgharabawy RM, Al-Najjar AH. Ameliorating effect of anti-Alzheimer's drugs on the bidirectional association between type 2 diabetes mellitus and Alzheimer's disease. *Experimental biology and medicine (Maywood, NJ)*. 2017;242(13):1335-44.

Ahmed HH, Estefan SF, Mohamd EM, Farrag AE-RH, Salah RS. Does melatonin ameliorate neurological changes associated with Alzheimer's disease in ovariectomized rat model? *Indian journal of clinical biochemistry : IJCB*. 2013;28(4):381-9.

Ahmed T, Blum D, Burnouf S, Demeyer D, Buee-Scherrer V, D'Hooge R, et al. Rescue of impaired late-phase long-term depression in a tau transgenic mouse model. *Neurobiology of aging*. 2015;36(2):730-9.

Ahn HJ, Glickman JF, Poon KL, Zamolodchikov D, Jno-Charles OC, Norris EH, et al. A novel Abeta-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice. *The Journal of experimental medicine*. 2014;211(6):1049-62.

Ahn S-H, Choi N-K, Kim Y-J, Seong J-M, Shin J-Y, Jung S-Y, et al. Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea. *Archives of pharmacal research*. 2015;38(6):1255-62.

Ai J, Sun L-H, Che H, Zhang R, Zhang T-Z, Wu W-C, et al. MicroRNA-195 protects against dementia induced by chronic brain hypoperfusion via its anti-amyloidogenic effect in rats. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(9):3989-4001.

Aitken L, Baillie G, Pannifer A, Morrison A, Jones PS, Smith TK, et al. In Vitro Assay Development and HTS of Small-Molecule Human ABAD/17beta-HSD10 Inhibitors as Therapeutics in Alzheimer's Disease. *SLAS discovery : advancing life sciences R & D*. 2017;22(6):676-85.

Aitken L, Quinn SD, Perez-Gonzalez C, Samuel IDW, Penedo JC, Gunn-Moore FJ. Morphology-Specific Inhibition of beta-Amyloid Aggregates by 17beta-Hydroxysteroid Dehydrogenase Type 10. *Chembiochem : a European journal of chemical biology*. 2016;17(11):1029-37.

Ajit D, Woods LT, Camden JM, Thebeau CN, El-Sayed FG, Greeson GW, et al. Loss of P2Y₆, nucleotide receptors enhances early pathology in the TgCRND8 mouse model of Alzheimer's disease. *Molecular neurobiology*. 2014;49(2):1031-42.

Ajith TA, Padmajanair G. Mitochondrial Pharmaceuticals: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer's Disease. *Current aging science*. 2015;8(3):235-40.

Ajmani S, Janardhan S, Viswanadhan VN. Toward a general predictive QSAR model for gamma-secretase inhibitors. *Molecular diversity*. 2013;17(3):421-34.

Akitake Y, Nakatani Y, Kamei D, Hosokawa M, Akatsu H, Uematsu S, et al. Microsomal prostaglandin E synthase-1 is induced in alzheimer's disease and its deletion mitigates alzheimer's disease-like pathology in a mouse model. *Journal of neuroscience research*. 2013;91(7):909-19.

Akoury E, Pickhardt M, Gajda M, Biernat J, Mandelkow E, Zweckstetter M. Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation. *Angewandte Chemie (International ed in English)*. 2013;52(12):3511-5.

Alanen H-M, Pitkanen A, Suontaka-Jamalainien K, Kampman O, Leinonen E. Acute Psychogeriatric Inpatient Treatment Improves Neuropsychiatric Symptoms but Impairs the Level of Functioning in Patients with Dementia. *Dementia and geriatric cognitive disorders*. 2015;40(5-6):290-6.

Alawdi SH, El-Denshary ES, Safar MM, Eidi H, David M-O, Abdel-Wahhab MA. Neuroprotective Effect of Nanodiamond in Alzheimer's Disease Rat Model: a Pivotal Role for Modulating NF-kappaB and STAT3 Signaling. *Molecular neurobiology*. 2017;54(3):1906-18.

Albert SM. Insights on the Early-Life Origins of Alzheimer's Disease: Relevance for Primary Prevention? *Neuroepidemiology*. 2015;45(4):255-6.

Alcantara Montero A, Sanchez Carnerero CI. Proton-pump inhibitors and risk of dementia. *Semergen*. 2017;43(3):e29-e30.

Alfieri JA, Pino NS, Igaz LM. Reversible behavioral phenotypes in a conditional mouse model of TDP-43 proteinopathies. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(46):15244-59.

Ali B, Jamal QMS, Shams S, Al-Wabel NA, Siddiqui MU, Alzohairy MA, et al. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment. *CNS & neurological disorders drug targets*. 2016;15(5):624-8.

Ali MRA-A, Abo-Youssef AMH, Messiha BAS, Khattab MM. Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxido-nitrosative stress. *Naunyn-Schmiedeberg's archives of pharmacology*. 2016;389(6):637-56.

Ali T, Badshah H, Kim TH, Kim MO. Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF- κ B/JNK signaling pathway in aging mouse model. *Journal of pineal research*. 2015;58(1):71-85.

Ali T, Kim MJ, Rehman SU, Ahmad A, Kim MO. Anthocyanin-Loaded PEG-Gold Nanoparticles Enhanced the Neuroprotection of Anthocyanins in an Abeta1-42 Mouse Model of Alzheimer's Disease. *Molecular neurobiology*. 2017;54(8):6490-506.

Ali TB, Schleret TR, Reilly BM, Chen WY, Abagyan R. Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. *PloS one*. 2015;10(12):e0144337.

Alichniewicz KK, Brunner F, Klunemann HH, Greenlee MW. Neural correlates of saccadic inhibition in healthy elderly and patients with amnesic mild cognitive impairment. *Frontiers in psychology*. 2013;4:467.

Aliev G, Ashraf GM, Kaminsky YG, Sheikh IA, Sudakov SK, Yakhno NN, et al. Implication of the nutritional and nonnutritional factors in the context of preservation of cognitive performance in patients with dementia/depression and Alzheimer disease. *American journal of Alzheimer's disease and other dementias*. 2013;28(7):660-70.

Alipour F, Oryan S, Sharifzadeh M, Karimzadeh F, Kafami L, Irannejad H, et al. The neuroprotective effect of a triazine derivative in an Alzheimer's rat model. *Acta medica Iranica*. 2015;53(1):8-16.

Alirezai M, Rezaei M, Hajighahramani S, Sookhtehzari A, Kiani K. Oleuropein attenuates cognitive dysfunction and oxidative stress induced by some anesthetic drugs in the hippocampal area of rats. *The journal of physiological sciences : JPS*. 2017;67(1):131-9.

Al-Khalil O. Anti-inflammatory drugs for dementia prevention? *Praxis*. 2015;104(21):1159.

Allen HB. Alzheimer's Disease: Assessing the Role of Spirochetes, Biofilms, the Immune System, and Amyloid-beta with Regard to Potential Treatment and Prevention. *Journal of Alzheimer's disease : JAD*. 2016;53(4):1271-6.

Allott KA, Killackey E, Sun P, Brewer WJ, Velligan DI. Improving vocational outcomes in first-episode psychosis by addressing cognitive impairments using Cognitive Adaptation Training. *Work (Reading, Mass)*. 2017;56(4):581-9.

Almeida OP, MacLeod C, Flicker L, Ford A, Grafton B, Etherton-Beer C. RAndomised controlled trial to imProve depressIon and the quality of life of people with Dementia using cognitive bias modification: RAPID study protocol. *BMJ open*. 2014;4(7):e005623.

Almoallim H, Mehdawi FS, Cheikh MM, Al-Dhaheer F, Aqeel AM. Reversible Vitamin B12 Deficiency Presenting with Acute Dementia, Paraparesis, and Normal Hemoglobin. *Case reports in neurological medicine*. 2016;2016:4301769.

Al-Nadaf AH, Taha MO, Aldal'in HK. Haloperidol inhibits Memapsin 2: innovation by docking simulation and in vitro assay. *Pakistan journal of pharmaceutical sciences*. 2015;28(1):139-46.

Alonso E, Otero P, Vale C, Alfonso A, Antelo A, Gimenez-Llort L, et al. Benefit of 13-desmethyl spirolide C treatment in triple transgenic mouse model of Alzheimer disease: beta-amyloid and neuronal markers improvement. *Current Alzheimer research*. 2013;10(3):279-89.

Alonso E, Vale C, Vieytes MR, Botana LM. Translocation of PKC by yessotoxin in an in vitro model of Alzheimer's disease with improvement of tau and beta-amyloid pathology. *ACS chemical neuroscience*. 2013;4(7):1062-70.

Alosco ML, Spitznagel MB, Cohen R, Sweet LH, Josephson R, Hughes J, et al. Decreases in body mass index after cardiac rehabilitation predict improved cognitive function in older adults with heart failure. *Journal of the American Geriatrics Society*. 2014;62(11):2215-6.

Alosco ML, Spitznagel MB, Strain G, Devlin M, Crosby RD, Mitchell JE, et al. Family history of Alzheimer's disease limits improvement in cognitive function after bariatric surgery. *SAGE open medicine*. 2014;2:2050312114539477.

Al-Qazzaz NK, Ali S, Ahmad SA, Escudero J. Classification enhancement for post-stroke dementia using fuzzy neighborhood preserving analysis with QR-decomposition. *Conference proceedings : Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual Conference*. 2017;2017:3174-7.

Alquezar C, Salado IG, de la Encarnacion A, Perez DI, Moreno F, Gil C, et al. Targeting TDP-43 phosphorylation by Casein Kinase-1delta inhibitors: a novel strategy for the treatment of frontotemporal dementia. *Molecular neurodegeneration*. 2016;11(1):36.

Al-Shawi R, Tennent GA, Millar DJ, Richard-Londt A, Brandner S, Werring DJ, et al. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Abeta amyloid deposits in vivo. *Open biology*. 2016;6(2):150202.

Alt JA, Mace JC, Smith TL, Soler ZM. Endoscopic sinus surgery improves cognitive dysfunction in patients with chronic rhinosinusitis. *International forum of allergy & rhinology*. 2016;6(12):1264-72.

Altamura C, Ventriglia M, Martini MG, Montesano D, Errante Y, Piscitelli F, et al. Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer's Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline. *Journal of Alzheimer's disease : JAD*. 2015;46(2):497-506.

Alto LT, Chen X, Ruhn KA, Trevino I, Tansey MG. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease. *PloS one*. 2014;9(5):e96544.

Alvarez XA, Alvarez I, Iglesias O, Crespo I, Figueroa J, Aleixandre M, et al. Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases. *The international journal of neuropsychopharmacology*. 2016.

Alvarez-Sabin J, Ortega G, Jacas C, Santamarina E, Maisterra O, Ribo M, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. *Cerebrovascular diseases (Basel, Switzerland)*. 2013;35(2):146-54.

Alvarez-Sabin J, Santamarina E, Maisterra O, Jacas C, Molina C, Quintana M. Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke. *International journal of molecular sciences*. 2016;17(3):390.

Alves S, Churlaud G, Audrain M, Michaelsen-Preusse K, Fol R, Souchet B, et al. Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice. *Brain : a journal of neurology*. 2017;140(3):826-42.

Alzheimer disease: Suppression of stress signalling prevents AD onset in mice. *Nature reviews Neurology*. 2015;11(12):668.

Alzheimer's Disease Anti-inflammatory Prevention Trial Research G. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013;9(6):714-23.

Alzheimer's disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors. *Prescrire international*. 2014;23(150):156.

Amaral M, Levy C, Heyes DJ, Lafite P, Outeiro TF, Giorgini F, et al. Structural basis of kynurenine 3-monooxygenase inhibition. *Nature*. 2013;496(7445):382-5.

Amat-Ur-Rasool H, Ahmed M. Designing Second Generation Anti-Alzheimer Compounds as Inhibitors of Human Acetylcholinesterase: Computational Screening of Synthetic Molecules and Dietary Phytochemicals. *PloS one*. 2015;10(9):e0136509.

Ambure P, Kar S, Roy K. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents. *Bio Systems*. 2014;116:10-20.

Ameen D, Michniak-Kohn B. Transdermal delivery of dimethyl fumarate for Alzheimer's disease: Effect of penetration enhancers. *International journal of pharmaceutics*. 2017;529(1-2):465-73.

Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alfoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment. *Journal of Alzheimer's disease : JAD*. 2014;42 Suppl 3:S281-8.

Amin FU, Shah SA, Badshah H, Khan M, Kim MO. Anthocyanins encapsulated by PLGA@PEG nanoparticles potentially improved its free radical scavenging capabilities via p38/JNK pathway against Abeta1-42-induced oxidative stress. *Journal of nanobiotechnology*. 2017;15(1):12.

Amin SA, Adhikari N, Jha T, Gayen S. First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington's disease: A proposal to chemists! *Bioorganic & medicinal chemistry letters*. 2016;26(23):5712-8.

Amoah SKS, Dalla Vecchia MT, Pedrini B, Carnhelutti GL, Goncalves AE, Dos Santos DA, et al. Inhibitory effect of sesquiterpene lactones and the sesquiterpene alcohol aromadendrane-4beta,10alpha-diol on memory impairment in a mouse model of Alzheimer. *European journal of pharmacology*. 2015;769:195-202.

Amorim JA, Canas PM, Tome AR, Rolo AP, Agostinho P, Palmeira CM, et al. Mitochondria in Excitatory and Inhibitory Synapses have Similar Susceptibility to Amyloid-beta Peptides Modeling Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;60(2):525-36.

An N, Jin L, Yang J, Yin Y, Jiang S, Jing B, et al. Data Platform for the Research and Prevention of Alzheimer's Disease. *Advances in experimental medicine and biology*. 2017;1028:55-78.

Anand KS, Garg J, Verma R, Chakraborty A. Hashimoto's Encephalitis: Unusual Cause of Reversible Dementia. *Journal of family medicine and primary care*. 2014;3(3):284-6.

Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer's disease. *Archives of pharmacol research*. 2013;36(4):375-99.

Andersen FL, Ladefoged CN, Beyer T, Keller SH, Hansen AE, Hojgaard L, et al. Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. *NeuroImage*. 2014;84:206-16.

Anderson K, Grossberg GT. Brain games to slow cognitive decline in Alzheimer's disease. *Journal of the American Medical Directors Association*. 2014;15(8):536-7.

Andre EM, Passirani C, Seijo B, Sanchez A, Montero-Menei CN. Nano and microcarriers to improve stem cell behaviour for neuroregenerative medicine strategies: Application to Huntington's disease. *Biomaterials*. 2016;83:347-62.

Andre S, Heinrich S, Kayser F, Menzler K, Kesselring J, Khader PH, et al. At-home tDCS of the left dorsolateral prefrontal cortex improves visual short-term memory in mild vascular dementia. *Journal of the neurological sciences*. 2016;369:185-90.

Andreasen N, Simeoni M, Ostlund H, Lisjo PI, Fladby T, Loercher AE, et al. First administration of the Fc-attenuated anti-beta amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. *PloS one*. 2015;10(3):e0098153.

Andreetto E, Malideli E, Yan L-M, Kracklauer M, Farbiarz K, Tatarek-Nossol M, et al. A Hot-Segment-Based Approach for the Design of Cross-Amyloid Interaction Surface Mimics as Inhibitors of Amyloid Self-Assembly. *Angewandte Chemie (International ed in English)*. 2015;54(44):13095-100.

Andrew MK. Let's Put the Pieces Together: Frailty, Social Vulnerability, the Continuum of Care, Prevention and Research are Key Considerations for a Dementia Care Strategy. *HealthcarePapers*. 2016;16(2):34-9.

Andrew RJ, Fernandez CG, Stanley M, Jiang H, Nguyen P, Rice RC, et al. Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2017;114(45):E9665-E74.

Andrews J. "Wise use of our resources will improve hospital dementia care". *Nursing times*. 2016;112(24):11.

Andrews KA, Modat M, Macdonald KE, Yeatman T, Cardoso MJ, Leung KK, et al. Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. *PloS one*. 2013;8(3):e58816.

Andrews SC, Dominguez JF, Mercieca E-C, Georgiou-Karistianis N, Stout JC. Cognitive interventions to enhance neural compensation in Huntington's disease. *Neurodegenerative disease management*. 2015;5(2):155-64.

Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. *The Lancet Neurology*. 2015;14(9):926-44.

Anglada-Huguet M, Xifro X, Giralt A, Zamora-Moratalla A, Martin ED, Alberch J. Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease. *Molecular neurobiology*. 2014;49(2):784-95.

Anitua E, Pascual C, Antequera D, Bolos M, Padilla S, Orive G, et al. Plasma rich in growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves cognitive functions in an Alzheimer's disease mouse model. *Neurobiology of aging*. 2014;35(7):1582-95.

Anitua E, Pascual C, Perez-Gonzalez R, Antequera D, Padilla S, Orive G, et al. Intranasal delivery of plasma and platelet growth factors using PRGF-Endoret system enhances neurogenesis in a mouse model of Alzheimer's disease. *PloS one*. 2013;8(9):e73118.

Annweiler C, Beauchet O, Bartha R, Montero-Odasso M, Kurland WT, WgA-Lf. Slow gait in MCI is associated with ventricular enlargement: results from the Gait and Brain Study. *Journal of neural transmission (Vienna, Austria : 1996)*. 2013;120(7):1083-92.

Annweiler C, Brugg B, Peyrin J-M, Bartha R, Beauchet O. Combination of memantine and vitamin D prevents axon degeneration induced by amyloid-beta and glutamate. *Neurobiology of aging*. 2014;35(2):331-5.

Annweiler C. Vitamin D in dementia prevention. *Annals of the New York Academy of Sciences*. 2016;1367(1):57-63.

Ano Y, Dohata A, Taniguchi Y, Hoshi A, Uchida K, Takashima A, et al. Iso-alpha-acids, Bitter Components of Beer, Prevent Inflammation and Cognitive Decline Induced in a Mouse Model of Alzheimer's Disease. *The Journal of biological chemistry*. 2017;292(9):3720-8.

Ano Y, Ozawa M, Kutsukake T, Sugiyama S, Uchida K, Yoshida A, et al. Preventive effects of a fermented dairy product against Alzheimer's disease and identification of a novel oleamide with enhanced microglial phagocytosis and anti-inflammatory activity. *PloS one*. 2015;10(3):e0118512.

Ansado J, Collins L, Joubert S, Fonov V, Monchi O, Brambati SM, et al. Interhemispheric coupling improves the brain's ability to perform low cognitive demand tasks in Alzheimer's disease and high cognitive demand tasks in normal aging. *Neuropsychology*. 2013;27(4):464-80.

Ansai JH, Andrade LP, Rossi PG, Takahashi ACM, Vale FAC, Rebelatto JR. Gait, dual task and history of falls in elderly with preserved cognition, mild cognitive impairment, and mild Alzheimer's disease. *Brazilian journal of physical therapy*. 2017;21(2):144-51.

Ansai JH, Andrade LPd, Nakagawa TH, Vale FAC, Caetano MJD, Lord SR, et al. Cognitive Correlates of Timed Up and Go Subtasks in Older People With Preserved Cognition, Mild Cognitive Impairment, and Alzheimer's Disease. *American journal of physical medicine & rehabilitation*. 2017;96(10):700-5.

Anstey KJ, Cherbuin N, Herath PM. Development of a new method for assessing global risk of Alzheimer's disease for use in population health approaches to prevention. *Prevention science : the official journal of the Society for Prevention Research*. 2013;14(4):411-21.

Anstey KJ, Eramudugolla R, Dixon RA. Contributions of a risk assessment approach to the prevention of Alzheimer's disease and dementia. *Journal of Alzheimer's disease : JAD*. 2014;42 Suppl 4:S463-73.

Anstey KJ, Peters R, Clare L, Lautenschlager NT, Dodge HH, Barnes DE, et al. Joining forces to prevent dementia: The International Research Network On Dementia Prevention (IRNDP). *International psychogeriatrics*. 2017;29(11):1757-60.

Antonenko D, Floel A. Non-invasive brain stimulation in neurology : Transcranial direct current stimulation to enhance cognitive functioning. *Der Nervenarzt*. 2016;87(8):838-45.

Antonios G, Saiepour N, Bouter Y, Richard BC, Paetau A, Verkkoniemi-Ahola A, et al. N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. *Acta neuropathologica communications*. 2013;1:56.

Antunes Wilhelm E, Ricardo Jesse C, Folharini Bortolatto C, Wayne Nogueira C. Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington's disease: protective effect of melatonin. *European journal of pharmacology*. 2013;701(1-3):65-72.

Appleby BS, Kelso R. Subclavian steal syndrome presenting as a reversible dementia. *The Journal of neuropsychiatry and clinical neurosciences*. 2015;27(1):e74-5.

Arafa RK, Elghazawy NH. Personalized Medicine and Resurrected Hopes for the Management of Alzheimer's Disease: A Modular Approach Based on GSK-3beta Inhibitors. *Advances in experimental medicine and biology*. 2017;1007:199-224.

Arai T, Ohno A, Mori K, Kuwata H, Mizuno M, Imai K, et al. Inhibition of amyloid fibril formation and cytotoxicity by caffeic acid-conjugated amyloid-beta C-terminal peptides. *Bioorganic & medicinal chemistry letters*. 2016;26(22):5468-71.

Araya JA, Ramirez AE, Figueroa-Aroca D, Sotes GJ, Perez C, Becerra J, et al. Modulation of neuronal nicotinic receptor by quinolizidine alkaloids causes neuroprotection on a cellular Alzheimer model. *Journal of Alzheimer's disease : JAD*. 2014;42(1):143-55.

Ard MC, Galasko DR, Edland SD. Improved statistical power of Alzheimer clinical trials by item-response theory: proof of concept by application to the activities of daily living scale. *Alzheimer disease and associated disorders*. 2013;27(2):187-91.

Arenaza-Urquijo EM, Bejanin A, Gonneaud J, Wirth M, La Joie R, Mutlu J, et al. Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation. *Neurobiology of aging*. 2017;59:72-9.

Ari C, Borysov SI, Wu J, Padmanabhan J, Potter H. Alzheimer amyloid beta inhibition of Eg5/kinesin 5 reduces neurotrophin and/or transmitter receptor function. *Neurobiology of aging*. 2014;35(8):1839-49.

Arias JJ. A time to step in: legal mechanisms for protecting those with declining capacity. *American journal of law & medicine*. 2013;39(1):134-59.

Arif M, Wei J, Zhang Q, Liu F, Basurto-Islas G, Grundke-Iqbal I, et al. Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau. *The Journal of biological chemistry*. 2014;289(40):27677-91.

Arjmand Abbassi Y, Mohammadi MT, Sarami Foroshani M, Raouf Sarshoori J. Captopril and Valsartan May Improve Cognitive Function Through Potentiation of the Brain Antioxidant Defense System and Attenuation of Oxidative/Nitrosative Damage in STZ-Induced Dementia in Rat. *Advanced pharmaceutical bulletin*. 2016;6(4):531-9.

Armand-Ugon M, Aso E, Moreno J, Riera-Codina M, Sanchez A, Vegas E, et al. Memory Improvement in the AbetaPP/PS1 Mouse Model of Familial Alzheimers Disease Induced by Carbamylated-Erythropoietin is Accompanied by Modulation of Synaptic Genes. *Journal of Alzheimer's disease : JAD*. 2015;45(2):407-21.

Arooj M, Sakkiah S, Cao GP, Kim S, Arulalapperumal V, Lee KW. Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach. *Proteins*. 2015;83(7):1209-24.

Arora RB, Kumar K, Deshmukh RR. FK506 attenuates intracerebroventricular streptozotocin-induced neurotoxicity in rats. *Behavioural pharmacology*. 2013;24(7):580-9.

Arrant AE, Filiano AJ, Unger DE, Young AH, Roberson ED. Restoring neuronal progranulin reverses deficits in a mouse model of frontotemporal dementia. *Brain : a journal of neurology*. 2017;140(5):1447-65.

Arrazola MS, Ramos-Fernandez E, Cisternas P, Ordenes D, Inestrosa NC. Wnt Signaling Prevents the Abeta Oligomer-Induced Mitochondrial Permeability Transition Pore Opening Preserving Mitochondrial Structure in Hippocampal Neurons. *PloS one*. 2017;12(1):e0168840.

Arribat Y, Bonneaud N, Talmat-Amar Y, Layalle S, Parmentier M-L, Maschat F. A huntingtin peptide inhibits polyQ-huntingtin associated defects. *PloS one*. 2013;8(7):e68775.

Arroyo-Anllo EM, Diaz JP, Gil R. Familiar music as an enhancer of self-consciousness in patients with Alzheimer's disease. *BioMed research international*. 2013;2013:752965.

Arunsundar M, Shanmugarajan TS, Ravichandran V. 3,4-dihydroxyphenylethanol attenuates spatio-cognitive deficits in an Alzheimer's disease mouse model: modulation of the molecular signals in neuronal survival-apoptotic programs. *Neurotoxicity research*. 2015;27(2):143-55.

Asadbegi M, Yaghmaei P, Salehi I, Ebrahim-Habibi A, Komaki A. Neuroprotective effects of metformin against Abeta-mediated inhibition of long-term potentiation in rats fed a high-fat diet. *Brain research bulletin*. 2016;121:178-85.

Asaduzzaman M, Uddin MJ, Kader MA, Alam AHMK, Rahman AA, Rashid M, et al. In vitro acetylcholinesterase inhibitory activity and the antioxidant properties of Aegle marmelos leaf extract: implications for the treatment of Alzheimer's disease. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2014;14(1):1-10.

Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. *Nature neuroscience*. 2015;18(11):1584-93.

Asante EA, Smidak M, Grimshaw A, Houghton R, Tomlinson A, Jeelani A, et al. A naturally occurring variant of the human prion protein completely prevents prion disease. *Nature*. 2015;522(7557):478-81.

Ashabi G, Alamdary SZ, Ramin M, Khodagholi F. Reduction of hippocampal apoptosis by intracerebroventricular administration of extracellular signal-regulated protein kinase and/or p38 inhibitors in amyloid beta rat model of Alzheimer's disease: involvement of nuclear-related factor-2 and nuclear factor-kappaB. *Basic & clinical pharmacology & toxicology*. 2013;112(3):145-55.

Ashabi G, Sarkaki A, Khodagholi F, Zareh Shahamati S, Goudarzvand M, Farbood Y, et al. Subchronic metformin pretreatment enhances novel object recognition memory task in forebrain ischemia: behavioural, molecular, and electrophysiological studies. *Canadian journal of physiology and pharmacology*. 2017;95(4):388-95.

Ashford JW, Mahoney L, Burkett T. A Role for Complementary and Integrative Medicine in Alzheimer's Disease Prevention. *Journal of Alzheimer's disease : JAD*. 2015;48(1):13-4.

Ashok BS, Ajith TA, Sivanesan S. Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease. *Clinical and experimental pharmacology & physiology*. 2017;44(3):327-34.

Aslam M, Sial AA. Neuroprotective Effect of Ethanol Extract of Leaves of *Malva parviflora* against Amyloid-beta- (A β -) Mediated Alzheimer's Disease. *International scholarly research notices*. 2014;2014:156976.

Asle-Rousta M, Kolahdooz Z, Dargahi L, Ahmadiani A, Nasoohi S. Prominence of central sphingosine-1-phosphate receptor-1 in attenuating abeta-induced injury by fingolimod. *Journal of molecular neuroscience : MN*. 2014;54(4):698-703.

Asle-Rousta M, Oryan S, Ahmadiani A, Rahnema M. Activation of sphingosine 1-phosphate receptor-1 by SEW2871 improves cognitive function in Alzheimer's disease model rats. *EXCLI journal*. 2013;12:449-61.

Aso E, Juves S, Maldonado R, Ferrer I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP/PS1 mice. *Journal of Alzheimer's disease : JAD*. 2013;35(4):847-58.

Asselineau D, Benlhassan K, Arosio B, Mari D, Ferri E, Casati M, et al. Interleukin-10 Production in Response to Amyloid-beta Differs between Slow and Fast Decliners in Patients with Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2015;46(4):837-42.

Atanasova M, Stavrakov G, Philipova I, Zheleva D, Yordanov N, Doytchinova I. Galantamine derivatives with indole moiety: Docking, design, synthesis and acetylcholinesterase inhibitory activity. *Bioorganic & medicinal chemistry*. 2015;23(17):5382-9.

Atherton N, Bridle C, Brown D, Collins H, Dosanjh S, Griffiths F, et al. Dementia and Physical Activity (DAPA) - an exercise intervention to improve cognition in people with mild to moderate dementia: study protocol for a randomized controlled trial. *Trials*. 2016;17:165.

Attar A, Chan W-TC, Klarner F-G, Schrader T, Bitan G. Safety and pharmacological characterization of the molecular tweezer CLR01 - a broad-spectrum inhibitor of amyloid proteins' toxicity. *BMC pharmacology & toxicology*. 2014;15:23.

Au A, Gallagher-Thompson D, Wong M-K, Leung J, Chan W-C, Chan CC, et al. Behavioral activation for dementia caregivers: scheduling pleasant events and enhancing communications. *Clinical interventions in aging*. 2015;10:611-9.

Au A, Wong MK, Leung LM, Leung P, Wong A. Telephone-assisted pleasant-event scheduling to enhance well-being of caregivers of people with dementia: a randomised controlled trial. *Hong Kong medical journal = Xianggang yi xue za zhi*. 2014;20(3 Suppl 3):30-3.

Auckland C. Protecting Me From My Directive: Ensuring Appropriate Safeguards for Advance Directives in Dementia. *Medical law review*. 2017.

Auclair-Ouellet N, Fossard M, Houde M, Laforce R, Macoir J. Production of morphologically derived words in the semantic variant of primary progressive aphasia: preserved decomposition and composition but impaired validation. *Neurocase*. 2016;22(2):170-8.

Auffret K, Jacolot C. Social and mood enhancement benefits of a cognitive remediation workshop. *Soins Gerontologie*. 2017;22(125):23-6.

Author-initiated retraction: Li et al., Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer's disease mouse model. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(16):5733.

Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. *The Journal of biological chemistry*. 2013;288(2):1295-306.

Ayaz M, Junaid M, Ullah F, Sadiq A, Khan MA, Ahmad W, et al. Comparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from *Polygonum hydropiper* L: a preliminary anti- Alzheimer's study. *Lipids in health and disease*. 2015;14:141.

Ayers KL, Mirshahi UL, Wardeh AH, Murray MF, Hao K, Glicksberg BS, et al. A loss of function variant in CASP7 protects against Alzheimer's disease in homozygous APOE epsilon4 allele carriers. *BMC genomics*. 2016;17 Suppl 2:445.

Ayutyanont N, Langbaum JBS, Hendrix SB, Chen K, Fleisher AS, Friesenhahn M, et al. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. *The Journal of clinical psychiatry*. 2014;75(6):652-60.

Azam F, Alabdullah NH, Ehmedat HM, Abulifa AR, Taban I, Upadhyayula S. NSAIDs as potential treatment option for preventing amyloid beta toxicity in Alzheimer's disease: an investigation by docking, molecular dynamics, and DFT studies. *Journal of biomolecular structure & dynamics*. 2017:1-19.

Baal PHMv, Hoogendoorn M, Fischer A. Preventing dementia by promoting physical activity and the long-term impact on health and social care expenditures. *Preventive medicine*. 2016;85:78-83.

Baba H. Depression and Bipolar Disorder: Risk Factors and Potential Prevention of Developing Dementia. *Brain and nerve = Shinkei kenkyu no shinpo*. 2016;68(7):753-65.

Babiloni C, Del Percio C, Bordet R, Bourriez J-L, Bentivoglio M, Payoux P, et al. Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients. *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology*. 2013;124(5):837-50.

Bacalhau P, San Juan AA, Marques CS, Peixoto D, Goth A, Guarda C, et al. New cholinesterase inhibitors for Alzheimer's disease: Structure Activity Studies (SARs) and molecular docking of isoquinolone and azepanone derivatives. *Bioorganic chemistry*. 2016;67:1-8.

Bach LL, Lazzaretto DL, Young CF, Lofholm PW. Improving Nursing Home Compliance via Revised Antipsychotic Use Survey Tool. *The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists*. 2017;32(4):228-38.

Bachoud-Levi AC, Perrier AL. Regenerative medicine in Huntington's disease: current status on fetal grafts and prospects for the use of pluripotent stem cell. *Revue neurologique*. 2014;170(12):749-62.

Bachyn'ska NI, Rozheliuk IF, Kholyn VO, Pishel IM, Leonov II. ApoE gene polymorphism as a predictor of therapeutic response to treatment acetylcholinesterase inhibitor for elderly patients with Alzheimer's and vascular dementia types. *Wiadomosci lekarskie (Warsaw, Poland : 1960)*. 2014;67(2 Pt 2):161-5.

Baddeley TC, McCaffrey J, Storey JMD, Cheung JKS, Melis V, Horsley D, et al. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. *The Journal of pharmacology and experimental therapeutics*. 2015;352(1):110-8.

Badiola N, Alcalde V, Pujol A, Munter L-M, Multhaup G, Lleo A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. *PloS one*. 2013;8(3):e58837.

Bae J-s, Jin HK, Lee JK, Richardson JC, Carter JE. Bone marrow-derived mesenchymal stem cells contribute to the reduction of amyloid-beta deposits and the improvement of synaptic transmission in a mouse model of pre-dementia Alzheimer's disease. *Current Alzheimer research*. 2013;10(5):524-31.

Baek H, Ye M, Kang G-H, Lee C, Lee G, Choi DB, et al. Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer's disease model. *Oncotarget*. 2016;7(43):69347-57.

Baek I-S, Kim T-K, Seo J-S, Lee K-W, Lee YA, Cho J, et al. AAD-2004 Attenuates Progressive Neuronal Loss in the Brain of Tg-betaCTF99/B6 Mouse Model of Alzheimer Disease. *Experimental neurobiology*. 2013;22(1):31-7.

Baek SH, Park SJ, Jeong JI, Kim SH, Han J, Kyung JW, et al. Inhibition of Drp1 Ameliorates Synaptic Depression, Abeta Deposition, and Cognitive Impairment in an Alzheimer's Disease Model. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(20):5099-110.

Baek S-S, Kim S-H. Treadmill exercise ameliorates symptoms of Alzheimer disease through suppressing microglial activation-induced apoptosis in rats. *Journal of exercise rehabilitation*. 2016;12(6):526-34.

Bag S, Tulsan R, Sood A, Datta S, Torok M. Pharmacophore Modeling, virtual and in vitro screening for acetylcholinesterase inhibitors and their effects on amyloid-beta self- assembly. *Current computer-aided drug design*. 2013;9(1):2-14.

Bagheri SM, Dashti-R MH. Influence of asafoetida on prevention and treatment of memory impairment induced by d-galactose and NaNO₂ in mice. *American journal of Alzheimer's disease and other dementias*. 2015;30(6):607-12.

Bagli E, Goussia A, Moschos MM, Agnantis N, Kitsos G. Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems. *In vivo (Athens, Greece)*. 2016;30(5):535-47.

Bagnato B, Marino MG, Franco E. Immunotherapeutic approach for the prevention and treatment of chronic diseases. *Igiene e sanita pubblica*. 2013;69(2):261-71.

Baguley TD, Nairn AC, Lombroso PJ, Ellman JA. Synthesis of benzopentathiepin analogs and their evaluation as inhibitors of the phosphatase STEP. *Bioorganic & medicinal chemistry letters*. 2015;25(5):1044-6.

Baharloo F, Moslemin MH, Nadri H, Asadipour A, Mahdavi M, Emami S, et al. Benzofuran-derived benzyropyridinium bromides as potent acetylcholinesterase inhibitors. *European journal of medicinal chemistry*. 2015;93:196-201.

Bahrani H, Mohamad J, Paydar MJ, Rothan HA. Isolation and characterisation of acetylcholinesterase inhibitors from *Aquilaria subintegra* for the treatment of Alzheimer's disease (AD). *Current Alzheimer research*. 2014;11(2):206-14.

Bai G, Cheung I, Shulha HP, Coelho JE, Li P, Dong X, et al. Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains. *Human molecular genetics*. 2015;24(5):1441-56.

Bai P, Peng X-M, Gao L, Huo S-X, Zhao P-P, Yan M. Study on protective effect of acteoside on cellular model of Alzheimer's disease induced by okadaic acid. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica*. 2013;38(9):1323-6.

Baiamonte BA, Lee FA, Brewer ST, Spano D, LaHoste GJ. Attenuation of Rhes activity significantly delays the appearance of behavioral symptoms in a mouse model of Huntington's disease. *PloS one*. 2013;8(1):e53606.

Baik T-K, Kim Y-J, Kang S-M, Song D-Y, Min SS, Woo R-S. Blocking the phosphatidylinositol 3-kinase pathway inhibits neuregulin-1-mediated rescue of neurotoxicity induced by Abeta1-42. *The Journal of pharmacy and pharmacology*. 2016;68(8):1021-9.

Bail K, Berry H, Grealish L, Draper B, Karmel R, Gibson D, et al. Potentially preventable complications of urinary tract infections, pressure areas, pneumonia, and delirium in hospitalised dementia patients: retrospective cohort study. *BMJ open*. 2013;3(6).

Bajda M, Panek D, Hebda M, Wieckowska A, Guzior N, Malawska B. SEARCH FOR POTENTIAL CHOLINESTERASE INHIBITORS FROM THE ZINC DATABASE BY VIRTUAL SCREENING METHOD. *Acta poloniae pharmaceutica*. 2015;72(4):737-45.

Bak T. Language lessons to help protect against dementia. *BMJ (Clinical research ed)*. 2016;354:i5039.

Baker C, Huxley P, Dennis M, Islam S, Russell I. Alleviating staff stress in care homes for people with dementia: protocol for stepped-wedge cluster randomised trial to evaluate a web-based Mindfulness- Stress Reduction course. *BMC psychiatry*. 2015;15:317.

Baker-Nigh AT, Mawuenyega KG, Bollinger JG, Ovod V, Kasten T, Franklin EE, et al. Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma. *The Journal of biological chemistry*. 2016;291(53):27204-18.

Bakhtiari M, Panahi Y, Ameli J, Darvishi B. Protective effects of flavonoids against Alzheimer's disease-related neural dysfunctions. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2017;93:218-29.

Baksi S, Jana NR, Bhattacharyya NP, Mukhopadhyay D. Grb2 is regulated by foxd3 and has roles in preventing accumulation and aggregation of mutant huntingtin. *PloS one*. 2013;8(10):e76792.

Balamurugan K, Murugan NA, Agren H. Multistep Modeling Strategy To Improve the Binding Affinity Prediction of PET Tracers to Abeta42: Case Study with Styrylbenzoxazole Derivatives. *ACS chemical neuroscience*. 2016;7(12):1698-705.

Balbag MA, Pedersen NL, Gatz M. Playing a Musical Instrument as a Protective Factor against Dementia and Cognitive Impairment: A Population-Based Twin Study. *International journal of Alzheimer's disease*. 2014;2014:836748.

Balducci C, Mancini S, Minniti S, La Vitola P, Zotti M, Sancini G, et al. Multifunctional liposomes reduce brain beta-amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(42):14022-31.

Balez R, Ooi L. Getting to NO Alzheimer's Disease: Neuroprotection versus Neurotoxicity Mediated by Nitric Oxide. *Oxidative medicine and cellular longevity*. 2016;2016:3806157.

Balez R, Steiner N, Engel M, Munoz SS, Lum JS, Wu Y, et al. Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer's disease. *Scientific reports*. 2016;6:31450.

Bali V, Chatterjee S, Carnahan RM, Chen H, Johnson ML, Aparasu RR. Risk of Dementia Among Elderly Nursing Home Patients Using Paroxetine and Other Selective Serotonin Reuptake Inhibitors. *Psychiatric services (Washington, DC)*. 2015;66(12):1333-40.

Balla C, Maertens de Noordhout A, Pepin JL. Motor cortex excitability changes in mild Alzheimer's disease are reversed by donepezil. *Dementia and geriatric cognitive disorders*. 2014;38(3-4):264-70.

Ballard C, Grimmer T. Improving diagnosis of possible DLB: is there a role for MIBG myocardial scintigraphy? *Neurology*. 2013;81(20):1730-1.

Ballmer PE, Uster A. Brain food. Importance of nutrition in the prevention and treatment of dementia. *Revue medicale suisse*. 2015;11(459):292, 4-7.

Balouch S, Rusted JM. Can verbal instruction enhance the recall of an everyday task and promote error-monitoring in people with dementia of the Alzheimer-type? *Neuropsychological rehabilitation*. 2017;27(2):239-62.

Balzer K, Schroder R, Junghans A, Stahl U, Trader J-M, Kopke S. Improving competencies in evidence-based dementia care: Results from a pilot study on a novel inter-professional training course (the KOMPIDEM project). *GMS journal for medical education*. 2016;33(2):Doc35.

Bamne MN, Demirci FY, Berman S, Snitz BE, Rosenthal SL, Wang X, et al. Investigation of an amyloid precursor protein protective mutation (A673T) in a North American case-control sample of late-onset Alzheimer's disease. *Neurobiology of aging*. 2014;35(7):1779.e15-6.

Bando N, Nakamura Y. Preliminary evidence that rivastigmine-induced inhibition of serum butyrylcholinesterase activity improves behavioral symptoms in Japanese patients with Alzheimer's disease. *Geriatrics & gerontology international*. 2017;17(9):1306-12.

Bane TJ, Cole C. Prevention of Alzheimer disease: The roles of nutrition and primary care. *The Nurse practitioner*. 2015;40(5):30-5; quiz 5-6.

Banerjee K, Munshi S, Xu H, Frank DE, Chen H-L, Chu CT, et al. Mild mitochondrial metabolic deficits by alpha-ketoglutarate dehydrogenase inhibition cause prominent changes in intracellular autophagic signaling: Potential role in the pathobiology of Alzheimer's disease. *Neurochemistry international*. 2016;96:32-45.

Banerjee P, Sahoo A, Anand S, Bir A, Chakrabarti S. The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-beta Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;49(3):681-93.

Banerjee P, Sahoo A, Anand S, Ganguly A, Righi G, Bovicelli P, et al. Multiple mechanisms of iron-induced amyloid beta-peptide accumulation in SHSY5Y cells: protective action of negletein. *Neuromolecular medicine*. 2014;16(4):787-98.

Banerjee S, Farina N, Daley S, Grosvenor W, Hughes L, Hebditch M, et al. How do we enhance undergraduate healthcare education in dementia? A review of the role of innovative approaches and development of the Time for Dementia Programme. *International journal of geriatric psychiatry*. 2017;32(1):68-75.

Bang SR, Ambavade SD, Jagdale PG, Adkar PP, Waghmare AB, Ambavade PD. Lacosamide reduces HDAC levels in the brain and improves memory: Potential for treatment of Alzheimer's disease. *Pharmacology, biochemistry, and behavior*. 2015;134:65-9.

Banks SJ, Raman R, He F, Salmon DP, Ferris S, Aisen P, et al. The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. *Dementia and geriatric cognitive disorders extra*. 2014;4(3):509-16.

Bao X-Q, Li N, Wang T, Kong X-C, Tai W-J, Sun H, et al. FLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylation. *PloS one*. 2013;8(11):e78033.

Baran Z, Cangoz B, Ozel-Kizil ET. The impact of aging and Alzheimer's disease on emotional enhancement of memory. *European neurology*. 2014;72(1-2):30-7.

Barban F, Annicchiarico R, Pantelopoulos S, Federici A, Perri R, Fadda L, et al. Protecting cognition from aging and Alzheimer's disease: a computerized cognitive training combined with reminiscence therapy. *International journal of geriatric psychiatry*. 2016;31(4):340-8.

Barber TJ, Moyle G, Hill A, Jagjit Singh G, Scourfield A, Yapa HM, et al. A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors. *HIV clinical trials*. 2016;17(3):123-30.

Barbui C, Gastaldon C, Cipriani A. Benzodiazepines and risk of dementia: true association or reverse causation? *Epidemiology and psychiatric sciences*. 2013;22(4):307-8.

Barnard ND, Bush AI, Ceccarelli A, Cooper J, de Jager CA, Erickson KI, et al. Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. *Neurobiology of aging*. 2014;35 Suppl 2:S74-8.

Barnes DE, Mehling W, Wu E, Beristianos M, Yaffe K, Skultety K, et al. Preventing loss of independence through exercise (PLIE): a pilot clinical trial in older adults with dementia. *PloS one*. 2015;10(2):e0113367.

Barnes DE, Santos-Modesitt W, Poelke G, Kramer AF, Castro C, Middleton LE, et al. The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults. *JAMA internal medicine*. 2013;173(9):797-804.

Barnes SR, Ng TSC, Montagne A, Law M, Zlokovic BV, Jacobs RE. Optimal acquisition and modeling parameters for accurate assessment of low Ktrans blood-brain barrier permeability using dynamic contrast-enhanced MRI. *Magnetic resonance in medicine*. 2016;75(5):1967-77.

Barnett JH, Hachinski V, Blackwell AD. Cognitive health begins at conception: addressing dementia as a lifelong and preventable condition. *BMC medicine*. 2013;11:246.

Barr RK, Verdile G, Wijaya LK, Morici M, Taddei K, Gupta VB, et al. Validation and Characterization of a Novel Peptide That Binds Monomeric and Aggregated beta-Amyloid and Inhibits the Formation of Neurotoxic Oligomers. *The Journal of biological chemistry*. 2016;291(2):547-59.

Barragan-Martinez D, Simarro-Diaz A, Calleja-Castano P, Hernandez-Lain A, Ramos-Gonzalez A, Villarejo-Galende A. Delayed tacrolimus leukoencephalopathy, a rare and reversible cause of dementia. *Neurology(R) neuroimmunology & neuroinflammation*. 2017;4(2):e319.

Barrera Guisasola EE, Andujar SA, Hubin E, Broersen K, Kraan IM, Mendez L, et al. New mimetic peptides inhibitors of Alphaseta aggregation. *Molecular guidance for rational drug design. European journal of medicinal chemistry*. 2015;95:136-52.

Barreto PdS, Rolland Y, Cesari M, Dupuy C, Andrieu S, Vellas B, et al. Effects of multidomain lifestyle intervention, omega-3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial. *Age and ageing*. 2017;1-8.

Barron AM, Garcia-Segura LM, Caruso D, Jayaraman A, Lee J-W, Melcangi RC, et al. Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(20):8891-7.

Barry AR, O'Neill DE, Graham MM. Primary Prevention of Cardiovascular Disease in Older Adults. *The Canadian journal of cardiology*. 2016;32(9):1074-81.

Barry HE, Cooper JA, Ryan C, Passmore AP, Robinson AL, Molloy GJ, et al. Potentially Inappropriate Prescribing Among People with Dementia in Primary Care: A Retrospective Cross-Sectional Study Using the Enhanced Prescribing Database. *Journal of Alzheimer's disease : JAD*. 2016;52(4):1503-13.

Barton M, Husmann M, Meyer MR. Accelerated Vascular Aging as a Paradigm for Hypertensive Vascular Disease: Prevention and Therapy. *The Canadian journal of cardiology*. 2016;32(5):680-6.e4.

Barua NU, Gill SS, Love S. Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations. *Brain pathology (Zurich, Switzerland)*. 2014;24(2):117-27.

Baruch K, Deczkowska A, Rosenzweig N, Tsitsou-Kampeli A, Sharif AM, Matcovitch-Natan O, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease. *Nature medicine*. 2016;22(2):135-7.

Baruch K, Rosenzweig N, Kertser A, Deczkowska A, Sharif AM, Spinrad A, et al. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology. *Nature communications*. 2015;6:7967.

Barucker C, Bittner HJ, Chang PKY, Cameron S, Hancock MA, Liebsch F, et al. Abeta42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-beta42 species and protects synaptic structure and function. *Scientific reports*. 2015;5:15410.

Basambombo LL, Carmichael P-H, Cote S, Laurin D. Use of Vitamin E and C Supplements for the Prevention of Cognitive Decline. *The Annals of pharmacotherapy*. 2017;51(2):118-24.

Basiri A, Xiao M, McCarthy A, Dutta D, Byraredy SN, Conda-Sheridan M. Design and synthesis of new piperidone grafted acetylcholinesterase inhibitors. *Bioorganic & medicinal chemistry letters*. 2017;27(2):228-31.

Baskys A. Integration of genomic information in development of pharmacological vascular dementia prevention and treatment strategies. *Journal of Alzheimer's disease : JAD*. 2014;42 Suppl 3:S267-76.

Bastin C, Willems S, Genon S, Salmon E. Enhancing the salience of fluency improves recognition memory performance in mild Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2013;33(4):1033-9.

Basu R. Willingness-to-pay to prevent Alzheimer's disease: a contingent valuation approach. *International journal of health care finance and economics*. 2013;13(3-4):233-45.

Batalini F, Avidan A, Moseley BD, Ringman JM. Improvement of Dream Enactment Behavior Associated With Levetiracetam Treatment in Dementia With Lewy Bodies. *Alzheimer disease and associated disorders*. 2016;30(2):175-7.

Batchelor R, Gilmartin JF-M, Kemp W, Hopper I, Liew D. Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. *Journal of gastroenterology and hepatology*. 2017;32(8):1426-35.

Bateman C, Anderson K, Bird M, Hungerford C. Volunteers improving person-centred dementia and delirium care in a rural Australian hospital. *Rural and remote health*. 2016;16(2):3667.

Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, et al. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2017;13(1):8-19.

Batty GD, Galobardes B, Starr JM, Jeffreys M, Davey Smith G, Russ TC. Examining if being overweight really confers protection against dementia: Sixty-four year follow-up of participants in the Glasgow University alumni cohort study. *Journal of negative results in biomedicine*. 2016;15(1):19.

Bauchner H, Redberg RF. Notice of Retraction: Sato Y, et al. The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer Disease: A Randomized Controlled Trial. *Arch Intern Med*. 2005;165(15):1737-1742. *JAMA internal medicine*. 2016;176(9):1256.

Bauer CM, Cabral HJ, Killiany RJ, Alzheimers Disease Neuroimaging I. It is unclear if adjusting cortical thickness for changes in gray/white matter intensity ratio improves discrimination between normal aging, MCI, and AD. *Brain imaging and behavior*. 2014;8(1):133-40.

Bautista-Aguilera OM, Esteban G, Bolea I, Nikolic K, Agbaba D, Moraleda I, et al. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. *European journal of medicinal chemistry*. 2014;75:82-95.

Bautista-Aguilera OM, Esteban G, Chioua M, Nikolic K, Agbaba D, Moraleda I, et al. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids. *Drug design, development and therapy*. 2014;8:1893-910.

Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. *European heart journal*. 2015;36(30):1967-73.

Bayer A, Phillips M, Porter G, Leonards U, Bompas A, Tales A. Abnormal inhibition of return in mild cognitive impairment: is it specific to the presence of prodromal dementia? *Journal of Alzheimer's disease : JAD*. 2014;40(1):177-89.

Bayrakdar ET, Armagan G, Uyanikgil Y, Kanit L, Koylu E, Yalcin A. Ex vivo protective effects of nicotinamide and 3-aminobenzamide on rat synaptosomes treated with Abeta(1-42). *Cell biochemistry and function*. 2014;32(7):557-64.

Bazzigaluppi P, Beckett TL, Koletar MM, Lai AY, Joo IL, Brown ME, et al. Early-stage attenuation of phase-amplitude coupling in the hippocampus and medial prefrontal cortex in a transgenic rat model of Alzheimer's disease. *Journal of neurochemistry*. 2017.

Beaumont V, Mrzljak L, Dijkman U, Freije R, Heins M, Rassoulpour A, et al. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. *Experimental neurology*. 2016;282:99-118.

Beaumont V, Zhong S, Lin H, Xu W, Bradaia A, Steidl E, et al. Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models. *Neuron*. 2016;92(6):1220-37.

Beauquis J, Pavia P, Pomilio C, Vinuesa A, Podlutskaya N, Galvan V, et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease. *Experimental neurology*. 2013;239:28-37.

Beckett MW, Ardern CI, Rotondi MA. A meta-analysis of prospective studies on the role of physical activity and the prevention of Alzheimer's disease in older adults. *BMC geriatrics*. 2015;15:9.

Beckett TL, Studzinski CM, Keller JN, Paul Murphy M, Niedowicz DM. A ketogenic diet improves motor performance but does not affect beta-amyloid levels in a mouse model of Alzheimer's disease. *Brain research*. 2013;1505:61-7.

Bee Gek Tay L, Chew Chan MP, Sian Chong M. Functional improvement in hospitalized older adults is independent of dementia diagnosis: experience of a specialized delirium management unit. *Journal of hospital medicine*. 2013;8(6):321-7.

Beedessee G, Ramanjooloo A, Surnam-Boodhun R, van Soest RWM, Marie DEP. Acetylcholinesterase-inhibitory activities of the extracts from sponges collected in mauritius waters. *Chemistry & biodiversity*. 2013;10(3):442-51.

Beeg M, Stravalaci M, Romeo M, Carra AD, Cagnotto A, Rossi A, et al. Clusterin Binds to Abeta1-42 Oligomers with High Affinity and Interferes with Peptide Aggregation by Inhibiting Primary and Secondary Nucleation. *The Journal of biological chemistry*. 2016;291(13):6958-66.

Before dementia begins: what helps? Diet, exercise, and appropriate medical care can slow the decline in memory and mental skills. *Harvard men's health watch*. 2013;18(3):1, 7.

Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Jorge R, Biglan K, et al. Results of the citalopram to enhance cognition in Huntington disease trial. *Movement disorders : official journal of the Movement Disorder Society*. 2014;29(3):401-5.

Behairi N, Belkhelfa M, Rafa H, Labsi M, Deghbar N, Bouzid N, et al. All-trans retinoic acid (ATRA) prevents lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment in aged rats. *Journal of neuroimmunology*. 2016;300:21-9.

Beishuizen CRL, Coley N, Moll van Charante EP, van Gool WA, Richard E, Andrieu S. Determinants of Dropout and Nonadherence in a Dementia Prevention Randomized Controlled Trial: The Prevention of Dementia by Intensive Vascular Care Trial. *Journal of the American Geriatrics Society*. 2017;65(7):1505-13.

Beitnere U, van Groen T, Kumar A, Jansone B, Klusa V, Kadish I. Mildronate improves cognition and reduces amyloid-beta pathology in transgenic Alzheimer's disease mice. *Journal of neuroscience research*. 2014;92(3):338-46.

Belghali M, Chastan N, Davenne D, Decker LM. Improving Dual-Task Walking Paradigms to Detect Prodromal Parkinson's and Alzheimer's Diseases. *Frontiers in neurology*. 2017;8:207.

Belkacemi A, Ramassamy C. Innovative Anthocyanin/Anthocyanidin Formulation Protects SK-N-SH Cells Against the Amyloid-beta Peptide-Induced Toxicity: Relevance to Alzheimer's Disease. *Central nervous system agents in medicinal chemistry*. 2015;16(1):37-49.

Belluti F, Rampa A, Gobbi S, Bisi A. Small-molecule inhibitors/modulators of amyloid-beta peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 - 2012). *Expert opinion on therapeutic patents*. 2013;23(5):581-96.

Ben Halima S, Mishra S, Raja KMP, Willem M, Baici A, Simons K, et al. Specific Inhibition of beta-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein. *Cell reports*. 2016;14(9):2127-41.

Ben Hmidene A, Hanaki M, Murakami K, Irie K, Isoda H, Shigemori H. Inhibitory Activities of Antioxidant Flavonoids from *Tamarix gallica* on Amyloid Aggregation Related to Alzheimer's and Type 2 Diabetes Diseases. *Biological & pharmaceutical bulletin*. 2017;40(2):238-41.

Ben Makhad M, Faucheux-Bourdon C, Guibe A, Tortevois A, Morel C, Loirat C, et al. Improving the quality of life of residents. *Revue de l'infirmiere*. 2017;66(227):25-6.

Ben Menachem-Zidon O, Ben Menahem Y, Ben Hur T, Yirmiya R. Intra-Hippocampal Transplantation of Neural Precursor Cells with Transgenic Over-Expression of IL-1 Receptor Antagonist Rescues Memory and Neurogenesis Impairments in an Alzheimer's Disease Model. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2015;40(2):524.

Benchekroun M, Romero A, Egea J, Leon R, Michalska P, Buendia I, et al. The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators. *Journal of medicinal chemistry*. 2016;59(21):9967-73.

Benek O, Hroch L, Aitken L, Dolezal R, Guest P, Benkova M, et al. 6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17beta-HSD10 and potential drugs for Alzheimer's disease treatment: Design, synthesis and in vitro evaluation. *Medicinal chemistry (Sharjah (United Arab Emirates))*. 2017.

Benhaberou-Brun D. Alzheimer disease. A protective gene. *Perspective infirmiere : revue officielle de l'Ordre des infirmieres et infirmiers du Quebec*. 2015;12(1):58-9.

Benhabib H, Lanctot KL, Eryavec GM, Li A, Herrmann N. Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer's Disease. *Canadian geriatrics journal : CGJ*. 2013;16(4):180-5.

Benigas JE, Bourgeois M. Using Spaced Retrieval With External Aids to Improve Use of Compensatory Strategies During Eating for Persons With Dementia. *American journal of speech-language pathology*. 2016;25(3):321-34.

Benilova I, Gallardo R, Ungureanu A-A, Castillo Cano V, Snellinx A, Ramakers M, et al. The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-beta (Abeta) aggregation. *The Journal of biological chemistry*. 2014;289(45):30977-89.

Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D, et al. Missense variant in TREML2 protects against Alzheimer's disease. *Neurobiology of aging*. 2014;35(6):1510.e19-26.

Benito E, Urbanke H, Ramachandran B, Barth J, Halder R, Awasthi A, et al. HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models. *The Journal of clinical investigation*. 2015;125(9):3572-84.

Ben-Menachem-Zidon O, Ben Menachem-Zidon O, Ben-Menahem Y, Ben-Hur T, Yirmiya R. Intra-hippocampal transplantation of neural precursor cells with transgenic over-expression of IL-1 receptor antagonist rescues memory and neurogenesis impairments in an Alzheimer's

disease model. *Neuropsychopharmacology* : official publication of the American College of Neuropsychopharmacology. 2014;39(2):401-14.

Bennett L, Kersaitis C, Macaulay SL, Munch G, Niedermayer G, Nigro J, et al. Vitamin D2-enriched button mushroom (*Agaricus bisporus*) improves memory in both wild type and APP^{swe}/PS1^{dE9} transgenic mice. *PloS one*. 2013;8(10):e76362.

Bennett RE, DeVos SL, Dujardin S, Corjuc B, Gor R, Gonzalez J, et al. Enhanced Tau Aggregation in the Presence of Amyloid beta. *The American journal of pathology*. 2017;187(7):1601-12.

Benoit ME, Hernandez MX, Dinh ML, Benavente F, Vasquez O, Tenner AJ. C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-beta neurotoxicity. *The Journal of biological chemistry*. 2013;288(1):654-65.

Ben-Shmuel S, Danon A, Fleisher-Berkovich S. Bradykinin decreases nitric oxide release from microglia via inhibition of cyclic adenosine monophosphate signaling. *Peptides*. 2013;40:133-40.

Bent-Enkhil N, Coste F, Xie L, Aigbogun MS, Wang Y, Kariburyo F, et al. A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer's Disease Patients. *Neurology and therapy*. 2017;6(1):131-44.

Benz N, Hatz F, Bousleiman H, Ehrensperger MM, Gschwandtner U, Hardmeier M, et al. Slowing of EEG background activity in Parkinson's and Alzheimer's disease with early cognitive dysfunction. *Frontiers in aging neuroscience*. 2014;6:314.

Berendonk C, Kaspar R, Bar M, Hoben M. Improving quality of work life for care providers by fostering the emotional well-being of persons with dementia: A cluster-randomized trial of a nursing intervention in German long-term care settings. *Dementia (London, England)*. 2017;1471301217698837.

Bermejo-Pareja F, Llamas-Velasco S, Villarejo-Galende A. Alzheimer's disease prevention: A way forward. *Revista clinica espanola*. 2016;216(9):495-503.

Bernard-Gauthier V, Bailey JJ, Mossine AV, Lindner S, Vomacka L, Aliaga A, et al. A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. *Journal of medicinal chemistry*. 2017;60(16):6897-910.

Bernstein KE, Koronyo Y, Salumbides BC, Sheyn J, Pelissier L, Lopes DHJ, et al. Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline. *The Journal of clinical investigation*. 2014;124(3):1000-12.

Berres M, Kukull WA, Miserez AR, Monsch AU, Monsell SE, Spiegel R. A Novel Study Paradigm for Long-term Prevention Trials in Alzheimer Disease: The Placebo Group Simulation Approach (PGSA): Application to MCI data from the NACC database. *The journal of prevention of Alzheimer's disease*. 2014;1(2):99-109.

Berrocal M, Corbacho I, Vazquez-Hernandez M, Avila J, Sepulveda MR, Mata AM. Inhibition of PMCA activity by tau as a function of aging and Alzheimer's neuropathology. *Biochimica et biophysica acta*. 2015;1852(7):1465-76.

Berry S. The slow farewell. If you can't do anything else, laugh. *JEMS : a journal of emergency medical services*. 2013;38(3):82-3.

Bertani I, Iori V, Trusel M, Maroso M, Foray C, Mantovani S, et al. Inhibition of IL-1 β Signaling Normalizes NMDA-Dependent Neurotransmission and Reduces Seizure Susceptibility in a Mouse Model of Creutzfeldt-Jakob Disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(43):10278-89.

Bertolin C, D'Ascenzo C, Querin G, Gaiani A, Boaretto F, Salvoro C, et al. Improving the knowledge of amyotrophic lateral sclerosis genetics: novel SOD1 and FUS variants. *Neurobiology of aging*. 2014;35(5):1212.e7-.e10.

Bertoux M, de Souza LC, Sarazin M, Funkiewiez A, Dubois B, Hornberger M. How Preserved is Emotion Recognition in Alzheimer Disease Compared With Behavioral Variant Frontotemporal Dementia? *Alzheimer disease and associated disorders*. 2015;29(2):154-7.

Bertram S, Brixius K, Brinkmann C. Exercise for the diabetic brain: how physical training may help prevent dementia and Alzheimer's disease in T2DM patients. *Endocrine*. 2016;53(2):350-63.

Besson G, Ceccaldi M, Tramoni E, Felician O, Didic M, Barbeau EJ. Fast, but not slow, familiarity is preserved in patients with amnesic mild cognitive impairment. *Cortex; a journal devoted to the study of the nervous system and behavior*. 2015;65:36-49.

Besson MT, Alegria K, Garrido-Gerter P, Barros LF, Lievens J-C. Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD *Drosophila* model. *PloS one*. 2015;10(3):e0118765.

Beste C, Humphries M, Saft C. Striatal disorders dissociate mechanisms of enhanced and impaired response selection - Evidence from cognitive neurophysiology and computational modelling. *NeuroImage Clinical*. 2014;4:623-34.

Beste C, Muckschel M, Elben S, J Hartmann C, McIntyre CC, Saft C, et al. Behavioral and neurophysiological evidence for the enhancement of cognitive control under dorsal pallidal deep brain stimulation in Huntington's disease. *Brain structure & function*. 2015;220(4):2441-8.

Betemps D, Verchere J, Brot S, Morignat E, Bousset L, Gaillard D, et al. Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological alpha-synuclein by enhanced ELISA. *Acta neuropathologica communications*. 2014;2:29.

Bezprozvanny I. Presenilins and calcium signaling-systems biology to the rescue. *Science signaling*. 2013;6(283):pe24.

Bhagya V, Christofer T, Shankaranarayana Rao BS. Neuroprotective effect of *Celastrus paniculatus* on chronic stress-induced cognitive impairment. *Indian journal of pharmacology*. 2016;48(6):687-93.

Bhakta HK, Park CH, Yokozawa T, Min B-S, Jung HA, Choi JS. Kinetics and molecular docking studies of loganin, morroniside and 7-O-galloyl-D-sedoheptulose derived from *Corni fructus* as cholinesterase and beta-secretase 1 inhibitors. *Archives of pharmacal research*. 2016;39(6):794-805.

Bhalla N, Estrela P. Biosensors for Screening Kinase Inhibitors. *Current topics in medicinal chemistry*. 2017;17(22):2470-81.

Bhardwaj M, Deshmukh R, Kaundal M, Krishna Reddy BV. Pharmacological induction of hemeoxygenase-1 activity attenuates intracerebroventricular streptozotocin induced neurocognitive deficit and oxidative stress in rats. *European journal of pharmacology*. 2016;772:43-50.

Bhardwaj M, Kumar A. Neuroprotective mechanism of Coenzyme Q10 (CoQ10) against PTZ induced kindling and associated cognitive dysfunction: Possible role of microglia inhibition. *Pharmacological reports : PR*. 2016;68(6):1301-11.

Bhatt PC, Pandey P, Panda BP, Anwar F, Kumar V. Commentary: L-3-n-butylphthalide Rescues Hippocampal Synaptic Failure and Attenuates Neuropathology in Aged APP/PS1 Mouse Model of Alzheimer's Disease. *Frontiers in aging neuroscience*. 2017;9:4.

Bhattacharya S, Haertel C, Maelicke A, Montag D. Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease. *PloS one*. 2014;9(2):e89454.

Bhattacharya S, Maelicke A, Montag D. Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice. *Journal of Alzheimer's disease : JAD*. 2015;46(1):123-36.

Bhattacharya S, Montag D. Acetylcholinesterase inhibitor modifications: a promising strategy to delay the progression of Alzheimer's disease. *Neural regeneration research*. 2015;10(1):43-5.

Bhowmik D, Mote KR, MacLaughlin CM, Biswas N, Chandra B, Basu JK, et al. Cell-Membrane-Mimicking Lipid-Coated Nanoparticles Confer Raman Enhancement to Membrane Proteins and Reveal Membrane-Attached Amyloid-beta Conformation. *ACS nano*. 2015;9(9):9070-7.

Bi J, Zhang H, Lu J, Lei W. Nobiletin ameliorates isoflurane-induced cognitive impairment via antioxidant, anti-inflammatory and anti-apoptotic effects in aging rats. *Molecular medicine reports*. 2016;14(6):5408-14.

Bi Oh S, Suh N, Kim I, Lee J-Y. Impacts of aging and amyloid-beta deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease. *Brain research*. 2015;1597:159-67.

Bian H, Bian W, Lin X, Ma Z, Chen W, Pu Y. RNA Interference Silencing of Glycogen Synthase Kinase 3 β Inhibits Tau Phosphorylation in Mice with Alzheimer Disease. *Neurochemical research*. 2016;41(9):2470-80.

Biasibetti R, Tramontina AC, Costa AP, Dutra MF, Quincozes-Santos A, Nardin P, et al. Green tea (-)epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia. *Behavioural brain research*. 2013;236(1):186-93.

Biberoglu K, Tek MY, Ghasemi ST, Tacal O. Toluidine blue O is a potent inhibitor of human cholinesterases. *Archives of biochemistry and biophysics*. 2016;604:57-62.

Biella G, Fusco F, Nardo E, Bernocchi O, Colombo A, Lichtenthaler SF, et al. Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid-beta Protein Precursor Processing in Two Alzheimer's Disease Mouse Models. *Journal of Alzheimer's disease : JAD*. 2016;53(3):1193-207.

Bier N, Brambati S, Macoir J, Paquette G, Schmitz X, Belleville S, et al. Relying on procedural memory to enhance independence in daily living activities: Smartphone use in a case of semantic dementia. *Neuropsychological rehabilitation*. 2015;25(6):913-35.

Bihaqi SW, Bahmani A, Adem A, Zawia NH. Infantile postnatal exposure to lead (Pb) enhances tau expression in the cerebral cortex of aged mice: relevance to AD. *Neurotoxicology*. 2014;44:114-20.

Bilkei-Gorzo A, Albayram O, Draffehn A, Michel K, Piyanova A, Oppenheimer H, et al. A chronic low dose of Delta9-tetrahydrocannabinol (THC) restores cognitive function in old mice. *Nature medicine*. 2017;23(6):782-7.

Billes V, Kovacs T, Hotzi B, Manzeger A, Tagscherer K, Komlos M, et al. AUTEN-67 (Autophagy Enhancer-67) Hampers the Progression of Neurodegenerative Symptoms in a Drosophila model of Huntington's Disease. *Journal of Huntington's disease*. 2016;5(2):133-47.

Bilotta C, Franchi C, Nobili A, Nicolini P, Djade CD, Tettamanti M, et al. Electrocardiographic monitoring for new prescriptions of quetiapine co-prescribed with acetylcholinesterase inhibitors or memantine from 2005 to 2009. A population study on community-dwelling older people in Italy. *European journal of clinical pharmacology*. 2014;70(12):1487-94.

Binawade Y, Jagtap A. Neuroprotective effect of lutein against 3-nitropropionic acid-induced Huntington's disease-like symptoms: possible behavioral, biochemical, and cellular alterations. *Journal of medicinal food*. 2013;16(10):934-43.

Biradar SM, Joshi H, Chheda TK. Biochanin-A ameliorates behavioural and neurochemical derangements in cognitive-deficit mice for the betterment of Alzheimer's disease. *Human & experimental toxicology*. 2014;33(4):369-82.

Bird M, Anderson K, MacPherson S, Blair A. Do interventions with staff in long-term residential facilities improve quality of care or quality for life people with dementia? A systematic review of the evidence. *International psychogeriatrics*. 2016;28(12):1937-63.

Bissonnette S, Vaillancourt M, Hebert SS, Drolet G, Samadi P. Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease. *PloS one*. 2013;8(9):e75099.

Biswas K, Azad AK, Sultana T, Khan F, Hossain S, Alam S, et al. Assessment of in-vitro cholinesterase inhibitory and thrombolytic potential of bark and seed extracts of *Tamarindus indica* (L.) relevant to the treatment of Alzheimer's disease and clotting disorders. *Journal of intercultural ethnopharmacology*. 2017;6(1):115-20.

Blacher E, Dadali T, Bespalko A, Hauptenthal VJ, Grimm MOW, Hartmann T, et al. Alzheimer's disease pathology is attenuated in a CD38-deficient mouse model. *Annals of neurology*. 2015;78(1):88-103.

Black DS, Cole SW, Irwin MR, Breen E, St Cyr NM, Nazarian N, et al. Yogic meditation reverses NF-kappaB and IRF-related transcriptome dynamics in leukocytes of family dementia caregivers in a randomized controlled trial. *Psychoneuroendocrinology*. 2013;38(3):348-55.

Black N, Dixon J, Tan S, Knapp M. Improving healthcare for people with dementia in England: good progress but more to do. *Journal of the Royal Society of Medicine*. 2015;108(12):478-81.

Blair GW, Appleton JP, Law ZK, Doubal F, Flaherty K, Dooley R, et al. Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on

intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination. *International journal of stroke : official journal of the International Stroke Society*. 2017;1747493017731947.

Blanco-Silvente L, Castells X, Saez M, Barcelo MA, Garre-Olmo J, Vilalta-Franch J, et al. Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients. *The international journal of neuropsychopharmacology*. 2017;20(7):519-28.

Blasco H, Patin F, Andres CR, Corcia P, Gordon PH. Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. *Expert opinion on pharmacotherapy*. 2016;17(12):1669-82.

Blattner CM, Markus B, Lear W. Preventing disruption of surgical dressings in patients with cognitive impairment. *Journal of the American Academy of Dermatology*. 2017;76(5):e173-e4.

Blazek MC, Struble L, Cavalcante A, Masse J. Medical Students in a Dementia Care Facility: an Enhanced Geriatric Psychiatry Experience. *Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry*. 2016;40(6):932-4.

Blazquez C, Chiarlone A, Bellocchio L, Resel E, Pruunsild P, Garcia-Rincon D, et al. The CB₁ cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. *Cell death and differentiation*. 2015;22(10):1618-29.

Bleiholder C, Do TD, Wu C, Economou NJ, Bernstein SS, Buratto SK, et al. Ion mobility spectrometry reveals the mechanism of amyloid formation of Abeta(25-35) and its modulation by inhibitors at the molecular level: epigallocatechin gallate and scyllo-inositol. *Journal of the American Chemical Society*. 2013;135(45):16926-37.

Blondell SJ, Hammersley-Mather R, Veerman JL. Does physical activity prevent cognitive decline and dementia?: A systematic review and meta-analysis of longitudinal studies. *BMC public health*. 2014;14:510.

Bo H, Kang W, Jiang N, Wang X, Zhang Y, Ji LL. Exercise-induced neuroprotection of hippocampus in APP/PS1 transgenic mice via upregulation of mitochondrial 8-oxoguanine DNA glycosylase. *Oxidative medicine and cellular longevity*. 2014;2014:834502.

Bo Y, Zhang X, Wang Y, You J, Cui H, Zhu Y, et al. The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial. *Nutrients*. 2017;9(1).

Bobkova N, Vorobyov V. The brain compensatory mechanisms and Alzheimer's disease progression: a new protective strategy. *Neural regeneration research*. 2015;10(5):696-7.

Bobkova NV, Lyabin DN, Medvinskaya NI, Samokhin AN, Nekrasov PV, Nesterova IV, et al. The Y-Box Binding Protein 1 Suppresses Alzheimer's Disease Progression in Two Animal Models. *PloS one*. 2015;10(9):e0138867.

Boccardi V, Baroni M, Smirne N, Clodomiro A, Ercolani S, Longo A, et al. Short-Term Response is not Predictive of Long-Term Response to Acetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer's Disease: A "Real World" Study. *Journal of Alzheimer's disease : JAD*. 2017;56(1):239-48.

Boespflug EL, Eliassen JC, Dudley JA, Shidler MD, Kalt W, Summer SS, et al. Enhanced neural activation with blueberry supplementation in mild cognitive impairment. *Nutritional neuroscience*. 2017:1-9.

Bogachouk AP, Storozheva ZI, Solovjeva OA, Sherstnev VV, Zolotarev YA, Azev VN, et al. Comparative study of the neuroprotective and nootropic activities of the carboxylate and amide forms of the HLDF-6 peptide in animal models of Alzheimer's disease. *Journal of psychopharmacology (Oxford, England)*. 2016;30(1):78-92.

Bohm C, Chen F, Sevalle J, Qamar S, Dodd R, Li Y, et al. Current and future implications of basic and translational research on amyloid-beta peptide production and removal pathways. *Molecular and cellular neurosciences*. 2015;66(Pt A):3-11.

Bokberg C, Ahlstrom G, Karlsson S, Hallberg IR, Janlov A-C. Best practice and needs for improvement in the chain of care for persons with dementia in Sweden: a qualitative study based on focus group interviews. *BMC health services research*. 2014;14:596.

Bolea I, Gella A, Monjas L, Perez C, Rodriguez-Franco MI, Marco-Contelles J, et al. Multipotent, permeable drug ASS234 inhibits Abeta aggregation, possesses antioxidant properties and protects from Abeta-induced apoptosis in vitro. *Current Alzheimer research*. 2013;10(8):797-808.

Bolea I, Gella A, Unzeta M. Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. *Journal of neural transmission (Vienna, Austria : 1996)*. 2013;120(6):893-902.

Bollen E, Vanmierlo T, Akkerman S, Wouters C, Steinbusch HMW, Prickaerts J. 7,8-Dihydroxyflavone improves memory consolidation processes in rats and mice. *Behavioural brain research*. 2013;257:8-12.

Bolognin S, Buffelli M, Puolivali J, Iqbal K. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. *Neurobiology of aging*. 2014;35(9):2134-46.

Bolos M, Antequera D, Aldudo J, Kristen H, Bullido MJ, Carro E. Choroid plexus implants rescue Alzheimer's disease-like pathologies by modulating amyloid-beta degradation. *Cellular and molecular life sciences : CMLS*. 2014;71(15):2947-55.

Bomba M, Ciavardelli D, Silvestri E, Canzoniero LMT, Lattanzio R, Chiappini P, et al. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. *Cell death & disease*. 2013;4:e612.

Bomball J, Stover M, Gorres S. Assuring nursing competence in education. Contribution for improving persons with dementia in clinics. *Pflege Zeitschrift*. 2016;69(3):180-4; quiz 5.

Bondi MW, Edmonds EC, Jak AJ, Clark LR, Delano-Wood L, McDonald CR, et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. *Journal of Alzheimer's disease : JAD*. 2014;42(1):275-89.

Bondulich MK, Guo T, Meehan C, Manion J, Rodriguez Martin T, Mitchell JC, et al. Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate. *Brain : a journal of neurology*. 2016;139(Pt 8):2290-306.

Bonesi M, Loizzo MR, Conforti F, Passalacqua NG, Saab A, Menichini F, et al. Berberis aetnensis and B.libanotica: a comparative study on the chemical composition, inhibitory effect on key enzymes linked to Alzheimer's disease and antioxidant activity. *The Journal of pharmacy and pharmacology*. 2013;65(12):1726-35.

Bonnery A-M. Rethinking the organization for preventing abuse. *Soins Gerontologie*. 2015(116):1.

Bonnet U, Taazimi B, Borda T, Grabbe H-D. Improvement of a woman's alcohol-related dementia via off-label memantine treatment: a 16-month clinical observation. *The Annals of pharmacotherapy*. 2014;48(10):1371-5.

Boonruamkaew P, Chonpathompikunlert P, Vong LB, Sakaue S, Tomidokoro Y, Ishii K, et al. Chronic treatment with a smart antioxidative nanoparticle for inhibition of amyloid plaque propagation in Tg2576 mouse model of Alzheimer's disease. *Scientific reports*. 2017;7(1):3785.

Booth V, Harwood R, Hood V, Masud T, Logan P. Understanding the theoretical underpinning of the exercise component in a fall prevention programme for older adults with mild dementia: a realist review protocol. *Systematic reviews*. 2016;5(1):119.

Boots EA, Schultz SA, Clark LR, Racine AM, Darst BF, Kosciuk RL, et al. BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention. *Neurology*. 2017;88(22):2098-106.

Borah A, Paul R, Choudhury S, Choudhury A, Bhuyan B, Das Talukdar A, et al. Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of action. *CNS neuroscience & therapeutics*. 2013;19(11):847-53.

Borella E, Carretti B, Mitolo M, Zavagnin M, Caffarra P, Mammarella N, et al. Characterizing cognitive inhibitory deficits in mild cognitive impairment. *Psychiatry research*. 2017;251:342-8.

Borhani M, Sharifzadeh M, Farzaei MH, Narimani Z, Sabbaghziarani F, Gholami M, et al. PROTECTIVE EFFECT OF IRIS GERMANICA L. IN Beta-AMYLOID-INDUCED ANIMAL MODEL OF ALZHEIMER'S DISEASE. *African journal of traditional, complementary, and alternative medicines : AJTCAM*. 2017;14(4):140-8.

Born HA, Kim J-Y, Savjani RR, Das P, Dabaghian YA, Guo Q, et al. Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(11):3826-40.

Borreca A, Gironi K, Amadoro G, Ammassari-Teule M. Opposite Dysregulation of Fragile-X Mental Retardation Protein and Heteronuclear Ribonucleoprotein C Protein Associates with Enhanced APP Translation in Alzheimer Disease. *Molecular neurobiology*. 2016;53(5):3227-34.

Borroni E, Bohrmann B, Grueninger F, Prinssen E, Nave S, Loetscher H, et al. Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease. *The Journal of pharmacology and experimental therapeutics*. 2017;362(3):413-23.

Borson S, Frank L, Bayley PJ, Boustani M, Dean M, Lin P-J, et al. Improving dementia care: the role of screening and detection of cognitive impairment. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013;9(2):151-9.

Borson S, Scanlan JM, Sadak T, Lessig M, Vitaliano P. Dementia Services Mini-Screen: a simple method to identify patients and caregivers in need of enhanced dementia care services. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2014;22(8):746-55.

Bortolatto CF, Jesse CR, Wilhelm EA, Chagas PM, Nogueira CW. Organoselenium bis selenide attenuates 3-nitropropionic acid-induced neurotoxicity in rats. *Neurotoxicity research*. 2013;23(3):214-24.

Bosch MN, Gimeno-Bayon J, Rodriguez MJ, Pugliese M, Mahy N. Rapid improvement of canine cognitive dysfunction with immunotherapy designed for Alzheimer's disease. *Current Alzheimer research*. 2013;10(5):482-93.

Bossers WJR, van der Woude LHV, Boersma F, Hortobagyi T, Scherder EJA, van Heuvelen MJG. A 9-Week Aerobic and Strength Training Program Improves Cognitive and Motor

Function in Patients with Dementia: A Randomized, Controlled Trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2015;23(11):1106-16.

Boulebd H, Ismaili L, Bartolini M, Bouraiou A, Andrisano V, Martin H, et al. Imidazopyranotacrines as Non-Hepatotoxic, Selective Acetylcholinesterase Inhibitors, and Antioxidant Agents for Alzheimer's Disease Therapy. Molecules (Basel, Switzerland). 2016;21(4):400.

Boulebd H, Ismaili L, Martin H, Bonet A, Chioua M, Marco Contelles J, et al. New (benz)imidazopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease. Future medicinal chemistry. 2017;9(8):723-9.

Bourgade K, Garneau H, Giroux G, Le Page AY, Bocti C, Dupuis G, et al. beta-Amyloid peptides display protective activity against the human Alzheimer's disease-associated herpes simplex virus-1. Biogerontology. 2015;16(1):85-98.

Boussicault L, Alves S, Lamaziere A, Planques A, Heck N, Moumne L, et al. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease. Brain : a journal of neurology. 2016;139(Pt 3):953-70.

Boutajangout A, Noorwali A, Atta H, Wisniewski T. Human Umbilical Cord Stem Cell Xenografts Improve Cognitive Decline and Reduce the Amyloid Burden in a Mouse Model of Alzheimer's Disease. Current Alzheimer research. 2017;14(1):104-11.

Bove-Fenderson E, Urano R, Straub JE, Harris DA. Cellular prion protein targets amyloid-beta fibril ends via its C-terminal domain to prevent elongation. The Journal of biological chemistry. 2017;292(41):16858-71.

Bowen RL, Perry G, Xiong C, Smith MA, Atwood CS. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. Journal of Alzheimer's disease : JAD. 2015;44(2):549-60.

Braak H, Feldengut S, Del Tredici K. Pathogenesis and prevention of Alzheimer's disease: when and in what way does the pathological process begin? Der Nervenarzt. 2013;84(4):477-82.

Bracco L, Bessi V, Padiglioni S, Marini S, Pepeu G. Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer's disease patients. Journal of Alzheimer's disease : JAD. 2014;40(3):737-42.

Bradford A. A joined-up approach to improving older people's health and wellbeing. Nursing management (Harrow, London, England : 1994). 2016;23(2):20-3.

Bradford NK. Enhanced Rehabilitation and Care Models for Adults With Dementia Following Hip Fracture Surgery. *Orthopedic nursing*. 2016;35(3):187-8.

Bradley P, Akehurst R, Ballard C, Banerjee S, Blennow K, Bremner J, et al. Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2015;11(4):455-61.

Bradley SJ, Bourgognon J-M, Sanger HE, Verity N, Mogg AJ, White DJ, et al. M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss. *The Journal of clinical investigation*. 2017;127(2):487-99.

Brady R, Weinman J. Adherence to cholinesterase inhibitors in Alzheimer's disease: a review. *Dementia and geriatric cognitive disorders*. 2013;35(5-6):351-63.

Braga ILS, Silva PN, Furuya TK, Santos LC, Pires BC, Mazzotti DR, et al. Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. *American journal of Alzheimer's disease and other dementias*. 2015;30(2):139-44.

Braidy N, Behzad S, Habtemariam S, Ahmed T, Daglia M, Nabavi SM, et al. Neuroprotective Effects of Citrus Fruit-Derived Flavonoids, Nobiletin and Tangeretin in Alzheimer's and Parkinson's Disease. *CNS & neurological disorders drug targets*. 2017;16(4):387-97.

Braidy N, Essa MM, Poljak A, Selvaraju S, Al-Adawi S, Manivasagam T, et al. Consumption of pomegranates improves synaptic function in a transgenic mice model of Alzheimer's disease. *Oncotarget*. 2016;7(40):64589-604.

Branca C, Shaw DM, Belfiore R, Gokhale V, Shaw AY, Foley C, et al. Dyrk1 inhibition improves Alzheimer's disease-like pathology. *Aging cell*. 2017;16(5):1146-54.

Brannstrom K, Ohman A, Lindhagen-Persson M, Olofsson A. Ca(2+) enhances Abeta polymerization rate and fibrillar stability in a dynamic manner. *The Biochemical journal*. 2013;450(1):189-97.

Brautigam H, Moreno CL, Steele JW, Bogush A, Dickstein DL, Kwok JBJ, et al. Physiologically generated presenilin 1 lacking exon 8 fails to rescue brain PS1^{-/-} phenotype and forms complexes with wildtype PS1 and nicastrin. *Scientific reports*. 2015;5:17042.

Bray J, Evans S, Bruce M, Carter C, Brooker D, Milosevic S, et al. Improving activity and engagement for patients with dementia. *Nursing older people*. 2015;27(8):22-6.

Bray J, Evans S, Bruce M, Carter C, Brooker D, Milosevic S, et al. Improving the hospital environment for people with dementia. *Nursing older people*. 2015;27(9):16, 8-20.

Brayne C, Wu Y-T. Preventing both stroke and dementia - Authors' reply. *The Lancet Neurology*. 2016;15(7):659.

Bredesen DE, Amos EC, Canick J, Ackerley M, Raji C, Fiala M, et al. Reversal of cognitive decline in Alzheimer's disease. *Aging*. 2016;8(6):1250-8.

Bredesen DE. Reversal of cognitive decline: a novel therapeutic program. *Aging*. 2014;6(9):707-17.

Breithardt OA. Reversing heart failure by CRT: how long do the effects last? *European heart journal*. 2013;34(33):2582-4.

Brendel M, Hogenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal (18)F -AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. *NeuroImage*. 2015;108:450-9.

Brendel M, Jaworska A, Herms J, Trambauer J, Rotzer C, Gildehaus FJ, et al. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic gamma-secretase modulator treatment. *Molecular psychiatry*. 2015;20(10):1179-87.

Brener O, Dunkelmann T, Gremer L, van Groen T, Mirecka EA, Kadish I, et al. QIAD assay for quantitating a compound's efficacy in elimination of toxic Abeta oligomers. *Scientific reports*. 2015;5:13222.

Brewer GJ. Copper-2 Hypothesis for Causation of the Current Alzheimer's Disease Epidemic Together with Dietary Changes That Enhance the Epidemic. *Chemical research in toxicology*. 2017;30(3):763-8.

Briggs R, O'Shea E, de Siun A, O'Neill D, Gallagher P, Timmons S, et al. Does admission to a specialist geriatric medicine ward lead to improvements in aspects of acute medical care for older patients with dementia? *International journal of geriatric psychiatry*. 2017;32(6):624-32.

Brinet D, Kaffy J, Oukacine F, Glumm S, Onger S, Taverna M. An improved capillary electrophoresis method for in vitro monitoring of the challenging early steps of Abeta1-42 peptide oligomerization: application to anti-Alzheimer's drug discovery. *Electrophoresis*. 2014;35(23):3302-9.

Brini S, Sohrabi HR, Peiffer JJ, Karrasch M, Hamalainen H, Martins RN, et al. Physical Activity in Preventing Alzheimer's Disease and Cognitive Decline: A Narrative Review. *Sports medicine (Auckland, NZ)*. 2017.

Brinton RD. Neurosteroids as regenerative agents in the brain: therapeutic implications. *Nature reviews Endocrinology*. 2013;9(4):241-50.

Brito V, Puigdemívol M, Giralt A, del Toro D, Alberch J, Gines S. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies. *Cell death & disease*. 2013;4:e595.

Brodtmann A, Cowie T, McLean C, Darby D. Phenocopy or variant: a longitudinal study of very slowly progressive frontotemporal dementia. *BMJ case reports*. 2013;2013.

Brody AA, Guan C, Cortes T, Galvin JE. Development and testing of the Dementia Symptom Management at Home (DSM-H) program: An interprofessional home health care intervention to improve the quality of life for persons with dementia and their caregivers. *Geriatric nursing (New York, NY)*. 2016;37(3):200-6.

Brogi S, Butini S, Maramai S, Colombo R, Verga L, Lanni C, et al. Disease-modifying anti-Alzheimer's drugs: inhibitors of human cholinesterases interfering with beta-amyloid aggregation. *CNS neuroscience & therapeutics*. 2014;20(7):624-32.

Brooks AF, Jackson IM, Shao X, Kropog GW, Sherman P, Quesada CA, et al. Synthesis and evaluation of (11)C PBD150, a radiolabeled glutaminy cyclase inhibitor for the potential detection of Alzheimer's disease prior to amyloid beta aggregation. *MedChemComm*. 2015;6(6):1065-8.

Broster LS, Jenkins SL, Holmes SD, Jicha GA, Jiang Y. Low Arousal Positive Emotional Stimuli Attenuate Aberrant Working Memory Processing in Persons with Mild Cognitive Impairment. *Journal of Alzheimer's disease : JAD*. 2017;60(4):1333-49.

Brown BM, Peiffer JJ, Martins RN. Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease? *Molecular psychiatry*. 2013;18(8):864-74.

Brown D, Spanjers K, Atherton N, Lowe J, Stonehewer L, Bridle C, et al. Development of an exercise intervention to improve cognition in people with mild to moderate dementia: Dementia And Physical Activity (DAPA) Trial, registration ISRCTN32612072. *Physiotherapy*. 2015;101(2):126-34.

Brown Wilson C, Swarbrick C, Pilling M, Keady J. The senses in practice: enhancing the quality of care for residents with dementia in care homes. *Journal of advanced nursing*. 2013;69(1):77-90.

Brownlow ML, Benner L, D'Agostino D, Gordon MN, Morgan D. Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology. *PloS one*. 2013;8(9):e75713.

Brownlow ML, Joly-Amado A, Azam S, Elza M, Selenica M-L, Pappas C, et al. Partial rescue of memory deficits induced by calorie restriction in a mouse model of tau deposition. *Behavioural brain research*. 2014;271:79-88.

Bruban J, Voloudakis G, Huang Q, Kajiwarra Y, Al Rahim M, Yoon Y, et al. Presenilin 1 is necessary for neuronal, but not glial, EGFR expression and neuroprotection via gamma-secretase-independent transcriptional mechanisms. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2015;29(9):3702-12.

Bruckmann S, Brenn A, Grube M, Niedrig K, Holtfreter S, von Bohlen und Halbach O, et al. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease. *Current Alzheimer research*. 2017;14(6):656-67.

Brunner D, Flunkert S, Neddens J, Duller S, Scopes DIC, Treherne JM, et al. SEN1500, a novel oral amyloid-beta aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease. *Neuroscience letters*. 2017;660:96-102.

Brunquell J, Bowers P, Westerheide SD. Fluorodeoxyuridine enhances the heat shock response and decreases polyglutamine aggregation in an HSF-1-dependent manner in *Caenorhabditis elegans*. *Mechanisms of ageing and development*. 2014;141-142:1-4.

Bu X-L, Jiao S-S, Lian Y, Wang Y-J. Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease. *Current Alzheimer research*. 2016;13(3):307-16.

Budworth H, Harris FR, Williams P, Lee DY, Holt A, Pahnke J, et al. Suppression of Somatic Expansion Delays the Onset of Pathophysiology in a Mouse Model of Huntington's Disease. *PLoS genetics*. 2015;11(8):e1005267.

Buendia I, Egea J, Parada E, Navarro E, Leon R, Rodriguez-Franco MI, et al. The melatonin-N,N-dibenzyl(N-methyl)amine hybrid ITH91/IQM157 affords neuroprotection in an in vitro Alzheimer's model via hemo-oxygenase-1 induction. *ACS chemical neuroscience*. 2015;6(2):288-96.

Buividas R, Dzingelevicius N, Kubiliute R, Stoddart PR, Khanh Truong V, Ivanova EP, et al. Statistically quantified measurement of an Alzheimer's marker by surface-enhanced Raman scattering. *Journal of biophotonics*. 2015;8(7):567-74.

Bukhari SNA, Jantan I. Synthetic Curcumin Analogs as Inhibitors of beta -Amyloid Peptide Aggregation: Potential Therapeutic and Diagnostic Agents for Alzheimer's Disease. *Mini reviews in medicinal chemistry*. 2015;15(13):1110-21.

Bulat T, Kerrigan MV, Rowe M, Kearns W, Craighead JD, Ramaiah P. Field Evaluations of Tracking/Locating Technologies for Prevention of Missing Incidents. *American journal of Alzheimer's disease and other dementias*. 2016;31(6):474-80.

Bulic B, Pickhardt M, Mandelkow E. Progress and developments in tau aggregation inhibitors for Alzheimer disease. *Journal of medicinal chemistry*. 2013;56(11):4135-55.

Bungart BL, Dong L, Sobek D, Sun GY, Yao G, Lee JCM. Nanoparticle-emitted light attenuates amyloid-beta-induced superoxide and inflammation in astrocytes. *Nanomedicine : nanotechnology, biology, and medicine*. 2014;10(1):15-7.

Burge E, Berchtold A, Maupetit C, Bourquin NMP, von Gunten A, Ducraux D, et al. Does physical exercise improve ADL capacities in people over 65 years with moderate or severe dementia hospitalized in an acute psychiatric setting? A multisite randomized clinical trial. *International psychogeriatrics*. 2017;29(2):323-32.

Burgess A, Dubey S, Yeung S, Hough O, Eterman N, Aubert I, et al. Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behavior. *Radiology*. 2014;273(3):736-45.

Burgess J. Improving dementia care with the Eden Alternative. *Nursing times*. 2015;111(12):24-5.

Burke RM, Norman TA, Haydar TF, Slack BE, Leeman SE, Blusztajn JK, et al. BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(48):19567-72.

Burke SL, Maramaldi P, Cadet T, Kukull W. Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. *International journal of geriatric psychiatry*. 2017.

Burli RW, Luckhurst CA, Aziz O, Matthews KL, Yates D, Lyons KA, et al. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. *Journal of medicinal chemistry*. 2013;56(24):9934-54.

Burnell KJ, Selwood A, Sullivan T, Charlesworth GM, Poland F, Orrell M. Involving service users in the development of the Support at Home: Interventions to Enhance Life in Dementia Carer Supporter Programme for family carers of people with dementia. *Health expectations : an international journal of public participation in health care and health policy*. 2015;18(1):95-110.

Burrell M, Henderson SJ, Ravnefjord A, Schweikart F, Fowler SB, Witt S, et al. Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen. *PloS one*. 2016;11(7):e0158114.

Burrell RC, Easter JA, Cassidy MP, Gillman KW, Olson RE, Bonacorsi SJ. Synthesis of carbon-14 and stable isotope labeled Avagacestat: a novel gamma secretase inhibitor for the treatment of Alzheimer's disease. *Journal of labelled compounds & radiopharmaceuticals*. 2014;57(10):600-5.

Buscema M, Vernieri F, Massini G, Scarscia F, Breda M, Rossini PM, et al. An improved I-FAST system for the diagnosis of Alzheimer's disease from unprocessed electroencephalograms by using robust invariant features. *Artificial intelligence in medicine*. 2015;64(1):59-74.

Busche MA, Kekus M, Adelsberger H, Noda T, Forstl H, Nelken I, et al. Rescue of long-range circuit dysfunction in Alzheimer's disease models. *Nature neuroscience*. 2015;18(11):1623-30.

Bustos FJ, Ampuero E, Jury N, Aguilar R, Falahi F, Toledo J, et al. Epigenetic editing of the Dlg4/PSD95 gene improves cognition in aged and Alzheimer's disease mice. *Brain : a journal of neurology*. 2017.

Buswell M, Goodman C, Roe B, Russell B, Norton C, Harwood R, et al. What Works to Improve and Manage Fecal Incontinence in Care Home Residents Living With Dementia? A Realist Synthesis of the Evidence. *Journal of the American Medical Directors Association*. 2017;18(9):752-60.e1.

Butini S, Brogi S, Novellino E, Campiani G, Ghosh AK, Brindisi M, et al. The structural evolution of beta-secretase inhibitors: a focus on the development of small-molecule inhibitors. *Current topics in medicinal chemistry*. 2013;13(15):1787-807.

Butler CR, Brodney MA, Beck EM, Barreiro G, Nolan CE, Pan F, et al. Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design. *Journal of medicinal chemistry*. 2015;58(6):2678-702.

Buzkova P, Barzilay JI, Fink HA, Robbins JA, Cauley JA, Fitzpatrick AL. Ratio of urine albumin to creatinine attenuates the association of dementia with hip fracture risk. *The Journal of clinical endocrinology and metabolism*. 2014;99(11):4116-23.

Bystad M, Gronli O, Rasmussen ID, Gundersen N, Nordvang L, Wang-Iversen H, et al. Transcranial direct current stimulation as a memory enhancer in patients with Alzheimer's disease: a randomized, placebo-controlled trial. *Alzheimer's research & therapy*. 2016;8(1):13.

Bystad M, Rasmussen ID, Gronli O, Aslaksen PM. Can 8 months of daily tDCS application slow the cognitive decline in Alzheimer's disease? A case study. *Neurocase*. 2017;23(2):146-8.

Cabello J, Lukas M, Forster S, Pyka T, Nekolla SG, Ziegler SI. MR-based attenuation correction using ultrashort-echo-time pulse sequences in dementia patients. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2015;56(3):423-9.

Cabello J, Lukas M, Rota Kops E, Ribeiro A, Shah NJ, Yakushev I, et al. Comparison between MRI-based attenuation correction methods for brain PET in dementia patients. *European journal of nuclear medicine and molecular imaging*. 2016;43(12):2190-200.

Caccamo A, Branca C, Talboom JS, Shaw DM, Turner D, Ma L, et al. Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2015;35(41):14042-56.

Caccamo A, De Pinto V, Messina A, Branca C, Oddo S. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(23):7988-98.

Caccamo A, Ferreira E, Branca C, Oddo S. p62 improves AD-like pathology by increasing autophagy. *Molecular psychiatry*. 2017;22(6):865-73.

Caetano AL, Dong-Creste KE, Amaral FA, Monteiro-Silva KC, Pesquero JB, Araujo MS, et al. Kinin B2 receptor can play a neuroprotective role in Alzheimer's disease. *Neuropeptides*. 2015;53:51-62.

Cagnin A, Cester A, Costa B, Ermani M, Gabelli C, Gambina G, et al. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2015;36(3):457-63.

Cahlikova L, Perez DI, Stepankova S, Chlebek J, Safratova M, Host'alkova A, et al. In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier. *Journal of natural products*. 2015;78(6):1189-92.

Cai C, Dai X, Zhu Y, Lian M, Xiao F, Dong F, et al. A specific RAGE-binding peptide biopanning from phage display random peptide library that ameliorates symptoms in amyloid beta peptide-mediated neuronal disorder. *Applied microbiology and biotechnology*. 2016;100(2):825-35.

Cai HY, Holscher C, Yue XH, Zhang SX, Wang XH, Qiao F, et al. Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats. *Neuroscience*. 2014;277:6-13.

Cai K, Groner A, Dichtelmuller HO, Fabbrizzi F, Flechsig E, Gajardo R, et al. Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies. *Transfusion*. 2013;53(9):1894-905.

Cai M, Lee JH, Yang EJ. Bee Venom Ameliorates Cognitive Dysfunction Caused by Neuroinflammation in an Animal Model of Vascular Dementia. *Molecular neurobiology*. 2017;54(8):5952-60.

Cai P, Fang S-Q, Yang X-L, Wu J-J, Liu Q-H, Hong H, et al. Rational Design and Multibiological Profiling of Novel Donepezil-Trolox Hybrids against Alzheimer's Disease, with Cholinergic, Antioxidant, Neuroprotective, and Cognition Enhancing Properties. *ACS chemical neuroscience*. 2017;8(11):2496-511.

Cai Z, Yan Y, Wang Y. Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder. *Clinical interventions in aging*. 2013;8:1089-95.

Cai Z, Zeng W, Tao K, E Z, Wang B, Yang Q. Chaperone-mediated autophagy: roles in neuroprotection. *Neuroscience bulletin*. 2015;31(4):452-8.

Cai Z. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review). *Molecular medicine reports*. 2014;9(5):1533-41.

Calabrese V, Giordano J, Signorile A, Laura Ontario M, Castorina S, De Pasquale C, et al. Major pathogenic mechanisms in vascular dementia: Roles of cellular stress response and hormesis in neuroprotection. *Journal of neuroscience research*. 2016;94(12):1588-603.

Calabro RS, De Luca R, Leo A, Balletta T, Marra A, Bramanti P. Lokomat training in vascular dementia: motor improvement and beyond! *Aging clinical and experimental research*. 2015;27(6):935-7.

Calcagno A, Simiele M, Alberione MC, Bracchi M, Marinaro L, Ecclesia S, et al. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2015;60(2):311-7.

Caldwell JP, Mazzola RD, Durkin J, Chen J, Chen X, Favreau L, et al. Discovery of potent iminoheterocycle BACE1 inhibitors. *Bioorganic & medicinal chemistry letters*. 2014;24(23):5455-9.

Caldwell K, Charlton KE, Roodenrys S, Jenner A. Anthocyanin-rich cherry juice does not improve acute cognitive performance on RAVLT. *Nutritional neuroscience*. 2016;19(9):423-4.

Callahan BL, Wong C, Ngang PN, Wolf U, Freedman M. Interventions Targeting Reversible Dementia in Down Syndrome. *Journal of the American Geriatrics Society*. 2016;64(4):917-9.

Callegari I, Mattei C, Benassi F, Krueger F, Grafman J, Yaldizli O, et al. Agomelatine Improves Apathy in Frontotemporal Dementia. *Neuro-degenerative diseases*. 2016;16(5-6):352-6.

Camargos EF, Louzada LL, Quintas JL, Naves JOS, Louzada FM, Nobrega OT. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2014;22(12):1565-74.

Camie PM, Williams CM, Meeten F. Does a 'Singing Together Group' improve the quality of life of people with a dementia and their carers? A pilot evaluation study. *Dementia (London, England)*. 2013;12(2):157-76.

Campanari M-L, Garcia-Ayllon M-S, Blazquez-Llorca L, Luk WKW, Tsim K, Saez-Valero J. Acetylcholinesterase protein level is preserved in the Alzheimer's brain. *Journal of molecular neuroscience : MN*. 2014;53(3):446-53.

Campbell NL, Boustani MA. Adverse cognitive effects of medications: turning attention to reversibility. *JAMA internal medicine*. 2015;175(3):408-9.

Campos CH, Ribeiro GR, Rodrigues Garcia RCM. Mastication and oral health-related quality of life in removable denture wearers with Alzheimer disease. *The Journal of prosthetic dentistry*. 2017.

Can we reverse Alzheimer's? New approaches from Harvard offer hope. *Harvard health letter*. 2013;38(3):1, 7.

Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset P-J, Cesari M, et al. Effects of Ginkgo biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2014;21(6):888-92.

Canevelli M, Bruno G, Remiddi F, Vico C, Lacorte E, Vanacore N, et al. Spontaneous Reversion of Clinical Conditions Measuring the Risk Profile of the Individual: From Frailty to Mild Cognitive Impairment. *Frontiers in medicine*. 2017;4:184.

Canevelli M, Grande G, Lacorte E, Quarchioni E, Cesari M, Mariani C, et al. Spontaneous Reversion of Mild Cognitive Impairment to Normal Cognition: A Systematic Review of Literature and Meta-Analysis. *Journal of the American Medical Directors Association*. 2016;17(10):943-8.

Canevelli M, Lucchini F, Quarata F, Bruno G, Cesari M. Nutrition and Dementia: Evidence for Preventive Approaches? *Nutrients*. 2016;8(3):144.

Cangelosi PR, Sorrell JM. Use of technology to enhance mental health for older adults. *Journal of psychosocial nursing and mental health services*. 2014;52(9):17-20.

Cano-Cuenca N, Solis-Garcia del Pozo JE, Jordan J. Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis. *Journal of Alzheimer's disease : JAD*. 2014;38(1):155-64.

Cansev M, van Wijk N, Turkyilmaz M, Orhan F, Sijben JWC, Broersen LM. Specific multi-nutrient enriched diet enhances hippocampal cholinergic transmission in aged rats. *Neurobiology of aging*. 2015;36(1):344-51.

Cantarella G, Di Benedetto G, Puzzo D, Privitera L, Loreto C, Saccone S, et al. Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease. *Brain : a journal of neurology*. 2015;138(Pt 1):203-16.

Canter RG, Penney J, Tsai L-H. The road to restoring neural circuits for the treatment of Alzheimer's disease. *Nature*. 2016;539(7628):187-96.

Cao Y, Bartolome-Martin D, Rotem N, Rozas C, Dellal SS, Chacon MA, et al. Rescue of homeostatic regulation of striatal excitability and locomotor activity in a mouse model of Huntington's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112(7):2239-44.

Cao Z, Wang F, Xiu C, Zhang J, Li Y. Hypericum perforatum extract attenuates behavioral, biochemical, and neurochemical abnormalities in Aluminum chloride-induced Alzheimer's disease rats. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2017;91:931-7.

Capone C, Cognat E, Ghezali L, Baron-Menguy C, Aubin D, Mesnard L, et al. Reducing Timp3 or vitronectin ameliorates disease manifestations in CADASIL mice. *Annals of neurology*. 2016;79(3):387-403.

Carapelle E, Serra L, Modoni S, Falcone M, Caltagirone C, Bozzali M, et al. How the cognitive reserve interacts with beta-amyloid deposition in mitigating FDG metabolism: An observational study. *Medicine*. 2017;96(16):e5876.

Carare RO, Hawkes CA, Jeffrey M, Kalaria RN, Weller RO. Review: cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. *Neuropathology and applied neurobiology*. 2013;39(6):593-611.

Carare RO, Teeling JL, Hawkes CA, Puntener U, Weller RO, Nicoll JAR, et al. Immune complex formation impairs the elimination of solutes from the brain: implications for immunotherapy in Alzheimer's disease. *Acta neuropathologica communications*. 2013;1:48.

Cardenas-Pena D, Collazos-Huertas D, Castellanos-Dominguez G. Centered Kernel Alignment Enhancing Neural Network Pretraining for MRI-Based Dementia Diagnosis. *Computational and mathematical methods in medicine*. 2016;2016:9523849.

Cardenas-Pena D, Collazos-Huertas D, Castellanos-Dominguez G. Enhanced Data Representation by Kernel Metric Learning for Dementia Diagnosis. *Frontiers in neuroscience*. 2017;11:413.

Cardinale A, Paldino E, Giampa C, Bernardi G, Fusco FR. PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease. *PloS one*. 2015;10(8):e0134482.

Cardone A, Brady M, Sriram R, Pant HC, Hassan SA. Computational study of the inhibitory mechanism of the kinase CDK5 hyperactivity by peptide p5 and derivation of a pharmacophore. *Journal of computer-aided molecular design*. 2016;30(6):513-21.

Cardoso S, Seica RM, Moreira PI. Mitochondria as a target for neuroprotection: implications for Alzheimer's disease. *Expert review of neurotherapeutics*. 2017;17(1):77-91.

Carlberg B. The challenge of preventing dementia by antihypertensive treatment. *Journal of hypertension*. 2013;31(9):1780-1.

Carlomagno Y, Zhang Y, Davis M, Lin W-L, Cook C, Dunmore J, et al. Casein kinase II induced polymerization of soluble TDP-43 into filaments is inhibited by heat shock proteins. *PloS one*. 2014;9(3):e90452.

Carman AJ, Dacks PA, Lane RF, Shineman DW, Fillit HM. Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease. *The journal of nutrition, health & aging*. 2014;18(4):383-92.

Carreras I, McKee AC, Choi J-K, Aytan N, Kowall NW, Jenkins BG, et al. R-flurbiprofen improves tau, but not A β pathology in a triple transgenic model of Alzheimer's disease. *Brain research*. 2013;1541:115-27.

Carrillo MC, Brashear HR, Logovinsky V, Ryan JM, Feldman HH, Siemers ER, et al. Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013;9(2):123-31.e1.

Carter RL, Chen Y, Kunkanjanawan T, Xu Y, Moran SP, Putkhao K, et al. Reversal of cellular phenotypes in neural cells derived from Huntington's disease monkey-induced pluripotent stem cells. *Stem cell reports*. 2014;3(4):585-93.

Casaca-Carreira J, Toonen LJA, Evers MM, Jahanshahi A, van-Roon-Mom WMC, Temel Y. In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2016;84:93-6.

Casarejos MJ, Perucho J, Gomez A, Munoz MP, Fernandez-Estevez M, Sagredo O, et al. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. *Journal of Alzheimer's disease : JAD*. 2013;35(3):525-39.

Cascella R, Conti S, Tatini F, Evangelisti E, Scartabelli T, Casamenti F, et al. Extracellular chaperones prevent Abeta42-induced toxicity in rat brains. *Biochimica et biophysica acta*. 2013;1832(8):1217-26.

Casey CS, Atagi Y, Yamazaki Y, Shinohara M, Tachibana M, Fu Y, et al. Apolipoprotein E Inhibits Cerebrovascular Pericyte Mobility through a RhoA Protein-mediated Pathway. *The Journal of biological chemistry*. 2015;290(22):14208-17.

Caspi E. Deaths as a Result of Resident-to-Resident Altercations in Dementia in Long-Term Care Homes: A Need for Research, Policy, and Prevention. *Journal of the American Medical Directors Association*. 2016;17(1):7-11.

Caspi E. Policy Recommendation: The National Center for Prevention of Resident-to-Resident Aggression in Dementia. *Journal of the American Medical Directors Association*. 2015;16(6):532.

Cassani R, Falk TH, Fraga FJ, Kanda PAM, Anghinah R. The effects of automated artifact removal algorithms on electroencephalography-based Alzheimer's disease diagnosis. *Frontiers in aging neuroscience*. 2014;6:55.

Castello MA, Jeppson JD, Soriano S. Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease. *BMC neurology*. 2014;14:169.

Castello NA, Nguyen MH, Tran JD, Cheng D, Green KN, LaFerla FM. 7,8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal loss. *PloS one*. 2014;9(3):e91453.

Castilla-Guerra L, Fernandez-Moreno MdC, Alvarez-Suero J, Jimenez-Hernandez MD. Can the treatment of arterial hypertension help to prevent dementia? *Revista de neurologia*. 2013;56(2):91-100.

Castillo WO, Aristizabal-Pachon AF. Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease. *Neural regeneration research*. 2017;12(6):916-7.

Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(12):4260-72.

Castro P, Zaman S, Holland A. Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments. *Journal of neurology*. 2017;264(4):804-13.

Castro-Alvarez JF, Uribe-Arias SA, Kosik KS, Cardona-Gomez GP. Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer's mice. *Frontiers in aging neuroscience*. 2014;6:243.

Catala-Lopez F, Crespo-Facorro B, Vieta E, Valderas JM, Valencia A, Tabares-Seisdedos R. Alzheimer's disease and cancer: current epidemiological evidence for a mutual protection. *Neuroepidemiology*. 2014;42(2):121-2.

Catricala E, Della Rosa PA, Parisi L, Zippo AG, Borsa VM, Iadanza A, et al. Functional correlates of preserved naming performance in amnesic Mild Cognitive Impairment. *Neuropsychologia*. 2015;76:136-52.

Catto M, Pisani L, Leonetti F, Nicolotti O, Pesce P, Stefanachi A, et al. Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. *Bioorganic & medicinal chemistry*. 2013;21(1):146-52.

Cavallucci V, Berretta N, Nobili A, Nistico R, Mercuri NB, D'Amelio M. Calcineurin inhibition rescues early synaptic plasticity deficits in a mouse model of Alzheimer's disease. *Neuromolecular medicine*. 2013;15(3):541-8.

Cavanagh C, Tse YC, Nguyen H-B, Krantic S, Breitner JCS, Quirion R, et al. Inhibiting tumor necrosis factor- α before amyloidosis prevents synaptic deficits in an Alzheimer's disease model. *Neurobiology of aging*. 2016;47:41-9.

Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, et al. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. *The journal of prevention of Alzheimer's disease*. 2014;1(3):181-202.

Ceccom J, Loukh N, Lauwers-Cances V, Touriol C, Nicaise Y, Gentil C, et al. Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease. *Acta neuropathologica communications*. 2014;2:12.

Cederholm T, Salem N, Jr., Palmblad J. omega-3 fatty acids in the prevention of cognitive decline in humans. *Advances in nutrition* (Bethesda, Md). 2013;4(6):672-6.

Cederholm T. Fish consumption and omega-3 fatty acid supplementation for prevention or treatment of cognitive decline, dementia or Alzheimer's disease in older adults - any news? *Current opinion in clinical nutrition and metabolic care*. 2017;20(2):104-9.

Celebi O, Temucin CM, Elibol B, Saka E. Cognitive profiling in relation to short latency afferent inhibition of frontal cortex in multiple system atrophy. *Parkinsonism & related disorders*. 2014;20(6):632-6.

Cepeda C, Galvan L, Holley SM, Rao SP, Andre VM, Botelho EP, et al. Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(17):7393-406.

Cesari M, Vanacore N, Canevelli M. What are we willing to accept for preventing Alzheimer's disease? *The Lancet Neurology*. 2016;15(7):659-60.

Cespon J, Galdo-Alvarez S, Diaz F. Inhibition deficit in the spatial tendency of the response in multiple-domain amnesic mild cognitive impairment. An event-related potential study. *Frontiers in aging neuroscience*. 2015;7:68.

Cevik B, Solmaz V, Yigitturk G, Cavusoglu T, Peker G, Erbas O. Neuroprotective effects of erythropoietin on Alzheimer's dementia model in rats. *Advances in clinical and experimental medicine : official organ Wroclaw Medical University*. 2017;26(1):23-9.

Cha M-Y, Cho HJ, Kim C, Jung YO, Kang MJ, Murray ME, et al. Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer's disease. *Human molecular genetics*. 2015;24(22):6492-504.

Cha M-Y, Kwon Y-W, Ahn H-S, Jeong H, Lee YY, Moon M, et al. Protein-Induced Pluripotent Stem Cells Ameliorate Cognitive Dysfunction and Reduce Abeta Deposition in a Mouse Model of Alzheimer's Disease. *Stem cells translational medicine*. 2017;6(1):293-305.

Cha Y, Lee SH, Jang SK, Guo H, Ban Y-H, Park D, et al. A silk peptide fraction restores cognitive function in AF64A-induced Alzheimer disease model rats by increasing expression of choline acetyltransferase gene. *Toxicology and applied pharmacology*. 2017;314:48-54.

Chacon PJ, del Marco A, Arevalo A, Dominguez-Gimenez P, Garcia-Segura LM, Rodriguez-Tebar A. Cerebellin 4, a synaptic protein, enhances inhibitory activity and resistance of neurons to amyloid-beta toxicity. *Neurobiology of aging*. 2015;36(2):1057-71.

Chae M-S, Kim J, Jeong D, Kim Y, Roh JH, Lee SM, et al. Enhancing surface functionality of reduced graphene oxide biosensors by oxygen plasma treatment for Alzheimer's disease diagnosis. *Biosensors & bioelectronics*. 2017;92:610-7.

Chahbazian K, Theaudin M, Lehmann P, Sachet M, Adams D, Saliou G. Reversible pseudo-Creutzfeldt-Jakob syndrome related to cerebral dural arteriovenous fistula. *Journal of the American Geriatrics Society*. 2014;62(10):2024-6.

Chai G-S, Duan D-X, Ma R-H, Shen J-Y, Li H-L, Ma Z-W, et al. Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid beta-peptide in rats. *Neuroscience bulletin*. 2014;30(6):923-35.

Chai G-S, Feng Q, Wang Z-H, Hu Y, Sun D-S, Li X-G, et al. Downregulating ANP32A rescues synapse and memory loss via chromatin remodeling in Alzheimer model. *Molecular neurodegeneration*. 2017;12(1):34.

Chai G-S, Jiang X, Ni Z-F, Ma Z-W, Xie A-J, Cheng X-S, et al. Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. *Journal of neurochemistry*. 2013;124(3):388-96.

Chai G-S, Wang Y-Y, Yasheng A, Zhao P. Beta 2-adrenergic receptor activation enhances neurogenesis in Alzheimer's disease mice. *Neural regeneration research*. 2016;11(10):1617-24.

Chainay H, Sava A, Michael GA, Landre L, Versace R, Krolak-Salmon P. Impaired emotional memory enhancement on recognition of pictorial stimuli in Alzheimer's disease: no influence of the nature of encoding. *Cortex; a journal devoted to the study of the nervous system and behavior*. 2014;50:32-44.

Chakrabarti M, McDonald AJ, Will Reed J, Moss MA, Das BC, Ray SK. Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;50(2):335-52.

Chakraborty J, Nthenge-Ngumbau DN, Rajamma U, Mohanakumar KP. Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease. *Behavioural brain research*. 2014;264:91-104.

Chakraborty J, Singh R, Dutta D, Naskar A, Rajamma U, Mohanakumar KP. Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's Disease. *CNS neuroscience & therapeutics*. 2014;20(1):10-9.

Chakraborty S, Bandyopadhyay J, Chakraborty S, Basu S. Multi-target screening mines hesperidin as a multi-potent inhibitor: Implication in Alzheimer's disease therapeutics. *European journal of medicinal chemistry*. 2016;121:810-22.

Chakraborty S, Basu S. Dual inhibition of BACE1 and Abeta aggregation by beta-ecdysone: Application of a phytoecdysteroid scaffold in Alzheimer's disease therapeutics. *International journal of biological macromolecules*. 2017;95:281-7.

Chalermchai T, Valcour V, Sithinamsuwan P, Pinyakorn S, Clifford D, Paul RH, et al. Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. *Journal of neurovirology*. 2013;19(2):137-43.

Chan AW, Yu DS, Choi KC, Lee DT, Sit JW, Chan HY. Tai chi qigong as a means to improve night-time sleep quality among older adults with cognitive impairment: a pilot randomized controlled trial. *Clinical interventions in aging*. 2016;11:1277-86.

Chan ES, Shetty MS, Sajikumar S, Chen C, Soong TW, Wong B-S. ApoE4 expression accelerates hippocampus-dependent cognitive deficits by enhancing Abeta impairment of insulin signaling in an Alzheimer's disease mouse model. *Scientific reports*. 2016;6:26119.

Chan S, Kantham S, Rao VM, Palanivelu MK, Pham HL, Shaw PN, et al. Metal chelation, radical scavenging and inhibition of Abeta β , fibrillation by food constituents in relation to Alzheimer's disease. *Food chemistry*. 2016;199:185-94.

Chand K, Alsoghier HM, Chaves S, Santos MA. Tacrine-(hydroxybenzoyl-pyridone) hybrids as potential multifunctional anti-Alzheimer's agents: AChE inhibition, antioxidant activity and metal chelating capacity. *Journal of inorganic biochemistry*. 2016;163:266-77.

Chandra A, Johri A, Beal MF. Prospects for neuroprotective therapies in prodromal Huntington's disease. *Movement disorders : official journal of the Movement Disorder Society*. 2014;29(3):285-93.

Chandra A, Sharma A, Calingasan NY, White JM, Shurubor Y, Yang XW, et al. Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease. *Human molecular genetics*. 2016;25(11):2269-82.

Chandra SR, Issac TG, Nagaraju BC, Philip M. A Study of Cortical Excitability, Central Motor Conduction, and Cortical Inhibition Using Single Pulse Transcranial Magnetic Stimulation in Patients with Early Frontotemporal and Alzheimer's Dementia. *Indian journal of psychological medicine*. 2016;38(1):25-30.

Chang C-Y, Chen S-M, Lu H-E, Lai S-M, Lai P-S, Shen P-W, et al. N-butylidenephthalide attenuates Alzheimer's disease-like cytopathy in Down syndrome induced pluripotent stem cell-derived neurons. *Scientific reports*. 2015;5:8744.

Chang F, Zhang L-H, Xu W-P, Jing P, Zhan P-Y. microRNA-9 attenuates amyloidbeta-induced synaptotoxicity by targeting calcium/calmodulin-dependent protein kinase kinase 2. *Molecular medicine reports*. 2014;9(5):1917-22.

Chang R, Knox J, Chang J, Derbedrossian A, Vasilevko V, Cribbs D, et al. Blood-Brain Barrier Penetrating Biologic TNF-alpha Inhibitor for Alzheimer's Disease. *Molecular pharmaceutics*. 2017;14(7):2340-9.

Chang R, Yee K-L, Sumbria RK. Tumor necrosis factor alpha Inhibition for Alzheimer's Disease. *Journal of central nervous system disease*. 2017;9:1179573517709278.

Chang W-H, Chen MC, Cheng IH. Antroquinonol Lowers Brain Amyloid-beta Levels and Improves Spatial Learning and Memory in a Transgenic Mouse Model of Alzheimer's Disease. *Scientific reports*. 2015;5:15067.

Chang X, Rong C, Chen Y, Yang C, Hu Q, Mo Y, et al. (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression. *Experimental cell research*. 2015;334(1):136-45.

Chang Y-S, Chen H-L, Hsu C-Y, Tang S-H, Liu C-K. Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer's disease: a case-control study. *Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society*. 2014;31(1):81-5.

Chao P-C, Chien W-C, Chung C-H, Chu C-W, Yeh C-B, Huang S-Y, et al. Cognitive enhancers associated with decreased risk of injury in patients with dementia: a nationwide cohort study in Taiwan. *Journal of investigative medicine : the official publication of the American Federation for Clinical Research*. 2017.

Charbord J, Poydenot P, Bonnefond C, Feyeux M, Casagrande F, Brinon B, et al. High throughput screening for inhibitors of REST in neural derivatives of human embryonic stem cells reveals a chemical compound that promotes expression of neuronal genes. *Stem cells (Dayton, Ohio)*. 2013;31(9):1816-28.

Chareamboon T, Jaisin K. Ginkgo biloba for prevention of dementia: a systematic review and meta-analysis. *Journal of the Medical Association of Thailand = Chotmaihet thangphaet*. 2015;98(5):508-13.

Chaudhary RK, Patel KA, Patel MK, Joshi RH, Roy I. Inhibition of Aggregation of Mutant Huntingtin by Nucleic Acid Aptamers In Vitro and in a Yeast Model of Huntington's Disease. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2015;23(12):1912-26.

Chaudhary S, Scouten A, Schwindt G, Janik R, Lee W, Sled JG, et al. Hemodynamic effects of cholinesterase inhibition in mild Alzheimer's disease. *Journal of magnetic resonance imaging : JMRI*. 2013;38(1):26-35.

Chaves M, Toral A, Bissonni A, Rojas JI, Fernandez C, Garcia Basalo MJ, et al. Treatment with vitamin D and slowing of progression to severe stage of Alzheimer's disease. *Vertex* (Buenos Aires, Argentina). 2014;25(114):85-91.

Che H, Du L, Cong P, Tao S, Ding N, Wu F, et al. Cerebrosides from Sea Cucumber Protect Against Oxidative Stress in SAMP8 Mice and PC12 Cells. *Journal of medicinal food*. 2017;20(4):392-402.

Chen B, Teng Y, Zhang X, Lv X, Yin Y. Metformin Alleviated Abeta-Induced Apoptosis via the Suppression of JNK MAPK Signaling Pathway in Cultured Hippocampal Neurons. *BioMed research international*. 2016;2016:1421430.

Chen C, Huang L, Nong Z, Li Y, Chen W, Huang J, et al. Hyperbaric Oxygen Prevents Cognitive Impairments in Mice Induced by D-Galactose by Improving Cholinergic and Anti-apoptotic Functions. *Neurochemical research*. 2017;42(4):1240-53.

Chen C, Li X, Gao P, Tu Y, Zhao M, Li J, et al. Baicalin attenuates alzheimer-like pathological changes and memory deficits induced by amyloid beta1-42 protein. *Metabolic brain disease*. 2015;30(2):537-44.

Chen C, Li X-H, Zhang S, Tu Y, Wang Y-M, Sun H-T. 7,8-dihydroxyflavone ameliorates scopolamine-induced Alzheimer-like pathologic dysfunction. *Rejuvenation research*. 2014;17(3):249-54.

Chen C, Meng S-Q, Xue Y-X, Han Y, Sun C-Y, Deng J-H, et al. Epigenetic modification of PKMzeta rescues aging-related cognitive impairment. *Scientific reports*. 2016;6:22096.

Chen C-H, Li W, Sultana R, You M-H, Kondo A, Shahpasand K, et al. Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease. *Neurobiology of disease*. 2015;76:13-23.

Chen C-W, Lin W-Y, Chen K-B, Wu Y-S, Kuo Y-C, Liu H-P, et al. Inhalational anesthetic sevoflurane rescues retina function in Alzheimer's disease transgenic *Drosophila*. *Current Alzheimer research*. 2013;10(9):1005-14.

Chen D. NEUROPROTECTIVE EFFECT OF AMORPHOPHALLUS CAMPANULATUS IN STZ INDUCED ALZHEIMER RAT MODEL. *African journal of traditional, complementary, and alternative medicines : AJTCAM*. 2016;13(4):47-54.

Chen D-L, Zhang P, Lin L, Zhang H-M, Deng S-D, Wu Z-Q, et al. Protective effects of bajijiasu in a rat model of Abeta β -induced neurotoxicity. *Journal of ethnopharmacology*. 2014;154(1):206-17.

Chen D-L, Zhang P, Lin L, Zhang H-M, Liu S-H. Protective effect of oligosaccharides from *Morinda officinalis* on beta-amyloid-induced dementia rats. *Zhongguo Zhong yao za zhi* = *Zhongguo zhongyao zazhi* = China journal of Chinese materia medica. 2013;38(9):1306-9.

Chen H, Liu S, Ji L, Wu T, Ji Y, Zhou Y, et al. Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial. *Mediators of inflammation*. 2016;2016:5912146.

Chen H-Y, Xu D-P, Tan G-L, Cai W, Zhang G-X, Cui W, et al. A Potent Multi-functional Neuroprotective Derivative of Tetramethylpyrazine. *Journal of molecular neuroscience : MN*. 2015;56(4):977-87.

Chen J, Li S, Sun W, Li J. Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity. *PloS one*. 2015;10(4):e0123864.

Chen J, Marks E, Lai B, Zhang Z, Duce JA, Lam LQ, et al. Iron accumulates in Huntington's disease neurons: protection by deferoxamine. *PloS one*. 2013;8(10):e77023.

Chen J, Shu H, Wang Z, Liu D, Shi Y, Xu L, et al. Protective effect of APOE epsilon 2 on intrinsic functional connectivity of the entorhinal cortex is associated with better episodic memory in elderly individuals with risk factors for Alzheimer's disease. *Oncotarget*. 2016;7(37):58789-801.

Chen J, Sun M, Wang X, Lu J, Wei Y, Tan Y, et al. The herbal compound geniposide rescues formaldehyde-induced apoptosis in N2a neuroblastoma cells. *Science China Life sciences*. 2014;57(4):412-21.

Chen J, Tao L-X, Xiao W, Ji S-S, Wang J-R, Li X-W, et al. Design, synthesis and biological evaluation of novel chiral oxazino-indoles as potential and selective neuroprotective agents against A β 25-35-induced neuronal damage. *Bioorganic & medicinal chemistry letters*. 2016;26(15):3765-9.

Chen J, Zhou SN, Zhang YM, Feng YL, Wang S. Glycosides of *cistanche* improve learning and memory in the rat model of vascular dementia. *European review for medical and pharmacological sciences*. 2015;19(7):1234-40.

Chen J-H, Ke K-F, Lu J-H, Qiu Y-H, Peng Y-P. Protection of TGF- β 1 against neuroinflammation and neurodegeneration in A β 1-42-induced Alzheimer's disease model rats. *PloS one*. 2015;10(2):e0116549.

Chen JJ, Liu Q, Yuan C, Gore V, Lopez P, Ma V, et al. Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious beta-secretase inhibitors for the potential treatment of Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2015;25(4):767-74.

Chen J-L, Zhang D-L, Sun Y, Zhao Y-X, Zhao K-X, Pu D, et al. Angiotensin-(1-7) administration attenuates Alzheimer's disease-like neuropathology in rats with streptozotocin-induced diabetes via Mas receptor activation. *Neuroscience*. 2017;346:267-77.

Chen JY, Tran C, Hwang L, Deng G, Jung ME, Faull KF, et al. Partial Amelioration of Peripheral and Central Symptoms of Huntington's Disease via Modulation of Lipid Metabolism. *Journal of Huntington's disease*. 2016;5(1):65-81.

Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2015;56(4):560-6.

Chen K-C, Weng C-Y, Hsiao S, Tsao W-L, Koo M. Cognitive decline and slower reaction time in elderly individuals with mild cognitive impairment. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2017.

Chen L, Hu L, Zhao J, Hong H, Feng F, Qu W, et al. Chotosan improves Abeta1-42-induced cognitive impairment and neuroinflammatory and apoptotic responses through the inhibition of TLR-4/NF-kappaB signaling in mice. *Journal of ethnopharmacology*. 2016;191:398-407.

Chen L, Na R, Ran Q. Enhanced defense against mitochondrial hydrogen peroxide attenuates age-associated cognition decline. *Neurobiology of aging*. 2014;35(11):2552-61.

Chen L, Yao Y, Wei C, Sun Y, Ma X, Zhang R, et al. T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment. *Scientific reports*. 2015;5:14308.

Chen L, Zhang Y, Li D, Zhang N, Liu R, Han B, et al. Everolimus (RAD001) ameliorates vascular cognitive impairment by regulating microglial function via the mTORC1 signaling pathway. *Journal of neuroimmunology*. 2016;299:164-71.

Chen L-Y, Liu L-K, Liu C-L, Peng L-N, Lin M-H, Chen L-K, et al. Predicting functional decline of older men living in veteran homes by minimum data set: implications for disability prevention programs in long term care settings. *Journal of the American Medical Directors Association*. 2013;14(4):309.e9-13.

Chen P, Yan Q, Wang S, Wang C, Zhao P. Transfer of three transcription factors via a lentiviral vector ameliorates spatial learning and memory impairment in a mouse model of Alzheimer's disease. *Gene*. 2016;587(1):59-63.

Chen P, Zhao W, Guo Y, Xu J, Yin M. CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection. *BioMed research international*. 2016;2016:8090918.

Chen P-T, Chen Z-T, Hou W-C, Yu L-C, Chen RPY. Polyhydroxycurcuminoids but not curcumin upregulate neprilysin and can be applied to the prevention of Alzheimer's disease. *Scientific reports*. 2016;6:29760.

Chen Q, Chen Y-Q, Ye H-Y, Yu J-Q, Shi Q-Q, Huang Y. The mechanism of tenuigenin for eliminating waste product accumulation in cerebral neurons of Alzheimer's disease rats via ubiquitin-proteasome pathway. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi* = Chinese journal of integrated traditional and Western medicine. 2015;35(3):327-32.

Chen Q, Hu J, Qin SS, Liu CL, Wu H, Wang JR, et al. Protective effects of naringin against gp120-induced injury mediated by P2X7 receptors in BV2 microglial cells. *Genetics and molecular research : GMR*. 2016;15(2).

Chen Q, Yang L, Zheng C, Zheng W, Zhang J, Zhou Y, et al. Mo polyoxometalate nanoclusters capable of inhibiting the aggregation of Abeta-peptide associated with Alzheimer's disease. *Nanoscale*. 2014;6(12):6886-97.

Chen R. Biomarker for mild cognitive impairment: is short latency afferent inhibition the answer? *Movement disorders : official journal of the Movement Disorder Society*. 2013;28(9):1171-2.

Chen R-J, Chang W-W, Lin Y-C, Cheng P-L, Chen Y-R. Alzheimer's amyloid-beta oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway. *ACS chemical neuroscience*. 2013;4(9):1287-96.

Chen S, Zhang X-J, Xie W-J, Qiu H-Y, Liu H, Le W-D. A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease. *CNS neuroscience & therapeutics*. 2015;21(8):662-71.

Chen T-Y, Lin C-E, Chen L-F, Tzeng N-S. Enhanced bleeding risk in an elderly dementia patient treated with warfarin and quetiapine. *The Journal of neuropsychiatry and clinical neurosciences*. 2013;25(4):E25.

Chen W, Gamache E, Rosenman DJ, Xie J, Lopez MM, Li Y-M, et al. Familial Alzheimer's mutations within APPTM increase Abeta42 production by enhancing accessibility of epsilon-cleavage site. *Nature communications*. 2014;5:3037.

Chen W, Mao L, Xing H, Xu L, Fu X, Huang L, et al. Lycopene attenuates Abeta1-42 secretion and its toxicity in human cell and *Caenorhabditis elegans* models of Alzheimer disease. *Neuroscience letters*. 2015;608:28-33.

Chen X, Hu J, Jiang L, Xu S, Zheng B, Wang C, et al. Brilliant Blue G improves cognition in an animal model of Alzheimer's disease and inhibits amyloid-beta-induced loss of filopodia and dendrite spines in hippocampal neurons. *Neuroscience*. 2014;279:94-101.

Chen Y, Guo Z, Mao Y-F, Zheng T, Zhang B. Intranasal Insulin Ameliorates Cerebral Hypometabolism, Neuronal Loss, and Astroglialosis in Streptozotocin-Induced Alzheimer's Rat Model. *Neurotoxicity research*. 2017.

Chen Y, Han S, Huang X, Ni J, He X. The Protective Effect of Icaritin on Mitochondrial Transport and Distribution in Primary Hippocampal Neurons from 3xTg-AD Mice. *International journal of molecular sciences*. 2016;17(2).

Chen Y, Lei Y, Mo L-Q, Li J, Wang M-H, Wei J-C, et al. Electroacupuncture pretreatment with different waveforms prevents brain injury in rats subjected to cecal ligation and puncture via inhibiting microglial activation, and attenuating inflammation, oxidative stress and apoptosis. *Brain research bulletin*. 2016;127:248-59.

Chen Y, Wang B, Liu D, Li JJ, Xue Y, Sakata K, et al. Hsp90 chaperone inhibitor 17-AAG attenuates Aβ-induced synaptic toxicity and memory impairment. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(7):2464-70.

Chen Y, Zhao Y, Dai C-L, Liang Z, Run X, Iqbal K, et al. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice. *Experimental neurology*. 2014;261:610-9.

Chen Y-d, Zhang J, Wang Y, Yuan J-l, Hu W-l. Efficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis. *European neurology*. 2016;75(3-4):132-41.

Chen Y-J, Zheng H-Y, Huang X-X, Han S-X, Zhang D-S, Ni J-Z, et al. Neuroprotective Effects of Icaritin on Brain Metabolism, Mitochondrial Functions, and Cognition in Triple-Transgenic Alzheimer's Disease Mice. *CNS neuroscience & therapeutics*. 2016;22(1):63-73.

Chen Y-S, Chen S-D, Wu C-L, Huang S-S, Yang D-I. Induction of sestrin2 as an endogenous protective mechanism against amyloid β-peptide neurotoxicity in primary cortical culture. *Experimental neurology*. 2014;253:63-71.

Chen Y-X, Li G-Z, Zhang B, Xia Z-Y, Zhang M. Molecular evaluation of herbal compounds as potent inhibitors of acetylcholinesterase for the treatment of Alzheimer's disease. *Molecular medicine reports*. 2016;14(1):446-52.

Chen Z-L, Revenko AS, Singh P, MacLeod AR, Norris EH, Strickland S. Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice. *Blood*. 2017;129(18):2547-56.

Cheng B, Zhang D, Chen S, Kaufer DI, Shen D, Alzheimers Disease Neuroimaging I. Semi-supervised multimodal relevance vector regression improves cognitive performance estimation from imaging and biological biomarkers. *Neuroinformatics*. 2013;11(3):339-53.

Cheng CPW, Chan SSM, Mak ADP, Chan WC, Cheng ST, Shi L, et al. Would transcranial direct current stimulation (tDCS) enhance the effects of working memory training in older adults with mild neurocognitive disorder due to Alzheimer's disease: study protocol for a randomized controlled trial. *Trials*. 2015;16:479.

Cheng D, Kong H, Pang W, Yang H, Lu H, Huang C, et al. B vitamin supplementation improves cognitive function in the middle aged and elderly with hyperhomocysteinemia. *Nutritional neuroscience*. 2016;19(10):461-6.

Cheng D, Low JK, Logge W, Garner B, Karl T. Chronic cannabidiol treatment improves social and object recognition in double transgenic APP^{swe}/PS1^{ΔE9} mice. *Psychopharmacology*. 2014;231(15):3009-17.

Cheng D, Spiro AS, Jenner AM, Garner B, Karl T. Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. *Journal of Alzheimer's disease : JAD*. 2014;42(4):1383-96.

Cheng J, Chen L, Han S, Qin L, Chen N, Wan Z. Treadmill Running and Rutin Reverse High Fat Diet Induced Cognitive Impairment in Diet Induced Obese Mice. *The journal of nutrition, health & aging*. 2016;20(5):503-8.

Cheng L, Zhang J, Li X-Y, Yuan L, Pan Y-F, Chen X-R, et al. A novel antibody targeting sequence 31-35 in amyloid beta protein attenuates Alzheimer's disease-related neuronal damage. *Hippocampus*. 2017;27(2):122-33.

Cheng M-C, Pan T-M. Prevention of hypertension-induced vascular dementia by *Lactobacillus paracasei* subsp. *paracasei* NTU 101-fermented products. *Pharmaceutical biology*. 2017;55(1):487-96.

Cheng N, Bai L, Steuer E, Belluscio L. Olfactory functions scale with circuit restoration in a rapidly reversible Alzheimer's disease model. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(30):12208-17.

Cheng P-H, Li C-L, Chang Y-F, Tsai S-J, Lai Y-Y, Chan AWS, et al. miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models. *American journal of human genetics*. 2013;93(2):306-12.

Cheng S, Cao D, Hottman DA, Yuan L, Bergo MO, Li L. Farnesyltransferase haplodeficiency reduces neuropathology and rescues cognitive function in a mouse model of Alzheimer disease. *The Journal of biological chemistry*. 2013;288(50):35952-60.

Cheng S, LeBlanc KJ, Li L. Triptolide preserves cognitive function and reduces neuropathology in a mouse model of Alzheimer's disease. *PloS one*. 2014;9(9):e108845.

Cheng S, Zheng W, Gong P, Zhou Q, Xie Q, Yu L, et al. (-)-Meptazinol-melatonin hybrids as novel dual inhibitors of cholinesterases and amyloid-beta aggregation with high antioxidant potency for Alzheimer's therapy. *Bioorganic & medicinal chemistry*. 2015;23(13):3110-8.

Cheng S-T, Chow PK, Song Y-Q, Yu ECS, Lam JHM. Can leisure activities slow dementia progression in nursing home residents? A cluster-randomized controlled trial. *International psychogeriatrics*. 2014;26(4):637-43.

Cheng S-T. Cognitive Reserve and the Prevention of Dementia: the Role of Physical and Cognitive Activities. *Current psychiatry reports*. 2016;18(9):85.

Cheng X, Zhou Y, Gu W, Wu J, Nie A, Cheng J, et al. The selective BACE1 inhibitor VIa reduces amyloid-beta production in cell and mouse models of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2013;37(4):823-34.

Cheng X-J, Gao Y, Zhao Y-W, Cheng X-D. Sodium Chloride Increases Abeta Levels by Suppressing Abeta Clearance in Cultured Cells. *PloS one*. 2015;10(6):e0130432.

Cheng X-S, Zhao K-P, Jiang X, Du L-L, Li X-H, Ma Z-W, et al. Nmnat2 attenuates Tau phosphorylation through activation of PP2A. *Journal of Alzheimer's disease : JAD*. 2013;36(1):185-95.

Cheng Y, Dong Z, Liu S. beta-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARgamma pathway. *Pharmacology*. 2014;94(1-2):1-12.

Cheng Y-H, Chuang L-Y, Chang H-W, Yang C-H. Improved candidate drug mining for Alzheimer's disease. *BioMed research international*. 2014;2014:897653.

Cheng Y-S, Chen Z-T, Liao T-Y, Lin C, Shen HCH, Wang Y-H, et al. An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. *EMBO molecular medicine*. 2017;9(5):703-15.

Cheng Y-W, Chen T-F, Cheng T-W, Lai Y-M, Hua M-S, Chen Y-F, et al. Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimer's disease. *Alzheimer's research & therapy*. 2015;7:72.

Chenoweth L, Stein-Parbury J, White D, McNeill G, Jeon Y-H, Zaratan B. Coaching in self-efficacy improves care responses, health and well-being in dementia carers: a pre/post-test/follow-up study. *BMC health services research*. 2016;16:166.

Cherif O, Allouche F, Chabchoub F, Chioua M, Soriano E, Yanez M, et al. Isoxazolotacrine as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer's disease. *Future medicinal chemistry*. 2014;6(17):1883-91.

Cheruvara H, Allen-Baume VL, Kad NM, Mason JM. Intracellular screening of a peptide library to derive a potent peptide inhibitor of alpha-synuclein aggregation. *The Journal of biological chemistry*. 2015;290(12):7426-35.

Cheston R, Howells L. A feasibility study of translating "Living Well with Dementia" groups into a Primary Care Improving Access to Psychological Therapy service (innovative practice). *Dementia (London, England)*. 2016;15(2):273-8.

Cheung KS-L, Lau BH-P, Wong PW-C, Leung AY-M, Lou VWQ, Chan GM-Y, et al. Multicomponent intervention on enhancing dementia caregiver well-being and reducing behavioral problems among Hong Kong Chinese: a translational study based on REACH II. *International journal of geriatric psychiatry*. 2015;30(5):460-9.

Chi T-Y, Wang L-H, Ji X-F, Shen L, Zou L-B. Protective effect of xanthoceraside against beta-amyloid-induced neurotoxicity in neuroblastoma SH-SY5Y cells. *Journal of Asian natural products research*. 2013;15(9):1013-22.

Chi Y, Sauve AA. Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. *Current opinion in clinical nutrition and metabolic care*. 2013;16(6):657-61.

Chiam JTW, Lunnon K, Voyle N, Proitsi P, Coppola G, Geschwind D, et al. No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2015;47(3):741-50.

Chiang M-C, Cheng Y-C, Nicol CJ, Lin K-H, Yen C-H, Chen S-J, et al. Rosiglitazone activation of PPARgamma-dependent signaling is neuroprotective in mutant huntingtin expressing cells. *Experimental cell research*. 2015;338(2):183-93.

Chiapinotto Spiazzi C, Bucco Soares M, Pinto Izaguirry A, Musacchio Vargas L, Zanchi MM, Frasson Pavin N, et al. Selenofuranoside Ameliorates Memory Loss in Alzheimer-Like Sporadic Dementia: AChE Activity, Oxidative Stress, and Inflammation Involvement. *Oxidative medicine and cellular longevity*. 2015;2015:976908.

Chiarini A, Armato U, Gardenal E, Gui L, Dal Pra I. Amyloid beta-Exposed Human Astrocytes Overproduce Phospho-Tau and Overrelease It within Exosomes, Effects Suppressed by Calcilytic NPS 2143-Further Implications for Alzheimer's Therapy. *Frontiers in neuroscience*. 2017;11:217.

Chiarini A, Gardenal E, Whitfield JF, Chakravarthy B, Armato U, Dal Pra I. Preventing the spread of Alzheimer's disease neuropathology: a role for calcilytics? *Current pharmaceutical biotechnology*. 2015;16(8):696-706.

Chierrito TPC, Pedersoli-Mantoani S, Roca C, Requena C, Sebastian-Perez V, Castillo WO, et al. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease. *European journal of medicinal chemistry*. 2017;139:773-91.

Chilumuri A, Odell M, Milton NGN. Benzothiazole aniline tetra(ethylene glycol) and 3-amino-1,2,4-triazole inhibit neuroprotection against amyloid peptides by catalase overexpression in vitro. *ACS chemical neuroscience*. 2013;4(11):1501-12.

Chin D, Huebbe P, Pallauf K, Rimbach G. Neuroprotective properties of curcumin in Alzheimer's disease--merits and limitations. *Current medicinal chemistry*. 2013;20(32):3955-85.

Chioua M, Perez M, Bautista-Aguilera OM, Yanez M, Lopez MG, Romero A, et al. Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer's disease. *Mini reviews in medicinal chemistry*. 2015;15(8):648-58.

Chioua M, Perez-Pena J, Garcia-Font N, Moraleda I, Iriepa I, Soriano E, et al. Pyranopyrazolotacrines as nonneurotoxic, Abeta-anti-aggregating and neuroprotective agents for Alzheimer's disease. *Future medicinal chemistry*. 2015;7(7):845-55.

Chirumbolo S, Bjorklund G. Commentary: The Flavonoid Baicalein Rescues Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer's Disease. *Frontiers in neurology*. 2016;7:141.

Chiruta C, Zhao Y, Tang F, Wang T, Schubert D. Metabolism of a potent neuroprotective hydrazide. *Bioorganic & medicinal chemistry*. 2013;21(10):2733-41.

Chitnis AS, Aparasu RR, Chen H, Kunik ME, Schulz PE, Johnson ML. Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure. *American journal of Alzheimer's disease and other dementias*. 2016;31(5):395-404.

Chiu M, Wesson V, Sadavoy J. Improving caregiving competence, stress coping, and mental well-being in informal dementia carers. *World journal of psychiatry*. 2013;3(3):65-73.

Cho CH, Kim E-A, Kim J, Choi SY, Yang S-J, Cho S-W. N-Adamantyl-4-methylthiazol-2-amine suppresses amyloid beta-induced neuronal oxidative damage in cortical neurons. *Free radical research*. 2016;50(6):678-90.

Cho J, Shin M-K, Kim D, Lee I, Kim S, Kang H. Treadmill Running Reverses Cognitive Declines due to Alzheimer Disease. *Medicine and science in sports and exercise*. 2015;47(9):1814-24.

Cho K, Yoon SY, Choi JE, Kang HJ, Jang HY, Kim D-H. CA-074Me, a cathepsin B inhibitor, decreases APP accumulation and protects primary rat cortical neurons treated with okadaic acid. *Neuroscience letters*. 2013;548:222-7.

Cho N, Kim HW, Lee HK, Jeon BJ, Sung SH. Ameliorative effect of betulin from *Betula platyphylla* bark on scopolamine-induced amnesic mice. *Bioscience, biotechnology, and biochemistry*. 2015;80(1):166-71.

Choi D-Y, Choi H. Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer's disease, Parkinson's disease and ischemic brain stroke: their molecular targets and action mechanisms. *Archives of pharmacal research*. 2015;38(2):139-70.

Choi H, Kim HJ, Kim J, Kim S, Yang J, Lee W, et al. Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of Aβ-induced impaired axonal transport. *Molecular neurodegeneration*. 2017;12(1):23.

Choi H, Park H-H, Lee K-Y, Choi N-Y, Yu H-J, Lee YJ, et al. Coenzyme Q10 restores amyloid β-inhibited proliferation of neural stem cells by activating the PI3K pathway. *Stem cells and development*. 2013;22(15):2112-20.

Choi J, Twamley EW. Cognitive rehabilitation therapies for Alzheimer's disease: a review of methods to improve treatment engagement and self-efficacy. *Neuropsychology review*. 2013;23(1):48-62.

Choi JG, Kim N, Huh E, Lee H, Oh MH, Park JD, et al. White Ginseng Protects Mouse Hippocampal Cells Against Amyloid-β Oligomer Toxicity. *Phytotherapy research : PTR*. 2017;31(3):497-506.

Choi JS, Bhakta HK, Fujii H, Min B-S, Park CH, Yokozawa T, et al. Inhibitory evaluation of oligonol on α-glucosidase, protein tyrosine phosphatase 1B, cholinesterase, and β-secretase 1 related to diabetes and Alzheimer's disease. *Archives of pharmacal research*. 2016;39(3):409-20.

Choi JY, Cho EJ, Lee HS, Lee JM, Yoon Y-H, Lee S. Tartary buckwheat improves cognition and memory function in an in vivo amyloid-β-induced Alzheimer model. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*. 2013;53:105-11.

Choi JY, Lee JM, Lee DG, Cho S, Yoon Y-H, Cho EJ, et al. The n-Butanol Fraction and Rutin from Tartary Buckwheat Improve Cognition and Memory in an In Vivo Model of Amyloid-β-Induced Alzheimer's Disease. *Journal of medicinal food*. 2015;18(6):631-41.

Choi M, Lee Y, Cho S-H. Angelica tenuissima Nakai ameliorates cognitive impairment and promotes neurogenesis in mouse model of Alzheimer's disease. Chinese journal of integrative medicine. 2017.

Choi RCY, Zhu JTT, Yung AWY, Lee PSC, Xu SL, Guo AJY, et al. Synergistic Action of Flavonoids, Baicalein, and Daidzein in Estrogenic and Neuroprotective Effects: A Development of Potential Health Products and Therapeutic Drugs against Alzheimer's Disease. Evidence-based complementary and alternative medicine : eCAM. 2013;2013:635694.

Choi S, Kim D, Kam T-I, Yun S, Kim S, Park H, et al. Lysosomal Enzyme Glucocerebrosidase Protects against Abeta1-42 Oligomer-Induced Neurotoxicity. PloS one. 2015;10(12):e0143854.

Choi S-H, Aid S, Caracciolo L, Minami SS, Niikura T, Matsuoka Y, et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. Journal of neurochemistry. 2013;124(1):59-68.

Choi SJ, Kim JK, Kim HK, Harris K, Kim C-J, Park GG, et al. 2,4-Di-tert-butylphenol from sweet potato protects against oxidative stress in PC12 cells and in mice. Journal of medicinal food. 2013;16(11):977-83.

Choi SJ, Kim JK, Suh SH, Kim CR, Kim HK, Kim C-J, et al. Ligularia fischeri extract protects against oxidative-stress-induced neurotoxicity in mice and PC12 cells. Journal of medicinal food. 2014;17(11):1222-31.

Choi SJ, Oh SS, Kim CR, Kwon YK, Suh SH, Kim JK, et al. Perilla frutescens Extract Ameliorates Acetylcholinesterase and Trimethyltin Chloride-Induced Neurotoxicity. Journal of medicinal food. 2016;19(3):281-9.

Choi SS, Lee S-R, Lee HJ. Neurorestorative Role of Stem Cells in Alzheimer's Disease: Astrocyte Involvement. Current Alzheimer research. 2016;13(4):419-27.

Choi Y, Jeong HJ, Liu QF, Oh ST, Koo B-S, Kim Y, et al. Clozapine Improves Memory Impairment and Reduces Abeta Level in the Tg-APPswe/PS1dE9 Mouse Model of Alzheimer's Disease. Molecular neurobiology. 2017;54(1):450-60.

Choi Y, Lee K, Ryu J, Kim HG, Jeong AY, Woo R-S, et al. Neuritin attenuates cognitive function impairments in tg2576 mouse model of Alzheimer's disease. PloS one. 2014;9(8):e104121.

Choi Y-H, Kwon H-S, Shin S-G, Chung C-K. Vaccinium uliginosum L. Improves Amyloid beta Protein-Induced Learning and Memory Impairment in Alzheimer's Disease in Mice. Preventive nutrition and food science. 2014;19(4):343-7.

Choi Y-J, Om J-Y, Kim N-H, Chang J-E, Park JH, Kim J-Y, et al. Heat shock transcription factor-1 suppresses apoptotic cell death and ROS generation in 3-nitropropionic acid-stimulated striatal cells. *Molecular and cellular biochemistry*. 2013;375(1-2):59-67.

Choi YY, Maeda T, Fujii H, Yokozawa T, Kim HY, Cho EJ, et al. Oligonol improves memory and cognition under an amyloid beta(25-35)-induced Alzheimer's mouse model. *Nutrition research (New York, NY)*. 2014;34(7):595-603.

Chojnacki JE, Liu K, Yan X, Toldo S, Selden T, Estrada M, et al. Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid 2-(5-methoxy-1H-indol-3-yl)-ethyl -amide as a neuroprotectant for Alzheimer's disease by hybridization of curcumin and melatonin. *ACS chemical neuroscience*. 2014;5(8):690-9.

Chongtham A, Agrawal N. Curcumin modulates cell death and is protective in Huntington's disease model. *Scientific reports*. 2016;6:18736.

Chopra V, Quinti L, Khanna P, Paganetti P, Kuhn R, Young AB, et al. LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease. *Journal of Huntington's disease*. 2016;5(4):347-55.

Chou T-F, Bulfer SL, Weihl CC, Li K, Lis LG, Walters MA, et al. Specific inhibition of p97/VCP ATPase and kinetic analysis demonstrate interaction between D1 and D2 ATPase domains. *Journal of molecular biology*. 2014;426(15):2886-99.

Chouraki V, Reitz C, Maury F, Bis JC, Bellenguez C, Yu L, et al. Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;53(3):921-32.

Christopher L, Napolioni V, Khan RR, Han SS, Greicius MD, Alzheimer's Disease Neuroimaging I. A variant in PPP4R3A protects against Alzheimer-related metabolic decline. *Annals of neurology*. 2017.

Chu C, Zhang X, Ma W, Li L, Wang W, Shang L, et al. Induction of autophagy by a novel small molecule improves abeta pathology and ameliorates cognitive deficits. *PloS one*. 2013;8(6):e65367.

Chu J, Li JG, Giannopoulos PF, Blass BE, Childers W, Abou-Gharbia M, et al. Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Abeta and tau neuropathology in the triple-transgenic mice. *Molecular psychiatry*. 2015;20(11):1329-38.

Chu J, Li J-G, Pratico D. Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles. *PloS one*. 2013;8(8):e70991.

Chu M-T, Khosla R, Khaksar SMS, Nguyen K. Service innovation through social robot engagement to improve dementia care quality. *Assistive technology : the official journal of RESNA*. 2017;29(1):8-18.

Chu S, Gu J, Feng L, Liu J, Zhang M, Jia X, et al. Ginsenoside Rg5 improves cognitive dysfunction and beta-amyloid deposition in STZ-induced memory impaired rats via attenuating neuroinflammatory responses. *International immunopharmacology*. 2014;19(2):317-26.

Chu S, Liu S, Duan W, Cheng Y, Jiang X, Zhu C, et al. The anti-dementia drug candidate, (-)-clausenamide, improves memory impairment through its multi-target effect. *Pharmacology & therapeutics*. 2016;162:179-87.

Chua L-M, Lim M-L, Wong B-S. The Kunitz-protease inhibitor domain in amyloid precursor protein reduces cellular mitochondrial enzymes expression and function. *Biochemical and biophysical research communications*. 2013;437(4):642-7.

Chun YS, Kim J, Chung S, Khorombi E, Naidoo D, Nthambeleni R, et al. Protective Roles of *Monsonia angustifolia* and Its Active Compounds in Experimental Models of Alzheimer's Disease. *Journal of agricultural and food chemistry*. 2017;65(15):3133-40.

Chung J, Choi S-I, Kim J. Experience of media presentations for the alleviation of agitation and emotional distress among dementia patients in a long-term nursing facility. *Dementia (London, England)*. 2016;15(5):1021-33.

Chung YJ, Lee BI, Ko JW, Park CB. Alzheimer Therapy: Photoactive g-C3 N4 Nanosheets for Light-Induced Suppression of Alzheimer's beta-Amyloid Aggregation and Toxicity (*Adv. Healthcare Mater.* 13/2016). *Advanced healthcare materials*. 2016;5(13):1526.

Chung YJ, Lee BI, Ko JW, Park CB. Photoactive g-C3 N4 Nanosheets for Light-Induced Suppression of Alzheimer's beta-Amyloid Aggregation and Toxicity. *Advanced healthcare materials*. 2016;5(13):1560-5.

Cifelli JL, Chung TS, Liu H, Prangkio P, Mayer M, Yang J. Benzothiazole Amphiphiles Ameliorate Amyloid beta-Related Cell Toxicity and Oxidative Stress. *ACS chemical neuroscience*. 2016;7(6):682-8.

Cimini A, Gentile R, Angelucci F, Benedetti E, Pitari G, Giordano A, et al. Neuroprotective effects of PrxI over-expression in an in vitro human Alzheimer's disease model. *Journal of cellular biochemistry*. 2013;114(3):708-15.

Cimini A, Gentile R, D'Angelo B, Benedetti E, Cristiano L, Avantaggiati ML, et al. Cocoa powder triggers neuroprotective and preventive effects in a human Alzheimer's disease model by modulating BDNF signaling pathway. *Journal of cellular biochemistry*. 2013;114(10):2209-20.

Cioanca O, Hritcu L, Mihasan M, Hancianu M. Cognitive-enhancing and antioxidant activities of inhaled coriander volatile oil in amyloid beta(1-42) rat model of Alzheimer's disease. *Physiology & behavior*. 2013;120:193-202.

Cipolotti L, Healy C, Spano B, Lecce F, Biondo F, Robinson G, et al. Strategy and suppression impairments after right lateral prefrontal and orbito-frontal lesions. *Brain : a journal of neurology*. 2016;139(Pt 2):e10.

Cirillo C, Capoccia E, Iuvone T, Cuomo R, Sarnelli G, Steardo L, et al. S100B Inhibitor Pentamidine Attenuates Reactive Gliosis and Reduces Neuronal Loss in a Mouse Model of Alzheimer's Disease. *BioMed research international*. 2015;2015:508342.

Ciro CA, Hershey LA, Garrison D. Enhanced task-oriented training in a person with dementia with Lewy bodies. *The American journal of occupational therapy : official publication of the American Occupational Therapy Association*. 2013;67(5):556-63.

Cisek K, Cooper GL, Huseby CJ, Kuret J. Structure and mechanism of action of tau aggregation inhibitors. *Current Alzheimer research*. 2014;11(10):918-27.

Cisse M, Duplan E, Lorivel T, Dunys J, Bauer C, Meckler X, et al. The transcription factor XBP1s restores hippocampal synaptic plasticity and memory by control of the Kalirin-7 pathway in Alzheimer model. *Molecular psychiatry*. 2017;22(11):1562-75.

Cisternas P, Lindsay CB, Salazar P, Silva-Alvarez C, Retamales RM, Serrano FG, et al. The increased potassium intake improves cognitive performance and attenuates histopathological markers in a model of Alzheimer's disease. *Biochimica et biophysica acta*. 2015;1852(12):2630-44.

Citron BA, Saykally JN, Cao C, Dennis JS, Runfeldt M, Arendash GW. Transcription factor Sp1 inhibition, memory, and cytokines in a mouse model of Alzheimer's disease. *American journal of neurodegenerative disease*. 2015;4(2):40-8.

Claassen JAHR. New cardiovascular targets to prevent late onset Alzheimer disease. *European journal of pharmacology*. 2015;763(Pt A):131-4.

Clare L, Nelis SM, Quinn C, Martyr A, Henderson C, Hindle JV, et al. Improving the experience of dementia and enhancing active life--living well with dementia: study protocol for the IDEAL study. *Health and quality of life outcomes*. 2014;12:164.

Clare L, Whitaker R, Woods RT, Quinn C, Jelley H, Hoare Z, et al. AwareCare: a pilot randomized controlled trial of an awareness-based staff training intervention to improve quality of life for residents with severe dementia in long-term care settings. *International psychogeriatrics*. 2013;25(1):128-39.

Clarelli F, Mascia E, Santangelo R, Mazzeo S, Giacalone G, Galimberti D, et al. CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients. *Journal of Alzheimer's disease : JAD*. 2016;52(4):1203-8.

Clark CN, Downey LE, Golden HL, Fletcher PD, de Silva R, Cifelli A, et al. "The mind is its own place": amelioration of claustrophobia in semantic dementia. *Behavioural neurology*. 2014;2014:584893.

Clark LR, Kosciak RL, Nicholas CR, Okonkwo OC, Engelman CD, Bratzke LC, et al. Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative Data. *Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists*. 2016.

Clark LR, Racine AM, Kosciak RL, Okonkwo OC, Engelman CD, Carlsson CM, et al. Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016;12(7):805-14.

Clarke PB, Shaw EG, Villalba JA, Alli R, Sink KM. Therapeutic interactions to enhance the mental health and wellness of dementia caregivers and patients. *Journal of gerontological nursing*. 2013;39(11):7-10.

Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, et al. Long Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease Dementia. *Journal of Alzheimer's disease : JAD*. 2015;45(4):1269-70.

Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. *Journal of Alzheimer's disease : JAD*. 2015;44(3):897-906.

Clemens LE, Weber JJ, Wlodkowski TT, Yu-Taeger L, Michaud M, Calaminus C, et al. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. *Brain : a journal of neurology*. 2015;138(Pt 12):3632-53.

Clementi ME, Tringali G, Triggiani D, Giardina B. Aloe arborescens Extract Protects IMR-32 Cells against Alzheimer Amyloid Beta Peptide via Inhibition of Radical Peroxide Production. *Natural product communications*. 2015;10(11):1993-5.

Clifford KM, Samboju V, Cobigo Y, Milanini B, Marx GA, Hellmuth JM, et al. Progressive Brain Atrophy Despite Persistent Viral Suppression in HIV Patients Older Than 60 Years. *Journal of acquired immune deficiency syndromes (1999)*. 2017;76(3):289-97.

Coart E, Barrado LG, Duits FH, Scheltens P, van der Flier WM, Teunissen CE, et al. Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2015;46(4):889-99.

Coca A, Monteagudo E, Domenech M, Camafort M, Sierra C. Can the Treatment of Hypertension in the Middle-Aged Prevent Dementia in the Elderly? High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension. 2016;23(2):97-104.

Cochran JN, Diggs PV, Nebane NM, Rasmussen L, White EL, Bostwick R, et al. AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for Alzheimer disease. *Journal of biomolecular screening*. 2014;19(10):1338-49.

Cockbain BC, Thompson S, Salisbury H, Mitter P, Martos L. A collaborative strategy to improve geriatric medical education. *Age and ageing*. 2015;44(6):1036-9.

Coelho FGdM, Andrade LP, Pedroso RV, Santos-Galduroz RF, Gobbi S, Costa JLR, et al. Multimodal exercise intervention improves frontal cognitive functions and gait in Alzheimer's disease: a controlled trial. *Geriatrics & gerontology international*. 2013;13(1):198-203.

Coffey EE, Beckel JM, Laties AM, Mitchell CH. Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer's disease-linked presenilin 1 A246E mutation can be reversed with cAMP. *Neuroscience*. 2014;263:111-24.

Coffey SR, Bragg RM, Minnig S, Ament SA, Cantle JP, Glickenhau A, et al. Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington's disease. *PloS one*. 2017;12(4):e0175968.

Cohen A, Lerner-Yardeni J, Meridor D, Kasher R, Nathan I, Parola AH. Humanin Derivatives Inhibit Necrotic Cell Death in Neurons. *Molecular medicine (Cambridge, Mass)*. 2015;21:505-14.

Cohen AD, Aizenstein HJ. Brain Amyloidosis and Triglycerides: Preventing Alzheimer Disease Pathology by Treating Vascular Disease? *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2016;24(8):613-4.

Coley N, Andrieu S, Group MS. Lessons from the Multidomain Alzheimer Preventive Trial - Authors' reply. *The Lancet Neurology*. 2017;16(8):586.

Coley N, Gallini A, Andrieu S. Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics. *CNS drugs*. 2015;29(7):519-28.

Coley N, Gallini A, Ousset P-J, Vellas B, Andrieu S, GuidAge study g. Evaluating the clinical relevance of a cognitive composite outcome measure: An analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016;12(12):1216-25.

Colin J, Thomas MH, Gregory-Paaron L, Pincon A, Lanhers M-C, Corbier C, et al. Maintenance of membrane organization in the aging mouse brain as the determining factor for preventing receptor dysfunction and for improving response to anti-Alzheimer treatments. *Neurobiology of aging*. 2017;54:84-93.

Colle D, Santos DB, Moreira ELG, Hartwig JM, dos Santos AA, Zimmermann LT, et al. Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats. *PloS one*. 2013;8(6):e67658.

Colombo L, Gamba A, Canto L, Salmona M, Tagliavini F, Rondelli V, et al. Pathogenic Abeta A2V versus protective Abeta A2T mutation: Early stage aggregation and membrane interaction. *Biophysical chemistry*. 2017;229:11-8.

Colom-Cadena M, Gelpi E, Marti MJ, Charif S, Dols-Icardo O, Blesa R, et al. MAPT H1 haplotype is associated with enhanced alpha-synuclein deposition in dementia with Lewy bodies. *Neurobiology of aging*. 2013;34(3):936-42.

Conejero-Goldberg C, Gomar JJ, Bobes-Bascaran T, Hyde TM, Kleinman JE, Herman MM, et al. APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms. *Molecular psychiatry*. 2014;19(11):1243-50.

Conejero-Goldberg C, Hyde TM, Chen S, Herman MM, Kleinman JE, Davies P, et al. Cortical Transcriptional Profiles in APOE4 Carriers with Alzheimer's Disease: Patterns of Protection and Degeneration. *Journal of Alzheimer's disease : JAD*. 2015;48(4):969-78.

Conforti P, Mas Monteys A, Zuccato C, Buckley NJ, Davidson B, Cattaneo E. In vivo delivery of DN:REST improves transcriptional changes of REST-regulated genes in HD mice. *Gene therapy*. 2013;20(6):678-85.

Conforti P, Zuccato C, Gaudenzi G, Ieraci A, Camnasio S, Buckley NJ, et al. Binding of the repressor complex REST-mSIN3b by small molecules restores neuronal gene transcription in Huntington's disease models. *Journal of neurochemistry*. 2013;127(1):22-35.

Cong W-N, Chadwick W, Wang R, Daimon CM, Cai H, Amma J, et al. Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model. *The Journal of biological chemistry*. 2015;290(5):2728-43.

Connolly C, Magnusson-Lind A, Lu G, Wagner PK, Southwell AL, Hayden MR, et al. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin. *Neuroscience*. 2016;325:74-88.

Consortium HDI. Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice. *Nature neuroscience*. 2017;20(5):648-60.

Cook CJ, Fletcher JM. Can education rescue genetic liability for cognitive decline? *Social science & medicine* (1982). 2015;127:159-70.

Cooper C, Mukadam N, Katona C, Lyketsos CG, Blazer D, Ames D, et al. Systematic review of the effectiveness of pharmacologic interventions to improve quality of life and well-being in people with dementia. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2013;21(2):173-83.

Cooper S-A, Caslake M, Evans J, Hassiotis A, Jahoda A, McConnachie A, et al. Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial. *Trials*. 2014;15:202.

Corbett A, Achterberg W, Husebo B, Lobbezoo F, de Vet H, Kunz M, et al. An international road map to improve pain assessment in people with impaired cognition: the development of the Pain Assessment in Impaired Cognition (PAIC) meta-tool. *BMC neurology*. 2014;14:229.

Corbett A, Ballard C. The value of vitamin E as a treatment for Alzheimer's disease remains unproven despite functional improvement, due to a lack of established effect on cognition or other outcomes from RCTs. *Evidence-based medicine*. 2014;19(4):140.

Corbett GT, Roy A, Pahan K. Sodium phenylbutyrate enhances astrocytic neurotrophin synthesis via protein kinase C (PKC)-mediated activation of cAMP-response element-binding protein (CREB): implications for Alzheimer disease therapy. *The Journal of biological chemistry*. 2013;288(12):8299-312.

Corbyn Z. New set of Alzheimer's trials focus on prevention. *Lancet* (London, England). 2013;381(9867):614-5.

Cornejo A, Aguilar Sandoval F, Caballero L, Machuca L, Munoz P, Caballero J, et al. Rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to beta sheet in tau protein linked to Alzheimer's disease. *Journal of enzyme inhibition and medicinal chemistry*. 2017;32(1):945-53.

Correction for the article "Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Disorders?" by Moussa B. H. Youdim. *Rambam Maimonides medical journal*. 2015;6(4).

Correction to: Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions: Magnetic Resonance Imaging Substudy of the PreDIVA Trial (Prevention of Dementia by Intensive Vascular Care). *Stroke*. 2017;48(9):e270.

Corrigan F, Arulsamy A, Teng J, Collins-Praino LE. Pumping the Brakes: Neurotrophic Factors for the Prevention of Cognitive Impairment and Dementia after Traumatic Brain Injury. *Journal of neurotrauma*. 2017;34(5):971-86.

Cortes N, Alvarez R, Osorio EH, Alzate F, Berkov S, Osorio E. Alkaloid metabolite profiles by GC/MS and acetylcholinesterase inhibitory activities with binding-mode predictions of five Amaryllidaceae plants. *Journal of pharmaceutical and biomedical analysis*. 2015;102:222-8.

Costa M, Bernardi J, Fiuza T, Costa L, Brandao R, Pereira ME. N-acetylcysteine protects memory decline induced by streptozotocin in mice. *Chemico-biological interactions*. 2016;253:10-7.

Costa V, Brighina F, Piccoli T, Realmuto S, Fierro B. Anodal transcranial direct current stimulation over the right hemisphere improves auditory comprehension in a case of dementia. *NeuroRehabilitation*. 2017;41(2):567-75.

Coulson EJ, Bartlett PF. An exercise path to preventing Alzheimer's disease: An Editorial Highlight on 'Exercise and BDNF reduce Ab production by enhancing alpha-secretase processing of APP'. *Journal of neurochemistry*. 2017;142(2):191-3.

Counts SE, Lahiri DK. Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD. *Current Alzheimer research*. 2014;11(7):623-5.

Counts SE, Perez SE, He B, Mufson EJ. Intravenous immunoglobulin reduces tau pathology and preserves neuroplastic gene expression in the 3xTg mouse model of Alzheimer's disease. *Current Alzheimer research*. 2014;11(7):655-63.

Coutadeur S, Benyamine H, Delalonde L, de Oliveira C, Leblond B, Foucourt A, et al. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro. *Journal of neurochemistry*. 2015;133(3):440-51.

Coutellier L, Ardestani PM, Shamloo M. beta1-adrenergic receptor activation enhances memory in Alzheimer's disease model. *Annals of clinical and translational neurology*. 2014;1(5):348-60.

Couttas TA, Kain N, Daniels B, Lim XY, Shepherd C, Kril J, et al. Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. *Acta neuropathologica communications*. 2014;2:9.

Cove J, Jacobi N, Donovan H, Orrell M, Stott J, Spector A. Effectiveness of weekly cognitive stimulation therapy for people with dementia and the additional impact of enhancing cognitive stimulation therapy with a carer training program. *Clinical interventions in aging*. 2014;9:2143-50.

Covey DP, Dantrassy HM, Zlebnik NE, Gildish I, Cheer JF. Compromised Dopaminergic Encoding of Reward Accompanying Suppressed Willingness to Overcome High Effort Costs Is a Prominent Prodromal Characteristic of the Q175 Mouse Model of Huntington's Disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2016;36(18):4993-5002.

Cox CJ, Choudhry F, Peacey E, Perkinson MS, Richardson JC, Howlett DR, et al. Dietary (-)-epicatechin as a potent inhibitor of betagamma-secretase amyloid precursor protein processing. *Neurobiology of aging*. 2015;36(1):178-87.

Cox K, Combs B, Abdelmesih B, Morfini G, Brady ST, Kanaan NM. Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition. *Neurobiology of aging*. 2016;47:113-26.

Coyle C, Prynne J, Kingdon S. Use of information technology and education improved screening for cognitive impairment in the over 65s. *Clinical medicine (London, England)*. 2016;16 Suppl 3:s26.

Crawford TJ, Higham S, Mayes J, Dale M, Shaunak S, Lekwuwa G. The role of working memory and attentional disengagement on inhibitory control: effects of aging and Alzheimer's disease. *Age (Dordrecht, Netherlands)*. 2013;35(5):1637-50.

Crawford TJ, Higham S. Distinguishing between impairments of working memory and inhibitory control in cases of early dementia. *Neuropsychologia*. 2016;81:61-7.

Crehan H, Hardy J, Pocock J. Blockage of CR1 prevents activation of rodent microglia. *Neurobiology of disease*. 2013;54:139-49.

Crenshaw DG, Gottschalk WK, Lutz MW, Grossman I, Saunders AM, Burke JR, et al. Using genetics to enable studies on the prevention of Alzheimer's disease. *Clinical pharmacology and therapeutics*. 2013;93(2):177-85.

Crespo MC, Tome-Carneiro J, Pintado C, Davalos A, Visioli F, Burgos-Ramos E. Hydroxytyrosol restores proper insulin signaling in an astrocytic model of Alzheimer's disease. *BioFactors (Oxford, England)*. 2017;43(4):540-8.

Criscuolo C, Fabiani C, Bonadonna C, Origlia N, Domenici L. BDNF prevents amyloid-dependent impairment of LTP in the entorhinal cortex by attenuating p38 MAPK phosphorylation. *Neurobiology of aging*. 2015;36(3):1303-9.

Criscuolo C, Fabiani C, Cerri E, Domenici L. Synaptic Dysfunction in Alzheimer's Disease and Glaucoma: From Common Degenerative Mechanisms Toward Neuroprotection. *Frontiers in cellular neuroscience*. 2017;11:53.

Criscuolo C, Fontebasso V, Middei S, Stazi M, Ammassari-Teule M, Yan SS, et al. Entorhinal Cortex dysfunction can be rescued by inhibition of microglial RAGE in an Alzheimer's disease mouse model. *Scientific reports*. 2017;7:42370.

Croce N, Gelfo F, Ciotti MT, Federici G, Caltagirone C, Bernardini S, et al. NPY modulates miR-30a-5p and BDNF in opposite direction in an in vitro model of Alzheimer disease: a possible role in neuroprotection? *Molecular and cellular biochemistry*. 2013;376(1-2):189-95.

Croft CL, Kurbatskaya K, Hanger DP, Noble W. Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimer's disease. *Scientific reports*. 2017;7(1):7434.

Crook N, Adams M, Shorten N, Langdon PE. Does the Well-Being of Individuals with Down Syndrome and Dementia Improve When Using Life Story Books and Rummage Boxes? A Randomized Single Case Series Experiment. *Journal of applied research in intellectual disabilities : JARID*. 2016;29(1):1-10.

Crous-Bou M, Minguillon C, Gramunt N, Molinuevo JL. Alzheimer's disease prevention: from risk factors to early intervention. *Alzheimer's research & therapy*. 2017;9(1):71.

Crunkhorn S. Alzheimer disease: Antisense oligonucleotide reverses tau pathology. *Nature reviews Drug discovery*. 2017;16(3):166.

Crunkhorn S. Alzheimer disease: BACE1 inhibitor reduces beta-amyloid production in humans. *Nature reviews Drug discovery*. 2016;16(1):18.

Crunkhorn S. Alzheimer disease: Identification of novel Abeta inhibitors. *Nature reviews Drug discovery*. 2017;16(2):88.

Cruz-Oliver DM, Malmstrom TK, Roegner M, Tumosa N, Grossberg GT. Cognitive deficit reversal as shown by changes in the Veterans Affairs Saint Louis University Mental Status (SLUMS) examination scores 7.5 years later. *Journal of the American Medical Directors Association*. 2014;15(9):687.e5-10.

Csukly G, Siraly E, Hidasi Z, Salacz P, Szabo A, Csibri E. Pharmacological and other options in preventing dementia: a literature review. *Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology*. 2014;16(3):121-6.

Cuadrado-Tejedor M, Garcia-Barroso C, Sanchez-Arias JA, Rabal O, Perez-Gonzalez M, Mederos S, et al. A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice. *Neuropsychopharmacology* : official publication of the American College of Neuropsychopharmacology. 2017;42(2):524-39.

Cuadrado-Tejedor M, Garcia-Barroso C, Sanchez-Arias J, Mederos S, Rabal O, Ugarte A, et al. Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease. *Clinical epigenetics*. 2015;7:108.

Cuadrado-Tejedor M, Ricobaraza AL, Torrijo R, Franco R, Garcia-Osta A. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimers disease-like phenotype of a commonly used mouse model. *Current pharmaceutical design*. 2013;19(28):5076-84.

Cuddy LL, Sikka R, Vanstone A. Preservation of musical memory and engagement in healthy aging and Alzheimer's disease. *Annals of the New York Academy of Sciences*. 2015;1337:223-31.

Cuesta M, Aungier J, Morton AJ. Behavioral therapy reverses circadian deficits in a transgenic mouse model of Huntington's disease. *Neurobiology of disease*. 2014;63:85-91.

Cui G-h, Shao S-j, Yang J-j, Liu J-r, Guo H-d. Designer Self-Assemble Peptides Maximize the Therapeutic Benefits of Neural Stem Cell Transplantation for Alzheimer's Disease via Enhancing Neuron Differentiation and Paracrine Action. *Molecular neurobiology*. 2016;53(2):1108-23.

Cui J, Jothishankar B, He P, Staufenbiel M, Shen Y, Li R. Amyloid precursor protein mutation disrupts reproductive experience-enhanced normal cognitive development in a mouse model of Alzheimer's disease. *Molecular neurobiology*. 2014;49(1):103-12.

Cui J, Wang X, Li X, Wang X, Zhang C, Li W, et al. Targeting the gamma-/beta-secretase interaction reduces beta-amyloid generation and ameliorates Alzheimer's disease-related pathogenesis. *Cell discovery*. 2015;1:15021.

Cui L, Cai Y, Cheng W, Liu G, Zhao J, Cao H, et al. A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice by Inhibiting Abeta Aggregation and Blocking the RAGE/Abeta Axis. *Molecular neurobiology*. 2017;54(3):1939-52.

Cui W, Wang S, Wang Z, Wang Z, Sun C, Zhang Y. Inhibition of PTEN Attenuates Endoplasmic Reticulum Stress and Apoptosis via Activation of PI3K/AKT Pathway in Alzheimer's Disease. *Neurochemical research*. 2017;42(11):3052-60.

Cui W, Zhang Y, Yang C, Sun Y, Zhang M, Wang S. Hydrogen sulfide prevents Abeta-induced neuronal apoptosis by attenuating mitochondrial translocation of PTEN. *Neuroscience*. 2016;325:165-74.

Cui Y, Ma S, Zhang C, Cao W, Liu M, Li D, et al. Human umbilical cord mesenchymal stem cells transplantation improves cognitive function in Alzheimer's disease mice by decreasing oxidative stress and promoting hippocampal neurogenesis. *Behavioural brain research*. 2017;320:291-301.

Cui Y, Ma S, Zhang C, Li D, Yang B, Lv P, et al. Pharmacological activation of the Nrf2 pathway by 3H-1, 2-dithiole-3-thione is neuroprotective in a mouse model of Alzheimer disease. *Behavioural brain research*. 2017;336:219-26.

Cui Y-Q, Wang Q, Zhang D-M, Wang J-Y, Xiao B, Zheng Y, et al. Triptolide Rescues Spatial Memory Deficits and Amyloid-beta Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice. *Current Alzheimer research*. 2016;13(3):288-96.

Cunnane SC, Courchesne-Loyer A, Vandenberghe C, St-Pierre V, Fortier M, Hennebelle M, et al. Can Ketones Help Rescue Brain Fuel Supply in Later Life? Implications for Cognitive Health during Aging and the Treatment of Alzheimer's Disease. *Frontiers in molecular neuroscience*. 2016;9:53.

Curatolo M, La Bianca G, Cosentino G, Baschi R, Salemi G, Talotta R, et al. Motor cortex tRNS improves pain, affective and cognitive impairment in patients with fibromyalgia: preliminary results of a randomised sham-controlled trial. *Clinical and experimental rheumatology*. 2017;35 Suppl 105(3):100-5.

Currais A, Chiruta C, Goujon-Svrzic M, Costa G, Santos T, Batista MT, et al. Screening and identification of neuroprotective compounds relevant to Alzheimer's disease from medicinal plants of S. Tome e Principe. *Journal of ethnopharmacology*. 2014;155(1):830-40.

Cusin C, Franco FB, Fernandez-Robles C, DuBois CM, Welch CA. Rapid improvement of depression and psychotic symptoms in Huntington's disease: a retrospective chart review of seven patients treated with electroconvulsive therapy. *General hospital psychiatry*. 2013;35(6):678.e3-5.

Cutler T, Sarkar A, Moran M, Steffensmeier A, Puli OR, Mancini G, et al. Drosophila Eye Model to Study Neuroprotective Role of CREB Binding Protein (CBP) in Alzheimer's Disease. *PloS one*. 2015;10(9):e0137691.

da Costa Dias FL, Ferreira Lisboa da Silva RM, de Moraes EN, Caramelli P. Cholinesterase inhibitors modulate autonomic function in patients with Alzheimers disease and mixed dementia. *Current Alzheimer research*. 2013;10(5):476-81.

da Costa M, Bernardi J, Costa L, Fiuza T, Brandao R, Ribeiro MF, et al. N-acetylcysteine treatment attenuates the cognitive impairment and synaptic plasticity loss induced by streptozotocin. *Chemico-biological interactions*. 2017;272:37-46.

Da Pozzo E, La Pietra V, Cosimelli B, Da Settimo F, Giacomelli C, Marinelli L, et al. p53 functional inhibitors behaving like pifithrin-beta counteract the Alzheimer peptide non-beta-amyloid component effects in human SH-SY5Y cells. *ACS chemical neuroscience*. 2014;5(5):390-9.

Dacks PA, Andrieu S, Blacker D, Carman AJ, Green AM, Grodstein F, et al. Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making. *The journal of prevention of Alzheimer's disease*. 2014;1(2):117-23.

Dacks PA, Armstrong JJ, Brannan SK, Carman AJ, Green AM, Kirkman MS, et al. A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. *Alzheimer's research & therapy*. 2016;8:33.

Dacks PA, Shineman DW, Fillit HM. Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease. *The journal of nutrition, health & aging*. 2013;17(3):240-51.

Dadashpour S, Tuylu Kucukkilinc T, Unsal Tan O, Ozadali K, Irannejad H, Emami S. Design, synthesis and in vitro study of 5,6-diaryl-1,2,4-triazine-3-ylthioacetate derivatives as COX-2 and beta-amyloid aggregation inhibitors. *Archiv der Pharmazie*. 2015;348(3):179-87.

Dagher NN, Najafi AR, Kayala KMN, Elmore MRP, White TE, Medeiros R, et al. Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. *Journal of neuroinflammation*. 2015;12:139.

Daher O, Nguyen S, Smith C, Bula C, Demonet J-F. Dementia: management and prevention. *Revue medicale suisse*. 2016;12(515):799-802.

Dai C-l, Chen X, Kazim SF, Liu F, Gong C-X, Grundke-Iqbal I, et al. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. *Journal of neural transmission (Vienna, Austria : 1996)*. 2015;122(4):607-17.

Dai C-L, Tung YC, Liu F, Gong C-X, Iqbal K. Tau passive immunization inhibits not only tau but also Abeta pathology. *Alzheimer's research & therapy*. 2017;9(1):1.

Dai Y, Ma T, Ren X, Wei J, Fu W, Ma Y, et al. Tongluo Xingnao Effervescent Tablet preserves mitochondrial energy metabolism and attenuates cognition deficits in APPswe/PS1De9 mice. *Neuroscience letters*. 2016;630:101-8.

Daianu M, Jahanshad N, Mendez MF, Bartzokis G, Jimenez EE, Thompson PM. Communication of brain network core connections altered in behavioral variant frontotemporal dementia but possibly preserved in early-onset Alzheimer's disease. *Proceedings of SPIE--the International Society for Optical Engineering*. 2015;9413.

Daiello LA, Gongvatana A, Dunsiger S, Cohen RA, Ott BR, Alzheimer's Disease Neuroimaging I. Association of fish oil supplement use with preservation of brain volume and cognitive function. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2015;11(2):226-35.

Dallerac G, Rouach N. Astrocytes as new targets to improve cognitive functions. *Progress in neurobiology*. 2016;144:48-67.

Dal-Pan A, Dudonne S, Bourassa P, Bourdoulous M, Tremblay C, Desjardins Y, et al. Cognitive-Enhancing Effects of a Polyphenols-Rich Extract from Fruits without Changes in Neuropathology in an Animal Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;55(1):115-35.

Damar U, Gersner R, Johnstone JT, Schachter S, Rotenberg A. Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease. *Medical hypotheses*. 2017;99:57-62.

Daneschvar HL, Aronson MD, Smetana GW. Do statins prevent Alzheimer's disease? A narrative review. *European journal of internal medicine*. 2015;26(9):666-9.

Daneshmand P, Saliminejad K, Dehghan Shasaltaneh M, Kamali K, Riazi GH, Nazari R, et al. Neuroprotective Effects of Herbal Extract (Rosa canina, Tanacetum vulgare and Urtica dioica) on Rat Model of Sporadic Alzheimer's Disease. *Avicenna journal of medical biotechnology*. 2016;8(3):120-5.

D'Angelo GM, Weissfeld LA. Application of copulas to improve covariance estimation for partial least squares. *Statistics in medicine*. 2013;32(4):685-96.

Daniell H, Chan H-T, Pasoreck EK. Vaccination via Chloroplast Genetics: Affordable Protein Drugs for the Prevention and Treatment of Inherited or Infectious Human Diseases. *Annual review of genetics*. 2016;50:595-618.

Daniels MJD, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. *Nature communications*. 2016;7:12504.

Danucalov MA, Kozasa EH, Afonso RF, Galduroz JC, Leite JR. Yoga and compassion meditation program improve quality of life and self-compassion in family caregivers of Alzheimer's disease patients: A randomized controlled trial. *Geriatrics & gerontology international*. 2017;17(1):85-91.

Dao AT, Zagaar MA, Alkadhi KA. Correction to: Moderate Treadmill Exercise Protects Synaptic Plasticity of the Dentate Gyrus and Related Signaling Cascade in a Rat Model of Alzheimer's Disease. *Molecular neurobiology*. 2017.

Dao AT, Zagaar MA, Alkadhi KA. Moderate Treadmill Exercise Protects Synaptic Plasticity of the Dentate Gyrus and Related Signaling Cascade in a Rat Model of Alzheimer's Disease. *Molecular neurobiology*. 2015;52(3):1067-76.

Dao AT, Zagaar MA, Levine AT, Salim S, Eriksen JL, Alkadhi KA. Treadmill exercise prevents learning and memory impairment in Alzheimer's disease-like pathology. *Current Alzheimer research*. 2013;10(5):507-15.

Dao AT, Zagaar MA, Salim S, Eriksen JL, Alkadhi KA. Regular exercise prevents non-cognitive disturbances in a rat model of Alzheimer's disease. *The international journal of neuropsychopharmacology*. 2014;17(4):593-602.

Dao P, Ye F, Liu Y, Du ZY, Zhang K, Dong CZ, et al. Development of Phenothiazine-Based Theranostic Compounds That Act Both as Inhibitors of beta-Amyloid Aggregation and as Imaging Probes for Amyloid Plaques in Alzheimer's Disease. *ACS chemical neuroscience*. 2017;8(4):798-806.

Daria A, Colombo A, Llovera G, Hampel H, Willem M, Liesz A, et al. Young microglia restore amyloid plaque clearance of aged microglia. *The EMBO journal*. 2017;36(5):583-603.

Darlington D, Deng J, Giunta B, Hou H, Sanberg CD, Kuzmin-Nichols N, et al. Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-beta-associated neuropathology in Alzheimer mice. *Stem cells and development*. 2013;22(3):412-21.

Darlington D, Li S, Hou H, Habib A, Tian J, Gao Y, et al. Human umbilical cord blood-derived monocytes improve cognitive deficits and reduce amyloid-beta pathology in PSAPP mice. *Cell transplantation*. 2015;24(11):2237-50.

Darragh M, Ahn HS, MacDonald B, Liang A, Peri K, Kerse N, et al. Homecare Robots to Improve Health and Well-Being in Mild Cognitive Impairment and Early Stage Dementia: Results From a Scoping Study. *Journal of the American Medical Directors Association*. 2017.

Darreh-Shori T, Hosseini SM, Nordberg A. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term

treatment with rapidly reversible inhibitors. *Journal of Alzheimer's disease* : JAD. 2014;39(2):423-40.

Darrow MC, Sergeeva OA, Isas JM, Galaz-Montoya JG, King JA, Langen R, et al. Structural Mechanisms of Mutant Huntingtin Aggregation Suppression by the Synthetic Chaperonin-like CCT5 Complex Explained by Cryoelectron Tomography. *The Journal of biological chemistry*. 2015;290(28):17451-61.

Das P, Chacko AR, Belfort G. Alzheimer's Protective Cross-Interaction between Wild-Type and A2T Variants Alters Abeta42 Dimer Structure. *ACS chemical neuroscience*. 2017;8(3):606-18.

Das P, Murray B, Belfort G. Alzheimer's protective A2T mutation changes the conformational landscape of the Abeta \bullet , \bullet , \bullet , \bullet , \bullet , monomer differently than does the A2V mutation. *Biophysical journal*. 2015;108(3):738-47.

Dau A, Gladding CM, Sepers MD, Raymond LA. Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice. *Neurobiology of disease*. 2014;62:533-42.

Daulatzai MA. Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia. *Neurochemical research*. 2014;39(4):624-44.

Dautzenberg L, Jessurum N, Dautzenberg PLJ, Keijsers CJPW. Reversible Methotrexate-Induced Dementia: A Case Report. *Journal of the American Geriatrics Society*. 2015;63(6):1273-4.

Dauwan M, Begemann MJH, Heringa SM, Sommer IE. Exercise Improves Clinical Symptoms, Quality of Life, Global Functioning, and Depression in Schizophrenia: A Systematic Review and Meta-analysis. *Schizophrenia bulletin*. 2016;42(3):588-99.

Davenport A, Bivona A, Latson W, Lemanski LF, Cheriya V. Loss of Masparidin Attenuates the Growth and Maturation of Mouse Cortical Neurons. *Neuro-degenerative diseases*. 2016;16(3-4):260-72.

Davey DA. Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease. Part I: Pathology, diagnosis and screening. *Neurodegenerative disease management*. 2014;4(3):253-9.

Davey DA. Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease? Part II: Management, prevention and future perspective. *Neurodegenerative disease management*. 2014;4(3):261-70.

Davey DA. Prevention of Alzheimer's disease, cerebrovascular disease and dementia in women: the case for menopause hormone therapy. *Neurodegenerative disease management*. 2017;7(1):85-94.

Davies J, Chen J, Pink R, Carter D, Saunders N, Sotiriadis G, et al. Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103. *Scientific reports*. 2015;5:12584.

Davies R. Gill Livingston: transforming dementia prevention and care. *Lancet* (London, England). 2017.

Davis C, Mudd J, Hawkins M. Neuroprotective effects of leptin in the context of obesity and metabolic disorders. *Neurobiology of disease*. 2014;72 Pt A:61-71.

Davis K, Willink A, Amjad H. What is the potential for improving care and lowering cost for persons with dementia? *International psychogeriatrics*. 2016;28(3):357-8.

Davis PR, Head E. Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges. *Frontiers in pharmacology*. 2014;5:47.

Davison TE, Nayer K, Coxon S, de Bono A, Eppingstall B, Jeon Y-H, et al. A personalized multimedia device to treat agitated behavior and improve mood in people with dementia: A pilot study. *Geriatric nursing* (New York, NY). 2016;37(1):25-9.

Davtyan H, Ghochikyan A, Hovakimyan A, Davtyan A, Cadagan R, Marleau AM, et al. A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-beta-amyloid antibody responses in mice with pre-existing virus specific memory. *Journal of neuroimmunology*. 2014;277(1-2):77-84.

Davtyan H, Ghochikyan A, Hovakimyan A, Petrushina I, Yu J, Flyer D, et al. Immunostimulant patches containing *Escherichia coli* LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines. *Journal of neuroimmunology*. 2014;268(1-2):50-7.

Davydow DS, Zivin K, Katon WJ, Pontone GM, Chwastiak L, Langa KM, et al. Neuropsychiatric disorders and potentially preventable hospitalizations in a prospective cohort study of older Americans. *Journal of general internal medicine*. 2014;29(10):1362-71.

Dawson N, Judge KS, Gerhart H. Improved Functional Performance in Individuals With Dementia After a Moderate-Intensity Home-Based Exercise Program: A Randomized Controlled Trial. *Journal of geriatric physical therapy* (2001). 2017.

Day JJ, Roberson ED. DNA methylation slows effects of C9orf72 mutations: An epigenetic brake on genetic inheritance. *Neurology*. 2015;84(16):1616-7.

de Almeida SM, Kamat R, Cherner M, Umlauf A, Ribeiro CE, de Pereira AP, et al. Improving Detection of HIV-Associated Cognitive Impairment: Comparison of the International HIV Dementia Scale and a Brief Screening Battery. *Journal of acquired immune deficiency syndromes* (1999). 2017;74(3):332-8.

de Bruijn RFAG, Bos MJ, Portegies MLP, Hofman A, Franco OH, Koudstaal PJ, et al. The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study. *BMC medicine*. 2015;13:132.

de Candia M, Zaetta G, Denora N, Tricarico D, Majellaro M, Cellamare S, et al. New azepino 4,3-b indole derivatives as nanomolar selective inhibitors of human butyrylcholinesterase showing protective effects against NMDA-induced neurotoxicity. *European journal of medicinal chemistry*. 2017;125:288-98.

de Freitas LV, da Silva CCP, Ellena J, Costa LAS, Rey NA. Structural and vibrational study of 8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone--a potential metal-protein attenuating compound (MPAC) for the treatment of Alzheimer's disease. *Spectrochimica acta Part A, Molecular and biomolecular spectroscopy*. 2013;116:41-8.

de Haan W, van Straaten ECW, Gouw AA, Stam CJ. Altering neuronal excitability to preserve network connectivity in a computational model of Alzheimer's disease. *PLoS computational biology*. 2017;13(9):e1005707.

de Jager M, Drukarch B, Hofstee M, Breve J, Jongenelen CAM, Bol JGJM, et al. Tissue transglutaminase-catalysed cross-linking induces Apolipoprotein E multimers inhibiting Apolipoprotein E's protective effects towards amyloid-beta-induced toxicity. *Journal of neurochemistry*. 2015;134(6):1116-28.

de la Monte SM, Tong M, Schiano I, Didsbury J. Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;55(2):849-64.

de la Rubia Orti JE, Garcia-Pardo MP, Cabanes Iranzo C, Ceron Madrigal JJ, Castillo SS, Julian Rochina M, et al. Does Music Therapy Improve Anxiety and Depression in Alzheimer's Patients? *Journal of alternative and complementary medicine* (New York, NY). 2017.

de la Torre Jack C. Do We Try Mending Humpty Dumpty or Prevent His Fall? An Alzheimer's Disease Dilemma. *Journal of Alzheimer's disease : JAD*. 2015;46(2):289-96.

de la Torre JC. Cerebral Perfusion Enhancing Interventions: A New Strategy for the Prevention of Alzheimer Dementia. *Brain pathology* (Zurich, Switzerland). 2016;26(5):618-31.

de la Torre JC. Detection, prevention, and pre-clinical treatment of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;42 Suppl 4:S327-8.

de la Tremblaye PB, Bondi CO, Lajud N, Cheng JP, Radabaugh HL, Kline AE. Galantamine and Environmental Enrichment Enhance Cognitive Recovery after Experimental Traumatic Brain Injury But Do Not Confer Additional Benefits When Combined. *Journal of neurotrauma*. 2017;34(8):1610-22.

de Matos AM, de Macedo MP, Rauter AP. Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential. *Medicinal research reviews*. 2017.

de Natale ER, Paulus KS, Aiello E, Sanna B, Manca A, Sotgiu G, et al. Dance therapy improves motor and cognitive functions in patients with Parkinson's disease. *NeuroRehabilitation*. 2017;40(1):141-4.

de Oliveira FF, Bertolucci PHF, Chen ES, Smith MC. Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;42 Suppl 3:S321-4.

de Oliveira FF, Chen ES, Smith MC, Bertolucci PHF. Pharmacogenetics of angiotensin-converting enzyme inhibitors in patients with Alzheimer's disease dementia. *Current Alzheimer research*. 2017.

de Oliveira JS, Abdalla FH, Dornelles GL, Adefegha SA, Palma TV, Signor C, et al. Berberine protects against memory impairment and anxiogenic-like behavior in rats submitted to sporadic Alzheimer's-like dementia: Involvement of acetylcholinesterase and cell death. *Neurotoxicology*. 2016;57:241-50.

De Roeck A, Van den Bossche T, van der Zee J, Verheijen J, De Coster W, Van Dongen J, et al. Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. *Acta neuropathologica*. 2017.

de Souza LG, Renna MN, Figueroa-Villar JD. Coumarins as cholinesterase inhibitors: A review. *Chemico-biological interactions*. 2016;254:11-23.

de Souza Silva MA, Lenz B, Rotter A, Biermann T, Peters O, Ramirez A, et al. Neurokinin3 receptor as a target to predict and improve learning and memory in the aged organism. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(37):15097-102.

de Timary P, Maurage P. Considering Cognitive Mentalizing Deficits as a Transient and Reversible Impairment in Alcohol Dependence: A Response to Fein's Commentary on Maurage et al.'s Paper. *Alcoholism, clinical and experimental research*. 2016;40(12):2692-3.

de Vos F, Schouten TM, Hafkemeijer A, Dopper EGP, van Swieten JC, de Rooij M, et al. Combining multiple anatomical MRI measures improves Alzheimer's disease classification. *Human brain mapping*. 2016;37(5):1920-9.

de Vries K, Brooker DJ, Smith P. Dementia skills and competencies for primary care liaison: a model for improving identification and timely diagnosis. *Primary health care research & development*. 2013;14(3):240-9.

de Waal H, Stam CJ, de Haan W, van Straaten ECW, Blankenstein MA, Scheltens P, et al. Alzheimer's disease patients not carrying the apolipoprotein E epsilon4 allele show more severe slowing of oscillatory brain activity. *Neurobiology of aging*. 2013;34(9):2158-63.

Deardorff WJ, Feen E, Grossberg GT. The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease. *Drugs & aging*. 2015;32(7):537-47.

Deardorff WJ, Shobassy A, Grossberg GT. Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication. *Expert review of neurotherapeutics*. 2015;15(1):7-17.

Deason RG, Hussey EP, Flannery S, Ally BA. Preserved conceptual implicit memory for pictures in patients with Alzheimer's disease. *Brain and cognition*. 2015;99:112-7.

Deckers K, van Boxtel MPJ, Schiepers OJG, de Vugt M, Munoz Sanchez JL, Anstey KJ, et al. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. *International journal of geriatric psychiatry*. 2015;30(3):234-46.

Deguil J, Auffret A, Schenker E, Aujard F, Lamberty Y, Bartres-Faz D, et al. Editorial: Combining Forces to Improve Alzheimer's Disease Drug Discovery: The Symptomatic Battle. *CNS & neurological disorders drug targets*. 2016;15(7):754-5.

Dehnel T. The European Dementia Prevention Initiative. *The Lancet Neurology*. 2013;12(3):227-8.

DeKosky ST, Schneider LS. Preventing Dementia: Many Issues and Not Enough Time. *JAMA neurology*. 2017;74(5):508-10.

del Ser T, Steinwachs KC, Gertz HJ, Andres MV, Gomez-Carrillo B, Medina M, et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. *Journal of Alzheimer's disease : JAD*. 2013;33(1):205-15.

Deleaye S, Waldron AM, Verhaeghe J, Bottelbergs A, Wyffels L, Van Broeck B, et al. Evaluation of muPET outcome measures to detect disease modification induced by BACE inhibition in a

transgenic mouse model of Alzheimer's disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017.

Delic V, Brownlow M, Joly-Amado A, Zivkovic S, Noble K, Phan T-A, et al. Calorie restriction does not restore brain mitochondrial function in P301L tau mice, but it does decrease mitochondrial F0F1-ATPase activity. Molecular and cellular neurosciences. 2015;67:46-54.

Dementia awareness training alone 'not enough to improve care'. Nursing standard (Royal College of Nursing (Great Britain)) : 1987). 2017;31(50):17.

Demetrius LA, Driver JA. Preventing Alzheimer's disease by means of natural selection. Journal of the Royal Society, Interface. 2015;12(102):20140919.

Demirci K, Naziroglu M, Ovey IS, Balaban H. Selenium attenuates apoptosis, inflammation and oxidative stress in the blood and brain of aged rats with scopolamine-induced dementia. Metabolic brain disease. 2017;32(2):321-9.

Demirhan A, Nir TM, Zavaliangos-Petropulu A, Jack CR, Jr., Weiner MW, Bernstein MA, et al. FEATURE SELECTION IMPROVES THE ACCURACY OF CLASSIFYING ALZHEIMER DISEASE USING DIFFUSION TENSOR IMAGES. Proceedings IEEE International Symposium on Biomedical Imaging. 2015;2015:126-30.

Deng M, Huang L, Ning B, Wang N, Zhang Q, Zhu C, et al. beta-asarone improves learning and memory and reduces Acetyl Cholinesterase and Beta-amyloid 42 levels in APP/PS1 transgenic mice by regulating Beclin-1-dependent autophagy. Brain research. 2016;1652:188-94.

Deng Y, Wei J, Cheng J, Zhong P, Xiong Z, Liu A, et al. Partial Amelioration of Synaptic and Cognitive Deficits by Inhibiting Cofilin Dephosphorylation in an Animal Model of Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2016;53(4):1419-32.

Denzer I, Munch G, Pischetsrieder M, Friedland K. S-allyl-L-cysteine and isoliquiritigenin improve mitochondrial function in cellular models of oxidative and nitrosative stress. Food chemistry. 2016;194:843-8.

Derungs R, Camici GG, Spescha RD, Welt T, Tackenberg C, Spani C, et al. Genetic ablation of the p66Shc adaptor protein reverses cognitive deficits and improves mitochondrial function in an APP transgenic mouse model of Alzheimer's disease. Molecular psychiatry. 2017;22(4):605-14.

Descamps O, Spilman P, Zhang Q, Libeu CP, Poksay K, Gorostiza O, et al. AbetaPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for alzheimer's disease. Journal of Alzheimer's disease : JAD. 2013;37(2):343-55.

Deshmukh R, Kaundal M, Bansal V, Samardeep. Caffeic acid attenuates oxidative stress, learning and memory deficit in intra-cerebroventricular streptozotocin induced experimental

dementia in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016;81:56-62.

Desmidt T, Hommet C, Camus V. Pharmacological treatments of behavioral and psychological symptoms of dementia in Alzheimer's disease: role of acetylcholinesterase inhibitors and memantine. *Geriatric et psychologie neuropsychiatrie du vieillissement*. 2016;14(3):300-6.

Dessolin J. N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta e 1,3 oxazin-4-yl)-phenyl)-amides as BACE1 inhibitors: a patent evaluation of WO2013041499. Expert opinion on therapeutic patents. 2014;24(2):239-42.

Detrait E, Maurice T, Hanon E, Leclercq K, Lamberty Y. Lack of synaptic vesicle protein SV2B protects against amyloid-beta β , β ,... β , β -induced oxidative stress, cholinergic deficit and cognitive impairment in mice. *Behavioural brain research*. 2014;271:277-85.

Deutsch SI, Burket JA, Benson AD. Targeting the alpha7 nicotinic acetylcholine receptor to prevent progressive dementia and improve cognition in adults with Down's syndrome. *Progress in neuro-psychopharmacology & biological psychiatry*. 2014;54:131-9.

Devanand DP, Lentz C, Chunga RE, Ciarleglio A, Scodes JM, Andrews H, et al. Change in Odor Identification Impairment is Associated with Improvement with Cholinesterase Inhibitor Treatment in Mild Cognitive Impairment. *Journal of Alzheimer's disease : JAD.* 2017;60(4):1525-31.

Devi L, Ohno M. Deletion of the eIF2alpha Kinase GCN2 fails to rescue the memory decline associated with Alzheimer's disease. *PloS one*. 2013;8(10):e77335.

Devi L, Tang J, Ohno M. Beneficial effects of the beta-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression. *Current Alzheimer research*. 2015;12(1):13-21.

DeVos SL, Hyman BT. Tau at the Crossroads between Neurotoxicity and Neuroprotection. *Neuron*. 2017;94(4):703-4.

Dewer B, Rogers P, Ricketts J, Mukonoweshuro W, Zeman A. The radiological diagnosis of frontotemporal dementia in everyday practice: an audit of reports, review of diagnostic criteria, and proposal for service improvement. *Clinical radiology*. 2016;71(1):40-7.

Dgachi Y, Bautista-Aguilera OM, Benchekroun M, Martin H, Bonet A, Knez D, et al. Synthesis and Biological Evaluation of Benzochromenopyrimidinones as Cholinesterase Inhibitors and Potent Antioxidant, Non-Hepatotoxic Agents for Alzheimer's Disease. *Molecules* (Basel, Switzerland). 2016;21(5).

Dgachi Y, Ismaili L, Knez D, Benchekroun M, Martin H, Szalaj N, et al. Synthesis and Biological Assessment of Racemic Benzochromenopyrimidinimines as Antioxidant, Cholinesterase, and Abeta1-42 Aggregation Inhibitors for Alzheimer's Disease Therapy. *ChemMedChem*. 2016;11(12):1318-27.

Dgachi Y, Sokolov O, Luzet V, Godyn J, Panek D, Bonet A, et al. Tetrahydropyranodiquinol-8-amines as new, non hepatotoxic, antioxidant, and acetylcholinesterase inhibitors for Alzheimer's disease therapy. *European journal of medicinal chemistry*. 2017;126:576-89.

Dhanjal JK, Sharma S, Grover A, Das A. Use of ligand-based pharmacophore modeling and docking approach to find novel acetylcholinesterase inhibitors for treating Alzheimer's. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2015;71:146-52.

Dhikav V, Singh P, Anand KS. Medication adherence survey of drugs useful in prevention of dementia of Alzheimer's type among Indian patients. *International psychogeriatrics*. 2013;25(9):1409-13.

Dhurandhar EJ, Allison DB, van Groen T, Kadish I. Hunger in the absence of caloric restriction improves cognition and attenuates Alzheimer's disease pathology in a mouse model. *PloS one*. 2013;8(4):e60437.

Di Lorenzo F, Martorana A, Ponzo V, Bonni S, D'Angelo E, Caltagirone C, et al. Cerebellar theta burst stimulation modulates short latency afferent inhibition in Alzheimer's disease patients. *Frontiers in aging neuroscience*. 2013;5:2.

Di Meco A, Joshi YB, Lauretti E, Pratico D. Maternal dexamethasone exposure ameliorates cognition and tau pathology in the offspring of triple transgenic AD mice. *Molecular psychiatry*. 2016;21(3):403-10.

Di Meco A, Lauretti E, Vagnozzi AN, Pratico D. Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice. *Neurobiology of aging*. 2014;35(11):2458-64.

Di Meco A, Li J-G, Blass BE, Abou-Gharbia M, Lauretti E, Pratico D. 12/15-Lipoxygenase Inhibition Reverses Cognitive Impairment, Brain Amyloidosis, and Tau Pathology by Stimulating Autophagy in Aged Triple Transgenic Mice. *Biological psychiatry*. 2017;81(2):92-100.

Di Pardo A, Amico E, Favellato M, Castrataro R, Fucile S, Squitieri F, et al. FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. *Human molecular genetics*. 2014;23(9):2251-65.

Di Stefano F, Epelbaum S, Coley N, Cantet C, Ousset P-J, Hampel H, et al. Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. *Journal of Alzheimer's disease* : JAD. 2015;48(3):793-804.

Dias HKI, Brown CLR, Polidori MC, Lip GYH, Griffiths HR. LDL-lipids from patients with hypercholesterolaemia and Alzheimer's disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention. *Clinical science (London, England : 1979)*. 2015;129(12):1195-206.

Diaz A, Rojas K, Espinosa B, Chavez R, Zenteno E, Limon D, et al. Aminoguanidine treatment ameliorates inflammatory responses and memory impairment induced by amyloid-beta 25-35 injection in rats. *Neuropeptides*. 2014;48(3):153-9.

Diaz MCB, Rosales RL. A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors. *Medicine*. 2015;94(34):e1364.

Diaz-Orueta U, Blanco-Campal A, Burke T. Process-based approach neuropsychological assessment: review of the evidence and proposal for improvement of dementia screening tools. *Revista de neurologia*. 2017;64(11):514-24.

DiBartolo MC. Comorbidities Matter: A Call to Improve Care for Hospitalized Patients with Alzheimer's and Parkinson's Disease. *Journal of gerontological nursing*. 2016;42(2):4-5.

Diener HC. Multidimensional prevention of dementia diseases. *MMW Fortschritte der Medizin*. 2015;157(18):39.

Dietrich P, Johnson IM, Alli S, Dragatsis I. Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. *PLoS genetics*. 2017;13(7):e1006846.

Dighe SN, Deora GS, De la Mora E, Nachon F, Chan S, Parat M-O, et al. Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening. *Journal of medicinal chemistry*. 2016;59(16):7683-9.

Dimitriadis SI, Tarnanas I, Wiederhold M, Wiederhold B, Tsolaki M, Fleisch E. Mnemonic strategy training of the elderly at risk for dementia enhances integration of information processing via cross-frequency coupling. *Alzheimer's & dementia (New York, N Y)*. 2016;2(4):241-9.

Ding X, Kryscio RJ, Turner J, Jicha GA, Cooper G, Caban-Holt A, et al. Self-Reported Sleep Apnea and Dementia Risk: Findings from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Trial. *Journal of the American Geriatrics Society*. 2016;64(12):2472-8.

Dingwall L, Fenton J, Kelly TB, Lee J. Sliding doors: Did drama-based inter-professional education improve the tensions round person-centred nursing and social care delivery for people with dementia: A mixed method exploratory study. *Nurse education today*. 2017;51:1-7.

Diniz LP, Tortelli V, Matias I, Morgado J, Bergamo Araujo AP, Melo HM, et al. Astrocyte Transforming Growth Factor Beta 1 Protects Synapses against Abeta Oligomers in Alzheimer's Disease Model. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(28):6797-809.

Dinkins MB, Enasko J, Hernandez C, Wang G, Kong J, Helwa I, et al. Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2016;36(33):8653-67.

Diomedea L, Rigacci S, Romeo M, Stefani M, Salmona M. Oleuropein aglycone protects transgenic *C. elegans* strains expressing Abeta42 by reducing plaque load and motor deficit. *PloS one*. 2013;8(3):e58893.

Dionisio PA, Amaral JD, Ribeiro MF, Lo AC, D'Hooge R, Rodrigues CMP. Amyloid-beta pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. *Neurobiology of aging*. 2015;36(1):228-40.

DiPisa F, Pozzi C, Benvenuti M, Andreini M, Marconi G, Mangani S. The soluble Y115E-Y117E variant of human glutaminyl cyclase is a valid target for X-ray and NMR screening of inhibitors against Alzheimer disease. *Acta crystallographica Section F, Structural biology communications*. 2015;71(Pt 8):986-92.

Dirzius E, Balnyte R, Steibliene V, Gleizniene R, Gudaviciene I, Radziunas A, et al. Sporadic Creutzfeldt-Jakob disease with unusual initial presentation as posterior reversible encephalopathy syndrome: a case report. *BMC neurology*. 2016;16(1):234.

Dissel S, Angadi V, Kirszenblat L, Suzuki Y, Donlea J, Klose M, et al. Sleep restores behavioral plasticity to *Drosophila* mutants. *Current biology : CB*. 2015;25(10):1270-81.

Dissel S, Klose M, Donlea J, Cao L, English D, Winsky-Sommerer R, et al. Enhanced sleep reverses memory deficits and underlying pathology in *Drosophila* models of Alzheimer's disease. *Neurobiology of sleep and circadian rhythms*. 2017;2:15-26.

Divison Garrote JA, Escobar Cervantes C. Potential for the primary prevention of Alzheimer disease: An analysis of population-based data. *Semergen / Sociedad Espanola de Medicina Rural y Generalista*. 2016;42(3):188-9.

Dixit S, Fessel JP, Harrison FE. Mitochondrial dysfunction in the APP/PSEN1 mouse model of Alzheimer's disease and a novel protective role for ascorbate. *Free radical biology & medicine*. 2017;112:515-23.

Dixon J, Karagiannidou M, Knapp M. The Effectiveness of Advance Care Planning in Improving End-of-Life Outcomes for People With Dementia and Their Carers: A Systematic Review and Critical Discussion. *Journal of pain and symptom management*. 2017.

Djamanakova A, Faria AV, Hsu J, Ceritoglu C, Oishi K, Miller MI, et al. Diffeomorphic brain mapping based on T1-weighted images: improvement of registration accuracy by multichannel mapping. *Journal of magnetic resonance imaging : JMRI*. 2013;37(1):76-84.

Djelti F, Braudeau J, Hudry E, Dhenain M, Varin J, Bieche I, et al. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. *Brain : a journal of neurology*. 2015;138(Pt 8):2383-98.

Do Carmo S, Hanzel CE, Jacobs ML, Machnes Z, Iulita MF, Yang J, et al. Rescue of Early bace-1 and Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves Cognition in an Alzheimer's Model. *Scientific reports*. 2016;6:34051.

Doane J, Stults B. Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review. *Journal of clinical hypertension (Greenwich, Conn)*. 2013;15(4):230-3.

Doens D, Valiente PA, Mfuh AM, X T Vo A, Tristan A, Carreno L, et al. Identification of Inhibitors of CD36-Amyloid Beta Binding as Potential Agents for Alzheimer's Disease. *ACS chemical neuroscience*. 2017;8(6):1232-41.

Doherty BM, Schultz SA, Oh JM, Kosciak RL, Dowling NM, Barnhart TE, et al. Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. *Alzheimer's & dementia (Amsterdam, Netherlands)*. 2015;1(2):160-9.

Doi T, Shimada H, Makizako H, Tsutsumimoto K, Hotta R, Nakakubo S, et al. Association of insulin-like growth factor-1 with mild cognitive impairment and slow gait speed. *Neurobiology of aging*. 2015;36(2):942-7.

Doi T, Shimada H, Makizako H, Tsutsumimoto K, Hotta R, Nakakubo S, et al. Mild Cognitive Impairment, Slow Gait, and Risk of Disability: A Prospective Study. *Journal of the American Medical Directors Association*. 2015;16(12):1082-6.

Doi T, Shimada H, Park H, Makizako H, Tsutsumimoto K, Uemura K, et al. Cognitive function and falling among older adults with mild cognitive impairment and slow gait. *Geriatrics & gerontology international*. 2015;15(8):1073-8.

Dolui S, Vidorreta M, Wang Z, Nasrallah IM, Alavi A, Wolk DA, et al. Comparison of PASL, PCASL, and background-suppressed 3D PCASL in mild cognitive impairment. Human brain mapping. 2017;38(10):5260-73.

Dominguez LJ, Barbagallo M. Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer's Disease. Current pharmaceutical design. 2016;22(6):688-700.

Dominguez-Prieto M, Velasco A, Vega L, Tabernero A, Medina JM. Aberrant Co-localization of Synaptic Proteins Promoted by Alzheimer's Disease Amyloid-beta Peptides: Protective Effect of Human Serum Albumin. Journal of Alzheimer's disease : JAD. 2017;55(1):171-82.

Dong J, Zhao J, Lin Y, Liang H, He X, Zheng X, et al. Exercise improves recognition memory and synaptic plasticity in the prefrontal cortex for rats modelling vascular dementia. Neurological research. 2017:1-10.

Dong M, Li H, Hu D, Zhao W, Zhu X, Ai H. Molecular Dynamics Study on the Inhibition Mechanisms of Drugs CQ1-3 for Alzheimer Amyloid-beta40 Aggregation Induced by Cu(2+). ACS chemical neuroscience. 2016;7(5):599-614.

Dong M, Zhao W, Hu D, Ai H, Kang B. N-Terminus Binding Preference for Either Tanshinone or Analogue in Both Inhibition of Amyloid Aggregation and Disaggregation of Preformed Amyloid Fibrils-Toward Introducing a Kind of Novel Anti-Alzheimer Compounds. ACS chemical neuroscience. 2017;8(7):1577-88.

Dong Y, Slavin MJ, Chan BP-L, Venketasubramanian N, Sharma VK, Collinson SL, et al. Improving screening for vascular cognitive impairment at three to six months after mild ischemic stroke and transient ischemic attack. International psychogeriatrics. 2014;26(5):787-93.

Dong Y, Wang Y, Liu Y, Yang N, Zuo P. Phytoestrogen alpha-zearalanol ameliorates memory impairment and neuronal DNA oxidation in ovariectomized mice. Clinics (Sao Paulo, Brazil). 2013;68(9):1255-62.

Dong Y, Wang Y, Yu H, Liu Y, Yang N, Zuo P. Involvement of heat shock protein 70 in the DNA protective effect from estrogen. American journal of Alzheimer's disease and other dementias. 2013;28(3):269-77.

Dong Z, Yan L, Huang G, Zhang L, Mei B, Meng B. Ibuprofen partially attenuates neurodegenerative symptoms in presenilin conditional double-knockout mice. Neuroscience. 2014;270:58-68.

Donnelly CJ, Zhang P-W, Pham JT, Haeusler AR, Heusler AR, Mistry NA, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80(2):415-28.

Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, et al. Peripheral and central effects of gamma-secretase inhibition by semagacestat in Alzheimer's disease. *Alzheimer's research & therapy*. 2015;7(1):36.

Doolaanea AA, Mansor NI, Mohd Nor NH, Mohamed F. Co-encapsulation of *Nigella sativa* oil and plasmid DNA for enhanced gene therapy of Alzheimer's disease. *Journal of microencapsulation*. 2016;33(2):114-26.

Dorey A, Perret-Liaudet A, Tholance Y, Fourier A, Quadrio I. Cerebrospinal Fluid Abeta40 Improves the Interpretation of Abeta42 Concentration for Diagnosing Alzheimer's Disease. *Frontiers in neurology*. 2015;6:247.

Doria JG, de Souza JM, Andrade JN, Rodrigues HA, Guimaraes IM, Carvalho TG, et al. The mGluR5 positive allosteric modulator, CDPBB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease. *Neurobiology of disease*. 2015;73:163-73.

Doria JG, Silva FR, de Souza JM, Vieira LB, Carvalho TG, Reis HJ, et al. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease. *British journal of pharmacology*. 2013;169(4):909-21.

Dorostkar MM, Burgold S, Filser S, Barghorn S, Schmidt B, Anumala UR, et al. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model. *Brain : a journal of neurology*. 2014;137(Pt 12):3319-26.

Dorresteyn B, Rotman M, Faber D, Schraevesande R, Suidgeest E, van der Weerd L, et al. Camelid heavy chain only antibody fragment domain against beta-site of amyloid precursor protein cleaving enzyme 1 inhibits beta-secretase activity in vitro and in vivo. *The FEBS journal*. 2015;282(18):3618-31.

Dos Santos VV, Rodrigues ALS, De Lima TC, de Barioglio SR, Raisman-Vozari R, Prediger RD. Ghrelin as a neuroprotective and palliative agent in Alzheimer's and Parkinson's disease. *Current pharmaceutical design*. 2013;19(38):6773-90.

Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(23):9523-8.

Dougherty RJ, Ellingson LD, Schultz SA, Boots EA, Meyer JD, Lindheimer JB, et al. Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer's disease. *Alzheimer's & dementia (Amsterdam, Netherlands)*. 2016;4:14-7.

Douglas JW, Lawrence JC. Environmental Considerations for Improving Nutritional Status in Older Adults with Dementia: A Narrative Review. *Journal of the Academy of Nutrition and Dietetics*. 2015;115(11):1815-31.

Dowling GA, Merrilees J, Mastick J, Chang VY, Hubbard E, Moskowitz JT. Life enhancing activities for family caregivers of people with frontotemporal dementia. *Alzheimer disease and associated disorders*. 2014;28(2):175-81.

Doyle SM, Genest O, Wickner S. Protein rescue from aggregates by powerful molecular chaperone machines. *Nature reviews Molecular cell biology*. 2013;14(10):617-29.

Drochioiu G, Tudorachi L, Murariu M. NOSH aspirin may have a protective role in Alzheimer's disease. *Medical hypotheses*. 2015;84(3):262-7.

Droogsma E, van Asselt D, Diekhuis M, Veeger N, van der Hooft C, De Deyn PP. Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease. *International psychogeriatrics*. 2015;27(8):1323-33.

Droogsma E, Veeger NJGM, van Walderveen PE, Niemarkt SM, van Asselt DZB. Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. *Neurology*. 2013;80(17):1622.

Du F, Yu Q, Yan S, Hu G, Lue L-F, Walker DG, et al. PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease. *Brain : a journal of neurology*. 2017.

Du J, Liang Y, Xu F, Sun B, Wang Z. Trehalose rescues Alzheimer's disease phenotypes in APP/PS1 transgenic mice. *The Journal of pharmacy and pharmacology*. 2013;65(12):1753-6.

Du L-L, Chai D-M, Zhao L-N, Li X-H, Zhang F-C, Zhang H-B, et al. AMPK activation ameliorates Alzheimer's disease-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer's disease model in rats. *Journal of Alzheimer's disease : JAD*. 2015;43(3):775-84.

Du S-Q, Wang X-R, Zhu W, Ye Y, Yang J-W, Ma S-M, et al. Acupuncture inhibits TXNIP-associated oxidative stress and inflammation to attenuate cognitive impairment in vascular dementia rats. *CNS neuroscience & therapeutics*. 2017.

Du X, Wang C, Liu Q. Potential Roles of Selenium and Selenoproteins in the Prevention of Alzheimer's Disease. *Current topics in medicinal chemistry*. 2016;16(8):835-48.

Du X, Wang Z, Zheng Y, Li H, Ni J, Liu Q. Inhibitory effect of selenoprotein P on Cu(+)/Cu(2+)-induced Aβ42 aggregation and toxicity. *Inorganic chemistry*. 2014;53(3):1672-8.

Du Y, Liu R, Sun G, Meng P, Song J. Pre-moxibustion and moxibustion prevent Alzheimer's disease. *Neural regeneration research*. 2013;8(30):2811-9.

Du Y, Qu J, Zhang W, Bai M, Zhou Q, Zhang Z, et al. Morin reverses neuropathological and cognitive impairments in APP^{swe}/PS1^{dE9} mice by targeting multiple pathogenic mechanisms. *Neuropharmacology*. 2016;108:1-13.

Duan S, Guan X, Lin R, Liu X, Yan Y, Lin R, et al. Silibinin inhibits acetylcholinesterase activity and amyloid beta peptide aggregation: a dual-target drug for the treatment of Alzheimer's disease. *Neurobiology of aging*. 2015;36(5):1792-807.

Dubner L, Wang J, Ho L, Ward L, Pasinetti GM. Recommendations for Development of New Standardized Forms of Cocoa Breeds and Cocoa Extract Processing for the Prevention of Alzheimer's Disease: Role of Cocoa in Promotion of Cognitive Resilience and Healthy Brain Aging. *Journal of Alzheimer's disease : JAD*. 2015;48(4):879-89.

Ducharme S, Dickerson BC, Price BH. Improvement in athletic performance as an early symptom of behavioral variant frontotemporal dementia. *The Journal of neuropsychiatry and clinical neurosciences*. 2015;27(2):e163-4.

Dudeffant C, Vandesquille M, Herbert K, Garin CM, Alves S, Blanchard V, et al. Contrast-enhanced MR microscopy of amyloid plaques in five mouse models of amyloidosis and in human Alzheimer's disease brains. *Scientific reports*. 2017;7(1):4955.

Dufouil C, Brayne C. The continuing challenge of turning promising observational evidence about risk for dementia to evidence supporting prevention. *JAMA internal medicine*. 2014;174(3):333-5.

Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2014;22(4):797-810.

Dukart J, Perneczky R, Forster S, Barthel H, Diehl-Schmid J, Draganski B, et al. Reference cluster normalization improves detection of frontotemporal lobar degeneration by means of FDG-PET. *PloS one*. 2013;8(2):e55415.

Dunn HC, Ager RR, Baglietto-Vargas D, Cheng D, Kitazawa M, Cribbs DH, et al. Restoration of lipoxin A4 signaling reduces Alzheimer's disease-like pathology in the 3xTg-AD mouse model. *Journal of Alzheimer's disease : JAD*. 2015;43(3):893-903.

Duran-Aniotz C, Cornejo VH, Hetz C. Targeting endoplasmic reticulum acetylation to restore proteostasis in Alzheimer's disease. *Brain : a journal of neurology*. 2016;139(Pt 3):650-2.

Durk MR, Han K, Chow ECY, Ahrens R, Henderson JT, Fraser PE, et al. 1alpha,25-Dihydroxyvitamin D3 reduces cerebral amyloid-beta accumulation and improves cognition in mouse models of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(21):7091-101.

Durschmid S, Reichert C, Kuhn J, Freund H-J, Hinrichs H, Heinze H-J. Deep brain stimulation of the nucleus basalis of Meynert attenuates early EEG components associated with defective sensory gating in patients with Alzheimer disease - a two-case study. *The European journal of neuroscience*. 2017.

Dutta M, Kumar MVS. 39 Inhibition of Abeta aggregation in Alzheimer's disease using the poly-ion short single stranded DNA: in silico study. *Journal of biomolecular structure & dynamics*. 2015;33 Suppl 1:27.

Duzel E, van Praag H, Sendtner M. Can physical exercise in old age improve memory and hippocampal function? *Brain : a journal of neurology*. 2016;139(Pt 3):662-73.

Dvorzhak A, Semtner M, Faber DS, Grantyn R. Tonic mGluR5/CB1-dependent suppression of inhibition as a pathophysiological hallmark in the striatum of mice carrying a mutant form of huntingtin. *The Journal of physiology*. 2013;591(4):1145-66.

Dwivedi AK, Iyer PK. Therapeutic strategies to prevent Alzheimer's disease pathogenesis using a fluorescent conjugated polyelectrolyte. *Macromolecular bioscience*. 2014;14(4):508-14.

Dworzak J, Renvoise B, Habchi J, Yates EV, Combadiere C, Knowles TP, et al. Neuronal Cx3cr1 Deficiency Protects against Amyloid beta-Induced Neurotoxicity. *PloS one*. 2015;10(6):e0127730.

Eckmann J, Clemens LE, Eckert SH, Hagl S, Yu-Taege L, Bordet T, et al. Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime. *Molecular neurobiology*. 2014;50(1):107-18.

Eden A, Marcotte TD, Heaton RK, Nilsson S, Zetterberg H, Fuchs D, et al. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. *PloS one*. 2016;11(6):e0157160.

Edersheim J, Murray ED, Padmanabhan JL, Price BH. Protecting the Health and Finances of the Elderly With Early Cognitive Impairment. *The journal of the American Academy of Psychiatry and the Law*. 2017;45(1):81-91.

Edis H. Improving care for patients with dementia in the recovery room. *British journal of nursing (Mark Allen Publishing)*. 2017;26(20):1102-8.

Editors PM. Dementia across the Lifespan and around the Globe-Pathophysiology, Prevention, Treatment, and Societal Impact: A Call for Papers. PLoS medicine. 2016;13(8):e1002117.

Edraki N, Firuzi O, Foroumadi A, Miri R, Madadkar-Sobhani A, Khoshneviszadeh M, et al. Phenylimino-2H-chromen-3-carboxamide derivatives as novel small molecule inhibitors of beta-secretase (BACE1). Bioorganic & medicinal chemistry. 2013;21(8):2396-412.

Edrey YH, Medina DX, Gaczynska M, Osmulski PA, Oddo S, Caccamo A, et al. Amyloid beta and the longest-lived rodent: the naked mole-rat as a model for natural protection from Alzheimer's disease. Neurobiology of aging. 2013;34(10):2352-60.

Eduviere AT, Umukoro S, Aderibigbe AO, Ajayi AM, Adewole FA. Methyl jasmonate enhances memory performance through inhibition of oxidative stress and acetylcholinesterase activity in mice. Life sciences. 2015;132:20-6.

Edwards JD. The Importance of Identifying Early Changes in Cardiac Structure and Function for the Prevention of Cognitive Impairment and Dementia. Journal of Alzheimer's disease : JAD. 2017;58(1):285-8.

Efjestad AS, Molden E, Oksengard AR. Pharmacist-initiated management of antagonistic interactions between anticholinergic drugs and acetyl cholinesterase inhibitors in individuals with dementia. Journal of the American Geriatrics Society. 2013;61(9):1624-5.

Eimar H, Perez Lara A, Tamimi I, Marquez Sanchez P, Gormaz Talavera I, Rojas Tomba F, et al. Acetylcholinesterase inhibitors and healing of hip fracture in Alzheimer's disease patients: a retrospective cohort study. Journal of musculoskeletal & neuronal interactions. 2013;13(4):454-63.

Eisenstein M. Molecular biology: Remove, reuse, recycle. Nature. 2014;514(7522):S2-4.

Ejaz Ahmed M, Khan MM, Javed H, Vaibhav K, Khan A, Tabassum R, et al. Amelioration of cognitive impairment and neurodegeneration by catechin hydrate in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. Neurochemistry international. 2013;62(4):492-501.

Eketjall S, Janson J, Jeppsson F, Svanhagen A, Kolmodin K, Gustavsson S, et al. AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2013;33(24):10075-84.

El Dayem SMA, Ahmed HH, Metwally F, Foda FMA, Shalby AB, Zaazaa AMA. Alpha-chymotrypsin ameliorates neuroinflammation and apoptosis characterizing Alzheimer's disease-induced in ovariectomized rats. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie. 2013;65(5):477-83.

El Haj M, Antoine P. Describe yourself to improve your autobiographical memory: A study in Alzheimer's disease. *Cortex; a journal devoted to the study of the nervous system and behavior*. 2017;88:165-72.

El Haj M, Gallouj K, Antoine P. Google Calendar Enhances Prospective Memory in Alzheimer's Disease: A Case Report. *Journal of Alzheimer's disease : JAD*. 2017;57(1):285-91.

El Haj M, Laroï F, Gely-Nargeot M-C, Raffard S. Inhibitory deterioration may contribute to hallucinations in Alzheimer's disease. *Cognitive neuropsychiatry*. 2015;20(4):281-95.

El Haj M. Memory suppression in Alzheimer's disease. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2016;37(3):337-43.

El Melik R, Dubil A, Pound MW. Duration of therapy with acetylcholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease as reported in the literature. *The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists*. 2014;29(6):400-7.

ElAli A, Bordeleau M, Theriault P, Filali M, Lampron A, Rivest S. Tissue-Plasminogen Activator Attenuates Alzheimer's Disease-Related Pathology Development in APP^{swe}/PS1 Mice. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2016;41(5):1297-307.

Elcioglu H, Kabasakal L, Alan S, Salva E, Tufan F, Karan M. Thalidomide attenuates learning and memory deficits induced by intracerebroventricular administration of streptozotocin in rats. *Biotechnic & histochemistry : official publication of the Biological Stain Commission*. 2013;88(3-4):145-52.

El-Dessouki AM, Galal MA, Awad AS, Zaki HF. Neuroprotective Effects of Simvastatin and Cilostazol in L-Methionine-Induced Vascular Dementia in Rats. *Molecular neurobiology*. 2017;54(7):5074-84.

Elharram A, Czegledy NM, Golod M, Milne GL, Pollock E, Bennett BM, et al. Deuterium-reinforced polyunsaturated fatty acids improve cognition in a mouse model of sporadic Alzheimer's disease. *The FEBS journal*. 2017.

El-Horany HE, El-Latif RNA, ElBatsh MM, Emam MN. Ameliorative Effect of Quercetin on Neurochemical and Behavioral Deficits in Rotenone Rat Model of Parkinson's Disease: Modulating Autophagy (Quercetin on Experimental Parkinson's Disease). *Journal of biochemical and molecular toxicology*. 2016;30(7):360-9.

Eliasova I, Anderkova L, Marecek R, Rektorova I. Non-invasive brain stimulation of the right inferior frontal gyrus may improve attention in early Alzheimer's disease: a pilot study. *Journal of the neurological sciences*. 2014;346(1-2):318-22.

Elkahloun AG, Hafko R, Saavedra JM. An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's disease. *Alzheimer's research & therapy*. 2016;8:5.

El-Khadragy MF, Al-Olayan EM, Abdel Moneim AE. Neuroprotective effects of Citrus reticulata in scopolamine-induced dementia oxidative stress in rats. *CNS & neurological disorders drug targets*. 2014;13(4):684-90.

Elliott K-EJ, Annear MJ, Bell EJ, Palmer AJ, Robinson AL. Residents with mild cognitive decline and family members report health students 'enhance capacity of care' and bring 'a new breath of life' in two aged care facilities in Tasmania. *Health expectations : an international journal of public participation in health care and health policy*. 2015;18(6):1927-40.

Elliott M, Harrington J, Moore K, Davis S, Kupeli N, Vickerstaff V, et al. A protocol for an exploratory phase I mixed-methods study of enhanced integrated care for care home residents with advanced dementia: the Compassion Intervention. *BMJ open*. 2014;4(6):e005661.

Ellison SM, Trabalza A, Tisato V, Pazarentzos E, Lee S, Papadaki V, et al. Dose-dependent neuroprotection of VEGF β in Huntington's disease striatum. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2013;21(10):1862-75.

El-Malah A, Gedawy EM, Kassab AE, Salam RMA. Novel tacrine analogs as potential cholinesterase inhibitors in Alzheimer's disease. *Archiv der Pharmazie*. 2014;347(2):96-103.

Elosua MR, Peinado M, Contreras MJ, Reales JM, Montoro PR. The suppression effect in visuospatial and verbal working memory span tasks in patients with Alzheimer's disease: a 2-year follow-up study. *Neurocase*. 2016;22(5):426-35.

Elvish R, Burrow S, Cawley R, Harney K, Graham P, Pilling M, et al. 'Getting to Know Me': the development and evaluation of a training programme for enhancing skills in the care of people with dementia in general hospital settings. *Aging & mental health*. 2014;18(4):481-8.

Embury CM, Dyavarshetty B, Lu Y, Wiederin JL, Ciborowski P, Gendelman HE, et al. Cathepsin B Improves SS-Amyloidosis and Learning and Memory in Models of Alzheimer's Disease. *Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology*. 2017;12(2):340-52.

Engelman CD, Kosciuk RL, Jonaitis EM, Hermann BP, La Rue A, Sager MA. Investigation of triggering receptor expressed on myeloid cells 2 variant in the Wisconsin Registry for Alzheimer's Prevention. *Neurobiology of aging*. 2014;35(6):1252-4.

Engelman CD, Kosciuk RL, Jonaitis EM, Okonkwo OC, Hermann BP, La Rue A, et al. Interaction between two cholesterol metabolism genes influences memory: findings from the

Wisconsin Registry for Alzheimer's Prevention. *Journal of Alzheimer's disease* : JAD. 2013;36(4):749-57.

Engels MMA, Hillebrand A, van der Flier WM, Stam CJ, Scheltens P, van Straaten ECW. Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer's Disease. An MEG Study with Virtual Electrodes. *Frontiers in human neuroscience*. 2016;10:238.

Ennis EM, Jr., Kazer MW. The role of spiritual nursing interventions on improved outcomes in older adults with dementia. *Holistic nursing practice*. 2013;27(2):106-13.

Encouraging news in Alzheimer's prevention and treatment. Research continues to underscore the value of cardiovascular health in relation to brain function. *Duke Medicine healthnews*. 2013;19(2):4-5.

Ernst JT, Neubert T, Liu M, Sperry S, Zuccola H, Turnbull A, et al. Identification of novel HSP90alpha/beta isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease. *Journal of medicinal chemistry*. 2014;57(8):3382-400.

Erratum to "Agmatine Improves Cognitive Dysfunction and Prevents Cell Death in a Streptozotocin-Induced Alzheimer Rat Model" by Song J, et al. (*Yonsei Med J* 2014;55:689-99.). *Yonsei medical journal*. 2015;56(6):1745.

Erratum to Lifestyle changes might prevent Alzheimer's disease. *Annals of translational medicine*. 2016;4(9):E1.

Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al. Common polygenic variation enhances risk prediction for Alzheimer's disease. *Brain : a journal of neurology*. 2015;138(Pt 12):3673-84.

Esfandiary E, Karimipour M, Mardani M, Ghanadian M, Alaei HA, Mohammadnejad D, et al. Neuroprotective effects of Rosa damascena extract on learning and memory in a rat model of amyloid-beta-induced Alzheimer's disease. *Advanced biomedical research*. 2015;4:131.

Eskici G, Gur M. Computational design of new Peptide inhibitors for amyloid Beta (abeta) aggregation in Alzheimer's disease: application of a novel methodology. *PloS one*. 2013;8(6):e66178.

Esmaili Tazangi P, Moosavi SMS, Shabani M, Haghani M. Erythropoietin improves synaptic plasticity and memory deficits by decrease of the neurotransmitter release probability in the rat model of Alzheimer's disease. *Pharmacology, biochemistry, and behavior*. 2015;130:15-21.

Espinosa J, Rocha A, Nunes F, Costa MS, Schein V, Kazlauskas V, et al. Caffeine consumption prevents memory impairment, neuronal damage, and adenosine A2A receptors upregulation in

the hippocampus of a rat model of sporadic dementia. *Journal of Alzheimer's disease : JAD*. 2013;34(2):509-18.

Esquerda-Canals G, Marti J, Rivera-Hernandez G, Gimenez-Llort L, Villegas S. Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid beta antibody fragment. *mAbs*. 2013;5(5):660-4.

Esquivias-Perez M, Maalej E, Romero A, Chabchoub F, Samadi A, Marco-Contelles J, et al. Nontoxic and neuroprotective beta-naphthotacrine for Alzheimer's disease. *Chemical research in toxicology*. 2013;26(6):986-92.

Essa MM, Subash S, Akbar M, Al-Adawi S, Guillemin GJ. Long-term dietary supplementation of pomegranates, figs and dates alleviate neuroinflammation in a transgenic mouse model of Alzheimer's disease. *PloS one*. 2015;10(3):e0120964.

Esteban G, Allan J, Samadi A, Mattevi A, Unzeta M, Marco-Contelles J, et al. Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease. *Biochimica et biophysica acta*. 2014;1844(6):1104-10.

Estebanez M, Stella-Ascariz N, Mingorance J, Perez-Valero I, Gonzalez-Baeza A, Bayon C, et al. A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy. *Journal of acquired immune deficiency syndromes (1999)*. 2014;67(4):419-23.

Esteves IM, Lopes-Aguiar C, Rossignoli MT, Ruggiero RN, Broggin ACS, Bueno-Junior LS, et al. Chronic nicotine attenuates behavioral and synaptic plasticity impairments in a streptozotocin model of Alzheimer's disease. *Neuroscience*. 2017;353:87-97.

Estrada LD, Chamorro D, Yanez MJ, Gonzalez M, Leal N, von Bernhardt R, et al. Reduction of Blood Amyloid-beta Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition. *Journal of Alzheimer's disease : JAD*. 2016;54(3):1193-205.

Estrada M, Herrera-Arozamena C, Perez C, Vina D, Romero A, Morales-Garcia JA, et al. New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties. *European journal of medicinal chemistry*. 2016;121:376-86.

Estrada M, Perez C, Soriano E, Laurini E, Romano M, Priol S, et al. New neurogenic lipoid-based hybrids as innovative Alzheimer's drugs with sigma-1 agonism and beta-secretase inhibition. *Future medicinal chemistry*. 2016;8(11):1191-207.

Estrada-Sanchez AM, Burroughs CL, Cavaliere S, Barton SJ, Chen S, Yang XW, et al. Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a

conditional mouse model of Huntington's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2015;35(10):4440-51.

Ettore E, Wyckaert E, David R, Robert P, Guerin O, Prate F. Robotics and improvement of the quality of geriatric care. *Soins Gerontologie*. 2016;21(121):15-7.

Evers MM, Tran H-D, Zalachoras I, Meijer OC, den Dunnen JT, van Ommen G-JB, et al. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification. *Nucleic acid therapeutics*. 2014;24(1):4-12.

Evgen'ev MB, Krasnov GS, Nesterova IV, Garbuz DG, Karpov VL, Morozov AV, et al. Molecular Mechanisms Underlying Neuroprotective Effect of Intranasal Administration of Human Hsp70 in Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;59(4):1415-26.

Evin G. Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors. *BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy*. 2016;30(3):173-94.

Exercise and brain health. Preventing Alzheimer's and more. *Mayo Clinic health letter (English ed)*. 2013;31(1):4-5.

Exercise slows decline in adults with Alzheimer's disease. *BMJ (Clinical research ed)*. 2013;346:f2422.

Eyre H, Baune B, Lavretsky H. Clinical Advances in Geriatric Psychiatry: A Focus on Prevention of Mood and Cognitive Disorders. *The Psychiatric clinics of North America*. 2015;38(3):495-514.

Fa M, Zhang H, Staniszewski A, Saeed F, Shen LW, Schiefer IT, et al. Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;49(3):707-21.

Fabiny A. Ask the doctor. Is there any medication or over-the-counter supplement or vitamin I can take to prevent dementia? *Harvard women's health watch*. 2013;21(4):2.

Faivre E, Holscher C. Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. *Alzheimer's research & therapy*. 2013;5(2):20.

Fallahpour M, Borell L, Luborsky M, Nygard L. Leisure-activity participation to prevent later-life cognitive decline: a systematic review. *Scandinavian journal of occupational therapy*. 2016;23(3):162-97.

Falode JA, Akinmoladun AC, Olaleye MT, Akindahunsi AA. Sausage tree (*Kigelia africana*) flavonoid extract is neuroprotective in A β 1-3-induced experimental Alzheimer's disease. *Pathophysiology : the official journal of the International Society for Pathophysiology*. 2017.

Falquez R, Dinu-Biringer R, Stopsack M, Arens EA, Wick W, Barnow S. Examining cognitive emotion regulation in frontal lobe patients: The mediating role of response inhibition. *NeuroRehabilitation*. 2015;37(1):89-98.

Famenini S, Rigali EA, Olivera-Perez HM, Dang J, Chang MT, Halder R, et al. Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on omega-3 supplementation. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2017;31(1):148-60.

Fang D, Wang Y, Zhang Z, Du H, Yan S, Sun Q, et al. Increased neuronal PreP activity reduces A β accumulation, attenuates neuroinflammation and improves mitochondrial and synaptic function in Alzheimer disease's mouse model. *Human molecular genetics*. 2015;24(18):5198-210.

Fang F, Peng T, Yang S, Wang W, Zhang Y, Li H. Lycium barbarum polysaccharide attenuates the cytotoxicity of mutant huntingtin and increases the activity of AKT. *International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience*. 2016;52:66-74.

Fang L, Chen M, Liu Z, Fang X, Gou S, Chen L. Ferulic acid-carbazole hybrid compounds: Combination of cholinesterase inhibition, antioxidant and neuroprotection as multifunctional anti-Alzheimer agents. *Bioorganic & medicinal chemistry*. 2016;24(4):886-93.

Fang X, Jiang Y, Ji H, Zhao L, Xiao W, Wang Z, et al. The Synergistic Beneficial Effects of Ginkgo Flavonoid and Coriolus versicolor Polysaccharide for Memory Improvements in a Mouse Model of Dementia. *Evidence-based complementary and alternative medicine : eCAM*. 2015;2015:128394.

Fang X, Zhong X, Yu G, Shao S, Yang Q. Vascular protective effects of KLF2 on A β -induced toxicity: Implications for Alzheimer's disease. *Brain research*. 2017;1663:174-83.

Fang Y, Sui R. ELECTROACUPUNCTURE AT THE WANGU ACUPOINT SUPPRESSES EXPRESSION OF INFLAMMATORY CYTOKINES IN THE HIPPOCAMPUS OF RATS WITH VASCULAR DEMENTIA. *African journal of traditional, complementary, and alternative medicines : AJTCAM*. 2016;13(5):17-24.

Fant X, Durieu E, Chicanne G, Payrastra B, Sbrissa D, Shisheva A, et al. cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases inhibitor leucettine L41 induces mTOR-

dependent autophagy: implication for Alzheimer's disease. *Molecular pharmacology*. 2014;85(3):441-50.

Faraco G, Park L, Zhou P, Luo W, Paul SM, Anrather J, et al. Hypertension enhances Abeta-induced neurovascular dysfunction, promotes beta-secretase activity, and leads to amyloidogenic processing of APP. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2016;36(1):241-52.

Farbood Y, Shabani S, Sarkaki A, Mard SA, Ahangarpour A, Khorsandi L. Peripheral and central administration of T3 improved the histological changes, memory and the dentate gyrus electrophysiological activity in an animal model of Alzheimer's disease. *Metabolic brain disease*. 2017;32(3):693-701.

Farfara D, Tuby H, Trudler D, Doron-Mandel E, Maltz L, Vassar RJ, et al. Low-level laser therapy ameliorates disease progression in a mouse model of Alzheimer's disease. *Journal of molecular neuroscience : MN*. 2015;55(2):430-6.

Farhat SM, Ahmed T. Neuroprotective and Neurotoxic Implications of alpha7 Nicotinic Acetylcholine Receptor and Abeta Interaction: Therapeutic Options in Alzheimer's Disease. *Current drug targets*. 2017;18(13):1537-44.

Farias GA, Guzman-Martinez L, Delgado C, Maccioni RB. Nutraceuticals: a novel concept in prevention and treatment of Alzheimer's disease and related disorders. *Journal of Alzheimer's disease : JAD*. 2014;42(2):357-67.

Farlow MR, Borson S, Connor SR, Grossberg GT, Mittelman MS. Quality Improvement in Skilled Nursing Facilities for Residents With Alzheimer's Disease. *American journal of Alzheimer's disease and other dementias*. 2016;31(2):156-62.

Farr SA, Ripley JL, Sultana R, Zhang Z, Niehoff ML, Platt TL, et al. Antisense oligonucleotide against GSK-3beta in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. *Free radical biology & medicine*. 2014;67:387-95.

Farr SA, Sandoval KE, Niehoff ML, Witt KA, Kumar VB, Morley JE. Peripheral Administration of GSK-3beta Antisense Oligonucleotide Improves Learning and Memory in SAMP8 and Tg2576 Mouse Models of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;54(4):1339-48.

Farran CJ, Etkin CD, Eisenstein A, Paun O, Rajan KB, Sweet CMC, et al. Effect of Moderate to Vigorous Physical Activity Intervention on Improving Dementia Family Caregiver Physical Function: A Randomized Controlled Trial. *Journal of Alzheimer's disease & Parkinsonism*. 2016;6(4).

Farran CJ, Paun O, Cothran F, Etkin CD, Rajan KB, Eisenstein A, et al. Impact of an Individualized Physical Activity Intervention on Improving Mental Health Outcomes in Family Caregivers of Persons with Dementia: A Randomized Controlled Trial. *AIMS medical science*. 2016;3(1):15-31.

Farrand P, Matthews J, Dickens C, Anderson M, Woodford J. Psychological interventions to improve psychological well-being in people with dementia or mild cognitive impairment: systematic review and meta-analysis protocol. *BMJ open*. 2016;6(1):e009713.

Farrand P, Woodford J, Llewellyn D, Anderson M, Venkatasubramanian S, Ukoumunne OC, et al. Behavioural activation written self-help to improve mood, wellbeing and quality of life in people with dementia supported by informal carers (PROMOTE): a study protocol for a single-arm feasibility study. *Pilot and feasibility studies*. 2016;2:42.

Farzampour S, Majdi A, Sadigh-Eteghad S. Intranasal insulin treatment improves memory and learning in a rat amyloid-beta model of Alzheimer's disease. *Physiology international*. 2016;103(3):344-53.

Fazal K, Perera G, Khondoker M, Howard R, Stewart R. Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer's disease. *BJPsych open*. 2017;3(4):158-64.

Fazili NA, Naeem A, Ashraf GM, Hua GS, Kamal MA. Therapeutic Interventions for the Suppression of Alzheimer's Disease: Quest for a Remedy. *Current drug metabolism*. 2015;16(5):346-53.

Federspiel C, Keipes M. Geriatrics from the 19th to the 21st century. 150 years of geriatric medicine: from increasing life expectancy to improving quality of life for the very old. *Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg*. 2014:69-78.

Fedotova J, Soultanov V, Nikitina T, Roschin V, Ordyan N, Hritcu L. Cognitive-enhancing activities of the polyprenol preparation Ropren in gonadectomized beta-amyloid (25-35) rat model of Alzheimer's disease. *Physiology & behavior*. 2016;157:55-62.

Fedotova J, Soultanov V, Nikitina T, Roschin V, Ordyan N, Hritcu L. Ropren treatment reverses anxiety-like behavior and monoamines levels in gonadectomized rat model of Alzheimer's disease. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2016;83:1444-55.

Fei Y-L, Lv H-J, Li Y-B, Liu J, Qian Y-H, Yang W-N, et al. Tongxinluo improves cognition by decreasing beta-amyloid in spontaneous hypertensive rats. *Brain research*. 2017;1663:151-60.

Fekih-Mrissa N, Mansour M, Sayeh A, Bedoui I, Mrad M, Riahi A, et al. The Plasminogen Activator Inhibitor 1 4G/5G Polymorphism and the Risk of Alzheimer's Disease. *American journal of Alzheimer's disease and other dementias*. 2017;32(6):342-6.

Feld M, Krawczyk MC, Sol Fustinana M, Blake MG, Baratti CM, Romano A, et al. Decrease of ERK/MAPK overactivation in prefrontal cortex reverses early memory deficit in a mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;40(1):69-82.

Felsenstein KM, Candelario KM, Steindler DA, Borchelt DR. Regenerative medicine in Alzheimer's disease. *Translational research : the journal of laboratory and clinical medicine*. 2014;163(4):432-8.

Femminella GD, Leosco D, Ferrara N, Rengo G. Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer's Disease Patients? *CNS & neurological disorders drug targets*. 2016;15(6):665-71.

Feng B, Li X, Xia J, Wu S. Discovery of novel isoflavone derivatives as AChE/BuChE dual-targeted inhibitors: synthesis, biological evaluation and molecular modelling. *Journal of enzyme inhibition and medicinal chemistry*. 2017;32(1):968-77.

Feng G, Wang W, Qian Y, Jin H. Anti-Abeta antibodies induced by Abeta-HBc virus-like particles prevent Abeta aggregation and protect PC12 cells against toxicity of Abeta1-40. *Journal of neuroscience methods*. 2013;218(1):48-54.

Feng H-L, Dang H-Z, Fan H, Chen X-P, Rao Y-X, Ren Y, et al. Curcumin ameliorates insulin signalling pathway in brain of Alzheimer's disease transgenic mice. *International journal of immunopathology and pharmacology*. 2016;29(4):734-41.

Feng H-L, Fan H, Dang H-Z, Chen X-P, Ren Y, Yang J-D, et al. Neuroprotective effect of curcumin to Abeta of double transgenic mice with Alzheimer's disease. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica*. 2014;39(19):3846-9.

Feng J-H, Cai B-C, Guo W-F, Wang M-Y, Ma Y, Lu Q-X. Neuroprotective effects of Tongmai Yizhi Decoction () against Alzheimer's disease through attenuating cyclin-dependent kinase-5 expression. *Chinese journal of integrative medicine*. 2017;23(2):132-7.

Feng X, Liang N, Zhu D, Gao Q, Peng L, Dong H, et al. Resveratrol inhibits beta-amyloid-induced neuronal apoptosis through regulation of SIRT1-ROCK1 signaling pathway. *PloS one*. 2013;8(3):e59888.

Fengler S, Kessler J, Timmermann L, Zapf A, Elben S, Wojtecki L, et al. Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting. *PloS one*. 2016;11(7):e0159318.

Ferguson S, Mouzon B, Paris D, Aponte D, Abdullah L, Stewart W, et al. Acute or Delayed Treatment with Anatabine Improves Spatial Memory and Reduces Pathological Sequelae at Late Time-Points after Repetitive Mild Traumatic Brain Injury. *Journal of neurotrauma*. 2017;34(8):1676-91.

Fernandes RA, Ingle AB. Arundic acid a potential neuroprotective agent: biological development and syntheses. *Current medicinal chemistry*. 2013;20(18):2315-29.

Fernandes TB, Cunha MR, Sakata RP, Candido TM, Baby AR, Tavares MT, et al. Synthesis, Molecular Modeling, and Evaluation of Novel Sulfonylhydrazones as Acetylcholinesterase Inhibitors for Alzheimer's Disease. *Archiv der Pharmazie*. 2017;350(11).

Fernandez-Bachiller MI, Horatscheck A, Lisurek M, Rademann J. Alzheimer's disease: identification and development of beta-secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS). *ChemMedChem*. 2013;8(7):1041-56.

Fernandez-Estevez MA, Casarejos MJ, Lopez Sendon J, Garcia Caldentey J, Ruiz C, Gomez A, et al. Trehalose reverses cell malfunction in fibroblasts from normal and Huntington's disease patients caused by proteasome inhibition. *PloS one*. 2014;9(2):e90202.

Fernandez-Funez P, Zhang Y, Sanchez-Garcia J, de Mena L, Khare S, Golde TE, et al. Anti-Abeta single-chain variable fragment antibodies exert synergistic neuroprotective activities in *Drosophila* models of Alzheimer's disease. *Human molecular genetics*. 2015;24(21):6093-105.

Fernandez-Moriano C, Gonzalez-Burgos E, Gomez-Serranillos MP. Mitochondria-Targeted Protective Compounds in Parkinson's and Alzheimer's Diseases. *Oxidative medicine and cellular longevity*. 2015;2015:408927.

Fernando WMADB, Martins IJ, Goozee KG, Brennan CS, Jayasena V, Martins RN. The role of dietary coconut for the prevention and treatment of Alzheimer's disease: potential mechanisms of action. *The British journal of nutrition*. 2015;114(1):1-14.

Fernando WMADB, Somaratne G, Goozee KG, Williams S, Singh H, Martins RN. Diabetes and Alzheimer's Disease: Can Tea Phytochemicals Play a Role in Prevention? *Journal of Alzheimer's disease : JAD*. 2017;59(2):481-501.

Ferreira D, Rivero-Santana A, Perestelo-Perez L, Westman E, Wahlund L-O, Sarria A, et al. Improving CSF Biomarkers' Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer's Disease by Considering Different Confounding Factors: A Meta-Analysis. *Frontiers in aging neuroscience*. 2014;6:287.

Ferreira de Oliveira F, Berretta JM, Suchi Chen E, Cardoso Smith M, Ferreira Bertolucci PH. Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and

creatinine variations in patients with dementia due to Alzheimer disease. *Colombia medica (Cali, Colombia)*. 2016;47(2):76-80.

Ferris SH, Farlow M. Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors. *Clinical interventions in aging*. 2013;8:1007-14.

Ferry M, Coley N, Andrieu S, Bonhomme C, Caubere JP, Cesari M, et al. How to design nutritional intervention trials to slow cognitive decline in apparently healthy populations and apply for efficacy claims: a statement from the International Academy on Nutrition and Aging Task Force. *The journal of nutrition, health & aging*. 2013;17(7):619-23.

Fessel WJ. Concordance of Several Subcellular Interactions Initiates Alzheimer's Dementia: Their Reversal Requires Combination Treatment. *American journal of Alzheimer's disease and other dementias*. 2017;32(3):166-81.

Fiala M, Terrando N, Dalli J. Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-beta Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment. *Journal of Alzheimer's disease : JAD*. 2015;48(2):293-301.

Fichou Y, Schiro G, Gallat F-X, Laguri C, Moulin M, Combet J, et al. Hydration water mobility is enhanced around tau amyloid fibers. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112(20):6365-70.

Fields J, Dumaop W, Rockenstein E, Mante M, Spencer B, Grant I, et al. Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer. *Journal of neurovirology*. 2013;19(1):89-101.

Figueiro MG, Plitnick BA, Lok A, Jones GE, Higgins P, Hornick TR, et al. Tailored lighting intervention improves measures of sleep, depression, and agitation in persons with Alzheimer's disease and related dementia living in long-term care facilities. *Clinical interventions in aging*. 2014;9:1527-37.

Finn M, McDonald S. Repetition-lag training to improve recollection memory in older people with amnesic mild cognitive impairment. A randomized controlled trial. *Neuropsychology, development, and cognition Section B, Aging, neuropsychology and cognition*. 2015;22(2):244-58.

Fiol-deRoque MA, Gutierrez-Lanza R, Teres S, Torres M, Barcelo P, Rial RV, et al. Cognitive recovery and restoration of cell proliferation in the dentate gyrus in the 5XFAD transgenic mice model of Alzheimer's disease following 2-hydroxy-DHA treatment. *Biogerontology*. 2013;14(6):763-75.

Fiorini A, Sultana R, Forster S, Perluigi M, Cenini G, Cini C, et al. Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and

reverses learning and memory impairment: a proteomics study. *Free radical biology & medicine*. 2013;65:1-14.

Fiorito J, Saeed F, Zhang H, Staniszewski A, Feng Y, Francis YI, et al. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. *European journal of medicinal chemistry*. 2013;60:285-94.

Fiorito J, Vendome J, Saeed F, Staniszewski A, Zhang H, Yan S, et al. Identification of a Novel 1,2,3,4-Tetrahydrobenzo b 1,6 naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer's Disease. *Journal of medicinal chemistry*. 2017;60(21):8858-75.

First rule of dementia prevention: take care of your heart. What you need to know about the link between cognitive decline, Alzheimer's and clogged arteries. *Harvard heart letter : from Harvard Medical School*. 2013;24(1):5.

Firth J, Stubbs B, Rosenbaum S, Vancampfort D, Malchow B, Schuch F, et al. Aerobic Exercise Improves Cognitive Functioning in People With Schizophrenia: A Systematic Review and Meta-Analysis. *Schizophrenia bulletin*. 2017;43(3):546-56.

Fisher A, Carney G, Bassett K, Chappell NL. Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. 2016;19(5):688-96.

Fisher A, Carney G, Bassett K, Dormuth CR. Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching. *Drugs & aging*. 2017;34(3):221-31.

Fissler P, Kuster O, Schlee W, Kolassa I-T. Novelty interventions to enhance broad cognitive abilities and prevent dementia: synergistic approaches for the facilitation of positive plastic change. *Progress in brain research*. 2013;207:403-34.

Fiszer A, Olejniczak M, Galka-Marciniak P, Mykowska A, Krzyzosiak WJ. Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression. *Nucleic acids research*. 2013;41(22):10426-37.

Fitz NF, Castranio EL, Carter AY, Kodali R, Lefterov I, Koldamova R. Improvement of memory deficits and amyloid-beta clearance in aged APP23 mice treated with a combination of anti-amyloid-beta antibody and LXR agonist. *Journal of Alzheimer's disease : JAD*. 2014;41(2):535-49.

Fitz NF, Cronican AA, Lefterov I, Koldamova R. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". *Science (New York, NY)*. 2013;340(6135):924-c.

Flaherty C, Kraft J, Brothers A, Harrison M, Legro RS, Manni A, et al. The relationship between oestrogen and executive functioning in ALS females with emerging Frontotemporal Lobar Degeneration (FTLD) supports a neuroendocrine model of FTLD attenuation. Amyotrophic lateral sclerosis & frontotemporal degeneration. 2017;18(1-2):74-85.

Flanigan TJ, Xue Y, Kishan Rao S, Dhanushkodi A, McDonald MP. Abnormal vibrissa-related behavior and loss of barrel field inhibitory neurons in 5xFAD transgenics. Genes, brain, and behavior. 2014;13(5):488-500.

Fleiner T, Dauth H, Gersie M, Zijlstra W, Haussermann P. Structured physical exercise improves neuropsychiatric symptoms in acute dementia care: a hospital-based RCT. Alzheimer's research & therapy. 2017;9(1):68.

Fleming MO, Haney TT. Improving patient outcomes with better care transitions: the role for home health. Cleveland Clinic journal of medicine. 2013;80 Electronic Suppl 1:eS2-6.

Flemming A. Alzheimer's disease: Abeta-fibrinogen interaction inhibitor improves cognition in AD. Nature reviews Drug discovery. 2014;13(7):494.

Flesch D, Ness J, Lamers C, Dehm F, Popella S, Steri R, et al. SAR-studies of gamma-secretase modulators with PPARgamma-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer's disease. Bioorganic & medicinal chemistry letters. 2015;25(4):841-6.

Fletcher CV. Editorial commentary: cerebrospinal fluid inhibitory quotients of antiretroviral drugs. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015;60(2):318-20.

Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, et al. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Alzheimer's disease : JAD. 2016;51(4):1237-47.

Fluegge K. Does MeCP2 deficiency in autism confer protection against later development of Alzheimer's disease? A reply to Oberman and Pascual-Leone (2014). Medical hypotheses. 2016;92:18-20.

Fluharty BR, Biasini E, Stravalaci M, Sclip A, Diomede L, Balducci C, et al. An N-terminal fragment of the prion protein binds to amyloid-beta oligomers and inhibits their neurotoxicity in vivo. The Journal of biological chemistry. 2013;288(11):7857-66.

Fluteau A, Ince PG, Minett T, Matthews FE, Brayne C, Garwood CJ, et al. The nuclear retention of transcription factor FOXO3a correlates with a DNA damage response and increased glutamine synthetase expression by astrocytes suggesting a neuroprotective role in the ageing brain. Neuroscience letters. 2015;609:11-7.

Flynn Longmire CV, Drye LT, Frangakis CE, Martin BK, Meinert CL, Mintzer JE, et al. Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2014;22(1):14-24.

Fockaert N, Van Orshoven M, Cras P, Van Broeckhoven C, Demaerel P, Vandenberghe W. Slowing of saccadic eye movements in sporadic Creutzfeldt-Jakob disease. Movement disorders : official journal of the Movement Disorder Society. 2013;28(3):291-3.

Fol R, Braudeau J, Ludewig S, Abel T, Weyer SW, Roederer J-P, et al. Viral gene transfer of APP α rescues synaptic failure in an Alzheimer's disease mouse model. Acta neuropathologica. 2016;131(2):247-66.

Foloppe DA, Richard P, Yamaguchi T, Etcharry-Bouyx F, Allain P. The potential of virtual reality-based training to enhance the functional autonomy of Alzheimer's disease patients in cooking activities: A single case study. Neuropsychological rehabilitation. 2015:1-25.

Fong RK, Johnson A, Gill SS. Cholinesterase inhibitors: an example of geographic variation in prescribing patterns within a drug class. International journal of geriatric psychiatry. 2015;30(2):220-2.

Forbes D, Blake CM, Thiessen EJ, Peacock S, Hawranik P. Light therapy for improving cognition, activities of daily living, sleep, challenging behaviour, and psychiatric disturbances in dementia. The Cochrane database of systematic reviews. 2014(2):CD003946.

Ford AH. Preventing delirium in dementia: Managing risk factors. Maturitas. 2016;92:35-40.

Ford RL, Swanson KA. Proton-Pump Inhibitors and Risk of Dementia. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. 2017;32(11):682-6.

Forlenza OV, De-Paula VJR, Diniz BSO. Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. ACS chemical neuroscience. 2014;5(6):443-50.

Formiga F, Lopez Trigo JA. Prevention and management of cognitive impairment. Revista espanola de geriatria y gerontologia. 2016;51 Suppl 1:1-2.

Fornazzari L, Ringer T, Ringer L, Fischer CE. Preserved drawing in a sculptor with dementia. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques. 2013;40(5):736-7.

Fortea Ormaechea J. Prevention of dementia, an immediate challenge. Revista clinica espanola. 2016;216(9):483-4.

Fosnacht AM, Patel S, Yucus C, Pham A, Rasmussen E, Frigerio R, et al. From Brain Disease to Brain Health: Primary Prevention of Alzheimer's Disease and Related Disorders in a Health System Using an Electronic Medical Record-Based Approach. *The journal of prevention of Alzheimer's disease*. 2017;4(3):157-64.

Fossati S, Giannoni P, Solesio ME, Cocklin SL, Cabrera E, Ghiso J, et al. The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain. *Neurobiology of disease*. 2016;86:29-40.

Fougere B, Li J. How to Implement Multidomain Interventions for the Prevention of Alzheimer Disease in China? *Journal of the American Medical Directors Association*. 2016;17(6):562-3.

Fougere B, Li J. How to Implement Traditional Chinese Medicine in Alzheimer Disease Prevention in Occidental Countries? *Journal of the American Medical Directors Association*. 2016;17(12):1154-6.

Fougere B, Oustric S, Delrieu J, Chicoulaa B, Escourrou E, Rolland Y, et al. Implementing Assessment of Cognitive Function and Frailty Into Primary Care: Data From Frailty and Alzheimer disease prevention into Primary care (FAP) Study Pilot. *Journal of the American Medical Directors Association*. 2017;18(1):47-52.

Fowler JH, Dannecker K, Stanley M, Wilson N, Snow AL, Kunik ME. Preventing aggression and other secondary features of dementia in elderly persons: Three case studies. *Bulletin of the Menninger Clinic*. 2015;79(2):95-115.

Fowler NR, Barnato AE, Degenholtz HB, Curcio AM, Becker JT, Kuller LH, et al. Effect of dementia on the use of drugs for secondary prevention of ischemic heart disease. *Journal of aging research*. 2014;2014:897671.

Fowler SW, Chiang ACA, Savjani RR, Larson ME, Sherman MA, Schuler DR, et al. Genetic modulation of soluble Abeta rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(23):7871-85.

Fraga FJ, Oliveira EF, Kanda PAM. EEG epoch selection: lack of alpha rhythm improves discrimination of Alzheimer's disease. *Conference proceedings : Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual Conference*. 2016;2016:2307-10.

Fragkouli A, Tsilibary EC, Tzinia AK. Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer's 5xFAD mice. *Neurobiology of disease*. 2014;70:179-89.

Fragoulis A, Siegl S, Fendt M, Jansen S, Soppa U, Brandenburg L-O, et al. Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease. *Redox biology*. 2017;12:843-53.

Francelle L, Galvan L, Gaillard M-C, Petit F, Bernay B, Guillermier M, et al. Striatal long noncoding RNA Abhd11os is neuroprotective against an N-terminal fragment of mutant huntingtin in vivo. *Neurobiology of aging*. 2015;36(3):1601.e7-16.

Franco R. Enhancing cognition before clinical symptoms of dementia. *Frontiers in systems neuroscience*. 2014;8:240.

Frank C, Forbes RF. A patient's experience in dementia care: Using the "lived experience" to improve care. *Canadian family physician Medecin de famille canadien*. 2017;63(1):22-6.

Frankish H, Horton R. Prevention and management of dementia: a priority for public health. *Lancet (London, England)*. 2017.

Frederiksen KS, Verdelho A, Madureira S, Bazner H, O'Brien JT, Fazekas F, et al. Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study. *International journal of geriatric psychiatry*. 2015;30(7):744-50.

Freedberg DE, Kim LS, Yang Y-X. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. *Gastroenterology*. 2017;152(4):706-15.

Freeman WD. Proton Pump Inhibitors and Dementia Incidence. *JAMA neurology*. 2016;73(8):1026-7.

Freeze WM, Schnerr RS, Palm WM, Jansen JF, Jacobs HI, Hoff EI, et al. Pericortical Enhancement on Delayed Postgadolinium Fluid-Attenuated Inversion Recovery Images in Normal Aging, Mild Cognitive Impairment, and Alzheimer Disease. *AJNR American journal of neuroradiology*. 2017.

French DD, LaMantia MA, Livin LR, Herceg D, Alder CA, Boustani MA. Healthy Aging Brain Center improved care coordination and produced net savings. *Health affairs (Project Hope)*. 2014;33(4):613-8.

Frenkel-Pinter M, Tal S, Scherzer-Attali R, Abu-Hussien M, Alyagor I, Eisenbaum T, et al. Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered Toxicity. *Neuro-degenerative diseases*. 2017;17(2-3):73-82.

Friedland RP, Nandi S. A modest proposal for a longitudinal study of dementia prevention (with apologies to Jonathan Swift, 1729). *Journal of Alzheimer's disease : JAD*. 2013;33(2):313-5.

Friedrich MJ. Researchers test strategies to prevent Alzheimer disease. *Jama*. 2014;311(16):1596-8.

Froestl W, Muhs A, Pfeifer A. Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors. Update 2014. *Journal of Alzheimer's disease : JAD*. 2014;41(4):961-1019.

Froestl W, Muhs A, Pfeifer A. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. *Journal of Alzheimer's disease : JAD*. 2013;33(3):547-658.

Froestl W, Muhs A, Pfeifer A. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014. *Journal of Alzheimer's disease : JAD*. 2014;42(1):1-68.

Froestl W, Pfeifer A, Muhs A. Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014. *Journal of Alzheimer's disease : JAD*. 2014;42(4):1079-149.

Frost JL, Liu B, Rahfeld J-U, Kleinschmidt M, O'Nuallain B, Le KX, et al. An anti-pyroglutamate-3 Abeta vaccine reduces plaques and improves cognition in APP^{swe}/PS1^{DeltaE9} mice. *Neurobiology of aging*. 2015;36(12):3187-99.

Fu AKY, Hung K-W, Huang H, Gu S, Shen Y, Cheng EYL, et al. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(27):9959-64.

Fu AKY, Hung K-W, Yuen MYF, Zhou X, Mak DSY, Chan ICW, et al. IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113(19):E2705-13.

Fu L, Li Y, Hu Y, Zheng Y, Yu B, Zhang H, et al. Norovirus P particle-based active Abeta immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer's disease. *Scientific reports*. 2017;7:41041.

Fu Y, Zhao J, Atagi Y, Nielsen HM, Liu C-C, Zheng H, et al. Apolipoprotein E lipoprotein particles inhibit amyloid-beta uptake through cell surface heparan sulphate proteoglycan. *Molecular neurodegeneration*. 2016;11(1):37.

Fuentealba J, Saez-Orellana F. Neuroactive alkaloids that modulate the neuronal nicotinic receptor and provide neuroprotection in an Alzheimer's disease model: the case of *Teline monspessulana*. *Neural regeneration research*. 2014;9(21):1880-1.

Fujikawa R, Higuchi S, Nakatsuji M, Yasui M, Ikedo T, Nagata M, et al. Deficiency in EP4 Receptor-Associated Protein Ameliorates Abnormal Anxiety-Like Behavior and Brain

Inflammation in a Mouse Model of Alzheimer Disease. *The American journal of pathology*. 2017;187(8):1848-54.

Fujioka H, Phelix CF, Friedland RP, Zhu X, Perry EA, Castellani RJ, et al. Apolipoprotein E4 prevents growth of malaria at the intraerythrocyte stage: implications for differences in racial susceptibility to Alzheimer's disease. *Journal of health care for the poor and underserved*. 2013;24(4 Suppl):70-8.

Fukumoto K, Mizoguchi H, Takeuchi H, Horiuchi H, Kawanokuchi J, Jin S, et al. Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid beta-induced memory impairment. *Behavioural brain research*. 2014;268:88-93.

Fukunaga K, Sakai D, Watanabe K, Nakayama K, Kohara T, Tanaka H, et al. Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3beta inhibitors for Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2015;25(5):1086-91.

Funamoto S, Sasaki T, Ishihara S, Nobuhara M, Nakano M, Watanabe-Takahashi M, et al. Substrate ectodomain is critical for substrate preference and inhibition of gamma-secretase. *Nature communications*. 2013;4:2529.

Futai E, Osawa S, Cai T, Fujisawa T, Ishiura S, Tomita T. Suppressor Mutations for Presenilin 1 Familial Alzheimer Disease Mutants Modulate gamma-Secretase Activities. *The Journal of biological chemistry*. 2016;291(1):435-46.

Fyfe I. Dementia: Researchers urge more dementia studies to focus on prevention rather than cure. *Nature reviews Neurology*. 2015;11(10):545.

Gabbita SP, Johnson MF, Kobritz N, Eslami P, Poteshkina A, Varadarajan S, et al. Oral TNFalpha Modulation Alters Neutrophil Infiltration, Improves Cognition and Diminishes Tau and Amyloid Pathology in the 3xTgAD Mouse Model. *PloS one*. 2015;10(10):e0137305.

Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, et al. Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. *Neurology*. 2014;82(17):1536-42.

Galimberti D, Scarpini E. Old and new acetylcholinesterase inhibitors for Alzheimer's disease. *Expert opinion on investigational drugs*. 2016;25(10):1181-7.

Gallucci M, Spagnolo P, Arico M, Grossi E. Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer's Disease: Data Mining from the TREDEM Registry. *Journal of Alzheimer's disease : JAD*. 2016;50(4):969-79.

Galvin JE, Tolea MI, George N, Wingbermuehle C. Public-private partnerships improve health outcomes in individuals with early stage Alzheimer's disease. *Clinical interventions in aging*. 2014;9:621-30.

Galvin JE. IMPROVING THE CLINICAL DETECTION OF LEWY BODY DEMENTIA WITH THE LEWY BODY COMPOSITE RISK SCORE. *Alzheimer's & dementia (Amsterdam, Netherlands)*. 2015;1(3):316-24.

Galvin JE. Prevention of Alzheimer's Disease: Lessons Learned and Applied. *Journal of the American Geriatrics Society*. 2017;65(10):2128-33.

Gama MAS, Raposo NRB, Mury FB, Lopes FCF, Dias-Neto E, Talib LL, et al. Conjugated linoleic acid-enriched butter improved memory and up-regulated phospholipase A2 encoding-genes in rat brain tissue. *Journal of neural transmission (Vienna, Austria : 1996)*. 2015;122(10):1371-80.

Gamage KK, Kumar S. Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(17):4430-2.

Gamba P, Guglielmotto M, Testa G, Monteleone D, Zerbinati C, Gargiulo S, et al. Up-regulation of beta-amyloidogenesis in neuron-like human cells by both 24- and 27-hydroxycholesterol: protective effect of N-acetyl-cysteine. *Aging cell*. 2014;13(3):561-72.

Gamberger D, Lavrac N, Srivatsa S, Tanzi RE, Doraiswamy PM. Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer's disease. *Scientific reports*. 2017;7(1):6763.

Gameiro I, Michalska P, Tenti G, Cores A, Buendia I, Rojo AI, et al. Discovery of the first dual GSK3beta inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease. *Scientific reports*. 2017;7:45701.

Gan X, Huang S, Wu L, Wang Y, Hu G, Li G, et al. Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell. *Biochimica et biophysica acta*. 2014;1842(2):220-31.

Gancheva SM, Zhelyazkova-Savova MD. Vitamin K2 Improves Anxiety and Depression but not Cognition in Rats with Metabolic Syndrome: a Role of Blood Glucose? *Folia medica*. 2016;58(4):264-72.

Gandy S, Bartfai T, Lees GV, Sano M. Midlife interventions are critical in prevention, delay, or improvement of Alzheimer's disease and vascular cognitive impairment and dementia. *F1000Research*. 2017;6:413.

Gandy S, DeKosky ST. Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. *Annual review of medicine*. 2013;64:367-83.

Gandy S. Alzheimer's disease: new data highlight nonneuronal cell types and the necessity for presymptomatic prevention strategies. *Biological psychiatry*. 2014;75(7):553-7.

Gangwar AK, Rawat A, Tiwari S, Tiwari SC, Narayan J, Tiwari S. Role of Vitamin-D in the prevention and treatment of Alzheimer's disease. *Indian journal of physiology and pharmacology*. 2015;59(1):94-9.

Gao C, Liu Y, Jiang Y, Ding J, Li L. Geniposide ameliorates learning memory deficits, reduces tau phosphorylation and decreases apoptosis via GSK3 β pathway in streptozotocin-induced alzheimer rat model. *Brain pathology (Zurich, Switzerland)*. 2014;24(3):261-9.

Gao H, Tao Y, He Q, Song F, Saffen D. Functional enrichment analysis of three Alzheimer's disease genome-wide association studies identifies DAB1 as a novel candidate liability/protective gene. *Biochemical and biophysical research communications*. 2015;463(4):490-5.

Gao J, Adam B-L, Terry AV, Jr. Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2014;24(6):1472-8.

Gao J, He H, Jiang W, Chang X, Zhu L, Luo F, et al. Salidroside ameliorates cognitive impairment in a d-galactose-induced rat model of Alzheimer's disease. *Behavioural brain research*. 2015;293:27-33.

Gao J, Midde N, Zhu J, Terry AV, McInnes C, Chapman JM. Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2016;26(22):5573-9.

Gao J, Zhou R, You X, Luo F, He H, Chang X, et al. Salidroside suppresses inflammation in a D-galactose-induced rat model of Alzheimer's disease via SIRT1/NF- κ B pathway. *Metabolic brain disease*. 2016;31(4):771-8.

Gao L, Chen X, Tang Y, Zhao J, Li Q, Fan X, et al. Neuroprotective effect of memantine on the retinal ganglion cells of APP^{swe}/PS1^{DeltaE9} mice and its immunomodulatory mechanisms. *Experimental eye research*. 2015;135:47-58.

Gao L, Tian M, Zhao H-Y, Xu Q-Q, Huang Y-M, Si Q-C, et al. TrkB activation by 7, 8-dihydroxyflavone increases synapse AMPA subunits and ameliorates spatial memory deficits in a mouse model of Alzheimer's disease. *Journal of neurochemistry*. 2016;136(3):620-36.

Gao N, Sun H, Dong K, Ren J, Qu X. Gold-nanoparticle-based multifunctional amyloid-beta inhibitor against Alzheimer's disease. *Chemistry (Weinheim an der Bergstrasse, Germany)*. 2015;21(2):829-35.

Gao S, Unverzagt FW, Hall KS, Lane KA, Murrell JR, Hake AM, et al. Mild cognitive impairment, incidence, progression, and reversion: findings from a community-based cohort of elderly African Americans. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2014;22(7):670-81.

Gao Y, Chu S-f, Li J-p, Zhang Z, Yan J-q, Wen Z-l, et al. Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease. *Acta pharmacologica Sinica*. 2015;36(3):311-22.

Gao Y, Hu Y-Z, Li R-S, Han Z-T, Geng Y, Xia Z, et al. Cattle encephalon glycoside and ignotin injection improves cognitive impairment in APPswe/PS1dE9 mice used as multitarget anti-Alzheimer's drug candidates. *Neuropsychiatric disease and treatment*. 2015;11:537-48.

Gao Y, O'Caomh R, Healy L, Kerins DM, Eustace J, Guyatt G, et al. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. *BMJ open*. 2013;3(7).

Garces P, Vicente R, Wibrál M, Pineda-Pardo JA, Lopez ME, Aurtenetxe S, et al. Brain-wide slowing of spontaneous alpha rhythms in mild cognitive impairment. *Frontiers in aging neuroscience*. 2013;5:100.

Garcia-Barroso C, Ricobaraza A, Pascual-Lucas M, Unceta N, Rico AJ, Goicolea MA, et al. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. *Neuropharmacology*. 2013;64:114-23.

Garcia-Cerro S, Rueda N, Vidal V, Lantigua S, Martinez-Cue C. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes. *Neurobiology of disease*. 2017;106:76-88.

Garcia-Font N, Hayour H, Belfaitah A, Pedraz J, Moraleda I, Iriepa I, et al. Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease. *European journal of medicinal chemistry*. 2016;118:178-92.

Garcia-Mesa Y, Colie S, Corpas R, Cristofol R, Comellas F, Nebreda AR, et al. Oxidative Stress Is a Central Target for Physical Exercise Neuroprotection Against Pathological Brain Aging. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2016;71(1):40-9.

Garcia-Mesa Y, Pareja-Galeano H, Bonet-Costa V, Revilla S, Gomez-Cabrera MC, Gambini J, et al. Physical exercise neuroprotects ovariectomized 3xTg-AD mice through BDNF mechanisms. *Psychoneuroendocrinology*. 2014;45:154-66.

Garcia-Miralles M, Ooi J, Ferrari Bardile C, Tan LJ, George M, Drum CL, et al. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. *Experimental neurology*. 2016;278:4-10.

Gareri P, Castagna A, Cotroneo AM, Putignano D, Conforti R, Santamaria F, et al. The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study. *Journal of Alzheimer's disease : JAD*. 2017;56(2):557-65.

Gareri P, Putignano D, Castagna A, Cotroneo AM, De Palo G, Fabbo A, et al. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study. *Journal of Alzheimer's disease : JAD*. 2014;41(2):633-40.

Gares V, Andrieu S, Dupuy J-F, Savy N. An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials. *Statistics in medicine*. 2015;34(4):541-57.

Garibotto V, Frisoni GB, Zilli T. Re: Cranial irradiation significantly reduces beta amyloid plaques in the brain and improves cognition in a murine model of Alzheimer's Disease (AD). *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2016;118(3):577-8.

Gasparova Z, Stara V, Janega P, Navarova J, Sedlackova N, Mach M, et al. Pyridoindole antioxidant-induced preservation of rat hippocampal pyramidal cell number linked with reduction of oxidative stress yet without influence on cognitive deterioration in Alzheimer-like neurodegeneration. *Neuro endocrinology letters*. 2014;35(6):454-62.

Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. *AIDS (London, England)*. 2016;30(4):591-600.

Gatt AP, Duncan OF, Attems J, Francis PT, Ballard CG, Bateman JM. Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency. *Movement disorders : official journal of the Movement Disorder Society*. 2016;31(3):352-9.

Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. *Lancet (London, England)*. 2016;388(10062):2873-84.

Gauthier S, Leuzy A, Rosa-Neto P. How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease? *Neurodegenerative diseases*. 2014;13(2-3):197-9.

Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013;9(3):326-31.

Gawali NB, Bulani VD, Gursahani MS, Deshpande PS, Kothavade PS, Juvekar AR. Agmatine attenuates chronic unpredictable mild stress-induced anxiety, depression-like behaviours and cognitive impairment by modulating nitrenergic signalling pathway. *Brain research*. 2017;1663:66-77.

Ge C-L, Wang X-M, Huang Z-G, Xia Q, Wang N, Xu D-J. Tongqiao Huoxue Decoction ameliorates learning and memory defects in rats with vascular dementia by up-regulating the Ca(2+)-CaMKII-CREB pathway. *Chinese journal of natural medicines*. 2015;13(11):823-30.

Geekiyana H, Upadhye A, Chan C. Inhibition of serine palmitoyltransferase reduces Abeta and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease. *Neurobiology of aging*. 2013;34(8):2037-51.

Geerts H, Spiros A, Roberts P. Phosphodiesterase 10 inhibitors in clinical development for CNS disorders. *Expert review of neurotherapeutics*. 2017;17(6):553-60.

Gejl M, Gjedde A, Egefjord L, Moller A, Hansen SB, Vang K, et al. In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. *Frontiers in aging neuroscience*. 2016;8:108.

Gelman BB. Neuropathology of HAND With Suppressive Antiretroviral Therapy: Encephalitis and Neurodegeneration Reconsidered. *Current HIV/AIDS reports*. 2015;12(2):272-9.

Geng J, Liu W, Xiong Y, Ding H, Jiang C, Yang X, et al. Andrographolide sulfonate improves Alzheimer-associated phenotypes and mitochondrial dysfunction in APP/PS1 transgenic mice. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2017;97:1032-9.

Gentier RJG, Verheijen BM, Zamboni M, Stroeken MMA, Hermes DJHP, Kusters B, et al. Localization of mutant ubiquitin in the brain of a transgenic mouse line with proteasomal inhibition and its validation at specific sites in Alzheimer's disease. *Frontiers in neuroanatomy*. 2015;9:26.

Genuis SJ, Kelln KL. Toxicant exposure and bioaccumulation: a common and potentially reversible cause of cognitive dysfunction and dementia. *Behavioural neurology*. 2015;2015:620143.

George C, Gontier G, Lacube P, Francois J-C, Holzenberger M, Aid S. The Alzheimer's disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons. *Brain : a journal of neurology*. 2017;140(7):2012-27.

George DR, Stuckey HL, Whitehead MM. An arts-based intervention at a nursing home to improve medical students' attitudes toward persons with dementia. *Academic medicine : journal of the Association of American Medical Colleges*. 2013;88(6):837-42.

George DR, Stuckey HL, Whitehead MM. How a creative storytelling intervention can improve medical student attitude towards persons with dementia: a mixed methods study. *Dementia (London, England)*. 2014;13(3):318-29.

George K. Urgent revision required of NICE guidance relating to prevention of spread of vCJD through neurosurgical instruments. *British journal of neurosurgery*. 2014;28(2):295.

Gerenu G, Liu K, Chojnacki JE, Saathoff JM, Martinez-Martin P, Perry G, et al. Curcumin/melatonin hybrid 5-(4-hydroxy-phenyl)-3-oxo-pentanoic acid 2-(5-methoxy-1H-indol-3-yl)-ethyl -amide ameliorates AD-like pathology in the APP/PS1 mouse model. *ACS chemical neuroscience*. 2015;6(8):1393-9.

Gerenu G, Martisova E, Ferrero H, Carracedo M, Rantamaki T, Ramirez MJ, et al. Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer's neuropathology and cognitive deficits. *Biochimica et biophysica acta*. 2017;1863(4):991-1001.

Gertsik N, Chau D-M, Li Y-M. gamma-Secretase Inhibitors and Modulators Induce Distinct Conformational Changes in the Active Sites of gamma-Secretase and Signal Peptide Peptidase. *ACS chemical biology*. 2015;10(8):1925-31.

Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, et al. Pridopidine activates neuroprotective pathways impaired in Huntington Disease. *Human molecular genetics*. 2016;25(18):3975-87.

Ghahremanitamadon F, Shahidi S, Zargooshnia S, Nikkhah A, Ranjbar A, Soleimani Asl S. Protective effects of *Borago officinalis* extract on amyloid beta-peptide(25-35)-induced memory impairment in male rats: a behavioral study. *BioMed research international*. 2014;2014:798535.

Ghanbarabadi M, Iranshahi M, Amoueian S, Mehri S, Motamedshariaty VS, Mohajeri SA. Neuroprotective and memory enhancing effects of auraptene in a rat model of vascular dementia: Experimental study and histopathological evaluation. *Neuroscience letters*. 2016;623:13-21.

Ghanim H, Dandona P. Comment on Vandal et al. Insulin Reverses the High-Fat Diet-Induced Increase in Brain Abeta and Improves Memory in an Animal Model of Alzheimer Disease. *Diabetes* 2014;63:4291-4301. *Diabetes*. 2015;64(7):e17.

Gharbiya M, Trebbastoni A, Parisi F, Manganiello S, Cruciani F, D'Antonio F, et al. Choroidal thinning as a new finding in Alzheimer's disease: evidence from enhanced depth imaging spectral domain optical coherence tomography. *Journal of Alzheimer's disease : JAD*. 2014;40(4):907-17.

Ghasemi Moravej F, Vahabian M, Soleimani Asl S. Dimethyloxalylglycine may be enhance the capacity of neural-like cells in treatment of Alzheimer disease. *Cell biology international*. 2016;40(6):619-20.

Ghidoni R, Flocco R, Paterlini A, Glionna M, Caruana L, Tonoli E, et al. Secretory leukocyte protease inhibitor protein regulates the penetrance of frontotemporal lobar degeneration in progranulin mutation carriers. *Journal of Alzheimer's disease : JAD*. 2014;38(3):533-9.

Ghilan M, Bostrom CA, Hryciw BN, Simpson JM, Christie BR, Gil-Mohapel J. YAC128 Huntington's disease transgenic mice show enhanced short-term hippocampal synaptic plasticity early in the course of the disease. *Brain research*. 2014;1581:117-28.

Ghofrani S, Joghataei M-T, Mohseni S, Baluchnejadmojarad T, Bagheri M, Khamse S, et al. Naringenin improves learning and memory in an Alzheimer's disease rat model: Insights into the underlying mechanisms. *European journal of pharmacology*. 2015;764:195-201.

Ghoneim FM, Khalaf HA, Elsamanoudy AZ, Abo El-Khair SM, Helaly AMN, Mahmoud E-HM, et al. Protective effect of chronic caffeine intake on gene expression of brain derived neurotrophic factor signaling and the immunoreactivity of glial fibrillary acidic protein and Ki-67 in Alzheimer's disease. *International journal of clinical and experimental pathology*. 2015;8(7):7710-28.

Ghosal K, Stathopoulos A, Thomas D, Phenis D, Vitek MP, Pimplikar SW. The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer's disease-like pathological features. *Neuro-degenerative diseases*. 2013;12(1):51-8.

Ghosh AK, Osswald HL. BACE1 (beta-secretase) inhibitors for the treatment of Alzheimer's disease. *Chemical Society reviews*. 2014;43(19):6765-813.

Ghosh AK, Tang J. Prospects of beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease. *ChemMedChem*. 2015;10(9):1463-6.

Ghosh D, LeVault KR, Brewer GJ. Dual-energy precursor and nuclear erythroid-related factor 2 activator treatment additively improve redox glutathione levels and neuron survival in aging and Alzheimer mouse neurons upstream of reactive oxygen species. *Neurobiology of aging*. 2014;35(1):179-90.

Ghosh S, Basak P, Dutta S, Chowdhury S, Sil PC. New insights into the ameliorative effects of ferulic acid in pathophysiological conditions. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*. 2017;103:41-55.

Ghosh S, Chatterjee S, Roy A, Ray K, Swarnakar S, Fujita D, et al. Resonant oscillation language of a futuristic nano-machine-module: eliminating cancer cells & Alzheimer abeta plaques. *Current topics in medicinal chemistry*. 2015;15(6):534-41.

Ghumatkar PJ, Patil SP, Jain PD, Tambe RM, Sathaye S. Nootropic, neuroprotective and neurotrophic effects of phloretin in scopolamine induced amnesia in mice. *Pharmacology, biochemistry, and behavior*. 2015;135:182-91.

Giannoni P, Gaven F, de Bundel D, Baranger K, Marchetti-Gauthier E, Roman FS, et al. Early administration of RS 67333, a specific 5-HT₄ receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease. *Frontiers in aging neuroscience*. 2013;5:96.

Giannopoulos PF, Chu J, Joshi YB, Sperow M, Li J-G, Kirby LG, et al. 5-lipoxygenase activating protein reduction ameliorates cognitive deficit, synaptic dysfunction, and neuropathology in a mouse model of Alzheimer's disease. *Biological psychiatry*. 2013;74(5):348-56.

Giannopoulos PF, Chu J, Joshi YB, Sperow M, Li JG, Kirby LG, et al. Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease. *Molecular psychiatry*. 2014;19(4):511-8.

Gibbs M. Reflections on glycogen and beta-amyloid: why does glycogenolytic beta₂-adrenoceptor stimulation not rescue memory after beta-amyloid? *Metabolic brain disease*. 2015;30(1):345-52.

Giebel CM, Burns A, Challis D. Taking a positive spin: preserved initiative and performance of everyday activities across mild Alzheimer's, vascular and mixed dementia. *International journal of geriatric psychiatry*. 2017;32(9):959-67.

Giebel CM, Zubair M, Jolley D, Bhui KS, Purandare N, Worden A, et al. South Asian older adults with memory impairment: improving assessment and access to dementia care. *International journal of geriatric psychiatry*. 2015;30(4):345-56.

Gietl AF, Unschuld PG. Screening and prevention of cognitive disorder in the elderly. *Revue medicale suisse*. 2015;11(491):1944-8.

Giil LM, Vedeler CA, Kristoffersen EK, Nordrehaug JE, Heidecke H, Dechend R, et al. Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function. *Journal of Alzheimer's disease : JAD*. 2017;59(3):929-39.

Gilbert EJ. 1,3-Oxazines as BACE1 and/or BACE2 inhibitors: a patent evaluation (WO2012156284). *Expert opinion on therapeutic patents*. 2013;23(8):1069-73.

Giles GM, Edwards DF, Morrison MT, Baum C, Wolf TJ. Screening for Functional Cognition in Postacute Care and the Improving Medicare Post-Acute Care Transformation (IMPACT) Act of 2014. *The American journal of occupational therapy : official publication of the American Occupational Therapy Association*. 2017;71(5):7105090010p1-p6.

Gill JS, Jamwal S, Kumar P, Deshmukh R. Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation. *Pharmacological reports : PR*. 2017;69(2):306-13.

Gillen R, Firbank MJ, Lloyd J, O'Brien JT. CT-based attenuation and scatter correction compared with uniform attenuation correction in brain perfusion SPECT imaging for dementia. *Physics in medicine and biology*. 2015;60(17):6775-87.

Gillespie AK, Jones EA, Lin Y-H, Karlsson MP, Kay K, Yoon SY, et al. Apolipoprotein E4 Causes Age-Dependent Disruption of Slow Gamma Oscillations during Hippocampal Sharp-Wave Ripples. *Neuron*. 2016;90(4):740-51.

Gillman AL, Lee J, Ramachandran S, Capone R, Gonzalez T, Wrasidlo W, et al. Small molecule NPT-440-1 inhibits ionic flux through Abeta1-42 pores: Implications for Alzheimer's disease therapeutics. *Nanomedicine : nanotechnology, biology, and medicine*. 2016;12(8):2331-40.

Gimenez-Llort L, Rivera-Hernandez G, Marin-Argany M, Sanchez-Quesada JL, Villegas S. Early intervention in the 3xTg-AD mice with an amyloid beta-antibody fragment ameliorates first hallmarks of Alzheimer disease. *mAbs*. 2013;5(5):665-77.

Ginis KAM, Heisz J, Spence JC, Clark IB, Antflick J, Ardern CI, et al. Formulation of evidence-based messages to promote the use of physical activity to prevent and manage Alzheimer's disease. *BMC public health*. 2017;17(1):209.

Giordano CR, Terlecky LJ, Bollig-Fischer A, Walton PA, Terlecky SR. Amyloid-beta neuroprotection mediated by a targeted antioxidant. *Scientific reports*. 2014;4:4983.

Giovagnoli AR, Oliveri S, Schifano L, Raglio A. Active music therapy improves cognition and behaviour in chronic vascular encephalopathy: a case report. *Complementary therapies in medicine*. 2014;22(1):57-62.

Giraldo E, Lloret A, Fuchsberger T, Vina J. Abeta and tau toxicities in Alzheimer's are linked via oxidative stress-induced p38 activation: protective role of vitamin E. *Redox biology*. 2014;2:873-7.

Giralt A, Saavedra A, Carreton O, Arumi H, Tyebji S, Alberch J, et al. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model. *Hippocampus*. 2013;23(8):684-95.

Giubilei F. Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer's Disease. *CNS & neurological disorders drug targets*. 2016;15(6):683-9.

Giuliani A, Beggiato S, Baldassarro VA, Mangano C, Giardino L, Imbimbo BP, et al. CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice. *Journal of neurochemistry*. 2013;124(5):613-20.

Giuliani D, Bitto A, Galantucci M, Zaffe D, Ottani A, Irrera N, et al. Melanocortins protect against progression of Alzheimer's disease in triple-transgenic mice by targeting multiple pathophysiological pathways. *Neurobiology of aging*. 2014;35(3):537-47.

Giuliani D, Galantucci M, Neri L, Canalini F, Calevro A, Bitto A, et al. Melanocortins protect against brain damage and counteract cognitive decline in a transgenic mouse model of moderate Alzheimer's disease. *European journal of pharmacology*. 2014;740:144-50.

Giuliani D, Ottani A, Zaffe D, Galantucci M, Strinati F, Lodi R, et al. Hydrogen sulfide slows down progression of experimental Alzheimer's disease by targeting multiple pathophysiological mechanisms. *Neurobiology of learning and memory*. 2013;104:82-91.

Gjerberg E, Hem MH, Forde R, Pedersen R. How to avoid and prevent coercion in nursing homes: a qualitative study. *Nursing ethics*. 2013;20(6):632-44.

Glasper A. A vision for enhanced dementia care. *British journal of nursing* (Mark Allen Publishing). 2013;22(8):486-7.

Glat M, Skaat H, Menkes-Caspi N, Margel S, Stern EA. Age-dependent effects of microglial inhibition in vivo on Alzheimer's disease neuropathology using bioactive-conjugated iron oxide nanoparticles. *Journal of nanobiotechnology*. 2013;11:32.

Glynn RW, Dolan C, Shelley E, Lawlor B. Evidence-based prevention and treatment of dementia. *The Lancet Neurology*. 2016;15(10):1006-7.

Glynn-Servedio BE, Ranola TS. AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease. *The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists*. 2017;32(9):511-8.

Godoy JA, Zolezzi JM, Inestrosa NC. INT131 increases dendritic arborization and protects against Abeta toxicity by inducing mitochondrial changes in hippocampal neurons. *Biochemical and biophysical research communications*. 2017;490(3):955-62.

Godyn J, Hebda M, Wieckowska A, Wieckowski K, Malawska B, Bajda M. Lipophilic properties of anti-Alzheimer's agents determined by micellar electrokinetic chromatography and reversed-phase thin-layer chromatography. *Electrophoresis*. 2017;38(9-10):1268-75.

Gol M, Ghorbanian D, Soltanpour N, Faraji J, Pourghasem M. Protective effect of raisin (currant) against spatial memory impairment and oxidative stress in Alzheimer disease model. *Nutritional neuroscience*. 2017;1-9.

Goldberg NRS, Caesar J, Park A, Sedgh S, Finogenov G, Masliah E, et al. Neural Stem Cells Rescue Cognitive and Motor Dysfunction in a Transgenic Model of Dementia with Lewy Bodies through a BDNF-Dependent Mechanism. *Stem cell reports*. 2015;5(5):791-804.

Goldberg NRS, Marsh SE, Ochaba J, Shelley BC, Davtyan H, Thompson LM, et al. Human Neural Progenitor Transplantation Rescues Behavior and Reduces alpha-Synuclein in a Transgenic Model of Dementia with Lewy Bodies. *Stem cells translational medicine*. 2017;6(6):1477-90.

Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. gamma-Secretase inhibitors and modulators. *Biochimica et biophysica acta*. 2013;1828(12):2898-907.

Goldeck D, Larbi A, Pellicano M, Alam I, Zerr I, Schmidt C, et al. Enhanced Chemokine Receptor Expression on Leukocytes of Patients with Alzheimer's Disease. *PloS one*. 2013;8(6):e66664.

Goldstein FC, Steenland K, Zhao L, Wharton W, Levey AI, Hajjar I. Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia. *Journal of the American Geriatrics Society*. 2017;65(9):1969-74.

Gomes JS, Ducos DV, Akiba H, Dias AM. A neurofeedback protocol to improve mild anxiety and sleep quality. *Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)*. 2016;38(3):264-5.

Gomm W, Haenisch B. Proton Pump Inhibitors and Dementia Incidence-Reply. *JAMA neurology*. 2016;73(8):1028-9.

Gomm W, von Holt K, Thome F, Broich K, Maier W, Fink A, et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. *JAMA neurology*. 2016;73(4):410-6.

Goncalves MB, Clarke E, Hobbs C, Malmqvist T, Deacon R, Jack J, et al. Amyloid beta inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor alpha agonist. *The European journal of neuroscience*. 2013;37(7):1182-92.

Gong B, Levine S, Barnum SR, Pasinetti GM. Role of complement systems in IVIG mediated attenuation of cognitive deterioration in Alzheimer's disease. *Current Alzheimer research*. 2014;11(7):637-44.

Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha

regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. *Neurobiology of aging*. 2013;34(6):1581-8.

Gong B, Pan Y, Zhao W, Knable L, Vempati P, Begum S, et al. IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway. *Molecular immunology*. 2013;56(4):619-29.

Gong Y-H, Hua N, Zang X, Huang T, He L. Melatonin ameliorates Abeta1-42 -induced Alzheimer's cognitive deficits in mouse model. *The Journal of pharmacy and pharmacology*. 2017.

Goni F, Herline K, Peyser D, Wong K, Ji Y, Sun Y, et al. Immunomodulation targeting of both Abeta and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models. *Journal of neuroinflammation*. 2013;10:150.

Gontier G, George C, Chaker Z, Holzenberger M, Aid S. Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-beta Clearance. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2015;35(33):11500-13.

Gonzalez EW, Polansky M, Lippa CF, Gitlin LN, Zauszniewski JA. Enhancing resourcefulness to improve outcomes in family caregivers and persons with Alzheimer's disease: a pilot randomized trial. *International journal of Alzheimer's disease*. 2014;2014:323478.

Gonzalez-Baeza A, Carvajal F, Bayon C, Perez-Valero I, Estebanez M, Bernardino JI, et al. Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: a detailed neuropsychological study. *Journal of neurovirology*. 2014;20(4):362-70.

Gonzalez-Lima F, Barksdale BR, Rojas JC. Mitochondrial respiration as a target for neuroprotection and cognitive enhancement. *Biochemical pharmacology*. 2014;88(4):584-93.

Gonzalez-Naranjo P, Perez-Macias N, Campillo NE, Perez C, Aran VJ, Giron R, et al. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. *European journal of medicinal chemistry*. 2014;73:56-72.

Gonzalez-Roman L, Bagur-Calafat C, Urrutia-Cuchi G, Garrido-Pedrosa J. Interventions based on exercise and physical environment for preventing falls in cognitively impaired older people living in long-term care facilities: A systematic review and meta-analysis. *Revista espanola de geriatria y gerontologia*. 2016;51(2):96-111.

Goozee KG, Shah TM, Sohrabi HR, Rainey-Smith SR, Brown B, Verdile G, et al. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease. *The British journal of nutrition*. 2016;115(3):449-65.

Gordon PJ. No evidence exists that "anti-dementia" drugs modify disease or improve outcome. *BMJ (Clinical research ed)*. 2014;348:g2607.

Gorelick PB. World Stroke Day Proclamation 2015: Call to Preserve Cognitive Vitality. *Stroke*. 2015;46(11):3037-8.

Goryawala M, Zhou Q, Barker W, Loewenstein DA, Duara R, Adjouadi M. Inclusion of Neuropsychological Scores in Atrophy Models Improves Diagnostic Classification of Alzheimer's Disease and Mild Cognitive Impairment. *Computational intelligence and neuroscience*. 2015;2015:865265.

Gotoh A, Hidaka M, Hirose K, Uchida T. Gas7b (growth arrest specific protein 7b) regulates neuronal cell morphology by enhancing microtubule and actin filament assembly. *The Journal of biological chemistry*. 2013;288(48):34699-706.

Gott C, Gates T, Dermody N, Brew BJ, Cysique LA. Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity. *PloS one*. 2017;12(3):e0171887.

Gougeon L, Payette H, Morais JA, Gaudreau P, Shatenstein B, Gray-Donald K. A prospective evaluation of the depression-nutrient intake reverse causality hypothesis in a cohort of community-dwelling older Canadians. *The British journal of nutrition*. 2017;117(7):1032-41.

Gouse H, Casson-Crook M, Decloedt EH, Joska JA, Thomas KGF. Adding a brief self-report cognitive tool to the IHDS improves effectiveness of identifying patients with HIV-associated dementia in South Africa. *Journal of neurovirology*. 2017;23(5):686-95.

Govindarajan N, Rao P, Burkhardt S, Sananbenesi F, Schluter OM, Bradke F, et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. *EMBO molecular medicine*. 2013;5(1):52-63.

Goyal D, Shuaib S, Mann S, Goyal B. Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-beta (A β) Aggregation: Potential Therapeutics of Alzheimer's Disease. *ACS combinatorial science*. 2017;19(2):55-80.

Goyal M, Dhanjal JK, Goyal S, Tyagi C, Hamid R, Grover A. Development of dual inhibitors against Alzheimer's disease using fragment-based QSAR and molecular docking. *BioMed research international*. 2014;2014:979606.

Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, et al. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide). *Journal of Alzheimer's disease : JAD*. 2014;40 Suppl 1:S23-36.

Gozes I, Yeheskel A, Pasmanik-Chor M. Activity-dependent neuroprotective protein (ADNP): a case study for highly conserved chordata-specific genes shaping the brain and mutated in cancer. *Journal of Alzheimer's disease : JAD*. 2015;45(1):57-73.

Gozes I. Activity-dependent neuroprotective protein (ADNP): from autism to Alzheimer's disease. *SpringerPlus*. 2015;4(Suppl 1):L37.

Gozes I. Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer's disease. *Journal of neuroscience research*. 2017;95(1-2):652-60.

Gozes I. Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress. *The EPMA journal*. 2017;8(3):255-9.

Gozes I. The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP. *Biological chemistry*. 2016;397(3):177-84.

Gracie DJ, Ford AC. The possible risks of proton pump inhibitors. *The Medical journal of Australia*. 2016;205(7):292-3.

Graham F. A New Frontier: Improving Nursing Care for People With Dementia and Delirium in Hospitals. *The Journal of nursing administration*. 2015;45(12):589-91.

Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer's Disease Therapy and Prevention Strategies. *Annual review of medicine*. 2017;68:413-30.

Graham-Phillips A, Roth DL, Huang J, Dilworth-Anderson P, Gitlin LN. Racial and Ethnic Differences in the Delivery of the Resources for Enhancing Alzheimer's Caregiver Health II Intervention. *Journal of the American Geriatrics Society*. 2016;64(8):1662-7.

Graipaspong N, Thaipisuttikul P, Vallipakorn SA-O. Cholinesterase Inhibitors and Behavioral & Psychological Symptoms of Alzheimer's Disease. *Journal of the Medical Association of Thailand = Chotmaihet thangphaet*. 2016;99(4):433-40.

Grande G, Cucumo V, Cova I, Ghiretti R, Maggiore L, Lacorte E, et al. Reversible Mild Cognitive Impairment: The Role of Comorbidities at Baseline Evaluation. *Journal of Alzheimer's disease : JAD*. 2016;51(1):57-67.

Granica S, Kiss AK, Jaronczyk M, Maurin JK, Mazurek AP, Czarnocki Z. Synthesis of imperatorin analogs and their evaluation as acetylcholinesterase and butyrylcholinesterase inhibitors. *Archiv der Pharmazie*. 2013;346(11):775-82.

Grant RL, Drennan VM, Rait G, Petersen I, Iliffe S. First diagnosis and management of incontinence in older people with and without dementia in primary care: a cohort study using The Health Improvement Network primary care database. *PLoS medicine*. 2013;10(8):e1001505.

Grasset L, Joly P, Jacqmin-Gadda H, Letenneur L, Wittwer J, Amieva H, et al. Real benefit of a protective factor against dementia: Importance of controlling for death. Example of sport practice. *PloS one*. 2017;12(4):e0174950.

Grassi D, Ferri C, Desideri G. Brain Protection and Cognitive Function: Cocoa Flavonoids as Nutraceuticals. *Current pharmaceutical design*. 2016;22(2):145-51.

Gratuze M, Julien J, Petry FR, Morin F, Planel E. Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer's disease-like tau pathology. *Scientific reports*. 2017;7:46359.

Gray NE, Zweig JA, Kawamoto C, Quinn JF, Soumyanath A. Centella asiatica improves synaptic plasticity and activates antioxidant and mitochondrial pathways in hippocampal neurons from an Alzheimer's disease mouse model. *Planta medica*. 2016;81(S 01):S1-S381.

Gray NE, Zweig JA, Murchison C, Caruso M, Matthews DG, Kawamoto C, et al. Centella asiatica attenuates Abeta-induced neurodegenerative spine loss and dendritic simplification. *Neuroscience letters*. 2017;646:24-9.

Gray SL, Walker RL, Dublin S, Yu O, Aiello Bowles EJ, Anderson ML, et al. Proton Pump Inhibitor Use and Dementia Risk: Prospective Population-Based Study. *Journal of the American Geriatrics Society*. 2017.

Green AR, Leff B, Wang Y, Spatz ES, Masoudi FA, Peterson PN, et al. Geriatric Conditions in Patients Undergoing Defibrillator Implantation for Prevention of Sudden Cardiac Death: Prevalence and Impact on Mortality. *Circulation Cardiovascular quality and outcomes*. 2016;9(1):23-30.

Greenberg BD, Carrillo MC, Ryan JM, Gold M, Gallagher K, Grundman M, et al. Improving Alzheimer's disease phase II clinical trials. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013;9(1):39-49.

Greengross BS. Contributions are welcomed on how to prevent dementia. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*. 2014;28(44):37.

Gregori M, Taylor M, Salvati E, Re F, Mancini S, Balducci C, et al. Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Abeta peptide. *Nanomedicine : nanotechnology, biology, and medicine*. 2017;13(2):723-32.

Gregory MA, Gill DP, Zou G, Liu-Ambrose T, Shigematsu R, Fitzgerald C, et al. Group-based exercise combined with dual-task training improves gait but not vascular health in active older adults without dementia. *Archives of gerontology and geriatrics*. 2016;63:18-27.

Greig NH, Reale M, Tata AM. New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors. *Recent patents on CNS drug discovery*. 2013;8(2):123-41.

Greig NH, Sambamurti K, Lahiri DK, Becker RE. Amyloid-beta precursor protein synthesis inhibitors for Alzheimer's disease treatment. *Annals of neurology*. 2014;76(4):629-30.

Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. *Neuron*. 2013;78(4):631-43.

Griffanti L, Dipasquale O, Lagana MM, Nemni R, Clerici M, Smith SM, et al. Effective artifact removal in resting state fMRI data improves detection of DMN functional connectivity alteration in Alzheimer's disease. *Frontiers in human neuroscience*. 2015;9:449.

Griffanti L, Wilcock GK, Voets N, Bonifacio G, Mackay CE, Jenkinson M, et al. Donepezil Enhances Frontal Functional Connectivity in Alzheimer's Disease: A Pilot Study. *Dementia and geriatric cognitive disorders extra*. 2016;6(3):518-28.

Grigoryan G, Biella G, Albani D, Forloni G, Segal M. Stress impairs synaptic plasticity in triple-transgenic Alzheimer's disease mice: rescue by ryanodine. *Neuro-degenerative diseases*. 2014;13(2-3):135-8.

Grigsby TJ, Unger JB, Molina GB, Baron M. Evaluation of an Audio-Visual Novela to Improve Beliefs, Attitudes and Knowledge toward Dementia: A Mixed-Methods Approach. *Clinical gerontologist*. 2017;40(2):130-8.

Grill JD, Monsell SE. Choosing Alzheimer's disease prevention clinical trial populations. *Neurobiology of aging*. 2014;35(3):466-71.

Grimm A, Biliouris EE, Lang UE, Gotz J, Mensah-Nyagan AG, Eckert A. Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid-beta or hyperphosphorylated tau protein. *Cellular and molecular life sciences : CMLS*. 2016;73(1):201-15.

Grimm MOW, Michaelson DM, Hartmann T. Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention. *Journal of lipid research*. 2017;58(11):2083-101.

Grinde B, Engdahl B. Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified. *Immunity & ageing : I & A*. 2017;14:20.

Griser S, Lipsey L, Montross-Thomas LP. Enjoy. Shuffle. Repeat: Using Personalized Music Playlists To Improve the Quality of Life for People with Dementia. *Journal of palliative medicine*. 2016;19(11):1232-3.

Grosas AB, Kalimuthu P, Smith AC, Williams PA, Millar TJ, Bernhardt PV, et al. The tachykinin peptide neurokinin B binds copper(I) and silver(I) and undergoes quasi-reversible electrochemistry: towards a new function for the peptide in the brain. *Neurochemistry international*. 2014;70:1-9.

Grossberg GT, Manes F, Allegri RF, Gutierrez-Robledo LM, Gloger S, Xie L, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. *CNS drugs*. 2013;27(6):469-78.

Group A-FR. Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2015;11(2):216-25.e1.

Grund B, Wright EJ, Brew BJ, Price RW, Roediger MP, Bain MP, et al. Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. *Journal of neurovirology*. 2013;19(4):383-92.

Gruslys A, Acosta-Cabronero J, Nestor PJ, Williams GB, Ansorge RE. A new fast accurate nonlinear medical image registration program including surface preserving regularization. *IEEE transactions on medical imaging*. 2014;33(11):2118-27.

Grydeland H, Westlye LT, Walhovd KB, Fjell AM. Improved prediction of Alzheimer's disease with longitudinal white matter/gray matter contrast changes. *Human brain mapping*. 2013;34(11):2775-85.

Gu G, Zhang W, Li M, Ni J, Wang P. Transplantation of NSC-derived cholinergic neuron-like cells improves cognitive function in APP/PS1 transgenic mice. *Neuroscience*. 2015;291:81-92.

Gu T, Wu W-Y, Dong Z-X, Yu S-P, Sun Y, Zhong Y, et al. Development and Structural Modification of BACE1 Inhibitors. *Molecules (Basel, Switzerland)*. 2016;22(1).

Gu X, Cai Z, Cai M, Liu K, Liu D, Zhang Q, et al. Protective effect of paeoniflorin on inflammation and apoptosis in the cerebral cortex of a transgenic mouse model of Alzheimer's disease. *Molecular medicine reports*. 2016;13(3):2247-52.

Gu X-H, Xu L-J, Liu Z-Q, Wei B, Yang Y-J, Xu G-G, et al. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease. *Behavioural brain research*. 2016;311:309-21.

Guan Y, Cao KJ, Cantlon A, Elbel K, Theodorakis EA, Walsh DM, et al. Real-Time Monitoring of Alzheimer's-Related Amyloid Aggregation via Probe Enhancement-Fluorescence Correlation Spectroscopy. *ACS chemical neuroscience*. 2015;6(9):1503-8.

Guerriero F, Botarelli E, Mele G, Polo L, Zoncu D, Renati P, et al. An innovative intervention for the treatment of cognitive impairment-Emisymmetric bilateral stimulation improves cognitive functions in Alzheimer's disease and mild cognitive impairment: an open-label study. *Neuropsychiatric disease and treatment*. 2015;11:2391-404.

Guideline Adaptation Committee CPGfDiA. Clinical Practice Guidelines for Dementia in Australia: A step towards improving uptake of research findings in health- and aged-care settings. *Australasian journal on ageing*. 2016;35(2):86-9.

Guillot-Sestier M-V, Doty KR, Gate D, Rodriguez J, Jr., Leung BP, Rezai-Zadeh K, et al. IL10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. *Neuron*. 2015;85(3):534-48.

Guo C, Wang P, Zhong M-L, Wang T, Huang X-S, Li J-Y, et al. Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. *Neurochemistry international*. 2013;62(2):165-72.

Guo C, Wang T, Zheng W, Shan Z-Y, Teng W-P, Wang Z-Y. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. *Neurobiology of aging*. 2013;34(2):562-75.

Guo C, Yang Z-H, Zhang S, Chai R, Xue H, Zhang Y-H, et al. Intranasal Lactoferrin Enhances alpha-Secretase-Dependent Amyloid Precursor Protein Processing via the ERK1/2-CREB and HIF-1alpha Pathways in an Alzheimer's Disease Mouse Model. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2017;42(13):2504-15.

Guo CN, Sun L, Liu GL, Zhao SJ, Liu WW, Zhao YB. Protective effect of nicotine on the cultured rat basal forebrain neurons damaged by beta-Amyloid (Abeta)25-35 protein cytotoxicity. *European review for medical and pharmacological sciences*. 2015;19(16):2964-72.

Guo H, Cao M, Zou S, Ye B, Dong Y. Cranberry Extract Standardized for Proanthocyanidins Alleviates beta-Amyloid Peptide Toxicity by Improving Proteostasis Through HSF-1 in *Caenorhabditis elegans* Model of Alzheimer's Disease. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2016;71(12):1564-73.

Guo H, Dong Y-Q, Ye B-P. Cranberry extract supplementation exerts preventive effects through alleviating Abeta toxicity in *Caenorhabditis elegans* model of Alzheimer's disease. *Chinese journal of natural medicines*. 2016;14(6):427-33.

Guo H-D, Zhu J, Tian J-X, Shao S-J, Xu Y-W, Mou F-F, et al. Electroacupuncture improves memory and protects neurons by regulation of the autophagy pathway in a rat model of Alzheimer's disease. *Acupuncture in medicine : journal of the British Medical Acupuncture Society*. 2016;34(6):449-56.

Guo J, Yang C, Yang J, Yao Y. Glycyrrhizic Acid Ameliorates Cognitive Impairment in a Rat Model of Vascular Dementia Associated with Oxidative Damage and Inhibition of Voltage-Gated Sodium Channels. *CNS & neurological disorders drug targets*. 2016;15(8):1001-8.

Guo J-P, Pan J-X, Xiong L, Xia W-F, Cui S, Xiong W-C. Iron Chelation Inhibits Osteoclastic Differentiation In Vitro and in Tg2576 Mouse Model of Alzheimer's Disease. *PloS one*. 2015;10(11):e0139395.

Guo J-W, Guan P-P, Ding W-Y, Wang S-L, Huang X-S, Wang Z-Y, et al. Erythrocyte membrane-encapsulated celecoxib improves the cognitive decline of Alzheimer's disease by concurrently inducing neurogenesis and reducing apoptosis in APP/PS1 transgenic mice. *Biomaterials*. 2017;145:106-27.

Guo K, Li L, Yin G, Zi X, Liu L. Bag5 protects neuronal cells from amyloid beta-induced cell death. *Journal of molecular neuroscience : MN*. 2015;55(4):815-20.

Guo K, Yin G, Zi XH, Zhu HX, Pan Q. Effect of selective serotonin reuptake inhibitors on expression of 5-HT1AR and neurotransmitters in rats with vascular dementia. *Genetics and molecular research : GMR*. 2016;15(4).

Guo L, Du H, Yan S, Wu X, McKhann GM, Chen JX, et al. Cyclophilin D deficiency rescues axonal mitochondrial transport in Alzheimer's neurons. *PloS one*. 2013;8(1):e54914.

Guo W, Sha S, Xing X, Jiang T, Cao Y. Reduction of cerebral Abeta burden and improvement in cognitive function in Tg-APPswe/PSEN1dE9 mice following vaccination with a multivalent Abeta3-10 DNA vaccine. *Neuroscience letters*. 2013;549:109-15.

Guo X, Disatnik M-H, Monbureau M, Shamloo M, Mochly-Rosen D, Qi X. Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. *The Journal of clinical investigation*. 2013;123(12):5371-88.

Guo X-D, Sun G-L, Zhou T-T, Xu X, Zhu Z-Y, Rukachaisirikul V, et al. Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid beta production and clearance. *Acta pharmacologica Sinica*. 2016;37(10):1281-97.

Guo Y, Zhao Y, Nan Y, Wang X, Chen Y, Wang S. (-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer's disease. *Neuroreport*. 2017;28(10):590-7.

Guo Z, Chen Y, Mao Y-F, Zheng T, Jiang Y, Yan Y, et al. Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer's rat model. *Scientific reports*. 2017;7:45971.

Gupta A, Lacoste B, Pistell PJ, Pistel PJ, Ingram DK, Hamel E, et al. Neurotherapeutic effects of novel HO-1 inhibitors in vitro and in a transgenic mouse model of Alzheimer's disease. *Journal of neurochemistry*. 2014;131(6):778-90.

Gupta M, Singh R, Singh K, Lehl SS. Reversible dementia and gait disturbance as a result of polypharmacy. *BMJ case reports*. 2013;2013.

Gupta S, Sharma B, Singh P, Sharma BM. Modulation of transient receptor potential vanilloid subtype 1 (TRPV1) and norepinephrine transporters (NET) protect against oxidative stress, cellular injury, and vascular dementia. *Current neurovascular research*. 2014;11(2):94-106.

Gupta S, Sharma B. Protective effects of phosphodiesterase-1 (PDE1) and ATP sensitive potassium (KATP) channel modulators against 3-nitropropionic acid induced behavioral and biochemical toxicities in experimental Huntington's disease. *European journal of pharmacology*. 2014;732:111-22.

Gupta S, Singh P, Sharma B. Neuroprotective Effects of Nicorandil in Chronic Cerebral Hypoperfusion-Induced Vascular Dementia. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association*. 2016;25(11):2717-28.

Gupta S, Singh P, Sharma BM, Sharma B. Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia. *Current neurovascular research*. 2015;12(3):240-52.

Gurjar AS, Andrisano V, Simone AD, Velingkar VS. Design, synthesis, in silico and in vitro screening of 1,2,4-thiadiazole analogues as non-peptide inhibitors of beta-secretase. *Bioorganic chemistry*. 2014;57:90-8.

Gurung AB, Aguan K, Mitra S, Bhattacharjee A. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease. *Journal of biomolecular structure & dynamics*. 2017;35(8):1729-42.

Gutierrez JM, Carvalho FB, Schetinger MRC, Marisco P, Agostinho P, Rodrigues M, et al. Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-induced sporadic dementia of Alzheimer's type. *Life sciences*. 2014;96(1-2):7-17.

Gutierrez BAO, Silva HSd, Guimaraes C, Campino AC. Economic impact of Alzheimer's Disease in Brazil: is it possible to improve care and minimize costs? *Ciencia & saude coletiva*. 2014;19(11):4479-86.

Gutierrez-Vargas JA, Moreno H, Cardona-Gomez GP. Targeting CDK5 post-stroke provides long-term neuroprotection and rescues synaptic plasticity. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2017;37(6):2208-23.

Guzman DC, Bratoeff E, Riveros AC, Brizuela NO, Mejia GB, Garcia EH, et al. Effect of two antiandrogens as protectors of prostate and brain in a Huntington's animal model. *Anti-cancer agents in medicinal chemistry*. 2014;14(9):1293-301.

Guzman R, Campos C, Yuguero R, Masego C, Gil P, Moragon AC. Protective effect of sulfurous water in peripheral blood mononuclear cells of Alzheimer's disease patients. *Life sciences*. 2015;132:61-7.

Guzzi C, Colombo L, Luigi AD, Salmona M, Nicotra F, Airolidi C. Flavonoids and Their Glycosides as Anti-amyloidogenic Compounds: Abeta1-42 Interaction Studies to Gain New Insights into Their Potential for Alzheimer's Disease Prevention and Therapy. *Chemistry, an Asian journal*. 2017;12(1):67-75.

Ha H, Kang DW, Kim H-M, Kang J-M, Ann J, Hyun HJ, et al. Discovery of an Orally Bioavailable Benzofuran Analogue that Serves as a beta-amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer's Disease. *Journal of medicinal chemistry*. 2017.

Haas LT, Salazar SV, Smith LM, Zhao HR, Cox TO, Herber CS, et al. Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes. *Cell reports*. 2017;20(1):76-88.

Haas LT, Strittmatter SM. Oligomers of Amyloid beta Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease. *The Journal of biological chemistry*. 2016;291(33):17112-21.

Habchi J, Arosio P, Perni M, Costa AR, Yagi-Utsumi M, Joshi P, et al. An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Abeta42 aggregates linked with Alzheimer's disease. *Science advances*. 2016;2(2):e1501244.

Habchi J, Chia S, Limbocker R, Mannini B, Ahn M, Perni M, et al. Systematic development of small molecules to inhibit specific microscopic steps of Abeta42 aggregation in Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2017;114(2):E200-E8.

Habib A, Sawmiller D, Li S, Xiang Y, Rongo D, Tian J, et al. LISPRO mitigates beta-amyloid and associated pathologies in Alzheimer's mice. *Cell death & disease*. 2017;8(6):e2880.

Habib A, Sawmiller D, Tan J. Restoring Soluble Amyloid Precursor Protein alpha Functions as a Potential Treatment for Alzheimer's Disease. *Journal of neuroscience research*. 2017;95(4):973-91.

Habtemariam S. Protective Effects of Caffeic Acid and the Alzheimer's Brain: An Update. *Mini reviews in medicinal chemistry*. 2017;17(8):667-74.

Hachinski V, Sposato LA, Kapral M. Preventing both stroke and dementia. *The Lancet Neurology*. 2016;15(7):659.

Hachinski V, World Stroke O. Stroke and Potentially Preventable Dementias Proclamation: Updated World Stroke Day Proclamation. *Stroke*. 2015;46(11):3039-40.

Hachinski V. Correction. World Stroke Organization. Stroke and potentially preventable dementias proclamation: updated World Stroke Day proclamation. *Stroke*. 2016;47(2):e37.

Hachinski V. Stoop to conquer: preventing stroke and dementia together. *Lancet (London, England)*. 2017;389(10078):1518.

Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. *European archives of psychiatry and clinical neuroscience*. 2015;265(5):419-28.

Hafeez MU, Molero H, Hurwitz TD, Khawaja IS. A Case Report of Wake State Misperception, or Reverse Sleep State Misperception, in a Patient With Dementia and REM Sleep Without Atonia. *The primary care companion for CNS disorders*. 2016;18(6).

Hafner A, Glavan G, Obermajer N, Zivin M, Schliebs R, Kos J. Neuroprotective role of gamma-enolase in microglia in a mouse model of Alzheimer's disease is regulated by cathepsin X. *Aging cell*. 2013;12(4):604-14.

Hagl S, Berressem D, Grewal R, Sus N, Frank J, Eckert GP. Rice bran extract improves mitochondrial dysfunction in brains of aged NMRI mice. *Nutritional neuroscience*. 2016;19(1):1-10.

Haider A, Inam W, Khan SA, Hifza, Mahmood W, Abbas G. beta-glucan attenuated scopolamine induced cognitive impairment via hippocampal acetylcholinesterase inhibition in rats. *Brain research*. 2016;1644:141-8.

Haidle AM, Childers KK, Zabierek AA, Katz JD, Jewell JP, Hou Y, et al. MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation. *Bioorganic & medicinal chemistry letters*. 2017;27(1):109-13.

Hajjar I, Rodgers K. Do angiotensin receptor blockers prevent Alzheimer's disease? *Current opinion in cardiology*. 2013;28(4):417-25.

Hakim AM. Perspective: silent, but preventable, perils. *Nature*. 2014;510(7506):S12.

Halawany AME, Sayed NSE, Abdallah HM, Dine RSE. Protective effects of gingerol on streptozotocin-induced sporadic Alzheimer's disease: emphasis on inhibition of beta-amyloid, COX-2, alpha-, beta - secretases and Aβ1a. *Scientific reports*. 2017;7(1):2902.

Hall CA, Reynolds-Lii CF. Late-life depression in the primary care setting: challenges, collaborative care, and prevention. *Maturitas*. 2014;79(2):147-52.

Halliday M, Radford H, Zents KAM, Molloy C, Moreno JA, Verity NC, et al. Repurposed drugs targeting eIF2 γ -P-mediated translational repression prevent neurodegeneration in mice. *Brain : a journal of neurology*. 2017;140(6):1768-83.

Halpern AR, Golden HL, Magdalinou N, Witoonpanich P, Warren JD. Musical tasks targeting preserved and impaired functions in two dementias. *Annals of the New York Academy of Sciences*. 2015;1337:241-8.

Hameed A, Zehra ST, Abbas S, Nisa RU, Mahmood T, Ayub K, et al. One-pot synthesis of tetrazole-1,2,5,6-tetrahydronicotinonitriles and cholinesterase inhibition: Probing the plausible reaction mechanism via computational studies. *Bioorganic chemistry*. 2016;65:38-47.

Hameed A, Zehra ST, Shah SJA, Khan KM, Alharthy RD, Furtmann N, et al. Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido 2,3-b pyrazine derivatives. *Chemical biology & drug design*. 2015;86(5):1115-20.

Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley RA, et al. Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. *Brain : a journal of neurology*. 2016;139(Pt 4):1252-64.

Hamidi G, Arabpour Z, Shabrang M, Rashidi B, Alaei H, Sharifi MR, et al. Erythropoietin improves spatial learning and memory in streptozotocin model of dementia. *Pathophysiology : the official journal of the International Society for Pathophysiology*. 2013;20(2):153-8.

Hamidpour M, Hamidpour R, Hamidpour S, Shahlari M. Chemistry, Pharmacology, and Medicinal Property of Sage (*Salvia*) to Prevent and Cure Illnesses such as Obesity, Diabetes, Depression, Dementia, Lupus, Autism, Heart Disease, and Cancer. *Journal of traditional and complementary medicine*. 2014;4(2):82-8.

Hamidpour R, Hamidpour M, Hamidpour S, Shahlari M. Cinnamon from the selection of traditional applications to its novel effects on the inhibition of angiogenesis in cancer cells and prevention of Alzheimer's disease, and a series of functions such as antioxidant, anticholesterol, antidiabetes, antibacterial, antifungal, nematocidal, acaricidal, and repellent activities. *Journal of traditional and complementary medicine*. 2015;5(2):66-70.

Hamidpour R, Hamidpour S, Hamidpour M, Shahlari M, Sohraby M. Summer Savory: From the Selection of Traditional Applications to the Novel Effect in Relief, Prevention, and Treatment of a Number of Serious Illnesses such as Diabetes, Cardiovascular Disease, Alzheimer's Disease, and Cancer. *Journal of traditional and complementary medicine*. 2014;4(3):140-4.

Hamilton A, Vasefi M, Vander Tuin C, McQuaid RJ, Anisman H, Ferguson SSG. Chronic Pharmacological mGluR5 Inhibition Prevents Cognitive Impairment and Reduces Pathogenesis in an Alzheimer Disease Mouse Model. *Cell reports*. 2016;15(9):1859-65.

Hamilton LK, Dufresne M, Joppe SE, Petryszyn S, Aumont A, Calon F, et al. Aberrant Lipid Metabolism in the Forebrain Niche Suppresses Adult Neural Stem Cell Proliferation in an Animal Model of Alzheimer's Disease. *Cell stem cell*. 2015;17(4):397-411.

Hampel H, O'Bryant SE, Castrillo JI, Ritchie C, Rojkova K, Broich K, et al. PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. *The journal of prevention of Alzheimer's disease*. 2016;3(4):243-59.

Hampstead BM, Mosti CB, Swirsky-Sacchetti T. Cognitively-based methods of enhancing and maintaining functioning in those at risk of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;42 Suppl 4:S483-93.

Hamuro A. Combination therapy with galantamine and memantine improves behavioral and psychological symptoms of dementia (BPSD) in patients with early-onset Alzheimer's disease. *The Australian and New Zealand journal of psychiatry*. 2013;47(6):583.

Han F, Zhuang T-T, Chen J-J, Zhu X-L, Cai Y-F, Lu Y-P. Novel derivative of Paeonol, Paeononlsilatie sodium, alleviates behavioral damage and hippocampal dendritic injury in Alzheimer's disease concurrent with cofilin1/phosphorylated-cofilin1 and RAC1/CDC42 alterations in rats. *PloS one*. 2017;12(9):e0185102.

Han J, Jung S, Jang J, Kam T-I, Choi H, Kim B-J, et al. OCIAD2 activates gamma-secretase to enhance amyloid beta production by interacting with nicastrin. *Cellular and molecular life sciences : CMLS*. 2014;71(13):2561-76.

Han JW, Lee H, Hong JW, Kim K, Kim T, Byun HJ, et al. Multimodal Cognitive Enhancement Therapy for Patients with Mild Cognitive Impairment and Mild Dementia: AMulti- Center, Randomized, Controlled, Double-Blind, Crossover Trial. *Journal of Alzheimer's disease : JAD*. 2017;55(2):787-96.

Han J-Y, Han S-H. Primary prevention of Alzheimer's disease: is it an attainable goal? *Journal of Korean medical science*. 2014;29(7):886-92.

Han K, Jia N, Li J, Yang L, Min L-Q. Chronic caffeine treatment reverses memory impairment and the expression of brain BNDF and TrkB in the PS1/APP double transgenic mouse model of Alzheimer's disease. *Molecular medicine reports*. 2013;8(3):737-40.

Han L, Ji Z, Chen W, Yin D, Xu F, Li S, et al. Protective effects of tao-Hong-si-wu decoction on memory impairment and hippocampal damage in animal model of vascular dementia. *Evidence-based complementary and alternative medicine : eCAM*. 2015;2015:195835.

Han P, Tang Z, Yin J, Maalouf M, Beach TG, Reiman EM, et al. Pituitary adenylate cyclase-activating polypeptide protects against beta-amyloid toxicity. *Neurobiology of aging*. 2014;35(9):2064-71.

Han Q, Cai S, Yang L, Wang X, Qi C, Yang R, et al. Molybdenum Disulfide Nanoparticles as Multifunctional Inhibitors against Alzheimer's Disease. *ACS applied materials & interfaces*. 2017;9(25):21116-23.

Han X, Yang L, Du H, Sun Q, Wang X, Cong L, et al. Insulin Attenuates Beta-Amyloid-Associated Insulin/Akt/EAAT Signaling Perturbations in Human Astrocytes. *Cellular and molecular neurobiology*. 2016;36(6):851-64.

Han Y-S, Araki T, Lee P-Y, Choi J-H, Kwon I-S, Kwon K-N, et al. Development and effect of a cognitive enhancement gymnastics program for elderly people with dementia. *Journal of exercise rehabilitation*. 2016;12(4):340-5.

Hancianu M, Cioanca O, Mihasan M, Hritcu L. Neuroprotective effects of inhaled lavender oil on scopolamine-induced dementia via anti-oxidative activities in rats. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2013;20(5):446-52.

Handels R, Wimo A. Challenges and recommendations for the health-economic evaluation of primary prevention programmes for dementia. *Aging & mental health*. 2017:1-7.

Handley A. A solid basis for improvement. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*. 2015;29(30):64-5.

Handley M, Bunn F, Goodman C. Dementia-friendly interventions to improve the care of people living with dementia admitted to hospitals: a realist review. *BMJ open*. 2017;7(7):e015257.

Hane FT, Lee BY, Petoyan A, Rauk A, Leonenko Z. Testing synthetic amyloid-beta aggregation inhibitor using single molecule atomic force spectroscopy. *Biosensors & bioelectronics*. 2014;54:492-8.

Hanseeuw B, Dricot L, Lhommel R, Quenon L, Ivanoiu A. Patients with Amyloid-Negative Mild Cognitive Impairment have Cortical Hypometabolism but the Hippocampus is Preserved. *Journal of Alzheimer's disease : JAD*. 2016;53(2):651-60.

Hansen HH, Fabricius K, Barkholt P, Niehoff ML, Morley JE, Jelsing J, et al. The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2015;46(4):877-88.

Hanson HA, Horn KP, Rasmussen KM, Hoffman JM, Smith KR. Is Cancer Protective for Subsequent Alzheimer's Disease Risk? Evidence From the Utah Population Database. *The journals of gerontology Series B, Psychological sciences and social sciences*. 2017;72(6):1032-43.

Hanson JE, Meilandt WJ, Gogineni A, Reynen P, Herrington J, Weimer RM, et al. Chronic GluN2B antagonism disrupts behavior in wild-type mice without protecting against synapse loss or memory impairment in Alzheimer's disease mouse models. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(24):8277-88.

Hanson LC, Song M-K, Zimmerman S, Gilliam R, Rosemond C, Chisholm L, et al. Fidelity to a behavioral intervention to improve goals of care decisions for nursing home residents with advanced dementia. *Clinical trials (London, England)*. 2016;13(6):599-604.

Hanyu H. Cognitive Function and Calcium. Vitamin D and calcium for the prevention of falls and fractures in patients with dementia. *Clinical calcium*. 2015;25(2):275-82.

Hao JR, Sun N, Lei L, Li XY, Yao B, Sun K, et al. L-Stepholidine rescues memory deficit and synaptic plasticity in models of Alzheimer's disease via activating dopamine D1 receptor/PKA signaling pathway. *Cell death & disease*. 2015;6:e1965.

Harada A, Suzuki K, Kimura H. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease. *The Journal of pharmacology and experimental therapeutics*. 2017;360(1):75-83.

Harada S, Tsujita T, Ono A, Miyagi K, Mori T, Tokuyama S. *Stachys sieboldii* (Labiatae, Chorogi) Protects against Learning and Memory Dysfunction Associated with Ischemic Brain Injury. *Journal of nutritional science and vitaminology*. 2015;61(2):167-74.

Haralambous B, Mackell P, Lin X, Fearn M, Dow B. Improving health literacy about dementia among older Chinese and Vietnamese Australians. *Australian health review : a publication of the Australian Hospital Association*. 2017.

Hardenacke K, Shubina E, Buhrle CP, Zapf A, Lenartz D, Klosterkötter J, et al. Deep brain stimulation as a tool for improving cognitive functioning in Alzheimer's dementia: a systematic review. *Frontiers in psychiatry*. 2013;4:159.

Hardy CJD, Hwang YT, Bond RL, Marshall CR, Ridha BH, Crutch SJ, et al. Donepezil enhances understanding of degraded speech in Alzheimer's disease. *Annals of clinical and translational neurology*. 2017;4(11):835-40.

Hariharan A, Shetty S, Shirole T, Jagtap AG. Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: mitochondrial dysfunction and neurodegeneration. *Neurotoxicology*. 2014;45:139-48.

Harrington CR, Storey JMD, Clunas S, Harrington KA, Horsley D, Ishaq A, et al. Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease. *The Journal of biological chemistry*. 2015;290(17):10862-75.

Harrington M. Refining HDAC inhibition to restore memory. *Lab animal*. 2015;44(6):194.

Harrison DJ, Busse M, Openshaw R, Rosser AE, Dunnett SB, Brooks SP. Exercise attenuates neuropathology and has greater benefit on cognitive than motor deficits in the R6/1 Huntington's disease mouse model. *Experimental neurology*. 2013;248:457-69.

Harrison JR. Improving inpatient care for older adults: Implementing Dementia Commissioning for Quality and Innovation (CQUIN). *BMJ quality improvement reports*. 2017;6(1).

Harrison M, Martin R. Exercise to Improve Functioning in Patients with Dementia. *American family physician*. 2016;94(3):242.

Hartmann T, van Wijk N, Wurtman RJ, Olde Rikkert MGM, Sijben JWC, Soininen H, et al. A nutritional approach to ameliorate altered phospholipid metabolism in Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;41(3):715-7.

Harvard research finds protective link between most cancers and Alzheimer's disease. *Harvard health letter*. 2013;38(12):8.

Hasegawa H, Liu L, Tooyama I, Murayama S, Nishimura M. The FAM3 superfamily member ILEI ameliorates Alzheimer's disease-like pathology by destabilizing the penultimate amyloid-beta precursor. *Nature communications*. 2014;5:3917.

Hashimoto M, Hossain S, Katakura M, Al Mamun A, Shido O. The binding of Abeta1-42 to lipid rafts of RBC is enhanced by dietary docosahexaenoic acid in rats: Implicates to Alzheimer's disease. *Biochimica et biophysica acta*. 2015;1848(6):1402-9.

Hashimoto M, Maekawa M, Katakura M, Hamazaki K, Matsuoka Y. Possibility of polyunsaturated fatty acids for the prevention and treatment of neuropsychiatric illnesses. *Journal of pharmacological sciences*. 2014;124(3):294-300.

Hashimoto Y, Matsuoka M. A mutation protective against Alzheimer's disease renders amyloid beta precursor protein incapable of mediating neurotoxicity. *Journal of neurochemistry*. 2014;130(2):291-300.

Hashimoto Y, Nawa M, Kurita M, Tokizawa M, Iwamatsu A, Matsuoka M. Secreted calmodulin-like skin protein inhibits neuronal death in cell-based Alzheimer's disease models via the heterotrimeric Humanin receptor. *Cell death & disease*. 2013;4:e555.

Haslam C, Sabah M. Preservation of person-specific knowledge in semantic memory disorder: a longitudinal investigation in two cases of dementia. *Journal of neuropsychology*. 2013;7(1):132-8.

Hassamal S, Jolles P, Pandurangi A. Reversal of cerebral glucose hypometabolism on positron emission tomography with electroconvulsive therapy in an elderly patient with a psychotic episode. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2016;16(6):376-81.

Hassan L, Swarbrick C, Sanders C, Parker A, Machin M, Tully MP, et al. Tea, talk and technology: patient and public involvement to improve connected health 'wearables' research in dementia. *Research involvement and engagement*. 2017;3:12.

Hassanzadeh G, Hosseini A, Pasbakhsh P, Akbari M, Ghaffarpour M, Takzare N, et al. Trimetazidine prevents oxidative changes induced in a rat model of sporadic type of Alzheimer's disease. *Acta medica Iranica*. 2015;53(1):17-24.

Hassanzadeh P, Arbabi E, Atyabi F, Dinarvand R. Ferulic acid exhibits antiepileptogenic effect and prevents oxidative stress and cognitive impairment in the kindling model of epilepsy. *Life sciences*. 2017;179:9-14.

Hatch RJ, Leinenga G, Gotz J. Scanning Ultrasound (SUS) Causes No Changes to Neuronal Excitability and Prevents Age-Related Reductions in Hippocampal CA1 Dendritic Structure in Wild-Type Mice. *PloS one*. 2016;11(10):e0164278.

Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. *JAMA psychiatry*. 2014;71(4):397-403.

Hattori Y, Kobayashi K, Deguchi A, Nohara Y, Akiyama T, Teruya K, et al. Evaluation of transition-state mimics in a superior BACE1 cleavage sequence as peptide-mimetic BACE1 inhibitors. *Bioorganic & medicinal chemistry*. 2015;23(17):5626-40.

Hatz F, Benz N, Hardmeier M, Zimmermann R, Rueegg S, Schindler C, et al. Quantitative EEG and apolipoprotein E-genotype improve classification of patients with suspected Alzheimer's

disease. *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology*. 2013;124(11):2146-52.

Hauber AB, Mohamed AF, Johnson FR, Cook M, Arrighi HM, Zhang J, et al. Understanding the relative importance of preserving functional abilities in Alzheimer's disease in the United States and Germany. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2014;23(6):1813-21.

Haure-Mirande J-V, Audrain M, Fanutza T, Kim SH, Klein WL, Glabe C, et al. Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology. *Acta neuropathologica*. 2017;134(5):769-88.

Hauser-Davis RA, de Freitas LV, Cukierman DS, Cruz WS, Miotto MC, Landeira-Fernandez J, et al. Disruption of zinc and copper interactions with Abeta(1-40) by a non-toxic, isoniazid-derived, hydrazone: a novel biometal homeostasis restoring agent in Alzheimer's disease therapy? *Metallomics : integrated biometal science*. 2015;7(5):743-7.

Hausmann R, Donix M. Memantine as add-on medication to acetylcholinesterase inhibitor therapy for Alzheimer dementia. *Der Nervenarzt*. 2017;88(1):40-5.

Hawkins Virani AK, Creighton SM, Hayden MR. Developing a comprehensive, effective patient-friendly website to enhance decision making in predictive testing for Huntington disease. *Genetics in medicine : official journal of the American College of Medical Genetics*. 2013;15(6):466-72.

Hay M, Vanderah TW, Samareh-Jahani F, Constantopoulos E, Uprety AR, Barnes CA, et al. Cognitive impairment in heart failure: A protective role for angiotensin-(1-7). *Behavioral neuroscience*. 2017;131(1):99-114.

Hayama T, Murakami K, Watanabe T, Maeda R, Kamata M, Kondo S. Single administration of a novel gamma-secretase modulator ameliorates cognitive dysfunction in aged C57BL/6J mice. *Brain research*. 2016;1633:52-61.

Hayashi Y, Yoshikura N, Takekoshi A, Yamada M, Asano T, Kimura A, et al. Preserved regional cerebral blood flow in the occipital cortices, brainstem, and cerebellum of patients with V180I-129M genetic Creutzfeldt-Jakob disease in serial SPECT studies. *Journal of the neurological sciences*. 2016;370:145-51.

Hazra A, Gu F, Aulakh A, Berridge C, Eriksen JL, Ziburkus J. Inhibitory neuron and hippocampal circuit dysfunction in an aged mouse model of Alzheimer's disease. *PloS one*. 2013;8(5):e64318.

He F, Cao Y-P, Che F-Y, Yang L-H, Xiao S-H, Liu J. Inhibitory effects of edaravone in beta-amyloid-induced neurotoxicity in rats. *BioMed research international*. 2014;2014:370368.

He J, Liao T, Zhong G-X, Zhang J-D, Chen Y-P, Wang Q, et al. Alzheimer's Disease-like Early-phase Brain Pathogenesis: Self-curing Amelioration of Neurodegeneration from Pro-inflammatory 'Wounding' to Anti-inflammatory 'Healing'. *Current Alzheimer research*. 2017;14(10):1123-35.

He P, Cheng X, Staufenbiel M, Li R, Shen Y. Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of beta-secretase in a mouse model of Alzheimer's disease. *PloS one*. 2013;8(2):e55091.

He P, Ouyang X, Zhou S, Yin W, Tang C, Laudon M, et al. A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease. *Hormones and behavior*. 2013;64(1):1-7.

He Q, Huang G, Chen Y, Wang X, Huang Z, Chen Z. The protection of novel 2-arylethenylquinoline derivatives against impairment of associative learning memory induced by neural Abeta in *C. elegans* Alzheimer's disease model. *Neurochemical research*. 2017;42(11):3061-72.

He Y, Pan S, Xu M, He R, Huang W, Song P, et al. Adeno-associated virus 9-mediated Cdk5 inhibitory peptide reverses pathologic changes and behavioral deficits in the Alzheimer's disease mouse model. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2017;31(8):3383-92.

Hearing loss could be linked to dementia. Treat age-related hearing loss to help prevent dementia. *DukeMedicine healthnews*. 2013;19(5):1-2.

Hebert PL, McBean AM, O'Connor H, Frank B, Good C, Maciejewski ML. Time until incident dementia among Medicare beneficiaries using centrally acting or non-centrally acting ACE inhibitors. *Pharmacoepidemiology and drug safety*. 2013;22(6):641-8.

Hebron M, Peyton M, Liu X, Gao X, Wang R, Lonskaya I, et al. Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models. *Journal of neuroimmunology*. 2017;311:1-9.

Heckman PRA, Wouters C, Prickaerts J. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview. *Current pharmaceutical design*. 2015;21(3):317-31.

Hedges EC, Mehler VJ, Nishimura AL. The Use of Stem Cells to Model Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: From Basic Research to Regenerative Medicine. *Stem cells international*. 2016;2016:9279516.

Hefner G, Brueckner A, Hiemke C, Fellgiebel A. Therapeutic drug monitoring for patients with Alzheimer dementia to improve treatment with donepezil. *Therapeutic drug monitoring*. 2015;37(3):353-61.

Heidari R, Monnier V, Martin E, Tricoire H. Methylene Blue Partially Rescues Heart Defects in a Drosophila Model of Huntington's Disease. *Journal of Huntington's disease*. 2015;4(2):173-86.

Heinrich S, Berwig M, Simon A, Janichen J, Hallensleben N, Nickel W, et al. German adaptation of the Resources for Enhancing Alzheimer's Caregiver Health II: study protocol of a single-centred, randomised controlled trial. *BMC geriatrics*. 2014;14:21.

Heitman E, Ingram DK. Cognitive and neuroprotective effects of chlorogenic acid. *Nutritional neuroscience*. 2017;20(1):32-9.

Heller L, Schwarz S, Obernauer A, Csuk R. Allobetulin derived seco-oleananedicarboxylates act as inhibitors of acetylcholinesterase. *Bioorganic & medicinal chemistry letters*. 2015;25(13):2654-6.

Hellmert M, Muller-Schiffmann A, Peters MS, Korth C, Schrader T. Hybridization of an Abeta-specific antibody fragment with aminopyrazole-based beta-sheet ligands displays striking enhancement of target affinity. *Organic & biomolecular chemistry*. 2015;13(10):2974-9.

Hellwig S, Masuch A, Nestel S, Katzmarski N, Meyer-Luehmann M, Biber K. Forebrain microglia from wild-type but not adult 5xFAD mice prevent amyloid-beta plaque formation in organotypic hippocampal slice cultures. *Scientific reports*. 2015;5:14624.

Helmfors L, Boman A, Civitelli L, Nath S, Sandin L, Janefjord C, et al. Protective properties of lysozyme on beta-amyloid pathology: implications for Alzheimer disease. *Neurobiology of disease*. 2015;83:122-33.

Hemmati F, Dargahi L, Nasoohi S, Omidbakhsh R, Mohamed Z, Chik Z, et al. Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine. *Behavioural brain research*. 2013;252:415-21.

Henderson VW. Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause. *The Journal of steroid biochemistry and molecular biology*. 2014;142:99-106.

Henderson VW. Three midlife strategies to prevent cognitive impairment due to Alzheimer's disease. *Climacteric : the journal of the International Menopause Society*. 2014;17 Suppl 2:38-46.

Hendrix SB, Welsh-Bohmer KA. Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease. *Alzheimer's research & therapy*. 2013;5(3):22.

Henley DB, Sundell KL, Sethuraman G, Dowsett SA, May PC. Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings. *Current medical research and opinion*. 2014;30(10):2021-32.

Hennekens CH, Bensadon BA, Zivin R, Gaziano JM. Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias. *Expert review of neurotherapeutics*. 2015;15(11):1245-8.

Hensley K, Gabbita SP, Venkova K, Hristov A, Johnson MF, Eslami P, et al. A derivative of the brain metabolite lanthionine ketimine improves cognition and diminishes pathology in the 3 * Tg-AD mouse model of Alzheimer disease. *Journal of neuropathology and experimental neurology*. 2013;72(10):955-69.

Heo J-H, Hyon L, Lee K-M. The possible role of antioxidant vitamin C in Alzheimer's disease treatment and prevention. *American journal of Alzheimer's disease and other dementias*. 2013;28(2):120-5.

Herbert MK, Aerts MB, Kuiperij HB, Claassen JAHR, Spies PE, Esselink RAJ, et al. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2014;10(4):448-55.e2.

Herculano B, Tamura M, Ohba A, Shimatani M, Kutsuna N, Hisatsune T. beta-alanyl-L-histidine rescues cognitive deficits caused by feeding a high fat diet in a transgenic mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2013;33(4):983-97.

Hering T, Braubach P, Landwehrmeyer GB, Lindenberg KS, Melzer W. Fast-to-Slow Transition of Skeletal Muscle Contractile Function and Corresponding Changes in Myosin Heavy and Light Chain Formation in the R6/2 Mouse Model of Huntington's Disease. *PloS one*. 2016;11(11):e0166106.

Hernandez-Rapp J, Rainone S, Goupil C, Dorval V, Smith PY, Saint-Pierre M, et al. microRNA-132/212 deficiency enhances Abeta production and senile plaque deposition in Alzheimer's disease triple transgenic mice. *Scientific reports*. 2016;6:30953.

Hernandorena I, Duron E, Vidal J-S, Hanon O. Treatment options and considerations for hypertensive patients to prevent dementia. *Expert opinion on pharmacotherapy*. 2017;18(10):989-1000.

Herran E, Perez-Gonzalez R, Igartua M, Pedraz JL, Carro E, Hernandez RM. Enhanced Hippocampal Neurogenesis in APP/Ps1 Mouse Model of Alzheimer's Disease After Implantation of VEGF-loaded PLGA Nanospheres. *Current Alzheimer research*. 2015;12(10):932-40.

Herring A, Munster Y, Akkaya T, Moghaddam S, Deinsberger K, Meyer J, et al. Kallikrein-8 inhibition attenuates Alzheimer's disease pathology in mice. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016;12(12):1273-87.

Herrmann N, O'Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, et al. A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease. *Journal of the American Medical Directors Association*. 2016;17(2):142-7.

Herskowitz JH, Feng Y, Matheyses AL, Hales CM, Higginbotham LA, Duong DM, et al. Pharmacologic inhibition of ROCK2 suppresses amyloid-beta production in an Alzheimer's disease mouse model. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(49):19086-98.

Hescham S, Lim LW, Jahanshahi A, Steinbusch HWM, Prickaerts J, Blokland A, et al. Deep brain stimulation of the fornix area enhances memory functions in experimental dementia: the role of stimulation parameters. *Brain stimulation*. 2013;6(1):72-7.

Hettiarachchi N, Dallas M, Al-Owais M, Griffiths H, Hooper N, Scragg J, et al. Heme oxygenase-1 protects against Alzheimer's amyloid-beta(1-42)-induced toxicity via carbon monoxide production. *Cell death & disease*. 2014;5:e1569.

Heyanka DJ, Scott JG, Adams RL. Improving the diagnostic accuracy of the RBANS in mild cognitive impairment with construct-consistent measures. *Applied neuropsychology Adult*. 2015;22(1):32-41.

Hickman LD, Neville S, Fischer T, Davidson PM, Phillips JL. Call to action: greater investment in the registered nurse role is required to improve care outcomes for dementia patients living in residential aged care and their families. *Contemporary nurse*. 2016;52(2-3):137-9.

Hielscher-Michael S, Griehl C, Buchholz M, Demuth H-U, Arnold N, Wessjohann LA. Natural Products from Microalgae with Potential against Alzheimer's Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors. *Marine drugs*. 2016;14(11).

High dose vitamin E may slow Alzheimer's decline. *Harvard men's health watch*. 2014;18(8):8.

Higham CF, Monckton DG. Modelling and inference reveal nonlinear length-dependent suppression of somatic instability for small disease associated alleles in myotonic dystrophy type 1 and Huntington disease. *Journal of the Royal Society, Interface*. 2013;10(88):20130605.

Hilgeman MM, Allen RS, Snow AL, Durkin DW, DeCoster J, Burgio LD. Preserving Identity and Planning for Advance Care (PIPAC): preliminary outcomes from a patient-centered intervention for individuals with mild dementia. *Aging & mental health*. 2014;18(4):411-24.

Hilpert H, Guba W, Woltering TJ, Wostl W, Pinard E, Mauser H, et al. beta-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. *Journal of medicinal chemistry*. 2013;56(10):3980-95.

Hipkiss AR. Depression, Diabetes and Dementia: Formaldehyde May Be a Common Causal Agent; Could Carnosine, a Pluripotent Peptide, Be Protective? *Aging and disease*. 2017;8(2):128-30.

Hippolyte L, Maillard AM, Rodriguez-Herreros B, Pain A, Martin-Brevet S, Ferrari C, et al. The Number of Genomic Copies at the 16p11.2 Locus Modulates Language, Verbal Memory, and Inhibition. *Biological psychiatry*. 2016;80(2):129-39.

Hirsch C. ACP Journal Club. Review: Cholinesterase inhibitors do not prevent dementia in patients with mild cognitive impairment. *Annals of internal medicine*. 2014;160(8):JC11.

Hjorth E, Zhu M, Toro VC, Vedin I, Palmblad J, Cederholm T, et al. Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-beta42 by human microglia and decrease inflammatory markers. *Journal of Alzheimer's disease : JAD*. 2013;35(4):697-713.

Ho L, Ono K, Tsuji M, Mazzola P, Singh R, Pasinetti GM. Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer's disease-type beta-amyloid neuropathological mechanisms. *Expert review of neurotherapeutics*. 2017:1-8.

Ho S-W, Teng Y-H, Yang S-F, Yeh H-W, Wang Y-H, Chou M-C, et al. Association of Proton Pump Inhibitors Usage with Risk of Pneumonia in Dementia Patients. *Journal of the American Geriatrics Society*. 2017;65(7):1441-7.

Hoang V-H, Tran P-T, Cui M, Ngo VTH, Ann J, Park J, et al. Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer's Agents Based on Rational Design. *Journal of medicinal chemistry*. 2017;60(6):2573-90.

Hochgrafe K, Sydow A, Mandelkow E-M. Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology. *The FEBS journal*. 2013;280(18):4371-81.

Hodgson N, Trivedi M, Muratore C, Li S, Deth R. Soluble oligomers of amyloid-beta cause changes in redox state, DNA methylation, and gene transcription by inhibiting EAAT3 mediated cysteine uptake. *Journal of Alzheimer's disease : JAD*. 2013;36(1):197-209.

Hodgson NA. Do interventions with staff in long-term residential facilities improve quality of care or quality of life for people with dementia? A systematic review of the evidence. *International psychogeriatrics*. 2016;28(12):1935-6.

Hoffmann K, Frederiksen KS, Sobol NA, Beyer N, Vogel A, Simonsen AH, et al. Preserving cognition, quality of life, physical health and functional ability in Alzheimer's disease: the effect of physical exercise (ADEX trial): rationale and design. *Neuroepidemiology*. 2013;41(3-4):198-207.

Hoffmann T, Meyer A, Heiser U, Kurat S, Bohme L, Kleinschmidt M, et al. Glutaminy Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy. *The Journal of pharmacology and experimental therapeutics*. 2017;362(1):119-30.

Hofrichter J, Krohn M, Schumacher T, Lange C, Feistel B, Walbroel B, et al. Sideritis spp. Extracts Enhance Memory and Learning in Alzheimer's beta-Amyloidosis Mouse Models and Aged C57Bl/6 Mice. *Journal of Alzheimer's disease : JAD*. 2016;53(3):967-80.

Hogan DB. Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. *Canadian journal of psychiatry Revue canadienne de psychiatrie*. 2014;59(12):618-23.

Hogan DB. Re: Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease. *Canadian journal of psychiatry Revue canadienne de psychiatrie*. 2015;60(7):338.

Hohenfeld C, Nellessen N, Dogan I, Kuhn H, Muller C, Papa F, et al. Cognitive Improvement and Brain Changes after Real-Time Functional MRI Neurofeedback Training in Healthy Elderly and Prodromal Alzheimer's Disease. *Frontiers in neurology*. 2017;8:384.

Hohsfield LA, Humpel C. Intravenous infusion of monocytes isolated from 2-week-old mice enhances clearance of Beta-amyloid plaques in an Alzheimer mouse model. *PloS one*. 2015;10(4):e0121930.

Hojati S, Ghahghaei A, Lagzian M. The potential inhibitory effect of beta-casein on the aggregation and deposition of Abeta1-42 fibrils in Alzheimer's disease: insight from in-vitro and in-silico studies. *Journal of biomolecular structure & dynamics*. 2017:1-13.

Hollands C, Tobin MK, Hsu M, Musaraca K, Yu T-S, Mishra R, et al. Depletion of adult neurogenesis exacerbates cognitive deficits in Alzheimer's disease by compromising hippocampal inhibition. *Molecular neurodegeneration*. 2017;12(1):64.

Holm H, Nagga K, Nilsson ED, Melander O, Minthon L, Bachus E, et al. Longitudinal and postural changes of blood pressure predict dementia: the Malmo Preventive Project. *European journal of epidemiology*. 2017;32(4):327-36.

Holmes HE, Colgan N, Ismail O, Ma D, Powell NM, O'Callaghan JM, et al. Imaging the accumulation and suppression of tau pathology using multiparametric MRI. *Neurobiology of aging*. 2016;39:184-94.

Holopainen A, Siltanen H, Pohjanvuori A, Makisalo-Ropponen M, Okkonen E. Factors associated with the quality of life of people with dementia and with quality of life-improving interventions: Scoping review. *Dementia (London, England)*. 2017;1471301217716725.

Holscher C. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases. *Sheng li xue bao : [Acta physiologica Sinica]*. 2014;66(5):497-510.

Holscher C. First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2014;10(1 Suppl):S33-7.

Holscher C. New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases. *Neural regeneration research*. 2014;9(21):1870-3.

Holscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulintropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2014;10(1 Suppl):S47-54.

Hong C, Luo W, Yao D, Su Y-B, Zhang X, Tian R-G, et al. Novel aromatic-polyamine conjugates as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase. *Bioorganic & medicinal chemistry*. 2014;22(12):3213-9.

Hong H-S, Maezawa I, Petrlova J, Zhao X-Y, C Voss J, Jin L-W. Tomoregulin (TMEFF2) Binds Alzheimer's Disease Amyloid-beta (A β) Oligomer and A β PP and Protects Neurons from A β -Induced Toxicity. *Journal of Alzheimer's disease : JAD*. 2015;48(3):731-43.

Hong X, Liu J, Zhu G, Zhuang Y, Suo H, Wang P, et al. Parkin overexpression ameliorates hippocampal long-term potentiation and beta-amyloid load in an Alzheimer's disease mouse model. *Human molecular genetics*. 2014;23(4):1056-72.

Hong Y, Zhao T, Li X-J, Li S. Mutant Huntingtin Inhibits alphaB-Crystallin Expression and Impairs Exosome Secretion from Astrocytes. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(39):9550-63.

Hook G, Yu J, Toneff T, Kindy M, Hook V. Brain pyroglutamate amyloid-beta is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. *Journal of Alzheimer's disease : JAD*. 2014;41(1):129-49.

Hooper M, Grill JD, Rodriguez-Agudelo Y, Medina LD, Fox M, Alvarez-Retuerto AI, et al. The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease. *Contemporary clinical trials*. 2013;36(1):256-62.

Hoppe JB, Salbego CG, Cimarosti H. SUMOylation: Novel Neuroprotective Approach for Alzheimer's Disease? *Aging and disease*. 2015;6(5):322-30.

Hopperton KE, Trepanier M-O, James NCE, Chouinard-Watkins R, Bazinet RP. Fish oil feeding attenuates neuroinflammatory gene expression without concomitant changes in brain eicosanoids and docosanoids in a mouse model of Alzheimer's disease. *Brain, behavior, and immunity*. 2017.

Hornberger M, Bertoux M. Reply: Strategy and suppression impairments after right lateral and orbito-frontal lesions. *Brain : a journal of neurology*. 2016;139(Pt 2):e11.

Hoshino T, Suzuki K, Matsushima T, Yamakawa N, Suzuki T, Mizushima T. Suppression of Alzheimer's disease-related phenotypes by geranylgeranylacetone in mice. *PloS one*. 2013;8(10):e76306.

Hosono T, Nishitsuji K, Nakamura T, Jung C-G, Kontani M, Tokuda H, et al. Arachidonic acid diet attenuates brain Abeta deposition in Tg2576 mice. *Brain research*. 2015;1613:92-9.

Hossain T, Mukherjee A, Saha A. Chemometric design to explore pharmacophore features of BACE inhibitors for controlling Alzheimer's disease. *Molecular bioSystems*. 2015;11(2):549-57.

Hossain T, Saha A, Mukherjee A. Exploring Structural and Physicochemical Profiles of Potential GSK-3beta Inhibitors Using Structure- and Ligand-Based Modeling Studies. *Combinatorial chemistry & high throughput screening*. 2016;19(4):298-306.

Hot P, Klein-Koerkamp Y, Borg C, Richard-Mornas A, Zsoldos I, Paignon Adeline A, et al. Fear recognition impairment in early-stage Alzheimer's disease: when focusing on the eyes region improves performance. *Brain and cognition*. 2013;82(1):25-34.

Hou Y, Ghosh P, Wan R, Ouyang X, Cheng H, Mattson MP, et al. Permeability transition pore-mediated mitochondrial superoxide flashes mediate an early inhibitory effect of amyloid beta1-42 on neural progenitor cell proliferation. *Neurobiology of aging*. 2014;35(5):975-89.

Hou Y, Wang Y, Zhao J, Li X, Cui J, Ding J, et al. Smart Soup, a traditional Chinese medicine formula, ameliorates amyloid pathology and related cognitive deficits. *PloS one*. 2014;9(11):e111215.

Houghton C, Murphy K, Meehan B, Thomas J, Brooker D, Casey D. From screening to synthesis: using nvivo to enhance transparency in qualitative evidence synthesis. *Journal of clinical nursing*. 2017;26(5-6):873-81.

Hoy AR, Ly M, Carlsson CM, Okonkwo OC, Zetterberg H, Blennow K, et al. Microstructural white matter alterations in preclinical Alzheimer's disease detected using free water elimination diffusion tensor imaging. *PloS one*. 2017;12(3):e0173982.

Hradcova D. Relational approach to ethics and quality improvement in institutional care for people with dementia. *Annals of palliative medicine*. 2017;6(4):319-26.

Hritcu L, Noumedem JA, Cioanca O, Hancianu M, Kuete V, Mihasan M. Methanolic extract of *Piper nigrum* fruits improves memory impairment by decreasing brain oxidative stress in amyloid beta(1-42) rat model of Alzheimer's disease. *Cellular and molecular neurobiology*. 2014;34(3):437-49.

Hritcu L, Stefan M, Brandsch R, Mihasan M. Enhanced behavioral response by decreasing brain oxidative stress to 6-hydroxy-l-nicotine in Alzheimer's disease rat model. *Neuroscience letters*. 2015;591:41-7.

Hroch L, Guest P, Benek O, Soukup O, Janockova J, Dolezal R, et al. Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer's disease treatment. *Bioorganic & medicinal chemistry*. 2017;25(3):1143-52.

Hsiao H-Y, Chiu F-L, Chen C-M, Wu Y-R, Chen H-M, Chen Y-C, et al. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. *Human molecular genetics*. 2014;23(16):4328-44.

Hsiao Y-H, Hung H-C, Chen S-H, Gean P-W. Social interaction rescues memory deficit in an animal model of Alzheimer's disease by increasing BDNF-dependent hippocampal neurogenesis. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(49):16207-19.

Hsiao Y-H, Hung H-C, Yu Y-J, Su C-L, Chen S-H, Gean P-W. Co-housing reverses memory decline by epigenetic regulation of brain-derived neurotrophic factor expression in an animal model of Alzheimer's disease. *Neurobiology of learning and memory*. 2017;141:1-8.

Hsieh M-H, Meng W-Y, Liao W-C, Weng J-C, Li H-H, Su H-L, et al. Ceftriaxone reverses deficits of behavior and neurogenesis in an MPTP-induced rat model of Parkinson's disease dementia. *Brain research bulletin*. 2017;132:129-38.

Hsieh S, Chang C-w, Chou H-h. Gold nanoparticles as amyloid-like fibrillogenesis inhibitors. *Colloids and surfaces B, Biointerfaces*. 2013;112:525-9.

Hsu C-H, Wang S-E, Lin C-L, Hsiao C-J, Sheu S-J, Wu C-H. Neuroprotective Effects of the Herbal Formula B401 in Both Cell and Mouse Models of Alzheimer's Disease. Evidence-based complementary and alternative medicine : eCAM. 2016;2016:1939052.

Hsu C-K, Hsu C-C, Lee JY-Y, Kuo Y-M, Pai M-C. Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor. Journal of the American Academy of Dermatology. 2013;68(2):e46-8.

Hsu C-N, Lin L-C, Wu S-C. The effects of spaced retrieval training in improving hyperphagia of people living with dementia in residential settings. Journal of clinical nursing. 2017;26(19-20):3224-31.

Hsu C-W, Lee Y, Lee C-Y, Lin P-Y. Reversible Pisa Syndrome Induced by Rivastigmine in a Patient With Early-Onset Alzheimer Disease. Clinical neuropharmacology. 2017;40(3):147-8.

Hsu C-Y, Hung C-S, Chang H-M, Liao W-C, Ho S-C, Ho Y-J. Ceftriaxone prevents and reverses behavioral and neuronal deficits in an MPTP-induced animal model of Parkinson's disease dementia. Neuropharmacology. 2015;91:43-56.

Hsu D, Marshall GA. Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward. Current Alzheimer research. 2017;14(4):426-40.

Hsu J-L, Fan Y-C, Huang Y-L, Wang J, Chen W-H, Chiu H-C, et al. Improved predictive ability of the Montreal Cognitive Assessment for diagnosing dementia in a community-based study. Alzheimer's research & therapy. 2015;7(1):69.

Hsu W-CJ, Wildburger NC, Haidacher SJ, Nenov MN, Folorunso O, Singh AK, et al. PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease. Experimental neurology. 2017;295:1-17.

Hu B, Dai F, Fan Z, Ma G, Tang Q, Zhang X. Nanotheranostics: Congo Red/Rutin-MNPs with Enhanced Magnetic Resonance Imaging and H₂O₂-Responsive Therapy of Alzheimer's Disease in APP^{swe}/PS1^{dE9} Transgenic Mice. Advanced materials (Deerfield Beach, Fla). 2015;27(37):5499-505.

Hu B, Geng C, Hou X-Y. Oligomeric amyloid-beta peptide disrupts olfactory information output by impairment of local inhibitory circuits in rat olfactory bulb. Neurobiology of aging. 2017;51:113-21.

Hu H-y, Chen Z-y, Xu D-m, Zhang Y-h, Wang Y-r, Wang W-h, et al. Study on the Mechanism of Three Kinds Extracts of Qingxin Kaiqiao Recipe in Improving Learning and Memory Capabilities of AD Rats. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 2015;35(5):595-602.

Hu H-Y, Cui Z-H, Li H-Q, Wang Y-R, Chen X, Li J-H, et al. Fumanjian, a Classic Chinese Herbal Formula, Can Ameliorate the Impairment of Spatial Learning and Memory through Apoptotic Signaling Pathway in the Hippocampus of Rats with Abeta 1-40 -Induced Alzheimer's Disease. *Evidence-based complementary and alternative medicine : eCAM*. 2014;2014:942917.

Hu J, Lin T, Gao Y, Xu J, Jiang C, Wang G, et al. The resveratrol trimer miyabenol C inhibits beta-secretase activity and beta-amyloid generation. *PloS one*. 2015;10(1):e0115973.

Hu J, Liu J, Yu D, Aiba Y, Lee S, Pendergraff H, et al. Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs. *Nucleic acid therapeutics*. 2014;24(3):199-209.

Hu M, Liu Z, Lv P, Wang H, Zhu Y, Qi Q, et al. Autophagy and Akt/CREB signalling play an important role in the neuroprotective effect of nimodipine in a rat model of vascular dementia. *Behavioural brain research*. 2017;325(Pt A):79-86.

Hu R, Wei P, Jin L, Zheng T, Chen W-Y, Liu X-Y, et al. Overexpression of EphB2 in hippocampus rescues impaired NMDA receptors trafficking and cognitive dysfunction in Alzheimer model. *Cell death & disease*. 2017;8(3):e2717.

Hu S, Cui W, Mak S, Xu D, Hu Y, Tang J, et al. Substantial Neuroprotective and Neurite Outgrowth-Promoting Activities by Bis(propyl)-cognitin via the Activation of Alpha7-nAChR, a Promising Anti-Alzheimer's Dimer. *ACS chemical neuroscience*. 2015;6(9):1536-45.

Hu S, Wang R, Cui W, Zhang Z, Mak S, Xu D, et al. Inhibiting beta-amyloid-associated Alzheimer's pathogenesis in vitro and in vivo by a multifunctional dimeric bis(12)-hupyridone derived from its natural analogue. *Journal of molecular neuroscience : MN*. 2015;55(4):1014-21.

Hu S-Q, Wang R, Cui W, Mak S-H, Li G, Hu Y-J, et al. Dimeric bis (heptyl)-Cognitin Blocks Alzheimer's beta-Amyloid Neurotoxicity Via the Inhibition of Abeta Fibrils Formation and Disaggregation of Preformed Fibrils. *CNS neuroscience & therapeutics*. 2015;21(12):953-61.

Hu Y, Lai J, Wan B, Liu X, Zhang Y, Zhang J, et al. Long-term exposure to ELF-MF ameliorates cognitive deficits and attenuates tau hyperphosphorylation in 3xTg AD mice. *Neurotoxicology*. 2016;53:290-300.

Hu Y, Li C, Shen W. Gastrodin alleviates memory deficits and reduces neuropathology in a mouse model of Alzheimer's disease. *Neuropathology : official journal of the Japanese Society of Neuropathology*. 2014;34(4):370-7.

Hu Y, Yang Y, Zhang M, Deng M, Zhang J-J. Intermittent Fasting Pretreatment Prevents Cognitive Impairment in a Rat Model of Chronic Cerebral Hypoperfusion. *The Journal of nutrition*. 2017;147(7):1437-45.

Hu Y-B, Zou Y, Huang Y, Zhang Y-F, Lourenco GF, Chen S-D, et al. ROCK1 Is Associated with Alzheimer's Disease-Specific Plaques, as well as Enhances Autophagosome Formation But not Autophagic Abeta Clearance. *Frontiers in cellular neuroscience*. 2016;10:253.

Hua F-Z, Ying J, Zhang J, Wang X-F, Hu Y-H, Liang Y-P, et al. Naringenin pre-treatment inhibits neuroapoptosis and ameliorates cognitive impairment in rats exposed to isoflurane anesthesia by regulating the PI3/Akt/PTEN signalling pathway and suppressing NF-kappaB-mediated inflammation. *International journal of molecular medicine*. 2016;38(4):1271-80.

Hua X, Hibar DP, Ching CRK, Boyle CP, Rajagopalan P, Gutman BA, et al. Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials. *NeuroImage*. 2013;66:648-61.

Huai Y, Dong Y, Xu J, Meng N, Song C, Li W, et al. L-3-n-butylphthalide protects against vascular dementia via activation of the Akt kinase pathway. *Neural regeneration research*. 2013;8(19):1733-42.

Huang AR, Redpath CJ, van Walraven C. The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada. *BMC neurology*. 2015;15:66.

Huang C, Chu H, Muheremu A, Zuo H. Neurorestorative strategies for Alzheimer's disease. *Neurology India*. 2015;63(4):583-8.

Huang D-S, Yu Y-C, Wu C-H, Lin J-Y. Protective Effects of Wogonin against Alzheimer's Disease by Inhibition of Amyloidogenic Pathway. *Evidence-based complementary and alternative medicine : eCAM*. 2017;2017:3545169.

Huang H, Ma Z-C, Wang Y-G, Hong Q, Tan H-L, Xiao C-R, et al. Ferulic acid alleviates Abeta25-35- and lipopolysaccharide-induced PC12 cellular damage: a potential role in Alzheimer's disease by PDE inhibition. *International journal of clinical pharmacology and therapeutics*. 2015;53(10):828-37.

Huang H-C, Chen Y-T, Chen P-Y, Huey-Lan Hu S, Liu F, Kuo Y-L, et al. Reminiscence Therapy Improves Cognitive Functions and Reduces Depressive Symptoms in Elderly People With Dementia: A Meta-Analysis of Randomized Controlled Trials. *Journal of the American Medical Directors Association*. 2015;16(12):1087-94.

Huang H-C, Zheng B-W, Guo Y, Zhao J, Zhao J-Y, Ma X-W, et al. Antioxidative and Neuroprotective Effects of Curcumin in an Alzheimer's Disease Rat Model Co-Treated with Intracerebroventricular Streptozotocin and Subcutaneous D-Galactose. *Journal of Alzheimer's disease : JAD*. 2016;52(3):899-911.

Huang H-J, Chen H-Y, Lee C-C, Chen CY-C. Computational design of apolipoprotein E4 inhibitors for Alzheimer's disease therapy from traditional Chinese medicine. *BioMed research international*. 2014;2014:452625.

Huang H-J, Chen S-L, Hsieh-Li HM. Administration of NaHS Attenuates Footshock-Induced Pathologies and Emotional and Cognitive Dysfunction in Triple Transgenic Alzheimer's Mice. *Frontiers in behavioral neuroscience*. 2015;9:312.

Huang H-J, Lee C-C, Chen CY-C. In silico design of BACE1 inhibitor for Alzheimer's disease by traditional Chinese medicine. *BioMed research international*. 2014;2014:741703.

Huang H-L, Kuo L-M, Chen Y-S, Liang J, Huang H-L, Chiu Y-C, et al. A home-based training program improves caregivers' skills and dementia patients' aggressive behaviors: a randomized controlled trial. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2013;21(11):1060-70.

Huang J-Z, Wu J, Xiang S, Sheng S, Jiang Y, Yang Z, et al. Catalpol preserves neural function and attenuates the pathology of Alzheimer's disease in mice. *Molecular medicine reports*. 2016;13(1):491-6.

Huang M, Jiang X, Liang Y, Liu Q, Chen S, Guo Y. Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of beta-amyloid in APP/tau/PS1 mouse model of Alzheimer's disease. *Experimental gerontology*. 2017;91:25-33.

Huang M, Xie S-S, Jiang N, Lan J-S, Kong L-Y, Wang X-B. Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-beta-amyloid (Abeta) aggregation and metal chelation properties against Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2015;25(3):508-13.

Huang N, Lu S, Liu X-G, Zhu J, Wang Y-J, Liu R-T. PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Abeta generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer's disease mice. *Oncotarget*. 2017;8(46):81001-13.

Huang S-L, Chang C-W, Lee Y-H, Yang F-Y. Protective Effect of Low-Intensity Pulsed Ultrasound on Memory Impairment and Brain Damage in a Rat Model of Vascular Dementia. *Radiology*. 2017;282(1):113-22.

Huang W, Li Z, Zhao L, Zhao W. Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2017;92:46-57.

Huang X, Wang Y, Ren K. Protective Effects of Liquiritin on the Brain of Rats with Alzheimer's Disease. *The West Indian medical journal*. 2015;64(5):468-72.

Huang Y, Huang X, Zhang L, Han F, Pang K-L, Li X, et al. Magnesium boosts the memory restorative effect of environmental enrichment in Alzheimer's disease mice. *CNS neuroscience & therapeutics*. 2017.

Huang Y, Skwarek-Maruszcwska A, Horre K, Vandewyer E, Wolfs L, Snellinx A, et al. Loss of GPR3 reduces the amyloid plaque burden and improves memory in Alzheimer's disease mouse models. *Science translational medicine*. 2015;7(309):309ra164.

Huang Z, Adachi H. Natural Compounds Preventing Neurodegenerative Diseases Through Autophagic Activation. *Journal of UOEH*. 2016;38(2):139-48.

Huang Z, Tan T, Du Y, Chen L, Fu M, Yu Y, et al. Low-Frequency Repetitive Transcranial Magnetic Stimulation Ameliorates Cognitive Function and Synaptic Plasticity in APP23/PS45 Mouse Model of Alzheimer's Disease. *Frontiers in aging neuroscience*. 2017;9:292.

Huded CB, Bharath S, Chandra SR, Sivakumar PT, Varghese M, Subramanian S. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India. *Asian journal of psychiatry*. 2015;13:44-7.

Hugel HM, Jackson N. Polyphenols for the prevention and treatment of dementia diseases. *Neural regeneration research*. 2015;10(11):1756-8.

Hughes LE, Rittman T, Regenthal R, Robbins TW, Rowe JB. Improving response inhibition systems in frontotemporal dementia with citalopram. *Brain : a journal of neurology*. 2015;138(Pt 7):1961-75.

Hughes ML, Lowe DA, Shine HE, Carpenter BD, Balsis S. Using the Alzheimer's Association web site to improve knowledge of Alzheimer's disease in health care providers. *American journal of Alzheimer's disease and other dementias*. 2015;30(1):98-100.

Huh E, Kim HG, Park H, Kang MS, Lee B, Oh MS. *Houttuynia cordata* Improves Cognitive Deficits in Cholinergic Dysfunction Alzheimer's Disease-Like Models. *Biomolecules & therapeutics*. 2014;22(3):176-83.

Hung T-C, Chang T-T, Fan M-J, Lee C-C, Chen CY-C. In Silico Insight into Potent of Anthocyanin Regulation of FKBP52 to Prevent Alzheimer's Disease. *Evidence-based complementary and alternative medicine : eCAM*. 2014;2014:450592.

Hung T-C, Lee W-Y, Chen K-B, Chan Y-C, Lee C-C, Chen CY-C. In silico investigation of traditional Chinese medicine compounds to inhibit human histone deacetylase 2 for patients with Alzheimer's disease. *BioMed research international*. 2014;2014:769867.

Hung Y-H, Chang S-H, Huang C-T, Yin J-H, Hwang C-S, Yang L-Y, et al. Inhibitor of Differentiation-1 and Hypoxia-Inducible Factor-1 Mediate Sonic Hedgehog Induction by Amyloid Beta-Peptide in Rat Cortical Neurons. *Molecular neurobiology*. 2016;53(2):793-809.

Hunsberger HC, Weitzner DS, Rudy CC, Hickman JE, Libell EM, Speer RR, et al. Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression. *Journal of neurochemistry*. 2015;135(2):381-94.

Huntley JD, Gould RL, Liu K, Smith M, Howard RJ. Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression. *BMJ open*. 2015;5(4):e005247.

Huo D-S, Sun J-F, Zhang B, Yan X-S, Wang H, Jia J-X, et al. Protective effects of testosterone on cognitive dysfunction in Alzheimer's disease model rats induced by oligomeric beta amyloid peptide 1-42. *Journal of toxicology and environmental health Part A*. 2016;79(19):856-63.

Huttenrauch M, BrauSs A, Kurdakova A, Borgers H, Klinker F, Liebetanz D, et al. Physical activity delays hippocampal neurodegeneration and rescues memory deficits in an Alzheimer disease mouse model. *Translational psychiatry*. 2016;6:e800.

Huvent-Grelle D, Boulanger E, Puisieux F. Relationship between Pisa syndrome and cholinesterase inhibitor use for elderly adults with Alzheimer's disease. *Journal of the American Geriatrics Society*. 2014;62(12):2450-3.

Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, et al. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. *Age and ageing*. 2013;42(1):14-20.

Hyde J, Perez R, Doyle PJ, Forester BP, Whitfield TH. The Impact of Enhanced Programming on Aging in Place for People With Dementia in Assisted Living. *American journal of Alzheimer's disease and other dementias*. 2015;30(8):733-7.

Hyeon JW, Kim SY, Lee J, Park JS, Hwang KJ, Lee SM, et al. Alternative application of Tau protein in Creutzfeldt-Jakob disease diagnosis: Improvement for weakly positive 14-3-3 protein in the laboratory. *Scientific reports*. 2015;5:15283.

Hyrskyluoto A, Bruelle C, Lundh SH, Do HT, Kivinen J, Rappou E, et al. Ubiquitin-specific protease-14 reduces cellular aggregates and protects against mutant huntingtin-induced cell degeneration: involvement of the proteasome and ER stress-activated kinase IRE1alpha. *Human molecular genetics*. 2014;23(22):5928-39.

Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. *Nature*. 2016;540(7632):230-5.

Ianiski FR, Alves CB, Ferreira CF, Rech VC, Savegnago L, Wilhelm EA, et al. Meloxicam-loaded nanocapsules as an alternative to improve memory decline in an Alzheimer's disease model in mice: involvement of Na(+), K(+)-ATPase. *Metabolic brain disease*. 2016;31(4):793-802.

Iglesias JE, Sabuncu MR, Van Leemput K, Alzheimers Disease Neuroimaging I. Improved inference in Bayesian segmentation using Monte Carlo sampling: application to hippocampal subfield volumetry. *Medical image analysis*. 2013;17(7):766-78.

Ihara M, Kalaria RN. Understanding and preventing the development of post-stroke dementia. *Expert review of neurotherapeutics*. 2014;14(9):1067-77.

Ihl R, Cujai N, Krah K. Admission into a Nursing Home. Delay or prevention with the use of a complete support network? *Zeitschrift fur Gerontologie und Geriatrie*. 2016;49(3):196-200.

Ihle-Hansen H, Thommessen B, Fagerland MW, Oksengard AR, Wyller TB, Engedal K, et al. Multifactorial vascular risk factor intervention to prevent cognitive impairment after stroke and TIA: a 12-month randomized controlled trial. *International journal of stroke : official journal of the International Stroke Society*. 2014;9(7):932-8.

Iida A, Usui T, Zar Kalai F, Han J, Isoda H, Nagumo Y. Protective effects of *Nitraria retusa* extract and its constituent isorhamnetin against amyloid beta-induced cytotoxicity and amyloid beta aggregation. *Bioscience, biotechnology, and biochemistry*. 2015;79(9):1548-51.

Iizuka T, Kameyama M. Cholinergic enhancement increases regional cerebral blood flow to the posterior cingulate cortex in mild Alzheimer's disease. *Geriatrics & gerontology international*. 2017;17(6):951-8.

Iizuka T, Morimoto K, Sasaki Y, Kameyama M, Kurashima A, Hayasaka K, et al. Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study. *Dementia and geriatric cognitive disorders extra*. 2017;7(2):204-14.

Ikeda K, Yanagihashi M, Sawada M, Hanashiro S, Kawabe K, Iwasaki Y. Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors. *Internal medicine (Tokyo, Japan)*. 2014;53(9):1007-10.

Ilhan Algin D, Dagli Atalay S, Ozkan S, Ozbabalik Adapinar D, Ak Sivrioiz I. Memantine improves semantic memory in patients with amnesic mild cognitive impairment: A single-photon emission computed tomography study. *The Journal of international medical research*. 2017;300060517715166.

Iliadou VV, Bamiou D-E, Sidiras C, Moschopoulos NP, Tsolaki M, Nimatoudis I, et al. The Use of the Gaps-In-Noise Test as an Index of the Enhanced Left Temporal Cortical Thinning

Associated with the Transition between Mild Cognitive Impairment and Alzheimer's Disease. *Journal of the American Academy of Audiology*. 2017;28(5):463-71.

Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, et al. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. *The Journal of clinical investigation*. 2013;123(3):1299-309.

Im KH, Nguyen TK, Choi J, Lee TS. In Vitro Antioxidant, Anti-Diabetes, Anti-Dementia, and Inflammation Inhibitory Effect of *Trametes pubescens* Fruiting Body Extracts. *Molecules (Basel, Switzerland)*. 2016;21(5).

Im W, Ban J, Lim J, Lee M, Lee S-T, Chu K, et al. Extracts of adipose derived stem cells slows progression in the R6/2 model of Huntington's disease. *PloS one*. 2013;8(4):e59438.

Imbeault H, Langlois F, Bocti C, Gagnon L, Bier N. Can people with Alzheimer's disease improve their day-to-day functioning with a tablet computer? *Neuropsychological rehabilitation*. 2016:1-18.

Improving cognitive function. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*. 2015;30(16):17.

Improving Detection of HIV-Associated Cognitive Impairment: Comparison of the International HIV Dementia Scale and a Brief Screening Battery: Erratum. *Journal of acquired immune deficiency syndromes (1999)*. 2017;76(2):e64.

Improving nutrition in dementia care. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*. 2016;30(23):7.

Imtiaz B, Tolppanen A-M, Kivipelto M, Soininen H. Future directions in Alzheimer's disease from risk factors to prevention. *Biochemical pharmacology*. 2014;88(4):661-70.

Indersmitten T, Tran CH, Cepeda C, Levine MS. Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease. *Journal of neurophysiology*. 2015;113(7):2953-66.

Inestrosa NC, Godoy JA, Vargas JY, Arrazola MS, Rios JA, Carvajal FJ, et al. Nicotine prevents synaptic impairment induced by amyloid-beta oligomers through alpha7-nicotinic acetylcholine receptor activation. *Neuromolecular medicine*. 2013;15(3):549-69.

Innes S, van Toorn R, Otjombe K, Dobbels E, van Zyl G, Cotton MF, et al. Late-Onset HIV Encephalopathy In Children With Long-Standing Virologic Suppression Followed By Slow Spontaneous Recovery Despite no Change In Antiretroviral Therapy: 4 Case Reports. *The Pediatric infectious disease journal*. 2017;36(11):e264-e7.

Inzitari M, Ruiz D, Martos J, Santa Eugenia S. "Move on Against Frailty": Time to Raise Awareness about Frailty and Prevention of Disability in the Community. *The Journal of frailty & aging*. 2016;5(4):201-3.

Iodice R, Meilan JJG, Carro J. Improvement of encoding and retrieval in normal and pathological aging with word-picture paradigm. *Aging & mental health*. 2015;19(10):940-6.

Iqbal J, Saeed A, Shah SJA, al-Rashida M, Shams-ul M. Biological Evaluation of Azomethine-dihydroquinazolinone Conjugates as Cancer and Cholinesterase Inhibitors. *Medicinal chemistry (Sharjah (United Arab Emirates))*. 2016;12(1):74-82.

Iqbal K, Kazim SF, Bolognin S, Blanchard J. Shifting balance from neurodegeneration to regeneration of the brain: a novel therapeutic approach to Alzheimer's disease and related neurodegenerative conditions. *Neural regeneration research*. 2014;9(16):1518-9.

Iraji A, Firuzi O, Khoshneviszadeh M, Tavakkoli M, Mahdavi M, Nadri H, et al. Multifunctional iminochromene-2H-carboxamide derivatives containing different aminomethylene triazole with BACE1 inhibitory, neuroprotective and metal chelating properties targeting Alzheimer's disease. *European journal of medicinal chemistry*. 2017;141:690-702.

Iram T, Trudler D, Kain D, Kanner S, Galron R, Vassar R, et al. Astrocytes from old Alzheimer's disease mice are impaired in A β uptake and in neuroprotection. *Neurobiology of disease*. 2016;96:84-94.

Irannejad H, Unsal Tan O, Ozadali K, Dadashpour S, Tuylu Kucukkilinc T, Ahangar N, et al. 1,2-Diaryl-2-hydroxyiminoethanones as dual COX-1 and beta-amyloid aggregation inhibitors: biological evaluation and in silico study. *Chemical biology & drug design*. 2015;85(4):494-503.

Iraqi A, Hughes TL. Is Mild Cognitive Impairment Really Reversible? *Journal of the American Medical Directors Association*. 2017;18(3):272-3.

Iraqi A, Hughes TL. Pneumonia Risk with Cholinesterase Inhibitors. *Journal of the American Geriatrics Society*. 2016;64(1):242.

Irish M, Bunk S, Tu S, Kamminga J, Hodges JR, Hornberger M, et al. Preservation of episodic memory in semantic dementia: The importance of regions beyond the medial temporal lobes. *Neuropsychologia*. 2016;81:50-60.

Irwin JA, Erisir A, Kwon I. Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2^{-/-} Mouse Model. *Current Alzheimer research*. 2016;13(6):663-77.

Irwin RW, Brinton RD. Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise. *Progress in neurobiology*. 2014;113:40-55.

Is there any way I can prevent, or at least reduce my risk of developing Alzheimer's disease or other dementias? DukeMedicine healthnews. 2013;19(5):8.

Isaacson R. Is Alzheimer's Prevention Possible Today? Journal of the American Geriatrics Society. 2017;65(10):2153-4.

Isaacson RS, Haynes N, Seifan A, Larsen D, Christiansen S, Berger JC, et al. Alzheimer's Prevention Education: If We Build It, Will They Come? www.AlzU.org. The journal of prevention of Alzheimer's disease. 2014;1(2):91-8.

Ishikawa M, Kusaka G, Terao S, Nagai M, Tanaka Y, Naritaka H. Improvement of neurovascular function and cognitive impairment after STA-MCA anastomosis. Journal of the neurological sciences. 2017;373:201-7.

Ishiwata A, Mizumura S, Mishina M, Yamazaki M, Katayama Y. The potentially protective effect of donepezil in Alzheimer's disease. Dementia and geriatric cognitive disorders. 2014;38(3-4):170-7.

Ishola IO, Adeyemi OO, Agbaje EO, Tota S, Shukla R. Combretum mucronatum and Capparis thoningii prevent scopolamine-induced memory deficit in mice. Pharmaceutical biology. 2013;51(1):49-57.

Isik AT, Soysal P, Usarel C. Effects of Acetylcholinesterase Inhibitors on Balance and Gait Functions and Orthostatic Hypotension in Elderly Patients With Alzheimer Disease. American journal of Alzheimer's disease and other dementias. 2016;31(7):580-4.

Isik AT, Soysal P, Yay A, Usarel C. The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer's disease. Diabetes research and clinical practice. 2017;123:192-8.

Islam MM, Gurung AB, Bhattacharjee A, Aguan K, Mitra S. Human serum albumin reduces the potency of acetylcholinesterase inhibitor based drugs for Alzheimer's disease. Chemico-biological interactions. 2016;249:1-9.

Ismail Z, Emeremni CA, Houck PR, Mazumdar S, Rosen J, Rajji TK, et al. A comparison of the E-BEHAVE-AD, NBRs, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2013;21(1):78-87.

Isopi E, Granzotto A, Corona C, Bomba M, Ciavardelli D, Curcio M, et al. Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology. Neurobiology of disease. 2015;81:214-24.

Ittner A, Chua SW, Bertz J, Volkerling A, van der Hoven J, Gladbach A, et al. Site-specific phosphorylation of tau inhibits amyloid-beta toxicity in Alzheimer's mice. *Science (New York, NY)*. 2016;354(6314):904-8.

Ittner AA, Gladbach A, Bertz J, Suh LS, Ittner LM. p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer's disease. *Acta neuropathologica communications*. 2014;2:149.

Iulita MF, Girouard H. Treating Hypertension to Prevent Cognitive Decline and Dementia: Re-Opening the Debate. *Advances in experimental medicine and biology*. 2017;956:447-73.

Ivachtchenko AV, Ivanenkov YA, Veselov MS, Okun IM. AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT₆R with Demonstrated Ability to Improve Impaired Memory in Animal Models. *Current Alzheimer research*. 2017;14(3):268-94.

Iwahara N, Hisahara S, Kawamata J, Matsumura A, Yokokawa K, Saito T, et al. Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APP^{swe}/PS1^{dE9} Mice. *Journal of Alzheimer's disease : JAD*. 2017;55(3):1235-47.

Iwamoto T. Prevention of dementia on the basis of modification of lifestyle and management of lifestyle-related diseases: a review. *Nihon rinsho Japanese journal of clinical medicine*. 2014;72(4):612-7.

Iwanami J, Mogi M, Tsukuda K, Wang X-L, Nakaoka H, Kan-no H, et al. Direct angiotensin II type 2 receptor stimulation by compound 21 prevents vascular dementia. *Journal of the American Society of Hypertension : JASH*. 2015;9(4):250-6.

Izuo N, Murakami K, Sato M, Iwasaki M, Izumi Y, Shimizu T, et al. Non-toxic conformer of amyloid beta may suppress amyloid beta-induced toxicity in rat primary neurons: implications for a novel therapeutic strategy for Alzheimer's disease. *Biochemical and biophysical research communications*. 2013;438(1):1-5.

Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, et al. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Aβ₄₂ oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. *PloS one*. 2014;9(11):e111898.

Jacobs DM, Ard MC, Salmon DP, Galasko DR, Bondi MW, Edland SD. Potential implications of practice effects in Alzheimer's disease prevention trials. *Alzheimer's & dementia (New York, N Y)*. 2017;3(4):531-5.

Jacobsen H, Ozmen L, Caruso A, Narquizian R, Hilpert H, Jacobsen B, et al. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid

reduction in APPLondon mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(35):11621-30.

Jacobsen J-H, Stelzer J, Fritz TH, Chetelat G, La Joie R, Turner R. Why musical memory can be preserved in advanced Alzheimer's disease. *Brain : a journal of neurology*. 2015;138(Pt 8):2438-50.

Jacqmin-Gadda H, Alperovitch A, Montlahuc C, Commenges D, Leffondre K, Dufouil C, et al. 20-Year prevalence projections for dementia and impact of preventive policy about risk factors. *European journal of epidemiology*. 2013;28(6):493-502.

Jahan H, Choudhary MI. Glycation, carbonyl stress and AGEs inhibitors: a patent review. *Expert opinion on therapeutic patents*. 2015;25(11):1267-84.

Jahng G-H, Lee DK, Lee J-M, Rhee HY, Ryu C-W. Double inversion recovery imaging improves the evaluation of gray matter volume losses in patients with Alzheimer's disease and mild cognitive impairment. *Brain imaging and behavior*. 2016;10(4):1015-28.

Jahrling JB, Hernandez CM, Denner L, Dineley KT. PPARgamma recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(11):4054-63.

Jain RS, Nagpal K, Handa R. Reversible dementia as presenting manifestation of racemose neurocysticercosis. *Annals of Indian Academy of Neurology*. 2013;16(3):452-3.

Jain S, Sharma B. Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia. *Physiology & behavior*. 2015;152(Pt A):182-93.

Jakubik M, Floriddia EM, Nicotera P, Bano D. Heterozygous Igf1r deletion does not ameliorate pathological features associated with polyglutamine-containing huntingtin fragment. *Neuroscience letters*. 2014;580:52-5.

Jalal H, Ganesh A, Lau R, Lysack J, Ismail Z. Cholinesterase-inhibitor Associated Mania: A Case Report and Literature Review. *The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques*. 2014;41(2):278-80.

Jalili-Baleh L, Nadri H, Moradi A, Bukhari SNA, Shakibaie M, Jafari M, et al. New racemic annulated pyrazolo 1,2-b phthalazines as tacrine-like AChE inhibitors with potential use in Alzheimer's disease. *European journal of medicinal chemistry*. 2017;139:280-9.

Jalkute CB, Barage SH, Dhanavade MJ, Sonawane KD. Molecular dynamics simulation and molecular docking studies of Angiotensin converting enzyme with inhibitor lisinopril and amyloid Beta Peptide. *The protein journal*. 2013;32(5):356-64.

Jamwal S, Kumar P. Antidepressants for neuroprotection in Huntington's disease: A review. *European journal of pharmacology*. 2015;769:33-42.

Jamwal S, Singh S, Kaur N, Kumar P. Protective Effect of Spermidine Against Excitotoxic Neuronal Death Induced by Quinolinic Acid in Rats: Possible Neurotransmitters and Neuroinflammatory Mechanism. *Neurotoxicity research*. 2015;28(2):171-84.

Jan A, Jansonius B, Delaidelli A, Somasekharan SP, Bhansali F, Vandal M, et al. eEF2K inhibition blocks Abeta42 neurotoxicity by promoting an NRF2 antioxidant response. *Acta neuropathologica*. 2017;133(1):101-19.

Jang H, Connelly L, Arce FT, Ramachandran S, Lal R, Kagan BL, et al. Alzheimer's disease: which type of amyloid-preventing drug agents to employ? *Physical chemistry chemical physics : PCCP*. 2013;15(23):8868-77.

Jang S, Lee JH, Sohn BK, Kim E, Park SG, Yoon KJ, et al. Suppression of AIMP1 protects cognition in Alzheimer's disease model mice 3xTg-AD. *Neuroreport*. 2017;28(2):82-6.

Janickova H, Rudajev V, Dolejsi E, Koivisto H, Jakubik J, Tanila H, et al. Lipid-Based Diets Improve Muscarinic Neurotransmission in the Hippocampus of Transgenic APPswe/PS1dE9 Mice. *Current Alzheimer research*. 2015;12(10):923-31.

Janik R, Thomason LAM, Chaudhary S, Dorr A, Scouten A, Schwindt G, et al. Attenuation of functional hyperemia to visual stimulation in mild Alzheimer's disease and its sensitivity to cholinesterase inhibition. *Biochimica et biophysica acta*. 2016;1862(5):957-65.

Janowska MK, Baum J. The loss of inhibitory C-terminal conformations in disease associated P123H beta-synuclein. *Protein science : a publication of the Protein Society*. 2016;25(1):286-94.

Janson J, Eketjall S, Tunblad K, Jeppsson F, Von Berg S, Niva C, et al. Population PKPD modeling of BACE1 inhibitor-induced reduction in Abeta levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig. *Pharmaceutical research*. 2014;31(3):670-83.

Jansone B, Kadish I, van Groen T, Beitnere U, Plotniece A, Pajuste K, et al. Memory-enhancing and brain protein expression-stimulating effects of novel calcium antagonist in Alzheimer's disease transgenic female mice. *Pharmacological research*. 2016;113(Pt B):781-7.

Jasinska M, Szydłowska I, Brodowska A, Starczewski A. Pro-health prevention in perimenopausal women with regard to estrogen treatment. *Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego*. 2015;39(229):53-5.

Jaul E, Meiron O. Systemic and Disease-Specific Risk Factors in Vascular Dementia: Diagnosis and Prevention. *Frontiers in aging neuroscience*. 2017;9:333.

Javed H, Khan A, Vaibhav K, Moshahid Khan M, Ahmad A, Ejaz Ahmad M, et al. Taurine ameliorates neurobehavioral, neurochemical and immunohistochemical changes in sporadic dementia of Alzheimer's type (SDAT) caused by intracerebroventricular streptozotocin in rats. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2013;34(12):2181-92.

Jawaid A, Pawlowicz E, Schulz PE. Do Acetylcholinesterase Inhibitors Increase Anxiety and Depression in Elderly Adults with Dementia? *Journal of the American Geriatrics Society*. 2015;63(8):1702-4.

Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. *The Journal of experimental medicine*. 2015;212(3):287-95.

Jayant S, Sharma BM, Sharma B. Protective effect of transient receptor potential vanilloid subtype 1 (TRPV1) modulator, against behavioral, biochemical and structural damage in experimental models of Alzheimer's disease. *Brain research*. 2016;1642:397-408.

Jayatilaka A, Ranasinghe DC, Falkner K, Visvanathan R, Wilson A. Care workers' voices in designing assistive technologies for preventing malnutrition in older people with dementia: Innovative Practice. *Dementia (London, England)*. 2017;1471301217722852.

Jeanet Y, Cayzac S, Cho YH. beta oscillation during slow wave sleep and rapid eye movement sleep in the electroencephalogram of a transgenic mouse model of Huntington's disease. *PloS one*. 2013;8(11):e79509.

Jefferson AL, Lambe S, Romano RR, Liu D, Islam F, Kowall N. An intervention to enhance Alzheimer's disease clinical research participation among older African Americans. *Journal of Alzheimer's disease : JAD*. 2013;36(3):597-606.

Jellings ME, Ferguson AH. Severe bradycardia in general anaesthesia in a patient treated with cholinesterase inhibitors for dementia. *Ugeskrift for laeger*. 2015;177(7).

Jeon J, Kim W, Jang J, Isacson O, Seo H. Gene therapy by proteasome activator, PA28gamma, improves motor coordination and proteasome function in Huntington's disease YAC128 mice. *Neuroscience*. 2016;324:20-8.

Jeon S, Park J-E, Lee J, Liu QF, Jeong HJ, Pak SC, et al. Illite improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease through Akt/CREB and GSK-3β phosphorylation in the brain. *Journal of ethnopharmacology*. 2015;160:69-77.

Jeon SJ, Lee HJ, Lee HE, Park SJ, Gwon Y, Kim H, et al. Oleanolic acid ameliorates cognitive dysfunction caused by cholinergic blockade via TrkB-dependent BDNF signaling. *Neuropharmacology*. 2017;113(Pt A):100-9.

Jeon Y-H, Clemson L, Naismith SL, Mowszowski L, McDonagh N, Mackenzie M, et al. Improving the social health of community-dwelling older people living with dementia through a reablement program. *International psychogeriatrics*. 2017:1-6.

Jeong DU, Lee JE, Lee SE, Chang WS, Kim SJ, Chang JW. Improvements in memory after medial septum stimulation are associated with changes in hippocampal cholinergic activity and neurogenesis. *BioMed research international*. 2014;2014:568587.

Jeong JH, Jeong HR, Jo YN, Kim HJ, Shin JH, Heo HJ. Ameliorating effects of aged garlic extracts against Abeta-induced neurotoxicity and cognitive impairment. *BMC complementary and alternative medicine*. 2013;13:268.

Jeong JJ, Woo JY, Kim KA, Han MJ, Kim DH. *Lactobacillus pentosus* var. *plantarum* C29 ameliorates age-dependent memory impairment in Fischer 344 rats. *Letters in applied microbiology*. 2015;60(4):307-14.

Jeong YJ, Kang G-Y, Kwon JH, Choi H-D, Pack J-K, Kim N, et al. 1950 MHz Electromagnetic Fields Ameliorate Abeta Pathology in Alzheimer's Disease Mice. *Current Alzheimer research*. 2015;12(5):481-92.

Jerzak KJ, Pallan S, Gerstein HC. Willingness to take drugs to prevent serious chronic diseases. *Journal of diabetes*. 2014;6(1):76-80.

Jhang KA, Lee EO, Kim H-S, Chong YH. Norepinephrine provides short-term neuroprotection against Abeta1-42 by reducing oxidative stress independent of Nrf2 activation. *Neurobiology of aging*. 2014;35(11):2465-73.

Ji C, Xue G-F, Li G, Li D, Holscher C. Neuroprotective effects of glucose-dependent insulintropic polypeptide in Alzheimer's disease. *Reviews in the neurosciences*. 2016;27(1):61-70.

Ji X-F, Chi T-Y, Liu P, Li L-Y, Xu J-K, Xu Q, et al. The total triterpenoid saponins of *Xanthoceras sorbifolia* improve learning and memory impairments through against oxidative stress and synaptic damage. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2017;25:15-24.

Ji Y, Wang J, Chen T, Du X, Zhan Y. Plasticity of inhibitory processes and associated far-transfer effects in older adults. *Psychology and aging*. 2016;31(5):415-29.

Ji Z-H, Xu Z-Q, Zhao H, Yu X-Y. Neuroprotective effect and mechanism of daucosterol palmitate in ameliorating learning and memory impairment in a rat model of Alzheimer's disease. *Steroids*. 2017;119:31-5.

Jia H, Morris CD, Williams RM, Loring JF, Thomas EA. HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112(1):E56-64.

Jia H, Wang Y, Morris CD, Jacques V, Gottesfeld JM, Rusche JR, et al. The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice. *PloS one*. 2016;11(3):e0152498.

Jia N, Han K, Kong J-J, Zhang X-M, Sha S, Ren G-R, et al. (-)-Epigallocatechin-3-gallate alleviates spatial memory impairment in APP/PS1 mice by restoring IRS-1 signaling defects in the hippocampus. *Molecular and cellular biochemistry*. 2013;380(1-2):211-8.

Jia S, Lu Z, Gao Z, An J, Wu X, Li X, et al. Chitosan oligosaccharides alleviate cognitive deficits in an amyloid-beta1-42-induced rat model of Alzheimer's disease. *International journal of biological macromolecules*. 2016;83:416-25.

Jia S-L, Wu X-L, Li X-X, Dai X-L, Gao Z-L, Lu Z, et al. Neuroprotective effects of liquiritin on cognitive deficits induced by soluble amyloid-beta1-42 oligomers injected into the hippocampus. *Journal of Asian natural products research*. 2016;18(12):1186-99.

Jia T, Sun Z, Lu Y, Gao J, Zou H, Xie F, et al. A dual brain-targeting curcumin-loaded polymersomes ameliorated cognitive dysfunction in intrahippocampal amyloid-beta1-42-injected mice. *International journal of nanomedicine*. 2016;11:3765-75.

Jian C, Lu M, Zhang Z, Liu L, Li X, Huang F, et al. miR-34a knockout attenuates cognitive deficits in APP/PS1 mice through inhibition of the amyloidogenic processing of APP. *Life sciences*. 2017;182:104-11.

Jiang H, He P, Xie J, Staufenbiel M, Li R, Shen Y. Genetic deletion of TNFR2 gene enhances the Alzheimer-like pathology in an APP transgenic mouse model via reduction of phosphorylated I κ B α . *Human molecular genetics*. 2014;23(18):4906-18.

Jiang J, Cleveland DW. Bidirectional Transcriptional Inhibition as Therapy for ALS/FTD Caused by Repeat Expansion in C9orf72. *Neuron*. 2016;92(6):1160-3.

Jiang J, Gao K, Zhou Y, Xu A, Shi S, Liu G, et al. Electroacupuncture Treatment Improves Learning-Memory Ability and Brain Glucose Metabolism in a Mouse Model of Alzheimer's Disease: Using Morris Water Maze and Micro-PET. *Evidence-based complementary and alternative medicine : eCAM*. 2015;2015:142129.

Jiang J, Wang Z-H, Qu M, Gao D, Liu X-P, Zhu L-Q, et al. Stimulation of EphB2 attenuates tau phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3 β . *Scientific reports*. 2015;5:11765.

Jiang J, Wen W, Sachdev PS. Macrophage inhibitory cytokine-1/growth differentiation factor 15 as a marker of cognitive ageing and dementia. *Current opinion in psychiatry*. 2016;29(2):181-6.

Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, et al. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. *Neuron*. 2016;90(3):535-50.

Jiang L-F, Liao H-L, Huang H-M, Zhou L-X, Li L, Cheng S-X, et al. Potential prevention and treatment of maifanite for Alzheimer's disease based on behavior test, oxidative stress assay, and trace element analysis in hippocampus of A β (1-42)-induced AD rats. *Biological trace element research*. 2013;152(1):50-6.

Jiang M, Peng Q, Liu X, Jin J, Hou Z, Zhang J, et al. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. *Human molecular genetics*. 2013;22(12):2462-70.

Jiang P, Li C, Xiang Z, Jiao B. Tanshinone IIA reduces the risk of Alzheimer's disease by inhibiting iNOS, MMP-2 and NF- κ B transcription and translation in the temporal lobes of rat models of Alzheimer's disease. *Molecular medicine reports*. 2014;10(2):689-94.

Jiang Q, Chen S, Hu C, Huang P, Shen H, Zhao W. Neuregulin-1 (Nrg1) signaling has a preventive role and is altered in the frontal cortex under the pathological conditions of Alzheimer's disease. *Molecular medicine reports*. 2016;14(3):2614-24.

Jiang T, Tan L, Zhu X-C, Zhang Q-Q, Cao L, Tan M-S, et al. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2014;39(13):2949-62.

Jiang T, Yu J-T, Zhu X-C, Tan M-S, Wang H-F, Cao L, et al. Temsirolimus promotes autophagic clearance of amyloid-beta and provides protective effects in cellular and animal models of Alzheimer's disease. *Pharmacological research*. 2014;81:54-63.

Jiang T, Zhang Y-D, Chen Q, Gao Q, Zhu X-C, Zhou J-S, et al. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice. *Neuropharmacology*. 2016;105:196-206.

Jiang X, Chai G-S, Wang Z-H, Hu Y, Li X-G, Ma Z-W, et al. CaMKII-dependent dendrite ramification and spine generation promote spatial training-induced memory improvement in a rat model of sporadic Alzheimer's disease. *Neurobiology of aging*. 2015;36(2):867-76.

Jiang X, Chai G-S, Wang Z-H, Hu Y, Li X-G, Ma Z-W, et al. Spatial training preserves associative memory capacity with augmentation of dendrite ramification and spine generation in Tg2576 mice. *Scientific reports*. 2015;5:9488.

Jiang X, Jia L-W, Li X-H, Cheng X-S, Xie J-Z, Ma Z-W, et al. Capsaicin ameliorates stress-induced Alzheimer's disease-like pathological and cognitive impairments in rats. *Journal of Alzheimer's disease : JAD*. 2013;35(1):91-105.

Jiang X, Zhou Z, Ding X, Deng X, Zou L, Li B. Level Set Based Hippocampus Segmentation in MR Images with Improved Initialization Using Region Growing. *Computational and mathematical methods in medicine*. 2017;2017:5256346.

Jiang Y, Gao H, Turdu G. Traditional Chinese medicinal herbs as potential AChE inhibitors for anti-Alzheimer's disease: A review. *Bioorganic chemistry*. 2017;75:50-61.

Jiang Y-Q, Wang X-L, Cao X-H, Ye Z-Y, Li L, Cai W-Q. Increased heat shock transcription factor 1 in the cerebellum reverses the deficiency of Purkinje cells in Alzheimer's disease. *Brain research*. 2013;1519:105-11.

Jiao J-J, Holscher C, Li T, Dong X-F, Qu X-S, Cao Y, et al. GLP-1/GIP/Gcg receptor Triagonist improves the cognitive behaviors in triple-transgenic mice of Alzheimer's disease. *Sheng li xue bao : [Acta physiologica Sinica]*. 2017;69(2):135-45.

Jiao SS, Shen LL, Zhu C, Bu XL, Liu YH, Liu CH, et al. Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease. *Translational psychiatry*. 2016;6(10):e907.

Jiao S-S, Yao X-Q, Liu Y-H, Wang Q-H, Zeng F, Lu J-J, et al. Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112(16):5225-30.

Jimenez-Aligaga K, Bermejo-Bescos P, Martin-Aragon S, Csaky AG. Discovery of alkenylboronic acids as neuroprotective agents affecting multiple biological targets involved in Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2013;23(2):426-9.

Jin F, Gong Q-H, Xu Y-S, Wang L-N, Jin H, Li F, et al. Icaritin, a phosphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling. *The international journal of neuropsychopharmacology*. 2014;17(6):871-81.

Jin G, Wang L-H, Ji X-F, Chi T-Y, Qi Y, Jiao Q, et al. Xanthoceraside rescues learning and memory deficits through attenuating beta-amyloid deposition and tau hyperphosphorylation in APP mice. *Neuroscience letters*. 2014;573:58-63.

Jin H, Wang W, Zhao S, Yang W, Qian Y, Jia N, et al. Abeta-HBc virus-like particles immunization without additional adjuvant ameliorates the learning and memory and reduces Abeta deposit in PDAPP mice. *Vaccine*. 2014;32(35):4450-6.

Jin J, Albertz J, Guo Z, Peng Q, Rudow G, Troncoso JC, et al. Neuroprotective effects of PPAR-gamma agonist rosiglitazone in N171-82Q mouse model of Huntington's disease. *Journal of neurochemistry*. 2013;125(3):410-9.

Jin J-l, Liou AKF, Shi Y, Yin K-l, Chen L, Li L-l, et al. CART treatment improves memory and synaptic structure in APP/PS1 mice. *Scientific reports*. 2015;5:10224.

Jin M, Selkoe DJ. Systematic analysis of time-dependent neural effects of soluble amyloid beta oligomers in culture and in vivo: Prevention by scyllo-inositol. *Neurobiology of disease*. 2015;82:152-63.

Jin N, Wu Y, Xu W, Gong C-X, Iqbal K, Liu F. C-terminal truncation of GSK-3beta enhances its dephosphorylation by PP2A. *FEBS letters*. 2017;591(7):1053-63.

Jin W-S, Shen L-L, Bu X-L, Zhang W-W, Chen S-H, Huang Z-L, et al. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. *Acta neuropathologica*. 2017;134(2):207-20.

Jin X, Li T, Zhang L, Ma J, Yu L, Li C, et al. Environmental Enrichment Improves Spatial Learning and Memory in Vascular Dementia Rats with Activation of Wnt/beta-Catenin Signal Pathway. *Medical science monitor : international medical journal of experimental and clinical research*. 2017;23:207-15.

Jin Y, Tsuchiya A, Kanno T, Nishizaki T. Amyloid-beta peptide increases cell surface localization of alpha7 ACh receptor to protect neurons from amyloid beta-induced damage. *Biochemical and biophysical research communications*. 2015;468(1-2):157-60.

Jing P, Zhang J-Y, Ouyang Q, Wu J, Zhang X-J. Lithium treatment induces proteasomal degradation of over-expressed acetylcholinesterase (AChE-S) and inhibit GSK3beta. *Chemico-biological interactions*. 2013;203(1):309-13.

Joffre C, Nadjar A, Lebbadi M, Calon F, Laye S. n-3 LCPUFA improves cognition: the young, the old and the sick. *Prostaglandins, leukotrienes, and essential fatty acids*. 2014;91(1-2):1-20.

Johansson JU, Woodling NS, Wang Q, Panchal M, Liang X, Trueba-Saiz A, et al. Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. *The Journal of clinical investigation*. 2015;125(1):350-64.

Johansson L, Bjorklund A, Sidenvall B, Christensson L. Staff views on how to improve mealtimes for elderly people with dementia living at home. *Dementia* (London, England). 2017;16(7):835-52.

Johansson L, Wijk H, Christensson L. Improving Nutritional Status of Older Persons with Dementia Using a National Preventive Care Program. *The journal of nutrition, health & aging*. 2017;21(3):292-8.

Johnson AA, Sarthi J, Pirooznia SK, Reube W, Elefant F. Increasing Tip60 HAT levels rescues axonal transport defects and associated behavioral phenotypes in a *Drosophila* Alzheimer's disease model. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(17):7535-47.

Johnson DA. The Possible Association Between Proton Pump Inhibitors and Dementia. *Gastroenterology & hepatology*. 2016;12(10):644-6.

Johnson ECB, Kang J. A small molecule targeting protein translation does not rescue spatial learning and memory deficits in the hAPP-J20 mouse model of Alzheimer's disease. *PeerJ*. 2016;4:e2565.

Johnston B, Lawton S, McCaw C, Law E, Murray J, Gibb J, et al. Living well with dementia: enhancing dignity and quality of life, using anovel intervention, Dignity Therapy. *International journal of older people nursing*. 2016;11(2):107-20.

Johnston B, Narayanasamy M. Exploring psychosocial interventions for people with dementia that enhance personhood and relate to legacy- an integrative review. *BMC geriatrics*. 2016;16:77.

Joling KJ, Bosmans JE, van Marwijk HWJ, van der Horst HE, Scheltens P, MacNeil Vroomen JL, et al. The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial. *Trials*. 2013;14:305.

Jonaitis EM, Kosciak RL, La Rue A, Johnson SC, Hermann BP, Sager MA. Aging, Practice Effects, and Genetic Risk in the Wisconsin Registry for Alzheimer's Prevention. *The Clinical neuropsychologist*. 2015;29(4):426-41.

Jones HE, Joshi A, Shenkin S, Mead GE. The effect of treatment with selective serotonin reuptake inhibitors in comparison to placebo in the progression of dementia: a systematic review and meta-analysis. *Age and ageing*. 2016;45(4):448-56.

Jones M, Wang J, Harmon S, Kling B, Heilmann J, Gilmer JF. Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer's Disease. *Molecules* (Basel, Switzerland). 2016;21(4):440.

Jones RS, Minogue AM, Fitzpatrick O, Lynch MA. Inhibition of JAK2 attenuates the increase in inflammatory markers in microglia from APP/PS1 mice. *Neurobiology of aging*. 2015;36(10):2716-24.

Jones WS, Mi X, Qualls LG, Turley RS, Vemulapalli S, Peterson ED, et al. Significant variation in P2Y₁₂ inhibitor use after peripheral vascular intervention in Medicare beneficiaries. *American heart journal*. 2016;179:10-8.

Jongstra S, Harrison JK, Quinn TJ, Richard E. Antihypertensive withdrawal for the prevention of cognitive decline. *The Cochrane database of systematic reviews*. 2016;11:CD011971.

Jordan K, Church T. A clinical learning experience: enhancing baccalaureate nursing students' self-efficacy in meeting the psychosocial needs of clients with dementia. *The Journal of nursing education*. 2013;52(3):171-4.

Joshi AS, Thakur AK. Biodegradable delivery system containing a peptide inhibitor of polyglutamine aggregation: a step toward therapeutic development in Huntington's disease. *Journal of peptide science : an official publication of the European Peptide Society*. 2014;20(8):630-9.

Joshi G, Chi Y, Huang Z, Wang Y. Abeta-induced Golgi fragmentation in Alzheimer's disease enhances Abeta production. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(13):E1230-9.

Joshi G, Wang Y. Golgi defects enhance APP amyloidogenic processing in Alzheimer's disease. *BioEssays : news and reviews in molecular, cellular and developmental biology*. 2015;37(3):240-7.

Joshi YB, Chu J, Pratico D. Knockout of 5-lipoxygenase prevents dexamethasone-induced tau pathology in 3xTg mice. *Aging cell*. 2013;12(4):706-11.

Joshi YB, Giannopoulos PF, Chu J, Sperow M, Kirby LG, Abood ME, et al. Absence of ALOX5 gene prevents stress-induced memory deficits, synaptic dysfunction and tauopathy in a mouse model of Alzheimer's disease. *Human molecular genetics*. 2014;23(25):6894-902.

Joubert J, Foka GB, Repsold BP, Oliver DW, Kapp E, Malan SF. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease. *European journal of medicinal chemistry*. 2017;125:853-64.

Jovalekic A, Bullich S, Catafau A, de Santi S. Advances in Abeta plaque detection and the value of knowing: overcoming challenges to improving patient outcomes in Alzheimer's disease. *Neurodegenerative disease management*. 2016;6(6):491-7.

Jovicic A, Zaldivar Jolissaint JF, Moser R, Silva Santos MdF, Luthi-Carter R. MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms. *PloS one*. 2013;8(1):e54222.

Ju Y, Li Z, Deng Y, Tong A, Zhou L, Luo Y. Identification of Novel BACE1 Inhibitors by Combination of Pharmacophore Modeling, Structure-Based Design and In Vitro Assay. *Current computer-aided drug design*. 2016;12(1):73-82.

Judge KS, Yarry SJ, Looman WJ, Bass DM. Improved Strain and Psychosocial Outcomes for Caregivers of Individuals with Dementia: Findings from Project ANSWERS. *The Gerontologist*. 2013;53(2):280-92.

Jun Z, Ibrahim MM, Dezheng G, Bo Y, Qiong W, Yuan Z. UCP2 protects against amyloid beta toxicity and oxidative stress in primary neuronal culture. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2015;74:211-4.

Jung HA, Ali MY, Jung HJ, Jeong HO, Chung HY, Choi JS. Inhibitory activities of major anthraquinones and other constituents from *Cassia obtusifolia* against beta-secretase and cholinesterases. *Journal of ethnopharmacology*. 2016;191:152-60.

Jung HA, Karki S, Kim JH, Choi JS. BACE1 and cholinesterase inhibitory activities of *Nelumbo nucifera* embryos. *Archives of pharmacal research*. 2015;38(6):1178-87.

Jung J-S, Yan J-J, Li H-M, Sultan MT, Yu J, Lee H-S, et al. Protective effects of a dimeric derivative of ferulic acid in animal models of Alzheimer's disease. *European journal of pharmacology*. 2016;782:30-4.

Juntunen H, Taipale H, Tanskanen A, Tolppanen A-M, Tiihonen J, Hartikainen S, et al. Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease. *European journal of clinical pharmacology*. 2017;73(9):1149-58.

Justin Thenmozhi A, Dhivyabharathi M, Manivasagam T, Essa MM. Tannoid principles of *Emblica officinalis* attenuated aluminum chloride induced apoptosis by suppressing oxidative stress and tau pathology via Akt/GSK-3 β signaling pathway. *Journal of ethnopharmacology*. 2016;194:20-9.

Justin Thenmozhi A, Dhivyabharathi M, William Raja TR, Manivasagam T, Essa MM. Tannoid principles of *Emblica officinalis* renovate cognitive deficits and attenuate amyloid pathologies against aluminum chloride induced rat model of Alzheimer's disease. *Nutritional neuroscience*. 2016;19(6):269-78.

Justin Thenmozhi A, Raja TRW, Janakiraman U, Manivasagam T. Erratum to: Neuroprotective Effect of Hesperidin on Aluminium Chloride Induced Alzheimer's Disease in Wistar Rats. *Neurochemical research*. 2015;40(9):2006.

Justin Thenmozhi A, Raja TRW, Janakiraman U, Manivasagam T. Neuroprotective effect of hesperidin on aluminium chloride induced Alzheimer's disease in Wistar rats. *Neurochemical research*. 2015;40(4):767-76.

Justin Thenmozhi A, William Raja TR, Manivasagam T, Janakiraman U, Essa MM. Hesperidin ameliorates cognitive dysfunction, oxidative stress and apoptosis against aluminium chloride induced rat model of Alzheimer's disease. *Nutritional neuroscience*. 2017;20(6):360-8.

Kalemenev SV, Zubareva OE, Sizov VV, Lavrent'eva VV, Lukomskaya NY, Kim KK, et al. Memantine attenuates cognitive impairments after status epilepticus induced in a lithium-pilocarpine model. *Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections*. 2016;470(1):224-7.

Kalenzaga S, Piolino P, Clarys D. The emotional memory effect in Alzheimer's disease: emotional words enhance recollective experience similarly in patients and control participants. *Cognition & emotion*. 2015;29(2):342-50.

Kalra J, Kumar P, Majeed ABA, Prakash A. Modulation of LOX and COX pathways via inhibition of amyloidogenesis contributes to mitoprotection against beta-amyloid oligomer-induced toxicity in an animal model of Alzheimer's disease in rats. *Pharmacology, biochemistry, and behavior*. 2016;146-147:1-12.

Kamal MA, Shakil S, Nawaz MS, Yu Q-S, Tweedie D, Tan Y, et al. Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses. *CNS & neurological disorders drug targets*. 2017;16(7):820-7.

Kamalinia G, Khodagholi F, Atyabi F, Amini M, Shaerzadeh F, Sharifzadeh M, et al. Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies. *Molecular pharmaceutics*. 2013;10(12):4418-31.

Kamat PK, Kyles P, Kalani A, Tyagi N. Hydrogen Sulfide Ameliorates Homocysteine-Induced Alzheimer's Disease-Like Pathology, Blood-Brain Barrier Disruption, and Synaptic Disorder. *Molecular neurobiology*. 2016;53(4):2451-67.

Kamat PK, Nath C. Okadaic acid: a tool to study regulatory mechanisms for neurodegeneration and regeneration in Alzheimer's disease. *Neural regeneration research*. 2015;10(3):365-7.

Kamat PK. Streptozotocin induced Alzheimer's disease like changes and the underlying neural degeneration and regeneration mechanism. *Neural regeneration research*. 2015;10(7):1050-2.

Kamei N, Tanaka M, Choi H, Okada N, Ikeda T, Itokazu R, et al. Effect of an Enhanced Nose-to-Brain Delivery of Insulin on Mild and Progressive Memory Loss in the Senescence-Accelerated Mouse. *Molecular pharmaceutics*. 2017;14(3):916-27.

Kamei N. Nose-to-Brain Delivery of Peptide Drugs Enhanced by Coadministration of Cell-penetrating Peptides: Therapeutic Potential for Dementia. *Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan*. 2017;137(10):1247-53.

Kaminari A, Giannakas N, Tzinia A, Tsilibary EC. Overexpression of matrix metalloproteinase-9 (MMP-9) rescues insulin-mediated impairment in the 5XFAD model of Alzheimer's disease. *Scientific reports*. 2017;7(1):683.

Kamkwalala AR, Newhouse PA. Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer's Disease. *Current Alzheimer research*. 2017;14(4):377-92.

Kamp D, Paschali M, Lange-Asschenfeldt C. Reversible Hypothermia in a Drug-naive Inpatient with Alzheimer's Disease Receiving Pipamperone. *Pharmacopsychiatry*. 2016;49(5):213-4.

Kamynina AV, Filatova MP, Koroev DO, Abramov AI, Vol'pina OM. Antibodies to synthetic fragment 95-123 of the prion protein protect neurons and astrocytes from beta-amyloid toxicity. *Bioorganicheskaya khimiya*. 2013;39(2):131-40.

Kan MJ, Lee JE, Wilson JG, Everhart AL, Brown CM, Hoofnagle AN, et al. Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2015;35(15):5969-82.

Kanamaru T, Kamimura N, Yokota T, Nishimaki K, Iuchi K, Lee H, et al. Intravenous transplantation of bone marrow-derived mononuclear cells prevents memory impairment in transgenic mouse models of Alzheimer's disease. *Brain research*. 2015;1605:49-58.

Kanda PAM, Oliveira EF, Fraga FJ. EEG epochs with less alpha rhythm improve discrimination of mild Alzheimer's. *Computer methods and programs in biomedicine*. 2017;138:13-22.

Kandiah N, Pai M-C, Senanarong V, Looi I, Ampil E, Park KW, et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. *Clinical interventions in aging*. 2017;12:697-707.

Kandimalla R, Manczak M, Fry D, Suneetha Y, Sesaki H, Reddy PH. Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease. *Human molecular genetics*. 2016;25(22):4881-97.

Kaneko J, Enya A, Enomoto K, Ding Q, Hisatsune T. Anserine (beta-alanyl-3-methyl-L-histidine) improves neurovascular-unit dysfunction and spatial memory in aged AbetaPPswe/PSEN1dE9 Alzheimer's-model mice. *Scientific reports*. 2017;7(1):12571.

Kaneta T, Nakatsuka M, Nakamura K, Seki T, Yamaguchi S, Tsuboi M, et al. Improved Diagnostic Accuracy of SPECT Through Statistical Analysis and the Detection of Hot Spots at the Primary Sensorimotor Area for the Diagnosis of Alzheimer Disease in a Community-Based Study: "The Osaka-Tajiri Project". *Clinical nuclear medicine*. 2016;41(1):e1-6.

Kang L, Xiong C, Crane P, Tian L. Linear combinations of biomarkers to improve diagnostic accuracy with three ordinal diagnostic categories. *Statistics in medicine*. 2013;32(4):631-43.

Kang S, Kim C-H, Jung H, Kim E, Song H-T, Lee JE. Agmatine ameliorates type 2 diabetes induced-Alzheimer's disease-like alterations in high-fat diet-fed mice via reactivation of blunted insulin signalling. *Neuropharmacology*. 2017;113(Pt A):467-79.

Kang S, Moon NR, Kim DS, Kim SH, Park S. Central acylated ghrelin improves memory function and hippocampal AMPK activation and partly reverses the impairment of energy and glucose metabolism in rats infused with beta-amyloid. *Peptides*. 2015;71:84-93.

Kang S-G, Na K-S, Kang JM, Yeon BK, Lee J-Y, Cho S-J. Dementia Care by Healthy Elderly Caregivers Is Associated with Improvement of Patients' Memory and the Caregivers' Quality of Life: A Before and After Study. *Psychiatry investigation*. 2017;14(4):458-62.

Kano O, Urita Y, Ito H, Takazawa T, Kawase Y, Murata K, et al. Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease. *Neuropsychiatric disease and treatment*. 2013;9:1411-5.

Kanuru M, Aradhyam GK. Chaperone-like Activity of Calnuc Prevents Amyloid Aggregation. *Biochemistry*. 2017;56(1):149-59.

Kao C-C, Lin L-C, Wu S-C, Lin K-N, Liu C-K. Effectiveness of different memory training programs on improving hyperphagic behaviors of residents with dementia: a longitudinal single-blind study. *Clinical interventions in aging*. 2016;11:707-20.

Kapila AK, Watts HR, Wang T, Ma D. The impact of surgery and anesthesia on post-operative cognitive decline and Alzheimer's disease development: biomarkers and preventive strategies. *Journal of Alzheimer's disease : JAD*. 2014;41(1):1-13.

Karaman N, Sicak Y, Taskin-Tok T, Ozturk M, Karakucuk-Iyidogan A, Dikmen M, et al. New piperidine-hydrazone derivatives: Synthesis, biological evaluations and molecular docking studies as AChE and BChE inhibitors. *European journal of medicinal chemistry*. 2016;124:270-83.

Karch A, Llorens F, Schmitz M, Arora AS, Zafar S, Lange P, et al. Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia. *Journal of Alzheimer's disease : JAD*. 2016;54(4):1385-93.

Karlawish J, Langa KM. Unfinished Business in Preventing Alzheimer Disease. *JAMA internal medicine*. 2016;176(12):1739-40.

Karunaweera N, Raju R, Gyengesi E, Munch G. Plant polyphenols as inhibitors of NF-kappaB induced cytokine production-a potential anti-inflammatory treatment for Alzheimer's disease? *Frontiers in molecular neuroscience*. 2015;8:24.

Kashima Y, Miyazawa M. Structure-activity relationships for bergenin analogues as beta-secretase (BACE1) inhibitors. *Journal of oleo science*. 2013;62(6):391-401.

Kaskie BP, Nattinger M, Potter A. Policies to protect persons with dementia in assisted living: deja vu all over again? *The Gerontologist*. 2015;55(2):199-209.

Kassar O, Pereira Morais M, Xu S, Adam EL, Chamberlain RC, Jenkins B, et al. Corrigendum: Macrophage Migration Inhibitory Factor is subjected to glucose modification and oxidation in Alzheimer's Disease. *Scientific reports*. 2017;7:45417.

Kassar O, Pereira Morais M, Xu S, Adam EL, Chamberlain RC, Jenkins B, et al. Macrophage Migration Inhibitory Factor is subjected to glucose modification and oxidation in Alzheimer's Disease. *Scientific reports*. 2017;7:42874.

Kastanenka KV, Bussiere T, Shakerdige N, Qian F, Weinreb PH, Rhodes K, et al. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2016;36(50):12549-58.

Kastanenka KV, Hou SS, Shakerdige N, Logan R, Feng D, Wegmann S, et al. Optogenetic Restoration of Disrupted Slow Oscillations Halts Amyloid Deposition and Restores Calcium Homeostasis in an Animal Model of Alzheimer's Disease. *PloS one*. 2017;12(1):e0170275.

Kasza A, Hunya A, Frank Z, Fulop F, Torok Z, Balogh G, et al. Dihydropyridine Derivatives Modulate Heat Shock Responses and have a Neuroprotective Effect in a Transgenic Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;53(2):557-71.

Kasza A, Penke B, Frank Z, Bozso Z, Szegedi V, Hunya A, et al. Studies for Improving a Rat Model of Alzheimer's Disease: Icv Administration of Well-Characterized beta-Amyloid 1-42 Oligomers Induce Dysfunction in Spatial Memory. *Molecules (Basel, Switzerland)*. 2017;22(11).

Katsel P, Tan W, Fam P, Purohit DP, Haroutunian V. Cell cycle checkpoint abnormalities during dementia: A plausible association with the loss of protection against oxidative stress in Alzheimer's disease corrected. *PloS one*. 2013;8(7):e68361.

Katsouri L, Vizcaychipi MP, McArthur S, Harrison I, Suarez-Calvet M, Lleo A, et al. Prazosin, an $\alpha(1)$ -adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease. *Neurobiology of aging*. 2013;34(4):1105-15.

Katusic ZS, Austin SA. Endothelial nitric oxide: protector of a healthy mind. *European heart journal*. 2014;35(14):888-94.

Katusic ZS, Austin SA. Neurovascular Protective Function of Endothelial Nitric Oxide—Recent Advances. *Circulation journal : official journal of the Japanese Circulation Society*. 2016;80(7):1499-503.

Katz JD, Haidle A, Childers KK, Zabierek AA, Jewell JP, Hou Y, et al. Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors. *Bioorganic & medicinal chemistry letters*. 2017;27(1):114-20.

Kaufman AC, Salazar SV, Haas LT, Yang J, Kostylev MA, Jeng AT, et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. *Annals of neurology*. 2015;77(6):953-71.

Kaufmann D, Kaur Dogra A, Tahrani A, Herrmann F, Wink M. Extracts from Traditional Chinese Medicinal Plants Inhibit Acetylcholinesterase, a Known Alzheimer's Disease Target. *Molecules (Basel, Switzerland)*. 2016;21(9).

Kaur J, Dodson JE, Steadman L, Vance DE. Predictors of improvement following speed of processing training in middle-aged and older adults with HIV: a pilot study. *The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses*. 2014;46(1):23-33.

Kaur J, Sharma S, Sandhu M, Sharma S. Neurokinin-1 receptor inhibition reverses ischaemic brain injury and dementia in bilateral common carotid artery occluded rats: possible mechanisms. *Inflammopharmacology*. 2016;24(4):133-43.

Kaur M, Prakash A, Kalia AN. Neuroprotective potential of antioxidant potent fractions from *Convolvulus pluricaulis* Choisy. in 3-nitropropionic acid challenged rats. *Nutritional neuroscience*. 2016;19(2):70-8.

Kaushik V, Smith ST, Mikobi E, Raji MA. Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease. *American journal of Alzheimer's disease and other dementias*. 2017;1533317517734352.

Kavoor AR, Mitra S, Mahintamani T, Chatterjee SS. Primary Prevention of Alzheimer's Disease in Developing Countries. *Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology*. 2015;13(3):327.

Kawada T. Proton Pump Inhibitors and Dementia Incidence. *JAMA neurology*. 2016;73(8):1025-6.

Kawaguchi K, Saigusa A, Yamada S, Gotoh T, Nakai S, Hiki Y, et al. Toward the treatment for Alzheimer's disease: adsorption is primary mechanism of removing amyloid beta protein with hollow-fiber dialyzers of the suitable materials, polysulfone and polymethyl methacrylate. *Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs*. 2016;19(2):149-58.

Kawaguchi K, Takeuchi M, Yamagawa H, Murakami K, Nakai S, Hori H, et al. A potential therapeutic system for Alzheimer's disease using adsorbents with alkyl ligands for removal of blood amyloid beta. *Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs*. 2013;16(2):211-7.

Kawakubo T, Mori R, Shirotani K, Iwata N, Asai M. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts. *Biological & pharmaceutical bulletin*. 2017;40(3):327-33.

Kazim SF, Blanchard J, Bianchi R, Iqbal K. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome. *Scientific reports*. 2017;7:45561.

Kazim SF, Chuang S-C, Zhao W, Wong RKS, Bianchi R, Iqbal K. Early-Onset Network Hyperexcitability in Presymptomatic Alzheimer's Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/Abeta Antibody and by mGluR5 Blockade. *Frontiers in aging neuroscience*. 2017;9:71.

Kazmerova Z, Zilka N, Cente M, Neradil P, Zilkova M, Novak M. Can we teach old dogs new tricks? Neuroprotective cell therapy in Alzheimer's and Parkinson's disease. *Journal of Alzheimer's disease : JAD*. 2013;37(2):251-72.

Kazui H, Kanemoto H, Yoshiyama K, Kishima H, Suzuki Y, Sato S, et al. Association between high biomarker probability of Alzheimer's disease and improvement of clinical outcomes after shunt surgery in patients with idiopathic normal pressure hydrocephalus. *Journal of the neurological sciences*. 2016;369:236-41.

Ke YD, van Hummel A, Stevens CH, Gladbach A, Ippati S, Bi M, et al. Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLTDP and ALS. *Acta neuropathologica*. 2015;130(5):661-78.

Keane KM, Haskell-Ramsay CF, Veasey RC, Howatson G. Montmorency Tart cherries (*Prunus cerasus* L.) modulate vascular function acutely, in the absence of improvement in cognitive performance. *The British journal of nutrition*. 2016;116(11):1935-44.

Kearney M-C, Caffarel-Salvador E, Fallows SJ, McCarthy HO, Donnelly RF. Microneedle-mediated delivery of donepezil: Potential for improved treatment options in Alzheimer's disease. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV*. 2016;103:43-50.

Keating M, Long J, Wright J. Leading culture change to improve dementia care. *Nursing times*. 2013;109(8):16-8.

Keefer KM, True HL. Prion-Associated Toxicity is Rescued by Elimination of Cotranslational Chaperones. *PLoS genetics*. 2016;12(11):e1006431.

Keenan B, Jenkins C, Ginesi L. Preventing and diagnosing dementia. *Nursing times*. 2016;112(26):22-5.

Keeney JT-R, Ibrahimi S, Zhao L. Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention. *Journal of Alzheimer's disease : JAD*. 2015;48(2):411-24.

Keillor JW, Apperley KYP. Transglutaminase inhibitors: a patent review. *Expert opinion on therapeutic patents*. 2016;26(1):49-63.

Keiser MS, Kordasiewicz HB, McBride JL. Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia. *Human molecular genetics*. 2016;25(R1):R53-64.

Keller DL. Proton Pump Inhibitors and Dementia Incidence. *JAMA neurology*. 2016;73(8):1025.

Keller H, Slaughter S. Training programmes and mealtime assistance may improve eating performance for elderly long-term care residents with dementia. *Evidence-based nursing*. 2016;19(1):32.

Keller HH. Improving food intake in persons living with dementia. *Annals of the New York Academy of Sciences*. 2016;1367(1):3-11.

Kelly P, McClean PL, Ackermann M, Konerding MA, Holscher C, Mitchell CA. Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide. *Microcirculation (New York, NY : 1994)*. 2015;22(2):133-45.

Kemppainen S, Lindholm P, Galli E, Lahtinen H-M, Koivisto H, Hamalainen E, et al. Cerebral dopamine neurotrophic factor improves long-term memory in APP/PS1 transgenic mice modeling Alzheimer's disease as well as in wild-type mice. *Behavioural brain research*. 2015;291:1-11.

Kenawy S, Hegazy R, Hassan A, El-Shenawy S, Gomaa N, Zaki H, et al. Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. *PloS one*. 2017;12(8):e0183565.

Kendall-Raynor P. Care home staff 'ill equipped' to improve end of life dementia care. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*. 2016;30(29):10.

Kendall-Raynor P. Enhancing acute care for older patients. *Nursing older people*. 2016;28(10):8-9.

Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer's disease patients. *Science translational medicine*. 2016;8(363):363ra150.

Kent BA. Synchronizing an aging brain: can entraining circadian clocks by food slow Alzheimer's disease? *Frontiers in aging neuroscience*. 2014;6:234.

Kent K, Charlton K, Roodenrys S, Batterham M, Potter J, Traynor V, et al. Consumption of anthocyanin-rich cherry juice for 12weeks improves memory and cognition in older adults with mild-to-moderate dementia. *European journal of nutrition*. 2017;56(1):333-41.

Keohane K, Balfe M. The Nun Study and Alzheimer's disease: Quality of vocation as a potential protective factor? *Dementia (London, England)*. 2017;1471301217725186.

Keowkase R, Weerapreeyakul N. Cratoxylum formosum Extract Protects against Amyloid-Beta Toxicity in a Caenorhabditis elegans Model of Alzheimer's Disease. *Planta medica*. 2016;82(6):516-23.

Keri RS, Quintanova C, Marques SM, Esteves AR, Cardoso SM, Santos MA. Design, synthesis and neuroprotective evaluation of novel tacrine-benzothiazole hybrids as multi-targeted compounds against Alzheimer's disease. *Bioorganic & medicinal chemistry*. 2013;21(15):4559-69.

Kerruish N. Growth Attenuation Therapy. *Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees*. 2016;25(1):70-83.

Keshava HB, Mowla A, Heinberg LJ, Schauer PR, Brethauer SA, Aminian A. Bariatric surgery may reduce the risk of Alzheimer's diseases through GLP-1 mediated neuroprotective effects. *Medical hypotheses*. 2017;104:4-9.

Keskin AD, Kekus M, Adelsberger H, Neumann U, Shimshek DR, Song B, et al. BACE inhibition-dependent repair of Alzheimer's pathophysiology. *Proceedings of the National Academy of Sciences of the United States of America*. 2017;114(32):8631-6.

Khachaturian AS, Hoffman DP, Frank L, Petersen R, Carson BR, Khachaturian ZS. Zeroing out preventable disability: Daring to dream the impossible dream for dementia care: Recommendations for a national plan to advance dementia care and maximize functioning. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2017;13(10):1077-80.

Khachaturian ZS, Khachaturian AS. Politics of science: Progress toward prevention of the dementia-Alzheimer's syndrome. *Molecular aspects of medicine*. 2015;43-44:3-15.

Khairallah MI, Kassem LA, Yassin NA, El Din MAG, Zekri M, Attia M. The hematopoietic growth factor "erythropoietin" enhances the therapeutic effect of mesenchymal stem cells in Alzheimer's disease. *Pakistan journal of biological sciences : PJBS*. 2014;17(1):9-21.

Khalaji N, Sarkissian J, Chavushyan V, Sarkisian V. Protective Effects of Proline-Rich Peptide in a Rat Model of Alzheimer Disease: An Electrophysiological Study. *Basic and clinical neuroscience*. 2017;8(1):5-12.

Khalid S, Paul S. Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: a plausible therapeutic approach in Alzheimer's disease. *Medical hypotheses*. 2014;83(1):39-46.

Khalid S, Surr C, Neagu D, Small N. Exploring the potential for secondary uses of Dementia Care Mapping (DCM) data for improving the quality of dementia care. *Dementia (London, England)*. 2017;1471301217701275.

Khalil A, Kovac S, Morris G, Walker MC. Carvacrol after status epilepticus (SE) prevents recurrent SE, early seizures, cell death, and cognitive decline. *Epilepsia*. 2017;58(2):263-73.

Khalil B, El Fissi N, Aouane A, Cabirol-Pol MJ, Rival T, Lievens JC. PINK1-induced mitophagy promotes neuroprotection in Huntington's disease. *Cell death & disease*. 2015;6:e1617.

Khalsa DS, Gustafson C. Dharma Singh Khalsa, MD: The pillars of Alzheimer's prevention. *Advances in mind-body medicine*. 2014;28(3):26-32.

Khalsa DS, Perry G. The Four Pillars of Alzheimer's Prevention. *Cerebrum : the Dana forum on brain science*. 2017;2017.

Khalsa DS. Stress, Meditation, and Alzheimer's Disease Prevention: Where The Evidence Stands. *Journal of Alzheimer's disease : JAD*. 2015;48(1):1-12.

Khan A, Vaibhav K, Javed H, Tabassum R, Ahmed ME, Khan MM, et al. 1,8-cineole (eucalyptol) mitigates inflammation in amyloid Beta toxicated PC12 cells: relevance to Alzheimer's disease. *Neurochemical research*. 2014;39(2):344-52.

Khan I, Ibrar A, Zaib S, Ahmad S, Furtmann N, Hameed S, et al. Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis. *Bioorganic & medicinal chemistry*. 2014;22(21):6163-73.

Khan I, Tantray MA, Alam MS, Hamid H. Natural and synthetic bioactive inhibitors of glycogen synthase kinase. *European journal of medicinal chemistry*. 2017;125:464-77.

Khan MB, Hoda MN, Vaibhav K, Giri S, Wang P, Waller JL, et al. Remote ischemic postconditioning: harnessing endogenous protection in a murine model of vascular cognitive impairment. *Translational stroke research*. 2015;6(1):69-77.

Khan MZ, Zhuang X, He L. GPR40 receptor activation leads to CREB phosphorylation and improves cognitive performance in an Alzheimer's disease mouse model. *Neurobiology of learning and memory*. 2016;131:46-55.

Khan S, Ahmad K, Alshammari EMA, Adnan M, Baig MH, Lohani M, et al. Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds. *BioMed research international*. 2015;2015:379817.

Kheradmand E, Hajizadeh Moghaddam A, Zare M. Neuroprotective effect of hesperetin and nano-hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of Alzheimer's disease. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2017;97:1096-101.

Khodaghali F, Ashabi G. Dietary supplementation with *Salvia sahendica* attenuates memory deficits, modulates CREB and its down-stream molecules and decreases apoptosis in amyloid beta-injected rats. *Behavioural brain research*. 2013;241:62-9.

Khosravan A, Marani S, Sadeghi Googheri MS. The effects of fluorine substitution on the chemical properties and inhibitory capacity of Donepezil anti-Alzheimer drug; density functional theory and molecular docking calculations. *Journal of molecular graphics & modelling*. 2017;71:124-34.

Kiasalari Z, Heydarifard R, Khalili M, Afshin-Majd S, Baluchnejadmojarad T, Zahedi E, et al. Ellagic acid ameliorates learning and memory deficits in a rat model of Alzheimer's disease: an exploration of underlying mechanisms. *Psychopharmacology*. 2017;234(12):1841-52.

Kielstein JT, Bernstein H-G. The reversible part of cognitive impairment in chronic kidney disease: can mice help men break the TEMPOLimit? *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2014;29(3):476-8.

Kilgore C. Improving communication when caring for acutely ill patients with dementia. *Nursing older people*. 2015;27(4):35-8.

Kilic A, Sayali ZC, Oztekin I. Aging Slows Access to Temporal Information From Working Memory. *The journals of gerontology Series B, Psychological sciences and social sciences*. 2017;72(6):996-1005.

Kilickap M, Bosch J, Eikelboom JW, Hart RG. Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. *The Canadian journal of cardiology*. 2016;32(9):1108-16.

Kim B, Figueroa-Romero C, Pacut C, Backus C, Feldman EL. Insulin Resistance Prevents AMPK-induced Tau Dephosphorylation through Akt-mediated Increase in AMPK Ser-485 Phosphorylation. *The Journal of biological chemistry*. 2015;290(31):19146-57.

Kim B-K, Shin M-S, Kim C-J, Baek S-B, Ko Y-C, Kim Y-P. Treadmill exercise improves short-term memory by enhancing neurogenesis in amyloid beta-induced Alzheimer disease rats. *Journal of exercise rehabilitation*. 2014;10(1):2-8.

Kim BM, You M-H, Chen C-H, Suh J, Tanzi RE, Ho Lee T. Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein. *Human molecular genetics*. 2016;25(12):2498-513.

Kim C, Nam DW, Park SY, Song H, Hong HS, Boo JH, et al. O-linked beta-N-acetylglucosaminidase inhibitor attenuates beta-amyloid plaque and rescues memory impairment. *Neurobiology of aging*. 2013;34(1):275-85.

Kim CR, Choi SJ, Kwon YK, Kim JK, Kim Y-J, Park GG, et al. Cinnamomum loureirii Extract Inhibits Acetylcholinesterase Activity and Ameliorates Trimethyltin-Induced Cognitive Dysfunction in Mice. *Biological & pharmaceutical bulletin*. 2016;39(7):1130-6.

Kim CR, Choi SJ, Oh SS, Kwon YK, Lee NY, Park GG, et al. Rubus coreanus Miquel inhibits acetylcholinesterase activity and prevents cognitive impairment in a mouse model of dementia. *Journal of medicinal food*. 2013;16(9):785-92.

Kim D-Y, Jung S-Y, Kim K, Kim C-J. Treadmill exercise ameliorates Alzheimer disease-associated memory loss through the Wnt signaling pathway in the streptozotocin-induced diabetic rats. *Journal of exercise rehabilitation*. 2016;12(4):276-83.

Kim D-Y, Jung S-Y, Kim T-W, Lee K-S, Kim K. Treadmill exercise decreases incidence of Alzheimer's disease by suppressing glycogen synthase kinase-3 β expression in streptozotocin-induced diabetic rats. *Journal of exercise rehabilitation*. 2015;11(2):87-94.

Kim G, Kim H, Kim KN, Son JI, Kim SY, Tamura T, et al. Relationship of cognitive function with B vitamin status, homocysteine, and tissue factor pathway inhibitor in cognitively impaired elderly: a cross-sectional survey. *Journal of Alzheimer's disease : JAD*. 2013;33(3):853-62.

Kim H, Kim SJ, Kim MS, Choi JE, Chang SO. Guide Map for Preserving Remaining Ability of Nursing Home Residents With Physical-Cognitive Functional Decline. *Journal of continuing education in nursing*. 2017;48(2):73-80.

Kim HG, Kim J-Y, Whang W-W, Oh MS. Neuroprotective effect of Chunghyuldan from amyloid beta oligomer induced neuroinflammation in vitro and in vivo. *Canadian journal of physiology and pharmacology*. 2014;92(6):429-37.

Kim HG, Park G, Lim S, Park H, Choi JG, Jeong HU, et al. Mori Fructus improves cognitive and neuronal dysfunction induced by beta-amyloid toxicity through the GSK-3 β pathway in vitro and in vivo. *Journal of ethnopharmacology*. 2015;171:196-204.

Kim H-J, Kim W, Kong S-Y. Antidepressants for neuro-regeneration: from depression to Alzheimer's disease. *Archives of pharmacal research*. 2013;36(11):1279-90.

Kim H-J, Shin E-J, Lee B-H, Choi S-H, Jung S-W, Cho I-H, et al. Oral Administration of Gintonin Attenuates Cholinergic Impairments by Scopolamine, Amyloid-beta Protein, and Mouse Model of Alzheimer's Disease. *Molecules and cells*. 2015;38(9):796-805.

Kim HV, Kim HY, Ehrlich HY, Choi SY, Kim DJ, Kim Y. Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model. *Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis*. 2013;20(1):7-12.

Kim HY, Kim HV, Jo S, Lee CJ, Choi SY, Kim DJ, et al. EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-beta oligomers and plaques. *Nature communications*. 2015;6:8997.

Kim IK, Lee KJ, Rhee S, Seo SB, Pak JH. Protective effects of peroxiredoxin 6 overexpression on amyloid beta-induced apoptosis in PC12 cells. *Free radical research*. 2013;47(10):836-46.

Kim J, Lee J-H. Integration of structural and functional magnetic resonance imaging improves mild cognitive impairment detection. *Magnetic resonance imaging*. 2013;31(5):718-32.

Kim J, Yoon H, Chung D-E, Brown JL, Belmonte KC, Kim J. miR-186 is decreased in aged brain and suppresses BACE1 expression. *Journal of neurochemistry*. 2016;137(3):436-45.

Kim JA, Ha S, Shin KY, Kim S, Lee KJ, Chong YH, et al. Neural stem cell transplantation at critical period improves learning and memory through restoring synaptic impairment in Alzheimer's disease mouse model. *Cell death & disease*. 2015;6:e1789.

Kim JA, Kim M, Kang SM, Lim KT, Kim TS, Kang JY. Magnetic bead droplet immunoassay of oligomer amyloid beta for the diagnosis of Alzheimer's disease using micro-pillars to enhance the stability of the oil-water interface. *Biosensors & bioelectronics*. 2015;67:724-32.

Kim JH, Kim E, Choi WH, Lee J, Lee JH, Lee H, et al. Inhibitory RNA Aptamers of Tau Oligomerization and Their Neuroprotective Roles against Proteotoxic Stress. *Molecular pharmaceutics*. 2016;13(6):2039-48.

Kim JH, Wang Q, Choi JM, Lee S, Cho EJ. Protective role of caffeic acid in an Abeta25-35-induced Alzheimer's disease model. *Nutrition research and practice*. 2015;9(5):480-8.

Kim JM, Park CH, Park SK, Seung TW, Kang JY, Ha JS, et al. Ginsenoside Re Ameliorates Brain Insulin Resistance and Cognitive Dysfunction in High Fat Diet-Induced C57BL/6 Mice. *Journal of agricultural and food chemistry*. 2017;65(13):2719-29.

Kim J-P, Yang J. Effectiveness of a community-based program for suicide prevention among elders with early-stage dementia: A controlled observational study. *Geriatric nursing (New York, NY)*. 2017;38(2):97-105.

Kim JW, Lee DY, Seo EH, Sohn BK, Choe YM, Kim SG, et al. Improvement of Screening Accuracy of Mini-Mental State Examination for Mild Cognitive Impairment and Non-Alzheimer's Disease Dementia by Supplementation of Verbal Fluency Performance. *Psychiatry investigation*. 2014;11(1):44-51.

Kim JW, Lee DY, Seo EH, Sohn BK, Park SY, Choo IH, et al. Improvement of dementia screening accuracy of mini-mental state examination by education-adjustment and supplementation of frontal assessment battery performance. *Journal of Korean medical science*. 2013;28(10):1522-8.

Kim JY, Lee HK, Jang JY, Yoo JK, Seong YH. *Ilex latifolia* Prevents Amyloid beta Protein (25-35)-Induced Memory Impairment by Inhibiting Apoptosis and Tau Phosphorylation in Mice. *Journal of medicinal food*. 2015;18(12):1317-26.

Kim K, Lee BI, Chung YJ, Choi WS, Park CB. Hematite-Based Photoelectrode Materials for Photoelectrocatalytic Inhibition of Alzheimer's beta-Amyloid Self-Assembly. *Advanced healthcare materials*. 2017;6(8).

Kim MW, Abid NB, Jo MH, Jo MG, Yoon GH, Kim MO. Suppression of adiponectin receptor 1 promotes memory dysfunction and Alzheimer's disease-like pathologies. *Scientific reports*. 2017;7(1):12435.

Kim S, Violette CJ, Ziff EB. Reduction of increased calcineurin activity rescues impaired homeostatic synaptic plasticity in presenilin 1 M146V mutant. *Neurobiology of aging*. 2015;36(12):3239-46.

Kim S. Effect of motor cognition program for improving temporal-spatial timing memory ability with mild cognitive impairment patients. *Journal of exercise rehabilitation*. 2017;13(4):430-5.

Kim SH, Kandiah N, Hsu J-L, Suthisisang C, Udommongkol C, Dash A. Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease. *British journal of pharmacology*. 2017.

Kim SH, Steele JW, Lee SW, Clemenson GD, Carter TA, Treuner K, et al. Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Abeta oligomer mouse. *Molecular psychiatry*. 2014;19(11):1235-42.

Kim SYH, Karlawish J, Berkman BE. Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. *Neurology*. 2015;84(14):1488-94.

Kim W, Seo H. Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington's disease model mice. *Biochemical and biophysical research communications*. 2014;443(2):706-11.

Kim YJ, Seo SW, Park SB, Yang JJ, Lee JS, Lee J, et al. Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study. *Scientific reports*. 2017;7(1):1910.

Kimoto A, Ohnuma T, Toda A, Takebayashi Y, Higashiyama R, Tagata Y, et al. Medium-chain triglycerides given in the early stage of mild-to-moderate Alzheimer's disease enhance memory function. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2017.

Kimura A, Hata S, Suzuki T. Alternative Selection of beta-Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid beta-Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the Abeta Sequence. *The Journal of biological chemistry*. 2016;291(46):24041-53.

Kimura D, Takeda T, Ohura T, Imai A. Evaluation of facilitative factors for preventing cognitive decline: A 3-year cohort study of community intervention. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2017;17(1):9-16.

Kimura J, Nemoto K, Yokosuka A, Mimaki Y, Degawa M, Ohizumi Y. 6-demethoxynobiletin, a nobiletin-analog citrus flavonoid, enhances extracellular signal-regulated kinase phosphorylation in PC12D cells. *Biological & pharmaceutical bulletin*. 2013;36(10):1646-9.

Kino R, Araya T, Arai T, Sohma Y, Kanai M. Covalent modifier-type aggregation inhibitor of amyloid-beta based on a cyclo-KLVFF motif. *Bioorganic & medicinal chemistry letters*. 2015;25(15):2972-5.

Kinsella GJ, Ames D, Storey E, Ong B, Pike KE, Saling MM, et al. Strategies for improving memory: a randomized trial of memory groups for older people, including those with mild cognitive impairment. *Journal of Alzheimer's disease : JAD*. 2016;49(1):31-43.

Kiprowska MJ, Stepanova A, Todaro DR, Galkin A, Haas A, Wilson SM, et al. Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease. *Biochimica et biophysica acta*. 2017;1863(6):1157-70.

Kirby T. Eric Reiman: aiming to prevent Alzheimer's disease. *The Lancet Neurology*. 2017;16(12):960.

Kirk M, Berntsen D. A short cut to the past: Cueing via concrete objects improves autobiographical memory retrieval in Alzheimer's disease patients. *Neuropsychologia*. 2017.

Kishi T, Matsunaga S, Oya K, Ikuta T, Iwata N. Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials. *The international journal of neuropsychopharmacology*. 2015;18(12).

Kiss E, Gorgas K, Schlicksupp A, GroSs D, Kins S, Kirsch J, et al. Biphasic Alteration of the Inhibitory Synapse Scaffold Protein Gephyrin in Early and Late Stages of an Alzheimer Disease Model. *The American journal of pathology*. 2016;186(9):2279-91.

Kitamura A, Saito S, Maki T, Oishi N, Ayaki T, Hattori Y, et al. Gradual cerebral hypoperfusion in spontaneously hypertensive rats induces slowly evolving white matter abnormalities and impairs working memory. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2016;36(9):1592-602.

Kitay BM, McCormack R, Wang Y, Tsoulfas P, Zhai RG. Mislocalization of neuronal mitochondria reveals regulation of Wallerian degeneration and NMNAT/WLD(S)-mediated axon protection independent of axonal mitochondria. *Human molecular genetics*. 2013;22(8):1601-14.

Kivimaki M, Batty GD, Batty D, Singh-Manoux A. Pointing the FINGER at multimodal dementia prevention. *Lancet (London, England)*. 2015;386(10004):1626-7.

Kivimaki M, Batty GD. Evidence-based prevention and treatment of dementia. *The Lancet Neurology*. 2016;15(10):1005.

Kivipelto M, Mangialasche F, Solomon A, Group FS. Pointing the FINGER at multimodal dementia prevention - Authors' reply. *Lancet (London, England)*. 2015;386(10004):1627.

Kivipelto M, Mangialasche F, Solomon A, Johansson G, Lannfelt L, Fratiglioni L, et al. 9th Key symposium introduction: updating Alzheimer's disease diagnosis implications for prevention and treatment. *Journal of internal medicine*. 2014;275(3):202-3.

Kivipelto M, Mangialasche F. Alzheimer disease: To what extent can Alzheimer disease be prevented? *Nature reviews Neurology*. 2014;10(10):552-3.

Kiyota T, Zhang G, Morrison CM, Bosch ME, Weir RA, Lu Y, et al. AAV2/1 CD74 Gene Transfer Reduces beta-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2015;23(11):1712-21.

Kizhakke P A, Olakkaran S, Antony A, Tilagul K S, Hunasanahally P G. Convolvulus pluricaulis (Shankhapushpi) ameliorates human microtubule-associated protein tau (hMAPtau) induced neurotoxicity in Alzheimer's disease Drosophila model. *Journal of chemical neuroanatomy*. 2017.

Kizilarlanoglu MC. Proton Pump Inhibitors and Risk of Pneumonia in Individuals with Dementia. *Journal of the American Geriatrics Society*. 2017;65(11):2547.

Klein A, Lane EL, Dunnett SB. Brain repair in a unilateral rat model of Huntington's disease: new insights into impairment and restoration of forelimb movement patterns. *Cell transplantation*. 2013;22(10):1735-51.

Klein C, Mathis C, Leva G, Patte-Mensah C, Cassel J-C, Maitre M, et al. gamma-Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer's disease. *Neurobiology of aging*. 2015;36(2):832-44.

Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, Lam TT, et al. Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice. *Neuron*. 2017;95(2):281-96.e6.

Klimova B, Maresova P, Kuca K. Non-Pharmacological Approaches to the Prevention and Treatment of Alzheimer's Disease with Respect to the Rising Treatment Costs. *Current Alzheimer research*. 2016;13(11):1249-58.

Klimova B, Valis M, Kuca K. Cognitive decline in normal aging and its prevention: a review on non-pharmacological lifestyle strategies. *Clinical interventions in aging*. 2017;12:903-10.

Kling A, Jantos K, Mack H, Hornberger W, Drescher K, Nimmrich V, et al. Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides. *Journal of medicinal chemistry*. 2017;60(16):7123-38.

Knesaurek K. Improving (18)F-Fluoro-D-Glucose-Positron Emission Tomography/Computed Tomography Imaging in Alzheimer's Disease Studies. *World journal of nuclear medicine*. 2015;14(3):171-7.

Knez D, Sova M, Kosak U, Gobec S. Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease. *Future medicinal chemistry*. 2017;9(8):811-32.

Knight A, Bryan J, Murphy K. Is the Mediterranean diet a feasible approach to preserving cognitive function and reducing risk of dementia for older adults in Western countries? New insights and future directions. *Ageing research reviews*. 2016;25:85-101.

Knight EM, Williams HN, Stevens AC, Kim SH, Kottwitz JC, Morant AD, et al. Evidence that small molecule enhancement of beta-hexosaminidase activity corrects the behavioral phenotype in Dutch APP(E693Q) mice through reduction of ganglioside-bound Abeta. *Molecular psychiatry*. 2015;20(1):109-17.

Knowles JK, Simmons DA, Nguyen T-VV, Vander Griend L, Xie Y, Zhang H, et al. Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model. *Neurobiology of aging*. 2013;34(8):2052-63.

Ko C-Y, Chu Y-Y, Narumiya S, Chi J-Y, Furuyashiki T, Aoki T, et al. CCAAT/enhancer-binding protein delta/miR135a/thrombospondin 1 axis mediates PGE2-induced angiogenesis in Alzheimer's disease. *Neurobiology of aging*. 2015;36(3):1356-68.

Ko C-Y, Wang W-L, Wang S-M, Chu Y-Y, Chang W-C, Wang J-M. Glycogen synthase kinase-3beta-mediated CCAAT/enhancer-binding protein delta phosphorylation in astrocytes promotes migration and activation of microglia/macrophages. *Neurobiology of aging*. 2014;35(1):24-34.

Ko SJ, Shin SH. Effects of dementia knowledge, self-efficacy and depression on dementia preventive behavior in elderly couples: dyadic data analysis. *Journal of Korean Academy of Nursing*. 2013;43(2):276-86.

Koal T, Klavins K, Seppi D, Kemmler G, Humpel C. Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-beta42, tau, and phospho-tau-181 levels. *Journal of Alzheimer's disease : JAD*. 2015;44(4):1193-201.

Kobayashi H, Ohnishi T, Nakagawa R, Yoshizawa K. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis. *International journal of geriatric psychiatry*. 2016;31(8):892-904.

Kobayashi Y, Sugahara H, Shimada K, Mitsuyama E, Kuhara T, Yasuoka A, et al. Therapeutic potential of *Bifidobacterium breve* strain A1 for preventing cognitive impairment in Alzheimer's disease. *Scientific reports*. 2017;7(1):13510.

Kobe T, Witte AV, Schnelle A, Lesemann A, Fabian S, Tesky VA, et al. Combined omega-3 fatty acids, aerobic exercise and cognitive stimulation prevents decline in gray matter volume of the frontal, parietal and cingulate cortex in patients with mild cognitive impairment. *NeuroImage*. 2016;131:226-38.

Kocahan S, Dogan Z. Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors. *Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology*. 2017;15(1):1-8.

Koch G, Di Lorenzo F, Del Olmo MF, Bonni S, Ponzo V, Caltagirone C, et al. Reversal of LTP-Like Cortical Plasticity in Alzheimer's Disease Patients with Tau-Related Faster Clinical Progression. *Journal of Alzheimer's disease : JAD*. 2016;50(2):605-16.

Kochi A, Lee HJ, Vithanarachchi SM, Padmini V, Allen MJ, Lim MH. Inhibitory Activity Of Curcumin Derivatives Towards Metal-free And Metal-induced Amyloid-beta Aggregation. *Current Alzheimer research*. 2015;12(5):415-23.

Koelsch G. BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology. *Molecules (Basel, Switzerland)*. 2017;22(10).

Kohler L, Meinke-Franze C, Hein J, Fendrich K, Heymann R, Thyrian JR, et al. Does an interdisciplinary network improve dementia care? Results from the IDemUck-study. *Current Alzheimer research*. 2014;11(6):538-48.

Koide R, Bandoh M. Patient with globus pallidus infarction presenting with reversible dementia. *The Journal of neuropsychiatry and clinical neurosciences*. 2013;25(3):E41-2.

Koivisto H, Grimm MO, Rothhaar TL, Berkecz R, Lutjohann D D, Giniatullina R, et al. Special lipid-based diets alleviate cognitive deficits in the APPswe/PS1dE9 transgenic mouse model of Alzheimer's disease independent of brain amyloid deposition. *The Journal of nutritional biochemistry*. 2014;25(2):157-69.

Kok K-S, Loke Y, Southgate J. Upper gastrointestinal bleed associated with cholinesterase inhibitor use. *BMJ case reports*. 2015;2015.

Kolli V, Dickson J, Amani M, Tan J. Posttraumatic stress disorder exacerbation with cholinesterase inhibitor in a patient with dementia. *Innovations in clinical neuroscience*. 2013;10(9-10):11-2.

Kolobov VV, Davydova TV, Fomina VG. Protective action of glutamate antibodies on increased expression of genes of programmed death of rat brain cells induced by injection of a beta-amyloid fragment (25-35). *Izvestiia Akademii nauk Serii biologicheskaja*. 2014(2):133-41.

Kolosova NG, Tyumentsev MA, Muraleva NA, Kiseleva E, Vitovtov AO, Stefanova NA. Antioxidant SkQ1 Alleviates Signs of Alzheimer's Disease-like Pathology in Old OXYS Rats by Reversing Mitochondrial Deterioration. *Current Alzheimer research*. 2017;14(12):1283-92.

Komaroff AL. Ask the doctor. I'm more forgetful that I used to be. I'm not worried about dementia, but are there tricks for improving my memory? *Harvard health letter*. 2013;38(10):2.

Kong D, Liu Q, Xu G, Huang Z, Luo N, Huang Y, et al. Synergistic effect of tanshinone IIA and mesenchymal stem cells on preventing learning and memory deficits via anti-apoptosis, attenuating tau phosphorylation and enhancing the activity of central cholinergic system in vascular dementia. *Neuroscience letters*. 2017;637:175-81.

Kong J, Ren G, Jia N, Wang Y, Zhang H, Zhang W, et al. Effects of nicorandil in neuroprotective activation of PI3K/AKT pathways in a cellular model of Alzheimer's disease. *European neurology*. 2013;70(3-4):233-41.

Kong Z-H, Chen X, Hua H-P, Liang L, Liu L-J. The Oral Pretreatment of Glycyrrhizin Prevents Surgery-Induced Cognitive Impairment in Aged Mice by Reducing Neuroinflammation and Alzheimer's-Related Pathology via HMGB1 Inhibition. *Journal of molecular neuroscience : MN*. 2017;63(3-4):385-95.

Konrath EL, Passos CdS, Klein LC, Jr., Henriques AT. Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer's disease. *The Journal of pharmacy and pharmacology*. 2013;65(12):1701-25.

Koo JH, Kwon IS, Kang EB, Lee CK, Lee NH, Kwon MG, et al. Neuroprotective effects of treadmill exercise on BDNF and PI3-K/Akt signaling pathway in the cortex of transgenic mice model of Alzheimer's disease. *Journal of exercise nutrition & biochemistry*. 2013;17(4):151-60.

Kook SY, Lee KM, Kim Y, Cha MY, Kang S, Baik SH, et al. High-dose of vitamin C supplementation reduces amyloid plaque burden and ameliorates pathological changes in the brain of 5XFAD mice. *Cell death & disease*. 2014;5:e1083.

Koppensteiner P, Trinchese F, Fa M, Puzzo D, Gulisano W, Yan S, et al. Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric Abeta42: an early index of Alzheimer's disease. *Scientific reports*. 2016;6:32553.

Korabecny J, Andrs M, Nepovimova E, Dolezal R, Babkova K, Horova A, et al. 7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer's Disease Treatment. *Molecules (Basel, Switzerland)*. 2015;20(12):22084-101.

Kornelius E, Lin C-L, Chang H-H, Li H-H, Huang W-N, Yang Y-S, et al. DPP-4 Inhibitor Linagliptin Attenuates Abeta-induced Cytotoxicity through Activation of AMPK in Neuronal Cells. *CNS neuroscience & therapeutics*. 2015;21(7):549-57.

Kortte KB, Rogalski EJ. Behavioural interventions for enhancing life participation in behavioural variant frontotemporal dementia and primary progressive aphasia. *International review of psychiatry* (Abingdon, England). 2013;25(2):237-45.

Kosaraju J, Gali CC, Khatwal RB, Dubala A, Chinni S, Holsinger RMD, et al. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. *Neuropharmacology*. 2013;72:291-300.

Kosaraju J, Holsinger RMD, Guo L, Tam KY. Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease. *Molecular neurobiology*. 2017;54(8):6074-84.

Kosaraju J, Madhunapantula SV, Chinni S, Khatwal RB, Dubala A, Muthureddy Nataraj SK, et al. Dipeptidyl peptidase-4 inhibition by *Pterocarpus marsupium* and *Eugenia jambolana* ameliorates streptozotocin induced Alzheimer's disease. *Behavioural brain research*. 2014;267:55-65.

Kosaraju J, Murthy V, Khatwal RB, Dubala A, Chinni S, Muthureddy Nataraj SK, et al. Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. *The Journal of pharmacy and pharmacology*. 2013;65(12):1773-84.

Koscik RL, Berman SE, Clark LR, Mueller KD, Okonkwo OC, Gleason CE, et al. Intraindividual Cognitive Variability in Middle Age Predicts Cognitive Impairment 8-10 Years Later: Results from the Wisconsin Registry for Alzheimer's Prevention. *Journal of the International Neuropsychological Society : JINS*. 2016;22(10):1016-25.

Koscik RL, La Rue A, Jonaitis EM, Okonkwo OC, Johnson SC, Bendlin BB, et al. Emergence of mild cognitive impairment in late middle-aged adults in the wisconsin registry for Alzheimer's prevention. *Dementia and geriatric cognitive disorders*. 2014;38(1-2):16-30.

Koster KP, Thomas R, Morris AW, Tai LM. Epidermal growth factor prevents oligomeric amyloid-beta induced angiogenesis deficits invitro. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2016;36(11):1865-71.

Kou X, Chen N. Resveratrol as a Natural Autophagy Regulator for Prevention and Treatment of Alzheimer's Disease. *Nutrients*. 2017;9(9).

Koukoulitsa C, Villalonga-Barber C, Csonka R, Alexi X, Leonis G, Dellis D, et al. Biological and computational evaluation of resveratrol inhibitors against Alzheimer's disease. *Journal of enzyme inhibition and medicinal chemistry*. 2016;31(1):67-77.

Kounnas MZ, Lane-Donovan C, Nowakowski DW, Herz J, Comer WT. NGP 555, a gamma-Secretase Modulator, Lowers the Amyloid Biomarker, Abeta42, in Cerebrospinal Fluid while Preventing Alzheimer's Disease Cognitive Decline in Rodents. *Alzheimer's & dementia* (New York, N Y). 2017;3(1):65-73.

Kracmarova A, Drtinova L, Pohanka M. Possibility of Acetylcholinesterase Overexpression in Alzheimer Disease Patients after Therapy with Acetylcholinesterase Inhibitors. *Acta medica* (Hradec Kralove). 2015;58(2):37-42.

Kraskovskaya NA, Kukanova EO, Lin'kova NS, Popugaeva EA, Khavinson VK. Correction to: Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease. *Bulletin of experimental biology and medicine*. 2017;163(5):699.

Kraskovskaya NA, Kukanova EO, Lin'kova NS, Popugaeva EA, Khavinson VK. Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease. *Bulletin of experimental biology and medicine*. 2017;163(4):550-3.

Krause D, Roupas P. Dietary interventions as a neuroprotective therapy for the delay of the onset of cognitive decline in older adults: an umbrella review protocol. *JBIM database of systematic reviews and implementation reports*. 2015;13(2):74-83.

Kreiner G, Bierhoff H, Armentano M, Rodriguez-Parkitna J, Sowodniok K, Naranjo JR, et al. A neuroprotective phase precedes striatal degeneration upon nucleolar stress. *Cell death and differentiation*. 2013;20(11):1455-64.

Krishna K, Behnisch T, Sajikumar S. Inhibition of Histone Deacetylase 3 Restores Amyloid-beta Oligomer-Induced Plasticity Deficit in Hippocampal CA1 Pyramidal Neurons. *Journal of Alzheimer's disease : JAD*. 2016;51(3):783-91.

Kroger E, Moulis M, Wilchesky M, Berkers M, Carmichael P-H, van Marum R, et al. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From Vigibase. *The Annals of pharmacotherapy*. 2015;49(11):1197-206.

Kroker KS, Mathis C, Marti A, Cassel J-C, Rosenbrock H, Dorner-Ciossek C. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. *Neurobiology of aging*. 2014;35(9):2072-8.

Kroker KS, Moreth J, Kussmaul L, Rast G, Rosenbrock H. Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitor and selective neuronal nicotinic receptor agonists. *Brain research bulletin*. 2013;96:28-38.

Krumm N, Larkin P, Connolly M, Rode P, Elsner F. Improving dementia care in nursing homes: experiences with a palliative care symptom-assessment tool (MIDOS). *International journal of palliative nursing*. 2014;20(4):187-92.

Kruppa AJ, Ott S, Chandraratna DS, Irving JA, Page RM, Speretta E, et al. Suppression of A β toxicity by puromycin-sensitive aminopeptidase is independent of its proteolytic activity. *Biochimica et biophysica acta*. 2013;1832(12):2115-26.

Kryscio RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK, et al. Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE). *JAMA neurology*. 2017;74(5):567-73.

Kryscio RJ, Abner EL, Schmitt FA, Goodman PJ, Mendiondo M, Caban-Holt A, et al. A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. *The journal of nutrition, health & aging*. 2013;17(1):72-5.

Kryscio RJ. Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point. *JAMA neurology*. 2014;71(8):947-9.

Ku L-JE, Pai M-C. Use of cognitive enhancers and associated medical care costs among patients with dementia: a nationwide study in Taiwan. *International psychogeriatrics*. 2014;26(5):795-804.

Kuan Y-C, Huang K-W, Yen D-J, Hu C-J, Lin C-L, Kao C-H. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension. *International journal of cardiology*. 2016;220:462-6.

Kuang X, Chen Y-S, Wang L-F, Li Y-J, Liu K, Zhang M-X, et al. Klotho upregulation contributes to the neuroprotection of ligustilide in an Alzheimer's disease mouse model. *Neurobiology of aging*. 2014;35(1):169-78.

Kuang X, Zhou H-J, Thorne AH, Chen X-N, Li L-J, Du J-R. Neuroprotective Effect of Ligustilide through Induction of alpha-Secretase Processing of Both APP and Klotho in a Mouse Model of Alzheimer's Disease. *Frontiers in aging neuroscience*. 2017;9:353.

Kubota T, Matsumoto H, Kirino Y. Ameliorative effect of membrane-associated estrogen receptor G protein coupled receptor 30 activation on object recognition memory in mouse models of Alzheimer's disease. *Journal of pharmacological sciences*. 2016;131(3):219-22.

Kuboyama T, Lee Y-A, Nishiko H, Tohda C. Inhibition of clathrin-mediated endocytosis prevents amyloid beta-induced axonal damage. *Neurobiology of aging*. 2015;36(5):1808-19.

Kuk S, Lee BI, Lee JS, Park CB. Rattle-Structured Upconversion Nanoparticles for Near-IR-Induced Suppression of Alzheimer's beta-Amyloid Aggregation. *Small (Weinheim an der Bergstrasse, Germany)*. 2017;13(11).

Kuller LH. Do Proton Pump Inhibitors Increase the Risk of Dementia? *JAMA neurology*. 2016;73(4):379-81.

Kulshreshtha A, Piplani P. Ameliorative effects of amide derivatives of 1,3,4-thiadiazoles on scopolamine induced cognitive dysfunction. *European journal of medicinal chemistry*. 2016;122:557-73.

Kumai K, Nakamura K, Meguro K. Improved learning of sequential behaviour during cane gait training or stair climbing after femoral neck fracture: an implication for donepezil for very mild Alzheimer's disease. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2017;17(2):144-5.

Kumar A, Chaudhary T, Mishra J. Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington's disease like symptoms in rats: behavioral, biochemical, cellular and histological evidences. *European journal of pharmacology*. 2013;720(1-3):16-28.

Kumar A, Jain S, Parle M, Jain N, Kumar P. 3-Aryl-1-phenyl-1H-pyrazole derivatives as new multitarget directed ligands for the treatment of Alzheimer's disease, with acetylcholinesterase and monoamine oxidase inhibitory properties. *EXCLI journal*. 2013;12:1030-42.

Kumar A, Kumar A, Jaggi AS, Singh N. Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia. *Pharmacology, biochemistry, and behavior*. 2015;135:20-30.

Kumar A, Sharma N, Mishra J, Kalonia H. Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats. *European journal of pharmacology*. 2013;709(1-3):1-12.

Kumar A, Sharma S, Prashar A, Deshmukh R. Effect of licofelone--a dual COX/5-LOX inhibitor in intracerebroventricular streptozotocin-induced behavioral and biochemical abnormalities in rats. *Journal of molecular neuroscience : MN*. 2015;55(3):749-59.

Kumar A, Singh A. A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions. *Frontiers in pharmacology*. 2015;6:206.

Kumar A, Singh N. Calcineurin inhibitors improve memory loss and neuropathological changes in mouse model of dementia. *Pharmacology, biochemistry, and behavior*. 2017;153:147-59.

Kumar A, Singh N. Inhibitor of Phosphodiesterase-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's Type. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2017;88:698-707.

Kumar A, Singh N. Pharmacological activation of protein kinase A improves memory loss and neuropathological changes in a mouse model of dementia of Alzheimer's type. *Behavioural pharmacology*. 2017;28(2 and 3 - Special Issue):187-98.

Kumar A, Singh PK, Parihar R, Dwivedi V, Lakhotia SC, Ganesh S. Decreased O-linked GlcNAcylation protects from cytotoxicity mediated by huntingtin exon1 protein fragment. *The Journal of biological chemistry*. 2014;289(19):13543-53.

Kumar A, Srivastava G, Sharma A. A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3 β as targets for Alzheimer's disease. *Computational biology and chemistry*. 2017;71:1-9.

Kumar A, Srivastava G, Srivastava S, Verma S, Negi AS, Sharma A. Investigation of naphthofuran moiety as potential dual inhibitor against BACE-1 and GSK-3 β : molecular dynamics simulations, binding energy, and network analysis to identify first-in-class dual inhibitors against Alzheimer's disease. *Journal of molecular modeling*. 2017;23(8):239.

Kumar Dasappa J, Nagendra HG. Preferential selectivity of inhibitors with human tau protein kinase gsk3 β elucidates their potential roles for off-target Alzheimer's therapy. *International journal of Alzheimer's disease*. 2013;2013:809386.

Kumar DKV, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, et al. Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. *Science translational medicine*. 2016;8(340):340ra72.

Kumar J, Sim V. D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease. *Prion*. 2014;8(1):119-24.

Kumar M, Kaur D, Bansal N. Caffeic Acid Phenethyl Ester (CAPE) Prevents Development of STZ-ICV Induced dementia in Rats. *Pharmacognosy magazine*. 2017;13(Suppl 1):S10-S5.

Kumar NS, Nisha N. Phytomedicines as potential inhibitors of beta amyloid aggregation: significance to Alzheimer's disease. *Chinese journal of natural medicines*. 2014;12(11):801-18.

Kumar P, Tiwari SC, Goel A, Sreenivas V, Kumar N, Tripathi RK, et al. Novel occupational therapy interventions may improve quality of life in older adults with dementia. *International archives of medicine*. 2014;7:26.

Kumar S, Narasimha A, Holla B, Viswanath B, Narayanaswamy JC, Math SB, et al. Reversible dementia in young persons due to cobalamin deficiency. *The Journal of neuropsychiatry and clinical neurosciences*. 2013;25(1):E62-3.

Kumar V, Bhatt PC, Pathak S, Panda BP. Attenuation of neurobehavioral and neurochemical abnormalities in animal model of cognitive deficits of Alzheimer's disease by fermented soybean nanonutraceutical. *Inflammopharmacology*. 2017.

Kumfor F, Hodges JR, Piguet O. Ecological assessment of emotional enhancement of memory in progressive nonfluent aphasia and Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;42(1):201-10.

Kumfor F, Irish M, Hodges JR, Piguet O. Frontal and temporal lobe contributions to emotional enhancement of memory in behavioral-variant frontotemporal dementia and Alzheimer's disease. *Frontiers in behavioral neuroscience*. 2014;8:225.

Kumfor F, Irish M, Hodges JR, Piguet O. The orbitofrontal cortex is involved in emotional enhancement of memory: evidence from the dementias. *Brain : a journal of neurology*. 2013;136(Pt 10):2992-3003.

Kunath N, van Groen T, Allison DB, Kumar A, Dozier-Sharpe M, Kadish I. Ghrelin agonist does not foster insulin resistance but improves cognition in an Alzheimer's disease mouse model. *Scientific reports*. 2015;5:11452.

Kundaikar HS, Agre NP, Degani MS. Pharmacophore based 3DQSAR of phenothiazines as specific human butyrylcholinesterase inhibitors for treatment of Alzheimer's disease. *Current computer-aided drug design*. 2014;10(4):335-48.

Kundu A, Mitra A. Flavoring extracts of *Hemidesmus indicus* roots and *Vanilla planifolia* pods exhibit in vitro acetylcholinesterase inhibitory activities. *Plant foods for human nutrition (Dordrecht, Netherlands)*. 2013;68(3):247-53.

Kunkanjanawan T, Carter RL, Prucha MS, Yang J, Parnpai R, Chan AWS. miR-196a Ameliorates Cytotoxicity and Cellular Phenotype in Transgenic Huntington's Disease Monkey Neural Cells. *PloS one*. 2016;11(9):e0162788.

Kunutsor SK, Khan H, Nyssonen K, Laukkanen JA. Is lipoprotein (a) protective of dementia? *European journal of epidemiology*. 2016;31(11):1149-52.

Kuo L-M, Huang H-L, Huang H-L, Liang J, Chiu Y-C, Chen S-T, et al. A home-based training program improves Taiwanese family caregivers' quality of life and decreases their risk for depression: a randomized controlled trial. *International journal of geriatric psychiatry*. 2013;28(5):504-13.

Kuo Y, Ren S, Lao U, Edgar BA, Wang T. Suppression of polyglutamine protein toxicity by co-expression of a heat-shock protein 40 and a heat-shock protein 110. *Cell death & disease*. 2013;4:e833.

Kuo Y-C, Chou P-R. Neuroprotection against degeneration of sk-N-mc cells using neuron growth factor-encapsulated liposomes with surface cereport and transferrin. *Journal of pharmaceutical sciences*. 2014;103(8):2484-97.

Kuo Y-C, Lee Y-J. Rescuing cholinergic neurons from apoptotic degeneration by targeting of serotonin modulator-and apolipoprotein E-conjugated liposomes to the hippocampus. *International journal of nanomedicine*. 2016;11:6809-24.

Kuo Y-C, Lin C-C. Rescuing apoptotic neurons in Alzheimer's disease using wheat germ agglutinin-conjugated and cardiolipin-conjugated liposomes with encapsulated nerve growth factor and curcumin. *International journal of nanomedicine*. 2015;10:2653-72.

Kuo Y-C, Lin C-Y, Li J-S, Lou Y-I. Wheat germ agglutinin-conjugated liposomes incorporated with cardiolipin to improve neuronal survival in Alzheimer's disease treatment. *International journal of nanomedicine*. 2017;12:1757-74.

Kuo Y-C, Tsao C-W. Neuroprotection against apoptosis of SK-N-MC cells using RMP-7- and lactoferrin-grafted liposomes carrying quercetin. *International journal of nanomedicine*. 2017;12:2857-69.

Kuo Y-C, Wang C-T. Protection of SK-N-MC cells against beta-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin. *Biomaterials*. 2014;35(22):5954-64.

Kuppusamy A, Arumugam M, George S. Combining in silico and in vitro approaches to evaluate the acetylcholinesterase inhibitory profile of some commercially available flavonoids in the management of Alzheimer's disease. *International journal of biological macromolecules*. 2017;95:199-203.

Kurata T, Miyazaki K, Morimoto N, Kawai H, Ohta Y, Ikeda Y, et al. Atorvastatin and pitavastatin reduce oxidative stress and improve IR/LDL-R signals in Alzheimer's disease. *Neurological research*. 2013;35(2):193-205.

Kurinami H, Shimamura M, Sato N, Nakagami H, Morishita R. Do angiotensin receptor blockers protect against Alzheimer's disease? *Drugs & aging*. 2013;30(6):367-72.

Kurisu M, Miyamae Y, Murakami K, Han J, Isoda H, Irie K, et al. Inhibition of amyloid beta aggregation by acteoside, a phenylethanoid glycoside. *Bioscience, biotechnology, and biochemistry*. 2013;77(6):1329-32.

Kurosawa M, Matsumoto G, Kino Y, Okuno M, Kurosawa-Yamada M, Washizu C, et al. Depletion of p62 reduces nuclear inclusions and paradoxically ameliorates disease phenotypes in Huntington's model mice. *Human molecular genetics*. 2015;24(4):1092-105.

Kuruppu S, Rajapakse NW, Parkinson HC, Smith AI. The characteristics of astrocyte on Abeta clearance altered in Alzheimer's disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate. *American journal of translational research*. 2017;9(7):3514-6.

Kuruva CS, Manczak M, Yin X, Ogunmokun G, Reddy AP, Reddy PH. Aqua-soluble DDQ reduces the levels of Drp1 and Abeta and inhibits abnormal interactions between Abeta and Drp1 and protects Alzheimer's disease neurons from Abeta- and Drp1-induced mitochondrial and synaptic toxicities. *Human molecular genetics*. 2017;26(17):3375-95.

Kuruva CS, Reddy PH. Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal. *Drug discovery today*. 2017;22(2):223-33.

Kusakari S, Nawa M, Sudo K, Matsuoka M. Calmodulin-like skin protein protects against spatial learning impairment in a mouse model of Alzheimer disease. *Journal of neurochemistry*. 2017.

Kwon KJ, Kim MK, Lee EJ, Kim JN, Choi B-R, Kim SY, et al. Effects of donepezil, an acetylcholinesterase inhibitor, on neurogenesis in a rat model of vascular dementia. *Journal of the neurological sciences*. 2014;347(1-2):66-77.

Kwon Y. Luteolin as a potential preventive and therapeutic candidate for Alzheimer's disease. *Experimental gerontology*. 2017;95:39-43.

Labeyrie MA, Lenck S, Saint-Maurice JP, Bresson D, Houdart E. Dural arteriovenous fistulas presenting with reversible dementia are associated with a specific venous drainage. *European journal of neurology*. 2014;21(3):545-7.

Labriere C, Lozach O, Blairvacq M, Meijer L, Guillou C. Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors. *European journal of medicinal chemistry*. 2016;124:920-34.

Lach HW, Harrison BE, Phongphanngam S. Falls and Fall Prevention in Older Adults With Early-Stage Dementia: An Integrative Review. *Research in gerontological nursing*. 2017;10(3):139-48.

Lachaine J, Beauchemin C, Crochard A, Bineau S. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Regie de l'Assurance Maladie du Quebec database. *Canadian journal of psychiatry Revue canadienne de psychiatrie*. 2013;58(4):195-200.

Lacoste B, Tong X-K, Lahjouji K, Couture R, Hamel E. Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer's disease mice. *Journal of neuroinflammation*. 2013;10:57.

Ladenbauer J, Ladenbauer J, Kulzow N, de Boer R, Avramova E, Grittner U, et al. Promoting Sleep Oscillations and Their Functional Coupling by Transcranial Stimulation Enhances Memory Consolidation in Mild Cognitive Impairment. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(30):7111-24.

Lafortune L, Brayne C. Dementia: Dementia prevention - a call for contextualized evidence. *Nature reviews Neurology*. 2017;13(10):579-80.

Lafortune L, Brayne C. Dementia: Dementia prevention - a call for contextualized evidence. *Nature reviews Neurology*. 2017;13(11):703.

Lahiri DK, Maloney B, Long JM, Greig NH. Lessons from a BACE1 inhibitor trial: off-site but not off base. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2014;10(5 Suppl):S411-9.

Lahmy V, Long R, Morin D, Villard V, Maurice T. Mitochondrial protection by the mixed muscarinic/sigma1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Abeta25-35 peptide-injected mice, a nontransgenic Alzheimer's disease model. *Frontiers in cellular neuroscience*. 2014;8:463.

Lai EC-C, Wong MB, Iwata I, Zhang Y, Hsieh C-Y, Kao Yang Y-H, et al. Risk of pneumonia in new users of cholinesterase inhibitors for dementia. *Journal of the American Geriatrics Society*. 2015;63(5):869-76.

Lahey-Beitia J, Gonzalez Y, Doens D, Stephens DE, Santamaria R, Murillo E, et al. Assessment of Novel Curcumin Derivatives as Potent Inhibitors of Inflammation and Amyloid-beta Aggregation in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;60(s1):S59-S68.

Laks J. Dementia and the protective role of cognitive reserve. *Arquivos de neuro-psiquiatria*. 2015;73(6):473.

Lakshmi BVS, Sudhakar M, Prakash KS. Protective effect of selenium against aluminum chloride-induced Alzheimer's disease: behavioral and biochemical alterations in rats. *Biological trace element research*. 2015;165(1):67-74.

Lam HT, Graber MC, Gentry KA, Bieschke J. Stabilization of alpha-Synuclein Fibril Clusters Prevents Fragmentation and Reduces Seeding Activity and Toxicity. *Biochemistry*. 2016;55(4):675-85.

Lam LC-W, Chan WC, Leung T, Fung AW-T, Leung EM-F. Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition?: a cluster randomized controlled trial. *PloS one*. 2015;10(3):e0118173.

Lambracht-Washington D, Rosenberg RN. Co-stimulation with TNF receptor superfamily 4/25 antibodies enhances in-vivo expansion of CD4+CD25+Foxp3+ T cells (Tregs) in a mouse study for active DNA Abeta42 immunotherapy. *Journal of neuroimmunology*. 2015;278:90-9.

Lampela P, Taipale H, Hartikainen S. Use of Cholinesterase Inhibitors Increases Initiation of Urinary Anticholinergics in Persons with Alzheimer's Disease. *Journal of the American Geriatrics Society*. 2016;64(7):1510-2.

Lampit A, Valenzuela M. Pointing the FINGER at multimodal dementia prevention. *Lancet (London, England)*. 2015;386(10004):1625-6.

Lan J-S, Hou J-W, Liu Y, Ding Y, Zhang Y, Li L, et al. Design, synthesis and evaluation of novel cinnamic acid derivatives bearing N-benzyl pyridinium moiety as multifunctional cholinesterase inhibitors for Alzheimer's disease. *Journal of enzyme inhibition and medicinal chemistry*. 2017;32(1):776-88.

Lan J-S, Zhang T, Liu Y, Yang J, Xie S-S, Liu J, et al. Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors. *European journal of medicinal chemistry*. 2017;133:184-96.

Lan Y-L, Zhao J, Li S. Update on the neuroprotective effect of estrogen receptor alpha against Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2015;43(4):1137-48.

Lan Y-L, Zou S, Chen J-J, Zhao J, Li S. The Neuroprotective Effect of the Association of Aquaporin-4/Glutamate Transporter-1 against Alzheimer's Disease. *Neural plasticity*. 2016;2016:4626593.

Lan Z, Xie G, Wei M, Wang P, Chen L. The protective effect of Epimedii Folium and Curculiginis Rhizoma on Alzheimer's disease by the inhibitions of NF-kappaB/MAPK pathway and NLRP3 inflammasome. *Oncotarget*. 2017;8(27):43709-20.

Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, et al. Response to comments on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". *Science (New York, NY)*. 2013;340(6135):924-g.

Lane JJ, Bolster B, Campeau NG, Welker KM, Gilbertson JR. Characterization of multiple sclerosis plaques using susceptibility-weighted imaging at 1.5 T: can perivenular localization improve specificity of imaging criteria? *Journal of computer assisted tomography*. 2015;39(3):317-20.

Lane RM, Darreh-Shori T. Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value. *Journal of Alzheimer's disease : JAD*. 2015;44(4):1039-62.

Lane-Donovan C, Philips GT, Wasser CR, Durakoglugil MS, Masiulis I, Upadhaya A, et al. Reelin protects against amyloid beta toxicity in vivo. *Science signaling*. 2015;8(384):ra67.

Lang M, Fan Q, Wang L, Zheng Y, Xiao G, Wang X, et al. Inhibition of human high-affinity copper importer Ctr1 orthologous in the nervous system of *Drosophila* ameliorates Aβ₄₂-induced Alzheimer's disease-like symptoms. *Neurobiology of aging*. 2013;34(11):2604-12.

Langbaum JB, Hendrix SB, Ayutyanont N, Chen K, Fleisher AS, Shah RC, et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2014;10(6):666-74.

Lante F, Chafai M, Raymond EF, Pereira ARS, Mouska X, Kootar S, et al. Subchronic glucocorticoid receptor inhibition rescues early episodic memory and synaptic plasticity deficits in a mouse model of Alzheimer's disease. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2015;40(7):1772-81.

Lanza G, Bella R, Giuffrida S, Cantone M, Pennisi G, Spampinato C, et al. Preserved transcallosal inhibition to transcranial magnetic stimulation in nondemented elderly patients with leukoaraiosis. *BioMed research international*. 2013;2013:351680.

Lara HH, Alanis-Garza EJ, Estrada Puente MF, Mureyko LL, Alarcon Torres DA, Ixtepan Turrent L. Nutritional approaches to modulate oxidative stress that induce Alzheimer's disease. Nutritional approaches to prevent Alzheimer's disease. *Gaceta medica de Mexico*. 2015;151(2):245-51.

Larocque N, Schotsman C, Kaasalainen S, Crawshaw D, McAiney C, Brazil E. Using a book chat to improve attitudes and perceptions of long-term care staff about dementia. *Journal of gerontological nursing*. 2014;40(5):46-52.

Larsen ME, Curry L, Mastellos N, Robb C, Car J, Middleton LT. Development of the CHARIOT Research Register for the Prevention of Alzheimer's Dementia and Other Late Onset Neurodegenerative Diseases. *PloS one*. 2015;10(11):e0141806.

Larson EB. ACP Journal Club. Review: In older persons at vascular risk, statins do not prevent dementia or cognitive decline at 3.5 to 5 years. *Annals of internal medicine*. 2016;164(8):JC42.

Lasagna-Reeves CA, de Haro M, Hao S, Park J, Rousseaux MWC, Al-Ramahi I, et al. Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model. *Neuron*. 2016;92(2):407-18.

Lathren CR, Sloane PD, Hoyle JD, Zimmerman S, Kaufer DI. Improving dementia diagnosis and management in primary care: a cohort study of the impact of a training and support program on physician competency, practice patterns, and community linkages. *BMC geriatrics*. 2013;13:134.

Lathuiliere A, Schneider BL. A bioactive implantable device to prevent Alzheimer's disease. *Medecine sciences : M/S*. 2017;33(1):81-4.

Lattante S, de Calbiac H, Le Ber I, Brice A, Ciura S, Kabashi E. Sqstm1 knock-down causes a locomotor phenotype ameliorated by rapamycin in a zebrafish model of ALS/FTLD. *Human molecular genetics*. 2015;24(6):1682-90.

Lattanzio F, Carboni L, Carretta D, Candeletti S, Romualdi P. Treatment with the neurotoxic Aβeta (25-35) peptide modulates the expression of neuroprotective factors Pin1, Sirtuin 1, and brain-derived neurotrophic factor in SH-SY5Y human neuroblastoma cells. *Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie*. 2016;68(5):271-6.

Latypova EM, Timoshenko SI, Kislik GA, Vitek M, Shvartsman AL, Sarantseva SV. Investigation of neuroprotective activity of apolipoprotein E peptide mimetic Cog1410 in transgenic lines of *Drosophila melanogaster*. *Biomeditsinskaia khimiia*. 2014;60(4):515-21.

Lau C-F, Ho Y-S, Hung CH-L, Wuwongse S, Poon C-H, Chiu K, et al. Protective effects of testosterone on presynaptic terminals against oligomeric beta-amyloid peptide in primary culture of hippocampal neurons. *BioMed research international*. 2014;2014:103906.

Laumbacher B, Fellerhoff-Loesch B, Wank R. Improved cognitive and memory abilities in a patient with Alzheimer's disease treated with activated immune cells: Immune cell therapy may benefit more AD patients. *Medical hypotheses*. 2017;99:19-22.

Launer LJ. Preventing Alzheimer's disease is difficult. *The Lancet Neurology*. 2015;14(9):872-4.

Laurent C, Burnouf S, Ferry B, Batalha VL, Coelho JE, Baqi Y, et al. A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. *Molecular psychiatry*. 2016;21(1):97-107.

Lauretani F, Galuppo L, Costantino C, Ticinesi A, Ceda G, Ruffini L, et al. Parkinson's disease (PD) with dementia and falls is improved by AChEI? A preliminary study report. *Aging clinical and experimental research*. 2016;28(3):551-5.

Laursen B, Mork A, Kristiansen U, Bastlund JF. Hippocampal P3-like auditory event-related potentials are disrupted in a rat model of cholinergic degeneration in Alzheimer's disease: reversal by donepezil treatment. *Journal of Alzheimer's disease : JAD*. 2014;42(4):1179-89.

Lautenschlager NT, Cox KL. Can participation in mental and physical activity protect cognition in old age?: Comment on "The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults". *JAMA internal medicine*. 2013;173(9):805-6.

Lauterbach EC. Neuroprotective effects of psychotropic drugs in Huntington's disease. *International journal of molecular sciences*. 2013;14(11):22558-603.

Lavaur J, Lemaire M, Pype J, Le Nogue D, Hirsch EC, Michel PP. Neuroprotective and neurorestorative potential of xenon. *Cell death & disease*. 2016;7:e2182.

Laver K, Hamilton C, McCluskey A. Computerised cognitive training programs improved the cognitive performance of healthy older adults on some cognitive tests including memory, speed of information processing and visuospatial skills. *Australian occupational therapy journal*. 2015;62(3):223-4.

Lavie CJ, DiNicolantonio JJ, O'Keefe JH, Milani RV. Do statins cause or prevent dementia? *European journal of neurology*. 2015;22(6):885-6.

Lawless M, Augoustinos M, LeCouteur A. "Your Brain Matters": Issues of Risk and Responsibility in Online Dementia Prevention Information. *Qualitative health research*. 2017;1049732317732962.

Le Page A, Garneau H, Dupuis G, Frost EH, Larbi A, Witkowski JM, et al. Differential Phenotypes of Myeloid-Derived Suppressor and T Regulatory Cells and Cytokine Levels in Amnesic Mild Cognitive Impairment Subjects Compared to Mild Alzheimer Diseased Patients. *Frontiers in immunology*. 2017;8:783.

Le XT, Nguyet Pham HT, Van Nguyen T, Minh Nguyen K, Tanaka K, Fujiwara H, et al. Protective effects of Bacopa monnieri on ischemia-induced cognitive deficits in mice: the possible contribution of bacopaside I and underlying mechanism. *Journal of ethnopharmacology*. 2015;164:37-45.

Lea E, Marlow A, Bramble M, Andrews S, Eccleston C, McInerney F, et al. Improving student nurses' aged care understandings through a supported placement. *International nursing review*. 2015;62(1):28-35.

Lea EJ, Andrews S, Stronach M, Marlow A, Robinson AL. Using action research to build mentor capacity to improve orientation and quality of nursing students' aged care placements: what to do when the phone rings. *Journal of clinical nursing*. 2017;26(13-14):1893-905.

Leach MJ, Francis A, Ziaian T. Improving the health and well-being of community-dwelling caregivers of dementia sufferers: study protocol of a randomized controlled trial of structured meditation training. *Journal of alternative and complementary medicine (New York, NY)*. 2014;20(2):136-41.

Leach MJ, Francis A, Ziaian T. Transcendental Meditation for the improvement of health and wellbeing in community-dwelling dementia caregivers TRANSCENDENT : a randomised wait-list controlled trial. *BMC complementary and alternative medicine*. 2015;15:145.

Leal FD, da Silva Lima CH, de Alencastro RB, Castro HC, Rodrigues CR, Albuquerque MG. Hologram QSAR models of a series of 6-arylquinazolin-4-amine inhibitors of a new Alzheimer's

disease target: dual specificity tyrosine-phosphorylation-regulated kinase-1A enzyme. *International journal of molecular sciences*. 2015;16(3):5235-53.

Leavey G, Abbott A, Watson M, Todd S, Coates V, McIlfactrick S, et al. The evaluation of a healthcare passport to improve quality of care and communication for people living with dementia (EQuIP): a protocol paper for a qualitative, longitudinal study. *BMC health services research*. 2016;16(a):363.

Lebedeva E, Gallant S, Tsai C-E, Koski L. Improving the Measurement of Cognitive Ability in Geriatric Patients. *Dementia and geriatric cognitive disorders*. 2015;40(3-4):148-57.

Lecoutey C, Hedou D, Freret T, Giannoni P, Gaven F, Since M, et al. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(36):E3825-30.

Ledgerd R, Hoe J, Hoare Z, Devine M, Toot S, Challis D, et al. Identifying the causes, prevention and management of crises in dementia. An online survey of stakeholders. *International journal of geriatric psychiatry*. 2016;31(6):638-47.

Lee BI, Suh YS, Chung YJ, Yu K, Park CB. Shedding Light on Alzheimer's beta-Amyloidosis: Photosensitized Methylene Blue Inhibits Self-Assembly of beta-Amyloid Peptides and Disintegrates Their Aggregates. *Scientific reports*. 2017;7(1):7523.

Lee C, Shen Y-C. Aripiprazole Improves Psychotic, Cognitive, and Motor Symptoms in a Patient With Lewy Body Dementia. *Journal of clinical psychopharmacology*. 2017;37(5):628-30.

Lee D, Lee W-S, Lim S, Kim YK, Jung H-Y, Das S, et al. A guanidine-appended scyllo-inositol derivative AAD-66 enhances brain delivery and ameliorates Alzheimer's phenotypes. *Scientific reports*. 2017;7(1):14125.

Lee DY, Hwang CJ, Choi JY, Park MH, Song MJ, Oh KW, et al. KRICT-9 inhibits neuroinflammation, amyloidogenesis and memory loss in Alzheimer's disease models. *Oncotarget*. 2017;8(40):68654-67.

Lee E, Eom J-E, Kim H-L, Baek KH, Jun K-Y, Kim H-J, et al. Effect of conjugated linoleic acid, mu-calpain inhibitor, on pathogenesis of Alzheimer's disease. *Biochimica et biophysica acta*. 2013;1831(4):709-18.

Lee EH, Seo SR. Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases. *BMB reports*. 2014;47(7):369-75.

Lee H-K, Kwon B, Lemere CA, de la Monte S, Itamura K, Ha AY, et al. mTORC2 (Rictor) in Alzheimer's Disease and Reversal of Amyloid-beta Expression-Induced Insulin Resistance and

Toxicity in Rat Primary Cortical Neurons. *Journal of Alzheimer's disease* : JAD. 2017;56(3):1015-36.

Lee HR, Shin HK, Park SY, Kim HY, Lee WS, Rhim BY, et al. Attenuation of beta-amyloid-induced tauopathy via activation of CK2 α /SIRT1: targeting for cilostazol. *Journal of neuroscience research*. 2014;92(2):206-17.

Lee HS, Park SW, Park YJ. Effects of Physical Activity Programs on the Improvement of Dementia Symptom: A Meta-Analysis. *BioMed research international*. 2016;2016:2920146.

Lee HW, Kim YJ, Nam S-J, Kim H. Potent Selective Inhibition of Monoamine Oxidase A by Alternariol Monomethyl Ether Isolated from *Alternaria brassicae*. *Journal of microbiology and biotechnology*. 2017;27(2):316-20.

Lee I-S, Jung K, Kim I-S, Lee H, Kim M, Yun S, et al. Human neural stem cells alleviate Alzheimer-like pathology in a mouse model. *Molecular neurodegeneration*. 2015;10:38.

Lee JH, Shelton JT, Scullin MK, McDaniel MA. An implementation intention strategy can improve prospective memory in older adults with very mild Alzheimer's disease. *The British journal of clinical psychology*. 2016;55(2):154-66.

Lee JH, Sowada MJ, Boudreau RL, Aerts AM, Thedens DR, Nopoulos P, et al. Rhes suppression enhances disease phenotypes in Huntington's disease mice. *Journal of Huntington's disease*. 2014;3(1):65-71.

Lee JH, Tecedor L, Chen YH, Monteys AM, Sowada MJ, Thompson LM, et al. Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes. *Neuron*. 2015;85(2):303-15.

Lee JK, Kim N-J. Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease. *Molecules (Basel, Switzerland)*. 2017;22(8).

Lee J-M, Shin M-S, Ji E-S, Kim T-W, Cho H-S, Kim C-J, et al. Treadmill exercise improves motor coordination through ameliorating Purkinje cell loss in amyloid beta23-35-induced Alzheimer's disease rats. *Journal of exercise rehabilitation*. 2014;10(5):258-64.

Lee JS, Lee BI, Park CB. Photo-induced inhibition of Alzheimer's beta-amyloid aggregation in vitro by rose bengal. *Biomaterials*. 2015;38:43-9.

Lee K, Kim H, An K, Kwon O-B, Park S, Cha JH, et al. Replenishment of microRNA-188-5p restores the synaptic and cognitive deficits in 5XFAD Mouse Model of Alzheimer's Disease. *Scientific reports*. 2016;6:34433.

Lee KM, Bang J, Kim BY, Lee IS, Han J-S, Hwang BY, et al. Fructus mume alleviates chronic cerebral hypoperfusion-induced white matter and hippocampal damage via inhibition of

inflammation and downregulation of TLR4 and p38 MAPK signaling. *BMC complementary and alternative medicine*. 2015;15:125.

Lee L, Hillier LM, Harvey D. Integrating community services into primary care: improving the quality of dementia care. *Neurodegenerative disease management*. 2014;4(1):11-21.

Lee M, McGeer EG, McGeer PL. Quercetin, not caffeine, is a major neuroprotective component in coffee. *Neurobiology of aging*. 2016;46:113-23.

Lee M, Wathier M, Love JA, McGeer E, McGeer PL. Inhibition of aberrant complement activation by a dimer of acetylsalicylic acid. *Neurobiology of aging*. 2015;36(10):2748-56.

Lee M-H, Amin ND, Venkatesan A, Wang T, Tyagi R, Pant HC, et al. Impaired neurogenesis and neurite outgrowth in an HIV-gp120 transgenic model is reversed by exercise via BDNF production and Cdk5 regulation. *Journal of neurovirology*. 2013;19(5):418-31.

Lee M-H, Shih Y-H, Lin S-R, Chang J-Y, Lin Y-H, Sze C-I, et al. Zfra restores memory deficits in Alzheimer's disease triple-transgenic mice by blocking aggregation of TRAPPC6ADelta, SH3GLB2, tau, and amyloid beta, and inflammatory NF-kappaB activation. *Alzheimer's & dementia (New York, N Y)*. 2017;3(2):189-204.

Lee M-S, Wahlqvist ML, Chou Y-C, Fang W-H, Lee J-T, Kuan J-C, et al. Turmeric improves post-prandial working memory in pre-diabetes independent of insulin. *Asia Pacific journal of clinical nutrition*. 2014;23(4):581-91.

Lee S, Bang SM, Hong YK, Lee JH, Jeong H, Park SH, et al. The calcineurin inhibitor Sarah (Nebula) exacerbates Abeta42 phenotypes in a Drosophila model of Alzheimer's disease. *Disease models & mechanisms*. 2016;9(3):295-306.

Lee S, Zemianek J, Shea TB. Rapid, reversible impairment of synaptic signaling in cultured cortical neurons by exogenously-applied amyloid-beta. *Journal of Alzheimer's disease : JAD*. 2013;35(2):395-402.

Lee SH, Choi BY, Kim JH, Kho AR, Sohn M, Song HK, et al. Late treatment with choline alfoscerate (l-alpha glycerylphosphorylcholine, alpha-GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment. *Brain research*. 2017;1654(Pt A):66-76.

Lee S-H, Kim Y, Kim HY, Kim YH, Kim MS, Kong JY, et al. Aminostyrylbenzofuran directly reduces oligomeric amyloid-beta and reverses cognitive deficits in Alzheimer transgenic mice. *PloS one*. 2014;9(4):e95733.

Lee SL, Thomas P, Fenech M. Extracellular amyloid beta 42 causes necrosis, inhibition of nuclear division, and mitotic disruption under both folate deficient and folate replete conditions

as measured by the cytokinesis-block micronucleus cytome assay. *Environmental and molecular mutagenesis*. 2014;55(1):1-14.

Lee SM, Chung M, Hwang KJ, Ju YR, Hyeon JW, Park J-S, et al. Biological network inferences for a protection mechanism against familial Creutzfeldt-Jakob disease with E200K pathogenic mutation. *BMC medical genomics*. 2014;7:52.

Lee W, Reyes RC, Gottipati MK, Lewis K, Lesort M, Parpura V, et al. Enhanced Ca(2+)-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model. *Neurobiology of disease*. 2013;58:192-9.

Lee WC, Almeida S, Prudencio M, Caulfield TR, Zhang Y-J, Tay WM, et al. Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency. *Human molecular genetics*. 2014;23(6):1467-78.

Lee Y. The recent decline in prevalence of dementia in developed countries: implications for prevention in the Republic of Korea. *Journal of Korean medical science*. 2014;29(7):913-8.

Lee YH, Shin MC, Yun YD, Shin SY, Kim JM, Seo JM, et al. Synthesis of aminoalkyl-substituted aurone derivatives as acetylcholinesterase inhibitors. *Bioorganic & medicinal chemistry*. 2015;23(1):231-40.

Lee Y-J, Choi D-Y, Yun Y-P, Han SB, Oh K-W, Hong JT. Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties. *The Journal of nutritional biochemistry*. 2013;24(1):298-310.

Lee YK, Bang HJ, Oh JB, Whang WK. Bioassay-Guided Isolated Compounds from *Morinda officinalis* Inhibit Alzheimer's Disease Pathologies. *Molecules* (Basel, Switzerland). 2017;22(10).

Lee YW, Kim DH, Jeon SJ, Park SJ, Kim JM, Jung JM, et al. Neuroprotective effects of salvianolic acid B on an Aβ₂₅₋₃₅ peptide-induced mouse model of Alzheimer's disease. *European journal of pharmacology*. 2013;704(1-3):70-7.

Lefort R. Reversing synapse loss in Alzheimer's disease: Rho-guanosine triphosphatases and insights from other brain disorders. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*. 2015;12(1):19-28.

Leggio GM, Catania MV, Puzzo D, Spatuzza M, Pellitteri R, Gulisano W, et al. The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-SS1-42 oligomers in mice. *Pharmacological research*. 2016;106:10-20.

Lehtisalo J, Lindstrom J, Ngandu T, Kivipelto M, Ahtiluoto S, Ilanne-Parikka P, et al. Association of Long-Term Dietary Fat Intake, Exercise, and Weight with Later Cognitive

Function in the Finnish Diabetes Prevention Study. *The journal of nutrition, health & aging.* 2016;20(2):146-54.

Lehtisalo J, Lindstrom J, Ngandu T, Kivipelto M, Ahtiluoto S, Ilanne-Parikka P, et al. Diabetes, glycaemia, and cognition-a secondary analysis of the Finnish Diabetes Prevention Study. *Diabetes/metabolism research and reviews.* 2016;32(1):102-10.

Lehtisalo J, Ngandu T, Valve P, Antikainen R, Laatikainen T, Strandberg T, et al. Nutrient intake and dietary changes during a 2-year multi-domain lifestyle intervention among older adults: secondary analysis of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) randomised controlled trial. *The British journal of nutrition.* 2017;118(4):291-302.

Lei H, Zhao C-Y, Liu D-M, Zhang Y, Li L, Wang X-L, et al. 1-3-n-Butylphthalide attenuates beta-amyloid-induced toxicity in neuroblastoma SH-SY5Y cells through regulating mitochondrion-mediated apoptosis and MAPK signaling. *Journal of Asian natural products research.* 2014;16(8):854-64.

Lei P, Ayton S, Appukuttan AT, Moon S, Duce JA, Volitakis I, et al. Lithium suppression of tau induces brain iron accumulation and neurodegeneration. *Molecular psychiatry.* 2017;22(3):396-406.

Lei P, Ayton S, Appukuttan AT, Volitakis I, Adlard PA, Finkelstein DI, et al. Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. *Neurobiology of disease.* 2015;81:168-75.

Lei Y, Yang L, Ye CY, Qin MY, Yang HY, Jiang HL, et al. Involvement of Intracellular and Mitochondrial Abeta in the Ameliorative Effects of Huperzine A against Oligomeric Abeta42-Induced Injury in Primary Rat Neurons. *PloS one.* 2015;10(5):e0128366.

Leibing A. The earlier the better: Alzheimer's prevention, early detection, and the quest for pharmacological interventions. *Culture, medicine and psychiatry.* 2014;38(2):217-36.

Leikin JB, Braund V, DesLauris C. Cholinergic symptoms with low serum cholinesterase from therapeutic cholinesterase inhibitor toxicity. *The American journal of emergency medicine.* 2014;32(7):815.e3-4.

Leinenga G, Gotz J. Scanning ultrasound removes amyloid-beta and restores memory in an Alzheimer's disease mouse model. *Science translational medicine.* 2015;7(278):278ra33.

Leinonen A, Koponen M, Hartikainen S. Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors. *PloS one.* 2015;10(5):e0124500.

Leiros M, Alonso E, Rateb ME, Ebel R, Jaspars M, Alfonso A, et al. The Streptomyces metabolite anhydroexfoliamycin ameliorates hallmarks of Alzheimer's disease in vitro and in vivo. *Neuroscience*. 2015;305:26-35.

Leitao MJ, Baldeiras I, Almeida MR, Ribeiro MH, Santos AC, Ribeiro M, et al. Sporadic Creutzfeldt-Jakob disease diagnostic accuracy is improved by a new CSF ELISA 14-3-3gamma assay. *Neuroscience*. 2016;322:398-407.

Leiva R, Grinan-Ferre C, Seira C, Valverde E, McBride A, Binnie M, et al. Design, synthesis and invivo study of novel pyrrolidine-based 11beta-HSD1 inhibitors for age-related cognitive dysfunction. *European journal of medicinal chemistry*. 2017;139:412-28.

Lemes LFN, de Andrade Ramos G, de Oliveira AS, da Silva FMR, de Castro Couto G, da Silva Boni M, et al. Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease. *European journal of medicinal chemistry*. 2016;108:687-700.

Lengacher CA, Reich RR, Kip KE, Paterson CL, Park HY, Ramesar S, et al. Moderating Effects of Genetic Polymorphisms on Improvements in Cognitive Impairment in Breast Cancer Survivors Participating in a 6-Week Mindfulness-Based Stress Reduction Program. *Biological research for nursing*. 2015;17(4):393-404.

Lenthe M. Using EHR Technology To Improve Dementia Care. *Provider* (Washington, DC). 2015;41(9):55, 7.

Leoutsakos JM, Gross AL, Jones RN, Albert MS, Breitner JCS. 'Alzheimer's Progression Score': Development of a Biomarker Summary Outcome for AD Prevention Trials. *The journal of prevention of Alzheimer's disease*. 2016;3(4):229-35.

Leoutsakos J-MS, Bartlett AL, Forrester SN, Lyketsos CG. Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2014;10(2):152-61.

Leroi I, Atkinson R, Overshott R. Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. *International journal of geriatric psychiatry*. 2014;29(9):899-905.

Leroi I, Pye A, Armitage CJ, Charalambous AP, Constantinidou F, Helmer C, et al. Research protocol for a complex intervention to support hearing and vision function to improve the lives of people with dementia. Pilot and feasibility studies. 2017;3:38.

Lescoutra-Etchegaray N, Jaffre N, Sumian C, Durand V, Correia E, Mikol J, et al. Evaluation of the protection of primates transfused with variant Creutzfeldt-Jakob disease-infected blood products filtered with prion removal devices: a 5-year update. *Transfusion*. 2015;55(6):1231-41.

Lesnik S, Stular T, Brus B, Knez D, Gobec S, Janezic D, et al. LiSiCA: A Software for Ligand-Based Virtual Screening and Its Application for the Discovery of Butyrylcholinesterase Inhibitors. *Journal of chemical information and modeling*. 2015;55(8):1521-8.

Levy B, Tsoy E, Gable S. Developing Cognitive Markers of Alzheimer's Disease for Primary Care: Implications for Behavioral and Global Prevention. *Journal of Alzheimer's disease : JAD*. 2016;54(4):1259-72.

Li B, Yu D, Xu Z. Activated protein C inhibits amyloid beta production via promoting expression of ADAM-10. *Brain research*. 2014;1545:35-44.

Li B-Y, Tang H-D, Qiao Y, Chen S-D. Mental Training for Cognitive Improvement in Elderly People: What have We Learned from Clinical and Neurophysiologic Studies? *Current Alzheimer research*. 2015;12(6):543-52.

Li C, Zug C, Qu H, Schluesener H, Zhang Z. Hesperidin ameliorates behavioral impairments and neuropathology of transgenic APP/PS1 mice. *Behavioural brain research*. 2015;281:32-42.

Li D-M, Li X-X. The effect of folk recreation program in improving symptoms: a study of Chinese elder dementia patients. *International journal of geriatric psychiatry*. 2017;32(8):901-8.

Li F, Han G, Wu K. Tanshinone IIA Alleviates the AD Phenotypes in APP and PS1 Transgenic Mice. *BioMed research international*. 2016;2016:7631801.

Li F, Tran L, Thung K-H, Ji S, Shen D, Li J. A Robust Deep Model for Improved Classification of AD/MCI Patients. *IEEE journal of biomedical and health informatics*. 2015;19(5):1610-6.

Li F, Wang Z-M, Wu J-J, Wang J, Xie S-S, Lan J-S, et al. Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer's disease. *Journal of enzyme inhibition and medicinal chemistry*. 2016;31(sup3):41-53.

Li F, Wu X, Li J, Niu Q. Ginsenoside Rg1 ameliorates hippocampal long-term potentiation and memory in an Alzheimer's disease model. *Molecular medicine reports*. 2016;13(6):4904-10.

Li F, Yan C-Q, Lin L-T, Li H, Zeng X-H, Liu Y, et al. Acupuncture attenuates cognitive deficits and increases pyramidal neuron number in hippocampal CA1 area of vascular dementia rats. *BMC complementary and alternative medicine*. 2015;15:133.

Li G, Hu Z-W, Chen P-G, Sun Z-Y, Chen Y-X, Zhao Y-F, et al. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid beta Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice. *ACS chemical neuroscience*. 2017;8(3):454-9.

Li H, Kang T, Qi B, Kong L, Jiao Y, Cao Y, et al. Neuroprotective effects of ginseng protein on PI3K/Akt signaling pathway in the hippocampus of D-galactose/ AlCl_3 inducing rats model of Alzheimer's disease. *Journal of ethnopharmacology*. 2016;179:162-9.

Li H, Liu Y, Lin L-T, Wang X-R, Du S-Q, Yan C-Q, et al. Acupuncture reversed hippocampal mitochondrial dysfunction in vascular dementia rats. *Neurochemistry international*. 2016;92:35-42.

Li H, Song J, Zhang J, Wang T, Yan Y, Tao Z, et al. Ginseng Protein Reverses Amyloid Beta Peptide and H_2O_2 Cytotoxicity in Neurons, and Ameliorates Cognitive Impairment in AD Rats Induced by a Combination of D-Galactose and AlCl_3 . *Phytotherapy research : PTR*. 2017;31(2):284-95.

Li H, Wang J, Wang P, Rao Y, Chen L. Resveratrol Reverses the Synaptic Plasticity Deficits in a Chronic Cerebral Hypoperfusion Rat Model. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association*. 2016;25(1):122-8.

Li H, Wang M, Gong Y-N, Yan A. Discrimination of Active and Weakly Active Human BACE1 Inhibitors Using Self-Organizing Map and Support Vector Machine. *Combinatorial chemistry & high throughput screening*. 2016;19(6):470-80.

Li H, Wang R. Blocking SIRT1 inhibits cell proliferation and promotes aging through the PI3K/AKT pathway. *Life sciences*. 2017;190:84-90.

Li H, Wu X, Wu Q, Gong D, Shi M, Guan L, et al. Green tea polyphenols protect against okadaic acid-induced acute learning and memory impairments in rats. *Nutrition (Burbank, Los Angeles County, Calif)*. 2014;30(3):337-42.

Li H-L, Lu S-J, Sun Y-M, Guo Q-H, Sadovnick AD, Wu Z-Y. The LRRK2 R1628P variant plays a protective role in Han Chinese population with Alzheimer's disease. *CNS neuroscience & therapeutics*. 2013;19(4):207-15.

Li J, Ding X, Zhang R, Jiang W, Sun X, Xia Z, et al. Harpagoside ameliorates the amyloid-beta-induced cognitive impairment in rats via up-regulating BDNF expression and MAPK/PI3K pathways. *Neuroscience*. 2015;303:103-14.

Li J, Ji X, Zhang J, Shi G, Zhu X, Wang K. Paeoniflorin attenuates A β 25-35-induced neurotoxicity in PC12 cells by preventing mitochondrial dysfunction. *Folia neuropathologica*. 2014;52(3):285-90.

Li J, Liu C-N, Wei N, Li X-D, Liu Y-Y, Yang R, et al. Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-beta peptides-induced oxidative stress in in-vivo and in-vitro models of Alzheimer's disease. *Brain research*. 2016;1642:327-35.

Li J-M, Liu C, Hu X, Cai Y, Ma C, Luo X-G, et al. Inverse correlation between Alzheimer's disease and cancer: implication for a strong impact of regenerative propensity on neurodegeneration? BMC neurology. 2014;14:211.

Li L, Liu Z, Liu J, Tai X, Hu X, Liu X, et al. Ginsenoside Rd attenuates beta-amyloid-induced tau phosphorylation by altering the functional balance of glycogen synthase kinase 3beta and protein phosphatase 2A. Neurobiology of disease. 2013;54:320-8.

Li L, Qin L, Lu H-L, Li P-J, Song Y-J, Yang R-L. Methylene blue improves streptozotocin-induced memory deficit by restoring mitochondrial function in rats. Brain research. 2017;1657:208-14.

Li L, Xu S, Liu L, Feng R, Gong Y, Zhao X, et al. Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-alpha and IL-1beta in an Abeta25-35-induced Rat Model of Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2017;56(4):1403-17.

Li L, Xue Z, Chen L, Chen X, Wang H, Wang X. Puerarin suppression of Abeta1-42-induced primary cortical neuron death is largely dependent on ERbeta. Brain research. 2017;1657:87-94.

Li L, Yu L, Kong Q. Exogenous galanin attenuates spatial memory impairment and decreases hippocampal beta-amyloid levels in rat model of Alzheimer's disease. The International journal of neuroscience. 2013;123(11):759-65.

Li L, Zhang S, Zhang X, Li T, Tang Y, Liu H, et al. Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-beta pathology in a mouse model of Alzheimer's disease. Current Alzheimer research. 2013;10(4):433-41.

Li M, Dong Y, Yu X, Li Y, Zou Y, Zheng Y, et al. Synthesis and Evaluation of Diphenyl Conjugated Imidazole Derivatives as Potential Glutaminy Cyclase Inhibitors for Treatment of Alzheimer's Disease. Journal of medicinal chemistry. 2017;60(15):6664-77.

Li M, Dong Y, Yu X, Zou Y, Zheng Y, Bu X, et al. Inhibitory effect of flavonoids on human glutaminy cyclase. Bioorganic & medicinal chemistry. 2016;24(10):2280-6.

Li M, Xu C, Wu L, Ren J, Wang E, Qu X. Self-assembled peptide-polyoxometalate hybrid nanospheres: two in one enhances targeted inhibition of amyloid beta-peptide aggregation associated with Alzheimer's disease. Small (Weinheim an der Bergstrasse, Germany). 2013;9(20):3455-61.

Li M, Yasumura D, Ma AAK, Matthes MT, Yang H, Nielson G, et al. Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease. PloS one. 2013;8(2):e56026.

Li M, Yuan Y, Hu B, Wu L. Study on Lentivirus-Mediated ABCA7 Improves Neurocognitive Function and Related Mechanisms in the C57BL/6 Mouse Model of Alzheimer's Disease. *Journal of molecular neuroscience* : MN. 2017;61(4):489-97.

Li M, Zhang W, Wang W, He Q, Yin M, Qin X, et al. Imidazole improves cognition and balances Alzheimer's-like intracellular calcium homeostasis in transgenic *Drosophila* model. *Neurourology and urodynamics*. 2017.

Li M, Zhao C, Duan T, Ren J, Qu X. New insights into Alzheimer's disease amyloid inhibition: nanosized metallo-supramolecular complexes suppress abeta-induced biosynthesis of heme and iron uptake in PC12 cells. *Advanced healthcare materials*. 2014;3(6):832-6.

Li M, Zhao C, Ren J, Qu X. Chiral Metallo-Supramolecular Complex Directed Enantioselective Self-Assembly of beta-Sheet Breaker Peptide for Amyloid Inhibition. *Small* (Weinheim an der Bergstrasse, Germany). 2015;11(36):4651-5.

Li M, Zhao C, Yang X, Ren J, Xu C, Qu X. In situ monitoring Alzheimer's disease beta-amyloid aggregation and screening of Abeta inhibitors using a perylene probe. *Small* (Weinheim an der Bergstrasse, Germany). 2013;9(1):52-5.

Li N, Jang H, Yuan M, Li W, Yun X, Lee J, et al. Graphite-Templated Amyloid Nanostructures Formed by a Potential Pentapeptide Inhibitor for Alzheimer's Disease: A Combined Study of Real-Time Atomic Force Microscopy and Molecular Dynamics Simulations. *Langmuir : the ACS journal of surfaces and colloids*. 2017;33(27):6647-56.

Li N, Liu Y, Li W, Zhou L, Li Q, Wang X, et al. A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease. *Journal of ginseng research*. 2016;40(1):9-17.

Li N, Wang J, Ma J, Gu Z, Jiang C, Yu L, et al. Neuroprotective Effects of Cistanches Herba Therapy on Patients with Moderate Alzheimer's Disease. *Evidence-based complementary and alternative medicine : eCAM*. 2015;2015:103985.

Li N, Zhou L, Li W, Liu Y, Wang J, He P. Protective effects of ginsenosides Rg1 and Rb1 on an Alzheimer's disease mouse model: a metabolomics study. *Journal of chromatography B, Analytical technologies in the biomedical and life sciences*. 2015;985:54-61.

Li P, Zhu M-L, Pan G-P, Lu J-X, Zhao F-R, Jian X, et al. Vitamin B6 prevents isocarbophos-induced vascular dementia in rats through N-methyl-D-aspartate receptor signaling. *Clinical and experimental hypertension* (New York, NY : 1993). 2017;1-10.

Li Q, Navakkode S, Rothkegel M, Soong TW, Sajikumar S, Korte M. Metaplasticity mechanisms restore plasticity and associativity in an animal model of Alzheimer's disease.

Proceedings of the National Academy of Sciences of the United States of America. 2017;114(21):5527-32.

Li Q, Yang H, Chen Y, Sun H. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. *European journal of medicinal chemistry*. 2017;132:294-309.

Li R, Xu DE, Ma T. Lovastatin suppresses the aberrant tau phosphorylation from FTDP-17 mutation and okadaic acid-induction in rat primary neurons. *Neuroscience*. 2015;294:14-20.

Li R, Zhang W, Suk H-I, Wang L, Li J, Shen D, et al. Deep learning based imaging data completion for improved brain disease diagnosis. *Medical image computing and computer-assisted intervention : MICCAI International Conference on Medical Image Computing and Computer-Assisted Intervention*. 2014;17(Pt 3):305-12.

Li R. Physical activity and prevention of Alzheimer's disease. *Journal of sport and health science*. 2016;5(4):381-2.

Li R-S, Wang X-B, Hu X-J, Kong L-Y. Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2013;23(9):2636-41.

Li S, Wei Z, Chen J, Chen Y, Lv Z, Yu W, et al. Oral administration of a fusion protein between the cholera toxin B subunit and the 42-amino acid isoform of amyloid-beta peptide produced in silkworm pupae protects against Alzheimer's disease in mice. *PloS one*. 2014;9(12):e113585.

Li S, Yan Y, Jiao Y, Gao Z, Xia Y, Kong L, et al. Neuroprotective Effect of Osthole on Neuron Synapses in an Alzheimer's Disease Cell Model via Upregulation of MicroRNA-9. *Journal of molecular neuroscience : MN*. 2016;60(1):71-81.

Li S-H, Gao P, Wang L-T, Yan Y-H, Xia Y, Song J, et al. Osthole Stimulated Neural Stem Cells Differentiation into Neurons in an Alzheimer's Disease Cell Model via Upregulation of MicroRNA-9 and Rescued the Functional Impairment of Hippocampal Neurons in APP/PS1 Transgenic Mice. *Frontiers in neuroscience*. 2017;11:340.

Li S-Q, Yu Y, Han J-Z, Wang D, Liu J, Qian F, et al. Deficiency of macrophage migration inhibitory factor attenuates tau hyperphosphorylation in mouse models of Alzheimer's disease. *Journal of neuroinflammation*. 2015;12:177.

Li W, Jiang M, Xiao Y, Zhang X, Cui S, Huang G. Folic acid inhibits tau phosphorylation through regulation of PP2A methylation in SH-SY5Y cells. *The journal of nutrition, health & aging*. 2015;19(2):123-9.

Li W, Jiang M, Zhao S, Liu H, Zhang X, Wilson JX, et al. Folic Acid Inhibits Amyloid beta-Peptide Production through Modulating DNA Methyltransferase Activity in N2a-APP Cells. *International journal of molecular sciences*. 2015;16(10):25002-13.

Li W, Silva HB, Real J, Wang Y-M, Rial D, Li P, et al. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models. *Neurobiology of disease*. 2015;79:70-80.

Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, et al. Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer's disease mouse model. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(19):8423-41.

Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, et al. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model. *Molecular brain*. 2014;7:65.

Li W, Yuan H, Yu Y, Cheong Y-K, Ren G, Yang Z. Etidronate rescues cognitive deficits through improving synaptic transmission and suppressing apoptosis in 2-vessel occlusion model rats. *Journal of neurochemistry*. 2017;140(3):476-84.

Li W-Z, Wu W-Y, Huang H, Wu Y-Y, Yin Y-Y. Protective effect of bilobalide on learning and memory impairment in rats with vascular dementia. *Molecular medicine reports*. 2013;8(3):935-41.

Li X, Cui J, Yu Y, Li W, Hou Y, Wang X, et al. Traditional Chinese Nootropic Medicine Radix Polygalae and Its Active Constituent Onjisaponin B Reduce beta-Amyloid Production and Improve Cognitive Impairments. *PloS one*. 2016;11(3):e0151147.

Li X, Lu F, Li W, Qin L, Yao Y, Ge X, et al. Edaravone injection reverses learning and memory deficits in a rat model of vascular dementia. *Acta biochimica et biophysica Sinica*. 2017;49(1):83-9.

Li X, Song Y, Sanders CR, Buxbaum JN. Transthyretin Suppresses Amyloid-beta Secretion by Interfering with Processing of the Amyloid-beta Protein Precursor. *Journal of Alzheimer's disease : JAD*. 2016;52(4):1263-75.

Li X, Wang Z, Tan L, Wang Y, Lu C, Chen R, et al. Correcting miR92a-vGAT-Mediated GABAergic Dysfunctions Rescues Human Tau-Induced Anxiety in Mice. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2017;25(1):140-52.

Li X, Zhang X, Ladiwala ARA, Du D, Yadav JK, Tessier PM, et al. Mechanisms of transthyretin inhibition of beta-amyloid aggregation in vitro. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(50):19423-33.

Li X, Zhu H, Sun X, Zuo F, Lei J, Wang Z, et al. Human Neural Stem Cell Transplantation Rescues Cognitive Defects in APP/PS1 Model of Alzheimer's Disease by Enhancing Neuronal Connectivity and Metabolic Activity. *Frontiers in aging neuroscience*. 2016;8:282.

Li X-y, Xu L, Liu C-l, Huang L-s, Zhu X-y. Electroacupuncture Intervention Inhibits the Decline of Learning-memory Ability and Overexpression of Cleaved Caspase-3 and Bax in Hippocampus Induced by Isoflurane in APPswe/PS 1. *Zhen ci yan jiu = Acupuncture research*. 2016;41(1):24-30.

Li Y, Hai S, Zhou Y, Dong BR. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. *The Cochrane database of systematic reviews*. 2015(3):CD009444.

Li Y, Qiang X, Li Y, Yang X, Luo L, Xiao G, et al. Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-beta-amyloid aggregation and antioxidant properties for the treatment of Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2016;26(8):2035-9.

Li Y, Qiang X, Luo L, Yang X, Xiao G, Liu Q, et al. Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-beta-amyloid aggregation and neuroprotective properties for the treatment of Alzheimer's disease. *European journal of medicinal chemistry*. 2017;126:762-75.

Li Y, Qiang X, Luo L, Yang X, Xiao G, Zheng Y, et al. Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties. *Bioorganic & medicinal chemistry*. 2017;25(2):714-26.

Li Y, Xu J, Xu P, Song S, Liu P, Chi T, et al. Xanthoceras sorbifolia extracts ameliorate dendritic spine deficiency and cognitive decline via upregulation of BDNF expression in a rat model of Alzheimer's disease. *Neuroscience letters*. 2016;629:208-14.

Li Y, Yuan X, Shen Y, Zhao J, Yue R, Liu F, et al. Bacopaside I ameliorates cognitive impairment in APP/PS1 mice via immune-mediated clearance of beta-amyloid. *Aging*. 2016;8(3):521-33.

Li Y, Zhang X-X, Jiang L-J, Yuan L, Cao T-T, Li X, et al. Inhibition of Acetylcholinesterase (AChE): A Potential Therapeutic Target to Treat Alzheimer's Disease. *Chemical biology & drug design*. 2015;86(4):776-82.

Li Y, Zhang Z. Gastrodin improves cognitive dysfunction and decreases oxidative stress in vascular dementia rats induced by chronic ischemia. *International journal of clinical and experimental pathology*. 2015;8(11):14099-109.

Li Y-F, Zhang S-X, Qi J-S. The neuroprotection of anti-diabetic medicine GLP-1 in Alzheimer's disease and its molecular mechanisms. *Sheng li ke xue jin zhan* [Progress in physiology]. 2016;47(1):47-52.

Li Y-P, Yang G-J, Jin L, Yang H-M, Chen J, Chai G-S, et al. Erythropoietin attenuates Alzheimer-like memory impairments and pathological changes induced by amyloid beta42 in mice. *Brain research*. 2015;1618:159-67.

Li Z, Chen X, Lu W, Zhang S, Guan X, Li Z, et al. Anti-Oxidative Stress Activity Is Essential for *Amanita caesarea* Mediated Neuroprotection on Glutamate-Induced Apoptotic HT22 Cells and an Alzheimer's Disease Mouse Model. *International journal of molecular sciences*. 2017;18(8).

Li Z, Fang F, Wang Y, Wang L. Resveratrol protects CA1 neurons against focal cerebral ischemic reperfusion-induced damage via the ERK-CREB signaling pathway in rats. *Pharmacology, biochemistry, and behavior*. 2016;146-147:21-7.

Li Z, Jia K, Duan Y, Wang D, Zhou Z, Dong S. Xanomeline derivative EUK1001 attenuates Alzheimer's disease pathology in a triple transgenic mouse model. *Molecular medicine reports*. 2017;16(5):7835-40.

Li Z, Li H, Zhao C, Lv C, Zhong C, Xin W, et al. Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer's Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Abeta Accumulation. *CNS & neurological disorders drug targets*. 2015;14(3):360-9.

Li Z, Mu C, Wang B, Jin J. Graveoline Analogs Exhibiting Selective Acetylcholinesterase Inhibitory Activity as Potential Lead Compounds for the Treatment of Alzheimer's Disease. *Molecules* (Basel, Switzerland). 2016;21(2):132.

Lian W, Fang J, Xu L, Zhou W, Kang D, Xiong W, et al. DL0410 Ameliorates Memory and Cognitive Impairments Induced by Scopolamine via Increasing Cholinergic Neurotransmission in Mice. *Molecules* (Basel, Switzerland). 2017;22(3).

Liang C, Yuan J-P, Ding T, Yan L, Ling L, Zhou X-F, et al. Neuroprotective Effect of *Fagopyrum dibotrys* Extract against Alzheimer's Disease. *Evidence-based complementary and alternative medicine : eCAM*. 2017;2017:3294586.

Liang H, Shi Y, Kou Z, Peng Y, Chen W, Li X, et al. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model. *PloS one*. 2015;10(10):e0140733.

Liang J, Lopez-Valdes HE, Martinez-Coria H, Lindemeyer AK, Shen Y, Shao XM, et al. Dihydromyricetin ameliorates behavioral deficits and reverses neuropathology of transgenic mouse models of Alzheimer's disease. *Neurochemical research*. 2014;39(6):1171-81.

Liang K, Zhang J, Yin C, Zhou X, Zhou S. Protective effects and mechanism of TPX2 on neurocyte apoptosis of rats in Alzheimer's disease model. *Experimental and therapeutic medicine*. 2017;13(2):576-80.

Liang Y, Ryan NS, Schott JM, Fox NC. Imaging the onset and progression of Alzheimer's disease: implications for prevention trials. *Journal of Alzheimer's disease : JAD*. 2013;33 Suppl 1:S305-12.

Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, et al. Anti-ApoE antibody given after plaque onset decreases Abeta accumulation and improves brain function in a mouse model of Abeta amyloidosis. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(21):7281-92.

Liapis J, Harding KE. Meaningful use of computers has a potential therapeutic and preventative role in dementia care: A systematic review. *Australasian journal on ageing*. 2017.

Libro R, Giacoppo S, Soundara Rajan T, Bramanti P, Mazzon E. Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview. *Molecules (Basel, Switzerland)*. 2016;21(4):518.

Ligthart SA, van den Eerenbeemt KDM, Pols J, van Bussel EF, Richard E, Moll van Charante EP. Perspectives of older people engaging in nurse-led cardiovascular prevention programmes: a qualitative study in primary care in the Netherlands. *The British journal of general practice : the journal of the Royal College of General Practitioners*. 2015;65(630):e41-8.

Lilja AM, Luo Y, Yu Q-s, Rojdnier J, Li Y, Marini AM, et al. Neurotrophic and neuroprotective actions of (-)- and (+)-pheneserine, candidate drugs for Alzheimer's disease. *PloS one*. 2013;8(1):e54887.

Lilja AM, Malmsten L, Rojdnier J, Voytenko L, Verkhatsky A, Ogren SO, et al. Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic alpha7 Nicotinic Receptor Drugs. *Neural plasticity*. 2015;2015:370432.

Lillekroken D, Hauge S, Slettebo A. The meaning of slow nursing in dementia care. *Dementia (London, England)*. 2017;16(7):930-47.

Lim HJ, Shim SB, Jee SW, Lee SH, Lim CJ, Hong JT, et al. Green tea catechin leads to global improvement among Alzheimer's disease-related phenotypes in NSE/hAPP-C105 Tg mice. *The Journal of nutritional biochemistry*. 2013;24(7):1302-13.

Lim S, Choi JG, Moon M, Kim HG, Lee W, Bak H-R, et al. An Optimized Combination of Ginger and Peony Root Effectively Inhibits Amyloid-beta Accumulation and Amyloid-beta-

Mediated Pathology in AbetaPP/PS1 Double-Transgenic Mice. *Journal of Alzheimer's disease* : JAD. 2016;50(1):189-200.

Lim SH, Lee J. Hot water extract of wheat bran attenuates white matter injury in a rat model of vascular dementia. *Preventive nutrition and food science*. 2014;19(3):145-55.

Lim SH, Lee J. Protection of the brain through supplementation with larch arabinogalactan in a rat model of vascular dementia. *Nutrition research and practice*. 2017;11(5):381-7.

Liman J, Deeg S, Voigt A, VoSsfeldt H, Dohm CP, Karch A, et al. CDK5 protects from caspase-induced Ataxin-3 cleavage and neurodegeneration. *Journal of neurochemistry*. 2014;129(6):1013-23.

Limb M. Public health campaigns should focus globally on preventing dementia, report says. *BMJ (Clinical research ed)*. 2014;349:g5698.

Lin A-L, Butterfield DA, Richardson A. mTOR: Alzheimer's disease prevention for APOE4 carriers. *Oncotarget*. 2016;7(29):44873-4.

Lin A-L, Jahrling JB, Zhang W, DeRosa N, Bakshi V, Romero P, et al. Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2017;37(1):217-26.

Lin A-L, Zheng W, Halloran JJ, Burbank RR, Hussong SA, Hart MJ, et al. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2013;33(9):1412-21.

Lin B, Hasegawa Y, Takane K, Koibuchi N, Cao C, Kim-Mitsuyama S. High-Fat-Diet Intake Enhances Cerebral Amyloid Angiopathy and Cognitive Impairment in a Mouse Model of Alzheimer's Disease, Independently of Metabolic Disorders. *Journal of the American Heart Association*. 2016;5(6).

Lin C-H, Chen P-K, Chang Y-C, Chuo L-J, Chen Y-S, Tsai GE, et al. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. *Biological psychiatry*. 2014;75(9):678-85.

Lin C-H, Hsieh Y-S, Wu Y-R, Hsu C-J, Chen H-C, Huang W-H, et al. Identifying GSK-3beta kinase inhibitors of Alzheimer's disease: Virtual screening, enzyme, and cell assays. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*. 2016;89:11-9.

Lin C-L, Cheng Y-S, Li H-H, Chiu P-Y, Chang Y-T, Ho Y-J, et al. Amyloid-beta suppresses AMP-activated protein kinase (AMPK) signaling and contributes to alpha-synuclein-induced cytotoxicity. *Experimental neurology*. 2016;275 Pt 1:84-98.

Lin C-L, Wang S-E, Hsu C-H, Sheu S-J, Wu C-H. Oral treatment with herbal formula B307 alleviates cardiac failure in aging R6/2 mice with Huntington's disease via suppressing oxidative stress, inflammation, and apoptosis. *Clinical interventions in aging*. 2015;10:1173-87.

Lin C-P, Chu C-P, Liu H-C. Bupropion improved apathy in behavioral variant frontotemporal dementia: a case report. *Neurocase*. 2016;22(5):466-8.

Lin F, Jia J, Qin W. Enhancement of beta-amyloid oligomer accumulation after intracerebroventricular injection of streptozotocin, which involves central insulin signaling in a transgenic mouse model. *Neuroreport*. 2014;25(16):1289-95.

Lin F, Ren P, Lo RY, Chapman BP, Jacobs A, Baran TM, et al. Insula and Inferior Frontal Gyrus' Activities Protect Memory Performance Against Alzheimer's Disease Pathology in Old Age. *Journal of Alzheimer's disease : JAD*. 2017;55(2):669-78.

Lin J, Dong B, Vellas B. Editorial: Preventive Trials for Alzheimer's Diseases: The Multi-domain and the Targeted Therapies Approaches Will Have to Be Associated. *The journal of nutrition, health & aging*. 2016;20(5):494-5.

Lin J, Huang L, Yu J, Xiang S, Wang J, Zhang J, et al. Fucoxanthin, a Marine Carotenoid, Reverses Scopolamine-Induced Cognitive Impairments in Mice and Inhibits Acetylcholinesterase in Vitro. *Marine drugs*. 2016;14(4).

Lin JS, O'Connor E, Rossom RC, Perdue LA, Eckstrom E. Screening for cognitive impairment in older adults: A systematic review for the U.S. Preventive Services Task Force. *Annals of internal medicine*. 2013;159(9):601-12.

Lin K-H, Chiu C-H, Kuo W-W, Ju D-T, Shen C-Y, Chen R-J, et al. The preventive effects of edible folic acid on cardiomyocyte apoptosis and survival in early onset triple-transgenic Alzheimer's disease model mice. *Environmental toxicology*. 2017.

Lin L, Jin Z, Tan H, Xu Q, Peng T, Li H. Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin. *Brain research*. 2016;1643:103-12.

Lin M-Y, Cheng X-T, Tammineni P, Xie Y, Zhou B, Cai Q, et al. Releasing Syntaphilin Removes Stressed Mitochondria from Axons Independent of Mitophagy under Pathophysiological Conditions. *Neuron*. 2017;94(3):595-610.e6.

Lin P-J, Yang Z, Fillit HM, Cohen JT, Neumann PJ. Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer's disease. *Health affairs (Project Hope)*. 2014;33(4):547-54.

Lin R, Wu Y, Tao J, Chen B, Chen J, Zhao C, et al. Electroacupuncture improves cognitive function through Rho GTPases and enhances dendritic spine plasticity in rats with cerebral ischemia-reperfusion. *Molecular medicine reports*. 2016;13(3):2655-60.

Lin R, Yu K, Li X, Tao J, Lin Y, Zhao C, et al. Electroacupuncture ameliorates post-stroke learning and memory through minimizing ultrastructural brain damage and inhibiting the expression of MMP-2 and MMP-9 in cerebral ischemia-reperfusion injured rats. *Molecular medicine reports*. 2016;14(1):225-33.

Lin T-W, Chang C-F, Chang Y-J, Liao Y-H, Yu H-M, Chen Y-R. Alzheimer's amyloid-beta A2T variant and its N-terminal peptides inhibit amyloid-beta fibrillization and rescue the induced cytotoxicity. *PloS one*. 2017;12(3):e0174561.

Lin W-T, Chen R-C, Lu W-W, Liu S-H, Yang F-Y. Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model. *Scientific reports*. 2015;5:9671.

Lin X, Bai G, Lin L, Wu H, Cai J, Ugen KE, et al. Vaccination induced changes in pro-inflammatory cytokine levels as an early putative biomarker for cognitive improvement in a transgenic mouse model for Alzheimer disease. *Human vaccines & immunotherapeutics*. 2014;10(7):2024-31.

Lin Y, Lu X, Dong J, He X, Yan T, Liang H, et al. Involuntary, Forced and Voluntary Exercises Equally Attenuate Neurocognitive Deficits in Vascular Dementia by the BDNF-pCREB Mediated Pathway. *Neurochemical research*. 2015;40(9):1839-48.

Lin Y-S, Cheng T-H, Chang C-P, Chen H-M, Chern Y. Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease. *Biochimica et biophysica acta*. 2013;1832(6):742-53.

Lin Y-T, Wu P-H, Chen C-S, Yang Y-H, Yang Y-H. Association between acetylcholinesterase inhibitors and risk of stroke in patients with dementia. *Scientific reports*. 2016;6:29266.

Linares GR, Chiu C-T, Scheuing L, Leng Y, Liao H-M, Maric D, et al. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease. *Experimental neurology*. 2016;281:81-92.

Lipinski B, Pretorius E. The role of iron-induced fibrin in the pathogenesis of Alzheimer's disease and the protective role of magnesium. *Frontiers in human neuroscience*. 2013;7:735.

Lisi L, Pizzoferrato M, Miscioscia FT, Topai A, Navarra P. Interactions between integrase inhibitors and human arginase 1. *Journal of neurochemistry*. 2017;142(1):153-9.

Lista S, Dubois B, Hampel H. Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies. *The journal of nutrition, health & aging*. 2015;19(2):154-63.

Liu A, Zhao X, Li H, Liu Z, Liu B, Mao X, et al. 5-Hydroxymethylfurfural, an antioxidant agent from *Alpinia oxyphylla* Miq. improves cognitive impairment in Abeta 1-42 mouse model of Alzheimer's disease. *International immunopharmacology*. 2014;23(2):719-25.

Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, et al. MER5101, a novel Abeta1-15:DT conjugate vaccine, generates a robust anti-Abeta antibody response and attenuates Abeta pathology and cognitive deficits in APP^{swe}/PS1^{DeltaE9} transgenic mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(16):7027-37.

Liu C, Yin H, Gao J, Xu X, Zhang T, Yang Z. Leonurine ameliorates cognitive dysfunction via antagonizing excitotoxic glutamate insults and inhibiting autophagy. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2016;23(13):1638-46.

Liu D, Pitta M, Jiang H, Lee J-H, Zhang G, Chen X, et al. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. *Neurobiology of aging*. 2013;34(6):1564-80.

Liu D, Tang H, Li X-Y, Deng M-F, Wei N, Wang X, et al. Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2017;25(3):752-64.

Liu D-s, Pan X-d, Zhang J, Shen H, Collins NC, Cole AM, et al. APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. *Molecular neurodegeneration*. 2015;10:7.

Liu DZ, Waldau B, Ander BP, Zhan X, Stamova B, Jickling GC, et al. Inhibition of Src family kinases improves cognitive function after intraventricular hemorrhage or intraventricular thrombin. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2017;37(7):2359-67.

Liu EY, Russ J, Wu K, Neal D, Suh E, McNally AG, et al. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. *Acta neuropathologica*. 2014;128(4):525-41.

Liu G-P, Wei W, Zhou X, Shi H-R, Liu X-H, Chai G-S, et al. Silencing PP2A inhibitor by lenti-shRNA interference ameliorates neuropathologies and memory deficits in tg2576 mice. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2013;21(12):2247-57.

Liu H, Deng Y, Gao J, Liu Y, Li W, Shi J, et al. Sodium Hydrosulfide Attenuates Beta-Amyloid-Induced Cognitive Deficits and Neuroinflammation via Modulation of MAPK/NF-kappaB Pathway in Rats. *Current Alzheimer research*. 2015;12(7):673-83.

Liu H, Li W, Zhao S, Zhang X, Zhang M, Xiao Y, et al. Folic acid attenuates the effects of amyloid beta oligomers on DNA methylation in neuronal cells. *European journal of nutrition*. 2016;55(5):1849-62.

Liu H, Sun X, Zou W, Leng M, Zhang B, Kang X, et al. Scalp acupuncture attenuates neurological deficits in a rat model of hemorrhagic stroke. *Complementary therapies in medicine*. 2017;32:85-90.

Liu H, Tian T, Qin S, Li W, Zhang X, Wang X, et al. Folic acid deficiency enhances abeta accumulation in APP/PS1 mice brain and decreases amyloid-associated miRNAs expression. *The Journal of nutritional biochemistry*. 2015;26(12):1502-8.

Liu H, Xue X, Shi H, Qi L, Gong D. Osthole Upregulates BDNF to Enhance Adult Hippocampal Neurogenesis in APP/PS1 Transgenic Mice. *Biological & pharmaceutical bulletin*. 2015;38(10):1439-49.

Liu H, Zhao M, Yang S, Gong D-R, Chen D-Z, Du D-Y. (2R,3S)-Pinobanksin-3-cinnamate improves cognition and reduces oxidative stress in rats with vascular dementia. *Journal of natural medicines*. 2015;69(3):358-65.

Liu H-l, Zhao G, Zhang H, Shi L-d. Long-term treadmill exercise inhibits the progression of Alzheimer's disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice. *Behavioural brain research*. 2013;256:261-72.

Liu H-R, Zhou C, Fan H-Q, Tang J-J, Liu L-B, Gao X-H, et al. Novel Potent and Selective Acetylcholinesterase Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease: Synthesis, Pharmacological Evaluation, and Molecular Modeling of Amino-Alkyl-Substituted Fluoro-Chalcones Derivatives. *Chemical biology & drug design*. 2015;86(4):517-22.

Liu J, Hu G, Xu R, Qiao Y, Wu H-P, Ding X, et al. Rhein lysinate decreases the generation of beta-amyloid in the brain tissues of Alzheimer's disease model mice by inhibiting inflammatory response and oxidative stress. *Journal of Asian natural products research*. 2013;15(7):756-63.

Liu J, Liu S, Matsumoto Y, Murakami S, Sugakawa Y, Kami A, et al. Angiotensin type 1a receptor deficiency decreases amyloid beta-protein generation and ameliorates brain amyloid pathology. *Scientific reports*. 2015;5:12059.

Liu J, Ma Y, Tian S, Zhang L, Zhao M, Zhang Y, et al. T cells promote the regeneration of neural precursor cells in the hippocampus of Alzheimer's disease mice. *Neural regeneration research*. 2014;9(16):1541-7.

Liu J, Pendergraff H, Narayanannair KJ, Lackey JG, Kuchimanchi S, Rajeev KG, et al. RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression. *Nucleic acids research*. 2013;41(18):8788-801.

Liu J, Su H, Qu Q-M. Carnosic Acid Prevents Beta-Amyloid-Induced Injury in Human Neuroblastoma SH-SY5Y Cells via the Induction of Autophagy. *Neurochemical research*. 2016;41(9):2311-23.

Liu J, Sun J, Wang F, Yu X, Ling Z, Li H, et al. Neuroprotective Effects of Clostridium butyricum against Vascular Dementia in Mice via Metabolic Butyrate. *BioMed research international*. 2015;2015:412946.

Liu J, Wang J, Tang Z, Hu B, Wu F-X, Pan Y. Improving Alzheimer's Disease Classification by Combining Multiple Measures. *IEEE/ACM transactions on computational biology and bioinformatics*. 2017.

Liu J, Yan X, Li L, Li Y, Zhou L, Zhang X, et al. Ginsenoside Rd Improves Learning and Memory Ability in APP Transgenic Mice. *Journal of molecular neuroscience : MN*. 2015;57(4):522-8.

Liu J-M, Wu P-F, Rao J, Zhou J, Shen Z-C, Luo H, et al. ST09, a Novel Thioester Derivative of Tacrine, Alleviates Cognitive Deficits and Enhances Glucose Metabolism in Vascular Dementia Rats. *CNS neuroscience & therapeutics*. 2016;22(3):220-9.

Liu J-x, Zhu M-y, Feng C-y, Ding H-b, Zhan Y, Zhao Z, et al. Bamboo leaf extract improves spatial learning ability in a rat model with senile dementia. *Journal of Zhejiang University Science B*. 2015;16(7):593-601.

Liu JYW, Lai C. Implementation of observational pain management protocol to improve pain management for long-term institutionalized older care residents with dementia: study protocol for a cluster-randomized controlled trial. *Trials*. 2014;15:78.

Liu K, Chojnacki JE, Wade EE, Saathoff JM, Lesnefsky EJ, Chen Q, et al. Bivalent Compound 17MN Exerts Neuroprotection through Interaction at Multiple Sites in a Cellular Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2015;47(4):1021-33.

Liu L, Fu L, Zhang X, Zhang J, Zhang X, Xu B, et al. Combination of dynamic (11)C-PIB PET and structural MRI improves diagnosis of Alzheimer's disease. *Psychiatry research*. 2015;233(2):131-40.

Liu M, Guo H, Li C, Wang D, Wu J, Wang C, et al. Cognitive improvement of compound danshen in an Aβ₂₅₋₃₅ peptide-induced rat model of Alzheimer's disease. *BMC complementary and alternative medicine*. 2015;15:382.

Liu M, Huo YR, Wang J, Liu S, Liu S, Wang C, et al. Polymorphisms of the neurotrophic factor-3 (NTF-3) in Alzheimer's disease: rs6332 associated with onset time and rs6489630 T allele exhibited a protective role. *Journal of neurogenetics*. 2015;29(4):183-7.

Liu MY, Wang S, Yao WF, Zhang ZJ, Zhong X, Sha L, et al. Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice. *Neuroscience*. 2014;273:141-51.

Liu P, Kong M, Liu S, Chen G, Wang P. Effect of reinforcing kidney-essence, removing phlegm, and promoting mental therapy on treating Alzheimer's disease. *Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan*. 2013;33(4):449-54.

Liu P, Zou L, Jiao Q, Chi T, Ji X, Qi Y, et al. Xanthoceraside attenuates learning and memory deficits via improving insulin signaling in STZ-induced AD rats. *Neuroscience letters*. 2013;543:115-20.

Liu Q, Wang X-J, Zhang Z-C, Xue R, Li P, Li B. Neuroprotection against vascular dementia after acupuncture combined with donepezil hydrochloride: P300 event related potential. *Neural regeneration research*. 2016;11(3):460-4.

Liu QF, Jeong H, Lee JH, Hong YK, Oh Y, Kim Y-M, et al. Coriandrum sativum Suppresses Abeta42-Induced ROS Increases, Glial Cell Proliferation, and ERK Activation. *The American journal of Chinese medicine*. 2016;44(7):1325-47.

Liu QF, Lee JH, Kim Y-M, Lee S, Hong YK, Hwang S, et al. In Vivo Screening of Traditional Medicinal Plants for Neuroprotective Activity against Abeta42 Cytotoxicity by Using Drosophila Models of Alzheimer's Disease. *Biological & pharmaceutical bulletin*. 2015;38(12):1891-901.

Liu R, Li J-z, Song J-k, Zhou D, Huang C, Bai X-y, et al. Pinocembrin improves cognition and protects the neurovascular unit in Alzheimer related deficits. *Neurobiology of aging*. 2014;35(6):1275-85.

Liu R, Liu Y-C, Meng J, Zhu H, Zhang X. A microfluidics-based mobility shift assay to identify new inhibitors of beta-secretase for Alzheimer's disease. *Analytical and bioanalytical chemistry*. 2017;409(28):6635-42.

Liu R-X, Huang C, Bennett DA, Li H, Wang R. The characteristics of astrocyte on Abeta clearance altered in Alzheimer's disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate. *American journal of translational research*. 2016;8(10):4082-94.

Liu S, Breitbart A, Sun Y, Mehta PD, Boutajangout A, Scholtzova H, et al. Blocking the apolipoprotein E/amyloid beta interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid beta and tau pathology. *Journal of neurochemistry*. 2014;128(4):577-91.

Liu S, Park S, Allington G, Prelli F, Sun Y, Marta-Ariza M, et al. Targeting Apolipoprotein E/Amyloid beta Binding by Peptoid CPO_Abeta17-21P Ameliorates Alzheimer's Disease Related Pathology and Cognitive Decline. *Scientific reports*. 2017;7(1):8009.

Liu S, Shang R, Shi L, Zhou R, He J, Wan DC-C. Design, synthesis, and evaluation of 7H-thiazolo- 3,2-b -1,2,4-triazin-7-one derivatives as dual binding site acetylcholinesterase inhibitors. *Chemical biology & drug design*. 2014;84(2):169-74.

Liu S, Tang S-Q, Cui H-J, Yin S, Yin M, Zhao H, et al. Dipotassium N-stearoyltyrosinate ameliorated pathological injuries intriple-transgenic mouse model of Alzheimer's disease. *Journal of pharmacological sciences*. 2016;132(1):92-9.

Liu S, Wu H, Xue G, Ma X, Wu J, Qin Y, et al. Metabolic alteration of neuroactive steroids and protective effect of progesterone in Alzheimer's disease-like rats. *Neural regeneration research*. 2013;8(30):2800-10.

Liu S-J, Yang C, Zhang Y, Su R-Y, Chen J-L, Jiao M-M, et al. Neuroprotective effect of beta-asarone against Alzheimer's disease: regulation of synaptic plasticity by increased expression of SYP and GluR1. *Drug design, development and therapy*. 2016;10:1461-9.

Liu T, Huang Y, Chen J, Chi H, Yu Z, Wang J, et al. Attenuated ability of BACE1 to cleave the amyloid precursor protein via silencing long noncoding RNA BACE1's expression. *Molecular medicine reports*. 2014;10(3):1275-81.

Liu T, Lee M, Ban J-J, Im W, Mook-Jung I, Kim M. Cytosolic Extract of Human Adipose Stem Cells Reverses the Amyloid Beta-Induced Mitochondrial Apoptosis via P53/Foxo3a Pathway. *PloS one*. 2017;12(1):e0168859.

Liu T, Xia Z, Zhang W-W, Xu J-r, Ge X-X, Li J, et al. Bis(9)-(-)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice. *Pharmacology, biochemistry, and behavior*. 2013;104:138-43.

Liu W, Lang M, Youdim MBH, Amit T, Sun Y, Zhang Z, et al. Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease. *Neuropharmacology*. 2016;109:376-85.

Liu W, Li G, Holscher C, Li L. Neuroprotective effects of geniposide on Alzheimer's disease pathology. *Reviews in the neurosciences*. 2015;26(4):371-83.

Liu W, Zhao J, Lu G. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease. *Biochemical and biophysical research communications*. 2016;478(2):852-7.

Liu X, Hao W, Qin Y, Decker Y, Wang X, Burkart M, et al. Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer's disease. *Brain, behavior, and immunity*. 2015;46:121-31.

Liu X, Wang C-E, Hong Y, Zhao T, Wang G, Gaertig MA, et al. N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy. *PLoS genetics*. 2016;12(5):e1006083.

Liu X, Zhou J, Abid MDN, Yan H, Huang H, Wan L, et al. Berberine attenuates axonal transport impairment and axonopathy induced by Calyculin A in N2a cells. *PloS one*. 2014;9(4):e93974.

Liu X, Zuo H, Wang D, Peng R, Song T, Wang S, et al. Improvement of spatial memory disorder and hippocampal damage by exposure to electromagnetic fields in an Alzheimer's disease rat model. *PloS one*. 2015;10(5):e0126963.

Liu X-H, Geng Z, Yan J, Li T, Chen Q, Zhang Q-Y, et al. Blocking GSK3 β -mediated dynamin1 phosphorylation enhances BDNF-dependent TrkB endocytosis and the protective effects of BDNF in neuronal and mouse models of Alzheimer's disease. *Neurobiology of disease*. 2015;74:377-91.

Liu Y, Deng Y, Liu H, Yin C, Li X, Gong Q. Hydrogen sulfide ameliorates learning memory impairment in APP/PS1 transgenic mice: A novel mechanism mediated by the activation of Nrf2. *Pharmacology, biochemistry, and behavior*. 2016;150-151:207-16.

Liu Y, Hettinger CL, Zhang D, Rezvani K, Wang X, Wang H. Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease. *Journal of neurochemistry*. 2014;129(3):539-47.

Liu Y, Jiang L, Li X. κ -carrageenan-derived pentasaccharide attenuates A β ₂₅₋₃₅-induced apoptosis in SH-SY5Y cells via suppression of the JNK signaling pathway. *Molecular medicine reports*. 2017;15(1):285-90.

Liu Y, Liu X, Hao W, Decker Y, Schomburg R, Fulop L, et al. IKK β deficiency in myeloid cells ameliorates Alzheimer's disease-related symptoms and pathology. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(39):12982-99.

Liu Y, Ni C, Li Z, Yang N, Zhou Y, Rong X, et al. Prophylactic Melatonin Attenuates Isoflurane-Induced Cognitive Impairment in Aged Rats through Hippocampal Melatonin Receptor 2 - cAMP Response Element Binding Signalling. *Basic & clinical pharmacology & toxicology*. 2017;120(3):219-26.

Liu Y, Pukala TL, Musgrave IF, Williams DM, Dehle FC, Carver JA. Gallic acid is the major component of grape seed extract that inhibits amyloid fibril formation. *Bioorganic & medicinal chemistry letters*. 2013;23(23):6336-40.

Liu Y, Wang X-J, Wang N, Cui C-L, Wu L-Z. Electroacupuncture Ameliorates Propofol-Induced Cognitive Impairment via an Opioid Receptor-Independent Mechanism. *The American journal of Chinese medicine*. 2016;44(4):705-19.

Liu Y, Xu L-P, Dai W, Dong H, Wen Y, Zhang X. Graphene quantum dots for the inhibition of beta amyloid aggregation. *Nanoscale*. 2015;7(45):19060-5.

Liu Y, Xu Y-F, Zhang L, Huang L, Yu P, Zhu H, et al. Effective expression of Drebrin in hippocampus improves cognitive function and alleviates lesions of Alzheimer's disease in APP (swe)/PS1 (DeltaE9) mice. *CNS neuroscience & therapeutics*. 2017;23(7):590-604.

Liu Y, Yang X, Lei Q, Li Z, Hu J, Wen X, et al. PEG-PEI/siROCK2 Protects Against Abeta42-Induced Neurotoxicity in Primary Neuron Cells for Alzheimer Disease. *Cellular and molecular neurobiology*. 2015;35(6):841-8.

Liu Y-L, Chen W-T, Lin Y-Y, Lu P-H, Hsieh S-L, Cheng IH-J. Amelioration of amyloid-beta-induced deficits by DcR3 in an Alzheimer's disease model. *Molecular neurodegeneration*. 2017;12(1):30.

Liu Y-W, He Y-H, Zhang Y-X, Cai W-W, Yang L-Q, Xu L-Y, et al. Absence of A673T variant in APP gene indicates an alternative protective mechanism contributing to longevity in Chinese individuals. *Neurobiology of aging*. 2014;35(4):935.e11-2.

Liu Z, Gao X, Kang T, Jiang M, Miao D, Gu G, et al. B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. *Bioconjugate chemistry*. 2013;24(6):997-1007.

Liu Z, Wang Q, Cui J, Wang L, Xiong L, Wang W, et al. Systemic Screening of Strains of the Lion's Mane Medicinal Mushroom *Herichium erinaceus* (Higher Basidiomycetes) and Its Protective Effects on Abeta-Triggered Neurotoxicity in PC12 Cells. *International journal of medicinal mushrooms*. 2015;17(3):219-29.

Liu Z, Zhao X, Liu B, Liu A-j, Li H, Mao X, et al. Jujuboside A, a neuroprotective agent from semen *Ziziphi Spinosae* ameliorates behavioral disorders of the dementia mouse model induced by Abeta 1-42. *European journal of pharmacology*. 2014;738:206-13.

Liu Z-J, Li Z-H, Liu L, Tang W-X, Wang Y, Dong M-R, et al. Curcumin Attenuates Beta-Amyloid-Induced Neuroinflammation via Activation of Peroxisome Proliferator-Activated Receptor-Gamma Function in a Rat Model of Alzheimer's Disease. *Frontiers in pharmacology*. 2016;7:261.

Livingston G, Lewis-Holmes E, Pitfield C, Manela M, Chan D, Constant E, et al. Improving the end-of-life for people with dementia living in a care home: an intervention study. *International psychogeriatrics*. 2013;25(11):1849-58.

Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. *Lancet* (London, England). 2017.

Llamas-Velasco S, Contador I, Villarejo-Galende A, Lora-Pablos D, Bermejo-Pareja F. Physical Activity as Protective Factor against Dementia: A Prospective Population-Based Study (NEDICES). *Journal of the International Neuropsychological Society : JINS*. 2015;21(10):861-7.

Llewelyn D. Writing can seriously improve your health. *Nursing older people*. 2017;29(3):15.

Llorens-Martin M, Fuster-Matanzo A, Teixeira CM, Jurado-Arjona J, Ulloa F, Defelipe J, et al. Alzheimer disease-like cellular phenotype of newborn granule neurons can be reversed in GSK-3beta-overexpressing mice. *Molecular psychiatry*. 2013;18(4):395.

Llorens-Martin M, Fuster-Matanzo A, Teixeira CM, Jurado-Arjona J, Ulloa F, Defelipe J, et al. GSK-3beta overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo. *Molecular psychiatry*. 2013;18(4):451-60.

Lloyd-Williams M, Dening KH, Crowther J. Dying with dementia-how can we improve the care and support of patients and their families. *Annals of palliative medicine*. 2017;6(4):306-9.

Lo AC, Callaerts-Vegh Z, Nunes AF, Rodrigues CMP, D'Hooze R. Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice. *Neurobiology of disease*. 2013;50:21-9.

Lo AC, Teseur I, Scopes DIC, Nerou E, Callaerts-Vegh Z, Vermaercke B, et al. Dose-dependent improvements in learning and memory deficits in APPPS1-21 transgenic mice treated with the orally active Abeta toxicity inhibitor SEN1500. *Neuropharmacology*. 2013;75:458-66.

Lobo RA, Davis SR, De Villiers TJ, Gompel A, Henderson VW, Hodis HN, et al. Prevention of diseases after menopause. *Climacteric : the journal of the International Menopause Society*. 2014;17(5):540-56.

Loewy R, Fisher M, Schlosser DA, Biagianti B, Stuart B, Mathalon DH, et al. Intensive Auditory Cognitive Training Improves Verbal Memory in Adolescents and Young Adults at Clinical High Risk for Psychosis. *Schizophrenia bulletin*. 2016;42 Suppl 1:S118-26.

Lohou E, Sasaki NA, Boullier A, Sonnet P. Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease. *European journal of medicinal chemistry*. 2016;122:702-22.

Loizzo S, Rimondini R, Travaglione S, Fabbri A, Guidotti M, Ferri A, et al. CNF1 increases brain energy level, counteracts neuroinflammatory markers and rescues cognitive deficits in a murine model of Alzheimer's disease. *PloS one*. 2013;8(5):e65898.

Lokon E, Li Y, Parajuli J. Using art in an intergenerational program to improve students' attitudes toward people with dementia. *Gerontology & geriatrics education*. 2017;38(4):407-24.

Lomarat P, Chancharunee S, Anantachoke N, Kitphati W, Sripha K, Bunyapraphatsara N. Bioactivity-guided Separation of the Active Compounds in *Acacia pennata* Responsible for the Prevention of Alzheimer's Disease. *Natural product communications*. 2015;10(8):1431-4.

Long Z, Zeng Q, Wang K, Sharma A, He G. Gender difference in valproic acid-induced neuroprotective effects on APP/PS1 double transgenic mice modeling Alzheimer's disease. *Acta biochimica et biophysica Sinica*. 2016;48(10):930-8.

Long Z, Zheng M, Zhao L, Xie P, Song C, Chu Y, et al. Valproic acid attenuates neuronal loss in the brain of APP/PS1 double transgenic Alzheimer's disease mice model. *Current Alzheimer research*. 2013;10(3):261-9.

Longin C, Roche NC, Bregigeton M, Sagui E, Oliver M, Brosset C. Reversible dementia: don't forget neurosarcoidosis! *Revue neurologique*. 2013;169(12):1013-5.

Long-Smith CM, Manning S, McClean PL, Coakley MF, O'Halloran DJ, Holscher C, et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease. *Neuromolecular medicine*. 2013;15(1):102-14.

Lopes C, Ribeiro M, Duarte AI, Humbert S, Saudou F, Pereira de Almeida L, et al. IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice. *Molecular neurobiology*. 2014;49(3):1126-42.

Lopez A, Lee SE, Wojta K, Ramos EM, Klein E, Chen J, et al. A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction. *Brain : a journal of neurology*. 2017;140(4):1128-46.

Lopez Mongil R, Lopez Trigo JA. Prognosis and progression of cognitive impairment. Preventive measures. *Revista espanola de geriatria y gerontologia*. 2016;51 Suppl 1:34-43.

Lopez Zunini RA, Knoefel F, Lord C, Breau M, Sweet L, Goubran R, et al. P300 amplitude alterations during inhibitory control in persons with Mild Cognitive Impairment. *Brain research*. 2016;1646:241-8.

Lopez-Iglesias B, Perez C, Morales-Garcia JA, Alonso-Gil S, Perez-Castillo A, Romero A, et al. New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease. *Journal of medicinal chemistry*. 2014;57(9):3773-85.

Lou G, Zhang Q, Xiao F, Xiang Q, Su Z, Huang Y. Intranasal TAT-haFGF Improves Cognition and Amyloid-beta Pathology in an AbetaPP/PS1 Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;51(4):985-90.

Lou J, Teng Z, Zhang L, Yang J, Ma L, Wang F, et al. beta-Caryophyllene/Hydroxypropyl-beta-Cyclodextrin Inclusion Complex Improves Cognitive Deficits in Rats with Vascular Dementia through the Cannabinoid Receptor Type 2 -Mediated Pathway. *Frontiers in pharmacology*. 2017;8:2.

Loughlin D, Brown M. Improving surgical outcomes for people with dementia. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*. 2015;29(38):50-8.

Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, et al. TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's beta-amyloid oligomers in mice and monkeys. *Cell metabolism*. 2013;18(6):831-43.

Lovden M, Xu W, Wang H-X. Lifestyle change and the prevention of cognitive decline and dementia: what is the evidence? *Current opinion in psychiatry*. 2013;26(3):239-43.

Lowe DA, Balsis S, Bengtson JF, Doody RS. Adding delayed recall to the ADAS-cog improves measurement precision in mild Alzheimer's disease: Implications for predicting instrumental activities of daily living. *Psychological assessment*. 2015;27(4):1234-40.

Lowin T, Bose T, Busse S, Busse M, Reinhold D, Schraven B, et al. Immunomodulation by memantine in therapy of Alzheimer's disease is mediated through inhibition of Kv1.3 channels and T cell responsiveness. *Oncotarget*. 2016;7(33):53797-807.

Lu B, Al-Ramahi I, Valencia A, Wang Q, Berenshteyn F, Yang H, et al. Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance. *Nature neuroscience*. 2013;16(5):562-70.

Lu C, Zhou Q, Yan J, Du Z, Huang L, Li X. A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease. *European journal of medicinal chemistry*. 2013;62:745-53.

Lu D-F, Hart LK, Lutgendorf SK, Oh H, Schilling M. Slowing progression of early stages of AD with alternative therapies: a feasibility study. *Geriatric nursing (New York, NY)*. 2013;34(6):457-64.

Lu J, Maezawa I, Weerasekara S, Erenler R, Nguyen TDT, Nguyen J, et al. Syntheses, neural protective activities, and inhibition of glycogen synthase kinase-3beta of substituted quinolines. *Bioorganic & medicinal chemistry letters*. 2014;24(15):3392-7.

Lu KP, Kondo A, Albayram O, Herbert MK, Liu H, Zhou XZ. Potential of the Antibody Against cis-Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury. *JAMA neurology*. 2016;73(11):1356-62.

Lu N, Yang Q, Li J, Tian R, Peng Y-Y. Inhibitory effect of human serum albumin on Cu-induced Abeta(40) aggregation and toxicity. *European journal of pharmacology*. 2015;767:160-4.

Lu X-H, Mattis VB, Wang N, Al-Ramahi I, van den Berg N, Fratantoni SA, et al. Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease. *Science translational medicine*. 2014;6(268):268ra178.

Lu Y, Dong Y, Tucker D, Wang R, Ahmed ME, Brann D, et al. Treadmill Exercise Exerts Neuroprotection and Regulates Microglial Polarization and Oxidative Stress in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;56(4):1469-84.

Lu Y-Q, Luo Y, He Z-F, Chen J, Yan B-L, Wang Y, et al. Hydroxysafflor yellow A ameliorates homocysteine-induced Alzheimer-like pathologic dysfunction and memory/synaptic disorder. *Rejuvenation research*. 2013;16(6):446-52.

Lu Z, Marks E, Chen J, Moline J, Barrows L, Raisbeck M, et al. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model. *Neurobiology of disease*. 2014;71:34-42.

Luccarini I, Grossi C, Rigacci S, Coppi E, Pugliese AM, Pantano D, et al. Oleuropein aglycone protects against pyroglutamylated-3 amyloid-SS toxicity: biochemical, epigenetic and functional correlates. *Neurobiology of aging*. 2015;36(2):648-63.

Luchtman DW, Song C. Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. *Neuropharmacology*. 2013;64:550-65.

Luck T, Riedel-Heller SG. Prevention of Alzheimer's dementia in Germany : A projection of the possible potential of reducing selected risk factors. *Der Nervenarzt*. 2016;87(11):1194-200.

Lukas A, Barber JB, Johnson P, Gibson SJ. Observer-rated pain assessment instruments improve both the detection of pain and the evaluation of pain intensity in people with dementia. *European journal of pain (London, England)*. 2013;17(10):1558-68.

Luo G, Liu M, He J, Guo H, Xue M, Wang X, et al. Quetiapine attenuates recognition memory impairment and hippocampal oxidative stress in a transgenic mouse model of Alzheimer's disease. *Neuroreport*. 2014;25(9):647-50.

Luo H, Li Y, Guo J, Liu Z, Zhang Z, Wang Y, et al. Tetrahydroxy stilbene glucoside improved the behavioral disorders of APP695V717I transgenic mice by inhibiting the expression of

Beclin-1 and LC3-II. *Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.* 2015;35(3):295-300.

Luo H-B, Xia Y-Y, Shu X-J, Liu Z-C, Feng Y, Liu X-H, et al. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. *Proceedings of the National Academy of Sciences of the United States of America.* 2014;111(46):16586-91.

Luo J, Lee SH, VandeVrede L, Qin Z, Piyankarage S, Tavassoli E, et al. Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia. *BMC neuroscience.* 2015;16:67.

Luo J, Warmlander SKTS, Graslund A, Abrahams JP. Human lysozyme inhibits the in vitro aggregation of Aβ peptides, which in vivo are associated with Alzheimer's disease. *Chemical communications (Cambridge, England).* 2013;49(58):6507-9.

Luo J, Warmlander SKTS, Graslund A, Abrahams JP. Non-chaperone proteins can inhibit aggregation and cytotoxicity of Alzheimer amyloid β peptide. *The Journal of biological chemistry.* 2014;289(40):27766-75.

Luo L, Li Y, Qiang X, Cao Z, Xu R, Yang X, et al. Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease. *Bioorganic & medicinal chemistry.* 2017;25(6):1997-2009.

Luo W, Liu W, Hu X, Hanna M, Caravaca A, Paul SM. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. *Scientific reports.* 2015;5:11161.

Luo X-T, Wang C-M, Liu Y, Huang Z-G. New multifunctional melatonin-derived benzylpyridinium bromides with potent cholinergic, antioxidant, and neuroprotective properties as innovative drugs for Alzheimer's disease. *European journal of medicinal chemistry.* 2015;103:302-11.

Luo Z, Liang L, Sheng J, Pang Y, Li J, Huang L, et al. Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease. *Bioorganic & medicinal chemistry.* 2014;22(4):1355-61.

Lust B, Flynn S, Cohen Sherman J, Gair J, Henderson CR, Jr., Cordella C, et al. Reversing Ribot: does regression hold in language of prodromal Alzheimer's disease? *Brain and language.* 2015;143:1-10.

Lutzenberger M, Burwinkel M, Riemer C, Bode V, Baier M. Ablation of CCAAT/Enhancer-Binding Protein Delta (C/EBPD): Increased Plaque Burden in a Murine Alzheimer's Disease Model. *PloS one.* 2015;10(7):e0134228.

Luxford K, Axam A, Hasnip F, Dobrohotoff J, Strudwick M, Reeve R, et al. Improving clinician-carer communication for safer hospital care: a study of the 'TOP 5' strategy in patients with dementia. *International journal for quality in health care : journal of the International Society for Quality in Health Care*. 2015;27(3):175-82.

Lv C, Liu X, Liu H, Chen T, Zhang W. Geniposide attenuates mitochondrial dysfunction and memory deficits in APP/PS1 transgenic mice. *Current Alzheimer research*. 2014;11(6):580-7.

Lv C, Wang L, Liu X, Yan S, Yan SS, Wang Y, et al. Multi-faced neuroprotective effects of geniposide depending on the RAGE-mediated signaling in an Alzheimer mouse model. *Neuropharmacology*. 2015;89:175-84.

Lv F, Yang X, Cui C, Su C. Exogenous expression of Drp1 plays neuroprotective roles in the Alzheimer's disease in the Abeta42 transgenic *Drosophila* model. *PloS one*. 2017;12(5):e0176183.

Lv Y-L, Wu Z-Z, Chen L-X, Wu B-X, Chen L-L, Qin G-C, et al. Neuroprotective effects of tetrandrine against vascular dementia. *Neural regeneration research*. 2016;11(3):454-9.

Ly PTT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, et al. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. *The Journal of clinical investigation*. 2013;123(1):224-35.

Lyons G, Arthur-Kelly M, Eidels A, Mavratzakis A. Deep Assessment: A Novel Framework for Improving the Care of People with Very Advanced Alzheimer's Disease. *BioMed research international*. 2015;2015:749451.

Ma B, Meng X, Wang J, Sun J, Ren X, Qin M, et al. Notoginsenoside R1 attenuates amyloid-beta-induced damage in neurons by inhibiting reactive oxygen species and modulating MAPK activation. *International immunopharmacology*. 2014;22(1):151-9.

Ma D, Stokes K, Mahngar K, Domazet-Damjanov D, Sikorska M, Pandey S. Inhibition of stress induced premature senescence in presenilin-1 mutated cells with water soluble Coenzyme Q10. *Mitochondrion*. 2014;17:106-15.

Ma DY, Wong CHY, Leung GTY, Fung AWT, Chan WC, Lam LCW. Physical Exercise Helped to Maintain and Restore Functioning in Chinese Older Adults With Mild Cognitive Impairment: A 5-Year Prospective Study of the Hong Kong Memory and Ageing Prospective Study (HK-MAPS). *Journal of the American Medical Directors Association*. 2017;18(4):306-11.

Ma H, Yao L, Pang L, Li X, Yao Q. Tetrandrine ameliorates sevoflurane-induced cognitive impairment via the suppression of inflammation and apoptosis in aged rats. *Molecular medicine reports*. 2016;13(6):4814-20.

Ma J, Gao Y, Jiang L, Chao F-L, Huang W, Zhou C-N, et al. Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APP^{sw}/PSEN1^{dE9} double transgenic Alzheimer's disease mice. *Oncotarget*. 2017;8(17):27676-92.

Ma J, Zhang J, Hou WW, Wu XH, Liao RJ, Chen Y, et al. Early treatment of minocycline alleviates white matter and cognitive impairments after chronic cerebral hypoperfusion. *Scientific reports*. 2015;5:12079.

Ma K, McLaurin J. alpha-Melanocyte stimulating hormone prevents GABAergic neuronal loss and improves cognitive function in Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(20):6736-45.

Ma Q, Ruan Y-y, Xu H, Shi X-m, Wang Z-x, Hu Y-l. Safflower yellow reduces lipid peroxidation, neuropathology, tau phosphorylation and ameliorates amyloid beta-induced impairment of learning and memory in rats. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2015;76:153-64.

Ma S, Zhong D, Ma P, Li G, Hua W, Sun Y, et al. Exogenous Hydrogen Sulfide Ameliorates Diabetes-Associated Cognitive Decline by Regulating the Mitochondria-Mediated Apoptotic Pathway and IL-23/IL-17 Expression in db/db Mice. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2017;41(5):1838-50.

Ma T, Chen Y, Vingtdeux V, Zhao H, Viollet B, Marambaud P, et al. Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid beta. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(36):12230-8.

Ma T, Gong K, Ao Q, Yan Y, Song B, Huang H, et al. Intracerebral transplantation of adipose-derived mesenchymal stem cells alternatively activates microglia and ameliorates neuropathological deficits in Alzheimer's disease mice. *Cell transplantation*. 2013;22 Suppl 1:S113-26.

Ma T, Trinh MA, Wexler AJ, Bourbon C, Gatti E, Pierre P, et al. Suppression of eIF2alpha kinases alleviates Alzheimer's disease-related plasticity and memory deficits. *Nature neuroscience*. 2013;16(9):1299-305.

Ma X, Sun Z, Liu Y, Jia Y, Zhang B, Zhang J. Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia. *Neural regeneration research*. 2013;8(22):2050-9.

Ma X, Xu W, Zhang Z, Liu N, Yang J, Wang M, et al. Salvianolic Acid B Ameliorates Cognitive Deficits Through IGF-1/Akt Pathway in Rats with Vascular Dementia. *Cellular physiology and*

biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2017;43(4):1381-91.

MacAulay RK, Wagner MT, Szeles D, Milano NJ. Improving Sensitivity to Detect Mild Cognitive Impairment: Cognitive Load Dual-Task Gait Speed Assessment. Journal of the International Neuropsychological Society : JINS. 2017;23(6):493-501.

Macdonald IR, Rockwood K, Martin E, Darvesh S. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer? Journal of Alzheimer's disease : JAD. 2014;42(2):379-84.

Machhi J, Sinha A, Patel P, Kanhed AM, Upadhyay P, Tripathi A, et al. Neuroprotective Potential of Novel Multi-Targeted Isoalloxazine Derivatives in Rodent Models of Alzheimer's Disease Through Activation of Canonical Wnt/beta-Catenin Signalling Pathway. Neurotoxicity research. 2016;29(4):495-513.

Machiels M, Metzelthin SF, Hamers JPH, Zwakhalen SMG. Interventions to improve communication between people with dementia and nursing staff during daily nursing care: A systematic review. International journal of nursing studies. 2017;66:37-46.

Machuca-Parra AI, Bigger-Allen AA, Sanchez AV, Boutabla A, Cardona-Velez J, Amarnani D, et al. Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL. The Journal of experimental medicine. 2017;214(8):2271-82.

Macklin EA, Blacker D, Hyman BT, Betensky RA. Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints. Journal of Alzheimer's disease : JAD. 2013;36(3):475-86.

Macoir J, Leroy M, Routhier S, Auclair-Ouellet N, Houde M, Laforce R, Jr. Improving verb anomia in the semantic variant of primary progressive aphasia: the effectiveness of a semantic-phonological cueing treatment. Neurocase. 2015;21(4):448-56.

MacPhail A, McDonough M, Ibrahim JE. Delayed discharge in alcohol-related dementia: consequences and possibilities for improvement. Australian health review : a publication of the Australian Hospital Association. 2013;37(4):482-7.

Madhavadas S, Kapgal VK, Kutty BM, Subramanian S. The Neuroprotective Effect of Dark Chocolate in Monosodium Glutamate-Induced Nontransgenic Alzheimer Disease Model Rats: Biochemical, Behavioral, and Histological Studies. Journal of dietary supplements. 2016;13(4):449-60.

Madhavadas S, Subramanian S. Cognition enhancing effect of the aqueous extract of Cinnamomum zeylanicum on non-transgenic Alzheimer's disease rat model: Biochemical, histological, and behavioural studies. Nutritional neuroscience. 2017;20(9):526-37.

Maeda Y, Kaneda E, Hasegawa S, Yoshida S, Fujii M, Sasaki H. Cholinesterase inhibitors and dramatic emotional therapy for dementia patients. *Geriatrics & gerontology international*. 2016;16(10):1174-5.

Maesako M, Uemura M, Tashiro Y, Sasaki K, Watanabe K, Noda Y, et al. High Fat Diet Enhances beta-Site Cleavage of Amyloid Precursor Protein (APP) via Promoting beta-Site APP Cleaving Enzyme 1/Adaptor Protein 2/Clathrin Complex Formation. *PloS one*. 2015;10(9):e0131199.

Magee M, McCorkell G, Guille S, Coates V. Feasibility of the Namaste Care Programme to enhance care for those with advanced dementia. *International journal of palliative nursing*. 2017;23(8):368-76.

Magistri M, Velmeshev D, Makhmutova M, Patel P, Sartor GC, Volmar C-H, et al. The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease. *Current Alzheimer research*. 2016;13(9):985-95.

Maguire LE, Wanschura PB, Battaglia MM, Howell SN, Flinn JM. Participation in active singing leads to cognitive improvements in individuals with dementia. *Journal of the American Geriatrics Society*. 2015;63(4):815-6.

Mahajan RK, Sharma S, Dhikav V, Anand KS, Duggal N. An unusual case of reversible mild cognitive impairment. *Neurocase*. 2017;23(1):82-3.

Maher A, El-Sayed NS-E, Breitingner H-G, Gad MZ. Overexpression of NMDAR2B in an inflammatory model of Alzheimer's disease: modulation by NOS inhibitors. *Brain research bulletin*. 2014;109:109-16.

Maheshwari M, Bhutani S, Das A, Mukherjee R, Sharma A, Kino Y, et al. Dexamethasone induces heat shock response and slows down disease progression in mouse and fly models of Huntington's disease. *Human molecular genetics*. 2014;23(10):2737-51.

Mahoney DF, Coon DW, Lozano C. Latino/Hispanic Alzheimer's caregivers experiencing dementia-related dressing issues: corroboration of the Preservation of Self model and reactions to a "smart dresser" computer-based dressing aid. *Digital health*. 2016;2.

Mahoney DF, LaRose S, Mahoney EL. Family caregivers' perspectives on dementia-related dressing difficulties at home: The preservation of self model. *Dementia (London, England)*. 2015;14(4):494-512.

Maidment ID, Shaw RL, Killick K, Damery S, Hilton A, Wilcock J, et al. Improving the management of behaviour that challenges associated with dementia in care homes: protocol for pharmacy-health psychology intervention feasibility study. *BMJ open*. 2016;6(3):e010279.

Maingat FG, Polyak MJ, Paul AM, Vivithanaporn P, Noorbakhsh F, Ahboucha S, et al. Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2013;27(2):725-37.

Maitre M, Klein C, Mensah-Nyagan AG. A proposed preventive role for Gamma-hydroxybutyrate (Xyrem(R)) in Alzheimer's disease. *Alzheimer's research & therapy*. 2016;8:37.

Majid DSA, Cai W, Corey-Bloom J, Aron AR. Proactive selective response suppression is implemented via the basal ganglia. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(33):13259-69.

Mak D-OD, Cheung K-H, Toglia P, Foskett JK, Ullah G. Analyzing and Quantifying the Gain-of-Function Enhancement of IP3 Receptor Gating by Familial Alzheimer's Disease-Causing Mutants in Presenilins. *PLoS computational biology*. 2015;11(10):e1004529.

Mak HK-F, Qian W, Ng KS, Chan Q, Song Y-Q, Chu LW, et al. Combination of MRI hippocampal volumetry and arterial spin labeling MR perfusion at 3-Tesla improves the efficacy in discriminating Alzheimer's disease from cognitively normal elderly adults. *Journal of Alzheimer's disease : JAD*. 2014;41(3):749-58.

Makani V, Jang Y-G, Christopher K, Judy W, Eckstein J, Hensley K, et al. BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR. *PloS one*. 2016;11(3):e0149715.

Makhaeva GF, Lushchekina SV, Boltneva NP, Serebryakova OG, Rudakova EV, Ustyugov AA, et al. 9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment. *Bioorganic & medicinal chemistry*. 2017;25(21):5981-94.

Makhaeva GF, Lushchekina SV, Boltneva NP, Sokolov VB, Grigoriev VV, Serebryakova OG, et al. Conjugates of gamma-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease. *Scientific reports*. 2015;5:13164.

Maki Y, Yoshida H, Yamaguchi T, Yamaguchi H. Relative preservation of the recognition of positive facial expression "happiness" in Alzheimer disease. *International psychogeriatrics*. 2013;25(1):105-10.

Malek N, Greene J. Cognition enhancers for the treatment of dementia. *Scottish medical journal*. 2015;60(1):44-9.

Malek-Ahmadi M. Reversion From Mild Cognitive Impairment to Normal Cognition: A Meta-Analysis. *Alzheimer disease and associated disorders*. 2016;30(4):324-30.

Malik J, Karan M, Dogra R. Ameliorating effect of *Celastrus paniculatus* standardized extract and its fractions on 3-nitropropionic acid induced neuronal damage in rats: possible antioxidant mechanism. *Pharmaceutical biology*. 2017;55(1):980-90.

Malik J, Munjal K, Deshmukh R. Attenuating effect of standardized lyophilized *Cinnamomum zeylanicum* bark extract against streptozotocin-induced experimental dementia of Alzheimer's type. *Journal of basic and clinical physiology and pharmacology*. 2015;26(3):275-85.

Malishkevich A, Amram N, Hachohen-Kleiman G, Magen I, Giladi E, Gozes I. Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies. *Translational psychiatry*. 2015;5:e501.

Malishkevich A, Marshall GA, Schultz AP, Sperling RA, Aharon-Peretz J, Gozes I. Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers. *Journal of Alzheimer's disease : JAD*. 2016;50(1):249-60.

Maliszewska-Cyna E, Lynch M, Oore JJ, Nagy PM, Aubert I. The Benefits of Exercise and Metabolic Interventions for the Prevention and Early Treatment of Alzheimer's Disease. *Current Alzheimer research*. 2017;14(1):47-60.

Malkki H. Alzheimer disease: BACE1 inhibition could block CSF tau increase. *Nature reviews Neurology*. 2017;13(1):6.

Malkki H. Alzheimer disease: NSAIDs protect neurons and preserve memory in a mouse model of AD. *Nature reviews Neurology*. 2016;12(7):370-1.

Malkki H. Alzheimer disease: Sleep alleviates AD-related neuropathological processes. *Nature reviews Neurology*. 2013;9(12):657.

Malkki H. Dementia: new study puts its FINGER on prevention of cognitive decline. *Nature reviews Neurology*. 2015;11(5):248.

Malm T, Mariani M, Donovan LJ, Neilson L, Landreth GE. Activation of the nuclear receptor PPARdelta is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation. *Journal of neuroinflammation*. 2015;12:7.

Maloney JA, Bainbridge T, Gustafson A, Zhang S, Kyauk R, Steiner P, et al. Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. *The Journal of biological chemistry*. 2014;289(45):30990-1000.

Mamik MK, Asahchop EL, Chan WF, Zhu Y, Branton WG, McKenzie BA, et al. Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral

Function in Models of HIV/AIDS Neurodegeneration. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2016;36(41):10683-95.

Mamo SK, Oh E, Lin FR. Enhancing Communication in Adults with Dementia and Age-Related Hearing Loss. *Seminars in hearing*. 2017;38(2):177-83.

Managing vascular disease could reduce Alzheimer's risk. Prevention and proper treatment can help prevent impaired blood flow to the brain. *DukeMedicine healthnews*. 2013;19(1):7.

Manchanda S, Kaur G. Withania somnifera leaf alleviates cognitive dysfunction by enhancing hippocampal plasticity in high fat diet induced obesity model. *BMC complementary and alternative medicine*. 2017;17(1):136.

Mancini S, Balducci C, Micotti E, Tolomeo D, Forloni G, Masserini M, et al. Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease. *Journal of controlled release : official journal of the Controlled Release Society*. 2017;258:121-9.

Manczak M, Kandimalla R, Fry D, Sesaki H, Reddy PH. Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease. *Human molecular genetics*. 2016;25(23):5148-66.

Manczak M, Reddy PH. Mitochondrial division inhibitor 1 protects against mutant huntingtin-induced abnormal mitochondrial dynamics and neuronal damage in Huntington's disease. *Human molecular genetics*. 2015;24(25):7308-25.

Manczak M, Reddy PH. RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity. *Biochimica et biophysica acta*. 2013;1832(12):2368-78.

Manczak M, Sheiko T, Craigen WJ, Reddy PH. Reduced VDAC1 protects against Alzheimer's disease, mitochondria, and synaptic deficiencies. *Journal of Alzheimer's disease : JAD*. 2013;37(4):679-90.

Manenti R, Brambilla M, Benussi A, Rosini S, Cobelli C, Ferrari C, et al. Mild cognitive impairment in Parkinson's disease is improved by transcranial direct current stimulation combined with physical therapy. *Movement disorders : official journal of the Movement Disorder Society*. 2016;31(5):715-24.

Mangat GS, Jaggi AS, Singh N. Ameliorative Effect of a Selective Endothelin ETA Receptor Antagonist in Rat Model of L-Methionine-induced Vascular Dementia. *The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology*. 2014;18(3):201-9.

Mangrolia P, Yang DT, Murphy RM. Transthyretin variants with improved inhibition of beta-amyloid aggregation. *Protein engineering, design & selection : PEDS*. 2016;29(6):209-18.

Mani V, Jaafar SM, Azahan NSM, Ramasamy K, Lim SM, Ming LC, et al. Ciproxifan improves cholinergic transmission, attenuates neuroinflammation and oxidative stress but does not reduce amyloid level in transgenic mice. *Life sciences*. 2017;180:23-35.

Manouilidou C, Dolenc B, Marvin T, Pirtosek Z. Processing complex pseudo-words in mild cognitive impairment: The interaction of preserved morphological rule knowledge with compromised cognitive ability. *Clinical linguistics & phonetics*. 2016;30(1):49-67.

Manral A, Meena P, Saini V, Siraj F, Shalini S, Tiwari M. DADS Analogues Ameliorated the Cognitive Impairments of Alzheimer-Like Rat Model Induced by Scopolamine. *Neurotoxicity research*. 2016;30(3):407-26.

Mantile F, Trovato M, Santoni A, Barba P, Ottonello S, De Berardinis P, et al. Alum and squalene-oil-in-water emulsion enhance the titer and avidity of anti-Aβ antibodies induced by multimeric protein antigen (1-11)E2, preserving the IgG1-skewed isotype distribution. *PloS one*. 2014;9(7):e101474.

Mantoani SP, Chierrito TPC, Vilela AFL, Cardoso CL, Martinez A, Carvalho I. Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors. *Molecules (Basel, Switzerland)*. 2016;21(2).

Manukhina EB, Downey HF, Shi X, Mallet RT. Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease. *Experimental biology and medicine (Maywood, NJ)*. 2016;241(12):1351-63.

Mao F, Li J, Wei H, Huang L, Li X. Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer's disease. *Journal of enzyme inhibition and medicinal chemistry*. 2015;30(6):995-1001.

Mao F, Wang H, Ni W, Zheng X, Wang M, Bao K, et al. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease. *ACS chemical neuroscience*. 2017.

Mar J, Soto-Gordoa M, Arrospide A, Moreno-Izco F, Martinez-Lage P. Fitting the epidemiology and neuropathology of the early stages of Alzheimer's disease to prevent dementia. *Alzheimer's research & therapy*. 2015;7(1):2.

Marangoni MN, Braun D, Situ A, Moyano AL, Kalinin S, Polak P, et al. Differential effects on glial activation by a direct versus an indirect thrombin inhibitor. *Journal of neuroimmunology*. 2016;297:159-68.

Marchionni M, Caramel S, Stagnaro S. Inherited real risk of Alzheimer's disease: bedside diagnosis and primary prevention. *Frontiers in aging neuroscience*. 2013;5:13.

Marchionni M, Stagnaro S, Caramel S. The role of 'modified Mediterranean diet' and quantum therapy in Alzheimer's disease primary prevention. *The journal of nutrition, health & aging*. 2014;18(1):96.

Marciani DJ. New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies. *Drug discovery today*. 2014;19(7):912-20.

Marco S, Giralt A, Petrovic MM, Pouladi MA, Martinez-Turrillas R, Martinez-Hernandez J, et al. Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. *Nature medicine*. 2013;19(8):1030-8.

Marei HES, Farag A, Althani A, Afifi N, Abd-Elmaksoud A, Lashen S, et al. Human olfactory bulb neural stem cells expressing hNGF restore cognitive deficit in Alzheimer's disease rat model. *Journal of cellular physiology*. 2015;230(1):116-30.

Marek GJ, Katz DA, Meier A, Greco Nt, Zhang W, Liu W, et al. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2014;10(5 Suppl):S364-73.

Mariano M, Schmitt C, Miralinaghi P, Catto M, Hartmann RW, Carotti A, et al. First selective dual inhibitors of tau phosphorylation and Beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer's disease. *ACS chemical neuroscience*. 2014;5(12):1198-202.

Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C. Improving Current Treatments for Schizophrenia. *Drug development research*. 2016;77(7):357-67.

Marienfeld S, Flerchinger C, Bojunga J. Prevention and treatment of dementia. It depends on nutrition. *Pflege Zeitschrift*. 2016;69(3):142-6.

Markoutsas E, Mourtas S, Bereczki E, Zona C, La Ferla B, Nicotra F, et al. Comparison of Various Types of Ligand Decorated Nanoliposomes for their Ability to Inhibit Amyloid Aggregation and to Reverse Amyloid Cytotoxicity. *Current topics in medicinal chemistry*. 2015;15(22):2267-76.

Marnane M, Hsiung G-YR. Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes? *Current Alzheimer research*. 2016;13(7):750-63.

Maron-Katz A, Amar D, Simon EB, Hendler T, Shamir R. RichMind: A Tool for Improved Inference from Large-Scale Neuroimaging Results. *PloS one*. 2016;11(7):e0159643.

Maroof N, Ravipati S, Pardon MC, Barrett DA, Kendall DA. Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the AbetaPPswe/PS1DeltaE9 mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;42(1):227-45.

Marples B, McGee M, Callan S, Bowen SE, Thibodeau BJ, Michael DB, et al. Cranial irradiation significantly reduces beta amyloid plaques in the brain and improves cognition in a murine model of Alzheimer's Disease (AD). *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2016;118(3):579-80.

Marples B, McGee M, Callan S, Bowen SE, Thibodeau BJ, Michael DB, et al. Cranial irradiation significantly reduces beta amyloid plaques in the brain and improves cognition in a murine model of Alzheimer's Disease (AD). *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2016;118(1):43-51.

Marquetand J, van Lessen M, Bender B, Reimold M, Elsen G, Stoecker W, et al. Slowly progressive LGI1 encephalitis with isolated late-onset cognitive dysfunction: a treatable mimic of Alzheimer's disease. *European journal of neurology*. 2016;23(5):e28-9.

Marquet-de Rouge P, Clamagirand C, Facchinetti P, Rose C, Sargueil F, Guihenneuc-Jouyaux C, et al. Citrulline diet supplementation improves specific age-related raft changes in wild-type rodent hippocampus. *Age (Dordrecht, Netherlands)*. 2013;35(5):1589-606.

Martin CM. Improving dementia care: new initiatives, new opportunities. *The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists*. 2014;29(1):16-23.

Martinelli-Boneschi F, Giacalone G, Magnani G, Biella G, Coppi E, Santangelo R, et al. Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. *Neurobiology of aging*. 2013;34(6):1711.e7-13.

Martinez A, Perez DI, Gil C. Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease. *Current topics in medicinal chemistry*. 2013;13(15):1808-19.

Martinez-Coria H, Yeung ST, Ager RR, Rodriguez-Ortiz CJ, Baglietto-Vargas D, LaFerla FM. Repeated cognitive stimulation alleviates memory impairments in an Alzheimer's disease mouse model. *Brain research bulletin*. 2015;117:10-5.

Martinez-Lapiscina EH, Clavero P, Toledo E, Estruch R, Salas-Salvado J, San Julian B, et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. *Journal of neurology, neurosurgery, and psychiatry*. 2013;84(12):1318-25.

Martinez-Torteya A, Trevino V, Tamez-Pena JG. Improved Diagnostic Multimodal Biomarkers for Alzheimer's Disease and Mild Cognitive Impairment. *BioMed research international*. 2015;2015:961314.

Martin-Maestro P, Gargini R, Perry G, Avila J, Garcia-Escudero V. PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer's disease. *Human molecular genetics*. 2016;25(4):792-806.

Martin-Pena A, Rincon-Limas DE, Fernandez-Funez P. Anti-Abeta single-chain variable fragment antibodies restore memory acquisition in a Drosophila model of Alzheimer's disease. *Scientific reports*. 2017;7(1):11268.

Martins I, Gomes S, Costa RO, Otvos L, Oliveira CR, Resende R, et al. Leptin and ghrelin prevent hippocampal dysfunction induced by Abeta oligomers. *Neuroscience*. 2013;241:41-51.

Martire A, Peponi R, Domenici MR, Ferrante A, Chiodi V, Popoli P. BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved. *Journal of neurochemistry*. 2013;125(2):225-35.

Martire S, Fusco A, Mosca L, Forte E, Correani V, Fontana M, et al. Bioenergetic Impairment in Animal and Cellular Models of Alzheimer's Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions. *Journal of Alzheimer's disease : JAD*. 2016;54(1):307-24.

Martis EAF, Chandarana RC, Shaikh MS, Ambre PK, D'Souza JS, Iyer KR, et al. Quantifying ligand-receptor interactions for gorge-spanning acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. *Journal of biomolecular structure & dynamics*. 2015;33(5):1107-25.

Martorana A, Di Lorenzo F, Manenti G, Semprini R, Koch G. Homotaurine induces measurable changes of short latency afferent inhibition in a group of mild cognitive impairment individuals. *Frontiers in aging neuroscience*. 2014;6:254.

Martorell P, Bataller E, Llopis S, Gonzalez N, Alvarez B, Monton F, et al. A cocoa peptide protects *Caenorhabditis elegans* from oxidative stress and beta-amyloid peptide toxicity. *PloS one*. 2013;8(5):e63283.

Martyr A, Boycheva E, Kudlicka A. Assessing inhibitory control in early-stage Alzheimer's and Parkinson's disease using the Hayling Sentence Completion Test. *Journal of neuropsychology*. 2017.

Marumoto S, Okuno Y, Miyazawa M. Inhibition of beta-Secretase Activity by Monoterpenes, Sesquiterpenes, and C13 Norisoprenoids. *Journal of oleo science*. 2017;66(8):851-5.

Maruszak A, Thuret S. Why looking at the whole hippocampus is not enough-a critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer's disease diagnosis. *Frontiers in cellular neuroscience*. 2014;8:95.

Masci A, Mattioli R, Costantino P, Baima S, Morelli G, Punzi P, et al. Neuroprotective Effect of Brassica oleracea Sprouts Crude Juice in a Cellular Model of Alzheimer's Disease. *Oxidative medicine and cellular longevity*. 2015;2015:781938.

Mason RP, Casu M, Butler N, Breda C, Campesan S, Clapp J, et al. Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. *Nature genetics*. 2013;45(10):1249-54.

Masoodi N. ACP Journal Club. Review: cholinesterase inhibitors do not reduce progression to dementia from mild cognitive impairment. *Annals of internal medicine*. 2013;158(4):JC3.

Massimo L, Evans LK. Differentiating subtypes of apathy to improve person-centered care in frontotemporal degeneration. *Journal of gerontological nursing*. 2014;40(10):58-65.

Masson M, Mauras T, Malhi GS. Lithium the magic ion: restoring and preventing? *The Australian and New Zealand journal of psychiatry*. 2014;48(9):874-6.

Masson P, Lushchekina SV. Slow-binding inhibition of cholinesterases, pharmacological and toxicological relevance. *Archives of biochemistry and biophysics*. 2016;593:60-8.

Massoud F. Cholinesterase inhibitors in vascular cognitive impairment. *The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques*. 2013;40(4):446-7.

Massoud F. Persistence with cholinesterase inhibitor treatment in Alzheimer's disease. *The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques*. 2013;40(5):623-4.

Mastroeni D, Khdour OM, Arce PM, Hecht SM, Coleman PD. Novel antioxidants protect mitochondria from the effects of oligomeric amyloid beta and contribute to the maintenance of epigenome function. *ACS chemical neuroscience*. 2015;6(4):588-98.

Mathews M, Abner E, Caban-Holt A, Kryscio R, Schmitt F. CERAD practice effects and attrition bias in a dementia prevention trial. *International psychogeriatrics*. 2013;25(7):1115-23.

Matlack KES, Tardiff DF, Narayan P, Hamamichi S, Caldwell KA, Caldwell GA, et al. Clioquinol promotes the degradation of metal-dependent amyloid-beta (A β) oligomers to restore endocytosis and ameliorate A β toxicity. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(11):4013-8.

Matos JO, Goldblatt G, Jeon J, Chen B, Tatulian SA. Pyroglutamylated amyloid-beta peptide reverses cross beta-sheets by a prion-like mechanism. *The journal of physical chemistry B*. 2014;118(21):5637-43.

Matsuda K, Chen C-Y, Whitted S, Chertova E, Roser DJ, Wu F, et al. Enhanced antagonism of BST-2 by a neurovirulent SIV envelope. *The Journal of clinical investigation*. 2016;126(6):2295-307.

Matsuda T, Hisatsune T. Cholinergic Modification of Neurogenesis and Gliosis Improves the Memory of AbetaPPswe/PSEN1dE9 Alzheimer's Disease Model Mice Fed a High-Fat Diet. *Journal of Alzheimer's disease : JAD*. 2017;56(1):1-23.

Matsumura S, Murata K, Yoshioka Y, Matsuda H. Search for beta-Secretase Inhibitors from Natural Spices. *Natural product communications*. 2016;11(4):507-10.

Matsunaga S, Kishi T, Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis. *The international journal of neuropsychopharmacology*. 2014;18(5).

Matsunaga S, Kishi T, Yasue I, Iwata N. Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis. *The international journal of neuropsychopharmacology*. 2015;19(2).

Matsuoka M, Hidaka K, Doi S, Hata A, Iwata T, Iijima S. Case report--cooperation among medical staff to improve home enteral nutrition and increase hope in a patient with dementia. *Gan to kagaku ryoho Cancer & chemotherapy*. 2013;40 Suppl 2:224-6.

Matsuoka M. Protective effects of Humanin and calmodulin-like skin protein in Alzheimer's disease and broad range of abnormalities. *Molecular neurobiology*. 2015;51(3):1232-9.

Matsuzono K, Hishikawa N, Ohta Y, Yamashita T, Deguchi K, Nakano Y, et al. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study. *Journal of Alzheimer's disease : JAD*. 2015;45(3):771-80.

Mattace-Raso F. Is memantine + acetylcholinesterase inhibitor treatment superior to either therapy alone in Alzheimer's disease? *Journal of Alzheimer's disease : JAD*. 2014;41(2):641-2.

Mattis VB, Wakeman DR, Tom C, Dodiya HB, Yeung SY, Tran AH, et al. Neonatal immune-tolerance in mice does not prevent xenograft rejection. *Experimental neurology*. 2014;254:90-8.

Matyas N, Auer S, Gisinger C, Kil M, Keser Aschenberger F, Klerings I, et al. Continuing education for the prevention of mild cognitive impairment and Alzheimer's-type dementia: a systematic review protocol. *Systematic reviews*. 2017;6(1):157.

Mauer S, Vergne D, Ghaemi SN. Standard and trace-dose lithium: a systematic review of dementia prevention and other behavioral benefits. *The Australian and New Zealand journal of psychiatry*. 2014;48(9):809-18.

Maung R, Hoefer MM, Sanchez AB, Sejbuk NE, Medders KE, Desai MK, et al. CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120. *Journal of immunology (Baltimore, Md : 1950)*. 2014;193(4):1895-910.

Maurice T, Mustafa M-H, Desrumaux C, Keller E, Naert G, de la C Garcia-Barcelo M, et al. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Abeta β , β ,... β , β ,... non-transgenic mouse model of Alzheimer's disease. *Journal of psychopharmacology (Oxford, England)*. 2013;27(11):1044-57.

Mausbach BT, Chattillion EA, Ho J, Flynn LM, Tiznado D, von Kanel R, et al. Why does placement of persons with Alzheimer's disease into long-term care improve caregivers' well-being? Examination of psychological mediators. *Psychology and aging*. 2014;29(4):776-86.

Maust DT. Improving psychotropic medication use among persons with dementia. *International psychogeriatrics*. 2016;28(10):1587-8.

Mavros Y, Gates N, Wilson GC, Jain N, Meiklejohn J, Brodaty H, et al. Mediation of Cognitive Function Improvements by Strength Gains After Resistance Training in Older Adults with Mild Cognitive Impairment: Outcomes of the Study of Mental and Resistance Training. *Journal of the American Geriatrics Society*. 2017;65(3):550-9.

May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2015;35(3):1199-210.

Mayor S. Slow walking speed may be early sign of Alzheimer's in older people, study finds. *BMJ (Clinical research ed)*. 2015;351:h6506.

Mazarei G, Budac DP, Lu G, Lee H, Moller T, Leavitt BR. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain. *Experimental neurology*. 2013;249:144-8.

Mazumder AG, Sharma P, Patial V, Singh D. Crocin Attenuates Kindling Development and Associated Cognitive Impairments in Mice via Inhibiting Reactive Oxygen Species-Mediated NF-kappaB Activation. *Basic & clinical pharmacology & toxicology*. 2017;120(5):426-33.

McAllister M, Dayton J, Oprescu F, Katsikitis M, Jones CM. Memory Keeper: A prototype digital application to improve engagement with people with dementia in long-term care (innovative practice). *Dementia* (London, England). 2017;1471301217737872.

McCarten JR, Borson S. Should family physicians routinely screen patients for cognitive impairment? Yes: screening is the first step toward improving care. *American family physician*. 2014;89(11):861-2.

McCartney M. Would doctors routinely asking older patients about their memory improve dementia outcomes? No. *BMJ* (Clinical research ed). 2013;346:f1745.

McClellan PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. *Neuropharmacology*. 2014;76 Pt A:57-67.

McClellan PL, Holscher C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. *Neuropharmacology*. 2014;86:241-58.

McClellan PL, Jalewa J, Holscher C. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. *Behavioural brain research*. 2015;293:96-106.

McClure R, Ong H, Janve V, Barton S, Zhu M, Li B, et al. Aerosol Delivery of Curcumin Reduced Amyloid-beta Deposition and Improved Cognitive Performance in a Transgenic Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;55(2):797-811.

McConnell ES, Karel MJ. Improving Management of Behavioral and Psychological Symptoms of Dementia in Acute Care: Evidence and Lessons Learned From Across the Care Spectrum. *Nursing administration quarterly*. 2016;40(3):244-54.

McConnell ES, Lee KH, Galkowski L, Downey C, Spainhour MV, Horwitz R. Improving Oral Hygiene for Veterans With Dementia in Residential Long-term Care. *Journal of nursing care quality*. 2017.

McConnell ES. Improving dementia care through behavioral interventions. *North Carolina medical journal*. 2014;75(5):355-8.

McCully KS. Hyperhomocysteinemia, Suppressed Immunity, and Altered Oxidative Metabolism Caused by Pathogenic Microbes in Atherosclerosis and Dementia. *Frontiers in aging neuroscience*. 2017;9:324.

McCurry SM, Logsdon RG, Pike KC, LaFazia DM, Teri L. Training area agencies on aging case managers to improve physical function, mood, and behavior in persons with dementia and

caregivers: examples from the RDAD-Northwest study. *Journal of gerontological social work*. 2017.

McDavid A, Crane PK, Newton KM, Crosslin DR, McCormick W, Weston N, et al. Enhancing the power of genetic association studies through the use of silver standard cases derived from electronic medical records. *PloS one*. 2013;8(6):e63481.

McDonald CL, Hennessy E, Rubio-Araiz A, Keogh B, McCormack W, McGuirk P, et al. Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer's disease. *Brain, behavior, and immunity*. 2016;58:191-200.

McEvoy P, Bellass S. Using drawings as a reflective tool to enhance communication in dementia care. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*. 2017;31(19):46-52.

McFall GP, Wiebe SA, Vergote D, Anstey KJ, Dixon RA. Alzheimer's Genetic Risk Intensifies Neurocognitive Slowing Associated with Diabetes in Non-Demented Older Adults. *Alzheimer's & dementia (Amsterdam, Netherlands)*. 2015;1(4):395-402.

McGilvray A. Ageing: Restoration project. *Nature*. 2016;531(7592):S4-5.

McGough E, Kirk-Sanchez N, Liu-Ambrose T. Integrating Health Promotion Into Physical Therapy Practice to Improve Brain Health and Prevent Alzheimer Disease. *Journal of neurologic physical therapy : JNPT*. 2017;41 Suppl 3 Supplement, IV STEP Special Issue:S55-S62.

McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. *The Cochrane database of systematic reviews*. 2016(1):CD003160.

McHardy SF, Wang H-YL, McCowen SV, Valdez MC. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015). *Expert opinion on therapeutic patents*. 2017;27(4):455-76.

McKee TD, Loureiro RMB, Dumin JA, Zarayskiy V, Tate B. An improved cell-based method for determining the gamma-secretase enzyme activity against both Notch and APP substrates. *Journal of neuroscience methods*. 2013;213(1):14-21.

McKoy AF, Chen J, Schupbach T, Hecht MH. Structure-activity relationships for a series of compounds that inhibit aggregation of the Alzheimer's peptide, Abeta42. *Chemical biology & drug design*. 2014;84(5):505-12.

McLeod MC, Kobayashi NR, Sen A, Baghbaderani BA, Sadi D, Ulalia R, et al. Transplantation of GABAergic cells derived from bioreactor-expanded human neural precursor cells restores motor and cognitive behavioral deficits in a rodent model of Huntington's disease. *Cell transplantation*. 2013;22(12):2237-56.

McManus RM, Mills KHG, Lynch MA. T Cells-Protective or Pathogenic in Alzheimer's Disease? *Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology*. 2015;10(4):547-60.

McMillan CT, Russ J, Wood EM, Irwin DJ, Grossman M, McCluskey L, et al. C9orf72 promoter hypermethylation is neuroprotective: Neuroimaging and neuropathologic evidence. *Neurology*. 2015;84(16):1622-30.

McNeilly AD, Gallagher JR, Dinkova-Kostova AT, Hayes JD, Sharkey J, Ashford MLJ, et al. Nrf2-Mediated Neuroprotection Against Recurrent Hypoglycemia Is Insufficient to Prevent Cognitive Impairment in a Rodent Model of Type 1 Diabetes. *Diabetes*. 2016;65(10):3151-60.

McPhee GM, Downey LA, Noble A, Stough C. Cognitive training and *Bacopa monnieri*: Evidence for a combined intervention to alleviate age associated cognitive decline. *Medical hypotheses*. 2016;95:71-6.

Mealer RG, Subramaniam S, Snyder SH. Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(9):4206-10.

Meamar R, Dehghani L, Ghasemi M, Saadatnia M, Basiri K, Faradonbeh NA, et al. Enalapril protects endothelial cells against induced apoptosis in Alzheimer's disease. *Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences*. 2013;18(Suppl 1):S1-5.

Medeiros R, Castello NA, Cheng D, Kitazawa M, Baglietto-Vargas D, Green KN, et al. alpha7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles. *The American journal of pathology*. 2014;184(2):520-9.

Meek AR, Simms GA, Weaver DF. Searching for an endogenous anti-Alzheimer molecule: identifying small molecules in the brain that slow Alzheimer disease progression by inhibition of SS-amyloid aggregation. *Journal of psychiatry & neuroscience : JPN*. 2013;38(4):269-75.

Meguro K, Akanuma K, Toraiwa K, Okubo M, Onodera K. Behavioral improvement of dementia residents in a group home with an increased number of residents after the Great East Japan Earthquake 2011. *International psychogeriatrics*. 2014;26(5):871-2.

Meguro K, Ouchi Y, Akanuma K, Meguro M, Kasai M. Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer's patients in long-term care health facilities. *BMC neurology*. 2014;14:243.

Meguro K. Cholinesterase inhibitors are compatible with psychosocial intervention for Alzheimer disease patients suggested by neuroimaging findings. *Psychiatry research*. 2017;259:29-33.

Meguro K. Measures to prevent Alzheimer's patients from discontinuing the use of cholinesterase inhibitors. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2014;14(3):210-1.

Mehra R, Sodhi RK, Aggarwal N. Memory restorative ability of clioquinol in copper-cholesterol-induced experimental dementia in mice. *Pharmaceutical biology*. 2015;53(9):1250-9.

Mehrotra A, Kanwal A, Banerjee SK, Sandhir R. Mitochondrial modulators in experimental Huntington's disease: reversal of mitochondrial dysfunctions and cognitive deficits. *Neurobiology of aging*. 2015;36(6):2186-200.

Mehrotra A, Sood A, Sandhir R. Mitochondrial modulators improve lipid composition and attenuate memory deficits in experimental model of Huntington's disease. *Molecular and cellular biochemistry*. 2015;410(1-2):281-92.

Mehta N, Rodrigues C, Lamba M, Wu W, Bronskill SE, Herrmann N, et al. Systematic Review of Sex-Specific Reporting of Data: Cholinesterase Inhibitor Example. *Journal of the American Geriatrics Society*. 2017;65(10):2213-9.

Mehta V, Parashar A, Sharma A, Singh TR, Udayabanu M. Quercetin ameliorates chronic unpredicted stress-mediated memory dysfunction in male Swiss albino mice by attenuating insulin resistance and elevating hippocampal GLUT4 levels independent of insulin receptor expression. *Hormones and behavior*. 2017;89:13-22.

Mejia S. Promoting multilevel primary prevention of depression and diabetes during midlife may protect against dementia. *Evidence-based mental health*. 2016;19(1):e4.

Melancon BJ, Tarr JC, Panarese JD, Wood MR, Lindsley CW. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease. *Drug discovery today*. 2013;18(23-24):1185-99.

Melief EJ, Cudaback E, Jorstad NL, Sherfield E, Postupna N, Wilson A, et al. Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer's disease. *Journal of neuroscience research*. 2015;93(9):1413-22.

Melkani GC, Trujillo AS, Ramos R, Bodmer R, Bernstein SI, Ocorr K. Huntington's disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the *Drosophila* heart. *PLoS genetics*. 2013;9(12):e1004024.

Mellor D, McCabe M, Bird M, Davison T, MacPherson S, Hallford D, et al. Staff compliance with protocols to improve the management of behavioral and psychological symptoms of dementia. *Journal of gerontological nursing*. 2015;41(2):44-52.

Mellott TJ, Pender SM, Burke RM, Langley EA, Blusztajn JK. IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice. *PloS one*. 2014;9(4):e94287.

Melnikova T, Fromholt S, Kim H, Lee D, Xu G, Price A, et al. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(9):3765-79.

Menalled LB, Kudwa AE, Oakeshott S, Farrar A, Paterson N, Filippov I, et al. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease. *PloS one*. 2014;9(6):e99520.

Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G. Therapies for Prevention and Treatment of Alzheimer's Disease. *BioMed research international*. 2016;2016:2589276.

Meng C, He Z, Xing D. Low-level laser therapy rescues dendrite atrophy via upregulating BDNF expression: implications for Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(33):13505-17.

Meng J, Li Y, Camarillo C, Yao Y, Zhang Y, Xu C, et al. The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity. *PloS one*. 2014;9(1):e85570.

Meng P, Yoshida H, Matsumiya T, Imaizumi T, Tanji K, Xing F, et al. Carnosic acid suppresses the production of amyloid-beta 1-42 by inducing the metalloprotease gene TACE/ADAM17 in SH-SY5Y human neuroblastoma cells. *Neuroscience research*. 2013;75(2):94-102.

Meng QH, Lou FL, Hou WX, Liu M, Guo H, Zhang XM. Acetylpuerarin reduces inflammation and improves memory function in a rat model of Alzheimer's disease induced by Abeta1-42. *Die Pharmazie*. 2013;68(11):904-8.

Meng T, Cao Q, Lei P, Bush AI, Xiang Q, Su Z, et al. Tat-haFGF14-154 Upregulates ADAM10 to Attenuate the Alzheimer Phenotype of APP/PS1 Mice through the PI3K-CREB-IRE1alpha/XBP1 Pathway. *Molecular therapy Nucleic acids*. 2017;7:439-52.

Meng X, Luo Y, Liang T, Wang M, Zhao J, Sun G, et al. Gypenoside XVII Enhances Lysosome Biogenesis and Autophagy Flux and Accelerates Autophagic Clearance of Amyloid-beta through TFEB Activation. *Journal of Alzheimer's disease : JAD*. 2016;52(3):1135-50.

Meng Y, Ding L, Zhang H, Yin W, Yan Y, Cao Y. Immunization of Tg-APPswe/PSEN1dE9 mice with Abeta3-10-KLH vaccine prevents synaptic deficits of Alzheimer's disease. *Behavioural brain research*. 2017;332:64-70.

Mengel D, Roskam S, Neff F, Balakrishnan K, Deuster O, Gold M, et al. Naturally occurring autoantibodies interfere with beta-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment. *Translational psychiatry*. 2013;3:e236.

Menting KW, Claassen JAHR. beta-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease. *Frontiers in aging neuroscience*. 2014;6:165.

Menze ET, Esmat A, Tadros MG, Khalifa AE, Abdel-Naim AB. Genistein improves sensorimotor gating: Mechanisms related to its neuroprotective effects on the striatum. *Neuropharmacology*. 2016;105:35-46.

Menzies FM, Garcia-Arencibia M, Imarisio S, O'Sullivan NC, Ricketts T, Kent BA, et al. Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity. *Cell death and differentiation*. 2015;22(3):433-44.

Merck C, Jonin P-Y, Vichard H, Boursiquot SLM, Leblay V, Belliard S. Relative category-specific preservation in semantic dementia? Evidence from 35 cases. *Brain and language*. 2013;124(3):257-67.

Merlo S, Basile L, Giuffrida ML, Sortino MA, Guccione S, Copani A. Identification of 5-Methoxyflavone as a Novel DNA Polymerase-Beta Inhibitor and Neuroprotective Agent against Beta-Amyloid Toxicity. *Journal of natural products*. 2015;78(11):2704-11.

Messer A, Joshi SN. Intrabodies as neuroprotective therapeutics. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*. 2013;10(3):447-58.

Methot JL, Fischer C, Li C, Rivkin A, Ahearn SP, Brown WC, et al. Potent benzoazepinone gamma-secretase modulators with improved bioavailability. *Bioorganic & medicinal chemistry letters*. 2015;25(17):3495-500.

Metzger FG, Ehli A-C, Haeussinger FB, Fallgatter AJ, Hagen K. Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy. *Psychopharmacology*. 2015;232(23):4383-91.

Metzler-Baddeley C, Cantera J, Coulthard E, Rosser A, Jones DK, Baddeley RJ. Improved Executive Function and Callosal White Matter Microstructure after Rhythm Exercise in Huntington's Disease. *Journal of Huntington's disease*. 2014;3(3):273-83.

Meulendyke KA, Queen SE, Engle EL, Shirk EN, Liu J, Steiner JP, et al. Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease. *Journal of neurovirology*. 2014;20(6):591-602.

Meunier J, Villard V, Givalois L, Maurice T. The gamma-secretase inhibitor 2- (1R)-1- (4-chlorophenyl)sulfonyl (2,5-difluorophenyl) amino ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Abeta1-42 seeding and short-term memory deficits in the Abeta25-35 mouse model of Alzheimer's disease. *European journal of pharmacology*. 2013;698(1-3):193-9.

Meyer C, Dow B, Hill KD, Tinney J, Hill S. "The Right Way at the Right Time": Insights on the Uptake of Falls Prevention Strategies from People with Dementia and Their Caregivers. *Frontiers in public health*. 2016;4:244.

Meyer C, Hill S, Dow B, Synnot A, Hill K. Translating Falls Prevention Knowledge to Community-Dwelling Older PLWD: A Mixed-Method Systematic Review. *The Gerontologist*. 2015;55(4):560-74.

Meyer C, Hill S, Hill KD, Dow B. Sharing knowledge of falls prevention for people with dementia: insights for community care practice. *Australian journal of primary health*. 2017.

Miao HH, Zhang Y, Ding GN, Hong FX, Dong P, Tian M. Ginsenoside Rb1 Attenuates Isoflurane/surgery-induced Cognitive Dysfunction via Inhibiting Neuroinflammation and Oxidative Stress. *Biomedical and environmental sciences : BES*. 2017;30(5):363-72.

Michaud J-P, Halle M, Lampron A, Theriault P, Prefontaine P, Filali M, et al. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(5):1941-6.

Micheli F, Palermo R, Talora C, Ferretti E, Vacca A, Napolitano M. Regulation of proapoptotic proteins Bak1 and p53 by miR-125b in an experimental model of Alzheimer's disease: Protective role of 17beta-estradiol. *Neuroscience letters*. 2016;629:234-40.

Mielcarek M, Bondulich MK, Inuabasi L, Franklin SA, Muller T, Bates GP. The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model. *PloS one*. 2014;9(9):e108961.

Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L, et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. *PLoS biology*. 2013;11(11):e1001717.

Miettinen PS, Jauhiainen AM, Tarkka IM, Pihlajamaki M, Grohn H, Niskanen E, et al. Long-Term Response to Cholinesterase Inhibitor Treatment Is Related to Functional MRI Response in Alzheimer's Disease. *Dementia and geriatric cognitive disorders*. 2015;40(5-6):243-55.

Miguez A, Garcia-Diaz Barriga G, Brito V, Straccia M, Giralt A, Gines S, et al. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by

preventing p75NTR up-regulation and astrocyte-mediated inflammation. *Human molecular genetics*. 2015;24(17):4958-70.

Mikulca JA, Nguyen V, Gajdosik DA, Teklu SG, Giunta EA, Lessa EA, et al. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. *Journal of clinical pharmacy and therapeutics*. 2014;39(1):25-37.

Milano NJ, Williamson JB, Heilman KM. Improved verbal learning in the semantic variant of primary progressive aphasia when using semantic cues. *Neurocase*. 2015;21(3):345-50.

Milders M, Bell S, Lorimer A, Jackson H, McNamee P. Improving access to a multi-component intervention for caregivers and people with dementia. *Dementia (London, England)*. 2016.

Mills JKA, Minhas JS, Robotham SL. An assessment of the dementia CQUIN--an audit of improving compliance. *Dementia (London, England)*. 2014;13(5):697-703.

Milojevic J, Costa M, Ortiz AM, Jorquera JI, Melacini G. In vitro amyloid-beta binding and inhibition of amyloid-beta self-association by therapeutic albumin. *Journal of Alzheimer's disease : JAD*. 2014;38(4):753-65.

Min L-J, Kobayashi Y, Mogi M, Tsukuda K, Yamada A, Yamauchi K, et al. Administration of bovine casein-derived peptide prevents cognitive decline in Alzheimer disease model mice. *PloS one*. 2017;12(2):e0171515.

Minami SS, Min S-W, Krabbe G, Wang C, Zhou Y, Asgarov R, et al. Progranulin protects against amyloid beta deposition and toxicity in Alzheimer's disease mouse models. *Nature medicine*. 2014;20(10):1157-64.

Minami SS, Shen V, Le D, Krabbe G, Asgarov R, Perez-Celajes L, et al. Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with alpha7 nicotinic acetylcholine receptor agonists. *Biochemical pharmacology*. 2015;97(4):454-62.

Minn Y-K, Suk S-H. Higher skeletal muscle mass may protect against ischemic stroke in community-dwelling adults without stroke and dementia: The PRESENT project. *BMC geriatrics*. 2017;17(1):45.

Minogue AM, Jones RS, Kelly RJ, McDonald CL, Connor TJ, Lynch MA. Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice. *Neurobiology of aging*. 2014;35(6):1442-52.

Mioshi E, McKinnon C, Savage S, O'Connor CM, Hodges JR. Improving burden and coping skills in frontotemporal dementia caregivers: a pilot study. *Alzheimer disease and associated disorders*. 2013;27(1):84-6.

Miranda A, Gomez-Gaete C, Mennickent S. Role of Mediterranean diet on the prevention of Alzheimer disease. *Revista medica de Chile*. 2017;145(4):501-7.

Miranda LFJR, Gomes KB, Silveira JN, Pianetti GA, Byrro RMD, Peles PRH, et al. Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study. *Journal of Alzheimer's disease : JAD*. 2015;45(2):609-20.

Miri R, Firuzi O, Razzaghi-Asl N, Javidnia K, Edraki N. Inhibitors of Alzheimer's BACE-1 with 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridine structure. *Archives of pharmacal research*. 2015;38(4):456-69.

Mirmosayyeb O, Tanhaei A, Sohrabi HR, Martins RN, Tanhaei M, Najafi MA, et al. Possible Role of Common Spices as a Preventive and Therapeutic Agent for Alzheimer's Disease. *International journal of preventive medicine*. 2017;8:5.

Miron AM, McFadden SH, Hermus NJ, Buelow J, Nazario AS, Seelman K. Contact and perspective taking improve humanness standards and perceptions of humanness of older adults and people with dementia: a cross-sectional survey study. *International psychogeriatrics*. 2017:1-11.

Mishra CB, Manral A, Kumari S, Saini V, Tiwari M. Design, synthesis and evaluation of novel indandione derivatives as multifunctional agents with cholinesterase inhibition, anti-beta-amyloid aggregation, antioxidant and neuroprotection properties against Alzheimer's disease. *Bioorganic & medicinal chemistry*. 2016;24(16):3829-41.

Mishra J, Chaudhary T, Kumar A. Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARgamma and HDAC pathways. *Neurotoxicity research*. 2014;26(2):130-51.

Mishra J, Kumar A. Improvement of mitochondrial function by paliperidone attenuates quinolinic acid-induced behavioural and neurochemical alterations in rats: implications in Huntington's disease. *Neurotoxicity research*. 2014;26(4):363-81.

Mishra J, Kumar A. Improvement of mitochondrial NAD(+)/FAD(+)-linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: implications in Huntington's disease. *Pharmacological reports : PR*. 2014;66(6):1148-55.

Mishra P, Ayyannan SR, Panda G. Perspectives on Inhibiting beta-Amyloid Aggregation through Structure-Based Drug Design. *ChemMedChem*. 2015;10(9):1467-74.

Misik J, Korabecny J, Nepovimova E, Kracmarova A, Kassa J. Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in

rats--Is there a potential for Alzheimer's disease treatment? *Neuroscience letters*. 2016;612:261-8.

Miskowiak KW, Rush AJ, Jr., Gerds TA, Vinberg M, Kessing LV. Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin. *The Journal of clinical psychiatry*. 2016;77(12):e1639-e46.

Misra S, Kuhad A, Chopra K. Neurobiological effect of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in experimental paradigm of Alzheimer's disease. *Indian journal of experimental biology*. 2013;51(12):1086-93.

Mistridis P, Egli SC, Iverson GL, Berres M, Willmes K, Welsh-Bohmer KA, et al. Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB). *European archives of psychiatry and clinical neuroscience*. 2015;265(5):407-17.

Mistridis P, Taylor KI, Kissler JM, Monsch AU, Kressig RW, Kivisaari SL. Distinct neural systems underlying reduced emotional enhancement for positive and negative stimuli in early Alzheimer's disease. *Frontiers in human neuroscience*. 2013;7:939.

Mita T, Furukawa-Hibi Y, Takeuchi H, Hattori H, Yamada K, Hibi H, et al. Conditioned medium from the stem cells of human dental pulp improves cognitive function in a mouse model of Alzheimer's disease. *Behavioural brain research*. 2015;293:189-97.

Mitani Y, Yarimizu J, Akashiba H, Shitaka Y, Ni K, Matsuoka N. Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble A β 42 without affecting other A β pools. *Journal of neurochemistry*. 2013;125(3):465-72.

Mitchell G, Agnelli J. Non-pharmacological approaches to alleviate distress in dementia care. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*. 2015;30(13):38-44.

Mittelman MS. The DAISY psychosocial intervention does not improve outcomes in patients with mild Alzheimer's disease or their carers. *Evidence-based mental health*. 2013;16(1):15.

Miyamoto T, Kim D, Knox JA, Johnson E, Mucke L. Increasing the Receptor Tyrosine Kinase EphB2 Prevents Amyloid-beta-induced Depletion of Cell Surface Glutamate Receptors by a Mechanism That Requires the PDZ-binding Motif of EphB2 and Neuronal Activity. *The Journal of biological chemistry*. 2016;291(4):1719-34.

Mizrahi M, Friedman-Levi Y, Larush L, Frid K, Binyamin O, Dori D, et al. Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: the case of genetic CJD. *Nanomedicine : nanotechnology, biology, and medicine*. 2014;10(6):1353-63.

Mizuno D, Konoha-Mizuno K, Mori M, Sadakane Y, Koyama H, Ohkawara S, et al. Protective activity of carnosine and anserine against zinc-induced neurotoxicity: a possible treatment for vascular dementia. *Metallomics : integrated biometal science*. 2015;7(8):1233-9.

Mocchetti I, Campbell LA, Harry GJ, Avdoshina V. When human immunodeficiency virus meets chemokines and microglia: neuroprotection or neurodegeneration? *Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology*. 2013;8(1):118-31.

Modh RP, Kumar SP, Jasrai YT, Chikhaliya KH. Design, synthesis, biological evaluation, and molecular modeling of coumarin-piperazine derivatives as acetylcholinesterase inhibitors. *Archiv der Pharmazie*. 2013;346(11):793-804.

Modi KK, Jana A, Ghosh S, Watson R, Pahan K. A physically-modified saline suppresses neuronal apoptosis, attenuates tau phosphorylation and protects memory in an animal model of Alzheimer's disease. *PloS one*. 2014;9(8):e103606.

Modi KK, Jana A, Ghosh S, Watson R, Pahan K. Correction: A Physically-Modified Saline Suppresses Neuronal Apoptosis, Attenuates Tau Phosphorylation and Protects Memory in an Animal Model of Alzheimer's Disease. *PloS one*. 2017;12(6):e0180602.

Modi KK, Roy A, Brahmachari S, Rangasamy SB, Pahan K. Cinnamon and Its Metabolite Sodium Benzoate Attenuate the Activation of p21^{rac} and Protect Memory and Learning in an Animal Model of Alzheimer's Disease. *PloS one*. 2015;10(6):e0130398.

Mohagheghi F, Prudencio M, Stuaní C, Cook C, Jansen-West K, Dickson DW, et al. TDP-43 functions within a network of hnRNP proteins to inhibit the production of a truncated human SORT1 receptor. *Human molecular genetics*. 2016;25(3):534-45.

Mohaibes RJ, Fiol-deRoque MA, Torres M, Ordinas M, Lopez DJ, Castro JA, et al. The hydroxylated form of docosahexaenoic acid (DHA-H) modifies the brain lipid composition in a model of Alzheimer's disease, improving behavioral motor function and survival. *Biochimica et biophysica acta*. 2017;1859(9 Pt B):1596-603.

Mohammad Ahmadi Soleimani S, Ekhtiari H, Cadet JL. Drug-induced neurotoxicity in addiction medicine: From prevention to harm reduction. *Progress in brain research*. 2016;223:19-41.

Mohammad D, Chan P, Bradley J, Lanctot K, Herrmann N. Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. *Expert opinion on drug safety*. 2017;16(9):1009-19.

Mohammadi M, Guan J, Khodaghali F, Yans A, Khalaj S, Gholami M, et al. Reduction of autophagy markers mediated protective effects of JNK inhibitor and bucladesine on memory

deficit induced by Aβeta in rats. *Naunyn-Schmiedeberg's archives of pharmacology*. 2016;389(5):501-10.

Mohammadi-Farani A, Abdi N, Moradi A, Aliabadi A. 2-(2-(4-Benzoylpiperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives: Synthesis, docking and acetylcholinesterase inhibitory evaluation as anti-alzheimer agents. *Iranian journal of basic medical sciences*. 2017;20(1):59-66.

Mohammadi-Farani A, Ahmadi A, Nadri H, Aliabadi A. Synthesis, docking and acetylcholinesterase inhibitory assessment of 2-(2-(4-Benzylpiperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with potential anti-Alzheimer effects. *Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences*. 2013;21(1):47.

Mohammadi-Farani A, Soltani Darbandi S, Aliabadi A. Synthesis and Acetylcholinesterase Inhibitory Evaluation of 4-(1,3-Dioxoisindolin-2-yl)-N-Phenyl Benzamide Derivatives as Potential Anti-Alzheimer Agents. *Iranian journal of pharmaceutical research : IJPR*. 2016;15(3):313-20.

Mohle L, Israel N, Paarmann K, Krohn M, Pietkiewicz S, Muller A, et al. Chronic *Toxoplasma gondii* infection enhances beta-amyloid phagocytosis and clearance by recruited monocytes. *Acta neuropathologica communications*. 2016;4:25.

Mok NY, Chadwick J, Kellett KAB, Casas-Arce E, Hooper NM, Johnson AP, et al. Discovery of biphenylacetamide-derived inhibitors of BACE1 using de novo structure-based molecular design. *Journal of medicinal chemistry*. 2013;56(5):1843-52.

Mokhtari Z, Baluchnejadmojarad T, Nikbakht F, Mansouri M, Roghani M. Riluzole ameliorates learning and memory deficits in Aβeta₂₅₋₃₅-induced rat model of Alzheimer's disease and is independent of cholinceptor activation. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2017;87:135-44.

Moll van Charante EP, Richard E, Eurelings LS, van Dalen J-W, Ligthart SA, van Bussel EF, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. *Lancet (London, England)*. 2016;388(10046):797-805.

Moll van Charante EP, Richard E, Eurelings LS, van Dalen JW, Ligthart SA, van Bussel EF, et al. Is dementia preventable through intensive vascular care? The preDIVA trial. *Nederlands tijdschrift voor geneeskunde*. 2017;161(0):D1184.

Monacelli F, Rosa G. Cholinesterase inhibitors: cardioprotection in Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;42(4):1071-7.

Mondal K, Regnstrom K, Morishige W, Barbour R, Probst G, Xu Y-Z, et al. Thermodynamic and kinetic characterization of hydroxyethylamine beta-secretase-1 inhibitors. *Biochemical and biophysical research communications*. 2013;441(2):291-6.

Mondragon-Rodriguez S, Perry G, Pena-Ortega F, Williams S. Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease. *Current Alzheimer research*. 2017;14(1):40-6.

Montacute R, Foley K, Forman R, Else KJ, Cruickshank SM, Allan SM. Enhanced susceptibility of triple transgenic Alzheimer's disease (3xTg-AD) mice to acute infection. *Journal of neuroinflammation*. 2017;14(1):50.

Montecinos-Oliva C, Schuller A, Inestrosa NC. Tetrahydrohyperforin: a neuroprotective modified natural compound against Alzheimer's disease. *Neural regeneration research*. 2015;10(4):552-4.

Montecinos-Oliva C, Schuller A, Parodi J, Melo F, Inestrosa NC. Effects of tetrahydrohyperforin in mouse hippocampal slices: neuroprotection, long-term potentiation and TRPC channels. *Current medicinal chemistry*. 2014;21(30):3494-506.

Montero-Odasso M, Muir-Hunter SW, Oteng-Amoako A, Gopaul K, Islam A, Borrie M, et al. Donepezil improves gait performance in older adults with mild Alzheimer's disease: a phase II clinical trial. *Journal of Alzheimer's disease : JAD*. 2015;43(1):193-9.

Montoya JL, Iudicello J, Fazeli PL, Hong S, Potter M, Ellis RJ, et al. Elevated Markers of Vascular Remodeling and Arterial Stiffness Are Associated With Neurocognitive Function in Older HIV+ Adults on Suppressive Antiretroviral Therapy. *Journal of acquired immune deficiency syndromes (1999)*. 2017;74(2):134-41.

Moon M, Cha M-Y, Mook-Jung I. Impaired hippocampal neurogenesis and its enhancement with ghrelin in 5XFAD mice. *Journal of Alzheimer's disease : JAD*. 2014;41(1):233-41.

Moon M, Kim HG, Choi JG, Oh H, Lee PKJ, Ha SK, et al. 6-Shogaol, an active constituent of ginger, attenuates neuroinflammation and cognitive deficits in animal models of dementia. *Biochemical and biophysical research communications*. 2014;449(1):8-13.

Moon M, Song H, Hong HJ, Nam DW, Cha MY, Oh MS, et al. Vitamin D-binding protein interacts with Abeta and suppresses Abeta-mediated pathology. *Cell death and differentiation*. 2013;20(4):630-8.

Moore JR, Sullivan MM. Enhancing the ADMIT Me Tool for Care Transitions for Individuals With Alzheimer's Disease. *Journal of gerontological nursing*. 2017;43(5):32-8.

Moore RC, Chattillion EA, Ceglowski J, Ho J, von Kanel R, Mills PJ, et al. A randomized clinical trial of Behavioral Activation (BA) therapy for improving psychological and physical health in dementia caregivers: results of the Pleasant Events Program (PEP). *Behaviour research and therapy*. 2013;51(10):623-32.

Moorhouse B, Fisher CA. Long-Term use of Modified Diets in Huntington's Disease: A Descriptive Clinical Practice Analysis on Improving Dietary Enjoyment. *Journal of Huntington's disease*. 2016;5(1):15-7.

Morales-Corraliza J, Schmidt SD, Mazzella MJ, Berger JD, Wilson DA, Wesson DW, et al. Immunization targeting a minor plaque constituent clears beta-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model. *Neurobiology of aging*. 2013;34(1):137-45.

Moran LM, Booze RM, Mactutus CF. Modeling deficits in attention, inhibition, and flexibility in HAND. *Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology*. 2014;9(4):508-21.

Moran MT, Tare M, Kango-Singh M, Singh A. Homeotic Gene teashirt (tsh) has a neuroprotective function in amyloid-beta 42 mediated neurodegeneration. *PloS one*. 2013;8(11):e80829.

More SS, Vartak AP, Vince R. Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimer's disease. *ACS chemical neuroscience*. 2013;4(2):330-8.

Morelli A, Sarchielli E, Guarnieri G, Coppi E, Pantano D, Comeglio P, et al. Young Human Cholinergic Neurons Respond to Physiological Regulators and Improve Cognitive Symptoms in an Animal Model of Alzheimer's Disease. *Frontiers in cellular neuroscience*. 2017;11:339.

Morena F, Argentati C, Trotta R, Crispoltoni L, Stabile A, Pistilli A, et al. A Comparison of Lysosomal Enzymes Expression Levels in Peripheral Blood of Mild- and Severe-Alzheimer's Disease and MCI Patients: Implications for Regenerative Medicine Approaches. *International journal of molecular sciences*. 2017;18(8).

Moreno CL, Ehrlich ME, Mobbs CV. Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT. *Neurobiology of disease*. 2016;85:25-34.

Moreno PA, Hernando ME, Gomez EJ. Design and technical evaluation of an enhanced location-awareness service enabler for spatial disorientation management of elderly with mild cognitive impairment. *IEEE journal of biomedical and health informatics*. 2015;19(1):37-43.

Morgenstern U, Ketelhut K, Rosler D. Concentration enhancement for retaining daily living competence in dementia. *Zeitschrift fur Gerontologie und Geriatrie*. 2017;50(1):28-34.

Mori E, Ikeda M, Nakai K, Miyagishi H, Nakagawa M, Kosaka K. Increased plasma donepezil concentration improves cognitive function in patients with dementia with Lewy bodies: An exploratory pharmacokinetic/pharmacodynamic analysis in a phase 3 randomized controlled trial. *Journal of the neurological sciences*. 2016;366:184-90.

Mori I. Anti-herpesviral activity of curcumin may attenuate the development of Alzheimer's disease. *Medical hypotheses*. 2015;84(6):603.

Mori T, Koyama N, Guillot-Sestier M-V, Tan J, Town T. Ferulic acid is a nutraceutical beta-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. *PloS one*. 2013;8(2):e55774.

Mori T, Koyama N, Segawa T, Maeda M, Maruyama N, Kinoshita N, et al. Methylene blue modulates beta-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice. *The Journal of biological chemistry*. 2014;289(44):30303-17.

Mori T, Koyama N, Tan J, Segawa T, Maeda M, Town T. Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease. *The Journal of biological chemistry*. 2017;292(27):11310-25.

Moriguchi S, Tagashira H, Sasaki Y, Yeh JZ, Sakagami H, Narahashi T, et al. CaMKII activity is essential for improvement of memory-related behaviors by chronic rivastigmine treatment. *Journal of neurochemistry*. 2014;128(6):927-37.

Morita M, Hamada T, Vestergaard MdC, Takagi M. Endo- and exocytic budding transformation of slow-diffusing membrane domains induced by Alzheimer's amyloid beta. *Physical chemistry chemical physics : PCCP*. 2014;16(19):8773-7.

Morita T, Higuchi A, Ozaki A, Shimada Y, Tanimoto T. The possibility of vascular care for prevention of dementia. *Lancet (London, England)*. 2017;389(10065):152-3.

Mormino EC, Papp KV. Cognitive Decline in Preclinical Stage 2 Alzheimer Disease and Implications for Prevention Trials. *JAMA neurology*. 2016;73(6):640-2.

Morris JK, Vidoni ED, Mahnken JD, Montgomery RN, Johnson DK, Thyfault JP, et al. Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin. *Neurobiology of aging*. 2016;39:19-24.

Moruno-Manchon JF, Uzor N-E, Blasco-Conesa MP, Mannuru S, Putluri N, Furr-Stimming EE, et al. Inhibiting sphingosine kinase 2 mitigates mutant Huntingtin-induced neurodegeneration in neuron models of Huntington disease. *Human molecular genetics*. 2017;26(7):1305-17.

Moss DE, Fariello RG, Sahlmann J, Sumaya I, Pericle F, Braglia E. A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease. *British journal of clinical pharmacology*. 2013;75(5):1231-9.

Moss DE, Perez RG, Kobayashi H. Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates. *Journal of Alzheimer's disease : JAD*. 2017;55(3):1285-94.

Mosser S, Alattia J-R, Dimitrov M, Matz A, Pascual J, Schneider BL, et al. The adipocyte differentiation protein APMAP is an endogenous suppressor of Abeta production in the brain. *Human molecular genetics*. 2015;24(2):371-82.

Mossmann D, Vogtle FN, Taskin AA, Teixeira PF, Ring J, Burkhart JM, et al. Amyloid-beta peptide induces mitochondrial dysfunction by inhibition of preprotein maturation. *Cell metabolism*. 2014;20(4):662-9.

Mostafa DK, El Azhary NM, Nasra RA. The hydrogen sulfide releasing compounds ATB-346 and diallyl trisulfide attenuate streptozotocin-induced cognitive impairment, neuroinflammation, and oxidative stress in rats: involvement of asymmetric dimethylarginine. *Canadian journal of physiology and pharmacology*. 2016;94(7):699-708.

Moussa CEH. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. *Expert opinion on investigational drugs*. 2017;26(10):1131-6.

Moussavi Nik SH, Newman M, Wilson L, Ebrahimie E, Wells S, Musgrave I, et al. Alzheimer's disease-related peptide PS2V plays ancient, conserved roles in suppression of the unfolded protein response under hypoxia and stimulation of gamma-secretase activity. *Human molecular genetics*. 2015;24(13):3662-78.

Mowrey C, Parikh PJ, Bharwani G, Bharwani M. Application of behavior-based ergonomics therapies to improve quality of life and reduce medication usage for Alzheimer's/dementia residents. *American journal of Alzheimer's disease and other dementias*. 2013;28(1):35-41.

Mowszowski L, Hermens DF, Diamond K, Norrie L, Cockayne N, Ward PB, et al. Cognitive training enhances pre-attentive neurophysiological responses in older adults 'at risk' of dementia. *Journal of Alzheimer's disease : JAD*. 2014;41(4):1095-108.

Moyer VA, Force USPST. Screening for cognitive impairment in older adults: U.S. Preventive Services Task Force recommendation statement. *Annals of internal medicine*. 2014;160(11):791-7.

Moyle W, Arnautovska U, Ownsworth T, Jones C. Potential of telepresence robots to enhance social connectedness in older adults with dementia: an integrative review of feasibility. *International psychogeriatrics*. 2017;29(12):1951-64.

Moyle W, Jones CJ, Murfield JE, Thalib L, Beattie ERA, Shum DKH, et al. Use of a Robotic Seal as a Therapeutic Tool to Improve Dementia Symptoms: A Cluster-Randomized Controlled Trial. *Journal of the American Medical Directors Association*. 2017;18(9):766-73.

Mroczo B, Groblewska M, Zboch M, Kulczynska A, Koper OM, Szmitkowski M, et al. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;40(2):351-7.

Mu J-S, Lin H, Ye J-X, Lin M, Cui X-P. Rgl exhibits neuroprotective effects by inhibiting the endoplasmic reticulum stress-mediated c-Jun N-terminal protein kinase apoptotic pathway in a rat model of Alzheimer's disease. *Molecular medicine reports*. 2015;12(3):3862-8.

Mu S, Wang J, Zhou G, Peng W, He Z, Zhao Z, et al. Transplantation of induced pluripotent stem cells improves functional recovery in Huntington's disease rat model. *PloS one*. 2014;9(7):e101185.

Mubeen AM, Asaei A, Bachman AH, Sidtis JJ, Ardekani BA, Alzheimer's Disease Neuroimaging I. A six-month longitudinal evaluation significantly improves accuracy of predicting incipient Alzheimer's disease in mild cognitive impairment. *Journal of neuroradiology Journal de neuroradiologie*. 2017;44(6):381-7.

Mudar RA, Chapman SB, Rackley A, Eroh J, Chiang H-S, Perez A, et al. Enhancing latent cognitive capacity in mild cognitive impairment with gist reasoning training: a pilot study. *International journal of geriatric psychiatry*. 2017;32(5):548-55.

Mueller C, Perera G, Hayes RD, Shetty H, Stewart R. Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis. *Age and ageing*. 2017:1-7.

Mueller KD, Kosciak RL, LaRue A, Clark LR, Hermann B, Johnson SC, et al. Verbal Fluency and Early Memory Decline: Results from the Wisconsin Registry for Alzheimer's Prevention. *Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists*. 2015;30(5):448-57.

Mueller T, Haberstroh J, Knebel M, Oswald F, Kaspar R, Kemper CJ, et al. Assessing capacity to consent to treatment with cholinesterase inhibitors in dementia using a specific and standardized version of the MacArthur Competence Assessment Tool (MacCAT-T). *International psychogeriatrics*. 2017;29(2):333-43.

Mukadam N, Cooper C, Livingston G. Improving access to dementia services for people from minority ethnic groups. *Current opinion in psychiatry*. 2013;26(4):409-14.

Mullard A. BACE inhibitor bust in Alzheimer trial. *Nature reviews Drug discovery*. 2017;16(3):155.

Muller AP, Ferreira GK, Pires AJ, de Bem Silveira G, de Souza DL, Brandolfi JdA, et al. Gold nanoparticles prevent cognitive deficits, oxidative stress and inflammation in a rat model of sporadic dementia of Alzheimer's type. *Materials science & engineering C, Materials for biological applications*. 2017;77:476-83.

Muller P, Schmicker M, Muller NG. Erratum to: Preventive strategies for dementia. *Zeitschrift fur Gerontologie und Geriatrie*. 2017;50(3):264.

Muller P, Schmicker M, Muller NG. Preventive strategies for dementia. *Zeitschrift fur Gerontologie und Geriatrie*. 2017;50(Suppl 2):89-95.

Munn F. Simple ideas that could help remove the stigma associated with Alzheimer's disease. *Nursing older people*. 2017;29(6):8-9.

Munoz G, Urrutia JC, Burgos CF, Silva V, Aguilar F, Sama M, et al. Low concentrations of ethanol protect against synaptotoxicity induced by Abeta in hippocampal neurons. *Neurobiology of aging*. 2015;36(2):845-56.

Muradashvili N, Tyagi R, Metreveli N, Tyagi SC, Lominadze D. Ablation of MMP9 gene ameliorates paracellular permeability and fibrinogen-amyloid beta complex formation during hyperhomocysteinemia. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2014;34(9):1472-82.

Murakami T, Qamar S, Lin JQ, Schierle GSK, Rees E, Miyashita A, et al. ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function. *Neuron*. 2015;88(4):678-90.

Murakoshi Y, Takahashi T, Mihara H. Modification of a small beta-barrel protein, to give pseudo-amyloid structures, inhibits amyloid beta-peptide aggregation. *Chemistry (Weinheim an der Bergstrasse, Germany)*. 2013;19(14):4525-31.

Muralidharan P, Fishbaugh J, Johnson HJ, Durrleman S, Paulsen JS, Gerig G, et al. Diffeomorphic shape trajectories for improved longitudinal segmentation and statistics. *Medical image computing and computer-assisted intervention : MICCAI International Conference on Medical Image Computing and Computer-Assisted Intervention*. 2014;17(Pt 3):49-56.

Murphy KE, Park JJ. Can Co-Activation of Nrf2 and Neurotrophic Signaling Pathway Slow Alzheimer's Disease? *International journal of molecular sciences*. 2017;18(6).

Murphy M, Wilson YM, Vargas E, Munro KM, Smith B, Huang A, et al. Reduction of p75 neurotrophin receptor ameliorates the cognitive deficits in a model of Alzheimer's disease. *Neurobiology of aging*. 2015;36(2):740-52.

Murray AP, Faraoni MB, Castro MJ, Alza NP, Cavallaro V. Natural AChE Inhibitors from Plants and their Contribution to Alzheimer's Disease Therapy. *Current neuropharmacology*. 2013;11(4):388-413.

Murray F. Can Alzheimer's disease be prevented? *Intractable & rare diseases research*. 2013;2(4):136-8.

Murray MF. Genomics: Prediction, Prevention, Priorities, and Punnett. *Annals of internal medicine*. 2016;164(3):197-8.

Mury FB, da Silva WC, Barbosa NR, Mendes CT, Bonini JS, Sarkis JES, et al. Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimer's disease. *European archives of psychiatry and clinical neuroscience*. 2016;266(7):607-18.

Mushtaq G, Greig NH, Anwar F, Al-Abbasi FA, Zamzami MA, Al-Talhi HA, et al. Neuroprotective Mechanisms Mediated by CDK5 Inhibition. *Current pharmaceutical design*. 2016;22(5):527-34.

Muth F, Gunther M, Bauer SM, Doring E, Fischer S, Maier J, et al. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38alpha mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases. *Journal of medicinal chemistry*. 2015;58(1):443-56.

Muthaiyah B, Essa MM, Lee M, Chauhan V, Kaur K, Chauhan A. Dietary supplementation of walnuts improves memory deficits and learning skills in transgenic mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;42(4):1397-405.

Muthukumaran K, Kanwar A, Vegh C, Marginean A, Elliott A, Guilbeault N, et al. Ubisol-Q10 (a Nanomicellar Water- Soluble Formulation of CoQ10) Treatment Inhibits Alzheimer-Type Behavioral and Pathological Symptoms in a Double Transgenic Mouse (TgAPEswe, PSEN1dE9) Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017.

Mzik M, Korabecny J, Nepovimova E, Vorisek V, Palicka V, Kuca K, et al. An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. *Journal of chromatography B, Analytical technologies in the biomedical and life sciences*. 2016;1020:85-9.

Na J-Y, Song K, Lee J-W, Kim S, Kwon J. 6-Shogaol has anti-amyloidogenic activity and ameliorates Alzheimer's disease via CysLT1R-mediated inhibition of cathepsin B. *Biochemical and biophysical research communications*. 2016;477(1):96-102.

Nabavi SF, Braidy N, Habtemariam S, Sureda A, Manayi A, Nabavi SM. Neuroprotective Effects of Fisetin in Alzheimer's and Parkinson's Diseases: From Chemistry to Medicine. *Current topics in medicinal chemistry*. 2016;16(17):1910-5.

Nadkarni NK, Perera S, Snitz BE, Mathis CA, Price J, Williamson JD, et al. Association of Brain Amyloid-beta With Slow Gait in Elderly Individuals Without Dementia: Influence of Cognition and Apolipoprotein E epsilon4 Genotype. *JAMA neurology*. 2017;74(1):82-90.

Naeem F. Can cognitive remediation improve subsequent response to low-intensity cognitive behaviour therapy for psychosis in people with schizophrenia? *The Australian and New Zealand journal of psychiatry*. 2017;51(2):117-8.

Nagahara AH, Mateling M, Kovacs I, Wang L, Eggert S, Rockenstein E, et al. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(39):15596-602.

Nagai M, Hoshida S, Kario K. Role of 24-hour blood pressure management in preventing kidney disease and stroke. *Contributions to nephrology*. 2013;179:67-80.

Nagamatsu LS, Chan A, Davis JC, Beattie BL, Graf P, Voss MW, et al. Physical activity improves verbal and spatial memory in older adults with probable mild cognitive impairment: a 6-month randomized controlled trial. *Journal of aging research*. 2013;2013:861893.

Naghizadeh B, Mansouri MT, Ghorbanzadeh B, Farbood Y, Sarkaki A. Protective effects of oral crocin against intracerebroventricular streptozotocin-induced spatial memory deficit and oxidative stress in rats. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2013;20(6):537-42.

Nagy D, Tingley FD, 3rd, Stoiljkovic M, Hajos M. Application of neurophysiological biomarkers for Huntington's disease: evaluating a phosphodiesterase 9A inhibitor. *Experimental neurology*. 2015;263:122-31.

Naharci MI, Ozturk A, Yasar H, Cintosun U, Kocak N, Bozoglu E, et al. Galantamine improves sleep quality in patients with dementia. *Acta neurologica Belgica*. 2015;115(4):563-8.

Naia L, Cunha-Oliveira T, Rodrigues J, Rosenstock TR, Oliveira A, Ribeiro M, et al. Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(10):2776-94.

Naia L, Ferreira IL, Cunha-Oliveira T, Duarte AI, Ribeiro M, Rosenstock TR, et al. Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington's Disease human lymphoblasts. *Molecular neurobiology*. 2015;51(1):331-48.

Najafi Z, Mahdavi M, Saeedi M, Karimpour-Razkenari E, Asatouri R, Vafadarnejad F, et al. Novel tacrine-1,2,3-triazole hybrids: Invitro, invivo biological evaluation and docking study of cholinesterase inhibitors. *European journal of medicinal chemistry*. 2017;125:1200-12.

Nakagawa T, Itoh M, Ohta K, Hayashi Y, Hayakawa M, Yamada Y, et al. Improvement of memory recall by quercetin in rodent contextual fear conditioning and human early-stage Alzheimer's disease patients. *Neuroreport*. 2016;27(9):671-6.

Nakajima A, Aoyama Y, Shin E-J, Nam Y, Kim H-C, Nagai T, et al. Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble Abeta levels in a triple transgenic mouse model of Alzheimer's disease (3XTg-AD). *Behavioural brain research*. 2015;289:69-77.

Nakamura Y, Yoshiyama Y. Cognitive Function and Calcium. Suppression of neurotoxicity by an anti-dementia drug managing calcium influx. *Clinical calcium*. 2015;25(2):263-73.

Nakanishi A, Minami A, Kitagishi Y, Ogura Y, Matsuda S. BRCA1 and p53 tumor suppressor molecules in Alzheimer's disease. *International journal of molecular sciences*. 2015;16(2):2879-92.

Nakanishi M, Hattori K. Percutaneous endoscopic gastrostomy (PEG) tubes are placed in elderly adults in Japan with advanced dementia regardless of expectation of improvement in quality of life. *The journal of nutrition, health & aging*. 2014;18(5):503-9.

Naninck EFG, Oosterink JE, Yam K-Y, de Vries LP, Schierbeek H, van Goudoever JB, et al. Early micronutrient supplementation protects against early stress-induced cognitive impairments. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2017;31(2):505-18.

Naqvi R, Liberman D, Rosenberg J, Alston J, Straus S. Preventing cognitive decline in healthy older adults. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2013;185(10):881-5.

Naranjo JR, Zhang H, Villar D, Gonzalez P, Dopazo XM, Moron-Oset J, et al. Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease. *The Journal of clinical investigation*. 2016;126(2):627-38.

Nardo L, Re F, Brioschi S, Cazzaniga E, Orlando A, Minniti S, et al. Fluorimetric detection of the earliest events in amyloid beta oligomerization and its inhibition by pharmacologically active liposomes. *Biochimica et biophysica acta*. 2016;1860(4):746-56.

Nascimento CMC, Pereira JR, Pires de Andrade L, Garuffi M, Ayan C, Kerr DS, et al. Physical exercise improves peripheral BDNF levels and cognitive functions in mild cognitive impairment elderly with different bdnf Val66Met genotypes. *Journal of Alzheimer's disease : JAD*. 2015;43(1):81-91.

Natarajan P, Priyadarshini V, Pradhan D, Manne M, Swargam S, Kanipakam H, et al. E-pharmacophore-based virtual screening to identify GSK-3beta inhibitors. *Journal of receptor and signal transduction research*. 2016;36(5):445-58.

Nattinger MC, Kaskie B. Determinants of the Rigor of State Protection Policies for Persons With Dementia in Assisted Living. *Journal of aging & social policy*. 2017;29(2):123-42.

Nawaz R, Asif H, Khan A, Ishtiaq H, Shad F, Siddiqui S. Drugs targeting SNPrs35753505 of the NRG1 gene may prevent the association of neurological disorder schizophrenia in a Pakistani population. *CNS & neurological disorders drug targets*. 2014;13(9):1604-14.

Naydenov AV, Sepers MD, Swinney K, Raymond LA, Palmiter RD, Stella N. Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice. *Neurobiology of disease*. 2014;71:140-50.

Nayton K, Fielding E, Brooks D, Graham FA, Beattie E. Development of an education program to improve care of patients with dementia in an acute care setting. *Journal of continuing education in nursing*. 2014;45(12):552-8.

Nazir A, Smucker WD. Heart Failure in Post-Acute and Long-Term Care: Evidence and Strategies to Improve Transitions, Clinical Care, and Quality of Life. *Journal of the American Medical Directors Association*. 2015;16(10):825-31.

Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, et al. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). *Journal of neurovirology*. 2014;20(6):571-82.

Nedlund A-C, Taghizadeh Larsson A. To protect and to support: How citizenship and self-determination are legally constructed and managed in practice for people living with dementia in Sweden. *Dementia (London, England)*. 2016;15(3):343-57.

Neha, Kumar A, Jaggi AS, Sodhi RK, Singh N. Silymarin ameliorates memory deficits and neuropathological changes in mouse model of high-fat-diet-induced experimental dementia. *Naunyn-Schmiedeberg's archives of pharmacology*. 2014;387(8):777-87.

Nehlig A. The neuroprotective effects of cocoa flavanol and its influence on cognitive performance. *British journal of clinical pharmacology*. 2013;75(3):716-27.

Nehls M. Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy. *Journal of molecular psychiatry*. 2016;4:3.

Nelson L, Tabet N. Slowing the progression of Alzheimer's disease; what works? *Ageing research reviews*. 2015;23(Pt B):193-209.

Nemetchek MD, Stierle AA, Stierle DB, Lurie DI. The Ayurvedic plant *Bacopa monnieri* inhibits inflammatory pathways in the brain. *Journal of ethnopharmacology*. 2017;197:92-100.

Nenov MN, Tempia F, Denner L, Dineley KT, Laezza F. Impaired firing properties of dentate granule neurons in an Alzheimer's disease animal model are rescued by PPARgamma agonism. *Journal of neurophysiology*. 2015;113(6):1712-26.

Nery LR, Eltz NS, Hackman C, Fonseca R, Altenhofen S, Guerra HN, et al. Brain intraventricular injection of amyloid-beta in zebrafish embryo impairs cognition and increases tau phosphorylation, effects reversed by lithium. *PloS one*. 2014;9(9):e105862.

Nestrasil I, Shapiro E, Svatkova A, Dickson P, Chen A, Wakumoto A, et al. Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I. *American journal of medical genetics Part A*. 2017;173(3):780-3.

Neudorfer C, Shanab K, Jurik A, Schreiber V, Neudorfer C, Vraka C, et al. Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2014;24(18):4490-5.

Neumann B, Yarman A, Wollenberger U, Scheller F. Characterization of the enhanced peroxidatic activity of amyloid beta peptide-hemin complexes towards neurotransmitters. *Analytical and bioanalytical chemistry*. 2014;406(14):3359-64.

Neumann U, Rueeger H, Machauer R, Veenstra SJ, Lueoend RM, Tintelnot-Blomley M, et al. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-beta and neuroinflammation in APP transgenic mice. *Molecular neurodegeneration*. 2015;10:44.

Nevado-Holgado AJ, Lovestone S. Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach. *Computational and structural biotechnology journal*. 2017;15:1-7.

Nevler N, Korczyn AD. Life style and the prevention of dementia. *Neuroepidemiology*. 2015;44(2):83-4.

New diet may protect against Alzheimer's. *Perspectives in public health*. 2015;135(3):112.

Newman M, Wilson L, Verdile G, Lim A, Khan I, Moussavi Nik SH, et al. Differential, dominant activation and inhibition of Notch signalling and APP cleavage by truncations of PSEN1 in human disease. *Human molecular genetics*. 2014;23(3):602-17.

Newsome RN, Duarte A, Pun C, Smith VM, Ferber S, Barense MD. A retroactive spatial cue improved VSTM capacity in mild cognitive impairment and medial temporal lobe amnesia but not in healthy older adults. *Neuropsychologia*. 2015;77:148-57.

Nexo MA, Meng A, Borg V. Can psychosocial work conditions protect against age-related cognitive decline? Results from a systematic review. *Occupational and environmental medicine*. 2016;73(7):487-96.

Ng KP, Ng A, Assam P, Heng E, Kandiah N. Role of cognitive enhancer therapy in Alzheimer's disease with concomitant cerebral white matter disease: findings from a long-term naturalistic study. *Drugs in R&D*. 2014;14(3):195-203.

Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. *Alzheimer's research & therapy*. 2017;9(1):25.

Ng LF, Gruber J, Cheah IK, Goo CK, Cheong WF, Shui G, et al. The mitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic *Caenorhabditis elegans* model of Alzheimer disease. *Free radical biology & medicine*. 2014;71:390-401.

Ng RC-L, Chan K-H. Potential Neuroprotective Effects of Adiponectin in Alzheimer's Disease. *International journal of molecular sciences*. 2017;18(3).

Ngo ST, Fang S-T, Huang S-H, Chou C-L, Huy PDQ, Li MS, et al. Anti-arrhythmic Medication Propafenone a Potential Drug for Alzheimer's Disease Inhibiting Aggregation of Aβeta: In Silico and in Vitro Studies. *Journal of chemical information and modeling*. 2016;56(7):1344-56.

Nguyen HT, Sawmiller DR, Markov O, Chen M. Elevated Ca²⁺ i levels occur with decreased calpain activity in aged fibroblasts and their reversal by energy-rich compounds: new paradigm for Alzheimer's disease prevention. *Journal of Alzheimer's disease : JAD*. 2013;37(4):835-48.

Nguyen L, Hur C. Proton Pump Inhibitors and Dementia Incidence. *JAMA neurology*. 2016;73(8):1027-8.

Nguyen M, Pachana NA, Beattie E, Fielding E, Ramis M-A. Effectiveness of interventions to improve family-staff relationships in the care of people with dementia in residential aged care: a systematic review protocol. *JBIC database of systematic reviews and implementation reports*. 2015;13(11):52-63.

Nguyen TL, Fruit C, Herault Y, Meijer L, Besson T. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature. *Expert opinion on therapeutic patents*. 2017;27(11):1183-99.

Nho K, Kim S, Risacher SL, Shen L, Corneveaux JJ, Swaminathan S, et al. Protective variant for hippocampal atrophy identified by whole exome sequencing. *Annals of neurology*. 2015;77(3):547-52.

Nichols P, Horner B, Fyfe K. Understanding and improving communication processes in an increasingly multicultural aged care workforce. *Journal of aging studies*. 2015;32:23-31.

Nie C, Nie H, Zhao Y, Wu J, Zhang X. Betaine reverses the memory impairments in a chronic cerebral hypoperfusion rat model. *Neuroscience letters*. 2016;615:9-14.

Nie H, Wang Z, Zhao W, Lu J, Zhang C, Lok K, et al. New nicotinic analogue ZY-1 enhances cognitive functions in a transgenic mice model of Alzheimer's disease. *Neuroscience letters*. 2013;537:29-34.

Nie L, Wei G, Peng S, Qu Z, Yang Y, Yang Q, et al. Melatonin ameliorates anxiety and depression-like behaviors and modulates proteomic changes in triple transgenic mice of Alzheimer's disease. *BioFactors (Oxford, England)*. 2017;43(4):593-611.

Nielsen TR, Phung TKT, Chaaya M, Mackinnon A, Waldemar G. Combining the Rowland Universal Dementia Assessment Scale and the Informant Questionnaire on Cognitive Decline in the Elderly to Improve Detection of Dementia in an Arabic-Speaking Population. *Dementia and geriatric cognitive disorders*. 2016;41(1-2):46-54.

Niemantsverdriet E, Ottoy J, Somers C, De Roeck E, Struyfs H, Soetewey F, et al. The Cerebrospinal Fluid Abeta1-42/Abeta1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. *Journal of Alzheimer's disease : JAD*. 2017;60(2):561-76.

Nieuwboer MS, Richters A, van der Marck MA. Triple aim improvement for individuals, services and society in dementia care : The DementiaNet collaborative care approach. *Zeitschrift fur Gerontologie und Geriatrie*. 2017;50(Suppl 2):78-83.

Nigam SM, Xu S, Kritikou JS, Marosi K, Brodin L, Mattson MP. Exercise and BDNF reduce Abeta production by enhancing alpha-secretase processing of APP. *Journal of neurochemistry*. 2017;142(2):286-96.

Nijhof N, van Gemert-Pijnen LJEWC, Woolrych R, Sixsmith A. An evaluation of preventive sensor technology for dementia care. *Journal of telemedicine and telecare*. 2013;19(2):95-100.

Nikolakopoulou AM, Georgakopoulos A, Robakis NK. Presenilin 1 promotes trypsin-induced neuroprotection via the PAR2/ERK signaling pathway. Effects of presenilin 1 FAD mutations. *Neurobiology of aging*. 2016;42:41-9.

Nillert N, Pannangrong W, Welbat JU, Chaijaroonkhanarak W, Sripanidkulchai K, Sripanidkulchai B. Neuroprotective Effects of Aged Garlic Extract on Cognitive Dysfunction and Neuroinflammation Induced by beta-Amyloid in Rats. *Nutrients*. 2017;9(1).

Nilsson M, Szczepankiewicz F, van Westen D, Hansson O. Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinson's Disease Dementia. *PloS one*. 2015;10(11):e0141825.

Ning R, Lei Y, Liu S, Wang H, Zhang R, Wang W, et al. Natural beta-Dihydroagarofuran-Type Sesquiterpenoids as Cognition-Enhancing and Neuroprotective Agents from Medicinal Plants of the Genus *Celastrus*. *Journal of natural products*. 2015;78(9):2175-86.

Nisha SA, Devi KP. *Gelidiella acerosa* protects against Abeta 25-35-induced toxicity and memory impairment in Swiss Albino mice: an in vivo report. *Pharmaceutical biology*. 2017;55(1):1423-35.

Nishigaki Y, Tanaka K, Kim J, Nakajima K. Development of an image processing support system based on fluorescent dye to prevent elderly people with dementia from wandering. Conference proceedings : Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual Conference. 2013;2013:7302-5.

Nishioka H, Tooi N, Isobe T, Nakatsuji N, Aiba K. BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer's disease models. *Scientific reports*. 2016;6:33427.

Nitta E, Onoda K, Ishitobi F, Okazaki R, Mishima S, Nagai A, et al. Enhanced Feedback-Related Negativity in Alzheimer's Disease. *Frontiers in human neuroscience*. 2017;11:179.

Niu F, Yao H, Zhang W, Sutliff RL, Buch S. Tat 101-mediated enhancement of brain pericyte migration involves platelet-derived growth factor subunit B homodimer: implications for human immunodeficiency virus-associated neurocognitive disorders. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(35):11812-25.

Niu Q, Yi Y, Sun X, Li T, Zhang B, Chen H, et al. The G41D mutation in the superoxide dismutase 1 gene is associated with slow motor neuron progression and mild cognitive impairment in a Chinese family with amyotrophic lateral sclerosis. *Journal of neurology, neurosurgery, and psychiatry*. 2016;87(7):788-9.

Niva C, Parkinson J, Olsson F, van Schaick E, Lundkvist J, Visser SAG. Has inhibition of Abeta production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of gamma-secretase inhibitor data. *European journal of clinical pharmacology*. 2013;69(6):1247-60.

Noble JM, Hedmann MG, Williams O. Improving dementia health literacy using the FLOW mnemonic: pilot findings from the Old SCHOOL hip-hop program. *Health education & behavior : the official publication of the Society for Public Health Education*. 2015;42(1):73-83.

Noda Y, Asada M, Kubota M, Maesako M, Watanabe K, Uemura M, et al. Copper enhances APP dimerization and promotes Abeta production. *Neuroscience letters*. 2013;547:10-5.

Noel A, Ingrand S, Barrier L. Inhibition of GSK3beta by pharmacological modulation of sphingolipid metabolism occurs independently of ganglioside disturbance in a cellular model of Alzheimer's disease. *Experimental neurology*. 2015;271:308-18.

Nogara PA, Saraiva RdA, Caeran Bueno D, Lissner LJ, Lenz Dalla Corte C, Braga MM, et al. Virtual screening of acetylcholinesterase inhibitors using the Lipinski's rule of five and ZINC databank. *BioMed research international*. 2015;2015:870389.

Noh M-Y, Chun K, Kang BY, Kim H, Park J-S, Lee H-C, et al. Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease. *Biochemical and biophysical research communications*. 2013;435(2):274-81.

Nolan W, McHale-Owen H, Bate C. Sialylated glycosylphosphatidylinositols suppress the production of toxic amyloid-beta oligomers. *The Biochemical journal*. 2017;474(17):3045-58.

Nomura J, Hosoi T, Kaneko M, Ozawa K, Nishi A, Nomura Y. Neuroprotection by Endoplasmic Reticulum Stress-Induced HRD1 and Chaperones: Possible Therapeutic Targets for Alzheimer's and Parkinson's Disease. *Medical sciences (Basel, Switzerland)*. 2016;4(3).

Nordstrom P, Religa D, Wimo A, Winblad B, Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. *European heart journal*. 2013;34(33):2585-91.

Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. *The Lancet Neurology*. 2014;13(8):788-94.

Nourishing Xin and Shen method improved mild cognitive impairment due to subcortical small vessel disease: a clinical study. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine*. 2015;35(1):41-5.

Nuechterlein KH, Ventura J, McEwen SC, Gretchen-Doorly D, Vinogradov S, Subotnik KL. Enhancing Cognitive Training Through Aerobic Exercise After a First Schizophrenia Episode: Theoretical Conception and Pilot Study. *Schizophrenia bulletin*. 2016;42 Suppl 1:S44-52.

Numadate A, Mita Y, Matsumoto Y, Fujii S, Hashimoto Y. Development of 2-thioxoquinazoline-4-one derivatives as dual and selective inhibitors of dynamin-related protein 1 (Drp1) and puromycin-sensitive aminopeptidase (PSA). *Chemical & pharmaceutical bulletin*. 2014;62(10):979-88.

Nunes A, Marques SM, Quintanova C, Silva DF, Cardoso SM, Chaves S, et al. Multifunctional iron-chelators with protective roles against neurodegenerative diseases. Dalton transactions (Cambridge, England : 2003). 2013;42(17):6058-73.

Nunes MA, Schowe NM, Monteiro-Silva KC, Baraldi-Tornisielo T, Souza SIG, Balthazar J, et al. Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer's Disease. PloS one. 2015;10(11):e0142267.

Nunes MA, Schowe NM, Monteiro-Silva KC, Baraldi-Tornisielo T, Souza SIG, Balthazar J, et al. Correction: Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer's Disease. PloS one. 2015;10(12):e0145695.

Nunomura A, Zhu X, Perry G. Modulation of Parkinson's Disease Associated Protein Rescues Alzheimer's Disease Degeneration. Journal of Alzheimer's disease : JAD. 2017;55(1):73-5.

Nuriel T, Angulo SL, Khan U, Ashok A, Chen Q, Figueroa HY, et al. Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer's disease-like pathology. Nature communications. 2017;8(1):1464.

Nyandoro S, Pickering S. Improving care for people with dementia in Devon. Community practitioner : the journal of the Community Practitioners' & Health Visitors' Association. 2014;87(10):45.

Nygaard HB, Kaufman AC, Sekine-Konno T, Huh LL, Going H, Feldman SJ, et al. Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer's disease mouse model. Alzheimer's research & therapy. 2015;7(1):25.

Nygaard HB, van Dyck CH, Strittmatter SM. Fyn kinase inhibition as a novel therapy for Alzheimer's disease. Alzheimer's research & therapy. 2014;6(1):8.

Nyman SR, Szymczynska P. Meaningful activities for improving the wellbeing of people with dementia: beyond mere pleasure to meeting fundamental psychological needs. Perspectives in public health. 2016;136(2):99-107.

Oberman LM, Pascual-Leone A. Hyperplasticity in Autism Spectrum Disorder confers protection from Alzheimer's disease. Medical hypotheses. 2014;83(3):337-42.

Oboh G, Agunloye OM, Akinyemi AJ, Ademiluyi AO, Adefegha SA. Comparative study on the inhibitory effect of caffeic and chlorogenic acids on key enzymes linked to Alzheimer's disease and some pro-oxidant induced oxidative stress in rats' brain-in vitro. Neurochemical research. 2013;38(2):413-9.

Oboh G, Akinyemi AJ, Ademiluyi AO, Bello FO. Inhibitory effect of some tropical green leafy vegetables on key enzymes linked to Alzheimer's disease and some pro-oxidant induced lipid peroxidation in rats' brain. *Journal of food science and technology*. 2014;51(5):884-91.

O'Brien JT. The importance of longitudinal cohort studies in understanding risk and protective factors for dementia. *International psychogeriatrics*. 2014;26(4):541-2.

Obulesu M, Jhansilakshmi M. Neuroprotective Role of Nanoparticles Against Alzheimer's Disease. *Current drug metabolism*. 2016;17(2):142-9.

O'Callaghan C, Hodges JR, Hornberger M. Inhibitory dysfunction in frontotemporal dementia: a review. *Alzheimer disease and associated disorders*. 2013;27(2):102-8.

O'Callaghan C, Naismith SL, Hodges JR, Lewis SJG, Hornberger M. Fronto-striatal atrophy correlates of inhibitory dysfunction in Parkinson's disease versus behavioural variant frontotemporal dementia. *Cortex; a journal devoted to the study of the nervous system and behavior*. 2013;49(7):1833-43.

O'Callaghan C, Naismith SL, Shine JM, Bertoux M, Lewis SJG, Hornberger M. A novel bedside task to tap inhibitory dysfunction and fronto-striatal atrophy in Parkinson's disease. *Parkinsonism & related disorders*. 2013;19(9):827-30.

O'Callaghan N, Parletta N, Milte CM, Benassi-Evans B, Fenech M, Howe PRC. Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with omega-3 fatty acid supplementation: a randomized controlled pilot study. *Nutrition (Burbank, Los Angeles County, Calif)*. 2014;30(4):489-91.

O'Caoimh R, Healy L, Gao Y, Svendrovski A, Kerins DM, Eustace J, et al. Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;40(3):595-603.

O'Caoimh R, Kehoe PG, Molloy DW. Renin Angiotensin aldosterone system inhibition in controlling dementia-related cognitive decline. *Journal of Alzheimer's disease : JAD*. 2014;42 Suppl 4:S575-86.

Ochoa JG. Topiramate improves psychiatric symptoms in a patient with Lewy body dementia. *Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology*. 2014;27(4):222-3.

O'Connor CM, Clemson L, Brodaty H, Gitlin LN, Piguet O, Mioshi E. Enhancing caregivers' understanding of dementia and tailoring activities in frontotemporal dementia: two case studies. *Disability and rehabilitation*. 2016;38(7):704-14.

Odenheimer G, Borson S, Sanders AE, Swain-Eng RJ, Kyomen HH, Tierney S, et al. Quality improvement in neurology: dementia management quality measures (executive summary). The American journal of occupational therapy : official publication of the American Occupational Therapy Association. 2013;67(6):704-10.

Odenheimer G, Borson S, Sanders AE, Swain-Eng RJ, Kyomen HH, Tierney S, et al. Quality improvement in neurology: dementia management quality measures. Journal of the American Geriatrics Society. 2014;62(3):558-61.

Odenheimer G, Borson S, Sanders AE, Swain-Eng RJ, Kyomen HH, Tierney S, et al. Quality improvement in neurology: dementia management quality measures. Neurology. 2013;81(17):1545-9.

Oehlrich D, Prokopcova H, Gijzen HJM. The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorganic & medicinal chemistry letters. 2014;24(9):2033-45.

Office P. Correction: Do cognitive interventions improve general cognition in dementia? a meta-analysis and meta-regression. BMJ open. 2017;7(8):e005247corr1.

Ogino R, Murayama N, Noshita T, Takemoto N, Toba T, Oka T, et al. SUN11602 has basic fibroblast growth factor-like activity and attenuates neuronal damage and cognitive deficits in a rat model of Alzheimer's disease induced by amyloid beta and excitatory amino acids. Brain research. 2014;1585:159-66.

Ogunraku OO, Oboh G, Passamonti S, Trammer F, Boligon AA. Capsicum annum var. grossum (Bell Pepper) Inhibits beta-Secretase Activity and beta-Amyloid1-40 Aggregation. Journal of medicinal food. 2017;20(2):124-30.

Oh J, Lee H-J, Song J-H, Park SI, Kim H. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease. Experimental gerontology. 2014;60:87-91.

Oh S, Son M, Choi J, Lee S, Byun K. sRAGE prolonged stem cell survival and suppressed RAGE-related inflammatory cell and T lymphocyte accumulations in an Alzheimer's disease model. Biochemical and biophysical research communications. 2017.

Oh SH, Kim HN, Park H-J, Shin JY, Lee PH. Mesenchymal Stem Cells Increase Hippocampal Neurogenesis and Neuronal Differentiation by Enhancing the Wnt Signaling Pathway in an Alzheimer's Disease Model. Cell transplantation. 2015;24(6):1097-109.

O'Hare E, Scopes DIC, Kim E-M, Palmer P, Jones M, Whymant AD, et al. Orally bioavailable small molecule drug protects memory in Alzheimer's disease models. Neurobiology of aging. 2013;34(4):1116-25.

Ohba T, Yoshino Y, Ishisaka M, Abe N, Tsuruma K, Shimazawa M, et al. Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice. *Bioscience, biotechnology, and biochemistry*. 2015;79(11):1838-44.

Ohia-Nwoko O, Montazari S, Lau Y-S, Eriksen JL. Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice. *Molecular neurodegeneration*. 2014;9:54.

Ohizumi Y. A new strategy for preventive and functional therapeutic methods for dementia--approach using natural products. *Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan*. 2015;135(3):449-64.

Ohno M, Hiraoka Y, Lichtenthaler SF, Nishi K, Saijo S, Matsuoka T, et al. Nardilysin prevents amyloid plaque formation by enhancing alpha-secretase activity in an Alzheimer's disease mouse model. *Neurobiology of aging*. 2014;35(1):213-22.

Ohta Y, Darwish M, Hishikawa N, Yamashita T, Sato K, Takemoto M, et al. Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease. *Geriatrics & gerontology international*. 2017.

Oikonomidi A, Tautvydaite D, Gholamrezaee MM, Henry H, Bacher M, Popp J. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia. *Journal of Alzheimer's disease : JAD*. 2017;60(1):273-81.

Ojagbemi A, Owolabi M. Do occupational therapy interventions improve quality of life in persons with dementia? A meta-analysis with implications for future directions. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2017;17(2):133-41.

Okabayashi S, Shimozaawa N, Yasutomi Y, Yanagisawa K, Kimura N. Diabetes mellitus accelerates Abeta pathology in brain accompanied by enhanced GAbeta generation in nonhuman primates. *PloS one*. 2015;10(2):e0117362.

Okonkwo OC, Schultz SA, Oh JM, Larson J, Edwards D, Cook D, et al. Physical activity attenuates age-related biomarker alterations in preclinical AD. *Neurology*. 2014;83(19):1753-60.

Okumura Y, Togo T, Fujita J. Trends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010. *International psychogeriatrics*. 2015;27(3):407-15.

Olajide OJ, Ugbosanmi AT, Enaibe BU, Ogunrinola KY, Lewu SF, Asogwa NT, et al. Cerebellar Molecular and Cellular Characterization in Rat Models of Alzheimer's Disease: Neuroprotective Mechanisms of Garcinia Biflavonoid Complex. *Annals of neurosciences*. 2017;24(1):32-45.

Olajide OJ, Yawson EO, Gbadamosi IT, Arogundade TT, Lambe E, Obasi K, et al. Ascorbic acid ameliorates behavioural deficits and neuropathological alterations in rat model of Alzheimer's disease. *Environmental toxicology and pharmacology*. 2017;50:200-11.

Olanrewaju O, Clare L, Barnes L, Brayne C. A multimodal approach to dementia prevention: A report from the Cambridge Institute of Public Health. *Alzheimer's & dementia (New York, N Y)*. 2015;1(3):151-6.

Olazarán J, Navarro E, Rojo JM. Persistence of cholinesterase inhibitor treatment in dementia: insights from a naturalistic study. *Dementia and geriatric cognitive disorders extra*. 2013;3(1):48-59.

Oliveira AM, Cardoso SM, Ribeiro M, Seixas RSGR, Silva AMS, Rego AC. Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington's disease mouse striatal cells. *Neurochemistry international*. 2015;91:1-12.

Oliveira AP, Matos RP, Silva ST, Andrade PB, Ferreres F, Gil-Izquierdo A, et al. A new iced tea base herbal beverage with *Spergularia rubra* extract: metabolic profile stability and in vitro enzyme inhibition. *Journal of agricultural and food chemistry*. 2013;61(36):8650-6.

Oliveira MF, Chaillon A, Nakazawa M, Vargas M, Letendre SL, Strain MC, et al. Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations. *PLoS pathogens*. 2017;13(1):e1006112.

Olivera-Perez HM, Lam L, Dang J, Jiang W, Rodriguez F, Rigali E, et al. Omega-3 fatty acids increase the unfolded protein response and improve amyloid-beta phagocytosis by macrophages of patients with mild cognitive impairment. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2017;31(10):4359-69.

Olmos-Alonso A, Schettters STT, Sri S, Askew K, Mancuso R, Vargas-Caballero M, et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology. *Brain : a journal of neurology*. 2016;139(Pt 3):891-907.

Olsen I, Taubman MA, Singhrao SK. *Porphyromonas gingivalis* suppresses adaptive immunity in periodontitis, atherosclerosis, and Alzheimer's disease. *Journal of oral microbiology*. 2016;8:33029.

Olszewski RT, Janczura KJ, Bzdega T, Der EK, Venzor F, O'Rourke B, et al. NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication. *Neurochemical research*. 2017;42(9):2646-57.

Omar SH, Scott CJ, Hamlin AS, Obied HK. The protective role of plant biophenols in mechanisms of Alzheimer's disease. *The Journal of nutritional biochemistry*. 2017;47:1-20.

Ong W-Y, Tanaka K, Dawe GS, Ittner LM, Farooqui AA. Slow excitotoxicity in Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2013;35(4):643-68.

Ongali B, Nicolakakis N, Tong X-K, Aboukassim T, Imboden H, Hamel E. Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;51(4):1183-95.

Ongali B, Nicolakakis N, Tong X-K, Aboukassim T, Papadopoulos P, Rosa-Neto P, et al. Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model. *Neurobiology of disease*. 2014;68:126-36.

Ooi J, Hayden MR, Pouladi MA. Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease. *Molecular neurobiology*. 2015;52(3):1850-61.

Oostendorp JC, Montel SR. Singing can enhance episodic memory functioning in elderly people with Alzheimer's disease. *Journal of the American Geriatrics Society*. 2014;62(5):982-3.

O'Regan J, Lanctot KL, Mazereeuw G, Herrmann N. Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials. *The Journal of clinical psychiatry*. 2015;76(11):e1424-31.

Orehek AJ. Dementia Improvement after Plasma Exchange for Familial Hypercholesterolemia. *Case reports in neurological medicine*. 2016;2016:6121878.

Orhan IE. Implications of some selected flavonoids towards Alzheimer's disease with the emphasis on cholinesterase inhibition and their bioproduction by metabolic engineering. *Current pharmaceutical biotechnology*. 2014;15(4):352-61.

Ormeno D, Romero F, Lopez-Fenner J, Avila A, Martinez-Torres A, Parodi J. Ethanol reduces amyloid aggregation in vitro and prevents toxicity in cell lines. *Archives of medical research*. 2013;44(1):1-7.

Oron A, Oron U. Low-Level Laser Therapy to the Bone Marrow Ameliorates Neurodegenerative Disease Progression in a Mouse Model of Alzheimer's Disease: A Minireview. *Photomedicine and laser surgery*. 2016;34(12):627-30.

Orr ME, Garbarino VR, Salinas A, Buffenstein R. Sustained high levels of neuroprotective, high molecular weight, phosphorylated tau in the longest-lived rodent. *Neurobiology of aging*. 2015;36(3):1496-504.

Orrell M, Brayne C, Interdem, Alzheimer E, Alzheimer's Disease I, European Association of Geriatric P. Dementia prevention: call to action. *Lancet* (London, England). 2015;386(10004):1625.

Orru CD, Hughson AG, Groveman BR, Campbell KJ, Anson KJ, Manca M, et al. Factors That Improve RT-QuIC Detection of Prion Seeding Activity. *Viruses*. 2016;8(5).

Osborne C, West E, Nolan W, McHale-Owen H, Williams A, Bate C. Glimepiride protects neurons against amyloid-beta-induced synapse damage. *Neuropharmacology*. 2016;101:225-36.

Oset-Gasque MJ, Gonzalez MP, Perez-Pena J, Garcia-Font N, Romero A, del Pino J, et al. Toxicological and pharmacological evaluation, antioxidant, ADMET and molecular modeling of selected racemic chromenotacrines {11-amino-12-aryl-8,9,10,12-tetrahydro-7H-chromeno 2,3-b quinolin-3-ols} for the potential prevention and treatment of Alzheimer's disease. *European journal of medicinal chemistry*. 2014;74:491-501.

O'Shea DM, De Wit L, Smith GE. Doctor, Should I Use Computer Games to Prevent Dementia? *Clinical gerontologist*. 2017:1-14.

Oshima E, Terada S, Sato S, Ikeda C, Oda K, Inoue S, et al. Left frontal lobe hypoperfusion and depressive symptoms in Alzheimer's disease patients taking cholinesterase inhibitors. *Psychiatry research*. 2014;224(3):319-23.

Osone A, Arai R, Hakamada R, Shimoda K. Cognitive and brain reserve in conversion and reversion in patients with mild cognitive impairment over 12 months of follow-up. *Journal of clinical and experimental neuropsychology*. 2016;38(10):1084-93.

Osone A, Arai R, Hakamada R, Shimoda K. Impact of lifestyle-related disease on conversion and reversion in patients with mild cognitive impairment: after 12 months of follow-up. *International journal of geriatric psychiatry*. 2016;31(7):740-8.

Ostergaard ME, Southwell AL, Kordasiewicz H, Watt AT, Skotte NH, Doty CN, et al. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. *Nucleic acids research*. 2013;41(21):9634-50.

Ostrovskaya RU, Vakhitova YV, Kuzmina US, Salimgareeva MK, Zainullina LF, Gudasheva TA, et al. Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. *Journal of biomedical science*. 2014;21:74.

Ota H, Ogawa S, Ouchi Y, Akishita M. Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil. *Experimental gerontology*. 2015;72:109-16.

Otero P, Smit F, Cuijpers P, DeRubeis RJ, Torres A, Vazquez FL. Differential response to depression prevention among a sample of informal caregivers: Moderator analysis of longer-term follow-up trial data. *Psychiatry research*. 2015;230(2):271-8.

Otilingam PG, Gatz M, Tello E, Escobar AJ, Goldstein A, Torres M, et al. Buenos habitos alimenticios para una buena salud : evaluation of a nutrition education program to improve heart health and brain health in Latinas. *Journal of aging and health*. 2015;27(1):177-92.

Otremba I, Wilczynski K, Szewieczek J. Delirium in the geriatric unit: proton-pump inhibitors and other risk factors. *Clinical interventions in aging*. 2016;11:397-405.

Otsuka M. Prevention of Alzheimer's Disease and Nutrients. *Brain and nerve = Shinkei kenkyu no shinpo*. 2016;68(7):809-17.

Ott BR, Davis JD, Bixby K. Video Feedback Intervention to Enhance the Safety of Older Drivers With Cognitive Impairment. *The American journal of occupational therapy : official publication of the American Occupational Therapy Association*. 2017;71(2):7102260020p1-p7.

Ott BR. The long and winding road Toward Alzheimer prevention FDA offers new guidance on developing drugs for early-stage AD; seeks input. *Rhode Island medical journal* (2013). 2013;96(4):14-5.

Ou S-M, Lee Y-J, Hu Y-W, Liu C-J, Chen T-J, Fuh J-L, et al. Does Alzheimer's disease protect against cancers? A nationwide population-based study. *Neuroepidemiology*. 2013;40(1):42-9.

Oulhaj A, Jerneren F, Refsum H, Smith AD, de Jager CA. Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment. *Journal of Alzheimer's disease : JAD*. 2016;50(2):547-57.

Ousset PJ, Delrieu J, Vellas B. Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants? *Alzheimer's research & therapy*. 2013;5(6):62.

Overhoff F, Brendel M, Jaworska A, Korzhova V, Delker A, Probst F, et al. Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved (18)F - Flortetaben PET Quantitation in Alzheimer's Model Mice. *Frontiers in neuroscience*. 2016;10:45.

Ozacmak VH, Sayan-Ozacmak H, Barut F. Chronic treatment with resveratrol, a natural polyphenol found in grapes, alleviates oxidative stress and apoptotic cell death in ovariectomized

female rats subjected to chronic cerebral hypoperfusion. *Nutritional neuroscience*. 2016;19(4):176-86.

Ozarowski M, Mikolajczak PL, Bogacz A, Gryszczynska A, Kujawska M, Jodynis-Liebert J, et al. *Rosmarinus officinalis* L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain. *Fitoterapia*. 2013;91:261-71.

Ozbeyli D, Sari G, Ozkan N, Karademir B, Yuksel M, Cilingir Kaya OT, et al. Protective effects of different exercise modalities in an Alzheimer's disease-like model. *Behavioural brain research*. 2017;328:159-77.

Ozturan Ozer E, Tan OU, Ozadali K, Kucukkilinc T, Balkan A, Ucar G. Synthesis, molecular modeling and evaluation of novel N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone derivatives as dual inhibitors for cholinesterases and Abeta aggregation. *Bioorganic & medicinal chemistry letters*. 2013;23(2):440-3.

Pa J, Berry AS, Compagnone M, Boccanfuso J, Greenhouse I, Rubens MT, et al. Cholinergic enhancement of functional networks in older adults with mild cognitive impairment. *Annals of neurology*. 2013;73(6):762-73.

Paban V, Manrique C, Filali M, Maunoir-Regimbal S, Fauvelle F, Alescio-Lautier B. Therapeutic and preventive effects of methylene blue on Alzheimer's disease pathology in a transgenic mouse model. *Neuropharmacology*. 2014;76 Pt A:68-79.

Padala KP, Padala PR, Lensing SY, Dennis RA, Bopp MM, Roberson PK, et al. Home-Based Exercise Program Improves Balance and Fear of Falling in Community-Dwelling Older Adults with Mild Alzheimer's Disease: A Pilot Study. *Journal of Alzheimer's disease : JAD*. 2017;59(2):565-74.

Padhy B, Hayat B, Nanda GG, Mohanty PP, Alone DP. Pseudoexfoliation and Alzheimer's associated CLU risk variant, rs2279590, lies within an enhancer element and regulates CLU, EPHX2 and PTK2B gene expression. *Human molecular genetics*. 2017;26(22):4519-29.

Padilla DV, Gonzalez MTD, Agis IF, Strizzi J, Rodriguez RA. The effectiveness of control strategies for dementia-driven wandering, preventing escape attempts: a case report. *International psychogeriatrics*. 2013;25(3):500-4.

Paganini M, Biggeri A, Romoli AM, Mechi C, Ghelli E, Berti V, et al. Fetal striatal grafting slows motor and cognitive decline of Huntington's disease. *Journal of neurology, neurosurgery, and psychiatry*. 2014;85(9):974-81.

Pagar KP, Sardar SM, Vavia PR. Novel L-lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer's disease. *Journal of biomedical nanotechnology*. 2014;10(3):415-26.

Paillard T, Rolland Y, de Souto Barreto P. Protective Effects of Physical Exercise in Alzheimer's Disease and Parkinson's Disease: A Narrative Review. *Journal of clinical neurology (Seoul, Korea)*. 2015;11(3):212-9.

Paillard T. Preventive effects of regular physical exercise against cognitive decline and the risk of dementia with age advancement. *Sports medicine - open*. 2015;1(1):20.

Palakurti R, Vadrevu R. Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics. *Journal of biomolecular structure & dynamics*. 2017;35(4):883-96.

Palan Lopez R, Mitchell SL, Givens JL. Preventing Burdensome Transitions of Nursing Home Residents with Advanced Dementia: It's More than Advance Directives. *Journal of palliative medicine*. 2017;20(11):1205-9.

Palisson J, Roussel-Baclet C, Maillet D, Belin C, Ankri J, Narme P. Music enhances verbal episodic memory in Alzheimer's disease. *Journal of clinical and experimental neuropsychology*. 2015;37(5):503-17.

Palit P, Mukherjee D, Mandal SC. Reconstituted mother tinctures of *Gelsemium sempervirens* L. improve memory and cognitive impairment in mice scopolamine-induced dementia model. *Journal of ethnopharmacology*. 2015;159:274-84.

Palmer JL. Preserving personhood of individuals with advanced dementia: lessons from family caregivers. *Geriatric nursing (New York, NY)*. 2013;34(3):224-9.

Pan K, Li X, Chen Y, Zhu D, Li Y, Tao G, et al. Deferoxamine pre-treatment protects against postoperative cognitive dysfunction of aged rats by depressing microglial activation via ameliorating iron accumulation in hippocampus. *Neuropharmacology*. 2016;111:180-94.

Pan W, Wang Q, Kwak S, Song Y, Qin B, Wang M, et al. Shen-zhi-ling oral liquid improves behavioral and psychological symptoms of dementia in Alzheimer's disease. *Evidence-based complementary and alternative medicine : eCAM*. 2014;2014:913687.

Pan X, Chen Z, Fei G, Pan S, Bao W, Ren S, et al. Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease. *Neuroscience bulletin*. 2016;32(6):591-6.

Pan X, Sang S, Fei G, Jin L, Liu H, Wang Z, et al. Enhanced Activities of Blood Thiamine Diphosphatase and Monophosphatase in Alzheimer's Disease. *PloS one*. 2017;12(1):e0167273.

Pan Y, Araujo JA, Burrows J, de Rivera C, Gore A, Bhatnagar S, et al. Cognitive enhancement in middle-aged and old cats with dietary supplementation with a nutrient blend containing fish oil, B vitamins, antioxidants and arginine. *The British journal of nutrition*. 2013;110(1):40-9.

Pancani T, Foster DJ, Moehle MS, Bichell TJ, Bradley E, Bridges TM, et al. Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112(45):14078-83.

Pandey D, Banerjee S, Basu M, Mishra N. Memory enhancement by Tamoxifen on amyloidosis mouse model. *Hormones and behavior*. 2016;79:70-3.

Pandya SY, Lacritz LH, Weiner MF, Deschner M, Woon FL. Predictors of Reversion from Mild Cognitive Impairment to Normal Cognition. *Dementia and geriatric cognitive disorders*. 2017;43(3-4):204-14.

Panek D, Wichur T, Godyn J, Pasieka A, Malawska B. Advances toward multifunctional cholinesterase and beta-amyloid aggregation inhibitors. *Future medicinal chemistry*. 2017;9(15):1835-54.

Pang X, Fu H, Yang S, Wang L, Liu A-L, Wu S, et al. Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches. *Molecules (Basel, Switzerland)*. 2017;22(8).

Pangestuti R, Vo T-S, Ngo D-H, Kim S-K. Fucoxanthin ameliorates inflammation and oxidative responses in microglia. *Journal of agricultural and food chemistry*. 2013;61(16):3876-83.

Pankiewicz JE, Guridi M, Kim J, Asuni AA, Sanchez S, Sullivan PM, et al. Blocking the apoE/Abeta interaction ameliorates Abeta-related pathology in APOE epsilon2 and epsilon4 targeted replacement Alzheimer model mice. *Acta neuropathologica communications*. 2014;2:75.

Pant JK, Krishnan S. Compressive sensing of foot-gait signals by enhancing group block-sparse structure on the first-order difference. *Conference proceedings : Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual Conference*. 2016;2016:3700-3.

Panza F, Lozupone M, Solfrizzi V, Stallone R, Bellomo A, Greco A, et al. Cognitive frailty: a potential target for secondary prevention of dementia. *Expert opinion on drug metabolism & toxicology*. 2017:1-5.

Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, et al. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. *Expert opinion on biological therapy*. 2017;1-11.

Panza F, Seripa D, Solfrizzi V, Imbimbo BP, Santamato A, Lozupone M, et al. Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy? *Expert opinion on pharmacotherapy*. 2016;17(4):457-61.

Panza F, Solfrizzi V, Barulli MR, Bonfiglio C, Guerra V, Osella A, et al. Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review. *The journal of nutrition, health & aging*. 2015;19(3):313-28.

Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. *Expert review of clinical immunology*. 2014;10(3):405-19.

Paolino N, O'Malley PG. ACP Journal Club. Review: nonpharmacologic caregiver interventions improve dementia symptoms and caregiver reactions. *Annals of internal medicine*. 2013;158(4):JC4.

Paouri E, Tzara O, Zenelak S, Georgopoulos S. Genetic Deletion of Tumor Necrosis Factor-alpha Attenuates Amyloid-beta Production and Decreases Amyloid Plaque Formation and Glial Response in the 5XFAD Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;60(1):165-81.

Papadopoulos P, Rosa-Neto P, Rochford J, Hamel E. Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-beta and cerebrovascular pathology. *PloS one*. 2013;8(7):e68612.

Papadopoulos P, Tong X-K, Imboden H, Hamel E. Losartan improves cerebrovascular function in a mouse model of Alzheimer's disease with combined overproduction of amyloid-beta and transforming growth factor-beta1. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2017;37(6):1959-70.

Pardini M, Serrati C, Guida S, Mattei C, Abate L, Massucco D, et al. Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study. *Neuro-degenerative diseases*. 2015;15(1):58-62.

Parente A, Giovagnoli AR. Crossed aphasia and preserved visuospatial functions in logopenic variant primary progressive aphasia. *Journal of neurology*. 2015;262(1):216-8.

Paris D, Beaulieu-Abdelahad D, Abdullah L, Bachmeier C, Ait-Ghezala G, Reed J, et al. Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation. *European journal of pharmacology*. 2013;698(1-3):145-53.

Park A. New hope for the treatment and prevention of Alzheimer's. *Time*. 2015;186(21):38.

Park B, Nam JH, Kim JH, Kim HJ, Onnis V, Balboni G, et al. 3,4-Dihydroquinazoline derivatives inhibit the activities of cholinesterase enzymes. *Bioorganic & medicinal chemistry letters*. 2017;27(5):1179-85.

Park GH, Jang J-H. Response to comment: "A note on the relevance of 6 -gingerol for the prevention and/or treatment of Alzheimer's disease". *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*. 2013;51:457.

Park HR, Lee H, Park H, Jeon JW, Cho W-K, Ma JY. Neuroprotective effects of Liriope platyphylla extract against hydrogen peroxide-induced cytotoxicity in human neuroblastoma SH-SY5Y cells. *BMC complementary and alternative medicine*. 2015;15:171.

Park J, Kwon KY. Reversible Dementia with Middle Cerebellar Peduncle Hyperintensity: 1-Year Follow-Up of HIV-Negative Neurosyphilis. *Journal of clinical neurology (Seoul, Korea)*. 2017;13(4):437-8.

Park J-C, Baik SH, Han S-H, Cho HJ, Choi H, Kim HJ, et al. Annexin A1 restores Abeta1-42 -induced blood-brain barrier disruption through the inhibition of RhoA-ROCK signaling pathway. *Aging cell*. 2017;16(1):149-61.

Park J-C, Ma J, Jeon WK, Han J-S. Fructus mume extracts alleviate cognitive impairments in 5XFAD transgenic mice. *BMC complementary and alternative medicine*. 2016;16:54.

Park JE, Park B, Kim SJ, Kim HS, Choi CG, Jung SC, et al. Improved Diagnostic Accuracy of Alzheimer's Disease by Combining Regional Cortical Thickness and Default Mode Network Functional Connectivity: Validated in the Alzheimer's Disease Neuroimaging Initiative Set. *Korean journal of radiology*. 2017;18(6):983-91.

Park K. Cover Story: Towards a preventive treatment of Alzheimer's disease with multi-functional liposomes. *Journal of controlled release : official journal of the Controlled Release Society*. 2017;258:254.

Park MH, Han C. Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles. *International psychogeriatrics*. 2015;27(3):429-37.

Park MH, Lee JK, Choi S, Ahn J, Jin HK, Park J-S, et al. Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice. *Brain research*. 2013;1529:113-24.

Park S, Kang S, Kim DS, Moon BR. *Agrimonia pilosa* Ledeb., *Cinnamomum cassia* Blume, and *Lonicera japonica* Thunb. protect against cognitive dysfunction and energy and glucose dysregulation by reducing neuroinflammation and hippocampal insulin resistance in beta-amyloid-infused rats. *Nutritional neuroscience*. 2017;20(2):77-88.

Park SH, Lee S, Hong YK, Hwang S, Lee JH, Bang SM, et al. Suppressive effects of SuHeXiang Wan on amyloid-beta₄₂-induced extracellular signal-regulated kinase hyperactivation and glial cell proliferation in a transgenic *Drosophila* model of Alzheimer's disease. *Biological & pharmaceutical bulletin*. 2013;36(3):390-8.

Park SJ, Ahn YJ, Lee HE, Hong E, Ryu JH. Standardized *Prunella vulgaris* var. *lilacina* Extract Enhances Cognitive Performance in Normal Naive Mice. *Phytotherapy research : PTR*. 2015;29(11):1814-21.

Park S-Y, Kim M-J, Kim YJ, Lee Y-H, Bae D, Kim S, et al. Selective PCAF inhibitor ameliorates cognitive and behavioral deficits by suppressing NF-kappaB-mediated neuroinflammation induced by A β in a model of Alzheimer's disease. *International journal of molecular medicine*. 2015;35(4):1109-18.

Park S-Y, Lee Y-H, Seong A-R, Lee J, Jun W, Yoon H-G. Selective inhibition of PCAF suppresses microglial-mediated beta-amyloid neurotoxicity. *International journal of molecular medicine*. 2013;32(2):469-75.

Park T-E, Singh B, Li H, Lee J-Y, Kang S-K, Choi Y-J, et al. Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease. *Biomaterials*. 2015;38:61-71.

Park T-S, Ryu Y-K, Park H-Y, Kim JY, Go J, Noh J-R, et al. *Humulus japonicus* inhibits the progression of Alzheimer's disease in a APP/PS1 transgenic mouse model. *International journal of molecular medicine*. 2017;39(1):21-30.

Park Y-J, Ko JW, Jeon S, Kwon YH. Protective Effect of Genistein against Neuronal Degeneration in ApoE^{-/-} Mice Fed a High-Fat Diet. *Nutrients*. 2016;8(11).

Parks L. Memory restored in Alzheimers disease brain cells: the compound AC253, originally designed to target diabetes, appears to restore memory. *Future medicinal chemistry*. 2013;5(2):121.

Paroni G, Seripa D, Fontana A, D'Onofrio G, Gravina C, Urbano M, et al. FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease. *Clinical interventions in aging*. 2014;9:1783-91.

Parrella E, Maxim T, Maialetti F, Zhang L, Wan J, Wei M, et al. Protein restriction cycles reduce IGF-1 and phosphorylated Tau, and improve behavioral performance in an Alzheimer's disease mouse model. *Aging cell*. 2013;12(2):257-68.

Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. *Neurotoxicity research*. 2013;24(3):358-69.

Parsons CG, Ruitenbergh M, Freitag CE, Sroka-Saidi K, Russ H, Rammes G. MRZ-99030 - A novel modulator of Abeta aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD). *Neuropharmacology*. 2015;92:158-69.

Parthsarathy V, McClean PL, Holscher C, Taylor M, Tinker C, Jones G, et al. A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APP^{swe}/PS1^{DeltaE9} mouse model of Alzheimer's disease. *PloS one*. 2013;8(1):e54769.

Pascual-Lucas M, Viana da Silva S, Di Scala M, Garcia-Barroso C, Gonzalez-Aseguinolaza G, Mulle C, et al. Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. *EMBO molecular medicine*. 2014;6(10):1246-62.

Pase MP, Satizabal CL, Seshadri S. Role of Improved Vascular Health in the Declining Incidence of Dementia. *Stroke*. 2017;48(7):2013-20.

Pasinetti GM, Wang J, Ho L, Zhao W, Dubner L. Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. *Biochimica et biophysica acta*. 2015;1852(6):1202-8.

Pasinetti GM. Towards prevention and therapy of Alzheimer's disease. *Molecular aspects of medicine*. 2015;43-44:1-2.

Pate KM, Rogers M, Reed JW, van der Munnik N, Vance SZ, Moss MA. Anthoxanthin Polyphenols Attenuate Abeta Oligomer-induced Neuronal Responses Associated with Alzheimer's Disease. *CNS neuroscience & therapeutics*. 2017;23(2):135-44.

Patel S, Meilandt WJ, Erickson RI, Chen J, Deshmukh G, Estrada AA, et al. Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease. *Journal of medicinal chemistry*. 2017;60(19):8083-102.

Paterniti I, Cordaro M, Campolo M, Siracusa R, Cornelius C, Navarra M, et al. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation. *CNS & neurological disorders drug targets*. 2014;13(9):1530-41.

Paterson RW, Abdi Z, Haines A, Schott JM. Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy. *Clinical neurology and neurosurgery*. 2016;144:64-6.

Pathak A, Srivastava AK, Singour PK, Gouda P. Synthetic and Natural Monoamine Oxidase Inhibitors as Potential Lead Compounds for Effective Therapeutics. *Central nervous system agents in medicinal chemistry*. 2016;16(2):81-97.

Patil PO, Bari SB, Firke SD, Deshmukh PK, Donda ST, Patil DA. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease. *Bioorganic & medicinal chemistry*. 2013;21(9):2434-50.

Patrono C. The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. *Journal of the American College of Cardiology*. 2015;66(1):74-85.

Patterson K, Newman C, Doona K. Improving the care of older persons in Australian prisons using the Policy Delphi method. *Dementia (London, England)*. 2016;15(5):1219-33.

Paul A, Nadimpally KC, Mondal T, Thalluri K, Mandal B. Inhibition of Alzheimer's amyloid-beta peptide aggregation and its disruption by a conformationally restricted alpha/beta hybrid peptide. *Chemical communications (Cambridge, England)*. 2015;51(12):2245-8.

Pauletti A, Terrone G, Shekh-Ahmad T, Salamone A, Ravizza T, Rizzi M, et al. Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy. *Brain : a journal of neurology*. 2017;140(7):1885-99.

Pavlicevic M, Tsiris G, Wood S, Powell H, Graham J, Sanderson R, et al. The 'ripple effect': Towards researching improvisational music therapy in dementia care homes. *Dementia (London, England)*. 2015;14(5):659-79.

Pazini AM, Gomes GM, Villarinho JG, da Cunha C, Pinheiro F, Ferreira APO, et al. Selegiline reverses A β , ... A β , ...-induced cognitive deficit in male mice. *Neurochemical research*. 2013;38(11):2287-94.

Peach T, Pollock K, van der Wardt V, das Nair R, Logan P, Harwood RH. Attitudes of older people with mild dementia and mild cognitive impairment and their relatives about falls risk and prevention: A qualitative study. *PloS one*. 2017;12(5):e0177530.

Peauger L, Azzouz R, Gembus V, Tintas M-L, Sopkova-de Oliveira Santos J, Bohn P, et al. Donepezil-Based Central Acetylcholinesterase Inhibitors by Means of a "Bio-Oxidizable" Prodrug Strategy: Design, Synthesis, and in Vitro Biological Evaluation. *Journal of medicinal chemistry*. 2017;60(13):5909-26.

Peccati F, Hernando J, Blancafort L, Solans-Monfort X, Sodupe M. Disaggregation-induced fluorescence enhancement of NIAD-4 for the optical imaging of amyloid-beta fibrils. *Physical chemistry chemical physics : PCCP*. 2015;17(30):19718-25.

Penazzi L, Tackenberg C, Ghorri A, Golovyashkina N, Niewidok B, Selle K, et al. Abeta-mediated spine changes in the hippocampus are microtubule-dependent and can be reversed by a subnanomolar concentration of the microtubule-stabilizing agent epothilone D. *Neuropharmacology*. 2016;105:84-95.

Peng F, Zhao Y, Huang X, Chen C, Sun L, Zhuang L, et al. Loss of Polo ameliorates APP-induced Alzheimer's disease-like symptoms in *Drosophila*. *Scientific reports*. 2015;5:16816.

Peng W, Achariyar TM, Li B, Liao Y, Mestre H, Hitomi E, et al. Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease. *Neurobiology of disease*. 2016;93:215-25.

Peng Y, Hou C, Yang Z, Li C, Jia L, Liu J, et al. Hydroxytyrosol mildly improve cognitive function independent of APP processing in APP/PS1 mice. *Molecular nutrition & food research*. 2016;60(11):2331-42.

Peng Y, Hu Y, Xu S, Rong X, Li J, Li P, et al. Potassium 2-(1-hydroxypentyl)-benzoate improves memory deficits and attenuates amyloid and tau pathologies in a mouse model of Alzheimer's disease. *The Journal of pharmacology and experimental therapeutics*. 2014;350(2):361-74.

Peng Y, Kim MJ, Hullinger R, O'Riordan KJ, Burger C, Pehar M, et al. Improved proteostasis in the secretory pathway rescues Alzheimer's disease in the mouse. *Brain : a journal of neurology*. 2016;139(Pt 3):937-52.

Pepeu G, Giovannini MG, Bracco L. Effect of cholinesterase inhibitors on attention. *Chemico-biological interactions*. 2013;203(1):361-4.

Perche F, Uchida S, Akiba H, Lin C-Y, Ikegami M, Dirisala A, et al. Improved Brain Expression of Anti-Amyloid beta scFv by Complexation of mRNA Including a Secretion Sequence with PEG-based Block Cationomer. *Current Alzheimer research*. 2017;14(3):295-302.

Pereira A, de Mendonca A, Silva D, Guerreiro M, Freeman J, Ellis J. Enhancing prospective memory in mild cognitive impairment: The role of enactment. *Journal of clinical and experimental neuropsychology*. 2015;37(8):863-77.

Pereira AC, Gray JD, Kogan JF, Davidson RL, Rubin TG, Okamoto M, et al. Age and Alzheimer's disease gene expression profiles reversed by the glutamate modulator riluzole. *Molecular psychiatry*. 2017;22(2):296-305.

Pereira GJS, Tressoldi N, Hirata H, Bincoletto C, Smaili SS. Autophagy as a neuroprotective mechanism against 3-nitropropionic acid-induced murine astrocyte cell death. *Neurochemical research*. 2013;38(11):2418-26.

Perera G, Khondoker M, Broadbent M, Breen G, Stewart R. Factors associated with response to acetylcholinesterase inhibition in dementia: a cohort study from a secondary mental health care case register in london. *PloS one*. 2014;9(11):e109484.

Peretti D, Bastide A, Radford H, Verity N, Molloy C, Martin MG, et al. RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration. *Nature*. 2015;518(7538):236-9.

Perez C, Ziburkus J, Ullah G. Analyzing and Modeling the Dysfunction of Inhibitory Neurons in Alzheimer's Disease. *PloS one*. 2016;11(12):e0168800.

Perez DI, Martinez A, Gil C, Campillo NE. From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease. *Current medicinal chemistry*. 2015;22(33):3789-806.

Perez-Canamas A, Sarroca S, Melero-Jerez C, Porquet D, Sansa J, Knafo S, et al. A diet enriched with plant sterols prevents the memory impairment induced by cholesterol loss in senescence-accelerated mice. *Neurobiology of aging*. 2016;48:1-12.

Perez-Cruz C, Diaz-Cintra S. Editorial: Nutrition and prevention of Alzheimer's disease. *Frontiers in aging neuroscience*. 2015;7:170.

Perez-Gonzalez R, Alvira-Botero MX, Robayo O, Antequera D, Garzon M, Martin-Moreno AM, et al. Leptin gene therapy attenuates neuronal damages evoked by amyloid-beta and rescues memory deficits in APP/PS1 mice. *Gene therapy*. 2014;21(3):298-308.

Perez-Gonzalez R, Pascual C, Antequera D, Bolos M, Redondo M, Perez DI, et al. Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. *Neurobiology of aging*. 2013;34(9):2133-45.

Perez-Valero I, Gonzalez-Baeza A, Estebanez M, Montes-Ramirez ML, Bayon C, Pulido F, et al. Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. *PloS one*. 2013;8(7):e69493.

Peri A. Neuroprotective effects of estrogens: the role of cholesterol. *Journal of endocrinological investigation*. 2016;39(1):11-8.

Perlmutter D. Preventing Alzheimer's Disease. *Journal of the American College of Nutrition*. 2016;35(8):732-3.

Peron JA, Piolino P, Moal-Boursiquot SL, Biseul I, Leray E, Bon L, et al. Preservation of Person-Specific Semantic Knowledge in Semantic Dementia: Does Direct Personal Experience Have a Specific Role? *Frontiers in human neuroscience*. 2015;9:625.

Perrochon A, Kemoun G, Dugue B. Should the concept of MCI be revised in order to improve detection of dementia? *Neurophysiologie clinique = Clinical neurophysiology*. 2014;44(2):235-7.

Perry J, Bell F, Shaw T, Fitzpatrick B, Sampson EL. The use of PDSA methodology to evaluate and optimise an inner city memory clinic: a quality improvement project. *BMC geriatrics*. 2014;14:4.

Perusini JN, Cajigas SA, Cohensedgh O, Lim SC, Pavlova IP, Donaldson ZR, et al. Optogenetic stimulation of dentate gyrus engrams restores memory in Alzheimer's disease mice. *Hippocampus*. 2017;27(10):1110-22.

Peters C, Fernandez-Perez EJ, Burgos CF, Espinoza MP, Castillo C, Urrutia JC, et al. Inhibition of amyloid beta-induced synaptotoxicity by a pentapeptide derived from the glycine zipper region of the neurotoxic peptide. *Neurobiology of aging*. 2013;34(12):2805-14.

Peters KR, Lynn Beattie B, Feldman HH, Illes J. A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. *Progress in neurobiology*. 2013;110:114-23.

Peters KR. Utility of an effect size analysis for communicating treatment effectiveness: a case study of cholinesterase inhibitors for Alzheimer's disease. *Journal of the American Geriatrics Society*. 2013;61(7):1170-4.

Peters OM, Connor-Robson N, Sokolov VB, Aksinenko AY, Kukharsky MS, Bachurin SO, et al. Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice. *Journal of Alzheimer's disease : JAD*. 2013;33(4):1041-9.

Peters OM, Shelkovernikova T, Tarasova T, Springe S, Kukharsky MS, Smith GA, et al. Chronic administration of Dimebon does not ameliorate amyloid-beta pathology in 5xFAD transgenic mice. *Journal of Alzheimer's disease : JAD*. 2013;36(3):589-96.

Petiau C, Onen H, Delgado A, Touchon J. Exploring sleep-related outcomes in patients with mild to moderate Alzheimer's disease initiating acetylcholinesterase inhibitor therapy: the Morpheus survey. *International journal of geriatric psychiatry*. 2013;28(6):657-9.

Petrone AB, Gatson JW, Simpkins JW, Reed MN. Non-feminizing estrogens: a novel neuroprotective therapy. *Molecular and cellular endocrinology*. 2014;389(1-2):40-7.

Petrushina I, Davtyan H, Hovakimyan A, Davtyan A, Passos GF, Cribbs DH, et al. Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of beta-Amyloid in an Animal Model of Alzheimer's Disease. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2017;25(1):153-64.

Petyaeva A, Kajander M, Lawrence V, Clifton L, Thomas AJ, Ballard C, et al. Feasibility of a staff training and support programme to improve pain assessment and management in people with dementia living in care homes. *International journal of geriatric psychiatry*. 2017.

Pezzati R, Molteni V, Bani M, Settanta C, Di Maggio MG, Villa I, et al. Can Doll therapy preserve or promote attachment in people with cognitive, behavioral, and emotional problems? A pilot study in institutionalized patients with dementia. *Frontiers in psychology*. 2014;5:342.

Pfeifer G. Can Dementia Be Prevented? *The American journal of nursing*. 2017;117(11):15.

Phelan EA, Debnam KJ, Anderson LA, Owens SB. A systematic review of intervention studies to prevent hospitalizations of community-dwelling older adults with dementia. *Medical care*. 2015;53(2):207-13.

Phillips JL, West PA, Davidson PM, Agar M. Does case conferencing for people with advanced dementia living in nursing homes improve care outcomes: evidence from an integrative review? *International journal of nursing studies*. 2013;50(8):1122-35.

Phillips LA. Delirium in geriatric patients: identification and prevention. *Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses*. 2013;22(1):9-12.

Philpott AL, Cummins TDR, Bailey NW, Churchyard A, Fitzgerald PB, Georgiou-Karistianis N. Cortical inhibitory deficits in premanifest and early Huntington's disease. *Behavioural brain research*. 2016;296:311-7.

Physical activity -- preventing dementia. *Sportverletzung Sportschaden : Organ der Gesellschaft für Orthopädisch-Traumatologische Sportmedizin*. 2014;28(2):57.

Piemontese L. New approaches for prevention and treatment of Alzheimer's disease: a fascinating challenge. *Neural regeneration research*. 2017;12(3):405-6.

Pierce A, Podlitskaya N, Halloran JJ, Hussong SA, Lin P-Y, Burbank R, et al. Over-expression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer's-like deficits in mice modeling the disease. *Journal of neurochemistry*. 2013;124(6):880-93.

Pierrot N, Lhommel R, Quenon L, Hanseeuw B, Dricot L, Sindic C, et al. Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;49(2):271-6.

Pietropaolo S, Bellocchio L, Ruiz-Calvo A, Cabanas M, Du Z, Guzman M, et al. Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease. *Neuropharmacology*. 2015;89:368-74.

Pietropaolo S, Feldon J, Yee BK. Environmental enrichment eliminates the anxiety phenotypes in a triple transgenic mouse model of Alzheimer's disease. *Cognitive, affective & behavioral neuroscience*. 2014;14(3):996-1008.

Pihlaja R, Takkinen J, Eskola O, Vasara J, Lopez-Picon FR, Haaparanta-Solin M, et al. Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cells. *Journal of neuroinflammation*. 2015;12:81.

Pilipenko V, Narbutė K, Beitnere U, Rumaks J, Pupure J, Jansone B, et al. Very low doses of muscimol and baclofen ameliorate cognitive deficits and regulate protein expression in the brain of a rat model of streptozocin-induced Alzheimer's disease. *European journal of pharmacology*. 2017;818:381-99.

Pillai JA, Bonner-Jackson A, Walker E, Mourany L, Cummings JL. Higher working memory predicts slower functional decline in autopsy-confirmed Alzheimer's disease. *Dementia and geriatric cognitive disorders*. 2014;38(3-4):224-33.

Pimouguet C, Bassi V, Somme D, Lavallart B, Helmer C, Dartigues JF. The 2008-2012 French Alzheimer plan: a unique opportunity for improving integrated care for dementia. *Journal of Alzheimer's disease : JAD*. 2013;34(1):307-14.

Pimplikar SW. Multi-omics and Alzheimer's disease: a slower but surer path to an efficacious therapy? *American journal of physiology Cell physiology*. 2017;313(1):C1-C2.

Pineau F, Canet G, Desrumaux C, Hunt H, Chevallier N, Ollivier M, et al. New selective glucocorticoid receptor modulators reverse amyloid-beta peptide-induced hippocampus toxicity. *Neurobiology of aging*. 2016;45:109-22.

Pinho BR, Ferreres F, Valentao P, Andrade PB. Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment. *The Journal of pharmacy and pharmacology*. 2013;65(12):1681-700.

Pinnock EC, Jovanovic K, Pinto MG, Ferreira E, Dias BDC, Penny C, et al. LRP/LR Antibody Mediated Rescuing of Amyloid-beta-Induced Cytotoxicity is Dependent on PrPc in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;49(3):645-57.

Pinsetta FR, Taft CA, de Paula da Silva CHT. Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease. *Journal of biomolecular structure & dynamics*. 2014;32(7):1047-63.

Pinto-Bruno AC, Garcia-Casal JA, Csipke E, Jenaro-Rio C, Franco-Martin M. ICT-based applications to improve social health and social participation in older adults with dementia. A systematic literature review. *Aging & mental health*. 2017;21(1):58-65.

Pisani L, Farina R, Soto-Otero R, Denora N, Mangiatordi GF, Nicolotti O, et al. Searching for Multi-Targeting Neurotherapeutics against Alzheimer's: Discovery of Potent AChE-MAO B Inhibitors through the Decoration of the 2H-Chromen-2-one Structural Motif. *Molecules (Basel, Switzerland)*. 2016;21(3):362.

Pitt J, Thorner M, Brautigan D, Larner J, Klein WL. Protection against the synaptic targeting and toxicity of Alzheimer's-associated Abeta oligomers by insulin mimetic chiro-inositols. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2013;27(1):199-207.

Platts-Mills TF. Capsule commentary on Davydow et al., neuropsychiatric disorders and potentially preventable hospitalizations in a prospective cohort study of older Americans. *Journal of general internal medicine*. 2014;29(10):1390.

Playfoot D, Izura C, Tree J. Are acronyms really irregular? Preserved acronym reading in a case of semantic dementia. *Neuropsychologia*. 2013;51(9):1673-83.

Pluta R, Bogucka-Kocka A, Ulamek-Kozioł M, Furmaga-Jablonska W, Januszewski S, Brzozowska J, et al. Neurogenesis and neuroprotection in postischemic brain neurodegeneration with Alzheimer phenotype: is there a role for curcumin? *Folia neuropathologica*. 2015;53(2):89-99.

Pluta S, Naka A, Veit J, Telian G, Yao L, Hakim R, et al. A direct translaminar inhibitory circuit tunes cortical output. *Nature neuroscience*. 2015;18(11):1631-40.

Pohland M, Hagl S, Pellowska M, Wurglics M, Schubert-Zsilavecz M, Eckert GP. MH84: A Novel gamma-Secretase Modulator/PPARgamma Agonist--Improves Mitochondrial Dysfunction in a Cellular Model of Alzheimer's Disease. *Neurochemical research*. 2016;41(1-2):231-42.

Polidori MC, Schulz R-J. Nutritional contributions to dementia prevention: main issues on antioxidant micronutrients. *Genes & nutrition*. 2014;9(2):382.

Polidori MC. Preventive benefits of natural nutrition and lifestyle counseling against Alzheimer's disease onset. *Journal of Alzheimer's disease : JAD*. 2014;42 Suppl 4:S475-82.

Polito VA, Li H, Martini-Stoica H, Wang B, Yang L, Xu Y, et al. Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB. *EMBO molecular medicine*. 2014;6(9):1142-60.

Pollock K, Dahlenburg H, Nelson H, Fink KD, Cary W, Hendrix K, et al. Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2016;24(5):965-77.

Polydoro M, de Calignon A, Suarez-Calvet M, Sanchez L, Kay KR, Nicholls SB, et al. Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(33):13300-11.

Polyzos A, Holt A, Brown C, Cosme C, Wipf P, Gomez-Marin A, et al. Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes. *Human molecular genetics*. 2016;25(9):1792-802.

Pomorska G, Ockene JK. A general neurologist's perspective on the urgent need to apply resilience thinking to the prevention and treatment of Alzheimer's disease. *Alzheimer's & dementia (New York, N Y)*. 2017;3(4):498-506.

Pomponi M, Pomponi MFL. Alzheimer's disease prevention & acetyl salicylic acid: a believable story. *The Indian journal of medical research*. 2014;139(1):1-3.

Pongan E, Tillmann B, Leveque Y, Trombert B, Getenet JC, Auguste N, et al. Can Musical or Painting Interventions Improve Chronic Pain, Mood, Quality of Life, and Cognition in Patients with Mild Alzheimer's Disease? Evidence from a Randomized Controlled Trial. *Journal of Alzheimer's disease : JAD*. 2017;60(2):663-77.

Popugaeva E, Pchitskaya E, Speshilova A, Alexandrov S, Zhang H, Vlasova O, et al. STIM2 protects hippocampal mushroom spines from amyloid synaptotoxicity. *Molecular neurodegeneration*. 2015;10:37.

Popugaeva E, Vlasova OL, Bezprozvanny I. Restoring calcium homeostasis to treat Alzheimer's disease: a future perspective. *Neurodegenerative disease management*. 2015;5(5):395-8.

Porquet D, Casadesus G, Bayod S, Vicente A, Canudas AM, Vilaplana J, et al. Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. *Age (Dordrecht, Netherlands)*. 2013;35(5):1851-65.

Porquet D, Grinan-Ferre C, Ferrer I, Camins A, Sanfeliu C, Del Valle J, et al. Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;42(4):1209-20.

Portbury SD, Hare DJ, Sgambelloni C, Perronnes K, Portbury AJ, Finkelstein DI, et al. Trehalose Improves Cognition in the Transgenic Tg2576 Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;60(2):549-60.

Posada-Duque RA, Lopez-Tobon A, Piedrahita D, Gonzalez-Billault C, Cardona-Gomez GP. p35 and Rac1 underlie the neuroprotection and cognitive improvement induced by CDK5 silencing. *Journal of neurochemistry*. 2015;134(2):354-70.

Poska H, Haslbeck M, Kurudenkandy FR, Hermansson E, Chen G, Kostallas G, et al. Dementia-related Bri2 BRICHOS is a versatile molecular chaperone that efficiently inhibits Abeta42 toxicity in *Drosophila*. *The Biochemical journal*. 2016;473(20):3683-704.

Postu PA, Noumedem JAK, Cioanca O, Hancianu M, Mihasan M, Ciorpac M, et al. *Lactuca capensis* reverses memory deficits in Abeta1-42-induced an animal model of Alzheimer's disease. *Journal of cellular and molecular medicine*. 2017.

Pot AM. Improving nursing home care for dementia: is the environment the answer? *Aging & mental health*. 2013;17(7):785-7.

Potticary J. Acquisition of diagnostic tracers to enhance understanding of tau protein in Alzheimer's disease. *Bioanalysis*. 2013;5(12):1471-3.

Pourkhodadad S, Alirezaei M, Moghaddasi M, Ahmadvand H, Karami M, Delfan B, et al. Neuroprotective effects of oleuropein against cognitive dysfunction induced by colchicine in hippocampal CA1 area in rats. *The journal of physiological sciences : JPS*. 2016;66(5):397-405.

Pourmemar E, Majdi A, Haramshahi M, Talebi M, Karimi P, Sadigh-Eteghad S. Intranasal Cerebrolysin Attenuates Learning and Memory Impairments in D-galactose-Induced Senescence in Mice. *Experimental gerontology*. 2017;87(Pt A):16-22.

Povarnina PY, Vorontsova ON, Gudasheva TA, Ostrovskaya RU, Seredenin SB. Original Nerve Growth Factor Mimetic Dipeptide GK-2 Restores Impaired Cognitive Functions in Rat Models of Alzheimer's Disease. *Acta naturae*. 2013;5(3):84-91.

Powell R. Is preventive suicide a rational response to a presymptomatic diagnosis of dementia? *Journal of medical ethics*. 2014;40(8):511-2.

Prakash A, Kumar A. Implicating the role of lycopene in restoration of mitochondrial enzymes and BDNF levels in beta-amyloid induced Alzheimer's disease. *European journal of pharmacology*. 2014;741:104-11.

Prakash A, Medhi B, Chopra K. Granulocyte colony stimulating factor (GCSF) improves memory and neurobehavior in an amyloid-beta induced experimental model of Alzheimer's disease. *Pharmacology, biochemistry, and behavior*. 2013;110:46-57.

Prasad KN, Bondy SC. Inhibition of Early Biochemical Defects in Prodromal Huntington's Disease by Simultaneous Activation of Nrf2 and Elevation of Multiple Micronutrients. *Current aging science*. 2016;9(1):61-70.

Prasad KN, Bondy SC. Inhibition of early upstream events in prodromal Alzheimer's disease by use of targeted antioxidants. *Current aging science*. 2014;7(2):77-90.

Prati F, Bottegoni G, Bolognesi ML, Cavalli A. BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease. *Journal of medicinal chemistry*. 2017.

Prati F, De Simone A, Bisignano P, Armirotti A, Summa M, Pizzirani D, et al. Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3 β inhibitors. *Angewandte Chemie (International ed in English)*. 2015;54(5):1578-82.

Prema A, Justin Thenmozhi A, Manivasagam T, Mohamed Essa M, Guillemin GJ. Fenugreek Seed Powder Attenuated Aluminum Chloride-Induced Tau Pathology, Oxidative Stress, and Inflammation in a Rat Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;60(s1):S209-S20.

Preserve your mind and prevent cognitive decline. Seven lifestyle threats to cognition are identified; modifying habits and patterns can help prevent dementia. *DukeMedicine healthnews*. 2014;20(10):1-2.

Prevention is best strategy for Alzheimer's disease. *Nursing older people*. 2016;28(8):12.

Price AR, Xu G, Sieminski ZB, Smithson LA, Borchelt DR, Golde TE, et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". *Science (New York, NY)*. 2013;340(6135):924-d.

Prickaerts J, Heckman PRA, Blokland A. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. *Expert opinion on investigational drugs*. 2017;26(9):1033-48.

Prieto GA, Trieu BH, Dang CT, Bilousova T, Gyllys KH, Berchtold NC, et al. Pharmacological Rescue of Long-Term Potentiation in Alzheimer Diseased Synapses. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(5):1197-212.

Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. *Alzheimer's research & therapy*. 2013;5(3):25.

Pritchard-Jones L. "This Man with Dementia"1-'Othering' the Person with Dementia in the Court of Protection. *Medical law review*. 2017.

Proenca CC, Stoehr N, Bernhard M, Seger S, Genoud C, Roscic A, et al. Atg4b-dependent autophagic flux alleviates Huntington's disease progression. *PloS one*. 2013;8(7):e68357.

Protect your memory and thinking skills. Keeping your blood sugar level in check may help ward off dementia. Harvard health letter. 2014;39(4):3.

Protecting against vascular dementia with exercise. The Johns Hopkins medical letter health after 50. 2013;25(1):8.

Pudlo M, Luzet V, Ismaili L, Tomassoli I, Iutzeler A, Refouvelet B. Quinolone-benzylpiperidine derivatives as novel acetylcholinesterase inhibitor and antioxidant hybrids for Alzheimer disease. Bioorganic & medicinal chemistry. 2014;22(8):2496-507.

Puig KL, Kulas JA, Franklin W, Rakoczy SG, Taglialatela G, Brown-Borg HM, et al. The Ames dwarf mutation attenuates Alzheimer's disease phenotype of APP/PS1 mice. Neurobiology of aging. 2016;40:22-40.

Pujadas L, Rossi D, Andres R, Teixeira CM, Serra-Vidal B, Parcerisas A, et al. Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer's disease. Nature communications. 2014;5:3443.

Pulikkal BP, Marunnnan SM, Bandaru S, Yadav M, Nayarisseri A, Sureshkumar S. Common SAR derived from linear and non-linear QSAR studies on AChE inhibitors used in the treatment of Alzheimer's disease. Current neuropharmacology. 2016.

Pulyk OR, Smolanka VI, Hyriavets MV. Prevention of cognitive impairments in patients after stroke. Wiadomosci lekarskie (Warsaw, Poland : 1960). 2014;67(2 Pt 2):235-8.

Puri V, Wang X, Vardigan JD, Kuduk SD, Uslaner JM. The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model. Behavioural brain research. 2015;287:96-9.

Purushothuman S, Johnstone DM, Nandasena C, Eersel Jv, Ittner LM, Mitrofanis J, et al. Near infrared light mitigates cerebellar pathology in transgenic mouse models of dementia. Neuroscience letters. 2015;591:155-9.

Purushothuman S, Johnstone DM, Nandasena C, Mitrofanis J, Stone J. Photobiomodulation with near infrared light mitigates Alzheimer's disease-related pathology in cerebral cortex - evidence from two transgenic mouse models. Alzheimer's research & therapy. 2014;6(1):2.

Puzzo D, Loreto C, Giunta S, Musumeci G, Frasca G, Podda MV, et al. Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. Neurobiology of aging. 2014;35(3):520-31.

Qi H, Shuai J. Alzheimer's disease via enhanced calcium signaling caused by the decrease of endoplasmic reticulum-mitochondrial distance. Medical hypotheses. 2016;89:28-31.

Qi L, Chen Z, Wang Y, Liu X, Liu X, Ke L, et al. Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3beta. *American journal of translational research*. 2017;9(2):247-60.

Qi L, Ke L, Liu X, Liao L, Ke S, Liu X, et al. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3beta pathway in an amyloid beta protein induced alzheimer disease mouse model. *European journal of pharmacology*. 2016;783:23-32.

Qi Y, Dou D-Q, Jiang H, Zhang B-B, Qin W-Y, Kang K, et al. Arctigenin Attenuates Learning and Memory Deficits through PI3k/Akt/GSK-3beta Pathway Reducing Tau Hyperphosphorylation in Abeta-Induced AD Mice. *Planta medica*. 2017;83(1-02):51-6.

Qi Y, Klyubin I, Harney SC, Hu N, Cullen WK, Grant MK, et al. Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human ASS-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-ASS agents. *Acta neuropathologica communications*. 2014;2:175.

Qi Y, Zou L-B, Wang L-H, Jin G, Pan J-J, Chi T-Y, et al. Xanthoceraside inhibits pro-inflammatory cytokine expression in Abeta25-35/IFN-gamma-stimulated microglia through the TLR2 receptor, MyD88, nuclear factor-kappaB, and mitogen-activated protein kinase signaling pathways. *Journal of pharmacological sciences*. 2013;122(4):305-17.

Qian J, Wolters FJ, Beiser A, Haan M, Ikram MA, Karlawish J, et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. *PLoS medicine*. 2017;14(3):e1002254.

Qiang X, Li Y, Yang X, Luo L, Xu R, Zheng Y, et al. DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-beta aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy. *Bioorganic & medicinal chemistry letters*. 2017;27(4):718-22.

Qiao A, Wang Y, Zhang W, He X. Neuroprotection of brain-targeted bioactive dietary artoindonesianin O (AIO) from mulberry on rat neurons as a novel intervention for Alzheimer's disease. *Journal of agricultural and food chemistry*. 2015;63(14):3687-93.

Qiao J, Wang J, Wang H, Zhang Y, Zhu S, Adilijiang A, et al. Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model. *Glia*. 2016;64(2):240-54.

Qin L, Zhang J, Qin M. Protective effect of cyanidin 3-O-glucoside on beta-amyloid peptide-induced cognitive impairment in rats. *Neuroscience letters*. 2013;534:285-8.

Qin X, Wang Y, Paudel HK. Inhibition of Early Growth Response 1 in the Hippocampus Alleviates Neuropathology and Improves Cognition in an Alzheimer Model with Plaques and Tangles. *The American journal of pathology*. 2017;187(8):1828-47.

Qin Y, Gu JW. A Surgical Method to Improve the Homeostasis of CSF for the Treatment of Alzheimer's Disease. *Frontiers in aging neuroscience*. 2016;8:261.

Qin Y, Liu Y, Hao W, Decker Y, Tomic I, Menger MD, et al. Stimulation of TLR4 Attenuates Alzheimer's Disease-Related Symptoms and Pathology in Tau-Transgenic Mice. *Journal of immunology (Baltimore, Md : 1950)*. 2016;197(8):3281-92.

Qiu L, Ng G, Tan EK, Liao P, Kandiah N, Zeng L. Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimer's disease mice. *Scientific reports*. 2016;6:23964.

Qiu WQ, Mwamburi M, Besser LM, Zhu H, Li H, Wallack M, et al. Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele. *Journal of Alzheimer's disease : JAD*. 2013;37(2):421-8.

Qiu WWQ, Lai A, Mon T, Mwamburi M, Taylor W, Rosenzweig J, et al. Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2014;22(2):177-85.

Qosa H, Batarseh YS, Mohyeldin MM, El Sayed KA, Keller JN, Kaddoumi A. Oleocanthal enhances amyloid-beta clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model. *ACS chemical neuroscience*. 2015;6(11):1849-59.

Qosa H, Mohamed LA, Batarseh YS, Alqahtani S, Ibrahim B, LeVine H, 3rd, et al. Extra-virgin olive oil attenuates amyloid-beta and tau pathologies in the brains of TgSwDI mice. *The Journal of nutritional biochemistry*. 2015;26(12):1479-90.

Qu B, Gong Y, Gill JM, Kenney K, Diaz-Arrastia R. Heterozygous knockout of cytosolic phospholipase A2alpha attenuates Alzheimer's disease pathology in APP/PS1 transgenic mice. *Brain research*. 2017;1670:248-52.

Qu F, Yang M, Rasooly A. Dual Signal Amplification Electrochemical Biosensor for Monitoring the Activity and Inhibition of the Alzheimer's Related Protease beta-Secretase. *Analytical chemistry*. 2016;88(21):10559-65.

Qu M-H, Yang X, Wang Y, Tang Q, Han H, Wang J, et al. Docosahexaenoic Acid-Phosphatidylcholine Improves Cognitive Deficits in an Aβ₂₃₋₃₅-Induced Alzheimer's Disease Rat Model. *Current topics in medicinal chemistry*. 2016;16(5):558-64.

Qualls C, Waters DL, Vellas B, Villareal DT, Garry PJ, Gallini A, et al. Reversible States of Physical and/or Cognitive Dysfunction: A 9-Year Longitudinal Study. *The journal of nutrition, health & aging*. 2017;21(3):271-5.

Quan L, Wu J, Lane LA, Wang J, Lu Q, Gu Z, et al. Enhanced Detection Specificity and Sensitivity of Alzheimer's Disease Using Amyloid-beta-Targeted Quantum Dots. *Bioconjugate chemistry*. 2016;27(3):809-14.

Quarmley M, Moberg PJ, Mechanic-Hamilton D, Kabadi S, Arnold SE, Wolk DA, et al. Odor Identification Screening Improves Diagnostic Classification in Incipient Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;55(4):1497-507.

Rabal O, Sanchez-Arias JA, Cuadrado-Tejedor M, de Miguel I, Perez-Gonzalez M, Garcia-Barroso C, et al. Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease. *Journal of medicinal chemistry*. 2016;59(19):8967-9004.

Rabinovich-Nikitin I, Solomon B. Inhibition of amyloid precursor protein processing leads to downregulation of apoptotic genes in Alzheimer's disease animal models. *Neuro-degenerative diseases*. 2014;13(2-3):107-9.

Rachmany L, Tweedie D, Li Y, Rubovitch V, Holloway HW, Miller J, et al. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. *Age (Dordrecht, Netherlands)*. 2013;35(5):1621-36.

Radford H, Moreno JA, Verity N, Halliday M, Mallucci GR. PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. *Acta neuropathologica*. 2015;130(5):633-42.

Rafii MS. Improving Memory and Cognition in Individuals with Down Syndrome. *CNS drugs*. 2016;30(7):567-73.

Raghavan N, Samtani MN, Farnum M, Yang E, Novak G, Grundman M, et al. The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013;9(1 Suppl):S21-31.

Raghavan P, Looby S, Bourne TD, Wintermark M. Cerebral amyloid angiopathy-related inflammation: A potentially reversible cause of dementia with characteristic imaging findings. *Journal of neuroradiology Journal de neuroradiologie*. 2016;43(1):11-7.

Raha AA, Henderson JW, Stott SRW, Vuono R, Foscari S, Friedland RP, et al. Neuroprotective Effect of TREM-2 in Aging and Alzheimer's Disease Model. *Journal of Alzheimer's disease : JAD*. 2017;55(1):199-217.

Rahim F, Javed MT, Ullah H, Wadood A, Taha M, Ashraf M, et al. Synthesis, molecular docking, acetylcholinesterase and butyrylcholinesterase inhibitory potential of thiazole analogs as new inhibitors for Alzheimer disease. *Bioorganic chemistry*. 2015;62:106-16.

Rahimian R, Fakhfouri G, Ejtemaei Mehr S, Ghia J-E, Genazzani AA, Payandemehr B, et al. Tropisetron attenuates amyloid-beta-induced inflammatory and apoptotic responses in rats. *European journal of clinical investigation*. 2013;43(10):1039-51.

Raitano S, Ordovas L, De Muynck L, Guo W, Espuny-Camacho I, Geraerts M, et al. Restoration of progranulin expression rescues cortical neuron generation in an induced pluripotent stem cell model of frontotemporal dementia. *Stem cell reports*. 2015;4(1):16-24.

Rajadas J, Sun W, Li H, Inayathullah M, Cereghetti D, Tan A, et al. Enhanced Abeta(1-40) production in endothelial cells stimulated with fibrillar Abeta(1-42). *PloS one*. 2013;8(3):e58194.

Raji CA, Eyre H, Wei SH, Bredesen DE, Moylan S, Law M, et al. Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline. *AJNR American journal of neuroradiology*. 2015;36(10):1803-9.

Raji CA. Conceptualizing cognitive health to optimize dementia prevention and care. *Journal of the neurological sciences*. 2017;372:126-7.

Rajput MS, Sarkar PD, Nirmal NP. Inhibition of DPP-4 Activity and Neuronal Atrophy with Genistein Attenuates Neurological Deficits Induced by Transient Global Cerebral Ischemia and Reperfusion in Streptozotocin-Induced Diabetic Mice. *Inflammation*. 2017;40(2):623-35.

Rakesh G, Szabo ST, Alexopoulos GS, Zannas AS. Strategies for dementia prevention: latest evidence and implications. *Therapeutic advances in chronic disease*. 2017;8(8-9):121-36.

Ramalho RM, Nunes AF, Dias RB, Amaral JD, Lo AC, D'Hooge R, et al. Tauroursodeoxycholic acid suppresses amyloid beta-induced synaptic toxicity in vitro and in APP/PS1 mice. *Neurobiology of aging*. 2013;34(2):551-61.

Ramanathan A, Nelson AR, Sagare AP, Zlokovic BV. Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer's disease: the role, regulation and restoration of LRP1. *Frontiers in aging neuroscience*. 2015;7:136.

Ramezani M, Darbandi N, Khodagholi F, Hashemi A. Myricetin protects hippocampal CA3 pyramidal neurons and improves learning and memory impairments in rats with Alzheimer's disease. *Neural regeneration research*. 2016;11(12):1976-80.

Ramirez A, van der Flier WM, Herold C, Ramonet D, Heilmann S, Lewczuk P, et al. SUCLG2 identified as both a determinant of CSF Abeta1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. *Human molecular genetics*. 2014;23(24):6644-58.

Rangasamy SB, Corbett GT, Roy A, Modi KK, Bennett DA, Mufson EJ, et al. Intranasal Delivery of NEMO-Binding Domain Peptide Prevents Memory Loss in a Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2015;47(2):385-402.

Rani A, Neha, Sodhi RK, Kaur A. Protective effect of a calcium channel blocker "diltiazem" on aluminum chloride-induced dementia in mice. *Naunyn-Schmiedeberg's archives of pharmacology*. 2015;388(11):1151-61.

Rao JA, Harrington DL, Durgerian S, Reece C, Mourany L, Koenig K, et al. Disruption of response inhibition circuits in prodromal Huntington disease. *Cortex; a journal devoted to the study of the nervous system and behavior*. 2014;58:72-85.

Rasmussen J. Would doctors routinely asking older patients about their memory improve dementia outcomes? Yes. *BMJ (Clinical research ed)*. 2013;346:f1780.

Rasool S, Martinez-Coria H, Wu JW, LaFerla F, Glabe CG. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Abeta deposition and tau pathology in 3xTg-AD mice. *Journal of neurochemistry*. 2013;126(4):473-82.

Ratia M, Gimenez-Llort L, Camps P, Munoz-Torrero D, Perez B, Clos MV, et al. Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD). *Neuro-degenerative diseases*. 2013;11(3):129-40.

Ratovitski T, Arbez N, Stewart JC, Chighladze E, Ross CA. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD). *Cell cycle (Georgetown, Tex)*. 2015;14(11):1716-29.

Raven F, Ward JF, Zoltowska KM, Wan Y, Bylykbashi E, Miller SJ, et al. Soluble Gamma-secretase Modulators Attenuate Alzheimer's beta-amyloid Pathology and Induce Conformational Changes in Presenilin 1. *EBioMedicine*. 2017;24:93-101.

Ravona-Springer R, Beeri MS, Goldbourt U. Satisfaction with current status at work and lack of motivation to improve it during midlife is associated with increased risk for dementia in subjects who survived thirty-seven years later. *Journal of Alzheimer's disease : JAD*. 2013;36(4):769-80.

Rawtaer I, Gao Q, Nyunt MSZ, Feng L, Chong MS, Lim WS, et al. Psychosocial Risk and Protective Factors and Incident Mild Cognitive Impairment and Dementia in Community Dwelling Elderly: Findings from the Singapore Longitudinal Ageing Study. *Journal of Alzheimer's disease : JAD*. 2017;57(2):603-11.

Ray A, Speese SD, Logan MA. Glial Draper rescues Abeta toxicity in a Drosophila model of Alzheimer's Disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017.

Raybuck JD, Hargus NJ, Thayer SA. A GluN2B-Selective NMDAR Antagonist Reverses Synapse Loss and Cognitive Impairment Produced by the HIV-1 Protein Tat. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(33):7837-47.

Raymond M, Warner A, Davies N, Baishnab E, Manthorpe J, Iliffe S, et al. Evaluating educational initiatives to improve palliative care for people with dementia: a narrative review. *Dementia (London, England)*. 2014;13(3):366-81.

Rdzak GM, Abdelghany O. Does insulin therapy for type 1 diabetes mellitus protect against Alzheimer's disease? *Pharmacotherapy*. 2014;34(12):1317-23.

Read KB, LaPolla FWZ, Tolea MI, Galvin JE, Surkis A. Improving data collection, documentation, and workflow in a dementia screening study. *Journal of the Medical Library Association : JMLA*. 2017;105(2):160-6.

Realdon O, Rossetto F, Nalin M, Baroni I, Cabinio M, Fioravanti R, et al. Technology-enhanced multi-domain at home continuum of care program with respect to usual care for people with cognitive impairment: the Ability-TelerehABILITation study protocol for a randomized controlled trial. *BMC psychiatry*. 2016;16(1):425.

Reale M, Di Nicola M, Velluto L, D'Angelo C, Costantini E, Lahiri DK, et al. Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-beta ex vivo activation of peripheral chemokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway. *Current Alzheimer research*. 2014;11(6):608-22.

Reckess GZ, Brandt J, Luis CA, Zandi P, Martin B, Breitner JCS, et al. Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial. *Journal of Alzheimer's disease : JAD*. 2013;36(3):433-43.

Reddy LF, Waltz JA, Green MF, Wynn JK, Horan WP. Probabilistic Reversal Learning in Schizophrenia: Stability of Deficits and Potential Causal Mechanisms. *Schizophrenia bulletin*. 2016;42(4):942-51.

Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Kandimalla R, et al. Protective effects of a natural product, curcumin, against amyloid beta induced mitochondrial and synaptic toxicities in Alzheimer's disease. *Journal of investigative medicine : the official publication of the American Federation for Clinical Research*. 2016;64(8):1220-34.

Reddy PH, Manczak M, Yin X. Mitochondria-Division Inhibitor 1 Protects Against Amyloid-beta induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;58(1):147-62.

Reddy PH, Tonk S, Kumar S, Vijayan M, Kandimalla R, Kuruva CS, et al. A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer's disease. *Biochemical and biophysical research communications*. 2017;483(4):1156-65.

Reddy PH. Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission. *Drug discovery today*. 2014;19(7):951-5.

Regal PJ. A new delirium phenotype with rapid high amplitude onset and nearly as rapid reversal: Central Coast Australia Delirium Intervention Study. *Clinical interventions in aging*. 2015;10:473-80.

Regan A, Tapley M, Jolley D. Improving end of life care for people with dementia. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*. 2014;28(48):37-43.

Rege SD, Geetha T, Griffin GD, Broderick TL, Babu JR. Neuroprotective effects of resveratrol in Alzheimer disease pathology. *Frontiers in aging neuroscience*. 2014;6:218.

Regitz C, DuSsling LM, Wenzel U. Amyloid-beta (A β)-induced paralysis in *Caenorhabditis elegans* is inhibited by the polyphenol quercetin through activation of protein degradation pathways. *Molecular nutrition & food research*. 2014;58(10):1931-40.

Reid LD, Aven FE, Wolf AA. Cognitive behavioral therapy (CBT) for preventing Alzheimer's disease. *Behavioural brain research*. 2017;334:163-77.

Reintjes W, Romijn MDM, Hollander D, Ter Brugge JP, van Marum RJ. Reversible dementia: two nursing home patients with voltage-gated potassium channel antibody-associated limbic encephalitis. *Journal of the American Medical Directors Association*. 2015;16(9):790-4.

Reiter K, Nielson KA, Smith TJ, Weiss LR, Alfini AJ, Smith JC. Improved Cardiorespiratory Fitness Is Associated with Increased Cortical Thickness in Mild Cognitive Impairment. *Journal of the International Neuropsychological Society : JINS*. 2015;21(10):757-67.

Religa D, Fereshtehnejad S-M, Cermakova P, Edlund A-K, Garcia-Porta S, Granqvist N, et al. SveDem, the Swedish Dementia Registry - a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. *PloS one*. 2015;10(2):e0116538.

Religa P, Cao R, Religa D, Xue Y, Bogdanovic N, Westaway D, et al. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. *Scientific reports*. 2013;3:2053.

Remya C, Dileep KV, Tintu I, Variyar EJ, Sadasivan C. In vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile. *Journal of molecular modeling*. 2013;19(3):1179-94.

Ren S-C, Shao H, Ji W-G, Jiang H-H, Xu F, Chen P-Z, et al. Riluzole prevents soluble Abeta1-42 oligomers-induced perturbation of spontaneous discharge in the hippocampal CA1 region of rats. *Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis*. 2015;22(1):36-44.

Reppas-Rindlisbacher CE, Fischer HD, Fung K, Gill SS, Seitz D, Tannenbaum C, et al. Anticholinergic Drug Burden in Persons with Dementia Taking a Cholinesterase Inhibitor: The Effect of Multiple Physicians. *Journal of the American Geriatrics Society*. 2016;64(3):492-500.

Ressler KJ, Smoller JW. Impact of Stress on the Brain: Pathology, Treatment and Prevention. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2016;41(1):1-2.

Retraction: 'Amelioration of Osteoporosis and Hypovitaminosis D by Sunlight Exposure in Hospitalized Elderly Women With Alzheimer's Disease: A Randomized Controlled Trial'. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 2015;30(12):2328.

Revilla S, Sunol C, Garcia-Mesa Y, Gimenez-Llort L, Sanfeliu C, Cristofol R. Physical exercise improves synaptic dysfunction and recovers the loss of survival factors in 3xTg-AD mouse brain. *Neuropharmacology*. 2014;81:55-63.

Revilla S, Ursulet S, Alvarez-Lopez MJ, Castro-Freire M, Perpina U, Garcia-Mesa Y, et al. Lenti-GDNF gene therapy protects against Alzheimer's disease-like neuropathology in 3xTg-AD mice and MC65 cells. *CNS neuroscience & therapeutics*. 2014;20(11):961-72.

Rezazadeh M, Gharesouran J, Movafagh A, Taheri M, Darvish H, Emamalizadeh B, et al. Dominant and Protective Role of the CYTH4 Primate-Specific GTTT-Repeat Longer Alleles Against Neurodegeneration. *Journal of molecular neuroscience : MN*. 2015;56(3):593-6.

Ribeiro CA, Oliveira SM, Guido LF, Magalhaes A, Valencia G, Arsequell G, et al. Transthyretin stabilization by iododiflunisal promotes amyloid-beta peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model. *Journal of Alzheimer's disease : JAD*. 2014;39(2):357-70.

Ribeiro M, Rosenstock TR, Oliveira AM, Oliveira CR, Rego AC. Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington's disease knock-in striatal cells. *Free radical biology & medicine*. 2014;74:129-44.

Ribeiro M, Silva AC, Rodrigues J, Naia L, Rego AC. Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells--protective effect of cystamine and creatine. *Toxicological sciences : an official journal of the Society of Toxicology*. 2013;136(2):487-99.

Ricciarelli R, Brullo C, Prickaerts J, Arancio O, Villa C, Reboisio C, et al. Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease. *Scientific reports*. 2017;7:46320.

Rice S. As drug trials fail, Alzheimer's researchers look toward prevention. *Modern healthcare*. 2014;44(4):8-9.

Richardson C, Gard PR, Klugman A, Isaac M, Tabet N. Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors. *International journal of geriatric psychiatry*. 2013;28(12):1312-7.

Richens JL, Morgan K, O'Shea P. Reverse engineering of Alzheimer's disease based on biomarker pathways analysis. *Neurobiology of aging*. 2014;35(9):2029-38.

Richetin K, Leclerc C, Toni N, Gallopin T, Pech S, Roybon L, et al. Genetic manipulation of adult-born hippocampal neurons rescues memory in a mouse model of Alzheimer's disease. *Brain : a journal of neurology*. 2015;138(Pt 2):440-55.

Richetin K, Moulis M, Millet A, Arrazola MS, Andraini T, Hua J, et al. Amplifying mitochondrial function rescues adult neurogenesis in a mouse model of Alzheimer's disease. *Neurobiology of disease*. 2017;102:113-24.

Richter M, Mewes A, Fritsch M, Krugel U, Hoffmann R, Singer D. Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation. *Vaccines*. 2014;2(3):601-23.

Ridler C. Alzheimer disease: Inhibition of IRE1 signalling reduces AD pathology. *Nature reviews Neurology*. 2017;13(5):258.

Ridler C. Dementia prevention hits the headlines at AAIC17. *Nature reviews Neurology*. 2017;13(10):576.

Riedel WJ. Preventing cognitive decline in preclinical Alzheimer's disease. *Current opinion in pharmacology*. 2014;14:18-22.

Riedel-Heller SG. Decreasing dementia incidence rates? Implications for public health and prevention. *Psychiatrische Praxis*. 2014;41(8):407-9.

Rijpma A, Meulenbroek O, Olde Rikkert MGM. Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer's disease: a systematic review of randomized controlled trials. *Ageing research reviews*. 2014;16:105-12.

Risacher SL, Wang Y, Wishart HA, Rabin LA, Flashman LA, McDonald BC, et al. Cholinergic Enhancement of Brain Activation in Mild Cognitive Impairment during Episodic Memory Encoding. *Frontiers in psychiatry*. 2013;4:105.

Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S, Lovestone S, et al. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. *The lancet Psychiatry*. 2016;3(2):179-86.

Ritchie CW, Wells K, Ritchie K. The PREVENT research programme--a novel research programme to identify and manage midlife risk for dementia: the conceptual framework. *International review of psychiatry (Abingdon, England)*. 2013;25(6):748-54.

Ritchie CW, Zhinchin G. Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease. *International psychogeriatrics*. 2013;25(4):511-5.

Ritchie K, Carriere I, Su L, O'Brien JT, Lovestone S, Wells K, et al. The midlife cognitive profiles of adults at high risk of late-onset Alzheimer's disease: The PREVENT study. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2017;13(10):1089-97.

Ritchie K, Ropacki M, Albala B, Harrison J, Kaye J, Kramer J, et al. Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2017;13(2):186-95.

Rivera A, Vanzuli I, Arellano JJR, Butt A. Decreased Regenerative Capacity of Oligodendrocyte Progenitor Cells (NG2-Glia) in the Ageing Brain: A Vicious Cycle of Synaptic Dysfunction, Myelin Loss and Neuronal Disruption? *Current Alzheimer research*. 2016;13(4):413-8.

Rivosecchi RM, Kane-Gill SL, Svec S, Campbell S, Smithburger PL. The implementation of a nonpharmacologic protocol to prevent intensive care delirium. *Journal of critical care*. 2016;31(1):206-11.

Rizvi SMD, Shaikh S, Khan M, Biswas D, Hameed N, Shakil S. Fetzima (levomilnacipran), a drug for major depressive disorder as a dual inhibitor for human serotonin transporters and beta-site amyloid precursor protein cleaving enzyme-1. *CNS & neurological disorders drug targets*. 2014;13(8):1427-31.

Rizvi SMD, Shaikh S, Naaz D, Shakil S, Ahmad A, Haneef M, et al. Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer's Disease-Diabetes Dual Therapy. *Neurochemical research*. 2016;41(6):1475-82.

Rizvi SMD, Shakil S, Biswas D, Shakil S, Shaikh S, Bagga P, et al. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study. *CNS & neurological disorders drug targets*. 2014;13(3):447-51.

Rizzo MR, Barbieri M, Boccardi V, Angellotti E, Marfella R, Paolisso G. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2014;69(9):1122-31.

Robbins NM, Bernat JL. Should Dementia Be Accepted as a Disability to Help Restore Hope during Cognitive Decline? *AMA journal of ethics*. 2017;19(7):649-55.

Roberts JS, McLaughlin SJ, Connell CM. Public beliefs and knowledge about risk and protective factors for Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2014;10(5 Suppl):S381-9.

Roberts PL, Dalton J, Evans D, Harrison P, Li Z, Ternouth K, et al. Removal of TSE agent from plasma products manufactured in the United Kingdom. *Vox sanguinis*. 2013;104(4):299-308.

Robertson M, Brown E, Whalley L. Dementia prevention: shared questions for research and clinical management. *Maturitas*. 2014;77(2):124-7.

Robillard JM, Feng TL. Health Advice in a Digital World: Quality and Content of Online Information about the Prevention of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;55(1):219-29.

Robinson H, MacDonald BA, Kerse N, Broadbent E. Suitability of healthcare robots for a dementia unit and suggested improvements. *Journal of the American Medical Directors Association*. 2013;14(1):34-40.

Rocchi A, Yamamoto S, Ting T, Fan Y, Sadleir K, Wang Y, et al. A Becn1 mutation mediates hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's disease. *PLoS genetics*. 2017;13(8):e1006962.

Rochais C, Lecoutey C, Gaven F, Giannoni P, Hamidouche K, Hedou D, et al. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. *Journal of medicinal chemistry*. 2015;58(7):3172-87.

Rocher AB, Gubellini P, Merienne N, Boussicault L, Petit F, Gipchtein P, et al. Synaptic scaling up in medium spiny neurons of aged BACHD mice: A slow-progression model of Huntington's disease. *Neurobiology of disease*. 2016;86:131-9.

Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A, et al. Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease. *Stem cell research*. 2015;15(1):54-67.

Rockenstein E, Ubhi K, Mante M, Florio J, Adame A, Winter S, et al. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies. *BMC neuroscience*. 2015;16:85.

Rockwood K, Howlett SE, Hoffman D, Schindler R, Mitnitski A. Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2017;13(10):1098-106.

Rodda J, Carter J. Cholesterol inhibitor and memantine in symptomatic dementia therapy. *Praxis*. 2013;102(5):293-300; discussion 298-9.

Rodrigues Brazete J, Gagnon J-F, Postuma RB, Bertrand J-A, Petit D, Montplaisir J. Electroencephalogram slowing predicts neurodegeneration in rapid eye movement sleep behavior disorder. *Neurobiology of aging*. 2016;37:74-81.

Rodrigues Brazete J, Montplaisir J, Petit D, Postuma RB, Bertrand J-A, Genier Marchand D, et al. Electroencephalogram slowing in rapid eye movement sleep behavior disorder is associated with mild cognitive impairment. *Sleep medicine*. 2013;14(11):1059-63.

Rodriguez Cruz Y, Strehaiano M, Rodriguez Obaya T, Garcia Rodriguez JC, Maurice T. An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;55(1):231-48.

Rodriguez JJ, Terzieva S, Olabarria M, Lanza RG, Verkhratsky A. Enriched environment and physical activity reverse astroglioneurodegeneration in the hippocampus of AD transgenic mice. *Cell death & disease*. 2013;4:e678.

Rodriguez-Casado A, Toledano-Diaz A, Toledano A. Defective Insulin Signalling, Mediated by Inflammation, Connects Obesity to Alzheimer Disease; Relevant Pharmacological Therapies and Preventive Dietary Interventions. *Current Alzheimer research*. 2017;14(8):894-911.

Rodriguez-Gomez O, Palacio-Lacambra ME, Palasi A, Ruiz-Laza A, Boada-Rovira M. Prevention of Alzheimer's disease: a global challenge for next generation neuroscientists. *Journal of Alzheimer's disease : JAD*. 2014;42 Suppl 4:S515-23.

Rodriguez-Perdigon M, Solas M, Moreno-Aliaga MJ, Ramirez MJ. Lipoic acid improves neuronal insulin signalling and rescues cognitive function regulating VGlut1 expression in high-

fat-fed rats: Implications for Alzheimer's disease. *Biochimica et biophysica acta*. 2016;1862(4):511-7.

Rodriguez-Ruiz M, Moreno E, Moreno-Delgado D, Navarro G, Mallol J, Cortes A, et al. Heteroreceptor Complexes Formed by Dopamine D1, Histamine H3, and N-Methyl-D-Aspartate Glutamate Receptors as Targets to Prevent Neuronal Death in Alzheimer's Disease. *Molecular neurobiology*. 2017;54(6):4537-50.

Rogers JT, Venkataramani V, Washburn C, Liu Y, Tummala V, Jiang H, et al. A role for amyloid precursor protein translation to restore iron homeostasis and ameliorate lead (Pb) neurotoxicity. *Journal of neurochemistry*. 2016;138(3):479-94.

Roh HW, Hong CH, Lee Y, Lee KS, Chang KJ, Kang DR, et al. Clinical Conversion or Reversion of Mild Cognitive Impairment in Community versus Hospital Based Studies: GDEMCIS (Gwangju Dementia and Mild Cognitive Impairment Study) and CREDOS (Clinical Research Center for Dementia of South Korea). *Journal of Alzheimer's disease : JAD*. 2016;53(2):463-73.

Rohe M, Hartl D, Fjorback AN, Klose J, Willnow TE. SORLA-mediated trafficking of TrkB enhances the response of neurons to BDNF. *PloS one*. 2013;8(8):e72164.

Roher AE, Maarouf CL, Kokjohn TA, Whiteside CM, Kalback WM, Serrano G, et al. Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the gamma-secretase inhibitor semagacestat. *American journal of neurodegenerative disease*. 2014;3(3):115-33.

Rojanathammanee L, Floden AM, Manocha GD, Combs CK. Attenuation of microglial activation in a mouse model of Alzheimer's disease via NFAT inhibition. *Journal of neuroinflammation*. 2015;12:42.

Rojanathammanee L, Puig KL, Combs CK. Pomegranate polyphenols and extract inhibit nuclear factor of activated T-cell activity and microglial activation in vitro and in a transgenic mouse model of Alzheimer disease. *The Journal of nutrition*. 2013;143(5):597-605.

Rojas-Fernandez C, Mikhail M, Brown SG. Psychotropic and cognitive-enhancing medication use and its documentation in contemporary long-term care practice. *The Annals of pharmacotherapy*. 2014;48(4):438-46.

Rojas-Fernandez CH. Little evidence that cholinesterase inhibitors prevent progression of mild cognitive impairment to dementia, but they are associated with adverse effects. *Evidence-based mental health*. 2013;16(2):39.

Rokstad AMM, Rosvik J, Kirkevold O, Selbaek G, Saltyte Benth J, Engedal K. The effect of person-centred dementia care to prevent agitation and other neuropsychiatric symptoms and

enhance quality of life in nursing home patients: a 10-month randomized controlled trial. *Dementia and geriatric cognitive disorders*. 2013;36(5-6):340-53.

Rollin-Sillaire A, Breuilh L, Salleron J, Bombois S, Cassagnaud P, Deramecourt V, et al. Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials. *British journal of clinical pharmacology*. 2013;75(4):1089-97.

Roman GC, Boller F. Vascular factors in neurodegenerative diseases: a path towards treatment and prevention. *Functional neurology*. 2014;29(2):85-6.

Romberg C, Horner AE, Bussey TJ, Saksida LM. A touch screen-automated cognitive test battery reveals impaired attention, memory abnormalities, and increased response inhibition in the TgCRND8 mouse model of Alzheimer's disease. *Neurobiology of aging*. 2013;34(3):731-44.

Rombouts FJR, Tresadern G, Delgado O, Martinez-Lamenca C, Van Gool M, Garcia-Molina A, et al. 1,4-Oxazine beta-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads. *Journal of medicinal chemistry*. 2015;58(20):8216-35.

Romero A, Egea J, Gonzalez-Munoz GC, Martin de Saavedra MD, del Barrio L, Rodriguez-Franco MI, et al. ITH12410/SC058: a new neuroprotective compound with potential in the treatment of Alzheimer's disease. *ACS chemical neuroscience*. 2014;5(9):770-5.

Romero HR, Welsh-Bohmer KA, Gwyther LP, Edmonds HL, Plassman BL, Germain CM, et al. Community engagement in diverse populations for Alzheimer disease prevention trials. *Alzheimer disease and associated disorders*. 2014;28(3):269-74.

Roncero C, Kniefel H, Service E, Thiel A, Probst S, Chertkow H. Inferior parietal transcranial direct current stimulation with training improves cognition in anomic Alzheimer's disease and frontotemporal dementia. *Alzheimer's & dementia (New York, N Y)*. 2017;3(2):247-53.

Rooney RFE. Preventing dementia: how lifestyle in midlife affects risk. *Current opinion in psychiatry*. 2014;27(2):149-57.

Roos K, Viklund J, Meuller J, Kaspersson K, Svensson M. Potency prediction of beta-secretase (BACE-1) inhibitors using density functional methods. *Journal of chemical information and modeling*. 2014;54(3):818-25.

Rorabaugh JM, Chalermpananupap T, Botz-Zapp CA, Fu VM, Lembeck NA, Cohen RM, et al. Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer's disease. *Brain : a journal of neurology*. 2017;140(11):3023-38.

Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu J-P, et al. PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. *Neurology*. 2014;82(10):850-7.

Rosenblum WI. Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. *Neurobiology of aging*. 2014;35(5):969-74.

Rosini F, Rufa A, Monti L, Tirelli L, Federico A. Adult-onset phenylketonuria revealed by acute reversible dementia, prosopagnosia and parkinsonism. *Journal of neurology*. 2014;261(12):2446-8.

Rosini M, Simoni E, Bartolini M, Soriano E, Marco-Contelles J, Andrisano V, et al. The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon. *ChemMedChem*. 2013;8(8):1276-81.

Rosini M, Simoni E, Minarini A, Melchiorre C. Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. *Neurochemical research*. 2014;39(10):1914-23.

Rosse G. Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Down's Syndrome or Alzheimer's Disease. *ACS medicinal chemistry letters*. 2013;4(6):502-3.

Rossignol J, Fink K, Davis K, Clerc S, Crane A, Matchynski J, et al. Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington's disease. *Stem cells (Dayton, Ohio)*. 2014;32(2):500-9.

Rosso AL, Verghese J, Metti AL, Boudreau RM, Aizenstein HJ, Kritchevsky S, et al. Slowing gait and risk for cognitive impairment: The hippocampus as a shared neural substrate. *Neurology*. 2017;89(4):336-42.

Rossor M. IN 2014 CAN WE PREVENT DEMENTIA? *Transactions of the Medical Society of London*. 2013;130:59-63.

Rotman M, Welling MM, Bunschoten A, de Backer ME, Rip J, Nabuurs RJA, et al. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease. *Journal of controlled release : official journal of the Controlled Release Society*. 2015;203:40-50.

Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. *CNS drugs*. 2015;29(2):113-30.

Roussos P, Katsel P, Fam P, Tan W, Purohit DP, Haroutunian V. The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2015;11(10):1163-70.

Rovner BW, Casten RJ. Preserving Cognition in Older African Americans with Mild Cognitive Impairment. *Journal of the American Geriatrics Society*. 2016;64(3):659-61.

Roy A, Jana M, Kundu M, Corbett GT, Rangaswamy SB, Mishra RK, et al. HMG-CoA Reductase Inhibitors Bind to PPAR α to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice. *Cell metabolism*. 2015;22(2):253-65.

Roy A, Modi KK, Khasnavis S, Ghosh S, Watson R, Pahan K. Enhancement of morphological plasticity in hippocampal neurons by a physically modified saline via phosphatidylinositol-3 kinase. *PloS one*. 2014;9(7):e101883.

Roy S, Kumar A, Baig MH, Masarik M, Provaznik I. Virtual screening, ADMET profiling, molecular docking and dynamics approaches to search for potent selective natural molecules based inhibitors against metallothionein-III to study Alzheimer's disease. *Methods (San Diego, Calif)*. 2015;83:105-10.

Roy SM, Grum-Tokars VL, Schavocky JP, Saeed F, Staniszewski A, Teich AF, et al. Targeting human central nervous system protein kinases: An isoform selective p38 α MAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. *ACS chemical neuroscience*. 2015;6(4):666-80.

Royall DR, Matsuoka T, Palmer RF, Kato Y, Taniguchi S, Ogawa M, et al. Greater than the sum of its parts: delta Improves upon a battery's diagnostic performance. *Neuropsychology*. 2015;29(5):683-92.

Rozpedek W, Pytel D, Diehl JA, Majsterek I. Small molecule inhibitors of PERK-dependent signaling pathway as a novel, therapeutic molecular strategy in Alzheimer's disease treatment. *Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego*. 2016;41(241):5-10.

Ruan Q, Yu Z, Chen M, Bao Z, Li J, He W. Cognitive frailty, a novel target for the prevention of elderly dependency. *Ageing research reviews*. 2015;20:1-10.

Rub U, Stratmann K, Heinsen H, Seidel K, Bouzrou M, Korf H-W. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches. *Journal of Alzheimer's disease : JAD*. 2017;57(3):683-96.

Rubbi I, Magnani D, Naldoni G, Di Lorenzo R, Cremonini V, Capucci P, et al. Efficacy of video-music therapy on quality of life improvement in a group of patients with Alzheimer's disease: a pre-post study. *Acta bio-medica : Atenei Parmensis*. 2016;87(4 - S):30-7.

Rudnitskaya EA, Muraleva NA, Maksimova KY, Kiseleva E, Kolosova NG, Stefanova NA. Melatonin Attenuates Memory Impairment, Amyloid-beta Accumulation, and

Neurodegeneration in a Rat Model of Sporadic Alzheimer's Disease. *Journal of Alzheimer's disease* : JAD. 2015;47(1):103-16.

Ruela ALM, Carvalho FC, Pereira GR. Exploring the Phase Behavior of Monoolein/Oleic Acid/Water Systems for Enhanced Donepezil Administration for Alzheimer Disease Treatment. *Journal of pharmaceutical sciences*. 2016;105(1):71-7.

Ruhlmann C, Wolk T, Blumel T, Stahn L, Vollmar B, Kuhla A. Long-term caloric restriction in ApoE-deficient mice results in neuroprotection via Fgf21-induced AMPK/mTOR pathway. *Aging*. 2016;8(11):2777-89.

Rullmann M, Dukart J, Hoffmann K-T, Luthardt J, Tiepolt S, Patt M, et al. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben beta-Amyloid PET Scans. *Journal of nuclear medicine* : official publication, Society of Nuclear Medicine. 2016;57(2):198-203.

Rumbaugh G, Sullivan SE, Ozkan ED, Rojas CS, Hubbs CR, Aceti M, et al. Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue. *Neuropsychopharmacology* : official publication of the American College of Neuropsychopharmacology. 2015;40(10):2307-16.

Russ TC. Cholinesterase inhibitors should not be prescribed for mild cognitive impairment. *Evidence-based medicine*. 2014;19(3):101.

Russell P, Banerjee S, Watt J, Adleman R, Agoe B, Burnie N, et al. Improving the identification of people with dementia in primary care: evaluation of the impact of primary care dementia coding guidance on identified prevalence. *BMJ open*. 2013;3(12):e004023.

Russino D, McDonald E, Hejazi L, Hanson GR, Jones CE. The tachykinin peptide neurokinin B binds copper forming an unusual CuII(NKB)₂ complex and inhibits copper uptake into 1321N1 astrocytoma cells. *ACS chemical neuroscience*. 2013;4(10):1371-81.

Russo E, Leo A, Crupi R, Aiello R, Lippiello P, Spiga R, et al. Everolimus improves memory and learning while worsening depressive- and anxiety-like behavior in an animal model of depression. *Journal of psychiatric research*. 2016;78:1-10.

Russo P, Del Bufalo A, Frustaci A, Fini M, Cesario A. Beyond acetylcholinesterase inhibitors for treating Alzheimer's disease: alpha7-nAChR agonists in human clinical trials. *Current pharmaceutical design*. 2014;20(38):6014-21.

Russo P, Frustaci A, Del Bufalo A, Fini M, Cesario A. From traditional European medicine to discovery of new drug candidates for the treatment of dementia and Alzheimer's disease: acetylcholinesterase inhibitors. *Current medicinal chemistry*. 2013;20(8):976-83.

Russo P, Kisialiou A, Moroni R, Prinzi G, Fini M. Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease. *Current drug targets*. 2017;18(10):1179-90.

Ruzicka J, Kulijewicz-Nawrot M, Rodriguez-Arellano JJ, Jendelova P, Sykova E. Mesenchymal Stem Cells Preserve Working Memory in the 3xTg-AD Mouse Model of Alzheimer's Disease. *International journal of molecular sciences*. 2016;17(2).

Ryazantseva M, Skobeleva K, Glushankova L, Kaznacheyeva E. Attenuated presenilin-1 endoproteolysis enhances store-operated calcium currents in neuronal cells. *Journal of neurochemistry*. 2016;136(5):1085-95.

Rygiel K. Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population. *Journal of postgraduate medicine*. 2016;62(4):242-8.

Ryotokuji K, Ishimaru K, Kihara K, Nakajima T, Otani S, Namiki Y. Preliminary results of highly localized plantar irradiation with low incident levels of mid-infrared energy which contributes to the prevention of dementia associated with underlying diabetes mellitus. *Laser therapy*. 2015;24(1):27-32.

Ryu B, Kawamata T, Wakai T, Shimizu M, Yagi S, Shimizu T. Reversible Cerebral Metabolism Changes Using Proton Magnetic Resonance Spectroscopy in a Patient with Intracranial Dural Arteriovenous Fistula: A Case Report. *World neurosurgery*. 2016;92:584.e1-6.

Ryu J, Hong BH, Kim YJ, Yang EJ, Choi M, Kim H, et al. Neuregulin-1 attenuates cognitive function impairments in a transgenic mouse model of Alzheimer's disease. *Cell death & disease*. 2016;7:e2117.

Ryu JK, Cho T, Choi HB, Jantaratnotai N, McLarnon JG. Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer's disease. *Journal of neuroinflammation*. 2015;12:144.

Sa Santos S, Santos SM, Pinto ART, Ramu VG, Heras M, Bardaji E, et al. Amidated and Ibuprofen-Conjugated Kyotorphins Promote Neuronal Rescue and Memory Recovery in Cerebral Hypoperfusion Dementia Model. *Frontiers in aging neuroscience*. 2016;8:1.

Saad Y, Segal D, Ayali A. Enhanced neurite outgrowth and branching precede increased amyloid-beta-induced neuronal apoptosis in a novel Alzheimer's disease model. *Journal of Alzheimer's disease : JAD*. 2015;43(3):993-1006.

Saathoff JM, Liu K, Chojnacki JE, He L, Chen Q, Lesnefsky EJ, et al. Mechanistic Insight of Bivalent Compound 21MO as Potential Neuroprotectant for Alzheimer's Disease. *Molecules (Basel, Switzerland)*. 2016;21(4):412.

Saba K, Rajnala N, Veeraiah P, Tiwari V, Rana RK, Lakhota SC, et al. Energetics of Excitatory and Inhibitory Neurotransmission in Aluminum Chloride Model of Alzheimer's Disease: Reversal of Behavioral and Metabolic Deficits by Rasa Sindoor. *Frontiers in molecular neuroscience*. 2017;10:323.

Sabogal-Guaqueta AM, Munoz-Manco JI, Ramirez-Pineda JR, Lamprea-Rodriguez M, Osorio E, Cardona-Gomez GP. The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice. *Neuropharmacology*. 2015;93:134-45.

Sabogal-Guaqueta AM, Osorio E, Cardona-Gomez GP. Linalool reverses neuropathological and behavioral impairments in old triple transgenic Alzheimer's mice. *Neuropharmacology*. 2016;102:111-20.

Sachdev PS, Lipnicki DM, Crawford J, Reppermund S, Kochan NA, Trollor JN, et al. Factors predicting reversion from mild cognitive impairment to normal cognitive functioning: a population-based study. *PloS one*. 2013;8(3):e59649.

Sachdev PS, Lipnicki DM, Kochan NA, Crawford JD, Rockwood K, Xiao S, et al. COSMIC (Cohort Studies of Memory in an International Consortium): an international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethnic and sociocultural groups. *BMC neurology*. 2013;13:165.

Sachdeva AK, Kuhad A, Chopra K. Naringin ameliorates memory deficits in experimental paradigm of Alzheimer's disease by attenuating mitochondrial dysfunction. *Pharmacology, biochemistry, and behavior*. 2014;127:101-10.

Sachs GA. Improving prescribing practices late in life: a task for all clinicians, not just nursing home physicians. *JAMA internal medicine*. 2014;174(11):1771-2.

Sadak T, Foster Zdon S, Ishado E, Zaslavsky O, Borson S. Potentially preventable hospitalizations in dementia: family caregiver experiences. *International psychogeriatrics*. 2017;29(7):1201-11.

Sadleir KR, Eimer WA, Kaufman RJ, Osten P, Vassar R. Genetic inhibition of phosphorylation of the translation initiation factor eIF2 α does not block A β -dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease. *PloS one*. 2014;9(7):e101643.

Safar MM, Arab HH, Rizk SM, El-Maraghy SA. Bone Marrow-Derived Endothelial Progenitor Cells Protect Against Scopolamine-Induced Alzheimer-Like Pathological Aberrations. *Molecular neurobiology*. 2016;53(3):1403-18.

Safouris A, Psaltopoulou T, Sergentanis TN, Boutati E, Kapaki E, Tsivgoulis G. Vascular risk factors and Alzheimer's disease pathogenesis: are conventional pharmacological approaches protective for cognitive decline progression? *CNS & neurological disorders drug targets*. 2015;14(2):257-69.

Sahakian BJ, Bruhl AB, Cook J, Killikelly C, Savulich G, Piercy T, et al. The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people. *Philosophical transactions of the Royal Society of London Series B, Biological sciences*. 2015;370(1677):20140214.

Sahakian BJ, Morein-Zamir S. Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people. *The lancet Psychiatry*. 2015;2(4):357-62.

Saint-Laurent Thibault C, Ozer Stillman I, Chen S, Getsios D, Proskorovsky I, Hernandez L, et al. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US. *Journal of medical economics*. 2015;18(11):930-43.

Sakai K, Oda H, Terashima A, Ishii K, Maeda K. Slow Progression of Cognitive Dysfunction of Alzheimer's Disease in Sexagenarian Women with Schizophrenia. *Case reports in psychiatry*. 2015;2015:968598.

Sakai K, Senda T, Hata R, Kuroda M, Hasegawa M, Kato M, et al. Patients that have Undergone Hemodialysis Exhibit Lower Amyloid Deposition in the Brain: Evidence Supporting a Therapeutic Strategy for Alzheimer's Disease by Removal of Blood Amyloid. *Journal of Alzheimer's disease : JAD*. 2016;51(4):997-1002.

Sakurai T, Kitadate K, Nishioka H, Fujii H, Ogasawara J, Kizaki T, et al. Oligomerised lychee fruit-derived polyphenol attenuates cognitive impairment in senescence-accelerated mice and endoplasmic reticulum stress in neuronal cells. *The British journal of nutrition*. 2013;110(9):1549-58.

Sakurai T. Preventive strategy for cognitive decline in elderly with diabetes mellitus. *Nihon rinsho Japanese journal of clinical medicine*. 2014;72(4):692-6.

Salameh A, Dhein S, Dahnert I, Klein N. Neuroprotective Strategies during Cardiac Surgery with Cardiopulmonary Bypass. *International journal of molecular sciences*. 2016;17(11).

Salazar SV, Gallardo C, Kaufman AC, Herber CS, Haas LT, Robinson S, et al. Conditional Deletion of Prnp Rescues Behavioral and Synaptic Deficits after Disease Onset in Transgenic Alzheimer's Disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(38):9207-21.

Salgado-Puga K, Prado-Alcala RA, Pena-Ortega F. Amyloid beta Enhances Typical Rodent Behavior While It Impairs Contextual Memory Consolidation. *Behavioural neurology*. 2015;2015:526912.

Saliu JA, Olabiyi AA. Aqueous extract of *Securidaca longipendunculata* Oliv. and *Ola* subscropioidea inhibits key enzymes (acetylcholinesterase and butyrylcholinesterase) linked with Alzheimer's disease in vitro. *Pharmaceutical biology*. 2017;55(1):252-7.

Salkovic-Petrisic M, Knezovic A, Osmanovic-Barilar J, Smailovic U, Trkulja V, Riederer P, et al. Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease. *Life sciences*. 2015;136:108-19.

Salles GN, Pereira FADS, Pacheco-Soares C, Marciano FR, Holscher C, Webster TJ, et al. A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer's Disease. *Molecular neurobiology*. 2016.

Sallustio F, Studer V. Targeting New Pharmacological Approaches for Alzheimer's Disease: Potential for Statins and Phosphodiesterase Inhibitors. *CNS & neurological disorders drug targets*. 2016;15(6):647-59.

Saltmarche AE, Naeser MA, Ho KF, Hamblin MR, Lim L. Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial Plus Intranasal Photobiomodulation: Case Series Report. *Photomedicine and laser surgery*. 2017;35(8):432-41.

Samadi A, de la Fuente Revenga M, Perez C, Iriepa I, Moraleda I, Rodriguez-Franco MI, et al. Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. *European journal of medicinal chemistry*. 2013;67:64-74.

Samaras N, Samaras D, Frangos E, Forster A. Dementia prevention: potential treatments and how to target high risk patients. *Revue medicale suisse*. 2013;9(387):1116-9.

Sampson EL, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's dementia. *The Cochrane database of systematic reviews*. 2014(2):CD005380.

Sampson EL, Vickerstaff V, Lietz S, Orrell M. Improving the care of people with dementia in general hospitals: evaluation of a whole-system train-the-trainer model. *International psychogeriatrics*. 2017;29(4):605-14.

Sancheti H, Kanamori K, Patil I, Diaz Brinton R, Ross BD, Cadenas E. Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer's disease: a ¹³C NMR

study. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2014;34(2):288-96.

Sanchez-Arias JA, Rabal O, Cuadrado-Tejedor M, de Miguel I, Perez-Gonzalez M, Ugarte A, et al. Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease. *ACS chemical neuroscience*. 2017;8(3):638-61.

Sanchez-Lopez E, Ettcheto M, Egea MA, Espina M, Calpena AC, Folch J, et al. New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9. *Nanomedicine : nanotechnology, biology, and medicine*. 2017;13(3):1171-82.

Sanders AE, Nininger J, Absher J, Bennett A, Shugarman S, Roca R. Quality improvement in neurology: Dementia management quality measurement set update. *Neurology*. 2017;88(20):1951-7.

Sanders AE, Nininger J, Absher J, Bennett A, Shugarman S, Roca R. Quality Improvement in Neurology: Dementia Management Quality Measurement Set Update. *The American journal of psychiatry*. 2017;174(5):493-8.

Sandhir R, Mahajan N, Mehrotra A, Aggarwal A, Sunkaria A. 4-hydroxy tempo improves mitochondrial and neurobehavioral deficits in experimental model of Huntington's disease. *Synapse (New York, NY)*. 2015;69(3):128-38.

Sandhir R, Mehrotra A. Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: implications in Huntington's disease. *Biochimica et biophysica acta*. 2013;1832(3):421-30.

Sandhir R, Yadav A, Mehrotra A, Sunkaria A, Singh A, Sharma S. Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington's disease. *Neuromolecular medicine*. 2014;16(1):106-18.

Sandoval KE, Farr SA, Banks WA, Crider AM, Morley JE, Witt KA. Somatostatin receptor subtype-4 agonist NNC 26-9100 mitigates the effect of soluble Abeta(42) oligomers via a metalloproteinase-dependent mechanism. *Brain research*. 2013;1520:145-56.

Sandoval-Hernandez AG, Restrepo A, Cardona-Gomez GP, Arboleda G. LXR activation protects hippocampal microvasculature in very old triple transgenic mouse model of Alzheimer's disease. *Neuroscience letters*. 2016;621:15-21.

Sands SA, Leung-Toung R, Wang Y, Connelly J, LeVine SM. Enhanced Histochemical Detection of Iron in Paraffin Sections of Mouse Central Nervous System Tissue: Application in the APP/PS1 Mouse Model of Alzheimer's Disease. *ASN neuro*. 2016;8(5).

Sang Z, Li Y, Qiang X, Xiao G, Liu Q, Tan Z, et al. Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease. *Bioorganic & medicinal chemistry*. 2015;23(4):668-80.

Sang Z, Pan W, Wang K, Ma Q, Yu L, Liu W. Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. *Bioorganic & medicinal chemistry*. 2017;25(12):3006-17.

Sang Z, Wang K, Wang H, Yu L, Wang H, Ma Q, et al. Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2017;27(22):5053-9.

Sangha S, George J, Winthrop C, Panchal S. Confusion: delirium and dementia - a smartphone app to improve cognitive assessment. *BMJ quality improvement reports*. 2015;4(1).

Sano M, Egelko S, Donohue M, Ferris S, Kaye J, Hayes TL, et al. Developing dementia prevention trials: baseline report of the Home-Based Assessment study. *Alzheimer disease and associated disorders*. 2013;27(4):356-62.

Sano O, Tsujita M, Shimizu Y, Kato R, Kobayashi A, Kioka N, et al. ABCG1 and ABCG4 Suppress gamma-Secretase Activity and Amyloid beta Production. *PloS one*. 2016;11(5):e0155400.

Sanphui P, Pramanik SK, Chatterjee N, Moorthi P, Banerji B, Biswas SC. Efficacy of cyclin dependent kinase 4 inhibitors as potent neuroprotective agents against insults relevant to Alzheimer's disease. *PloS one*. 2013;8(11):e78842.

Santana S, Sastre I, Recuero M, Bullido MJ, Aldudo J. Oxidative stress enhances neurodegeneration markers induced by herpes simplex virus type 1 infection in human neuroblastoma cells. *PloS one*. 2013;8(10):e75842.

Santini ZI, Koyanagi A, Tyrovolas S, Haro JM, Donovan RJ, Nielsen L, et al. The protective properties of Act-Belong-Commit indicators against incident depression, anxiety, and cognitive impairment among older Irish adults: Findings from a prospective community-based study. *Experimental gerontology*. 2017;91:79-87.

Santos DB, Colle D, Moreira ELG, Peres KC, Ribeiro RP, dos Santos AA, et al. Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice. *Neuroscience*. 2015;284:590-600.

Santos-Lozano A, Pareja-Galeano H, Sanchis-Gomar F, Quindos-Rubial M, Fiuza-Luces C, Cristi-Montero C, et al. Physical Activity and Alzheimer Disease: A Protective Association. *Mayo Clinic proceedings*. 2016;91(8):999-1020.

Sanz JM, Falzoni S, Rizzo R, Cipollone F, Zuliani G, Di Virgilio F. Possible protective role of the 489C>T P2X7R polymorphism in Alzheimer's disease. *Experimental gerontology*. 2014;60:117-9.

Saranathan M, Tourdias T, Kerr AB, Bernstein JD, Kerchner GA, Han MH, et al. Optimization of magnetization-prepared 3-dimensional fluid attenuated inversion recovery imaging for lesion detection at 7 T. *Investigative radiology*. 2014;49(5):290-8.

Sarfraz M, Sultana N, Rashid U, Akram MS, Sadiq A, Tariq MI. Synthesis, biological evaluation and docking studies of 2,3-dihydroquinazolin-4(1H)-one derivatives as inhibitors of cholinesterases. *Bioorganic chemistry*. 2017;70:237-44.

Sarkar S, Raymick J, Ray B, Lahiri DK, Paule MG, Schmued L. Oral Administration of Thioflavin T Prevents Beta Amyloid Plaque Formation in Double Transgenic AD Mice. *Current Alzheimer research*. 2015;12(9):837-46.

Sarroca S, Molina-Martinez P, Areste C, Etzrodt M, Garcia de Frutos P, Gasa R, et al. Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype. *Neurobiology of aging*. 2016;46:169-79.

Sasaoka N, Sakamoto M, Kanemori S, Kan M, Tsukano C, Takemoto Y, et al. Long-term oral administration of hop flower extracts mitigates Alzheimer phenotypes in mice. *PloS one*. 2014;9(1):e87185.

Sasazawa Y, Sato N, Umezawa K, Simizu S. Conophylline protects cells in cellular models of neurodegenerative diseases by inducing mammalian target of rapamycin (mTOR)-independent autophagy. *The Journal of biological chemistry*. 2015;290(10):6168-78.

Sase S, Yamamoto H, Kawashima E, Tan X, Sawa Y. Discrimination Between Patients With Alzheimer Disease and Healthy Subjects Using Layer Analysis of Cerebral Blood Flow and Xenon Solubility Coefficient in Xenon-Enhanced Computed Tomography. *Journal of computer assisted tomography*. 2017;41(3):477-83.

Sase S, Yamamoto H, Kawashima E, Tan X, Sawa Y. Discrimination between patients with mild Alzheimer's disease and healthy subjects based on cerebral blood flow images of the lateral views in xenon-enhanced computed tomography. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2017.

Sassi C, Nalls MA, Ridge PG, Gibbs JR, Ding J, Lupton MK, et al. ABCA7 p.G215S as potential protective factor for Alzheimer's disease. *Neurobiology of aging*. 2016;46:235.e1-9.

Sato M, Murakami K, Uno M, Nakagawa Y, Katayama S, Akagi K-i, et al. Site-specific inhibitory mechanism for amyloid beta42 aggregation by catechol-type flavonoids targeting the Lys residues. *The Journal of biological chemistry*. 2013;288(32):23212-24.

Sato N. Neurological common diseases in the super-elder society. Topics: III. Dementia; 1. Prevention of dementia by the control of non-genetic risk factors. *Nihon Naika Gakkai zasshi The Journal of the Japanese Society of Internal Medicine*. 2014;103(8):1815-22.

Sato Y, Iwamoto J, Kanoko T, Satoh K. Amelioration of Osteoporosis and Hypovitaminosis D by Sunlight Exposure in Hospitalized Elderly Women With Alzheimer's Disease: A Randomized Controlled Trial. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 2015;30(9):1745.

Satoh J, Tabunoki H, Ishida T, Saito Y, Arima K. Accumulation of a repulsive axonal guidance molecule RGMa in amyloid plaques: a possible hallmark of regenerative failure in Alzheimer's disease brains. *Neuropathology and applied neurobiology*. 2013;39(2):109-20.

Satoh M, Yuba T, Tabei K-I, Okubo Y, Kida H, Sakuma H, et al. Music Therapy Using Singing Training Improves Psychomotor Speed in Patients with Alzheimer's Disease: A Neuropsychological and fMRI Study. *Dementia and geriatric cognitive disorders extra*. 2015;5(3):296-308.

Sava A-A, Paquet C, Dumurgier J, Hugon J, Chainay H. The role of attention in emotional memory enhancement in pathological and healthy aging. *Journal of clinical and experimental neuropsychology*. 2016;38(4):434-54.

Sava A-A, Paquet C, Krolak-Salmon P, Dumurgier J, Hugon J, Chainay H. Emotional memory enhancement in respect of positive visual stimuli in Alzheimer's disease emerges after rich and deep encoding. *Cortex; a journal devoted to the study of the nervous system and behavior*. 2015;65:89-101.

Savage SA, Ballard KJ, Piguet O, Hodges JR. Bringing words back to mind - Improving word production in semantic dementia. *Cortex; a journal devoted to the study of the nervous system and behavior*. 2013;49(7):1823-32.

Sawikr Y, Yarla NS, Peluso I, Kamal MA, Aliev G, Bishayee A. Neuroinflammation in Alzheimer's Disease: The Preventive and Therapeutic Potential of Polyphenolic Nutraceuticals. *Advances in protein chemistry and structural biology*. 2017;108:33-57.

Saydoff JA, Olariu A, Sheng J, Hu Z, Li Q, Garcia R, et al. Uridine prodrug improves memory in Tg2576 and TAPP mice and reduces pathological factors associated with Alzheimer's disease in related models. *Journal of Alzheimer's disease : JAD*. 2013;36(4):637-57.

Sayed AS, El Sayed NSED. Co-administration of 3-Acetyl-11-Keto-Beta-Boswellic Acid Potentiates the Protective Effect of Celecoxib in Lipopolysaccharide-Induced Cognitive Impairment in Mice: Possible Implication of Anti-inflammatory and Antiglutamatergic Pathways. *Journal of molecular neuroscience* : MN. 2016;59(1):58-67.

Scala F, Fusco S, Ripoli C, Piacentini R, Li Puma DD, Spinelli M, et al. Intraneuronal A β accumulation induces hippocampal neuron hyperexcitability through A-type K(+) current inhibition mediated by activation of caspases and GSK-3. *Neurobiology of aging*. 2015;36(2):886-900.

Scarmeas N. Dementia: Multimodal dementia prevention - does trial design mask efficacy? *Nature reviews Neurology*. 2017;13(6):322-3.

Schall A, Tesky VA, Adams A-K, Pantel J. Art museum-based intervention to promote emotional well-being and improve quality of life in people with dementia: The ARTEMIS project. *Dementia (London, England)*. 2017;1471301217730451.

Schapira AHV, Olanow CW, Greenamyre JT, Beza E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. *Lancet (London, England)*. 2014;384(9942):545-55.

Schafele M, Hoell A, Hendlmeier I, Kohler L, Weyerer S. Primary Prevention of Impairments of Mobility Among Nursing Home Residents with Dementia. *Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany))*. 2015;77 Suppl 1:S105-6.

Schecker M, Kochler C, Schmidtke K, Rauh R. Are There Any Connections between Language Deficits and Cognitive Slowing in Alzheimer's Disease? *Dementia and geriatric cognitive disorders extra*. 2014;4(3):442-9.

Schejbal J, Slezackova L, Reminek R, Glatz Z. A capillary electrophoresis-mass spectrometry based method for the screening of beta-secretase inhibitors as potential Alzheimer's disease therapeutics. *Journal of chromatography A*. 2017;1487:235-41.

Schelke MW, Hackett K, Chen JL, Shih C, Shum J, Montgomery ME, et al. Nutritional interventions for Alzheimer's prevention: a clinical precision medicine approach. *Annals of the New York Academy of Sciences*. 2016;1367(1):50-6.

Schenk C, Wuerz T, Lerner AJ. Small vessel disease and memory loss: what the clinician needs to know to preserve patients' brain health. *Current cardiology reports*. 2013;15(12):427.

Scherrer B, Andrieu S, Ousset PJ, Berrut G, Dartigues JF, Dubois B, et al. Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761. *The journal of nutrition, health & aging*. 2015;19(10):1009-11.

Scherzer-Attali R, Convertino M, Pellarin R, Gazit E, Segal D, Caflisch A. Methylations of tryptophan-modified naphthoquinone affect its inhibitory potential toward Abeta aggregation. *The journal of physical chemistry B*. 2013;117(6):1780-9.

Schiepers OJG, Kohler S, Deckers K, Irving K, O'Donnell CA, van den Akker M, et al. Lifestyle for Brain Health (LIBRA): a new model for dementia prevention. *International journal of geriatric psychiatry*. 2017.

Schmidt HL, Garcia A, Martins A, Mello-Carpes PB, Carpes FP. Green tea supplementation produces better neuroprotective effects than red and black tea in Alzheimer-like rat model. *Food research international (Ottawa, Ont)*. 2017;100(Pt 1):442-8.

Schindel Martin L, Gillies L, Coker E, Pizzacalla A, Montemuro M, Suva G, et al. An Education Intervention to Enhance Staff Self-Efficacy to Provide Dementia Care in an Acute Care Hospital in Canada: A Nonrandomized Controlled Study. *American journal of Alzheimer's disease and other dementias*. 2016;31(8):664-77.

Schirer Y, Malishkevich A, Ophir Y, Lewis J, Giladi E, Gozes I. Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation. *PloS one*. 2014;9(1):e87383.

Schlesinger D, Grinberg LT, Alba JG, Naslavsky MS, Licinio L, Farfel JM, et al. African ancestry protects against Alzheimer's disease-related neuropathology. *Molecular psychiatry*. 2013;18(1):79-85.

Schmid NS, Ehrensperger MM, Berres M, Beck IR, Monsch AU. The Extension of the German CERAD Neuropsychological Assessment Battery with Tests Assessing Subcortical, Executive and Frontal Functions Improves Accuracy in Dementia Diagnosis. *Dementia and geriatric cognitive disorders extra*. 2014;4(2):322-34.

Schmidt R, Hofer E, Bouwman FH, Buerger K, Cordonnier C, Fladby T, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. *European journal of neurology*. 2015;22(6):889-98.

Schneider LS. Reduce vascular risk to prevent dementia? *Lancet (London, England)*. 2016;388(10046):738-40.

Schnoder L, Hao W, Qin Y, Liu S, Tomic I, Liu X, et al. Deficiency of Neuronal p38alpha MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1. *The Journal of biological chemistry*. 2016;291(5):2067-79.

Schober ME, Requena DF, Abdullah OM, Casper TC, Beachy J, Malleske D, et al. Dietary Docosahexaenoic Acid Improves Cognitive Function, Tissue Sparing, and Magnetic Resonance

Imaging Indices of Edema and White Matter Injury in the Immature Rat after Traumatic Brain Injury. *Journal of neurotrauma*. 2016;33(4):390-402.

Schoon Y, van Iersel MB, Jacobsen DE, Smit JWA, de Boer M-J, Olde Rikkert MGM. Improved hospital care for elderly patients: guidance on vulnerability and goal assessment. *Nederlands tijdschrift voor geneeskunde*. 2013;157(34):A6224.

Schrott LM, Jackson K, Yi P, Dietz F, Johnson GS, Basting TF, et al. Acute oral Bryostatin-1 administration improves learning deficits in the APP/PS1 transgenic mouse model of Alzheimer's disease. *Current Alzheimer research*. 2015;12(1):22-31.

Schulman JD, Stern HJ. Low utilization of prenatal and pre-implantation genetic diagnosis in Huntington disease-risk discounting in preventive genetics. *Clinical genetics*. 2015;88(3):220-3.

Schultke E, Nanko N, Pinsker M, Katzev M, Sebastian A, Feige B, et al. Improving MRT image quality in patients with movement disorders. *Acta neurochirurgica Supplement*. 2013;117:13-7.

Schultz SA, Boots EA, Almeida RP, Oh JM, Einerson J, Korcarz CE, et al. Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. *Journal of the International Neuropsychological Society : JINS*. 2015;21(10):841-50.

Schwam EM, Nicholas T, Chew R, Billing CB, Davidson W, Ambrose D, et al. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. *Current Alzheimer research*. 2014;11(5):413-21.

Schwartz JB. Primary prevention: do the very elderly require a different approach? *Trends in cardiovascular medicine*. 2015;25(3):228-39.

Schwartz M, Meyer B, Wirnitzer B, Hopf C. Standardized processing of MALDI imaging raw data for enhancement of weak analyte signals in mouse models of gastric cancer and Alzheimer's disease. *Analytical and bioanalytical chemistry*. 2015;407(8):2255-64.

Schwarz CG, Reid RI, Gunter JL, Senjem ML, Przybelski SA, Zuk SM, et al. Improved DTI registration allows voxel-based analysis that outperforms tract-based spatial statistics. *NeuroImage*. 2014;94:65-78.

Schwarz F, Springer SA, Altheide TK, Varki NM, Gagneux P, Varki A. Human-specific derived alleles of CD33 and other genes protect against postreproductive cognitive decline. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113(1):74-9.

Schwarz P. An active life protects against dementia. *MMW Fortschritte der Medizin*. 2015;157(17):49.

Schwenk BM, Hartmann H, Serdaroglu A, Schludi MH, Hornburg D, Meissner F, et al. TDP-43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons. *The EMBO journal*. 2016;35(21):2350-70.

Schwenk M, Dutzi I, Englert S, Micol W, Najafi B, Mohler J, et al. An intensive exercise program improves motor performances in patients with dementia: translational model of geriatric rehabilitation. *Journal of Alzheimer's disease : JAD*. 2014;39(3):487-98.

Schwenk M, Zieschang T, Englert S, Grewal G, Najafi B, Hauer K. Improvements in gait characteristics after intensive resistance and functional training in people with dementia: a randomised controlled trial. *BMC geriatrics*. 2014;14:73.

Schworer R, Zubkova OV, Turnbull JE, Tyler PC. Synthesis of a targeted library of heparan sulfate hexa- to dodecasaccharides as inhibitors of beta-secretase: potential therapeutics for Alzheimer's disease. *Chemistry (Weinheim an der Bergstrasse, Germany)*. 2013;19(21):6817-23.

Scichilone JM, Yarraguntla K, Charalambides A, Harney JP, Butler D. Environmental Enrichment Mitigates Detrimental Cognitive Effects of Ketogenic Diet in Weanling Rats. *Journal of molecular neuroscience : MN*. 2016;60(1):1-9.

Scientists ID compounds that target amyloid fibrils in Alzheimer's, other brain diseases. Study first to use 'structural' approach in hunt for amyloid-inhibiting agents. *American journal of Alzheimer's disease and other dementias*. 2013;28(6):642-3.

Scimemi A, Meabon JS, Woltjer RL, Sullivan JM, Diamond JS, Cook DG. Amyloid-beta1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(12):5312-8.

Scoralick FM, Louzada LL, Quintas JL, Naves JOS, Camargos EF, Nobrega OT. Mirtazapine does not improve sleep disorders in Alzheimer's disease: results from a double-blind, placebo-controlled pilot study. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2017;17(2):89-96.

Scott JD, Li SW, Brunskill APJ, Chen X, Cox K, Cumming JN, et al. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease. *Journal of medicinal chemistry*. 2016;59(23):10435-50.

Scott JS, Goldberg FW, Turnbull AV. Medicinal chemistry of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). *Journal of medicinal chemistry*. 2014;57(11):4466-86.

Scott-McKean JJ, Surewicz K, Choi J-K, Ruffin VA, Salameh AI, Nieznanski K, et al. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Abeta oligomers: Implications for novel therapeutic strategy in Alzheimer's disease. *Neurobiology of disease*. 2016;91:124-31.

Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. *Cell death & disease*. 2014;5:e1419.

Scullion GA, Hewitt KN, Pardon M-C. Corticotropin-releasing factor receptor 1 activation during exposure to novelty stress protects against Alzheimer's disease-like cognitive decline in AbetaPP/PS1 mice. *Journal of Alzheimer's disease : JAD*. 2013;34(3):781-93.

Scuteri A, Tesauro M, Di Daniele N. Preventive geriatrics the cross-talk between arterial and brain aging: A lifelong condition. *Experimental gerontology*. 2017;87(Pt B):148-50.

Scutt P, Blackburn D, Krishnan K, Ballard C, Burns A, Ford GA, et al. Baseline characteristics, analysis plan and report on feasibility for the Prevention Of Decline in Cognition After Stroke Trial (PODCAST). *Trials*. 2015;16:509.

Segev Y, Barrera I, Ounallah-Saad H, Wibrand K, Sporild I, Livne A, et al. PKR Inhibition Rescues Memory Deficit and ATF4 Overexpression in ApoE epsilon4 Human Replacement Mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2015;35(38):12986-93.

Segui Diaz M. Can a multifactorial intervention prevent cognitive impairment in the elderly patient? *Semergen*. 2016;42(4):263-5.

Sehgal V, Kesav P, Modi M, Ahuja CK. Acute Marchiafava-Bignami disease presenting as reversible dementia in a chronic alcoholic. *BMJ case reports*. 2013;2013.

Seidl JNT, Massman PJ. Rapidly Versus Slowly Progressing Patients With Alzheimer's Disease: Differences in Baseline Cognition. *American journal of Alzheimer's disease and other dementias*. 2016;31(4):318-25.

Seifan A, Ganzer CA, Vermeulen F, Parry S, Zhu J, Lyons A, et al. Development and validation of the Alzheimer's prevention beliefs measure in a multi-ethnic cohort-a behavioral theory approach. *Journal of public health (Oxford, England)*. 2017.

Seifan A, Isaacson R. The Alzheimer's Prevention Clinic at Weill Cornell Medical College / New York - Presbyterian Hospital: Risk Stratification and Personalized Early Intervention. *The journal of prevention of Alzheimer's disease*. 2015;2(4):254-66.

Seitz DP, Gill SS. Review: non-pharmacological interventions delivered by family caregivers improve symptoms in people with dementia. *Evidence-based mental health*. 2013;16(1):22.

Seixas da Silva GS, Melo HM, Lourenco MV, Lyra E Silva NM, de Carvalho MB, Alves-Leon SV, et al. Amyloid-beta oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons. *The Journal of biological chemistry*. 2017;292(18):7395-406.

Sekiya H, Kawamoto M, Togo M, Yoshimura H, Imai Y, Kohara N. HIV encephalopathy due to drug resistance despite 2-year suppression of HIV viremia by cART. *Rinsho shinkeigaku = Clinical neurology*. 2014;54(9):721-5.

Sekiya H, Kawamoto M, Togo M, Yoshimura H, Imai Y, Kohara N. Response regarding "HIV encephalopathy due to drug resistance despite 2-year suppression of HIV viremia by cART". *Rinsho shinkeigaku = Clinical neurology*. 2015;55(6):437.

Sell GL, Schaffer TB, Margolis SS. Reducing expression of synapse-restricting protein Ephexin5 ameliorates Alzheimer's-like impairment in mice. *The Journal of clinical investigation*. 2017;127(5):1646-50.

Semenov VE, Zueva IV, Mukhamedyarov MA, Lushchekina SV, Kharlamova AD, Petukhova EO, et al. 6-Methyluracil Derivatives as Bifunctional Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease. *ChemMedChem*. 2015;10(11):1863-74.

Semighini EP. In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease. *Chemical biology & drug design*. 2015;86(3):284-90.

Semplicini A. Cerebral White Matter Lesions as a Clinically Relevant Intermediate Target of Cerebrovascular Prevention. *Journal of clinical hypertension (Greenwich, Conn)*. 2015;17(9):699-700.

Sengupta K, Chatterjee S, Pramanik D, Dey SG, Dey A. Self-assembly of stable oligomeric and fibrillar aggregates of Aβ peptides relevant to Alzheimer's disease: morphology dependent Cu/heme toxicity and inhibition of PROS generation. *Dalton transactions (Cambridge, England : 2003)*. 2014;43(35):13377-83.

Seniya C, Khan GJ, Uchadia K. Identification of potential herbal inhibitor of acetylcholinesterase associated Alzheimer's disorders using molecular docking and molecular dynamics simulation. *Biochemistry research international*. 2014;2014:705451.

Senol FS, Slusarczyk S, Matkowski A, Perez-Garrido A, Giron-Rodriguez F, Ceron-Carrasco JP, et al. Selective invitro and in silico butyrylcholinesterase inhibitory activity of diterpenes and rosmarinic acid isolated from *Perovskia atriplicifolia* Benth. and *Salvia glutinosa* L. *Phytochemistry*. 2017;133:33-44.

Seo B-R, Lee S-J, Cho KS, Yoon YH, Koh J-Y. The zinc ionophore clioquinol reverses autophagy arrest in chloroquine-treated ARPE-19 cells and in APP/mutant presenilin-1-transfected Chinese hamster ovary cells. *Neurobiology of aging*. 2015;36(12):3228-38.

Seo J, Kritskiy O, Watson LA, Barker SJ, Dey D, Raja WK, et al. Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(41):9917-24.

Seo JY, Lim SS, Kim J, Lee KW, Kim J-S. Alantolactone and Isoalantolactone Prevent Amyloid beta₂₅₋₃₅ -induced Toxicity in Mouse Cortical Neurons and Scopolamine-induced Cognitive Impairment in Mice. *Phytotherapy research : PTR*. 2017;31(5):801-11.

Serini S, Calviello G. Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer's Disease. *Current Alzheimer research*. 2016;13(2):123-34.

Serino S, Pedroli E, Tuena C, De Leo G, Stramba-Badiale M, Goulene K, et al. A Novel Virtual Reality-Based Training Protocol for the Enhancement of the "Mental Frame Syncing" in Individuals with Alzheimer's Disease: A Development-of-Concept Trial. *Frontiers in aging neuroscience*. 2017;9:240.

Servello A, Andreozzi P, Bechini F, De Angelis R, Pontecorvo ML, Vulcano A, et al. Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type). *Minerva medica*. 2014;105(2):167-74.

Servello A, Ettorre E, Cacciafesta M. Improvement in behavioral and psychological symptoms of dementia by rivastigmine patch in a group of Italian elderly patients with Alzheimer's disease. *Panminerva medica*. 2017;59(3):275-7.

Sery O, Hlinecka L, Balcar VJ, Janout V, Povova J. Diabetes, hypertension and stroke - does Alzheimer protect you? *Neuro endocrinology letters*. 2014;35(8):691-6.

Seshadri M, Mazi-Kotwal N, Aguis M. Reversible mild cognitive impairment--a case report. *Psychiatria Danubina*. 2013;25 Suppl 2:S358-61.

Seshadri S. Delaying dementia: can antihypertensives prevent Alzheimer dementia? *Neurology*. 2013;81(10):860-2.

Sfera A. Can neurostimulation prevent the risk of Alzheimer's disease in elderly individuals with schizophrenia? *Frontiers in psychiatry*. 2013;4:111.

Sha S, Xing X-N, Cao Y-P. Active immunotherapy facilitates Abeta plaque removal following through microglial activation without obvious T cells infiltrating the CNS. *Journal of neuroimmunology*. 2014;274(1-2):62-70.

Shabani S, Sarkaki A, Ali Mard S, Ahangarpour A, Khorsandi L, Farbood Y. Central and peripheral administrations of levothyroxine improved memory performance and amplified brain electrical activity in the rat model of Alzheimer's disease. *Neuropeptides*. 2016;59:111-6.

Shackleton B, Crawford F, Bachmeier C. Inhibition of ADAM10 promotes the clearance of Abeta across the BBB by reducing LRP1 ectodomain shedding. *Fluids and barriers of the CNS*. 2016;13(1):14.

Shaerzadeh F, Motamedi F, Khodaghali F. Inhibition of akt phosphorylation diminishes mitochondrial biogenesis regulators, tricarboxylic acid cycle activity and exacerbates recognition memory deficit in rat model of Alzheimer's disease. *Cellular and molecular neurobiology*. 2014;34(8):1223-33.

Shah MS, Khan SU, Ejaz SA, Afridi S, Rizvi SUF, Najam-Ul-Haq M, et al. Cholinesterases inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones. *Biochemical and biophysical research communications*. 2017;482(4):615-24.

Shah R, Li S, Stampelcoski M, Kapral MK. Low Use of Oral Anticoagulant Prescribing for Secondary Stroke Prevention: Results From the Ontario Stroke Registry. *Medical care*. 2016;54(10):907-12.

Shah SA, Yoon GH, Chung SS, Abid MN, Kim TH, Lee HY, et al. Novel osmotin inhibits SREBP2 via the AdipoR1/AMPK/SIRT1 pathway to improve Alzheimer's disease neuropathological deficits. *Molecular psychiatry*. 2017;22(3):407-16.

Shah SA, Yoon GH, Chung SS, Abid MN, Kim TH, Lee HY, et al. Osmotin reduced amyloid beta (Abeta) burden by inhibiting SREBP2 expression in APP/PS1 mice. *Molecular psychiatry*. 2017;22(3):323.

Shahbazi S, Kaur J, Kuanar A, Kar D, Singh S, Sobti RC. Risk of Late-Onset Alzheimer's Disease by Plasma Cholesterol: Rational In Silico Drug Investigation of Pyrrole-Based HMG-CoA Reductase Inhibitors. *Assay and drug development technologies*. 2017;15(7):342-51.

Shaik JB, Palaka BK, Penumala M, Eadlapalli S, Darla Mark M, Ampasala DR, et al. Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano 2,3-f chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease. *Chemical biology & drug design*. 2016;88(1):43-53.

Shaikh S, Rizvi SMD, Hameed N, Biswas D, Khan M, Shakil S, et al. Aptiom (eslicarbazepine acetate) as a dual inhibitor of beta-secretase and voltage-gated sodium channel: advancement in Alzheimer's disease-epilepsy linkage via an enzoinformatics study. *CNS & neurological disorders drug targets*. 2014;13(7):1258-62.

Shaikh S, Rizvi SMD, Suhail T, Shakil S, Abuzenadah AM, Anis R, et al. Prediction of Anti-Diabetic Drugs as Dual Inhibitors Against Acetylcholinesterase and Beta-Secretase: A Neuroinformatics Study. *CNS & neurological disorders drug targets*. 2016;15(10):1216-21.

Shakersain B, Santoni G, Larsson SC, Faxen-Irving G, Fastbom J, Fratiglioni L, et al. Prudent diet may attenuate the adverse effects of Western diet on cognitive decline. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016;12(2):100-9.

Shamim D, Laskowski M. Inhibition of Inflammation Mediated Through the Tumor Necrosis Factor alpha Biochemical Pathway Can Lead to Favorable Outcomes in Alzheimer Disease. *Journal of central nervous system disease*. 2017;9:1179573517722512.

Shang Y, Wang L, Li Y, Gu P-F. Vinpocetine Improves Scopolamine Induced Learning and Memory Dysfunction in C57 BL/6J Mice. *Biological & pharmaceutical bulletin*. 2016;39(9):1412-8.

Shanmuganathan B, Sheeja Malar D, Sathya S, Pandima Devi K. Antiaggregation Potential of *Padina gymnospora* against the Toxic Alzheimer's Beta-Amyloid Peptide 25-35 and Cholinesterase Inhibitory Property of Its Bioactive Compounds. *PloS one*. 2015;10(11):e0141708.

Shao B-Y, Xia Z, Xie Q, Ge X-X, Zhang W-W, Sun J, et al. Meserine, a novel carbamate AChE inhibitor, ameliorates scopolamine-induced dementia and alleviates amyloidogenesis of APP/PS1 transgenic mice. *CNS neuroscience & therapeutics*. 2014;20(2):165-71.

Shao H, Zhang Y, Dong Y, Yu B, Xia W, Xie Z. Chronic treatment with anesthetic propofol improves cognitive function and attenuates caspase activation in both aged and Alzheimer's disease transgenic mice. *Journal of Alzheimer's disease : JAD*. 2014;41(2):499-513.

Shao Z-Q. Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease. *International journal of clinical and experimental medicine*. 2015;8(2):2944-8.

Sharma A, Menon PK, Patnaik R, Muresanu DF, Lafuente JV, Tian ZR, et al. Novel Treatment Strategies Using TiO₂-Nanowired Delivery of Histaminergic Drugs and Antibodies to Tau With Cerebrolysin for Superior Neuroprotection in the Pathophysiology of Alzheimer's Disease. *International review of neurobiology*. 2017;137:123-65.

Sharma A, Piplani P. Design and synthesis of some acridine-piperazine hybrids for the improvement of cognitive dysfunction. *Chemical biology & drug design*. 2017;90(5):926-35.

Sharma B, Sharma PM. Arsenic toxicity induced endothelial dysfunction and dementia: pharmacological interdiction by histone deacetylase and inducible nitric oxide synthase inhibitors. *Toxicology and applied pharmacology*. 2013;273(1):180-8.

Sharma B, Singh N. Pharmacological inhibition of inducible nitric oxide synthase (iNOS) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, convalesce behavior and biochemistry of hypertension induced vascular dementia in rats. *Pharmacology, biochemistry, and behavior*. 2013;103(4):821-30.

Sharma K, Minagar A, Sun H. Proton Pump Inhibitors and Dementia Incidence. *JAMA neurology*. 2016;73(8):1027.

Sharma S, Modi M, Lal V, Prabhakar S, Bhardwaj A, Sehgal R. Reversible dementia as a presenting manifestation of racemose neurocysticercosis. *Annals of Indian Academy of Neurology*. 2013;16(1):88-90.

Sharma S, Nehru B, Saini A. Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone: Insight into mechanism of action. *Neurochemistry international*. 2017;108:481-93.

Sharoar MG, Islam MI, Shahnawaz M, Shin SY, Park I-S. Amyloid beta binds procaspase-9 to inhibit assembly of Apaf-1 apoptosome and intrinsic apoptosis pathway. *Biochimica et biophysica acta*. 2014;1843(4):685-93.

Sharoar MG, Shahnawaz M, Islam MI, Ramasamy VS, Shin SY, Park I-S. The inhibitory effects of Escherichia coli maltose binding protein on beta-amyloid aggregation and cytotoxicity. *Archives of biochemistry and biophysics*. 2013;538(1):41-8.

Shaw JL, Chang KT. Nebula/DSCR1 upregulation delays neurodegeneration and protects against APP-induced axonal transport defects by restoring calcineurin and GSK-3 β signaling. *PLoS genetics*. 2013;9(9):e1003792.

She A, Kurtser I, Reis SA, Hennig K, Lai J, Lang A, et al. Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia. *Cell chemical biology*. 2017;24(7):892-906.e5.

Sheffrin M, Miao Y, Boscardin WJ, Steinman MA. Weight Loss Associated with Cholinesterase Inhibitors in Individuals with Dementia in a National Healthcare System. *Journal of the American Geriatrics Society*. 2015;63(8):1512-8.

Shekhar S, Vatsa N, Kumar V, Singh BK, Jamal I, Sharma A, et al. Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease. *Human molecular genetics*. 2017;26(2):420-9.

Shekhar S, Yadav SK, Rai N, Kumar R, Yadav Y, Tripathi M, et al. 5-LOX in Alzheimer's Disease: Potential Serum Marker and In Vitro Evidences for Rescue of Neurotoxicity by Its Inhibitor YWCS. *Molecular neurobiology*. 2017.

Sheline CT, Zhu J, Zhang W, Shi C, Cai A-L. Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo. *Neuro-degenerative diseases*. 2013;11(1):49-58.

Shelton JT, Lee JH, Scullin MK, Rose NS, Rendell PG, McDaniel MA. Improving Prospective Memory in Healthy Older Adults and Individuals with Very Mild Alzheimer's Disease. *Journal of the American Geriatrics Society*. 2016;64(6):1307-12.

Shen J-N, Xu L-X, Wang R. Cyclooxygenases, lipoxygenases, their targeted drugs and the prevention of Alzheimer's disease. *Yao xue xue bao = Acta pharmaceutica Sinica*. 2013;48(12):1743-54.

Shen L, Han B, Geng Y, Wang J, Wang Z, Wang M. Amelioration of cognitive impairments in APPswe/PS1dE9 mice is associated with metabolites alteration induced by total salvianolic acid. *PloS one*. 2017;12(3):e0174763.

Shen Y, Tian M, Zheng Y, Gong F, Fu AKY, Ip NY. Stimulation of the Hippocampal POMC/MC4R Circuit Alleviates Synaptic Plasticity Impairment in an Alzheimer's Disease Model. *Cell reports*. 2016;17(7):1819-31.

Sheng C, Xu P, Zhou K, Deng D, Zhang C, Wang Z. Icaritin Attenuates Synaptic and Cognitive Deficits in an Abeta1-42-Induced Rat Model of Alzheimer's Disease. *BioMed research international*. 2017;2017:7464872.

Sheng M, Lu H, Liu P, Li Y, Ravi H, Peng S-L, et al. Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;60(4):1351-64.

Sheridan C. Pivotal trials for beta-secretase inhibitors in Alzheimer's. *Nature biotechnology*. 2015;33(2):115-6.

Shevtsova EF, Vinogradova DV, Neganova ME, Avila-Rodriguez M, Ashraf GM, Barreto GE, et al. Mitochondrial Permeability Transition Pore as a Suitable Target for Neuroprotective Agents Against Alzheimer's Disease. *CNS & neurological disorders drug targets*. 2017;16(6):677-85.

Shi C, Viccaro K, Lee H-G, Shah K. Cdk5-Foxo3 axis: initially neuroprotective, eventually neurodegenerative in Alzheimer's disease models. *Journal of cell science*. 2016;129(9):1815-30.

Shi C, Viccaro K, Lee H-G, Shah K. Cdk5-FOXO3a axis: initially neuroprotective, eventually neurodegenerative in Alzheimer's disease models. *Journal of cell science*. 2016.

Shi C, Wu F, Xu J. Incorporation of beta-sitosterol into mitochondrial membrane enhances mitochondrial function by promoting inner mitochondrial membrane fluidity. *Journal of bioenergetics and biomembranes*. 2013;45(3):301-5.

Shi C-G, Yang Y-S, Li H, Zhang Y, Wang N, Wang S-M, et al. Tanshinol protects hippocampus and attenuates vascular dementia development. *Journal of Asian natural products research*. 2014;16(6):667-76.

Shi J, Zhang X, Yin L, Wei M, Ni J, Li T, et al. Herbal formula GAPT prevents beta amyloid deposition induced Ca(2+)/Calmodulin-dependent protein kinase II and Ca(2+)/Calmodulin-dependent protein phosphatase 2B imbalance in APPV717I mice. *BMC complementary and alternative medicine*. 2016;16:159.

Shi J-Q, Wang B-R, Tian Y-Y, Xu J, Gao L, Zhao S-L, et al. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. *CNS neuroscience & therapeutics*. 2013;19(11):871-81.

Shi J-Q, Zhang C-C, Sun X-L, Cheng X-X, Wang J-B, Zhang Y-D, et al. Antimalarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice via inhibition of nuclear factor-kappaB and NLRP3 inflammasome activation. *CNS neuroscience & therapeutics*. 2013;19(4):262-8.

Shi L, Zhang Z, Li L, Holscher C. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. *Behavioural brain research*. 2017;327:65-74.

Shi L-M, Jiang H, Xie J-X. Neuroprotective effects of ghrelin in Parkinsons disease and Alzheimer's disease. *Sheng li ke xue jin zhan [Progress in physiology]*. 2014;45(2):140-4.

Shi S, Liang D, Chen Y, Xie Y, Wang Y, Wang L, et al. Gx-50 reduces beta-amyloid-induced TNF-alpha, IL-1beta, NO, and PGE2 expression and inhibits NF-kappaB signaling in a mouse model of Alzheimer's disease. *European journal of immunology*. 2016;46(3):665-76.

Shi T-Y, Zhao D-Q, Wang H-B, Feng S, Liu S-B, Xing J-H, et al. A new chiral pyrrolyl alpha-nitronyl nitroxide radical attenuates beta-amyloid deposition and rescues memory deficits in a mouse model of Alzheimer disease. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*. 2013;10(2):340-53.

Shi X, Lin X, Hu R, Sun N, Hao J, Gao C. Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors. *American journal of Alzheimer's disease and other dementias*. 2016;31(5):405-12.

Shi X-D, Sun K, Hu R, Liu X-Y, Hu Q-M, Sun X-Y, et al. Blocking the Interaction between EphB2 and ADDLs by a Small Peptide Rescues Impaired Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer's Disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2016;36(47):11959-73.

Shi Z, Lu C, Sun X, Wang Q, Chen S, Li Y, et al. Tong Luo Jiu Nao ameliorates Abeta1-40-induced cognitive impairment on adaptive behavior learning by modulating ERK/CaMKII/CREB signaling in the hippocampus. *BMC complementary and alternative medicine*. 2015;15:55.

Shi Z, Wu Y, Wang M, Cao J, Feng W, Cheng Y, et al. Greater attenuation of retinal nerve fiber layer thickness in Alzheimer's disease patients. *Journal of Alzheimer's disease : JAD*. 2014;40(2):277-83.

Shiao Y-J, Su M-H, Lin H-C, Wu C-R. Echinacoside ameliorates the memory impairment and cholinergic deficit induced by amyloid beta peptides via the inhibition of amyloid deposition and toxicology. *Food & function*. 2017;8(6):2283-94.

Shibuya Y, Niu Z, Bryleva EY, Harris BT, Murphy SR, Kheirollah A, et al. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage. *Neurobiology of aging*. 2015;36(7):2248-59.

Shih H-I, Lin C-C, Tu Y-F, Chang C-M, Hsu H-C, Chi C-H, et al. An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: a population-based case-control study. *Medicine*. 2015;94(17):e809.

Shih RA, Concannon TW, Liu JL, Friedman EM. Improving Dementia Long-Term Care: A Policy Blueprint. *Rand health quarterly*. 2014;4(2):2.

Shih Y-J, Wang Y-H, Yang Y-J. A nursing experience using the props-integrated communicative approach to ameliorate aggression in a frontotemporal dementia patient. *Hu li za zhi The journal of nursing*. 2014;61(6):98-103.

Shijo M, Honda H, Suzuki SO, Hamasaki H, Hokama M, Abolhassani N, et al. Association of adipocyte enhancer-binding protein 1 with Alzheimer's disease pathology in human hippocampi. *Brain pathology (Zurich, Switzerland)*. 2016.

Shilling D, Muller M, Takano H, Mak D-OD, Abel T, Coulter DA, et al. Suppression of InsP3 receptor-mediated Ca²⁺ signaling alleviates mutant presenilin-linked familial Alzheimer's disease pathogenesis. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(20):6910-23.

Shimada H, Makizako H, Doi T, Lee S, Lee S. Conversion and Reversion Rates in Japanese Older People With Mild Cognitive Impairment. *Journal of the American Medical Directors Association*. 2017;18(9):808.e1-e6.

Shimada H, Makizako H, Doi T. Exercise and Physical Activity for Dementia Prevention. *Brain and nerve = Shinkei kenkyu no shinpo*. 2016;68(7):799-808.

Shimatani Y, Nakano Y, Tsuyama N, Murayama S, Oki R, Miyamoto R, et al. Extranodal NK/T-cell lymphoma, nasal type, manifesting as rapidly progressive dementia without any mass or enhancing brain lesion. *Neuropathology : official journal of the Japanese Society of Neuropathology*. 2016;36(5):456-63.

Shimizu H, Nagami S, Takahashi N. A case of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in which lomerizine hydrochloride was suggested to prevent recurrent stroke. *Rinsho shinkeigaku = Clinical neurology*. 2014;54(1):22-6.

Shimizu S, Kanetaka H, Hirose D, Sakurai H, Hanyu H. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial. *Dementia and geriatric cognitive disorders extra*. 2015;5(1):135-46.

Shin JY, Park HJ, Kim HN, Oh SH, Bae J-S, Ha H-J, et al. Mesenchymal stem cells enhance autophagy and increase beta-amyloid clearance in Alzheimer disease models. *Autophagy*. 2014;10(1):32-44.

Shin K, Cha Y, Kim KS, Choi E-K, Choi Y, Guo H, et al. Human Neural Stem Cells Overexpressing Choline Acetyltransferase Restore Unconditioned Fear in Rats with Amygdala Injury. *Behavioural neurology*. 2016;2016:8521297.

Shin K, Guo H, Cha Y, Ban Y-H, Seo DW, Choi Y, et al. Cereboost, an American ginseng extract, improves cognitive function via up-regulation of choline acetyltransferase expression and neuroprotection. *Regulatory toxicology and pharmacology : RTP*. 2016;78:53-8.

Shin M-K, Kim H-G, Baek S-H, Jung W-R, Park D-I, Park J-S, et al. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques. *Neurobiology of aging*. 2014;35(5):990-1001.

Shinagawa S, Shigeta M. Acetylcholinesterase inhibitors for treatment of Alzheimer's disease. *Brain and nerve = Shinkei kenkyu no shinpo*. 2014;66(5):507-16.

Shinde P, Vidyasagar N, Dhulap S, Dhulap A, Hirwani R. Natural Products based P-glycoprotein Activators for Improved beta-amyloid Clearance in Alzheimer's Disease: An in silico Approach. *Central nervous system agents in medicinal chemistry*. 2015;16(1):50-9.

Shineman DW, Carman AJ, Dacks PA, Lane RF, Fillit HM. Progress in novel cognitive enhancers for cognitive aging and Alzheimer's disease. *Alzheimer's research & therapy*. 2013;5(5):45.

Shivasharan BD, Nagakannan P, Thippeswamy BS, Veerapur VP, Bansal P, Unnikrishnan MK. Protective effect of *Calendula officinalis* Linn. flowers against 3-nitropropionic acid induced experimental Huntington's disease in rats. *Drug and chemical toxicology*. 2013;36(4):466-73.

Shmuel-Galia L, Klug Y, Porat Z, Charni M, Zarmi B, Shai Y. Intramembrane attenuation of the TLR4-TLR6 dimer impairs receptor assembly and reduces microglia-mediated neurodegeneration. *The Journal of biological chemistry*. 2017;292(32):13415-27.

Shokouhi S, Campbell D, Brill AB, Gwirtsman HE, Alzheimer's Disease Neuroimaging I. Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective. *Brain pathology (Zurich, Switzerland)*. 2016;26(5):664-71.

Shropshire TD, Reifert J, Rajagopalan S, Baker D, Feinstein SC, Daugherty PS. Amyloid beta peptide cleavage by kallikrein 7 attenuates fibril growth and rescues neurons from Abeta-mediated toxicity in vitro. *Biological chemistry*. 2014;395(1):109-18.

Shruster A, Offen D. Targeting neurogenesis ameliorates danger assessment in a mouse model of Alzheimer's disease. *Behavioural brain research*. 2014;261:193-201.

Shukla M, Govitrapong P, Boontem P, Reiter RJ, Satayavivad J. Mechanisms of Melatonin in Alleviating Alzheimer's Disease. *Current neuropharmacology*. 2017;15(7):1010-31.

Shukla V, Zheng Y-L, Mishra SK, Amin ND, Steiner J, Grant P, et al. A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2013;27(1):174-86.

Shultz SR, Wright DK, Zheng P, Stuchbery R, Liu S-J, Sashindranath M, et al. Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury. *Brain : a journal of neurology*. 2015;138(Pt 5):1297-313.

Sibener L, Zaganjor I, Snyder HM, Bain LJ, Egge R, Carrillo MC. Alzheimer's Disease prevalence, costs, and prevention for military personnel and veterans. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2014;10(3 Suppl):S105-10.

Siddique YH, Ali F. Protective effect of nordihydroguaiaretic acid (NDGA) on the transgenic *Drosophila* model of Alzheimer's disease. *Chemico-biological interactions*. 2017;269:59-66.

Siddiqui SS, Springer SA, Verhagen A, Sundaramurthy V, Alisson-Silva F, Jiang W, et al. The Alzheimer's disease-protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool. *The Journal of biological chemistry*. 2017;292(37):15312-20.

Siegel E, Cations M, Wright C, Naganathan V, Deutsch A, Aerts L, et al. Interventions to Improve the Oral Health of People with Dementia or Cognitive Impairment: A Review of the Literature. *The journal of nutrition, health & aging*. 2017;21(8):874-86.

Sierksma ASR, Rutten K, Sydlik S, Rostamian S, Steinbusch HWM, van den Hove DLA, et al. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. *Neuropharmacology*. 2013;64:124-36.

Sierksma ASR, van den Hove DLA, Pfau F, Philippens M, Bruno O, Fedele E, et al. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. *Neuropharmacology*. 2014;77:120-30.

Sillerud LO, Solberg NO, Chamberlain R, Orlando RA, Heidrich JE, Brown DC, et al. SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AbetaPP/PS-1 transgenic mouse brain. *Journal of Alzheimer's disease : JAD*. 2013;34(2):349-65.

Silva A, Naia L, Dominguez A, Ribeiro M, Rodrigues J, Vieira OV, et al. Overexpression of BDNF and Full-Length TrkB Receptor Ameliorate Striatal Neural Survival in Huntington's Disease. *Neuro-degenerative diseases*. 2015;15(4):207-18.

Silva AR, Pinho MS, Macedo L, Moulin C, Caldeira S, Firmino H. It is not only memory: effects of sensecam on improving well-being in patients with mild alzheimer disease. *International psychogeriatrics*. 2017;29(5):741-54.

Silva CS, Eira J, Ribeiro CA, Oliveira A, Sousa MM, Cardoso I, et al. Transthyretin neuroprotection in Alzheimer's disease is dependent on proteolysis. *Neurobiology of aging*. 2017;59:10-4.

Silva-Junior EF, Franca PHB, Quintas-Junior LJ, Mendonca-Junior FJB, Scotti L, Scotti MT, et al. Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme beta-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer`s Disease. *Current computer-aided drug design*. 2017.

Sim Y-J. Treadmill exercise alleviates impairment of spatial learning ability through enhancing cell proliferation in the streptozotocin-induced Alzheimer's disease rats. *Journal of exercise rehabilitation*. 2014;10(2):81-8.

Siman R, Cocca R, Dong Y. The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy. *PloS one*. 2015;10(11):e0142340.

Simic G, Babic Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milosevic N, et al. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies. *Biomolecules*. 2016;6(1):6.

Simmons DA, Knowles JK, Belichenko NP, Banerjee G, Finkle C, Massa SM, et al. A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. *PloS one*. 2014;9(8):e102136.

Simmons M, Peraza-Smith GB, Harris M, Scanland S. Application of resources for non-pharmacological interventions to improve dementia care in nursing homes. *Geriatric nursing* (New York, NY). 2015;36(3):242-4.

Simonson W. Do proton pump inhibitors cause dementia? *Geriatric nursing* (New York, NY). 2016;37(3):228-9.

Simpson K. Improving acute care for patients with dementia. *Nursing times*. 2016;112(5):22-4.

Sindi S, Mangialasche F, Kivipelto M. Advances in the prevention of Alzheimer's Disease. *F1000prime reports*. 2015;7:50.

Sindorio C, Abbritti RV, Raffa G, Priola SM, Germano A, Visocchi M, et al. Neuropsychological Assessment in the Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus. An Important Tool for the Maintenance and Restoration of Neuronal and Neuropsychological Functions. *Acta neurochirurgica Supplement*. 2017;124:283-8.

Singh B, Sharma B, Jaggi AS, Singh N. Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer's disease type: possible involvement of PPAR-gamma agonistic property. *Journal of the renin-angiotensin-aldosterone system : JRAAS*. 2013;14(2):124-36.

Singh BK, Vatsa N, Kumar V, Shekhar S, Sharma A, Jana NR. Ube3a deficiency inhibits amyloid plaque formation in APPswe/PS1deltaE9 mouse model of Alzheimer's disease. *Human molecular genetics*. 2017;26(20):4042-54.

Singh M, Kaur M, Kukreja H, Chugh R, Silakari O, Singh D. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. *European journal of medicinal chemistry*. 2013;70:165-88.

Singh NA, Mandal AKA, Khan ZA. Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). *Nutrition journal*. 2016;15(1):60.

Singh P, Gupta S, Sharma B. Antagonism of Endothelin (ETA and ETB) Receptors During Renovascular Hypertension-Induced Vascular Dementia Improves Cognition. *Current neurovascular research*. 2016;13(3):219-29.

Singh R, Bansal R. Investigations on 16-Arylideno Steroids as a New Class of Neuroprotective Agents for the Treatment of Alzheimer's and Parkinson's Diseases. *ACS chemical neuroscience*. 2017;8(1):186-200.

Singh S, Kumar P. Neuroprotective Activity of Curcumin in Combination with Piperine against Quinolinic Acid Induced Neurodegeneration in Rats. *Pharmacology*. 2016;97(3-4):151-60.

Singh SK, Gaur R, Kumar A, Fatima R, Mishra L, Srikrishna S. The flavonoid derivative 2-(4' Benzyloxyphenyl)-3-hydroxy-chromen-4-one protects against Abeta42-induced neurodegeneration in transgenic Drosophila: insights from in silico and in vivo studies. *Neurotoxicity research*. 2014;26(4):331-50.

Sinha A, Tamboli RS, Seth B, Kanhed AM, Tiwari SK, Agarwal S, et al. Neuroprotective Role of Novel Triazine Derivatives by Activating Wnt/beta Catenin Signaling Pathway in Rodent Models of Alzheimer's Disease. *Molecular neurobiology*. 2015;52(1):638-52.

Siracusa R, Impellizzeri D, Cordaro M, Crupi R, Esposito E, Petrosino S, et al. Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia. *Frontiers in neurology*. 2017;8:233.

Sirohi D, Kuhn RJ. Can an FDA-Approved Alzheimer's Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus? *mBio*. 2017;8(3).

Sivapriya TR, Kamal ARNB, Thangaiah PRJ. Ensemble Merit Merge Feature Selection for Enhanced Multinomial Classification in Alzheimer's Dementia. *Computational and mathematical methods in medicine*. 2015;2015:676129.

Sjolund B-M, Wimo A, Engstrom M, von Strauss E. Incidence of ADL Disability in Older Persons, Physical Activities as a Protective Factor and the Need for Informal and Formal Care--Results from the SNAC-N Project. *PloS one*. 2015;10(9):e0138901.

Skerrett R, Pellegrino MP, Casali BT, Taraboanta L, Landreth GE. Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor gamma Agonist Treatment Reduces Amyloid beta Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. *The Journal of biological chemistry*. 2015;290(35):21591-602.

Skoloudik D, Hurtikova E, Brat R, Herzig R, Group ST. Sonolysis in Prevention of Brain Infarction During Cardiac Surgery (SONORESCUE): Randomized, Controlled Trial. *Medicine*. 2016;95(20):e3615.

Skotte NH, Southwell AL, Ostergaard ME, Carroll JB, Warby SC, Doty CN, et al. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. *PloS one*. 2014;9(9):e107434.

Skouta R, Dixon SJ, Wang J, Dunn DE, Orman M, Shimada K, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. *Journal of the American Chemical Society*. 2014;136(12):4551-6.

Slaets S, Le Bastard N, Martin J-J, Slegers K, Van Broeckhoven C, De Deyn PP, et al. Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. *Journal of Alzheimer's disease : JAD*. 2013;36(4):759-67.

Sleeman KE, Ho YK, Verne J, Gao W, Higginson IJ, project GUC. Reversal of English trend towards hospital death in dementia: a population-based study of place of death and associated individual and regional factors, 2001-2010. *BMC neurology*. 2014;14:59.

Slomski A. Improving Shared Decision Making in Management of Dementia. *Jama*. 2017;317(8):798.

Slomski A. Vitamin E and Selenium Fail to Prevent Dementia in Men. *Jama*. 2017;317(20):2054.

Smail S, Bahga D, McDole B, Guthrie K. Increased Olfactory Bulb BDNF Expression Does Not Rescue Deficits in Olfactory Neurogenesis in the Huntington's Disease R6/2 Mouse. *Chemical senses*. 2016;41(3):221-32.

Smallfield S, Heckenlaible C. Effectiveness of Occupational Therapy Interventions to Enhance Occupational Performance for Adults With Alzheimer's Disease and Related Major Neurocognitive Disorders: A Systematic Review. *The American journal of occupational therapy : official publication of the American Occupational Therapy Association*. 2017;71(5):7105180010p1-p9.

Smeets CHW, Smalbrugge M, Gerritsen DL, Nelissen-Vrancken MHJMG, Wetzels RB, van der Spek K, et al. Improving psychotropic drug prescription in nursing home patients with dementia: design of a cluster randomized controlled trial. *BMC psychiatry*. 2013;13:280.

Smit D, Willemse B, de Lange J, Pot AM. Wellbeing-enhancing occupation and organizational and environmental contributors in long-term dementia care facilities: an explorative study. *International psychogeriatrics*. 2014;26(1):69-80.

Smith AD, Refsum H, Jacoby R. Evidence-based prevention and treatment of dementia. *The Lancet Neurology*. 2016;15(10):1005-6.

Smith AD, Yaffe K. Dementia (including Alzheimer's disease) can be prevented: statement supported by international experts. *Journal of Alzheimer's disease : JAD*. 2014;38(4):699-703.

Smith GE. Healthy cognitive aging and dementia prevention. *The American psychologist*. 2016;71(4):268-75.

Smith K, Flicker L, Atkinson D, Dwyer A, Lautenschlager NT, Thomas J, et al. The KICA Carer: informant information to enhance the Kimberley Indigenous Cognitive Assessment. *International psychogeriatrics*. 2016;28(1):101-7.

Smith M, Schultz SK, Seydel LL, Reist J, Kelly M, Weckmann M, et al. Improving antipsychotic agent use in nursing homes: development of an algorithm for treating problem behaviors in dementia. *Journal of gerontological nursing*. 2013;39(5):24-35; quiz 6-7.

Smith MR, Syed A, Lukacsovich T, Purcell J, Barbaro BA, Worthge SA, et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease. *Human molecular genetics*. 2014;23(11):2995-3007.

Smith TO, Hameed YA, Cross JL, Henderson C, Sahota O, Fox C. Enhanced rehabilitation and care models for adults with dementia following hip fracture surgery. *The Cochrane database of systematic reviews*. 2015(6):CD010569.

Snyder HM, Shineman DW, Friedman LG, Hendrix JA, Khachaturian A, Le Guillou I, et al. Guidelines to improve animal study design and reproducibility for Alzheimer's disease and related dementias: For funders and researchers. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016;12(11):1177-85.

Soares LM, De Vry J, Steinbusch HWM, Milani H, Prickaerts J, Weffort de Oliveira RM. Rolipram improves cognition, reduces anxiety- and despair-like behaviors and impacts hippocampal neuroplasticity after transient global cerebral ischemia. *Neuroscience*. 2016;326:69-83.

Sobhia ME, Grewal BK, Paul MLS, Patel J, Kaur A, Haokip T, et al. Protein kinase C inhibitors: a patent review (2010 - present). *Expert opinion on therapeutic patents*. 2013;23(11):1451-68.

Sodhi RK, Singh N. All-trans retinoic acid rescues memory deficits and neuropathological changes in mouse model of streptozotocin-induced dementia of Alzheimer's type. *Progress in neuro-psychopharmacology & biological psychiatry*. 2013;40:38-46.

Sodhi RK, Singh N. Liver X receptor agonist T0901317 reduces neuropathological changes and improves memory in mouse models of experimental dementia. *European journal of pharmacology*. 2014;732:50-9.

Sofic E, Salkovic-Petrisic M, Tahirovic I, Sapcanin A, Mandel S, Youdim M, et al. Brain catalase in the streptozotocin-rat model of sporadic Alzheimer's disease treated with the iron chelator-monoamine oxidase inhibitor, M30. *Journal of neural transmission (Vienna, Austria : 1996)*. 2015;122(4):559-64.

Sofola-Adesakin O, Castillo-Quan JI, Rallis C, Tain LS, Bjedov I, Rogers I, et al. Lithium suppresses Aβ pathology by inhibiting translation in an adult *Drosophila* model of Alzheimer's disease. *Frontiers in aging neuroscience*. 2014;6:190.

Sohanaki H, Baluchnejadmojarad T, Nikbakht F, Roghani M. Pelargonidin improves memory deficit in amyloid β25-35 rat model of Alzheimer's disease by inhibition of glial activation,

cholinesterase, and oxidative stress. *Biomedicine & pharmacotherapy* = *Biomedecine & pharmacotherapie*. 2016;83:85-91.

Sohanaki H, Baluchnejadmojarad T, Nikbakht F, Roghani M. Pelargonidin Improves Passive Avoidance Task Performance in a Rat Amyloid Beta25-35 Model of Alzheimer's Disease Via Estrogen Receptor Independent Pathways. *Acta medica Iranica*. 2016;54(4):245-50.

Soheili M, Tavirani MR, Salami M. *Lavandula angustifolia* extract improves deteriorated synaptic plasticity in an animal model of Alzheimer's disease. *Iranian journal of basic medical sciences*. 2015;18(11):1147-52.

Solberg NO, Chamberlin R, Vigil JR, Deck LM, Heidrich JE, Brown DC, et al. Optical and SPION-enhanced MR imaging shows that trans-stilbene inhibitors of NF-kappaB concomitantly lower Alzheimer's disease plaque formation and microglial activation in AbetaPP/PS-1 transgenic mouse brain. *Journal of Alzheimer's disease : JAD*. 2014;40(1):191-212.

Sole-Casals J, Vialatte F-B. Towards Semi-Automatic Artifact Rejection for the Improvement of Alzheimer's Disease Screening from EEG Signals. *Sensors (Basel, Switzerland)*. 2015;15(8):17963-76.

Solfrizzi V, Scafato E, Frisardi V, Seripa D, Logroscino G, Kehoe PG, et al. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. *The Italian Longitudinal Study on Aging*. *Age (Dordrecht, Netherlands)*. 2013;35(2):441-53.

Solfrizzi V, Scafato E, Seripa D, Lozupone M, Imbimbo BP, D'Amato A, et al. Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. *The Italian Longitudinal Study on Aging*. *Journal of the American Medical Directors Association*. 2017;18(1):89.e1-e8.

Solmaz V, Cinar BP, Yigitturk G, Cavusoglu T, Taskiran D, Erbas O. Exenatide reduces TNF-alpha expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. *European journal of pharmacology*. 2015;765:482-7.

Solomon A, Kivipelto M, Soininen H. Prevention of Alzheimer's disease: moving backward through the lifespan. *Journal of Alzheimer's disease : JAD*. 2013;33 Suppl 1:S465-9.

Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, et al. Advances in the prevention of Alzheimer's disease and dementia. *Journal of internal medicine*. 2014;275(3):229-50.

Solomon A, Soininen H. Dementia: Risk prediction models in dementia prevention. *Nature reviews Neurology*. 2015;11(7):375-7.

Solovyev ND. Importance of selenium and selenoprotein for brain function: From antioxidant protection to neuronal signalling. *Journal of inorganic biochemistry*. 2015;153:1-12.

Sommerbakk R, Haugen DF, Tjora A, Kaasa S, Hjerstad MJ. Barriers to and facilitators for implementing quality improvements in palliative care - results from a qualitative interview study in Norway. *BMC palliative care*. 2016;15:61.

Son SM, Nam DW, Cha M-Y, Kim KH, Byun J, Ryu H, et al. Thrombospondin-1 prevents amyloid beta-mediated synaptic pathology in Alzheimer's disease. *Neurobiology of aging*. 2015;36(12):3214-27.

Sonali N, Tripathi M, Sagar R, Velpandian T, Subbiah V. Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease. *Dementia and geriatric cognitive disorders*. 2014;37(1-2):58-70.

Song F-X, Wang L, Liu H, Wang Y-L, Zou Y. Brain cell apoptosis inhibition by butylphthalide in Alzheimer's disease model in rats. *Experimental and therapeutic medicine*. 2017;13(6):2771-4.

Song G, Zhang Z, Wen L, Chen C, Shi Q, Zhang Y, et al. Selenomethionine ameliorates cognitive decline, reduces tau hyperphosphorylation, and reverses synaptic deficit in the triple transgenic mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;41(1):85-99.

Song H, Chang YJ, Moon M, Park SK, Tran P-T, Hoang V-H, et al. Inhibition of glutaminyl cyclase ameliorates amyloid pathology in an animal model of Alzheimer's disease via the modulation of gamma-secretase activity. *Journal of Alzheimer's disease : JAD*. 2015;43(3):797-807.

Song HR, Woo YS, Wang H-R, Jun T-Y, Bahk W-M. Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep. *International clinical psychopharmacology*. 2013;28(6):346-8.

Song J, Hur BE, Bokara KK, Yang W, Cho HJ, Park KA, et al. Agmatine improves cognitive dysfunction and prevents cell death in a streptozotocin-induced Alzheimer rat model. *Yonsei medical journal*. 2014;55(3):689-99.

Song J, Zhang X, Zhao Y, Yang H, Zhang J, Zhang X, et al. (R)- and (S)-18F-labeled 2-arylbenzofurans with improved pharmacokinetics as beta-amyloid imaging probes. *European journal of medicinal chemistry*. 2017;134:271-80.

Song JM, DiBattista AM, Sung YM, Ahn JM, Turner RS, Yang J, et al. A tetra(ethylene glycol) derivative of benzothiazole aniline ameliorates dendritic spine density and cognitive function in a mouse model of Alzheimer's disease. *Experimental neurology*. 2014;252:105-13.

Song J-Z, Sun J, Jin D-C, Deng Y-Q. Rosiglitazone improves learning and memory impairment of 3 x Tg mice. *Yao xue xue bao = Acta pharmaceutica Sinica*. 2014;49(6):807-12.

Song Q, Huang M, Yao L, Wang X, Gu X, Chen J, et al. Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer's disease by accelerating the clearance of amyloid-beta. *ACS nano*. 2014;8(3):2345-59.

Song S, Wang X, Sava V, Weeber EJ, Sanchez-Ramos J. In vivo administration of granulocyte colony-stimulating factor restores long-term depression in hippocampal slices prepared from transgenic APP/PS1 mice. *Journal of neuroscience research*. 2014;92(8):975-80.

Song TY, Lin HC, Chen CL, Wu JH, Liao JW, Hu ML. Ergothioneine and melatonin attenuate oxidative stress and protect against learning and memory deficits in C57BL/6J mice treated with D-galactose. *Free radical research*. 2014;48(9):1049-60.

Song W-J, Son M-Y, Lee H-W, Seo H, Kim JH, Chung S-H. Enhancement of BACE1 Activity by p25/Cdk5-Mediated Phosphorylation in Alzheimer's Disease. *PloS one*. 2015;10(8):e0136950.

Song X, Zhu W, An R, Li Y, Du Z. Protective effect of Daming capsule against chronic cerebral ischemia. *BMC complementary and alternative medicine*. 2015;15:149.

Song X-Y, Hu J-F, Chu S-F, Zhang Z, Xu S, Yuan Y-H, et al. Ginsenoside Rg1 attenuates okadaic acid induced spatial memory impairment by the GSK3beta/tau signaling pathway and the Abeta formation prevention in rats. *European journal of pharmacology*. 2013;710(1-3):29-38.

Song Y, Cui T, Xie N, Zhang X, Qian Z, Liu J. Protocatechuic acid improves cognitive deficits and attenuates amyloid deposits, inflammatory response in aged AbetaPP/PS1 double transgenic mice. *International immunopharmacology*. 2014;20(1):276-81.

Song Y, Kim H-D, Lee M-K, Hong I-H, Won C-K, Bai H-W, et al. Maysin and Its Flavonoid Derivative from Centipedegrass Attenuates Amyloid Plaques by Inducing Humoral Immune Response with Th2 Skewed Cytokine Response in the Tg (APP^{swe}, PS1^{dE9}) Alzheimer's Mouse Model. *PloS one*. 2017;12(1):e0169509.

Soodi M, Saeidnia S, Sharifzadeh M, Hajimehdipoor H, Dashti A, Sepand MR, et al. Satureja bachtiarica ameliorate beta-amyloid induced memory impairment, oxidative stress and cholinergic deficit in animal model of Alzheimer's disease. *Metabolic brain disease*. 2016;31(2):395-404.

Sooy K, Noble J, McBride A, Binnie M, Yau JLW, Seckl JR, et al. Cognitive and Disease-Modifying Effects of 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibition in Male Tg2576 Mice, a Model of Alzheimer's Disease. *Endocrinology*. 2015;156(12):4592-603.

Sopina E, Martikainen JA, Spackman E, Sorensen J. Validation of A Markov Model for Economic Evaluation of Screening and Preventive Interventions In Alzheimer's Disease In

Denmark. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2015;18(7):A695.

Sorgjerd KM, Zako T, Sakono M, Stirling PC, Leroux MR, Saito T, et al. Human prefoldin inhibits amyloid-beta (Abeta) fibrillation and contributes to formation of nontoxic Abeta aggregates. Biochemistry. 2013;52(20):3532-42.

Sorial ME, El Sayed NSED. Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer's disease mouse model: possible involvement of the cholinergic system. Naunyn-Schmiedeberg's archives of pharmacology. 2017;390(6):581-93.

Soriano-Barcelo J, Alonso MT, Traba MBP, Vilar AA, Kahn DA. A case with reversible neurotoxicity after 2 years of dementia secondary to maintenance lithium treatment. Journal of psychiatric practice. 2015;21(2):154-9.

Soto ME, van Kan GA, Nourhashemi F, Gillette-Guyonnet S, Cesari M, Cantet C, et al. Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Réseau sur la Maladie d'Alzheimer Français cohort. Journal of the American Geriatrics Society. 2013;61(9):1482-8.

Soudy R, Patel A, Fu W, Kaur K, MacTavish D, Westaway D, et al. Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's disease. Alzheimer's & dementia (New York, N Y). 2017;3(1):44-56.

Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiology of disease. 2015;76:46-56.

Southwell AL, Smith SEP, Davis TR, Caron NS, Villanueva EB, Xie Y, et al. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Scientific reports. 2015;5:12166.

Southwell AL, Smith-Dijak A, Kay C, Sepers M, Villanueva EB, Parsons MP, et al. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Human molecular genetics. 2016;25(17):3654-75.

Souza ACG, Sari MHM, Pinton S, Luchese C, Neto JSS, Nogueira CW. 2-Phenylethynyl-butyltellurium attenuates amyloid-beta peptide(25-35)-induced learning and memory impairments in mice. Journal of neuroscience research. 2013;91(6):848-53.

Souza LC, Filho CB, Goes ATR, Fabbro LD, de Gomes MG, Savegnago L, et al. Neuroprotective effect of physical exercise in a mouse model of Alzheimer's disease induced by beta-amyloid β peptide. Neurotoxicity research. 2013;24(2):148-63.

Soysal P, Isik AT, Stubbs B, Solmi M, Volpe M, Luchini C, et al. Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis. *Journal of neurology, neurosurgery, and psychiatry*. 2016;87(12):1368-74.

Soysal P, Isik AT. Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study. *The journal of nutrition, health & aging*. 2016;20(4):398-403.

Sozio P, Cerasa LS, Laserra S, Cacciatore I, Cornacchia C, Di Filippo ES, et al. Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*. 2013;49(2):187-98.

Spalletta G, Caltagirone C, Padovani A, Sorbi S, Attar M, Colombo D, et al. Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study. *PloS one*. 2014;9(2):e89216.

Spalletta G, Gianni W, Giubilei F, Casini AR, Sancesario G, Caltagirone C, et al. Rivastigmine patch ameliorates depression in mild AD: preliminary evidence from a 6-month open-label observational study. *Alzheimer disease and associated disorders*. 2013;27(3):289-91.

Spangenberg EE, Lee RJ, Najafi AR, Rice RA, Elmore MRP, Blurton-Jones M, et al. Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-beta pathology. *Brain : a journal of neurology*. 2016;139(Pt 4):1265-81.

Speck-Planche A, Kleandrova VV, Luan F, Cordeiro MNDS. Multi-target inhibitors for proteins associated with Alzheimer: in silico discovery using fragment-based descriptors. *Current Alzheimer research*. 2013;10(2):117-24.

Speer G. Impact of vitamin D in neurological diseases and neurorehabilitation: from dementia to multiple sclerosis. Part I: the role of vitamin D in the prevention and treatment of multiple sclerosis. *Ideggyogyaszati szemle*. 2013;66(9-10):293-303.

Spence JD. Metabolic vitamin B12 deficiency: a missed opportunity to prevent dementia and stroke. *Nutrition research (New York, NY)*. 2016;36(2):109-16.

Spencer B, Desplats PA, Overk CR, Valera-Martin E, Rissman RA, Wu C, et al. Reducing Endogenous alpha-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2016;36(30):7971-84.

Spencer B, Verma I, Desplats P, Morvinski D, Rockenstein E, Adame A, et al. A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis. *The Journal of biological chemistry*. 2014;289(25):17917-31.

Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease: implications for prevention trials. *Neuron*. 2014;84(3):608-22.

Spiegel R, Doody RS, Hendrix S, Kahle-Wroblewski K. Modeling the course of Alzheimer's disease to improve clinical trials: symposium report. *Alzheimer's research & therapy*. 2013;5(3):29.

Spilman PR, Corset V, Gorostiza O, Poksay KS, Galvan V, Zhang J, et al. Netrin-1 Interrupts Amyloid-beta Amplification, Increases sAbetaPPalpha in vitro and in vivo, and Improves Cognition in a Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;52(1):223-42.

Spilovska K, Korabecny J, Kral J, Horova A, Musilek K, Soukup O, et al. 7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer's disease treatment--synthesis, biological evaluation and molecular modeling studies. *Molecules (Basel, Switzerland)*. 2013;18(2):2397-418.

Spilovska K, Korabecny J, Nepovimova E, Dolezal R, Mezeiova E, Soukup O, et al. Multitarget Tacrine Hybrids with Neuroprotective Properties to Confront Alzheimer's Disease. *Current topics in medicinal chemistry*. 2017;17(9):1006-26.

Spinelli KJ, Osterberg VR, Meshul CK, Soumyanath A, Unni VK. Curcumin Treatment Improves Motor Behavior in alpha-Synuclein Transgenic Mice. *PloS one*. 2015;10(6):e0128510.

Spira AP, Gottesman RF. Sleep disturbance: an emerging opportunity for Alzheimer's disease prevention? *International psychogeriatrics*. 2017;29(4):529-31.

Sposato LA, Kapral MK, Fang J, Gill SS, Hackam DG, Cipriano LE, et al. Declining Incidence of Stroke and Dementia: Coincidence or Prevention Opportunity? *JAMA neurology*. 2015;72(12):1529-31.

Springer S, Gagneux P. New genes protect old minds. *Medecine sciences : M/S*. 2016;32(10):806-8.

Sprinks J. College launches initiative to improve the dementia skills of care home nurses. *Nursing older people*. 2016;28(1):6.

Sproul AA. Being human: The role of pluripotent stem cells in regenerative medicine and humanizing Alzheimer's disease models. *Molecular aspects of medicine*. 2015;43-44:54-65.

Squitieri F, Di Pardo A, Favellato M, Amico E, Maglione V, Frati L. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. *Journal of cellular and molecular medicine*. 2015;19(11):2540-8.

Squitti R, Siotto M, Polimanti R. Low-copper diet as a preventive strategy for Alzheimer's disease. *Neurobiology of aging*. 2014;35 Suppl 2:S40-50.

Sreenivasachary N, Kroth H, Benderitter P, Hamel A, Varisco Y, Hickman DT, et al. Discovery and characterization of novel indole and 7-azaindole derivatives as inhibitors of beta-amyloid-42 aggregation for the treatment of Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2017;27(6):1405-11.

Srisuwan P. Primary prevention of dementia: focus on modifiable risk factors. *Journal of the Medical Association of Thailand = Chotmaihet thangphaet*. 2013;96(2):251-8.

Stahl SM. Does treating hearing loss prevent or slow the progress of dementia? Hearing is not all in the ears, but who's listening? *CNS spectrums*. 2017;22(3):247-50.

Stamelou M. Commentary for "Slowing of saccadic eye movements in sporadic Creutzfeldt-Jakob disease". *Movement disorders : official journal of the Movement Disorder Society*. 2013;28(3):293-4.

Stamford A, Strickland C. Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story. *Current opinion in chemical biology*. 2013;17(3):320-8.

St-Amour I, Pare I, Tremblay C, Coulombe K, Bazin R, Calon F. IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Abeta pathology. *Journal of neuroinflammation*. 2014;11:54.

Stanek LM, Sardi SP, Mastis B, Richards AR, Treleaven CM, Taksir T, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. *Human gene therapy*. 2014;25(5):461-74.

Starling S. Alzheimer disease: PINK1 rescues pathology in Alzheimer disease. *Nature reviews Neurology*. 2017.

Staveness D, Abdelnabi R, Near KE, Nakagawa Y, Neyts J, Delang L, et al. Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway. *Journal of natural products*. 2016;79(4):680-4.

Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. *Molecular psychiatry*. 2013;18(8):889-97.

Stefanova NA, Maksimova KY, Kiseleva E, Rudnitskaya EA, Muraleva NA, Kolosova NG. Melatonin attenuates impairments of structural hippocampal neuroplasticity in OXYS rats during

active progression of Alzheimer's disease-like pathology. *Journal of pineal research*. 2015;59(2):163-77.

Steffens EB, Steffens DC. Getting on Message: Preventing Alzheimer Disease Through Diet and Exercise. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2016;24(9):738-9.

Steffensmeier AM, Tare M, Puli OR, Modi R, Nainaparampil J, Kango-Singh M, et al. Novel neuroprotective function of apical-basal polarity gene crumbs in amyloid beta 42 (abeta42) mediated neurodegeneration. *PloS one*. 2013;8(11):e78717.

Steiner JP, Bachani M, Wolfson-Stofko B, Lee M-H, Wang T, Wang T, et al. Interaction of paroxetine with mitochondrial proteins mediates neuroprotection. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*. 2015;12(1):200-16.

Stenhagen M, Ekstrom H, Nordell E, Elmstahl S. Both deterioration and improvement in activities of daily living are related to falls: a 6-year follow-up of the general elderly population study Good Aging in Skane. *Clinical interventions in aging*. 2014;9:1839-46.

Stenovec M, Trkov S, Lasic E, Terzieva S, Kreft M, Rodriguez Arellano JJ, et al. Expression of familial Alzheimer disease presenilin 1 gene attenuates vesicle traffic and reduces peptide secretion in cultured astrocytes devoid of pathologic tissue environment. *Glia*. 2016;64(2):317-29.

Stephan BCM, Tzourio C, Auriacombe S, Amieva H, Dufouil C, Alperovitch A, et al. Usefulness of data from magnetic resonance imaging to improve prediction of dementia: population based cohort study. *BMJ (Clinical research ed)*. 2015;350:h2863.

Stephenson J. Innovative HCA team eliminates falls among dementia inpatients. *Nursing times*. 2016;112(1-2):6.

Steventon JJ, Harrison DJ, Trueman RC, Rosser AE, Jones DK, Brooks SP. In Vivo MRI Evidence that Neuropathology is Attenuated by Cognitive Enrichment in the Yac128 Huntington's Disease Mouse Model. *Journal of Huntington's disease*. 2015;4(2):149-60.

Stockburger C, Kurz C, Koch KA, Eckert SH, Leuner K, Muller WE. Improvement of mitochondrial function and dynamics by the metabolic enhancer piracetam. *Biochemical Society transactions*. 2013;41(5):1331-4.

Stoddard SV, Hamann MT, Wadkins RM. Insights and ideas garnered from marine metabolites for development of dual-function acetylcholinesterase and amyloid-beta aggregation inhibitors. *Marine drugs*. 2014;12(4):2114-31.

Stopford MJ, Higginbottom A, Hautbergue GM, Cooper-Knock J, Mulcahy PJ, De Vos KJ, et al. C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten. *Human molecular genetics*. 2017;26(6):1133-45.

Stotani S, Giordanetto F, Medda F. DYRK1A inhibition as potential treatment for Alzheimer's disease. *Future medicinal chemistry*. 2016;8(6):681-96.

Stratakou GD, Plerou A. Cognitive Enhancement for Elderly Facing Dementia with the Use of Cognitive Rehabilitation Therapy Techniques and Psychological Treatment. A Case Study. *Advances in experimental medicine and biology*. 2017;987:89-98.

Streltsov VA, Chandana Epa V, James SA, Churches QI, Caine JM, Kenche VB, et al. Structural insights into the interaction of platinum-based inhibitors with the Alzheimer's disease amyloid-beta peptide. *Chemical communications (Cambridge, England)*. 2013;49(97):11364-6.

Strohmeyer R, Shelton J, Loughheed C, Breitkopf T. CCAAT-enhancer binding protein-beta expression and elevation in Alzheimer's disease and microglial cell cultures. *PloS one*. 2014;9(1):e86617.

Stromberg K, Eketjall S, Georgievska B, Tunblad K, Eliason K, Olsson F, et al. Combining an amyloid-beta (A β) cleaving enzyme inhibitor with a gamma-secretase modulator results in an additive reduction of A β production. *The FEBS journal*. 2015;282(1):65-73.

Struyfs H, Niemantsverdriet E, Goossens J, Fransen E, Martin J-J, De Deyn PP, et al. Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. *Frontiers in neurology*. 2015;6:138.

Stubbs B, Chen L-J, Chang C-Y, Sun W-J, Ku P-W. Accelerometer-assessed light physical activity is protective of future cognitive ability: A longitudinal study among community dwelling older adults. *Experimental gerontology*. 2017;91:104-9.

Studart Neto A, Nobrega PR, Duarte MIS, Lucato LT, Castro LHM, Nitrini R. Adult-onset subacute sclerosing panencephalitis manifesting as slowly progressive dementia. *Journal of neurovirology*. 2015;21(4):468-71.

Stumm C, Hiebel C, Hanstein R, Purrio M, Nagel H, Conrad A, et al. Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. *Neurobiology of aging*. 2013;34(11):2574-84.

Sturm S, Forsberg A, Nave S, Stenkrona P, Seneca N, Varrone A, et al. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of selegiline. *European journal of nuclear medicine and molecular imaging*. 2017;44(3):382-91.

Su J, Liu H, Guo K, Chen L, Yang M, Chen Q. Research Advances and Detection Methodologies for Microbe-Derived Acetylcholinesterase Inhibitors: A Systemic Review. *Molecules* (Basel, Switzerland). 2017;22(1).

Su T, Caan MWA, Wit FWNM, Schouten J, Geurtsen GJ, Cole JH, et al. White matter structure alterations in HIV-1-infected men with sustained suppression of viraemia on treatment. *AIDS* (London, England). 2016;30(2):311-22.

Su T, Zhang T, Xie S, Yan J, Wu Y, Li X, et al. Discovery of novel PDE9 inhibitors capable of inhibiting Abeta aggregation as potential candidates for the treatment of Alzheimer's disease. *Scientific reports*. 2016;6:21826.

Suarez-Gonzalez A, Green Heredia C, Savage SA, Gil-Neciga E, Garcia-Casares N, Franco-Macias E, et al. Restoration of conceptual knowledge in a case of semantic dementia. *Neurocase*. 2015;21(3):309-21.

Subaiea GM, Adwan LI, Ahmed AH, Stevens KE, Zawia NH. Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice. *Neurobiology of aging*. 2013;34(10):2421-30.

Subash S, Braidy N, Essa MM, Zayana A-B, Ragini V, Al-Adawi S, et al. Long-term (15 mo) dietary supplementation with pomegranates from Oman attenuates cognitive and behavioral deficits in a transgenic mice model of Alzheimer's disease. *Nutrition* (Burbank, Los Angeles County, Calif). 2015;31(1):223-9.

Subash S, Essa MM, Al-Asmi A, Al-Adawi S, Vaishnav R, Braidy N, et al. Pomegranate from Oman Alleviates the Brain Oxidative Damage in Transgenic Mouse Model of Alzheimer's disease. *Journal of traditional and complementary medicine*. 2014;4(4):232-8.

Subash S, Essa MM, Braidy N, Al-Jabri A, Vaishnav R, Al-Adawi S, et al. Consumption of fig fruits grown in Oman can improve memory, anxiety, and learning skills in a transgenic mice model of Alzheimer's disease. *Nutritional neuroscience*. 2016;19(10):475-83.

Subash S, Essa MM, Braidy N, Awlad-Thani K, Vaishnav R, Al-Adawi S, et al. Diet rich in date palm fruits improves memory, learning and reduces beta amyloid in transgenic mouse model of Alzheimer's disease. *Journal of Ayurveda and integrative medicine*. 2015;6(2):111-20.

Subedee L, Suresh RN, Mk J, Hl K, Am S, Vh P. Preventive role of Indian black pepper in animal models of Alzheimer's disease. *Journal of clinical and diagnostic research : JCDR*. 2015;9(4):FF01-4.

Suemoto CK, Gilsanz P, Mayeda ER, Glymour MM. Body mass index and cognitive function: the potential for reverse causation. *International journal of obesity* (2005). 2015;39(9):1383-9.

Suganthi N, Malar DS, Devi KP. Rhizophora mucronata attenuates beta-amyloid induced cognitive dysfunction, oxidative stress and cholinergic deficit in Alzheimer's disease animal model. *Metabolic brain disease*. 2016;31(4):937-49.

Sugiura Y, Ikeda K, Nakano M. High Membrane Curvature Enhances Binding, Conformational Changes, and Fibrillation of Amyloid-beta on Lipid Bilayer Surfaces. *Langmuir : the ACS journal of surfaces and colloids*. 2015;31(42):11549-57.

Suhonen NM, Kaivorinne AL, Moilanen V, Bode M, Takalo R, Hanninen T, et al. Slowly progressive frontotemporal lobar degeneration caused by the C9ORF72 repeat expansion: a 20-year follow-up study. *Neurocase*. 2015;21(1):85-9.

Sumathi T, Christinal J. Neuroprotective Effect of Portulaca oleraceae Ethanolic Extract Ameliorates Methylmercury Induced Cognitive Dysfunction and Oxidative Stress in Cerebellum and Cortex of Rat Brain. *Biological trace element research*. 2016;172(1):155-65.

Summaries for patients. Screening for cognitive impairment in older adults: U.S. Preventive Services Task Force recommendation statement. *Annals of internal medicine*. 2014;160(11).

Summers MJ, Saunders NLJ, Valenzuela MJ, Summers JJ, Ritchie K, Robinson A, et al. The Tasmanian Healthy Brain Project (THBP): a prospective longitudinal examination of the effect of university-level education in older adults in preventing age-related cognitive decline and reducing the risk of dementia. *International psychogeriatrics*. 2013;25(7):1145-55.

Sun A, Xu X, Lin J, Cui X, Xu R. Neuroprotection by saponins. *Phytotherapy research : PTR*. 2015;29(2):187-200.

Sun C-S, Lee C-C, Li Y-N, Yao-Chen Yang S, Lin C-H, Chang Y-C, et al. Conformational switch of polyglutamine-expanded huntingtin into benign aggregates leads to neuroprotective effect. *Scientific reports*. 2015;5:14992.

Sun D, Chen J, Bao X, Cai Y, Zhao J, Huang J, et al. Protection of Radial Glial-Like Cells in the Hippocampus of APP/PS1 Mice: a Novel Mechanism of Memantine in the Treatment of Alzheimer's Disease. *Molecular neurobiology*. 2015;52(1):464-77.

Sun D, Zhang W, Yu Q, Chen X, Xu M, Zhou Y, et al. Chiral penicillamine-modified selenium nanoparticles enantioselectively inhibit metal-induced amyloid beta aggregation for treating Alzheimer's disease. *Journal of colloid and interface science*. 2017;505:1001-10.

Sun G-J, Luo L, Du Y-J, Kong L-H. Protective mechanism of acupuncture-moxibustion on hippocampal neuron mitochondria in rats with Alzheimer's disease. *Zhongguo zhen jiu = Chinese acupuncture & moxibustion*. 2014;34(2):157-62.

Sun P, Ding H, Liang M, Li X, Mo W, Wang X, et al. Neuroprotective effects of geniposide in SH-SY5Y cells and primary hippocampal neurons exposed to Abeta42. *BioMed research international*. 2014;2014:284314.

Sun Q, Hu H, Wang W, Jin H, Feng G, Jia N. Taurine attenuates amyloid beta 1-42-induced mitochondrial dysfunction by activating of SIRT1 in SK-N-SH cells. *Biochemical and biophysical research communications*. 2014;447(3):485-9.

Sun W, Lee S, Huang X, Liu S, Inayathullah M, Kim K-M, et al. Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment. *Scientific reports*. 2016;6:34784.

Sun X, Marque LO, Cordner Z, Pruitt JL, Bhat M, Li PP, et al. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. *Human molecular genetics*. 2014;23(23):6302-17.

Sun Y, Chen J, Chen X, Huang L, Li X. Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids. *Bioorganic & medicinal chemistry*. 2013;21(23):7406-17.

Sun Y, Fan J, Zhu Z, Guo X, Zhou T, Duan W, et al. Small molecule TBTC as a new selective retinoid X receptor alpha agonist improves behavioral deficit in Alzheimer's disease model mice. *European journal of pharmacology*. 2015;762:202-13.

Sun Y, Qian Z, Wei G. The inhibitory mechanism of a fullerene derivative against amyloid-beta peptide aggregation: an atomistic simulation study. *Physical chemistry chemical physics : PCCP*. 2016;18(18):12582-91.

Sun Z, Zhan L, Liang L, Sui H, Zheng L, Sun X, et al. ZiBu PiYin recipe prevents diabetes-associated cognitive decline in rats: possible involvement of ameliorating mitochondrial dysfunction, insulin resistance pathway and histopathological changes. *BMC complementary and alternative medicine*. 2016;16:200.

Sundaram JR, Poore CP, Sulaimi NHB, Pareek T, Cheong WF, Wenk MR, et al. Curcumin Ameliorates Neuroinflammation, Neurodegeneration, and Memory Deficits in p25 Transgenic Mouse Model that Bears Hallmarks of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;60(4):1429-42.

Sung YM, Lee T, Yoon H, DiBattista AM, Song JM, Sohn Y, et al. Mercaptoacetamide-based class II HDAC inhibitor lowers Abeta levels and improves learning and memory in a mouse model of Alzheimer's disease. *Experimental neurology*. 2013;239:192-201.

Suominen MH, Puranen TM, Jyvakorpi SK, Eloniemi-Sulkava U, Kautiainen H, Siljamäki-Ojansuu U, et al. Nutritional Guidance Improves Nutrient Intake and Quality of Life, and May

Prevent Falls in Aged Persons with Alzheimer Disease Living with a Spouse (NuAD Trial). *The journal of nutrition, health & aging*. 2015;19(9):901-7.

Susmith SD, Haider S, Landwehrmeyer GB, Farmer R, Frost C, Tripepi G, et al. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease. *British journal of clinical pharmacology*. 2015;79(3):465-76.

Sutalangka C, Wattanathorn J, Muchimapura S, Thukham-Mee W, Wannanon P, Tong-un T. Laser acupuncture improves memory impairment in an animal model of Alzheimer's disease. *Journal of acupuncture and meridian studies*. 2013;6(5):247-51.

Sutalangka C, Wattanathorn J, Muchimapura S, Thukham-mee W. *Moringa oleifera* mitigates memory impairment and neurodegeneration in animal model of age-related dementia. *Oxidative medicine and cellular longevity*. 2013;2013:695936.

Sutalangka C, Wattanathorn J. Neuroprotective and cognitive-enhancing effects of the combined extract of *Cyperus rotundus* and *Zingiber officinale*. *BMC complementary and alternative medicine*. 2017;17(1):135.

Suttner N. Comment on: Urgent revision required of NICE guidance relating to the prevention of spread of vCJD through neurosurgical instruments. *British journal of neurosurgery*. 2014;28(2):296.

Swaminathan A, Jicha GA. Nutrition and prevention of Alzheimer's dementia. *Frontiers in aging neuroscience*. 2014;6:282.

Swartz RH, Cayley ML, Lancot KL, Murray BJ, Cohen A, Thorpe KE, et al. The "DOC" screen: Feasible and valid screening for depression, Obstructive Sleep Apnea (OSA) and cognitive impairment in stroke prevention clinics. *PloS one*. 2017;12(4):e0174451.

Sylla T, Pouysegur L, Da Costa G, Deffieux D, Monti J-P, Quideau S. Gallotannins and Tannic Acid: First Chemical Syntheses and In Vitro Inhibitory Activity on Alzheimer's Amyloid beta-Peptide Aggregation. *Angewandte Chemie (International ed in English)*. 2015;54(28):8217-21.

Szutowicz A, Bielarczyk H, Jankowska-Kulawy A, Ronowska A, Pawelczyk T. Retinoic acid as a therapeutic option in Alzheimer's disease: a focus on cholinergic restoration. *Expert review of neurotherapeutics*. 2015;15(3):239-49.

Tabari S-SS, Babri S, Mirzaie F, Farajdokht F, Mohaddes G. Enduring amnesia induced by ICV scopolamine is reversed by sesame oil in male rats. *Acta chirurgica brasileira*. 2016;31(8):520-6.

Tabassum S, Sheikh AM, Yano S, Ikeue T, Handa M, Nagai A. A carboxylated Zn-phthalocyanine inhibits fibril formation of Alzheimer's amyloid beta peptide. *The FEBS journal*. 2015;282(3):463-76.

Tabuchi H, Konishi M, Saito N, Kato M, Mimura M. Reverse Fox test for detecting visuospatial dysfunction corresponding to parietal hypoperfusion in mild Alzheimer's disease. *American journal of Alzheimer's disease and other dementias*. 2014;29(2):177-82.

Tafoya MA, Madi S, Sillerud LO. Superparamagnetic nanoparticle-enhanced MRI of Alzheimer's disease plaques and activated microglia in 3X transgenic mouse brains: Contrast optimization. *Journal of magnetic resonance imaging : JMRI*. 2017;46(2):574-88.

Taghizadeh M, Talaei SA, Djazayeri A, Salami M. Vitamin D supplementation restores suppressed synaptic plasticity in Alzheimer's disease. *Nutritional neuroscience*. 2014;17(4):172-7.

Taghialatela G, Rastellini C, Cicalese L. Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors. *Journal of Alzheimer's disease : JAD*. 2015;47(2):329-33.

Taguchi A, Takata Y, Ihara M, Kasahara Y, Tsuji M, Nishino M, et al. Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society*. 2013;13(3):164-9.

Tai J, Liu W, Li Y, Li L, Holscher C. Neuroprotective effects of a Triple GLP-1/GIP/Glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease. *Brain research*. 2017.

Tai S-Y, Chien C-Y, Wu D-C, Lin K-D, Ho B-L, Chang Y-H, et al. Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan. *PloS one*. 2017;12(2):e0171006.

Taipale H, Tolppanen A-M, Tiihonen M, Tanskanen A, Tiihonen J, Hartikainen S. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease. *The American journal of gastroenterology*. 2017.

Tajadini H, Choopani R, Saifadini R. Lifestyle Methods for Prevention of Alzheimer's Disease From the Perspective of Traditional Persian Medicine. *Journal of evidence-based complementary & alternative medicine*. 2016;21(3):243-5.

Takach O, Gill TB, Silverman MA. Modulation of insulin signaling rescues BDNF transport defects independent of tau in amyloid-beta oligomer-treated hippocampal neurons. *Neurobiology of aging*. 2015;36(3):1378-82.

Takahashi K, Kong Q, Lin Y, Stouffer N, Schulte DA, Lai L, et al. Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer's disease. *The Journal of experimental medicine*. 2015;212(3):319-32.

Takamura R, Watamura N, Nikkuni M, Ohshima T. All-trans retinoic acid improved impaired proliferation of neural stem cells and suppressed microglial activation in the hippocampus in an Alzheimer's mouse model. *Journal of neuroscience research*. 2017;95(3):897-906.

Takane K, Hasegawa Y, Lin B, Koibuchi N, Cao C, Yokoo T, et al. Detrimental Effects of Centrally Administered Angiotensin II are Enhanced in a Mouse Model of Alzheimer Disease Independently of Blood Pressure. *Journal of the American Heart Association*. 2017;6(4).

Takeda A, Tamano H, Tempaku M, Sasaki M, Uematsu C, Sato S, et al. Extracellular Zn²⁺ Is Essential for Amyloid beta1-42-Induced Cognitive Decline in the Normal Brain and Its Rescue. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(30):7253-62.

Takeda S, Morishita R. Angiotensin Receptor Blocker Protects Alzheimer's Disease Brain From Ischemic Insult. *American journal of hypertension*. 2017;30(2):110-1.

Takeshita Y, Hashimoto Y, Nawa M, Uchino H, Matsuoka M. SH3-binding protein 5 mediates the neuroprotective effect of the secreted bioactive peptide humanin by inhibiting c-Jun NH2-terminal kinase. *The Journal of biological chemistry*. 2013;288(34):24691-704.

Takeyoshi K, Kurita M, Nishino S, Teranishi M, Numata Y, Sato T, et al. Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function. *Neuropsychiatric disease and treatment*. 2016;12:641-9.

Tan L, Chen X, Wang W, Zhang J, Li S, Zhao Y, et al. Pharmacological inhibition of PTEN attenuates cognitive deficits caused by neonatal repeated exposures to isoflurane via inhibition of NR2B-mediated tau phosphorylation in rats. *Neuropharmacology*. 2017;114:135-45.

Tan M-S, Yu J-T, Jiang T, Zhu X-C, Guan H-S, Tan L. IL12/23 p40 inhibition ameliorates Alzheimer's disease-associated neuropathology and spatial memory in SAMP8 mice. *Journal of Alzheimer's disease : JAD*. 2014;38(3):633-46.

Tanaka K, Tajima S, Takenaka S, Yoshida K-i. An improved *Bacillus subtilis* cell factory for producing scyllo-inositol, a promising therapeutic agent for Alzheimer's disease. *Microbial cell factories*. 2013;12:124.

Tanaka K-I, Kawahara M. Copper Enhances Zinc-Induced Neurotoxicity and the Endoplasmic Reticulum Stress Response in a Neuronal Model of Vascular Dementia. *Frontiers in neuroscience*. 2017;11:58.

Tanaka N, Meguro K, Ishikawa H, Yamaguchi S. Improved functional status by comprehensive physical and psychosocial approach through right insula activation in poststroke vascular dementia. *The International journal of neuroscience*. 2013;123(10):698-704.

Tanev KS, Vento JA. Ms L: a case of a reversible phenotypic and brain function equivalent of frontotemporal dementia. *American journal of Alzheimer's disease and other dementias*. 2014;29(6):513-20.

Tang A, Eng JJ, Krassioukov AV, Tsang TSM, Liu-Ambrose T. High- and low-intensity exercise do not improve cognitive function after stroke: A randomized controlled trial. *Journal of rehabilitation medicine*. 2016;48(10):841-6.

Tang Y, Huang D, Zhang M-H, Zhang W-S, Tang Y-X, Shi Z-X, et al. Salvianolic Acid B Inhibits Abeta Generation by Modulating BACE1 Activity in SH-SY5Y-APPsw Cells. *Nutrients*. 2016;8(6).

Tanji K, Odagiri S, Miki Y, Maruyama A, Nikaido Y, Mimura J, et al. p62 Deficiency Enhances alpha-Synuclein Pathology in Mice. *Brain pathology (Zurich, Switzerland)*. 2015;25(5):552-64.

Tannenberg RK, Shamaileh HA, Lauridsen LH, Kanwar JR, Dodd PR, Veedu RN. Nucleic acid aptamers as novel class of therapeutics to mitigate Alzheimer's disease pathology. *Current Alzheimer research*. 2013;10(4):442-8.

Tao CC, Hsu WL, Ma YL, Cheng SJ, Lee EH. Epigenetic regulation of HDAC1 SUMOylation as an endogenous neuroprotection against Abeta toxicity in a mouse model of Alzheimer's disease. *Cell death and differentiation*. 2017;24(4):597-614.

Tao Y, Fang L, Yang Y, Jiang H, Yang H, Zhang H, et al. Quantitative proteomic analysis reveals the neuroprotective effects of huperzine A for amyloid beta treated neuroblastoma N2a cells. *Proteomics*. 2013;13(8):1314-24.

Tapia-Rojas C, Aranguiz F, Varela-Nallar L, Inestrosa NC. Voluntary Running Attenuates Memory Loss, Decreases Neuropathological Changes and Induces Neurogenesis in a Mouse Model of Alzheimer's Disease. *Brain pathology (Zurich, Switzerland)*. 2016;26(1):62-74.

Tarazi H, Odeh RA, Al-Qawasmeh R, Yousef IA, Voelter W, Al-Tel TH. Design, synthesis and SAR analysis of potent BACE1 inhibitors: Possible lead drug candidates for Alzheimer's disease. *European journal of medicinal chemistry*. 2017;125:1213-24.

Tariot PN, Langbaum JB, Reiman EM, Alzheimer's Prevention I. What are we willing to accept for preventing Alzheimer's disease? - Investigators' reply. *The Lancet Neurology*. 2016;15(7):660-1.

Tariot PN, Wirth Y, Graham SM, Tocco M, Fokkens J. Important error in 'systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias' by muayqil and camicioli. *Dementia and geriatric cognitive disorders extra*. 2014;4(2):122-4.

Tariq S, Barber PA. Dementia risk and prevention by targeting modifiable vascular risk factors. *Journal of neurochemistry*. 2017.

Tarrant SD, Bardach SH, Bates K, Nichols H, Towner J, Tamatha C, et al. The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. *Alzheimer disease and associated disorders*. 2017;31(2):141-5.

Tartaglione AM, Popoli P, Calamandrei G. Regenerative medicine in Huntington's disease: Strengths and weaknesses of preclinical studies. *Neuroscience and biobehavioral reviews*. 2017;77:32-47.

Tarus B, Nguyen PH, Berthoumieu O, Faller P, Doig AJ, Derreumaux P. Molecular structure of the NQTrp inhibitor with the Alzheimer Abeta1-28 monomer. *European journal of medicinal chemistry*. 2015;91:43-50.

Tashakori-Sabzevar F, Hosseinzadeh H, Motamedshariaty VS, Movassaghi AR, Mohajeri SA. Crocetin attenuates spatial learning dysfunction and hippocampal injury in a model of vascular dementia. *Current neurovascular research*. 2013;10(4):325-34.

Taswell C, Villemagne VL, Yates P, Shimada H, Leyton CE, Ballard KJ, et al. 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2015;56(10):1547-53.

Taylor CE, Abdelhadi SO, Dosoretz CG. Horseradish and radish peroxidases eaten with fish could help explain observed associations between fish consumption and protection from age-related dementia. *Medical hypotheses*. 2017;107:5-8.

Taylor DM, Moser R, Regulier E, Breuillaud L, Dixon M, Beesen AA, et al. MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(6):2313-25.

Taylor HA, Kuwana E, Wilfond BS. Protecting research subject welfare in preventive trials for autosomal dominant Alzheimer's disease. *The American journal of bioethics : AJOB*. 2015;15(4):83-4.

Taylor ME, Lasschuit DA, Lord SR, Delbaere K, Kurrle SE, Mikolaizak AS, et al. Slow gait speed is associated with executive function decline in older people with mild to moderate dementia: A one year longitudinal study. *Archives of gerontology and geriatrics*. 2017;73:148-53.

Taylor ME, Lord SR, Brodaty H, Kurrle SE, Hamilton S, Ramsay E, et al. A home-based, carer-enhanced exercise program improves balance and falls efficacy in community-dwelling older people with dementia. *International psychogeriatrics*. 2017;29(1):81-91.

Taylor N. A 2-year physical activity program for sedentary older adults does not improve cognitive functioning more than a health education program. *Journal of physiotherapy*. 2016;62(2):115; discussion

Tchalla AE, Lachal F, Cardinaud N, Saulnier I, Rialle V, Preux P-M, et al. Preventing and managing indoor falls with home-based technologies in mild and moderate Alzheimer's disease patients: pilot study in a community dwelling. *Dementia and geriatric cognitive disorders*. 2013;36(3-4):251-61.

Telerman A, Ofir R, Kashman Y, Elmann A. 3,5,4'-trihydroxy-6,7,3'-trimethoxyflavone protects against beta amyloid-induced neurotoxicity through antioxidative activity and interference with cell signaling. *BMC complementary and alternative medicine*. 2017;17(1):332.

Tell V, Hilbrich I, Holzer M, Totzke F, Schachtele C, Slynko I, et al. Drug Development of Small-Molecule Inhibitors of AD-Relevant Kinases as Novel Perspective Multitargeted Approach. *Current Alzheimer research*. 2016;13(12):1330-6.

Tello-Franco V, Lozada-Garcia MC, Soriano-Garcia M. Experimental and computational studies on the inhibition of acetylcholinesterase by curcumin and some of its derivatives. *Current computer-aided drug design*. 2013;9(2):289-98.

Telpoukhovskaia MA, Patrick BO, Rodriguez-Rodriguez C, Orvig C. Exploring the multifunctionality of thioflavin- and deferiprone-based molecules as acetylcholinesterase inhibitors for potential application in Alzheimer's disease. *Molecular bioSystems*. 2013;9(4):792-805.

Templier L, Chetouani M, Plaza M, Belot Z, Bocquet P, Chaby L. Altered identification with relative preservation of emotional prosody production in patients with Alzheimer's disease. *Geriatric et psychologie neuropsychiatrie du vieillissement*. 2015;13(1):106-15.

Teng E. People with mild cognitive impairment that improves in the shorter term remain at increased risk of future cognitive decline. *Evidence-based mental health*. 2013;16(2):34.

Teng Y, Zhang M-Q, Wang W, Liu L-T, Zhou L-M, Miao S-K, et al. Compound danshen tablet ameliorated abeta25-35-induced spatial memory impairment in mice via rescuing imbalance between cytokines and neurotrophins. *BMC complementary and alternative medicine*. 2014;14:23.

Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". *Science* (New York, NY). 2013;340(6135):924-e.

Thai NQ, Tseng N-H, Vu MT, Nguyen TT, Linh HQ, Hu C-K, et al. Discovery of DNA dyes Hoechst 34580 and 33342 as good candidates for inhibiting amyloid beta formation: in silico and in vitro study. *Journal of computer-aided molecular design*. 2016;30(8):639-50.

Thaisrivongs DA, Miller SP, Molinaro C, Chen Q, Song ZJ, Tan L, et al. Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease. *Organic letters*. 2016;18(22):5780-3.

Thakkar K, Suman S, Billa G. A drug utilization study of cognition enhancers in dementia in a tertiary care hospital in mumbai. *Journal of clinical and diagnostic research : JCDR*. 2014;8(5):HC05-8.

Thalen L, Heimann Muhlenbock K, Almkvist O, Eriksdotter M, Sundstrom E, Tallberg I-M. Do adapted vignettes improve medical decision-making capacity for individuals with Alzheimer's disease? *Scandinavian journal of psychology*. 2017;58(6):497-503.

Thangarajan S, Ramachandran S, Krishnamurthy P. Chrysin exerts neuroprotective effects against 3-Nitropropionic acid induced behavioral despair-Mitochondrial dysfunction and striatal apoptosis via upregulating Bcl-2 gene and downregulating Bax-Bad genes in male wistar rats. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2016;84:514-25.

Thavorn K, Gomes T, Camacho X, Yao Z, Juurlink D, Mamdani M. Upper gastrointestinal bleeding in elderly adults with dementia receiving cholinesterase inhibitors: a population-based cohort study. *Journal of the American Geriatrics Society*. 2014;62(2):382-4.

The Lancet N. Finding a cure for Alzheimer's disease starts with prevention. *The Lancet Neurology*. 2016;15(7):649.

The Lancet N. Pointing the way to primary prevention of dementia. *The Lancet Neurology*. 2017;16(9):677.

The Lancet N. The road map to integrated dementia prevention and care. *The Lancet Neurology*. 2013;12(9):839.

Theendakara V, Patent A, Peters Libeu CA, Philpot BD, Flores S, Descamps O, et al. Neuroprotective Sirtuin ratio reversed by ApoE4. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(45):18303-8.

Theiss S, Maetzler W, Deuschle C, Lerche H, Koch H, Dihne M. Dementia with Lewy bodies: cerebrospinal fluid suppresses neuronal network activity. *Neuroreport*. 2017;28(16):1061-5.

Then FS, Luck T, Angermeyer MC, Riedel-Heller SG. Education as protector against dementia, but what exactly do we mean by education? *Age and ageing*. 2016;45(4):523-8.

Thoma-Lurken T, Bleijlevens MHC, Lexis MAS, de Witte LP, Hamers JPH. Facilitating aging in place: A qualitative study of practical problems preventing people with dementia from living at home. *Geriatric nursing* (New York, NY). 2017.

Thomas AG, O'Driscoll CM, Bressler J, Kaufmann W, Rojas CJ, Slusher BS. Small molecule glutaminase inhibitors block glutamate release from stimulated microglia. *Biochemical and biophysical research communications*. 2014;443(1):32-6.

Thomas AG, Rojas C, Tanega C, Shen M, Simeonov A, Boxer MB, et al. Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors. *Biochemical and biophysical research communications*. 2013;438(2):243-8.

Thomas AJ, Taylor JP, McKeith I, Bamford C, Burn D, Allan L, et al. Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. *International journal of geriatric psychiatry*. 2016.

Thomas J, Thomas CJ, Radcliffe J, Itsiopoulos C. Omega-3 Fatty Acids in Early Prevention of Inflammatory Neurodegenerative Disease: A Focus on Alzheimer's Disease. *BioMed research international*. 2015;2015:172801.

Thomas KS, Baier R, Kosar C, Ogarek J, Trepman A, Mor V. Individualized Music Program is Associated with Improved Outcomes for U.S. Nursing Home Residents with Dementia. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2017;25(9):931-8.

Thomas R, Zuchowska P, Morris AWJ, Marottoli FM, Sunny S, Deaton R, et al. Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice. *Acta neuropathologica communications*. 2016;4(1):111.

Thorpe L. Re: Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease. *Canadian journal of psychiatry Revue canadienne de psychiatrie*. 2015;60(7):338.

Tian X, Liu Y, Ren G, Yin L, Liang X, Geng T, et al. Resveratrol limits diabetes-associated cognitive decline in rats by preventing oxidative stress and inflammation and modulating hippocampal structural synaptic plasticity. *Brain research*. 2016;1650:1-9.

Tian X, Zhang L, Wang J, Dai J, Shen S, Yang L, et al. The protective effect of hyperbaric oxygen and Ginkgo biloba extract on Abeta25-35-induced oxidative stress and neuronal apoptosis in rats. *Behavioural brain research*. 2013;242:1-8.

Tian Y, Zhang X, Li Y, Shoup TM, Teng X, Elmaleh DR, et al. Crown ethers attenuate aggregation of amyloid beta of Alzheimer's disease. *Chemical communications (Cambridge, England)*. 2014;50(99):15792-5.

Tian YL, Lv M, Li JJ, Xu T, Zhai HL, Zhang XY. Study on the active mechanism of beta-secretase inhibitors by molecular simulations. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*. 2015;76:138-48.

Tiernan CT, Combs B, Cox K, Morfini G, Brady ST, Counts SE, et al. Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport. *Experimental neurology*. 2016;283(Pt A):318-29.

Tietzen AC, Richards AG. A Visual Arts Education pedagogical approach for enhancing quality of life for persons with dementia (innovative practice). *Dementia (London, England)*. 2017;1471301217726612.

Timmers M, Barao S, Van Broeck B, Tesseur I, Slemmon J, De Waepenaert K, et al. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. *Journal of Alzheimer's disease : JAD*. 2017;56(4):1437-49.

Tiribuzi R, Crispoltoni L, Chiurchio V, Casella A, Montecchiani C, Del Pino AM, et al. Trans-crocetin improves amyloid-beta degradation in monocytes from Alzheimer's Disease patients. *Journal of the neurological sciences*. 2017;372:408-12.

Tiwari SK, Agarwal S, Seth B, Yadav A, Nair S, Bhatnagar P, et al. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer's disease model via canonical Wnt/beta-catenin pathway. *ACS nano*. 2014;8(1):76-103.

Tiwari SK, Seth B, Agarwal S, Yadav A, Karmakar M, Gupta SK, et al. Ethosuximide Induces Hippocampal Neurogenesis and Reverses Cognitive Deficits in an Amyloid-beta Toxin-induced Alzheimer Rat Model via the Phosphatidylinositol 3-Kinase (PI3K)/Akt/Wnt/beta-Catenin Pathway. *The Journal of biological chemistry*. 2015;290(47):28540-58.

Tiwari SS, d'Orange M, Troakes C, Shurovi BN, Engmann O, Noble W, et al. Evidence that the presynaptic vesicle protein CSPalpha is a key player in synaptic degeneration and protection in Alzheimer's disease. *Molecular brain*. 2015;8:6.

Tjia J, Lemay CA, Bonner A, Compher C, Paice K, Field T, et al. Informed Family Member Involvement to Improve the Quality of Dementia Care in Nursing Homes. *Journal of the American Geriatrics Society*. 2017;65(1):59-65.

Tjong E, McHugh W, Peng Y-Y. Reversible dementia: subclinical seizure in early-onset dementia. *Clinical case reports*. 2017;5(3):321-7.

Toba J, Nikkuni M, Ishizeki M, Yoshii A, Watamura N, Inoue T, et al. PPARgamma agonist pioglitazone improves cerebellar dysfunction at pre-Abeta deposition stage in APPswe/PS1dE9 Alzheimer's disease model mice. *Biochemical and biophysical research communications*. 2016;473(4):1039-44.

Toba K, Nakamura Y, Endo H, Okochi J, Tanaka Y, Inaniwa C, et al. Intensive rehabilitation for dementia improved cognitive function and reduced behavioral disturbance in geriatric health service facilities in Japan. *Geriatrics & gerontology international*. 2014;14(1):206-11.

Toepper M, Beblo T, Beckmann N, Gebhardt H, Thomas C, Driessen M, et al. The block suppression test uncovers specific inhibitory deficits in mild cognitive impairment. *International journal of geriatric psychiatry*. 2013;28(7):769-70.

Toglia P, Ullah G. The gain-of-function enhancement of IP3-receptor channel gating by familial Alzheimer's disease-linked presenilin mutants increases the open probability of mitochondrial permeability transition pore. *Cell calcium*. 2016;60(1):13-24.

Tohda C, Lee Y-A, Goto Y, Nemere I. Diosgenin-induced cognitive enhancement in normal mice is mediated by 1,25D α ,f-MARRS. *Scientific reports*. 2013;3:3395.

Tohda C, Watari H. Kamikihito improves memory dysfunction in Alzheimer's disease. *Nihon yakurigaku zasshi Folia pharmacologica Japonica*. 2015;145(5):224-8.

Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease. *Acta neuropathologica*. 2013;126(5):683-97.

Toledo-Sherman LM, Prime ME, Mrzljak L, Beconi MG, Beresford A, Brookfield FA, et al. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease. *Journal of medicinal chemistry*. 2015;58(3):1159-83.

Tolhurst E, Weicht B. Preserving personhood: The strategies of men negotiating the experience of dementia. *Journal of aging studies*. 2017;40:29-35.

Tolson D, Holmerova I, Macrae R, Waugh A, Hvalic-Touzery S, de Abreu W, et al. Improving Advanced Dementia Care: An Interprofessional Palliative Learning Framework. *Journal of the American Medical Directors Association*. 2017;18(7):561-3.

Tomita T. BACE1 inhibitors for the treatment of Alzheimer disease. *Nihon rinsho Japanese journal of clinical medicine*. 2016;74(3):427-31.

Tommonaro G, Garcia-Font N, Vitale RM, Pejin B, Iodice C, Canadas S, et al. Avarol derivatives as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer's disease. *European journal of medicinal chemistry*. 2016;122:326-38.

Tomycz ND. The proposed use of cervical spinal cord stimulation for the treatment and prevention of cognitive decline in dementias and neurodegenerative disorders. *Medical hypotheses*. 2016;96:83-6.

Tonelli M, Catto M, Tasso B, Novelli F, Canu C, Iusco G, et al. Multitarget Therapeutic Leads for Alzheimer's Disease: Quinolizidinyl Derivatives of Bi- and Tricyclic Systems as Dual Inhibitors of Cholinesterases and beta-Amyloid (A β) Aggregation. *ChemMedChem*. 2015;10(6):1040-53.

Tong G, Wang J-S, Sverdllov O, Huang S-P, Slemmon R, Croop R, et al. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the gamma-secretase inhibitor avagacestat. *British journal of clinical pharmacology*. 2013;75(1):136-45.

Tong LM, Djukic B, Arnold C, Gillespie AK, Yoon SY, Wang MM, et al. Inhibitory interneuron progenitor transplantation restores normal learning and memory in ApoE4 knock-in mice without or with A β accumulation. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(29):9506-15.

Tong M, Dominguez C, Didsbury J, de la Monte SM. Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. *Journal of Alzheimer's disease & Parkinsonism*. 2016;6(3).

Tordoff JM, Ailabouni NJ, Browne DP, Al-Sallami HS, Gray AR. Improvements in the prescribing of antipsychotics in dementia and psychogeriatric units in New Zealand. *International journal of clinical pharmacy*. 2016;38(4):941-9.

Torika N, Asraf K, Cohen H, Fleisher-Berkovich S. Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer's disease mice. *Brain, behavior, and immunity*. 2017;64:80-90.

Torika N, Asraf K, Roasso E, Danon A, Fleisher-Berkovich S. Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease. *Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology*. 2016;11(4):774-85.

Torjesen I. Proton pump inhibitor use does not raise dementia and Alzheimer's risk, study suggests. *BMJ (Clinical research ed)*. 2017;357:j3063.

Torres-Lista V, Lopez-Pousa S, Gimenez-Llort L. Marble-burying is enhanced in 3xTg-AD mice, can be reversed by risperidone and it is modulable by handling. *Behavioural processes*. 2015;116:69-74.

Tortosa MA, Granell R, Fuenmayor A, Martinez M. Effects of a physical restraint removal program on older people with dementia in residential care. *Revista espanola de geriatria y gerontologia*. 2016;51(1):5-10.

Torvinen-Kiiskinen S, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S. Concomitant use of acetylcholine esterase inhibitors and urinary antispasmodics among Finnish community-dwelling persons with Alzheimer disease. *Journal of clinical psychopharmacology*. 2014;34(6):722-7.

Toth ME, Szegedi V, Varga E, Juhasz G, Horvath J, Borbely E, et al. Overexpression of Hsp27 ameliorates symptoms of Alzheimer's disease in APP/PS1 mice. *Cell stress & chaperones*. 2013;18(6):759-71.

Toth P, Tarantini S, Tucsek Z, Ashpole NM, Sosnowska D, Gautam T, et al. Resveratrol treatment rescues neurovascular coupling in aged mice: role of improved cerebrovascular endothelial function and downregulation of NADPH oxidase. *American journal of physiology Heart and circulatory physiology*. 2014;306(3):H299-308.

Touchon J, Lachaine J, Beauchemin C, Granghaud A, Rive B, Bineau S. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. *The European journal of health economics : HEPAC : health economics in prevention and care*. 2014;15(8):791-800.

Toye C, Jiwa M, Holloway K, Horner BJ, Andrews S, McInerney F, et al. Can a community of practice enhance a palliative approach for people drawing close to death with dementia? *International journal of palliative nursing*. 2015;21(11):548-56.

Trager U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, et al. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFkappaB pathway dysregulation. *Brain : a journal of neurology*. 2014;137(Pt 3):819-33.

Tran P-T, Hoang V-H, Thorat SA, Kim SE, Ann J, Chang YJ, et al. Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template. *Bioorganic & medicinal chemistry*. 2013;21(13):3821-30.

Tranvag O, Petersen KA, Naden D. Dignity-preserving dementia care: a metasynthesis. *Nursing ethics*. 2013;20(8):861-80.

Tranvag O, Petersen KA, Naden D. Relational interactions preserving dignity experience: Perceptions of persons living with dementia. *Nursing ethics*. 2015;22(5):577-93.

Trebbastoni A, Marcelli M, Mallone F, D'Antonio F, Imbriano L, Campanelli A, et al. Attenuation of Choroidal Thickness in Patients With Alzheimer Disease: Evidence From an Italian Prospective Study. *Alzheimer disease and associated disorders*. 2017;31(2):128-34.

Trebbastoni A, Raccah R, de Lena C, Zangen A, Inghilleri M. Repetitive deep transcranial magnetic stimulation improves verbal fluency and written language in a patient with primary progressive aphasia-logopenic variant (LPPA). *Brain stimulation*. 2013;6(4):545-53.

Trechot P, Schmutz JL. Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor. *Annales de dermatologie et de venerologie*. 2013;140(10):669-70.

Triana-Vidal LE, Carvajal-Varona SM. Protective effect of galantamine against oxidative damage using human lymphocytes: a novel in vitro model. *Archives of medical research*. 2013;44(2):85-92.

Tricco AC, Ashoor HM, Soobiah C, Rios P, Veroniki AA, Hamid JS, et al. Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis. *Journal of the American Geriatrics Society*. 2017.

Tricco AC, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2013;185(16):1393-401.

Tropak MB, Zhang J, Yonekawa S, Rigat BA, Aulakh VS, Smith MR, et al. Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant beta-N-acetylhexosaminidase Activity. *Journal of medicinal chemistry*. 2015;58(11):4483-93.

Trossman S. The innovative edge. Nurses work to reduce readmissions, improve at-home Alzheimer's care. *The American nurse*. 2014;46(6):1, 6.

Trueland J. Admirals to the rescue. Nursing standard (Royal College of Nursing (Great Britain) : 1987). 2013;28(2):22-3.

Trueland J. Outdoor spaces improve dementia care. Nursing standard (Royal College of Nursing (Great Britain) : 1987). 2017;32(2):24-6.

Trujillo-Estrada L, Jimenez S, De Castro V, Torres M, Baglietto-Vargas D, Moreno-Gonzalez I, et al. In vivo modification of Abeta plaque toxicity as a novel neuroprotective lithium-mediated therapy for Alzheimer's disease pathology. *Acta neuropathologica communications*. 2013;1:73.

Trushina E, Canaria CA, Lee D-Y, McMurray CT. Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo. *Human molecular genetics*. 2014;23(1):129-44.

Tsai C-H, Huang H-C, Liu B-L, Li C-I, Lu M-K, Chen X, et al. Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia. *Psychiatry and clinical neurosciences*. 2014;68(9):692-700.

Tsai L-H, Madabhushi R. Alzheimer's disease: A protective factor for the ageing brain. *Nature*. 2014;507(7493):439-40.

Tsai P-H, Chang S-C, Liu F-C, Tsao J, Wang Y-H, Lo M-T. A Novel Application of Multiscale Entropy in Electroencephalography to Predict the Efficacy of Acetylcholinesterase Inhibitor in Alzheimer's Disease. *Computational and mathematical methods in medicine*. 2015;2015:953868.

Tsai-Teng T, Chin-Chu C, Li-Ya L, Wan-Ping C, Chung-Kuang L, Chien-Chang S, et al. Erinacine A-enriched *Hericium erinaceus* mycelium ameliorates Alzheimer's disease-related pathologies in APP^{swe}/PS1^{dE9} transgenic mice. *Journal of biomedical science*. 2016;23(1):49.

Tseng BY, Cullum CM, Zhang R. Older adults with amnesic mild cognitive impairment exhibit exacerbated gait slowing under dual-task challenges. *Current Alzheimer research*. 2014;11(5):494-500.

Tsvetkov PO, Cheglakov IB, Ovsepyan AA, Mediannikov OY, Morozov AO, Telegin GB, et al. Peripherally Applied Synthetic Tetrapeptides HAEE and RADD Slow Down the Development of Cerebral beta-Amyloidosis in AbetaPP/PS1 Transgenic Mice. *Journal of Alzheimer's disease : JAD*. 2015;46(4):849-53.

Tucker S, Sutcliffe C, Bowns I, Challis D, Saks K, Verbeek H, et al. Improving the mix of institutional and community care for older people with dementia: an application of the balance of care approach in eight European countries. *Aging & mental health*. 2016;20(12):1327-38.

Tundis R, Bonesi M, Menichini F, Loizzo MR. Recent Knowledge on Medicinal Plants as Source of Cholinesterase Inhibitors for the Treatment of Dementia. *Mini reviews in medicinal chemistry*. 2016;16(8):605-18.

Tung BT, Hai NT, Thu DK. Antioxidant and acetylcholinesterase inhibitory activities in vitro of different fraction of *Huperzia squarrosa* (Forst.) Trevis extract and attenuation of scopolamine-induced cognitive impairment in mice. *Journal of ethnopharmacology*. 2017;198:24-32.

Turewicz M, May C, Ahrens M, Woitalla D, Gold R, Casjens S, et al. Improving the default data analysis workflow for large autoimmune biomarker discovery studies with ProtoArrays. *Proteomics*. 2013;13(14):2083-7.

Turgut NH, Kara H, Arslanbas E, Mert DG, Tepe B, Gungor H. Effect of *Capparis spinosa* L. on cognitive impairment induced by D-galactose in mice via inhibition of oxidative stress. *Turkish journal of medical sciences*. 2015;45(5):1127-36.

Tuven B, Soysal P, Unutmaz G, Kaya D, Isik AT. Uric acid may be protective against cognitive impairment in older adults, but only in those without cardiovascular risk factors. *Experimental gerontology*. 2017;89:15-9.

Tweedie D, Fukui K, Li Y, Yu Q-S, Barak S, Tamargo IA, et al. Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms. *PloS one*. 2016;11(6):e0156493.

Tweedie D, Rachmany L, Rubovitch V, Lehrmann E, Zhang Y, Becker KG, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. *Experimental neurology*. 2013;239:170-82.

Tzanoulinou S, Brandi R, Arisi I, D'Onofrio M, Urfer SM, Sandi C, et al. Pathogen-free husbandry conditions alleviate behavioral deficits and neurodegeneration in AD10 anti-NGF mice. *Journal of Alzheimer's disease : JAD*. 2014;38(4):951-64.

Tzeng H-M, Yin C-Y. Frequently observed risk factors for fall-related injuries and effective preventive interventions: a multihospital survey of nurses' perceptions. *Journal of nursing care quality*. 2013;28(2):130-8.

Ubhi K, Rockenstein E, Vazquez-Roque R, Mante M, Inglis C, Patrick C, et al. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease. *Journal of neuroscience research*. 2013;91(2):167-77.

Uchida N, Takasaki K, Sakata Y, Nogami A, Oishi H, Watanabe T, et al. Cholinergic involvement and synaptic dynamin 1 expression in Yokukansan-mediated improvement of spatial memory in a rat model of early Alzheimer's disease. *Phytotherapy research : PTR*. 2013;27(7):966-72.

Uddin MS, Mamun AA, Hossain MS, Akter F, Iqbal MA, Asaduzzaman M. Exploring the Effect of *Phyllanthus emblica* L. on Cognitive Performance, Brain Antioxidant Markers and Acetylcholinesterase Activity in Rats: Promising Natural Gift for the Mitigation of Alzheimer's Disease. *Annals of neurosciences*. 2016;23(4):218-29.

Ueberschaer H, Allescher H-D. Proton pump inhibitor - side effects and complications of long-term proton pump inhibitor administration. *Zeitschrift fur Gastroenterologie*. 2017;55(1):63-74.

Ueckert S, Plan EL, Ito K, Karlsson MO, Corrigan B, Hooker AC, et al. Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling. *Pharmaceutical research*. 2014;31(8):2152-65.

Uekawa K, Hasegawa Y, Senju S, Nakagata N, Ma M, Nakagawa T, et al. Intracerebroventricular Infusion of Angiotensin-(1-7) Ameliorates Cognitive Impairment and Memory Dysfunction in a Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;53(1):127-33.

Ueno M. Elucidation of mechanism of blood-brain barrier damage for prevention and treatment of vascular dementia. *Rinsho shinkeigaku = Clinical neurology*. 2017;57(3):95-109.

Ugolev Y, Segal T, Yaffe D, Gros Y, Schuldiner S. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine. *The Journal of biological chemistry*. 2013;288(45):32160-71.

Ugolino J, Ji YJ, Conchina K, Chu J, Nirujogi RS, Pandey A, et al. Loss of C9orf72 Enhances Autophagic Activity via Deregulated mTOR and TFEB Signaling. *PLoS genetics*. 2016;12(11):e1006443.

Uguz AC, Oz A, Naziroglu M. Curcumin inhibits apoptosis by regulating intracellular calcium release, reactive oxygen species and mitochondrial depolarization levels in SH-SY5Y neuronal cells. *Journal of receptor and signal transduction research*. 2016;36(4):395-401.

Umeda T, Ono K, Sakai A, Yamashita M, Mizuguchi M, Klein WL, et al. Rifampicin is a candidate preventive medicine against amyloid-beta and tau oligomers. *Brain : a journal of neurology*. 2016;139(Pt 5):1568-86.

Umegaki H. Dementia: type 2 diabetes has a slow and insidious effect on cognition. *Nature reviews Neurology*. 2015;11(3):127-8.

Unno K, Konishi T. Preventive Effect of Soybean on Brain Aging and Amyloid-beta Accumulation: Comprehensive Analysis of Brain Gene Expression. *Recent patents on food, nutrition & agriculture*. 2015;7(2):83-91.

Urakami K. Early detection and prevention of dementia. *Nihon rinsho Japanese journal of clinical medicine*. 2014;72(4):607-11.

Urakami K. Prevention of dementia. *Nihon rinsho Japanese journal of clinical medicine*. 2016;74(3):395-8.

Uribe-Arias A, Posada-Duque RA, Gonzalez-Billault C, Villegas A, Lopera F, Cardona-Gomez GP. p120-catenin is necessary for neuroprotection induced by CDK5 silencing in models of Alzheimer's disease. *Journal of neurochemistry*. 2016;138(4):624-39.

Uslaner JM, Eddins D, Puri V, Cannon CE, Sutcliffe J, Chew CS, et al. The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque. *Psychopharmacology*. 2013;225(1):21-30.

Utkan T, Yazir Y, Karson A, Bayramgurler D. Etanercept improves cognitive performance and increases eNOS and BDNF expression during experimental vascular dementia in streptozotocin-induced diabetes. *Current neurovascular research*. 2015;12(2):135-46.

Uzarski D, Burke J, Turner B, Vroom J, Short N. A Plan for Academic Biobank Solvency-Leveraging Resources and Applying Business Processes to Improve Sustainability. *Clinical and translational science*. 2015;8(5):553-7.

Valasani KR, Hu G, Chaney MO, Yan SS. Structure-based design and synthesis of benzothiazole phosphonate analogues with inhibitors of human ABAD-Abeta for treatment of Alzheimer's disease. *Chemical biology & drug design*. 2013;81(2):238-49.

Valasani KR, Vangavaragu JR, Day VW, Yan SS. Structure based design, synthesis, pharmacophore modeling, virtual screening, and molecular docking studies for identification of novel cyclophilin D inhibitors. *Journal of chemical information and modeling*. 2014;54(3):902-12.

Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Munoz E, Sagredo O. Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*. 2015;12(1):185-99.

Valenza M, Chen JY, Di Paolo E, Ruozi B, Belletti D, Ferrari Bardile C, et al. Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice. *EMBO molecular medicine*. 2015;7(12):1547-64.

Valor LM. Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspective. *Molecular neurobiology*. 2015;51(1):406-23.

van Blitterswijk M, Mullen B, Nicholson AM, Bieniek KF, Heckman MG, Baker MC, et al. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. *Acta neuropathologica*. 2014;127(3):397-406.

van Dalen JW, Moll van Charante EP, Caan MWA, Scheltens P, Majoie CBLM, Nederveen AJ, et al. Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions: Magnetic Resonance Imaging Substudy of the PreDIVA Trial (Prevention of Dementia by Intensive Vascular Care). *Stroke*. 2017;48(7):1842-8.

van der Bom IMJ, Moser RP, Gao G, Mondo E, O'Connell D, Gounis MJ, et al. Finding the striatum in sheep: use of a multi-modal guided approach for convection enhanced delivery. *Journal of Huntington's disease*. 2013;2(1):41-5.

van der Harg JM, Nolle A, Zwart R, Boerema AS, van Haastert ES, Strijkstra AM, et al. The unfolded protein response mediates reversible tau phosphorylation induced by metabolic stress. *Cell death & disease*. 2014;5:e1393.

van der Maaden T, de Vet HCW, Achterberg WP, Boersma F, Schols JMGA, Mehr DR, et al. Improving comfort in people with dementia and pneumonia: a cluster randomized trial. *BMC medicine*. 2016;14(1):116.

van der Plas E, Schachar RJ, Hitzler J, Crosbie J, Guger SL, Spiegler BJ, et al. Brain structure, working memory and response inhibition in childhood leukemia survivors. *Brain and behavior*. 2017;7(2):e00621.

van der Steen JT, van Soest-Poortvliet MC, Gijsberts M-JHE, Onwuteaka-Philipsen BD, Achterberg WP, Ribbe MW, et al. Improved end-of-life care for patients with dementia: greater family satisfaction and possibly greater end-of-life comfort. *Nederlands tijdschrift voor geneeskunde*. 2013;157(17):A5324.

Van der Walt MM, Terre'Blanche G, Petzer A, Petzer JP. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues. *Bioorganic chemistry*. 2015;59:117-23.

van Duinen-van den Ijssel JCL, Appelhof B, Zwijsen SA, Smalbrugge M, Verhey FRJ, de Vugt ME, et al. Behavior and Evolution of Young ONset Dementia part 2 (BEYOND-II) study: an intervention study aimed at improvement in the management of neuropsychiatric symptoms in institutionalized people with young onset dementia. *International psychogeriatrics*. 2017:1-10.

van Gijssel-Bonnello M, Baranger K, Benech P, Rivera S, Khrestchatisky M, de Reggi M, et al. Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer's disease: Alleviation by pantethine. *PloS one*. 2017;12(4):e0175369.

van Greunen DG, Cordier W, Nell M, van der Westhuyzen C, Steenkamp V, Panayides J-L, et al. Targeting Alzheimer's disease by investigating previously unexplored chemical space surrounding the cholinesterase inhibitor donepezil. *European journal of medicinal chemistry*. 2017;127:671-90.

van Groen T, Kadish I, Funke SA, Bartnik D, Willbold D. Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged AbetaPP/PS1 double transgenic mice. *Journal of Alzheimer's disease : JAD*. 2013;34(3):609-20.

Van Mierlo LD, Bootsma-Van der Wiel A, Meiland FJM, Van Hout HPJ, Stek ML, Droes RM. Tailored mental health care after nursing home admission: improving transfers of people with dementia with behavioral problems. An explorative study. *Aging & mental health*. 2015;19(10):902-11.

Van Poeck I, Ahmad R, Van Laere K, Vandenbulcke M. Reversible parietal hypometabolism in late-onset psychosis. *The Journal of neuropsychiatry and clinical neurosciences*. 2013;25(2):E32-3.

van Waalwijk van Doorn LJC, Gispert JD, Kuiperij HB, Claassen JAHR, Arighi A, Baldeiras I, et al. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. *Journal of Alzheimer's disease : JAD*. 2017;56(2):543-55.

Vandal M, Calon F. Response to Comment on Vandal et al. Insulin Reverses the High-Fat Diet-Induced Increase in Brain Abeta and Improves Memory in an Animal Model of Alzheimer Disease. *Diabetes* 2014;63:4291-4301. *Diabetes*. 2015;64(7):e18.

Vandal M, White PJ, Tremblay C, St-Amour I, Chevrier G, Emond V, et al. Insulin reverses the high-fat diet-induced increase in brain Abeta and improves memory in an animal model of Alzheimer disease. *Diabetes*. 2014;63(12):4291-301.

Vaney C. Restore the connection...between physician and patient as well. *Revue medicale suisse*. 2015;11(459):233-4.

Vangavaragu JR, Valasani KR, Fang D, Williams TD, Yan SS. Determination of small molecule ABAD inhibitors crossing blood-brain barrier and pharmacokinetics. *Journal of Alzheimer's disease : JAD*. 2014;42(1):333-44.

VanItallie TB. Biomarkers, ketone bodies, and the prevention of Alzheimer's disease. *Metabolism: clinical and experimental*. 2015;64(3 Suppl 1):S51-7.

Vanitallie TB. Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention. *Metabolism: clinical and experimental*. 2013;62 Suppl 1:S30-3.

Varanese S, Perfetti B, Gilbert-Wolf R, Thomas A, Onofri M, Di Rocco A. Modafinil and armodafinil improve attention and global mental status in Lewy bodies disorders: preliminary evidence. *International journal of geriatric psychiatry*. 2013;28(10):1095-7.

Vardigan JD, Cannon CE, Puri V, Dancho M, Koser A, Wittmann M, et al. Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. *Psychopharmacology*. 2015;232(11):1859-66.

Varga AW, Wohlleber ME, Gimenez S, Romero S, Alonso JF, Ducca EL, et al. Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid Abeta42 Levels in Cognitively Normal Elderly. *Sleep*. 2016;39(11):2041-8.

Vargas JY, Fuenzalida M, Inestrosa NC. In vivo activation of Wnt signaling pathway enhances cognitive function of adult mice and reverses cognitive deficits in an Alzheimer's disease model.

The Journal of neuroscience : the official journal of the Society for Neuroscience. 2014;34(6):2191-202.

Varnum MM, Kiyota T, Ingraham KL, Ikezu S, Ikezu T. The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease. *Neurobiology of aging*. 2015;36(11):2995-3007.

Vasenina EE. Cholinesterase inhibitors in the treatment of mixed dementia. *Zhurnal nevrologii i psikiatrii imeni SS Korsakova*. 2013;113(7 Pt 2):98-103.

Vasilkova L. Impact of Treatments to Improve Cognitive Function and Quality of Life on Cancer Patients with Carcinoma of the Testes. *Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti*. 2016;29(4):267-73.

Vassallo M, Durant J, Biscay V, Lebrun-Frenay C, Dunais B, Laffon M, et al. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? *AIDS (London, England)*. 2014;28(4):493-501.

Vassallo M, Durant J, Lebrun-Frenay C, Fabre R, Tichioni M, Andersen S, et al. Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation. *HIV medicine*. 2015;16(7):431-40.

Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. *Alzheimer's research & therapy*. 2014;6(9):89.

Vazquez-Manrique RP, Farina F, Cambon K, Dolores Sequeda M, Parker AJ, Millan JM, et al. AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease. *Human molecular genetics*. 2016;25(6):1043-58.

Vedagiri A, Thangarajan S. Mitigating effect of chrysin loaded solid lipid nanoparticles against Amyloid beta25-35 induced oxidative stress in rat hippocampal region: An efficient formulation approach for Alzheimer's disease. *Neuropeptides*. 2016;58:111-25.

Veerappan K, Natarajan S, Ethiraj P, Vetrivel U, Samuel S. Inhibition of IKKbeta by celastrol and its analogues - an in silico and in vitro approach. *Pharmaceutical biology*. 2017;55(1):368-73.

Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". *Science (New York, NY)*. 2013;340(6135):924-f.

Vegh MJ, Heldring CM, Kamphuis W, Hijazi S, Timmerman AJ, Li KW, et al. Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimer's disease. *Acta neuropathologica communications*. 2014;2:76.

Velazquez R, Shaw DM, Caccamo A, Oddo S. Pim1 inhibition as a novel therapeutic strategy for Alzheimer's disease. *Molecular neurodegeneration*. 2016;11(1):52.

Veldman MB, Rios-Galdamez Y, Lu X-H, Gu X, Qin W, Li S, et al. The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington's disease model. *Molecular neurodegeneration*. 2015;10:67.

Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA. *The journal of prevention of Alzheimer's disease*. 2014;1(1):13-22.

Vellas B, Oustric S. Alzheimer's preventive approaches and cognitive monitoring must be integrated into the primary care setting. *Journal of the American Medical Directors Association*. 2014;15(11):783-5.

Vellas B. Integrating Frailty into Clinical Practice to Prevent the Risk of Dependency in the Elderly. *Nestle Nutrition Institute workshop series*. 2015;83:99-104.

Velusamy T, Panneerselvam AS, Purushottam M, Anusuyadevi M, Pal PK, Jain S, et al. Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease. *Oxidative medicine and cellular longevity*. 2017;2017:3279061.

Vemuri P, Knopman DS, Lesnick TG, Przybelski SA, Mielke MM, Graff-Radford J, et al. Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. *JAMA neurology*. 2017;74(6):718-26.

Venci JV, Eisenberg KW. Proton Pump Inhibitors and Dementia Incidence. *JAMA neurology*. 2016;73(8):1026.

Vendel E, de Lange ECM. Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier. *Neuromolecular medicine*. 2014;16(3):620-42.

Ventura I, Russo MT, De Nuccio C, De Luca G, Degan P, Bernardo A, et al. hMTH1 expression protects mitochondria from Huntington's disease-like impairment. *Neurobiology of disease*. 2013;49:148-58.

Vepsalainen S, Koivisto H, Pekkarinen E, Makinen P, Dobson G, McDougall GJ, et al. Anthocyanin-enriched bilberry and blackcurrant extracts modulate amyloid precursor protein

processing and alleviate behavioral abnormalities in the APP/PS1 mouse model of Alzheimer's disease. *The Journal of nutritional biochemistry*. 2013;24(1):360-70.

Verma A, Sharma S. Beneficial Effect of Protein Tyrosine Phosphatase Inhibitor and Phytoestrogen in Dyslipidemia-Induced Vascular Dementia in Ovariectomized Rats. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association*. 2015;24(11):2434-46.

Verma M, Beaulieu-Abdelahad D, Ait-Ghezala G, Li R, Crawford F, Mullan M, et al. Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD. *PloS one*. 2015;10(5):e0128224.

Verma M, Beaulieu-Abdelahad D, Ait-Ghezala G, Li R, Crawford F, Mullan M, et al. Correction: Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD. *PloS one*. 2015;10(7):e0134776.

Verma N, Beretvas SN, Pascual B, Masdeu JC, Markey MK, Alzheimers Disease Neuroimaging I. New scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. *Alzheimer's research & therapy*. 2015;7(1):64.

Veroniki AA, Straus SE, Ashoor HM, Hamid JS, Hemmelgarn BR, Holroyd-Leduc J, et al. Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: protocol for a systematic review and individual patient data network meta-analysis. *BMJ open*. 2016;6(1):e010251.

Verreault R, Arcand M, Misson L, Durand PJ, Kroger E, Aubin M, et al. Quasi-experimental evaluation of a multifaceted intervention to improve quality of end-of-life care and quality of dying for patients with advanced dementia in long-term care institutions. *Palliative medicine*. 2017;269216317719588.

Verret L, Krezymon A, Halley H, Trouche S, Zerwas M, Lazouret M, et al. Transient enriched housing before amyloidosis onset sustains cognitive improvement in Tg2576 mice. *Neurobiology of aging*. 2013;34(1):211-25.

Vezenkov LT, Ilieva L, Danalev DL, Bakalova A, Vassilev DN, Danchev N, et al. Synthesis of New Peptide Derivatives of Galanthamine Designed for Prevention and Treatment of Alzheimer's Disease. *Protein and peptide letters*. 2015;22(10):913-22.

Viayna E, Sabate R, Munoz-Torrero D. Dual inhibitors of beta-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates. *Current topics in medicinal chemistry*. 2013;13(15):1820-42.

Vidal EIO, Fukushima FB, Valle AP, Villas Boas PJF. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia. *Journal of the American Geriatrics Society*. 2013;61(1):170-2.

Videira R, Castanheira P, Graos M, Resende R, Salgueiro L, Faro C, et al. Dose-dependent inhibition of BACE-1 by the monoterpenoid 2,3,4,4-tetramethyl-5-methylenecyclopent-2-enone in cellular and mouse models of Alzheimer's disease. *Journal of natural products*. 2014;77(6):1275-9.

Video-Based Coping Skills to Reduce Health Risk and Improve Psychological and Physical Well-Being in Alzheimer's Disease Family Caregivers: Erratum. *Psychosomatic medicine*. 2016;78(7):886.

Viemont I, Pariel S. Therapeutic education for carers, an innovative concept to prevent burnout. *Revue de l'infirmiere*. 2017;66(227):30-1.

Vigliotti AA, Chinchilli VM, George DR. Enhancing Quality of Life and Caregiver Interactions for Persons with Dementia Using TimeSlips Group Storytelling: A 6-Month Longitudinal Study. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2017.

Vignini A, Morganti S, Salvolini E, Sartini D, Luzzi S, Fiorini R, et al. Amyloid precursor protein expression is enhanced in human platelets from subjects with Alzheimer's disease and frontotemporal lobar degeneration: a real-time PCR study. *Experimental gerontology*. 2013;48(12):1505-8.

Vila-Real H, Coelho H, Rocha J, Fernandes A, Ventura MR, Maycock CD, et al. Peptidomimetic beta-Secretase Inhibitors Comprising a Sequence of Amyloid-beta Peptide for Alzheimer's Disease. *Journal of medicinal chemistry*. 2015;58(14):5408-18.

Vilibic M, Jukic V, Vidovic A, Brecic P. Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report. *Collegium antropologicum*. 2013;37(1):317-9.

Villmow M, Baumann M, Malesevic M, Sachs R, Hause G, Fandrich M, et al. Inhibition of Abeta(1-40) fibril formation by cyclophilins. *The Biochemical journal*. 2016;473(10):1355-68.

Viola S, Viola P, Buongarzone MP, Fiorelli L, Mattucci F, Litterio P. New brain reperfusion rehabilitation therapy improves cognitive impairment in mild Alzheimer's disease: a prospective, controlled, open-label 12-month study with NIRS correlates. *Aging clinical and experimental research*. 2014;26(4):417-25.

Vivar C. Adult Hippocampal Neurogenesis, Aging and Neurodegenerative Diseases: Possible Strategies to Prevent Cognitive Impairment. *Current topics in medicinal chemistry*. 2015;15(21):2175-92.

Vladimir-Knezevic S, Blazekovic B, Kindl M, Vladic J, Lower-Nedza AD, Brantner AH. Acetylcholinesterase inhibitory, antioxidant and phytochemical properties of selected medicinal plants of the Lamiaceae family. *Molecules (Basel, Switzerland)*. 2014;19(1):767-82.

Vo TM, Perry P, Ellerby M, Bohnert K. Is lithium a neuroprotective agent? *Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists*. 2015;27(1):49-54.

Volland J, Fisher A, Drexler D. Delirium and Dementia in the Intensive Care Unit: Increasing Awareness for Decreasing Risk, Improving Outcomes, and Family Engagement. *Dimensions of critical care nursing : DCCN*. 2015;34(5):259-64.

Volmar C-H, Salah-Uddin H, Janczura KJ, Halley P, Lambert G, Wodrich A, et al. M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory. *Proceedings of the National Academy of Sciences of the United States of America*. 2017;114(43):E9135-E44.

Volpe R, Sotis G, Cianciabella M. Is it always Alzheimer's? Let's talk to our patients about "cardiocerebrovascular" prevention. *Aging clinical and experimental research*. 2016;28(1):159-60.

Volpe SL. Magnesium in disease prevention and overall health. *Advances in nutrition (Bethesda, Md)*. 2013;4(3):378S-83S.

Volpina OM, Korojev DO, Volkova TD, Kamynina AV, Filatova MP, Zaporozhskaya YV, et al. Fragment of Receptor for Advanced Glycation End Products Improves Memory State in a Model of Alzheimer's Disease. *Bioorganicheskaya khimiya*. 2015;41(6):709-16.

Volpina OM, Medvinskaya NI, Kamynina AV, Zaporozhskaya IV, Aleksandrova II, Korojev DO, et al. Immunization with a synthetic fragment 155-164 of neurotrophin receptor p75 prevents memory loss and decreases beta-amyloid level in mice with experimentally induced Alzheimer's disease. *Bioorganicheskaya khimiya*. 2014;40(4):451-7.

Volpina OM, Volkova TD, Medvinskaya NI, Kamynina AV, Zaporozhskaya YV, Aleksandrova II, et al. Protective Activity of Prion Protein Fragments after Immunization of Animals with Experimentally Induced Alzheimer's Disease. *Bioorganicheskaya khimiya*. 2015;41(2):145-53.

Vorobyov V, Kaptsov V, Gordon R, Makarova E, Podolski I, Sengpiel F. Neuroprotective effects of hydrated fullerene C60: cortical and hippocampal EEG interplay in an amyloid-infused rat model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2015;45(1):217-33.

Vossel KA, Xu JC, Fomenko V, Miyamoto T, Suberbielle E, Knox JA, et al. Tau reduction prevents Abeta-induced axonal transport deficits by blocking activation of GSK3beta. *The Journal of cell biology*. 2015;209(3):419-33.

Voytyuk I, De Strooper B, Chavez-Gutierrez L. Modulation of gamma- and beta-Secretases as Early Prevention Against Alzheimer's Disease. *Biological psychiatry*. 2017.

Vyas NA, Bhat SS, Kumbhar AS, Sonawane UB, Jani V, Joshi RR, et al. Ruthenium(II) polypyridyl complex as inhibitor of acetylcholinesterase and Abeta aggregation. *European journal of medicinal chemistry*. 2014;75:375-81.

Wade L, Forlini C, Racine E. Generating genius: how an Alzheimer's drug became considered a 'cognitive enhancer' for healthy individuals. *BMC medical ethics*. 2014;15:37.

Wagle KC, Rowan PJ, Poon O-YI, Kunik ME, Taffet GE, Braun UK. Initiation of cholinesterase inhibitors in an inpatient setting. *American journal of Alzheimer's disease and other dementias*. 2013;28(4):377-83.

Wagner LK, Gilling KE, Schormann E, Kloetzel PM, Heppner FL, Kruger E, et al. Immunoproteasome deficiency alters microglial cytokine response and improves cognitive deficits in Alzheimer's disease-like APPPS1 mice. *Acta neuropathologica communications*. 2017;5(1):52.

Wahlund L-O, Westman E, Van Westen D, Wallin A, Cavallin L, Larsson E-M. Structural brain imaging may improve diagnostics in dementia. *Lakartidningen*. 2013;110(47):2116-8.

Waldum HL, Martinsen TC. Proton Pump Inhibitors and Dementia Incidence. *JAMA neurology*. 2016;73(8):1026.

Walker DG, Whetzel AM, Lue LF. Expression of suppressor of cytokine signaling genes in human elderly and Alzheimer's disease brains and human microglia. *Neuroscience*. 2015;302:121-37.

Walker JM, Dixit S, Saulsberry AC, May JM, Harrison FE. Reversal of high fat diet-induced obesity improves glucose tolerance, inflammatory response, beta-amyloid accumulation and cognitive decline in the APP/PSEN1 mouse model of Alzheimer's disease. *Neurobiology of disease*. 2017;100:87-98.

Walker MP, LaFerla FM, Oddo SS, Brewer GJ. Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease. *Age (Dordrecht, Netherlands)*. 2013;35(3):519-31.

Walker VM, Davies NM, Jones T, Kehoe PG, Martin RM. Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer's and other neurodegenerative diseases?

Protocol for an observational cohort study in the UK Clinical Practice Research Datalink. *BMJ open*. 2016;6(12):e012044.

Walsh KA, O'Riordan D, Kearney PM, Timmons S, Byrne S. Improving the appropriateness of prescribing in older patients: a systematic review and meta-analysis of pharmacists' interventions in secondary care. *Age and ageing*. 2016;45(2):201-9.

Walter C, Clemens LE, Muller AJ, Fallier-Becker P, Proikas-Cezanne T, Riess O, et al. Activation of AMPK-induced autophagy ameliorates Huntington disease pathology invitro. *Neuropharmacology*. 2016;108:24-38.

Wan L, Cheng Y, Luo Z, Guo H, Zhao W, Gu Q, et al. Neuroprotection, learning and memory improvement of a standardized extract from Renshen Shouwu against neuronal injury and vascular dementia in rats with brain ischemia. *Journal of ethnopharmacology*. 2015;165:118-26.

Wan W, Zhang C, Danielsen M, Li Q, Chen W, Chan Y, et al. EGb761 improves cognitive function and regulates inflammatory responses in the APP/PS1 mouse. *Experimental gerontology*. 2016;81:92-100.

Wan Z, Mah D, Simtchouk S, Kluftinger A, Little JP. Human adipose tissue conditioned media from lean subjects is protective against H₂O₂ induced neurotoxicity in human SH-SY5Y neuronal cells. *International journal of molecular sciences*. 2015;16(1):1221-31.

Wang B, Liu Y, Huang L, Chen J, Li JJ, Wang R, et al. A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer's mouse model via an HSF1-mediated mechanism. *Molecular psychiatry*. 2017;22(7):990-1001.

Wang B, Wang Z, Chen H, Lu C-J, Li X. Synthesis and evaluation of 8-hydroxyquinolin derivatives substituted with (benzo d 1,2 selenazol-3(2H)-one) as effective inhibitor of metal-induced Abeta aggregation and antioxidant. *Bioorganic & medicinal chemistry*. 2016;24(19):4741-9.

Wang C, Chen T, Li G, Zhou L, Sha S, Chen L. Simvastatin prevents beta-amyloid(25-35)-impaired neurogenesis in hippocampal dentate gyrus through alpha7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate. *Neuropharmacology*. 2015;97:122-32.

Wang C, Xiao Y, Yang B, Wang Z, Wu L, Su X, et al. Isolation and screened neuroprotective active constituents from the roots and rhizomes of *Valeriana amurensis*. *Fitoterapia*. 2014;96:48-55.

Wang CH, Lin YF, Lee CK. *Rhodiola rosea*, a potential Chinese herbal medicine prevents Alzheimer's disease. *Planta medica*. 2016;81(S 01):S1-S381.

Wang CH, Wang LS, Zhu N. Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer's disease therapies: an updated umbrella review of systematic reviews and meta-analyses. *European review for medical and pharmacological sciences*. 2016;20(22):4801-17.

Wang C-J, Chen C-C, Tsay H-J, Chiang F-Y, Wu M-F, Shiao Y-J. *Cudrania cochinchinensis* attenuates amyloid beta protein-mediated microglial activation and promotes glia-related clearance of amyloid beta protein. *Journal of biomedical science*. 2013;20:55.

Wang C-L, Kuo L-M, Chiu Y-C, Huang H-L, Huang H-L, Hsu W-C, et al. Protective preparation: a process central to family caregivers of persons with mild cognitive impairment. *International psychogeriatrics*. 2017:1-10.

Wang C-Y, Wang Z-Y, Xie J-W, Cai J-H, Wang T, Xu Y, et al. CD36 upregulation mediated by intranasal LV-NRF2 treatment mitigates hypoxia-induced progression of Alzheimer's-like pathogenesis. *Antioxidants & redox signaling*. 2014;21(16):2208-30.

Wang C-Y, Wang Z-Y, Xie J-W, Wang T, Wang X, Xu Y, et al. D1-3-n-butylphthalide-induced upregulation of antioxidant defense is involved in the enhancement of cross talk between CREB and Nrf2 in an Alzheimer's disease mouse model. *Neurobiology of aging*. 2016;38:32-46.

Wang C-Y, Xie J-W, Xu Y, Wang T, Cai J-H, Wang X, et al. Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-kappaB pathway in a transgenic mouse model of Alzheimer's disease. *Antioxidants & redox signaling*. 2013;19(17):2024-39.

Wang D, Ho L, Faith J, Ono K, Janle EM, Lachcik PJ, et al. Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer's disease beta-amyloid oligomerization. *Molecular nutrition & food research*. 2015;59(6):1025-40.

Wang D, Li X, Gao K, Lu D, Zhang X, Ma C, et al. Cardiotrophin-1 (CTF1) ameliorates glucose-uptake defects and improves memory and learning deficits in a transgenic mouse model of Alzheimer's disease. *Pharmacology, biochemistry, and behavior*. 2013;107:48-57.

Wang D, Lin Q, Su S, Liu K, Wu Y, Hai J. URB597 improves cognitive impairment induced by chronic cerebral hypoperfusion by inhibiting mTOR-dependent autophagy. *Neuroscience*. 2017;344:293-304.

Wang D, Liu L, Zhu X, Wu W, Wang Y. Hesperidin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress in a mouse model of Alzheimer's disease. *Cellular and molecular neurobiology*. 2014;34(8):1209-21.

Wang DB. Monophosphoryl lipid A is an lipopolysaccharide-derived Toll-like receptor 4 agonist which may improve Alzheimer's disease pathology. *Expert opinion on biological therapy*. 2013;13(12):1639-41.

Wang D-D, Li J, Yu L-P, Wu M-N, Sun L-N, Qi J-S. Desipramine improves depression-like behavior and working memory by up-regulating p-CREB in Alzheimer's disease associated mice. *Journal of integrative neuroscience*. 2016;15(2):247-60.

Wang D-M, Feng B, Fu H, Liu A-L, Wang L, Du G-H, et al. Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase. *Molecules (Basel, Switzerland)*. 2017;22(1).

Wang D-M, Yang Y-J, Zhang L, Zhang X, Guan F-F, Zhang L-F. Naringin Enhances CaMKII Activity and Improves Long-Term Memory in a Mouse Model of Alzheimer's Disease. *International journal of molecular sciences*. 2013;14(3):5576-86.

Wang E, Zhu H, Wang X, Gower AC, Wallack M, Blusztajn JK, et al. Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer's Disease Mouse Model. *Journal of Alzheimer's disease : JAD*. 2017;56(1):47-61.

Wang F, Chang G, Geng X. NGF and TERT co-transfected BMSCs improve the restoration of cognitive impairment in vascular dementia rats. *PloS one*. 2014;9(6):e98774.

Wang F, Chang G-m, Yu Q, Geng X. The neuroprotection of repetitive transcranial magnetic stimulation pre-treatment in vascular dementia rats. *Journal of molecular neuroscience : MN*. 2015;56(1):198-204.

Wang F, Jia Y, Liu J, Zhai J, Cao N, Yue W, et al. Dental pulp stem cells promote regeneration of damaged neuron cells on the cellular model of Alzheimer's disease. *Cell biology international*. 2017;41(6):639-50.

Wang F, Liu H, Shen X, Ao H, Moore N, Gao L, et al. Combined treatment of amyloid-beta₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APP^{swe}/PSEN1^{ΔE9} mice. *Neurobiology of aging*. 2015;36(1):111-22.

Wang F, Shen X, Li S, Chen L, Wang Y, Qin J, et al. Splenocytes derived from young WT mice prevent AD progression in APP^{swe}/PSEN1^{ΔE9} transgenic mice. *Oncotarget*. 2015;6(25):20851-62.

Wang F, Zhang Y, Wang L, Sun P, Luo X, Ishigaki Y, et al. Improvement of spatial learning by facilitating large-conductance calcium-activated potassium channel with transcranial magnetic stimulation in Alzheimer's disease model mice. *Neuropharmacology*. 2015;97:210-9.

Wang F, Zhao M, Han Z, Li D, Zhang S, Zhang Y, et al. Hyperuricemia as a Protective Factor for Mild Cognitive Impairment in Non-Obese Elderly. *The Tohoku journal of experimental medicine*. 2017;242(1):37-42.

Wang F, Zhong H, Li X, Peng Y, Kinden R, Liang W, et al. Electroacupuncture attenuates reference memory impairment associated with astrocytic NDRG2 suppression in APP/PS1 transgenic mice. *Molecular neurobiology*. 2014;50(2):305-13.

Wang G, Chen L, Pan X, Chen J, Wang L, Wang W, et al. The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling. *Oncotarget*. 2016;7(14):17380-92.

Wang G, Fang H, Zhen Y, Xu G, Tian J, Zhang Y, et al. Sulforaphane Prevents Neuronal Apoptosis and Memory Impairment in Diabetic Rats. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2016;39(3):901-7.

Wang G, Huang Y, Wang L-L, Zhang Y-F, Xu J, Zhou Y, et al. MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease. *Scientific reports*. 2016;6:26697.

Wang H, Hong X, Li S, Wang Y. Oxygen Supplementation Improves Protein Milieu Supportive of Protein Synthesis and Antioxidant Function in the Cortex of Alzheimer's Disease Model Mice-a Quantitative Proteomic Study. *Journal of molecular neuroscience : MN*. 2017;63(2):243-53.

Wang H, Raleigh DP. General amyloid inhibitors? A critical examination of the inhibition of IAPP amyloid formation by inositol stereoisomers. *PloS one*. 2014;9(9):e104023.

Wang H, Wang H, Cheng H, Che Z. Ameliorating effect of luteolin on memory impairment in an Alzheimer's disease model. *Molecular medicine reports*. 2016;13(5):4215-20.

Wang H-C, Yu Y-Z, Liu S, Zhao M, Xu Q. Peripherally administered sera antibodies recognizing amyloid-beta oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3* Tg-AD mice. *Vaccine*. 2016;34(15):1758-66.

Wang H-F, Yu J-T, Tang S-W, Jiang T, Tan C-C, Meng X-F, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. *Journal of neurology, neurosurgery, and psychiatry*. 2015;86(2):135-43.

Wang H-L, Liu H, Xue Z-G, Liao Q-W, Fang H. Minocycline attenuates post-operative cognitive impairment in aged mice by inhibiting microglia activation. *Journal of cellular and molecular medicine*. 2016;20(9):1632-9.

Wang H-M, Zhang T, Huang J-K, Sun X-J. 3-N-butylphthalide (NBP) attenuates the amyloid-beta-induced inflammatory responses in cultured astrocytes via the nuclear factor-kappaB

signaling pathway. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2013;32(1):235-42.

Wang H-X, MacDonald SWS, Dekhtyar S, Fratiglioni L. Association of lifelong exposure to cognitive reserve-enhancing factors with dementia risk: A community-based cohort study. *PLoS medicine*. 2017;14(3):e1002251.

Wang H-Y, Lee K-C, Pei Z, Khan A, Bakshi K, Burns LH. PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis. *Neurobiology of aging*. 2017;55:99-114.

Wang IF, Tsai K-J, Shen C-KJ. Autophagy activation ameliorates neuronal pathogenesis of FTL-D mice: a new light for treatment of TARDBP/TDP-43 proteinopathies. *Autophagy*. 2013;9(2):239-40.

Wang J, Cai P, Yang X-L, Li F, Wu J-J, Kong L-Y, et al. Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease. *European journal of medicinal chemistry*. 2017;139:68-83.

Wang J, Fang Y, Wang X, Yang H, Yu X, Wang H. Enhanced Gamma Activity and Cross-Frequency Interaction of Resting-State Electroencephalographic Oscillations in Patients with Alzheimer's Disease. *Frontiers in aging neuroscience*. 2017;9:243.

Wang J, Jing Y, Song L, Xing Y. Neuroprotective effects of Wnt/beta-catenin signaling pathway against Abeta -induced tau protein over-phosphorylation in PC12 cells. *Biochemical and biophysical research communications*. 2016;471(4):628-32.

Wang J, Lu R, Yang J, Li H, He Z, Jing N, et al. TRPC6 specifically interacts with APP to inhibit its cleavage by gamma-secretase and reduce Abeta production. *Nature communications*. 2015;6:8876.

Wang J, Tan L, Yu J-T. Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives. *Journal of Alzheimer's disease : JAD*. 2016;50(4):927-45.

Wang J, Varghese M, Ono K, Yamada M, Levine S, Tzavaras N, et al. Cocoa extracts reduce oligomerization of amyloid-beta: implications for cognitive improvement in Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2014;41(2):643-50.

Wang J, Wu D, Chen Y, Yuan Y, Zhang M. Effects of transcranial direct current stimulation on language improvement and cortical activation in nonfluent variant primary progressive aphasia. *Neuroscience letters*. 2013;549:29-33.

Wang J, Zhang S, Ma H, Yang S, Liu Z, Wu X, et al. Chronic Intermittent Hypobaric Hypoxia Pretreatment Ameliorates Ischemia-Induced Cognitive Dysfunction Through Activation of ERK1/2-CREB-BDNF Pathway in Anesthetized Mice. *Neurochemical research*. 2017;42(2):501-12.

Wang J, Zhang X, Cheng X, Cheng J, Liu F, Xu Y, et al. LW-AFC, A New Formula Derived from Liuwei Dihuang Decoction, Ameliorates Cognitive Deterioration and Modulates Neuroendocrine-Immune System in SAMP8 Mouse. *Current Alzheimer research*. 2017;14(2):221-38.

Wang J, Zhang Y, Xu H, Zhu S, Wang H, He J, et al. Fluoxetine improves behavioral performance by suppressing the production of soluble beta-amyloid in APP/PS1 mice. *Current Alzheimer research*. 2014;11(7):672-80.

Wang J-H, Lei X, Cheng X-R, Zhang X-R, Liu G, Cheng J-P, et al. LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAbetaPPswe/PS1DeltaE9 transgenic mice. *Alzheimer's research & therapy*. 2016;8(1):57.

Wang K, Fernandez-Escobar A, Han S, Zhu P, Wang J-H, Sun Y. Lamotrigine Reduces Inflammatory Response and Ameliorates Executive Function Deterioration in an Alzheimer's-Like Mouse Model. *BioMed research international*. 2016;2016:7810196.

Wang L, Day J, Roe CM, Brier MR, Thomas JB, Benzinger TL, et al. The effect of APOE epsilon4 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging. *Alzheimer disease and associated disorders*. 2014;28(2):122-7.

Wang L, Esteban G, Ojima M, Bautista-Aguilera OM, Inokuchi T, Moraleda I, et al. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. *European journal of medicinal chemistry*. 2014;80:543-61.

Wang L, Wang M, Hu J, Shen W, Hu J, Yao Y, et al. Protective effect of 3H-1, 2-dithiole-3-thione on cellular model of Alzheimer's disease involves Nrf2/ARE signaling pathway. *European journal of pharmacology*. 2017;795:115-23.

Wang L-S, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, et al. Rarity of the Alzheimer disease-protective APP A673T variant in the United States. *JAMA neurology*. 2015;72(2):209-16.

Wang M, Bi W, Fan K, Li T, Yan T, Xiao F, et al. Ameliorating effect of *Alpinia oxyphylla*-*Schisandra chinensis* herb pair on cognitive impairment in a mouse model of Alzheimer's disease. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2017;97:128-35.

Wang M, Li Y, Ni C, Song G. Honokiol Attenuates Oligomeric Amyloid beta1-42-Induced Alzheimer's Disease in Mice Through Attenuating Mitochondrial Apoptosis and Inhibiting the Nuclear Factor Kappa-B Signaling Pathway. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2017;43(1):69-81.

Wang N, Chen X, Geng D, Huang H, Zhou H. Ginkgo biloba leaf extract improves the cognitive abilities of rats with D-galactose induced dementia. *Journal of biomedical research*. 2013;27(1):29-36.

Wang N, Gray M, Lu X-H, Cattle JP, Holley SM, Greiner E, et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. *Nature medicine*. 2014;20(5):536-41.

Wang P, Cao J, Liu N, Ma L, Zhou X, Zhang H, et al. Protective Effects of Edaravone in Adult Rats with Surgery and Lipopolysaccharide Administration-Induced Cognitive Function Impairment. *PloS one*. 2016;11(4):e0153708.

Wang P, Guan P-P, Yu X, Zhang L-C, Su Y-N, Wang Z-Y. Prostaglandin I α , Attenuates Prostaglandin E α , -Stimulated Expression of Interferon gamma in a beta-Amyloid Protein- and NF-kappaB-Dependent Mechanism. *Scientific reports*. 2016;6:20879.

Wang P, Li J, Li H, Li B, Jiang Y, Bao F, et al. Is emotional memory enhancement preserved in amnesic mild cognitive impairment? Evidence from separating recollection and familiarity. *Neuropsychology*. 2013;27(6):691-701.

Wang P, Su C, Li R, Wang H, Ren Y, Sun H, et al. Mechanisms and effects of curcumin on spatial learning and memory improvement in APP^{swe}/PS1^{dE9} mice. *Journal of neuroscience research*. 2014;92(2):218-31.

Wang Q, Xiao B, Cui S, Song H, Qian Y, Dong L, et al. Triptolide treatment reduces Alzheimer's disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD. *Disease models & mechanisms*. 2014;7(12):1385-95.

Wang Q, Yu X, Li L, Zheng J. Inhibition of amyloid-beta aggregation in Alzheimer's disease. *Current pharmaceutical design*. 2014;20(8):1223-43.

Wang Q-H, Wang Y-R, Zhang T, Jiao S-S, Liu Y-H, Zeng F, et al. Intramuscular delivery of p75NTR ectodomain by an AAV vector attenuates cognitive deficits and Alzheimer's disease-like pathologies in APP/PS1 transgenic mice. *Journal of neurochemistry*. 2016;138(1):163-73.

Wang Q-Q, Zhu L-J, Wang X-H, Zuo J, He H-Y, Tian M-M, et al. Chronic Trigeminal Nerve Stimulation Protects Against Seizures, Cognitive Impairments, Hippocampal Apoptosis, and Inflammatory Responses in Epileptic Rats. *Journal of molecular neuroscience* : MN. 2016;59(1):78-89.

Wang S, Cui Y, Cu Y, Wang C, Xie W, Ma L, et al. Protective Effects of Dietary Supplementation with a Combination of Nutrients in a Transgenic Mouse Model of Alzheimer's Disease. *PloS one*. 2015;10(11):e0143135.

Wang S, Cui Y, Wang C, Xie W, Ma L, Zhu J, et al. Correction: Protective Effects of Dietary Supplementation with a Combination of Nutrients in a Transgenic Mouse Model of Alzheimer's Disease. *PloS one*. 2015;10(12):e0146252.

Wang S, Yang H, Yu L, Jin J, Qian L, Zhao H, et al. Oridonin attenuates Abeta1-42-induced neuroinflammation and inhibits NF-kappaB pathway. *PloS one*. 2014;9(8):e104745.

Wang S, Yu L, Yang H, Li C, Hui Z, Xu Y, et al. Oridonin Attenuates Synaptic Loss and Cognitive Deficits in an Abeta1-42-Induced Mouse Model of Alzheimer's Disease. *PloS one*. 2016;11(3):e0151397.

Wang S, Yu Y, Geng S, Wang D, Zhang L, Xie X, et al. A coimmunization vaccine of Abeta42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model. *Alzheimer's research & therapy*. 2014;6(3):26.

Wang S-E, Lin C-L, Hsu C-H, Sheu S-J, Chien C-T, Wu C-H. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease. *Drug design, development and therapy*. 2015;9:887-900.

Wang S-E, Lin C-L, Hsu C-H, Sheu S-J, Wu C-H. Oral treatment with the herbal formula B401 protects against aging-dependent neurodegeneration by attenuating oxidative stress and apoptosis in the brain of R6/2 mice. *Clinical interventions in aging*. 2015;10:1825-37.

Wang S-M, Lee Y-C, Ko C-Y, Lai M-D, Lin D-Y, Pao P-C, et al. Increase of zinc finger protein 179 in response to CCAAT/enhancer binding protein delta conferring an antiapoptotic effect in astrocytes of Alzheimer's disease. *Molecular neurobiology*. 2015;51(1):370-82.

Wang S-W, Liu D-Q, Zhang L-X, Ji M, Zhang Y-X, Dong Q-X, et al. A vaccine with Abeta oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease. *Alzheimer's research & therapy*. 2017;9(1):41.

Wang S-W, Yang S-G, Liu W, Zhang Y-X, Xu P-X, Wang T, et al. Alpha-tocopherol quinine ameliorates spatial memory deficits by reducing beta-amyloid oligomers, neuroinflammation and oxidative stress in transgenic mice with Alzheimer's disease. *Behavioural brain research*. 2016;296:109-17.

Wang S-Y, Liu J-P, Ji W-W, Chen W-J, Fu Q, Feng L, et al. Qifu-Yin attenuates AGEs-induced Alzheimer-like pathophysiological changes through the RAGE/NF-kappaB pathway. *Chinese journal of natural medicines*. 2014;12(12):920-8.

Wang T, Xiao S, Chen K, Yang C, Dong S, Cheng Y, et al. Prevalence, Incidence, Risk and Protective Factors of Amnesic Mild Cognitive Impairment in the Elderly in Shanghai. *Current Alzheimer research*. 2017;14(4):460-6.

Wang W, Arakawa H, Wang L, Okolo O, Siedlak SL, Jiang Y, et al. Motor-Coordination and Cognitive Dysfunction Caused by Mutant TDP-43 Could Be Reversed by Inhibiting Its Mitochondrial Localization. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2017;25(1):127-39.

Wang W, Wang L, Lu J, Siedlak SL, Fujioka H, Liang J, et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. *Nature medicine*. 2016;22(8):869-78.

Wang W, Yin J, Ma X, Zhao F, Siedlak SL, Wang Z, et al. Inhibition of mitochondrial fragmentation protects against Alzheimer's disease in rodent model. *Human molecular genetics*. 2017;26(21):4118-31.

Wang X, Blanchard J, Grundke-Iqbal I, Iqbal K. Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment. *PloS one*. 2015;10(12):e0145441.

Wang X, Chen A, Wu H, Ye M, Cheng H, Jiang X, et al. Enriched environment improves post-stroke cognitive impairment in mice by potential regulation of acetylation homeostasis in cholinergic circuits. *Brain research*. 2016;1650:232-42.

Wang X, Hu X, Yang Y, Takata T, Sakurai T. Nicotinamide mononucleotide protects against beta-amyloid oligomer-induced cognitive impairment and neuronal death. *Brain research*. 2016;1643:1-9.

Wang X, Kim J-R, Lee S-B, Kim Y-J, Jung MY, Kwon H-W, et al. Effects of curcuminoids identified in rhizomes of *Curcuma longa* on BACE-1 inhibitory and behavioral activity and lifespan of Alzheimer's disease *Drosophila* models. *BMC complementary and alternative medicine*. 2014;14:88.

Wang X, Li J, Qian L, Zang XF, Zhang SY, Wang XY, et al. Icarin promotes histone acetylation and attenuates post-stroke cognitive impairment in the central cholinergic circuits of mice. *Neuroscience*. 2013;236:281-8.

Wang X, Mitchell CC, Varghese T, Jackson DC, Rocque BG, Hermann BP, et al. Improved Correlation of Strain Indices with Cognitive Dysfunction with Inclusion of Adventitial Layer with Carotid Plaque. *Ultrasonic imaging*. 2016;38(3):194-208.

Wang X, Wang Y, Hu J-P, Yu S, Li B-K, Cui Y, et al. Astragaloside IV, a Natural PPARgamma Agonist, Reduces Abeta Production in Alzheimer's Disease Through Inhibition of BACE1. *Molecular neurobiology*. 2017;54(4):2939-49.

Wang X, Wu J, Yu C, Tang Y, Liu J, Chen H, et al. Lychee Seed Saponins Improve Cognitive Function and Prevent Neuronal Injury via Inhibiting Neuronal Apoptosis in a Rat Model of Alzheimer's Disease. *Nutrients*. 2017;9(2).

Wang X, Yu S, Gao S-J, Hu J-P, Wang Y, Liu H-X. Insulin inhibits Abeta production through modulation of APP processing in a cellular model of Alzheimer's disease. *Neuro endocrinology letters*. 2014;35(3):224-9.

Wang X, Zhang H, Liu J, Chen R, Tang Y, Chen H, et al. Inhibitory Effect of Lychee Seed Saponins on Apoptosis Induced by Abeta25-35 through Regulation of the Apoptotic and NF-kappaB Pathways in PC12 Cells. *Nutrients*. 2017;9(4).

Wang X-L, Liu Q, Chen G-J, Li M-L, Ding Y-H. Overexpression of MTERF4 promotes the amyloidogenic processing of APP by inhibiting ADAM10. *Biochemical and biophysical research communications*. 2017;482(4):928-34.

Wang X-R, Shi G-X, Yang J-W, Yan C-Q, Lin L-T, Du S-Q, et al. Acupuncture ameliorates cognitive impairment and hippocampus neuronal loss in experimental vascular dementia through Nrf2-mediated antioxidant response. *Free radical biology & medicine*. 2015;89:1077-84.

Wang Y, Cai B, Shao J, Wang T-T, Cai R-Z, Ma C-J, et al. Genistein suppresses the mitochondrial apoptotic pathway in hippocampal neurons in rats with Alzheimer's disease. *Neural regeneration research*. 2016;11(7):1153-8.

Wang Y, Cai S-C, Song X-G, Zhu W-L, Yang K, Qian J-J, et al. Moxibustion Improves Learning Ability by Regulating Hippocampal Neurotrophic Factor Expression and Notch Signaling in Vascular Dementia Rats. *Zhen ci yan jiu = Acupuncture research*. 2017;42(5):377-83.

Wang Y, Meng R, Song H, Liu G, Hua Y, Cui D, et al. Remote Ischemic Conditioning May Improve Outcomes of Patients With Cerebral Small-Vessel Disease. *Stroke*. 2017;48(11):3064-72.

Wang Y, Sun Y, Guo Y, Wang Z, Huang L, Li X. Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives. *Journal of enzyme inhibition and medicinal chemistry*. 2016;31(3):389-97.

Wang Y, Wang H, Chen H-z. AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease. *Current neuropharmacology*. 2016;14(4):364-75.

Wang Y, Wu C, Han B, Xu F, Mao M, Guo X, et al. Dexmedetomidine attenuates repeated propofol exposure-induced hippocampal apoptosis, PI3K/Akt/Gsk-3 β signaling disruption, and juvenile cognitive deficits in neonatal rats. *Molecular medicine reports*. 2016;14(1):769-75.

Wang Y, Wu Z, Bai Y-T, Wu G-Y, Chen G. Gad67 haploinsufficiency reduces amyloid pathology and rescues olfactory memory deficits in a mouse model of Alzheimer's disease. *Molecular neurodegeneration*. 2017;12(1):73.

Wang Y-R, Yang Y-H, Lu C-Y, Lin S-J, Chen S-H. Trace analysis of acetylcholinesterase inhibitors with antipsychotic drugs for Alzheimer's disease by capillary electrophoresis with on column field-amplified sample injection. *Analytical and bioanalytical chemistry*. 2013;405(10):3233-42.

Wang Z, Fan J, Wang J, Li Y, Xiao L, Duan D, et al. Protective effect of lycopene on high-fat diet-induced cognitive impairment in rats. *Neuroscience letters*. 2016;627:185-91.

Wang Z, Wang Y, Li W, Liu Z, Luo Z, Sun Y, et al. Computer-assisted designed "selenoxy-chinolin": a new catalytic mechanism of the GPx-like cycle and inhibition of metal-free and metal-associated A β aggregation. *Dalton transactions (Cambridge, England : 2003)*. 2015;44(48):20913-25.

Wang Z, Wang Y, Wang B, Li W, Huang L, Li X. Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease. *Journal of medicinal chemistry*. 2015;58(21):8616-37.

Wang Z, Xiong L, Wan W, Duan L, Bai X, Zu H. Intranasal BMP9 Ameliorates Alzheimer Disease-Like Pathology and Cognitive Deficits in APP/PS1 Transgenic Mice. *Frontiers in molecular neuroscience*. 2017;10:32.

Wang Z-D, Yao G-D, Wang W, Wang W-B, Wang S-J, Song S-J. Synthesis and evaluation of 26-amino acid methyl ester substituted sarsapogenin derivatives as neuroprotective agents for Alzheimer's disease. *Steroids*. 2017;125:93-106.

Wang Z-F, Pan Z-Y, Xu C-S, Li Z-Q. Activation of G-protein coupled estrogen receptor 1 improves early-onset cognitive impairment via PI3K/Akt pathway in rats with traumatic brain injury. *Biochemical and biophysical research communications*. 2017;482(4):948-53.

Wang Z-H, Liu P, Liu X, Manfredsson FP, Sandoval IM, Yu SP, et al. Delta-Secretase Phosphorylation by SRPK2 Enhances Its Enzymatic Activity, Provoking Pathogenesis in Alzheimer's Disease. *Molecular cell*. 2017;67(5):812-25.e5.

Wang Z-J, Han W-N, Yang G-Z, Yuan L, Liu X-J, Li Q-S, et al. The neuroprotection of Rattin against amyloid beta peptide in spatial memory and synaptic plasticity of rats. *Hippocampus*. 2014;24(1):44-53.

Wang Z-M, Cai P, Liu Q-H, Xu D-Q, Yang X-L, Wu J-J, et al. Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. *European journal of medicinal chemistry*. 2016;123:282-97.

Watari H, Shimada Y, Tohda C. New Treatment for Alzheimer's Disease, Kamikihito, Reverses Amyloid-beta-Induced Progression of Tau Phosphorylation and Axonal Atrophy. *Evidence-based complementary and alternative medicine : eCAM*. 2014;2014:706487.

Wattanathorn J, Muchimapura S, Thukham-Mee W, Ingkaninan K, Wittaya-Areekul S. *Mangifera indica* fruit extract improves memory impairment, cholinergic dysfunction, and oxidative stress damage in animal model of mild cognitive impairment. *Oxidative medicine and cellular longevity*. 2014;2014:132097.

Wattmo C, Londos E, Minthon L. Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death. *BMC neurology*. 2016;16(1):156.

Wattmo C, Londos E, Minthon L. Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services. *Dementia and geriatric cognitive disorders*. 2015;40(5-6):297-310.

Wattmo C, Londos E, Minthon L. Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease. *BMC neurology*. 2014;14:173.

Wattmo C, Minthon L, Wallin AK. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. *Alzheimer's research & therapy*. 2016;8:7.

Wattmo C, Paulsson E, Minthon L, Londos E. A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy. *Clinical interventions in aging*. 2013;8:329-39.

Wauters M, Wattiez R, Ris L. Internalization of the Extracellular Full-Length Tau Inside Neuro2A and Cortical Cells Is Enhanced by Phosphorylation. *Biomolecules*. 2016;6(3).

Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, et al. Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. *PloS one*. 2017;12(6):e0179521.

Weeks J. Integrative MEND Protocol for Reversing Alzheimer's Picked Up in Aging and by George Washington University plus more. *Integrative medicine (Encinitas, Calif)*. 2016;15(4):24-6.

Weeks J. Into the Light: Reflections on Whole-Systems Research After a Case Series Finds Reversal of Alzheimer's. *Journal of alternative and complementary medicine (New York, NY)*. 2016;22(8):585-7.

Wegmann S, Maury EA, Kirk MJ, Saqrán L, Roe A, DeVos SL, et al. Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. *The EMBO journal*. 2015;34(24):3028-41.

Wei C, Zhang W, Zhou Q, Zhao C, Du Y, Yan Q, et al. Mithramycin A Alleviates Cognitive Deficits and Reduces Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. *Neurochemical research*. 2016;41(8):1924-38.

Wei C-Y, Chiu P-Y, Hou P-N, Matsuda H, Hung G-U. The Value of 99mTc ECD SPECT With Statistical Image Analysis on Enhancing the Early Diagnosis of Primary Progressive Aphasia. *Clinical nuclear medicine*. 2017;42(2):e117-e20.

Wei D, Tang J, Bai W, Wang Y, Zhang Z. Ameliorative effects of baicalein on an amyloid-beta induced Alzheimer's disease rat model: a proteomics study. *Current Alzheimer research*. 2014;11(9):869-81.

Wei G, Chen Y-b, Chen D-F, Lai X-P, Liu D-H, Deng R-D, et al. beta-Asarone inhibits neuronal apoptosis via the CaMKII/CREB/Bcl-2 signaling pathway in an in vitro model and AbetaPP/PS1 mice. *Journal of Alzheimer's disease : JAD*. 2013;33(3):863-80.

Wei H, Gao Z, Zheng L, Zhang C, Liu Z, Yang Y, et al. Protective Effects of Fucoidan on Abeta25-35 and d-Gal-Induced Neurotoxicity in PC12 Cells and d-Gal-Induced Cognitive Dysfunction in Mice. *Marine drugs*. 2017;15(3).

Wei L, Lv S, Huang Q, Wei J, Zhang S, Huang R, et al. Pratensein attenuates Abeta-induced cognitive deficits in rats: enhancement of synaptic plasticity and cholinergic function. *Fitoterapia*. 2015;101:208-17.

Wei S, Chen W, Qin J, Huangli Y, Wang L, Shen Y, et al. Multitarget-directed oxoisoporphine derivatives: Anti-acetylcholinesterase, anti-beta-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease. *Bioorganic & medicinal chemistry*. 2016;24(22):6031-9.

Weigmann K. The Babylonian benefit: Neurological research shows that being bilingual enhances mental performance and may protect from Alzheimer's disease. *EMBO reports*. 2014;15(10):1015-8.

Weih M. MRI does not improve the prediction of dementia. *MMW Fortschritte der Medizin*. 2015;157 Spec No 2:46.

Weinberg RB, Mufson EJ, Counts SE. Evidence for a neuroprotective microRNA pathway in amnesic mild cognitive impairment. *Frontiers in neuroscience*. 2015;9:430.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2017;13(4):e1-e85.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2017;13(5):561-71.

Weinreb O, Amit T, Bar-Am O, Youdim MBH. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and beta-amyloid in ageing and Alzheimer's disease. *British journal of pharmacology*. 2016;173(13):2080-94.

Weissmiller AM, Natera-Naranjo O, Reyna SM, Pearn ML, Zhao X, Nguyen P, et al. A gamma-secretase inhibitor, but not a gamma-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. *PloS one*. 2015;10(2):e0118379.

Welk B, McArthur E, Ordon M, Morrow SA, Hayward J, Dixon S. The risk of dementia with the use of 5 alpha reductase inhibitors. *Journal of the neurological sciences*. 2017;379:109-11.

Wen X, Wang L, Liu Z, Liu Y, Hu J. Intracranial injection of PEG-PEI/ROCK II-siRNA improves cognitive impairment in a mouse model of Alzheimer's disease. *The International journal of neuroscience*. 2014;124(9):697-703.

Weng P-H, Chen J-H, Chen T-F, Sun Y, Wen L-L, Yip P-K, et al. CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease. *PloS one*. 2013;8(12):e84059.

Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, et al. Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016;12(5):631-2.

Werner S. Preserving dignity. *Pflege Zeitschrift*. 2014;67(10):604-7.

Werner S. The pain management challenge. Alleviating pain with music. *Pflege Zeitschrift*. 2014;67(9):570-1.

Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. *International journal of geriatric psychiatry*. 2015;30(1):46-54.

Wessa M, King AV, Meyer P, Frolich L, Flor H, Poupon C, et al. Impaired and preserved aspects of feedback learning in aMCI: contributions of structural connectivity. *Brain structure & function*. 2016;221(5):2831-46.

Wesson DW, Morales-Corraliza J, Mazzella MJ, Wilson DA, Mathews PM. Chronic anti-murine Abeta immunization preserves odor guided behaviors in an Alzheimer's beta-amyloidosis model. *Behavioural brain research*. 2013;237:96-102.

Wesson J, Clemson L, Brodaty H, Lord S, Taylor M, Gitlin L, et al. A feasibility study and pilot randomised trial of a tailored prevention program to reduce falls in older people with mild dementia. *BMC geriatrics*. 2013;13:89.

Whalley K. Neurodegenerative disease: Restoring balance in Huntington disease. *Nature reviews Neuroscience*. 2015;16(2):66-7.

Whalley LJ. Are gender-specific approaches required to prevent dementia? *Maturitas*. 2016;92:7-8.

Wharton W, Goldstein FC, Zhao L, Steenland K, Levey AI, Hajjar I. Modulation of Renin-Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease. *Journal of the American Geriatrics Society*. 2015;63(9):1749-56.

Whitaker R, Ballard C, Stafford J, Orrell M, Moniz-Cook E, Woods RT, et al. Feasibility study of an optimised person-centred intervention to improve mental health and reduce antipsychotics amongst people with dementia in care homes: study protocol for a randomised controlled trial. *Trials*. 2013;14:13.

Whitaker R, Fossey J, Ballard C, Orrell M, Moniz-Cook E, Woods RT, et al. Improving Well-being and Health for People with Dementia (WHELD): study protocol for a randomised controlled trial. *Trials*. 2014;15:284.

White BD. Reply to letters: Urgent revision required of NICE guidance relating to prevention of spread of vCJD through neurosurgical instruments. *British journal of neurosurgery*. 2014;28(3):302.

White MR, Kandel R, Tripathi S, Condon D, Qi L, Taubenberger J, et al. Alzheimer's associated beta-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. *PloS one*. 2014;9(7):e101364.

White PC, Wyatt J, Chalfont G, Bland JM, Neale C, Trepel D, et al. Exposure to nature gardens has time-dependent associations with mood improvements for people with mid- and late-stage dementia: Innovative practice. *Dementia (London, England)*. 2017;1471301217723772.

Wiert C. A note on the relevance of 6 -Gingerol for the prevention and/or treatment of Alzheimer's disease. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*. 2013;51:456.

Wieckowska A, Kolaczowski M, Bucki A, Godyn J, Marcinkowska M, Wieckowski K, et al. Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT₆ receptor antagonists. Design, synthesis and biological evaluation. *European journal of medicinal chemistry*. 2016;124:63-81.

Wieckowska A, Wieckowski K, Bajda M, Brus B, Salat K, Czerwinska P, et al. Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with beta-amyloid anti-aggregation properties and beneficial effects on memory in vivo. *Bioorganic & medicinal chemistry*. 2015;23(10):2445-57.

Wiesmann M, Jansen D, Zerbi V, Broersen LM, Garthe A, Kiliaan AJ. Improved spatial learning strategy and memory in aged Alzheimer AbetaPP^{swe}/PS1dE9 mice on a multi-nutrient diet. *Journal of Alzheimer's disease : JAD*. 2013;37(1):233-45.

Wiesmann M, Zerbi V, Jansen D, Haast R, Lutjohann D, Broersen LM, et al. A Dietary Treatment Improves Cerebral Blood Flow and Brain Connectivity in Aging apoE4 Mice. *Neural plasticity*. 2016;2016:6846721.

Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Proton pump inhibitors and risk of dementia. *Annals of translational medicine*. 2016;4(12):240.

Wijma EM, Veerbeek MA, Prins M, Pot AM, Willemse BM. A virtual reality intervention to improve the understanding and empathy for people with dementia in informal caregivers: results of a pilot study. *Aging & mental health*. 2017:1-9.

Wilcock J, Iliffe S, Griffin M, Jain P, Thune-Boyle I, Lefford F, et al. Tailored educational intervention for primary care to improve the management of dementia: the EVIDEM-ED cluster randomized controlled trial. *Trials*. 2013;14:397.

Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S, et al. eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. *Nature*. 2015;526(7573):443-7.

Williams K, Weatherhead I. Improving nutrition and care for people with dementia. *British journal of community nursing*. 2013;Suppl:S20-5.

Williams MA, McGowan AJ, Cardwell CR, Cheung CY, Craig D, Passmore P, et al. Retinal microvascular network attenuation in Alzheimer's disease. *Alzheimer's & dementia (Amsterdam, Netherlands)*. 2015;1(2):229-35.

Williams RSB, Bate C. An in vitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling. *Neuropharmacology*. 2016;101:566-75.

Willis KJ, Hakim AM. Stroke prevention and cognitive reserve: emerging approaches to modifying risk and delaying onset of dementia. *Frontiers in neurology*. 2013;4:13.

Winblad B, Qiu C, Ballard C, Johansson G. Evidence-based prevention and treatment of dementia - Authors' reply. *The Lancet Neurology*. 2016;15(10):1007-8.

Winkler D, Beconi M, Toledo-Sherman LM, Prime M, Ebner A, Dominguez C, et al. Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO). *Journal of biomolecular screening*. 2013;18(8):879-89.

Winkler E, Julius A, Steiner H, Langosch D. Homodimerization Protects the Amyloid Precursor Protein C99 Fragment from Cleavage by gamma-Secretase. *Biochemistry*. 2015;54(40):6149-52.

Wirth M, Haase CM, Villeneuve S, Vogel J, Jagust WJ. Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. *Neurobiology of aging*. 2014;35(8):1873-82.

Wischik CM, Harrington CR, Storey JMD. Tau-aggregation inhibitor therapy for Alzheimer's disease. *Biochemical pharmacology*. 2014;88(4):529-39.

Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JMD, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2015;44(2):705-20.

Wise J. 90m package to improve dementia care is announced in England. *BMJ (Clinical research ed)*. 2014;348:g1879.

Wise J. Dementia research focuses on prevention, as drugs fail to deliver. *BMJ (Clinical research ed)*. 2017;358:j3466.

Wise J. Neither vitamin E nor selenium prevents dementia, researchers find. *BMJ (Clinical research ed)*. 2017;356:j1436.

Wise J. Proton pump inhibitors may be linked to dementia risk. *BMJ (Clinical research ed)*. 2016;352:i972.

Withdrawn: An assessment of the dementia CQUIN - An audit of improving compliance. *Dementia (London, England)*. 2017;1471301217705792.

Withdrawn: An assessment of the dementia CQUIN - An audit of improving compliance. *Dementia (London, England)*. 2017;16(6):NP1.

Wittenberg SM, Toxopeus KA, Schulte PFJ. Lithium and its protective effect in Alzheimer's disease. *Tijdschrift voor psychiatrie*. 2017;59(9):559-63.

Wittwer J. Gait improves after 12 weeks of intensive resistance and functional training in people with mild to moderate dementia. *Journal of physiotherapy*. 2015;61(2):97.

Wityak J, McGee KF, Conlon MP, Song RH, Duffy BC, Clayton B, et al. Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors. *Journal of medicinal chemistry*. 2015;58(7):2967-87.

Wiwanitkit S, Wiwanitkit V. Racemose neurocysticercosis and reversible dementia. *Annals of Indian Academy of Neurology*. 2013;16(4):730.

Wojtowicz AM, Dvorzhak A, Semtner M, Grantyn R. Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3. *Frontiers in neural circuits*. 2013;7:188.

Wolf TJ, Doherty M, Kallogjeri D, Coalson RS, Nicklaus J, Ma CX, et al. The Feasibility of Using Metacognitive Strategy Training to Improve Cognitive Performance and Neural Connectivity in Women with Chemotherapy-Induced Cognitive Impairment. *Oncology*. 2016;91(3):143-52.

Wolfe KJ, Ren HY, Trepte P, Cyr DM. Polyglutamine-rich suppressors of huntingtin toxicity act upstream of Hsp70 and Stt1 in spatial quality control of amyloid-like proteins. *PloS one*. 2014;9(5):e95914.

Wolter DK. Eliminate noxious agents acting as triggers. *Deutsches Arzteblatt international*. 2013;110(1-2):8.

Woltering TJ, Wostl W, Hilpert H, Rogers-Evans M, Pinard E, Mayweg A, et al. BACE1 inhibitors: a head group scan on a series of amides. *Bioorganic & medicinal chemistry letters*. 2013;23(14):4239-43.

Wong BKY, Ehrnhoefer DE, Graham RK, Martin DDO, Ladha S, Uribe V, et al. Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. *Neurobiology of disease*. 2015;76:24-36.

Wong CW. Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine. *Drugs & aging*. 2016;33(7):451-60.

Wong C-Y, Chung L-H, Lu L, Wang M, He B, Liu L-J, et al. Dual Inhibition And Monitoring Of Beta-amyloid Fibrillation By A Luminescent Iridium(III) Complex. *Current Alzheimer research*. 2015;12(5):439-44.

Wong KY, Mercader AG, Saavedra LM, Honarparvar B, Romanelli GP, Duchowicz PR. QSAR analysis on tacrine-related acetylcholinesterase inhibitors. *Journal of biomedical science*. 2014;21:84.

Wong VKW, Wu AG, Wang JR, Liu L, Law BY-K. Neferine attenuates the protein level and toxicity of mutant huntingtin in PC-12 cells via induction of autophagy. *Molecules (Basel, Switzerland)*. 2015;20(3):3496-514.

Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding. *Pharmacoepidemiology and drug safety*. 2013;22(4):345-58.

Woo JA, Boggess T, Uhlar C, Wang X, Khan H, Cappos G, et al. RanBP9 at the intersection between cofilin and Abeta pathologies: rescue of neurodegenerative changes by RanBP9 reduction. *Cell death & disease*. 2015;6:1676.

Wood H. Alzheimer disease: Anticancer drug prevents nucleation of toxic amyloid-beta42 aggregates. *Nature reviews Neurology*. 2016;12(3):126.

Wood H. Alzheimer disease: Meta-analysis finds high reversion rate from MCI to normal cognition. *Nature reviews Neurology*. 2016;12(4):189.

Wood N, Cairns Y, Sharp B. How collaboration is improving acute hospital admission for people with dementia. *Nursing older people*. 2017;29(9):21-5.

Wood R, Moodley K, Hodges JR, Allinson K, Spillantini MG, Chan D. Slowly progressive behavioural presentation in two UK cases with the R406W MAPT mutation. *Neuropathology and applied neurobiology*. 2016;42(3):291-5.

Woodberry E, Browne G, Hodges S, Watson P, Kapur N, Woodberry K. The use of a wearable camera improves autobiographical memory in patients with Alzheimer's disease. *Memory (Hove, England)*. 2015;23(3):340-9.

Woodling NS, Andreasson KI. Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease. *ACS chemical neuroscience*. 2016;7(4):454-63.

Woodling NS, Colas D, Wang Q, Minhas P, Panchal M, Liang X, et al. Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice. *Brain : a journal of neurology*. 2016;139(Pt 7):2063-81.

Woodling NS, Wang Q, Priyam PG, Larkin P, Shi J, Johansson JU, et al. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(17):5882-94.

Wouters H, Van Campen JPCM, Appels BA, Beijnen JH, Zwinderman AH, Van Gool WA, et al. Individualized evaluation of cholinesterase inhibitors effects in dementia with adaptive cognitive testing. *International journal of methods in psychiatric research*. 2016;25(3):190-8.

Wozniak MA, Frost AL, Itzhaki RF. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1. *Antiviral research*. 2013;99(3):401-4.

Wrasidlo W, Crews LA, Tsigelny IF, Stocking E, Kouznetsova VL, Price D, et al. Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders. *British journal of pharmacology*. 2014;171(24):5757-73.

Wray LO, Wade M, Beehler GP, Hershey LA, Vair CL. A program to improve detection of undiagnosed dementia in primary care and its association with healthcare utilization. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2014;22(11):1282-91.

Wright DJ, Renoir T, Smith ZM, Frazier AE, Francis PS, Thorburn DR, et al. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease. *Translational psychiatry*. 2015;5:e492.

Wu A-G, Wong VK-W, Xu S-W, Chan W-K, Ng C-I, Liu L, et al. Onjisaponin B derived from *Radix Polygalae* enhances autophagy and accelerates the degradation of mutant alpha-synuclein and huntingtin in PC-12 cells. *International journal of molecular sciences*. 2013;14(11):22618-41.

Wu B, Jiang M, Peng Q, Li G, Hou Z, Milne GL, et al. 2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease. *Experimental neurology*. 2017;293:83-90.

Wu B-K, Yuan R-Y, Lien H-W, Hung C-C, Hwang P-P, Chen RP-Y, et al. Multiple signaling factors and drugs alleviate neuronal death induced by expression of human and zebrafish tau proteins in vivo. *Journal of biomedical science*. 2016;23:25.

Wu C-R, Lin H-C, Su M-H. Reversal by aqueous extracts of *Cistanche tubulosa* from behavioral deficits in Alzheimer's disease-like rat model: relevance for amyloid deposition and central neurotransmitter function. *BMC complementary and alternative medicine*. 2014;14:202.

Wu D-X, Feng L, Yao S-Q, Tian X-F, Mahendran R, Kua E-H. The early dementia prevention programme in Singapore. *The lancet Psychiatry*. 2014;1(1):9-11.

Wu E, Barnes DE, Ackerman SL, Lee J, Chesney M, Mehling WE. Preventing Loss of Independence through Exercise (PLIE): qualitative analysis of a clinical trial in older adults with dementia. *Aging & mental health*. 2015;19(4):353-62.

Wu G, Li L, Li HM, Zeng Y, Wu WC. Electroacupuncture ameliorates spatial learning and memory impairment via attenuating NOX2-related oxidative stress in a rat model of Alzheimer's disease induced by Abeta1-42. *Cellular and molecular biology (Noisy-le-Grand, France)*. 2017;63(4):38-45.

Wu H. Can small molecule inhibitors of glutaminyl cyclase be used as a therapeutic for Alzheimer's disease? *Future medicinal chemistry*. 2017.

Wu HS, Lin LC, Wu SC, Lin KN, Liu HC. The effectiveness of spaced retrieval combined with Montessori-based activities in improving the eating ability of residents with dementia. *Journal of advanced nursing*. 2014;70(8):1891-901.

Wu J, Bie B, Yang H, Xu JJ, Brown DL, Naguib M. Suppression of central chemokine fractalkine receptor signaling alleviates amyloid-induced memory deficiency. *Neurobiology of aging*. 2013;34(12):2843-52.

Wu J, Hocevar M, Foss JF, Bie B, Naguib M. Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer's disease. *European journal of pharmacology*. 2017;811:12-20.

Wu J, Ryskamp DA, Liang X, Egorova P, Zakharova O, Hung G, et al. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2016;36(1):125-41.

Wu J, Zhang M, Li H, Sun X, Hao S, Ji M, et al. BDNF pathway is involved in the protective effects of SS-31 on isoflurane-induced cognitive deficits in aging mice. *Behavioural brain research*. 2016;305:115-21.

Wu K, Gao X, Shi B, Chen S, Zhou X, Li Z, et al. Enriched endogenous n-3 polyunsaturated fatty acids alleviate cognitive and behavioral deficits in a mice model of Alzheimer's disease. *Neuroscience*. 2016;333:345-55.

Wu L, Tong T, Wan S, Yan T, Ren F, Bi K, et al. Protective Effects of Puerarin against Abeta 1-42-Induced Learning and Memory Impairments in Mice. *Planta medica*. 2017;83(3-04):224-31.

Wu L-Y, Bao X-Q, Pang H-Y, Sun H, Zhang D. FLZ attenuates learning and memory deficits via suppressing neuroinflammation induced by LPS in mice. *Journal of Asian natural products research*. 2015;17(3):306-17.

Wu P-H, Lin Y-T, Hsu P-C, Yang Y-H, Lin T-H, Huang C-T. Impact of acetylcholinesterase inhibitors on the occurrence of acute coronary syndrome in patients with dementia. *Scientific reports*. 2015;5:15451.

Wu P-J, Hung Y-F, Liu H-Y, Hsueh Y-P. Deletion of the Inflammasome Sensor Aim2 Mitigates Abeta Deposition and Microglial Activation but Increases Inflammatory Cytokine Expression in an Alzheimer Disease Mouse Model. *Neuroimmunomodulation*. 2017;24(1):29-39.

Wu Q, Sun J-X, Song X-H, Wang J, Xiong C-Q, Teng F-X, et al. Blocking beta 2-adrenergic receptor inhibits dendrite ramification in a mouse model of Alzheimer's disease. *Neural regeneration research*. 2017;12(9):1499-506.

Wu Q, Ye X, Xiong Y, Zhu H, Miao J, Zhang W, et al. The Protective Role of microRNA-200c in Alzheimer's Disease Pathologies Is Induced by Beta Amyloid-Trigged Endoplasmic Reticulum Stress. *Frontiers in molecular neuroscience*. 2016;9:140.

Wu W-h, Liu Q, Sun X, Yu J-s, Zhao D-s, Yu Y-p, et al. Fibrillar seeds alleviate amyloid-beta cytotoxicity by omitting formation of higher-molecular-weight oligomers. *Biochemical and biophysical research communications*. 2013;439(3):321-6.

Wu W-L, Burnett DA, Clader J, Greenlee WJ, Jiang Q, Hyde LA, et al. Design and synthesis of water soluble beta-aminosulfone analogues of SCH 900229 as gamma-secretase inhibitors. *Bioorganic & medicinal chemistry letters*. 2016;26(23):5836-41.

Wu X, Kosaraju J, Zhou W, Tam KY. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease. *ACS chemical neuroscience*. 2017;8(3):676-85.

Wu Y, Luo X, Liu X, Liu D, Wang X, Guo Z, et al. Intraperitoneal Administration of a Novel TAT-BDNF Peptide Ameliorates Cognitive Impairments via Modulating Multiple Pathways in Two Alzheimer's Rodent Models. *Scientific reports*. 2015;5:15032.

Wu Y-J, Guernon J, Rajamani R, Toyn JH, Ahlijanian MK, Albright CF, et al. Discovery of furo 2,3-d 1,3 thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors. *Bioorganic & medicinal chemistry letters*. 2016;26(23):5729-31.

Wu Z, Guo Z, Gearing M, Chen G. Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's corrected disease model. *Nature communications*. 2014;5:4159.

Wu Z, Zhao L, Chen X, Cheng X, Zhang Y. Galantamine attenuates amyloid-beta deposition and astrocyte activation in APP/PS1 transgenic mice. *Experimental gerontology*. 2015;72:244-50.

Xi Y-D, Li X-Y, Ding J, Yu H-L, Ma W-W, Yuan L-H, et al. Soy isoflavone alleviates Abeta1-42-induced impairment of learning and memory ability through the regulation of RAGE/LRP-1 in neuronal and vascular tissue. *Current neurovascular research*. 2013;10(2):144-56.

Xia F, Yiu A, Stone SSD, Oh S, Lozano AM, Josselyn SA, et al. Entorhinal Cortical Deep Brain Stimulation Rescues Memory Deficits in Both Young and Old Mice Genetically Engineered to Model Alzheimer's Disease. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2017;42(13):2493-503.

Xia N, Liu L. Metallothioneins and synthetic metal chelators as potential therapeutic agents for removal of aberrant metal ions from metal-Abeta species. *Mini reviews in medicinal chemistry*. 2014;14(3):271-81.

Xia W, Li D-W, Xiang L, Chang J-J, Xia Z-L, Han E-J. Neuroprotective effects of an aqueous extract of *Futokadsura* stem in an Abeta-induced Alzheimer's disease-like rat model. *The Chinese journal of physiology*. 2015;58(2):104-13.

Xia W, Mo H. Potential of tocotrienols in the prevention and therapy of Alzheimer's disease. *The Journal of nutritional biochemistry*. 2016;31:1-9.

Xia Z, Peng W, Cheng S, Zhong B, Sheng C, Zhang C, et al. Naoling decoction restores cognitive function by inhibiting the neuroinflammatory network in a rat model of Alzheimer's disease. *Oncotarget*. 2017;8(26):42648-63.

Xian Y-F, Mao Q-Q, Wu JCY, Su Z-R, Chen J-N, Lai X-P, et al. Isorhynchophylline treatment improves the amyloid-beta-induced cognitive impairment in rats via inhibition of neuronal apoptosis and tau protein hyperphosphorylation. *Journal of Alzheimer's disease : JAD*. 2014;39(2):331-46.

Xiang PY, Janc O, Grochowska KM, Kreutz MR, Reymann KG. Dopamine agonists rescue Abeta-induced LTP impairment by Src-family tyrosine kinases. *Neurobiology of aging*. 2016;40:98-102.

Xiang S, Liu F, Lin J, Chen H, Huang C, Chen L, et al. Fucoxanthin Inhibits beta-Amyloid Assembly and Attenuates beta-Amyloid Oligomer-Induced Cognitive Impairments. *Journal of agricultural and food chemistry*. 2017;65(20):4092-102.

Xiao C, Davis FJ, Chauhan BC, Viola KL, Lacor PN, Velasco PT, et al. Brain transit and ameliorative effects of intranasally delivered anti-amyloid-beta oligomer antibody in 5XFAD mice. *Journal of Alzheimer's disease : JAD*. 2013;35(4):777-88.

Xiao R. Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer's disease. *Current topics in medicinal chemistry*. 2016;16(5):565-73.

Xiao S, Wang T, Ma X, Qin Y, Li X, Zhao Z, et al. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial. *Age and ageing*. 2017;46(5):767-73.

Xiao Y, Zhao L, Kuang S-X, Guan Z-Z. Inhibited Expression of alpha4beta2 Nicotinic Acetylcholine Receptor in Blood Leukocytes of Chinese Patients with Vascular Dementia and in Blood Leukocytes as Well as the Hippocampus of Brain from Ischemic Rats. *Cellular and molecular neurobiology*. 2016;36(8):1377-87.

Xicota L, Rodriguez-Morato J, Dierssen M, de la Torre R. Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease. *Current drug targets*. 2017;18(2):174-95.

Xie G, Tian W, Wei T, Liu F. The neuroprotective effects of beta-hydroxybutyrate on Abeta-injected rat hippocampus in vivo and in Abeta-treated PC-12 cells in vitro. *Free radical research*. 2015;49(2):139-50.

Xie H, Wen H, Zhang D, Liu L, Liu B, Liu Q, et al. Designing of dual inhibitors for GSK-3beta and CDK5: Virtual screening and in vitro biological activities study. *Oncotarget*. 2017;8(11):18118-28.

Xie J-W, Zhao Y, Feng X-L, Lin F-B, Luo J, Liu X, et al. Protective effect of butylphthalide in a cell model of Alzheimer's disease induced by Abeta25-35 in Neuro 2a cells. *Nan fang yi ke da xue xue bao = Journal of Southern Medical University*. 2017;37(9):1228-33.

Xie K, Liu Y, Hao W, Walter S, Penke B, Hartmann T, et al. Tenascin-C deficiency ameliorates Alzheimer's disease-related pathology in mice. *Neurobiology of aging*. 2013;34(10):2389-98.

Xie L, Luo Y, Lin D, Xi W, Yang X, Wei G. The molecular mechanism of fullerene-inhibited aggregation of Alzheimer's beta-amyloid peptide fragment. *Nanoscale*. 2014;6(16):9752-62.

Xie S, Chen J, Li X, Su T, Wang Y, Wang Z, et al. Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease. *Bioorganic & medicinal chemistry*. 2015;23(13):3722-9.

Xie S, Jin N, Gu J, Shi J, Sun J, Chu D, et al. O-GlcNAcylation of protein kinase A catalytic subunits enhances its activity: a mechanism linked to learning and memory deficits in Alzheimer's disease. *Aging cell*. 2016;15(3):455-64.

Xie S-S, Lan J-S, Wang X-B, Jiang N, Dong G, Li Z-R, et al. Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties. *European journal of medicinal chemistry*. 2015;93:42-50.

Xie S-S, Wang X, Jiang N, Yu W, Wang KDG, Lan J-S, et al. Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease. *European journal of medicinal chemistry*. 2015;95:153-65.

Xie S-S, Wang X-B, Li J-Y, Yang L, Kong L-Y. Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease. *European journal of medicinal chemistry*. 2013;64:540-53.

Xie W, Wang J-Q, Wang Q-C, Wang Y, Yao S, Tang T-S. Adult neural progenitor cells from Huntington's disease mouse brain exhibit increased proliferation and migration due to enhanced calcium and ROS signals. *Cell proliferation*. 2015;48(5):517-31.

Xie Y, Tan Y, Zheng Y, Du X, Liu Q. Ebselen ameliorates beta-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice. *Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry*. 2017;22(6):851-65.

Xin L, Yamujala R, Wang Y, Wang H, Wu W-H, Lawton MA, et al. Acetylcholinesterase-inhibiting alkaloids from *Lycoris radiata* delay paralysis of amyloid beta-expressing transgenic *C. elegans* CL4176. *PloS one*. 2013;8(5):e63874.

Xing H, Guo S, Zhang Y, Zheng Z, Wang H. Upregulation of microRNA-206 enhances lipopolysaccharide-induced inflammation and release of amyloid-beta by targeting insulin-like growth factor1 in microglia. *Molecular medicine reports*. 2016;14(2):1357-64.

Xing H-Y, Li B, Peng D, Wang C-Y, Wang G-Y, Li P, et al. A novel monoclonal antibody against the N-terminus of Abeta1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease. *PloS one*. 2017;12(6):e0180076.

Xing W, Fu Y, Shi Z, Lu D, Zhang H, Hu Y. Discovery of novel 2,6-disubstituted pyridazinone derivatives as acetylcholinesterase inhibitors. *European journal of medicinal chemistry*. 2013;63:95-103.

Xing Y, Feng X-Z, Zhang L, Hou J, Han G-C, Chen Z. A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles. *International journal of nanomedicine*. 2017;12:3171-9.

Xiong C, van Belle G, Chen K, Tian L, Luo J, Gao F, et al. Combining Multiple Markers to Improve the Longitudinal Rate of Progression-Application to Clinical Trials on the Early Stage of Alzheimer's Disease. *Statistics in biopharmaceutical research*. 2013;5(1).

Xiong H, Zheng C, Wang J, Song J, Zhao G, Shen H, et al. The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice. *Journal of Alzheimer's disease : JAD*. 2013;37(3):623-35.

Xiong Y, Zhao K, Wu J, Xu Z, Jin S, Zhang YQ. HDAC6 mutations rescue human tau-induced microtubule defects in *Drosophila*. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(12):4604-9.

Xu H, Gelyana E, Rajsombath M, Yang T, Li S, Selkoe D. Environmental Enrichment Potently Prevents Microglia-Mediated Neuroinflammation by Human Amyloid beta-Protein Oligomers. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2016;36(35):9041-56.

Xu J, Chatterjee M, Baguley TD, Brouillette J, Kurup P, Ghosh D, et al. Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease. *PLoS biology*. 2014;12(8):e1001923.

Xu J, de Winter F, Farrokhi C, Rockenstein E, Mante M, Adame A, et al. Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model. *Scientific reports*. 2016;6:31692.

Xu M, Dong Y, Wan S, Yan T, Cao J, Wu L, et al. Schisantherin B ameliorates Abeta1-42-induced cognitive decline via restoration of GLT-1 in a mouse model of Alzheimer's disease. *Physiology & behavior*. 2016;167:265-73.

Xu N-G, Xiao Z-J, Zou T, Huang Z-L. Ameliorative effects of physcion 8-O-beta-glucopyranoside isolated from *Polygonum cuspidatum* on learning and memory in dementia rats induced by Abeta1-40. *Pharmaceutical biology*. 2015;53(11):1632-8.

Xu P, Wang H, Li Z, Yang Z. Triptolide attenuated injury via inhibiting oxidative stress in Amyloid-Beta25-35-treated differentiated PC12 cells. *Life sciences*. 2016;145:19-26.

Xu P, Xu S-P, Wang K-Z, Lu C, Zhang H-X, Pan R-l, et al. Cognitive-enhancing effects of hydrolysate of polygalasaponin in SAMP8 mice. *Journal of Zhejiang University Science B*. 2016;17(7):503-14.

Xu P, Zhang M, Sheng R, Ma Y. Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, Abeta1-42 aggregation inhibitors and metal-chelating agents for Alzheimer's disease. *European journal of medicinal chemistry*. 2017;127:174-86.

Xu P-X, Wang S-W, Yu X-L, Su Y-J, Wang T, Zhou W-W, et al. Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Abeta oligomer level and attenuating oxidative stress and neuroinflammation. *Behavioural brain research*. 2014;264:173-80.

Xu Q, Huang S, Song M, Wang C-E, Yan S, Liu X, et al. Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms. *The Journal of cell biology*. 2013;202(7):1123-38.

Xu Q-Q, Xu Y-J, Yang C, Tang Y, Li L, Cai H-B, et al. Sodium Tanshinone IIA Sulfonate Attenuates Scopolamine-Induced Cognitive Dysfunctions via Improving Cholinergic System. *BioMed research international*. 2016;2016:9852536.

Xu S, Panikker P, Iqbal S, Elefant F. Tip60 HAT Action Mediates Environmental Enrichment Induced Cognitive Restoration. *PloS one*. 2016;11(7):e0159623.

Xu W, Xu Q, Cheng H, Tan X. The Efficacy and Pharmacological Mechanism of Zn7MT3 to Protect against Alzheimer's Disease. *Scientific reports*. 2017;7(1):13763.

Xu X, Zhang B, Lu K, Deng J, Zhao F, Zhao B-Q, et al. Prevention of Hippocampal Neuronal Damage and Cognitive Function Deficits in Vascular Dementia by Dextromethorphan. *Molecular neurobiology*. 2016;53(5):3494-502.

Xu Y, Zhang Z-Q, Zhao Y, Dong X-W, Wang X-Y, Zhang L-Q. Enhanced effect of guizhi plus Gegen Decoction on learning and memory disorder in LPS induced neuroinflammatory mice. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine*. 2014;34(2):179-84.

Xu Z-P, Li L, Bao J, Wang Z-H, Zeng J, Liu E-J, et al. Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model. *PloS one*. 2014;9(9):e108645.

Xuan A-G, Pan X-B, Wei P, Ji W-D, Zhang W-J, Liu J-H, et al. Valproic acid alleviates memory deficits and attenuates amyloid-beta deposition in transgenic mouse model of Alzheimer's disease. *Molecular neurobiology*. 2015;51(1):300-12.

Xue M, Zhu L, Zhang J, Qiu J, Du G, Qiao Z, et al. Low dose nicotine attenuates Abeta neurotoxicity through activation early growth response gene 1 pathway. *PloS one*. 2015;10(3):e0120267.

Xue X, Wang L-R, Sato Y, Jiang Y, Berg M, Yang D-S, et al. Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer's disease. *Nano letters*. 2014;14(9):5110-7.

Yabuki Y, Matsuo K, Hirano K, Shinoda Y, Moriguchi S, Fukunaga K. Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice. *Pharmacology*. 2017;99(3-4):160-71.

Yadav A, Sunkaria A, Singhal N, Sandhir R. Resveratrol loaded solid lipid nanoparticles attenuate mitochondrial oxidative stress in vascular dementia by activating Nrf2/HO-1 pathway. *Neurochemistry international*. 2017.

Yadav R, Murthy RV, Kikkeri R. Sialic Acid Hydroxamate: A Potential Antioxidant and Inhibitor of Metal-Induced beta-Amyloid Aggregates. *Chembiochem : a European journal of chemical biology*. 2015;16(10):1448-53.

Yaffe K, Hoang T. Nonpharmacologic treatment and prevention strategies for dementia. *Continuum (Minneapolis, Minn)*. 2013;19(2 Dementia):372-81.

Yalvac ME, Yarat A, Mercan D, Rizvanov AA, Palotas A, Sahin F. Characterization of the secretome of human tooth germ stem cells (hTGSCs) reveals neuro-protection by fine-tuning micro-environment. *Brain, behavior, and immunity*. 2013;32:122-30.

Yamada M, Ono K, Hamaguchi T, Noguchi-Shinohara M. Natural Phenolic Compounds as Therapeutic and Preventive Agents for Cerebral Amyloidosis. *Advances in experimental medicine and biology*. 2015;863:79-94.

Yamakawa MY, Uchino K, Watanabe Y, Adachi T, Nakanishi M, Ichino H, et al. Anthocyanin suppresses the toxicity of Aβ deposits through diversion of molecular forms in in vitro and in vivo models of Alzheimer's disease. *Nutritional neuroscience*. 2016;19(1):32-42.

Yamamoto N, Arima H, Sugiura T, Hirate H, Kusama N, Suzuki K, et al. Midazolam inhibits the formation of amyloid fibrils and GM1 ganglioside-rich microdomains in presynaptic membranes through the gamma-aminobutyric acid A receptor. *Biochemical and biophysical research communications*. 2015;457(4):547-53.

Yamanaka D, Kawano T, Nishigaki A, Aoyama B, Tateiwa H, Shigematsu-Locatelli M, et al. Preventive effects of dexmedetomidine on the development of cognitive dysfunction following systemic inflammation in aged rats. *Journal of anesthesia*. 2017;31(1):25-35.

Yamazaki H, Jin Y, Tsuchiya A, Kanno T, Nishizaki T. Adipose-derived stem cell-conditioned medium ameliorates antidepressant-related behaviors in the mouse model of Alzheimer's disease. *Neuroscience letters*. 2015;609:53-7.

Yamazaki M, Okabe M, Yamamoto N, Yarimizu J, Harada K. Novel 5-HT_{5A} receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats. *Journal of pharmacological sciences*. 2015;127(3):362-9.

Yamini P, Ray RS, Chopra K. Vitamin D3 attenuates cognitive deficits and neuroinflammatory responses in ICV-STZ induced sporadic Alzheimer's disease. *Inflammopharmacology*. 2017.

Yan H, Yan Z, Niu X, Wang J, Gui Y, Zhang P. D1-3-n-butylphthalide can improve the cognitive function of patients with acute ischemic stroke: a prospective intervention study. *Neurological research*. 2017;39(4):337-43.

Yan J, Liu X-H, Han M-Z, Wang Y-M, Sun X-L, Yu N, et al. Blockage of GSK3 β -mediated Drp1 phosphorylation provides neuroprotection in neuronal and mouse models of Alzheimer's disease. *Neurobiology of aging*. 2015;36(1):211-27.

Yan J-J, Ahn W-G, Jung J-S, Kim H-S, Hasan MA, Song D-K. Protective effects of *Acanthopanax divaricatus* extract in mouse models of Alzheimer's disease. *Nutrition research and practice*. 2014;8(4):386-90.

Yan J-J, Jung J-S, Kim T-K, Hasan A, Hong C-W, Nam J-S, et al. Protective effects of ferulic acid in amyloid precursor protein plus presenilin-1 transgenic mouse model of Alzheimer disease. *Biological & pharmaceutical bulletin*. 2013;36(1):140-3.

Yan R, Fan Q, Zhou J, Vassar R. Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease. *Neuroscience and biobehavioral reviews*. 2016;65:326-40.

Yan R, Zhang Z, Wang Y, Yang H, Zeng Q, Zhu D. Efficient strategy for maintaining and enhancing the huperzine A production of *Shiraiia* sp. Slf14 through inducer elicitation. *Journal of industrial microbiology & biotechnology*. 2014;41(7):1175-9.

Yan R. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. *Translational neurodegeneration*. 2016;5:13.

Yan W, Yun Y, Ku T, Li G, Sang N. NO₂ inhalation promotes Alzheimer's disease-like progression: cyclooxygenase-2-derived prostaglandin E₂ modulation and monoacylglycerol lipase inhibition-targeted medication. *Scientific reports*. 2016;6:22429.

Yan Z-Q, Chen J, Xing G-X, Huang J-G, Hou X-H, Zhang Y. Salidroside prevents cognitive impairment induced by chronic cerebral hypoperfusion in rats. *The Journal of international medical research*. 2015;43(3):402-11.

Yanagiha K, Ishii K, Tamaoka A. Acetylcholinesterase inhibitor treatment alleviated cognitive impairment caused by delayed encephalopathy due to carbon monoxide poisoning: Two case reports and a review of the literature. *Medicine*. 2017;96(8):e6125.

Yanez M, Vina D. Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease. *Current topics in medicinal chemistry*. 2013;13(14):1692-706.

Yang C, Li X, Mo Y, Liu S, Zhao L, Ma X, et al. beta-Asarone Mitigates Amyloidosis and Downregulates RAGE in a Transgenic Mouse Model of Alzheimer's Disease. *Cellular and molecular neurobiology*. 2016;36(1):121-30.

Yang C, Liu Y, Ni X, Li N, Zhang B, Fang X. Enhancement of the nonamyloidogenic pathway by exogenous NGF in an Alzheimer transgenic mouse model. *Neuropeptides*. 2014;48(4):233-8.

Yang D-S, Stavrides P, Saito M, Kumar A, Rodriguez-Navarro JA, Pawlik M, et al. Defective macroautophagic turnover of brain lipids in the TgCRND8 Alzheimer mouse model: prevention by correcting lysosomal proteolytic deficits. *Brain : a journal of neurology*. 2014;137(Pt 12):3300-18.

Yang E-J, Ahn S, Ryu J, Choi M-S, Choi S, Chong YH, et al. Phloroglucinol Attenuates the Cognitive Deficits of the 5XFAD Mouse Model of Alzheimer's Disease. *PloS one*. 2015;10(8):e0135686.

Yang G, Song Y, Zhou X, Deng Y, Liu T, Weng G, et al. MicroRNA-29c targets beta-site amyloid precursor protein-cleaving enzyme 1 and has a neuroprotective role in vitro and in vivo. *Molecular medicine reports*. 2015;12(2):3081-8.

Yang H, Qu T, Yang H, Wei L, Xie Z, Wang P, et al. Self-assembling nanofibers improve cognitive impairment in a transgenic mice model of Alzheimer's disease. *Neuroscience letters*. 2013;556:63-8.

Yang H, Shi O, Jin Y, Henrich-Noack P, Qiao H, Cai C, et al. Functional protection of learning and memory abilities in rats with vascular dementia. *Restorative neurology and neuroscience*. 2014;32(5):689-700.

Yang H, Wang S, Yu L, Zhu X, Xu Y. Esculentoside A suppresses Abeta(1-42)-induced neuroinflammation by down-regulating MAPKs pathways in vivo. *Neurological research*. 2015;37(10):859-66.

Yang H, Yang H, Xie Z, Wei L, Bi J. Systemic transplantation of human umbilical cord derived mesenchymal stem cells-educated T regulatory cells improved the impaired cognition in AbetaPPswe/PS1dE9 transgenic mice. *PloS one*. 2013;8(7):e69129.

Yang HJ, Hwang JT, Kwon DY, Kim MJ, Kang S, Moon NR, et al. Yuzu extract prevents cognitive decline and impaired glucose homeostasis in beta-amyloid-infused rats. *The Journal of nutrition*. 2013;143(7):1093-9.

Yang HJ, Kwon DY, Kim HJ, Kim MJ, Jung DY, Kang HJ, et al. Fermenting soybeans with *Bacillus licheniformis* potentiates their capacity to improve cognitive function and glucose homeostasis in diabetic rats with experimental Alzheimer's type dementia. *European journal of nutrition*. 2015;54(1):77-88.

Yang HJ, Kwon DY, Kim MJ, Kang S, Moon NR, Daily JW, et al. Red peppers with moderate and severe pungency prevent the memory deficit and hepatic insulin resistance in diabetic rats with Alzheimer's disease. *Nutrition & metabolism*. 2015;12:9.

Yang H-L, Cai P, Liu Q-H, Yang X-L, Li F, Wang J, et al. Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-beta aggregation for the treatment of Alzheimer's disease. *European journal of medicinal chemistry*. 2017;138:715-28.

Yang J, Huang X-B, Wan Q-L, Ding A-J, Yang Z-L, Qiu M-H, et al. Otophyllaside B Protects Against Abeta Toxicity in *Caenorhabditis elegans* Models of Alzheimer's Disease. *Natural products and bioprospecting*. 2017;7(2):207-14.

Yang J, Ju B, Yan Y, Xu H, Wu S, Zhu D, et al. Neuroprotective effects of phenylethanoid glycosides in an in vitro model of Alzheimer's disease. *Experimental and therapeutic medicine*. 2017;13(5):2423-8.

Yang J, Yao Y, Wang L, Yang C, Wang F, Guo J, et al. Gastrin-releasing peptide facilitates glutamatergic transmission in the hippocampus and effectively prevents vascular dementia induced cognitive and synaptic plasticity deficits. *Experimental neurology*. 2017;287(Pt 1):75-83.

Yang J-C, Rodriguez A, Royston A, Niu Y-Q, Avar M, Brill R, et al. Memantine Improves Attentional Processes in Fragile X-Associated Tremor/Ataxia Syndrome: Electrophysiological Evidence from a Randomized Controlled Trial. *Scientific reports*. 2016;6:21719.

Yang J-S, Wu X-H, Yu H-G, Teng L-S. Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats. *Inflammopharmacology*. 2017;25(4):471-84.

Yang M, Xu DD, Zhang Y, Liu X, Hoeven R, Cho WCS. A systematic review on natural medicines for the prevention and treatment of Alzheimer's disease with meta-analyses of intervention effect of ginkgo. *The American journal of Chinese medicine*. 2014;42(3):505-21.

Yang R, Wang Q, Li F, Li J, Liu X. Edaravone injection ameliorates cognitive deficits in rat model of Alzheimer's disease. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2015;36(11):2067-72.

Yang R, Wang Q, Min L, Sui R, Li J, Liu X. Monosialoanglioside improves memory deficits and relieves oxidative stress in the hippocampus of rat model of Alzheimer's disease. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2013;34(8):1447-51.

Yang R-Y, Zhao G, Wang D-M, Pang X-C, Wang S-B, Fang J-S, et al. DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice. *Pharmacology, biochemistry, and behavior*. 2015;139(Pt A):15-26.

Yang S, Chang R, Yang H, Zhao T, Hong Y, Kong HE, et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease. *The Journal of clinical investigation*. 2017;127(7):2719-24.

Yang S, Gong Q, Wu Q, Li F, Lu Y, Shi J. Alkaloids enriched extract from *Dendrobium nobile* Lindl. attenuates tau protein hyperphosphorylation and apoptosis induced by lipopolysaccharide in rat brain. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2014;21(5):712-6.

Yang S, Zhou G, Liu H, Zhang B, Li J, Cui R, et al. Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia. *BioMed research international*. 2013;2013:215798.

Yang S-F, Yeh C-B. Reply to: Proton Pump Inhibitors and Risk of Pneumonia in Individuals with Dementia. *Journal of the American Geriatrics Society*. 2017;65(11):2547-8.

Yang S-H, Lee DK, Shin J, Lee S, Baek S, Kim J, et al. Nec-1 alleviates cognitive impairment with reduction of Abeta and tau abnormalities in APP/PS1 mice. *EMBO molecular medicine*. 2017;9(1):61-77.

Yang S-S, Zhang R, Wang G, Zhang Y-F. The development prospect of HDAC inhibitors as a potential therapeutic direction in Alzheimer's disease. *Translational neurodegeneration*. 2017;6:19.

Yang W, Zhou X, Zimmermann HR, Cavener DR, Klann E, Ma T. Repression of the eIF2alpha kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer's disease. *Neurobiology of aging*. 2016;41:19-24.

Yang X, Qiang X, Li Y, Luo L, Xu R, Zheng Y, et al. Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease. *Bioorganic chemistry*. 2017;71:305-14.

Yang X, Zhang Y, Xu H, Luo X, Yu J, Liu J, et al. Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases. *Current topics in medicinal chemistry*. 2016;16(8):858-66.

Yang X-N, Li C-S, Chen C, Tang X-Y, Cheng G-Q, Li X. Protective effect of Shouwu Yizhi decoction against vascular dementia by promoting angiogenesis. *Chinese journal of natural medicines*. 2017;15(10):740-50.

Yang Y, Aloï MS, Cudaback E, Josephsen SR, Rice SJ, Jorstad NL, et al. Wild-type bone marrow transplant partially reverses neuroinflammation in progranulin-deficient mice. *Laboratory investigation; a journal of technical methods and pathology*. 2014;94(11):1224-36.

Yang Y, Cudaback E, Jorstad NL, Hemingway JF, Hagan CE, Melief EJ, et al. APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer disease. *The American journal of pathology*. 2013;183(3):905-17.

Yang Y, Ma D, Wang Y, Jiang T, Hu S, Zhang M, et al. Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. *Journal of Alzheimer's disease : JAD*. 2013;33(2):329-38.

Yang Y, Qin M, Bao P, Xu W, Xu J. Secretory carrier membrane protein 5 is an autophagy inhibitor that promotes the secretion of alpha-synuclein via exosome. *PloS one*. 2017;12(7):e0180892.

Yang Y, Wang L, Wu Y, Su D, Wang N, Wang J, et al. Tanshinol suppresses inflammatory factors in a rat model of vascular dementia and protects LPS-treated neurons via the MST1-FOXO3 signaling pathway. *Brain research*. 2016;1646:304-14.

Yang Y, Zhang J, Ma D, Zhang M, Hu S, Shao S, et al. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. *Journal of Alzheimer's disease : JAD*. 2013;37(3):637-48.

Yang Y-X. Proton Pump Inhibitor Therapy and Dementia: What Is the Evidence? *Journal of the American Geriatrics Society*. 2017.

Yang Z-Y, Kuboyama T, Kazuma K, Konno K, Tohda C. Active Constituents from *Drynaria fortunei* Rhizomes on the Attenuation of Abeta(25-35)-Induced Axonal Atrophy. *Journal of natural products*. 2015;78(9):2297-300.

Yano H, Baranov SV, Baranova OV, Kim J, Pan Y, Yablonska S, et al. Inhibition of mitochondrial protein import by mutant huntingtin. *Nature neuroscience*. 2014;17(6):822-31.

Yao J, Gao X, Sun W, Yao T, Shi S, Ji L. Molecular hairpin: a possible model for inhibition of tau aggregation by tannic acid. *Biochemistry*. 2013;52(11):1893-902.

Yao L, Gu X, Song Q, Wang X, Huang M, Hu M, et al. Nanoformulated alpha-mangostin ameliorates Alzheimer's disease neuropathology by elevating LDLR expression and accelerating amyloid-beta clearance. *Journal of controlled release : official journal of the Controlled Release Society*. 2016;226:1-14.

Yao L, Zhou Q. Enhancing NMDA Receptor Function: Recent Progress on Allosteric Modulators. *Neural plasticity*. 2017;2017:2875904.

Yao XQ, Jiao SS, Saadipour K, Zeng F, Wang QH, Zhu C, et al. p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimer's disease. *Molecular psychiatry*. 2015;20(11):1301-10.

Yao Y, Gao Z, Liang W, Kong L, Jiao Y, Li S, et al. Osthole promotes neuronal differentiation and inhibits apoptosis via Wnt/beta-catenin signaling in an Alzheimer's disease model. *Toxicology and applied pharmacology*. 2015;289(3):474-81.

Yao Z, Yang W, Gao Z, Jia P. Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. *Neuroscience letters*. 2017;647:133-40.

Yao Z-G, Jing H-Y, Wang D-M, Lv B-B, Li J-M, Liu F-F, et al. Valproic acid ameliorates olfactory dysfunction in APP/PS1 transgenic mice of Alzheimer's disease: Ameliorations from the olfactory epithelium to the olfactory bulb. *Pharmacology, biochemistry, and behavior*. 2016;144:53-9.

Yao Z-G, Liang L, Liu Y, Zhang L, Zhu H, Huang L, et al. Valproate improves memory deficits in an Alzheimer's disease mouse model: investigation of possible mechanisms of action. *Cellular and molecular neurobiology*. 2014;34(6):805-12.

Yarishkin O, Lee J, Jo S, Hwang EM, Lee CJ. Disinhibitory Action of Astrocytic GABA at the Perforant Path to Dentate Gyrus Granule Neuron Synapse Reverses to Inhibitory in Alzheimer's Disease Model. *Experimental neurobiology*. 2015;24(3):211-8.

Yarnall AJ, Rochester L, Baker MR, David R, Khoo TK, Duncan GW, et al. Short latency afferent inhibition: a biomarker for mild cognitive impairment in Parkinson's disease? *Movement disorders : official journal of the Movement Disorder Society*. 2013;28(9):1285-8.

Yassine HN, Schneider LS. Lessons from the Multidomain Alzheimer Preventive Trial. *The Lancet Neurology*. 2017;16(8):585-6.

Yassine HN. Targeting prodromal Alzheimer's disease: too late for prevention? *The Lancet Neurology*. 2017;16(12):946-7.

Ye CY, Lei Y, Tang XC, Zhang HY. Donepezil attenuates Abeta-associated mitochondrial dysfunction and reduces mitochondrial Abeta accumulation in vivo and in vitro. *Neuropharmacology*. 2015;95:29-36.

Ye M, Chung H-S, Lee C, Yoon MS, Yu AR, Kim JS, et al. Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer's disease. *Journal of neuroinflammation*. 2016;13:10.

Ye M, Moon J, Yang J, Hwa Lim H, Bin Hong S, Shim I, et al. The standardized Lycium chinense fruit extract protects against Alzheimer's disease in 3xTg-AD mice. *Journal of ethnopharmacology*. 2015;172:85-90.

Ye S, Wang T-T, Cai B, Wang Y, Li J, Zhan J-X, et al. Genistein protects hippocampal neurons against injury by regulating calcium/calmodulin dependent protein kinase IV protein levels in Alzheimer's disease model rats. *Neural regeneration research*. 2017;12(9):1479-84.

Ye Y, Li H, Yang J-W, Wang X-R, Shi G-X, Yan C-Q, et al. Acupuncture Attenuated Vascular Dementia-Induced Hippocampal Long-Term Potentiation Impairments via Activation of D1/D5 Receptors. *Stroke*. 2017;48(4):1044-51.

Yefimova MG, Bere E, Cantereau-Becq A, Harnois T, Meunier A-C, Messaddeq N, et al. Myelinosomes act as natural secretory organelles in Sertoli cells to prevent accumulation of aggregate-prone mutant Huntingtin and CFTR. *Human molecular genetics*. 2016;25(19):4170-85.

Yeong KY, Liew W-L, Murugaiyah V, Ang CW, Osman H, Tan SC. Ethyl nitrobenzoate: A novel scaffold for cholinesterase inhibition. *Bioorganic chemistry*. 2017;70:27-33.

Yi B, Sahn JJ, Ardestani PM, Evans AK, Scott LL, Chan JZ, et al. Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease. *Journal of neurochemistry*. 2017;140(4):561-75.

Yi C, Ezan P, Fernandez P, Schmitt J, Saez JC, Giaume C, et al. Inhibition of glial hemichannels by boldine treatment reduces neuronal suffering in a murine model of Alzheimer's disease. *Glia*. 2017;65(10):1607-25.

Yi JH, Baek SJ, Heo S, Park HJ, Kwon H, Lee S, et al. Direct pharmacological Akt activation rescues Alzheimer's disease like memory impairments and aberrant synaptic plasticity. *Neuropharmacology*. 2017;128:282-92.

Yi JH, Park HJ, Lee S, Jung JW, Kim BC, Lee YC, et al. Cassia obtusifolia seed ameliorates amyloid beta-induced synaptic dysfunction through anti-inflammatory and Akt/GSK-3beta pathways. *Journal of ethnopharmacology*. 2016;178:50-7.

Yi R, Chen B, Zhao J, Zhan X, Zhang L, Liu X, et al. Kruppel-like factor 8 ameliorates Alzheimer's disease by activating beta-catenin. *Journal of molecular neuroscience* : MN. 2014;52(2):231-41.

Yi X, Han H, Zhang Y, Wang J, Zhang Y, Zhou F. Amplified voltammetric characterization of cleavage of the biotinylated peptide by BACE1 and screening of BACE1 inhibitors. *Biosensors & bioelectronics*. 2013;50:224-8.

Yi Y, Wu S, Ye M, Zeng Y, Zhang P, Xie Y. Effect of Abeta1-42 injection on hippocampus cells in rats and protective role of polygona-polysaccharose for Alzheimer's disease. *Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences*. 2014;39(4):344-8.

Yin HL, Wang YL, Li JF, Han B, Zhang XX, Wang YT, et al. Effects of curcumin on hippocampal expression of NgR and axonal regeneration in Abeta-induced cognitive disorder rats. *Genetics and molecular research : GMR*. 2014;13(1):2039-47.

Yin J, Zhao F, Chojnacki JE, Fulp J, Klein WL, Zhang S, et al. NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer's Disease. *Molecular neurobiology*. 2017.

Yin JX, Maalouf M, Han P, Zhao M, Gao M, Dharshaun T, et al. Ketones block amyloid entry and improve cognition in an Alzheimer's model. *Neurobiology of aging*. 2016;39:25-37.

Yin R, Yin K, Guo Z, Zhang Z, Chen L, Cao L, et al. Protective Effects of Colivelin Against Alzheimer's Disease in a PDAPP Mouse Model. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2016;38(3):1138-46.

Yin T, Xie W, Sun J, Yang L, Liu J. Penetratin Peptide-Functionalized Gold Nanostars: Enhanced BBB Permeability and NIR Photothermal Treatment of Alzheimer's Disease Using Ultralow Irradiance. *ACS applied materials & interfaces*. 2016;8(30):19291-302.

Yin Y, Liu Y, Pan X, Chen R, Li P, Wu H-J, et al. Interleukin-1beta Promoter Polymorphism Enhances the Risk of Sleep Disturbance in Alzheimer's Disease. *PloS one*. 2016;11(3):e0149945.

Yin Y, Liu Y, Zhuang J, Pan X, Li P, Yang Y, et al. Low-Dose Atypical Antipsychotic Risperidone Improves the 5-Year Outcome in Alzheimer's Disease Patients with Sleep Disturbances. *Pharmacology*. 2015;96(3-4):155-62.

Yook J-S, Cho J-Y. Treadmill exercise ameliorates the regulation of energy metabolism in skeletal muscle of NSE/PS2m-transgenic mice with Alzheimer's disease. *Journal of exercise nutrition & biochemistry*. 2017.

Yook J-S, Cho J-Y. Treadmill exercise ameliorates the regulation of energy metabolism in skeletal muscle of NSE/PS2mtransgenic mice with Alzheimer's disease. *Journal of exercise nutrition & biochemistry*. 2017;21(1):40-7.

Yoon H, Myung W, Lim SW, Kang HS, Kim S, Won HH, et al. Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer's disease. *Pharmacopsychiatry*. 2015;48(3):111-7.

Yoon J-H, Youn K, Ho C-T, Karwe MV, Jeong W-S, Jun M. p-Coumaric acid and ursolic acid from Corni fructus attenuated beta-amyloid(25-35)-induced toxicity through regulation of the NF-kappaB signaling pathway in PC12 cells. *Journal of agricultural and food chemistry*. 2014;62(21):4911-6.

Yoshida J, Seino H, Ito Y, Nakano T, Satoh T, Ogane Y, et al. Inhibition of glycogen synthase kinase-3beta by faltarindiol isolated from Japanese Parsley (*Oenanthe javanica*). *Journal of agricultural and food chemistry*. 2013;61(31):7515-21.

Yoshida K, Roberts R, Suzuki T, Lebowitz B, Reeves S, Howard R, et al. Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2017;25(7):708-16.

Yoshimura Y, Holmberg MA, Kukic P, Andersen CB, Mata-Cabana A, Falsone SF, et al. MOAG-4 promotes the aggregation of alpha-synuclein by competing with self-protective electrostatic interactions. *The Journal of biological chemistry*. 2017;292(20):8269-78.

Yoshino Y, Mori T, Yoshida T, Toyota Y, Shimizu H, Iga J-I, et al. Improvement of Visuo-spatial Function Assessed by Raven's Colored Progressive Matrices in Dementia with Lewy Bodies by Donepezil Treatment. *Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology*. 2017;15(3):243-7.

Yoshioka T, Murakami K, Ido K, Hanaki M, Yamaguchi K, Midorikawa S, et al. Semisynthesis and Structure-Activity Studies of Uncarinic Acid C Isolated from *Uncaria rhynchophylla* as a Specific Inhibitor of the Nucleation Phase in Amyloid beta42 Aggregation. *Journal of natural products*. 2016;79(10):2521-9.

Youdim MBH. Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline. *Experimental neurobiology*. 2013;22(1):1-10.

Youn K, Jun M. In vitro BACE1 inhibitory activity of geraniin and corilagin from *Geranium thunbergii*. *Planta medica*. 2013;79(12):1038-42.

Youn K, Park J-H, Lee J, Jeong W-S, Ho C-T, Jun M. The Identification of Biochanin A as a Potent and Selective beta-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor. *Nutrients*. 2016;8(10).

Youn K, Yun E-Y, Lee J, Kim J-Y, Hwang J-S, Jeong W-S, et al. Oleic acid and linoleic acid from *Tenebrio molitor* larvae inhibit BACE1 activity in vitro: molecular docking studies. *Journal of medicinal food*. 2014;17(2):284-9.

Young K-W, Ng P, Kwok T, Cheng D. The effects of holistic health group interventions on improving the cognitive ability of persons with mild cognitive impairment: a randomized controlled trial. *Clinical interventions in aging*. 2017;12:1543-52.

Young-Mason J. Enhancing the lives of people living with dementia. *Clinical nurse specialist CNS*. 2015;29(1):57-9.

Young-Mason J. The patient's voice--does it still matter?: The February 2014 landmark case Westminster London Court of Protection deciding in favor of Manuela Sykes' petition to return home despite suffering from dementia. *Clinical nurse specialist CNS*. 2014;28(4):248-50.

Youssofzadeh V, McGuinness B, Maguire LP, Wong-Lin K. Corrigendum: Multi-Kernel Learning with Dartel Improves Combined MRI-PET Classification of Alzheimer's Disease in AIBL Data: Group and Individual Analyses. *Frontiers in human neuroscience*. 2017;11:457.

Youssofzadeh V, McGuinness B, Maguire LP, Wong-Lin K. Multi-Kernel Learning with Dartel Improves Combined MRI-PET Classification of Alzheimer's Disease in AIBL Data: Group and Individual Analyses. *Frontiers in human neuroscience*. 2017;11:380.

Ysselstein D, Dehay B, Costantino IM, McCabe GP, Frosch MP, George JM, et al. Endosulfine-alpha inhibits membrane-induced alpha-synuclein aggregation and protects against alpha-synuclein neurotoxicity. *Acta neuropathologica communications*. 2017;5(1):3.

Yu C-J, Liu W, Chen H-Y, Wang L, Zhang Z-R. BACE1 RNA interference improves spatial memory and attenuates Abeta burden in a streptozotocin-induced tau hyperphosphorylated rat model. *Cell biochemistry and function*. 2014;32(7):590-6.

Yu C-W, Chang P-T, Hsin L-W, Chern J-W. Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease. *Journal of medicinal chemistry*. 2013;56(17):6775-91.

Yu D, Tao B-B, Yang Y-Y, Du L-S, Yang S-S, He X-J, et al. The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2015;43(1):291-302.

Yu F, Gong P, Hu Z, Qiu Y, Cui Y, Gao X, et al. Cu(II) enhances the effect of Alzheimer's amyloid-beta peptide on microglial activation. *Journal of neuroinflammation*. 2015;12:122.

Yu F. Improving recruitment, retention, and adherence to 6-month cycling in Alzheimer's disease. *Geriatric nursing (New York, NY)*. 2013;34(3):181-6.

Yu J-T, Tan L. Lifestyle changes might prevent Alzheimer's disease. *Annals of translational medicine*. 2015;3(15):222.

Yu L, Wang S, Chen X, Yang H, Li X, Xu Y, et al. Orientin alleviates cognitive deficits and oxidative stress in Abeta1-42-induced mouse model of Alzheimer's disease. *Life sciences*. 2015;121:104-9.

Yu Q, Fang D, Swerdlow RH, Yu H, Chen JX, Yan SS. Antioxidants Rescue Mitochondrial Transport in Differentiated Alzheimer's Disease Trans-Mitochondrial Cybrid Cells. *Journal of Alzheimer's disease : JAD*. 2016;54(2):679-90.

Yu Q-S, Reale M, Kamal MA, Holloway HW, Luo W, Sambamurti K, et al. Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, alpha-Synuclein synthesis, interleukin-1beta release, and cholinergic action. *Anti-inflammatory & anti-allergy agents in medicinal chemistry*. 2013;12(2):117-28.

Yu R, Hui E, Lee J, Poon D, Ng A, Sit K, et al. Use of a Therapeutic, Socially Assistive Pet Robot (PARO) in Improving Mood and Stimulating Social Interaction and Communication for People With Dementia: Study Protocol for a Randomized Controlled Trial. *JMIR research protocols*. 2015;4(2):e45.

Yu X-L, Li Y-N, Zhang H, Su Y-J, Zhou W-W, Zhang Z-P, et al. Rutin inhibits amylin-induced neurocytotoxicity and oxidative stress. *Food & function*. 2015;6(10):3296-306.

Yu Y, Li X, Blanchard J, Li Y, Iqbal K, Liu F, et al. Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice. *Journal of neural transmission (Vienna, Austria : 1996)*. 2015;122(4):593-606.

Yu Y-F, Huang Y-D, Zhang C, Wu X-N, Zhou Q, Wu D, et al. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease. *ACS chemical neuroscience*. 2017;8(11):2522-34.

Yu Y-Z, Liu S, Wang H-C, Shi D, Xu Q, Zhou X-W, et al. A Novel Abeta B-Cell Epitope Vaccine (rCV01) for Alzheimer's Disease Improved Synaptic and Cognitive Functions in 3*Tg-AD Mice. *Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology*. 2016;11(4):657-68.

Yu Y-Z, Liu S, Wang H-C, Shi D-Y, Xu Q, Zhou X-W, et al. A novel recombinant 6Abeta15-THc-C chimeric vaccine (rCV02) mitigates Alzheimer's disease-like pathology, cognitive decline and synaptic loss in aged 3*Tg-AD mice. *Scientific reports*. 2016;6:27175.

Yu Y-Z, Wang W-B, Chen A, Chang Q, Liu S, Zhao M, et al. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant

chimeric vaccines by hexavalent foldable Abeta α , β , γ , δ , ϵ , κ ,... fused to toxin-derived carrier proteins. Journal of Alzheimer's disease : JAD. 2014;41(1):243-60.

Yu Z-H, Zhang C-Y, Pu B-H, Xiao S-Y, Dong Z-H, Li Y-M. Ginkgo leaves tablet improved the memory quotient of patients with mild cognitive impairment: a clinical observation. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 2014;34(3):287-91.

Yuan D, Zeng C, Chen Q, Wang F, Yuan L, Zhu Y, et al. Root-Securing and Brain-Fortifying Liquid Upregulates Caveolin-1 in Cell Model with Alzheimer's Disease through Inhibiting Tau Phosphorylation. Neurology research international. 2017;2017:6248351.

Yuan J, Venkatraman S, Zheng Y, McKeever BM, Dillard LW, Singh SB. Structure-based design of beta-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease. Journal of medicinal chemistry. 2013;56(11):4156-80.

Yuan P, Grutzendler J. Attenuation of beta-Amyloid Deposition and Neurotoxicity by Chemogenetic Modulation of Neural Activity. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2016;36(2):632-41.

Yuan T, Ma H, Liu W, Niesen DB, Shah N, Crews R, et al. Pomegranate's Neuroprotective Effects against Alzheimer's Disease Are Mediated by Urolithins, Its Ellagitannin-Gut Microbial Derived Metabolites. ACS chemical neuroscience. 2016;7(1):26-33.

Yuan T-F, Shan C. "Glial inhibition" of memory in Alzheimer's disease. Science China Life sciences. 2014;57(12):1238-40.

Yuan Z, Luan G, Wang Z, Hao X, Li J, Suo Y, et al. Flavonoids from *Potentilla parvifolia* Fisch. and Their Neuroprotective Effects in Human Neuroblastoma SH-SY5Y Cells in vitro. Chemistry & biodiversity. 2017;14(6).

Yue W, Li Y, Zhang T, Jiang M, Qian Y, Zhang M, et al. ESC-Derived Basal Forebrain Cholinergic Neurons Ameliorate the Cognitive Symptoms Associated with Alzheimer's Disease in Mouse Models. Stem cell reports. 2015;5(5):776-90.

Yue X-H, Tong J-Q, Wang Z-J, Zhang J, Liu X, Liu X-J, et al. Steroid sulfatase inhibitor DU-14 protects spatial memory and synaptic plasticity from disruption by amyloid beta protein in male rats. Hormones and behavior. 2016;83:83-92.

Yui D, Nishida Y, Nishina T, Mogushi K, Tajiri M, Ishibashi S, et al. Enhanced Phospholipase A2 Group 3 Expression by Oxidative Stress Decreases the Insulin-Degrading Enzyme. PloS one. 2015;10(12):e0143518.

Yulug B, Hanoglu L, Kilic E, Schabitz WR. RIFAMPICIN: an antibiotic with brain protective function. *Brain research bulletin*. 2014;107:37-42.

Yulug B, Hanoglu L, Ksanmemmedov E, Duz OA, Polat B, Hanoglu T, et al. Beyond The Therapeutic Effect Of Rtns In Alzheimer's Disease: A Possible Neuroprotective Role Of Hippocampal Bdnf? : A Minireview. *Mini reviews in medicinal chemistry*. 2017.

Yun HM, Kim HS, Park KR, Shin JM, Kang AR, il Lee K, et al. Placenta-derived mesenchymal stem cells improve memory dysfunction in an Abeta1-42-infused mouse model of Alzheimer's disease. *Cell death & disease*. 2013;4:e958.

Yuzwa SA, Cheung AH, Okon M, McIntosh LP, Vocadlo DJ. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. *Journal of molecular biology*. 2014;426(8):1736-52.

Yuzwa SA, Shan X, Jones BA, Zhao G, Woodward ML, Li X, et al. Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice. *Molecular neurodegeneration*. 2014;9:42.

Zabalegui A, Hamers JPH, Karlsson S, Leino-Kilpi H, Renom-Guiteras A, Saks K, et al. Best practices interventions to improve quality of care of people with dementia living at home. *Patient education and counseling*. 2014;95(2):175-84.

Zafar S, Shafiq M, Younas N, Schmitz M, Ferrer I, Zerr I. Prion Protein Interactome: Identifying Novel Targets in Slowly and Rapidly Progressive Forms of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;59(1):265-75.

Zaheer S, Thangavel R, Wu Y, Khan MM, Kempuraj D, Zaheer A. Enhanced expression of glia maturation factor correlates with glial activation in the brain of triple transgenic Alzheimer's disease mice. *Neurochemical research*. 2013;38(1):218-25.

Zahodne LB, Schupf N, Brickman AM, Mayeux R, Wall MM, Stern Y, et al. Dementia Risk and Protective Factors Differ in the Context of Memory Trajectory Groups. *Journal of Alzheimer's disease : JAD*. 2016;52(3):1013-20.

Zakaria A, Hamdi N, Abdel-Kader RM. Methylene Blue Improves Brain Mitochondrial ABAD Functions and Decreases Abeta in a Neuroinflammatory Alzheimer's Disease Mouse Model. *Molecular neurobiology*. 2016;53(2):1220-8.

Zamani M, Rohampour K, Zeraati M, Hosseinmardi N, Kazemian MM. Pre-training Catechin gavage prevents memory impairment induced by intracerebroventricular streptozotocin in rats. *Neurosciences (Riyadh, Saudi Arabia)*. 2015;20(3):225-9.

Zamberlan DC, Arantes LP, Machado ML, Golombieski R, Soares FAA. Diphenyl-diselenide suppresses amyloid-beta peptide in *Caenorhabditis elegans* model of Alzheimer's disease. *Neuroscience*. 2014;278:40-50.

Zanchetti A, Liu L, Mancina G, Parati G, Grassi G, Stramba-Badiale M, et al. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. *Journal of hypertension*. 2014;32(9):1888-97.

Zara S, De Colli M, Rapino M, Pacella S, Nasuti C, Sozio P, et al. Ibuprofen and lipoic acid conjugate neuroprotective activity is mediated by Ngb/Akt intracellular signaling pathway in Alzheimer's disease rat model. *Gerontology*. 2013;59(3):250-60.

Zare-Zardini H, Tolueinia B, Hashemi A, Ebrahimi L, Fesahat F. Antioxidant and cholinesterase inhibitory activity of a new peptide from *Ziziphus jujuba* fruits. *American journal of Alzheimer's disease and other dementias*. 2013;28(7):702-9.

Zarrouk A, Nury T, Riedinger JM, Rouaud O, Hammami M, Lizard G. Dual effect of docosahexaenoic acid (attenuation or amplification) on C22:0-, C24:0-, and C26:0-induced mitochondrial dysfunctions and oxidative stress on human neuronal SK-N-BE cells. *The journal of nutrition, health & aging*. 2015;19(2):198-205.

Zavoreo I, Madzar Z, Demarin V, Kes VB. Vascular cognitive impairment in diabetes mellitus: are prevention and treatment effective? *Acta clinica Croatica*. 2014;53(3):326-33.

Zeiss CJ. Improving the predictive value of interventional animal models data. *Drug discovery today*. 2015;20(4):475-82.

Zemek F, Drtinova L, Nepovimova E, Sepsova V, Korabecny J, Klimes J, et al. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. *Expert opinion on drug safety*. 2014;13(6):759-74.

Zeng G-F, Zhang Z-Y, Lu L, Xiao D-Q, Zong S-H, He J-M. Protective effects of ginger root extract on Alzheimer disease-induced behavioral dysfunction in rats. *Rejuvenation research*. 2013;16(2):124-33.

Zeng L, Hu C, Zhang F, Xu DC, Cui M-Z, Xu X. Cellular FLICE-like Inhibitory Protein (c-FLIP) and PS1-associated Protein (PSAP) Mediate Presenilin 1-induced gamma-Secretase-dependent and -independent Apoptosis, Respectively. *The Journal of biological chemistry*. 2015;290(30):18269-80.

Zeng L, Zou Y, Kong L, Wang N, Wang Q, Wang L, et al. Can Chinese Herbal Medicine Adjunctive Therapy Improve Outcomes of Senile Vascular Dementia? Systematic Review with Meta-analysis of Clinical Trials. *Phytotherapy research : PTR*. 2015;29(12):1843-57.

Zeng Y, Guo W, Xu G, Wang Q, Feng L, Long S, et al. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in *Caenorhabditis elegans* model of Huntington's disease. *Drug design, development and therapy*. 2016;10:1443-51.

Zeng Y, Zhang J, Zhu Y, Zhang J, Shen H, Lu J, et al. Tripchlorolide improves cognitive deficits by reducing amyloid beta and upregulating synapse-related proteins in a transgenic model of Alzheimer's Disease. *Journal of neurochemistry*. 2015;133(1):38-52.

Zengin G, Sarikurkcu C, Gunes E, Uysal A, Ceylan R, Uysal S, et al. Two *Ganoderma* species: profiling of phenolic compounds by HPLC-DAD, antioxidant, antimicrobial and inhibitory activities on key enzymes linked to diabetes mellitus, Alzheimer's disease and skin disorders. *Food & function*. 2015;6(8):2794-802.

Zenthofer A, Cabrera T, Rammelsberg P, Hassel AJ. Improving oral health of institutionalized older people with diagnosed dementia. *Aging & mental health*. 2016;20(3):303-8.

Zenthofer A, Meyer-Kuhling I, Hufeland A-L, Schroder J, Cabrera T, Baumgart D, et al. Carers' education improves oral health of older people suffering from dementia - results of an intervention study. *Clinical interventions in aging*. 2016;11:1755-62.

Zerbi V, Jansen D, Wiesmann M, Fang X, Broersen LM, Veltien A, et al. Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer's disease. *Neurobiology of aging*. 2014;35(3):600-13.

Zha G-F, Zhang C-P, Qin H-L, Jantan I, Sher M, Amjad MW, et al. Biological evaluation of synthetic alpha,beta-unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-beta aggregation. *Bioorganic & medicinal chemistry*. 2016;24(10):2352-9.

Zhang B, Wang Y, Li H, Xiong R, Zhao Z, Chu X, et al. Neuroprotective effects of salidroside through PI3K/Akt pathway activation in Alzheimer's disease models. *Drug design, development and therapy*. 2016;10:1335-43.

Zhang C, Kuo C-C, Moghadam SH, Monte L, Campbell SN, Rice KC, et al. Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016;12(5):527-37.

Zhang C-Z, Dong L, Mu F-H, Yang X-H, Sun W. Progress in the studies on neuronal nitric oxide synthase inhibitors. *Yao xue xue bao = Acta pharmaceutica Sinica*. 2014;49(6):781-8.

Zhang F, Ho YW, Fung HH. Learning from Normal Aging: Preserved Emotional Functioning Facilitates Adaptation among Early Alzheimer's Disease Patients. *Aging and disease*. 2015;6(3):208-15.

Zhang F-F, Li J. Inhibitory effect of chloroquine derivatives on presenilin 1 and ubiquitin 1 expression in Alzheimer's disease. *International journal of clinical and experimental pathology*. 2015;8(6):7640-3.

Zhang H, Ma L, Yin Y-L, Dong L-Q, Cheng G-G, Ma Y-Q, et al. Over-expression of TSPO in the hippocampal CA1 area alleviates cognitive dysfunction caused by lipopolysaccharide in mice. *Brain research*. 2016;1646:402-9.

Zhang H, Petit GH, Gaughwin PM, Hansen C, Ranganathan S, Zuo X, et al. NGF rescues hippocampal cholinergic neuronal markers, restores neurogenesis, and improves the spatial working memory in a mouse model of Huntington's Disease. *Journal of Huntington's disease*. 2013;2(1):69-82.

Zhang H, Sun R, Liu X-Y, Shi X-M, Wang W-F, Yu L-G, et al. A tetramethylpyrazine piperazine derivate CXC137 prevents cell injury in SH-SY5Y cells and improves memory dysfunction of rats with vascular Dementia. *Neurochemical research*. 2014;39(2):276-86.

Zhang H, Zhang L, Zhou D, He X, Wang D, Pan H, et al. Ablating ErbB4 in PV neurons attenuates synaptic and cognitive deficits in an animal model of Alzheimer's disease. *Neurobiology of disease*. 2017;106:171-80.

Zhang J, An S, Hu W, Teng M, Wang X, Qu Y, et al. The Neuroprotective Properties of *Herichium erinaceus* in Glutamate-Damaged Differentiated PC12 Cells and an Alzheimer's Disease Mouse Model. *International journal of molecular sciences*. 2016;17(11).

Zhang J, Cao Q, Li S, Lu X, Zhao Y, Guan J-S, et al. 3-Hydroxybutyrate methyl ester as a potential drug against Alzheimer's disease via mitochondria protection mechanism. *Biomaterials*. 2013;34(30):7552-62.

Zhang J, Ding Y-R, Wang R. Inhibition of tissue transglutaminase promotes A β -induced apoptosis in SH-SY5Y cells. *Acta pharmacologica Sinica*. 2016;37(12):1534-42.

Zhang J, Guo J, Zhao X, Chen Z, Wang G, Liu A, et al. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. *Behavioural brain research*. 2013;250:230-7.

Zhang J, Guo W, Tian B, Sun M, Li H, Zhou L, et al. Puerarin attenuates cognitive dysfunction and oxidative stress in vascular dementia rats induced by chronic ischemia. *International journal of clinical and experimental pathology*. 2015;8(5):4695-704.

Zhang J, Hu M, Teng Z, Tang Y-P, Chen C. Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(45):14919-33.

Zhang J, Li P, Wang Y, Liu J, Zhang Z, Cheng W, et al. Ameliorative effects of a combination of baicalin, jasminoidin and cholic acid on ibotenic acid-induced dementia model in rats. *PloS one*. 2013;8(2):e56658.

Zhang J, Wei S-Y, Yuan L, Kong L-L, Zhang S-X, Wang Z-J, et al. Davunetide improves spatial learning and memory in Alzheimer's disease-associated rats. *Physiology & behavior*. 2017;174:67-73.

Zhang J, Zhang L, Sun X, Yang Y, Kong L, Lu C, et al. Acetylcholinesterase Inhibitors for Alzheimer's Disease Treatment Ameliorate Acetaminophen-Induced Liver Injury in Mice via Central Cholinergic System Regulation. *The Journal of pharmacology and experimental therapeutics*. 2016;359(2):374-82.

Zhang JS, Zhou SF, Wang Q, Guo JN, Liang HM, Deng JB, et al. Gastrodin suppresses BACE1 expression under oxidative stress condition via inhibition of the PKR/eIF2alpha pathway in Alzheimer's disease. *Neuroscience*. 2016;325:1-9.

Zhang L, Fang Y, Lian Y, Chen Y, Wu T, Zheng Y, et al. Brain-derived neurotrophic factor ameliorates learning deficits in a rat model of Alzheimer's disease induced by abeta1-42. *PloS one*. 2015;10(4):e0122415.

Zhang L, Fang Y, Xu Y, Lian Y, Xie N, Wu T, et al. Curcumin Improves Amyloid beta-Peptide (1-42) Induced Spatial Memory Deficits through BDNF-ERK Signaling Pathway. *PloS one*. 2015;10(6):e0131525.

Zhang L, Han L, Qin J, Lu W, Wang J. The use of borneol as an enhancer for targeting aprotinin-conjugated PEG-PLGA nanoparticles to the brain. *Pharmaceutical research*. 2013;30(10):2560-72.

Zhang L, Liu C, Wu J, Tao J-J, Sui X-L, Yao Z-G, et al. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice. *Journal of Alzheimer's disease : JAD*. 2014;41(4):1193-205.

Zhang L, Ma Q, Yang W, Qi X, Yao Z, Liu Y, et al. Recombinant DNA vaccine against neurite outgrowth inhibitors attenuates behavioral deficits and decreases Abeta in an Alzheimer's disease mouse model. *Neuropharmacology*. 2013;70:200-10.

Zhang L, Sun C, Jin Y, Gao K, Shi X, Qiu W, et al. Dickkopf 3 (Dkk3) Improves Amyloid-beta Pathology, Cognitive Dysfunction, and Cerebral Glucose Metabolism in a Transgenic Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;60(2):733-46.

Zhang L, Yang J, Cao Y. What is the new target inhibiting the progression of Alzheimer's disease. *Neural regeneration research*. 2013;8(21):1938-47.

Zhang L-D, Ma L, Zhang L, Dai J-G, Chang L-G, Huang P-L, et al. Hyperbaric Oxygen and Ginkgo Biloba Extract Ameliorate Cognitive and Memory Impairment via Nuclear Factor Kappa-B Pathway in Rat Model of Alzheimer's Disease. *Chinese medical journal*. 2015;128(22):3088-93.

Zhang L-G, Wang L-J, Shen Q-Q, Wang H-F, Zhang Y, Shi C-G, et al. Paeoniflorin improves regional cerebral blood flow and suppresses inflammatory factors in the hippocampus of rats with vascular dementia. *Chinese journal of integrative medicine*. 2017;23(9):696-702.

Zhang L-N, Sun Y-J, Pan S, Li J-X, Qu Y-E, Li Y, et al. Na⁺-K⁺-ATPase, a potent neuroprotective modulator against Alzheimer disease. *Fundamental & clinical pharmacology*. 2013;27(1):96-103.

Zhang M, Wang Y, Qian F, Li P, Xu X. Hypericin inhibits oligomeric amyloid beta42-induced inflammation response in microglia and ameliorates cognitive deficits in an amyloid beta injection mouse model of Alzheimer's disease by suppressing MKL1. *Biochemical and biophysical research communications*. 2016;481(1-2):71-6.

Zhang M, Xu G-H, Wang W-X, Meng D-J, Ji Y. Electroacupuncture improves cognitive deficits and activates PPAR-gamma in a rat model of Alzheimer's disease. *Acupuncture in medicine : journal of the British Medical Acupuncture Society*. 2017;35(1):44-51.

Zhang M-Y, Zheng C-Y, Zou M-M, Zhu J-W, Zhang Y, Wang J, et al. Lamotrigine attenuates deficits in synaptic plasticity and accumulation of amyloid plaques in APP/PS1 transgenic mice. *Neurobiology of aging*. 2014;35(12):2713-25.

Zhang N, Xing M, Wang Y, Liang H, Yang Z, Shi F, et al. Hydroxysafflor yellow A improves learning and memory in a rat model of vascular dementia by increasing VEGF and NR1 in the hippocampus. *Neuroscience bulletin*. 2014;30(3):417-24.

Zhang N, Xing M, Wang Y, Tao H, Cheng Y. Repetitive transcranial magnetic stimulation enhances spatial learning and synaptic plasticity via the VEGF and BDNF-NMDAR pathways in a rat model of vascular dementia. *Neuroscience*. 2015;311:284-91.

Zhang P, Xie MQ, Ding YQ, Liao M, Qi SS, Chen SX, et al. Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APP^{swe}/PSEN1 mice. *Neuroscience*. 2015;290:214-26.

Zhang Q, Descamps O, Hart MJ, Poksay KS, Spilman P, Kane DJ, et al. Paradoxical effect of TrkA inhibition in Alzheimer's disease models. *Journal of Alzheimer's disease : JAD*. 2014;40(3):605-17.

Zhang Q, Li J, Liu C, Song C, Li P, Yin F, et al. Protective effects of low molecular weight chondroitin sulfate on amyloid beta (Abeta)-induced damage in vitro and in vivo. *Neuroscience*. 2015;305:169-82.

Zhang R, Miao Q-W, Zhu C-X, Zhao Y, Liu L, Yang J, et al. Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid beta deposits and peroxidation in mice with Alzheimer-like lesions. *American journal of Alzheimer's disease and other dementias*. 2015;30(2):183-91.

Zhang R, Zhang J, Fang L, Li X, Zhao Y, Shi W, et al. Neuroprotective effects of sulforaphane on cholinergic neurons in mice with Alzheimer's disease-like lesions. *International journal of molecular sciences*. 2014;15(8):14396-410.

Zhang S, Li X, Wang Z, Liu Y, Gao Y, Tan L, et al. Paternal spatial training enhances offspring's cognitive performance and synaptic plasticity in wild-type but not improve memory deficit in Alzheimer's mice. *Scientific reports*. 2017;7(1):1521.

Zhang S-F, Dong Y-C, Zhang X-F, Wu X-G, Cheng J-J, Guan L-H, et al. Flavonoids from *Scutellaria* attenuate okadaic acid-induced neuronal damage in rats. *Brain injury*. 2015;29(11):1376-82.

Zhang T, Xu W, Mu Y, Derreumaux P. Atomic and dynamic insights into the beneficial effect of the 1,4-naphthoquinon-2-yl-L-tryptophan inhibitor on Alzheimer's Abeta1-42 dimer in terms of aggregation and toxicity. *ACS chemical neuroscience*. 2014;5(2):148-59.

Zhang T, Zhang J, Derreumaux P, Mu Y. Molecular mechanism of the inhibition of EGCG on the Alzheimer Abeta(1-42) dimer. *The journal of physical chemistry B*. 2013;117(15):3993-4002.

Zhang W, Gu G-J, Shen X, Zhang Q, Wang G-M, Wang P-J. Neural stem cell transplantation enhances mitochondrial biogenesis in a transgenic mouse model of Alzheimer's disease-like pathology. *Neurobiology of aging*. 2015;36(3):1282-92.

Zhang W, Wang P-J, Sha H-y, Ni J, Li M-h, Gu G-j. Neural stem cell transplants improve cognitive function without altering amyloid pathology in an APP/PS1 double transgenic model of Alzheimer's disease. *Molecular neurobiology*. 2014;50(2):423-37.

Zhang W, Zhi D, Ren H, Wang D, Wang X, Zhang Z, et al. Shengmai Formula Ameliorates Pathological Characteristics in AD *C.elegans*. *Cellular and molecular neurobiology*. 2016;36(8):1291-302.

Zhang X, Hernandez I, Rei D, Mair W, Laha JK, Cornwell ME, et al. Diaminotiazoles modify Tau phosphorylation and improve the tauopathy in mouse models. *The Journal of biological chemistry*. 2013;288(30):22042-56.

Zhang X, Schmitt FA, Caban-Holt AM, Ding X, Kryscio RJ, Abner E. Diabetes mitigates the role of memory complaint in predicting dementia risk: Results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study. *The journal of prevention of Alzheimer's disease*. 2017;4(3):143-8.

Zhang X, Tian Y, Li Z, Tian X, Sun H, Liu H, et al. Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease. *Journal of the American Chemical Society*. 2013;135(44):16397-409.

Zhang X, Tian Y, Yuan P, Li Y, Yaseen MA, Grutzendler J, et al. A bifunctional curcumin analogue for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer's disease. *Chemical communications (Cambridge, England)*. 2014;50(78):11550-3.

Zhang X, Zhao X, Lang Y, Li Q, Liu X, Cai C, et al. Low anticoagulant heparin oligosaccharides as inhibitors of BACE-1, the Alzheimer's beta-secretase. *Carbohydrate polymers*. 2016;151:51-9.

Zhang XD, Liu XQ, Kim YH, Whang WK. Chemical constituents and their acetyl cholinesterase inhibitory and antioxidant activities from leaves of *Acanthopanax henryi*: potential complementary source against Alzheimer's disease. *Archives of pharmacal research*. 2014;37(5):606-16.

Zhang Y, Cai J, An L, Hui F, Ren T, Ma H, et al. Does music therapy enhance behavioral and cognitive function in elderly dementia patients? A systematic review and meta-analysis. *Ageing research reviews*. 2017;35:1-11.

Zhang Y, Huang L-J, Shi S, Xu S-F, Wang X-L, Peng Y. L-3-n-butylphthalide Rescues Hippocampal Synaptic Failure and Attenuates Neuropathology in Aged APP/PS1 Mouse Model of Alzheimer's Disease. *CNS neuroscience & therapeutics*. 2016;22(12):979-87.

Zhang Y, Li Q, Liu C, Gao S, Ping H, Wang J, et al. MiR-214-3p attenuates cognition defects via the inhibition of autophagy in SAMP8 mouse model of sporadic Alzheimer's disease. *Neurotoxicology*. 2016;56:139-49.

Zhang Y, Li Q, Zou J, Zuo Z, Yao Z. Continuous vaccinations of 4Abeta1-15 induces specific fluctuation of inflammatory factors accompany with pathologic alterations alleviation in APP/PS1 mice. *Human vaccines & immunotherapeutics*. 2015;11(11):2674-81.

Zhang Y, Lin C, Zhang L, Cui Y, Gu Y, Guo J, et al. Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled Trial. *PloS one*. 2015;10(6):e0130353.

Zhang Y, Liu M, Sun H, Yin K. Matrine improves cognitive impairment and modulates the balance of Th17/Treg cytokines in a rat model of Abeta1-42-induced Alzheimer's disease. *Central-European journal of immunology*. 2015;40(4):411-9.

Zhang Y, Pi Z, Song F, Liu Z. Ginsenosides attenuate d-galactose- and AlCl₃-induced spatial memory impairment by restoring the dysfunction of the neurotransmitter systems in the rat model of Alzheimer's disease. *Journal of ethnopharmacology*. 2016;194:188-95.

Zhang Y, Simon-Vermot L, Araque Caballero MA, Gesierich B, Taylor ANW, Duering M, et al. Enhanced resting-state functional connectivity between core memory-task activation peaks is associated with memory impairment in MCI. *Neurobiology of aging*. 2016;45:43-9.

Zhang Y, Wang F, Luo X, Wang L, Sun P, Wang M, et al. Cognitive Improvement by Photic Stimulation in a Mouse Model of Alzheimer's Disease. *Current Alzheimer research*. 2015;12(9):860-9.

Zhang Y, Wang L-L, Wu Y, Wang N, Wang S-M, Zhang B, et al. Paeoniflorin attenuates hippocampal damage in a rat model of vascular dementia. *Experimental and therapeutic medicine*. 2016;12(6):3729-34.

Zhang Y, Yang X, Jin G, Yang X, Zhang Y. Polysaccharides from *Pleurotus ostreatus* alleviate cognitive impairment in a rat model of Alzheimer's disease. *International journal of biological macromolecules*. 2016;92:935-41.

Zhang Y, Yin F, Liu J, Liu Z, Guo L, Xia Z, et al. Geniposide attenuates insulin-deficiency-induced acceleration of beta-amyloidosis in an APP/PS1 transgenic model of Alzheimer's disease. *Neurochemistry international*. 2015;89:7-16.

Zhang Y, Yin F, Liu J, Liu Z. Geniposide Attenuates the Phosphorylation of Tau Protein in Cellular and Insulin-deficient APP/PS1 Transgenic Mouse Model of Alzheimer's Disease. *Chemical biology & drug design*. 2016;87(3):409-18.

Zhang Y, Yong H-y, Shi X-t, Zhou J, Ma Q, Lian Q-q, et al. Protective effect of curcumin against Abeta₂₅₋₃₅-induced neurotoxicity in differentiated PC12 cells. *Zhonghua yi xue za zhi*. 2013;93(35):2826-9.

Zhang Y, Zhang Z, Wang H, Cai N, Zhou S, Zhao Y, et al. Neuroprotective effect of ginsenoside Rg1 prevents cognitive impairment induced by isoflurane anesthesia in aged rats via antioxidant, anti-inflammatory and anti-apoptotic effects mediated by the PI3K/AKT/GSK-3 β pathway. *Molecular medicine reports*. 2016;14(3):2778-84.

Zhang Y-H, Mann D, Raymick J, Sarkar S, Paule MG, Lahiri DK, et al. K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice. *Current Alzheimer research*. 2014;11(3):299-308.

Zhang Y-P, Lou Y, Hu J, Miao R, Ma F. DHA supplementation improves cognitive function via enhancing Abeta-mediated autophagy in Chinese elderly with mild cognitive impairment: a randomised placebo-controlled trial. *Journal of neurology, neurosurgery, and psychiatry*. 2017.

Zhang Y-Y, Fan Y-C, Wang M, Wang D, Li X-H. Atorvastatin attenuates the production of IL-1beta, IL-6, and TNF-alpha in the hippocampus of an amyloid beta1-42-induced rat model of Alzheimer's disease. *Clinical interventions in aging*. 2013;8:103-10.

Zhang Z, Li X, Li F, An L. Berberine alleviates postoperative cognitive dysfunction by suppressing neuroinflammation in aged mice. *International immunopharmacology*. 2016;38:426-33.

Zhang Z, Liu X, Schroeder JP, Chan C-B, Song M, Yu SP, et al. 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2014;39(3):638-50.

Zhang Z, Obianyo O, Dall E, Du Y, Fu H, Liu X, et al. Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer's disease. *Nature communications*. 2017;8:14740.

Zhang Z, Takeda-Uchimura Y, Foyez T, Ohtake-Niimi S, Narentuya, Akatsu H, et al. Deficiency of a sulfotransferase for sialic acid-modified glycans mitigates Alzheimer's pathology. *Proceedings of the National Academy of Sciences of the United States of America*. 2017;114(14):E2947-E54.

Zhang Z, Wu Z, Zhu X, Hui X, Pan J, Xu Y. Hydroxy-safflor yellow A inhibits neuroinflammation mediated by Abeta, in BV-2 cells. *Neuroscience letters*. 2014;562:39-44.

Zhang Z, Yuan H, Zhao H, Qi B, Li F, An L. PPARgamma activation ameliorates postoperative cognitive decline probably through suppressing hippocampal neuroinflammation in aged mice. *International immunopharmacology*. 2017;43:53-61.

Zhang Z-H, Chen C, Wu Q-Y, Zheng R, Chen Y, Liu Q, et al. Selenomethionine Ameliorates Neuropathology in the Olfactory Bulb of a Triple Transgenic Mouse Model of Alzheimer's Disease. *International journal of molecular sciences*. 2016;17(10).

Zhang Z-H, Chen C, Wu Q-Y, Zheng R, Liu Q, Ni J-Z, et al. Selenomethionine reduces the deposition of beta-amyloid plaques by modulating beta-secretase and enhancing selenoenzymatic

activity in a mouse model of Alzheimer's disease. *Metallomics : integrated biometal science*. 2016;8(8):782-9.

Zhang Z-H, Wen L, Wu Q-Y, Chen C, Zheng R, Liu Q, et al. Long-Term Dietary Supplementation with Selenium-Enriched Yeast Improves Cognitive Impairment, Reverses Synaptic Deficits, and Mitigates Tau Pathology in a Triple Transgenic Mouse Model of Alzheimer's Disease. *Journal of agricultural and food chemistry*. 2017;65(24):4970-9.

Zhang Z-H, Wu Q-Y, Zheng R, Chen C, Chen Y, Liu Q, et al. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017;37(9):2449-62.

Zhang Z-H, Yu L-J, Hui X-C, Wu Z-Z, Yin K-L, Yang H, et al. Hydroxy-safflor yellow A attenuates Abeta α , β , γ -induced inflammation by modulating the JAK2/STAT3/NF-kappaB pathway. *Brain research*. 2014;1563:72-80.

Zhang Z-X, Zhao R-P, Wang D-S, Li Y-B. Fuzhisan Ameliorates the Memory Deficits in Aged SAMP8 Mice via Decreasing Abeta Production and Tau Hyperphosphorylation of the Hippocampus. *Neurochemical research*. 2016;41(11):3074-82.

Zhang Z-X, Zhao R-P, Wang D-S, Wang A-N. Fuzhisan ameliorates Abeta production and tau phosphorylation in hippocampal of 11month old APP/PS1 transgenic mice: A Western blot study. *Experimental gerontology*. 2016;84:88-95.

Zhang Z-Y, Li C, Zug C, Schluesener HJ. Icaritin ameliorates neuropathological changes, TGF-beta1 accumulation and behavioral deficits in a mouse model of cerebral amyloidosis. *PloS one*. 2014;9(8):e104616.

Zhang Z-Y, Schluesener HJ. Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. *Journal of neuropathology and experimental neurology*. 2013;72(3):178-85.

Zhao B, Pan Y, Wang Z, Xu H, Song X. Hyperbaric Oxygen Pretreatment Improves Cognition and Reduces Hippocampal Damage Via p38 Mitogen-Activated Protein Kinase in a Rat Model. *Yonsei medical journal*. 2017;58(1):131-8.

Zhao C, Zhang H, Li H, Lv C, Liu X, Li Z, et al. Geniposide ameliorates cognitive deficits by attenuating the cholinergic defect and amyloidosis in middle-aged Alzheimer model mice. *Neuropharmacology*. 2017;116:18-29.

Zhao F-C, Wu Y, Song X-J. Design and Development of a Novel Chalcone Derivative as an Anticholinesterase Inhibitor for Possible Treatment of Dementia. *Medical science monitor : international medical journal of experimental and clinical research*. 2017;23:3311-7.

Zhao F-L, Fang F, Qiao P-f, Yan N, Gao D, Yan Y. AP39, a Mitochondria-Targeted Hydrogen Sulfide Donor, Supports Cellular Bioenergetics and Protects against Alzheimer's Disease by Preserving Mitochondrial Function in APP/PS1 Mice and Neurons. *Oxidative medicine and cellular longevity*. 2016;2016:8360738.

Zhao G, Liu HL, Zhang H, Tong XJ. Treadmill exercise enhances synaptic plasticity, but does not alter beta-amyloid deposition in hippocampi of aged APP/PS1 transgenic mice. *Neuroscience*. 2015;298:357-66.

Zhao HF, Li N, Wang Q, Cheng XJ, Li XM, Liu TT. Resveratrol decreases the insoluble Abeta1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats. *Neuroscience*. 2015;310:641-9.

Zhao J, Li Z, Cong Y, Zhang J, Tan M, Zhang H, et al. Repetitive transcranial magnetic stimulation improves cognitive function of Alzheimer's disease patients. *Oncotarget*. 2017;8(20):33864-71.

Zhao L, Chen T, Wang C, Li G, Zhi W, Yin J, et al. Atorvastatin in improvement of cognitive impairments caused by amyloid beta in mice: involvement of inflammatory reaction. *BMC neurology*. 2016;16:18.

Zhao L, Mao Z, Chen S, Schneider LS, Brinton RD. Early intervention with an estrogen receptor beta-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2013;37(2):403-19.

Zhao L, Wang J-L, Liu R, Li X-X, Li J-F, Zhang L. Neuroprotective, anti-amyloidogenic and neurotrophic effects of apigenin in an Alzheimer's disease mouse model. *Molecules (Basel, Switzerland)*. 2013;18(8):9949-65.

Zhao L, Wang J-L, Wang Y-R, Fa X-Z. Apigenin attenuates copper-mediated beta-amyloid neurotoxicity through antioxidation, mitochondrion protection and MAPK signal inactivation in an AD cell model. *Brain research*. 2013;1492:33-45.

Zhao L, Zhou C, Li L, Liu J, Shi H, Kan B, et al. Acupuncture Improves Cerebral Microenvironment in Mice with Alzheimer's Disease Treated with Hippocampal Neural Stem Cells. *Molecular neurobiology*. 2017;54(7):5120-30.

Zhao M, Cheah FSH, Chen M, Lee CG, Law H-Y, Chong SS. Improved high sensitivity screen for Huntington disease using a one-step triplet-primed PCR and melting curve assay. *PloS one*. 2017;12(7):e0180984.

Zhao M, Lee CG, Law H-Y, Chong SS. Enhanced Detection and Sizing of the HTT CAG Repeat Expansion in Huntington Disease Using an Improved Triplet-Primed PCR Assay. *Neurodegenerative diseases*. 2016;16(5-6):348-51.

Zhao M, Wang S-w, Wang Y-j, Zhang R, Li Y-n, Su Y-j, et al. Pan-amyloid oligomer specific scFv antibody attenuates memory deficits and brain amyloid burden in mice with Alzheimer's disease. *Current Alzheimer research*. 2014;11(1):69-78.

Zhao S-s, Yang W-n, Jin H, Ma K-g, Feng G-f. Puerarin attenuates learning and memory impairments and inhibits oxidative stress in STZ-induced SAD mice. *Neurotoxicology*. 2015;51:166-71.

Zhao X, Kotilinek LA, Smith B, Hlynialuk C, Zahs K, Ramsden M, et al. Caspase-2 cleavage of tau reversibly impairs memory. *Nature medicine*. 2016;22(11):1268-76.

Zhao X-J, Gong D-M, Jiang Y-R, Guo D, Zhu Y, Deng Y-C. Multipotent AChE and BACE-1 inhibitors for the treatment of Alzheimer's disease: Design, synthesis and bio-analysis of 7-amino-1,4-dihydro-2H-isoquin-3-one derivatives. *European journal of medicinal chemistry*. 2017;138:738-47.

Zhao Y, Dou J, Wu T, Aisa HA. Investigating the antioxidant and acetylcholinesterase inhibition activities of *Gossypium herbaceum*. *Molecules (Basel, Switzerland)*. 2013;18(1):951-62.

Zhao Z, Pissarnitski DA, Josien HB, Bara TA, Clader JW, Li H, et al. Substituted 4-morpholine N-arylsulfonamides as gamma-secretase inhibitors. *European journal of medicinal chemistry*. 2016;124:36-48.

Zhao Z, Pissarnitski DA, Josien HB, Wu W-L, Xu R, Li H, et al. Discovery of a Novel, Potent Spirocyclic Series of gamma-Secretase Inhibitors. *Journal of medicinal chemistry*. 2015;58(22):8806-17.

Zhen J, Qian Y, Fu J, Su R, An H, Wang W, et al. Deep Brain Magnetic Stimulation Promotes Neurogenesis and Restores Cholinergic Activity in a Transgenic Mouse Model of Alzheimer's Disease. *Frontiers in neural circuits*. 2017;11:48.

Zhen J, Qian Y, Weng X, Su W, Zhang J, Cai L, et al. Gamma rhythm low field magnetic stimulation alleviates neuropathologic changes and rescues memory and cognitive impairments in a mouse model of Alzheimer's disease. *Alzheimer's & dementia (New York, N Y)*. 2017;3(4):487-97.

Zhen J-L, Chang Y-N, Qu Z-Z, Fu T, Liu J-Q, Wang W-P. Luteolin rescues pentylentetrazole-induced cognitive impairment in epileptic rats by reducing oxidative stress and activating PKA/CREB/BDNF signaling. *Epilepsy & behavior : E&B*. 2016;57(Pt A):177-84.

Zheng J-Y, Liang K-S, Wang X-J, Zhou X-Y, Sun J, Zhou S-N. Chronic Estradiol Administration During the Early Stage of Alzheimer's Disease Pathology Rescues Adult Hippocampal Neurogenesis and Ameliorates Cognitive Deficits in Abeta1-42 Mice. *Molecular neurobiology*. 2017;54(10):7656-69.

Zheng J-Y, Sun J, Ji C-M, Shen L, Chen Z-J, Xie P, et al. Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer's disease (APP/PS1) mice by inhibiting TGF-beta/Smad2/STAT3 signaling. *Neurobiology of aging*. 2017;54:112-32.

Zheng M, Liu J, Ruan Z, Tian S, Ma Y, Zhu J, et al. Intrahippocampal injection of Abeta1-42 inhibits neurogenesis and down-regulates IFN-gamma and NF-kappaB expression in hippocampus of adult mouse brain. *Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis*. 2013;20(1):13-20.

Zheng X, Liu D, Roychaudhuri R, Teplow DB, Bowers MT. Amyloid beta-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer's Disease Mutation. *ACS chemical neuroscience*. 2015;6(10):1732-40.

Zheng X, Pang X, Yang P, Wan X, Wei Y, Guo Q, et al. A hybrid siRNA delivery complex for enhanced brain penetration and precise amyloid plaque targeting in Alzheimer's disease mice. *Acta biomaterialia*. 2017;49:388-401.

Zheng X, Wu C, Liu D, Li H, Bitan G, Shea J-E, et al. Mechanism of C-Terminal Fragments of Amyloid beta-Protein as Abeta Inhibitors: Do C-Terminal Interactions Play a Key Role in Their Inhibitory Activity? *The journal of physical chemistry B*. 2016;120(8):1615-23.

Zheng X, Zhang X, Kang A, Ran C, Wang G, Hao H. Thinking outside the brain for cognitive improvement: Is peripheral immunomodulation on the way? *Neuropharmacology*. 2015;96(Pt A):94-104.

Zhitkova JV. Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia. *Zhurnal nevrologii i psikiatrii imeni SS Korsakova*. 2015;115(8):53-60.

Zhong L, Chen X-F, Wang T, Wang Z, Liao C, Wang Z, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. *The Journal of experimental medicine*. 2017;214(3):597-607.

Zhong S-Z, ma S-P, Hong Z-Y. Peoniflorin activates Nrf2/ARE pathway to alleviate the Abeta(1-42)-induced hippocampal neuron injury in rats. *Yao xue xue bao = Acta pharmaceutica Sinica*. 2013;48(8):1353-7.

Zhou A, Hu J, Wang L, Zhong G, Pan J, Wu Z, et al. Combined 3D-QSAR, molecular docking, and molecular dynamics study of tacrine derivatives as potential acetylcholinesterase (AChE) inhibitors of Alzheimer's disease. *Journal of molecular modeling*. 2015;21(10):277.

Zhou B, Li C-L, Hao Y-Q, Johnny MC, Liu Y-N, Li J. Ferrocene tripeptide Gly-Pro-Arg conjugates: synthesis and inhibitory effects on Alzheimer's Abeta(1-42) fibrillogenesis and Abeta-induced cytotoxicity in vitro. *Bioorganic & medicinal chemistry*. 2013;21(2):395-402.

Zhou B. Editorial: Prevention Strategies Targeting Different Preclinical Stages of Alzheimer's Disease. *Current Alzheimer research*. 2015;12(6):504-6.

Zhou D, Zhou W, Song J-K, Feng Z-Y, Yang R-Y, Wu S, et al. DL0410, a novel dual cholinesterase inhibitor, protects mouse brains against Abeta-induced neuronal damage via the Akt/JNK signaling pathway. *Acta pharmacologica Sinica*. 2016;37(11):1401-12.

Zhou H, Xue W, Chu S-F, Wang Z-Z, Li C-J, Jiang Y-N, et al. Polygalasaponin XXXII, a triterpenoid saponin from *Polygalae Radix*, attenuates scopolamine-induced cognitive impairments in mice. *Acta pharmacologica Sinica*. 2016;37(8):1045-53.

Zhou L, Ma SL, Yeung PKK, Wong YH, Tsim KWK, So KF, et al. Anxiety and depression with neurogenesis defects in exchange protein directly activated by cAMP 2-deficient mice are ameliorated by a selective serotonin reuptake inhibitor, Prozac. *Translational psychiatry*. 2016;6(9):e881.

Zhou L, Tan S, Shan Y-L, Wang Y-G, Cai W, Huang X-H, et al. Baicalein improves behavioral dysfunction induced by Alzheimer's disease in rats. *Neuropsychiatric disease and treatment*. 2016;12:3145-52.

Zhou L-Y, Zhu Y, Jiang Y-R, Zhao X-J, Guo D. Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease. *Bioorganic & medicinal chemistry letters*. 2017;27(17):4180-4.

Zhou Q, Wang M, Du Y, Zhang W, Bai M, Zhang Z, et al. Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APP^{swe}/PS1^{dE9} mice. *Annals of neurology*. 2015;77(4):637-54.

Zhou S, Yu G, Chi L, Zhu J, Zhang W, Zhang Y, et al. Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats. *Neurotoxicology*. 2013;38:136-45.

Zhou W, Zhong G, Fu S, Xie H, Chi T, Li L, et al. Microglia-Based Phenotypic Screening Identifies a Novel Inhibitor of Neuroinflammation Effective in Alzheimer's Disease Models. *ACS chemical neuroscience*. 2016;7(11):1499-507.

Zhou W-b, Lin L, Li Z-y, Bi T, Ye T-y, Ma C-q, et al. Study on active ingredient and mechanism in preventing vascular dementia of Tianzhusan coming from Tujia medicine. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica*. 2015;40(13):2668-73.

Zhou W-w, Lu S, Su Y-j, Xue D, Yu X-l, Wang S-w, et al. Decreasing oxidative stress and neuroinflammation with a multifunctional peptide rescues memory deficits in mice with Alzheimer disease. *Free radical biology & medicine*. 2014;74:50-63.

Zhou X, Li Y, Shi X, Ma C. An overview on therapeutics attenuating amyloid beta level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. *American journal of translational research*. 2016;8(2):246-69.

Zhou Y, Xie N, Li L, Zou Y, Zhang X, Dong M. Puerarin alleviates cognitive impairment and oxidative stress in APP/PS1 transgenic mice. *The international journal of neuropsychopharmacology*. 2014;17(4):635-44.

Zhu CW, Livote EE, Scarmeas N, Albert M, Brandt J, Blacker D, et al. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013;9(6):733-40.

Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Galasko D, et al. Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. *Journal of the American Geriatrics Society*. 2014;62(5):985-8.

Zhu D, Yang N, Liu Y-Y, Zheng J, Ji C, Zuo P-P. M2 Macrophage Transplantation Ameliorates Cognitive Dysfunction in Amyloid-beta-Treated Rats Through Regulation of Microglial Polarization. *Journal of Alzheimer's disease : JAD*. 2016;52(2):483-95.

Zhu H-X, Xue Z-Q, Qiu W-Y, Zeng Z-J, Dai J-P, Ma C, et al. Age-related intraneuronal accumulation of alphaII-spectrin breakdown product SBDP120 in the human cerebrum is enhanced in Alzheimer's disease. *Experimental gerontology*. 2015;69:43-52.

Zhu L, Yang J-y, Xue X, Dong Y-x, Liu Y, Miao F-r, et al. A novel phosphodiesterase-5 Inhibitor: Yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP/PS1 transgenic mice model. *Mechanisms of ageing and development*. 2015;150:34-45.

Zhu L, Zhong M, Zhao J, Rhee H, Caesar I, Knight EM, et al. Reduction of synaptojanin 1 accelerates Abeta clearance and attenuates cognitive deterioration in an Alzheimer mouse model. *The Journal of biological chemistry*. 2013;288(44):32050-63.

Zhu M, Shu K, Wang H, Li X, Xiao Q, Chan W, et al. Microtransplantation of whole ganglionic eminence cells ameliorates motor deficit, enlarges the volume of grafts, and prolongs survival in a rat model of Huntington's disease. *Journal of neuroscience research*. 2013;91(12):1563-71.

Zhu S, Shi R, Li V, Wang J, Zhang R, Tempier A, et al. Quetiapine attenuates glial activation and proinflammatory cytokines in APP/PS1 transgenic mice via inhibition of nuclear factor-kappaB pathway. *The international journal of neuropsychopharmacology*. 2014;18(3).

Zhu X, Wang S, Yu L, Yang H, Tan R, Yin K, et al. TL-2 attenuates beta-amyloid induced neuronal apoptosis through the AKT/GSK-3beta/beta-catenin pathway. *The international journal of neuropsychopharmacology*. 2014;17(9):1511-9.

Zhu Y, Wang J. Wogonin increases beta-amyloid clearance and inhibits tau phosphorylation via inhibition of mammalian target of rapamycin: potential drug to treat Alzheimer's disease. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2015;36(7):1181-8.

Zhu Y, Zhang Q, Zhang W, Li N, Dai Y, Tu J, et al. Protective Effect of 17beta-Estradiol Upon Hippocampal Spine Density and Cognitive Function in an Animal Model of Vascular Dementia. *Scientific reports*. 2017;7:42660.

Zhu Y-Z, Yao R, Zhang Z, Xu H, Wang L-W. Parecoxib prevents early postoperative cognitive dysfunction in elderly patients undergoing total knee arthroplasty: A double-blind, randomized clinical consort study. *Medicine*. 2016;95(28):e4082.

Zhu Z, Yan J, Jiang W, Yao X-g, Chen J, Chen L, et al. Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both beta-amyloid production and clearance. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2013;33(32):13138-49.

Zhuang X, Chen Y, Zhuang X, Xing T, Chen T, Jiang G, et al. Impaired Center-Surround Suppression in Patients with Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;55(3):1101-8.

Ziehm T, Brener O, van Groen T, Kadish I, Frenzel D, Tusche M, et al. Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Abeta Species. *ACS chemical neuroscience*. 2016;7(8):1088-96.

Zilberter M, Ivanov A, Ziyatdinova S, Mukhtarov M, Malkov A, Alpar A, et al. Dietary energy substrates reverse early neuronal hyperactivity in a mouse model of Alzheimer's disease. *Journal of neurochemistry*. 2013;125(1):157-71.

Zilkens RR, Duke J, Horner B, Semmens JB, Bruce DG. Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2014;10(3):310-8.

Zimmerer VC, Dabrowska E, Romanowski CAJ, Blank C, Varley RA. Preservation of passive constructions in a patient with primary progressive aphasia. *Cortex; a journal devoted to the study of the nervous system and behavior*. 2014;50:7-18.

Zimushkina NA, Kosareva PV, Cherkasova VG, Khorinko VP. Degenerative and regenerative changes in hippocampus in postnatal ontogenesis. *Zhurnal nevrologii i psikiatrii imeni SS Korsakova*. 2014;114(4):73-7.

Zou F, Belbin O, Carrasquillo MM, Culley OJ, Hunter TA, Ma L, et al. Linking protective GAB2 variants, increased cortical GAB2 expression and decreased Alzheimer's disease pathology. *PloS one*. 2013;8(5):e64802.

Zou J, Cai P-s, Xiong C-m, Ruan J-l. Neuroprotective effect of peptides extracted from walnut (*Juglans Sigilata* Dode) proteins on Abeta25-35-induced memory impairment in mice. *Journal of Huazhong University of Science and Technology Medical sciences = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban*. 2016;36(1):21-30.

Zou Z, Xu P, Zhang G, Cheng F, Chen K, Li J, et al. Selagintriflavonoids with BACE1 inhibitory activity from the fern *Selaginella doederleinii*. *Phytochemistry*. 2017;134:114-21.

Zueva IV, Semenov VE, Mukhamedyarov MA, Lushchekina SV, Kharlamova AD, Petukhova EO, et al. 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease. *The International journal of risk & safety in medicine*. 2015;27 Suppl 1:S69-71.

Zumkehr J, Rodriguez-Ortiz CJ, Cheng D, Kieu Z, Wai T, Hawkins C, et al. Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease. *Neurobiology of aging*. 2015;36(7):2260-71.